<SEC-DOCUMENT>0001564590-22-009929.txt : 20220314
<SEC-HEADER>0001564590-22-009929.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220311194445
ACCESSION NUMBER:		0001564590-22-009929
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		22734769

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>eypt-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-11T22:57:28.5073984+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ed9f53d5b78741d19b453bb1246c3522 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:eypt="http://eyepointpharma.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
eypt-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001314102_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001314102_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:EntityCentralIndexKey" contextRef="C_0001314102_20210101_20211231">0001314102</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001314102_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000388" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000390" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000956" name="us-gaap:OpenTaxYear" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231">2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000957" name="us-gaap:OpenTaxYear" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20210101_20211231">2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020</ix:nonNumeric>
			<ix:nonNumeric id="F_000550" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000571" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000638" name="us-gaap:DebtInstrumentTerm" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000736" name="eypt:WarrantsExercisePeriod" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000737" name="eypt:WarrantsExercisePeriod" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000517" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231">P9Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000579" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000580" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20201231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000601" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20211231">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</ix:nonNumeric>
			<ix:nonNumeric id="F_000602" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20201231">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</ix:nonNumeric>
			<ix:nonNumeric id="F_000605" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000606" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20201231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000609" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000610" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001314102_20201231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000757" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231">P8Y21D</ix:nonNumeric>
			<ix:nonNumeric id="F_000758" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000768" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">P4Y9M</ix:nonNumeric>
			<ix:nonNumeric id="F_000769" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">P5Y6M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000772" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF">0.72</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000773" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231" decimals="INF">0.64</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000776" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF">0.0042</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000777" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231" decimals="INF">0.0032</ix:nonFraction>
			<ix:nonNumeric id="F_000770" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000771" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">P6Y1M6D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000774" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF">0.83</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000775" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231" decimals="INF">0.70</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF">0.0144</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000779" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231" decimals="INF">0.0176</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001314102_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001314102_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:PreferredStockValue" contextRef="C_0001314102_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:PreferredStockValue" contextRef="C_0001314102_20201231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="eypt-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001314102_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_20220304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-04</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_eyptProduct">
				<xbrli:measure>eypt:Product</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_eypt_People">
				<xbrli:measure>eypt:_People</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_eyptCase">
				<xbrli:measure>eypt:Case</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptCostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">eypt:InvestmentInstrumentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">eypt:InvestmentInstrumentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-27</xbrli:startDate>
					<xbrli:endDate>2018-03-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-17</xbrli:startDate>
					<xbrli:endDate>2020-12-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltySaleAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltySaleAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltySaleAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20130331_20130331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-03-31</xbrli:startDate>
					<xbrli:endDate>2013-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20181101_20181130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-11-01</xbrli:startDate>
					<xbrli:endDate>2018-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20190801_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:TechnologyServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:TechnologyServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:PropertyAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:PropertyAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OriginalLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OriginalLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SecondAmendmentLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SecondAmendmentLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:ThirdAmendmentLeaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:FourthAmendmentLeaseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-08</xbrli:startDate>
					<xbrli:endDate>2022-03-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:FourthAmendmentLeaseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:BaskingRidgeOfficeSpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_eyptTranche">
				<xbrli:measure>eypt:Tranche</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:BaskingRidgeOfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:BaskingRidgeOfficeSpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtCounterpartyNameAxis_eyptCaladriusMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eypt:CaladriusMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_eyptLease">
				<xbrli:measure>eypt:Lease</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptFirstLabEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:FirstLabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptSecondLabEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:SecondLabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptThirdLabEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:ThirdLabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200408">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-22</xbrli:startDate>
					<xbrli:endDate>2020-04-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210616_20210616">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-16</xbrli:startDate>
					<xbrli:endDate>2021-06-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptInitialAdvanceMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:InitialAdvanceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentPriorToDecember312019Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentPriorToDecember312019Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentAfterDecember312021Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-17</xbrli:startDate>
					<xbrli:endDate>2020-12-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodFourMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-12</xbrli:startDate>
					<xbrli:endDate>2019-02-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodFourMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-17</xbrli:startDate>
					<xbrli:endDate>2020-12-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-01</xbrli:startDate>
					<xbrli:endDate>2021-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SharePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-30</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SharePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200622">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20200623">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-27</xbrli:startDate>
					<xbrli:endDate>2018-03-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-24</xbrli:startDate>
					<xbrli:endDate>2018-06-26</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20161212">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20190625">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210622">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansAndInducementAwardGrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansAndInducementAwardGrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansAndInducementAwardGrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-30</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181230_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-30</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtTitleOfIndividualAxis_eyptNewlyAppointedNonExecutiveDirectorMember_20181230_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:NewlyAppointedNonExecutiveDirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-30</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtTitleOfIndividualAxis_eyptDirectorsAndExternalConsultantsMember_20181230_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:DirectorsAndExternalConsultantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-30</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:NonExecutiveDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eypt:DeferredStockUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eypt:DeferredStockUnitsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190625">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210622">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-24</xbrli:startDate>
					<xbrli:endDate>2019-06-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eypt:SalesAndMarketingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eypt:SalesAndMarketingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210801_20210831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AerpioPharmaceuticalsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-08-01</xbrli:startDate>
					<xbrli:endDate>2021-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AerpioPharmaceuticalsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eypt:FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217GBP">
				<xbrli:measure>iso4217:GBP</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:HerMajestysRevenueAndCustomsHMRCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateTaxMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eypt:FederalAndStateTaxMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:HerMajestysRevenueAndCustomsHMRCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryCN_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryGB_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryCN_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryGB_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-09</xbrli:startDate>
					<xbrli:endDate>2022-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-09</xbrli:startDate>
					<xbrli:endDate>2022-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20220309_20220309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-09</xbrli:startDate>
					<xbrli:endDate>2022-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-09</xbrli:startDate>
					<xbrli:endDate>2022-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001314102_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000391 F_000392"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000393 F_000394"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-top:0pt;border-top:none 0pt;padding-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:4pt;border-top:none 0pt;padding-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549 </p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001314102_20210101_20211231">10-K</ix:nonNumeric> </p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:3pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:DocumentAnnualReport" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001314102_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001314102_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:3pt;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:DocumentTransitionReport" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:3pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="margin-left:36pt;"></span>to </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000015" name="dei:EntityFileNumber" contextRef="C_0001314102_20210101_20211231">000-51122</ix:nonNumeric> </p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001314102_20210101_20211231">EyePoint Pharmaceuticals, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001314102_20210101_20211231">26-2774444</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityAddressAddressLine1" contextRef="C_0001314102_20210101_20211231">480 Pleasant Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:EntityAddressCityOrTown" contextRef="C_0001314102_20210101_20211231">Watertown</ix:nonNumeric>, <ix:nonNumeric id="F_000019" name="dei:EntityAddressStateOrProvince" contextRef="C_0001314102_20210101_20211231">MA</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityAddressPostalZipCode" contextRef="C_0001314102_20210101_20211231">02472</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric id="F_000021" name="dei:CityAreaCode" contextRef="C_0001314102_20210101_20211231">(617)</ix:nonNumeric> <ix:nonNumeric id="F_000022" name="dei:LocalPhoneNumber" contextRef="C_0001314102_20210101_20211231">926-5000</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:8pt;">
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:Security12bTitle" contextRef="C_0001314102_20210101_20211231">Common Stock, par value $0.001</ix:nonNumeric></p></td>
<td valign="top" style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:TradingSymbol" contextRef="C_0001314102_20210101_20211231">EYPT</ix:nonNumeric></p></td>
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC (<ix:nonNumeric id="F_000027" name="dei:SecurityExchangeName" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Global Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000030" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001314102_20210101_20211231">No</ix:nonNumeric>&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000031" name="dei:EntityVoluntaryFilers" contextRef="C_0001314102_20210101_20211231">No</ix:nonNumeric>&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000029" name="dei:EntityCurrentReportingStatus" contextRef="C_0001314102_20210101_20211231">Yes</ix:nonNumeric>&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000028" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001314102_20210101_20211231">Yes</ix:nonNumeric>&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:14.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:64.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:17.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:14.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="width:64.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="width:17.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:14.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityFilerCategory" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:64.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" style="width:17.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:4pt;">
<td valign="middle" style="width:14.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="width:64.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="width:17.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:64.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:17.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging&#160;growth&#160;company</p></td>
<td valign="bottom" style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;color:#000000;"><ix:nonNumeric id="F_000032" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityShellCompany" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the common stock held by non-affiliates of the registrant, computed by reference to the closing price of the common stock on the Nasdaq Global Market on June&#160;30, 2021, the last trading day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000011" name="dei:EntityPublicFloat" contextRef="C_0001314102_20210630" decimals="0" format="ixt:numdotdecimal">192,416,944</ix:nonFraction>. </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000010" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001314102_20220304" decimals="INF" format="ixt:numdotdecimal">34,044,255</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value, outstanding as of March 4, 2022. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE </p>
<p style="margin-bottom:4pt;margin-top:3pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000272" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2022 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form 10-K </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Fiscal Year Ended December&#160;31, 2021 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:95.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:95.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">BUSINESS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1A.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">RISK FACTORS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1B.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">UNRESOLVED STAFF COMMENTS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;2.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">PROPERTIES</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">LEGAL PROCEEDINGS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">MINE SAFETY DISCLOSURES.</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART II</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;5.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;6.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">[RESERVED]</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM 7.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;7A.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;8.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9A.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">CONTROLS AND PROCEDURES</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9B.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">OTHER INFORMATION</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9C.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C"><span style="text-decoration:underline;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART III</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;10.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;11.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">EXECUTIVE COMPENSATION</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM 12.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM 13.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;14.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART IV</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;15.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;16.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">FORM 10-K SUMMARY</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preliminary Note Regarding Forward-Looking Statements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various statements made in this Annual Report on Form 10-K are forward-looking and involve risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. Such statements give our current expectations or forecasts of future events and are not statements of historical or current facts. These statements include, among others, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;">the potential for EYP-1901, as a six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration (&#8220;wet AMD&#8221;), diabetic retinopathy (&#8220;DR&#8221;) and retinal vein occlusion (&#8220;RVO&#8221;)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;">our expectations regarding the timing and outcome of Phase 2 clinical trials for EYP-1901 for the treatment of wet AMD, DR and RVO&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;font-size:10pt;">our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and YUTIQ 50&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which our business, the medical community and the global economy will continue to be materially and adversely impacted by the effects of the COVID-19 pandemic (the &#8220;Pandemic&#8221;), or by other pandemics, epidemics or outbreaks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our cash flow expectations from commercial sales of YUTIQ and DEXYCU&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to manufacture YUTIQ, DEXYCU, EYP-1901 or any future products or product candidates, in sufficient quantities and quality&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our belief that our cash, cash equivalents, and investments in marketable securities of $211.6&#160;million at December&#160;31, 2021, </span><span style="color:#000000;font-size:10pt;">and anticipated net cash inflows from product sales will </span><span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">fund our operating plan into the second half of 2024, under current expectations regarding t</span><span style="font-size:10pt;color:#000000;">he timing and outcomes of our Phase 2 clinical trials for EYP-1901&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain additional capital in sufficient amounts and on terms acceptable to us, and the consequences of failing to do so&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our future expenses and capital expenditures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for EYP-1901, YUTIQ, DEXYCU and YUTIQ 50 and any future products or product candidates, and to avoid claims of infringement of third-party intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectation that we will continue to incur significant expenses and that our operating losses and our net cash outflows to fund operations will continue for the foreseeable future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">our expectations regarding our expanded commercial alliance with ImprimisRx for the sales and marketing of DEXYCU, and ImprimisRx&#8217;s ability to execute on sales and marketing activities for the brand&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the effect of legal and regulatory developments.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements also include statements other than statements of current or historical fact, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items&#59; any statements of the plans, strategies and objectives of management for future operations&#59; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals&#59; any other statements of expectations, plans, intentions or beliefs&#59; and any statements of assumptions underlying any of the foregoing. We often, although not always, identify forward-looking statements by using words or phrases such as &#8220;likely&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221; and &#8220;outlook&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which the Pandemic impacts our business, the medical community and the global economy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the effectiveness and timeliness of our preclinical studies and clinical trials, and the usefulness of the data&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectations regarding the timing and clinical development of our product candidates, including EYP-1901, and the potential for EYP-1901 as a six-month treatment for serious eye diseases, including wet AMD, DR and RVO&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to achieve profitable operations and access to needed capital&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">fluctuations in our operating results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for the commercialization of YUTIQ and DEXYCU&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">consequences of fluocinolone acetonide side effects for YUTIQ&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">consequences of dexamethasone side effects for DEXYCU&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of current and future license and collaboration agreements, including our agreements with Ocumension Therapeutics (&#8220;Ocumension&#8221;) and Equinox Science, LLC (&#8220;Equinox&#8221;)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our dependence on contract research organizations, contract sales organizations, vendors and investigators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">effects of competition and other developments affecting sales of products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">market acceptance of our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">protection of intellectual property and avoiding intellectual property infringement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product liability&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">other factors described in our filings with the SEC.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. The risks set forth under Item 1A of this Annual Report on Form 10-K describe major risks to our business, and you should read and interpret any forward-looking statements together with these risks. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, and Durasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> are our trademarks. Retisert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Vitrasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> are Bausch&#160;&#38; Lomb&#8217;s trademarks. ILUVIEN<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is Alimera Sciences Inc.&#8217;s trademark. Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is a trademark owned by Ramscor, Inc. and exclusively licensed to us. The reports we file or furnish with the SEC, including this Annual Report on Form 10-K, also contain trademarks, trade names and service marks of other companies, which are the property of their respective owners.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risk Factor Summary</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk factors summarized below could materially harm our business, operating results and/or financial condition, impair our future prospects and/or cause the price of our common stock to decline. For more information, see &#8220;Item 1A. Risk Factors&#8221; in this Annual Report on Form 10-K for the year ended December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, the following:</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related To Our Financial Position and our Capital Resources </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We will likely need additional capital to fund our operations. If we are unable to obtain sufficient capital, we will need to curtail and reduce our operations and costs and modify our business strategy.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may never achieve profitability from future operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The ongoing novel coronavirus (COVID-19) pandemic has had and will likely continue to have a material and adverse impact on our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We will need to raise additional capital in the future, which may not be available on favorable terms and may be dilutive to stockholders or impose operational restrictions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We must maintain compliance with the terms of our Credit Facilities or receive a waiver for any non-compliance. Our failure to comply with the covenants or other terms of the Credit Facilities, including as a result of events beyond our control, could result in a default under the SVB Loan Agreement that would materially and adversely affect the ongoing viability of our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our Loan Agreement contains restrictions that limit our flexibility in operating our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Certain potential payments to the Lenders could impede a sale of our company.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">To service our indebtedness, we will require a significant amount of cash and our ability to generate cash depends on many factors beyond our control.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related To The Regulatory Approval And Clinical Development Of Our Product Candidates </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We are substantially dependent on the success of our lead product candidate, EYP-1901, which is in the early stages of development and must go through additional clinical trials, which are very expensive, time-consuming and difficult to design and implement. The outcomes of clinical trials are uncertain, and delays in the completion of or the termination of any clinical trial of EYP-1901 or our other product candidates could harm our business, financial condition and prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Clinical trial results may fail to support approval of EYP-1901 or our other product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may expend significant resources to pursue our lead product candidate, EYP-1901 for the potential treatment of wet AMD, and fail to capitalize on the potential of EYP-1901, or our other product candidates, for the potential treatment of other indications that may be more profitable or for which there is a greater likelihood of success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Initial results from a clinical trial do not ensure that the trial will be successful and success in early-stage clinical trials does not ensure success in later-stage clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We face risks related to health epidemics and outbreaks, including the Pandemic, which could significantly disrupt our preclinical studies and clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent clinical trials of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We are largely dependent on the clinical and future commercial success of our lead product candidate, EYP-1901.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related To The Commercialization Of Our Products And Product Candidates</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our current business strategy relies in part on our ability to successfully commercialize YUTIQ and DEXYCU in the U.S.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We could be adversely affected by our exposure to customer concentration risk.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, including DEXYCU pass-through status, which could harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Even though regulatory approvals for YUTIQ and DEXYCU have been obtained in the U.S., we will still face extensive FDA regulatory requirements and may face future regulatory difficulties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our relationships with physicians, patients and payors in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. In addition, we are subject to patient privacy regulation by both the federal government and the states in which we conduct our business. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If any of our products have newly discovered or developed safety problems, our business would be seriously harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The Affordable Care Act and any changes in healthcare laws may increase the difficulty and cost for us to commercialize DEXYCU and YUTIQ in the U.S. and affect the prices we may obtain.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related To Our Intellectual Property</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our product candidates, our competitors could develop and commercialize technology and products similar to ours, and our competitive position could be harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may not be able to protect our intellectual property rights throughout the world.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:12pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products or product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may be subject to claims asserting that our employees, consultants, independent contractors and advisors have wrongfully used or disclosed confidential information and/or alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Intellectual property rights do not prevent all potential threats to competitive advantages we may have.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:12pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related To Our Reliance On Third Parties</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The development and commercialization of our lead product candidate, EYP-1901, is dependent on intellectual property we license and API supply of vorolanib from Equinox Science. If we breach our agreement with Equinox or the agreement is terminated, we could lose license rights or API supply of vorolanib that are material to our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If we are unable to maintain our agreement with ImprimisRx to co-promote DEXYCU, we may be unable to generate significant revenue from this product.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If we encounter issues with our CMOs or suppliers, we may need to qualify alternative manufacturers or suppliers, which could impair our ability to sufficiently and timely manufacture and supply DEXYCU.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We use our own facility for the manufacturing of YUTIQ, and rely on third party suppliers for key components and any disruptions to our operations or to the operations of our suppliers could adversely affect YUTIQ&#8217;s commercial viability.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related To Ownership Of Our Common Stock </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The trading price of the shares of our common stock has been highly volatile, and purchasers of our common stock could incur substantial losses.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">EW Healthcare and Ocumension own a substantial amount of our common stock and can exert significant control over matters subject to stockholder approval, which would prevent new investors from influencing significant corporate decisions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Certain covenants related to our share purchase agreement with Ocumension may restrict our ability to obtain future financing and cause additional dilution for our stockholders.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">ITEM&#160;1. BUSINESS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our pipeline leverages our proprietary Durasert</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup><span style="Background-color:#FFFFFF;">technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration (&#8220;wet AMD&#8221;), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a once every three-year treatment for chronic&#160;non-infectious&#160;uveitis affecting the posterior segment of the eye, and DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application (&#8220;sNDA&#8221;) strategy. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Local drug delivery for treating ocular diseases is a significant challenge due to the effectiveness of the blood-eye barrier. This barrier makes it difficult for systemically-administered drugs to reach the eye in sufficient quantities to have a beneficial effect without causing unacceptable adverse side effects to other organs. Our validated Durasert technology, which has already been included in four products approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), is designed to provide consistent, sustained intravitreal delivery of small molecule drugs over a period of months to years through a single intravitreal injection. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our lead product candidate, EYP-1901, combines a bioerodible formulation of our proprietary Durasert technology with vorolanib, a tyrosine kinase inhibitor (&#8220;TKI&#8221;) that has demonstrated anti-VEGF activity. Current FDA approved anti-VEGF treatments for wet AMD require monthly or bi-monthly intravitreal injections in a physician&#8217;s office which can cause inconvenience and often lead to reduced compliance and poor outcomes. We are currently evaluating EYP-1901 in a Phase 1 clinical trial as a potential six-month sustained delivery treatment for wet AMD and we reported positive interim six-month safety and efficacy data in November 2021. In February 2022, we updated the results of the DAVIO clinical trial through 8-months reporting continued positive safety and efficacy results. We expect to initiate a Phase 2 clinical trial in wet AMD in the third quarter of 2022 and a Phase 2 clinical trial in DR in the second half of 2022 with initial top-line data for the wet AMD clinical trial anticipated in second half of 2023.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;(fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is a non-erodible intravitreal implant containing fluocinolone acetonide (&#8220;FA&#8221;) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This disease affects between 60,000 to 100,000 people each year in the U.S., causes approximately 30,000 new cases of blindness every year and is the third leading cause of blindness. YUTIQ utilizes our proprietary Durasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;sustained-release drug delivery technology platform.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;(dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation, with our primary focus on its use&#160;immediately following cataract surgery as a single dose treatment. DEXYCU utilizes our proprietary Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;drug-delivery&#160;technology. In December 2021, we announced that our commercial alliance partner, ImprimisRx, assumed responsibility for all sales and marketing activity for DEXYCU beginning on January 1, 2022.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are also developing YUTIQ 50 as a potential six-month treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. We dosed the first patient in a Phase 3 clinical trial in November 2021.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect to identify and evaluate additional product candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, potential research collaborations and/or&#160;in-licensing&#160;arrangements with partner molecules and potential acquisitions of additional ophthalmic products, product candidates or technologies that complement our current product portfolio.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> ongoing coronavirus&#160;(COVID-19)&#160;pandemic (the &#8220;Pandemic&#8221;) has had a material and adverse impact on our business, including as a result of measures that we, other businesses, and government have taken and will likely continue to take. This includes a significant impact on cash flows from expected revenues due to the closure of ambulatory surgery centers for DEXYCU and a significant reduction in physician office visits impacting YUTIQ. The ongoing Pandemic continued to have an adverse impact on our revenues, financial condition and cash flows through 2021. For the year ended December 31, 2021, we recorded impairment charges of $1.2 million to cost of sales, excluding amortization of acquired intangible assets and $0.1 million to sales and marketing expense, respectively, associated with the write-off of obsolete inventory of DEXYCU units and DEXYCU sample units, respectively, whose inventory levels were higher than our updated forecasts of future demand for those units. Additionally, the emergence of the Omicron variant and the continued Pandemic continue to have an adverse impact on our revenues, financial condition and cash flows into the first quarter of 2022 and may continue to cause intermittent or prolonged periods of reduced patient services at our customers&#8217; </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">facilities, which may negatively affect customer demand. The progression of the Pandemic and its effects on our business and operations are uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, our revenues, financial condition and cash flows may be adversely affected in the future as well. We are continuously monitoring the Pandemic and its potential effect on our financial position, results of operations and cash flows.</span><span style="color:#000000;"> </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline and Commercial Products</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table describes the stage of each of our programs:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0exp3o4wshp000001.jpg" title="" alt="" style="width:720px;height:372px;" /></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategy </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to become a leading pharmaceutical company commercializing <span style="Background-color:#FFFFFF;">innovative therapeutics to help improve the lives of patients with serious eye disorders.</span> The key elements of our strategy include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Advance EYP-1901 </span><span style="color:#000000;font-size:10pt;">through clinical development for wet AMD.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Advance EYP-1901 </span><span style="font-size:10pt;color:#000000;">through clinical development in</span><span style="color:#000000;font-size:10pt;"> additional indications, including DR and RVO</span><span style="font-size:10pt;color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Advance YUTIQ 50 </span><span style="font-size:10pt;color:#000000;">through clinical development under a potential sNDA filing as a six-month sustained delivery treatment for chronic non-infectious uveitis affecting the posterior segment of the eye.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Identify and in-license, partner or acquire </span><span style="font-size:10pt;color:#000000;">additional transformative ophthalmology products to build long-term stockholder value targeting programs that can utilize our Durasert technology.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Grow commercial product revenues </span><span style="font-size:10pt;color:#000000;">for both YUTIQ and DEXYCU in the U.S. and reach franchise break-even financial performance.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;color:#000000;">Leverage our Durasert and Verisome drug delivery technologies</span><span style="font-size:10pt;color:#000000;"> through research collaborations and out-licenses with other pharmaceutical and biopharmaceutical companies, institutions and other organizations. We believe these technologies can provide sustained, targeted delivery of therapeutic agents, resulting in improved therapeutic effectiveness, safer administration and better patient compliance and convenience, with reduced product development risk and cost.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Unmet Need in the Treatment of Eye Disease</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are primarily focused on diseases affecting the posterior segment of the eye, particularly retinal diseases. Diseases of the retina of the eye include conditions such as wet AMD, DR, and RVO. These diseases share an underlying propensity to cause leakage from either pre-existing damaged blood vessels or new vessels (neovascularization) in the back of the eye, that, if untreated, can lead to severe visual loss. We also have an FDA-approved corticosteroid implant called YUTIQ which is indicated in chronic non-infectious uveitis a posterior segment eye disease. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hese conditions can lead to retinal damage, scarring and irreversible loss of vision. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of these disease</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are treated locally with </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intravitreal injections. However, there are several limitations of frequent intravitreal injections. First, these injections can be </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uncomfortable and may</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in rare cases,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cause infection or severe bleeding inside the eye.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant issue</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with intravitreal injections of anti-VEGF medications for diseases like wet AMD and DR, however</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is the frequency and duration of the therapy.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many patients with retinal </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other posterior</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> segment</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diseases </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such as non-infectious uv</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eitis </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require lifelong treatment</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Further, most ocular drugs are delivered via a bolus injection that requires monthly or bi-monthly re-injections.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of this intense and long lasting therapeutic regimen, interruptions in therapy can result in disease reactivation and permanent visual loss</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Thus, monthly or bi-monthly injections are not an effective </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">long term </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means of delivering a steady state dose to the site of disease</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">many patients</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Finally, the risk of patient non-compliance increases when treatment involves multiple products or complex or painful dosing regimens, as patients age or suffer cognitive impairment or serious illness, or when the treatment is lengthy or expensive.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug delivery for treating ophthalmic diseases in posterior segments of the eye is a significant challenge. Due to the effectiveness of the blood-eye barrier, it is difficult for systemically (orally or intravenously) administered drugs to reach the retina in sufficient quantities to have a beneficial effect without causing adverse side effects to other parts of the body.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the drawbacks of frequent intravitreal injections, we believe the development of methods to deliver drugs to patients in a more precise, micro dose zero order release kinetics over longer periods of time with Durasert can satisfy a large patient and physician unmet medical need. In addition, with less frequent injections, we believe patients will be able to comply better with their prescribed treatment regimen as the burden of having to frequently go into the physician&#8217;s office for eye injections, usually over a lifetime after diagnosis, presents issues for patients.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Durasert Technology Platform</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Durasert technology platform uses proprietary sustained release technology to deliver drugs over periods of weeks, months or years through a single intravitreal injection. To date, four products utilizing successive generations of the Durasert technology have been approved by the FDA. In addition to our own YUTIQ, these products include ILUVIEN (FA intravitreal implant) 0.19 mg, licensed to Alimera Sciences Inc. (&#8220;Alimera&#8221;), and Retisert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (FA intravitreal implant) 0.59 mg and Vitrasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (ganciclovir) 4.5 mg, which are both licensed to Bausch&#160;&#38; Lomb. The earlier ophthalmic products that utilize the Durasert technology, Retisert and Vitrasert, are surgically implanted&#59; ILUVIEN and YUTIQ were designed to be injected during a physician office visit.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Durasert technology platform creates a solid, injectable, sustained release insert of a small molecule compound that can deliver a drug for periods of weeks, months or years. The current FDA-approved Durasert products utilize the non-erodible formulation of Durasert. For these products, the drug core matrix is coated with one or more polymer layers, and the permeability of those layers and other design aspects control the rate and duration of drug release. By changing elements of the design, we can alter both the rate and duration of release to meet different therapeutic needs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Durasert technology platform is designed to provide sustained delivery of drugs for ophthalmic diseases and conditions with the following features:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Extended Delivery</span><span style="font-size:10pt;color:#000000;">. The delivery of drugs for predetermined periods of time ranging from months to years. We believe that uninterrupted, sustained delivery offers the opportunity to develop products that reduce the need for repeated applications, thereby reducing the risks of patient noncompliance and adverse effects from repeated administrations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Controlled Release Rate</span><span style="font-size:10pt;color:#000000;">. The release of therapeutics at a zero-order kinetics controlled rate. We believe that this feature allows us to develop products that deliver optimal concentrations of therapeutics over time and eliminate excessive variability in dosing during treatment.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Local Delivery</span><span style="font-size:10pt;color:#000000;">. The delivery of therapeutics directly to a target site. We believe this administration can allow the natural barriers of the body to isolate and assist in maintaining appropriate concentrations at the target site to achieve the maximum therapeutic effect while minimizing unwanted systemic effects.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Candidates</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EYP-1901 for wet AMD, DR and RVO</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EYP-1901 is a<span style="Background-color:#FFFFFF;"> potential six-month sustained delivery anti-VEGF treatment</span> that utilizes a bioerodible formulation of the Durasert technology with <span style="Background-color:#FFFFFF;">vorolanib, a TKI that has demonstrated anti-VEGF activity.</span> The bioerodible formulation eliminates the non-erodible polymer coating allowing the body to absorb the drug core matrix and potentially allow for regular re-injection.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vorolanib, the active drug candidate in EYP-1901, is a small molecule TKI that blocks all 3 isoforms of VEGFR, the main driver of the proliferation of blood vessels that are the hallmark of wet AMD. Vorolanib has been previously studied in Phase 1 and 2 clinical trials by Tyrogenix, Inc. (&#8220;Tyrogenix&#8221;) as an orally delivered therapy for the treatment of wet AMD and data from these trials demonstrated a positive clinical signal. Although the Phase 2 clinical trial was discontinued due to systemic toxicity, no significant ocular adverse events were observed in either clinical <span style="color:#000000;">trial</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Market Opportunity in wet AMD</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W<span style="Background-color:#FFFFFF;">et AMD occurs when new, abnormal blood vessels grow under the retina. These vessels may leak blood or other fluids, causing scarring of the macula. This form of AMD is less common but much more serious. AMD is one of the major causes of vision loss of the total vision impairment globally. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As the proportion of people in the U.S. age 65 and older grows larger, more people are developing age-related diseases such as AMD. From 2000-2010, the number of people with AMD grew 18 percent, from 1.75 million to 2.07 million. By 2050, the estimated number of people with AMD is expected to more than double from 2.07 million to 5.44 million. White Americans are expected to continue to account for the majority of cases. However, Hispanics are expected to account for the greatest rate of increase, with a nearly six-fold rise in the number of expected cases from 2010 to 2050.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Age is the greatest risk factor for developing AMD and individuals aged 50+ are more prone to the disease. Among all AMD patients in the United States, wet AMD accounts for only 10% of cases, yet it alone accounts for 90% of legal blindness.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">There are several effective and safe treatments for wet AMD available on the market, including anti-VEGF intravitreal injectable drugs marketed under the brands names Lucentis, Eylea, Beovu, and Avastin (off label use). However, these treatments must be injected in a physician&#8217;s office either monthly, bi-monthly or every three months, which can cause inconvenience and discomfort and often lead to reduced compliance and poor outcomes. The branded drug, SUSVIMO&#8482;, a port delivery technology for ranibizumab, was approved by the FDA in 2021 and requires an initial surgical placement of the port. The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg continuously delivered via the SUSVIMO implant with refills approximately every 6 months.&#160;&#160;In January 2022, the FDA approved faricimab (VABYSMO</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><span style="Background-color:#FFFFFF;">), an intravitreal bispecific antibody angiopoietin-2 (&#8220;Ang-2&#8221;) and vascular endothelial growth factor A (&#8220;VEGF-A&#8221;) inhibitor.&#160;&#160;Results from two Phase 3 studies in wet AMD showed that by week 48, nearly 80% of the patients in the faricimab arm had achieved a 12- or 16-week treatment interval, and in particular 45% achieved a 16-week interval. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Separate published studies using real world data (one study in the U.S. and another that includes Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela) indicate that despite initial efficacy, approved wet AMD treatments still result in vision loss over time.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We believe that EYP-1901, as a potential six-month sustained delivery maintenance therapy, has the potential to offer wet AMD sufferers a convenient and effective treatment option, if approved.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Market Opportunity in DR</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DR is a frequent complication of diabetes mellitus. Slow but progressive changes in the small blood vessels of the retina may cause no symptoms or only mild vision problems in early stages. As the disease progresses, retina bleeding and fluid accumulation can eventually lead to blindness. Diabetes is the leading cause of new cases of blindness in adults. This is a growing problem as the number of people living with diabetes increases, so does the number of people with impaired vision due to DR. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The central retina area that is located between the main branches (superior and inferior arcades) of the central retinal vessels in the eye is known as the &#8220;macular area&#8221;. The retina beyond this is considered &#8220;peripheral retina&#8221;. The central retinal area can develop abnormal findings in DR. These findings can be present in the non-proliferative or the proliferative forms of the disease. These changes in the macula include the presence of abnormally dilated small vessel outpouchings (called microaneurysms), retinal bleeding (retinal hemorrhages) and yellow lipid and protein deposits (hard exudates). The macula can get thicker than normal, referred to as macular edema (DME). </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-proliferative retinopathy (&#8220;NPDR&#8221;) can be classified into mild, moderate or severe stages based upon the presence or absence of retinal bleeding, abnormal venous beading of the vessel wall (venous beading) or abnormal vascular findings (intraretinal microvascular anomalies or &#8220;IRMA&#8221;). No treatment is usually done at this stage. Proliferative retinopathy (&#8220;PDR&#8221;) is progressive and requires treatment to prevent bleeding and scar tissue formation. Macular edema is a complication of DR and is a major cause of vision loss in a diabetic eye.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Market Opportunity in RVO</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RVO is a common cause of vision loss in older individuals with over 90% of cases occurring in patients over the age of 55 years. It is the second most common retinal vascular disease after DR. In 2015, the global prevalence of BRVO and CRVO in people aged 30-89 years was 0.64% and 0.13%, translating to a total of 23.38 million and 4.67 million affected individuals respectively. As in wet AMD, the hypoxic retinal tissue in RVO releases VEGF and inflammatory mediators, thereby inducing the complication of macular edema, a cause of significant visual acuity loss.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Development</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The IND application for EYP-1901 was filed with the FDA in December 2020 in support of initiation of a Phase 1 clinical trial in wet AMD patients. We enrolled the first patient dosed in the Phase 1 DAVIO clinical trial in January 2021 and announced the completion of enrollment in May 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1 DAVIO clinical trial is a dose escalation trial that enrolled 17 wet AMD patients across 4 separate doses. The primary endpoint of the trial is safety, and key secondary endpoints are best corrected visual acuity (&#8220;BCVA&#8221;) and central subfield thickness.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we reported positive interim six-month safety and efficacy data for the DAVIO clinical trial. There were no ocular Serious Adverse Events (&#8220;SAEs&#8221;) reported, no drug-related systemic SAEs reported and all ocular adverse events (&#8220;AEs&#8221;) were &#8804; grade 2&#59; the only grade 3 AE was not drug-related. Regarding efficacy, stable visual acuity (&#8220;VA&#8221;) and optical coherence tomography (&#8220;OCT&#8221;) and a clinically significant reduction in treatment burden of 79% was observed with the median time to rescue was 6 months. The six-month interim data also reported that 53% of patients in the trial did not require a supplemental anti-VEGF treatment up-to the six-month visit.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, we updated the results of the DAVIO clinical trial through 8-months reporting continued positive safety and efficacy results. This included a continuation of a clinically significant reduction in treatment burden of 75% at 8 months. The eight-month interim data also reported that 41% of patients in the trial did not require a supplemental anti-VEGF treatment up-to the nine-month visit.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A randomized controlled Phase 2 trial for EYP-1901 for wet AMD is anticipated to initiate in the third quarter of 2022. This trial is expected to enroll approximately 144 patients across three arms comprised of two separate doses of EYP-1901 with an aflibercept control. We also anticipate leveraging Phase 1 clinical findings and observations around biomarkers to refine Phase 2 clinical trial design. In addition, a Phase 2 trial in DR is expected to initiate in the second half of 2022 following the initiation of the Phase 2 wet AMD trial.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, we entered into an Exclusive License Agreement with Equinox Science, LLC<span style="Background-color:#FFFFFF;"> (&#8220;Equinox&#8221;), pursuant to which Equinox granted us an exclusive, sublicensable, royalty-bearing right and license to certain patents and other Equinox intellectual property to research, develop, make, have made, use, sell, offer for sale and import the compound vorolanib and any pharmaceutical products comprising the compound for the prevention or treatment of wet AMD, DR and RVO using our proprietary localized delivery technologies, in each case, throughout the world except China, Hong Kong, Taiwan and Macau (the &#8220;Territory&#8221;).</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In consideration for the rights granted by Equinox, we (i) made a one time, non-refundable, non-creditable upfront cash payment of $1.0 million to Equinox in February 2020, and (ii) agreed to pay milestone payments totaling up to $50 million upon the achievement of certain development and regulatory milestones, consisting of (a) completion of a Phase 2 clinical trial for the compound or a licensed product, (b) the filing of a new drug application or foreign equivalent for the compound or a licensed product in the United States, European Union or United Kingdom and (c) regulatory approval of the compound or a licensed product in the United States, European Union or United Kingdom.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We also agreed to pay Equinox tiered royalties based upon annual net sales of licensed products in the Territory. The royalties are payable with respect to a licensed product in a particular country in the Territory on a country-by-country and licensed product-by-licensed product basis until the later of (i) twelve years after the first commercial sale of such licensed product in such country and (ii) the first day of the month following the month in which a generic product corresponding to such licensed product is launched in such country (collectively, the &#8220;Royalty Term&#8221;). </span>The royalty rates range from the high-single digits to low-double digits depending on the level of annual net sales. The royalty rates are subject to reduction during certain periods when there is no valid patent claim that covers a licensed product in a particular country.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, we entered into an Asset Purchase Agreement with Aerpio Pharmaceuticals Inc. (&#8220;Aerpio&#8221;), pursuant to which we acquired all right title and interest in and to certain US and ex-US patents and applications relating to certain Tie-2 activating molecules for a one-time cash payment of $450,000. The assets we acquired from Aerpio included hundreds of patents and applications.</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">YUTIQ 50 </p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">YUTIQ 50 is a potential six-month sustained delivery treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, using the same non-erodible Durasert formulation and steroid (FA) as in YUTIQ. This program is designed to offer an intravitreal micro insert with a shorter delivery period, providing physicians with flexibility for multiple dosing intervals. Our market research has indicated a strong preference amongst those physicians surveyed for a six to nine-month drug delivery product in addition to the three-year drug delivery option provided by YUTIQ. Although we believe many patients would likely opt for a longer-acting treatment option, some doctors may prefer to initially treat their uveitis patients over shorter time periods. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We dosed the first patient in a Phase 3 clinical trial in </span><span style="Background-color:#FFFFFF;">November 2021</span><span style="Background-color:#FFFFFF;">. This </span><span style="Background-color:#FFFFFF;">trial is a prospective, randomized trial comparing</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">a single injection of YUTIQ 50 compared to sham injection. The trial includes 60 patients (30 active + 30 sham) with chronic uveitis (all non-infections etiologies, including post-operative). Its primary endpoint is rate of uveitis recurrence at 6 months post-injection.</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">We </span><span style="Background-color:#FFFFFF;">will provide additional information on the expected timing of the data release when available</span><span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Commercial Products</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">YUTIQ (fluocinolone acetonide intravitreal implant or &#8220;FA&#8221; 0.18 mg) for intravitreal injection, was approved by the FDA in October 2018 and we commercially launched YUTIQ in the U.S. in February 2019. YUTIQ is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is a once every three-year treatment utilizing a nonerodable formulation of our proprietary Durasert technology that is administered during a physician office visit.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to commercialization of YUTIQ in the U.S., we have licensed (i) regulatory, reimbursement and distribution rights to the product to Alimera for Europe, Middle East, and Africa (&#8220;EMEA&#8221;)<span style="font-weight:bold;font-style:italic;"> </span>under its ILUVIEN tradename and (ii)&#160;clinical development, regulatory, reimbursement and distribution rights to Durasert FA to Ocumension Therapeutics (&#8220;Ocumension&#8221;) for Mainland China, Hong Kong, Macau, Taiwan, South Korea and <span style="color:#000000;">other jurisdictions across&#160;Southeast Asia</span>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Market Opportunity</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic non-infectious uveitis affecting the posterior segment of the eye is an inflammatory disease that afflicts people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision&#160;loss and blindness. This disease affects between 60,000 to 100,000 people each year in the U.S. and causes approximately 30,000 new cases of blindness every year. The standard of care treatment for this disease typically involves the use of short-acting corticosteroids to reduce uveitic flares followed by additional treatments of sustained release, lower dose steroids to minimize the risk of further flares.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Clinical Development Highlights</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">CALM real world registry study is ongoing and collecting real world data on YUTIQ for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment. There were two initial baseline posters presented at the American Society of Retina Specialists (&#8220;ASRS&#8221;) and Retina Society conferences in 2021. Additional data will be analyzed and presented or published as the study continues and the data are analyzed.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">A Phase 4 Study, the SYNCRONICITY study, of YUTIQ&#174; (fluocinolone acetonide intravitreal implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis is expected to start in the first quarter of 2022. This is a 2-year, prospective, open-label, uncontrolled, safety and efficacy study. Its objective is to evaluate the safety and efficacy of YUTIQ&#174; for the management of chronic non-infectious posterior segment uveitis that has responded to previous steroid therapy. We plan to enroll approximately 125 subjects with at least 100 subjects expected to complete 2 years of follow-up. The primary efficacy endpoints will be evaluated at 6 months and will be as follows: 1) Mean change from baseline in BCVA letter score in the study eye measured by Early Treatment Diabetic Retinopathy Study (&#8220;ETDRS&#8221;) visual acuity charts and 2) Mean change from baseline central subfield thickness (&#8220;CST&#8221;, also known as central foveal thickness) measured by spectral domain optical coherence tomography (&#8220;SD-OCT&#8221;) in the study eye.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own the rights for YUTIQ<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> in the U.S. and all foreign jurisdictions and have licensed these rights in EMEA and Mainland China, Hong Kong, Macau and Taiwan. <span style="color:#000000;">In August 2020, we expanded the out-license agreement with Ocumension to include South Korea&#160;and other jurisdictions across&#160;Southeast Asia. </span>We have patent rights for YUTIQ<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> in the U.S. through at least August 2027 and internationally through dates ranging from October 2024 to May 2027.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Sales and Marketing</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">YUTIQ was granted a permanent and specific J-code </span><span style="color:#000000;">by the </span>Centers for Medicare&#160;&#38; Medicaid Services (&#8220;CMS&#8221;),<span style="Background-color:#FFFFFF;"> effective October&#160;1, 2019</span><span style="color:#000000;">.</span><span style="Background-color:#FFFFFF;"> Approximately 19 Key Account Managers (&#8220;KAMs&#8221;) are dedicated to calling on uveitis and retinal specialists across the U.S. as of February 28, 2022.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the retinal and uveitis markets were impacted by the Pandemic as most teaching hospitals and many independent practices significantly reduced the patient access and flow into the clinics. As a result, many patients were unable to receive the treatments needed to control the inflammatory disease in a timely manner. We started to see customer demand return in the third and fourth quarter of 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, the pandemic continued to impact the ability of KAMs to promote YUTIQ, especially in the institutional segment.&#160;&#160;However, there was a significant expansion of utilization in the retinal segment and the fourth quarter of 2021 saw record sales and customer demand.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU (dexamethasone intraocular suspension) 9%, for intraocular administration, was approved by the FDA in February 2018 for the treatment of post-operative ocular inflammation and commercially launched in the U.S. in March 2019 with a primary focus on its use immediately following cataract surgery. DEXYCU is administered as a single dose directly into the surgical site at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes our proprietary Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> drug-delivery technology, which allows for a single intraocular injection that releases dexamethasone, a corticosteroid, for up to 22 days.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Market Opportunity</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU is approved for ocular post-surgical inflammation. The initial market we have focused on for DEXYCU is post-operative inflammation associated with cataract surgery as there were approximately 3.8&#160;million cataract surgeries performed in 2018 in the U.S.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the launch of DEXYCU, the standard of care for post-operative reduction of inflammation and pain in cataract surgery had been a combination of steroid, antibiotic and non-steroidal eye drops administered multiple times each day over a period of several weeks.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Clinical Development Highlights</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Retrospective study data were presented at the Association for Research in Vision and Ophthalmology (&#8220;ARVO&#8221;) and American Society of Cataract and Refractive Surgery (&#8220;ASCRS&#8221;) 2021. This completed study was a multicenter retrospective study of real world data from use of DEXYCU. ARVO 2021 data from this study highlighted real world data in patients with a history of glaucoma treated with DEXYCU for inflammation control following cataract surgery. Anti-inflammatory efficacy, as measured by anterior chamber cell (&#8220;ACC&#8221;) count clearing and safety with regard to intraocular pressure (&#8220;IOP&#8221;) elevation were similar in patients with glaucoma to the full study population.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own the worldwide rights to all indications for DEXYCU<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> and in January 2020 we out-licensed clinical development, regulatory, reimbursement and distribution rights to Ocumension for the product in Mainland China, Hong Kong, Macau and Taiwan. <span style="color:#000000;">In August 2020, we expanded the out-license agreement with Ocumension to include South Korea&#160;and other jurisdictions across&#160;Southeast Asia.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales and Marketing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2022, our commercial alliance partner, ImprimisRx, assumed responsibility for all sales and marketing activities for DEXYCU in the U.S. and absorbed the majority of our DEXYCU commercial organization. We will continue to recognize net product revenue and maintain manufacturing and distribution responsibilities for DEXYCU along with non-sales related regulatory compliance. We will pay ImprimisRx a commission based on the net sales of DEXYCU and will retain all commercial rights and the NDA for DEXYCU. <span style="color:#000000;">ImprimisRx is utilizing their internal sales representatives and their numerous indirect representatives to promote DEXYCU to their existing cataract surgery customers.</span> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2018, DEXYCU was granted &#8220;pass through status&#8221; by the CMS that provides for reimbursement of DEXYCU separate from the cataract procedure payment bundle for a 3-year period. The 3-year period commenced in April 2019, the quarter that the first claim for reimbursement for DEXYCU was made with CMS and will expire in March 2022. In addition, in November 2018, CMS assigned a specific and permanent J-code for DEXYCU, effective January&#160;1, 2019, that enabled reimbursement across all types of payers. <span style="color:#000000;">In the 2022 CMS Hospital Outpatient Prospective Payment System Final Rule, which was released in November of 2021, CMS decided that DEXYCU would receive adjusted separate payment for nine months equivalent to an extension of pass through status through December 31, 2022 as a result of the Public Health Emergency which limited access to many therapies provided in the ASC or outpatient setting.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of the Pandemic has been significant on the cataract market as elective surgeries were completely eliminated or vastly reduced in many parts of the country for extended periods of time in 2020. <span style="color:#000000;">We started to see customer demand return in the third and fourth quarter of 2020. In 2021, cataract procedures returned to near normal levels in most areas until the outbreak of the Omicron variant. Several states, localities, and health systems again recommended postponing some elective surgeries which impacted access to cataract procedures in the fourth quarter of 2021. </span>At this time, it is unknown how long the Pandemic will continue to impact patient access to these procedures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA regulates the quality of pharmaceuticals very carefully.&#160;The main regulatory standard for ensuring pharmaceutical quality is the Current Good Manufacturing Practice (&#8220;cGMPs&#8221;) regulation for human pharmaceuticals. Manufacturing of our clinical trial materials (&#8220;CTM&#8221;) and of our commercial products is subject to these cGMPs which govern record-keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among other activities. Incoming raw materials and components from suppliers are inspected upon arrival according to pre-specified criteria prior to use in the CTM or the commercial product. During product manufacture, in-process tests are conducted on intermediate products according to pre-specified criteria&#59; testing is finally conducted on the finished product prior to its release. Our systems and our contractors are required to comply with cGMP requirements, and we assess compliance regularly through performance monitoring and audits.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EYP-1901</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production, assembly, and packaging of EYP-1901 CTM is done in the Class&#160;10,000 clean room located at our Watertown, MA facility. We source the active pharmaceutical ingredient (&#8220;API&#8221;) vorolanib from Equinox and various raw materials and components for both EYP-1901 and its injector from third-party vendors. Our agreements with Equinox and these third parties include confidentiality and intellectual property provisions to protect our proprietary rights related to EYP-1901.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">YUTIQ 50</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production, assembly, and packaging of YUTIQ 50 CTM is done in the Class&#160;10,000 clean room located at our Watertown, MA facility. We utilize the same vendors for YUTIQ 50 materials and components as for YUTIQ, as described below. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">YUTIQ</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Production, assembly and packaging of YUTIQ is done in the Class&#160;10,000 clean room located at our Watertown, MA facility. We source the API and various raw materials and components for YUTIQ from third-party vendors. Our agreements with these third parties include confidentiality and intellectual property provisions to protect our proprietary rights related to YUTIQ.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DEXYCU</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently use a contract manufacturer for&#160;the commercial supply of DEXYCU. A separate contract manufacturer provides kitting and packaging of the finished product, and other vendors provide sterilization, testing and storage services. Our agreements with these third parties include confidentiality and intellectual property provisions to protect our proprietary rights related to DEXYCU. We require our contract manufacturers to operate in accordance with cGMPs and all other applicable laws and regulations. We employ personnel with extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S. Sales and Marketing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="color:#000000;"> launched YUTIQ and DEXYCU in the U.S. during the first quarter of 2019 utilizing a contract sales organization (&#8220;CSO&#8221;) model. This model involved the hiring of sales and marketing leadership professionals providing oversight and leadership to the CSO teams. We were able to utilize CSO installed systems and processes for, </span><span style="font-style:italic;color:#000000;">inter alia</span><span style="color:#000000;">, regulatory filings, data tracking, field incentive compensation, training, hiring of KAMS, territory sizing / alignment, sample tracking, and customer relationship management systems. In January 2020, the YUTIQ KAMs were converted to full-time employees from our CSO, and in October of 2020 the DEXYCU KAMs were converted to full-time employees.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Members<span style="color:#000000;"> of our sales and marketing leadership team have extensive commercialization experience with ophthalmic products at previous companies. We have 19 KAMS selling YUTIQ as of February 28, 2022.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2022, our commercial alliance partner, ImprimisRx, assumed responsibility for all sales and marketing activities for DEXYCU in the U.S. and absorbed the majority of our DEXYCU commercial organization.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S. Market Access and Payer Reimbursement</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018 we recruited a team of highly experienced personnel to form our market access team. The team is comprised of our VP of Market Access and Government Affairs, Assoc. Director of Patient Access, Director of National Accounts (&#8220;NAD&#8221;), and Field Reimbursement Managers (&#8220;FRMs&#8221;) who handle the reimbursement for both YUTIQ and DEXYCU. Their roles include the discussions with payers regarding the costs and benefits of our products for their members&#59; assisting with the addition of our products to the medical policy of payers&#59; and providing the market with assistance regarding reimbursement queries.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated a patient assistance platform called EyePoint Assist<sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup> to provide co-pay and coinsurance relief for eligible commercial patients.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement for YUTIQ is obtained using a permanent J code, established October 1, 2019, which enables reimbursement from both Medicare and commercial payers. DEXYCU has three-year pass through status with Medicare whereby it is routinely reimbursed for Medicare Part&#160;B patients. The issuance of a specific and permanent J code for DEXYCU in November 2018 has enabled our market access team to work with non-Medicare payers with regard to adding DEXYCU to their medical policies. We believe that products that are reimbursable using a specific J code (as opposed to a C code or miscellaneous J code) are simpler for payers to process and therefore have a greater likelihood of reimbursement.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S. Product Distribution Channel </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a distribution channel in the United States for the commercialization of YUTIQ and DEXYCU that provides physicians with several options for ordering our products. This includes agreements with a nationally recognized third-party logistics provider (&#8220;3PL&#8221;), several distributors and a specialty pharmacy provider for physicians who prefer to use a traditional buy-and-bill model. The 3PL provides fee-based services related to logistics, warehousing, order fulfilment, invoicing, returns and accounts receivable management.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time we enter into research agreements with third parties to evaluate our technology platforms for the treatment of ophthalmic and other diseases. We intend to continue this activity with partner compounds that could be successfully delivered with our Durasert and, potentially, Verisome technology platforms on a fee-for-service basis with the potential for future clinical and commercial milestones and royalties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FDA Approved Products Licensed to Others</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ILUVIEN for DME</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ILUVIEN is an injectable, sustained-release micro-insert based on our Durasert technology platform and delivers 0.19 mg of FA to the back of the eye for treatment of DME. DME is a disease suffered by diabetics where leaking capillaries cause swelling in the macula, the most sensitive part of the retina. DME is a leading cause of blindness in the working-age population in most developed countries. The ILUVIEN micro-insert is substantially the same micro-insert as YUTIQ.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We originally licensed our Durasert proprietary insert technology to Alimera for use in ILUVIEN for the treatment of all ocular diseases (excluding uveitis). On July 10, 2017, we entered into the Amended Alimera Agreement, pursuant to which we (i) expanded the license to Alimera to our proprietary Durasert sustained-release drug delivery technology platform to include uveitis, including chronic non-infectious uveitis affecting the posterior segment of the eye, in the EMEA and (ii) converted the net profit share arrangement for each licensed product (including ILUVIEN) under the original collaboration agreement with Alimera (the &#8220;Prior Alimera Agreement&#8221;) to a sales-based royalty on a calendar quarter basis commencing July 1, 2017, with payments from Alimera due 60 days following the end of each calendar quarter.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales-based royalties started at the rate of 2% and increased, commencing December&#160;12, 2018, to 6% on aggregate calendar year net sales up to $75&#160;million and 8% in excess of $75&#160;million. Alimera&#8217;s share of contingently recoverable accumulated ILUVIEN commercialization losses under the Prior Alimera Agreement, capped at $25&#160;million, are to be reduced as follows: (i) $10.0&#160;million was cancelled in lieu of an upfront license fee on the effective date of the Amended Alimera Agreement&#59; (ii)&#160;for calendar years 2019 and 2020, 50% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments otherwise due from Alimera&#59; (iii)&#160;in March 2020, another $5&#160;million was cancelled upon Alimera&#8217;s receipt of regulatory approval for ILUVIEN for the uveitis indication&#59; and (iv)&#160;commencing in calendar year 2021, 20% of earned sales-based royalties in excess of 2% will be offset against the quarterly royalty payments due from Alimera until such time as the balance of the original $25&#160;million of recoverable commercialization losses has been fully recouped. On <span style="Background-color:#FFFFFF;color:#000000;">December&#160;17, 2020, we sold our interest in royalties payable to us under our license agreement with Alimera in connection with Alimera&#8217;s sales of ILUVIEN</span><span style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="Background-color:#FFFFFF;color:#000000;"> to SWK Funding, LLC (&#8220;SWK&#8221;) in exchange for a one-time $16.5 million payment from SWK.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Retisert for chronic non-infectious uveitis affecting the posterior segment of the eye</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Retisert is a sustained-release non-erodible implant based on our Durasert technology platform for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Surgically implanted, it delivers 0.59 mg of FA to the back of the eye for approximately 30 months. Retisert is licensed to Bausch&#160;&#38; Lomb, with which we co-developed the product. Retisert is approved in the U.S., Bausch&#160;&#38; Lomb sells the product and paid sales-based royalties to us. The patent with which Retisert is marketed expired in March 2019. As such, pursuant to our agreement with Bausch &#38; Lomb, payment of sales-based royalties concluded at the end of March 2019 following patent expiration.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategic Collaborations</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into a number of collaboration/license agreements to develop and commercialize our product candidates and technologies. In all of these agreements, we have retained the right to use and develop the underlying technologies outside of the scope of the exclusive licenses granted. The license and collaboration arrangements typically include, among other terms and conditions, non-refundable upfront license fees, milestone payments and royalty and/or profit sharing obligations.<span style="Background-color:#FFFFFF;color:#212529;font-family:Calibri;"> </span>See Note 3, "<span style="font-size:12pt;"> </span>Product Revenue Reserves and Allowances-License and Collaboration Agreements" to the Consolidated Financial Statements included under Item 15, "Exhibits and Financial Statement Schedules."</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or license patents in the U.S. and other countries. Our patents generally cover the design, formulation, manufacturing methods and use of our sustained release therapeutics, devices and technologies. For example, we own and/or license US and foreign patents and patent applications for our DURASERT&#174; technology and our VERISOME&#174; technology.&#160;&#160;In addition, we own US and foreign patents and patent applications covering other technologies, such as devices used to administer some of our products. Patents for individual products extend for varying periods according to the date of patent filing or grant and legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends upon the type of patent, the scope of its coverage and the availability of legal remedies in the country. Patent term extension may be available in various countries to compensate for a patent office delay or a regulatory delay in approval of the product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. patents that were previously listed in the USFDA Orange Book for Retisert expired in March 2019. The latest expiring patent listed in the USFDA Orange Book covering ILUVIEN<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> and YUTIQ<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> expires in August 2027 in the U.S. and in October 2024 in the EU, although extensions have been obtained or applied for through May 2027 in various EU countries.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The last of the previously issued patents covering DEXYCU<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> expire in July 2023, but additional patents have issued in the U.S. that will cover DEXYCU<span style="font-weight:bold;font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> until at least 2034.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The last expiring patent covering the vorolanib compound licensed to us by Equinox Science and used in EYP-1901 expires in September 2037, but EyePoint has filed an additional patent application for EYP-1901 that, if issued, would extend coverage of EYP-1901 until at least 2041.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquired Aerpio patent portfolio includes more than 200 US or ex-US patents and pending applications that claim compositions of matter, pharmaceutical formulations and methods of use covering both small molecule and mono and bi-specific antibody inhibitors of the protein tyrosine phosphatase (VE-PTP). Some of the antibodies covered include both VE-PTP and VEGF binding domains. VE-PTP is a negative Tie2 regulator that, when inhibited, can activate the Tie2 pathway leading to downstream signaling that promotes vascular health, stability and decreases vascular permeability and inflammation associated with a number of posterior segment eye diseases. The patent claims to methods of use relate primarily to disease indications where activation of Tie2 and associated vascular stabilization are potentially beneficial. The potential expiration dates of the patents and applications in this portfolio range from 2027 to 2041. This date range is estimated and based on certain assumptions, including that certain applications will be granted, all necessary fees will be paid and no terminal disclaimers or other limitations on expiration are required for certain patents or applications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To achieve the goals and expectations of our Company, it is critical that we continue to attract and retain top talent.&#160;&#160;To facilitate talent attraction and retention we strive to make our company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits and health and wellness programs, and by programs that build connections between our employees.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2022, <span style="Background-color:#FFFFFF;color:#000000;">we had 123 </span>employees, 122<span style="Background-color:#FFFFFF;"> of whom </span>were full-time employees in the United States. None of our employees are represented by a collective bargaining agreement. During fiscal 2021 our voluntary turnover rate was 10%, which is consistent with the average voluntary turnover rates for Boston-area Biotech companies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are committed to their health, safety, and wellness. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs, including benefits that provide protection and security so that they have peace of mind concerning events that may require time away from work, or that impact their financial well-being, that support their physical and mental health and providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors, and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families.&#160;&#160;In response to the Pandemic we implemented significant changes that we determined were in the best interest of our employees, as well as the communities in which we operate, and which comply with government regulations. This includes having many of our non-laboratory employees work from home, while implementing additional safety measures for employees continuing on-site work.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provide robust compensation and benefits programs to meet the needs of our employees. In addition to competitive base salaries, these programs include annual discretionary bonuses, stock awards, a 401(k) plan and employer match, a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n employee stock purchase</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> program, health, dental and vision insurance benefits, health savings and flexible spending accounts, paid time off, family leave and flexible work schedules, among others. Our broad-based equity programs include all employees with vesting conditions to facilitate the retention of employees with critical skills and experience and motivate employees to perform to the best of their abilities, while </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we achieve our </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">objectives.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our workforce &#8211; from working with managers to recruit diverse team members to the advancement of leaders from different backgrounds.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market for products treating eye diseases is highly competitive and is characterized by extensive research efforts and rapid technological progress. We face substantial competition for our FDA-approved products and our product candidates. Pharmaceutical, drug delivery and biotechnology companies, as well as research organizations, governmental entities, universities, hospitals, other nonprofit organizations and individual scientists, have developed and are seeking to develop drugs, therapies and novel delivery methods to treat diseases targeted by our products and product candidates. Most of our competitors and potential competitors are larger, better established, more experienced and have substantially more resources than we or our partners have. Competitors may reach the market earlier, may have obtained or could obtain patent protection that dominates or adversely affects our products and potential products, and may offer products with greater efficacy, lesser or fewer side effects and/or other competitive advantages. We believe that competition for treatments of eye diseases is based upon the effectiveness of the treatment, side effects, time to market, reimbursement and price, reliability, ease of administration, dosing or injection frequency, patent position and other factors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have or are pursuing products to treat eye diseases that are or would be competitive with EYP-1901, YUTIQ 50, YUTIQ, and DEXYCU. Some of these products and product candidates include the following: </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EYP-1901 for Wet Age-Related Macular Degeneration<span style="font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wet AMD, a common condition and a leading cause of vision loss for people age 50 and older, is most commonly treated with intravitreal injections of biologics that block VEGF. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA-approved LUCENTIS and EYLEA and off-label use of the cancer drug AVASTIN<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> are the leading treatments for wet AMD. EYLEA was approved for dosing every 12 weeks after one year of effective therapy. In 2021, the FDA approved Susvimo, a first-of-its-kind port delivery system (&#8220;PDS&#8221;) with ranibizumab for the treatment of patients with wet, or neovascular, AMD who have previously responded to at least 2 anti-VEGF injections. In January 2022 the FDA approved VABYSMO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (faricimab), an intravitreal bispecific antibody Ang-2 and VEGF-A inhibitor. The FDA also approved Beovu&#174; brolucizumab injection on October 8, 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of several other companies that are actively developing product candidates for wet AMD. Kodiak Sciences is developing KSI-301, an anti-VEGF antibody biopolymer conjugate being developed for treatment-na&#239;ve wet AMD, DME, RVO and NPDR. Graybug Vision, Inc.&#8217;s, GB-102, is an intravitreal injectable depot formulation of sunitinib malate, an anti-VEGF TKI, that blocks multiple angiogenesis pathways. Ocular Therapeutix, Inc. is developing OTX-TKI, a bioresorbable hydrogel formulated with TKI particles in an injectable fiber that can be delivered through a small-gauge, sterile injection needle to the back of the eye. OTX-TKI is designed to deliver drugs to the target tissues for a period of up to nine months. Aerie Pharmaceuticals is developing AR-13503, an inhibitor of rho kinase and protein kinase C (&#8220;PKC&#8221;), is a sustained-release implant being investigated for the treatment of wet AMD and DME. Clearside Biomedical is developing CLS-AX (axitinib injectable suspension for investigation in patients with neovascular wet AMD.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REGENXBIO Inc. and Adverum Biotechnologies, Inc. are developing gene therapy treatments for wet AMD. REGENXBIO is developing RGX-314, a gene therapy utilizing its NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment which inhibits VEGF. Adverum is developing ADVM-022, a gene therapy utilizing an AAV.7m8 vector containing a gene encoding for a protein that expresses aflibercept.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EYP-1901 for DR </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to their efficacy at treating wet AMD, anti-VEGF drugs Avastin, Lucentis and Eylea, have all been shown in a number of studies to have promise for halting and reversing DR. Looking towards the future, the treatment intervals and follow-up required to maintain improvements in DR and PDR will need to be determined, but long-acting anti-VEGF agents and small molecules, such as TKIs, formulated in novel sustained&#160;delivery methods have the potential to transform&#160;the DR treatment landscape. We anticipate that the anti-VEGF programs being developed by competitors for wet AMD, listed above, may have application in DR as well.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EY</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">P</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">-1901 for RVO </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mainstay of therapy is now anti-VEGF therapy for macular edema with either CRVO or BRVO. Both Lucentis and Eylea have been shown to be efficacious in the treatment of macular edema. Avastin (bevacizumab) is also used off-label to treat macular edema. RVO physiopathology is highly dependent on VEGF levels resulting from retina ischemia and requires frequent intravitreal injections of current therapies. Therefore, long-acting anti-VEGF agents and small molecules, such as TKIs, formulated in novel sustained delivery methods and being developed for wet AMD and DR have the potential to transform the treatment landscape in this condition as well. We anticipate that the anti-VEGF programs being developed by competitors for wet AMD, listed above,&#160;&#160;may have application in RVO as well.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">YUTIQ and YUTIQ 50 for Posterior Segment Uveitis </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periocular and intravitreal steroid injections, and systemic delivery of corticosteroids are routinely used to treat posterior segment uveitis, which is a chronic, inflammatory condition of the eye. It is treated both aggressively and frequently by physicians in order to minimize the disease &#8220;flares&#8221;, which are the main cause of vision deterioration and potential blindness.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OZURDEX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, marketed by Allergan, is approved in the U.S. and EU for posterior segment uveitis through an intravitreal bioerodible implant that provides treatment which lasts for several months. This limited duration effectiveness of OZURDEX can result in frequent intravitreal injections of the implant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie, Inc. has FDA approval for HUMIRA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (adalimumab) for the treatment of all types of non-infectious uveitis (intermediate, posterior and panuveitis) and it is administered subcutaneously every other week for systemic delivery. HUMIRA is a biologic that blocks tumor necrosis factor alpha, a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Humira&#8217;s retail price in the U.S. is approximately $50,000 per year.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other companies have ongoing trials of posterior segment uveitis treatments, including Santen Pharmaceutical Co. Ltd., which received a Complete Response Letter (&#8220;CRL&#8221;), in December 2017 from the FDA for its filed NDA for sirolimus, which is administered through intravitreal injection every two months. Sirolimus is a mammalian target of rapamycin inhibitor and modulator of the immune system and is being developed for chronic non-infectious uveitis affecting the posterior segment of the eye. Santen initiated a Phase 3 clinical trial of sirolimus in December 2018 in the U.S. The study is entitled: LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye, and its primary readout is expected in June 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clearside Biomedical Inc.&#8217;s (&#8220;Clearside&#8221;) CLS-TA (triamcinolone acetonide, a steroid) for macular edema associated with non-infectious uveitis has been accepted by the FDA for review and it is administered through a suprachoroidal injection administered every 12 weeks. Preliminary clinical data indicated that the suprachoroidal route may reduce the risk of increased IOP that is typically associated with intraocular injection of steroids. The results of the Phase 3 trial, presented in September 2018, indicated that while about 50% of patients experienced significant improvements in visual acuity through 24 weeks, adverse events of IOP increase were reported in about 12% of patients. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;19, 2018, Clearside submitted an NDA for XIPERE&#8482; (CLS-TA) to the FDA for the treatment of macular edema associated with uveitis. On October 18, 2019, Clearside received a CRL from the FDA regarding its NDA for XIPERE.<span style="font-size:12pt;"> </span>The CRL included the FDA&#8217;s request for additional stability data, reinspection of the drug product manufacturer and additional data on clinical use of the final to-be-marketed SCS Microinjector&#8482; delivery system.<span style="font-size:12pt;"> </span>Clearside indicated that it expects to resubmit its New Drug Application for XIPERE to FDA for review in the first quarter of 2020. On October 23, 2019, Bausch Health Companies Inc. acquired an exclusive license for the commercialization and development of XIPERE in the United States and Canada. XIPERE was eventually approved in the US in October 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DEXYCU for Inflammation following cataract surgery.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kala Pharmaceuticals, Inc.&#8217;s (&#8220;Kala&#8221;) FDA approved INVELTYS&#8482; (loteprednol etabonate ophthalmic suspension) 1% is a topical treatment for post-operative inflammation and pain following ocular surgery. INVELTYS is the first twice-daily ocular corticosteroid approved for this indication. In addition, there are various formulations of steroids that are produced by&#160;compounding pharmacies&#160;and that are in drop form or are injected into the eye following ocular surgery.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ocular Therapeutix<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8482;</sup> Inc.&#8217;s (&#8220;Ocular&#8221;) FDA approved DEXTENZA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>(dexamethasone ophthalmic insert) 0.4 mg is a corticosteroid intracanalicular insert placed through the punctum, a natural opening in the eye lid, into the canaliculus, and is designed to deliver dexamethasone to the ocular surface for up to 30 days.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bausch &#38; Lomb&#8217;s FDA approved LOTEMAX<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>SM (loteprednol etabonate ophthalmic gel) 0.38% is a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. LOTEMAX SM delivers a submicron particle size for faster drug dissolution in tears.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The Federal Food, Drug and Cosmetic Act (the &#8220;FD&#38;C Act&#8221;), and FDA&#8217;s implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record-keeping, reporting, distribution, import, export, advertising and promotion of our products and product candidates. Although the discussion below focuses on regulation in the U.S., we currently out-license certain of our products and may seek approval for, and market, other products in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope to that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in the EU are addressed in a centralized way through the EMA, and the European Commission, but country-specific regulation remains essential in many respects. The process of obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and may not be successful. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Development and Approval </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FD&#38;C Act, FDA approval of an NDA is required before any new drug can be marketed in the U.S. NDAs require extensive studies and submission of a large amount of data by the applicant. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pre-clinical Testing.<span style="font-style:normal;"> Before testing any compound in human patients in the U.S., a company must generate extensive pre-clinical data. Pre-clinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the toxicity and dosing of the product. Certain animal studies must be performed in compliance with the FDA&#8217;s GLP, regulations and the U.S. Department of Agriculture&#8217;s Animal Welfare Act. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">IND Application.<span style="font-style:normal;"> Human clinical trials in the U.S. cannot commence until an IND, application is submitted and becomes effective. A company must submit pre-clinical testing results to the FDA as part of the IND, and the FDA must evaluate whether there is an adequate basis for testing the drug in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND becomes effective 30&#160;days following its receipt by the FDA, and the clinical trial proposed in the IND may begin. Once human clinical trials have commenced, the FDA may stop a clinical trial by placing it on &#8220;clinical hold&#8221; because of concerns about the safety of the product being tested, or for other reasons. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials.<span style="font-style:normal;"> Clinical trials involve the administration of a drug to healthy human volunteers or to patients under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA&#8217;s bioresearch monitoring regulations and Good Clinical Practice, or GCP, requirements, which establish standards for conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. Each protocol is reviewed by the FDA as part of the IND. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board, or IRB, for each clinical site. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with, as applicable, regulations and guidelines for obtaining informed consent from the study patients, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events, or AEs. Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with GCP and the FDA is able to validate the data. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A study sponsor is required to publicly post specified details about certain clinical trials and clinical trial results on government or independent websites (e.g.,&#160;http://clinicaltrials.gov). Human clinical trials typically are conducted in three sequential phases, although the phases may overlap or be combined: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase&#160;1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase&#160;1 clinical trials generally are intended to evaluate the safety, metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase&#160;2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population and are designed to develop initial data regarding the product&#8217;s effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential AEs. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase&#160;3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained and are intended to gather the additional information about </span><span style="font-size:10pt;color:#000000;">dosage, safety </span><span style="font-size:10pt;color:#000000;">and effectiveness necessary to evaluate the drug&#8217;s overall risk-benefit profile, and to provide a basis for </span><span style="font-size:10pt;color:#000000;">regulatory approval</span><span style="font-size:10pt;color:#000000;">. Generally, Phase&#160;3 clinical development programs consist of expanded, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sponsoring company, the FDA, or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Further, success in early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">NDA Submission and Review.<span style="font-style:normal;"> The FD&#38;C Act provides two pathways for the approval of new drugs through an NDA. An NDA under Section&#160;505(b)(1) of the FD&#38;C Act is a comprehensive application to support approval of a product candidate that includes, among other things, data and information to demonstrate that the proposed drug is safe and effective for its proposed uses, that production methods are adequate to ensure its identity, strength, quality, and purity of the drug, and that proposed labeling is appropriate and contains all necessary information. A 505(b)(1) NDA contains results of the full set of pre-clinical studies and clinical trials conducted by or on behalf of the applicant to characterize and evaluate the product candidate. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;505(b)(2) of the FD&#38;C Act provides an alternate regulatory pathway to obtain FDA approval that permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely to some extent upon the FDA&#8217;s findings of safety and effectiveness for an approved product that acts as the reference drug, and submit its own product-specific data&#160;&#8212; which may include data from pre-clinical studies or clinical trials conducted by or on behalf of the applicant&#160;&#8212; to address differences between the product candidate and the reference drug. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The submission of an NDA under either Section&#160;505(b)(1) or Section&#160;505(b)(2) generally requires payment of a substantial user fee to the FDA, subject to certain limited deferrals, waivers and reductions. The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#8217;s identity, strength, quality, and purity. For some NDAs, the FDA may convene an advisory committee to seek insights and recommendations on issues relevant to approval of the application. Although the FDA is not bound by the recommendation of an advisory committee, the agency usually considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our products and product candidates include products that combine drug and device components in a manner that meet the definition of a "combination product" under FDA regulations. The FDA exercises significant discretion over the regulation of combination products, including the discretion to require separate marketing applications for the drug and device components in a combination product. For YUTIQ, FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221;) had primary jurisdiction for review of the NDA, and both the drug and device components were reviewed under one marketing application. For a drug-device combination product for which CDER has primary jurisdiction, CDER typically consults with the Center for Devices and Radiological Health in the NDA review process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may determine that a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), certain applications for approval must also include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject drug in relevant pediatric populations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP, requirements and adequate to assure consistent production of the product within required specifications. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the FDA accepts an NDA submission for filing&#160;&#8212; which occurs, if at all, within 60&#160;days after submission of the NDA&#160;&#8212; the FDA&#8217;s goal for a non-priority review of an NDA is ten months. The review process can be and often is significantly extended, however, by FDA requests for additional information, studies, or clarification. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After review of an NDA and the facilities where the product candidate is manufactured, the FDA either issues an approval letter or a complete response letter (&#8220;CRL&#8221;), outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional pre-clinical or clinical data, for the FDA to reconsider the application. Even if such additional information and data are submitted, the FDA may decide that the NDA still does not meet the standards for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor. FDA approval of any application may include many delays or never be granted. If FDA grants approval, an approval letter authorizes commercial marketing of the product candidate with specific prescribing information for specific indications.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining regulatory approval often takes a number of years, involves the expenditure of substantial resources, and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials. Additionally, as a condition of approval, the FDA may impose restrictions that could affect the commercial success of a drug or require post-approval commitments, including the completion within a specified time period of additional clinical studies, which often are referred to as &#8220;Phase&#160;4&#8221; or &#8220;post-marketing&#8221; studies. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval modifications to the drug, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional pre-clinical studies or clinical trials, to be submitted in a new or supplemental NDA, which would require FDA approval. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Regulation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once approved, drug products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met, or if safety or manufacturing problems occur after the product reaches the market, the FDA may at any time withdraw product approval or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials, changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution-related restrictions, if there are new safety information developments. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Good Manufacturing Practices.<span style="font-style:normal;"> Companies engaged in manufacturing drug products or their components must comply with applicable cGMP requirements and product-specific regulations enforced by the FDA and other regulatory agencies. Compliance with cGMP includes adhering to requirements relating to organization and training of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, quality control and quality assurance, packaging and labeling controls, holding and distribution, laboratory controls, and records and reports. The FDA regulates and inspects equipment, facilities, and processes used in manufacturing pharmaceutical products prior to approval. If, after receiving approval, a company makes a material change in manufacturing equipment, location, or process (all of which are, to some degree, incorporated in the NDA), additional regulatory review and approval may be required. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product. Failure to comply with applicable cGMP requirements and conditions of product approval may lead the FDA to take enforcement actions or seek sanctions, including fines, issuance of warning letters, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval, seizure or recall of products, and criminal prosecution. Although we periodically monitor the FDA compliance of our third-party manufacturers, we cannot be certain that our present or future third-party manufacturers will consistently comply with cGMP and other applicable FDA regulatory requirements. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to cGMP requirements, drug-device combination products are also subject to certain additional manufacturing and safety reporting regulations for devices. Specifically, the FDA requires that drug-device combination products comply with certain provisions of the Quality System Regulation (&#8220;QSR&#8221;), which sets forth the FDA&#8217;s manufacturing quality standards for medical devices. In addition to drug safety reporting requirements, the FDA also requires that we comply with some device safety reporting requirements for our drug-device combination product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advertising and Promotion.<span style="font-style:normal;"> The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, advertising and promotion to healthcare professionals, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses&#160;&#8212; that is, uses not approved by the FDA and not described in the product&#8217;s labeling&#160;&#8212; because the FDA does not regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers&#8217; communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain conditions may engage in non-promotional, balanced, scientific communication regarding off-label use. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Requirements.<span style="font-style:normal;"> NDA holders must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse drug experiences, and maintaining certain records. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hatch-Waxman Act </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, establishes two abbreviated approval pathways for pharmaceutical products that are in some way follow-on versions of already approved products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Generic Drugs.</span><span style="font-style:normal;"> A generic version of an approved drug is approved by means of an abbreviated NDA, or ANDA, by which the sponsor demonstrates that the proposed product is the same as the approved, brand-name drug, which is referred to as the </span><span style="font-style:normal;">reference listed drug, or </span><span style="font-style:normal;">RLD. Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (</span><span style="font-style:normal;">i</span><span style="font-style:normal;">)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (ii)&#160;are intended for the same uses, and (iii)&#160;are bioequivalent. This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA previously found to be safe and effective. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">505(b)(2) NDAs.<span style="font-style:normal;"> As discussed previously, products may also be submitted for approval via an NDA under section&#160;505(b)(2) of the FD&#38;C Act. Unlike an ANDA, this does not excuse the sponsor from demonstrating the proposed product&#8217;s safety and effectiveness. Rather, the sponsor is permitted to rely to some degree on information from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference and must submit its own product-specific data of safety and effectiveness to an extent necessary because of the differences between the products. An NDA approved under 505(b)(2) may in turn serve as an RLD for subsequent applications from other sponsors. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RLD Patents.<span style="font-style:normal;"> In an NDA, a sponsor must identify patents that claim the drug substance or drug product or a method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </span>Approved Drug Products with Therapeutic Equivalence Evaluations<span style="font-style:normal;">, which is referred to as the </span>Orange Book<span style="font-style:normal;">. The sponsor of an ANDA or 505(b)(2) application seeking to rely on an approved product as the RLD must make one of several certifications regarding each listed patent. A &#8220;Paragraph&#160;I&#8221; certification is the sponsor&#8217;s statement that patent information has not been filed for the RLD. A &#8220;Paragraph II&#8221; certification is the sponsor&#8217;s statement that the RLD&#8217;s patents have expired. A &#8220;Paragraph III&#8221; certification is the sponsor&#8217;s statement that it will wait for the patent to expire before obtaining approval for its product. A &#8220;Paragraph&#160;IV&#8221; certification is an assertion that the patent does not block approval of the later product, either because the patent is invalid or unenforceable or because the patent, even if valid, is not infringed by the new product. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Regulatory Exclusivities.<span style="font-style:normal;"> The Hatch-Waxman Act provides periods of regulatory exclusivity for products that would serve as RLDs for an ANDA or 505(b)(2) application. If a product is a &#8220;new chemical entity,&#8221; or NCE&#160;&#8212; generally meaning that the drug contains no active moiety that has been approved by the FDA in any other NDA submitted under section 505(b) of the FD&#38;C Act&#160;&#8212; there is a period of five years from the product&#8217;s approval during which the FDA may not accept for filing any ANDA or 505(b)(2) application for a drug with the same active moiety. An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a Paragraph&#160;IV certification. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product that is not an NCE may qualify for a three-year period of exclusivity if the NDA contains new clinical data (other than bioavailability studies), derived from studies conducted by or for the sponsor, that were necessary for approval. In that instance, the exclusivity period does not preclude filing or review of an ANDA or 505(b)(2) application&#59; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2) application until three years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that required submission of the clinical data. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the FDA accepts for filing an ANDA or 505(b)(2) application containing a Paragraph&#160;IV certification, the applicant must within 20&#160;days provide notice to the RLD NDA holder and patent owner that the application has been submitted and provide the factual and legal basis for the applicant&#8217;s assertion that the patent is invalid or not infringed. If the NDA holder or patent owner files suit against the ANDA or 505(b)(2) applicant for patent infringement within 45&#160;days of receiving the Paragraph&#160;IV notice, the FDA is prohibited from approving the ANDA or 505(b)(2) application for a period of 30&#160;months or the resolution of the underlying suit, whichever is earlier. If the RLD has NCE exclusivity and the notice is given and suit filed during the fifth year of exclusivity, the regulatory stay extends to 7.5 years after the RLD approval. The FDA may approve the proposed product before the expiration of the regulatory stay if a court finds the patent invalid or not infringed or if the court shortens the period because the parties have failed to cooperate in expediting the litigation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Restoration.<span style="font-style:normal;"> A portion of the patent term lost during product development and FDA review of an NDA is restored if approval of the application is the first permitted commercial marketing of a drug containing the active ingredient. The patent term restoration period is generally one-half the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the NDA, plus the time between the date of submission of the NDA and the date of FDA approval of the product. The maximum period of restoration is five years, and the patent cannot be extended to more than 14&#160;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The USPTO, in consultation with the FDA, reviews and approves the application for patent term restoration. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European and Other International Government Regulation </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., we are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Some countries outside of the U.S. have a similar process that requires the submission of a clinical trial application, or CTA, much like the IND prior to the commencement of human clinical trials. In the EU, for example, similar to the FDA a CTA must be submitted for authorization to the competent national authority of each EU Member State in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee, much like the IRB, has issued a favorable opinion. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC, or Clinical Trials Directive, and the related national implementing provisions of the relevant individual EU Member States&#8217; requirements, clinical trial development may proceed. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014, or Clinical Trials Regulation, was adopted. The Regulation entered into force on January 31, 2022. The Clinical Trials Regulation is directly applicable in all the EU Member States, repealing the current Clinical Trials Directive. The new Clinical Trials Regulation allows parties to start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January 31, 2022. The transition period for the trials ongoing at the moment of applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January 31, 2023 can continue to be conducted under the Clinical Trials Directive until January 31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of the transitional period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure through a single entry point, the Clinical Trials Information System (&#8220;CTIS&#8221;)&#59; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors&#59; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval to commercialize a new drug under EU regulatory systems, we must submit a MAA, to the competent regulatory authority. In the EU, marketing authorization for a medicinal product can be obtained through a centralized, mutual recognition, decentralized procedure, or the national procedure of an individual EU Member State.&#160;A marketing authorization, irrespective of its route to authorization, may be granted only to an applicant established in the EU. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all 27 EU Member States and three of the four European Free Trade Association States, Iceland, Liechtenstein and Norway. Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for conducting the initial assessment of a product. The maximum timeframe for the evaluation of an MAA is 210 days. This period excludes clock stops during which additional information or written or oral explanation is to be provided by the applicant in response to questions posed by the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest. A major public health interest defined by three cumulative criteria: (i)&#160;the seriousness of the disease (for example, heavy disabling or life-threatening diseases) to be treated, (ii)&#160;the absence or insufficiency of an appropriate alternative therapeutic approach, and (iii)&#160;anticipation of high therapeutic benefit. If the CHMP accepts to review a medicinal product as a major public health interest, the time limit of 210 days will be reduced to 150 days. It is, however, possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Irrespective of the related procedure, at the completion of the review period the CHMP will provide a scientific opinion concerning whether or not a marketing authorization should be granted in relation to a medicinal product. This opinion is based on a review of the quality, safety, and efficacy of the product.&#160;Within 15 days of the adoption, the EMA will forward its opinion to the European Commission for its decision. Following the opinion of the EMA, the European Commission makes a final decision to grant a centralized marketing authorization.&#160;The centralized procedure is mandatory for certain types of medicinal products, including orphan medicinal products, medicinal products derived from certain biotechnological processes, advanced therapy medicinal products and medicinal products containing a new active substance for the treatment of certain diseases. This route is optional for certain other products, including medicinal products that are of significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public or animal health at EU level. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed.&#160;This application process is identical to the application that would be submitted to the EMA for authorization through the centralized procedure</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and must be completed within 210 days, excluding potential clock-stops, during which the applica</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t can respond to questions.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The reference EU Member State prepares a draft assessment and drafts of the related materials</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> concerned EU Member States must decide whether to approve the assessment report and related materials.&#160;If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mutual recognition procedure is similarly based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States.&#160;The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing authorization holders are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual EU Member States both before and after grant of marketing authorization. This includes control of compliance by the entities with EU cGMP rules, which govern quality control of the manufacturing process and require documentation policies and procedures. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origin in the Declaration of Helsinki. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Compliance </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of development and in the post-market setting, failure to comply with applicable regulatory requirements may result in administrative or judicial sanctions. These sanctions could include the FDA&#8217;s imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, warning letters or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Third country authorities can impose equivalent penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Exclusivities </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Exclusivity.<span style="font-style:normal;"> Section&#160;505A of the FD&#38;C Act provides for six months of additional exclusivity or patent protection if an NDA sponsor submits pediatric data that fairly respond to a Written Request from the FDA for such data. The data do not need to show that the product is effective in the pediatric population studied&#59; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or </span>Orange Book<span style="font-style:normal;"> listed patent protection that cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents. When any product is approved, we will evaluate seeking pediatric exclusivity as appropriate. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, Regulation No 1901/2006, or the Pediatric Regulation, requires that prior to obtaining a marketing authorization in the EU, applicants demonstrate compliance with all measures included in an EMA, approved Pediatric Investigation Plan, or PIP. This PIP covers all subsets in a pediatric population, unless the EMA has granted either, a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. Where all measures provided in the agreed PIP are completed, a six-month extension period of qualifying Supplementary Protection Certificates is granted. Between May 2021 and July 2021, the European Commission organized a public consultation to revise, among others, the Pediatric Regulation, as part of its Pharmaceutical Strategy for Europe. The current intention is for the European Commission to publish a proposal for new legislation in the first quarter of 2022.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Exclusivity.</span><span style="font-style:normal;"> The Orphan Drug Act provides incentives for the development of drugs intended to treat rare diseases or conditions, which are diseases or conditions affecting less than 200,000 individuals in the U.S.</span><span style="font-style:normal;">,</span><span style="font-style:normal;"> or a disease or condition affecting more than 200,000 individuals in the U.S. but there is no reasonable expectation that the cost of developing and making the drug product would be recovered from sales in the U.S.</span><span style="font-style:normal;"> If a sponsor demonstrates that a drug </span><span style="font-style:normal;">product qualifies for orphan drug designation</span><span style="font-style:normal;">, the FDA may grant orphan drug designation to the product for that use. The benefits of orphan drug designation include research and development tax credits and exemption from user fees. A drug that is approved for the orphan drug designated indication generally is granted seven years of orphan drug exclusivity. During that period, the FDA generally may not approve any other application for the same product for the same indication, although there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. </span><span style="font-style:normal;">The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same biologic for a different disease or condition.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, medicinal products: (a)&#160;that are used to diagnose, treat or prevent life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the EU&#59; or (b)&#160;that are used to treat or prevent life-threatening or chronically debilitating conditions and that, for economic reasons, would be unlikely to be developed without incentives&#59; and (c)&#160;where no satisfactory method of diagnosis, prevention or treatment of the condition concerned exists, or, if such a method exists, the medicinal product would be of significant benefit to those affected by the condition, may be granted an orphan designation in the EU. The application for orphan designation must be submitted to the EMA&#8217;s Committee for Orphan Medicinal Products and approved by the European Commission before an application is made for marketing authorization for the product. Once authorized, orphan medicinal product designation entitles an applicant to financial incentives such as reduction of fees or fee waivers. In addition, orphan medicinal products are entitled to ten years of market exclusivity following authorization. During this ten-year period, with a limited number of exceptions, neither the competent authorities of the EU Member States, the EMA, or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal products with the same therapeutic indication. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this latter product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data Exclusivity.<span style="font-style:normal;"> In the EU, if a marketing authorization is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity, during which generic marketing authorization applications referring to the data of that product may not be accepted by the regulatory authorities. The product also benefits from 10 years&#8217; market exclusivity during which generic products, even if authorized, may not be placed on the market. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, as amended, which we refer to as the Affordable Care Act, or ACA, is a sweeping measure intended to expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals, the provision of subsidies to eligible individuals enrolled in plans offered on the health insurance exchanges, and expansion of the Medicaid program. This law substantially changed the way healthcare is financed by both governmental and private insurers and has significantly impacted the pharmaceutical industry. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, benefits for patients within a coverage gap in the Medicare Part&#160;D prescription drug program (commonly known as the &#8220;donut hole&#8221;), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicaid Drug Rebate program, expansion of the Public Health Service Act&#8217;s 340B drug pricing discount program, or 340B program, fraud and abuse, and enforcement. These changes have impacted and will continue to impact existing government healthcare programs and have resulted in the development of new programs, including Medicare payment for performance initiatives.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some states have elected not to expand their Medicaid programs to individuals with an income of up to 133% of the federal poverty level, as is permitted under the Affordable Care Act. For each state that does not choose to expand its Medicaid program, there may be fewer insured patients overall, which could impact our sales of products and product candidates for which we receive regulatory approval, and our business and financial condition. Where new patients receive insurance coverage under any of the new Medicaid options made available through the Affordable Care Act, the possibility exists that manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, a decision that could impact manufacturer revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provisions of the Affordable Care Act have been subject to judicial challenges</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts to repeal</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> replace</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or otherwise modify</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them or</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to alter the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ir interpretation and</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> implementation. For example, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congress eliminated, starting</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January&#160;1, 2019, the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax penalty for not complying with</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Affordable Care Act</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual mandate</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> carry health insurance.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drugs plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January&#160;1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, but the nature and extent of such potential changes or challenges are uncertain at this time</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. It is unclear how the Affordable Care Act and its implementation, as well as efforts to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modify</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalidate</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Affordable Care Act, or portions thereof, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or its</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mplementation</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will affect our business, financial condition and results of operations. It is possible that the Affordable Care Act, as currently enacted or as it may be amended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our products or product candidates for which we receive regulatory approval or to successfully commercialize our products and product candidates.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes relating to reimbursement have been adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, which triggered the legislation&#8217;s automatic reductions. In concert with subsequent legislation, this has resulted in aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030 (with the exception of a temporary suspension from May 1, 2020, through March 31, 2022, due to the COVID-19 pandemic). The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. As long as these cuts remain in effect, they could adversely impact payment for any products we may commercialize in the future. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For example, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient programs, and reform government healthcare program reimbursement methodologies for drug products. If healthcare policies intended to curb healthcare costs are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited, and/or our revenues from sales of our products may be negatively impacted.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any of our products and product candidates, if approved, depend, in part, on the extent to which the costs of the products will be covered by Medicare and Medicaid, and private payors, such as commercial health insurers and managed care organizations. Third-party payors determine which drugs they will cover and the amount of reimbursement they will provide for a covered drug. In the U.S., there is no uniform system among payors for making coverage and reimbursement decisions. In addition, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for our products, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costly studies required to obtain FDA or other comparable regulatory approvals. Even if we conduct pharmacoeconomic studies, our product candidates may not be considered medically necessary or cost-effective by payors. Further, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved because HCPs negotiate their own reimbursement directly with commercial payors.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, payors have implemented reimbursement metrics and periodically revised those metrics as well as the methodologies used as the basis for reimbursement rates, such as ASP, average manufacturer price, or AMP, and actual acquisition cost. The existing data for reimbursement based on these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates. CMS surveys and publishes retail pharmacy acquisition cost information in the form of National Average Drug Acquisition Cost files to provide state Medicaid agencies with a basis of comparison for their own reimbursement and pricing methodologies and rates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We participate in</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and have certain price reporting obligations to, the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Medicaid Drug Rebate Program. This program requires us to pay a rebate for each unit of drug reimbursed by Medicaid. The amount of the &#8220;basic&#8221; portion of the rebate for each product is set by law as the larger of: (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;23.1% of quarterly AMP, or (ii)&#160;the difference between quarterly AMP and the quarterly best price available from us to any commercial or non-governmental customer, or Best Price. AMP must be reported on a monthly and quarterly basis and Best Price is reported on a quarterly basis only. In addition, the rebate also includes the &#8220;additional&#8221; portion, which adjusts the overall rebate amount upward as an &#8220;inflation penalty&#8221; when the drug&#8217;s latest quarter&#8217;s AMP exceeds the drug&#8217;s AMP from the first full quarter of sales after launch, adjusted for increases in the Consumer Price Index-Urban. The upward adjustment in the rebate amount per unit is equal to the excess amount of the current AMP over the inflation-adjusted AMP from the first full quarter of sales. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicaid Drug Rebate Program caps are currently set at 100 percent of AMP, but that cap is set to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be removed, effective January 1, 2024, which could increase our rebate liability</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebate amount is computed each quarter based on our report to CMS of current quarterly AMP and Best Price for our drug. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to report revisions to AMP or Best Price within a period not to exceed 12 quarters from the quarter in which the data was originally due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act made significant changes to the Medicaid Drug Rebate Program, and CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. On December 21, 2020, CMS issued a final regulation that modified existing Medicaid Drug Rebate Program regulations to permit reporting multiple Best Price figures with regard to value</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;based purchasing arrangements (beginning in 2022)&#59; provide definitions for &#8220;line extension,&#8221; &#8220;new formulation,&#8221; and related terms with the practical effect of expanding the scope of drugs considered to be line extensions (beginning in 2022)&#59; and revise AMP and Best Price exclusions of manufacturer-sponsored patient benefit programs, specifically regarding inapplicability of such exclusions in the context of pharmacy benefit manager &#8220;accumulator&#8221; programs (beginning in 2023).</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal law requires that any manufacturer that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part&#160;B. The 340B program, which is administered by the Health Resources and Services Administration, or HRSA, requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. Any changes to the definition of AMP and the Medicaid rebate amount under the Affordable Care Act or other legislation could affect our 340B ceiling price calculations and negatively impact our results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&#160;1, 2019. It is currently unclear how HRSA will apply its enforcement authority under this regulation. HRSA has also implemented a ceiling price reporting requirement related to the 340B program under which we are required to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA then publishes that information to covered entities.&#160;&#160;Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;), process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal law also requires that a company that participates in the Medicaid Drug Rebate program report ASP information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. For calendar quarters beginning January 1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate Program. Manufacturers calculate the ASP based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologicals, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory or regulatory changes or CMS guidance could affect the pricing of our approved products, and could negatively affect our results of operations. For example, Congress could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation. In addition, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the non-federal average manufacturer price. These or any other public policy changes could impact the market conditions for our products. We further expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies. For more information about Medicare Part B, refer to the risk factor entitled &#8220;Our products may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could harm our business&#8221; set forth under the section titled &#8220;Risk Factors&#8221; in this </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on Form 10-K.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S. Medicare program, outpatient prescription drugs may be covered under Medicare Part&#160;D. Medicare Part&#160;D is a voluntary prescription drug benefit, through which Medicare beneficiaries may enroll in prescription drug plans offered by private entities for coverage of outpatient prescription drugs. Part&#160;D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans provided for under Medicare Part&#160;C.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coverage and reimbursement for covered outpatient drugs under Part&#160;D are not standardized. Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Although Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, they have some flexibility to establish those categories and classes and are not required to cover all of the drugs in each category or class. Medicare Part&#160;D prescription drug plans may use formularies to limit the number of drugs that will be covered in any therapeutic class and/or impose differential cost sharing or other utilization management techniques.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare Part&#160;D coverage is available for our products and may be available for any future product candidates for which we receive marketing approval. However, in order for the products that we market to be included on the formularies of Part&#160;D prescription drug plans, we likely will have to offer pricing that is lower than the prices we might otherwise obtain. Changes to Medicare Part&#160;D that give plans more freedom to limit coverage or manage utilization, and other cost reduction initiatives in the program, could decrease the coverage and price that we receive for any approved products and could seriously harm our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers are currently required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Congress could further enact a Medicare Part D inflation rebate, under which manufacturers would owe additional rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part&#160;B programs and purchased by certain federal agencies and grantees, we must participate in the U.S. Department of Veterans Affairs, (&#8220;VA&#8221;), Federal Supply Schedule, (&#8220;FSS&#8221;), pricing program. Under this program, we are obligated to make our &#8220;innovator&#8221; drugs available for procurement on an FSS contract and charge a price to four federal agencies&#160;&#8212; the VA, U.S. Department of Defense, (&#8220;DoD&#8221;), Public Health Service and U.S. Coast Guard&#160;&#8212; that is no higher than the statutory Federal Ceiling Price, (&#8220;FCP&#8221;). The FCP is based on the non-federal average manufacturer price, (&#8220;Non-FAMP&#8221;), which we calculate and report to the VA on a quarterly and annual basis. We also may participate in the Tricare Retail Pharmacy program, under which we would pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. We could be held liable for errors associated with our submission of pricing data. In addition to retroactive Medicaid rebates and the potential for issuing 340B program refunds, if we are found to have knowingly submitted false AMP, Best Price, or Non-FAMP information to the government, we may be liable for significant civil monetary penalties per item of false information. If we are found to have made a misrepresentation in the reporting of our ASP, the Medicare statute provides for significant civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. Our failure to submit monthly/quarterly AMP and Best Price data on a timely basis could result in a significant civil monetary penalty per day for each day the information is late beyond the due date. Such conduct also could be grounds for CMS to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part&#160;B for our covered outpatient drugs. Significant civil monetary penalties also could apply to late submissions of Non-FAMP information. Civil monetary penalties could also be applied if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price or HRSA could terminate our agreement to participate in the 340B program, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. In addition, claims submitted to federally-funded healthcare programs, such as Medicare and Medicaid, for drugs priced based on incorrect pricing data provided by a manufacturer can implicate the federal civil False Claims Act. Civil monetary penalties could be due if we fail to offer discounts to beneficiaries under the Medicare Part D coverage gap discount program. And, once the refund program for discarded drug takes effect in 2023, manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs, and reform government program reimbursement methodologies for drug products. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning April&#160;1, 2013, Medicare payments for all items and services, including drugs, were reduced by 2% under the sequestration (i.e.,&#160;automatic spending reductions) required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012. Subsequent legislation extended the 2% reduction, generally to 2030, with a pause during the Pandemic through March 31, 2022. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. In 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. As long as these cuts remain in effect, they could adversely impact payment for any products we now sell or may commercialize in the future. If Congress does not take action in the future to modify these sequestrations, Medicare Part&#160;D plans could seek to reduce their negotiated prices for drugs. Other legislative or regulatory cost containment legislation could have a similar effect. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the Affordable Care Act may reduce the profitability of drug products. It expanded manufacturers&#8217; rebate liability under the Medicaid program from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well, and increased the minimum Medicaid rebate due for most innovator drugs. The Affordable Care Act and subsequent legislation also changed the definition of AMP. On February&#160;1, 2016, CMS issued final regulations to implement the changes to the Medicaid drug rebate program under the Affordable Care Act. These regulations became effective on April&#160;1, 2016. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription drug fee to the federal government. Each such manufacturer pays a prorated share of the branded prescription drug fee of $2.8&#160;billion in 2019 and thereafter, based on the dollar value of its branded prescription drug sales to certain federal programs identified in the law. The Affordable Care Act also expanded the Public Health Service Act&#8217;s 340B program to include additional types of covered entities. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners. It appears likely that the Affordable Care Act will continue the pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and may also increase our regulatory burdens and operating costs. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible, as discussed above under the heading &#8220;U.S. Healthcare Reform.&#8221; In addition, there likely will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payors to contain healthcare costs. Thus, even if we obtain favorable coverage and reimbursement status for our products and any product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Different pricing and reimbursement schemes exist in other countries. In the EU, each EU Member State can restrict the range of medicinal products for which its national health insurance system provides reimbursement and can control the prices of medicinal products for human use marketed on its territory. As a result, following receipt of marketing authorization in an EU Member State, through any application route, the applicant is required to engage in pricing discussions and negotiations with the competent pricing authority in the individual EU Member State. The governments of the EU Member States influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers.&#160;Some EU Member States operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU Member States allow companies to fix their own prices for medicines, but monitor and control company profits.&#160;Others adopt a system of reference pricing, basing the price or reimbursement level in their territories either on the pricing and reimbursement levels in other countries or on the pricing and reimbursement levels of medicinal products intended for the same therapeutic indication. Further, some EU Member States approve a specific price for the medicinal product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal on the market. The downward pressure on healthcare costs in general, particularly prescription drugs, has become more intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, we may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health Technology Assessment, or HTA, of medicinal products, however, is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States.&#160;These EU Member States include France, Germany, Ireland, Italy and Sweden. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted.&#160;HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system.&#160;Those elements of medicinal products are compared with other treatment options available on the market. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States.&#160;The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product varies between EU Member States. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to Directive 2011/24/EU on the application of patients&#8217; rights in cross-border healthcare, a voluntary network of national authorities or bodies responsible for HTA in the individual EU Member States was established.&#160;The purpose of the network is to facilitate and support the exchange of scientific information concerning HTAs.&#160;This may lead to harmonization of the criteria taken into account in the conduct of HTAs between EU Member States and in pricing and reimbursement decisions and may negatively affect price in at least some EU Member States.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2018, the European Commission adopted a proposal for an HTA Regulation intended to set out an EU-wide framework for HTA and boost cooperation among EU Member States in assessing health technologies, including new medicinal products. The HTA Regulation provides the basis for permanent and sustainable cooperation at the EU level for joint clinical assessments in these areas, and is therefore complementary to Directive 2011/24/EU. The HTA Regulation was finally adopted on December 13, 2021 and entered into force on January 11, 2022. The HTA Regulation will apply to all EU Member States from January 12, 2025.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The HTA Regulation provides that EU Member States will be able to use common HTA tools, methodologies, and procedures across the EU. Individual EU Member States will continue to be responsible for drawing conclusions on the overall value of a new health technology for their healthcare system, and pricing and reimbursement decisions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Fraud and Abuse Laws </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to FDA restrictions on marketing of pharmaceutical products, our business is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These laws include, but are not limited to the following: </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A violation of the Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceuticals, including certain discounts, or engaging such individuals as consultants, speakers or advisors, may be subject to scrutiny if they do not fit squarely within the exception or safe harbor. In November 2020, the U.S. Department of Health and Human Services finalized a previously abandoned proposal to amend the discount safe harbor regulation of the Anti-Kickback Statute in a purported effort to create incentives to manufacturers to lower their list prices, and to lower federal program beneficiary out-of-pocket costs.&#160;&#160;The rule, which is currently slated to take full effect January 1, 2023, revises the Anti-Kickback Statute discount safe harbor to exclude manufacturer rebates to Medicare Part D plans, either directly or through pharmacy benefit managers (&#8220;PBMs&#8221;), creates a new safe harbor for point-of-sale price reductions that are set in advance and are available to the beneficiary at the point-of-sale, and creates a new safe harbor for service fees paid by manufacturers to PBMs for services rendered to the manufacturer. It is too early to know whether the Biden Administration will further delay, rewrite, or allow the rule to go into effect, and what effect the rule may have on negotiations for coverage for products with Medicare Part D plans or commercial insurers. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants, charitable donations, product support and patient assistance programs. Arrangements that implicate the Anti-Kickback Statute and do not fit within an exception or safe harbor are reviewed on a case-by-case basis to determine whether, based on the facts and circumstances, they violate the statute.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by private individuals known as qui tam relators in the name of the government</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and to share in any monetary recovery</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In recent years, several pharmaceutical and other healthcare companies have faced enforcement actions under the False Claims Act for, among other things, providing free product to customers with the expectation that the customers would bill federal programs for the product, and other interactions with prescribers and other customers including interactions that may have affected customers&#8217; billing or coding practices on claims submitted to the federal government. Other companies have faced enforcement actions for causing false claims to be submitted because of the company&#8217;s marketing the product for unapproved, and thus non-reimbursable, uses. Federal enforcement agencies also have shown increased interest in pharmaceutical companies&#8217; product and patient assistance programs, including reimbursement and co-pay support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively &#8220;HIPAA&#8221;) prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. We may obtain health information from third parties that are subject to privacy and security requirements under HIPAA and we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Several states now require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to individual health care providers in those states. Some of these states also prohibit certain marketing-related activities including the provision of gifts, meals, or other items to certain health care providers. Other states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients. In addition, several states require pharmaceutical companies to implement compliance programs or marketing codes. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with such laws and regulations will require substantial resources. Because of the breadth of these various fraud and abuse laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have material adverse effects on our business, financial condition and results of operations. In the event governmental authorities conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, they may impose sanctions under these laws, which are potentially significant and may include civil monetary penalties, damages, exclusion of an entity or individual from participation in government health care programs, criminal fines and imprisonment, additional reporting requirements if we become subject to a corporate integrity agreement or other settlement to resolve allegations of violations of these laws, as well as the potential curtailment or restructuring of our operations. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Privacy Laws</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to federal, state and foreign laws and regulations governing data privacy and security of health information, and the collection, use, disclosure, and protection of health-related and other personal information, including state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws, such as Section 5 of the FTC Act, many of which differ from each other in significant ways, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, and time consuming. Many of these state laws enable a state attorney general to bring actions and provide private rights of action to consumers as enforcement mechanisms. There is also heightened sensitivity around certain types of health information, such as sensitive condition information or the health information of minors, which may be subject </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to additional protections. Federal</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulators, state attorneys general, and plaintiffs&#8217; attorneys</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including class action attorneys,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have been and will likely continue to be active in this space.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Failure to comply with these laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant civil and/or criminal penalties), private litigation and/or adverse publicity that could negatively affect our business. We may obtain health information from third parties, such as health care providers who prescribe our products, and research institutions we collaborate with, who are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, other than potentially with respect to providing certain employee benefits, we could be subject to criminal penalties if we or our affiliates or agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In California, the California Consumer Privacy Act (&#8220;CCPA&#8221;) establishes certain requirements for data use and sharing transparency and provides California consumers (as defined in the law) certain rights concerning the use, disclosure, and retention of their personal data. In November 2020, California voters approved the California Privacy Rights Act (&#8220;CPRA&#8221;) ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (&#8220;CPPA&#8221;). The amendments introduced by the CPRA go into effect on January 1, 2023, and new implementing regulations are expected to be introduced by the CPPA. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and damages. Similarly, there are a number of legislative proposals in the EU, the United States, at both the federal and state level, as well as other jurisdictions that could impose new obligations or limitations in areas affecting our business. In addition, some countries are considering or have passed legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of delivering our services and research activities. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. The obligations to comply with the CCPA and evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive acts or practices in violation of Section 5(a) of the Federal Trade Commission Act (&#8220;FTC Act&#8221;). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. Enforcement by the FTC under the FTC Act can result in civil penalties or decades-long enforcement actions. These laws and regulations, as well as any associated claims, inquiries, or investigations or any other government actions may lead to unfavorable outcomes including increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, and remedies that harm our business, including fines or demands or orders that we modify or cease existing business practices.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the U.S., the legislative and regulatory landscape for privacy and data security continues to evolve. There has been increased attention to privacy and data security issues that could potentially affect our business, including the EU General Data Protection Regulation (&#8220;GDPR&#8221;), which imposes penalties up to EUR 20 million or 4% of a noncompliant company&#8217;s annual global revenue, whichever is greater. The GDPR regulates the processing of personal data and imposes strict obligations and restrictions on the ability to collect, analyze and transfer personal data from the EU to the US, including health data from clinical trials. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the processing details disclosed to the individuals, the sharing of personal data with third parties, the transfer of personal data out of the EU, contracting requirements (such as with clinical trial sites and vendors), and security breach notifications. Data protection authorities from the different EU Member States may interpret the GDPR and applicable related national laws differently and impose requirements additional to those provided in the GDPR. In addition, guidance on implementation and compliance practices may be updated or otherwise revised, which adds to the complexity of processing personal data in the EU. Enforcement by EU regulators is active, and failure to comply with the GDPR or applicable Member State law may result in substantial fines.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Corrupt Practices Act </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the U.S. Foreign Corrupt Practices Act of 1977, as amended, (&#8220;FCPA&#8221;), prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any official of another country, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in that capacity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the state of Delaware on March&#160;19, 2008 under the name New pSivida, Inc. Our predecessor, pSivida Limited, was formed in December 2000 as an Australian company incorporated in Western Australia. We subsequently changed our name to pSivida Corp. in May 2008 and again to EyePoint Pharmaceuticals, Inc. in March 2018. Our principal executive office is located at 480 Pleasant Street, Suite B300, Watertown, Massachusetts 02472 and our telephone number is (617)&#160;926-5000. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Information </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is http://www.eyepointpharma.com. Information contained on, or connected to, our website is not incorporated by reference into this Annual Report on Form 10-K. Copies of this Annual Report on Form 10-K, and our annual reports on Form&#160;10-K, proxy statements, quarterly reports on Form 10-Q, current reports on Form 8-K and, if applicable, amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website under &#8220;Investors &#8211; Financial Information &#8211; SEC Filings&#8221; as soon as reasonably practicable after we electronically file these materials with, or otherwise furnish them to, the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at <span style="text-decoration:underline;">www.sec.gov</span>. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">ITEM&#160;1A.<span style="font-weight:normal;"> </span>RISK FACTORS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISKS RELATED TO OUR FINANCIAL POSITION AND OUR CAPITAL RESOURCES </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will likely need additional capital to fund our operations. If we are unable to obtain sufficient capital, we will need to curtail and reduce our operations and costs and modify our business strategy. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed substantial amounts of cash. To date, we have financed our operations primarily through the sale of capital stock, proceeds from term loan agreements, the receipt of license fees, milestone payments, research and development funding and royalty payments from our collaboration partners, and product sales. <span style="color:#auto;">In 2019, we commenced the U.S. launch of our first two commercial products, YUTIQ and DEXYCU, and, in the first quarter of 2021, we commenced the Phase 1 clinical trial for EYP-1901 as a potential six-month sustained delivery treatment for wet AMD</span>,<span style="color:#auto;"> and we reported positive six-month interim safety and efficacy data in November 2021. However, we have no expectation of revenues from our research and development programs, including EYP-1901, prior to the successful completion of clinical trials for such programs. Therefore, we have no sufficient historical evidence to assert that it is probable that we will receive sufficient revenues from our product sales to fund operations. </span>As of December&#160;31, 2021, our cash, cash equivalents, and investments in marketable securities totaled $211.6&#160;million. We <span style="Background-color:#auto;color:#auto;">believe that our cash, cash equivalents</span>,<span style="Background-color:#auto;color:#auto;"> and investments in marketable securities of $211.6 million at December 31, 2021, together with </span><span style="color:#auto;">the anticipated net cash inflows from product sales will fund our operating plan </span>into the second half of <span style="color:#auto;">2024, under current expectations regarding the timing and outcomes of our </span>Phase 2 <span style="color:#auto;">clinical trials for EYP-1901.</span><span style="Background-color:#auto;color:#auto;"> </span>Due to the difficulty and uncertainty associated with the design and implementation of clinical trials, w<span style="Background-color:#auto;">e will continue to assess our cash and cash equivalents and future funding requirements. </span><span style="Background-color:#auto;color:#auto;">Actual cash requirements could differ from our projections due to many factors, including the continued effect of the Pandemic on our business and the medical community, the timing and results of our </span>Phase 2 <span style="Background-color:#auto;color:#auto;">clinical trials for EYP-1901, additional investments in research and development programs, the success of commercialization for YUTIQ and DEXYCU, the actual costs of these commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will need to curtail and reduce our operations and costs, and modify our business strategy, which may require us to, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significantly delay, scale back or discontinue the commercialization or development of one or more of our products or product candidates or one or more of our other research and development initiatives&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek partners or collaborators for one or more of our products or product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">sell or license on unfavorable terms our rights to one or more of our technologies, products or product candidates that we otherwise would seek to develop or commercialize ourselves&#59; and/or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek to sell our company at an earlier stage than would otherwise be desirable or on terms that are less favorable than might otherwise be available. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception, have not generated significant revenue from commercial sales of our products and are not profitable. Investment in drug development is highly speculative because it entails substantial upfront operating expenses and significant risk that a product candidate will fail to successfully complete clinical trials, gain regulatory approval or become commercially viable. We continue to incur significant operating expenses due primarily to investments in clinical trials, sales and marketing infrastructure, research and development, and other expenses related to our ongoing operations. For the years ended December 31, 2021 and 2020, we had losses from operations of $55.3&#160;million and $37.3&#160;million, respectively, and net losses of $58.4&#160;million and $45.4&#160;million, respectively, and we had a total accumulated deficit of $569.1&#160;million at December&#160;31, 2021. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will continue to be significant if, and as, we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continue the research and pre-clinical and clinical development of our product candidates, including EYP-1901 and YUTIQ 50&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">initiate additional pre-clinical studies, clinical trials or other studies or trials for EYP-1901 and our other product candidates, including YUTIQ 50&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continue to commercialize YUTIQ and DEXYCU&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">add additional operational, financial and management information systems and personnel, including personnel to support our development and commercialization efforts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">hire additional commercial, clinical, manufacturing and scientific personnel and engage third party commercial, clinical and manufacturing organizations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">further develop the manufacturing process for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">change or add additional manufacturers or suppliers&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek regulatory approvals for our product candidates that successfully complete clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek to identify and validate additional product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">acquire or in-license other products, product candidates and technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">maintain, protect and expand our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">create additional infrastructure to support our product development and planned future commercial sale efforts&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">experience any delays or encounter issues with any of the above. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may never achieve profitability from future operations. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully commercialize our current products and complete the development of, and obtain the regulatory approvals necessary for, the manufacture and commercialization of our product candidates, including EYP-1901 and YUTIQ 50. To become and remain profitable, we must succeed in developing and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing pre-clinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates, manufacturing, marketing and selling any products for which we or our licensees may&#160;obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. We do not know the extent to which YUTIQ or DEXYCU, or any of our product candidates, including EYP-1901, if approved, will generate significant revenue for us, if at all. We may never succeed in these activities and, even if we do, we may never generate revenues significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately project when or if we will be able to achieve profitability from operations. Even if we do so, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. Our ability to generate revenue from our current or future products and product candidates will depend on a number of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to successfully complete development activities, including the necessary clinical trials, with respect to EYP-1901 and our other product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to successfully commercialize YUTIQ and DEXYCU&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities, if we choose to commercialize YUTIQ and DEXYCU in unpartnered jurisdictions outside the U.S.&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the size of the markets in the territories for which we gain regulatory approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to further develop our commercial organization capable of sales, marketing and distribution for YUTIQ and DEXYCU, and any of our other product candidates for which we may obtain marketing approval&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to enter into and maintain commercially reasonable agreements with manufacturers, wholesalers, distributors and other third parties in our supply chain&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our success in establishing a commercially viable price for our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to manufacture commercial quantities of our products at acceptable cost levels&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain coverage and adequate reimbursement from third parties, including government payors </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The ongoing novel coronavirus&#160;(COVID-19)&#160;pandemic has had and will likely continue to have a material and adverse impact on our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing Pandemic has had a material and adverse impact on our business, including as a result of measures that we, other businesses, and government have taken and will likely continue to take. This includes a significant impact on cash flows from expected revenues due to the closure of ambulatory surgery centers for DEXYCU and a significant reduction in physician office visits impacting YUTIQ in 2020. The ongoing Pandemic continued to have an adverse impact on our revenues, financial condition and cash flows through 2021. For the year ended December 31, 2021, we recorded impairment charges of $1.2 million to cost of sales excluding amortization of acquired intangible assets and $0.1 million to sales and marketing expense, respectively, associated with the write-off of obsolete inventory of DEXYCU units and DEXYCU sample units, respectively, whose inventory levels were higher than our updated forecasts of future demand for those units. Additionally, the emergence of the Omicron variant continues to have an adverse impact on our revenues, financial condition and cash flows into the first quarter of 2022 and may continue to cause intermittent or prolonged periods of reduced patient services at our customers&#8217; facilities, which may negatively affect customer demand. The progression of the Pandemic and its effects on our business and operations are uncertain at this time. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we cannot presently predict the future scope and severity of current or any potential business shutdowns or disruptions related to&#160;COVID-19,&#160;if we or any of the third parties with whom we engage, including the suppliers,&#160;manufacturers and other third parties in our&#160;global&#160;supply chain, clinical trial sites, clinical research organizations, patients who may be candidates for clinical trials, regulators, surgeons, ASCs,&#160;potential business development partners and other third parties with whom we conduct business, were to experience prolonged shutdowns or other business disruptions, including the imposition of restrictions on the export or import of our key supplies from countries outside of the United States, our&#160;ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. Further, any sustained disruption in the capital markets from the Pandemic could negatively impact our ability to raise capital.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the&#160;Pandemic continues to adversely affect our business, results of operations, financial condition and cash flows, it may also heighten many of the other risks described herein as well as in any amendment or update to our risk factors reflected in subsequent filings with the SEC.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ultimate impact of&#160;the Pandemic&#160;on our business, results of operations, financial condition and cash flows is dependent on future developments, which are still highly uncertain and cannot be predicted with confidence, including the duration of the Pandemic, as well as the timing and phasing of business reopening, including the full resumption of the performance of elective surgical procedures such as cataract surgeries.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to raise additional capital in the future, which may not be available on favorable terms and may be dilutive to stockholders or impose operational restrictions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional capital in the future to help fund the development and commercialization of EYP-1901 and our other product candidates, if approved, and the continued commercialization of YUTIQ and DEXYCU. The amount of additional capital we will require will be influenced by many factors, including, but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our clinical development plans for EYP-1901 and our other product candidates including YUTIQ 50&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the outcome, timing and cost of the regulatory approval process for EYP-1901 and our other product candidates, including the potential for the FDA to require that we perform more studies and clinical trials than those we currently expect&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product revenues received and cash flow generated from sales of YUTIQ and DEXYCU&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">whether and to what extent we internally fund, whether and when we initiate, and how we conduct other product development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">whether and when we are able to enter into strategic arrangements for our products or product candidates and the nature of those arrangements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs involved in preparing, filing, and prosecuting patent applications, and maintaining, and enforcing our intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in our operating plan, resulting in increases or decreases in our need for capital&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our views on the availability, timing and desirability of raising capital&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs of operating as a public company. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know if additional capital will be available to us when needed or on terms favorable to us or our stockholders. Collaboration, licensing or other commercial agreements may not be available on favorable terms, or at all. If we seek to sell our equity securities under our at-the-market (&#8220;ATM&#8221;) program or in another offering, we do not know whether and to what extent we will be able to do so, or on what terms. Further, the rules and regulations of the Nasdaq Stock Market LLC, (&#8220;Nasdaq&#8221;), require us to obtain stockholder approval for sales of our equity securities under certain circumstances, which could delay or prevent us from raising additional capital from such sales. Also, the state of the economy and financial and credit markets at the time or times we seek any additional financing may make it more difficult or more expensive to obtain. If available, additional equity financing may be dilutive to stockholders, debt financing may involve restrictive covenants or other unfavorable terms and dilute our existing stockholders&#8217; equity, and funding through collaboration, licensing or other commercial agreements may be on unfavorable terms, including requiring us to relinquish rights to certain of our technologies or products. If adequate financing is not available if and when needed, we may delay, reduce the scope of, or eliminate research or development programs, postpone or cancel the pursuit of product candidates such as EYP-1901, including pre-clinical and clinical trials and new business opportunities, independent U.S. commercialization of YUTIQ and DEXYCU, or other new products, if any, reduce staff and operating costs, or otherwise significantly curtail our operations to reduce our cash requirements and extend our capital. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We must maintain compliance with the terms of our Credit Facilities or receive a waiver for any&#160;non-compliance.&#160;Our failure to comply with the covenants or other terms of the Credit Facilities, including as a result of events beyond our control, could result in a default under the SVB Loan Agreement that would materially and adversely affect the ongoing viability of our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 9, 2022 (the &#8220;SVB Closing Date&#8221;), we entered into a loan agreement (the &#8220;SVB Loan Agreement&#8221;) among us, as borrower, and Silicon Valley Bank, as lender (&#8220;SVB&#8221;), providing for (i) a senior secured term loan facility of $30 million (the &#8220;Term Facility&#8221;) and (ii) a senior secured revolving credit facility of up to $15.0 million (the &#8220;Revolving Facility&#8221; and together with the Term Facility, the &#8220;Credit Facilities&#8221;). The maximum amount available for borrowing at any time under the Revolving Facility is limited to a borrowing base valuation of our eligible accounts receivable. On the SVB Closing Date, $30 million of the Term Facility and approximately $11.5 million of the Revolving Facility, was advanced,<span style="font-size:12pt;"> </span>to pay off the CRG Loan, including the accrued interests through this date. We utilized the proceeds from the Credit Facilities, together with cash on hand, for the repayment in full of all outstanding obligations under our term loan agreement (the &#8220;CRG Credit Agreement&#8221;) with CRG Servicing LLC (&#8220;CRG&#8221;).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loans under the Credit Facilities are due and payable on January 1, 2027 (the &#8220;Maturity Date&#8221;). The Credit Facilities bear interest that is payable monthly in arrears at a per annum rate (subject to increase during an event of default) equal to (i) with respect to the Term Facility, the greater of (x) the Wall Street Journal prime rate plus 2.25% and (y) 5.50% and (ii) with respect to the Revolving Facility, the Wall Street Journal Prime Rate. An unused commitment fee of 0.25% per annum applies to unutilized borrowing capacity under the Revolving Facility. Commencing on February 1, 2024, we are required to repay the principal of the Term Facility in 36 consecutive equal monthly installments. At maturity or if earlier prepaid, we will also be required to pay an exit fee equal to 2.00% of the aggregate principal amount of the Term Facility.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may make a voluntary prepayment of the Term Facility, in whole but not in part, at any time. All voluntary and mandatory prepayments of the Term Facility are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs on or prior to the first anniversary of the SVB Closing Date, an amount equal to 3.0% of the aggregate outstanding principal amount of the Term Facility being prepaid, (ii) if prepayment occurs after the first anniversary of the SVB Closing Date and on or prior to the second anniversary of the SVB Closing Date, 2.0% of the aggregate outstanding principal amount of the Term Facility being prepaid, (iii) if prepayment occurs after the second anniversary of the SVB Closing Date and on or prior to the third anniversary of the SVB Closing Date, 1.0% of the aggregate outstanding principal amount of the Term Facility being prepaid and (iii) if prepayment occurs after the third anniversary of the SVB Closing Date but prior to the Maturity Date, an amount equal to 0.50% of the aggregate outstanding principal amount of the Term Facility being prepaid. We may voluntarily terminate the Revolving Facility at any time, subject to the payment of a termination fee as follows: (i) if such termination occurs on or prior to the first anniversary of the Closing Date, an amount equal to 3.0% of the Revolving Facility and (ii) if such termination occurs after the first anniversary of the Closing Date, 1.0% of the Revolving Facility.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SVB Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, enter into affiliate transactions and change our line of business, in each case, subject to certain exceptions. In addition, the SVB Loan Agreement contains the following financial covenants requiring us to maintain either:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">minimum product revenue from YUTIQ</span><span style="Background-color:#FFFFFF;font-size:10pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;color:#000000;"> and DEXYCU</span><span style="Background-color:#FFFFFF;font-size:10pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;color:#000000;"> assessed on a quarterly basis commencing from the three-month period ending on March 31, 2022 through the Maturity Date, with such minimum quarterly product revenue ranging from approximately $7.8 million to approximately $11.5 million in fiscal year 2022. Such minimum quarterly product revenue will be subject to incremental increases in fiscal year 2023 and will thereafter be such amounts as agreed upon between the Company and the Lender based on certain agreed-upon factors commencing for the three-month period ending on March 31, 2024 and for each three-month period thereafter through the Maturity Date&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">if the Company is unable to achieve the minimum quarterly product revenue level required as of the end of any three-month period, cash and cash equivalents in an amount equal to the greater of (i) $50,000,000 and (ii) the Company&#8217;s six-month Cash Burn (as defined in the SVB Loan Agreement).</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the effects on our business of the Pandemic and the potential loss of the pass-through status of DEXYCU, we may not meet the financial covenants associated with our revenue derived from sales of YUTIQ</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and DEXYCU</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the twelve-month period ending December 31, 2022</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or in subsequent years</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. If we do not maintain compliance with all of the continuing covenants and other terms and conditions of the Credit Facilities or secure a waiver for any non-compliance, then SVB may choose to declare an event of default and require that we immediately repay all amounts outstanding, plus penalties and interest, including an exit fee, any termination fees and any prepayment fees, and foreclose on the collateral granted to them to secure such indebtedness. Such repayment would have a material adverse effect on our business, operating results and financial condition.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the repayment of all unpaid principal and accrued interest under the Credit Facilities may be accelerated upon consummation of a specified change of control transaction or the occurrence of certain other events of default (as specified in the SVB Loan Agreement), including, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our default in a payment obligation under the SVB Loan Agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our default under any of our agreements (i) evidencing indebtedness in an aggregate principal amount in excess of $250,000 or (ii) that could reasonably be expected to have a material adverse effect on our and our subsidiaries&#8217; business or operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our breach of certain affirmative covenants and the negative covenants or, subject to specified cure periods, other terms of the SVB Loan Agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a material impairment in the perfection or priority of SVB&#8217;s security interest in the collateral&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the occurrence of a material adverse effect (as specified in the SVB Loan Agreement)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">certain specified insolvency and bankruptcy-related events&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">certain specified events relating to governmental approvals.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to any applicable cure period set forth in the SVB Loan Agreement, upon the occurrence of an event of default, SVB may accelerate all or any amounts outstanding with respect to the Credit Facilities (principal, accrued interest, exit fee, any termination fees and any prepayment fees). Our assets or cash flow may not be sufficient to fully repay our obligations under the SVB Loan Agreement if the obligations thereunder are accelerated upon an event of default. Further, if we are unable to repay, refinance or restructure our obligations under the SVB Loan Agreement, SVB could proceed to protect and enforce their rights under the SVB Loan Agreement by exercising such remedies as are available to SVB thereunder and in respect thereof under applicable law, either by suit in equity or by action at law, or both, whether for specific performance of any covenant or other agreement contained in the SVB Loan Agreement or in aid of the exercise of any power granted in the SVB Loan Agreement. The foregoing would materially and adversely affect the ongoing viability of our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Loan Agreement contains restrictions that limit our flexibility in operating our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SVB Loan Agreement contains various covenants that limit our ability to engage in specified types of transactions without SVB&#8217;s prior consent. These covenants limit our ability to, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">sell, transfer, lease or dispose of our assets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">create, incur or assume additional indebtedness&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">encumber or permit liens on certain of our assets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">make restricted payments, including paying dividends on, repurchasing or making distributions with respect to, our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">make specified investments (including loans and advances) and acquisitions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">consolidate, merge, sell or otherwise dispose of all or substantially all of our assets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">enter into certain transactions with our affiliates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">permit our cash held in deposit accounts with SVB to be less than the lesser of (i) 100.0% of our consolidated cash, including our subsidiaries&#8217; and affiliates&#8217; cash, and (ii) 110.0% of all outstanding obligations owing under the SVB Loan Agreement&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">permit our annual product revenue from YUTIQ and DEXYCU to fall below certain agreed projection levels or permit liquidity to fall below certain agreed levels.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The covenants in our Loan Agreement may limit our ability to take certain actions that may be in our long-term best interests. In the event that we breach one or more covenants, SVB may choose to declare an event of default and require that we immediately repay all amounts outstanding, plus penalties and interest, including the exit fee, any termination fees and any prepayment fees, terminate their commitments to extend further credit and foreclose on the collateral granted to them to secure such indebtedness. Such repayment could have a material adverse effect on our business, operating results and financial condition. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain potential payments to the Lenders could impede a sale of our company.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain exceptions, we are also required to make mandatory prepayments of outstanding loans under the Credit Facilities with the proceeds of assets sales and insurance proceeds, which amounts in the case of the Revolving Facility, subject to the conditions set forth in the Loan Agreement, may re-borrowed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All voluntary and mandatory prepayments of the Term Facility are subject to the payment of prepayment premiums as follows: (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) if prepayment occurs on or prior to the first anniversary of the SVB Closing Date, an amount equal to 3.0% of the aggregate outstanding principal amount of the Term Facility being prepaid, (ii) if prepayment occurs after the first anniversary of the SVB Closing Date and on or prior to the second anniversary of the SVB Closing Date, 2.0% of the aggregate outstanding principal amount of the Term Facility being prepaid, (iii) if prepayment occurs after the second anniversary of the SVB Closing Date and on or prior to the third anniversary of the SVB Closing Date, 1.0% of the aggregate outstanding principal amount of the Term Facility being prepaid and (iii) if prepayment occurs after the third anniversary of the SVB Closing Date but prior to the Maturity Date, an amount equal to 0.50% of the aggregate outstanding principal amount of the Term Facility being prepaid. The prepayment of the Term Facility in full is also subject to the payment of an exit fee of $600,000. We may voluntarily terminate the Revolving Facility at any time, subject to the payment of a termination fee as follows: (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) if such termination occurs on or prior to the first anniversary of the Closing Date, an amount equal to 3.0% of the Revolving Facility and (ii) if such termination occurs after the first anniversary of the Closing Date, 1.0% of the Revolving Facility.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions may make it more costly for a potential acquirer to engage in a business combination transaction with us. Provisions that have the effect of discouraging, delaying or preventing a change in control could discourage a third party from attempting to acquire us, limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">To service our indebtedness, we will require a significant amount of cash and our ability to generate cash depends on many factors beyond our control.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to make cash payments on our indebtedness will depend on our ability to generate significant operating cash flow in the future. This ability is, to a significant extent, subject to general economic, financial, competitive, legislative, regulatory and other factors, that will be beyond our control. In addition, our business may not generate sufficient cash flow from operations to enable us to pay our indebtedness or to fund our other liquidity needs. In any such circumstance, we may need to refinance all or a portion of our indebtedness, on or before maturity. We may not be able to refinance any indebtedness on commercially reasonable terms or at all. If we cannot service our indebtedness, we may have to take actions such as selling assets, seeking additional equity or reducing or delaying capital expenditures, strategic acquisitions and investments. Any such action, if necessary, may not be effected on commercially reasonable terms or at all. The instruments governing our indebtedness may restrict our ability to sell assets and our use of the proceeds from such sales.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our profitability will be impacted by our obligations to make royalty and milestone payments to the former securityholders of Icon Bioscience, Inc. and other third-party collaborators. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Icon Bioscience, Inc. (&#8220;Icon&#8221;) in March 2018 (the &#8220;Icon Acquisition&#8221;), we are obligated to pay certain post-closing contingent cash payments upon the achievement of specified milestones and based upon certain net sales and partnering revenue standards, in each case subject to the terms and conditions set forth in the Merger Agreement, dated March 28, 2018 (the &#8220;Merger Agreement&#8221;). These future obligations include (i) sales milestone payments totaling up to $95.0&#160;million, beginning no earlier than three years after the October&#160;1, 2018 effective date of the pass-through reimbursement code approved by CMS, upon the achievement of certain sales thresholds and subject to certain CMS reimbursement conditions set forth in the Merger Agreement, (<span style="Background-color:#FFFFFF;">ii</span>)&#160;quarterly earn-out payments equal to 12% on net sales of DEXYCU, which earn-out payments will increase to 16% of net sales of DEXYCU in a given year beginning in the calendar quarter for a given year to the extent aggregate annual consideration of DEXYCU exceeds $200.0&#160;million in such year, (iii)&#160;quarterly earn-out payments equal to 20% of partnering revenue received by us for DEXYCU outside of the U.S., and (iv)&#160;single-digit percentage quarterly earn-out payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates we might develop utilizing the Verisome technology acquired in the Icon Acquisition. As of December 31, 2021, we made DEXYCU product revenue-based royalty payments totaling $2.5 million,<span style="Background-color:#FFFFFF;color:#000000;"> of which $0 were related to the partnering income in connection with the Icon Acquisition.</span> Our profitability with respect to DEXYCU is impacted by our obligations to make payments to the former securityholders of Icon. Our obligations to the former securityholders of Icon and other third-party collaborators could have a material adverse effect on our business, financial condition and results of operations if we are unable to manage our operating costs and expenses at profitable levels. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, including pre-acquisition amounts related to Icon , we had U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $301.2 million for U.S. federal income tax and approximately $222.6 million for state income tax purposes available to offset future taxable income and U.S. federal and state research and development tax credits of approximately $5.7 million, prior to consideration of annual limitations that may be imposed under Section&#160;382 of the Internal Revenue Code of 1986, as amended (&#8220;Section&#160;382&#8221;). Our U.S. NOL carryforwards begin to expire in 2023 if not utilized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our U.S. NOL and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under Section&#160;382, and corresponding provisions of U.S. state law, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change U.S. NOLs and other pre-change tax attributes, such as research and development tax credits, to offset its post-change income may be limited. The latest analysis performed under Section&#160;382, performed through September&#160;30, 2018, confirmed that the exercise of certain warrants in late September 2018 resulted in a greater than 50% cumulative ownership change, which will cause annual limitations on the use of our then existing NOL balances and other pre-change tax attributes. As a result, if we earn net taxable income in future periods, our ability to use our pre-change U.S. NOL carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liabilities to us. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, including through completed or contemplated financings, some of which may be outside of our control. If we determine that a future ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISKS RELATED TO THE REGULATORY APPROVAL AND CLINICAL DEVELOPMENT OF OUR PRODUCT CANDIDATES </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are substantially dependent on the success of our lead product candidate, EYP-1901, which is in the early stages of development and must go through clinical trials, which are very expensive, time-consuming and difficult to design and implement. The outcomes of clinical trials are uncertain, and delays in the completion of or the termination of any clinical trial of EYP-1901 or our other product candidates could harm our business, financial condition and prospects. </p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our research and development program for our lead product candidate, EYP-1901, and certain of our other product candidates, are at an early stage of development. We must demonstrate EYP-1901&#8217;s and our other product candidates&#8217; safety and efficacy in humans through extensive clinical testing. Such testing is expensive and time-consuming and requires specialized knowledge and expertise.</span></p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming, and the outcome is not certain. We estimate that clinical trials of our product candidates will take multiple years to complete. Failure can occur at any stage of a clinical trial, and we could encounter problems that cause us to abandon or repeat clinical trials. The commencement and completion of clinical trials may be delayed or precluded by a number of factors, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">decisions not to pursue development of product candidates due to pre-clinical or clinical trial results or market factors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">lack of sufficient funding&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays or inability to attract clinical investigators for trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical sites dropping out of a clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">time required to add new clinical sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">any shelter-in-place orders from local, state or federal governments or clinical trial site policies resulting from the COVID-19 pandemic that determine essential and non-essential functions and staff, which may impact the ability of site staff to conduct assessments, or result in delays to the conduct of the assessments, as part of our clinical trial protocols, or the ability to enter assessment results into clinical trial databases in a timely manner&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays or inability to recruit patients in sufficient numbers or at the expected rate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">decisions by licensees not to exercise options for products or not to pursue or promote products licensed to them&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">adverse side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure of trials to demonstrate safety and efficacy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure to reach agreement with the FDA or other regulatory agency requirements for clinical trial design or scope of the development program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">patients&#8217; delays or failure to complete participation in a clinical trial or inability to follow patients adequately after treatment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in the design or manufacture of a product candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failures by, changes in our (or our licensees&#8217;) relationship with, or other issues at, CROs, vendors and investigators responsible for pre-clinical testing and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays or failures in obtaining required IRB approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">inability to obtain supplies and/or to manufacture sufficient quantities of materials for use in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">stability issues with clinical materials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure to comply with GLP, GCP, cGMP or similar foreign regulatory requirements that affect the conduct of pre-clinical and clinical studies and the manufacturing of product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">requests by regulatory authorities for additional data or clinical trials&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">governmental or regulatory agency assessments of pre-clinical or clinical testing that differ from our (or our licensees&#8217;) interpretations or conclusions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">governmental or regulatory delays, or changes in approval policies or regulations&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments, clinical trial results and other factors with respect to competitive products and treatments.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We, the FDA, other regulatory authorities outside the United States, or an IRB may suspend a clinical trial at any time for various reasons, including if it appears that the clinical trial is exposing participants to unacceptable health risks or if the FDA or one or more other regulatory authorities outside the United States find deficiencies in our IND or similar application outside the United States or the conduct of the trial. If we experience delays in the completion of, or the termination of, any clinical trial of any of our product candidates, including EYP-1901, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, results of operations, cash flows and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trial results may fail to support approval of EYP-1901 or our other product candidates.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Even if our clinical trials are successfully completed as planned, the results may not support approval of EYP-1901 or our other product candidates under the laws and regulations of the FDA or other regulatory authorities outside the United States. The clinical trial process may fail to demonstrate that our product candidates are both safe and effective for their intended uses. Pre-clinical and clinical data and analyses are often able to be interpreted in different ways. Even if we view our results favorably, if a regulatory authority has a different view, we may still fail to obtain regulatory approval of our product candidates. This, in turn, would significantly adversely affect our business prospects.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend significant resources to pursue our lead product candidate, EYP-1901 for the potential treatment of wet AMD, and fail to capitalize on the potential of EYP-1901, or our other product candidates, for the potential treatment of other indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. Specifically, with regard to EYP-1901, we are initially focusing our efforts on the treatment of wet AMD.&#160;&#160;As a result, we may forego or delay pursuit of opportunities with EYP-1901 or other product candidates for the treatment of other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Furthermore, until such time as we are able to build a broader product candidate pipeline, if ever, any adverse developments with respect to our leading product candidate, EYP-1901, would have a more significant adverse effect on our overall business than if we maintained a broader portfolio of product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically based our research and development efforts primarily on our proprietary technologies for the treatment of chronic eye diseases. As a result of pursuing the development of product candidates using our proprietary technologies, we may fail to develop product candidates or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial results from a clinical trial do not ensure that the trial will be successful and success in early stage clinical trials does not ensure success in later-stage clinical trials. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from pre-clinical testing, early clinical trials,&#160;&#160;prior clinical trials, investigator-sponsored studies and other data and information often do not accurately predict final pivotal clinical trial results. EYP-1901 relies on vorolanib as its active pharmaceutical agent. Vorolanib is a small molecule TKI that has been previously studied by Tyrogenix in Phase 1 and 2 clinical trials as an orally delivered therapy for the treatment of wet AMD. The Phase 2 clinical trial was discontinued due to systemic toxicity. There can be no assurance that such systemic toxicities will not occur in our Phase 1 clinical trial for EYP-1901. In addition, data from one pivotal clinical trial may not be predictive of the results of other pivotal clinical trials for the same product candidate, even if the trial designs are the same or similar. Data obtained from pre-clinical studies and clinical trials are susceptible to varying interpretations, which may delay, limit or prevent regulatory approval. Adverse side effects may be observed in clinical trials that delay, limit or prevent regulatory approval, and even after a product candidate has received marketing approval, the emergence of adverse side effects in more widespread clinical practice may cause the product&#8217;s regulatory approval to be limited or even rescinded. Additional trials necessary for approval may not be undertaken or may ultimately fail to establish the safety and efficacy of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while the clinical trials of our product candidates, including our lead product candidate, EYP-1901, are designed based on the available relevant information, in view of the uncertainties inherent in drug development, such clinical trials may not be designed with a focus on indications, patient populations, dosing regimens, safety or efficacy parameters or other variables that will provide the necessary safety and efficacy data to support regulatory approval to commercialize the product. In addition, the methods we select to assess particular safety or efficacy parameters may not yield statistically significant results regarding our product candidates&#8217; effects on patients. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face risks related to health epidemics and outbreaks, including the Pandemic, which could significantly disrupt our preclinical studies and clinical trials.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to conduct Phase 2 clinical trials for EYP-1901 in multiple jurisdictions within the U.S. beginning in 2022. Enrollment of patients in these clinical trials and future clinical trials in these regions may be delayed due to the outbreak of the Pandemic. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs. As a result, the expected timeline for data readouts of our preclinical studies and clinical trials and certain regulatory filings may be negatively impacted, which would adversely affect our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent clinical trials of our product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in clinical trials of our product candidates, including EYP-1901, is critical to our success. The timing of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates. If patients are unwilling to participate in our trials because of the COVID-19 pandemic and restrictions on travel or healthcare institution policies, negative publicity from adverse events in the biotechnology industries, public perception of vaccine safety issues or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of the clinical trials altogether.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a clinical trial, or complete our clinical trials in a timely manner. Patient enrollment is affected by a variety factors including, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">severity of the disease under investigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">design of the trial protocol and size of the patient population required for analysis of the trial&#8217;s primary endpoints&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">size of the patient population&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">eligibility criteria for the trial in question&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">perceived risks and benefits of the product candidate being tested&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">willingness or availability of patients to participate in our clinical trials (including due to the COVID-19 pandemic)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">proximity and availability of clinical trial sites for prospective patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to recruit clinical trial investigators with the appropriate competencies and experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">availability of competing vaccines and/or therapies and related clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">efforts to facilitate timely enrollment in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain and maintain patient consents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before completion&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">patient referral practices of physicians&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">ability to monitor patients adequately during and after treatment.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by regulatory agencies. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we enroll a sufficient number of eligible patients to initiate our clinical trials, we may be unable to maintain participation of these patients throughout the course of the clinical trial as required by the clinical trial protocol, in which event we may be unable to use the research results from those patients. If we have difficulty enrolling and maintaining the enrollment of a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are largely dependent on the clinical and future commercial success of our lead product candidate, EYP-1901.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenues and become profitable will depend in large part on the future commercial success of our lead product candidate, EYP-1901, if it is approved for marketing.&#160; If EYP-1901 or any other product that we commercialize in the future does not gain an adequate level of acceptance among physicians, patients and third parties, we may not generate significant product revenues or become profitable. Market acceptance by physicians, patients and third party payors of EYP-1901 or other products we may commercialize in the future will depend on a number of factors, some of which are beyond our control, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">their efficacy, safety and other potential advantages in relation to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">their relative convenience and ease of administration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the prevalence and severity of adverse events&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">their cost of treatment in relation to alternative treatments, including generic products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent and strength of our third party manufacturer and supplier support&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent and strength of marketing and distribution support&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the limitations or warnings contained in a product&#8217;s approved labeling&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">distribution and use restrictions imposed by the FDA or other regulatory authorities outside the United States.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, even if EYP-1901 gains approval by the FDA, physicians and patients may not immediately be receptive to it and may be slow to adopt it. If EYP-1901 does not achieve an adequate level of acceptance among physicians, patients and third party payors, we may not generate meaningful revenues from EYP-1901 and we may not become profitable.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISKS RELATED TO THE COMMERCIALIZATION OF OUR PRODUCTS AND PRODUCT CANDIDATES </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current business strategy relies in part on our ability to successfully commercialize YUTIQ and DEXYCU and in the U.S.&#160;Our approved products may not achieve market acceptance or be commercially successful. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully commercialize YUTIQ and DEXYCU in the U.S. is important to the execution of our business strategy.&#160;Neither YUTIQ nor DEXYCU may achieve broad market acceptance among retinal specialists and other doctors, patients, government health administration authorities and other third-party payors, and may not be commercially successful in the U.S. The degree of market acceptance and commercial success of our approved products will depend on a number of factors, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the acceptance of our products by patients and the medical community and the availability, perceived advantages and relative cost, safety and efficacy of alternative and competing treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">unless separate payment for DEXYCU is further extended by CMS beyond December 31, 2022, the loss of separate payment would significantly hinder the purchase and utilization of DEXYCU by ASCs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the current lack of a separately payable CPT code (i.e. outside of the cataract payment bundle) for the injection of DEXYCU into the posterior chamber of the anterior segment of the eye&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain reimbursement for our products from third party payors at levels sufficient to support commercial success&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost effectiveness of our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the effectiveness of our commercial alliance partner in its efforts to market and sell DEXYCU&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the effectiveness of our distribution strategies and operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability and the ability of our contract manufacturing organizations, or CMOs, as applicable, to manufacture commercial supplies of our products, to remain in good standing with regulatory agencies, and to develop, validate and maintain commercially viable manufacturing processes that are, to the extent required, compliant with cGMP regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the degree to which the approved labeling supports promotional initiatives for commercial success&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a continued acceptable safety profile of our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">results from additional clinical trials of our products or further analysis of clinical data from completed clinical trials of our products by us or our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our products&#8217; potential advantages over other therapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to avoid third-party patent interference or patent infringement claims&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">maintaining compliance with all applicable regulatory requirements. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As many of these factors are beyond our control, we cannot assure you that we will ever be able to generate meaningful revenues through product sales. In particular, if governments, private insurers, governmental insurers and other third-party payors do not provide adequate and timely coverage and reimbursement levels for our products or limit the frequency of administration, the market acceptance of our products and product candidates will be limited. Governments, governmental insurers, private insurers and other third-party payors attempt to contain healthcare costs by limiting coverage and the level of reimbursement for products and, accordingly, they may challenge the price and cost-effectiveness of our products or refuse to provide coverage for our products. Any inability on our part to successfully commercialize YUTIQ and DEXYCU, and our other product candidates in the U.S. or any foreign territories where they may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and our future business prospects. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be adversely affected by our exposure to customer concentration risk.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our commercialization partner for DEXYCU sells a significant amount of DEXYCU to a limited number of customers, resulting in a small number of customers accounting for a significant portion of our DEXYCU revenues. If our commercialization partner were to lose the business of one or more of these customers, or if any of these customers negotiated specialized rebate or extended payment terms, it could have a material adverse effect on our commercial business, results of operations and cash flows.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, including DEXYCU pass-through status, which could harm our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more of our products. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success also depends in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may seek additional clinical evidence, beyond the data required to obtain marketing approval, demonstrating clinical benefits and value in specific patient populations, before covering our products for those patients. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. For example, under current Medicare Part B policy, payment to hospital outpatient departments and ambulatory surgical centers for products furnished to patients during a procedure is typically packaged into the payment for the associated procedure and thus not paid separately. Products granted pass-through status are excluded from this payment packaging policy and currently receive separate payment from the associated procedure for a period of three years. While DEXYCU has been granted pass-through status and will receive separate payment in these settings from Medicare for a period of three years (measured on the basis of the date Medicare receives its first claim for reimbursement for DEXYCU), at the end of that three year period or any future extension of the three year period, or if such three-year period is shortened by a change in law, regulation or Administrative interpretation, payment for DEXYCU may be packaged into the payment for the associated procedure and no longer be paid separately, which we expect would materially decrease our revenues from sales of DEXYCU and correspondingly have a material adverse effect on our results of operations and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacturing, selling and distribution costs. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We participate in, and have certain price reporting obligations to, the Medicaid Drug Rebate Program. This program requires us to pay a rebate for each unit of drug reimbursed by Medicaid. The amount of the &#8220;basic&#8221; portion of the rebate for each product is set by law as the larger of: (i)&#160;23.1% of quarterly average manufacturer price, or AMP, or (ii)&#160;the difference between quarterly AMP and the quarterly best price available from us to any commercial or non-governmental customer, or Best Price. AMP must be reported on a monthly and quarterly basis and Best Price is reported on a quarterly basis only. In addition, the rebate also includes the &#8220;additional&#8221; portion, which adjusts the overall rebate amount upward as an &#8220;inflation penalty&#8221; when the drug&#8217;s latest quarter&#8217;s AMP exceeds the drug&#8217;s AMP from the first full quarter of sales after launch, adjusted for increases in the Consumer Price Index-Urban. The upward adjustment in the rebate amount per unit is equal to the excess amount of the current AMP over the inflation-adjusted AMP from the first full quarter of sales. The rebate amount is computed each quarter based on our report to CMS of current quarterly AMP and Best Price for our drug. Medicaid Drug Rebate Program caps are currently set at 100 percent of AMP, but that cap is set to be removed, effective January 1, 2024, which could increase our rebate liability. We are required to report revisions to AMP or Best Price within a period not to exceed 12 quarters from the quarter in which the data was originally due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. The Affordable Care Act made significant changes to the Medicaid Drug Rebate Program, and CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. On December 21, 2020, CMS issued a final regulation that modified existing Medicaid Drug Rebate Program regulations to permit reporting multiple Best Price figures with regard to value&#8209;based purchasing arrangements (beginning in 2022)&#59; provide definitions for &#8220;line extension,&#8221; &#8220;new formulation,&#8221; and related terms with the practical effect of expanding the scope of drugs considered to be line extensions (beginning in 2022)&#59; and revise AMP and Best Price exclusions of manufacturer-sponsored patient benefit programs, specifically regarding inapplicability of such exclusions in the context of pharmacy benefit manager &#8220;accumulator&#8221; programs (beginning in 2023).&#160;&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal law also requires that any manufacturer that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B drug pricing program, which is administered by the Health Resources and Services Administration, or HRSA, requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. These 340B covered entities include, but are not limited to, a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. Any changes to the definition of AMP and the Medicaid rebate amount under the Affordable Care Act or other legislation could affect our 340B ceiling price calculations and negatively impact our results of operations. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&#160;1, 2019. It is currently unclear how HRSA will apply its enforcement authority under this regulation. HRSA has also implemented a ceiling price reporting requirement related to the 340B program under which we are required to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA then publishes that information to covered entities.&#160;&#160;Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal law also requires that a company that participates in the Medicaid Drug Rebate program report average sales price, or ASP, information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. For calendar quarters beginning January 1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate Program. Manufacturers calculate the ASP based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologicals, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory or regulatory changes or CMS guidance could affect the pricing of our approved products, and could negatively affect our results of operations. For example, Congress could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation, or enact other legislation that would otherwise limit reimbursement of Part B products. In addition, manufacturers are currently required to provide a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. In addition, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the non-federal average manufacturer price. These or any other public policy change could impact the market conditions for our products. We further expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we must participate in the VA FSS pricing program. Under this program, we would be obligated to make our &#8220;innovator&#8221; drugs available for procurement on an FSS contract and charge a price to four federal agencies&#8212;VA, DoD, Public Health Service and U.S. Coast Guard&#8212;that is no higher than the statutory FCP. The FCP is based on the Non-FAMP, which we calculate and report to the VA on a quarterly and annual basis. We do not currently participate in the Tricare Retail Pharmacy program, under which we would need to pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to TRICARE beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP. The requirements under the 340B, FSS, and TRICARE programs will impact gross-to-net revenue for our current products and any product candidates that are commercialized in the future and could adversely affect our business and operating results. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are shipping YUTIQ directly to physician offices or clinics to be administered to patients. YUTIQ is being shipped to physician offices or clinics primarily through specialty pharmacies and distributors. Most prefer to buy the product directly through our select distributors under a &#8220;buy and bill&#8221; model. Physicians who may not be willing to purchase our products through a specialty distributor because they do not prefer the buy and bill method may prefer to have another entity called a specialty pharmacy ship them the product at no cost to the physician. The specialty pharmacy bills the health plan for our product directly and then ships the product to the physician such that no costs are incurred by the physician. We have obtained a permanent &#8220;J&#8221; code for YUTIQ which assists physicians and hospitals in their ability to bill all payer types for the product. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are shipping DEXYCU to ASCs, or to hospital outpatient surgical centers through specialty pharmacies and distributors. DEXYCU is being reimbursed for Medicare Part B patients in these settings through a transitional pass-through payment utilizing a &#8220;J&#8221; code. After the initial 3-year period (measured on the basis of the date Medicare receives its first claim for reimbursement for DEXYCU), DEXYCU may not qualify for separate payment and, therefore, may be subject to cataract bundled payment rates, which would significantly limit our ability to gain utilization and subsequent revenues. In addition, ImprimisRx may terminate our Commercial Alliance Agreement in the event of loss a pass-through status in accordance with the terms of the commercial alliance arrangement with ImprimisRX. DEXYCU received an adjusted separate payment for nine months in the Final Rule of the 2022 Hospital Outpatient Prospective Payment System, which preserves separate payment for the product through December 31, 2022. A decision by CMS as to whether separate payment for DEXYCU will continue beyond calendar year 2022 is anticipated during the fourth quarter of 2022. The loss of pass-through status with respect to DEXYCU would materially decrease our revenues from sales of DEXYCU and correspondingly result in an impairment of the DEXYCU asset on our balance sheet, which would negatively impact our financial results.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our price reporting and other obligations under the Medicaid Drug Rebate Program, Medicare Part B, the 340B program, and the VA/FSS program are described in the risk factor entitled &#8220;Our products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could harm our business.&#8221; Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. In the case of Medicaid pricing data, if we become aware that our reporting for a prior period was incorrect or has </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changed as a result of a recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data were originally due. Such restatements and recalculations will increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program and may require us to offer refunds to covered entities.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are liable for errors associated with our submission of pricing data. That liability could be significant. In addition to retroactive Medicaid rebates and the potential for issuing 340B program refunds, if we are found to have knowingly submitted false AMP, Best Price, or Non-FAMP information to the government, we may be liable for significant civil monetary penalties per item of false information. If we are found to have made a misrepresentation in the reporting of our ASP, the Medicare statute provides for significant civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. Our failure to submit monthly/quarterly AMP and Best Brice data on a timely basis could result in a significant civil monetary penalty per day for each day the information is late beyond the due date. Such conduct also could be grounds for CMS to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. Significant civil monetary penalties also could apply to late submissions of Non-FAMP information. Civil monetary penalties could also be applied if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price or HRSA could terminate our agreement to participate in the 340B program, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an ADR process that has jurisdiction over claims by covered entities that a manufacturer has engaged in overcharging. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability.&#160;&#160;In addition, claims submitted to federally-funded healthcare programs, such as Medicare and Medicaid, for drugs priced based on incorrect pricing data provided by a manufacturer can implicate the federal civil False Claims Act. Finally, civil monetary penalties could be due if we fail to offer discounts to beneficiaries under the Medicare Part D coverage gap discount program. And, once the refund program for discarded drug takes effect in 2023, manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we overcharge the government in connection with our FSS contract or our anticipated Tricare Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We cannot assure you that our submissions will not be found by CMS or another governmental agency to be incomplete or incorrect.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even though regulatory approvals for YUTIQ and DEXYCU have been obtained in the U.S., we will still face extensive FDA regulatory requirements and may face future regulatory difficulties. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though regulatory approvals for YUTIQ and DEXYCU have been obtained in the U.S., the FDA and state regulatory authorities may still impose significant restrictions on the indicated uses or marketing of YUTIQ and DEXYCU, or impose ongoing requirements for potentially costly post-approval studies or post-marketing surveillance. For example, as part of its approval of DEXYCU for the treatment of postoperative ocular inflammation, the FDA required under the Pediatric Research Equity Act (&#8220;PREA&#8221;), that a Phase 3/4 prospective, randomized, active treatment-controlled, parallel-design multicenter trial be conducted to evaluate the safety of DEXYCU for the treatment of inflammation following ocular surgery for childhood cataract. This pediatric study will likely require us to undergo a costly and time-consuming development process. If we do not meet our obligations under the PREA for this pediatric study, the FDA may issue a non-compliance letter and may also consider DEXYCU to be misbranded and subject to potential enforcement action. We requested an extension in October 2020 but were denied by the FDA in November 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were advised by the FDA to show diligence and enroll at least one patient in the protocolled trial before submitting a new Deferral Extension Request.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We submitted a pediatric study protocol to the FDA as required. We have identified clinical sites and are continuing study start-up activities that have resulted in dosing of a first patient in January 2022. In February 2022, we requested a PREA Deferral Extension because of the unavoidable delays in this program due, among other things, to the Pandemic.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-marketing information. The holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA regulations and may be subject to other potentially applicable federal and state laws. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of drug products and their facilities are subject to payment of substantial user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and adherence to commitments made in the NDA. We </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also need to comply with some of the FDA&#8217;s manufacturing regulations for devices with respect to YUTIQ. We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to cGMP, the FDA requires that YUTIQ and DEXYCU manufacturers comply with certain provisions of the Quality System Regulation, or QSR, particularly in light of the D.C. Circuit Court of Appeals decision in Genus Medical Technologies LLC v. FDA. The QSR sets forth the FDA&#8217;s manufacturing quality standards for medical devices, and other applicable government regulations and corresponding foreign standards. If we, or a regulatory authority, discover previously unknown problems with YUTIQ or DEXYCU, such as adverse events of unanticipated severity or frequency, or problems with a facility where the product is manufactured, a regulatory authority may impose restrictions relative to YUTIQ, DEXYCU or their respective manufacturing facilities, including requiring recall or withdrawal of the product from the market, suspension of manufacturing, or other FDA action or other action by foreign regulatory authorities. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements for YUTIQ or DEXYCU, a regulatory authority may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">issue a warning letter asserting that we are in violation of the law&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek an injunction or impose civil or criminal penalties or monetary fines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">suspend, modify or withdraw regulatory approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">suspend any ongoing clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refuse to approve a pending NDA or a pending application for marketing authorization or supplements to an NDA or to an application for marketing authorization submitted by us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seize our product&#59; and/or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refuse to allow us to enter into supply contracts, including government contracts. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with physicians, patients and payors in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. In addition, we are subject to patient privacy regulation by both the federal government and the states in which we conduct our business. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future operations with respect to the commercialization of YUTIQ and DEXYCU are subject to various U.S. federal and state healthcare laws and regulations. These laws impact, among other things, our proposed sales, marketing, support and education programs and constrain our business and financial arrangements and relationships with third-party payors, healthcare professionals and others who may prescribe, recommend, purchase or provide our products, and other parties through which we market, sell and distribute our products. Finally, our current and future operations are subject to additional healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws include, but are not limited to, the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The U.S. federal Anti-Kickback Statute prohibits persons or entities from, among other things, knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and Medicare patients, prescribers, purchasers and formulary managers on the other. In addition, the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common manufacturer business arrangements and activities from prosecution and administrative sanction, the exemptions and safe harbors are drawn narrowly, and practices or arrangements that involve remuneration may be subject to scrutiny if they do not qualify for an exemption or safe harbor. In November 2020, the U.S. Department of Health and Human Services finalized a previously abandoned proposal to amend the discount safe harbor regulation of the Anti-Kickback Statute in a purported effort to create incentives to manufacturers to lower their list prices, and to lower federal program beneficiary out-of-pocket costs.&#160;&#160;The rule, which is currently slated to take full effect January 1, 2023, revises the Anti-Kickback Statute discount safe harbor to exclude manufacturer rebates to Medicare Part D plans, either directly or through PBMs, </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">creates a new safe harbor for point-of-sale price reductions that are set in advance and are available to the beneficiary at the point-of-sale, and creates a new safe harbor for service fees paid by manufacturers to PBMs for services rendered to the manufacturer.&#160;&#160;It is too early to know whether the Biden Administration will further delay, rewrite, or allow the rule to go into effect, and what effect the rule </span><span style="font-size:10pt;color:#000000;">may have on negotiations for coverage for products with Medicare Part D plans or commercial insurers. </span><span style="font-size:10pt;color:#000000;">Our practices may not in all cases meet all of the criteria for safe harbor protection, and therefore would be subject to a facts and circumstances analysis to determine potential Anti-Kickback </span><span style="font-size:10pt;color:#000000;">S</span><span style="font-size:10pt;color:#000000;">tatute liability. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The federal civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government) prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government. Many pharmaceutical and other healthcare companies have been investigated or subject to lawsuits by whistleblowers and have reached substantial financial settlements with the federal government under the False Claims Act for a variety of alleged improper marketing activities, including providing free product to customers with the expectation that the customers would bill federal programs for the product&#59; providing consulting fees, grants, free travel, and other benefits to physicians to induce them to prescribe the company&#8217;s products&#59; and inflating prices reported to private price publication services, which are used to set drug reimbursement rates under government healthcare programs. In addition, the government and private whistleblowers have pursued False Claims Act cases against pharmaceutical companies for causing false claims to be submitted as a result of the marketing of their products for unapproved uses. Pharmaceutical and other healthcare companies also are subject to other federal false claim laws, including federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs&#59; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, and its implementing regulations, impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information and impose notification obligations in the event of a breach of the privacy or security of individually identifiable health information. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Numerous federal and state laws and regulations that address privacy and data security, including state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act, or FTC Act), govern the collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, and time consuming, and companies that do not comply with these state laws may face civil penalties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The majority of states have adopted analogous laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers. Other states have adopted laws that, among other things, require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities. In addition, some states have laws requiring pharmaceutical sales representatives to be registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that a healthcare or pharmaceutical company may fail to comply fully with one or more of these requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and reporting requirements if we become subject to a corporate integrity agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to the same criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert resources and the attention of our management from operating our business. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may inhibit our ability to commercialize YUTIQ and DEXYCU in the U.S. and generate revenues, which would have a material adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the market opportunities for our products and product candidates, including EYP-1901, are smaller than we believe they are, our results of operations may be adversely affected and our business may suffer. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and product development primarily on treatments for eye&#160;diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our products and product candidates, such as our projections of the number of patients with wet AMD who may benefit from treatment with EYP-1901 if it is approved for use, are based on estimates. These estimates may prove to be incorrect and new studies or clinical trials may change the estimated incidence or prevalence of these diseases. The number of patients in the U.S. and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. For example, we are developing our leading product candidate, EYP-1901, for the treatment of wet AMD.&#160;&#160;Although we believe wet AMD is a common condition and a leading cause of vision loss for people age 50 and older, our estimates of the potential market opportunity for EYP-1901 may be incorrect.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of our products have newly discovered or developed safety problems, our business would be seriously harmed. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our approved products are and will be subject to continued oversight by the FDA or other foreign regulatory bodies, and we cannot assure you that newly discovered or developed safety issues will not arise. Although we have observed no material safety issues to date, we cannot rule out that issues may arise in the future. For example, with the use of any newly marketed drug by a wider patient population, serious adverse events may occur from time to time that initially do not appear to relate to the drug itself. If such events are subsequently associated with the drug, or if any other safety issue emerges, we or our collaboration partners may voluntarily, or FDA or other regulatory authorities may require that we suspend or cease marketing of our approved products or modify how we or they market our approved products. In addition, newly discovered safety issues may subject us to substantial potential liabilities and adversely affect our financial condition and business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Affordable Care Act and any changes in healthcare laws may increase the difficulty and cost for us to commercialize DEXYCU and YUTIQ in the U.S. and affect the prices we may obtain. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. and state governments have enacted and proposed legislative and regulatory changes affecting the healthcare system that could affect our ability to profitably sell YUTIQ and DEXYCU, prevent or delay marketing of our other product candidates, and restrict or regulate post-approval activities. The U.S. and state governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Affordable Care Act was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among the provisions of the Affordable Care Act that have been implemented since enactment and are of importance to the commercialization of YUTIQ and DEXYCU in the U.S. are the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs or biologic agents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expansion of healthcare fraud and abuse laws, including the U.S. civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (such manufacturer discounts were increased from 50% to 70% effective as of January 1, 2019 as required by the Bipartisan Budget Act of 2018)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">price reporting requirements for drugs that are inhaled, infused, instilled, implanted, or injected&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expansion of eligibility criteria for Medicaid programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">addition of entity types eligible for participation in the Public Health Service Act&#8217;s 340B drug pricing program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain provisions of the Affordable Care Act have been subject to judicial challenges as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation or implementation. For example, Congress eliminated, starting January&#160;1, 2019, the tax<span style="font-size:12pt;"> </span>penalty for not complying with the Affordable Care Act&#8217;s individual mandate to carry health insurance Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drugs plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January&#160;1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. It is unclear how the Affordable Care Act and its implementation, as well as efforts to modify or invalidate the Affordable Care Act, or portions thereof or its implementation, will affect our business, financial condition and results of operations. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of YUTIQ and DEXYCU in the U.S. or to successfully commercialize either product in the U.S. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect that the Affordable Care Act, as well as other healthcare reform measures that have been adopted and that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we receive for YUTIQ and DEXYCU in the U.S., and could seriously harm our future revenues. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or successfully commercialize YUTIQ and DEXYCU in the U.S. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. For example, in November 2020, the U.S. Department of Health and Human Services finalized a previously abandoned proposal to amend the discount safe harbor regulation of the federal anti-kickback statute in a purported effort to create incentives to manufacturers to lower their list prices, and to lower federal program beneficiary out-of-pocket costs. The rule, which is currently slated to take full effect January 1, 2023, revises the discount safe harbor to exclude manufacturer rebates to Medicare Part D plans, either directly or through PBMs, creates a new safe harbor for point-of-sale price reductions that are set in advance and are available to the beneficiary at the point-of-sale, and creates a new safe harbor for service fees paid by manufacturers to PBMs for services rendered to the manufacturer. The effective date of the rule was already delayed by the Biden Administration and legal challenges. It is unclear whether the rule will be further delayed, rewritten, or allowed to go into effect, and if so, what the effect of the rule will be on negotiations of coverage for our products with Medicare Part D plans, or whether the rule will affect our coverage arrangements with commercial insurers. It is also unclear whether the rule will have the intended effect of reducing net prices and beneficiary out-of-pocket costs without also increasing Medicare Part D premiums, which may impact the willingness of Part D plans to cover our products and the price concessions or other terms the plans or their PBMs may seek from us.&#160;&#160;In addition, in November 2020, the OIG issued a Special Fraud Alert to highlight certain inherent fraud and abuse risks associated with speaker fees, honorariums and expenses paid by pharmaceutical and medical device companies to healthcare professionals participating in company-sponsored events. The Special Fraud Alert sent a clear signal that speaker programs will be subject to potentially heightened enforcement scrutiny.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patient assistance programs for pharmaceutical products have come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing prices or demand for our products, harming our business or reputation, or subjecting us to fines or penalties. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sponsor patient assistance programs, which are available to qualified patients for our products, including insurance premium and copay assistance programs.&#160;&#160;We also make donations to third-party charities that provide such assistance. Recently, there has been enhanced scrutiny of such company-sponsored programs and services.&#160;&#160;If we, our vendors or donation recipients, are deemed to have failed to comply with relevant laws, regulations or government guidance in any of these areas, we could be subject to criminal and civil sanctions, including significant fines, civil monetary penalties and exclusion from participation in government healthcare programs, including Medicare and Medicaid, and burdensome remediation measures. Actions could also be brought against executives overseeing our business or other employees. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that any actions taken by the Department of Justice (&#8220;DOJ&#8221;) as a result of this industry-wide inquiry could reduce demand for our products and/or reduce coverage of our products, including by federal and state health care programs such as Medicare and Medicaid. If any or all of these events occur, our business, prospects and stock price could be materially and adversely affected. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If competitive products are more effective, have fewer side effects, are more effectively marketed and/or cost less than our products or product candidates, or receive regulatory approval or reach the market earlier, our product candidates may not be approved, and our products or product candidates may not achieve the sales we anticipate and could be rendered noncompetitive or obsolete. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that pharmaceutical, drug delivery and biotechnology companies, research organizations, governmental entities, universities, hospitals, other nonprofit organizations and individual scientists are seeking to develop drugs, therapies, products, approaches or methods to treat our targeted diseases or their underlying causes. For our targeted diseases, competitors have alternate therapies that are already commercialized or are in various stages of development, ranging from discovery to advanced clinical trials. Any of these drugs, therapies, products, approaches or methods may receive government approval or gain market acceptance more rapidly than our products and product candidates, may offer therapeutic or cost advantages, or may more effectively treat our targeted diseases or their underlying causes, which could result in our product candidates not being approved, reduce demand for our products and product candidates or render them noncompetitive or obsolete. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors and potential competitors for our leading product candidate, EYP-1901, and our commercialized products, YUTIQ and DEXYCU, have substantially greater financial, technological, research and development, marketing and personnel resources than we do. Our competitors may succeed in developing alternate technologies and products that, in comparison to the products or product candidates we have and are seeking to develop: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">are more effective and easier to use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">are more economical&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">have fewer side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">offer other benefits&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">may otherwise render our products less competitive or obsolete. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these competitors have greater experience in developing products, conducting clinical trials, obtaining regulatory approvals or clearances and manufacturing and marketing products than we do. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DEXYCU is an intraocular suspension that delivers dexamethasone, a corticosteroid that is associated with certain adverse side effects in the eye, which may affect the success of DEXYCU for the treatment of post-operative inflammation. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU is an intraocular suspension that delivers dexamethasone, a corticosteroid, which is associated with certain adverse side effects in the eye. The safety analyses from DEXYCU&#8217;s clinical trials revealed that the most commonly reported adverse reactions were increases in intraocular pressure (&#8220;IOP&#8221;), corneal edema and iritis, a type of uveitis affecting the front of the eye. These side effects may adversely affect sales of DEXYCU. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, it could reduce our sales of those products or product candidates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., after an NDA is approved, the product generally becomes a &#8220;listed drug&#8221; which can, in turn, be relied upon by potential competitors in support of approval of an ANDA. The Federal Food, Drug, and Cosmetic Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create generic, non-infringing versions of a drug to facilitate the approval of an ANDA. These manufacturers might show that their product has the same active ingredients, dosage form, strength, route of administration, conditions of use, and labeling as our product candidate and might conduct a relatively inexpensive study to demonstrate that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product. These generic equivalents would be significantly less costly than ours to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our products would substantially limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our products. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of YUTIQ and DEXYCU, and any other product candidates that we may develop and commercialize, including EYP-1901. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face the risk of product liability exposure as we commercialize YUTIQ and DEXYCU, and other product candidates that we may develop and commercialize. We also may face product liability claims from patients who are treated with any of our product candidates in clinical trials. If we cannot successfully defend ourselves against claims that our products or product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">decreased demand for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">injury to our reputation and significant negative media attention&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">termination of clinical trial sites or entire trial programs that we conduct in the future relating to YUTIQ, DEXYCU, EYP-1901 or our other product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">withdrawal of clinical trial participants from any future clinical trial relating to YUTIQ, DEXYCU, EYP-1901 or our other product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significant costs to defend the related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">substantial money awards to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">loss of revenue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">diversion of management and scientific resources from our business operations&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an increase in product liability insurance premiums or an inability to maintain product liability insurance coverage. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently carry product liability insurance with coverage up to $30.0&#160;million in the aggregate, with a per incident limit of $30.0&#160;million, which may not be adequate to cover all liabilities that we may incur. Further, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to maintain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of YUTIQ and DEXYCU, or the development and commercialization of our other product candidates, including EYP-1901.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, any agreements we may enter into in the future with collaborators in connection with the development or commercialization of YUTIQ, DEXYCU, EYP-1901 or any of our other product candidates may entitle us to indemnification against product liability losses, but such indemnification may not be available or adequate should any claim arise. In addition, several of our agreements require us to indemnify third parties and these indemnification obligations may exceed the coverage under our product liability insurance policy. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our product candidates, our competitors could develop and commercialize technology and products similar to ours, and our competitive position could be harmed. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and trademark laws, and confidentiality and other agreements with employees and third parties, all of which offer only limited protection. We seek patent protection for many different aspects of our product candidates, including their compositions, their methods of use, processes for their manufacture, and any other aspects that we deem to be commercially important to the development of our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive and&#160;time-consuming,&#160;and we and any licensors and licensees may not be able to apply for or prosecute patents on certain aspects of our product candidates or delivery technologies at a reasonable cost, in a timely fashion, or at all. For technology licensed to third parties, we may not have the right to control the preparation, filing and/or prosecution of the corresponding patent applications, or to maintain patent rights corresponding to such technology. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is also possible that we, or any licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If any licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, such patent rights could be compromised, and we might not be able to prevent third parties from making, using, and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods, and&#160;know-how.&#160;Any of these outcomes could impair our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition, and operating results. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patents that issue, are highly uncertain. For example, recent changes to the patent laws of the U.S. provide additional procedures for third parties to challenge the validity of issued patents. Under the&#160;Leahy-Smith&#160;America Invents Act, or AIA, which was signed into law on September&#160;16, 2011, patents issued from applications with an effective filing date after March&#160;15, 2013, may be challenged by third parties using the post-grant review procedure which allows challenges for a number of reasons, including prior art, sufficiency of disclosure, and subject matter eligibility. Under the AIA, patents may also be challenged under the<span style="font-style:italic;">&#160;inter partes</span>&#160;review procedure.<span style="font-style:italic;">&#160;Inter partes</span>&#160;review provides a mechanism by which any third party may challenge the validity of any issued U.S. Patent in the USPTO on the basis of prior art. Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings as compared to the evidentiary standard relied on in U.S. federal court, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to foreign jurisdictions, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Also, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patents and patent applications, even if unchallenged by a third party, may not adequately protect our intellectual property or prevent others from designing around our claims. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the U.S. Further, the examination process may require us to narrow the claims of pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be impaired. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2022, we had several patents and pending applications, including patents and pending applications covering our Durasert&#174;, Verisome&#174; and other technologies. With respect to these patent rights, we do not know whether any of our patent applications will result in issued patents or, if any of our patent applications do issue, whether such patents will protect our technology in whole or in part, or whether such patents will effectively prevent others from commercializing competitive technologies and products. There is no guarantee that any of our issued or granted patents will not later be found invalid or unenforceable. Furthermore, since patent applications in the U.S. and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or (ii)&#160;invent any of the inventions claimed in our patents or patent applications. For applications with an effective filing date before March&#160;16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March&#160;16, 2013, the U.S. transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. The change to &#8220;first-to-file&#8221; from &#8220;first-to-invent&#8221; is one of the changes to the patent laws of the U.S. resulting from the AIA. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing or in some cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we were the first to make the inventions claimed in our pending patent applications, that we were the first to file for patent protection of such inventions, or that we have found all of the potentially relevant prior art relating to our patents and patent applications that could invalidate one or more of our patents or prevent one or more of our patent applications from issuing. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate oppositions, interferences,&#160;re-examinations,&#160;post-grant&#160;reviews,<span style="font-style:italic;">&#160;inter partes</span>&#160;reviews, nullification or derivation actions in court or before patent offices or similar proceedings challenging the validity, enforceability, or scope of such patents, which may result in the patent claims being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of any party from whom we may license patents from in the future. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and&#160;time-consuming.&#160;In a patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or&#160;non-enablement.&#160;Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. A court may decide that a patent of ours or of any of our future licensors is not valid, or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. In addition, to the extent that we have to file patent litigation in a federal court against a U.S. patent holder, we would be required to initiate the proceeding in the state of incorporation or residency of such entity. With respect to the validity question, for example, we cannot be certain that no invalidating prior art exists. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found unenforceable, or interpreted narrowly, and it could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products. Such a loss of patent protection could compromise our ability to pursue our business strategy. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, interference proceedings brought by the USPTO for applications with an effective filing date before March&#160;16, 2013, or for patents issuing from such applications may be necessary to determine the priority of inventions with respect to our patents and patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone or with any of our future licensors, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we may be subject to a&#160;third-party&#160;pre-issuance&#160;submission of prior art to the USPTO or other foreign patent offices, or become involved in opposition, derivation, reexamination,<span style="font-style:italic;">&#160;inter partes</span>&#160;review,&#160;post-grant&#160;review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could invalidate or reduce the scope of, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party&#160;patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our product candidates throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. may be less extensive than those in the U.S. In addition, the laws and practices of some foreign countries do not protect intellectual property rights, especially those relating to life sciences, to the same extent as federal and state laws in the U.S. For example, novel formulations of drugs and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Also, some foreign countries, including EU countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. Consequently, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, and we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventions into or within the U.S. or other jurisdictions. This could limit our potential revenue opportunities. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing with us in these jurisdictions. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from our intellectual property. We may not prevail in any lawsuits that we initiate in these foreign countries and the damages or other remedies awarded, if any, may not be commercially meaningful. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents and applications. The USPTO and various&#160;non-U.S.&#160;governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which&#160;non-compliance&#160;can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability, and the ability of our partners and collaborators, to develop, manufacture, market and sell our products and product candidates, if approved, and use our proprietary technologies without infringing the proprietary rights of third parties. While many of our product candidates are in pre-clinical studies and clinical trials, we believe that the use of our product candidates in these pre-clinical studies and clinical trials falls within the scope of the exemptions provided by 35 U.S.C. Section&#160;271(e) in the U.S., which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA. As our other product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to significant delay and expensive and&#160;time-consuming&#160;patent litigation before our product candidates may be commercialized. There can be no assurance that our products or product candidates do not infringe other parties&#8217; patents or other proprietary rights, and competitors or other parties may assert that we infringe their proprietary rights in any event. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates, including interference or derivation proceedings before the USPTO. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue commercializing our products or product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if a license can be obtained on acceptable terms, the rights may be&#160;non-exclusive,&#160;which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we may be unable to effectively market products or product candidates based on our technology, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenues sufficient to sustain our operations. Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Under certain circumstances, we could be forced, including by court order, to cease commercializing our products or product candidates. In addition, in any such proceeding or litigation, we could be found liable for substantial monetary damages, potentially including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed. A finding of infringement could prevent us from commercializing our products or product candidates or force us to cease some of our business operations, which could harm our business. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar negative impact on our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our commercialization efforts, delay our research and development efforts and limit our ability to continue our operations. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a&#160;non-infringing&#160;manner. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may seek approval to market their own products that are the same as, similar to or otherwise competitive with our products or product candidates. In these circumstances, we may need to defend or assert our patents by various means, including filing lawsuits alleging patent infringement requiring us to engage in complex, lengthy and costly litigation or other proceedings. In any of these types of proceedings, a court or government agency with jurisdiction may find our patents invalid, unenforceable or not infringed. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in either U.S. or foreign patent law or interpretation of such laws could diminish the value of patents in general, thereby impairing our ability to protect our products or product candidates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and it therefore is costly,&#160;time-consuming&#160;and inherently uncertain. As noted above, the AIA has significantly changed U.S. patent law. In addition to transitioning from a &#8220;first-to-invent&#8221; to &#8220;first-to-file&#8221; system, the AIA also limits where a patentee may file&#160;a patent infringement suit and provides opportunities for third parties to challenge issued patents in the USPTO via post-grant review or<span style="font-style:italic;">&#160;inter partes</span>&#160;review, for example. All of our U.S. patents, even those issued before March&#160;16, 2013, may be challenged by a third party seeking to institute<span style="font-style:italic;">&#160;inter partes</span>&#160;review. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by the U.S. Congress, the federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims asserting that our employees, consultants, independent contractors and advisors have wrongfully used or disclosed confidential information and/or alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the proprietary information or&#160;know-how&#160;of others in their work for us, we may be subject to claims that these individuals or we have inadvertently or otherwise used or disclosed confidential information and/or intellectual property, including trade secrets or other proprietary information, of the companies that any such individual currently or formerly worked for or provided services to. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while we require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be&#160;self-executing&#160;or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not prevent all potential threats to competitive advantages we may have. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following examples are illustrative: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may be able to make drug and device components that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or any of our licensors or collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or any of our licensors or collaborators might not have been the first to file patent applications covering certain of our inventions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the prosecution of our pending patent applications may not result in granted patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">granted patents that we own or have licensed may not cover our products or may be held not infringed, invalid or unenforceable, as a result of legal challenges by our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">with respect to granted patents that we own or have licensed, especially patents that we either acquire or&#160;in-license,&#160;if certain information was withheld from or misrepresented to the patent examiner, such patents might be held to be unenforceable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may not develop additional proprietary technologies that are patentable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patents of others may have an adverse effect on our business&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may choose not to file&#160;a patent application for certain technologies, trade secrets or&#160;know-how,&#160;and a third party may subsequently file&#160;a patent covering such intellectual property. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patent protection for certain aspects of our product candidates and technologies, we also consider trade secrets, including confidential and unpatented&#160;know-how,&#160;important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented&#160;know-how,&#160;in part, by customarily entering into&#160;non-disclosure&#160;and confidentiality agreements with parties who have access to such knowledge, such as our employees, outside scientific and commercial collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and&#160;time-consuming,&#160;and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely on trademarks as one means to distinguish any of our approved products from the products of our competitors. We have received registrations for YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, DELIVERING INNOVATION TO THE EYE<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and DURASERT<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. The Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> technology is exclusively licensed to us by Ramscor, Inc and the Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>mark is owned by Ramscor, Inc. Our and our licensees&#8217; trademarks may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. For our trademarks, we have entered into a co-existence agreement with Sun Pharma and a settlement agreement with Merck allowing continued, though somewhat limited, use of two of our marks. If we are unable to establish name recognition based on our trademarks, we may not be able to compete effectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ILUVIEN<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is Alimera&#8217;s trademark. Retisert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Vitrasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;are Bausch&#160;&#38; Lomb&#8217;s trademarks.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The development and commercialization of our lead product candidate, EYP-1901, is dependent on intellectual property we license and API supply of vorolanib from Equinox Science. If we breach our agreement with Equinox or the agreement is terminated, we could lose license rights that are material to our business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our license agreement with Equinox, we acquired exclusive rights to patents, patent applications and know-how owned or controlled by Equinox relating to the compound vorolanib, a tyrosine kinase inhibitor, for the treatment of wet AMD, DR, and RVO. Our lead product candidate, EYP-1901, utilizes vorolanib in combination with our proprietary Durasert sustained release </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equinox also provides us with the API supply of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vorolanib</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to support our clinical trials.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license agreement with Equinox imposes various development, regulatory, commercial, financial and other obligations on us.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If we fail to comply with our obligations under the agreement with Equinox, or otherwise materially breach the agreement with Equinox, and fail to remedy such failure or cure such breach within 90 days, Equinox will have the right to terminate the agreement.&#160;&#160;If our agreement with Equinox is terminated by Equinox for our uncured material breach, we would lose our license and all rights to the use of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vorolanib</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for EYP-1901.&#160;&#160;The loss of the license from Equinox would prevent us from developing and commercializing EYP-1901 and could subject us to claims of breach of contract and patent infringement from Equinox if any continued research, development, manufacture or commercialization of EYP-1901 is covered by the affected patents.&#160;&#160;Accordingly, the loss of our license from Equinox would materially harm our business.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to maintain our agreement with ImprimisRx&#160;&#160;to co-promote DEXYCU, we may be unable to generate significant revenue from this product. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When we launched YUTIQ and DEXYCU in 2019, we contracted with an outsourced CSO to commercialize the products. We terminated our relationship with the CSO and converted the CSO&#8217;s remaining YUTIQ KAMs to full-time employees as of January 2020, and we converted the CSO&#8217;s remaining DEXYCU KAMs to full-time employees as of October 2020.&#160;&#160;In August 2020, to complement and augment the efforts of our internal sales team for DEXYCU, we entered into a Commercial Alliance Agreement, effective as of August 1, 2020 and amended as of November 12, 2020 (the &#8220;Commercial Alliance Agreement&#8221;) with ImprimisRx for the sale of DEXYCU to its customers. On December 6, 2021, we entered into a letter agreement (the &#8220;Letter Agreement&#8221;) to expand the commercial alliance previously established by the parties pursuant to the Commercial Alliance Agreement. During the two-year term of the Letter Agreement, ImprimisRx will assume full responsibility for the sales and marketing of DEXYCU and has absorbed the majority of our DEXYCU commercial organization. We will continue to recognize net product revenue and maintain manufacturing and distribution responsibilities for DEXYCU along with non-sales related regulatory compliance responsibilities. We will pay ImprimisRx a commission based on the net sales of DEXYCU in the U.S. and will retain control over all regulatory approvals and commercial rights for DEXYCU. The Letter Agreement was effective as of January 1, 2022 and will continue through December 31, 2023, unless such term is amended by mutual agreement of the parties or terminated in accordance therewith. Upon expiration or termination of the Letter Agreement, the parties will revert to the terms of the Commercial Alliance Agreement in existence prior to the effectiveness of the Letter Agreement for the remainder of the original term of the Commercial Alliance Agreement.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Letter Agreement provides that either party may terminate the Commercial Alliance Agreement upon 30 days&#8217; prior written notice in the event DEXYCU ceases to have Medicare Part B &#8220;pass-through&#8221; payment status for a period of not less than 6 months. ImprimisRx has an additional right to terminate the Letter Agreement with 30 days&#8217; written notice if (i) a proposed or final Hospital Outpatient Prospective Payment System (HOPPS) rule issued by the Centers for Medicare &#38; Medicaid Services (CMS) during calendar year 2022 does not contain an extension of the pass-through payment period for DEXYCU beyond December 31, 2022, and (ii) we have not otherwise waived any minimum sales for a respective quarterly period.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To a significant degree, we are relying on our strategic collaboration with ImprimisRx to sell DEXYCU.&#160;&#160;As a result of our agreement with ImprimisRx, ImprimisRx now executes all of the sales efforts for DEXYCU and those efforts may be affected by ImprimisRx&#8217;s organization, operations, activities and events both related and unrelated to DEXYCU. Our co-promotion efforts with ImprimisRx have encountered and continue to encounter a number of difficulties, uncertainties and challenges, including curtailments in the performance of cataract surgeries due to the Pandemic, which have impacted DEXYCU sales growth. Any failure to fully optimize this arrangement with ImprimisRx, including pursuant to a termination by ImprimisRx in accordance with the terms of the arrangement, would cause DEXYCU sales and our financial results with respect to DEXYCU to be materially reduced and hurt the price of our common stock. Further, any disputes with ImprimisRx over these or other issues would materially harm the promotion and sales of DEXYCU and result in substantial costs to us.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we encounter issues with our CMOs or suppliers, we may need to qualify alternative manufacturers or suppliers, which could impair our ability to sufficiently and timely manufacture and supply DEXYCU. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently depend on CMOs and suppliers for DEXYCU. Although we could obtain the drug product and other components for DEXYCU from other CMOs and suppliers, we would need to qualify and obtain FDA approval for such CMOs or suppliers as alternative sources, which could be costly and cause significant delays. In addition, the manufacturer of the drug product in DEXYCU conducts its manufacturing operations for us at a single facility. Unless and until we qualify additional facilities, we may face limitations in our ability to respond to manufacturing issues. For example, if regulatory, manufacturing or other problems require this manufacturer to discontinue production at its facility, or if the equipment used for the production of the drug product in this facility is significantly damaged or destroyed by fire, flood, earthquake, power loss or similar events, the ability of such manufacturer to manufacture DEXYCU may be significantly impaired. In the event that this party suffers a temporary or protracted loss of its materials, facility or equipment, we would still be required to obtain FDA approval to qualify a new manufacturer as an alternate manufacturer for the drug product before any drug product manufactured by such manufacturer could be sold or used. Any production </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shortfall that impairs the supply of DEXYCU could adversely affect our ability to satisfy demand for DEXYCU, which could have a material adverse effect on our product sales, results of operations and financial condition.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pandemic may also have an adverse impact on our CMOs or suppliers as a result of employees or other key personnel becoming infected, preventive and precautionary measures that governments or such third parties are taking, such as social distancing, quarantines, and other restrictions, and shortages of supplies necessary for the manufacture of DEXYCU. Any of these circumstances could adversely impact the ability of third parties on which we rely to manufacture and distribute adequate volumes of DEXYCU.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We use our own facility for the manufacturing of YUTIQ and rely on third party suppliers for key components, and any disruptions to our suppliers&#8217; operations could adversely affect YUTIQ&#8217;s commercial viability. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently manufacture commercial supplies of YUTIQ ourselves at our Watertown, MA facility and rely on third party suppliers for key components of YUTIQ. We have, and will continue, to perform extensive audits of our suppliers, vendors and contract laboratories. The cGMP requirements govern, among other things, recordkeeping, production processes and controls, personnel and quality control. To ensure that we continue to meet these requirements, we have and will continue to expend significant time, money and effort. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial manufacture of medical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of medical products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. We cannot assure you that any issue relating to the manufacture of YUTIQ will not occur in the future. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may, at any time following approval of a product for sale, audit our manufacturing facilities. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulation occurs independent of such an inspection or audit, FDA may issue a Form FDA-483 and/or an untitled or warning letter, or we or the FDA may require remedial measures that may be costly and/or time consuming for us to implement and that may include the temporary or permanent suspension of commercial sales, recalls, market withdrawals, seizures or the temporary or permanent closure of a facility. For example, we received a Form FDA-483 at the conclusion of an FDA inspection in September 2021. Although we believe we have successfully addressed and responded to FDA concerning those observations, FDA has not yet determined whether our facility will remain classified as Official Action Indicated (&#8220;OAI&#8221;), which could lead to enforcement action or affect the approval of an application. As of the date of this filing, the FDA has not yet posted the September 2021 inspection in the FDA Inspections database. We are monitoring the database closely, as it is expected that the inspection should be posted soon. The FDA has cited issues related to the Pandemic as a reason for the delay in much of their inspection activity. Any such remedial measures imposed upon us could materially harm our business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we could contract with other third parties to manufacture YUTIQ, we would need to qualify and obtain FDA approval for a contract manufacturer or supplier as an alternative source for YUTIQ, which could be costly and cause significant delays. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our YUTIQ manufacturing operations depend on our Watertown, MA facility. If this facility is destroyed or is out of operation for a substantial period of time, our business may be adversely impacted. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently conduct our manufacturing operations related to YUTIQ in our facility located in Watertown, MA. If regulatory, manufacturing or other problems, including Pandemic-related impacts on our employees, require us to suspend or discontinue production at our Watertown, MA facility, we will not be able to have or maintain adequate commercial supply of YUTIQ, which would adversely impact our business. If the facility or the equipment in it is significantly damaged or destroyed by fire, flood, power loss or similar events, we may not be able to quickly or inexpensively replace our facility. In the event of a temporary or protracted loss of either facility or equipment, we might not be able to transfer manufacturing to a third party. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with necessary regulatory requirements. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pandemic may also have an adverse impact on our manufacturing activities for YUTIQ as a result of employees or other key personnel becoming infected, preventive and precautionary measures that governments or such third parties are taking, such as social distancing, quarantines, and other restrictions, and shortages of supplies necessary for the manufacture of YUTIQ. Any of these circumstances could adversely impact our ability to manufacture and distribute adequate volumes of YUTIQ.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If third-party manufacturers, wholesalers and distributors fail to devote sufficient time and resources to DEXYCU or their performance is substandard, our product supply may be impacted. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on a limited number of manufacturers, wholesalers and distributors exposes us to the following risks, any of which could limit commercial supply of our products, result in higher costs, or deprive us of potential product revenues: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our CMOs, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our wholesalers and distributors could become unable to sell and deliver DEXYCU for regulatory, compliance and other reasons&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our CMOs, wholesalers and distributors could default on their agreements with us to meet our requirements for commercial supply of DEXYCU&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our CMOs, wholesalers and distributors may not perform as agreed or may not remain in business for the time required to successfully produce, store, sell and distribute DEXYCU and we may incur additional cost&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">if our CMOs, wholesalers and distributors were to terminate our arrangements or fail to meet their contractual obligations, we may be forced to delay the commercialization of DEXYCU. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on third parties reduces our control over our development and commercialization activities but does not relieve us of our responsibility to ensure compliance with all required legal, regulatory and scientific standards. For example, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates or supply our commercial volume of DEXYCU. In addition, such failure could be the basis for the FDA to issue a warning or untitled letter, withdraw approvals for products previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction, imposing civil penalties or pursuing criminal prosecution. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our CROs, vendors and investigators do not successfully carry out their responsibilities or if we lose our relationships with them, our development efforts with respect to our product candidates could be delayed. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on CROs, vendors and investigators for pre-clinical testing and clinical trials related to our product development programs, including for EYP-1901. These parties are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If they do not timely fulfill their responsibilities or if their performance is inadequate, the development and commercialization of our product candidates could be delayed. The parties with which we contract for execution of clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Their failure to meet their obligations could adversely affect clinical development of our product candidates. In addition, if we or our CROs fail to comply with applicable current Good Clinical Practices (&#8220;GCP&#8221;), the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving any marketing applications. Upon inspection, the FDA may determine that our clinical trials did not comply with GCP. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switching or adding additional CROs involves additional cost and requires management time and focus. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. If any of our relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our ability to advance our product candidates through clinical trials will be compromised. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, collaborators, service providers, independent contractors, principal investigators, consultants, co-promotion partners, vendors and CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, collaborators, independent contractors, principal investigators, consultants, co-promotion partners, vendors and CROs may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">manufacturing standards&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal and state healthcare fraud and abuse laws and regulations&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">laws that require the true, complete and accurate reporting of financial information or data. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee receiving an FDA debarment could result in a loss of business from third parties and severe reputational harm. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have adopted a Code of Business Conduct to govern and deter such behaviors, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The trading price of the shares of our common stock has been highly volatile, and purchasers of our common stock could incur substantial losses. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The price of our common stock is highly volatile and may be affected by developments directly affecting our business, as well as by developments out of our control or not specific to us. The pharmaceutical and biotechnology industries, in particular, and the stock market generally, are vulnerable to abrupt changes in investor sentiment. Prices of securities and trading volumes of companies in the pharmaceutical and biotechnology industries, including ours, can swing dramatically in ways unrelated to, or that bear a disproportionate relationship to, our performance. The price of our common stock and their trading volumes may fluctuate based on a number of factors including, but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical trials and their results, and other product and technological developments and innovations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing, costs and progress of our commercialization efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA and other domestic and international governmental regulatory actions, receipt and timing of approvals of our product candidates, and any denials and withdrawal of approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">competitive factors, including the commercialization of new products in our markets by our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">advancements with respect to treatment of the diseases targeted by our products or product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments relating to, and actions by, our collaborative partners, including execution, amendment and termination of agreements, achievement of milestones and receipt of payments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of our collaborative partners in marketing any approved products and the amount and timing of payments to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">availability and cost of capital and our financial and operating results&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actions with respect to pricing, reimbursement and coverage, and changes in reimbursement policies or other practices relating to our products or the pharmaceutical or biotechnology industries generally&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">meeting, exceeding or failing to meet analysts&#8217; or investors&#8217; expectations, and changes in evaluations and recommendations by securities analysts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the use of social media platforms by customers or investors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the issuance of additional shares upon the exercise of currently outstanding options or warrants or upon the settlement of stock units&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">future sales of substantial amounts of shares of our common stock in the market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">economic, industry and market conditions, changes or trends&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">other factors unrelated to us or the pharmaceutical and biotechnology industries. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, low trading volume in our common stock may increase their price volatility. Holders of our common stock may not be able to liquidate their positions at the desired time or price. Finally, we will need to continue to meet the listing requirements of Nasdaq including the minimum stock price, for our stock to continue to be traded on Nasdaq. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">EW Healthcare and Ocumension own a substantial amount of our common stock and can exert significant control over matters subject to stockholder approval, which would prevent new investors from influencing significant corporate decisions.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EW Healthcare and Ocumension, our largest stockholders, beneficially own 4,190,921 and 3,010,722 shares of our common stock, respectively, or 12.3% and 8.8% of our total outstanding common stock, respectively, as of March 4, 2022. EW Healthcare and Ocumension each have the ability to significantly influence the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation or sale of all or substantially all of our assets. EW Healthcare and Ocumension have agreed that, for so long as such investor owns a number of shares equal to at least 75% of the shares of common stock it owns as of December 31, 2020, at any meeting of our stockholders, however called, or at any adjournment thereof, or in any other circumstances in which EW Healthcare or Ocumension, as applicable, are entitled to vote, consent or give any other approval, except as otherwise agreed to in writing in advance by us, EW Healthcare and Ocumension shall (a) appear at each such meeting or otherwise cause the shares of our common stock owned by such investor or their respective affiliates to be counted as present thereat for purposes of calculating a quorum&#59; and (b) vote (or cause to be voted), in person or by proxy, all such shares of our common stock that are beneficially owned by such investor or as to which such investor has, directly or indirectly, the right to vote or direct the voting, (i) in favor of any proposals recommended by our board of directors for approval&#59; and (ii) against any proposals that our board of directors recommends our stockholders vote against&#59; provided, however, that the foregoing does not apply to meetings or proposals that are inconsistent with the investor&#8217;s rights and obligations under certain agreements between the applicable investor and us.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the concentration of voting power in EW Healthcare and Ocumension may: (i)&#160;delay, defer or prevent a change in control&#59; (ii)&#160;entrench our management and Board&#59; or (iii)&#160;delay or prevent a merger, consolidation, takeover or other business combination involving us on terms that other stockholders may desire. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, each of EW Healthcare and Ocumension currently have the right to nominate one or more individuals to our board of directors. While the directors appointed by EW Healthcare and Ocumension are obligated to act in accordance with their fiduciary duties under Delaware law, they may have equity or other interests in EW Healthcare or Ocumension and, accordingly, their personal interests may be aligned with EW Healthcare&#8217;s or Ocumension&#8217;s interests, which may not always coincide with our corporate interests or the interests of our other stockholders.&#160; The directors are required to disclose any potential material conflicts of interest. The current EW Healthcare nominated directors are Dr. G&#246;ran Ando and Ron Eastman. The current Ocumension nominated director is Ye Liu.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain covenants related to our share purchase agreement with Ocumension may restrict our ability to obtain future financing and cause additional dilution for our stockholders.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2020 we entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Ocumension Therapeutics,&#160;incorporated in the Cayman Islands with limited liability (&#8220;Ocumension&#8221;), pursuant to which we offered and sold to the Ocumension 3,010,722 shares of our common stock at a purchase price of $5.2163 per share, which was the five-day volume weighted average price of our common stock as of the close of trading on December 29, 2020 (the &#8220;Ocumension Transaction&#8221;). Pursuant to the Share Purchase Agreement, for so long as Ocumension owns a number of shares of our common stock equal to at least 75% of the shares of our common stock it acquired at the closing of the Ocumension Transaction, Ocumension is entitled to participate in subsequent issuances of our equity securities in order to maintain its ownership percentage, subject to certain exceptions for, among other things, the issuance of equity awards pursuant to equity incentive plans, inducement awards and/or employee stock purchase plans and the issuance of shares of our common stock pursuant to &#8220;at-the-market&#8221; equity offering programs. Any participation rights granted to Ocumension in the Share Purchase Agreement would be effected via a separate private placement. These&#160;participation rights&#160;could severely impact our ability to engage investment bankers to structure a financing transaction and raise additional financing on favorable terms. Furthermore, negotiating and obtaining a waiver to these&#160;participation&#160;rights&#160;may either not be possible or may be costly to us. If Ocumension exercises its participation rights, our existing stockholders would be further diluted to the extent of the number of shares Ocumension acquires to maintain its ownership percentage. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our charter documents could prevent or delay stockholders&#8217; attempts takeover our company. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is authorized to issue &#8220;blank check&#8221; preferred stock, with designations, rights and preferences as they may determine. Accordingly, our board of directors may in the future, without stockholder approval, issue shares of preferred stock with dividend, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the holders of our common stock. This type of preferred stock could also be issued to discourage, delay or prevent a change in our control. The ability to issue &#8220;blank check&#8221; preferred stock is a traditional anti-takeover measure. This provision in our charter documents makes it difficult for a majority stockholder to gain control of our company. Provisions like this may be beneficial to our management and our board of directors in a hostile tender offer and may have an adverse impact on stockholders who may want to participate in such a tender offer. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our bylaws provide for indemnification of officers and directors, which could require us to direct funds away from our business and the development of our product candidates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide for the indemnification of our officers and directors. We may in the future be required to advance costs incurred by an officer or director and to pay judgments, fines and expenses incurred by an officer or director, including reasonable attorneys&#8217; fees, as a result of actions or proceedings in which our officers and directors are involved by reason of being or having been an officer or director of our company. Funds paid in satisfaction of judgments, fines and expenses may be funds we need for the operation of our business and the development of our product candidates, thereby affecting our ability to attain profitability. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERAL RISK FACTORS</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of our development and commercialization of product strategies will require additional managerial, operational, sales, marketing, financial and other resources. Our current management, personnel and systems may not be adequate to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, employee turnover and reduced productivity. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product candidates. Future growth would impose significant added responsibilities on members of management, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">overseeing our clinical trials for EYP-1901 effectively&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">managing the commercialization of YUTIQ and DEXYCU&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">identifying, recruiting, maintaining, motivating and integrating additional employees, including any research and development personnel engaged in our clinical trials for EYP-1901, as well as sales and marketing personnel engaged in connection with the commercialization of YUTIQ and DEXYCU&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">engaging and managing our relationship with any co-promotion partners or contract sales organizations&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties&#59; and improving our managerial, development, operational and financial systems and procedures. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. Failure to accomplish any of these activities could prevent us from successfully growing our company. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Such an event could cause interruption of our operations. As part of our business, we and our vendors maintain large amounts of confidential information, including non-public personal information on patients and our employees. Breaches in security could result in the loss or misuse of this information, which could, in turn, result in potential regulatory actions or litigation, including material claims for damages, interruption to our operations, damage to our reputation or otherwise have a material adverse effect on our business, financial condition and operating results. We expect to have appropriate information security policies and systems in place in order to prevent unauthorized use or disclosure of confidential information, including non-public personal information, but there can be no assurance that such use or disclosure will not occur. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with data protection laws and regulations, we could be subject to government enforcement actions, which could include civil or criminal penalties, as well as private litigation and/or adverse publicity, any of which could negatively affect our operating results and business. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to laws and regulations that address privacy and data security in the U.S. and in states in which we conduct our business. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. In the U.S., numerous federal and state laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information, including state data breach notification laws, state health information privacy laws, state genetic privacy laws, and federal and state consumer protection and privacy laws (including, for example, Section&#160;5 of the FTC Act and the CCPA). Compliance with these laws is difficult, constantly evolving, and time consuming. In addition, state laws govern the privacy and security of health, research and genetic information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws and regulations could result in government enforcement actions and create liability for us, which could include civil and/or criminal penalties, as well as private litigation and/or adverse publicity that could negatively affect our operating results and business.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, HIPAA imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information and imposes notification obligations in the event of a breach of the privacy or security of individually identifiable health information on entities subject to HIPAA and their business associates that perform certain activities that involve the use or disclosure of protected health information on their behalf. We may obtain health information from third parties (e.g., research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA &#8211; other than potentially with respect to providing certain employee benefits &#8211; we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the CCPA establishes certain requirements for data use and sharing transparency, and provides California consumers (as defined in the law) certain rights concerning the use, disclosure, and retention of their personal data. In November 2020, California voters approved the California Privacy Rights Act (&#8220;CPRA&#8221;) ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (&#8220;CPPA&#8221;).&#160;&#160;The amendments introduced by the CPRA go into effect on January 1, 2023, and new implementing regulations are expected to be introduced by the CPPA. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and damages. Similarly, there are a number of legislative proposals in the United States, at both the federal and state level, that could impose new obligations or limitations in areas affecting our business. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business.&#160;&#160;The obligations to comply with the CCPA and evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners. We may be subject to fines, penalties, or private actions in the event of non-compliance with such laws. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive acts or practices in violation of Section 5(a) of the Federal Trade Commission Act (&#8220;FTC Act&#8221;). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. Enforcement by the FTC under the FTC Act can result in civil penalties or decades-long enforcement actions.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, our agents, or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection and privacy laws and regulations, or if we were to experience a data breach involving personal information, we could be subject to government enforcement actions or private lawsuits.&#160;&#160;Any associated claims, inquiries, or investigations or other government actions could lead to unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other remedies that harm our business, including orders that we modify or cease existing business practices.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the U.S., the legislative and regulatory landscape for privacy and data security continues to evolve.&#160;&#160;There has been increased attention to privacy and data security issues that could potentially affect our business, including the EU General Data Protection Regulation (&#8220;GDPR&#8221;), which imposes strict obligations on the processing of personal data, including relating to the transfer of personal data from the European Economic Area to third countries such as the US. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the processing details disclosed to the individuals, the sharing of personal data with third parties, the transfer of personal data out of the European Economic Area, contracting requirements (such as with clinical trial sites and vendors), and security breach notifications. Data protection authorities from the different European Economic Area Member States may interpret the GDPR and applicable related national laws differently and impose requirements additional to those provided in the GDPR. In addition, guidance on implementation and compliance practices may be updated or otherwise revised, which adds to the complexity of processing personal data in the European Economic Area. Enforcement by European Economic Area regulators is active, and failure to comply with the GDPR or applicable Member State law may result in substantial fines. For example, if we act in violation of the GDPR we may face significant penalties of up to EUR 20 million or 4% of our annual global revenue, whichever is greater.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European data protection laws, including the GDPR, generally restrict the transfer of personal data from Europe, including the EU, United Kingdom and Switzerland, to the U.S. and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards allowing U.S. companies to import personal data from Europe had been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the EU-U.S. Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (&#8220;CJEU&#8221;) in a case known colloquially as &#8220;Schrems II.&#8221; Following this decision, the Swiss Federal Data Protection and Information Commissioner (&#8220;FDPIC&#8221;), announced that the Swiss-U.S. Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to the U.S. While the FDPIC does not have authority to invalidate the Swiss-U.S. Privacy Shield regime, the FDPIC&#8217;s announcement casts doubt on the viability of the Swiss-U.S. Privacy Shield as a future compliance mechanism for Swiss-U.S. data transfers. The CJEU&#8217;s decision in Schrems II also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the U.S. or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in Schrems II, it made clear that reliance on those Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in Schrems II and subsequent draft guidance from the European Data Protection Board (&#8220;EDPB&#8221;), would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a compliant &#8220;transfer mechanism.&#8221; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that no combination of such measures could be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8220;in the clear&#8221; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8220;necessary and proportionate in a democratic society&#8221; &#8211; which may, following the CJEU&#8217;s conclusions in Schrems II on relevant powers of U.S. public authorities and commentary in that draft EDPB guidance, include the U.S. in certain circumstances (e.g., where Section 702 of the US Foreign Intelligence Surveillance Act applies). At present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield and the Standard Contractual Clauses. However, the Court of Justice of the European Union recently invalidated the EU-U.S. Privacy Shield. The decision in Schrems II also affects transfers from the United Kingdom to the U.S..</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As such, if we are unable to implement a valid solution for personal data transfers from Europe, including, for example, obtaining individuals&#8217; explicit consent to transfer their personal data from Europe to the U.S. or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from Europe. Inability to import personal data from Europe may also restrict our clinical trials activities in Europe&#59; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to European data protection laws&#59; and require us to increase our data processing capabilities in Europe at significant expense. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The type of challenges we face in Europe will likely also arise in other jurisdictions that adopt laws similar in construction to the GDPR or regulatory frameworks of equivalent complexity.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">ITEM&#160;2. PROPERTIES </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own any real property. On May&#160;17, 2018, we amended our lease, dated November&#160;1, 2013, to extend our Watertown, Massachusetts lease term from April 2019 through approximately May 2025 and to add an additional 6,590 square feet of rentable area for a resulting total of 20,240 square feet. Following build-out of the additional space, for which the landlord provided a construction allowance of $671,000, we took occupancy on September&#160;10, 2018. On April 5, 2021, we further amended the lease to include an additional 1,409 square feet of rentable area of the building through May 2025. On March 8, 2022, we further amended the lease (i) to extend the term to May 31, 2028 for 13,650 square feet of laboratory and manufacturing operations space, with the landlord agreeing to provide the Company a construction allowance of up to $555,960 to be applied toward upgrades and improvements within the space&#59; (ii) to rent an additional 11,999 square feet of office space within the building through May 31, 2028, with an anticipated commencement date in the third quarter of 2022&#59; and (iii) to terminate a portion of the lease comprising 7,999 square feet of office space in the building on May 31, 2025. We have an option to extend the term of the lease for one additional five-year period at market rates. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease 3,000 square feet of office space in Liberty Corner, New Jersey under a lease agreement that expires in June 2022. On June&#160;11, 2018, we subleased an additional 1,381 square feet of office space in this building through May 2022. We have given notice that we will not be renewing this lease and we will vacate the facility upon expiration.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our leased facilities are adequate for our present and anticipated needs. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">ITEM&#160;3. LEGAL PROCEEDINGS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to various routine legal proceedings and claims incidental to our business, which management believes will not have a material effect on our financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Securities and Exchange Commission Subpoena</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="color:#000000;"> previously disclosed that on May 14, 2020 we had received a subpoena from the Division of Enforcement of the SEC seeking production of certain documents and information on topics including product sales and demand, revenue recognition and accounting in relation to product sales, product sales and cash projections, and related financial reporting, disclosure and compliance matters. On May 4, 2021, we were advised by the SEC Division of Enforcement that it has concluded its investigation of us and that, based on the information it has to date, the Enforcement Division does not intend to recommend an enforcement action against us.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">ITEM&#160;4. MINE SAFETY DISCLOSURES </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#8220;EYPT&#8221;. As of March&#160;4, 2022, we had approximately 76 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by Item 5 of Form 10-K regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than as previously disclosed on our Current Reports on Form 8-K or Quarterly Reports on Form 10-Q filed with the SEC, we did not issue any unregistered equity securities during the twelve months ended December&#160;31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED">ITEM&#160;6. [RESERVED]</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our audited Consolidated Financial Statements and related Notes beginning on page F-1 of this Annual Report on Form 10-K. This discussion contains forward-looking statements, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ significantly from those anticipated or implied in these forward-looking statements as a result of many important factors, including, but not limited to, those set forth under Item 1A, &#8220;Risk Factors&#8221;, and elsewhere in this report. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following Management&#8217;s Discussion and Analysis (&#8220;MD&#38;A&#8221;) provides a narrative of our results of operations for the year ended December 31, 2021 and the comparable period ended December 31, 2020, respectively, and our financial position as of&#160;December&#160;31, 2021 and 2020, respectively. The MD&#38;A should be read together with our consolidated financial statements and related notes included on pages F-1 through F-33 of this Annual Report on Form&#160;10-K. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. Our pipeline leverages our proprietary Durasert</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup><span style="Background-color:#FFFFFF;">technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration (&#8220;wet AMD&#8221;), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a once every three-year treatment for chronic&#160;non-infectious&#160;uveitis affecting the posterior segment of the eye, and DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application (sNDA) strategy.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fiscal 2021 Overview and COVID-19 Impact</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fiscal year ended December&#160;31, 2021 was highlighted by the following events:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Underlying customer demand and distributor purchases by specialty distributors and specialty pharmacies of both YUTIQ and DEXYCU was negatively impacted beginning in the first and especially the second quarter of 2020 due to shutdowns associated with the Pandemic in the U.S. A modest return of customer demand began in June 2020 which contributed to sequential product sales growth in the third and fourth quarters of 2020, and Pandemic-related restrictions on elective surgeries and physician office visits were largely removed during the first and second quarters of 2021. However, the emergence of new variants of the coronavirus has caused and may continue to cause intermittent or prolonged periods of reduced patient services at our customers&#8217; facilities, which may negatively affect customer demand. The future progression of the Pandemic and its effects on our business and operations are uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, our customer demand may be adversely affected in the future as well. During the Pandemic, our sales organization has continued to call on physician offices, though at a reduced frequency.</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;">There have been no disruptions to the supply chains for YUTIQ and DEXYCU during the Pandemic and we continue to produce finished product for commercial sale.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">In February 2021, </span><span style="color:#000000;font-size:10pt;">we sold 10,465,000 shares of common stock in an underwritten public offering at a price of $11.00 per share, including the exercise in full by the underwriters of their option to purchase up to 1,365,000 additional shares of our common stock. The gross proceeds of the offering are approximately $115.1 million. Underwriter discounts and commissions and other share issue costs totaled approximately $7.2 million</span><span style="font-size:10pt;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#auto;color:#auto;font-size:10pt;">In a press release dated April 7, 2021, our Asia partner, Ocumension, announced that the new drug application (&#8220;NDA&#8221;) for OT-401 (YUTIQ) had been accepted by the National Medical Products Administration of the People&#8217;s Republic of China (&#8220;NMPA&#8221;). Ocumension reported that YUTIQ is its first ophthalmic drug for which an NDA has been accepted by the NMPA and is also the first sustained-release micro-insert submitted for NDA approval in mainland China that has a controlled release rate for up to 36 months. Ocumension&#8217;s press release also announced that this is the first time the NMPA has accepted an NDA based on real world study data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#auto;color:#auto;font-size:10pt;">In June 2021, we received notification from Silicon Valley Bank (&#8220;SVB&#8221;) that the Paycheck Protection Program Loan (&#8220;PPP Loan&#8221;) of $2.0 million has been fully forgiven by the U.S. Small Business Administration (&#8220;SBA&#8221;), and that payment and all accrued interest thereon were remitted by the SBA to SVB on June 16, 2021.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#auto;color:#auto;font-size:10pt;">In June 2021, we announced that we had joined the Russell 2000&#174; and the Russell 3000&#174; indices.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#auto;color:#auto;font-size:10pt;">In July 2021, we announced that the American Medical Association created a new Category III Current Procedural Terminology (CPT&#174;) Code to describe the injection of medicines like DEXYCU&#174;. The code, OX78T, is for the administration of a drug into the posterior chamber of the anterior segment of the eye and bec</span><span style="font-size:10pt;color:#000000;">a</span><span style="Background-color:#auto;color:#auto;font-size:10pt;">me effective January 1, 2022. </span><span style="color:#000000;"> </span><span style="font-size:10pt;color:#000000;">The new CPT code, as implemented, adds DEXYCU administration to the reimbursement bundle for cataract surgery, in addition to the pass-through payment for the drug itself.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#auto;color:#auto;font-size:10pt;">In July 2021, we announced that we expect to receive a nine month extension of separate payment for DEXYCU, which would otherwise expire on March 31, 2022, with the end of the drug&#8217;s pass-through status. The announcement was based on the fiscal year (FY) 2022 Medicare Hospital Outpatient Prospective Payment System (OPPS) proposed rule. The rule includes a proposal to extend the period of separate payment for select pass-through drugs and devices that have their pass-through status scheduled to expire between December 31, 2021 and September 30, 2022, including DEXYCU. CMS proposes to extend the period of separate payment for these therapies beyond the expiration of pass-through status in light of the COVID-19 public health emergency. The proposal is subject to a public comment period and may be either adopted as proposed, modified, or withdrawn in the FY 2022 OPPS final rule, which is anticipated to be released in November 2021.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">In August 2021, we announced the establishment of our Executive Scientific Advisory Board with prestigious members made up of some of the leading retinal surgeons in the world and chaired by Dr. Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital</span><span style="font-size:10pt;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">On November 1, 2021, we appointed Jay S. Duker, M.D. as our Chief Operating Officer. In his new role, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing. Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after serving as an independent member of our Board of Directors since 2016. Dr. Duker has spent over 30 years in academic ophthalmology, and for the past 21 years served as Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, a position he relinquished to join EyePoint full time.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">In November 2021, we sold 5,122,273 shares of Common Stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of common stock. The shares of common stock were sold at a public offering price of $13.75 per share, and the pre-funded warrants were sold at a purchase price of $13.74 per pre-funded warrants, for aggregate gross proceeds of approximately $115.4 million. Underwriter discounts and commissions and other share issue costs totaled approximately $7.2 million.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">In December, we announced the expansion of our commercial alliance in which ImprimisRx will assume responsibility for U.S. sales and marketing activities for D</span><span style="font-size:10pt;color:#000000;">EXYCU</span><span style="font-size:10pt;"> 9% for the treatment of post-operative inflammation following ocular surgery in the U.S. The amended agreement expands the commercial alliance previously established in August 2020 between EyePoint and ImprimisRx. Under terms of the expanded alliance, ImprimisRx absorbed the majority of EyePoint&#8217;s D</span><span style="font-size:10pt;color:#000000;">EXYCU</span><span style="font-size:10pt;"> commercial organization. EyePoint will continue to recognize net product revenue and maintain manufacturing and distribution responsibilities for D</span><span style="font-size:10pt;color:#000000;">EXYCU</span><span style="font-size:10pt;"> along with non-sales related regulatory compliance. EyePoint will pay ImprimisRx a commission based on net sales of D</span><span style="font-size:10pt;color:#000000;">EXYCU</span><span style="font-size:10pt;"> and will retain all commercial rights for D</span><span style="font-size:10pt;color:#000000;">EXYCU</span><span style="font-size:10pt;">. The amended agreement became effective on January 1, 2022.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">R&#38;D Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;font-size:10pt;">In January 2021, we dosed our first patient in our Phase 1 DAVIO clinical trial for EYP-1901.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">In May 2021, studies of DEXYCU were presented in two separate poster sessions at the Association for Research in Vision and Ophthalmology (&#8220;ARVO&#8221;) Annual meeting.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In May 2021, we announced the completion of enrollment in our Phase 1 DAVIO clinical trial of EYP-1901 for the potential treatment of Wet AMD.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;font-size:10pt;">In July 2021, we reported positive 30-day safety results for all cohorts from the DAVIO clinical trial.&#160;&#160;K</span><span style="font-size:10pt;">ey safety observations through at least 30-Day post-dosing follow-up for all patients include:</span><span style="Background-color:#FFFFFF;font-size:10pt;"> (i) No serious adverse events (SAEs), ocular or systemic, (ii) no reported adverse events (AEs) related to significant intraocular inflammation, best-corrected visual acuity (BCVA) reduction, or elevation of intraocular pressure (IOP) and (iii) no events of endophthalmitis, retinal detachment or migration into the anterior chamber.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;font-size:10pt;">In July 2021, DEXYCU was presented in three separate oral presentations, one poster session and a video symposium at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In September 2021, we announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD was selected for presentation at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In October 2021, we reported positive 3-month safety data for all dose levels from our ongoing DAVIO trial of EYP-1901 for the potential treatment of wet AMD at the American Society of Retina Specialists (ASRS) Annual Meeting.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In October 2021, we reported preliminary data from our ongoing YUTIQ&#174; CALM real-world registry study at Retina Society and ASRS.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In November, 2021 we reported positive safety and efficacy from our ongoing Phase 1 DAVIO trial of EYP-1901 at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Retina Subspecialty Day.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Developments</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Customer demand for YUTIQ in Q4, represented as units purchased by physicians from our distributors, was up 16% over Q3, driven by underlying growth.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Customer demand for DEXYCU in Q4, represented as units purchased by ambulatory surgical centers, was up 5% over Q3, driven by increases in cataract surgeries and some re-opening of ASC</span><span style="color:#000000;">&#8217;</span><span style="color:#000000;">s. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On January 10, 2022, we appointed Michael C. Pine Chief Corporate Development and Strategy Officer. Mr. Pine&#160;</span><span style="Background-color:#auto;color:#auto;">brings over 20 years of business and corporate development expertise, leveraging experience from various roles at small and large pharmaceutical companies.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On March 7, 2022, we appointed Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings over 30 years of global regulatory affairs experience across all phases of drug development including ophthalmic and ocular conditions.&#160;&#160;Ms. Lefebvre is succeeding John Weet, Ph.D., who be leaving his role as Senior Vice President, Regulatory, following a transition period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On March 9, 2022, we entered into a loan agreement for senior secured credit facilities in the aggregate amount of $45 million with Silicon Valley Bank to replace our existing credit facility with CRG Services LLC. Under the terms of the new agreement, a $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will be utilized to replace the existing approximately $40.5 million of obligations under the existing CRG credit facility.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of Critical Accounting Policies and Estimates </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires that we make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We base our estimates on historical experience, anticipated results and trends and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available from other sources. By their nature, these estimates, judgments and assumptions are subject to an inherent degree of uncertainty, and management evaluates them on an ongoing basis for changes in facts and circumstances. Changes in estimates are recorded in the period in which they become known. Actual results may differ from our estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are more fully described in Note 2 in the accompanying Notes to the Consolidated Financial Statements contained in this Annual Report on Form 10-K, we believe that the following accounting policies are critical to understanding the judgments and estimates used in the preparation of our financial statements. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies discussed below. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), we perform the following five steps: (i) identify the contract(s) with a customer&#59; (ii) identify the performance obligations in the contract&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product sales, net<span style="font-weight:normal;font-style:normal;">&#160;&#8212; We sell YUTIQ and DEXYCU to a limited number of specialty distributors and specialty pharmacies (collectively the &#8220;Distributors&#8221;) in the U.S., with whom we have entered into formal agreements, for delivery to physician practices for YUTIQ and to hospital outpatient departments and ambulatory surgical centers for DEXYCU. We recognize revenue on sales of our products when Distributors obtain control of the products, which occurs at a point in time, typically upon delivery. In addition to agreements with Distributors, we also enter into arrangements with healthcare providers, ambulatory surgical centers, and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to their purchase of our products from Distributors.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reserves for variable consideration&#160;<span style="color:#000000;font-style:normal;">&#8212;&#160;</span><span style="font-style:normal;">Product sales are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, provider chargebacks and discounts, payor rebates, product returns, and other allowances that are offered within contracts between us and our Distributors, payors, and other contracted purchasers relating to our product sales. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified either as reductions of product revenue and accounts receivable or a current liability, depending on how the amount is to be settled. Overall, these reserves reflect our best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#FF0000;font-style:normal;">&#160;&#160;</span><span style="font-style:normal;">Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from the estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Distribution fees&#160;<span style="font-style:normal;">&#8212;&#160;We compensate our Distributors for services explicitly stated in our contracts and they are recorded as a reduction of revenue in the period the related product sale is recognized.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Provider chargebacks and discounts&#160;<span style="font-style:normal;">&#8212;&#160;Chargebacks are discounts that represent the estimated obligations resulting from contractual commitments to sell products at prices lower than the list prices charged to our Distributors. These Distributors charge us for the difference between what they pay for the product and our contracted selling price. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of&#160;product revenue and the establishment of a current liability.&#160;&#160;Reserves for chargebacks consist of amounts that we expect to pay for units that remain in the distribution channel inventories at each reporting period-end that we expect will be sold under a contracted selling price, and chargebacks that Distributors have claimed, but for which we have not yet settled.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government rebates&#160;<span style="font-style:normal;">&#8212; We are subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. Our liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payor rebates&#160;<span style="font-style:normal;">&#8212; We contract with certain private payor organizations, primarily insurance companies, for the payment of rebates with respect to utilization of our products. We estimate these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Co-Payment assistance&#160;<span style="font-style:normal;">&#8212; We offer co-payment assistance to commercially insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with product that has been recognized as revenue.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Product returns&#160;<span style="font-style:normal;">&#8212; We generally offer a limited right of return based on our returned goods policy, which includes damaged product and remaining shelf life. We estimate the amount of our product sales that may be returned and record this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to trade receivables, net on the condensed consolidated balance sheets.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">License and collaboration agreement revenue<span style="font-style:normal;">&#160;&#8212; We analyze each element of our license and collaboration arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, we determine that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, we assess each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, we will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, we do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of&#160;December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reimbursement of costs<span style="font-style:normal;"> &#8212; We may provide research and development services and incur maintenance costs of licensed patents under collaboration arrangements to assist in advancing the development of licensed products. We act primarily as a principal in these transactions and, accordingly, reimbursement amounts received are classified as a component of revenue to be recognized consistent with the revenue recognition policy summarized above. We record the expenses incurred and reimbursed on a gross basis.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<span style="font-weight:bold;"> </span><span style="font-style:normal;">&#8212; We recognize revenue from license arrangements with our commercial partners&#8217; net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner&#8217;s products occurs. Our commercial partners are obligated to report their net product sales and the resulting royalty due to us typically within 60&#160;days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, we recognize royalty income each quarter and subsequently determine a true-up when we receive royalty reports and payment from our commercial partners. Historically, these true-up adjustments have been immaterial.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sale of Future Royalties<span style="font-style:normal;"> &#8212; We have sold our rights to receive certain royalties on product sales. In the circumstance where we have sold our rights to future royalties under a royalty purchase agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), we defer recognition of the proceeds we receive for the sale of royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to our estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research Collaborations &#8212; <span style="font-style:normal;">We recognize revenue over the term of the statements of work under any funded research collaborations. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations. Please refer to Note 3 for further details on the license and collaboration agreements into which we have entered and corresponding amounts of revenue recognized during the current and prior year periods.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized within one year following the balance sheet date are classified as non-current deferred revenue. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please refer to Note 3 for further details on the license and collaboration agreements into which we have entered and corresponding amounts of revenue recognized for the years ended December&#160;31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognition of Expense in Outsourced Clinical Trial Agreements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize research and development expense with respect to outsourced agreements for clinical trials with contract research organizations (&#8220;CROs&#8221;) as the services are provided, based on our assessment of the services performed. We make our assessments of the services performed based on various factors, including evaluation by the third-party CROs and our own internal review of the work performed during the period, measurements of progress by us or by the third-party CROs, data analysis with respect to work completed and our management&#8217;s judgment. Our financial obligations under the agreements are determined by the services that we request from time to time under the agreements. The actual amounts owed under the agreements and the timing of those obligations will depend on various factors, including changes to the protocols and/or services requested, the number of patients to be enrolled and the rate of patient enrollment, achievement of pre-defined direct cost milestone events and other factors relating to the clinical trials. We can terminate the agreements at any time without penalty, and if terminated, we would be liable only for services through the termination date plus non-cancellable CRO obligations to third parties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Years Ended December&#160;31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands except percentages)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Product sales, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,312</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,831</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,481</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration agreements (including licensing fees from a related party of $543 and $11,500 for the years ended December 31, 2021 and 2020, respectively)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,942</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,186</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">871</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,664</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(793</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,939</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,437</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,502</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales, excluding amortization of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,177</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,824</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,353</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,424</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,076</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,503</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,293</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,210</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,575</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,726</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,849</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,215</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,727</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,488</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,276</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,290</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,986</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Interest income and other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,498</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,257</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,759</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Gain (loss) on extinguishment of debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,065</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(905</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,970</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,141</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,104</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,963</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,417</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,394</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product <span style="color:#000000;">Sales</span>, net</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product<span style="color:#000000;"> sales, net represents the gross sales of YUTIQ and DEXYCU less provisions for product sales allowances. Product sales, net increased by $14.5 million to $35.3 million for 2021 compared to $20.8 million in the prior year. The increase was driven by a return of customer demand for both products as patient procedures at physician offices and ambulatory service centers resumed due to facility closures driven by the Pandemic. Customer demand has a direct impact on product orders from our specialty distributors that we record as net product sales. Net product revenue represents product purchased by our distributors whereas customer demand represents purchases of product by physician practices and ASCs from our distributors. The progression of the Pandemic and its effects on our business and operations remain uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, our customer demand may be adversely affected in the future as well.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License<span style="color:#000000;"> and collaboration agreement</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License<span style="color:#000000;"> and collaboration agreement revenues decreased by $11.2 million to $0.8 million in 2021 compared to $11.9 million in 2020. This decrease was attributable primarily to (i) the recognition in the prior year period of&#160;$9.5 million under our&#160;Ocumension&#160;</span><span style="Background-color:#auto;color:#000000;">2020 MOU entered into&#160;in&#160;August 2020 (see Note 3) </span><span style="color:#000000;">and (ii) the recognition of approximately $2.0 million from Ocumension upon signing a license agreement for DEXYCU in China also during the prior year period, partially offset by other collaboration revenue in the current year period</span><span style="font-size:12pt;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;" id="fe_1fde86c7d597425f9bfaf728bbfaae0f">Royalty Income</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty income decreased by $793,000 to $0.9 million for fiscal 2021 from $1.7 million in the prior year. The decrease was attributable to the impact of the royalty monetization agreement with SWK Holdings that grants to SWK all future royalty payments under the Amended Alimera Agreement beginning with Q4 2020 for a one-time payment of $16.5 million. Due to the accounting treatment for this agreement (see Revenue Recognition section), we recognize a non-cash portion of deferred revenue as Alimera pays royalties to SWK beginning in the first quarter of 2021 (see Note 3).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales, excluding amortization of acquired intangible assets, increased by $2.4 million to $8.2 million for fiscal 2021 from $5.8 million in the prior year. This increase was primarily attributable to costs associated with higher product sales, primarily costs of goods and royalties, and due to higher DEXYCU product mix, as well as a $1.3 million provision for anticipated DEXYCU inventory expiration.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by $11.1 million to $28.5 million for 2021 from $17.4 million in the prior year. This increase was attributable primarily to (i) $5.2 million in personnel expense, including stock based compensation, due to expansion of our clinical and research organizations, (ii) $3.5 million in clinical costs, primarily related to our EYP-1901 Phase 1 clinical trial and YUTIQ 50 Phase 3 clinical trial, (iii) $1.8 million in research in additional formulations and injector technologies, and (iv) $581,000 in medical affairs and pharmacovigilance costs. The first quarter of 2020 also included a one-time $1.0 million payment for the licensing of vorolanib for EYP-1901 and the current year periods include a one-time payment of $0.5 million under the Asset Purchase Agreement with Aerpio (see Note 12).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our research and development expenses will increase for the year ending December 31, 2022 as compared to the year ended December 31, 2021 as a result of the expansion of our research and development organization to support additional clinical and development work, initiation of our EYP-1901 phase 2 clinical trial for wAMD, new formulation and injector development, and studies for additional indications for EYP-1901.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales and Marketing</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses increased by approximately $2.2 million to $27.5 million for fiscal 2021 from $25.3 million in the prior year.&#160;&#160;This increase was primarily attributable to (i) $1.7 million in sales and promotional expense, including commissions due to our commercial partner for DEXYCU, and (ii) $582,000 in other communications and marketing programs.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by $4.9 million to $25.6 million for 2021 from $20.7 million in the prior year. This increase was attributable primarily to (i) $2.2 million in personnel expense, including stock based compensation, for executive, Finance, HR, and IT functions, (ii) $2.1 million in consulting, investor relations, and other spending initiatives, and (iii) $414,000 in D&#38;O insurance expense.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase for the year ending December 31, 2022 as compared to the year ended December 31, 2021 as a result of additional Human Resources, Information Technology, and Finance personnel to support organizational growth.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amortization of Acquired Intangible Assets</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of acquired intangible assets totaled $2.5 million for both 2021 as well as the same period in the prior year. This amount was attributable to the DEXYCU product intangible asset that resulted from the Icon Acquisition (see Note 5).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest (Expense) Income</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense totaled $5.5 million for 2021.&#160;&#160;We incurred lower interest expense in 2021 due to the $13.7 million partial principal paydown in Q4 2020 on the CRG term loan. Interest expense in 2020 was $7.3 million, which included $745,000 of amortization of debt discount and $977,000 of non-cash payment-in-kind interest expense all related to the CRG Debt. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income from amounts invested in an institutional money market fund increased to $292,000 for fiscal 2021 compared to $58,000, due primarily to increased interest-bearing assets versus 2020 driven by the 2021 equity financings.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gain on Extinguishment of Debt</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forgiveness by the SBA of our PPP Loan resulted in a gain on extinguishment of debt, which consisted of approximately (i) $2.0 million of principal and (ii) $24,000 of interest in 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a full discussion of recently adopted and recently issued accounting pronouncements, see Note 2, "Significant Accounting Policies" to the Consolidated Financial Statements included under Item 15, "Exhibits and Financial Statement Schedules."</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="Background-color:#FFFFFF;"> have had a history of operating losses and an absence of significant recurring cash inflows from revenue, and at December 31, 2021 we had a total accumulated deficit of $569.1 million.&#160;</span>Our operations have been financed primarily from sales of our equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from collaboration partners<span style="Background-color:#FFFFFF;">. In the first quarter of 2019, we commenced the U.S. launch of our first two commercial products, YUTIQ and DEXYCU. However, we have not received sufficient revenues from our product sales to fund operations and we do not expect revenues from our product sales to generate sufficient funding to sustain our operations in the near-term.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Financing Activities</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations for fiscal 2021 were financed primarily from $44.9&#160;million of cash and cash equivalents at December&#160;31, 2020, approximately $108.2&#160;million of net proceeds from the November 2021 underwritten stock offering and approximately $107.9&#160;million of net proceeds from the February 2021 underwritten stock offering. <span style="Background-color:#auto;color:#auto;">We also sold shares of our common stock under our at-the-market facility </span>in Q1 2021 <span style="Background-color:#auto;color:#auto;">and recorded net proceeds of approximately $499,000.</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Facilities are due and payable on January 1, 2027 (the &#8220;Maturity Date&#8221;). The Term Facility bears interest at a per annum rate (subject to increase during an event of default) equal to the higher of 5.5% and the Prime Rate plus 2.25%. The Revolving Facility bears interest at a per annum rate equal to the Prime Rate. We are required to make interest only payments on a monthly basis until the Maturity Date. In addition, we may make a voluntary prepayment of the SVB Loan, in whole or in part, at any time. All mandatory and voluntary prepayments of the SVB Loan are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs on or prior to March 9, 2023, 3% of the aggregate outstanding principal amount of the SVB Loan being prepaid, (ii) if prepayment occurs after March 9, 2023 but on or prior to March 9, 2024, an amount equal to 2% of the aggregate outstanding principal amount of the SVB Loan being prepaid, (iii) if prepayment occurs after March 9, 2024 but on or prior to March 9, 2025, an amount equal to 1% of the aggregate outstanding principal amount of the SVB Loan being prepaid, and (iv) if prepayment occurs after March 9, 2025 but prior to the Term Loan Maturity Date, an amount equal to 0.5% of the aggregate outstanding principal amount of the SVB Loan being prepaid. No prepayment premium is due on any principal prepaid after December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our future subsidiaries<span style="font-size:12pt;"> </span>will be required to guarantee the obligations of ours under the Loan Agreement. Our obligations under the Loan Agreement and the guarantee of such obligations are secured by a pledge of substantially all of our and such subsidiaries&#8217; assets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SVB Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the Loan Agreement contains the following quarterly financial covenants requiring the Borrowers to maintain either:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">minimum product revenue from YUTIQ&#174; and DEXYCU&#174; assessed on a quarterly basis commencing from the three-month period ending on March 31, 2022 through the Maturity Date, with such minimum quarterly product revenue ranging from approximately $7.8 million to approximately $11.5 million in fiscal year 2022. Such minimum quarterly product revenue will be subject to incremental increases in fiscal year 2023 and will thereafter be such amounts as agreed upon between the Company and the Lender based on certain agreed-upon factors commencing for the three-month period ending on March 31, 2024 and for each three-month period thereafter through the Maturity Date&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">if the Company is unable to achieve the minimum quarterly product revenue level required as of the end of any three-month period, cash and cash equivalents in an amount equal to the greater of (i) $50,000,000 and (ii) the Company&#8217;s six-month Cash Burn (as defined in the SVB Loan Agreement).</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future Funding Requirements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, we had cash, cash equivalents, and investments in marketable securities of $211.6 million. We expect that our cash and cash equivalents and anticipated net cash inflows from product sales will fund our operating plan into the second half of 2024,<span style="font-size:12pt;"> </span>under current expectations regarding <span style="Background-color:#FFFFFF;color:#000000;">t</span>he timing and outcomes of our Phase 2 clinical trials for EYP-1901. Due to the difficulty and uncertainty associated with the design and implementation of clinical trials, we will continue to assess our cash and cash equivalents and future funding requirements.&#160;&#160;However, there is no assurance that additional funding will be achieved and that we will succeed in our future operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Actual cash requirements could differ from management&#8217;s projections due to many factors, including cash generation from sales of YUTIQ and DEXYCU, additional investments in research and development programs, clinical trial expenses for EYP-1901, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities. In addition, the Pandemic has had, and will likely continue to have, a material and adverse impact on our business, including as a result of preventive and precautionary measures that we, other businesses, and governments are taking. Due to these impacts and measures, we have experienced and will likely continue to experience significant and unpredictable reductions in the demand for our commercial products as customers have shut down their facilities and non-essential surgical procedures have been postponed in an effort to promote social distancing and to redirect medical resources and priorities towards the treatment of COVID-19.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of additional capital we will require will be influenced by many factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;">the potential for EYP-1901, as a twice-yearly sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration (&#8220;wet AMD&#8221;), with potential in diabetic retinopathy (&#8220;DR&#8221;) and retinal vein occlusion (&#8220;RVO&#8221;)</span><span style="font-size:10pt;color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;font-size:10pt;">our expectations regarding the timing and clinical development of our product candidates, including EYP-1901 and YUTIQ 50</span><span style="font-size:10pt;color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of our U.S. direct commercialization of YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye including, among other things, patient and physician acceptance of YUTIQ and our ability to obtain adequate coverage and reimbursement for YUTIQ&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of our U.S. direct commercialization of DEXYCU for the treatment of postoperative ocular inflammation including, among other things, patient and physician acceptance of DEXYCU and our ability to obtain adequate coverage and reimbursement for DEXYCU&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of commercialization activities for YUTIQ and DEXYCU, including product manufacturing, marketing, sales and distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">whether and to what extent we internally fund, whether and when we initiate, and how we conduct other product development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">payments we receive under any new collaboration agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">whether and when we are able to enter into strategic arrangements for our products or product candidates and the nature of those arrangements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in our operating plan, resulting in increases or decreases in our need for capital&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our views on the availability, timing and desirability of raising capital&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which our business could be adversely impacted by the effects of the Pandemic or by other pandemics, epidemics or outbreaks.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="color:#000000;"> do not know if additional capital will be available when needed or on terms favorable to us or our stockholders. Collaboration, licensing or other agreements may not be available on favorable terms, or at all. We do not know the extent to which we will receive funds from the commercialization of YUTIQ or DEXYCU. If we seek to sell our equity securities, we do not know whether and to what extent we will be able to do so, or on what terms. If available, additional equity financing may be dilutive to stockholders, debt financing may involve restrictive covenants or other unfavorable terms and dilute our existing stockholders&#8217; equity, and funding through collaboration, licensing or other commercial agreements may be on unfavorable terms, including requiring us to relinquish rights to certain of our technologies or products. If adequate financing is not available if and when needed, we may delay, reduce the scope of, or eliminate research or development programs, independent commercialization of YUTIQ and DEXYCU, or other new products, if any, postpone or cancel the pursuit of product candidates,</span><span style="text-decoration:underline;color:#0000FF;"> </span>or otherwise significantly curtail our operations to reduce our cash requirements and extend our capital.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated statements of historical cash flows are summarized as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,417</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,394</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,739</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,136</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other adjustments to reconcile net loss to cash flows</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; from operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,059</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,823</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,097</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,435</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows (used in) provided by investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,121</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(362</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,902</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,492</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash outflows for the year ended December&#160;31, 2021 totaled $50.1&#160;million, primarily due to our net loss of $58.4&#160;million, reduced by $10.1&#160;million of non-cash expenses, which included $7.5&#160;million of stock-based compensation and $2.5&#160;million of amortization of the DEXYCU finite-lived intangible asset, $628,000 of amortization of debt discount and a $2.1 million gain on extinguishment of debt from the forgiveness of our PPP Loan.. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash outflows for the year ended December&#160;31, 2020 totaled $14.4&#160;million, primarily due to our net loss of $45.4&#160;million, reduced by $10.8&#160;million of non-cash expenses, which included $5.5&#160;million of stock-based compensation and $2.5&#160;million of amortization of the DEXYCU finite-lived intangible asset. Further adjustments of cash in operating activities resulted from an increase of $16.5 million in deferred revenue primarily related to the SWK Royalty Payment Agreement and a $1.9 million decrease in accounts receivable from product sales.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December 31, 2021 consisted of the purchase of $33.0 million of marketable securities, and purchases of property and equipment of $155,000.&#160;&#160;Net cash used in the year ended December 31, 2020 consisted of purchases of property and equipment totaling $362,000.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for fiscal 2021 totaled $216.9 million and consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(i)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$108.2 million of net proceeds from the issuance of 5,122,273 shares of our common stock and 3,272,727 pre-funded warrants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(ii)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$107.9 million of net proceeds from the issuance of 10,465,000 shares of our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iii)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$499,000 of net proceeds from the issuance of 48,538 shares of our common stock sold utilizing our ATM&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iv)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$273,000 of proceeds from stock issued under our employee stock purchase plan.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for fiscal 2020 totaled $37.50 million and consisted of the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(i)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$20.0 million of net proceeds from the issuance of 1,500,000 shares of our Common Stock&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(ii)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$2.0 million of net proceeds from the PPP Loan&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iii)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$294,000 of proceeds from stock issued our employee stock purchase plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iv)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$14.2 million of net proceeds from the issuance of 2,590,093 shares of our Common Stock sold utilizing our ATM&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(v)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$15.7 million of net proceeds from the issuance of 3,010,722 shares of our Common Stock to Ocumension Therapeutics&#59; partially offset by</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(vi)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">$14.6 million partial repayment of the CRG Term Loan, which included $13.7 million of principal and $828,000 in Exit Fee.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to investors. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this Item. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item may be found on pages F-1 through F-33 of this Annual Report on Form 10-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">ITEM&#160;9A. CONTROLS AND PROCEDURES </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2021. The term &#8220;disclosure controls and procedures&#8221;, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2021, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;color:#000000;"></span><span style="font-size:10pt;color:#000000;">Management&#8217;s Report on Internal Control over Financial Reporting </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) or 15d-15(f) of the Exchange Act, as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the U.S., and includes those policies and procedures that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and our directors&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All internal control systems, no matter how well designed, have inherent limitations and may not prevent or detect misstatements. Projections of any evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span>. Based on this assessment, our management concluded that, as of such date, our internal control over financial reporting was effective based on those criteria. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Changes in Internal Control over Financial Reporting </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the last quarter of the period covered by this Annual Report on Form 10-K that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting<span style="font-weight:bold;">.</span> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">ITEM&#160;9B.<span style="font-weight:normal;"> </span>OTHER INFORMATION </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Silicon Valley Bank Credit Facilities</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 9, 2022 (the &#8220;Closing Date&#8221;), we entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;), among us and Icon Bioscience, Inc., as borrowers (the &#8220;Borrowers&#8221;), and Silicon Valley Bank, as lender (the &#8220;SVB Lender&#8221;), providing for (i) a senior secured term loan facility of $30 million (the &#8220;Term Facility&#8221;) and (ii) a senior secured revolving credit facility of up to $15.0 million (the &#8220;Revolving Facility&#8221; and together with the Term Facility, the &#8220;Credit Facilities&#8221;). The maximum amount available for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">borrowing at any time under the Revolving Facility is limited to a borrowing base valuation of the Borrowers&#8217; eligible accounts receivable. The proceeds of the Credit Facilities were and will be used to repay certain existing indebtedness and obligations of the Company, to pay fees and expenses related to the Loan Agreement, and for general working capital and corporate purposes.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loans under the Credit Facilities (i) are due and payable on January 1, 2027 (the &#8220;Maturity Date&#8221;) and (ii) bear interest that is payable monthly in arrears at a per annum rate (subject to increase during an event of default) equal to (i) with respect to the Term Facility, the greater of (x) the Wall Street Journal prime rate plus 2.25% and (y) 5.50% and (ii) with respect to the Revolving Facility, the Wall Street Journal Prime Rate. An unused commitment fee of 0.25% per annum applies to unutilized borrowing capacity under the Revolving Facility. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencing on February 1, 2024, we are required to repay the principal amount of the Term Facility in 36 consecutive equal monthly installments. At maturity or if earlier prepaid, we will also be required to pay an exit fee equal to 2.00% of the aggregate principal amount of the Term Facility.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may make a voluntary prepayment of the Term Facility, in whole but not in part, at any time. All voluntary and mandatory prepayments of the Term Facility are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs on or prior to the 1st anniversary of the Closing Date, an amount equal to 3.0% of the aggregate outstanding principal amount of the Term Facility being prepaid, (ii) if prepayment occurs after the 1st anniversary of the Closing Date and on or prior to the 2nd anniversary of the Closing Date, 2.0% of the aggregate outstanding principal amount of the Term Facility being prepaid, (iii) if prepayment occurs after the 2nd anniversary of the Closing Date and on or prior to the 3rd anniversary of the Closing Date, 1.0% of the aggregate outstanding principal amount of the Term Facility being prepaid and (iii) if prepayment occurs after the 3rd anniversary of the Closing Date but prior to the Maturity Date, an amount equal to 0.50% of the aggregate outstanding principal amount of the Term Facility being prepaid.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain exceptions, we are required to make mandatory prepayments of outstanding loans under the Revolving Facility with the proceeds of assets sales, which amounts, subject to the conditions set forth in the Loan Agreement, may re-borrowed. We may voluntarily terminate the Revolving Facility at any time. A termination of the Revolving Facility is subject to the payment of a termination fee as follows: (i) if such termination occurs on or prior to the 1st anniversary of the Closing Date, an amount equal to 3.0% of the Revolving Facility and (ii) if such termination occurs after the 1st anniversary of the Closing Date, 1.0% of the Revolving Facility. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The obligations of the Borrowers under the Loan Agreement are secured by a pledge of substantially all of the Borrowers&#8217; assets, excluding intellectual property. Certain of our future subsidiaries will be required to become co-borrowers under the Loan Agreement or guarantee the obligations of the Borrowers under the Loan Agreement. In addition, such subsidiaries will be required to pledge substantially all of their assets, excluding intellectual property, to secure the obligations of the Borrowers under the Loan Agreement.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, enter into affiliate transactions and change our line of business, in each case, subject to certain exceptions. In addition, the Loan Agreement contains the following quarterly financial covenants requiring the Borrowers to maintain either:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">minimum product revenue from YUTIQ</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;"> and DEXYCU</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;"> assessed on a quarterly basis commencing from the three-month period ending on March 31, 2022 through the Maturity Date, with such minimum quarterly product revenue ranging from approximately $7.8 million to approximately $11.5 million in fiscal year 2022. Such minimum quarterly product revenue will be subject to incremental increases in fiscal year 2023 and will thereafter be such amounts as agreed upon between the Company and the Lender based on certain agreed-upon factors commencing for the three-month period ending on March 31, 2024 and for each three-month period thereafter through the Maturity Date&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if the Company is unable to achieve the minimum quarterly product revenue level required as of the end of any three-month period, cash and cash equivalents in an amount equal to the greater of (i) $50,000,000 and (ii) the Company&#8217;s six-month Cash Burn (as defined in the SVB Loan Agreement).</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement also contains representations and warranties of the Borrowers customary for financings of this type. In addition, such representations and warranties (i) are intended not as statements of fact, but rather as a way of allocating the risk between the parties to the Loan Agreement, (ii) have been qualified by reference to confidential disclosures made by the parties in connection with the Loan Agreement and (iii) may apply standards of materiality in a way that is different from what may be viewed as material by our stockholders or other investors. Accordingly, the Loan Agreement is included with this filing only to provide investors with information regarding the terms of the transaction, and not to provide stockholders or other investors with any other factual information. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">characterizations our or any of our subsidiaries or affiliates actual state of facts or condition. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Loan Agreement, which subsequent information may or may not be fully reflected in public disclosures.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to cure, following which the Lender may accelerate all amounts outstanding under the Credit Facilities.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed as an exhibit to this Annual Report and is incorporated herein by reference.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Termination of CRG Credit Agreement</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the Closing Date, our existing Term Loan Agreement (as amended, the &#8220;CRG Credit Agreement&#8221;), dated as of February 13, 2019, by and among us, as borrower, CRG Servicing LLC, as administrative agent and collateral agent (&#8220;CRG&#8221;) and the lenders party thereto, which provided for a senior secured term loan of up to $60 million, terminated and all outstanding amounts under such loan were repaid in full, and all security interests and other liens granted to or held by CRG were terminated and released. The aggregate principal amount of the loan outstanding under the CRG Credit Agreement was approximately $38.2 million at the time of termination and the loan bore interest at a per annum rate of 12.50%. At the time of termination, we also paid CRG approximately $903,000, which consisted of interest accrued or deemed payable under the CRG Credit Agreement. Absent termination, the loan made pursuant to the CRG Credit Agreement would have matured on December 31, 2023. We also paid a 6% exit fee of the aggregate principal amount advanced under the CRG Credit Agreement.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the CRG Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the CRG Credit Agreement, a copy of which is filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on February 19, 2019, and incorporated herein by reference, the Fee Letter, a copy of which is filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on February 19, 2019, and incorporated herein by reference, the Waiver to the CRG Credit Agreement, a copy of which is filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on November 22, 2019, and incorporated herein by reference and Amendment No. 2 to the Waiver to the CRG Credit Agreement, a copy of which is filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on October 8, 2020, and incorporated herein by reference.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amendment to Watertown Lease</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 8, 2022, we amended our Watertown, Massachusetts lease (i) to extend the term to May 31, 2028 for 13,650 square feet of laboratory and manufacturing operations space, with the landlord agreeing to provide the Company a construction allowance of up to $555,960 to be applied toward upgrades and improvements within the space&#59; (ii) to rent an additional 11,999 square feet of office space within the building through May 31, 2028, with an anticipated commencement date in the third quarter of 2022&#59; and (iii) to terminate a portion of the lease comprising 7,999 square feet of office space in the building on May 31, 2025 (the &#8220;Lease Amendment&#8221;). We have an option to extend the term of the lease for one additional five-year period at market rates. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease Amendment, a copy of which is filed as an exhibit to this Annual Report and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9C">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated herein by reference from our definitive proxy statement relating to our 2022 annual meeting of stockholders, pursuant to Regulation 14A of the Exchange Act of 1934, also referred to in this Annual Report on Form 10-K as our 2022 Proxy Statement, which we expect to file with the SEC no later than May 2, 2022. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Governance </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a written Code of Business Conduct that applies to all of our employees, officers and directors. This Code of Business Conduct is designed to ensure that our business is conducted with integrity and in compliance with SEC regulations and Nasdaq listing standards. The Code of Business Conduct covers adherence to laws and regulations as well as professional conduct, including employment policies, conflicts of interest and the protection of confidential information. The Code of Business Conduct is available under &#8220;Governance Overview&#8221; within the &#8220;Investors &#8211; Corporate Governance&#8221; section of our website at www.eyepointpharma.com. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to disclose any future amendments to, or waivers from, the Code of Business Conduct that affect our directors or senior financial and executive officers within four business days of the amendment or waiver by posting such information on the website address and location specified above. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Information </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The other information required to be disclosed in Item 10 is hereby incorporated by reference to our 2022 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">ITEM&#160;11. EXECUTIVE COMPENSATION </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required to be disclosed in Item 11 is hereby incorporated by reference to our 2022 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required to be disclosed in Item 12 is hereby incorporated by reference to our 2022 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required to be disclosed in Item 13 is hereby incorporated by reference to our 2022 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required to be disclosed in Item 14 is hereby incorporated by reference to our 2022 Proxy Statement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENTS">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)(1)&#160;&#160;&#160;&#160;Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements filed as part of this report are listed on the Index to Consolidated Financial Statements on page&#160;F-1. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)(2)&#160;&#160;&#160;&#160;Financial Statement Schedules </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in our Consolidated Financial Statements or Notes thereto. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">ITEM&#160;16. FORM 10-K SUMMARY </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)(3) Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.12%;">
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="5" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;to&#160;SEC&#160;Filing</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC&#160;Filing Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Articles of Incorporation and By-Laws</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312508136629/dex31.htm"><span style="text-decoration:underline;">Certificate of Incorporation of pSivida Corp. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K12G3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/19/08</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312517283875/d326107dex32.htm"><span style="text-decoration:underline;">Certificate of Amendment of the Certificate of Incorporation of pSivida Corp. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/13/17</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.3</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518104855/d544168dex31.htm"><span style="text-decoration:underline;">Certificate of Correction to Certificate of Amendment of the Certificate of Incorporation of pSivida Corp. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/02/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.4</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518205723/d633682dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Certificate of Incorporation, as amended of EyePoint Pharmaceuticals, Inc. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/27/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.5</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518276414/d617568dex35.htm"><span style="text-decoration:underline;">By-Laws of EyePoint Pharmaceuticals, Inc. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/18/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.6</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518318982/d651294dex31.htm"><span style="text-decoration:underline;">Amendment No.&#160;1 to the By-Laws of EyePoint Pharmaceuticals, Inc. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/06/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.7</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020030273/eypt-ex31_9.htm"><span style="text-decoration:underline;">Certificate of Amendment of the Certificate of Incorporation, as amended, of EyePoint Pharmaceuticals, Inc.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/23/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.8</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020056386/eypt-ex31_9.htm"><span style="text-decoration:underline;">Certificate of Amendment of the Certificate of Incorporation, as amended, of EyePoint Pharmaceuticals, Inc.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/08/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Instruments Defining the Rights of Security Holders</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312508136629/dex41.htm"><span style="text-decoration:underline;">Form of Specimen Stock Certificate for Common Stock </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K12G3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/19/08</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518100410/d560059dex41.htm"><span style="text-decoration:underline;">Warrant to Purchase Common Stock of pSivida Corp., issued March 28, 2018, to SWK Funding, LLC </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/29/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518100410/d560059dex103.htm"><span style="text-decoration:underline;">Registration Rights Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/29/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518205723/d633682dex101.htm"><span style="text-decoration:underline;">Second Registration Rights Agreement, dated as of June 25, 2018, by and among EyePoint Pharmaceuticals, Inc. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. and each other person identified on the signature pages thereto </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/27/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.5</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021012894/eypt-ex45_629.htm"><span style="text-decoration:underline;">Description of Securities of EyePoint Pharmaceuticals, Inc.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/12/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.6</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021057763/eypt-ex41_93.htm"><span style="text-decoration:underline;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/19/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Material Contracts - Management Contracts and Compensatory Plans</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312516763095/d269971dex101.htm"><span style="text-decoration:underline;">Employment Agreement between pSivida Corp. and Nancy Lurker, dated September 15, 2016</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/08/16</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.12%;">
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="5" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;to&#160;SEC&#160;Filing</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC&#160;Filing Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312516763095/d269971dex103.htm"><span style="text-decoration:underline;">Nonstatutory Stock Option Inducement Award granted to Nancy Lurker, subject to shareholder approval, with effect from September&#160; 15, 2016 </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/08/16</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518159375/d537374dex107.htm"><span style="text-decoration:underline;">Employment Agreement, between EyePoint Pharmaceuticals, Inc. and Dario Paggiarino, dated March&#160;27, 2018 </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/10/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459019029987/eypt-ex104_247.htm"><span style="text-decoration:underline;">Employment Agreement between EyePoint Pharmaceuticals, Inc. Scott Jones, dated May 30, 2019</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/07/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0066CC;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459019043812/eypt-ex101_7.htm"><span style="text-decoration:underline;">Employment Agreement, dated November 14, 2019, by and between EyePoint Pharmaceuticals, Inc. and George Elston</span><span style="text-decoration:underline;color:#000000;"> </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/19/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312508193969/dex101.htm"><span style="text-decoration:underline;">Form of Stock Option Certificate for grants to executive officers under the pSivida Corp. 2008 Incentive Plan </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/08</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518036206/d524731dex101.htm"><span style="text-decoration:underline;">Form of Stock Option Certificate for grants to executive officers under the EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan, as amended </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/08/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518036206/d524731dex102.htm"><span style="text-decoration:underline;">Form of Deferred Stock Unit Award for grants to non-executive directors under the EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan, as amended </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/08/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518276414/d617568dex1015.htm"><span style="text-decoration:underline;">Form of Stock Option Award Agreement for Inducement grants to executive officers </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/18/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312515316983/d96257dex106.htm"><span style="text-decoration:underline;">2008 Equity Incentive Plan, as amended on November&#160;19, 2009 </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/15</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312517036133/d327971dex41.htm"><span style="text-decoration:underline;">pSivida Corp. 2016 Long Term Incentive Plan, as amended </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/09/17</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312517283875/d326107dex1018.htm"><span style="text-decoration:underline;">Form of Restricted Stock Unit Award for grants to executive officers under the pSivida Corp. 2016 Long Term Incentive Plan, as amended </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/13/17</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312517283875/d326107dex1019.htm"><span style="text-decoration:underline;">Form of Performance-Based Stock Unit Award for grants under the pSivida Corp. 2016 Long Term Incentive Plan, as amended </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/13/17</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518323795/d635570dex105.htm"><span style="text-decoration:underline;">Stock Option Award Agreement, dated August&#160;14, 2018, by and between EyePoint Pharmaceuticals, Inc. and John Weet </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312519078454/d701050dex1025.htm"><span style="text-decoration:underline;">Stock Option Award Agreement, dated November 26, 2018, by and between EyePoint Pharmaceuticals, Inc. and Ron Honig</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/18/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0066CC;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312519185970/d766592dex101.htm"><span style="text-decoration:underline;">EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan</span><span style="text-decoration:underline;color:#000000;"> </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/28/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0066CC;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312519185970/d766592dex102.htm"><span style="text-decoration:underline;">Amendment No.&#160;1 to EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan</span><span style="text-decoration:underline;color:#000000;"> </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/28/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0066CC;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312519185970/d766592dex103.htm"><span style="text-decoration:underline;">EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/28/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19(a)+</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex1019_924.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#337AB7;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021034107/eypt-ex101_16.htm"><span style="text-decoration:underline;">EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive Plan, as amended</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/24/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#337AB7;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021034107/eypt-ex102_17.htm"><span style="text-decoration:underline;">EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, as amended</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/24/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021053039/eypt-ex101_27.htm"><span style="text-decoration:underline;">Employment Agreement, effective November 1, 2021, between EyePoint Pharmaceuticals, Inc. and Jay Duker, M.D.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/01/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459022000853/eypt-ex101_8.htm"><span style="text-decoration:underline;">Employment Agreement, dated January 10, 2022, by and between EyePoint Pharmaceuticals, Inc. and Michael C. Pine</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/10/22</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.12%;">
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="5" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;to&#160;SEC&#160;Filing</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC&#160;Filing Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Material Contracts &#8211; Leases</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312513439868/d616544dex101.htm"><span style="text-decoration:underline;">Lease Agreement between pSivida Corp. and Farley White Aetna Mills, LLC dated November&#160;1, 2013 </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/13/13</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518276414/d617568dex1024.htm"><span style="text-decoration:underline;">First Amendment of Lease, dated February&#160;6, 2014, between Farley White Aetna Mills and pSivida Corp. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/18/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518276414/d617568dex1025.htm"><span style="text-decoration:underline;">Second Amendment of Lease, dated May&#160;14, 2018, between Whetstone Riverworks Holdings, LLC and EyePoint Pharmaceuticals, Inc. </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/18/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021023626/eypt-ex101_136.htm"><span style="text-decoration:underline;">Third Amendment to Lease, dated April 5, 2021, between GRE Riverworks, LLC and EyePoint Pharmaceuticals, Inc.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/5/2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex1028_1698.htm"><span style="text-decoration:underline;">Fourth Amendment to Lease, dated March 8, 2022, between GRE Riverworks, LLC and EyePoint Pharmaceuticals, Inc.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Material Contracts - License and Collaboration Agreements</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29#</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020010956/eypt-ex1032_519.htm"><span style="text-decoration:underline;">Exclusive License Agreement between EyePoint Pharmaceuticals, Inc. and Equinox Science, LLC.  </span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/16/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Material Contracts - Other Agreements</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518100410/d560059dex101.htm"><span style="text-decoration:underline;">Securities Purchase Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/29/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518100410/d560059dex102.htm"><span style="text-decoration:underline;">Second Securities Purchase Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. and each other person identified on the signature pages thereto</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/29/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312518100410/d560059dex105.htm"><span style="text-decoration:underline;">Agreement and Plan of Merger, dated March 28, 2018, by and among pSivida Corp., Oculus Merger Sub, Inc., Icon Bioscience, Inc. and Shareholder Representative Services LLC</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/29/18</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312519044197/d686689dex101.htm"><span style="text-decoration:underline;">Term Loan Agreement, dated February 13, 2019, among EyePoint Pharmaceuticals, Inc., as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as Subsidiary Guarantors, and CRG Servicing LLC, as Administrative Agent and Collateral Agent</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/19/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312519044197/d686689dex102.htm"><span style="text-decoration:underline;">Fee Letter, dated February&#160;13, 2019, by and between EyePoint Pharmaceuticals, Inc. and CRG Servicing LLC</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/19/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0066CC;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459019044172/eypt-ex101_20.htm"><span style="text-decoration:underline;">Waiver To Term Loan Agreement, dated November 19, 2019, among EyePoint Pharmaceuticals, as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as subsidiary guarantors and CRG Servicing LLC, as Administrative Agent and Collateral Agent</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/22/19</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020019253/eypt-ex991_18.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Note dated April 21, 2020 between EyePoint Pharmaceuticals, Inc. and Silicon Valley Bank</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/28/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020036461/eypt-ex11_58.htm"><span style="text-decoration:underline;">Controlled Equity Offering</span><span style="font-size:8.5pt;text-decoration:underline;"><sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup></span><span style="text-decoration:underline;">&#160;Sales Agreement, dated August 5, 2020, by and between EyePoint Pharmaceuticals, Inc. and Cantor Fitzgerald &#38; Co</span></a><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/05/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.38</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020046049/eypt-ex101_7.htm"><span style="text-decoration:underline;">Amendment No. 2 and Waiver To Term Loan Agreement, dated October 8, 2020, among EyePoint Pharmaceuticals, Inc. as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as subsidiary guarantors and CRG Servicing LLC, as Administrative Agent and Collateral Agent</span></a><span style="text-decoration:underline;">.</span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/08/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.39#</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459020051654/eypt-ex101_120.htm"><span style="text-decoration:underline;">Commercial Alliance agreement, dated as of August 1, 2020 between EyePoint Pharmaceuticals, Inc. and ImprimisRx, LLC.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/06/20</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.40</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459021000011/eypt-ex101_19.htm"><span style="text-decoration:underline;">Share Purchase Agreement, dated December 31, 2020, by and between EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/04/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.12%;">
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="5" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;to&#160;SEC&#160;Filing</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC&#160;Filing Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000156459021000011/eypt-ex102_20.htm"><span style="text-decoration:underline;">Voting and Investor Rights Agreement, dated December 31, 2020, by and among EyePoint Pharmaceuticals, Inc., Ocumension Therapeutics, and EW Healthcare Partners, L.P. and EW Healthcare Partners-A,L.P.</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">01/04/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1314102/000119312521027308/d116559dex101.htm"><span style="text-decoration:underline;">First Amendment to Share Purchase Agreement, dated February&#160;1, 2021, by and between EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/03/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.43</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021012894/eypt-ex1035_845.htm"><span style="text-decoration:underline;">Amendment One to the Commercial Alliance Agreement dated November 12, 2020 between EyePoint Pharmaceuticals, Inc. and ImprimisRx, LLC</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/12/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.44</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001314102/000156459021012894/eypt-ex1036_284.htm"><span style="text-decoration:underline;">Royalty Purchase Agreement, dated December 17, 2020, by and between EyePoint Pharmaceuticals, Inc. and SWK Funding, LLC</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/12/21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45#(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex1045_1565.htm"><span style="text-decoration:underline;">Commercial Alliance Expansion Term Letter Agreement dated December 6, 2021 between EyePoint Pharmaceuticals, Inc. and ImprimisRx, LLC</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46#(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex1046_2496.htm"><span style="text-decoration:underline;">Loan and Security Agreement, dated March 9, 2022, among EyePoint Pharmaceuticals, Inc., EyePoint Pharmaceuticals US, Inc., Icon Bioscience, Inc. and Silicon Valley Bank</span></a></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex211_8.htm"><span style="text-decoration:underline;">Subsidiaries of EyePoint Pharmaceuticals, Inc.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex231_9.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm, Deloitte&#160;&#38; Touche LLP</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex311_11.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2(a)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex312_6.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1(b)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2(b)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eypt-ex322_10.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS&#160;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH&#160;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:none;">101.CAL</span><span style="Background-color:#FFFFFF;">&#160;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF&#160;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB&#160;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE&#160;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document&#160;</p></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101).</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:61.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The final versions of documents denoted as &#8220;form of&#8221; have been omitted pursuant to Rule 12b-31. Such final versions are substantially identical in all material respects to the filed versions of such documents, provided that the name of the investor, and the investor&#8217;s and/or the Company&#8217;s signatures are included in the final versions. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Filed herewith </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Furnished herewith</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:37%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nancy Lurker</p></td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:37%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Lurker</p></td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2022</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ G&#214;RAN ANDO</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">G&#246;ran Ando</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ NANCY LURKER</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nancy Lurker</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ GEORGE O. ELSTON</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial Officer and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Accounting Officer)</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">George O. Elston</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ WENDY DICICCO</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Wendy DiCicco</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ YE LIU</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ye Liu</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ RONALD W. EASTMAN</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ronald W. Eastman</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ JOHN LANDIS</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">John Landis</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/<span style="font-size:7.5pt;">S</span>/ DAVID R. GUYER</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:24.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">David R. Guyer</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:57.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Financial Statements:</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm on the Financial Statements</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (PCAOB ID No. <ix:nonNumeric id="F_000033" name="dei:AuditorFirmId" contextRef="C_0001314102_20210101_20211231">34</ix:nonNumeric>)</span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:underline;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of EyePoint Pharmaceuticals, Inc. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of EyePoint Pharmaceuticals, Inc. and subsidiaries (the "Company") as of December 31, 2021 and 2020, the related consolidated statements of comprehensive loss, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prepaid and Accrued Clinical Trial Expenses&#8212; Refer to Note 2 and 7 to the financial statements.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Critical Audit Matter Description</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">As disclosed in Note 2 to the financial statements, the Company expenses research and development costs as incurred, which include costs relating to clinical trial activities. Expenses related to clinical trial studies are based on estimates of the services received and efforts expended pursuant to contracts with each of the Contract Research Organizations (&#8220;CROs&#8221;) and investigative sites. Tracking the progress of the clinical trials, including payments made by the Company and by the CROs, allows the Company to record the appropriate expense, prepayments, and accruals under the terms of the agreements.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">We identified the accruals for research and development expenses and clinical trials as a critical audit matter due to the (i) the significant judgment by management in determining the prepaid or accrued costs and (ii) high degree of auditor judgment and subjectivity and effort in performing procedures and evaluating audit evidence for these accrued or prepaid costs and the factors related to progress towards or the estimated current stage of completion of the research and development activities or studies, invoicing to date under the contracts, and communications from the research institution, or other companies, of any actual costs incurred during the period that have not yet been invoiced. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">How the Critical Audit Matter Was Addressed in the Audit</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our audit procedures related to prepaid and accrued clinical trials included the following, among others: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:9pt;color:#000000;">We evaluated the appropriateness of the method used by management to develop the estimates</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:9pt;color:#000000;">Tested the completeness and accuracy of inputs through inspection of the terms of contracts and statements of work between the Company and third-party vendors and testing of actual billed expenses under the contracts</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Verdana;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:3pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:9pt;color:#000000;">Evaluated the reasonableness of the assumptions used in developing the estimates (including the progress towards completion of specific tasks and the associated cost incurred for services the Company has not yet been invoiced or otherwise notified of the actual cost at period end) through inquiries of Company personnel responsible for overseeing the research and development activities to understand progress of the activities, and inspection of correspondence between the Company and these organizations</span></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <ix:nonNumeric id="F_000034" name="dei:AuditorName" contextRef="C_0001314102_20210101_20211231">Deloitte &#38; Touche LLP</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000035" name="dei:AuditorLocation" contextRef="C_0001314102_20210101_20211231">Boston, Massachusetts</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2008.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands except share amounts) &#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,593</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts and other receivables, net (including due from a related party of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001314102_20211231" decimals="INF" scale="3">414</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001314102_20201231" decimals="INF" scale="3">104</ix:nonFraction> at December 31, 2021 and 2020, respectively)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,453</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:InventoryNet" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:InventoryNet" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AssetsCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">237,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">63,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_20211231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_20201231" decimals="-3" scale="3">630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:Assets" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Assets" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,811</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">945</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">782</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:Liabilities" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:Liabilities" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contingencies (Note 16)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000077">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000078">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, <span>$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000095" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001314102_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000096" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001314102_20201231" decimals="INF">.001</ix:nonFraction></ix:nonFraction></span> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001314102_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001314102_20201231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001314102_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001314102_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001314102_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001314102_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000079">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000080">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000103" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001314102_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000104" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001314102_20201231" decimals="INF">.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000105" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001314102_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000106" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001314102_20201231" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2021 and 2020, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000107" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001314102_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000109" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001314102_20211231" decimals="INF" format="ixt:numdotdecimal">33,905,826</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000108" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001314102_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000110" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001314102_20201231" decimals="INF" format="ixt:numdotdecimal">18,139,981</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:CommonStockValue" contextRef="C_0001314102_20211231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommonStockValue" contextRef="C_0001314102_20201231" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">752,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">528,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001314102_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">569,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001314102_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">510,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001314102_20211231" decimals="-3" scale="3">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001314102_20201231" decimals="-3" scale="3">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands except per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration agreements (including licensing fees from a related party of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231" decimals="-3" scale="3">543</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,500</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231" decimals="-3" scale="3">756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20210101_20211231" decimals="-3" scale="3">871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,664</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales, excluding amortization of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,424</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:SellingAndMarketingExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:SellingAndMarketingExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="eypt:AmortizationOfAcquisitionCostOfIntangibleAssets" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="eypt:AmortizationOfAcquisitionCostOfIntangibleAssets" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:OperatingExpenses" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:OperatingExpenses" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">71,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:InterestExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:InterestExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) on extinguishment of debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" scale="3">905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000143" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001314102_20210101_20211231" decimals="2" sign="-">2.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000144" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001314102_20200101_20201231" decimals="2" sign="-">3.54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands except share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Par Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000155" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">10,941,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">472,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">465,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock, net of issue costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">7,100,815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000169" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">33,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of stock units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000172" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">63,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" sign="-" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000177" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">18,139,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">528,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">510,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:NetIncomeLoss" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of stock and pre-funded warrants, net of issue costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000185" name="eypt:StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">15,635,811</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">216,570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">216,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000189" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">43,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000192" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">8,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000195" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">78,557</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" sign="-" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000200" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">33,905,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">752,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">569,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" scale="3">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockholdersEquity" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:ProfitLoss" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:ProfitLoss" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to cash flows used in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:Depreciation" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:Depreciation" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="eypt:AmortizationOfDebtDiscount" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="eypt:AmortizationOfDebtDiscount" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:PaidInKindInterest" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:PaidInKindInterest" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on extinguishment of debt</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for excess and obsolescence inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:InventoryWriteDown" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:InventoryWriteDown" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:ShareBasedCompensation" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:ShareBasedCompensation" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,603</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets and operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="eypt:IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" scale="3">28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="eypt:IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" scale="3">931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">50,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">33,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" scale="3">362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of stock and pre-funded warrants, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="eypt:ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">216,825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="eypt:ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds under paycheck protection program loan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="eypt:ProceedsFromPaycheckProtectionProgramLoan" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="eypt:ProceedsFromPaycheckProtectionProgramLoan" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of long-term debt principal</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of extinguishment of debt costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlement of stock units to satisfy statutory tax withholding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments on finance lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">216,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign exchange rate changes on cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">133,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,059</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001314102_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,059</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash interest paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:InterestPaidNet" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:InterestPaidNet" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="eypt:NonCashUnpaidStockIssuanceCosts" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="eypt:NonCashUnpaidStockIssuanceCosts" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued term loan exit fee</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="eypt:DebtInstrumentExitFee" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="eypt:DebtInstrumentExitFee" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments forgiven under paycheck protection program loan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="eypt:PaymentsForgivenUnderPaycheckProtectionProgramLoan" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="eypt:PaymentsForgivenUnderPaycheckProtectionProgramLoan" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </p><ix:nonNumeric id="F_000273" name="us-gaap:NatureOfOperations" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000273_dcnt_3aaa826e-1a25-45dd-844d-f2fc6873542b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Operations</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;), incorporated in Delaware, is<span style="Background-color:#FFFFFF;"> a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company&#8217;s pipeline leverages its proprietary Durasert</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup><span style="Background-color:#FFFFFF;">technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration (&#8220;wet AMD&#8221;), the leading cause of vision loss among people 50 years of age and older in the United States. The Company&#8217;s product candidate pipeline also includes YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application (&#8220;sNDA&#8221;) strategy. The Company also has <ix:nonFraction unitRef="U_eyptProduct" id="F_000335" name="eypt:NumberOfProducts" contextRef="C_0001314102_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> commercial products: YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a once every three-year treatment for chronic&#160;non-infectious&#160;uveitis affecting the posterior segment of the eye, and DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a single dose treatment for postoperative inflammation following ocular surgery.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Local drug delivery for treating ocular diseases is a significant challenge due to the effectiveness of the blood-eye barrier. This barrier makes it difficult for systemically-administered drugs to reach the eye in sufficient quantities to have a beneficial effect without causing unacceptable adverse side effects to other organs. The Company&#8217;s validated Durasert technology, which has already been included in <ix:nonFraction unitRef="U_eyptProduct" id="F_000336" name="eypt:NumberOfProductsApproved" contextRef="C_0001314102_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> products approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), is designed to provide consistent, sustained delivery of small molecule drugs over a period of months to years through a single intravitreal injection. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s lead product candidate, EYP-1901, combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor (&#8220;TKI&#8221;) that has demonstrated anti-VEGF activity. Current FDA approved anti-VEGF treatments for wet AMD require monthly or bi-monthly intravitreal injections in a physician&#8217;s office. The Company is currently evaluating EYP-1901 in a Phase 1 clinical trial as a potential six-month sustained delivery treatment for wet AMD and reported positive six-month interim safety and efficacy data in November 2021. In February 2022, the Company updated the results of the DAVIO clinical trial through 8-months reporting continued positive safety and efficacy results. The Company expects to initiate a Phase 2 clinical trial in wet AMD in the third quarter of 2022 and a Phase 2 clinical trial in diabetic retinopathy later in the second half of 2022.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;(fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is a non-erodible intravitreal implant containing fluocinolone acetonide (&#8220;FA&#8221;) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This disease affects between <ix:nonFraction unitRef="U_eypt_People" id="F_000337" name="eypt:NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMinimumMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">60,000</ix:nonFraction> to <ix:nonFraction unitRef="U_eypt_People" id="F_000338" name="eypt:NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMaximumMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction> people each year in the U.S. causes approximately <ix:nonFraction unitRef="U_eyptCase" id="F_000339" name="eypt:NumberOfNewBlindnessCasesEveryYear" contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">30,000</ix:nonFraction> new cases of blindness every year and is the third leading cause of blindness. YUTIQ utilizes the Company&#8217;s proprietary Durasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;sustained-release drug delivery technology platform.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;(dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation, with the Company&#8217;s primary focus on its use&#160;immediately following cataract surgery as a single dose treatment. DEXYCU utilizes the Company&#8217;s proprietary Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;drug-delivery&#160;technology. In December 2021, the Company announced that its commercial alliance partner, ImprimisRx, assumed responsibility for all sales and marketing activity for DEXYCU effective January 1, 2022.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is also developing YUTIQ 50 as a potential six-month intravitreal treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. The Company dosed the first patient in a Phase 3 clinical trial in November 2021.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company is also seeking to potentially identify and advance additional product candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, potential research collaborations and/or&#160;in-licensing&#160;arrangements with partner molecules and potential acquisition of additional ophthalmic products, product candidates or technologies that complement the Company&#8217;s current product portfolio.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Effects of the COVID-19 Coronavirus Pandemic<span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span><span style="color:#000000;"> ongoing COVID-19 coronavirus pandemic</span><span style="Background-color:#FFFFFF;color:#000000;"> (the &#8220;Pandemic&#8221;)</span><span style="color:#000000;"> has had a material and adverse impact on the Company&#8217;s business, including as a result of measures that the Company, other businesses, and government have taken and will likely continue to take. This includes a significant impact on cash flows from expected revenues due to the closure of ambulatory surgery centers for DEXYCU and a significant reduction in physician office visits impacting YUTIQ in 2020. The ongoing Pandemic continued to have an adverse impact on the Company&#8217;s revenues, financial condition and cash flows through 2021. For the year ended December 31, 2021, the Company recorded impairment charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:AssetImpairmentCharges" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptCostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_20210101_20211231" decimals="-5" scale="6">1.2</ix:nonFraction> million to cost of sales, excluding amortization of acquired intangible assets and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:AssetImpairmentCharges" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million to sales and marketing expense, respectively, associated with the write-off of obsolete inventory of DEXYCU units and DEXYCU sample units, respectively, whose inventory levels were higher than the Company&#8217;s updated forecasts of future demand </span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000273_dcnt_3aaa826e-1a25-45dd-844d-f2fc6873542b">
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">for those units. </span><span style="color:#000000;">Additionally, the emergence of </span><span style="color:#000000;">the Omicron </span><span style="color:#000000;">variant has </span><span style="color:#000000;">continued to have an adverse impact on the Company&#8217;s revenues, financial condition and cash flows into the first quarter of 2022</span><span style="color:#000000;"> and may continue to cause intermittent or prolonged periods of reduced patient services at the Company&#8217;s customers&#8217; facilities, which may negatively affect customer demand. The progression of the Pandemic and its effects on the Company&#8217;s business and operations are uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, the Company&#8217;s revenues, financial condition and cash flows may be adversely affected in the future as well.</span><span style="color:#000000;"> </span><span style="color:#000000;">The Company is </span><span style="color:#000000;">continuously </span><span style="color:#000000;">monitoring the Pandemic and its potential effect on the Company&#8217;s financial position, results of operations and cash flows. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company&#8217;s periodic financial results, including reserves for variable consideration related to product sales, realizability of certain receivables, assessment for excess or obsolete inventory, and impairment of long-lived assets. </span><span style="Background-color:#FFFFFF;color:#000000;">Uncertainty around the extent and duration of the Pandemic, and any future related financial impact cannot be reasonably estimated at this time.</span><span style="Background-color:#FFFFFF;color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span><span style="color:#000000;"> Company had cash, cash equivalents, and investments in marketable securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001314102_20211231" decimals="-5" scale="6">211.6</ix:nonFraction></span><span style="font-size:12pt;">&#160;</span><span style="color:#000000;">million at December 31, 2021.&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">The Company has a history of operating losses and has not had significant recurring cash inflows from revenue.</span><span style="color:#000000;"> The Company&#8217;s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates and the Company does not expect revenues from its product sales to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenues of its product sales, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents, and investments in marketable securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001314102_20211231" decimals="-5" scale="6">211.6</ix:nonFraction></span><span style="font-size:12pt;">&#160;</span><span style="color:#000000;">million at December 31, 2021, coupled with expected cash inflows from its product sales will enable the Company to fund its current and planned operations for </span><span style="Background-color:#FFFFFF;color:#000000;">at least the next twelve months from the date these consolidated financial statements were issued. A</span><span style="color:#000000;">ctual cash requirements could differ from management&#8217;s projections due to many factors, including the continued effect of the Pandemic on the Company&#8217;s business and the medical community, </span><span style="Background-color:#FFFFFF;color:#000000;">the timing and results of the Company&#8217;s clinical trials for EYP-1901, </span><span style="color:#000000;">additional </span><span style="Background-color:#FFFFFF;color:#000000;">investments</span><span style="color:#000000;"> in research and development programs, the success of ongoing </span><span style="Background-color:#FFFFFF;color:#000000;">commercialization</span><span style="color:#000000;"> efforts for YUTIQ and DEXYCU, the actual costs of these ongoing commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.</span></p></ix:continuation><ix:nonNumeric id="F_000274" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000274_dcnt_a97dbdee-8c63-4221-bfc5-3cdb422ac78e">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Significant Accounting Policies </p></td></tr></table></div><ix:nonNumeric id="F_000291" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements are presented in U.S. dollars in accordance with generally accepted accounting principles in the U.S. (&#8220;U.S. GAAP&#8221;) and include the accounts of EyePoint Pharmaceuticals, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. </p></ix:nonNumeric><ix:nonNumeric id="F_000292" name="us-gaap:UseOfEstimates" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to reserves for variable consideration related to product sales, revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recording of excess or obsolete inventory write-offs and reserves, and realization of deferred tax assets. Actual results could differ from these and other estimates and there may be changes to the Company&#8217;s estimates in future periods. </p></ix:nonNumeric><ix:nonNumeric id="F_000293" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000293_dcnt_4fba6aff-b9ac-4b23-a12d-007a8404429b">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company and each of its subsidiaries is the currency of the primary economic environment in which each such entity operates&#8212;the U.S. dollar or the Pound&#160;Sterling. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities of the Company&#8217;s foreign subsidiary are translated at period-end exchange rates. Amounts included in the consolidated statements of comprehensive loss and cash flows are translated at the weighted average exchange rates for the period. Gains and losses from currency translation are included in accumulated other comprehensive income as a separate component of stockholders&#8217; equity in the consolidated balance sheets. The balance of accumulated other comprehensive income attributable to foreign currency translation was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="C_0001314102_20211231" decimals="0" format="ixt:numdotdecimal">841,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="C_0001314102_20201231" decimals="0" format="ixt:numdotdecimal">841,000</ix:nonFraction> at December&#160;31, 2021 and 2020, respectively. Foreign currency gains or </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_a97dbdee-8c63-4221-bfc5-3cdb422ac78e" continuedAt="F_000274_dcnt_aedff01a-22ec-4b88-9472-070181a051e9"><ix:continuation id="F_000293_dcnt_4fba6aff-b9ac-4b23-a12d-007a8404429b">
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">losses arising from transactions denominated in foreign currencies, whether realized or unrealized, are recorded in interest and other income, net in the consolidated statements of comprehensive loss and were not </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for all periods presented.</span></p></ix:continuation><ix:nonNumeric id="F_000294" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents represent highly liquid investments with maturities of three months or less at the date of purchase, principally consisting of institutional money market funds and investment-grade commercial paper. </p></ix:nonNumeric><ix:nonNumeric id="F_000295" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with an original or remaining maturity of greater than three months but less than six months at the date of purchase. The Company has historically classified its marketable securities as available-for-sale. Accordingly, the Company records these investments at fair value, with unrealized gains and losses excluded from earnings and reported, net of tax, in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. If the Company determines that a decline of any investment is other-than-temporary, the investment is written down to fair value. Marketable securities at December 31, 2021 consisted of investment-grade commercial paper. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001314102_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> marketable security investments at December 31, 2020. The Company&#8217;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. During fiscal 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001314102_20210101_20211231" decimals="-5" scale="6">33.0</ix:nonFraction> million of marketable securities were purchased and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001314102_20210101_20211231" decimals="0">0</ix:nonFraction> matured.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of marketable securities is determined based on quoted market prices at the balance sheet date of the same or similar instruments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts through to the earlier of sale or maturity. Such amortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the specific identification method.</p></ix:nonNumeric><ix:nonNumeric id="F_000296" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and investments in marketable securities. At December&#160;31, 2021, a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_0001314102_20211231" decimals="-5" scale="6">155.6</ix:nonFraction>&#160;million, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000351" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">90.4</ix:nonFraction>% of the Company&#8217;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:CommercialPaperAtCarryingValue" contextRef="C_0001314102_20211231" decimals="-5" scale="6">16.5</ix:nonFraction> million, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000352" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">9.6</ix:nonFraction>% of the Company&#8217;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001314102_20211231" decimals="-5" scale="6">33.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001314102_20201231" decimals="0">0</ix:nonFraction> in marketable securities at December&#160;31, 2021 and 2020, respectively. The Company&#8217;s investment policy, approved by the Company&#8217;s Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, accounts receivable from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for <ix:nonFraction unitRef="U_xbrlipure" id="F_000356" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">54.7</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000355" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">38.3</ix:nonFraction>% of total accounts receivable, respectively. For the year ended December 31, 2021, revenues from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for <ix:nonFraction unitRef="U_xbrlipure" id="F_000358" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">46.6</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000357" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">43.1</ix:nonFraction>% of total revenues, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, accounts receivable from ASD Specialty Healthcare LLC and McKesson Specialty Care Distribution LLC accounted for <ix:nonFraction unitRef="U_xbrlipure" id="F_000359" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">56.0</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000360" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">37.0</ix:nonFraction>% of total accounts receivable, respectively. For the year ended December 31, 2020, revenues from ASD Specialty Healthcare LLC, Ocumension Therapeutics, and McKesson Specialty Care Distribution LLC accounted for <ix:nonFraction unitRef="U_xbrlipure" id="F_000361" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">39.0</ix:nonFraction>%, <ix:nonFraction unitRef="U_xbrlipure" id="F_000362" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">33.0</ix:nonFraction>%, and <ix:nonFraction unitRef="U_xbrlipure" id="F_000363" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">18.0</ix:nonFraction>% of total revenues, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000297" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000297_dcnt_5ef21261-9a75-46b4-aab7-2c8fe7bc1dfa">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level&#160;1 &#8211; Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_aedff01a-22ec-4b88-9472-070181a051e9" continuedAt="F_000274_dcnt_c7404f34-d43a-4294-947e-b84c2254fb3f"><ix:continuation id="F_000297_dcnt_5ef21261-9a75-46b4-aab7-2c8fe7bc1dfa">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level&#160;2 &#8211; Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets). </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level&#160;3 &#8211; Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#8217; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity. </p></ix:continuation><ix:nonNumeric id="F_000298" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts and Other Receivables, Net</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables arise primarily from the Company&#8217;s products sold in the U.S. The balance in accounts and other receivables, net consists primarily of amounts due from customers, net of applicable revenue reserves. The majority of the Company&#8217;s accounts receivable have standard payment terms that require payment within <ix:nonNumeric id="F_000366" name="eypt:AccountsReceivableStandardPaymentTerms" contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_2c172b90-2ff8-41b4-a2ad-7bafae735407">120</ix:nonNumeric>-<ix:nonNumeric id="F_000367" name="eypt:AccountsReceivableStandardPaymentTerms" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:durwordsen">127<ix:continuation id="C_2c172b90-2ff8-41b4-a2ad-7bafae735407"> days</ix:continuation></ix:nonNumeric>. The Company <span style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.2pt;">performs ongoing credit evaluations of its customers&#8217; financial condition and continuously monitor collections and payments from its customers and</span> analyzes accounts that are past due for collectability. <span style="color:#000000;">The allowance for credit losses is estimated based on the Company&#8217;s analysis of trends in overall receivables aging, specific identification of certain receivables that are at risk of not being paid, past collection experience and current economic trends. </span>G<span style="Background-color:#FFFFFF;color:#000000;">iven the nature and limited history of collectability of the Company&#8217;s accounts receivable, </span>the Company recorded <ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" contextRef="C_0001314102_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" contextRef="C_0001314102_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> allowance for credit losses as of December 31, 2021 and 2020.</p></ix:nonNumeric><ix:nonNumeric id="F_000299" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inventory </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or net realizable value, net on a first-in, first-out (&#8220;FIFO&#8221;) basis. The inventory costs for YUTIQ include purchases of various components and the active pharmaceutical ingredient (&#8220;API&#8221;) and internal labor and overhead for the product manufactured in the Company&#8217;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalization of inventory costs begins after FDA approval of the product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assesses the recoverability of inventory and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Write-downs are based on the age of the inventory, lower of cost or market, along with significant management judgments concerning future demands for the inventory. Such impairment charges, should they occur, are recorded within cost of sales, excluding amortization of acquired intangible assets. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory might be recorded in future periods.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost <span style="Background-color:#FFFFFF;">of</span> sales, excluding amortization of acquired intangible assets, consist of costs associated with the manufacture of YUTIQ and DEXYCU, certain period costs for DEXYCU product revenue, product shipping and, as applicable, royalty expense. The inventory costs for YUTIQ include purchases of various components, the active pharmaceutical ingredient (&#8220;API&#8221;) and direct labor and overhead for the product manufactured in the Company&#8217;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly. Capitalization of inventory costs begins after FDA approval of a product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company accrued DEXYCU product revenue-based royalty expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="eypt:AccruedRevenueBasedRoyaltyExpense" contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231" decimals="-5" scale="6">2.5</ix:nonFraction> million and $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="eypt:AccruedRevenueBasedRoyaltyExpense" contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231" decimals="-5" scale="6">2.3</ix:nonFraction></span> million for the years ended December 31, 2021 and 2020, respectively, as a component of cost of sales, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="eypt:AccruedRevenueBasedRoyaltyExpense" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231" decimals="-6" scale="6">0</ix:nonFraction> and $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="eypt:AccruedRevenueBasedRoyaltyExpense" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231" decimals="-5" scale="6">1.3</ix:nonFraction></span> million of accrued revenue-based royalty expense were related to the partnering income equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000372" name="eypt:PercentageOfAcceleratedMilestonePaymentReceived" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200801_20200831" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000373" name="eypt:PercentageOfUpfrontPaymentReceived" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200201_20200229" decimals="2" scale="-2">20</ix:nonFraction></ix:nonFraction>% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, in connection with the acquisition of Icon Bioscience, Inc. in March 2018 for the years ended December 31, 2021 and 2020, respectively.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_c7404f34-d43a-4294-947e-b84c2254fb3f" continuedAt="F_000274_dcnt_565389ec-5aa4-4ae4-8dce-c0e5312781fe"><ix:nonNumeric id="F_000300" name="eypt:DebtAndEquityInstrumentsPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Debt and Equity Instruments </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Debt</span><span style="color:#000000;"> and equity instruments are classified as either liabilities or equity in accordance with the substance of the contractual arrangement. </span></p></ix:nonNumeric><ix:nonNumeric id="F_000301" name="us-gaap:DerivativesPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Instruments </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Derivative</span><span style="color:#000000;"> financial liabilities are recorded at fair value, with gains and losses arising from changes in fair value recognized in change in fair value of derivative liability within the consolidated statements of comprehensive loss at each period end while such instruments are outstanding. The Company&#8217;s derivative liabilities from certain financing transactions were primarily valued using Monte Carlo simulation models. </span></p></ix:nonNumeric><ix:nonNumeric id="F_000302" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated over their estimated useful lives (generally <ix:nonNumeric id="F_000374" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_f814630f-8a9f-49ea-b67d-0f726f5f6c5e">three</ix:nonNumeric> to <ix:nonNumeric id="F_000375" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:durwordsen">five<ix:continuation id="C_f814630f-8a9f-49ea-b67d-0f726f5f6c5e"> years</ix:continuation></ix:nonNumeric>) using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining non-cancellable lease term or their estimated useful lives. Repair and maintenance costs are expensed as incurred. When assets are retired or sold, the assets and accumulated depreciation are derecognized from the respective accounts and any gain or loss is recognized. </p></ix:nonNumeric><ix:nonNumeric id="F_000303" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Software Development Cost</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC 350 <span style="font-style:italic;">Intangibles &#8211; Goodwill and Other</span>, and classified as a prepaid asset in the balance sheets. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud completing arrangement, over the term of the arrangement, plus reasonably certain renewals.</p></ix:nonNumeric><ix:nonNumeric id="F_000304" name="us-gaap:LessorLeasesPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases real estate and office equipment under operating leases. Its primary real estate lease contains rent holiday and rent escalation clauses. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether the arrangement is or contains a lease at inception. Operating leases are recognized on the consolidated balance sheets as ROU assets, current portion of lease liabilities and long-term lease liabilities. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. <span style="color:#000000;">For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. </span>The operating lease ROU assets also include any lease payments made and adjustments for prepayments and lease incentives. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilized its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. </p></ix:nonNumeric><ix:nonNumeric id="F_000305" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Intangible Assets </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s finite life intangible assets include the DEXYCU product (utilizing the Verisome technology) following the March 2018 acquisition of Icon. The DEXYCU intangible asset is being amortized on a straight-line basis over its estimated useful life of <ix:nonNumeric id="F_000376" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328" format="ixt-sec:durwordsen">thirteen years</ix:nonNumeric>. The intangible asset lives were determined based upon the anticipated period that the Company would derive future cash flows from the intangible assets, considering the effects of legal, regulatory, contractual, competitive and other economic factors. The Company continually monitors whether events or circumstances have occurred that indicate that the remaining estimated useful life of its intangible assets may warrant revision. The Company assesses potential impairments to its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the future undiscounted net cash flows expected to result from the use of an asset are less than its carrying value. If the Company considers an asset to be impaired, the impairment charge to be recognized is measured as the amount by which the carrying value of the asset exceeds its estimated fair value. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_565389ec-5aa4-4ae4-8dce-c0e5312781fe" continuedAt="F_000274_dcnt_187e895c-f5a6-47a6-a915-5458084affde"><ix:nonNumeric id="F_000306" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000306_dcnt_372e52f1-b1ed-4dc9-989d-9a69a9d59b63">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Revenue</span><span style="color:#000000;"> is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company performs the following five steps: (i) identify the contract(s) with a customer&#59; (ii) identify the performance obligations in the contract&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product sales, net<span style="font-weight:normal;font-style:normal;"> &#8212; The Company sells YUTIQ and DEXYCU to a limited number of specialty distributors and specialty pharmacies (collectively the &#8220;Distributors&#8221;) in the U.S., with whom the Company has entered into formal agreements, for delivery to physician practices for YUTIQ and to hospital outpatient departments and ambulatory surgical centers for DEXYCU. The Company recognizes revenue on sales of its products when Distributors obtain control of the products, which occurs at a point in time, typically upon delivery. In addition to agreements with Distributors, the Company also enters into arrangements with healthcare providers, ambulatory surgical centers, and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products from Distributors. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reserves for variable consideration <span style="color:#000000;font-style:normal;">&#8212; </span><span style="font-style:normal;">Product sales are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, provider chargebacks and discounts, payor rebates, product returns, and other allowances that are offered within contracts between the Company and its Distributors, payors, and other contracted purchasers relating to the Company&#8217;s product sales. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified either as reductions of product revenue and accounts receivable or a current liability, depending on how the amount is to be settled. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#FF0000;font-style:normal;"> </span><span style="font-style:normal;">Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Distribution fees <span style="font-style:normal;">&#8212; </span><span style="font-style:normal;color:#000000;">The Company compensates its Distributors for services explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product sale is recognized. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Provider chargebacks and discounts <span style="font-style:normal;">&#8212; </span><span style="font-style:normal;color:#000000;">Chargebacks are discounts that represent the estimated obligations resulting from contractual commitments to sell products at prices lower than the list prices charged to the Company&#8217;s Distributors. These Distributors charge the Company for the difference between what they pay for the product and the Company&#8217;s contracted selling price. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of </span><span style="font-style:normal;">product revenue and the establishment of a current liability</span><span style="font-style:normal;color:#000000;">. Reserves for chargebacks consist of amounts that the Company expects to pay for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold under a contracted selling price, and chargebacks that Distributors have claimed, but for which the Company has not yet settled.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government rebates <span style="font-style:normal;">&#8212; The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payor rebates <span style="font-style:normal;">&#8212; The Company contracts with certain private payor organizations, primarily insurance companies, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Co-Payment assistance <span style="font-style:normal;">&#8212; The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.</span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_187e895c-f5a6-47a6-a915-5458084affde" continuedAt="F_000274_dcnt_27378351-c286-4706-afea-4b2b970139f7"><ix:continuation id="F_000306_dcnt_372e52f1-b1ed-4dc9-989d-9a69a9d59b63" continuedAt="F_000306_dcnt_b2121a93-780e-4fbf-a154-30b284474981">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Product returns </span><span style="font-style:normal;">&#8212; The Company generally offers a limited right of return based on its returned goods policy, which includes damaged product and remaining shelf life. The Company estimates the amount of its product sales that may be returned and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to trade receivables, net on the </span><span style="font-style:normal;">condensed</span><span style="font-style:normal;"> consolidated balance sheets. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and collaboration agreement revenue<span style="font-weight:normal;font-style:normal;"> &#8212; The Company analyzes each element of its license and collaboration arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#8217;s contracts contained a significant financing component as of December&#160;31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalties <span style="font-weight:normal;font-style:normal;">&#8212; The Company recognizes revenue from license arrangements with its commercial partners&#8217; net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner&#8217;s products occurs. The Company&#8217;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60&#160;days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company recognizes royalty income each quarter and subsequently determines a true-up when it receives royalty reports and payment from its commercial partners. Historically, these true-up adjustments have been immaterial. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sale of Future Royalties <span style="font-weight:normal;font-style:normal;">&#8212; The Company has sold its rights to receive certain royalties on product sales. In the circumstance where the Company has sold its rights to future royalties under a royalty purchase agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Collaborations<span style="font-weight:normal;font-style:normal;"> &#8212; The Company recognizes revenue over the term of the statements of work under any funded research collaborations (including feasibility study agreements). Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations (including feasibility study agreements). </span></p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_27378351-c286-4706-afea-4b2b970139f7" continuedAt="F_000274_dcnt_606094d3-b3a6-4203-8b00-35bb20940917"><ix:continuation id="F_000306_dcnt_b2121a93-780e-4fbf-a154-30b284474981">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please refer to Note 3 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized within one year following the balance sheet date are classified as non-current deferred revenue. </p></ix:continuation><ix:nonNumeric id="F_000307" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are charged to operations as incurred. These costs include all direct costs, including cash and stock-based compensation and benefits for research, clinical development, quality assurance, quality control, operations and medical affairs personnel, amortization of intangible assets, third-party costs and services for clinical trials, clinical materials, pre-clinical programs, regulatory and medical affairs, external consultants, and other operational costs related to the Company&#8217;s research and development of its product candidates.</p></ix:nonNumeric><ix:nonNumeric id="F_000308" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation cost related to share-based payment awards is based on the fair value of the instrument on the grant date and is recognized on a graded vesting basis over the requisite service period for each separately vesting tranche of the awards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may also grant share-based payment awards that are subject to objectively measurable performance and service criteria. Compensation expense for performance-based awards begins at such time as it becomes probable that the respective performance conditions will be achieved. The Company continues to recognize the grant date fair value of performance-based awards through the vesting date of the respective awards so long as it remains probable that the related performance conditions will be satisfied. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model and the fair value of performance stock units, restricted stock units and deferred stock units based on the observed grant date fair value of the underlying Common Stock.</p></ix:nonNumeric><ix:nonNumeric id="F_000309" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the weighted-average number of common shares outstanding the average number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000377" name="eypt:PreFundedWarrantsToPurchaseCommonStock" contextRef="C_0001314102_20211231" decimals="INF" format="ixt:numdotdecimal">3,272,727</ix:nonFraction> shares of Pre-Funded Warrants to purchase common stock, issued in connection with the November 2021 underwritten public offering (see Note 10), were included in the basic and diluted net loss per share calculation. </p><ix:nonNumeric id="F_000313" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000378" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,517,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000379" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,338,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000380" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">23,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000381" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">27,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000382" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">48,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000383" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">48,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000384" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">291,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000385" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">149,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000386" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,881,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000387" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001314102_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,564,280</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000274_dcnt_606094d3-b3a6-4203-8b00-35bb20940917">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000310" name="eypt:ComprehensiveLossPolicyPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is comprised of net loss, foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable securities. </p></ix:nonNumeric><ix:nonNumeric id="F_000311" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Tax </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future benefit to be derived from tax credits and loss carry forwards. Such deferred income tax computations are measured based on enacted tax laws and rates applicable to the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is provided against net deferred tax assets if, based on the available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the uncertainty. The Company accounts for interest and penalties related to uncertain tax positions as part of its income tax benefit. </p></ix:nonNumeric><ix:nonNumeric id="F_000312" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company&#8217;s financial position, results of operations and cash flows or do not apply to the Company&#8217;s operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740)</span><span style="color:#000000;"> (&#8220;ASU 2019-12&#8221;)</span><span style="font-style:italic;">: Simplifying the Accounting for Income Taxes.</span>&#160;The amendments simplify the accounting for income taxes by removing certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company adopted ASU 2019-12 on <ix:nonNumeric id="F_000389" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric>. The adoption of this standard did not have a material impact on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </span>(&#8220;ASU 2021-04&#8221;)<span style="font-style:italic;">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.</span> The amendments are designed to clarify an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options that remain equity-classified after modification or exchange. The ASU provides guidance on how an issuer would measure and recognize the effects of these transactions. The standard provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. ASU 2021-04 will be effective for the Company in the first quarter of its fiscal year ending December 31, 2022. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000275" name="eypt:ProductRevenueReservesAndAllowancesTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000275_dcnt_b2a710d3-e509-4e56-8cf8-c6b4e1dbf2aa">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Product Revenue Reserves and Allowances</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product revenues have been primarily from sales of YUTIQ and DEXYCU in the U.S.</p><ix:nonNumeric id="F_000314" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000314_dcnt_8a9a72cf-5650-4a48-8fa0-50fd1aac786a">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product revenues by product for the years ended December 31, 2021 and 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">YUTIQ (A)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU (B)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product sales, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_b2a710d3-e509-4e56-8cf8-c6b4e1dbf2aa" continuedAt="F_000275_dcnt_a210df05-e924-4ccd-8b76-3a590b01c584"><ix:continuation id="F_000314_dcnt_8a9a72cf-5650-4a48-8fa0-50fd1aac786a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(A)</span></p></td>
<td valign="top"><ix:footnote id="FNT_000000" xml:lang="en-US">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Included approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231" decimals="-3" scale="3">25</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231" decimals="-3" scale="3">205</ix:nonFraction> of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></ix:footnote></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(B)</span></p></td>
<td valign="top"><ix:footnote id="FNT_000001" xml:lang="en-US">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Included approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231" decimals="-3" scale="3">283</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231" decimals="-3" scale="3">8</ix:nonFraction> of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></ix:footnote></td></tr></table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000315" name="eypt:ProductRevenueAllowanceAndReserveTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebates</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance at January 1, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20201231" decimals="-3" scale="3">574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20201231" decimals="-3" scale="3">535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20201231" decimals="-3" scale="3">603</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to sales in the current year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231" decimals="-3" scale="3">785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,396</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior period sales</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231" decimals="-3" sign="-" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231" decimals="-3" sign="-" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231" decimals="-3" sign="-" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" scale="3">272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deductions applied and payments made</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,645</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231" decimals="-3" sign="-" scale="3">809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">11,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,821</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20211231" decimals="-3" scale="3">379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebates</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20191231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20191231" decimals="-3" scale="3">352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to sales in the current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231" decimals="-3" scale="3">978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="eypt:ContractWithCustomerAllowanceForCreditLossAdditions" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,175</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior period sales</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231" decimals="-3" sign="-" scale="3">387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231" decimals="-3" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" scale="3">337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deductions applied and payments made</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20200101_20201231" decimals="-3" sign="-" scale="3">792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231" decimals="-3" sign="-" scale="3">777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20201231" decimals="-3" scale="3">574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20201231" decimals="-3" scale="3">535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20201231" decimals="-3" scale="3">603</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Returns are recorded as a reduction of accounts receivable on the condensed consolidated balance sheets. Chargebacks, discounts and fees and rebates are recorded as a component of accrued expenses on the condensed consolidated balance sheets (see Note 7). </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements and Royalty Income</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alimera </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a licensing and development agreement, as amended, Alimera Sciences, Inc. has a worldwide exclusive license to develop, make, market and sell ILUVIEN in return for royalties based on sales and patent fee reimbursements. Total revenue was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">54,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231" decimals="-5" scale="6">1.7</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively. In addition to patent fee reimbursements in those periods, the Company recorded royalty income totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231" decimals="-5" scale="6">1.7</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SWK Royalty Purchase Agreement</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2020, the Company entered into a royalty purchase agreement (the &#8220;RPA&#8221;) with SWK Funding LLC (&#8220;SWK&#8221;). Under the RPA, the Company sold its right to receive royalty payments on future sales of products subject to the Amended Alimera Agreement for an upfront cash payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="eypt:UpfrontCashPayment" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217" decimals="-5" scale="6">16.5</ix:nonFraction> million. Except for the rights to the royalties, the Company retains all rights and obligations under the Amended Alimera Agreement, pursuant to which, Alimera owns worldwide rights to the Company&#8217;s Durasert technology in ILUVIEN for DME and rights for ILUVIEN (currently marketed by the Company as YUTIQ in the U.S.) for non-infectious posterior uveitis in the EMEA. Alimera has the sole rights to utilize the intellectual property developed under the Amended Alimera Agreement. There has been no intellectual property developed jointly by Alimera and the Company as part of the Amended Alimera Agreement. The Company cannot utilize the intellectual property for the indication licensed to Alimera in order to manufacture and sell ILUVIEN.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ongoing efforts under the Amended Alimera Agreement will consist of continuing to maintain and enforce its patents as well as providing safety data and regulatory support as necessary. None of these obligations require significant efforts on the part of the Company with respect to the generation of sales in the market. The Company will only be required to expend more extensive efforts if litigation were to arise that requires the Company to protect its patents rights pursuant to the terms of the Amended Alimera Agreement. Historically, such a defense has not been required. Similarly, regulatory support and safety data is only provided </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_a210df05-e924-4ccd-8b76-3a590b01c584" continuedAt="F_000275_dcnt_54d84ccc-236b-4811-9e22-ae973b6231b5">
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on an ad-hoc basis depending on the regulatory requests</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which has been </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">minimal </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">historically</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. It remains Alimera&#8217;s sole responsibility to manufacture, actively market and promote the products under the Amended Alimera Agreement to generate the sales, which ultimately generate the royalties to be paid to SWK.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified the proceeds received from SWK as deferred revenue, to be recognized as revenue under the units-of-revenue method over the life of the RPA because of the Company&#8217;s limited continuing involvement in the Amended Alimera Agreement. SWK has no recourse and the Company assumes no credit risk in event that Alimera fails to make a royalty payment. The Company must only forward all material correspondence from Alimera to SWK, including royalty reports, notices and any other correspondence with respect to royalties to SWK. SWK has the right to audit and inspect the books and records pertaining to net sales and royalties under the Amended Alimera Agreement. Neither the Company nor SWK has the unilateral ability to cancel the transaction. There is no cap or limitation on the royalties to be received by SWK in the future and its return will reflect all royalties paid by Alimera. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to SWK and there is no limitation on the rates of return to SWK, the Company recorded the total proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217" decimals="-5" scale="6">16.5</ix:nonFraction> million as deferred revenue under royalty sale agreement. The deferred revenue is being recognized as revenue over the life of the RPA under the &#8220;units-of-revenue&#8221; method. Under this method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from SWK to the payments expected to be made by Alimera to SWK over the term of the Amended Alimera Agreement, and then applying that ratio to the period&#8217;s cash payment. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">872,000</ix:nonFraction> of royalty revenue related to the RPA for the year ended December 31, 2021, in connection with the royalty payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:PaymentsForRoyalties" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231" decimals="-5" scale="6">2.8</ix:nonFraction> million for the year ended December 31, 2021, from Alimera to SWK, pursuant to the Amended Alimera Agreement. <ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> revenue was recognized related to the RPA for the year ended December 31, 2020. As of December 31, 2021, the Company has $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20211231" decimals="-5" scale="6">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20211231" decimals="-5" scale="6">14.6</ix:nonFraction> million as current and non-current deferred revenue recognized under royalty sale agreement, respectively. As of December 31, 2020, the Company classified $<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201231" decimals="0" format="ixt:numdotdecimal">885,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201231" decimals="-5" scale="6">15.6</ix:nonFraction> million as current and non-current deferred revenue recognized under royalty sale agreement, respectively. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OncoSil Medica<span style="font-weight:normal;">l</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company entered into an exclusive, worldwide royalty-bearing license agreement in <ix:nonNumeric id="F_000459" name="eypt:LicenseAgreementStartYearMonth" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231" format="ixt:datemonthyearen">December 2012</ix:nonNumeric>, amended and restated in March 2013, with OncoSil Medical UK Limited (f/k/a Enigma Therapeutics Limited), a wholly-owned subsidiary of OncoSil Medical Ltd (&#8220;OncoSil&#8221;) for the development of BrachySil, the Company&#8217;s previous product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="eypt:UpfrontLicenseFeeReceived" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20130331_20130331" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction> and is entitled to <ix:nonFraction unitRef="U_xbrlipure" id="F_000454" name="eypt:RoyaltyPercentageEarnedFromProductSales" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231" decimals="INF" scale="-2">8</ix:nonFraction>% sales-based royalties, <ix:nonFraction unitRef="U_xbrlipure" id="F_000455" name="eypt:NonRoyaltyConsiderationPercentage" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231" decimals="INF" scale="-2">20</ix:nonFraction>% of sublicense consideration and milestone payments based on aggregate product sales. OncoSil is obligated to pay an annual license maintenance fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction> by the end of each calendar year, the most recent of which was received in December 2021. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any patent maintenance costs, sales-based royalties and </span>sub-licensee<span style="Background-color:#FFFFFF;"> sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. </span><span style="color:#000000;">In March 2020, the U.S. Food and Drug Administration granted Breakthrough Device Designation for the OncoSil&#8482; device for treatment of unresectable locally advanced pancreatic cancer (LAPC) in combination with chemotherapy.&#160; In April 2020, the British Standards Institute (BSI) grants European CE marking for the OncoSil&#8482; System and designates OncoSil&#8482; a breakthrough device for the treatment of locally advanced pancreatic cancer (LAPC) in combination with chemotherapy.&#160;As of December 31, 2021, OncoSil has received regulatory approval in the EU, United Kingdom, Switzerland, Singapore, Malaysia, Hong Kong, New Zealand, Turkey, and Israel. </span><span style="Background-color:#FFFFFF;">The Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> consequential performance obligations under the OncoSil license agreement. For the years ended December 31, 2021 and 2020, revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20211231" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20201231" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction> was recorded for this agreement, respectively.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ocumension Therapeutics </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="Background-color:#FFFFFF;">November</span> 2018, the Company entered into an exclusive license agreement with Ocumension Therapeutics (&#8220;Ocumension&#8221;) for the development and commercialization of its three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (YUTIQ in the U.S.) in Mainland China, Hong Kong, Macau and Taiwan. The Company received a one-time upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="eypt:UpfrontLicenseFeeReceived" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20181101_20181130" decimals="-4" scale="6">1.75</ix:nonFraction>&#160;million from Ocumension and is eligible to receive up to (i) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="-4" scale="6">7.25</ix:nonFraction>&#160;million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="-5" scale="6">3.0</ix:nonFraction> million commercial sales-based milestones. In addition, the Company is entitled to receive mid-single digit sales-based royalties. Ocumension has also received a special approval by the Hainan Province People&#8217;s Government to market this product for chronic, non-infectious posterior segment uveitis in the Hainan Bo Ao Lecheng International Medical Tourism Pilot Zone (&#8220;Hainan Pilot Zone&#8221;). In March 2019, the Company entered into a Memorandum of Understanding (&#8220;2019 MOU&#8221;), pursuant to which, the Company will supply product for the clinical trials and Hainan Pilot Zone use. Paralleling to Ocumension&#8217;s normal registration process of the product with the Chinese Regulatory Authorities, the 2019 MOU modified the Company&#8217;s entitlement to the development and regulatory milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="-4" scale="6">7.25</ix:nonFraction> million under the license agreement to product supply milestones or development milestones, whichever comes first, totaling up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="eypt:ProductSupplyMilestonesAndDevelopmentMilestones" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="-4" scale="6">7.25</ix:nonFraction> million. In August 2019, the Company began shipping this product to Ocumension.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_54d84ccc-236b-4811-9e22-ae973b6231b5" continuedAt="F_000275_dcnt_15421926-1770-489b-85fb-8b77f2879000">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was required to provide a fixed number of hours of technical assistance support to Ocumension at no cost, which support has been completed and no future performance obligation exists. Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested. Ocumension has a first right of negotiation for an additional exclusive license to the Company&#8217;s shorter-duration line extension candidate for this indication. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, the Company received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="eypt:DevelopmentMilestonePaymentReceived" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20190801_20190831" decimals="-5" scale="6">1.0</ix:nonFraction> million development milestone payment from Ocumension triggered by the approval of its Investigational New Drug (&#8220;IND&#8221;) in China for this program. The IND allows the importation of finished product into China for use in a clinical trial to support regulatory filing.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020,&#160;the Company entered into an exclusive license agreement with Ocumension for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU for the treatment of post-operative inflammation following ocular surgery. Pursuant to the terms of the license agreement, the Company received upfront payments of&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="eypt:UpfrontLicenseFeeReceived" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200201_20200229" decimals="-5" scale="6">2.0</ix:nonFraction> million&#160;from Ocumension in February 2020 and will be eligible to receive up to (i) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20200131" decimals="-5" scale="6">6.0</ix:nonFraction> million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20200131" decimals="-5" scale="6">6.0</ix:nonFraction> million commercial sales-based milestones. In addition, the Company is entitled to receive mid-single digit sales-based royalties. In exchange, Ocumension will receive exclusive rights to develop and commercialize DEXYCU in Mainland China, Hong Kong, Macau and Taiwan, at its own cost and expense with the Company supplying product for clinical trials and commercial sale. In addition, Ocumension will receive a fixed number of hours of technical assistance support from the Company at no cost.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into a Memorandum of Understanding (&#8220;2020 MOU&#8221;), pursuant to which, <span style="Background-color:#FFFFFF;">the Company received a one-time non-refundable payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="eypt:UpfrontLicenseFeeReceived" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-5" scale="6">9.5</ix:nonFraction> million (the &#8220;Accelerated Milestone Payment&#8221;) from Ocumension as a full and final payment of the combined remaining development, regulatory and sales milestone payments under the Company&#8217;s license agreements with Ocumension for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and for the treatment of post-operative inflammation following ocular surgery, respectively. Upon payment of the Accelerated Milestone Payment, the remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-4" scale="6">11.75</ix:nonFraction> million in combined remaining development and sales milestone payments under the Company&#8217;s original </span>license agreement with Ocumension upon the achievement by Ocumension of (i) remaining development and regulatory milestones of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-4" scale="6">6.25</ix:nonFraction> million and commercial sales-based milestones of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-5" scale="6">3.0</ix:nonFraction> million for the development and commercialization of its three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye&#59; and (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-5" scale="6">6.0</ix:nonFraction> million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-5" scale="6">6.0</ix:nonFraction> million commercial sales-based milestones for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU for the treatment of post-operative inflammation following ocular surgery, totaling up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="eypt:UponAchievementOfMilestones" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831" decimals="-4" scale="6">21.25</ix:nonFraction> million, <span style="Background-color:#FFFFFF;">were permanently extinguished and will no longer be due and owed to the Company. In exchange, Ocumension also received exclusive rights to develop and commercialize YUTIQ and DEXYCU products under its own brand names in South Korea and other jurisdictions across Southeast Asia in Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand and Vietnam, </span>at its own cost and expense with the Company supplying product for clinical trials and commercial sale. The Company continues to be entitled to royalties on future product sales by Ocumension. In April 2021, Ocumension announced its filing of a New Drug Application (&#8220;NDA&#8221;) for YUTIQ under Ocumension&#8217;s distinct name to Chinese regulatory authorities and it is under review. Ocumension has been granted approval to have its NDA submission reviewed based on the U.S. NDA data and the real world data Ocumension has collected from marketing the product in Hainan Pilot Zone. In September 2021, Ocumension announced its receipt of approval from Chinese regulatory authorities for DEXYCU under Ocumension&#8217;s distinct name to conduct a Phase 3 clinical trial in China.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than a fixed number of hours of technical assistance support to be provided at no cost by the Company, Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested. All technical assistance was provided during 2020. The Chief Executive Officer of Ocumension became a director of the Company starting December 31, 2020, pursuant to a Share Purchase Agreement pursuant to which the Company sold to Ocumension <ix:nonFraction unitRef="U_xbrlishares" id="F_000477" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,010,722</ix:nonFraction> shares of common stock, at which time, Ocumension became a related party of the Company.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, in addition to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">308,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">213,000</ix:nonFraction> of revenue from product sales, respectively, the Company recognized approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">543,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231" decimals="-5" scale="6">11.5</ix:nonFraction> million of license and collaboration revenue, respectively, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">499,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231" decimals="0">0</ix:nonFraction> of revenue related to additional technical assistance, respectively. As of December 31, 2021 and 2020, <ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> deferred revenue was recorded for this agreement, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> Company recognized </span> sales-based royalty expense of<span style="font-size:12pt;color:#000000;"> </span><span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="eypt:SalesBasedRoyaltyExpense" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20210101_20211231" decimals="0">0</ix:nonFraction></span> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="eypt:SalesBasedRoyaltyExpense" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20200101_20201231" decimals="-5" scale="6">1.3</ix:nonFraction> million during the year ended December 31, 2021 and 2020, related to the earn-out payment equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000488" name="eypt:PercentageOfAcceleratedMilestonePaymentReceived" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20200101_20201231" decimals="2" scale="-2">20</ix:nonFraction>% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, as the payment of the partnering income in connection with the Icon acquisition in March 2018. <span style="Background-color:#FFFFFF;"> </span> </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000275_dcnt_15421926-1770-489b-85fb-8b77f2879000">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaborations</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third-party drug candidates. Consideration received is generally recognized as revenue over the term of the research collaborations. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations.  Revenues under research collaborations  totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">60,000</ix:nonFraction> and $</span><span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">255,000</ix:nonFraction> </span><span style="Background-color:#FFFFFF;"> </span>for the years ended December 31, 2021 and 2020, respectively. <span style="color:#000000;">At December 31, 2021 and 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20211231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20201231" decimals="0" format="ixt:numdotdecimal">60,000</ix:nonFraction> deferred revenue was recorded for the research collaborations, respectively.</span></p></ix:continuation><ix:nonNumeric id="F_000276" name="us-gaap:InventoryDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Inventory </p></td></tr></table></div><ix:nonNumeric id="F_000316" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,664</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="C_0001314102_20211231" decimals="-3" scale="3">405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="C_0001314102_20201231" decimals="-3" scale="3">747</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="C_0001314102_20211231" decimals="-3" scale="3">484</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:InventoryNet" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:InventoryNet" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000277" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Intangible Assets </p></td></tr></table></div><ix:nonNumeric id="F_000317" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of intangible assets for the years ended December 31, 2021 and 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patented technologies</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross carrying amount at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001314102_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross carrying amount at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001314102_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,653</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization at end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net book value at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000318" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net book value of the Company&#8217;s intangible assets at December&#160;31, 2021 and 2020 is summarized as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful&#160;Life&#160;at</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patented technologies</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU / Verisome</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000517">9.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization expense totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001314102_20210101_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001314102_20200101_20201231" decimals="-5" scale="6">2.5</ix:nonFraction></ix:nonFraction> million in each of the two years ended December 31, 2021 and 2020, respectively. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Icon Acquisition, the initial purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328" decimals="-5" scale="6">32.0</ix:nonFraction>&#160;million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected remaining useful life of <ix:nonNumeric id="F_000522" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231" format="ixt-sec:duryear">9.25</ix:nonNumeric> years at the rate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="eypt:EstimatedRateOfAnnualAmortizationExpense" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231" decimals="-5" scale="6">2.5</ix:nonFraction>&#160;million per year. Amortization expense was reported as a component of cost of sales for the years ended December 31, 2021 and 2020, respectively. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000278" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Property and Equipment, Net </p></td></tr></table></div><ix:nonNumeric id="F_000319" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,732</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_20211231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_20201231" decimals="-3" scale="3">630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:Depreciation" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal">311,000</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:Depreciation" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal">189,000</ix:nonFraction> in the years ended December 31, 2021 and 2020, respectively. </p></ix:nonNumeric><ix:nonNumeric id="F_000279" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Accrued Expenses </p></td></tr></table></div><ix:nonNumeric id="F_000320" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel costs</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="eypt:AccruedClinicalExpenseCurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">753</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="eypt:AccruedClinicalExpenseCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales chargebacks, rebates and other revenue reserves</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="eypt:AccruedSalesChargebacksRebatesAndOtherRevenueReserves" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="eypt:AccruedSalesChargebacksRebatesAndOtherRevenueReserves" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissions due to commercialization partner for DEXYCU</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" contextRef="C_0001314102_20201231" decimals="-3" scale="3">254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000280" name="eypt:LesseeOperatingAndFinanceLeasesDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000280_dcnt_2b95bc51-16c0-47a2-a0cb-e69b4166076a">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Leases</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;17, 2018, <span style="Background-color:#FFFFFF;">the Company amended the lease for its headquarters in Watertown, Massachusetts. The original </span><span style="-sec-ix-hidden:F_000550">five-year</span><span style="Background-color:#FFFFFF;"> lease for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000549" name="eypt:LeasePropertyAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">13,650</ix:nonFraction> square feet of combined office and laboratory space was set to expire in <ix:nonNumeric id="F_000551" name="eypt:LeaseExpirationMonthYear" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20210101_20211231" format="ixt:datemonthyearen">April 2019</ix:nonNumeric>. Under the amendment, the Company leased an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000554" name="eypt:AdditionalLeasePropertyAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">6,590</ix:nonFraction> square feet of rentable area of the building, with a commencement date of <ix:nonNumeric id="F_000552" name="eypt:LeaseInceptionDate" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231" format="ixt:datemonthdayyearen">September&#160;10, 2018</ix:nonNumeric>. The amendment extended the term of the lease for the combined space through <ix:nonNumeric id="F_000553" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231" format="ixt:datemonthdayyearen">May 31, 2025</ix:nonNumeric>, and the landlord provided the Company a construction allowance of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="eypt:ConstructionAllowanceCredit" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_20211231" decimals="INF" format="ixt:numdotdecimal">670,750</ix:nonFraction> to be applied toward renovations and improvements within the total space. On April 5, 2021, the Company further amended the lease to include an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000557" name="eypt:LeasePropertyAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,409</ix:nonFraction> square feet of rentable area of the building through <ix:nonNumeric id="F_000559" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231" format="ixt:datemonthdayyearen">May 31, 2025</ix:nonNumeric>, with a commencement date of <ix:nonNumeric id="F_000558" name="eypt:LeaseInceptionDate" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231" format="ixt:datemonthdayyearen">July 1, 2021</ix:nonNumeric>. On March 8, 2022, the Company further amended the lease (i) to extend the term to <ix:nonNumeric id="F_000561" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308" format="ixt:datemonthdayyearen">May 31, 2028</ix:nonNumeric> for <ix:nonFraction unitRef="U_utrsqft" id="F_000563" name="eypt:LeasePropertyAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308" decimals="0" format="ixt:numdotdecimal">13,650</ix:nonFraction> square feet of laboratory and manufacturing operations space, with the landlord agreeing to provide the Company a construction allowance of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="eypt:ConstructionAllowanceCredit" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308" decimals="INF" format="ixt:numdotdecimal">555,960</ix:nonFraction> to be applied toward upgrades and improvements within the space&#59; (ii) to rent an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000560" name="eypt:AdditionalLeasePropertyAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308" decimals="0" format="ixt:numdotdecimal">11,999</ix:nonFraction> square feet of office space within the building through <ix:nonNumeric id="F_000562" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308" format="ixt:datemonthdayyearen">May 31, 2028</ix:nonNumeric>, with an anticipated commencement date in the third quarter of 2022&#59; and (iii) to terminate a portion of the lease comprising <ix:nonFraction unitRef="U_utrsqft" id="F_000565" name="eypt:TerminationOfPortionOfLeasePropertyAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308" decimals="0" format="ixt:numdotdecimal">7,999</ix:nonFraction> square feet of office space in the building on <ix:nonNumeric id="F_000566" name="eypt:LeaseTerminationDate" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308" format="ixt:datemonthdayyearen">May 31, 2025</ix:nonNumeric>. The Company previously provided a cash-collateralized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:SecurityDeposit" contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20211231" decimals="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> irrevocable standby letter of credit as security for the Company&#8217;s obligations under the lease, which will remain in effect through the period that is four months beyond the expiration date of the amended lease. The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises in excess of new base year amounts.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <ix:nonNumeric id="F_000568" name="eypt:LeaseInceptionMonthYear" contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231" format="ixt:datemonthyearen">July 2017</ix:nonNumeric>, the Company leased approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000567" name="eypt:LeasePropertyOfficeAreaCovered" contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">3,000</ix:nonFraction> square feet of office space in Basking Ridge, New Jersey under a lease term extending through <ix:nonNumeric id="F_000569" name="eypt:LeaseExpirationMonthYear" contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231" format="ixt:datemonthyearen">June 2022</ix:nonNumeric>, with <ix:nonFraction unitRef="U_eyptTranche" id="F_000570" name="eypt:NumberOfRenewalOptions" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> <span style="-sec-ix-hidden:F_000571">five-year</span> renewal options at <ix:nonFraction unitRef="U_xbrlipure" id="F_000572" name="eypt:OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231" decimals="2" scale="-2">95</ix:nonFraction>% of the then-prevailing market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In June 2018, the Company subleased an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000573" name="eypt:AdditionalSubleasedPropertyOfficeArea" contextRef="C_0001314102_srtCounterpartyNameAxis_eyptCaladriusMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">1,381</ix:nonFraction> square feet of adjoining space from Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;) through May 2022. The Chief Executive Officer of Caladrius was a director of the Company through June 2020. Per the terms of the lease and sublease agreements, the Company does not have any residual value guarantees. The Company has given notice that the Company will not be renewing this lease and the Company will vacate the facility upon expiration.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000280_dcnt_2b95bc51-16c0-47a2-a0cb-e69b4166076a" continuedAt="F_000280_dcnt_006594e7-787b-4ba2-afe2-33f311d6c017">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified and assessed the following significant assumptions in recognizing its right-of-use (&#8220;ROU&#8221;) assets and corresponding lease liabilities:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized the borrowing rate under its existing <ix:nonNumeric id="F_000574" name="us-gaap:LineOfCreditFacilityExpirationPeriod" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:duryear">5</ix:nonNumeric>-year term loan facility (see Note 9) as the discount rate.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">The expected lease terms include noncancelable lease periods. Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Variable lease payments, such as common area maintenance, real estate taxes and property insurance are not included in the determination of the lease&#8217;s ROU asset or lease liability.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the weighted average remaining term of the Company&#8217;s operating leases was <ix:nonNumeric id="F_000575" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001314102_20211231" format="ixt-sec:duryear">3.4</ix:nonNumeric>&#160;years and the lease liabilities arising from obtaining ROU assets reflect a weighted average discount rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000576" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001314102_20211231" decimals="3" scale="-2">12.5</ix:nonFraction>%. </p><ix:nonNumeric id="F_000321" name="eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental<span style="color:#000000;"> balance sheet information related to operating leases as of December 31, 2021 and 2020, respectively are as follows (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities - operating lease current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">645</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities &#8211; noncurrent portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,898</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating<span style="color:#000000;"> lease expense recognized related to ROU assets was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001314102_20210101_20211231" decimals="0" format="ixt:numdotdecimal">885,000</ix:nonFraction> and</span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">852,000</ix:nonFraction>, excluding $<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:VariableLeaseCost" contextRef="C_0001314102_20210101_20211231" decimals="0" format="ixt:numdotdecimal">30,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:VariableLeaseCost" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">36,000</ix:nonFraction> of variable lease costs, during each of the years ended December 31, 2021 and 2020, respectively, and were included in general and administrative expense in the Company&#8217;s statement of comprehensive loss. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:OperatingLeasePayments" contextRef="C_0001314102_20210101_20211231" decimals="0" format="ixt:numdotdecimal">920,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:OperatingLeasePayments" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">867,000</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="color:#000000;">Company</span> is a party to <ix:nonFraction unitRef="U_eyptLease" id="F_000591" name="eypt:NumberOfFinanceLeases" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> finance leases for laboratory equipment. The equipment leases expire in <ix:nonNumeric id="F_000592" name="eypt:LeaseExpirationMonthYear" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptFirstLabEquipmentMember_20210101_20211231" format="ixt:datemonthyearen">December 2021</ix:nonNumeric>, <ix:nonNumeric id="F_000593" name="eypt:LeaseExpirationMonthYear" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptSecondLabEquipmentMember_20210101_20211231" format="ixt:datemonthyearen">December 2022</ix:nonNumeric> and <ix:nonNumeric id="F_000594" name="eypt:LeaseExpirationMonthYear" contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptThirdLabEquipmentMember_20210101_20211231" format="ixt:datemonthyearen">June 2023</ix:nonNumeric>, respectively. </p><ix:nonNumeric id="F_000322" name="eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental<span style="color:#000000;"> balance sheet information related to the finance lease as of December 31, 2021 and 2020, respectively are as follows (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="eypt:FinanceLeasePropertyAndEquipmentGross" contextRef="C_0001314102_20211231" decimals="-3" scale="3">371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="eypt:FinanceLeasePropertyAndEquipmentGross" contextRef="C_0001314102_20201231" decimals="-3" scale="3">239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="eypt:FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" contextRef="C_0001314102_20211231" decimals="-3" scale="3">205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="eypt:FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" contextRef="C_0001314102_20201231" decimals="-3" scale="3">52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0001314102_20211231" decimals="-3" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0001314102_20201231" decimals="-3" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities <span style="font-family:Calibri;">&#8211;</span> finance lease current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0001314102_20211231" decimals="-3" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0001314102_20201231" decimals="-3" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:FinanceLeaseLiability" contextRef="C_0001314102_20211231" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:FinanceLeaseLiability" contextRef="C_0001314102_20201231" decimals="-3" scale="3">190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000280_dcnt_006594e7-787b-4ba2-afe2-33f311d6c017">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of finance lease expense recognized during the years ended December 31, 2021 and 2020 related to ROU assets were&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0001314102_20210101_20211231" decimals="0" format="ixt:numdotdecimal">151,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">52,000</ix:nonFraction>, respectively. Interest on lease liabilities were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0001314102_20210101_20211231" decimals="0" format="ixt:numdotdecimal">23,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction>&#160;during the years ended December 31, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of finance lease liabilities was operating cash flows of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0001314102_20210101_20211231" decimals="0" format="ixt:numdotdecimal">23,000</ix:nonFraction> and financing cash flows of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal">146,000</ix:nonFraction> during the year ended December 31, 2021, respectively. Cash paid for amounts included in the measurement of finance lease liabilities was operating cash flows of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">9,000</ix:nonFraction> and financing cash flows of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal">49,000</ix:nonFraction> during the year ended December 31, 2020, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the weighted average remaining term of the Company&#8217;s finance lease was <ix:nonNumeric id="F_000621" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001314102_20211231" format="ixt-sec:duryear">1.3</ix:nonNumeric> years and the lease liabilities arising from obtaining ROU assets reflect a weighted average discount rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000622" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001314102_20211231" decimals="3" scale="-2">12.5</ix:nonFraction>%.<span style="color:#000000;">&#160;&#160;</span></p><ix:nonNumeric id="F_000323" name="eypt:ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T<span style="color:#000000;">he Company&#8217;s total future minimum lease payments under non-cancellable leases at December 31, 2021 were as follows (in thousands): </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001314102_20211231" decimals="-3" scale="3">911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001314102_20211231" decimals="-3" scale="3">149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001314102_20211231" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001314102_20211231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001314102_20211231" decimals="-3" scale="3">894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001314102_20211231" decimals="-3" scale="3">373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,055</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="C_0001314102_20211231" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001314102_20211231" decimals="-3" scale="3">550</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001314102_20211231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:FinanceLeaseLiability" contextRef="C_0001314102_20211231" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000281" name="us-gaap:LongTermDebtTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000281_dcnt_6842528e-f974-4c12-a196-fa362b1b2ae1">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Loan Agreements </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Paycheck Protection Program Loan</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 8, 2020, the Company applied to Silicon Valley Bank (the &#8220;SVB&#8221;) for a Paycheck Protection Program Loan (the &#8220;PPP Loan&#8221;) of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200408" decimals="-5" scale="6">2.0</ix:nonFraction> million that is administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;), under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;). On <ix:nonNumeric id="F_000636" name="us-gaap:DebtInstrumentIssuanceDate1" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422" format="ixt:datemonthdayyearen">April 22, 2020</ix:nonNumeric>, the PPP Loan was approved and the Company received the PPP Loan proceeds.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The PPP Loan bears interest at a fixed rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000637" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422" decimals="INF" scale="-2">1.0</ix:nonFraction>% per annum and has a <span style="-sec-ix-hidden:F_000638">two-year</span> term that matures on <ix:nonNumeric id="F_000639" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422" format="ixt:datemonthdayyearen">April 21, 2022</ix:nonNumeric>. Monthly principal and interest payments commenced on November 21, 2020, subject to possible partial or full forgiveness and principal and interest payments can be deferred as described below, if the PPP Loan proceeds are used for covered payroll costs, rent and utility costs and the maintenance of employee and compensation levels.</span> </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000640" name="us-gaap:DebtInstrumentDescription" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210101_20211231"><span style="Background-color:#FFFFFF;">The Paycheck Protection Program Flexibility Act of 2020 (the &#8220;PPP Flexibility Act&#8221;), enacted on June 5, 2020, amended the&#160;Paycheck Protection Program, among others, as follows: (i) extended the covered period from 8 weeks to the earlier of 24 weeks from the date the PPP Loan is originated and December 31, 2020, </span><span style="Background-color:#FFFFFF;color:#000000;">during which PPP funds needed to be expended in order to be forgiven</span><span style="Background-color:#FFFFFF;">.&#160;A borrower may submit a loan forgiveness application any time on or before the maturity date of the loan &#8211; including before the end of the covered period &#8211; if the borrower has used all of the loan proceeds for which the borrower is requesting forgiveness&#59; (ii</span><span style="Background-color:#FFFFFF;color:#000000;">) at least 60% of PPP funds must be spent on payroll costs, with the remaining 40% available to spend on other eligible expenses&#59;&#160;(iii)</span><span style="color:#000000;"> payments are deferred until the date on which the amount of forgiveness determined is remitted to the lender. If a borrower fails to seek forgiveness within 10 months after the last day of its covered period, then payments will begin on the date that is 10 months after the last day of the covered period.&#160;In addition, the PPP Flexibility Act modified the CARES Act by increasing the maturity date for loans made after the effective date from two years to a minimum maturity of five years from the date on which the borrower applies for loan forgiveness. Existing PPP loans made before the new legislation retain their original two-year term, but may be renegotiated between a lender and a borrower to match the 5-year term permitted under the PPP Flexibility Act</span></ix:nonNumeric>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company used all of the loan proceeds from the PPP Loan to pay expenses during the covered period that the Company believes were for eligible purposes. On September 25, 2020, the Company submitted an application to SVB for full loan forgiveness.<span style="Background-color:#FFFFFF;"> On June 19, 2021, the Company received notification from SVB that the PPP Loan of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210616_20210616" decimals="-5" scale="6">2.0</ix:nonFraction> million has been fully forgiven by the SBA, and that payment and all accrued interest of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="eypt:DebtInstrumentAccruedInterestForgiveness" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210616_20210616" decimals="0" format="ixt:numdotdecimal">24,000</ix:nonFraction> thereon were remitted by the SBA to SVB on June 16, 2021. In connection with the full loan forgiveness, the Company recorded a gain on extinguishment of debt of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210101_20211231" decimals="-5" scale="6">2.1</ix:nonFraction> million in the year ended December 30, 2021.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000281_dcnt_6842528e-f974-4c12-a196-fa362b1b2ae1" continuedAt="F_000281_dcnt_4c316344-b5c1-4ece-8608-cd2a75845ba1">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG Term Loan Agreement </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000644" name="us-gaap:LineOfCreditFacilityInitiationDate1" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" format="ixt:datemonthdayyearen">February&#160;13, 2019</ix:nonNumeric> (the &#8220;CRG Closing Date&#8221;), the Company entered into the CRG Loan Agreement among the Company, as borrower, <span style="Background-color:#FFFFFF;">CRG Servicing LLC, as administrative agent and collateral agent (the &#8220;Agent&#8221;),</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;">and the lenders party thereto from time to time (the &#8220;Lenders&#8221;), </span>providing for a senior secured term loan of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213" decimals="INF" scale="6">60</ix:nonFraction>&#160;million (the &#8220;CRG Loan&#8221;). <span style="color:#000000;">On the CRG Closing Date, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="eypt:TermLoansAgreementInitialAdvance" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213" decimals="-6" scale="6">35</ix:nonFraction> million of the CRG Loan was advanced (the &#8220;CRG Initial Advance&#8221;). The Company utilized the proceeds from the CRG Initial Advance for the repayment in full of all outstanding obligations under its prior credit agreement (the &#8220;SWK Credit Agreement&#8221;) with SWK. In April 2019, the Company exercised its option to borrow an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="eypt:TermLoanAgreementAdditionalAdvance" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190430" decimals="-6" scale="6">15</ix:nonFraction> million of the CRG Loan (the &#8220;CRG Second Advance&#8221;). The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t draw any additional funds under the CRG Loan by the final draw deadline of March 31, 2020.</span> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CRG Loan is due and payable on <ix:nonNumeric id="F_000649" name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" format="ixt:datemonthdayyearen">December&#160;31, 2023</ix:nonNumeric> (the &#8220;Maturity Date&#8221;). The CRG Loan bears interest at a fixed rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000650" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213" decimals="INF" scale="-2">12.5</ix:nonFraction>% per annum payable in arrears on the last business day of each calendar quarter. The Company is required to make quarterly, interest only payments until the Maturity Date. <ix:nonNumeric id="F_000651" name="us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">So long as no default has occurred and is continuing, the Company may elect on each applicable interest payment date to pay 2.5% of the 12.5% per annum interest as Paid In-Kind (&#8220;PIK&#8221;), whereby such PIK amount would be added to the aggregate principal amount and accrue interest at 12.5% per annum.</ix:nonNumeric> Through December 31, 2021, PIK amounts of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="eypt:PaidInKindInterestAddedToPrincipal" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231" decimals="-6" scale="6">0</ix:nonFraction></span> have been added to the principal balance of the CRG Loan. In addition, the Company is required to pay an upfront fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000653" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="-2">1.5</ix:nonFraction>% of amounts borrowed under the CRG Loan (excluding any paid-in-kind amounts), which is payable as amounts are advanced under the CRG Loan. The Company will also be required to pay an exit fee equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000654" name="eypt:LineOfCreditFacilityExitFeesPercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="-2">6</ix:nonFraction>% of (i) the aggregate principal amounts advanced and (ii) PIK amounts issued, under the CRG Loan Agreement. <span style="Background-color:#FFFFFF;">In connection with the CRG Initial Advance, a <ix:nonFraction unitRef="U_xbrlipure" id="F_000655" name="eypt:LineOfCreditFacilityFinancingFeePercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptInitialAdvanceMember_20190212_20190213" decimals="INF" scale="-2">1.5</ix:nonFraction>% financing fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptInitialAdvanceMember_20190212_20190213" decimals="0" format="ixt:numdotdecimal">525,000</ix:nonFraction> and an expense reimbursement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="eypt:ReimbursedExpense" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="0" format="ixt:numdotdecimal">350,000</ix:nonFraction> were deducted from the net borrowing proceeds. In connection with the CRG Second Advance, a <ix:nonFraction unitRef="U_xbrlipure" id="F_000658" name="eypt:LineOfCreditFacilityFinancingFeePercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213" decimals="INF" scale="-2">1.5</ix:nonFraction>% financing fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213" decimals="0" format="ixt:numdotdecimal">225,000</ix:nonFraction> was deducted from the net borrowing proceeds.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of a bankruptcy-related event of default, all amounts outstanding with respect to the CRG Loan become due and payable immediately, and upon the occurrence of any other Event of Default (as defined in the CRG Loan Agreement), all or any amounts outstanding with respect to the CRG Loan may become due and payable upon request of the Agent or majority Lenders. Subject to certain exceptions, the Company is required to make mandatory prepayments of the CRG Loan with the proceeds of assets sales and in the event of a change of control of the Company. In addition, the Company may make a voluntary prepayment of the CRG Loan, in whole or in part, at any time. All mandatory and voluntary prepayments of the CRG Loan are subject to the payment of prepayment premiums as follows: (i)&#160;if prepayment occurs on or prior to December&#160;31, 2019, an amount equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000660" name="eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentPriorToDecember312019Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="-2">10</ix:nonFraction>% of the aggregate outstanding principal amount of the CRG Loan being prepaid, (ii)&#160;if prepayment occurs after December&#160;31, 2019 and on or prior to December&#160;31, 2020, <ix:nonFraction unitRef="U_xbrlipure" id="F_000661" name="eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="-2">5</ix:nonFraction>% of the aggregate outstanding principal amount of the CRG Loan being prepaid, which was waived on December 17, 2020 when the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="eypt:UpfrontCashPayment" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217" decimals="-5" scale="6">15.0</ix:nonFraction> million against the CRG Loan obligations in connection with the consummation of the RPA agreement (see Note 3), and (iii)&#160;if prepayment occurs after December&#160;31, 2020 and on or prior to December&#160;31, 2021, an amount equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000662" name="eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="-2">3</ix:nonFraction>% of the aggregate outstanding principal amount of the Loan being prepaid. <ix:nonFraction unitRef="U_xbrlipure" id="F_000663" name="eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" format="ixt-sec:numwordsen" scale="-2">No</ix:nonFraction> prepayment premium is due on any principal prepaid after December&#160;31, 2021. Certain of the Company&#8217;s existing and future subsidiaries are guaranteeing the obligations of the Company under the CRG Loan Agreement. The obligations of the Company under the CRG Loan Agreement and the guarantee of such obligations are secured by a pledge of substantially all of the Company&#8217;s and the guarantors&#8217; assets.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CRG Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the CRG Loan Agreement contains the following financial covenants requiring the Company and the Guarantors to maintain: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>liquidity in an amount which shall exceed the greater of (i) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="eypt:MinimumLiquidityAmount" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="6">5</ix:nonFraction>&#160;million and (ii)&#160;to the extent the Company has incurred certain permitted debt, the minimum cash balance, if any, required of the Company by the creditors of such permitted debt&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>annual minimum product revenue from YUTIQ and DEXYCU: (i) for the twelve-month period beginning <span style="color:#000000;"><ix:nonNumeric id="F_000667" name="eypt:AnnualMinimumProductRevenuePeriod" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">on January 1, 2019 and ending on December 31, 2019</ix:nonNumeric></span>, of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="6">15</ix:nonFraction>&#160;million, (ii)&#160;for the twelve-month period beginning on <span style="color:#000000;"><ix:nonNumeric id="F_000669" name="eypt:AnnualMinimumProductRevenuePeriod" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">January 1, 2020 and ending on December 31, 2020</ix:nonNumeric></span>, of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="6">45</ix:nonFraction>&#160;million, (iii)&#160;for the twelve-month period beginning on <span style="color:#000000;"><ix:nonNumeric id="F_000671" name="eypt:AnnualMinimumProductRevenuePeriod" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">January 1, 2021 and ending on December 31, 2021</ix:nonNumeric></span>, of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="6">80</ix:nonFraction>&#160;million and (iv)&#160;for the twelve-month period beginning on <span style="color:#000000;"><ix:nonNumeric id="F_000673" name="eypt:AnnualMinimumProductRevenuePeriod" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">January 1, 2022 and ending on December 31, 2022</ix:nonNumeric></span>, of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="6">90</ix:nonFraction>&#160;million.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, CRG waived the financial covenant associated with the Company&#8217;s revenue derived from sales of its products, DEXYCU and YUTIQ, for the twelve-month period ending December 31, 2019. In October 2020, CRG (i) waived the financial covenant associated with the Company&#8217;s revenue derived from sales of its products, DEXYCU and YUTIQ, for the twelve-month period ending December 31, 2020 and (ii) amended the financial covenant associated with the Company&#8217;s minimum product revenue to $<span style="Background-color:#FFFFFF;color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031" decimals="INF" scale="6">45</ix:nonFraction></span> million from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="INF" scale="6">80</ix:nonFraction> million, for the twelve-month period ending December 31, 2021. In May 2021, CRG further amended the financial covenant associated with the Company&#8217;s minimum product revenue to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210501_20210531" decimals="INF" scale="6">25</ix:nonFraction> million from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="eypt:AnnualMinimumProductRevenue" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031" decimals="INF" scale="6">45</ix:nonFraction> million, for the </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000281_dcnt_4c316344-b5c1-4ece-8608-cd2a75845ba1">
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">twelve-month period ending December 31, 2021. </span><span style="Background-color:#FFFFFF;color:#000000;">There were no other material changes to the Loan Agreement and the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="eypt:IncrementalChargesForIssuanceOfWaivers" contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="Background-color:#FFFFFF;color:#000000;"> incremental charges for the issuance of the waivers.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"> </span>The total debt discount related to the CRG Initial Advance was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="eypt:OriginalAmountOfDebtDiscount" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213" decimals="-5" scale="6">3.2</ix:nonFraction> million and consisted of (i) the accrual of a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="eypt:ExitFeeAccrued" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213" decimals="-5" scale="6">2.1</ix:nonFraction> million exit fee&#59; (ii) the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="0" format="ixt:numdotdecimal">525,000</ix:nonFraction> upfront fee&#59; and (iii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="eypt:LineOfCreditFacilityLegalAndTransactionCosts" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213" decimals="0" format="ixt:numdotdecimal">591,000</ix:nonFraction> of legal and other transaction costs. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest rate method. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total debt discount related to the CRG Second Advance was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="eypt:OriginalAmountOfDebtDiscount" contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213" decimals="-5" scale="6">1.1</ix:nonFraction> million and consisted of (i) the accrual of a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="eypt:ExitFeeAccrued" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213" decimals="0" format="ixt:numdotdecimal">900,000</ix:nonFraction> exit fee&#59; and (ii) the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213" decimals="0" format="ixt:numdotdecimal">225,000</ix:nonFraction> upfront fee. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest rate method. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2020, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="eypt:UpfrontCashPayment" contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217" decimals="-5" scale="6">15.0</ix:nonFraction> million against the CRG Loan obligations in connection with the consummation of the RPA agreement (see Note 3). This payment included (i) a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217" decimals="-5" scale="6">13.8</ix:nonFraction> million principal portion of the CRG Loan (ii) the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="eypt:DebInstrumentExitFee" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217" decimals="0" format="ixt:numdotdecimal">828,000</ix:nonFraction> Exit Fee, and (iii) accrued and unpaid interest of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="eypt:PaymentOfAccruedAndUnpaidInterest" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217" decimals="0" format="ixt:numdotdecimal">378,000</ix:nonFraction> through that date. <span style="Background-color:#FFFFFF;color:#000000;">In connection with the partial prepayment of the CRG Loan, the Company recorded a loss on partial extinguishment of debt of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20201231" decimals="0" sign="-" format="ixt:numdotdecimal">905,000</ix:nonFraction> in the year ended December 31, 2020, associated with the write-off of the remaining balance of unamortized debt discount related to the partial prepayment of the CRG Loan.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization<span style="color:#000000;"> of debt discount under the CRG Loan totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">628,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">745,000</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><ix:nonNumeric id="F_000282" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000282_dcnt_ef166e3a-bb6e-4491-8b7c-e0edb15c65b7">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.<span style="margin-left:36pt;">Stockholders&#8217; Equity</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Financings</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Offerings</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000693" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130" decimals="INF" format="ixt:numdotdecimal">5,122,273</ix:nonFraction> shares of its common stock in an underwritten public offering at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000696" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130" decimals="INF">13.75</ix:nonFraction> per share, including the exercise in full by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000694" name="eypt:StockIssuedDuringPeriodAdditionalSharesIssued" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130" decimals="INF" format="ixt:numdotdecimal">1,095,000</ix:nonFraction> shares of the Company&#8217;s common stock, and pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000695" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130" decimals="INF" format="ixt:numdotdecimal">3,272,727</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000697" name="eypt:ClassOfWarrantOrRightIssuePriceOfWarrants" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130" decimals="INF">13.74</ix:nonFraction> per pre-funded warrant. The gross proceeds of the offering to the Company were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="eypt:GrossProceedsFromIssuanceOfCommonStock" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130" decimals="-5" scale="6">115.4</ix:nonFraction> million. Underwriter discounts and commissions and other share issue costs totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130" decimals="-5" scale="6">7.2</ix:nonFraction> million. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pre-funded warrants were classified as a component of permanent equity because they met the permanent equity criteria classification. The pre-funded warrants are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable and permit the holders to receive a fixed number of shares of common stock upon exercise. The pre-funded warrants do not embody an obligation for the Company to repurchase its shares and do not provide any guarantee of value or return.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000700" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228" decimals="INF" format="ixt:numdotdecimal">10,465,000</ix:nonFraction> shares of its common stock in an underwritten public offering at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000702" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210228" decimals="INF">11.00</ix:nonFraction> per share, including the exercise in full by the underwriters of their option to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000701" name="eypt:StockIssuedDuringPeriodAdditionalSharesIssued" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228" decimals="INF" format="ixt:numdotdecimal">1,365,000</ix:nonFraction> additional shares of the Company&#8217;s common stock. The gross proceeds of the offering to the Company were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="eypt:GrossProceedsFromIssuanceOfCommonStock" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228" decimals="-5" scale="6">115.1</ix:nonFraction> million. Underwriter discounts and commissions and other share issue costs totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228" decimals="-5" scale="6">7.2</ix:nonFraction> million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2020, the Company entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Ocumension, pursuant to which the Company sold to Ocumension <ix:nonFraction unitRef="U_xbrlishares" id="F_000705" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231" decimals="INF" format="ixt:numdotdecimal">3,010,722</ix:nonFraction> shares of Common Stock, at a purchase price of approximately $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000706" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201231" decimals="INF">5.22</ix:nonFraction> per share, which was the five-day volume weighted average price of the Common Stock as of the close of trading on December 29, 2020. The aggregate gross proceeds from the Transaction were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="eypt:GrossProceedsFromIssuanceOfCommonStock" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231" decimals="-5" scale="6">15.7</ix:nonFraction> million. Share issue costs totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000709" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229" decimals="INF" format="ixt:numdotdecimal">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock in an underwritten public offering at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000710" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200229" decimals="INF">14.50</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="eypt:GrossProceedsFromIssuanceOfCommonStock" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229" decimals="-4" scale="6">21.75</ix:nonFraction> million. Underwriter discounts and commissions and other share issue costs totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229" decimals="-5" scale="6">1.8</ix:nonFraction> million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Annual Meeting of Stockholders held on June 23, 2020, the Company&#8217;s stockholders approved the adoption of an amendment to the Company&#8217;s Certificate of Incorporation, to increase the number of authorized shares of its common stock from <ix:nonFraction unitRef="U_xbrlishares" id="F_000713" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200622" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="U_xbrlishares" id="F_000714" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001314102_20200623" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction> shares. The Company filed the Certificate of Amendment on June 23, 2020.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000282_dcnt_ef166e3a-bb6e-4491-8b7c-e0edb15c65b7">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATM Facility</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In August 2020, the Company entered into an at-the-market facility (the &#8220;ATM Facility&#8221;) with Cantor Fitzgerald&#160;&#38; Co (&#8220;Cantor&#8221;). Pursuant to the ATM Facility, the Company may, at its option, offer and sell shares of its Common Stock from time to time, through or to Cantor Fitzgerald, acting as sales agent. The Company will pay Cantor a commission of <ix:nonFraction unitRef="U_xbrlipure" id="F_000715" name="eypt:StockIssuanceCostsSalesAgentCommissionMaximumPercentage" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200801_20200831" decimals="INF" scale="-2">3.0</ix:nonFraction>% of the gross proceeds from any future sales of such shares.</span> </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000716" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,590,093</ix:nonFraction> shares of its Common Stock at a weighted average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000717" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20201231" decimals="INF">5.74</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="eypt:GrossProceedsFromIssuanceOfCommonStock" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231" decimals="-5" scale="6">14.9</ix:nonFraction> million. Share issue costs, including sales agent commissions, totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">646,000</ix:nonFraction> during the reporting period.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000720" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">48,538</ix:nonFraction> shares of its Common Stock at a weighted average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000721" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20211231" decimals="INF">11.37</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="eypt:GrossProceedsFromIssuanceOfCommonStock" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">552,000</ix:nonFraction>. Share issue costs, including sales agent commissions, totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">53,000</ix:nonFraction> during the reporting period.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants<span style="color:#000000;"> to Purchase Common Shares</span></p><ix:nonNumeric id="F_000324" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of fixed price warrants to purchase shares of the Company&#8217;s Common Stock for the years ended December 31, 2021 and 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000724" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001314102_20201231" decimals="INF" format="ixt:numdotdecimal">48,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000728" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001314102_20201231" decimals="INF">12.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000725" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001314102_20191231" decimals="INF" format="ixt:numdotdecimal">48,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000729" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001314102_20191231" decimals="INF">12.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance and exercisable at end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000726" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001314102_20211231" decimals="INF" format="ixt:numdotdecimal">48,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000730" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001314102_20211231" decimals="INF">12.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000727" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001314102_20201231" decimals="INF" format="ixt:numdotdecimal">48,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000731" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001314102_20201231" decimals="INF">12.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a credit agreement, the Company issued a warrant to SWK Funding LLC to purchase (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000732" name="eypt:WarrantsIssuedInConnectionWithTermLoanFacility" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328" decimals="INF" format="ixt:numdotdecimal">40,910</ix:nonFraction> Initial Advance Warrant Shares on March 28, 2018 at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000734" name="eypt:ExercisePriceOfIssuedWarrants" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328" decimals="INF">11.00</ix:nonFraction> per share with a <span style="-sec-ix-hidden:F_000736">seven-year</span> term and (ii) <ix:nonFraction unitRef="U_xbrlishares" id="F_000733" name="eypt:WarrantsIssuedInConnectionWithTermLoanFacility" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626" decimals="INF" format="ixt:numdotdecimal">7,773</ix:nonFraction> Additional Advance Warrant Shares on June 26, 2018 at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000735" name="eypt:ExercisePriceOfIssuedWarrants" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626" decimals="INF">19.30</ix:nonFraction> per share with a <span style="-sec-ix-hidden:F_000737">seven-year</span> term. At December 31, 2021, the weighted average remaining life of the warrants was approximately <ix:nonNumeric id="F_000738" name="eypt:WeightedAverageRemainingLifeOfLenderWarrants" contextRef="C_0001314102_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231" format="ixt-sec:duryear">3.3</ix:nonNumeric> years.</p></ix:continuation><ix:nonNumeric id="F_000283" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000283_dcnt_c69bc42e-f849-44a0-bf8d-57c9f3d939df">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Share-Based Payment Awards </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Incentive Plans </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2016 Long-Term Incentive Plan (the &#8220;2016 Plan&#8221;), approved by the Company&#8217;s stockholders on December 12, 2016 (the &#8220;Adoption Date&#8221;), provides for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000739" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20161212" decimals="INF" format="ixt:numdotdecimal">300,000</ix:nonFraction> shares of the Company&#8217;s Common Stock reserved for issuance under the 2016 Plan plus any additional shares of the Company&#8217;s Common Stock that were available for grant under the 2008 Incentive Plan (the &#8220;2008 Plan&#8221;) at the Adoption Date or would otherwise become available for grant under the 2008 Plan as a result of subsequent termination or forfeiture of awards under the 2008 Plan. At the Company&#8217;s Annual Meeting of Stockholders held on June 25, 2019, the Company&#8217;s stockholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="U_xbrlishares" id="F_000740" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20190625" decimals="INF" format="ixt:numdotdecimal">1,100,000</ix:nonFraction> shares. At the Company&#8217;s Annual Meeting of Stockholders held on June 22, 2021, the Company&#8217;s stockholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="U_xbrlishares" id="F_000741" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210622" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction> shares. At December 31, 2021, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000742" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,683,368</ix:nonFraction>&#160;shares were available for new awards. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain inducement awards, although not awarded under the 2016 Plan or the 2008 Plan, are subject to and governed by the terms and conditions of the 2016 Plan or 2008 Plan, as applicable.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000283_dcnt_c69bc42e-f849-44a0-bf8d-57c9f3d939df" continuedAt="F_000283_dcnt_a193f1ad-3c86-4c9f-ac1a-380e7d525eb4">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options</span></p><ix:nonNumeric id="F_000325" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000325_cnt_1">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of stock option activity under the Company&#8217;s equity incentive plans and for inducement awards for the year ended December 31, 2021:</p></ix:nonNumeric><ix:continuation id="F_000325_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000743" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,338,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000750" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231" decimals="2">20.86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000744" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,313,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000751" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="2">12.59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000745" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">8,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000752" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="2">12.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000746" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">75,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000753" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="2">16.46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000747" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">51,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000754" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231" decimals="2">31.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000748" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,517,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231" decimals="2">16.49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000757">8.06</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231" decimals="-3" scale="3">775</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000749" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231" decimals="INF" format="ixt:numdotdecimal">916,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000756" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231" decimals="2">22.41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000758">6.25</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company expanded the terms of its annual stock option grants to include vesting ratable monthly over <ix:nonNumeric id="F_000761" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131" format="ixt-sec:durwordsen">four years</ix:nonNumeric>, or with 25% vesting after <ix:nonNumeric id="F_000763" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181230_20190131" format="ixt-sec:durwordsen">one year</ix:nonNumeric> followed by ratable monthly vesting over <ix:nonNumeric id="F_000762" name="eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181230_20190131" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. Previously, the Company&#8217;s option grants generally had ratable annual vesting over <ix:nonNumeric id="F_000764" name="eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptNewlyAppointedNonExecutiveDirectorMember_20181230_20190131" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, or <ix:nonNumeric id="F_000765" name="eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptDirectorsAndExternalConsultantsMember_20181230_20190131" format="ixt-sec:duryear">1</ix:nonNumeric>-year cliff vesting. Nonemployee awards are granted similar to the Company&#8217;s employee awards. All option grants have a <ix:nonNumeric id="F_000766" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131" format="ixt-sec:duryear">10</ix:nonNumeric>-year term. Options to purchase a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000767" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">297,361</ix:nonFraction> shares of the Company&#8217;s Common Stock vested during the year ended December 31, 2021.</p><ix:nonNumeric id="F_000326" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the grant date fair value of option awards during the years ended December 31, 2021 and 2020, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option life (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000768">4.75 - 6.08</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000769">5.50 - 6.10</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000772">72% - 83%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000773">64% - 70%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000776">0.42% - 1.44%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000777">0.32% - 1.76%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividends</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000780" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="3" scale="-2">0.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000781" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000327" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about employee, consultant and director stock options under the Company&#8217;s equity incentive plans for the years ended December 31, 2021 and 2020 (in thousands except per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000782" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231" decimals="2">8.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000783" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20200101_20201231" decimals="2">7.07</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash received from exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intrinsic value of stock options exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Time-Vested Restricted Stock Units </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time-vested restricted stock units (&#8220;RSUs&#8221;) issued to date under the 2016 Plan generally vest on a ratable annual basis over <ix:nonNumeric id="F_000786" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" format="ixt-sec:duryear">3</ix:nonNumeric> years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period. The fair value of all time-vested RSUs is based on the closing share price of the Common Stock on the date of grant. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000283_dcnt_a193f1ad-3c86-4c9f-ac1a-380e7d525eb4"><ix:nonNumeric id="F_000328" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of RSU activity under the 2016 Plan for the year ended December&#160;31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at January 1, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000787" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">149,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000792" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231" decimals="2">13.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000788" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">242,399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000793" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="2">12.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000789" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">89,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000794" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="2">13.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000790" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">10,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000795" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" decimals="2">12.15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000791" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">291,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000796" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231" decimals="2">13.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining vesting term of the RSUs at December&#160;31, 2021 was <ix:nonNumeric id="F_000797" name="eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231" format="ixt-sec:duryear">1.37</ix:nonNumeric> years. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Stock Units </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000798" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> non-vested deferred stock units (&#8220;DSUs&#8221;) issued and outstanding to the Company&#8217;s non-executive directors at each of December 31, 2021 and 2020, respectively. Each DSU vests <ix:nonNumeric id="F_000800" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_20210101_20211231" format="ixt-sec:durwordsen">one year</ix:nonNumeric> from the date of grant. Subsequent to vesting, the DSUs will be settled in shares of the Company&#8217;s Common Stock upon the earliest to occur of (i) each director&#8217;s termination of service on the Company&#8217;s Board of Directors and (ii) the occurrence of a change of control as defined in the award agreement. At December 31, 2021, there was <ix:nonFraction unitRef="U_xbrlishares" id="F_000801" name="eypt:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" contextRef="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> vested DSUs that have not been settled in shares of the Company&#8217;s Common Stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 25, 2019, the Company&#8217;s stockholders approved the adoption of the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and authorized up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000802" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190625" decimals="INF" format="ixt:numdotdecimal">110,000</ix:nonFraction> shares of Common Stock reserved for issuance to participating employees. At the Company&#8217;s Annual Meeting of Stockholders held on June 22, 2021, the Company&#8217;s stockholders approved an amendment to the ESPP to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="U_xbrlishares" id="F_000803" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210622" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction> shares. The ESPP allows qualified participants to purchase the Company&#8217;s Common Stock twice a year at <ix:nonFraction unitRef="U_xbrlipure" id="F_000804" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625" decimals="2" scale="-2">85</ix:nonFraction>% of the lesser of the average of the high and low sales price of the Company&#8217;s Common Stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. <span style="Background-color:#FFFFFF;">The number of shares of the Company&#8217;s Common Stock each employee may purchase under this plan, when combined with all other employee stock purchase plans, is limited to the lower of an aggregate fair market value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000805" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> during each calendar year, or <ix:nonFraction unitRef="U_xbrlishares" id="F_000806" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625" decimals="INF" format="ixt:numdotdecimal">5,000</ix:nonFraction> shares of the Company&#8217;s Common Stock in any one offering period. The Company has maintained consecutive six-month offering periods since <ix:nonNumeric id="F_000807" name="eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625" format="ixt:datemonthdayyearen">August 1, 2019</ix:nonNumeric>. </span>As of December 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000808" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">43,365</ix:nonFraction> shares of the Company&#8217;s Common Stock were issued pursuant to the ESPP.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company estimated the fair value of the option component of the ESPP shares at the date of grant using a Black-Scholes valuation model. During the year ended December 31, 2021, the compensation expense from ESPP shares was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">113,000</ix:nonFraction>. During the year ended December 31, 2020, the compensation expense from ESPP shares was immaterial.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense </p><ix:nonNumeric id="F_000329" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s statements of comprehensive loss included total compensation expense from stock-based payment awards as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense included in:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20200101_20201231" decimals="-3" scale="3">907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,966</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, there was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001314102_20211231" decimals="-5" scale="6">9.3</ix:nonFraction>&#160;million of unrecognized compensation expense related to outstanding equity awards under the 2016 Plan, the 2008 Plan, The inducement awards and the ESPP that is expected to be recognized as expense over a weighted-average period of approximately <ix:nonNumeric id="F_000819" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001314102_20210101_20211231" format="ixt-sec:duryear">1.7</ix:nonNumeric> years. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000284" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.<span style="margin-left:22pt;"></span>License and Asset Purchase Agreements</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aerpio Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the Company entered into an Asset Purchase Agreement with Aerpio Pharmaceuticals, Inc. (&#8220;Aerpio&#8221;), pursuant to which Aerpio sold to the Company all of its right, title and interest in and to certain of its patents and patent applications and other intellectual property, including but not limited to patents covering certain human protein tyrosine phosphate inhibitors and methods of use.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights purchased from Aerpio, the Company made a one time, non-refundable, non-creditable upfront cash payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="eypt:NonRefundableNonCreditableUpfrontCashPayment" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210801_20210831" decimals="0" format="ixt:numdotdecimal">450,000</ix:nonFraction> to Aerpio in August 2021. The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">450,000</ix:nonFraction> of R&#38;D expense for the year ended December 31, 2021, due to the early stage of its preclinical drug development activities.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equinox Science, LLC </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company entered into an Exclusive License Agreement with Equinox Science, LLC<span style="Background-color:#FFFFFF;"> (&#8220;Equinox&#8221;), pursuant to which Equinox granted us an exclusive, sublicensable, royalty-bearing right and license to certain patents and other Equinox intellectual property to research, develop, make, have made, use, sell, offer for sale and import the compound vorolanib and any pharmaceutical products comprising the compound for the prevention or treatment of age-related macular degeneration, diabetic retinopathy and retinal vein occlusion using our proprietary localized delivery technologies, in each case, throughout the world except China, Hong Kong, Taiwan and Macau (the &#8220;Territory&#8221;).</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In </span>consideration<span style="Background-color:#FFFFFF;"> for the rights granted by Equinox, the Company (i) made a one time, non-refundable, non-creditable upfront cash payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="eypt:NonRefundableNonCreditableUpfrontCashPayment" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229" decimals="-5" scale="6">1.0</ix:nonFraction> million to Equinox in February 2020, and (ii) agreed to pay milestone payments totaling up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="eypt:MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229" decimals="-6" scale="6">50</ix:nonFraction> million upon the achievement of certain development and regulatory milestones, consisting of (a) completion of a Phase II clinical trial for the compound or a licensed product, (b) the filing of a new drug application or foreign equivalent for the compound or a licensed product in the United States, European Union or United Kingdom and (c) regulatory approval of the compound or a licensed product in the United States, European Union or United Kingdom.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company also agreed to pay Equinox tiered royalties based upon annual net sales of licensed products in the Territory. The royalties are payable with respect to a licensed product in a particular country in the Territory on a country-by-country and licensed product-by-licensed product basis until the later of (i) twelve years after the first commercial sale of such licensed product in such country and (ii) the first day of the month following the month in which a generic product corresponding to such licensed product is launched in such country (collectively, the &#8220;Royalty Term&#8221;). </span>The royalty rates range from the high-single digits to low-double digits depending on the level of annual net sales. The royalty rates are subject to reduction during certain periods when there is no valid patent claim that covers a licensed product in a particular country. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20210101_20211231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200101_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million of R&#38;D expense during the years ended December 31, 2021 and 2020 for this license.</p></ix:nonNumeric><ix:nonNumeric id="F_000285" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000285_dcnt_1503ae90-96b9-44ea-822a-c56b2b73cfe2">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.<span style="margin-left:22pt;"></span>Fair Value Measurements </p><ix:nonNumeric id="F_000330" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000330_dcnt_78f0aa81-a46d-40e5-af14-4080ec1a639a">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s assets carried at fair value measured on a recurring basis at December 31, 2021 and 2020, respectively, by valuation hierarchy (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 1:</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">155,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000836" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">155,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000846" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">155,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000851" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">155,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000837" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">155,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000847" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">155,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000852" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 2:</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000838" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000848" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,549</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000853" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000844" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000849" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,549</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000854" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">205,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000845" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">205,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000850" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">172,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000285_dcnt_1503ae90-96b9-44ea-822a-c56b2b73cfe2"><ix:continuation id="F_000330_dcnt_78f0aa81-a46d-40e5-af14-4080ec1a639a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 1:</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000856" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000863" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000865" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000867" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_0001314102_20211231" decimals="-5" scale="6">155.6</ix:nonFraction> million, or&#160;&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000869" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">90.4</ix:nonFraction>% of the Company&#8217;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $<ix:nonFraction unitRef="U_iso4217USD" id="F_000870" name="us-gaap:CommercialPaperAtCarryingValue" contextRef="C_0001314102_20211231" decimals="-5" scale="6">16.5</ix:nonFraction> million, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000871" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231" decimals="3" scale="-2">9.6</ix:nonFraction>% of the Company&#8217;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_20211231" decimals="-5" scale="6">33.0</ix:nonFraction> million in marketable securities at December 31, 2021.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#8217; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, substantially all of the Company&#8217;s interest-bearing cash equivalent balances were concentrated in one U.S. Government money market fund that has investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001314102_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> investments in marketable securities at December 31, 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The </span><span style="color:#000000;">carrying</span><span style="Background-color:#FFFFFF;"> amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the Company&#8217;s CRG Loan is determined using a discounted cash flow analysis based on market rates for observable similar instruments as of the condensed consolidated balance sheet dates. Accordingly, the fair value of the CRG Loan is categorized as Level 2 within the fair value hierarchy. At December 31, 2021, the fair value of the CRG Loan was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000880" name="us-gaap:LongTermDebtFairValue" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231" decimals="-5" scale="6">38.7</ix:nonFraction> million, and the carrying value of the CRG Loan was approximately $</span><span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000874" name="us-gaap:LongTermDebt" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231" decimals="-5" scale="6">38.9</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> million, and consisted of $</span><span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000876" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231" decimals="-5" scale="6">36.6</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> million of its carrying amount as reported in long-term debt, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="eypt:ExitFeeAccrued" contextRef="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231" decimals="-5" scale="6">2.3</ix:nonFraction> million of debt exit fee as reported in other long-term liabilities of the consolidated balance sheet, respectively. At December 31, 2020, the fair value of the CRG Loan was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000881" name="us-gaap:LongTermDebtFairValue" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231" decimals="-5" scale="6">38.0</ix:nonFraction> million, and the carrying value of the CRG Loan was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000875" name="us-gaap:LongTermDebt" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231" decimals="-5" scale="6">38.3</ix:nonFraction></span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;">million, and consisted of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000877" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231" decimals="-5" scale="6">36.0</ix:nonFraction></span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;">million of its carrying amount as reported in long-term debt, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000879" name="eypt:ExitFeeAccrued" contextRef="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231" decimals="-5" scale="6">2.3</ix:nonFraction> million of debt exit fee as reported in other long-term liabilities of the condensed consolidated balance sheet, respectively.</span></p></ix:continuation><ix:nonNumeric id="F_000286" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retirement Plans </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a defined contribution plan intended to qualify under Section&#160;401(k) of the U.S. Internal Revenue Code. Participating U.S. employees may contribute a portion of their pre-tax compensation, as defined, subject to statutory maximums. The Company matches employee contributions up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000882" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001314102_20210101_20211231" decimals="2" scale="-2">5</ix:nonFraction>% of eligible compensation, subject to a stated calendar year Internal Revenue Service maximum. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operated a defined contribution pension plan for U.K. employees pursuant to which the Company made contributions on behalf of employees plus a matching percentage of elective employee contributions. This pension plan was terminated in the quarter ending September&#160;30, 2016 following termination of employment of all U.K. employees. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company contributed a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="eypt:DefinedContributionPlanContributionsByEmployer" contextRef="C_0001314102_20210101_20211231" decimals="1">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000884" name="eypt:DefinedContributionPlanContributionsByEmployer" contextRef="C_0001314102_20200101_20201231" decimals="0" format="ixt:numdotdecimal">690,000</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively, in connection with these retirement plans. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000287" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000287_dcnt_e8927cdd-0991-4531-8a3b-5449a0504ea5">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div><ix:nonNumeric id="F_000331" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000885" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">98</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000889" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000890" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="color:#000000;">n December&#160;22, 2017, the </span><span style="font-style:italic;color:#000000;">Tax Cuts and Jobs Act </span><span style="color:#000000;">(the &#8220;Tax Act&#8221;) was signed into law, making significant changes to the federal tax law. Amongst other things, the Tax Act reduces the federal corporate tax rate from <ix:nonFraction unitRef="U_xbrlipure" id="F_000891" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001314102_20170101_20171231" decimals="2" scale="-2">34</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000892" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001314102_20190101_20191231" decimals="2" scale="-2">21</ix:nonFraction>% effective for tax years beginning after December&#160;31, 2017 and has resulted in a remeasurement of the Company&#8217;s deferred tax assets included in the Company&#8217;s fiscal 2018 rate reconciliation.</span> <ix:nonNumeric id="F_000332" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000332_cnt_1">The difference between the Company&#8217;s expected income tax benefit, as computed by applying the blended statutory U.S. federal tax rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000893" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001314102_20210101_20211231" decimals="2" scale="-2">21</ix:nonFraction>% for the year ended December 31, 2021 and <ix:nonFraction unitRef="U_xbrlipure" id="F_000894" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001314102_20200101_20201231" decimals="2" scale="-2">21</ix:nonFraction>% for the year ended December 31, 2020, to loss before income taxes, and actual income tax benefit is reconciled in the following table (in thousands):</ix:nonNumeric> </p><ix:continuation id="F_000332_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit at statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,533</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. income tax rate differential</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="eypt:IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="eypt:IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in federal tax rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="eypt:IncomeTaxReconciliationPermanentItems" contextRef="C_0001314102_20210101_20211231" decimals="-3" scale="3">729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="eypt:IncomeTaxReconciliationPermanentItems" contextRef="C_0001314102_20200101_20201231" decimals="-3" scale="3">288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_0001314102_20210101_20211231" decimals="-3" sign="-" scale="3">626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_0001314102_20200101_20201231" decimals="-3" sign="-" scale="3">652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000333" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<span style="font-size:10pt;">The significant components of deferred income taxes are as follows (in thousands): </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000917" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001314102_20201231" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000919" name="eypt:DeferredTaxAssetsLeasingArrangements" contextRef="C_0001314102_20211231" decimals="-3" scale="3">722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000920" name="eypt:DeferredTaxAssetsLeasingArrangements" contextRef="C_0001314102_20201231" decimals="-3" scale="3">806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000921" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000922" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000923" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000925" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000926" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000927" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000928" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000929" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000930" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000931" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="C_0001314102_20211231" decimals="-3" scale="3">615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000932" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="C_0001314102_20201231" decimals="-3" scale="3">713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000933" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000934" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000935" name="eypt:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000936" name="eypt:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">82,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000937" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000938" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">82,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000939" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001314102_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000940" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001314102_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000287_dcnt_e8927cdd-0991-4531-8a3b-5449a0504ea5">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation allowance generally reflects limitations on the Company&#8217;s ability to use the tax attributes and reduces the value of such attributes to the more-likely-than-not realizable amount. Management assessed the available positive and negative evidence to estimate if sufficient taxable income will be generated to use the existing net deferred tax assets. Based on a weighting of the objectively verifiable negative evidence in the form of cumulative operating losses over the three-year period ended June&#160;30, 2018, management believes that it is not more likely than not that the deferred tax assets will be realized and, accordingly, a full valuation allowance has been established. The valuation allowance increased $<ix:nonFraction unitRef="U_iso4217USD" id="F_000941" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001314102_20210101_20211231" decimals="-5" scale="6">15.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000942" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001314102_20200101_20201231" decimals="-5" scale="6">13.1</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively, with such increases attributed to the re-measurement of the net deferred tax assets at the year-end dates. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has tax net operating loss and tax credit carry forwards in its individual tax jurisdictions. Including approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000943" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231" decimals="-5" scale="6">49.3</ix:nonFraction>&#160;million related to the Icon acquisition, at December&#160;31, 2021, the Company had U.S. federal net operating loss carry forwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000944" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231" decimals="-5" scale="6">301.2</ix:nonFraction>&#160;million. The net operating losses consist of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000945" name="eypt:NetOperatingLossCarryforwards" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231" decimals="-5" scale="6">151.8</ix:nonFraction> million, which expire at various dates between calendar years <ix:nonNumeric id="F_000954" name="eypt:OperatingLossCarryForwardsExpirationYearRangeStart" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231">2023</ix:nonNumeric> and <ix:nonNumeric id="F_000955" name="eypt:OperatingLossCarryForwardsExpirationYearRangeEnd" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231">2038</ix:nonNumeric>. The utilization of certain of these loss and tax credit carry forwards may be limited by Sections 382 and 383 of the Internal Revenue Code as a result of historical or future changes in the Company&#8217;s ownership. At December&#160;31, 2021, the Company had state net operating loss carry forwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">222.6</ix:nonFraction>&#160;million, which expire between <ix:nonNumeric id="F_000947" name="eypt:OperatingLossCarryForwardsExpirationYearRangeStart" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">2033</ix:nonNumeric> and <ix:nonNumeric id="F_000948" name="eypt:OperatingLossCarryForwardsExpirationYearRangeEnd" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">2038</ix:nonNumeric>, as well as U.S. federal and state research and development tax credit carry forwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_20211231" decimals="-5" scale="6">5.7</ix:nonFraction>&#160;million, which expire at various dates between calendar years <ix:nonNumeric id="F_000952" name="eypt:ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" contextRef="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateTaxMember_20210101_20211231">2021</ix:nonNumeric> and <ix:nonNumeric id="F_000953" name="eypt:ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" contextRef="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateTaxMember_20210101_20211231">2038</ix:nonNumeric>. In addition, at December&#160;31, 2021 the Company had net operating loss carry forwards in the U.K. of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000950" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20211231" decimals="-5" scale="6">20.9</ix:nonFraction>&#160;million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20211231" decimals="-5" scale="6">27.6</ix:nonFraction> million), which are not subject to any expiration dates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s U.S. federal income tax returns for calendar years 2003 through 2020 remain subject to examination by the Internal Revenue Service. The Company&#8217;s U.K. tax returns for fiscal years 2006 through 2020 remain subject to examination. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through December&#160;31, 2021, the Company had no unrecognized tax benefits in its consolidated statements of comprehensive loss and <ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001314102_20211231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001314102_20201231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits in its consolidated balance sheets as of December&#160;31, 2021 and 2020, respectively. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001314102_20211231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001314102_20201231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued penalties or interest related to uncertain tax positions.</p></ix:continuation><ix:nonNumeric id="F_000288" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to various other routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company&#8217;s financial position, results of operations or cash flows. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Securities and Exchange Commission Subpoena </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> Company previously disclosed that on May 14, 2020 it had received a subpoena from the Division of Enforcement of the SEC seeking production of certain documents and information on topics including product sales and demand, revenue recognition and accounting in relation to product sales, product sales and cash projections, and related financial reporting, disclosure and compliance matters. On May 4, 2021, the Company was advised by the SEC Division of Enforcement that it has concluded its investigation of the Company and that, based on the information it has to date, the Enforcement Division does not intend to recommend an enforcement action against the Company. </span></p></ix:nonNumeric><ix:nonNumeric id="F_000289" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true" continuedAt="F_000289_dcnt_4416b1ad-9932-4f4d-8fb8-052cb558e890">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment and Geographic Area Information </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Segment </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in <ix:nonFraction unitRef="U_xbrlipure" id="F_000962" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001314102_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> business segment, which is the business of developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating decision maker made such decisions and assessed performance at the company level, as one segment. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000289_dcnt_4416b1ad-9932-4f4d-8fb8-052cb558e890">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geographic Area Information </p><ix:nonNumeric id="F_000334" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s revenues and long-lived assets, net by geographic area (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve&#160;Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve&#160;Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At&#160;December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At&#160;December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000971" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20211231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20201231" decimals="-3" scale="3">630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtStatementGeographicalAxis_countryCN_20210101_20211231" decimals="-3" scale="3">851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtStatementGeographicalAxis_countryCN_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.K.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtStatementGeographicalAxis_countryGB_20210101_20211231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_srtStatementGeographicalAxis_countryGB_20200101_20201231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001314102_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_20211231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001314102_20201231" decimals="-3" scale="3">630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000290" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001314102_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Events<span style="color:#000000;font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 9, 2022, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (the &#8220;SVB Loan Agreement&#8221;). The SVB Loan Agreement provides (i) a senior secured term loan facility of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309" decimals="-6" scale="6">30</ix:nonFraction> million (the &#8220;Term Loan&#8221;) and (ii) a senior secured revolving credit facility of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000976" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309" decimals="-5" scale="6">15.0</ix:nonFraction> million in available credit (the &#8220;Revolving Facility&#8221; and together with the Term Loan, &#8220;the SVB Loan&#8221;). The maximum amount available for borrowing at any time under the Revolving Facility is limited to a borrowing base valuation, or <ix:nonFraction unitRef="U_xbrlipure" id="F_000977" name="eypt:PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="2" scale="-2">80</ix:nonFraction>% of the Company&#8217;s eligible accounts receivable. An unused commitment fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000978" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="4" scale="-2">0.25</ix:nonFraction>% per annum applies to unutilized borrowing capacity under the Revolving Facility. The SVB Loan Agreement replaced its existing CRG Loan (see Note 9). Pursuant to the SVB Loan Agreement, the Company (i) made an initial draw of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="-6" scale="6">30</ix:nonFraction> million with respect to the Term Loan and of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="-5" scale="6">11.5</ix:nonFraction> million with respect to the Revolving Facility, to pay off the CRG Loan, including the accrued interests through this date. Certain prepayment premiums apply to any repayments made (i) with respect to the Term Loan prior to the maturity date on <ix:nonNumeric id="F_000981" name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" format="ixt:datemonthdayyearen">January 1, 2027</ix:nonNumeric>, and (ii) with respect to the Revolving Facility prior to the maturity date on January 1, 2027.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SVB Loan Agreement bears interest at (i) the greater of (x) Wall Street Journal Prime Rate plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000982" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20220309_20220309" decimals="4" scale="-2">2.25</ix:nonFraction>% and (y) <ix:nonFraction unitRef="U_xbrlipure" id="F_000983" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309" decimals="4" scale="-2">5.50</ix:nonFraction>%, with respect to the Term Loan&#59; (ii) the Wall Street Journal Prime Rate, with respect to the Revolving Facility&#59; per annum payable in arrears on the last business day of each calendar month. Commencing on February 1, 2024, the Company is required to repay the principal amount of the Term Loan in 36 consecutive equal monthly installments plus monthly payments of accrued interest. Amounts borrowed under the Revolving Facility may be prepaid or repaid and, prior to the Revolving Facility Maturity Date, reborrowed, subject to the applicable terms and conditions set forth in the SVB Loan Agreement. The SVB Loan is due at maturity on <ix:nonNumeric id="F_000984" name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" format="ixt:datemonthdayyearen">January 1, 2027</ix:nonNumeric> (the &#8220;Maturity Date&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the same date, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="eypt:UpfrontCashPayment" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="-5" scale="6">41.4</ix:nonFraction> million. This payment included (i) a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="-5" scale="6">38.2</ix:nonFraction> million principal portion of the CRG Loan (ii) an $<ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="eypt:DebInstrumentExitFee" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="-5" scale="6">2.3</ix:nonFraction> million exit fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000988" name="eypt:LineOfCreditFacilityExitFeesPercentage" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="2" scale="-2">6</ix:nonFraction>% of the aggregate principal amount advanced under the CRG Loan (iii) accrued and unpaid interest of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="eypt:PaymentOfAccruedAndUnpaidInterest" contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309" decimals="-5" scale="6">0.9</ix:nonFraction> million through that date. As a result of the early repayment of the CRG Loan, the Company expects to record a loss on extinguishment of debt of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_0001314102_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20220101_20220331" decimals="-5" sign="-" scale="6">1.5</ix:nonFraction> million for the quarter ending March 31, 2022 in association with the write-off of the remaining balance of unamortized debt discount.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-33</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>eypt-ex1019_924.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex1019_924.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 10.19</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">INDEMNIFICATION AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Indemnification Agreement (&#8220;Agreement&#8221;) is made as of _________, 2022 by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ________ (&#8220;Indemnitee&#8221;).&nbsp;&nbsp;This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Board of Directors of the Company (the &#8220;Board&#8221;) believes that highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Board has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities.&nbsp;&nbsp;Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions.&nbsp;&nbsp;At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself.&nbsp;&nbsp;The Certificate of Incorporation of the Company (as amended, the &#8220;Certificate of Incorporation&#8221;) requires indemnification of the officers and directors of the Company.&nbsp;&nbsp;Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;).&nbsp;&nbsp;The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the uncertainties relating to such insurance and to indemnification may increase the difficulty of attracting and retaining such persons;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Indemnitee does not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve or continue to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve or continue to serve in such capacity.&nbsp;&nbsp;Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Services to the Company.</font><font style="color:#000000;">&nbsp;&nbsp;Indemnitee agrees to serve as a director or officer, as applicable, of the Company.&nbsp;&nbsp;Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position.&nbsp;&nbsp;This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.&nbsp;&nbsp;Indemnitee specifically acknowledges that Indemnitee&#8217;s employment with the Company (or any of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the Company&#8217;s By-laws (the &#8220;By-laws&#8221;), and the DGCL.&nbsp;&nbsp;The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as an officer or director of the Company, as provided in Section 16 hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Definitions.</font><font style="color:#000000;">&nbsp;&nbsp;As used in this Agreement:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">References to &#8220;agent&#8221; shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">A &#8220;Change in Control&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">i.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Acquisition of Stock by Third Party.&nbsp;&nbsp;Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&#8217;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">ii.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Change in Board of Directors.&nbsp;&nbsp;During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">iii.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Corporate Transactions.&nbsp;&nbsp;The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the Surviving Entity) more than 50% of the combined voting power of the voting securities of the Surviving Entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such Surviving Entity;</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">iv.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liquidation.&nbsp;&nbsp;The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, including by license; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">v.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Other Events.&nbsp;&nbsp;There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Section 2(b), the following terms shall have the following meanings:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">&#8220;Exchange Act&#8221; shall mean the Securities Exchange Act of 1934, as amended from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">&#8220;Person&#8221; shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)<font style="margin-left:36pt;">&#8220;Beneficial Owner&#8221; shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:36pt;">&#8220;Surviving Entity&#8221; shall mean the surviving entity in a merger or consolidation or any entity that controls, directly or indirectly, such surviving entity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;Corporate Status&#8221; describes the status of a person who is or was a director, officer, employee or agent of the Company or of any other corporation, limited liability company, partnership or joint venture, trust or other enterprise which such person is or was serving at the request of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;Disinterested Director&#8221; shall mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;Enterprise&#8221; shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or fiduciary.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;Expenses&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding.&nbsp;&nbsp;Expenses shall also include (i)</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise.&nbsp;&nbsp;The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee&#8217;s counsel as being reasonable in the good faith judgment of such counsel shall be presumed conclusively to be reasonable.&nbsp;&nbsp;Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;Independent Counsel&#8221; shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent:&nbsp;&nbsp;(i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.&nbsp;&nbsp;Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.&nbsp;&nbsp;The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The term &#8220;Proceeding&#8221; shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of Indemnitee&#8217;s Corporate Status, by reason of any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&#8217;s part while acting pursuant to Indemnitee&#8217;s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement.&nbsp;&nbsp;If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Reference to &#8220;other enterprise&#8221; shall include employee benefit plans; references to &#8220;fines&#8221; shall include any excise tax assessed with respect to any employee benefit plan; references to &#8220;serving at the request of the Company&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner Indemnitee&nbsp;&nbsp;reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;not opposed to the best interests of the Company&#8221; as referred to in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Indemnity in Third-Party Proceedings.</font><font style="color:#000000;">&nbsp;&nbsp;The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor.&nbsp;&nbsp;Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.&nbsp;&nbsp;The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the By-laws, vote of its stockholders or disinterested directors or applicable law.</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Indemnity in Proceedings by or in the Right of the Company.</font><font style="color:#000000;">&nbsp;&nbsp;The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.&nbsp;&nbsp;Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company.&nbsp;&nbsp;No </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court (as hereinafter defined) or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</font><font style="color:#000000;"> Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee in connection therewith.&nbsp;&nbsp;If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law.&nbsp;&nbsp;For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Indemnification For Expenses of a Witness.</font><font style="color:#000000;">&nbsp;&nbsp;Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of Indemnitee&#8217;s Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Partial Indemnification.</font><font style="color:#000000;">&nbsp;&nbsp;If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional Indemnification.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) by reason of Indemnitee&#8217;s Corporate Status. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For purposes of Section 8(a), the meaning of the phrase &#8220;to the fullest extent permitted by applicable law&#8221; shall include, but not be limited to:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">i.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">ii.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exclusions.</font><font style="color:#000000;">&nbsp;&nbsp;Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim involving Indemnitee:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act) or (iii) any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Advances of Expenses.</font><font style="color:#000000;">&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary (other than Section 14(d)), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee or any Proceeding initiated by Indemnitee with the prior approval of the Board as provided in Section 9(c), and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding.&nbsp;&nbsp;Advances shall be unsecured and interest free.&nbsp;&nbsp;Advances shall be made without regard to Indemnitee&#8217;s ability to repay the Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement.&nbsp;&nbsp;In accordance with Section 14(d), advances shall include any and all Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed.&nbsp;&nbsp;The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company.&nbsp;&nbsp;No other form of undertaking shall be required other than the execution of this Agreement.&nbsp;&nbsp;This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Procedure for Notification and Defense of Claim.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof.&nbsp;&nbsp;The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding.&nbsp;&nbsp;To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding.&nbsp;&nbsp;The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement.&nbsp;&nbsp;The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company will be entitled to participate in the Proceeding at its own expense.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Procedure Upon Application for Indemnification.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case:&nbsp;&nbsp;(i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination.&nbsp;&nbsp;Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.&nbsp;&nbsp;Any costs or Expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">hold Indemnitee harmless therefrom.&nbsp;&nbsp;The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section&#160;12(b).&nbsp;&nbsp;If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising Indemnitee of the identity of the Independent Counsel so selected.&nbsp;&nbsp;If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected.&nbsp;&nbsp;In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section&#160;2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.&nbsp;&nbsp;Absent a proper and timely objection, the person so selected shall act as Independent Counsel.&nbsp;&nbsp;If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit.&nbsp;&nbsp;If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section&#160;11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#8217;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&#160;12(a) hereof.&nbsp;&nbsp;Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Presumptions and Effect of Certain Proceedings.</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.&nbsp;&nbsp;Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if </font><font style="font-weight:bold;color:#000000;">(</font><font style="color:#000000;">A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="text-decoration:underline;color:#000000;">nolo</font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">contendere</font><font style="color:#000000;"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee&#8217;s conduct was unlawful.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise (as defined below) in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Enterprise.&nbsp;&nbsp;The provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall not be </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Remedies of Indemnitee.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section&#160;10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section&#160;5, 6 or 7 or the second to last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of Indemnitee&#8217;s entitlement to such indemnification or advancement of Expenses.&nbsp;&nbsp;Alternatively, Indemnitee, at Indemnitee&#8217;s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.&nbsp;&nbsp;Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a).&nbsp;&nbsp;The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&#160;14 shall be conducted in all respects as a </font><font style="text-decoration:underline;color:#000000;">de</font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">novo</font><font style="color:#000000;"> trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.&nbsp;&nbsp;In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If a determination shall have been made pursuant to Section&#160;12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&#160;14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.&nbsp;&nbsp;It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder.&nbsp;&nbsp;The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Non-exclusivity; Survival of Rights; Insurance; Subrogation.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise.&nbsp;&nbsp;No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by Indemnitee in Indemnitee&#8217;s Corporate Status prior to such amendment, alteration or repeal.&nbsp;&nbsp;To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.&nbsp;&nbsp;No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.&nbsp;&nbsp;The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies.&nbsp;&nbsp;If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies.&nbsp;&nbsp;The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event of any payment made by the Company under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</font><font style="margin-left:36pt;color:#000000;"></font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust or other enterprise.</font></p>
<p style="text-align:justify;margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 16.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Duration of Agreement.</font><font style="color:#000000;">&nbsp;&nbsp;This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company and (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section&#160;14 of this Agreement relating thereto.&nbsp;&nbsp;The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and Indemnitee&#8217;s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 17.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Severability.</font><font style="color:#000000;">&nbsp;&nbsp;If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 18.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Enforcement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a director or officer of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the By-laws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 19.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Modification and Waiver.</font><font style="color:#000000;">&nbsp;&nbsp;No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto.&nbsp;&nbsp;No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 20.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice by Indemnitee.</font><font style="color:#000000;">&nbsp;&nbsp;Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder.&nbsp;&nbsp;The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 21.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices.</font><font style="color:#000000;">&nbsp;&nbsp;All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission or email, with receipt of oral confirmation that such transmission has been received:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.</font></p>
<p style="text-align:justify;margin-bottom:18pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If to the Company to</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc.<br />480 Pleasant Street<br />Watertown, MA 02472<br />Attention: Chief Legal Officer<br />Facsimile: (617) 926-5050<br />Email: rhonig@eyepointpharma.com</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to any other address as may have been furnished to Indemnitee by the Company.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">Section 22.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Contribution.</font><font style="color:#000000;">&nbsp;&nbsp;To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="QuickMark"></a><font style="Background-color:#auto;text-decoration:none;">Section 23.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Applicable Law and Consent to Jurisdiction.</font><font style="color:#000000;"><a name="QuickMark"></a>&nbsp;&nbsp;This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.&nbsp;&nbsp;Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Court of Chancery of the State of Delaware (the &#8220;Delaware Court&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably RL&amp;F Service Corp., 920 North King Street, 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> Floor, Wilmington, New Castle County, Delaware 19801 as its agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 24.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Identical Counterparts.</font><font style="color:#000000;">&nbsp;&nbsp;This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.&nbsp;&nbsp;Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">Section 25.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Miscellaneous.</font><font style="color:#000000;">&nbsp;&nbsp;Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate.&nbsp;&nbsp;The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:8.65%;"></td>
<td style="width:14.38%;"></td>
<td style="width:20.24%;"></td>
<td style="width:15.38%;"></td>
<td style="width:9.62%;"></td>
<td style="width:31.72%;"></td>
<td style="width:0.24%;"></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT <font style="text-transform:uppercase;">Pharmaceuticals, Inc.</font></p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDEMNITEE</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td colspan="2" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ron Honig</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&amp; Company Secretary</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule of Material Differences</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following directors and executive officers are parties to an Indemnification Agreement with the Company, each of which are substantially identical in all material respects to the representative Indemnification Agreement filed herewith as Exhibit 10.19 except as to the name of the signatory and the date of each signatory&#8217;s Indemnification Agreement, which are listed below. The actual Indemnification Agreements are omitted pursuant to Instruction 2 to Item 601 of Regulation S-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68.37%;">
<tr>
<td style="width:34.6%;"></td>
<td style="width:33.76%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Indemnitee</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Effective Date</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy S. Lurker</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 15, 2016</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Paggiarino, M.D.</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 26, 2016</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ronald W. Eastman</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 28, 2018</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay S. Duker, M.D.</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 27, 2016</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&#246;ran Ando, M.D.</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 14, 2018</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Landis</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 30, 2018</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David R. Guyer M.D.</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 25, 2019</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scott Jones</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wendy DiCicco</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 15, 2019</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George Elston</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 14, 2019</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ye Liu</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael C. Pine</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 10, 2022</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>3
<FILENAME>eypt-ex1028_1698.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex1028_1698.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.62%;">Exhibit 10.28</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:7.62%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">FOURTH amendment to Lease</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.62%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS FOURTH AMENDMENT TO LEASE <font style="font-weight:normal;">(this &#8220;</font>Amendment<font style="font-weight:normal;">&#8221;) is made and entered into as of the ___8th__day of ____March____________, 2022 (the &#8220;</font>Effective Date<font style="font-weight:normal;">&#8221;), by and between </font>GRE RIVERWORKS, LLC<font style="font-weight:normal;">, a Delaware limited liability company (&#8220;</font>Landlord<font style="font-weight:normal;">&#8221;), and </font>EYEPOINT PHARMACEUTICALS, INC.<font style="font-weight:normal;">, a Delaware corporation (&#8220;</font>Tenant<font style="font-weight:normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk88491832"></a><a name="_cp_text_1_2"></a><a name="_cp_text_1_4"></a><font style="Background-color:#auto;text-decoration:none;">A.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord&#8217;s predecessors-in-interest and</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">Tenant entered into that certain Lease dated November 1, 2013 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Original Lease</font><font style="color:#000000;">&#8221;), as amended by that certain First Amendment to Lease dated February 6, 2014 (the &#8220;</font><font style="font-weight:bold;color:#000000;">First Amendment</font><font style="color:#000000;">&#8221;), that certain Second Amendment to Lease dated May 14, 2018 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Second Amendment</font><font style="color:#000000;">&#8221;), that certain Confirmation of Suite A-210 Effective Date dated November 29, 2018 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Confirmation</font><font style="color:#000000;">&#8221;) and that certain Third Amendment to Lease dated April 5, 2021 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Third Amendment</font><font style="color:#000000;">&#8221;; collectively with the Original Lease, the First Amendment, the Second Amendment and the Confirmation, the &#8220;</font><font style="font-weight:bold;color:#000000;">Lease</font><font style="color:#000000;"><a name="_Hlk88491832"></a>&#8221;), pursuant to which Tenant currently leases certain premises known as <a name="_cp_text_1_2"></a>Suite A210 on the second floor containing approximately 7,999 rentable square feet (&#8220;</font><font style="font-weight:bold;color:#000000;">Suite A210</font><font style="color:#000000;"><a name="_cp_text_1_4"></a>&#8221; and now includes and incorporates the suite formerly known as Suite B210 on the second floor containing approximately 1,409 rentable square feet) and Suite B300 on the third floor containing approximately 13,650 rentable square feet (&#8220;</font><font style="font-weight:bold;color:#000000;">Suite B300</font><font style="color:#000000;">&#8221;), all as shown on </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Amended Exhibit A</font><font style="color:#000000;"> which shall replace </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;"> attached to the Lease in its entirety (together, the &#8220;</font><font style="font-weight:bold;color:#000000;">Existing Premises</font><font style="color:#000000;">&#8221;) in the building commonly known as the </font><font style="color:#242424;">Riverworks Innovation Center located at 480 Pleasant Street, Watertown, Massachusetts </font><font style="color:#000000;">(the &#8220;</font><font style="font-weight:bold;color:#000000;">Building</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.62%;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;">The Term is currently scheduled to expire on May 31, 2025 (&#8220;</font><font style="font-weight:bold;">Prior Expiration Date</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.62%;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;">Landlord and Tenant desire to further expand the Existing Premises, extend the Term, and otherwise modify the Lease as set forth below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Recitals</font><font style="color:#000000;">.&nbsp;&nbsp;The recitals set forth above are hereby incorporated into and made a material part of this Amendment.&nbsp;&nbsp;Capitalized terms used but not otherwise defined herein shall have the same meanings ascribed to them in the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Second Expansion</font><font style="color:#000000;">.&nbsp;&nbsp; Effective as of the Second Expansion Premises Commencement Date (as hereinafter defined), the Existing Premises are hereby expanded to include Suite C400 on the fourth floor containing approximately 11,999 rentable square feet on the fourth floor of the Building as shown on </font><font style="text-decoration:underline;color:#000000;">Exhibit A-2</font><font style="color:#000000;"> attached hereto and made a part hereof (&#8220;</font><font style="font-weight:bold;color:#000000;">Second Expansion Premises</font><font style="color:#000000;">&#8221;), which </font><font style="text-decoration:underline;color:#000000;">Exhibit A-2</font><font style="color:#000000;"> shall be deemed part of and attached to the Original Lease.&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;color:#000000;">Second Expansion Premises Commencement Date</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">SEPCD</font><font style="color:#000000;">&#8221; shall mean the earliest to occur of (a) the date Tenant occupies the Second Expansion Premises or any portion thereof for the conduct of Tenant's business; or (b) the date Landlord Substantially Completes the Expansion Work (as these terms are defined in </font><font style="text-decoration:underline;color:#000000;">Exhibit B-1</font><font style="color:#000000;"> attached hereto) in the Second Expansion Premises and tenders possession of the Second Expansion Premises to Tenant or (c) the date Landlord would have Substantially Completed the Expansion Work in the Second Expansion Premises and tendered possession to Tenant but for a Tenant Delay Day (as defined in </font><font style="text-decoration:underline;color:#000000;">Exhibit B-1</font><font style="color:#000000;">).&nbsp;&nbsp;As of the Second Expansion Premises Commencement Date, the &#8220;Premises&#8221; shall include both the Existing Premises and the Second Expansion Premises.&nbsp;&nbsp;After the Second Expansion Premises Commencement Date occurs, Landlord </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">shall deliver to Tenant an instrument confirming the Second Expansion Premises Commencement Date.&nbsp;&nbsp;The rentable square feet stated herein shall be conclusive on both parties.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Extension of Term</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.62%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Term is hereby extended for Suite B300 of the Existing Premises only (the &#8220;</font><font style="font-weight:bold;color:#000000;">Second Extended Term</font><font style="color:#000000;">&#8221;) such that the Expiration Date (herein called the &#8220;</font><font style="font-weight:bold;color:#000000;">Extended Expiration Date</font><font style="color:#000000;">&#8221;) for Suite B300 and the Second Expansion Premises shall be May 31, 2028 unless sooner terminated or renewed in accordance with the terms of the Lease, as amended hereby.&nbsp;&nbsp;All of the terms and conditions of the Lease shall be applicable to Suite B300 and the Second Expansion Premises during the Second Extended Term, except as is otherwise provided in this Amendment. The Term of the Lease for Suite A210 shall expire on the Prior Expiration Date and Tenant shall surrender and vacate same on the Prior Expiration Date in accordance with the terms of the Lease and any failure to do so shall be deemed a holdover with respect thereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.24%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Term for the Second Expansion Premises (the &#8220;</font><font style="font-weight:bold;color:#000000;">Second Expansion Premises Term</font><font style="color:#000000;">&#8221;) shall commence on the SEPCD and shall end on the Extended Expiration Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.24%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base Rent for Suite B300 During the Second Extended Term</font><font style="color:#000000;">.&nbsp;&nbsp;Prior to June 1, 2025, Tenant shall continue to pay Base Rent for the Existing Premises in accordance with Sections 4 and 5 of the Third Amendment.&nbsp;&nbsp;Commencing on June 1, 2025, Tenant shall pay Base Rent for Suite B300 in the same manner as is required under the Lease, as amended hereby, pursuant to the schedule set forth below:</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:41.48%;"></td>
<td style="width:19.78%;"></td>
<td style="width:38.63%;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#272727;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk88489690"></a><font style="text-decoration:underline;">Period</font></p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#272727;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent Per Rentable Square Foot</font></p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#272727;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Installments of Base Rent for Suite B300</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2025 &#8211; May 31, 2026</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$75.00</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$86,868.75</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2026 &#8211; May 31, 2027</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$77.25</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$89,474.81</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2027 &#8211; May 31, 2028</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$79.57</p></td>
<td valign="bottom"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_8"></a><a name="_cp_text_1_10"></a><a name="_cp_text_2_8"></a><a name="_cp_text_1_10"></a>$92,161.95</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_13"></a><a name="_cp_text_2_11"></a><a name="_cp_text_2_14"></a><a name="_cp_text_1_16"></a><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base Rent for the Second Expansion Premises</font><font style="color:#000000;"><a name="_cp_text_1_13"></a><a name="_cp_text_2_11"></a>.&nbsp;&nbsp;In addition to Base Rent for the Current Premises, commencing on the SEPCD (subject to the Second Expansion Premises Abatement Period below), Tenant shall pay Base Rent for the Second Expansion Premises in the same manner as is required under the Lease, as amended hereby, in the amount of $40.00 per rentable square foot of the Second Expansion Premises (or $39,996.67 per month) and on each anniversary of the SEPCD (except as expressly hereinafter provided) during the Second Expansion Premises Term, Base Rent for the Second Expansion Premises shall increase by three percent (3%) (i.e., to $41.20 per rentable square foot or $41,196.57 per month on the first anniversary of the SEPCD, to $42.44 per rentable square foot or $42,436.46 <a name="_cp_text_2_14"></a><a name="_cp_text_1_16"></a>per month on the second anniversary of the SEPCD and to $43.71 per rentable square foot or $43,706.36 per month on the third anniversary of the SEPCD and so on through May 31, 2028).&nbsp;&nbsp;If, however, the SEPCD does not occur on the first day of a calendar month, (a) Tenant shall pay prorated Rent for the Second Expansion Premises on a per diem basis for such partial month on the SEPCD, and (b) solely for purposes of determining the rate applicable for such partial month and for the balance of the Second Expansion Premises Term, the period from the SEPCD through and including the day immediately preceding the first day of the next full calendar month (such first day being hereinafter referred to as the &#8220;SEP Base Rent Anniversary Date&#8221;) shall be deemed included within the first full calendar month of the Second Expansion Premises Term and the annual Base Rent increase contemplated hereinabove shall occur on each anniversary of the Base Rent Anniversary Date not on the SEPCD.&nbsp;&nbsp;By way of example only, if the SEPCD is July 2, 2022, the SEP Base Rent </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Anniversary Date shall be August 1, 2022 and therefore the Base Rent shall increase annually as set forth hereinabove on each August 1st falling within the Second Expansion Premises Term.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Second Expansion Premises Abatement Period</font><font style="color:#000000;">.&nbsp;&nbsp; Notwithstanding the foregoing, provided Tenant is not in an Event of Default under the Lease, as amended hereby, Tenant&#8217;s obligation to pay Base Rent for the Second Expansion Premises only shall be abated for the first two (2) calendar months after the SEPCD (the &#8220;</font><font style="font-weight:bold;color:#000000;">Second Expansion Premises</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Abatement Period</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;To illustrate, if the SEPCD occurs on July 2, 2022, then the Second Expansion Premises Abatement Period will commence on the SEPCD and end on September 1, 2022.&nbsp;&nbsp;If the Second Expansion Premises Abatement Period does not end on the last day of a calendar month, then on the day following the Second Expansion Premises Abatement Period, Tenant shall make a prorated payment of Base Rent for the remainder of such month.&nbsp;&nbsp;If Tenant commits an Event of Default and fails to cure same before Landlord files suit to terminate the Lease, as amended hereby, or regain possession of the Second Expansion Premises, then all sums so abated shall be immediately due and payable to Landlord. Notwithstanding such abatement of Base Rent, all other sums due under the Lease, as amended hereby, shall be payable as provided in the Lease, as amended hereby.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional Rent.</font><font style="color:#000000;">&nbsp;&nbsp;In addition to the Base Rent for the entire Premises, Tenant shall continue to pay as additional rent in the manner and at the times required under Article III of the Original Lease, as amended by Section 5 of the Second Amendment and Section 6 of the Third Amendment, for the balance of the Term, except that:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">effective as of June 1, 2025, the Lease is amended to reflect that the &#8220;RSF of the Building&#8221; with respect to the entire Premises is 202,000 rentable square feet based on a remeasurement of the Building.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.24%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">effective as of June 1, 2025, the Lease is amended to reflect that</font><font style="font-size:12pt;color:#000000;"> </font><font style="color:#000000;">Suite B300 contains approximately 13,899 rentable square feet based upon a remeasurement thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.24%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">effective as of the SEPCD, (i) Tenant&#8217;s Percentage with respect to the Second Expansion Premises shall be 5.94%, being the 11,999 rentable square feet in the Second Expansion Premises divided by the current rentable square footage of the Building (i.e., 202,000 rentable square feet), and (ii) Tenant shall pay Tenant&#8217;s Share of Operating Expenses and Taxes for the Second Expansion Premises without regard to any base year (i.e., for each calendar year, Tenant's Share of Operating Expenses shall include the total Operating Expenses for the Property multiplied by the Tenant's Percentage and for each fiscal year, Tenant's Share of Taxes shall mean the total Taxes for the Property for that fiscal year multiplied by the Tenant's Percentage), including, without limitation, the Operating Expense Base and Real Estate Tax Base and any all references thereto in the Lease thereto shall have no applicability with respect to the Second Expansion Premises.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">effective as of June 1, 2025, Tenant&#8217;s Percentage with respect to Suite B300 shall be 6.89% (13,899/202,000) based upon the remeasurement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">effective as of June 1, 2025, the terms &#8220;Operating Expense Base&#8221; and &#8220;Real Estate Tax Base&#8221; and any and all references thereto in the Lease are hereby deleted in their entirety and deemed null, void and of no further force or effect with respect to Suite B300 and Tenant shall pay Tenant&#8217;s Share of Operating Expenses and Taxes for Suite B300 without regard to any base year, including, without limitation, the Operating Expense Base and Real Estate Tax Base.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.24%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">effective as of June 1, 2025, Section 3.2(a) of the Original Lease is hereby deleted in its entirety and the following provision is substituted in lieu thereof:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.62%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.62%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Hlk95819998"></a><a name="_cp_text_2_17"></a><a name="_cp_text_1_20"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk95819998"></a>Tenant shall pay, as additional rent, Tenant's Share of Operating Expenses and Taxes for the Property. For each calendar year, Tenant's Share of Operating Expenses shall consist of the sum of (x) the total Operating Expenses for the Property for that calendar year multiplied by the Tenant's Percentage and (y) a commercially reasonable charge for the provision of services to operate the Building during periods other than 8:00 am. to 5:00 pm. on weekdays and 9:00 a.m. to 1:00 p.m. on Saturdays and to operate the Building on holidays (which are all days on which commercial banks in Boston, Massachusetts are authorized or required by law to close) (such periods being referred to herein as "Non-Business Hours") that are fairly allocable to the Premises, if such services are requested by Tenant or are necessary, in Landlord's reasonable judgment, for Tenant's operations during Non-Business Hours. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each fiscal year, Tenant's Share of Taxes shall consist of the total Taxes for the Property for that fiscal year multiplied by the Tenant's Percentage</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_17"></a><a name="_cp_text_1_20"></a>. For any partial calendar year or fiscal year at the beginning or end of the Term, Tenant's Share of Operating Expenses and Taxes shall be adjusted proportionately for the part of the calendar year or fiscal year falling within the Term. Tenant's Percentage may be reduced if the Property is changed or reconfigured, but shall in all cases not exceed the percentage that the Rentable Square Feet in the Premises bears to the total rentable square footage in the Property, calculated on a consistent basis. In addition, Tenant shall pay, as additional rent, one hundred percent (100%) of any increase in Taxes not otherwise billed to Tenant which may result from any alteration, addition or improvement to the Premises that is made by or on behalf of Tenant other than the Leasehold Improvements, but only as and to the extent it is reasonably determinable from the records of the assessing authority that such increase in Taxes is based solely upon such alteration, addition or improvement.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tenant&#8217;s Electricity</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall continue to pay the cost of all submetered electricity for the Existing Premises directly to Landlord, as additional rent, as shown on the submeter as and when bills are rendered by Landlord as provided in Section 3.3 of the Original Lease.&nbsp;&nbsp;To the extent not already existing, as part of the Expansion Work in the Second Expansion Premises, Landlord shall ensure that all electricity used in the Second Expansion Premises is separately submetered or otherwise included in Tenant&#8217;s existing submeter for the Existing Premises. Tenant&#8217;s obligation to commence paying electricity for the Second Expansion Premises shall commence on the SEPCD.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Security Deposit</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord currently holds a Security Deposit in the form of a Letter of Credit in the amount of $150,000.00. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Parking</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.24%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">From and after the Effective Date through May 31, 2025, the first paragraph of </font><font style="font-weight:bold;text-decoration:underline;">Exhibit E</font> attached to the Second Amendment, as amended by Section 10 of the Third Amendment, is hereby deleted in its entirety and replaced with the following:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.62%;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant shall be provided a total of sixty-eight (68) parking access cards for unreserved parking spaces (i.e., 2 parking spaces per 1,000 square feet of Rentable Area) of which twenty-seven (27) such parking spaces (i.e., .8 parking spaces per 1,000 square feet of Rentable Area) shall be allocated to the lower lot located on the south side of Pleasant Street (the &#8220;<font style="font-weight:bold;">Lower Lot</font>&#8221;) and forty-one (41) of such parking spaces (i.e., 1.2 parking spaces per 1,000 square feet of Rentable Area) shall be allocated to the upper lot located on the north side of Pleasant Street (the &#8220;<font style="font-weight:bold;">Upper Lot</font>&#8221; and with the Lower Lot, the &#8220;Parking Area&#8221;) subject to such terms, conditions and regulations as are from time to time applicable to patrons of the Parking Area.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.24%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;">From and after June 1, 2025, the first paragraph of </font><font style="font-weight:bold;text-decoration:underline;">Exhibit E</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attached to the Second Amendment, as amended by Section 10 of the Third Amendment and as amended by Section 10(a) of this Fourth Amendment, is hereby deleted in its entirety and replaced with the following:&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.62%;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant shall be provided a total of fifty-one (51) parking access cards for unreserved parking spaces (i.e., 2 parking spaces per 1,000 square feet of Rentable Area) of which twenty (20) such parking spaces (i.e., .8 parking spaces per 1,000 square feet of Rentable Area) shall be allocated to the lower lot located on the south side of Pleasant Street (the &#8220;<font style="font-weight:bold;">Lower Lot</font>&#8221;) and thirty-one (31) of such parking spaces (i.e., 1.2 parking spaces per 1,000 square feet of Rentable Area) shall be allocated to the upper lot located on the north side of Pleasant Street (the &#8220;<font style="font-weight:bold;">Upper Lot</font>&#8221; and with the Lower Lot, the &#8220;Parking Area&#8221;) subject to such terms, conditions and regulations as are from time to time applicable to patrons of the Parking Area.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Condition of Premises</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant hereby re-accepts the Existing Premises in its current &#8220;AS-IS&#8221; &#8220;WHERE IS&#8221; condition.&nbsp;&nbsp;Landlord shall deliver the Second Expansion Premises to Tenant on the SEPCD in its current &#8220;AS-IS&#8221; &#8220;WHERE-IS&#8221; condition, subject to the Expansion Work being Substantially Completed.</font><font style="font-size:12pt;color:#000000;"> </font><font style="color:#000000;">Landlord will also promptly repair the HVAC problems in the Suite A210 at Landlord&#8217;s sole cost and expense.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Suite B300 Allowance</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">From and after the Effective Date, Landlord shall provide to Tenant a construction allowance not to exceed $40.00 per rentable square foot in Suite B300 or $555,960.00 (the &#8220;</font><font style="font-weight:bold;">Suite B300 Allowance</font>&#8221;). The Suite B300 Allowance<font style="font-size:12pt;"> </font>shall only be applied toward the total hard and soft construction costs of Alterations to be performed by Tenant in the Suite B300 in accordance with Section 4.2 of the Original Lease and all other applicable sections of the Lease.&nbsp;&nbsp;Tenant shall pay to Landlord a construction supervision fee equal to three percent (3%) of the total construction costs of the Alterations, which shall be deducted from the Suite B300 Allowance. No advance of the Suite B300 Allowance shall be made by Landlord until Tenant has first paid to the contractor from its own funds (and provided reasonable evidence thereof to Landlord) the anticipated amount by which the projected total construction costs exceed the amount of the Suite B300 Allowance.&nbsp;&nbsp;Thereafter, Landlord shall pay to Tenant the Suite B300 Allowance in multiple disbursements (but not more than once in any calendar month) following the receipt by Landlord of the following items:&nbsp;&nbsp;(a) a request for payment, (b) final or partial lien waivers, as the case may be, from all persons performing work or supplying or fabricating materials for the Alterations, fully executed, acknowledged and in recordable form, (c) the Architect&#8217;s certification that the Alterations for which reimbursement has been requested has been finally completed, including (with respect to the last application for payment only) any punch-list items, on the appropriate AIA form or another form approved by Landlord, and, with respect to the disbursement of the last 10% of the Suite B300 Allowance, (w) &#8220;as built&#8221; drawings in both paper and AutoCad format; (x) the permanent certificate of occupancy issued for Suite B300, (y) Tenant&#8217;s continued occupancy of Suite B300, and (z) an estoppel certificate confirming such factual matters as Landlord or Landlord&#8217;s mortgagee may reasonably request (collectively, a &#8220;<font style="font-weight:bold;">Completed Application for Payment</font>&#8221;).&nbsp;&nbsp;Landlord shall pay the amount requested in the applicable Completed Application for Payment to Tenant within thirty (30) days following Tenant&#8217;s submission of the Completed Application for Payment.&nbsp;&nbsp;If, however, the Completed Application for Payment is incomplete or incorrect, Landlord&#8217;s payment of such request shall be deferred until thirty (30) days following Landlord&#8217;s receipt of the Completed Application for Payment.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Section, Landlord shall not be obligated to make any disbursement of the Suite B300 Allowance during the pendency of any of the following: (1) Landlord has received written notice of any unpaid claims relating to any portion of the Alterations or materials in connection therewith, other than claims which will be paid in full from such disbursement, (2) there is an unbonded lien outstanding against the Building or Suite B300 or Tenant&#8217;s interest therein by reason of work done, or claimed to have been done, or materials supplied or specifically </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fabricated, claimed to have been supplied or specifically fabricated, to or for Tenant or Suite B300, (3) the conditions to the advance of the Suite B300 Allowance are not satisfied, or (4) Tenant is in an Event of Default under the Lease.&nbsp;&nbsp;No portion of the Suite B300 Allowance may be used as a credit against Rent.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.62%;">(b)<font style="margin-left:36pt;">Any portion of the Suite B300 Allowance that remains unexpended by Landlord for Alterations performed in accordance with Section 4.2 of the Original Lease and all other applicable sections of the Lease within eighteen (18) months following the Effective Date shall be deemed forfeited with no further obligation by Landlord with respect thereto and shall be the sole and exclusive property of Landlord.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Option to Extend</font><font style="color:#000000;">.&nbsp;&nbsp;Section 10.23 of the Original Lease is hereby reinstated in its entirety and shall be deemed in full force and effect and exercisable by Tenant upon Landlord&#8217;s receipt of written notice from Tenant thereof no later than twelve (12) months prior to the Extended Expiration Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Brokers</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant represents that Tenant has not dealt with any broker, agent or finder in connection with this Amendment other than Paradigm Properties (&#8220;the </font><font style="font-weight:bold;color:#000000;">&#8220;Broker</font><font style="color:#000000;">&#8221;), whose right to a commission shall be paid by Landlord pursuant to separate written agreement, and Tenant agrees to indemnify and hold Landlord harmless from all damages, judgments, liabilities and expenses (including reasonable attorneys&#8217; fees) arising from any claims or demands of any broker, agent or finder other than the Broker with whom Tenant has dealt for any commission or fee alleged to be due in connection with its participation in the procurement of Tenant or the negotiation with Tenant of this Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Binding Effect</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment shall not be binding until executed and delivered by both Landlord and Tenant. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Electronic Counterparts</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment may be executed in any number of electronic (facsimile or PDF) counterparts, any one of which shall be an original, but all of which together shall be one and the same instrument.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Estoppel</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant hereby represents, warrants and agrees that: to the best of Tenant's knowledge, (i) there exists no breach, default or event of default by Landlord under the Lease, or any event or condition which, with the giving of notice or passage of time or both, would constitute a breach, default or event of default by Landlord under the Lease; (ii) the Lease continues to be a legal, valid and binding agreement and obligation of Tenant; and (iii) Tenant has no current offset or defense to its performance or obligations under the Lease. Tenant hereby waives and releases all demands, charges, claims, accounts or causes of action of any nature against Landlord or Landlord's employees or agents, including without limitation, both known and unknown demands, charges, claims, accounts, and causes of action that have previously arisen out of or in connection with the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exhibits</font><font style="color:#000000;">.&nbsp;&nbsp;Each Exhibit attached hereto is made a part hereof for all purposes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">19.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Representations</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord and Landlord's agents have made no representations or promises, express or implied, in connection with this Amendment, except as expressly set forth herein, and Tenant has not relied on any representations except as expressly set forth herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">OFAC</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant represents and warrants to Landlord that (1) Tenant is not acting, directly or indirectly, for or on behalf of any person, group, entity, or nation named by any Executive Order or the United States Treasury Department as a terrorist, "Specially Designated National," "Blocked Person," or other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule, or regulation that is enforced or administered by the Office of Foreign Assets Control; and (2) Tenant is not engaged in this transaction, directly or indirectly on behalf of, or instigating or facilitating this transaction, directly or indirectly on behalf of, any such person, group, entity or nation.&nbsp;&nbsp; Tenant agrees to defend, indemnify, and hold harmless Landlord from and against any and all claims, damages, losses, risks, liabilities, and expenses </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">(including reasonable attorney's fees and costs) arising or related to any breach of the foregoing representation and warranty.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">21.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Miscellaneous</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment sets forth the entire agreement with respect to the matters set forth herein.&nbsp;&nbsp;There have been no additional oral or written representations or agreements.&nbsp;&nbsp;As modified by this Amendment, the Lease is hereby ratified and confirmed, and shall remain in full force and effect.&nbsp;&nbsp;In the event of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall control.&nbsp;&nbsp;Headings used in this Amendment are for convenience only and shall not serve to limit, expand or otherwise alter the terms of this Amendment.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-weight:bold;font-style:italic;">remainder of page intentionally left blank; signature page follows</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.62%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.62%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant have executed this Fourth Amendment to Lease as of the date first above written.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:6.28%;"></td>
<td style="width:0.94%;"></td>
<td style="width:42.78%;"></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GRE RIVERWORKS, LLC<font style="font-weight:normal;">, a Delaware limited liability company</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/<font style="font-size:12pt;"> </font>Marija Tatic</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marija Tatic</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC.<font style="font-weight:normal;">, a Delaware corporation</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ George Elston</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George Elston</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">AMENDED EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXISTING premises</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_6_21"></a><img src="gzirfjcguvpf000001.jpg" title="" alt="" style="width:620px;height:803px;"><font style="text-decoration:none;"></font></p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended A-1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_6_22"></a><img src="gzirfjcguvpf000002.jpg" title="" alt="" style="width:620px;height:803px;"><font style="text-decoration:none;"></font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;text-transform:uppercase;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="Background-color:#FFFFFF;">Amended A-2</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT A-2</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">SECOND EXPANSION PREMISES</font></p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_6_23"></a><img src="gzirfjcguvpf000003.jpg" title="" alt="" style="width:634px;height:481px;"><font style="text-decoration:none;"></font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">A-2-1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT B-1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">WORKLETTER</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Acceptance of Premises</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Except as set forth in this Exhibit, Tenant accepts the Existing Premises and Second Expansion Premises in their &#8220;AS-IS&#8221; &#8220;WHERE IS&#8221; condition on the Effective Date.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Space Plans</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Landlord and Tenant have approved the space plan and scope notes depicting improvements to be installed in the Second Expansion Premises, which plans are attached hereto as </font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Schedule I </font><font style="font-size:11pt;color:#000000;">(the &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Space Plans</font><font style="font-size:11pt;color:#000000;">&#8221;).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Working Drawings</font><font style="font-size:11pt;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:7.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Preparation and Delivery</font>.&nbsp;&nbsp;If additional drawings are necessary, as reasonably determined by Landlord, on or before the date which is twenty (20) days after the Effective Date, Landlord shall cause to be prepared final working drawings of all improvements to be installed in the Second Expansion Premises and deliver the same to Tenant for its review and approval (which approval shall not be unreasonably withheld, delayed or conditioned).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:7.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Approval Proces</font>s. Tenant shall notify Landlord whether it approves of the submitted working drawings within three (3) business days after Landlord&#8217;s submission thereof.&nbsp;&nbsp;If Tenant disapproves of such working drawings, then Tenant shall notify Landlord thereof specifying in reasonable detail the reasons for such disapproval, in which case Landlord shall, within three (3) business days after such notice, revise such working drawings in accordance with Tenant&#8217;s objections and submit the revised working drawings to Tenant for its review and approval.&nbsp;&nbsp;Tenant shall notify Landlord in writing whether it approves of the resubmitted working drawings within one (1) business day after its receipt thereof.&nbsp;&nbsp;This process shall be repeated until the working drawings have been finally approved by Landlord and Tenant.&nbsp;&nbsp;If Tenant fails to notify Landlord that it disapproves of the initial working drawings within three (3) business days (or, in the case of resubmitted working drawings, within one (1) business day) after the submission thereof, then Tenant shall be deemed to have approved the working drawings in question.&nbsp;&nbsp;Any delay caused by Tenant&#8217;s unreasonable withholding of its consent or delay in giving its written approval as to such working drawings shall constitute a Tenant Delay Day (defined below).&nbsp;&nbsp;If the working drawings are not fully approved (or deemed approved) by both Landlord and Tenant by the 20th business day after the delivery of the initial draft thereof, then each day after such time period that such working drawings are not fully approved (or deemed approved) by both Landlord and Tenant shall constitute a Tenant Delay Day.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Landlord&#8217;s Approval; Performance of Expansion Work</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;If any of Tenant&#8217;s proposed construction work will affect the Building&#8217;s structure or the Building&#8217;s systems and equipment, then the working drawings pertaining thereto must be approved by the Building&#8217;s engineer of record.&nbsp;&nbsp;Landlord&#8217;s approval of such working drawings shall not be unreasonably withheld, provided that (a) they comply with all laws, (b) the improvements depicted thereon do not adversely affect (in the reasonable discretion of Landlord) the Building&#8217;s structure or the Building&#8217;s systems and equipment, the exterior appearance of the Building, or the appearance of the Common Areas, (c) such working drawings are sufficiently detailed to allow construction of the improvements in a good and workmanlike manner, and (d) the improvements depicted thereon conform to the rules and regulations promulgated from time to time by Landlord for the construction of tenant improvements.&nbsp;&nbsp;As used herein, &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Working Drawings</font><font style="font-size:11pt;color:#000000;">&#8221; shall mean the final working drawings approved by Landlord, as amended from time to time by any approved changes thereto, and &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Expansion Work</font><font style="font-size:11pt;color:#000000;">&#8221; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-1-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:11pt;color:#000000;">shall mean all improvements to be constructed in the Second Expansion Premises in accordance with and as indicated on the Working Drawings, together with any work required by governmental authorities to be made to other areas of the Building as a result of the improvements indicated by the Working Drawings.&nbsp;&nbsp;Landlord&#8217;s approval of the Working Drawings shall not be a representation or warranty of Landlord that such drawings are adequate for any use or comply with any law, but shall merely be the consent of Landlord thereto.&nbsp;&nbsp;Tenant shall, at Landlord&#8217;s request, sign the Working Drawings to evidence its review and approval thereof.&nbsp;&nbsp;After the Working Drawings have been approved, Landlord shall cause the Expansion Work to be performed in accordance with the Working Drawings.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Change Orders</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Tenant may initiate changes in the Expansion Work.&nbsp;&nbsp;Each such change must receive the prior written approval of Landlord, such approval not to be unreasonably withheld or delayed; however, (a) if such requested change would adversely affect (in the reasonable discretion of Landlord) (i) the Building&#8217;s structure or the Building&#8217;s systems and equipment (including the Building&#8217;s restrooms or mechanical rooms), (ii) the exterior appearance of the Building, or (iii) the appearance of the Common Areas or (b) if any such requested change might delay the Second Expansion Premises Commencement Date, Landlord may withhold its consent in its sole and absolute discretion.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Definitions</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp; As used herein, a &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Tenant Delay Day</font><font style="font-size:11pt;color:#000000;">&#8221; shall mean each day of delay in the performance of the Expansion Work that occurs: (a) because of Tenant&#8217;s failure to timely deliver or approve any required documentation such as the Working Drawings, (b) because Tenant fails to timely furnish any material information or deliver or approve any required documents such as the Working Drawings (whether preliminary, interim revisions or final), pricing estimates, construction bids, and the like, (c) because of any change to the Working Drawings, (d) because Tenant fails to attend any meeting with Landlord, the Architect, any design professional, or any contractor, or their respective employees or representatives, as may be required or scheduled hereunder or otherwise necessary in connection with the preparation or completion of any construction documents, such as the Working Drawings, or in connection with the performance of the Expansion Work, (e) because of any specification by Tenant of materials or installations in addition to or other than Landlord&#8217;s standard finish-out materials, or (f) because Tenant, its agents, employees, or contractors otherwise delay completion of the Expansion Work.&nbsp;&nbsp;As used herein &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Substantial Completion</font><font style="font-size:11pt;color:#000000;">,&#8221; &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Substantially Completed</font><font style="font-size:11pt;color:#000000;">,&#8221; and any derivations thereof mean the Expansion Work in the Second Expansion Premises is substantially completed (as reasonably determined by Landlord) in substantial accordance with the Working Drawings.&nbsp;&nbsp;Substantial Completion shall have occurred even though minor details of construction, decoration, landscaping and mechanical adjustments remain to be completed by Landlord.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Walk-Through; Punch-list</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;When Landlord considers the Expansion Work in the Second Expansion Premises to be Substantially Completed, Landlord will notify Tenant and within three (3) business days thereafter, Landlord&#8217;s representative and Tenant&#8217;s representative shall conduct a walk-through of the Second Expansion Premises and identify any necessary touch-up work, repairs and minor completion items that are necessary for final completion of the Expansion Work.&nbsp;&nbsp;Neither Landlord&#8217;s representative nor Tenant&#8217;s representative shall unreasonably withhold his or her agreement on punch-list items.&nbsp;&nbsp;Landlord shall use reasonable efforts to cause the contractor performing the Expansion Work to complete all punch-list items within thirty (30) days after agreement thereon; however, Landlord shall not be obligated to engage overtime labor in order to complete such items.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Costs</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Landlord shall bear the entire cost of performing the Expansion Work depicted on the Space Plans attached hereto that were initially submitted to and approved by Landlord.&nbsp;&nbsp;Tenant shall pay </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-1-2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:7.66%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord an amount equal to 100% of the estimated additional costs of any change to the Space Plans or the Working Drawings at the time of receipt of&nbsp;&nbsp;applicable contractor invoice for such change and any remaining costs upon Substantial Completion of the Expansion Work. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.66%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;font-size:11pt;color:#000000;">Construction Representatives</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Landlord&#8217;s and Tenant&#8217;s representatives for coordination of construction and approval of change orders will be as follows, provided that either party may change its representative upon written notice to the other:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:5.5%;width:94.5%;">
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Landlord&#8217;s Representative:</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paradigm Properties</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Tenant&#8217;s Representative:</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Maciocio</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP, Operations</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480 Pleasant Street, Suite B-300</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Watertown, MA 02472</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone: 857-341-0924</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="text-decoration:none;color:#000000;">mmaciocio@eyepointpharma.com</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:60.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_28"></a><img src="gzirfjcguvpf000004.jpg" title="" alt="" style="width:586px;height:806px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>4
<FILENAME>eypt-ex1045_1565.htm
<DESCRIPTION>EX-10.45
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex1045_1565.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-right:1.07%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.45</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 6, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VIA EMAIL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imprimis Rx, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12264 El Camino Real</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 350</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California 92130</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: John Saharek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: jsaharek@imprimisrx.com</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Re:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Commercial Alliance Agreement: Expansion of Imprimis Responsibilities</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear John:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc. (&#8220;<font style="font-weight:bold;">EyePoint</font>&#8221;) and ImprimisRx, LLC (&#8220;<font style="font-weight:bold;">Imprimis</font>&#8221;) entered into a Commercial Alliance Agreement effective as of August 1, 2020, as modified by the Letter Agreement dated November 12, 2020 (collectively, the &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;).&nbsp;&nbsp;Capitalized terms used but not defined in this letter have their respective meanings set forth in the Agreement.&nbsp;&nbsp;All changes to the Agreement described below shall be effective as of January 1, 2022 (the &#8220;<font style="font-weight:bold;">Expansion Effective Date&#8221;</font>). For good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Changes to the Agreement</font>:&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary in the Agreement, the terms of this letter describe certain provisional changes and other amendments in and to the responsibilities and obligations of the parties that will be effective from the Expansion Effective Date through December 31, 2023 (the <font style="font-weight:bold;">&#8220;Expansion Term&#8221;</font>), unless the Expansion Term is shortened or extended by mutual agreement, or as described below. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">To provide for commercial continuity in the event the pass-through period lapses and is granted during a subsequent CMS cycle, Section 13.3 will be replaced with the following text:</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">End of Pass-Through Payment Status</font><font style="color:#000000;">. If Pass-Through Payment Status ceases for a period of not less than </font><font style="color:#000000;">six</font><font style="color:#000000;"> (</font><font style="color:#000000;">6</font><font style="color:#000000;">) months, then either Party may terminate this Agreement by providing </font><font style="color:#000000;">thirty (30)</font><font style="color:#000000;"> days&#8217; prior written notice of termination to the other Party.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">During the Expansion Term:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Imprimis assumes the following responsibilities and obligations, and will indemnify and hold EyePoint harmless, pursuant to Section 12.2 of the Agreement, from and against all Liabilities resulting from any Third-Party Claim resulting from any of the following:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Full responsibility for all current Dexycu Sales, Marketing and Medical Science Liaison (MSL) functions, including compliance with all applicable laws or regulations related to such responsibilities</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:12pt;font-family:Times New Roman;color:#000000;">Exception</font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">: EyePoint marketing and MSL personnel currently dedicated to Dexycu will remain with EyePoint in new roles, but will provide 90 days of transition services from the commencement of the Expansion Term.&nbsp;&nbsp;Imprimis shall pay EyePoint for such transition services at EyePoint&#8217;s cost.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Imprimis will offer full-time employment to these current EyePoint personnel, as of the Expansion Effective Date, on equivalent or better salary, bonus, equity opportunities:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">[***]</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Imprimis will also assume full responsibility and all associated costs for the following functions pertaining to Dexycu:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Promotional Review Committee (PRC): Imprimis to work with its existing firm, rather than EyePoint&#8217;s consultant</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Compliance (Sunshine Act, SOPs, training, etc.): Imprimis to engage EyePoint&#8217;s current consultant at G&amp;M Healthcare</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Speaker Programs</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Trade Shows</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Customer Training</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">EyePoint will provide transition services to Imprimis pertaining to the above responsibilities for a mutually agreed upon period and rate of compensation to EyePoint. <br /></font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In addition, EyePoint shall provide the following services to Imprimis, at cost (payable by Imprimis to EyePoint):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Field Reimbursement and Government Pricing Management</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">HUB Management (as required)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Safety and Pharmacovigilance</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Information Technology support (as required)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Distribution Management</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">EyePoint shall retain the following responsibilities and obligations, and will indemnify and hold Imprimis harmless, pursuant to Section 12.1 of the Agreement, from and against all Liabilities resulting from any Third-Party Claim resulting from any of the following:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Manufacturing, sterilization, packaging</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Product design</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Product labeling</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Engagement of pass-through extension consultants and counsel</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">EyePoint will continue to pursue pass-through extension for Dexycu in a manner consistent with its good faith efforts to secure pass-through extension to date</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Engagement of physician consultants</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Research &amp; Development</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Reimbursement management</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Required Clinical Trials</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Including, but not limited to, the FDA-required pediatric study</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Quality</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Regulatory</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Intellectual Property protection</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Fulfillment of obligations to licensees outside of the Territory, including but not limited to, Ocumension</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">A summary of material items related to these activities will be reported through the Commercialization Committee on a monthly basis with a particular focus related to pass-through extension and label expansion activity (e.g., sNDA)</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Sales-related specifics during the Expansion Term:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The term &#8220;</font><font style="text-decoration:underline;color:#000000;">Customers</font><font style="color:#000000;">&#8221; shall mean, collectively, all customers for the Product in the Territory.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The [***] Remittance Percentage shall apply to Net Sales of the Product in the Territory</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Imprimis shall be permitted to negotiate GPO, private equity, and related contracts, subject to the following requirements:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All such contracts shall only be effective during the Expansion Term; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All contract terms that could affect ASP, such as rebates, volume discounts, assurance of commercial and Med Advantage carrier reimbursement, bundling with other products or services, etc., must be approved by EyePoint in writing in advance if such terms fall outside the parameters set forth in </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;"> attached to this letter.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Commercialization Committee shall continue to meet monthly, primarily to review and, if applicable, approve contract terms with key accounts and other matters as needed.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Audit Rights:&nbsp;&nbsp;In addition to the rights specified in Section 8.6 of the Agreement, EyePoint or its designee shall have the right, but not the obligation, during the Expansion Term and for the remainder of the Term:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">To observe directly through field rides the performance of Imprimis personnel and 1099 reps in the field, to ensure compliance with the Agreement and with the terms of this Letter.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Mandatory Milestones and Downside Protection for EyePoint; Early Termination of Expansion Term</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Imprimis shall achieve quarterly Customer demand milestones for the Product of at least [***] Dexycu units (&#8220;Minimum Quarterly Units&#8221; or &#8220;MQUs&#8221;).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Imprimis shall pay to EyePoint an annually-determined per-unit penalty for Customer demand units that fall below the MQUs, as measured on January 31, 2023 and January 31, 2024, respectively, and in the amounts set forth on </font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="color:#000000;"> attached hereto; provided however, in any event, such penalty amount shall not exceed total commissions payable by EyePoint to Imprimis for Customer demand achieved during 2022 and 2023, respectively. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">EyePoint shall have the right, but not the obligation, to terminate the Expansion Term upon 90-days written notice to Imprimis, if Imprimis fails to achieve the MQUs or to pay any applicable penalties set forth in </font><font style="text-decoration:underline;color:#000000;">Exhibit B.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Imprimis shall have the right, but not the obligation to terminate the Expansion Term upon 30 days written notice if (i) a proposed or final Hospital Outpatient Prospective </font><font style="color:#000000;">Payment</font><font style="color:#000000;"> System (HOPPS) rule issued from CMS during calendar year 2022 does not contain an extension of the Pass-Through Payment Period for Dexycu beyond December 31, 2022, and (ii) EyePoint has not otherwise waived the MQU for a quarterly period inclusive of or following the date of the proposed or final HOPPS rule described in (i) above.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Additional Terms</font>:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This letter will be governed by and construed under and in accordance with the laws of the State of Delaware, without regard to the conflicts of laws principles thereof.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless expressly modified by this Letter, all terms and conditions set forth in the Agreement shall remain in full force and effect for the duration of the Section 13.1 Term.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the foregoing is acceptable to you, please sign and return one fully-executed copy of this letter to us at your earliest convenience, which shall evidence your acknowledgement and acceptance thereto.&nbsp;&nbsp;This letter may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page Follows</font>.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Nancy Lurker</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Lurker</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President &amp; CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreed to and accepted:</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImprimisRx, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ John Saharek</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Saharek</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 6, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebate/Volume Discount Limits for 2022</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Blank_Page"></a>Downside Protection Penalties</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(EXAMPLE)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;margin-right:1.07%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>5
<FILENAME>eypt-ex1046_2496.htm
<DESCRIPTION>EX-10.46
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex1046_2496.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">E<font style="color:#auto;text-transform:none;">xhibit</font> 10.46</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">LOAN AND SECURITY AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">THIS LOAN AND SECURITY AGREEMENT<font style="font-weight:normal;"> (this &#8220;Agreement&#8221;) is dated as of the Effective Date between </font>SILICON VALLEY BANK<font style="font-weight:normal;">, a California corporation (&#8220;</font>Bank<font style="font-weight:normal;">&#8221;), and the borrowers listed on Schedule I hereto (&#8220;</font>Borrowers<font style="font-weight:normal;">&#8221; or collectively, &#8220;</font>Borrower<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;The parties agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832031"></a><font style="Background-color:#auto;text-decoration:none;">1</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">LOAN AND TERMS OF PAYMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45798597"></a><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Revolving Line.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Availability</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement and to deduction of Reserves, Bank shall make Advances not exceeding the Availability Amount.&nbsp;&nbsp;Amounts borrowed under the Revolving Line may be prepaid or repaid as set forth on Schedule I hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination; Repayment</font><font style="color:#000000;">.&nbsp;&nbsp;The Revolving Line terminates on the Revolving Line Maturity Date, when the outstanding principal amount of all Advances, the accrued and unpaid interest thereon, and all other outstanding Obligations relating to the Revolving Line shall be immediately due and payable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Term Loan.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Availability</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, upon Borrower&#8217;s request, on or about the Effective Date, Bank shall make one (1) term loan advance in an original principal amount equal to the Term Loan Availability Amount (the &#8220;</font><font style="font-weight:bold;color:#000000;">Term Loan Advance</font><font style="color:#000000;">&#8221;), provided that all or a portion of the proceeds of the Term Loan Advance shall be used to repay in full all of Borrower&#8217;s outstanding obligations and liabilities to CRG (including, without limitation, obligations and liabilities set forth in the CRG Credit Agreement).&nbsp;&nbsp;Borrower may request the Term Loan Advance as set forth on Schedule I hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Repayment</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower shall repay the Term Loan Advance as set forth in Schedule I hereto.&nbsp;&nbsp;All outstanding principal and accrued and unpaid interest under the Term Loan Advance, and all other outstanding Obligations with respect to the Term Loan Advance, are due and payable in full on the Term Loan Maturity Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45728312"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Permitted Prepayment</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower shall have the option to prepay all, but not less than all, of the Term Loan Advance, provided Borrower (i) delivers written notice to Bank of its election to prepay the Term Loan Advance at least five (5) Business Days prior to such prepayment, and (ii) pays, on the date of such prepayment (A) the outstanding principal plus accrued and unpaid interest with respect to the Term Loan Advance, (B) the Final Payment, (C) the Prepayment Fee, and (D) all other sums, if any, that shall have become due and payable with respect to the Term Loan Advance, including interest at the Default Rate with respect to any past due amounts.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45728317"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Mandatory Prepayment Upon an Acceleration</font><font style="color:#000000;">.&nbsp;&nbsp;If the Term Loan Advance is accelerated by Bank following the occurrence and during the continuance of an Event of Default, Borrower shall immediately pay to Bank an amount equal to the sum of (i) all outstanding principal plus accrued and unpaid interest with respect to the Term Loan Advance, (ii) the Final Payment, (iii) the Prepayment Fee, and (iv) all other sums, if any, that shall have become due and payable with respect to the Term Loan Advance, including interest at the Default Rate with respect to any past due amounts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref51947312"></a><a name="_Ref44345066"></a><a name="_Ref45893412"></a><a name="_Ref45792905"></a><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Overadvances.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"><a name="_Ref45792905"></a>&nbsp;&nbsp;If, at any time, the aggregate outstanding principal amount of any Advances, exceeds the lesser of (i) the Revolving Line or (ii) the Borrowing Base, Borrower shall immediately pay to Bank in cash the amount of such excess (such excess, the &#8220;</font><font style="font-family:Times New Roman;color:#000000;">Overadvance</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Without limiting Borrower&#8217;s obligation to repay Bank any Overadvance, Borrower shall pay Bank interest on the outstanding amount of any Overadvance, on demand, at a rate per annum equal to the rate that is otherwise applicable to Advances plus three percent (3.0%).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Payment of Interest on the Credit Extensions</font><font style="font-family:Times New Roman;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44417823"></a><a name="_Ref52172172"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Interest Payments</font><font style="color:#000000;"><a name="_Ref52172172"></a>. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44344211"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advances.&nbsp;&nbsp;Interest on the principal amount of each Advance is payable as set forth on Schedule I hereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Term Loan Advance.&nbsp;&nbsp;Interest on the principal amount of the Term Loan Advance is payable as set forth on Schedule I hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Interest Rate</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52172073"></a><a name="_Ref44332111"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advances.&nbsp;&nbsp;Subject to Section 1.4(c), the outstanding principal amount of any Advance shall accrue interest as set forth on Schedule I hereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Term Loan Advance.&nbsp;&nbsp;Subject to Section 1.4(c), the outstanding principal amount of any Term Loan Advance shall accrue interest as set forth on Schedule I hereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44342839"></a><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All-In Rate.&nbsp;&nbsp;Notwithstanding any terms in this Agreement to the contrary, if at any time the interest rate applicable to any Obligations is less than zero percent (0.0%), such interest rate shall be deemed to be zero percent (0.0%)<a name="_Ref44342839"></a> for all purposes of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44578688"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Default Rate</font><font style="color:#000000;">.&nbsp;&nbsp;Immediately upon the occurrence and during the continuance of an Event of Default, the outstanding Obligations shall bear interest at a rate per annum which is three percent (3.0%) above the rate that is otherwise applicable thereto (the &#8220;</font><font style="font-weight:bold;color:#000000;">Default Rate</font><font style="color:#000000;">&#8221;) unless Bank otherwise elects, in its sole and absolute discretion, to impose a lesser or no increase.&nbsp;&nbsp;Fees and expenses which are required to be paid by Borrower pursuant to the Loan Documents (including, without limitation, Bank Expenses) but are not paid when due shall bear interest until paid at a rate equal to the highest rate applicable to the Obligations.&nbsp;&nbsp;Payment or acceptance of the increased interest rate provided in this Section 1.4(c) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Adjustment to Interest Rate</font><font style="color:#000000;">.&nbsp;&nbsp;Each change in the interest rate applicable to any amounts payable under the Loan Documents based on changes to the Prime Rate shall be effective on the effective date of any change to the Prime Rate and to the extent of such change. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44341349"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Interest Computation</font><font style="color:#000000;">.&nbsp;&nbsp;Interest shall be computed as set forth on Schedule I hereto.&nbsp;&nbsp;In computing interest, the date of the making of any Credit Extension shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44602415"></a><a name="_Ref44342445"></a><font style="Background-color:#auto;text-decoration:none;">1.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Fees.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower shall pay to Bank:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Final Payment</font><font style="color:#000000;">. The Final Payment, when due hereunder, which shall be fully earned and non-refundable as of such date; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Prepayment Fee</font><font style="color:#000000;">. The Prepayment Fee, when due hereunder, which shall be fully earned and non-refundable as of such date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Fee</font><font style="color:#000000;">.&nbsp;&nbsp;Upon termination of this Agreement or the termination of the Revolving Line for any reason prior to the Revolving Line Maturity Date, in addition to the payment of any other amounts then-owing, a termination fee (the &#8220;</font><font style="font-weight:bold;color:#000000;">Termination Fee</font><font style="color:#000000;">&#8221;) in an amount equal to (i) three percent (3.0%) of the Revolving Line if such termination occurs prior to the first anniversary of the Effective Date, or (ii) one percent (1.0%) of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Revolving Line if such termination occurs on or at any time after the first anniversary of the Effective Date, which shall be fully earned and non-refundable as of such date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45728192"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Unused Revolving Line Facility Fee</font><font style="color:#000000;">.&nbsp;&nbsp;Payable quarterly in arrears on the last calendar day of each calendar quarter occurring prior to the Revolving Line Maturity Date, and on the Revolving Line Maturity Date, a fee (the &#8220;</font><font style="font-weight:bold;color:#000000;">Unused Revolving Line Facility Fee</font><font style="color:#000000;">&#8221;) in an amount equal to one-quarter of one percent (0.25%) per annum of the average unused portion of the Revolving Line, as determined by Bank, computed on the basis of a year with the applicable number of days as set forth in Section 1.2(e), which shall be fully earned and non-refundable as of such date.&nbsp;&nbsp;The unused portion of the Revolving Line, for purposes of this calculation, shall be calculated on a calendar year basis and shall equal the difference between (i) the Revolving Line, and (ii) the average for the period of the daily closing balance of the Revolving Line outstanding; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Bank Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;All Bank Expenses incurred through and after the Effective Date, when due (or, if no stated due date, upon demand by Bank).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise provided in this Agreement or in a separate writing by Bank, Borrower shall not be entitled to any credit, rebate, or repayment of any fees earned by Bank pursuant to this Agreement, notwithstanding any termination of this Agreement or the suspension or termination of Bank&#8217;s obligation to make loans and advances hereunder.&nbsp;&nbsp;Bank may deduct amounts owing by Borrower under the clauses of this Section 1.5 pursuant to the terms of Section 1.6(c).&nbsp;&nbsp;Bank shall provide Borrower written notice of deductions made pursuant to the terms of the clauses of this Section 1.5.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Payments; Application of Payments; Debit of Accounts.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All payments (including prepayments) to be made by Borrower under any Loan Document shall be made in immediately available funds in Dollars, without setoff, counterclaim, or deduction, before 12:00 p.m. Eastern time on the date when due.&nbsp;&nbsp;Payments of principal and/or interest received after 12:00 p.m. Eastern time are considered received at the opening of business on the next Business Day.&nbsp;&nbsp;When a payment is due on a day that is not a Business Day, the payment shall be due the next Business Day, and additional fees or interest, as applicable, shall continue to accrue until paid.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Bank has the exclusive right to determine the order and manner in which all payments with respect to the Obligations may be applied.&nbsp;&nbsp;Borrower shall have no right to specify the order or the accounts to which Bank shall allocate or apply any payments required to be made by Borrower to Bank or otherwise received by Bank under this Agreement when any such allocation or application is not specified elsewhere in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44342455"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Bank may debit any of Borrower&#8217;s deposit accounts maintained with Bank, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrower owes Bank when due under the Loan Documents.&nbsp;&nbsp;These debits shall not constitute a set-off.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref91498230"></a><a name="_Ref44600793"></a><font style="Background-color:#auto;text-decoration:none;">1.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Change in Circumstances.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Increased Costs</font><font style="color:#000000;">.&nbsp;&nbsp;If any Change in Law shall: (i) impose, modify, or deem applicable any reserve, special deposit, compulsory loan, insurance charge, or similar requirement against assets of, deposits with or for the account of, or advances, loans, or other credit extended or participated in by, Bank, (ii) subject Bank to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes, and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitment, or other obligations, or its deposits, reserves, other liabilities, or capital attributable thereto, or (iii) impose on Bank any other condition, cost, or expense (other than Taxes) affecting this Agreement or Credit Extensions made by Bank, and the result of any of the foregoing shall be to increase the cost to Bank of making, converting to, continuing, or maintaining any Credit Extension (or of maintaining its obligation to make any such Credit Extension), or to reduce the amount of any sum received or receivable by Bank hereunder (whether of principal, interest, or any other amount) then, upon written request of Bank, Borrower shall promptly pay to Bank such additional amount or amounts as will compensate Bank for such additional costs incurred or reduction suffered.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Capital Requirements</font><font style="color:#000000;">.&nbsp;&nbsp;If Bank determines that any Change in Law affecting Bank regarding capital or liquidity requirements, has or would have the effect of reducing the rate of return on Bank&#8217;s capital as a consequence of this Agreement, </font><font style="color:#000000;">the Revolving Line, </font><font style="color:#000000;">any term loan facility, or the </font><font style="color:#000000;">Credit Extensions </font><font style="color:#000000;">made by Bank to a level below that which Bank could have achieved but for such Change in Law (taking into consideration Bank&#8217;s policies with respect to capital adequacy and liquidity), then from time to time upon written request of Bank, Borrower shall promptly pay to Bank such additional amount or amounts as will compensate Bank for any such reduction suffered.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Delay in Requests</font><font style="color:#000000;">.&nbsp;&nbsp;Failure or delay on the part of Bank to demand compensation pursuant to this Section 1.7 shall not constitute a waiver of Bank&#8217;s right to demand such compensation; provided that Borrower shall not be required to compensate Bank pursuant to subsection (a) for any increased costs incurred or reductions suffered more than nine (9) months prior to the date that Bank notifies Borrower of the Change in Law giving rise to such increased costs or reductions (except that if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine (9)-month period shall be extended to include the period of retroactive effect).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52171839"></a><font style="Background-color:#auto;text-decoration:none;">1.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Taxes.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payments Free of Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;Any and all payments by or on account of any obligation of Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by Applicable Law.&nbsp;&nbsp;If any Applicable Law (as determined in the good-faith discretion of Borrower) requires the deduction or withholding of any Tax from any such payment by Borrower, then (i)&#160;Borrower shall be entitled to make such deduction or withholding, (ii)&#160;Borrower shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law, and (iii) if such Tax is an Indemnified Tax, the sum payable by Borrower shall be increased as necessary so that, after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 1.8), Bank receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payment of Other Taxes by Borrower</font><font style="color:#000000;">.&nbsp;&nbsp;Without limiting the provisions of subsection&#160;(a) above, Borrower shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with Applicable Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Indemnification</font><font style="color:#000000;">.&nbsp;&nbsp;Without limiting the provisions of subsections (a) and (b) above, Borrower shall, and does hereby, indemnify Bank, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section&#160;1.8) payable or paid by Bank or required to be withheld or deducted from a payment to Bank and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.&nbsp;&nbsp;A certificate as to the amount of such payment or liability delivered to Borrower by Bank shall be conclusive absent manifest error.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref87253486"></a><a name="_Ref22361183"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Evidence of Payments</font><font style="color:#000000;">.&nbsp;&nbsp;As soon as practicable after any payment of Taxes by Borrower to a Governmental Authority pursuant to this Section&#160;1.8, Borrower shall deliver to Bank a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment, or other evidence of such payment reasonably satisfactory to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54873920"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Status of Bank</font><font style="color:#000000;">.&nbsp;&nbsp;If Bank (including any assignee or successor) is entitled to an exemption from or reduction of withholding tax with respect to payments made under any Loan Document, Bank shall deliver to Borrower, at the time or times reasonably requested by Borrower, such properly completed and executed documentation reasonably requested by Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding.&nbsp;&nbsp;In addition, Bank, if reasonably requested by Borrower, shall deliver such other documentation prescribed by Applicable Law or reasonably requested by Borrower as will enable Borrower to determine whether or not Bank is subject to backup withholding or information reporting requirements.&nbsp;&nbsp;Without limiting the generality of the foregoing, Bank shall deliver whichever of IRS Form W-9, IRS Form W-8BEN-E, IRS Form W-8ECI or W-8IMY is applicable, as well as any applicable supporting documentation or certifications. If a payment made to Bank under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if Bank were to fail to comply with the applicable reporting requirements of FATCA (including those </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">contained in Section 1471(b) or 1472(b) of the Internal Revenue Code, as applicable), Bank shall deliver to Borrower at the time or times prescribed by law and at such time or times reasonably requested by Borrower such documentation prescribed by Applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code) and such additional documentation reasonably requested by Borrower as may be necessary for Borrower to comply with its obligations under FATCA and to determine that Bank has complied with Bank&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of the preceding sentence, &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Treatment of Certain Refunds</font><font style="color:#000000;">. If Bank determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section (including by the payment of additional amounts pursuant to this Section), it shall pay to Borrower an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of Bank and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Borrower, upon the request of Bank, shall repay to Bank the amount paid over pursuant to this paragraph (f) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that Bank is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (f), in no event will Bank be required to pay any amount to Borrower pursuant to this paragraph (f) the payment of which would place Bank in a less favorable net after-Tax position than Bank would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require Bank to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to Borrower or any other Person. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45892711"></a><font style="Background-color:#auto;text-decoration:none;">1.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Procedures for Borrowing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Advances</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the prior satisfaction of all other applicable conditions to the making of an Advance set forth in this Agreement (which must be satisfied no later than 12:00 p.m. Eastern time on the applicable Funding Date), to obtain an Advance Borrower (via an individual duly authorized by an Administrator) shall notify Bank (which notice shall be irrevocable) by 12:00 p.m. Eastern time on the Funding Date of the Advance.&nbsp;&nbsp;Such notice shall be made through Bank&#8217;s online banking program, provided, however, if Borrower is not utilizing Bank&#8217;s online banking program, then such notice shall be in a written format acceptable to Bank that is executed by an Authorized Signer.&nbsp;&nbsp;In connection with any such notification, Borrower shall deliver to Bank by electronic mail or through Bank&#8217;s online banking program such reports and information, including without limitation, sales journals, cash receipts journals, accounts receivable aging reports, as Bank may reasonably request.&nbsp;&nbsp;Bank shall have received satisfactory evidence that the Board has approved that such Authorized Signer may provide such notices and request Advances (which requirement may be deemed satisfied by the prior delivery of Borrowing Resolutions or a secretary&#8217;s certificate that certifies as to such Board approval).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term Loan Advance</font><font style="color:#000000;">. Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan Advance set forth in this Agreement (which must be satisfied no later than 12:00 p.m. Eastern time on the applicable Funding Date), to obtain a Term Loan Advance, Borrower shall notify Bank (which notice shall be irrevocable) by 12:00 p.m. Eastern time at least 2 Business Days prior to the proposed Funding Date of the Term Loan Advance.&nbsp;&nbsp;Such notice shall be made by electronic mail or by telephone and, together with any such notification, Borrower shall deliver to Bank by electronic mail a completed Payment/Advance Form executed by an Authorized Signer and such other reports and information as Bank may reasonably request.&nbsp;&nbsp;Bank may rely on any telephone notice given by a person whom Bank believes is an Authorized Signer.&nbsp;&nbsp;Borrower will indemnify Bank for any loss Bank suffers due to such belief or reliance. Bank shall have received satisfactory evidence that the Board has approved that such Authorized Signer may provide such notices and request the Term Loan Advance (which requirement may be deemed satisfied by the prior delivery of Borrowing Resolutions or a secretary&#8217;s certificate that certifies as to such Board approval).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Bank shall credit proceeds of a Credit Extension to the Designated Deposit Account.&nbsp;&nbsp;Bank may make Advances or the Term Loan Advance under this Agreement based on instructions from an Authorized Signer or without instructions if such the Credit Extension is necessary to meet Obligations which have become due. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">CONDITIONS OF CREDIT EXTENSIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Conditions Precedent to Initial Credit Extension.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Bank&#8217;s obligation to make the initial Credit Extension is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, such documents, and completion of such other matters, as Bank may have reasonably requested, including, without limitation:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">duly executed Loan Documents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">duly executed Control Agreements as required by Bank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) the Operating Documents of each Borrower, and (ii) (A) good standing certificates of each Borrower certified by the Secretary of State of the State of Delaware, (B) a good standing/foreign qualification certificate of Parent certified by the Secretary of State of the Commonwealth of Massachusetts, and (C) good standing/foreign qualification certificates of Icon and EyePoint US certified by the Secretary of State (or equivalent agency) of each other jurisdiction in which Icon and EyePoint US are qualified to conduct business; in each case, as of a date no earlier than 30 days prior to the Effective Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">certificate duly executed by a Responsible Officer or secretary of each Borrower with respect to Borrower&#8217;s (i) Operating Documents and (ii) Borrowing Resolutions;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">duly executed payoff letter from CRG Servicing LLC (&#8220;</font><font style="font-weight:bold;color:#000000;">CRG</font><font style="color:#000000;">&#8221;);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">evidence that (i) the Liens securing Indebtedness owed by Borrower to CRG; will be terminated and (ii) the documents and/or filings evidencing the perfection of such Liens, including without limitation any financing statements and/or control agreements, have or will, concurrently with the initial Credit Extension, be terminated;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">certified copies, dated as of a recent date, of searches for financing statement filed in the central filing office of the State of Delaware, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">duly executed Perfection Certificate of each Borrower;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">duly executed signature to the Stock Pledge Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a legal opinion of Borrower&#8217;s counsel dated as of the Effective Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">evidence satisfactory to Bank that the insurance policies required by Section 5.8 hereof are in full force and effect; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">payment of the fees and Bank Expenses then due as specified in Section 1.5 hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Conditions Precedent to all Credit Extensions.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Bank&#8217;s obligation to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">receipt of Borrower&#8217;s Credit Extension request and the related materials and documents as required by and in accordance with Section 1.9;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the representations and warranties in this Agreement shall be true and correct in all material respects as of the date of any Credit Extension request&nbsp;&nbsp;and as of the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true and correct in all material respects as of such date, and no Default or Event of Default shall have occurred and be continuing or result from the Credit Extension.&nbsp;&nbsp;Each Credit Extension is Borrower&#8217;s representation and warranty on that date that the representations and warranties in this Agreement remain true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">expressly referring to a specific date shall be true and correct in all material respects as of such date; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a Material Adverse Change shall not have occurred and be continuing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Covenant to Deliver.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower shall deliver to Bank each item required to be delivered to Bank under this Agreement as a condition precedent to any Credit Extension.&nbsp;&nbsp;A Credit Extension made prior to the receipt by Bank of any such item shall not constitute a waiver by Bank of Borrower&#8217;s obligation to deliver such item, and the making of any Credit Extension in the absence of a required item shall be in Bank&#8217;s sole discretion.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">CREATION OF SECURITY INTEREST</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45640207"></a><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Grant of Security Interest.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower hereby grants Bank, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Bank, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower acknowledges that it previously has entered, or may in the future enter, into Bank Services Agreements with Bank.&nbsp;&nbsp;Regardless of the terms of any Bank Services Agreement, Borrower agrees that any amounts Borrower owes Bank thereunder shall be deemed to be Obligations hereunder and that it is the intent of Borrower and Bank to have all such Obligations secured by the first priority perfected security interest in the Collateral granted herein (subject to Permitted Liens).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Authorization to File Financing Statements.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower hereby authorizes Bank to file financing statements, without notice to Borrower, with all jurisdictions deemed necessary or appropriate by Bank to perfect or protect Bank&#8217;s interest or rights hereunder, including a notice that any disposition of the Collateral, by Borrower or any other Person, shall be deemed to violate the rights of Bank under the Code.&nbsp;&nbsp;Such financing statements may indicate the Collateral as &#8220;all assets of the Debtor&#8221; or words of similar effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Termination</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;If this Agreement is terminated, Bank&#8217;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations or other obligations which by their terms, survive termination of this Agreement) are repaid in full in cash.&nbsp;&nbsp;Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations or other obligations which by their terms, survive termination of this Agreement) and at such time as Bank&#8217;s obligation to make Credit Extensions has terminated, Bank shall, at Borrower&#8217;s sole cost and expense, terminate its security interest in the Collateral and all rights therein shall revert to Borrower, and Bank shall take such actions as may be reasonably requested by Borrower to evidence such repayment and release (including delivery of a payoff letter, filing of UCC-3 termination statements (or authorizing Borrower to file such UCC-3 termination statements) and delivering possessory Collateral in Bank&#8217;s possession to Borrower) and all of Borrower&#8217;s obligations pursuant to Sections 5 and 6 herein shall terminate. Furthermore, in connection with a Transfer permitted under this Agreement Bank shall take such actions as may be reasonably requested by Borrower to evidence such release (including filing of UCC-3 termination statements (or authorizing Borrower to file such UCC-3 termination statements)). In the event (a) all Obligations (other than inchoate indemnity obligations or other obligations which by their terms, survive termination of this Agreement), except for Bank Services, are satisfied in full, and (b) this Agreement is terminated, Bank shall terminate the security interest granted herein upon Borrower providing cash collateral acceptable to Bank in its sole discretion for Bank Services, if any.&nbsp;&nbsp;In the event such Bank Services consist of outstanding Letters of Credit, Borrower shall provide to Bank cash collateral in an amount equal to at least (x) 105.0% of the face amount of all such Letters of Credit denominated in Dollars and (y) 115.0% of the Dollar Equivalent of the face amount of all such Letters of Credit denominated in a Foreign Currency, plus, in each case, all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">interest, fees, and costs due or estimated by Bank to become due in connection therewith, to secure all of the Obligations relating to such&nbsp;&nbsp;Letters of Credit.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45545764"></a><font style="Background-color:#auto;text-decoration:none;">4</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">REPRESENTATIONS AND WARRANTIES</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrower represents and warrants as follows: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Due Organization, Authorization; Power and Authority.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower and each of its Subsidiaries are each duly existing and in good standing as a Registered Organization in their respective jurisdiction of formation and are qualified and licensed to do business and are in good standing in any jurisdiction in which the conduct of their respective business or their ownership of property requires that they be qualified, except where the failure to do so could not reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries is true and correct in all material respects (it being understood and agreed that Borrower may from time to time update certain information in the Perfection Certificate after the Effective Date to the extent permitted by one or more specific provisions in this Agreement and the Perfection Certificate shall be deemed to be updated to the extent such notice is provided to Bank of such permitted update).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The execution, delivery, and performance by Borrower and each of its Subsidiaries of the Loan Documents to which they are parties have been duly authorized, and do not (i) conflict with any of Borrower&#8217;s or any such Subsidiary&#8217;s organizational documents, (ii) contravene, conflict with, constitute a default under, or violate any material Applicable Law, (iii) contravene, conflict with, or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect), or (v) conflict with, contravene, constitute a default or breach under, or result in or permit the termination or acceleration of, any material agreement by which Borrower or any of its Subsidiaries is bound.&nbsp;&nbsp;Neither Borrower nor any of its Subsidiaries are in default under any agreement to which they are parties or by which it is bound in which the default could reasonably be expected to have a material adverse effect on Borrower&#8217;s or any of its Subsidiary&#8217;s business or operations.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Collateral.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral (subject to Permitted Liens).&nbsp;&nbsp;Borrower has good title to, rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens except Permitted Liens.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower has no Collateral Accounts at or with any bank or financial institution other than Bank or Bank&#8217;s Affiliates except for the Collateral Accounts described in the Perfection Certificate delivered to Bank in connection herewith and which Borrower has taken such actions as are necessary to give Bank a perfected security interest therein, pursuant to the terms of Section 5.9(c).&nbsp;&nbsp;The Accounts are bona fide, existing obligations of the Account Debtors.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Collateral is not in the possession of any third-party bailee (such as a warehouse) except as otherwise provided in the Perfection Certificate or as permitted pursuant to Section 6.2.&nbsp;&nbsp;None of the components of the Collateral shall be maintained at locations other than as provided in the Perfection Certificate or as permitted pursuant to Section 6.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All Inventory is in all material respects of good and marketable quality, free from material defects (other than resulting from any casualty or any taking under power of eminent domain or by condemnation).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower owns, or possesses the right to use to the extent necessary in its business, all Intellectual Property, licenses</font><font style="color:#000000;">,</font><font style="color:#000000;"> and other intangible assets that are used in the conduct of its business as now operated, except to the extent that such failure to own or possess the right to use such asset would not reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations, and no such asset, to the best knowledge of Borrower, conflicts with the valid Intellectual Property, license, or intangible asset of any other Person to the extent that such conflict could reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as noted on the Perfection Certificate or for which notice has been given to Bank pursuant to and in accordance with Section 5.11(b), Borrower is not a party to, nor is it bound by, any Restricted License.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45727570"></a><font style="Background-color:#auto;text-decoration:none;">4.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Accounts Receivable.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For each Account included in the most recent Borrowing Base Statement, on the date each Advance is requested and made, such Account shall be an Eligible Account.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All statements made and all unpaid balances appearing in all invoices, instruments and other documents evidencing the Eligible Accounts are and shall be true and correct in all material respsects and all such invoices, instruments and other documents, and all of Borrower&#8217;s Books are genuine and in all respects what they purport to be.&nbsp;&nbsp;All sales and other transactions underlying or giving rise to each Eligible Account shall comply in all material respects with all Applicable Law.&nbsp;&nbsp;Borrower has no knowledge of any actual or imminent Insolvency Proceeding of any Account Debtor whose accounts are Eligible Accounts in the then applicable Borrowing Base Statement. To the best of Borrower&#8217;s knowledge, all signatures and endorsements on all documents, instruments, and agreements relating to all Eligible Accounts are genuine, and all such documents, instruments and agreements are legally enforceable in accordance with their terms.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Litigation. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> Other than as set forth in the Perfection Certificate or as disclosed to Bank pursuant to Section 5.3(j), there are no actions, investigations or proceedings pending or, to the knowledge of any Responsible Officer, threatened in writing by or against Borrower or any of its Subsidiaries involving more than, individually or in the aggregate, $250,000.00 not covered by independent third party insurance as to which liability has been accepted by the carrier providing such insurance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Financial Statements; Financial Condition. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> All consolidated financial statements for Borrower and any of its Subsidiaries delivered to Bank by submission to the Financial Statement Repository or otherwise submitted to Bank fairly present in all material respects Borrower&#8217;s consolidated financial condition and Borrower&#8217;s consolidated results of operations for the periods covered thereby, subject, in the case of unaudited financial statements, to normal year-end adjustments and the absence of footnote disclosures.&nbsp;&nbsp;There has not been any material deterioration in Borrower&#8217;s consolidated financial condition since the date of the most recent financial statements submitted to the Financial Statement Repository or otherwise submitted to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634412"></a><font style="Background-color:#auto;text-decoration:none;">4.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Solvency.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;The fair salable value of Borrower&#8217;s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of Borrower&#8217;s liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement; and Borrower and each of its Subsidiaries are able to pay their debts (including trade debts) as they mature.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Regulatory Compliance</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Borrower is not an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.&nbsp;&nbsp;Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).&nbsp;&nbsp;Borrower and each of its Subsidiaries (a) have complied in all material respects with all Applicable Law, and (b) have not violated any Applicable Law the violation of which could reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations.&nbsp;&nbsp;Borrower and each of its Subsidiaries have duly complied with, and their respective facilities, business, assets, property, leaseholds, real property and Equipment are in compliance with, Environmental Laws, except where the failure to do so could not reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations; there have been no outstanding citations, notices or orders of non-compliance issued to Borrower or any of its Subsidiaries or relating to their respective facilities, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">businesses, assets, property, leaseholds, real property or Equipment under such Environmental Laws</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">except where </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">the</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">same would not reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Borrower and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted, except where the failure to obtain or make or file the same would not reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Subsidiaries; Investments.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower does not own any stock, partnership, or other ownership interest or other equity securities except for Permitted Investments.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45891453"></a><font style="Background-color:#auto;text-decoration:none;">4.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Tax Returns and Payments; Pension Contributions.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45540756"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower and each of its Subsidiaries have timely filed (subject to validly filed extensions), or submitted extensions for, all required tax returns and reports, and Borrower and each of its Subsidiaries have timely paid all foreign, federal, state and local taxes, assessments, deposits, and contributions owed by Borrower and each of its Subsidiaries except (a) to the extent such taxes are being contested in good faith by appropriate proceedings promptly instituted and diligently conducted, so long as such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall have been made therefor, or (b) if such taxes, assessments, deposits, and contributions do not, individually or in the aggregate, exceed $50,000.00.&nbsp;&nbsp;Borrower is unaware of any claims or adjustments proposed for any of Borrower&#8217;s or any of its Subsidiary&#8217;s prior tax years which could result in additional taxes becoming due and payable by Borrower or any of its Subsidiaries in excess of $50,000.00 in the aggregate.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing, and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries has withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832329"></a><font style="Background-color:#auto;text-decoration:none;">4.10</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Full Disclosure. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> No written representation, warranty, or other statement of Borrower or any of its Subsidiaries in any report, certificate, or written statement submitted to the Financial Statement Repository or otherwise submitted to Bank, as of the date such representation, warranty, or other statement was made, taken together with all such reports, certificates, and written statements submitted to the Financial Statement Repository or otherwise submitted to Bank, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the reports, certificates, or written statements not misleading in light of the circumstances under which they were made (it being recognized by Bank that the projections and forecasts provided by Borrower or any of its Subsidiaries in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref91596469"></a><font style="Background-color:#auto;text-decoration:none;">4.11</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Sanctions</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Neither Borrower nor any of its Subsidiaries is: (a) in violation of any Sanctions; or (b) a Sanctioned Person.&nbsp;&nbsp;Neither Borrower nor any of its Subsidiaries, directors, or officers, or, to the knowledge of Borrower, any of its employees, agents, or Affiliates: (i) conducts any business or engages in any transaction or dealing with any Sanctioned Person, including making or receiving any contribution of funds, goods, or services to or for the benefit of any Sanctioned Person; (ii) deals in, or otherwise engages in any transaction relating to, any property or interests in property blocked pursuant to any Sanctions; (iii) engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Sanctions; or (iv) otherwise engages in any transaction that could cause Bank to violate any Sanctions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45800049"></a><font style="Background-color:#auto;text-decoration:none;">5</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">AFFIRMATIVE COVENANTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrower shall do all of the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45633681"></a><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Use of Proceeds.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Cause the proceeds of the Credit Extensions to be used solely (a) as working capital or (b) to fund its general business purposes, and not for personal, family, household or agricultural purposes.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45633696"></a><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Government Compliance.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Maintain its and all of its Subsidiaries&#8217; legal existence (except as permitted under Section 6.3 with respect to Subsidiaries only) and good standing in their respective jurisdictions of formation and maintain qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations.&nbsp;&nbsp;Borrower shall comply, and have each Subsidiary comply, in all material respects, with all laws, ordinances and regulations to which it is subject, the failure to comply with which could reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Obtain all of the Governmental Approvals necessary for the performance by Borrower and each of its Subsidiaries of their obligations under the Loan Documents to which they are parties, including any grant of a security interest to Bank in the Collateral.&nbsp;&nbsp;Borrower shall, upon Bank&#8217;s reasonable request, promptly provide copies of any such obtained Governmental Approvals to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45545721"></a><font style="Background-color:#auto;text-decoration:none;">5.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Financial Statements, Reports. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> Deliver to Bank by submitting to the Financial Statement Repository:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44075387"></a><a name="_Ref44429960"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Borrowing Base Statement.</font><font style="color:#000000;">&nbsp;&nbsp;A Borrowing Base Statement (and any schedules related thereto and including any other information requested by Bank with respect to Borrower&#8217;s Accounts) within 30 days after the end of each month;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Accounts Receivable Information</font><font style="color:#000000;">.&nbsp;&nbsp;Within 30 days after the end of each month, (A) monthly accounts receivable agings, aged by invoice date, (B) monthly accounts payable agings, aged by invoice date, if any, (C) monthly reconciliations of accounts receivable agings (aged by invoice date), and an accounts receivable general ledger and (D) a deferred revenue report, in form an substance satisfactory to Bank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Monthly Compliance Statement</font><font style="color:#000000;">.&nbsp;&nbsp;Within 30 days after the last day of each month, a duly completed Compliance Statement, confirming that as of the end of such month, Borrower was in full compliance with all of the terms and conditions of this Agreement, and setting forth calculations showing compliance with the financial covenants set forth in this Agreement and such other information as Bank may reasonably request; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref91760779"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">10-Q reports</font><font style="color:#000000;">.&nbsp;&nbsp;Within 45 days after the end of the first three fiscal quarters of Borrower, a company prepared consolidated balance sheet and income statement covering Borrower&#8217;s consolidated operations for such quarter, consistent with such quarterly financial statements submitted to the SEC, in a form of presentation acceptable to Bank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Annual Operating Budget and Financial Projections</font><font style="color:#000000;">.&nbsp;&nbsp;As soon as available, and in any event within 90 days after the last day of each fiscal year of Borrower, and contemporaneously with any updates or amendments thereto, (A) annual operating budgets (including income statements, balance sheets and cash flow statements, by month) for the current fiscal year of Borrower, and (B) annual financial projections for the current fiscal year (on a quarterly basis), in each case as approved by the Board, together with any related business forecasts used in the preparation of such annual financial projections;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">10-K Reports and Annual Audited Financial Statements</font><font style="color:#000000;">.&nbsp;&nbsp;As soon as available, and in any event within 90 days following the end of Borrower&#8217;s fiscal year, Borrower&#8217;s 10-K report, together with audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion (provided that such unqualified opinion may contain a going concern qualification typical for venture backed companies similar to Borrower) on the financial statements from Deloitte LLP, any &#8220;Big 4&#8221; accounting firm, or any other independent certified public accounting firm reasonably acceptable to Bank</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45197329"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">SEC Filings</font><font style="color:#000000;">.&nbsp;&nbsp;Within five (5) days of filing, notification of the filing and copies of all periodic and other reports, proxy statements and other materials filed by Borrower and/or any of its Subsidiaries or any Guarantor with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC, or with any national securities exchange, or distributed to its shareholders, as the case may be.&nbsp;&nbsp;Documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower or any of its Subsidiaries posts such documents, or provides a link thereto, on Borrower&#8217;s or any of its Subsidiaries&#8217; website on the internet at Borrower&#8217;s or any of its Subsidiaries&#8217; website address; provided, however, Borrower shall promptly notify Bank in writing (which may be by electronic mail) of the posting of any such documents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Security Holder and Subordinated Debt Holder Reports</font><font style="color:#000000;">.&nbsp;&nbsp;Within five (5) days of delivery, copies of all material statements, reports, and notices made available to Borrower&#8217;s security holders or to any holders of Subordinated Debt (solely in their capacities as security holders or holders of Subordinated Debt and not in any other role);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Beneficial Ownership Information</font><font style="color:#000000;">. Concurrently with delivery of the Compliance Statement pursuant to Section 5.3(c), written notice of any changes to the beneficial ownership information set out in Section 14 of the Perfection Certificate.&nbsp;&nbsp;Borrower understands and acknowledges that Bank relies on such true, accurate, and up-to-date beneficial ownership information to meet Bank&#8217;s regulatory obligations to obtain, verify, and record information about the beneficial owners of its legal entity customers;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45539781"></a><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Legal Action Notice</font><font style="color:#000000;">.&nbsp;&nbsp;Concurrently with delivery of the Compliance Statement pursuant to Section 5.3(c), written notice of any legal actions, investigations or proceedings pending or threatened in writing against Borrower or any of its Subsidiaries that could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of, individually or in the aggregate, $250,000.00 or more; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tort Claim Notice</font><font style="color:#000000;">.&nbsp;&nbsp;If Borrower shall acquire a commercial tort claim with a value of $250,000.00 or more, Borrower shall promptly notify Bank in a writing signed by Borrower of the general details thereof, and grant to Bank in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Bank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Government Filings</font><font style="color:#000000;">.&nbsp;&nbsp;Within ten (10) Business Days after the same are sent or received, copies of all material correspondence, reports, documents, and other filings by Borrower or any of its Subsidiaries with any Governmental Authority regarding compliance with or maintenance of Governmental Approvals or Applicable Law or that could reasonably be expected to have a material effect on any of the Governmental Approvals or otherwise on the business of Borrower or any of its Subsidiaries; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Registered Organization</font><font style="color:#000000;">.&nbsp;&nbsp;If Borrower is not a Registered Organization as of the Effective Date but later becomes one, promptly notify Bank of such occurrence and provide Bank with Borrower&#8217;s organizational identification number; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Default</font><font style="color:#000000;">.&nbsp;&nbsp;Prompt written notice of the occurrence of a Default or Event of Default; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Other Information</font><font style="color:#000000;">.&nbsp;&nbsp;Promptly, from time to time, such other information regarding Borrower or any of its Subsidiaries or compliance with the terms of any Loan Documents as reasonably requested by Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any submission by Borrower of a Compliance Statement, Borrowing Base Statement, or any other financial statement submitted to the Financial Statement Repository pursuant to this Section 5.3 or otherwise submitted to Bank shall be deemed to be a representation by Borrower that (i) as of the date of such Compliance Statement, Borrowing Base Statement, or other financial statement, the information and calculations set forth therein are true and correct, (ii) as of the end of the compliance period set forth in such submission, Borrower is in compliance with all required covenants except as noted in such Compliance Statement, Borrowing Base Statement,  or other financial statement, as applicable, (iii) as of the date of such submission, no Events of Default have occurred or are continuing, (iv) all representations and warranties other than any representations or warranties that are made as of a specific date in Section 4 remain true and correct in all material respects as of the date of such submission except as noted in such Compliance Statement, Borrowing Base Statement, or other financial statement, as applicable, (v) as of the date of such submission, Borrower and each of its Subsidiaries has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitted pursuant to the terms of Section</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 5.6(a)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and (vi) as of the date of such submission, no Liens have been levied or claims made against Borrow</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er or any of its Subsidiaries </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating to unpaid employee payroll or benefits of which Borrower has not previously provided wr</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">itten notification to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45724414"></a><a name="_Ref45549674"></a><font style="Background-color:#auto;text-decoration:none;">5.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Accounts Receivable</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832102"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Schedules and Documents Relating to Accounts</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower shall deliver to Bank transaction reports and schedules of collections, as provided in Section 5.3, on Bank&#8217;s standard forms; provided, however, that Borrower&#8217;s failure to execute and deliver the same shall not affect or limit Bank&#8217;s Lien and other rights in all of Borrower&#8217;s Accounts, nor shall Bank&#8217;s failure to advance or lend against a specific Account affect or limit Bank&#8217;s Lien and other rights therein.&nbsp;&nbsp;If requested by Bank, Borrower shall furnish Bank with copies (or, at Bank&#8217;s request, originals) of all contracts, orders, invoices, and other similar documents, and all shipping instructions, delivery receipts, bills of lading, and other evidence of delivery, for any goods the sale or disposition of which gave rise to such Accounts.&nbsp;&nbsp;In addition, Borrower shall deliver to Bank, on its request, the originals of all instruments, chattel paper, security agreements, guarantees and other documents and property evidencing or securing any Accounts, in the same form as received, with all necessary indorsements, and copies of all credit memos.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disputes</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower shall promptly, but no later than with the then next-due Compliance Statement pursuant to Section 5.3(c), notify Bank of all disputes or claims relating to Accounts in excess of $100,000.00 individually, or $200,000.00 in the aggregate.&nbsp;&nbsp;Borrower may forgive (completely or partially), compromise, or settle any Account for less than payment in full, or agree to do any of the foregoing so long as (i) Borrower does so in good faith, in a commercially reasonable manner, in the ordinary course of business, in arm&#8217;s-length transactions, and reports the same to Bank in the regular reports provided to Bank; (ii) no Event of Default has occurred and is continuing; and (iii) there shall not be an Overadvance after taking into account all such discounts, settlements and forgiveness.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45550181"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Collection of Accounts</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower shall direct Account Debtors to deliver or transmit all proceeds of Accounts into a lockbox account, or such other &#8220;blocked account&#8221; as specified by Bank (either such account, the &#8220;</font><font style="font-weight:bold;color:#000000;">Cash Collateral Account</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Whether or not an Event of Default has occurred and is continuing, Borrower shall promptly deliver all payments on and proceeds of Accounts to the Cash Collateral Account.&nbsp;&nbsp;Subject to Bank&#8217;s right to maintain a reserve pursuant to Section 5.4(d), all amounts received in the Cash Collateral Account shall be applied to immediately reduce the Obligations under the Revolving Line (unless Bank, in its sole discretion, at times when an Event of Default exists, elects not to so apply such amounts). Borrower hereby authorizes Bank to transfer to the Cash Collateral Account any amounts that Bank reasonably determines are proceeds of the Accounts (provided that Bank is under no obligation to do so and this allowance shall in no event relieve Borrower of its obligations hereunder).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45549676"></a><a name="_Ref45890157"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Reserves</font><font style="color:#000000;">.<a name="_Ref45890157"></a>&nbsp;&nbsp;Notwithstanding any terms in this Agreement to the contrary, at times when a Default or an Event of Default exists, Bank may hold any proceeds of the Accounts and any amounts in the Cash Collateral Account that are not applied to the Obligations pursuant to Section 5.4(c) above (including amounts otherwise required to be transferred to Borrower&#8217;s operating account with Bank) as a reserve to be applied to any Obligations regardless of whether such Obligations are then due and payable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Returns</font><font style="color:#000000;">.&nbsp;&nbsp;Provided no Event of Default has occurred and is continuing, if any Account Debtor returns any Inventory to Borrower, Borrower shall promptly (i) determine the reason for such return, (ii) issue a credit memorandum to the Account Debtor in the appropriate amount in accordance with Borrower&#8217;s customary business practices, and (iii) provide a copy of such credit memorandum to Bank, upon request from Bank.&nbsp;&nbsp;In the event any attempted return occurs after the occurrence and during the continuance of any Event of Default, Borrower shall hold the returned Inventory in trust for Bank, and promptly notify Bank of the return of the Inventory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45724405"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Verifications; Confirmations; Credit Quality; Notifications</font><font style="color:#000000;">.&nbsp;&nbsp;Bank may, from time to time, (i) verify and confirm directly with the respective Account Debtors the validity, amount and other matters relating to the Accounts, either in the name of Borrower or Bank or such other name as Bank may choose, and notify any Account Debtor of Bank&#8217;s security interest in such Account and/or (ii) conduct a credit check of any Account Debtor to approve any such Account Debtor&#8217;s credit.&nbsp;&nbsp;In addition, Bank may notify Account Debtors to make payments in respect of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Accounts directly to Bank.</font><font style="color:#000000;"> </font><font style="color:#000000;">Notwithstanding the foregoing, provided no Event of Default has occurred or is continuing, Bank shall consult with and provide notice to Borrower before contacting Account</font><font style="color:#000000;"> </font><font style="color:#000000;">Debtors directly.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Liability</font><font style="color:#000000;">.&nbsp;&nbsp;Bank shall not be responsible or liable for any shortage or discrepancy in, damage to, or loss or destruction of, any goods, the sale or other disposition of which gives rise to an Account, or for any error, act, omission, or delay of any kind occurring in the settlement, failure to settle, collection or failure to collect any Account, or for settling any Account in good faith for less than the full amount thereof, nor shall Bank be deemed to be responsible for any of Borrower&#8217;s obligations under any contract or agreement giving rise to an Account.&nbsp;&nbsp;Nothing herein shall, however, relieve Bank from liability for its own gross negligence or willful misconduct.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45551046"></a><font style="Background-color:#auto;text-decoration:none;">5.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Remittance of Proceeds.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Except (a) as otherwise provided in Section 5.4(c), and (b) proceeds from licensing fees, in connection with transactions permitted pursuant to Sections 6.1(f), (g), and (l) , with respect to the Company&#8217;s license and collaboration agreements in an aggregate amount not to exceed $100,000.00 in any 12 month period, deliver, in kind, all proceeds arising from the disposition of any Collateral to Bank in the original form in which received by Borrower not later than the following Business Day after receipt by Borrower, to be applied to the Obligations (x) prior to an Event of Default, pursuant to the terms of Section 5.4(c) hereof, and (y) after the occurrence and during the continuance of an Event of Default, pursuant to the terms of Section 8.4 hereof; provided that, if no Event of Default has occurred and is continuing, Borrower shall not be obligated to remit to Bank the proceeds of the sale of worn out or obsolete Equipment disposed of by Borrower in good faith in an arm&#8217;s length transaction for an aggregate purchase price of $500,000.00 or less (for all such transactions in any fiscal year).&nbsp;&nbsp;Borrower agrees that it will not commingle proceeds of Collateral with any of Borrower&#8217;s other funds or property, but will hold such proceeds separate and apart from such other funds and property and in an express trust for Bank.&nbsp;&nbsp;Nothing in this Section 5.5 limits the restrictions on disposition of Collateral set forth elsewhere in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Taxes; Pensions.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Timely file, and require each of its Subsidiaries to timely file (in each case, unless subject to a valid extension), all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state, and local taxes, assessments, deposits, and contributions owed by Borrower and each of its Subsidiaries, except for (i) taxes with respect to amounts that do not in the aggregate exceed the amount set forth in Section 4.9(a) hereof, and (ii) deferred payment of any taxes contested pursuant to the terms of Section 4.9(a) hereof, and shall deliver to Bank, on demand, appropriate certificates attesting to such payments, and pay, and require each of its Subsidiaries to pay, all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent Borrower or any of its Subsidiaries defers payment of any contested taxes, (i) notify Bank in writing of the commencement of, and any material development in, the proceedings, and (ii) post bonds or take any other steps required to prevent the Governmental Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a &#8220;Permitted Lien.&#8221;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44603949"></a><font style="Background-color:#auto;text-decoration:none;">5.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Access to Collateral; Books and Records. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">At reasonable times, on five (5) Business Days notice (provided no notice is required if an Event of Default has occurred and is continuing), Bank, or its agents, shall have the right to inspect the Collateral and the right to audit and copy Borrower&#8217;s Books.&nbsp;&nbsp;Such inspections and audits shall be conducted no more often than twice every 12 months, unless an Event of Default has occurred and is continuing, in which case such inspections and audits shall occur as often as Bank shall determine is necessary.  Notwithstanding the foregoing, the Initial Audit shall be completed within 90 days of the Effective Date. The foregoing inspections and audits shall be conducted at Borrower&#8217;s expense and the charge therefor shall be $1,000.00 per person per day (or such higher amount as shall represent Bank&#8217;s then-current standard charge for the same), plus out-of-pocket expenses.&nbsp;&nbsp;In the event Borrower and Bank schedule an audit more than eight (8) days in advance, and Borrower cancels or seeks to or reschedules the audit with less than eight (8) days written notice to Bank, then (without limiting any of Bank&#8217;s rights or remedies) Borrower shall pay Bank a fee of $2,000.00 plus any out-of-pocket expenses incurred by Bank to compensate Bank for the anticipated costs and expenses of the cancellation or rescheduling.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref91498376"></a><font style="text-decoration:none;Background-color:#auto;">5.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Insurance.</font><font style="font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Keep its business and the Collateral insured for risks and in amounts standard for companies of Borrower&#8217;s size in Borrower&#8217;s industry and location and as Bank may reasonably request.&nbsp;&nbsp;Insurance policies shall be in a form, with financially sound and reputable insurance companies that are not Affiliates of Borrower, and in amounts that are reasonably satisfactory to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All property policies shall have a lender&#8217;s loss payable endorsement showing Bank as lender loss payee.&nbsp;&nbsp;All liability policies shall show, or have endorsements showing, Bank as an additional insured.&nbsp;&nbsp;Bank shall be named as lender loss payee and/or additional insured with respect to any such insurance providing coverage in respect of any Collateral. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ensure that proceeds payable under any property policy are, at Bank&#8217;s option, payable to Bank on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to $250,000.00 with respect to any loss, but not exceeding $500,000.00 in the aggregate for all losses under all casualty policies in any 12 month period, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Bank has been granted a first priority security interest (subject only to Permitted Liens that are permitted pursuant to the terms of this Agreement to have superior priority to Bank&#8217;s Lien), and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Bank, be payable to Bank on account of the Obligations then due.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">At Bank&#8217;s request, Borrower shall deliver certified copies of insurance policies and evidence of all premium payments.&nbsp;&nbsp;Each provider of any such insurance required under this Section 5.8 shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to Bank, that it will give Bank 30 days&#8217; prior written notice before any such policy or policies shall be canceled.&nbsp;&nbsp;If Borrower fails to obtain insurance as required under this Section 5.8 or to pay any amount or furnish any required proof of payment to third persons and Bank, Bank may make all or part of such payment or obtain such insurance policies required in this Section 5.8, and take any action under the policies Bank deems prudent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832548"></a><a name="_Ref45887692"></a><font style="Background-color:#auto;text-decoration:none;">5.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Accounts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Maintain all of Borrower&#8217;s, any of its Subsidiaries&#8217; (excluding Securities Corp.), and any Guarantor&#8217;s operating accounts, depository accounts and excess cash with Bank or Bank&#8217;s Affiliates. In addition to the foregoing, Borrower shall at all times have on deposit in operating and depository accounts maintained in the name of Borrower with Bank, unrestricted cash in an amount equal to the lesser of (i) one hundred percent (100.0%) of the Dollar value of Borrower&#8217;s consolidated cash, including any Subsidiaries&#8217;, or Affiliates&#8217; (other than senior executives or directors of the Borrower) cash, in the aggregate, at all financial institutions, and (ii) one hundred ten percent (110.0%) of the then-outstanding Obligations of Borrower to Bank. Bank may restrict withdrawals or transfers by or on behalf of Borrower that would violate this Section 5.9(a) regardless of whether an Event of Default exists at such time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition to the foregoing, Borrower, any Subsidiary of Borrower, and any Guarantor shall obtain any business credit card (other than the Permitted Credit Card) and letter of credit exclusively from Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45532026"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition to and without limiting the restrictions in (a), Borrower shall provide Bank five (5) days prior written notice before establishing any Collateral Account at or with any bank or financial institution other than Bank or Bank&#8217;s Affiliates.&nbsp;&nbsp;For each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable bank or financial institution (other than Bank) at or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Bank&#8217;s Lien in such Collateral Account in accordance with the terms hereunder which Control Agreement may not be terminated without the prior written consent of Bank.&nbsp;&nbsp;The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes, and other employee wage and benefit </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">payments to or for the benefit of Borrower&#8217;s employees and identified to Bank by Borrower as such</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;color:#000000;">Excluded</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Accounts</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.10</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Financial Covenant.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Borrower shall either:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Achieve, to be tested as of the last day of each quarter, minimum Product Revenue for the trailing three (3) month period ending on such date, of at least:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:65.91%;">
<tr>
<td style="width:32.69%;"></td>
<td style="width:33.22%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Period</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Minimum Product Revenue</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2022</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2022</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2022</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2023</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2023</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2023</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2023</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Maintain, at all times, unrestricted and unencumbered cash in accounts in the name of Borrower with Bank in an amount equal to least the greater of (i) $50,000,000.00, or (ii) the amount of Borrower&#8217;s Cash Burn,&nbsp;&nbsp;multiplied by six (6).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the period ending March 31, 2023 and each period thereafter through December 31, 2023, Bank may, in its sole and absolute discretion, agree in writing to update the applicable covenant levels of Minimum Product Revenue based upon, among other factors, an updated Board-approved operating plan and financial projections provided by Borrower to Bank and the Bank&#8217;s then current credit underwriting.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the period ending March 31, 2024 and each period thereafter through the Maturity Date, the levels of minimum Product Revenue shall be mutually agreed upon between Borrower and Bank, based upon, among other factors, [***]% of the projected Product Revenue in Borrower&#8217;s Board-approved operating plan and financial projections (which projections shall demonstrate year-over-year growth), which shall be acceptable to Bank, and subject to Bank&#8217;s then current credit underwriting. With respect thereto, Borrower&#8217;s failure to agree in writing (which agreement shall be set forth in a written amendment to this Agreement) on or before January 15, 2024, to any minimum Product Revenue covenant levels mutually agreed upon between Borrower and Bank with respect to the periods ending on and after March 31, 2024, shall result in an immediate Event of Default for which there shall be no grace or cure period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.11</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Protection of Intellectual Property Rights.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) Protect, defend, and maintain the validity and enforceability of Borrower&#8217;s and each Subsidiary&#8217;s Intellectual Property, except to the extent that such failure to do so would not reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations; (ii) promptly, but no later than with the then next-due Compliance Statement pursuant to Section 5.3(c),  advise Bank in writing of infringements or any other event </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">that </font><font style="color:#000000;">could reasonably be expected to materially and adversely affect the value Borrower&#8217;s and each Subsidiary&#8217;s Intellectual Property</font><font style="color:#000000;"> material to Borrower&#8217;s business</font><font style="color:#000000;">; and (iii) not allow any Intellectual Property material to Borrower&#8217;s or any Subsidiary&#8217;s business to be abandoned, forfeited</font><font style="color:#000000;">,</font><font style="color:#000000;"> or dedicated to the public without Bank&#8217;s written consent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45532478"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provide written notice to Bank promptly, but no later than with the then next-due Compliance Statement pursuant to Section 5.3(c), after entering or becoming bound by any Restricted License (other than over-the-counter software that is commercially available to the public).&nbsp;&nbsp;Borrower shall take such commercially reasonable steps as Bank reasonably requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (i) any such Restricted License to be deemed &#8220;Collateral&#8221; and for Bank to have a security interest in it that might otherwise be restricted or prohibited by law or by the terms of any such Restricted License, whether now existing or entered into in the future, and (ii) Bank to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Bank&#8217;s rights and remedies under this Agreement and the other Loan Documents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45633723"></a><font style="Background-color:#auto;text-decoration:none;">5.12</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Litigation Cooperation.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;From the date hereof and continuing through the termination of this Agreement, make available to Bank, without expense to Bank, Borrower and its officers, employees, and agents and Borrower&#8217;s books and records, to the extent that Bank may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Bank with respect to any Collateral or relating to Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.13</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Online Banking.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Utilize Bank&#8217;s online banking platform for all matters requested by Bank which shall include, without limitation (and without request by Bank for the following matters), uploading information pertaining to Accounts and Account Debtors, requesting approval for exceptions, requesting Credit Extensions, and uploading financial statements and other reports required to be delivered by this Agreement (including, without limitation, those described in Section </font>5.3 of this Agreement).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">Comply with the terms of Bank&#8217;s Online Banking Agreement as in effect from time to time and ensure that all persons utilizing Bank&#8217;s online banking platform are duly authorized to do so by an Administrator.&nbsp;&nbsp;Bank shall be entitled to assume the authenticity, accuracy and completeness of any information, instruction or request for a Credit Extension submitted via Bank&#8217;s online banking platform and to further assume that any submissions or requests made via Bank&#8217;s online banking platform have been duly authorized by an</font> Administrator.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45633765"></a><font style="Background-color:#auto;text-decoration:none;">5.14</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Inventory; Returns</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Keep all Inventory in good and marketable condition, free from material defects (other than resulting from any casualty or any taking under power of eminent domain or by condemnation).&nbsp;&nbsp;Returns and allowances between Borrower and its Account Debtors shall follow Borrower&#8217;s customary practices as they exist at the Effective Date.&nbsp;&nbsp;Borrower shall promptly notify Bank of all returns, recoveries, disputes and claims that involve more than $500,000.00.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45633790"></a><font style="Background-color:#auto;text-decoration:none;">5.15</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Further Assurances.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Execute any further instruments and take such further action as Bank reasonably requests to perfect, protect, ensure the priority of or continue Bank&#8217;s Lien on the Collateral or to effect the purposes of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref91596484"></a><a name="_Ref45633808"></a><font style="Background-color:#auto;text-decoration:none;">5.16</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Sanctions</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;(a) Not, and not permit any of its Subsidiaries to, engage in any of the activities described in Section 4.11 in the future; (b) not, and not permit any of its Subsidiaries to, become a Sanctioned Person; (c) ensure that the proceeds of the Obligations are not used to violate any Sanctions; and (d) deliver to Bank any certification or other evidence requested from time to time by Bank in its sole discretion, confirming each such Person&#8217;s compliance with this Section 5.16.&nbsp;&nbsp;In addition, have implemented, and will consistently apply while this Agreement is in effect, procedures to ensure that the representations and warranties in Section 4.11 remain true and correct while this Agreement is in effect.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">5.17</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Post-Closing Deliverables. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within 30 days of the Effective Date, Borrower shall (i) use commercially best efforts to deliver to Bank a duly executed bailee&#8217;s waiver in favor of Bank for each location where Borrower maintains property with a third party, by each such third party, in form and substance satisfactory to Bank; (ii) deliver to Bank evidence satisfactory to Bank that the insurance policies and endorsements required by Section 5.8 hereof are in full force and effect, together with appropriate evidence showing lender loss payable and additional insured clauses or endorsements in favor of Bank, in form and substance satisfactory to Bank; and (iii) deliver to Bank a stock power form (1 original) executed by EyePoint US with respect to capital stock of Securities Corp. and delivery of stock certificates evidencing ownership interest in Securities Corp., in form and substance satisfactory to Bank. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within 10 days of the Effective Date, deliver to Bank the duly executed Control Agreement with respect to Parent&#8217;s SVB Asset Management account, in form and substance satisfactory to Bank. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832300"></a><font style="Background-color:#auto;text-decoration:none;">6</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">NEGATIVE COVENANTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrower shall not do any of the following without Bank&#8217;s prior written consent:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45887557"></a><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Dispositions</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;Convey, sell, lease, transfer, assign, or otherwise dispose of (including, without limitation, pursuant to a Division) (collectively, &#8220;</font><font style="font-family:Times New Roman;color:#000000;">Transfer</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn-out, surplus or obsolete Equipment that is, in the reasonable judgment of Borrower, no longer economically practicable to maintain or useful in the ordinary course of business of Borrower; (c) consisting of Permitted Liens and Permitted Investments; (d) consisting of the sale or issuance of any stock, partnership, membership, or other ownership interest or other equity securities of Borrower permitted under Section 6.2 of this Agreement; (e) consisting of Borrower&#8217;s or its Subsidiaries&#8217; use or transfer of money or Cash Equivalents in a manner that is not prohibited by the terms of this Agreement or the other Loan Documents; (f) consisting of non-exclusive licenses for the use of the property of Borrower or its Subsidiaries in the ordinary course of business, and licenses of Intellectual Property that could not result in a legal transfer of title of the licensed property but that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discreet geographical areas outside of the United States, (g) consisting of development, co-promotion, distribution and other collaborative arrangements where such arrangements provide for the licenses or disclosure of Intellectual Property in the ordinary course of business and consistent with general market practices where such license requires periodic payments based on per unit sales of a product over a period of time; provided that each such license does not effect a legal transfer of title to such Intellectual Property and that each such license must be a true license as opposed to a license that is a sales transaction in substance; (h) of property from any Borrower or Subsidiary to any Borrower; (i) leases or subleases of real property entered into in the ordinary course of Borrower&#8217;s business; (j) resulting from any casualty or any taking under power of eminent domain or by condemnation; (k) of other immaterial assets not otherwise permitted under this Section 6.1 with a value not to exceed $500,000.00 in the aggregate in any 12 month period, and (l) in accordance with the Alimera License Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45533065"></a><font style="Background-color:#auto;text-decoration:none;">6.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Changes in Business, Management, Control, or Business Locations</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;(a) Engage in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower and such Subsidiary, as applicable, or reasonably related thereto; (b) liquidate or dissolve or permit any of its Subsidiaries to liquidate or dissolve (provided that any Subsidiary may liquidate or dissolve, so long as it transfers all of its assets to Borrower); (c) fail to provide notice to Bank of any Key Person departing from or ceasing to be employed by Borrower within five (5) days after such Key Person&#8217;s departure from Borrower; (d) permit, allow or suffer to occur any Change in Control; or (e) without at least 10 days&#8217; prior written notice to Bank, (i) add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than $250,000.00 in Borrower&#8217;s assets or property) or deliver any portion of the Collateral valued, individually or in the aggregate, in excess of $250,000.00 to a bailee at a location other than to a bailee and at a location already disclosed in the Perfection Certificate, (ii) change its jurisdiction of organization, (iii) change its organizational structure or type, (iv) change its legal name, or (v) change any organizational number (if any) assigned by its jurisdiction of organization.&nbsp;&nbsp;If Borrower intends to add any new offices or business locations, including warehouses, containing in excess of $250,000.00 of Borrower&#8217;s assets or property, then Borrower will use commercially reasonable efforts to cause the landlord of any such new offices or business locations, including warehouses, to execute and deliver a landlord consent in form and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">substance </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">satisfactory </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">to Bank.&nbsp;&nbsp;If Borrower intends to deliver any portion of the Collateral valued, individually or </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">in the aggregate, in excess o</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">f $250</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">,000.00</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> to a bailee, and Bank and such bailee are not already parties to a bailee agreement governing both the Collateral and the location to which Borrower intends to deliver the Collateral, then Borrower will </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">use commercially reasonable efforts to</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">cause such bailee to execute and deliver a bailee agreement in form and substance </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">satisfactory </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45542297"></a><font style="Background-color:#auto;text-decoration:none;">6.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Mergers or Acquisitions.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;(a) Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, provided that (i) a Subsidiary may merge or consolidate into another Subsidiary or into Borrower, (ii) a Subsidiary may merge or consolidate with another Person pursuant to a Permitted Acquisition, so long as the surviving Person is a Subsidiary; or (b) acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the stock, partnership, membership, or other ownership interest or other equity securities or property of another Person (including, without limitation, by the formation of any Subsidiary or pursuant to a Division), other than a Permitted Acquisition. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45887517"></a><font style="Background-color:#auto;text-decoration:none;">6.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Indebtedness.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Encumbrance.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Create, incur, allow, or suffer to exist any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, permit any Collateral not to be subject to the first priority security interest granted herein, except for Permitted Liens, or enter into any agreement, document, instrument, or other arrangement (except with or in favor of Bank) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower or any Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower&#8217;s or any Subsidiary&#8217;s Intellectual Property, except (i) as is otherwise permitted in Section 6.1 hereof and the definition of &#8220;Permitted Liens&#8221; herein, (ii) for customary restrictions on assignment, transfer and encumbrances in license agreements under which Borrower or any Subsidiary is the licensee, or (iii) for covenants with such restrictions in merger or acquisition agreements; provided that such covenants do not prohibit Borrower or any Subsidiary from granting a security interest in Borrower&#8217;s or any such Subsidiary&#8217;s Intellectual Property in favor of Bank; and provided further that the counter-parties to such covenants are not permitted to receive a security interest in Borrower&#8217;s or any Subsidiary&#8217;s Intellectual Property.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Maintenance of Collateral Accounts.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Maintain any Collateral Account except pursuant to the terms of Section 5.9(c).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45630566"></a><font style="Background-color:#auto;text-decoration:none;">6.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Distributions; Investments.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;(a) Pay any dividends or make any distribution or payment or redeem, retire or purchase any stock, partnership, membership, or other ownership interest or other equity securities, provided that (i) Borrower may convert any of its convertible securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof, (ii) Borrower may make cash payments in lieu of fractional shares in connection with any such conversions in an aggregate amount not to exceed $10,000.00 in any twelve (12) month period, (iii) Borrower may pay dividends solely in common stock, (iv) Borrower may repurchase the stock, partnership, membership, or other ownership interest or other equity securities of current or former employees, directors, or consultants pursuant to stock repurchase agreements, or similar agreements, so long as an Event of Default does not exist at the time of any such repurchase and would not exist after giving effect to any such repurchase, provided that the aggregate amount of all such repurchases does not exceed $50,000.00 in any 12 month period, (v) any Subsidiary may pay dividends or make distributions to Borrower, or (vi) Borrower or any Subsidiary may acquire (or withhold) its equity interests pursuant to any employee stock option or similar plan to pay withholding taxes for which Borrower is liable in respect of a current or former officer, director, employee, member of management or consultant upon such grant or award (or upon vesting or exercise thereof); or (b) directly or indirectly make any Investment (including, without limitation, by the formation of any Subsidiary) other than Permitted Investments, or permit any of its Subsidiaries to do so.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Transactions with Affiliates.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower, except for (a) transactions between or among Borrowers, (b) transactions that are in the ordinary course of Borrower&#8217;s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm&#8217;s-length transaction with a non-affiliated Person, (c) sales of equity </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">securities in bona fide venture financing transactions that are</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> not prohibited by Section 6.2, </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">(</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">d</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">) the incurrence of Subordinated Debt, (</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">e</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">) reasonable and customary compensation and other benefits arrangements (including retirement, health, stock option, and other benefit plans and indemnification arrangements approved by the relevant board of directors, board of managers or equivalent corporate body</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> to the extent such approval is required by the organizational documents of such Borrower or Subsidiary</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">) with Borrower&#8217;s and its Subsidiaries employees, officers, directors and managers approved by the Board or such Subsidiary&#8217;s board of directors</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> (to the extent such approval is required by the organizational documents of such Borrower or Subsidiary)</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, and (</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">f</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">) transactions permitted pursuant to Section 6.1, 6.4 or 6.7.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832568"></a><font style="Background-color:#auto;text-decoration:none;">6.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Subordinated Debt.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Except as expressly permitted under the terms of the subordination, intercreditor, or other similar agreement to which any Subordinated Debt is subject: (a) make or permit any payment on such Subordinated Debt; or (b) amend any provision in any document relating to such Subordinated Debt which would increase the amount thereof, provide for earlier or greater principal, interest, or other payments thereon, or adversely affect the subordination thereof to Obligations owed to Bank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.10</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Compliance.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;(a) Become an &#8220;investment company&#8221; or a company controlled by an &#8220;investment company&#8221;, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; (b)(i) fail to meet the minimum funding requirements of ERISA, (ii) permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur, (iii) fail to comply with the Federal Fair Labor Standards Act, or (iv) violate any other law or regulation, if the foregoing subclauses (i) through (iv), individually or in the aggregate, could reasonably be expected to have a material adverse effect on Borrower&#8217;s business or operations, or permit any of its Subsidiaries to do so; or (c) withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing, and deferred compensation plan which could reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634075"></a><font style="Background-color:#auto;text-decoration:none;">7</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">EVENTS OF DEFAULT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any one of the following shall constitute an event of default (an &#8220;<font style="font-weight:bold;">Event of Default</font>&#8221;) under this Agreement:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832198"></a><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Payment Default.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day cure period shall not apply to payments due on the Maturity Date).&nbsp;&nbsp;During the cure period, the failure to make or pay any payment specified under clause (b) hereunder is not an Event of Default (but no Credit Extension will be made during the cure period);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832171"></a><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Covenant Default.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634107"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower fails or neglects to perform any obligation in Section 5 (other than Sections 5.2 (Government Compliance), 5.12 (Litigation Cooperation), 5.14 (Inventory; Returns) and 5.15 (Further Assurances)) or violates any covenant in Section 6; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower fails or neglects to perform, keep, or observe any other term, provision, condition, covenant, or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 7) under such other term, provision, condition, covenant, or agreement that can be cured, has failed to cure the default within ten (10) days after the occurrence thereof (but no Credit Extensions shall be made during such cure period).&nbsp;&nbsp;Cure periods provided under this section shall not apply, among other things, to financial covenants or any other covenants that are required to be satisfied, completed, or tested by a date certain or any covenants set forth in clause (a) above;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634918"></a><a name="_Ref45634926"></a><font style="Background-color:#auto;text-decoration:none;">7.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Material Adverse Change.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;A Material Adverse Change occurs;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref91761172"></a><font style="Background-color:#auto;text-decoration:none;">7.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Attachment; Levy; Restraint on Business.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or any Subsidiary in an amount equal to or greater than $100,000.00 individually or in the aggregate, or (ii) a notice of lien or levy is filed against any of Borrower&#8217;s or any of its Subsidiaries&#8217; assets valued at or greater than $100,000.00 individually or in the aggregate by any Governmental Authority, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10) day cure period; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) any material portion of Borrower&#8217;s or any of its Subsidiaries&#8217; assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting all or any material part of its business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634931"></a><font style="Background-color:#auto;text-decoration:none;">7.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Insolvency.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;(a) Borrower or any of its Subsidiaries are unable to pay its debts (including trade debts) as they become due or otherwise becomes insolvent; (b) Borrower or any of its Subsidiaries begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and is not dismissed or stayed within 45 days (but no Credit Extensions shall be made while any of the conditions described in clause (a) exist or until any Insolvency Proceeding is dismissed);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634503"></a><a name="_Ref45640755"></a><font style="Background-color:#auto;text-decoration:none;">7.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Other Agreements.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;There is, under any agreement to which Borrower, any of Borrower&#8217;s Subsidiaries, or any Guarantor is a party with a third party or parties, (a) any default resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount individually or in the aggregate in excess of $250,000.00; or (b) any breach or default by Borrower, any of Borrower&#8217;s Subsidiaries, or any Guarantor, the result of which could reasonably be expected to have a material adverse effect on Borrower&#8217;s, any of Borrower&#8217;s Subsidiaries&#8217;, or any Guarantor&#8217;s business or operations; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634940"></a><font style="Background-color:#auto;text-decoration:none;">7.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Judgments; Penalties.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;One or more fines, penalties or final judgments, orders or decrees for the payment of money in an amount, individually or in the aggregate, of at least $250,000.00 (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower or any of its Subsidiaries by any Governmental Authority, and the same are not, within ten (10) days after the entry, assessment or issuance thereof, discharged, or after execution thereof, or stayed pending appeal, or such judgments are not discharged prior to the expiration of any such stay (provided that no Credit Extensions will be made prior to the discharge, or stay of such fine, penalty, judgment, order or decree);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45634951"></a><font style="Background-color:#auto;text-decoration:none;">7.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Misrepresentations.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made (it being agreed and acknowledged by Bank that the projections and forecasts provided by Borrower or any of its Subsidiaries in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Subordinated Debt.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;If: (a) any document, instrument, or agreement evidencing any Subordinated Debt shall for any reason be revoked or invalidated or otherwise cease to be in full force and effect, or any Person (other than Bank) shall be in breach thereof or contest in any manner the validity or enforceability thereof or deny that it has any further liability or obligation thereunder; (b) a default or event of default (however defined) has occurred under any document, instrument, or agreement evidencing any Subordinated Debt, which default shall not have been cured or waived within any applicable grace period; or (c) the Obligations shall for any reason be subordinated or shall not have the priority contemplated by this Agreement or any applicable subordination or intercreditor agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.10</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Lien Priority</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">.&nbsp;&nbsp;There is a material impairment in the perfection or priority of Bank&#8217;s security interest in the Collateral; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">7.11</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Guaranty.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;(a) Any guaranty of any Obligations terminates or ceases for any reason to be in full force and effect; (b) any Guarantor does not perform any obligation or covenant under any guaranty of the Obligations; (c) any circumstance described in Sections</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> 7.3</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">7.4</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">7.5</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">7.6</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">7.7</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, or </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">7.8</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> of this Agreement occurs with respect to any Guarantor, (d) the death, liquidation, winding up, or termination of existence of any Guarantor</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> (other as a result of consummating a transaction permitted under Section 6.3 hereof)</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">; or (e)</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">(i) a material impairment in the perfection or priority of Bank&#8217;s Lien in the collateral provided by Guarantor or in the value of such collateral</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">,</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> or (ii) a material adverse change in the general affairs, management, results of operation, condition (financial or otherwise)</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">,</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> or the prospect of repayment of the Obligations occurs with respect to any Guarantor; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.12</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Governmental Approvals.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Any Governmental Approval shall have been (a) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the ordinary course for a full term or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of the actions described in clause (a) above, and such decision or such revocation, rescission, suspension, modification or non-renewal (i) causes or could reasonably be expected to cause a Material Adverse Change, or (ii) materially and adversely affects the legal qualifications of Borrower or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension, modification or non-renewal could reasonably be expected to affect the status of or legal qualifications of Borrower or any of its Subsidiaries to hold any Governmental Approval in any other jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">BANK&#8217;S RIGHTS AND REMEDIES</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45639071"></a><font style="Background-color:#auto;text-decoration:none;">8.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Rights and Remedies.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Upon the occurrence and during the continuance of an Event of Default, Bank may, without notice or demand, do any or all of the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">declare all Obligations immediately due and payable (but if an Event of Default described in Section 7.5 occurs, all Obligations are immediately due and payable without any action by Bank);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">stop advancing money or extending credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Bank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">demand that Borrower (i) deposit cash with Bank in an amount equal to at least (A) 105.0% of the aggregate face amount of any Letters of Credit denominated in Dollars remaining undrawn, and (B) 115.0% of the Dollar Equivalent of the aggregate face amount of any Letters of Credit denominated in a Foreign Currency remaining undrawn (plus, in each case, all interest, fees, and costs due or estimated by Bank to become due in connection therewith), to secure all of the Obligations relating to such Letters of Credit, as collateral security for the repayment of any future drawings under such Letters of Credit, and Borrower shall forthwith deposit and pay such amounts, and (ii) pay in advance all letter of credit fees scheduled to be paid or payable over the remaining term of any Letters of Credit;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">terminate any FX Contracts (it being understood and agreed that (i) Bank is not obligated to deliver the currency which Borrower has contracted to receive under any FX Contract, and Bank may cover its exposure for any FX Contracts by purchasing or selling currency in the interbank market as Bank deems appropriate; (ii) Borrower shall be liable for all losses, damages, costs, margin obligations, and expenses incurred by Bank arising from Borrower&#8217;s failure to satisfy its obligations under any FX Contract or the execution of any FX Contract; and (iii) Bank shall not be liable to Borrower for any gain in value of a FX Contract that Bank may obtain in covering Borrower&#8217;s breach);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">verify the amount of, demand payment of and performance under, and collect any Accounts and General Intangibles, settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Bank considers advisable, and notify any Person owing Borrower money of Bank&#8217;s security interest in such funds. Borrower shall collect all payments in trust for Bank and, if requested by Bank, immediately deliver the payments to Bank in the form received from the Account Debtor, with proper endorsements for deposit;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral.&nbsp;&nbsp;Borrower shall assemble the Collateral if Bank requests and make it available as Bank designates.&nbsp;&nbsp;Bank may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Bank a license to enter and occupy any of its premises, without charge, to exercise any of Bank&#8217;s rights or remedies;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">apply to the Obligations any (i) balances and deposits of Borrower it holds, or (ii) amount held by Bank owing to or for the credit or the account of Borrower;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral.&nbsp;&nbsp;For use solely upon the occurrence and during the continuation of an Event of Default, Bank is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower&#8217;s labels, Patents, Copyrights, mask works, rights of use of any name, trade secrets, trade names, Trademarks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Bank&#8217;s exercise of its rights under this Section 8.1, Borrower&#8217;s rights under all licenses and all franchise agreements inure to Bank&#8217;s benefit;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">place a &#8220;hold&#8221; on any account maintained with Bank and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">demand and receive possession of Borrower&#8217;s Books; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">exercise all rights and remedies available to Bank under the Loan Documents or at law or equity, including all remedies provided under the Code or any Applicable Law (including disposal of the Collateral pursuant to the terms thereof).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Power of Attorney.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Borrower hereby irrevocably appoints Bank as its true and lawful attorney-in-fact, (a) exercisable upon the occurrence and during the continuance of an Event of Default, to: (i) sign Borrower&#8217;s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (ii) demand, collect, sue, and give releases to any Account Debtor for monies due, settle and adjust disputes and claims about the Accounts directly with Account Debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Bank&#8217;s or Borrower&#8217;s name, as Bank chooses); (iii) make, settle, and adjust all claims under Borrower&#8217;s insurance policies; (iv) pay, contest, or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (v) transfer the Collateral into the name of Bank or a third party as the Code permits, and (vi) receive, open and dispose of mail addressed to Borrower; and (b) regardless of whether an Event of Default has occurred: (i) endorse Borrower&#8217;s name on any checks, payment instruments, or other forms of payment or security; (ii) notify all Account Debtors to pay Bank directly; and (iii) to sign Borrower&#8217;s name on any documents necessary to perfect or continue the perfection of Bank&#8217;s security interest in the Collateral.&nbsp;&nbsp;Bank&#8217;s foregoing appointment as Borrower&#8217;s attorney in fact, and all of Bank&#8217;s rights and powers, coupled with an interest, are irrevocable until such time as all Obligations (other than inchoate indemnity obligations) have been satisfied in full, Bank is under no further obligation to make Credit Extensions and the Loan Documents have been terminated. Bank shall not incur any liability in connection with or arising from the exercise of such power of attorney and shall have no obligation to exercise any of the foregoing rights and remedies.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Protective Payments.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;If Borrower fails to obtain the insurance called for by Section 5.8 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Bank may obtain such insurance or make such payment, and all amounts so paid by Bank are Bank Expenses and immediately due and payable, bearing interest at the then highest rate applicable to the Obligations, and secured by the Collateral.&nbsp;&nbsp;Bank will make reasonable efforts to provide Borrower with notice of Bank obtaining such insurance at the time it is obtained or within a reasonable time thereafter.&nbsp;&nbsp;No payments by Bank are deemed an agreement to make similar payments in the future or Bank&#8217;s waiver of any Event of Default.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45550936"></a><font style="text-decoration:none;Background-color:#auto;">8.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Application of </font><font style="font-family:Times New Roman;color:#000000;">Payments and Proceeds.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">If an Event of Default has occurred and is continuing (or at any time on the terms set forth in Section 5.4(c), regardless of whether an Event of Default exists), </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Bank may apply any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Accounts or other disposition of the Collateral, or otherwise, to the Obligations in such order as Bank shall determine in its sole discretion.&nbsp;&nbsp;Any surplus shall be paid to Borrower or other Persons legally entitled thereto; Borrower shall remain liable to Bank for any deficiency.&nbsp;&nbsp;If Bank, in its commercially reasonable discretion, directly or</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> indirectly, enters into a deferred payment or other credit transaction with any purchaser at any sale of Collateral, Bank shall have the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or deferring the reduction of the Obligations until the actual receipt by Bank of cash therefor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref46832350"></a><font style="Background-color:#auto;text-decoration:none;">8.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Bank&#8217;s Liability for Collateral.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Bank&#8217;s sole duty with respect to the custody, safekeeping, and physical preservation of the Collateral in its possession or under its control, under Section 9-207 of the Code or otherwise, shall be to deal with it in the same manner as Bank deals with its own property consisting of similar instruments or interests.&nbsp;&nbsp;Borrower bears all risk of loss, damage, or destruction of the Collateral.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">No Waiver; Remedies Cumulative.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Bank&#8217;s failure, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Bank thereafter to demand strict performance and compliance herewith or therewith.&nbsp;&nbsp;No waiver hereunder shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance and purpose for which it is given.&nbsp;&nbsp;Bank&#8217;s rights and remedies under this Agreement and the other Loan Documents are cumulative.&nbsp;&nbsp;Bank has all rights and remedies provided under the Code, by law, or in equity.&nbsp;&nbsp;Bank&#8217;s exercise of one right or remedy is not an election and shall not preclude Bank from exercising any other remedy under this Agreement or other remedy available at law or in equity, and Bank&#8217;s waiver of any Event of Default is not a continuing waiver.&nbsp;&nbsp;Bank&#8217;s delay in exercising any remedy is not a waiver, election, or acquiescence.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Demand Waiver.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Bank on which Borrower is liable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Borrower Liability.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Any Borrower may, acting singly, request Credit Extensions hereunder.&nbsp;&nbsp;Each Borrower hereby appoints each other as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder.&nbsp;&nbsp;Each Borrower hereunder shall be liable for the Credit Extensions and Obligations as set forth on Schedule I hereto.&nbsp;&nbsp;Each Borrower waives (a) any suretyship defenses available to it under the Code or any other Applicable Law, and (b) any right to require Bank to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy.&nbsp;&nbsp;Bank may exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower&#8217;s liability.&nbsp;&nbsp;Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Bank under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise.&nbsp;&nbsp;Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section 8.8 shall be null and void.&nbsp;&nbsp;If any payment is made to a Borrower in contravention of this Section 8.8, such Borrower shall hold such payment in trust for Bank and such payment shall be promptly delivered to Bank for application to the Obligations, whether matured or unmatured.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45197592"></a><font style="Background-color:#auto;text-decoration:none;">9</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">NOTICES</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address or email address indicated below; provided that, for clause (b), if such notice, consent, request, approval, demand</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other communication is not sent during the normal business hours of the recipient, it shall be deemed to have been sent at the opening of business on the next Business Day of the recipient.&nbsp;&nbsp;Bank or Borrower may change its mailing or electronic mail address by giving the other party written notice thereof in accordance with the terms of this Section </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Borrower:</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS US, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ICON BIOSCIENCE, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480 Pleasant Street</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite A210</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Watertown, Massachusetts 02472</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Ron Honig, Chief Legal Officer and Company Secretary</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: rhonig@eyepointpharma.com</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Website URL: https://eyepointpharma.com/</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hogan Lovells US LLP</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1735 Market St.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Floor 23</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philadelphia, PA 19103</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Steve Abrams</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: steve.abrams@hoganlovells.com</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hogan Lovells US LLP</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Columbia Square</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555 Thirteenth Street, NW</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20004</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Edward (Ned) Sinclaire Purdon </p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: edward.purdon@hoganlovells.com</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Bank:</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silicon Valley Bank</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275 Grove Street, Suite 2-200</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Newton, MA 02466</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Lauren Cole</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: LCole@svb.com</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:41.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to (which shall not </p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Morrison &amp; Foerster LLP</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:41.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constitute notice):</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200 Clarendon Street, Floor 20</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts&nbsp;&nbsp;02116</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:&#160;&#160;&#160;&#160;&#160;David A. Ephraim, Esquire</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.1%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.92%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: &#160;&#160;&#160;&#160;&#160;DEphraim@mofo.com</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45197117"></a><a name="_Ref46832374"></a><font style="Background-color:#auto;text-decoration:none;">10</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">CHOICE OF LAW, VENUE and JURY TRIAL WAIVER</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise expressly provided in any of the Loan Documents, New York law governs the Loan Documents without regard to principles of conflicts of law that would require the application of the laws of another jurisdiction.&nbsp;&nbsp;Borrower and Bank each irrevocably and unconditionally submit to the exclusive jurisdiction of the State and Federal courts in New York, New York; provided, however, that nothing in this Agreement shall be deemed to operate to preclude Bank from bringing suit or taking other legal action in any other jurisdiction with respect to the Loan Documents or to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of Bank.&nbsp;&nbsp;Borrower expressly, irrevocably and unconditionally submits and consents in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby irrevocably and unconditionally waives, to the fullest extent permitted by Applicable Law, any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby irrevocably and unconditionally consents to the granting of such legal or equitable relief as is deemed appropriate by such court.&nbsp;&nbsp;Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Agreement and that service so made shall be deemed completed upon the earlier to occur of Borrower&#8217;s actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER AND BANK EACH WAIVES ITS RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE PARTIES HERETO TO ENTER INTO THIS AGREEMENT.&nbsp;&nbsp;EACH PARTY HERETO HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Section 10 shall survive the termination of this Agreement and the repayment of all Obligations.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">GENERAL PROVISIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Termination Prior to Maturity Date; Survival. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> All covenants, representations and warranties made in this Agreement shall continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations) have been satisfied.&nbsp;&nbsp;So long as Borrower has satisfied the Obligations (other than inchoate indemnity obligations, and any other obligations which, by their terms, are to survive the termination of this Agreement and the repayment of all Obligations, and any Obligations under Bank Services Agreements that are cash collateralized in accordance with Section 3.3 of this Agreement), this Agreement may be terminated prior to the Maturity Date by Borrower, effective three (3) Business Days after written notice of termination is given to Bank.&nbsp;&nbsp;Those obligations that are expressly specified in this Agreement as surviving this Agreement&#8217;s termination and the repayment of all Obligations shall continue to survive notwithstanding this Agreement&#8217;s termination and the repayment of all Obligations. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44600824"></a><font style="Background-color:#auto;text-decoration:none;">11.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Successors and Assigns.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;This Agreement binds and is for the benefit of the successors and permitted assigns of each party.&nbsp;&nbsp;Borrower may not assign or transfer this Agreement or any rights or obligations under it without Bank&#8217;s prior written consent (which may be granted or withheld in Bank&#8217;s sole discretion) and any other attempted assignment or transfer by Borrower shall be null and void.&nbsp;&nbsp;Bank has the right, without the consent of or notice to Borrower, to sell, transfer, assign, negotiate, or grant participation in all or any part of, or any interest in, Bank&#8217;s obligations, rights, and benefits under this Agreement and the other Loan Documents. Notwithstanding the foregoing, so long as no Event of Default shall have occurred and is continuing, Bank shall not assign its interest in the Loan Documents to any Person who in the reasonable estimation of Bank is (a) a direct competitor of Borrower, whether as an operating company or direct or indirect parent with voting control over such operating company or (b) a vulture fund or distressed debt fund.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45196890"></a><font style="Background-color:#auto;text-decoration:none;">11.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Indemnification. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General Indemnification</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower shall indemnify, defend, and hold Bank and its Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors, and representatives of Bank and its Affiliates (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Indemnified Person</font><font style="color:#000000;">&#8221;) harmless against: all losses, claims, damages, liabilities, and related expenses (including Bank Expenses and the reasonable fees, charges, and disbursements of any counsel for any Indemnified Person)&nbsp;&nbsp;(collectively, &#8220;</font><font style="font-weight:bold;color:#000000;">Claims</font><font style="color:#000000;">&#8221;) arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document, or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder, or the consummation of the transactions contemplated hereby or thereby, (ii) any Credit Extension or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of hazardous materials on or from any property owned or operated by Borrower or any of its Subsidiaries, or any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">environmental liability related in any way to Borrower or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort</font><font style="color:#000000;">,</font><font style="color:#000000;"> or any other theory, whether brought by a third party or by Borrower, and regardless of whether any Indemnified Person is a party thereto; provided that such indemnity shall not, as to any Indemnified Person, be available to the extent that such losses, claims, damages, liabilities</font><font style="color:#000000;">,</font><font style="color:#000000;"> or related expenses are determined by a court of competent jurisdiction by final and non</font><font style="color:#000000;">-</font><font style="color:#000000;">appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnified Person.&nbsp;&nbsp;All amounts due under this Section </font><font style="color:#000000;">11.3</font><font style="color:#000000;"> shall be payable promptly after demand therefor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver of Consequential Damages, Etc.</font><font style="color:#000000;">&nbsp;&nbsp;To the fullest extent permitted by Applicable Law, Borrower shall not assert, and hereby waives, any claim against any Indemnified Person, on any theory of liability, for special, indirect, consequential, or punitive damages (as opposed to direct or actual damages) or any loss of profits arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Credit Extension, or the use of the proceeds thereof.&nbsp;&nbsp;No Indemnified Person shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic, or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Section 11.3 shall survive the termination of this Agreement and the repayment of all Obligations until all statutes of limitation with respect to the Claims, losses, and expenses for which indemnity is given shall have run.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Time of Essence.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Time is of the essence for the performance of all Obligations in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Severability of Provisions.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44583483"></a><font style="Background-color:#auto;text-decoration:none;">11.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Amendments in Writing; Waiver; Integration.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;No purported amendment or modification of any Loan Document, or waiver, discharge, or termination of any obligation under any Loan Document, shall be effective unless, and only to the extent, expressly set forth in a writing signed by each party hereto.&nbsp;&nbsp;Without limiting the generality of the foregoing, no oral promise or statement, nor any action, inaction, delay, failure to require performance, or course of conduct shall operate as, or evidence, an amendment, supplement or waiver or have any other effect on any Loan Document.&nbsp;&nbsp;Any waiver granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver.&nbsp;&nbsp;The Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.&nbsp;&nbsp;All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of the Loan Documents merge into the Loan Documents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Counterparts.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.&nbsp;&nbsp;Delivery of an executed signature page of this Agreement by electronic mail transmission shall be effective as delivery of a manually executed counterpart hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44077439"></a><font style="Background-color:#auto;text-decoration:none;">11.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Confidentiality.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Bank agrees to maintain the confidentiality of Information (as defined below), except that Information may be disclosed (a) to Bank&#8217;s Subsidiaries and Affiliates and their respective employees, directors, agents, attorneys, accountants, and other professional advisors (collectively, &#8220;</font><font style="font-family:Times New Roman;color:#000000;">Representatives</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221; and, together with Bank, collectively, &#8220;</font><font style="font-family:Times New Roman;color:#000000;">Bank Entities</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;); (b) to prospective transferees, assignees, credit providers or purchasers of Bank&#8217;s interests under or in connection with this Agreement and their Representatives (provided, however, any such prospective transferee, assignee, credit provider, purchaser, or their Representative shall have entered into an agreement containing provisions substantially the same as those in this Section); (c) as required by law, regulation, subpoena, or other order; (d) to Bank&#8217;s regulators or as otherwise required or requested in connection with Bank&#8217;s examination or audit; (e) in connection with the exercise of remedies under the Loan Documents or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder; and (f) to third-party service providers of Bank so long as such service providers have executed a confidentiality agreement with Bank with terms no less restrictive than those contained herein.&nbsp;&nbsp;&#8220;</font><font style="font-family:Times New Roman;color:#000000;">Information</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221; means </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">all information received from Borrower regarding Borrower or its business, in each case other than information that is either: (i) in the public domain or in Bank&#8217;s possession when disclosed to Bank, or becomes part of the public domain (other than as a result of its disclosure by Bank in violation of this Agreement) after disclosure to Bank; or (ii) disclosed to Bank by a third party, if Bank does not know that the third party is prohibited from disclosing the information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45722691"></a><font style="Background-color:#auto;text-decoration:none;">11.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Electronic Execution of Documents.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in any Loan Document shall be deemed to include electronic signatures, including any Electronic Signature as defined in the Electronic Transactions Law (2003 Revision) of the Cayman Islands (the &#8220;</font><font style="font-family:Times New Roman;color:#000000;">Cayman Islands Electronic Signature Law</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;), if applicable, or the keeping of records in electronic form, including any Electronic Record, as defined in Cayman Islands Electronic Signature Law, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any Applicable Law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Cayman Islands Electronic Signature Law; provided, however that sections 8 and 19(3) of the Cayman Islands Electronic Signature Law shall not apply to this Agreement or the execution or delivery thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.10</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Right of Setoff.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp; Borrower hereby grants to Bank a Lien and a right of setoff as security for all Obligations to Bank, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Bank or any entity under the control of Bank (including a subsidiary of Bank) or in transit to any of them, and other obligations owing to Bank or any such entity.&nbsp;&nbsp;At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Bank may setoff the same or any part thereof and apply the same to any liability or Obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations.&nbsp;&nbsp;ANY AND ALL RIGHTS TO REQUIRE BANK TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER, ARE HEREBY KNOWINGLY, VOLUNTARILY, AND IRREVOCABLY WAIVED.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.11</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Captions and Section References.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;The headings used in this Agreement are for convenience only and shall not affect the interpretation of this Agreement.&nbsp;&nbsp;Unless indicated otherwise, section references herein are to sections of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.12</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Construction of Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;The parties hereto mutually acknowledge that they and their attorneys have participated in the preparation and negotiation of this Agreement.&nbsp;&nbsp;In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the uncertainty to exist.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.13</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Relationship.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;The relationship of the parties to this Agreement is determined solely by the provisions of this Agreement.&nbsp;&nbsp;The parties do not intend to create any agency, partnership, joint venture, trust, fiduciary, or other relationship with duties or incidents different from those of parties to an arm&#8217;s-length contract.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.14</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Third Parties.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Nothing in this Agreement, whether express or implied, is intended to: (a) confer any benefits, rights, or remedies under or by reason of this Agreement on any Persons other than the express parties to it and their respective permitted successors and assigns; (b) relieve or discharge the obligation or liability of any Person not an express party to this Agreement; or (c) give any Person not an express party to this Agreement any right of subrogation or action against any party to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.15</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Anti-Terrorism Law.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Bank hereby notifies Borrower that, pursuant to the requirements of Anti-Terrorism Law, Bank may be required to obtain, verify, and record information that identifies Borrower, which information may include the name and address of Borrower and other information that will allow Bank to identify Borrower in accordance with Anti-Terrorism Law. Borrower hereby agrees to take any action necessary to enable Bank to comply with the requirements of Anti-Terrorism Law. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">12</font><font style="text-decoration:underline;text-transform:uppercase;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;text-transform:uppercase;color:#000000;">accounting terms and other DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Accounting and Other Terms.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref45553584"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounting terms not defined in this Agreement shall be construed following GAAP.&nbsp;&nbsp;Calculations and determinations must be made following GAAP (except for with respect to unaudited financial statements for the absence of footnotes and subject to year-end audit adjustments), provided that if at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either Borrower or Bank shall so request, Borrower and Bank shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP; provided, further, that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) Borrower shall provide Bank financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. Notwithstanding the foregoing, any obligations of a Person that are or would have been treated as operating leases for purposes of GAAP prior to the issuance by the Financial Accounting Standards Board on February 25, 2016 of an Accounting Standards Update (the &#8220;ASU&#8221;) shall continue to be accounted for as operating leases for purposes of all financial definitions, calculations and covenants for purpose of this Agreement (whether or not such operating lease obligations were in effect on such date) notwithstanding the fact that such obligations are required in accordance with the ASU (on a prospective or retroactive basis or otherwise) to be treated as capitalized lease obligations in accordance with GAAP (for the avoidance of doubt, other than for purposes of the delivery of financial statements prepared in accordance with GAAP).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As used in the Loan Documents: (i) the words &#8220;shall&#8221; or &#8220;will&#8221; are mandatory, the word &#8220;may&#8221; is permissive, the word &#8220;or&#8221; is not exclusive, the words &#8220;includes&#8221; and &#8220;including&#8221; are not limiting, the singular includes the plural, and numbers denoting amounts that are set off in brackets are negative; (ii) the term &#8220;continuing&#8221; in the context of an Event of Default means that the Event of Default has not been remedied (if capable of being remedied) or waived; and (iii) whenever a representation or warranty is made to Borrower&#8217;s knowledge or awareness, to the &#8220;best of&#8221; Borrower&#8217;s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of any Responsible Officer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref44075053"></a><font style="Background-color:#auto;text-decoration:none;">12.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Definitions.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in this Section 12.2.&nbsp;&nbsp;All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein.&nbsp;&nbsp;As used in this Agreement, the following capitalized terms have the following meanings:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Account</font>&#8221; is, as to any Person, any &#8220;account&#8221; of such Person as &#8220;account&#8221; is defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to such Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Account Debtor</font>&#8221; is any &#8220;account debtor&#8221; as defined in the Code, with such additions to such term as may hereafter be made.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Administrator</font>&#8221; is an individual that is named:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">as an &#8220;Administrator&#8221; in the &#8220;SVB Online Services&#8221; form completed by Borrower with the authority to determine who will be authorized to use SVB Online Services (as defined in Bank&#8217;s Online Banking Agreement as in effect from time to time) on behalf of Borrower; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">as an Authorized Signer of Borrower in an approval by the Board.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Advance</font>&#8221; or &#8220;<font style="font-weight:bold;">Advances</font>&#8221; means a revolving credit loan (or revolving credit loans) under the Revolving Line.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Affiliate</font>&#8221; is, with respect to any Person, each other Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Person&#8217;s senior executive officers, directors, partners</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and, for any Person that is a limited liability company, that Person&#8217;s managers and members. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the definition of Eligible Accounts, Affiliate shall include a Specified Affiliate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Agreement</font>&#8221; is defined in the preamble hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Alimera License Agreement</font>&#8221; means that certain Second Amended and Restated Collaboration Agreement dated as of July 10, 2017, by and between Eyepont Pharmaceuticals US, Inc. (f/k/a pSivida US, Inc.) and Alimera Sciences, Inc. (as amended from time to time).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Anti-Terrorism Law</font>&#8221; means any law relating to terrorism or money-laundering, including Executive Order No. 13224 and the USA Patriot Act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Applicable Law</font>&#8221; means all applicable provisions of constitutions, laws, statutes, ordinances, rules, treaties, regulations, permits, licenses, approvals, interpretations and orders of courts or Governmental Authorities and all orders and decrees of all courts and arbitrators.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Authorized Signer</font>&#8221; means any individual listed in Borrower&#8217;s Borrowing Resolution who is authorized to execute the Loan Documents, including making (and executing if applicable) any Credit Extension request, on behalf of Borrower.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Availability Amount</font>&#8221; is the lesser of (a) the Revolving Line or (b) the Borrowing Base, minus the sum of all outstanding principal amounts of any Advances.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Bank</font>&#8221; is defined in the preamble hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Bank Entities</font>&#8221; is defined in Section 11.8. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Bank Expenses</font>&#8221; are all audit fees, costs, and reasonable expenses (including reasonable, out-of-pocket and documented attorneys&#8217; fees and expenses) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred with respect to Borrower or any Guarantor.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Bank Services</font>&#8221;&nbsp;&nbsp;are any products, credit services, and/or financial accommodations previously, now, or hereafter provided to Borrower or any of its Subsidiaries by Bank or any Bank Affiliate, including, without limitation, any letters of credit, cash management services (including, without limitation, merchant services, direct deposit of payroll, business credit cards, and check cashing services), interest rate swap arrangements, and foreign exchange services as any such products or services may be identified in Bank&#8217;s various agreements related thereto (each, a &#8220;<font style="font-weight:bold;">Bank Services Agreement</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Bank Services Agreement</font>&#8221; is defined in the definition of Bank Services.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Board</font>&#8221; is Borrower&#8217;s board of directors or equivalent governing body.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Borrower</font>&#8221; or &#8220;<font style="font-weight:bold;">Borrowers</font>&#8221; are each set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Borrower&#8217;s Books</font>&#8221; are all Borrower&#8217;s books and records including ledgers, federal and state tax returns, records regarding Borrower&#8217;s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Borrowing Base<font style="font-weight:normal;">&#8221; is 80.0% of Eligible Accounts, as determined by Bank from Borrower&#8217;s most recent Borrowing Base Statement; provided, however, that Bank has the right to decrease the foregoing percentage in its sole discretion to mitigate the impact of events, conditions, contingencies, or risks which may adversely affect the Collateral or its value.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Borrowing Base Statement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; is that certain statement </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the value of certain Collateral in the form specified by Bank to Borrower from time to time.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Borrowing Resolutions</font>&#8221; are, with respect to any Person, those resolutions adopted by such Person&#8217;s board of directors (and, if required under the terms of such Person&#8217;s Operating Documents, stockholders) and delivered by such Person to Bank approving the Loan Documents to which such Person is a party and the transactions contemplated thereby, together with a certificate executed by its secretary on behalf of such Person certifying (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Loan Documents to which it is a party, (b) that set forth as a part of or attached as an exhibit to such certificate is a true, correct, and complete copy of the resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Loan Documents to which it is a party, (c) the name(s) of the Person(s) authorized to execute the Loan Documents, including making (and executing if applicable) any Credit Extension request, on behalf of such Person, together with a sample of the true signature(s) of such Person(s), and (d) that Bank may conclusively rely on such certificate unless and until such Person shall have delivered to Bank a further certificate canceling or amending such prior certificate.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Business Day</font>&#8221; is a day other than a Saturday, Sunday or other day on which commercial banks in the State of California are authorized or required by law to close, except if any determination of a &#8220;Business Day&#8221; shall relate to an FX Contract, the term &#8220;Business Day&#8221; shall also mean a day on which dealings are carried on in the country of settlement of the Foreign Currency.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Cash Burn</font>&#8221; is, as of any date of determination, (a) Borrower&#8217;s total cash, divided by (b) Borrower&#8217;s average quarterly, as determined as of the most recent fiscal quarter then ended, (i) Net Income, plus to the extent deducted in the calculation of Net Income (ii) depreciation expense and amortization expense, (iii) non-cash stock compensation, and (iv) other one-time expenses, as approved by Bank in writing in its sole and absolute discretion, each as determined in accordance with GAAP, divided by three (3). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Cash Collateral Account</font>&#8221; is defined in Section 5.4(c).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Cash Equivalents</font>&#8221; are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &amp; Poor&#8217;s Ratings Group or Moody&#8217;s Investors Service, Inc.; (c) Bank&#8217;s certificates of deposit issued maturing no more than one (1) year after issue; and (d) money market funds at least 95.0% of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Cayman Islands Electronic Signature Law</font>&#8221; is defined in Section 11.9.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Change in Control</font>&#8221; means (a) at any time, any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act), shall become, or obtain rights (whether by means of warrants, options, or otherwise) to become, the &#8220;beneficial owner&#8221; (as defined in Rules 13(d)-3 and 13(d)&#8209;5 under the Exchange Act), directly or indirectly, of 49.0% or more of the ordinary voting power for the election of directors, partners, managers, and members, as applicable, of Parent (determined on a fully diluted basis) other than by the sale of Parent&#8217;s equity securities in a public offering or to venture capital or private equity investors so long as Parent identifies to Bank the venture capital or private equity investors at least seven (7) Business Days prior to the closing of the transaction and provides to Bank a description of the material terms of the transaction; (b) during any period of 12<font style="font-style:italic;Background-color:#FFFFFF;"> </font>consecutive months, a majority of the members of the Board of Parent cease to be composed of individuals (i)&#160;who were members of that board or equivalent governing body on the first day of such period, (ii)&#160;whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i)&#160;above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body, or (iii)&#160;whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (i)&#160;and (ii)&#160;above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body; or (c) at any time, Borrower shall cease to own and control, of record and beneficially, directly or indirectly, 100.0% of each class of outstanding stock, partnership, membership, or other ownership interest or other equity securities of each Subsidiary of Borrower free and clear of all Liens (except Permitted Liens).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Change in Law</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the occurrence, after the Effective Date, of:&nbsp;&nbsp;(a) the adoption or taking effect of any law, rule, regulation, or treaty; (b) any change in Applicable Law or in the administration, interpretation, implementation, or application thereof by any Governmental Authority; or (c) the making or issuance of any request, rule, guideline, or directive (whether or not having the force of law) by any Governmental Authority; provided that, notwithstanding anything herein to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines, or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines, or directives promulgated by Bank</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or issued.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Claims</font>&#8221; is defined in Section 11.3.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Code</font>&#8221; is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Bank&#8217;s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &#8220;Code&#8221; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Collateral</font>&#8221; consists of all of Borrower&#8217;s right, title and interest in and to the following personal property:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) all goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (except as provided below), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, securities accounts, securities entitlements and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and (ii) all Borrower&#8217;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding the foregoing, the Collateral does not include (i) SWK Purchased Receivables, (ii) any property to the extent that such grant of security interest is prohibited by any requirement of law of a Governmental Authority or constitutes a breach or default under or results in the termination of or requires any consent not obtained under, any contract, license, agreement, instrument or other document evidencing or giving rise to such property, except to the extent that such requirement of law or the term in such contract, license, agreement, instrument or other document providing for such prohibition, breach, default or termination or requiring such consent is ineffective under Section 9-406, 9-407, 9-408 or 9-409 of the Code (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity; provided, however, that such security interest shall attach immediately at such time as such requirement of law is not effective or applicable, or such prohibition, breach, default or termination is no longer applicable or is waived, and to the extent severable, shall attach immediately to any portion of the Collateral that does not result in such consequences, (iii) any interest of Borrower as a lessee under an Equipment lease if Borrower is prohibited by the terms of such lease from granting a security interest in such lease or under which such an assignment or Lien would cause a default to occur under such lease; provided, however, that upon termination of such prohibition, such interest shall immediately become Collateral without any action by Borrower or Bank, (iv) the Excluded Accounts, (v) any leasehold interest in real property; (vi) any United States intent-to-use trademark or service mark applications filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. &#167; 1051, at all times prior to the filing of a &#8220;Statement of Use&#8221; pursuant to Section 1(d) of the Lanham Act or an &#8220;Amendment to Allege Use&#8221; pursuant to Section 1(c) of the Lanham Act with respect thereto with the United States Patent and Trademark Office or otherwise, or (vii) any Intellectual Property; provided, however, the Collateral shall include all Accounts and all proceeds of Intellectual Property.&nbsp;&nbsp;If a judicial authority </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">(including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Bank&#8217;s security interest in such Accounts and such other property of Borrower that are proceed</font><font style="color:#000000;">s of the Intellectual Property.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Pursuant to the terms of Section 6.5, Borrower has agreed not to encumber any of its Intellectual Property without Bank&#8217;s prior written consent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Collateral Account</font>&#8221; is any Deposit Account, Securities Account, or Commodity Account.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Commodity Account</font>&#8221; is any &#8220;commodity account&#8221; as defined in the Code, with such additions to such term as may hereafter be made.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Compliance Statement</font>&#8221; is that certain statement in the form attached hereto as Exhibit A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Connection Income Taxes</font>&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Contingent Obligation</font>&#8221; is, for any Person, any direct or indirect liability of that Person for (a) any direct or indirect guaranty by such Person of any indebtedness, lease, dividend, letter of credit, credit card, or other obligation of another, (b) any other obligation endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (c) any obligations for undrawn letters of credit for the account of that Person; and (d) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates, or commodity prices; but &#8220;Contingent Obligation&#8221; does not include endorsements in the ordinary course of business.&nbsp;&nbsp;The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Control Agreement</font>&#8221; is any control agreement entered into among the depository institution at which Borrower maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Bank pursuant to which Bank obtains control (within the meaning of the Code) over such Deposit Account, Securities Account, or Commodity Account.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Copyrights</font>&#8221; are any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Credit Extension</font>&#8221; is any Advance, any FX Contract, the Term Loan Advance, or any other extension of credit by Bank for Borrower&#8217;s benefit.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">CRG</font>&#8221; is defined in Section 2.1(e).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">CRG Credit Agreement</font>&#8221; means that certain Term Loan Agreement dated as of February 13, 2019 among the Borrowers, as borrower or guarantor, the lenders party thereto and CRG, as administrative agent and collateral agent.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Default</font>&#8221; means any event which with notice or passage of time or both, would constitute an Event of Default.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Default Rate</font>&#8221; is defined in Section 1.4(c).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Deferred Revenue</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; is all amounts received or invoiced in advance of performance under contracts and not yet recognized as revenue.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Deposit Account</font>&#8221; is any &#8220;<font style="font-weight:bold;">deposit account</font>&#8221; as defined in the Code with such additions to such term as may hereafter be made.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Designated Deposit Account</font>&#8221; is the deposit account established by Borrower with Bank for purposes of receiving Credit Extensions.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Division</font>&#8221; means, in reference to any Person which is an entity, the division of such Person into 2 or more separate Persons, with the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as contemplated under Section 18-217 of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware law, Section 17-220 of the Delaware Revised Uniform Limited Partnership Act for limited partnerships formed under Delaware law, or any analogous action taken pursuant to any other Applicable Law with respect to any corporation, limited liability company, partnership or other entity.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Dollars</font>,&#8221; &#8220;<font style="font-weight:bold;">dollars</font>&#8221; or use of the sign &#8220;$&#8221; means only lawful money of the United States and not any other currency, regardless of whether that currency uses the &#8220;$&#8221; sign to denote its currency or may be readily converted into lawful money of the United States.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Dollar Equivalent</font>&#8221; is, at any time, (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Effective Date</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Eligible Accounts</font>&#8221; means Accounts owing to Borrower which arise in the ordinary course of Borrower&#8217;s business that meet all Borrower&#8217;s representations and warranties in Section 4.3, that have been, at the option of Bank, confirmed in accordance with Section 5.4(f) of this Agreement, and are due and owing from Account Debtors deemed creditworthy by Bank in its sole discretion.&nbsp;&nbsp;Bank reserves the right, at any time after the Effective Date, in its sole discretion in each instance, to either (i) adjust any of the criteria set forth below and to establish new criteria or (ii) deem any Accounts owing from a particular Account Debtor or Account Debtors to not meet the criteria to be Eligible Accounts.&nbsp;&nbsp;Unless Bank otherwise agrees in writing, Eligible Accounts shall not include:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts (i) for which the Account Debtor is Borrower&#8217;s Affiliate, officer, employee, investor, or agent, or (ii) that are intercompany Accounts;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts that the Account Debtor has not paid within 120 days, except for McKesson and ASD Specialty Healthcare for which such period is 130 days, of invoice date regardless of invoice payment period terms;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts with credit balances over 120 days from invoice date, except for McKesson and ASD Specialty Healthcare for which such period is 130 days, to the extent of such credit balances;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor if 50.0% or more of the Accounts owing from such Account Debtor have not been paid within 120 days of invoice date, except for McKesson and ASD Specialty Healthcare for which such period is 130 days;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor (i) which does not have its principal place of business in the United States or (ii) whose billing address (as set forth in the applicable invoice for such Account) is not in the United States, unless in the case of both (i) and (ii) such Accounts are otherwise approved by Bank in writing;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts billed from and/or paya</font><font style="color:#000000;">ble to Borrower outside of the </font><font style="color:#000000;">United States (sometimes called foreign invoiced accounts);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts in which Bank does not have a first priority, perfected security interest under all Applicable Law;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts billed and/or payable in a Currency other than Dollars;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor to the extent that Borrower is indebted or obligated in any manner to the Account Debtor (as creditor, lessor, supplier or otherwise - sometimes called &#8220;contra&#8221; accounts, accounts payable, customer deposits or credit accounts), but only to the extent of such Indebtedness or obligations; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts with or in respect of accruals for marketing allowances, incentive rebates, price protection, cooperative advertising and other similar marketing credits, unless otherwise approved by Bank in writing, but only to the extent of such credits;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor which is a United States government entity or any department, agency, or instrumentality thereof unless Borrower has assigned its payment rights to Bank and the assignment has been acknowledged under the Federal Assignment of Claims Act of 1940, as amended;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts with customer deposits and/or with respect to which Borrower has received an upfront payment, to the extent of such customer deposit and/or upfront payment;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts for demonstration or promotional equipment, or in which goods are consigned, or sold on a &#8220;sale guaranteed&#8221;, &#8220;sale or return&#8221;, &#8220;sale on approval&#8221;, or other terms if Account Debtor&#8217;s payment may be conditional;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor where goods or services have not yet been rendered to the Account Debtor (sometimes called memo billings or pre-billings);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts subject to contractual arrangements between Borrower and an Account Debtor where payments shall be scheduled or due according to completion or fulfillment requirements (sometimes called contracts accounts receivable, progress billings, milestone billings, or fulfillment contracts);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor the amount of which may be subject to withholding based on the Account Debtor&#8217;s satisfaction of Borrower&#8217;s complete performance (but only to the extent of the amount withheld; sometimes called retainage billings);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts subject to trust provisions, subrogation rights of a bonding company, or a statutory trust;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor that has been invoiced for goods that have not been shipped to the Account Debtor unless Bank, Borrower, and the Account Debtor have entered into an agreement acceptable to Bank wherein the Account Debtor acknowledges that (i) it has title to and has ownership of the goods wherever located, (ii) a bona fide sale of the goods has occurred, and (iii) it owes payment for such goods in accordance with invoices from Borrower (sometimes called &#8220;bill and hold&#8221; accounts);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(s)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts for which the Account Debtor has not been invoiced;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts that represent non-trade receivables or that are derived by means other than in the ordinary course of Borrower&#8217;s business;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(u)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts for which Borrower has permitted Account Debtor&#8217;s paym</font><font style="color:#000000;">ent to extend beyond 12</font><font style="color:#000000;">0 days (including Accounts with a due date that is more than </font><font style="color:#000000;">12</font><font style="color:#000000;">0 days from invoice date)</font><font style="color:#000000;"> </font><font style="color:#000000;">except for </font><font style="color:#000000;">McKesson and ASD Specialty Healthcare</font><font style="color:#000000;"> for which such</font><font style="color:#000000;"> period is 130 days</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts arising from chargebacks, debit memos or other payment deductions taken by an Account Debtor;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(w)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts arising from product returns and/or exchanges (sometimes called &#8220;warranty&#8221; or &#8220;RMA&#8221; accounts);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(x)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts in which the Account Debtor disputes liability or makes any claim (but only up to the disputed or claimed amount), or if the Account Debtor is subject to an Insolvency Proceeding (whether voluntary or involuntary), or becomes insolvent, or goes out of business; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(y)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> Accounts owing from an Account Debtor with respect to which Borrower has received Deferred Revenue (but only to the extent of such Deferred Revenue); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(z)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts owing from an Account Debtor, whose total obligations to Borrower exceed 25.0% of all Accounts, except for McKesson and ASD Specialty Healthcare for which such percentage is 50.0%, for the amounts that exceed that percentage, unless Bank approves in writing; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(aa)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Accounts for which Bank in its sole discretion determines collection to be doubtful, including, without limitation, accounts represented by &#8220;refreshed&#8221; or &#8220;recycled&#8221; invoices.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Environmental Laws</font>&#8221; means any Applicable Law (including any permits, concessions, grants, franchises, licenses, agreements, or governmental restrictions) relating to pollution or the protection of health, safety, or the environment or the release of any materials into the environment (including those related to hazardous materials, air emissions, discharges to waste or public systems, and health and safety matters).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Equinox License Agreement</font>&#8221; means that certain Exclusive License Agreement, dated as of January 31, 2020, by and between the Borrower and Equinox Science, LLC (as amended from time to time).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Equipment</font>&#8221; is all &#8220;equipment&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">ERISA</font>&#8221; is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Event of Default</font>&#8221; is defined in Section 7.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Exchange Act</font>&#8221; is the Securities Exchange Act of 1934, as amended.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Excluded</font> <font style="font-weight:bold;">Accounts</font>&#8221; is defined in Section 5.9(c).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Excluded Taxes</font>&#8221; means any of the following Taxes imposed on or with respect to Bank or required to be withheld or deducted from a payment to Bank, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of Bank being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) U.S. federal withholding Taxes imposed on amounts payable to or for the account of Bank with respect to an applicable interest in a Credit Extension or the Revolving Line pursuant to a law in effect on the date on which (i) Bank acquires such interest in the Credit Extensions or the Revolving Line or (ii) Bank changes its lending office, except in each case to the extent that, pursuant to Section&#160;1.8, amounts with respect to such Taxes were payable either to Bank&#8217;s assignor immediately </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before Bank became a party hereto or to Bank immediately before it changed its lending office, (c) Taxes attributable to Bank&#8217;s failure to comply with Section&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and (d) any withholding Taxes imposed under FATCA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">EyePoint US</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">FATCA</font>&#8221; means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section&#160;1471(b)(1) of the Internal Revenue Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Internal Revenue Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Final Payment</font>&#8221; is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to occur of (a) the Term Loan Maturity Date, (b) the repayment of the Term Loan Advance in full, (c) as required pursuant to Sections 1.2(c) or 1.2(d), or (d) the termination of this Agreement, in an amount equal to $600,000.00.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Financial Statement Repository</font>&#8221; is NECreditSolutions@svb.com or such other means of collecting information approved and designated by Bank after providing notice thereof to Borrower from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Foreign Currency</font>&#8221; is the lawful money of a country other than the United States.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Funding Date</font>&#8221; is any date on which a Credit Extension is made to or for the account of Borrower which shall be a Business Day.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">FX Contract</font>&#8221; is any foreign exchange contract by and between Borrower and Bank under which Borrower commits to purchase from or sell to Bank a specific amount of Foreign Currency at a set price or on a specified date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">GAAP</font>&#8221; is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">General Intangibles</font>&#8221; is all &#8220;general intangibles&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation, all Intellectual Property, claims, income and other tax refunds, security and other deposits, payment intangibles, contract rights, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Governmental</font> <font style="font-weight:bold;">Approval</font>&#8221; is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Governmental Authority</font>&#8221; is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Guarantor</font>&#8221; is any Person providing a Guaranty in favor of Bank.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Guaranty</font>&#8221; is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Icon</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">set forth on Schedule I hereto</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Indebtedness</font>&#8221; is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, (d) Contingent Obligations and (e) other short- and long-term obligations under debt agreements, lines of credit and extensions of credit.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Indemnified Person</font>&#8221; is defined in Section 11.3.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Indemnified Taxes</font>&#8221; means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of Borrower under any Loan Document and (b) to the extent not otherwise described in clause (a), Other Taxes.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Information</font>&#8221; is defined in Section 11.8.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Initial Audit</font>&#8221; is Bank&#8217;s inspection of Borrower&#8217;s Accounts, the Collateral, and Borrower&#8217;s Books, with results satisfactory to Bank in its sole discretion.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Insolvency Proceeding</font>&#8221; is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, receivership or other relief.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Intellectual Property</font>&#8221; means, with respect to any Person, all of such Person&#8217;s right, title, and interest in and to the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">its Copyrights, Trademarks and Patents; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how and operating manuals;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any and all source code;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any and all design rights which may be available to such Person;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Internal Revenue Code</font>&#8221; means the U.S. Internal Revenue Code of 1986, and the rules and regulations promulgated thereunder, each as amended or modified from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Inventory</font>&#8221; is all &#8220;<font style="font-weight:bold;">inventory</font>&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of Borrower&#8217;s custody or possession or in transit and including any returned goods and any documents of title representing any of the above.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Investment</font>&#8221; is any beneficial ownership interest in any Person (including stock, partnership, membership, or other ownership interest or other equity securities), and any loan, advance or capital contribution to any Person.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Key Person</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; is each of Borrower&#8217;s </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chief executive officer, chief financial officer, chief development officer, chief commercial officer, chief medical officer and chief operating officer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Letter of Credit</font>&#8221; is a standby or commercial letter of credit issued by Bank upon request of Borrower based upon an application, guarantee, indemnity, or similar agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Lien</font>&#8221; is a claim, mortgage, deed of trust, levy, attachment charge, pledge, hypothecation, security interest or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Loan Documents</font>&#8221; are, collectively, this Agreement and any schedules, exhibits, certificates, notices, and any other documents related to this Agreement, the Perfection Certificate, the Stock Pledge Agreement, any Control Agreements, any Bank Services Agreement, any subordination agreement, any note, or notes or guaranties executed by Borrower or any Guarantor, landlord waivers and consents, bailee waivers and consents, and any other present or future agreement by Borrower and/or any Guarantor with or for the benefit of Bank in connection with this Agreement or Bank Services, all as amended, restated, or otherwise modified in accordance with the terms thereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Material Adverse Change</font>&#8221; is (a) a material impairment in the perfection or priority of Bank&#8217;s Lien in the Collateral or in the value of such Collateral; (b) a material adverse change in the business, operations, or condition (financial or otherwise) of Borrower; (c) a material impairment of the prospect of repayment of any portion of the Obligations; or (d) Bank determines, based upon information available to it and in its reasonable judgment, that there is a likelihood that Borrower shall fail to comply with one or more of the financial covenants in Section 5 during the next succeeding financial reporting period</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Maturity Date</font>&#8221; means the Term Loan Maturity Date and/or Revolving Line Maturity Date, as applicable. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Net Income</font>&#8221; means, as calculated on a consolidated basis for Borrower for any period as at any date of determination, the net profit (or loss), after provision for taxes, of Borrower for such period taken as a single accounting period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Obligations</font>&#8221; are Borrower&#8217;s obligations to pay when due any debts, principal, interest, fees, Bank Expenses, the Final Payment, the Prepayment Fee, the Unused Revolving Line Facility Fee, the Termination Fee, and other amounts Borrower owes Bank now or later, whether under this Agreement, the other Loan Documents, or otherwise, including, without limitation, all obligations relating to Bank Services and interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Bank, and to perform Borrower&#8217;s duties under the Loan Documents.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">OFAC</font>&#8221; is the Office of Foreign Assets Control of the United States Department of the Treasury and any successor thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Operating Documents</font>&#8221; are, for any Person, such Person&#8217;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&#8217;s jurisdiction of organization on a date that is no earlier than 30 days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership or limited partnership, its partnership agreement or limited partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Other Connection Taxes</font>&#8221; means, with respect to Bank, Taxes imposed as a result of a present or former connection between Bank and the jurisdiction imposing such Tax (other than connections arising from Bank having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to, or enforced any Loan Document, or sold or assigned an interest in any Credit Extension or Loan Document).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Other Taxes</font>&#8221; means all present or future stamp, court, documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Overadvance</font>&#8221; is defined in Section 1.3.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Patents</font>&#8221; means all patents, patent applications, and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Parent</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Payment/Advance Form</font>&#8221; is that certain form in the form attached hereto as Exhibit B.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Payment Date</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Perfection Certificate</font>&#8221; is the Perfection Certificate delivered by Borrower in connection with this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Permitted</font> <font style="font-weight:bold;">Acquisition</font>&#8221; means a transaction whereby Borrower acquires all or substantially all of the capital stock or property of another Person (a &#8220;<font style="font-weight:bold;">Target</font>&#8221;), which satisfies each of the following conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower shall be in compliance with the financial covenant set forth in Section 5.10 of the Loan Agreement on the date of such proposed transaction and provide Bank with evidence that Borrower shall be in pro forma compliance (for the immediately following twelve (12) month period) with the financial covenants set forth in Section 5.10 of the Loan Agreement after giving effect to each such proposed transaction;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such proposed transaction shall only involve an entity formed, and assets located, in the United States, and the party or parties being acquired is in the same or a substantially similar line of business as Borrower;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">no Event of Default has occurred and is continuing or would exist after giving effect to the transaction and Bank has received satisfactory evidence that Borrower is in compliance with all terms and conditions of this Agreement (and that it will be in compliance after giving effect to the transaction);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the transaction is approved by the board of directors (or equivalent control group) of all parties to the transaction;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all consideration to be paid by Borrower and its Subsidiaries in connection with any transaction shall be in the form of stock and no Indebtedness will be incurred, assumed, or would exist with respect to Borrower or its Subsidiaries as a result of the contemplated transaction, other than Permitted Indebtedness, and no Liens will be incurred, assumed, or would exist with respect to the assets of Borrower or its Subsidiaries as a result of the contemplated transaction, other than Permitted Liens;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower provides Bank (i) written notice of the transaction at least 10 days before the closing of the transaction, and (ii) copies of the transaction agreement and other material documents relative to the contemplated transaction and such other financial information, financial analysis, documentation or other information relating to such transaction as Bank shall reasonably request at least 10 days before the closing of the transaction;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower is a surviving legal entity after completion of the contemplated transaction;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the contemplated transaction is consensual and non-hostile;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Target acquired in the transaction shall, within 30 days of the consummation of the transaction, provide Bank either joinder documentation to cause such Target to become a co-borrower hereunder or a guaranty to cause such Target to become a Guarantor hereunder (as determined by Bank in its sole discretion), together </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">with documentation, all in form and substance satisfactory to Bank (including being sufficient to grant Bank a first priority Lien (subject to Permitted Liens) in and to the assets of such Target);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the transaction and Target are accretive in all respects; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower shall have delivered to Bank, at least 1 Business Days prior to the date on which any such transaction is to be consummated (or such later date as is agreed by Bank in its sole discretion), a certificate of a Responsible Officer of Borrower, in form and substance reasonably satisfactory to Bank, certifying that all of the requirements set forth in this definition have been satisfied or will be satisfied on or prior to the consummation of such purchase or other acquisition.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Permitted Indebtedness</font>&#8221; is:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower&#8217;s Indebtedness to Bank under this Agreement and the other Loan Documents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness existing on the Effective Date which is shown on the Perfection Certificate (excluding, for clarity, the Indebtedness owed to CRG);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subordinated Debt;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">unsecured Indebtedness to trade creditors incurred in the ordinary course of business; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">unsecured guarantees by Borrower or a secured Guarantor of Indebtedness of Borrower or a secured Guarantor in an aggregate amount outstanding not to exceed $100,000.00 at any time;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness secured by Liens permitted under clause (c) of the definition of &#8220;Permitted Liens&#8221; hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">unsecured Indebtedness incurred in connection with Borrower&#8217;s corporate credit card with American Express in an aggregate amount outstanding not to exceed $700,000.00 at any time (the &#8220;</font><font style="font-weight:bold;color:#000000;">Permitted Credit Card</font><font style="color:#000000;">&#8221;);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indebtedness incurred to finance insurance premiums in the ordinary course of Borrower&#8217;s business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">other unsecured Indebtedness not otherwise permitted hereunder in an aggregate amount not to exceed $250,000.00 outstanding at any time; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">intercompany Indebtedness permitted as a Permitted Investment under clause (g) of the definition thereof; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (k) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Permitted Investments</font>&#8221; are:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) Investments (including, without limitation, Subsidiaries) existing on the Effective Date which are shown on the Perfection Certificate (excluding, for clarity, the Indebtedness owed to CRG), and (ii) the Equinox License Agreement and transactions contemplated thereby;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">cash Investments by Borrower in Securities Corp.; provided that (i) an Event of Default does not exist at the time of any such Investment, and would not exist after giving effect to any such Investment, and (ii) Borrower and its Subsidiaries are at all time</font><font style="color:#000000;">s in compliance with Section 5.9</font><font style="color:#000000;">(a);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) Investments consisting of Cash Equivalents, and (ii) any Investments permitted by Borrower&#8217;s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Bank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments consisting of accounts (but only to the extent that Borrower is permitted to maintain such accounts pursuant to Section 5.9 of this Agreement) in which Bank has a first priority perfected security interest (to the extent required pursuant to Section 5.9 of this Agreement);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments accepted in connection with Transfers permitted by Section 6.1;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments (i) by one Borrower in another Borrower, and (ii) by Borrower or a secured Guarantor in a Subsidiary that is not a Borrower or a secured Guarantor for the ordinary and necessary current operating expenses of such Subsidiary in an amount not to exceed $100,000.00 in the aggregate in any twelve (12) month period;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers, directors, partners, managers and members relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee equity purchase plans or similar agreements approved by the Board; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business; provided that this paragraph (j) shall not apply to Investments of Borrower in any Subsidiary;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">joint ventures or strategic alliances in the ordinary course of Borrower&#8217;s business consisting of the non-exclusive licensing of technology, the development of technology or the providing of technical support, provided that any cash investments by Borrower do not exceed $250,000.00 in the aggregate in any twelve (12) month period;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Permitted Acquisitions; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to the extent constituting an Investment, security deposits with utilities, landlords and other like Persons made in the ordinary course of Borrower&#8217;s business in an aggregate amount not to exceed $250,000.00 during the term of this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">other Investments not otherwise permitted by Section 6.6 not exceeding $100,000.00 in the aggregate in any fiscal year.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Permitted Liens</font>&#8221; are:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens existing on the Effective Date which are shown on the Perfection Certificate (excluding, for clarity, any Liens in favor of CRG) or arising under this Agreement or the other Loan Documents;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and for which Borrower maintains adequate reserves on Borrower&#8217;s Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code;</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">purchase money Liens (i) on Equipment acquired or held by Borrower incurred for financing the acquisition of the Equipment securing no more than $500,000.00 in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of the Equipment; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed $250,000.00 and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens to secure payment of workers&#8217; compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens incurred in the extension, renewal or refinancing of the Indebtedness secured by Liens described in (a) through (c), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">easements, rights-of-way, zoning restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">leases or subleases of real property granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Bank a security interest therein;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens in favor of customs or revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens securing Indebtedness permitted under clause (i) of the definition of &#8220;Permitted Indebtedness&#8221; herein;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">(i) non-exclusive licenses of Intellectual Property granted to third parties in the ordinary course of business, and licenses of Intellectual Property that could not result in a legal transfer of title of the licensed property that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discreet geographical areas outside of the United States; (ii) development, co-promotion, distribution and other collaborative arrangements where such arrangements provide for the licenses or disclosure of Intellectual Property in the ordinary course of business and consistent with general market practices where such license requires periodic payments based on per unit sales of a product over a period of time; provided that each such license does not effect a legal transfer of title to such Intellectual Property and that each such license must be a true license as opposed to a license that is a sales transaction in substance; and (iii) the Alimera License Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Liens arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default under Sections 7.4 and 7.7; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">customary Liens of any bank in connection with statutory, common law and contractual rights of setoff and recoupment with respect to any deposit account or securities account of Borrower, provided that </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">(i) Bank has a first priority perfected security interest in such account</font><font style="color:#000000;"> (to the extent required pursuant to Section 5.9 of this Agreement)</font><font style="color:#000000;">,</font><font style="color:#000000;"> and (ii) such account is permitted to be maintained pursuant to Section </font><font style="color:#000000;">5.9</font><font style="color:#000000;"> of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Person</font>&#8221; is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Prepayment Fee</font>&#8221; shall be an additional fee, payable to Bank, with respect to the Term Loan Advance, in an amount equal to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">for a prepayment of the Term Loan Advance made on or prior to the first (1st) anniversary of the Effective Date, three percent (3.0%) of the outstanding principal amount of the Term Loan Advance immediately prior to the date of such prepayment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">for a prepayment of the Term Loan Advance made after the first (1st) anniversary of the Effective Date, but on or prior to the second (2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup>) anniversary of the Effective Date, two percent (2.0%) of the outstanding principal amount of the Term Loan Advance immediately prior to the date of such prepayment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">for a prepayment of the Term Loan Advance made after the second (2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup>) anniversary of the Effective Date, but on or prior to the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) anniversary of the Effective Date, one percent (1.0%) of the outstanding principal amount of the Term Loan Advance immediately prior to the date of such prepayment; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">for a prepayment of the Term Loan Advance made after the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) anniversary of the Effective Date, but prior to the Term Loan Maturity Date, one-half of one percent (0.50%) of the outstanding principal amount of the Term Loan Advance immediately prior to the date of such prepayment.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, provided no Event of Default has occurred and is continuing, the Prepayment Fee shall be waived by Bank, if Bank closes on the refinance and redocumentation of the Term Loan Advance (in its sole and absolute discretion) prior to the Term Loan Maturity Date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Prime Rate</font>&#8221; is set forth on Schedule I hereto. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Prime Rate Margin</font>&#8221; is set forth on Schedule I hereto. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Product Revenue</font>&#8221; is Borrower&#8217;s net revenue, determined in accordance with GAAP, attributable to Borrower&#8217;s sales of Dexycu and Yutiq.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Registered Organization</font>&#8221; is any &#8220;registered organization&#8221; as defined in the Code with such additions to such term as may hereafter be made.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Representatives</font>&#8221; is defined in Section 11.8.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Reserves<font style="font-weight:normal;">&#8221; means, as of any date of determination, such amounts as Bank may from time to time establish and revise in its sole discretion, reducing the amount of Advances and other financial accommodations which would otherwise be available to Borrower (a) to reflect events, conditions, contingencies or risks which, as determined by Bank in its sole discretion, do or may adversely affect (i) the Collateral or any other property which is security for the Obligations or its value (including without limitation any increase in delinquencies of Accounts), (ii) the assets, business or prospects of Borrower or any Guarantor, or (iii) the security interests and other rights of Bank in the Collateral (including the enforceability, perfection and priority thereof); or (b) to reflect Bank's reasonable belief that any collateral report or financial information furnished by or on behalf of Borrower or any Guarantor to Bank is or may have been incomplete, inaccurate or misleading in any material respect; or (c)&#160;in respect of any state of facts which Bank determines in its sole discretion constitutes a Default or an Event of Default.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;</font><font style="font-weight:bold;">Responsible Officer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; is any of the Chief Executive Officer, President, Chief Financial Officer and Controller of Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Restricted License</font>&#8221; is any material license or other material agreement with respect to which Borrower is the licensee (a) that prohibits or otherwise restricts Borrower from granting a security interest in Borrower&#8217;s interest in such license or agreement or any other property, or (b) for which a default under or termination of could interfere with Bank&#8217;s right to sell any Collateral.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Revolving Line</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Revolving Line Maturity Date</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Sanctioned Person</font>&#8221; means a Person that: (a) is listed on any Sanctions list maintained by OFAC or any similar Sanctions list maintained by any other Governmental Authority having jurisdiction over Borrower; (b) is located, organized, or resident in any country, territory, or region that is the subject or target of Sanctions; or (c) is 50.0% or more owned or controlled by one (1) or more Persons described in clauses (a) and (b) hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Sanctions</font>&#8221; means the economic sanctions laws, regulations, embargoes or restrictive measures administered, enacted or enforced by the United States government and any of its agencies, including, without limitation, OFAC and the U.S. State Department, or any other Governmental Authority having jurisdiction over Borrower.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">SEC</font>&#8221; is the Securities and Exchange Commission, any successor thereto, and any analogous Governmental Authority.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Securities Account</font>&#8221; is any &#8220;securities account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Securities Corp.</font>&#8221; is EYE POINT PHARMACEUTICALS SECURITIES CORPORATION, a corporation organized under the laws of the Commonwealth of Massachusetts and a Subsidiary of EyePoint US.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Specified Affiliate</font>&#8221; is any Person (a) more than ten percent (10.0%) of whose aggregate issued and outstanding equity or ownership securities or interests, voting, non-voting or both, are owned or held directly or indirectly, beneficially or of record, by Borrower, and/or (b) whose equity or ownership securities or interests representing more than ten percent (10.0%) of such Person&#8217;s total outstanding combined voting power are owned or held directly or indirectly, beneficially or of record, by Borrower.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Stock</font> <font style="font-weight:bold;">Pledge Agreement</font>&#8221; means that certain Stock Pledge Agreement executed by EyePoint US in favor of Bank dated as of Effective Date, as may be amended, modified, supplemented or restated from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Subordinated Debt</font>&#8221; is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all of Borrower&#8217;s or any of its Subsidiaries&#8217; now or hereafter indebtedness to Bank (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Bank entered into between Bank and the other creditor), on terms acceptable to Bank.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Subsidiary</font>&#8221; is, as to any Person, a corporation, partnership, limited liability company or other entity of which shares of stock, partnership, membership, or other ownership interest or other equity securities having ordinary voting power (other than stock, partnership, membership, or other ownership interest or other equity securities having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person.&nbsp;&nbsp;Unless the context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of Borrower or Guarantor.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">SWK Purchase Receivables</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means</font><font style="font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrower&#8217;s right, title and interest in and to all Purchase Receivables (as defined in the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SWK </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty Purchase Agreement).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">SWK</font> <font style="font-weight:bold;">Royalty Purchase Agreement</font>&#8221; is that certain Royalty Purchase Agreement dated as of December 17, 2020 between Parent, EyePoint US and SWK Funding LLC, a Delaware limited liability company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Taxes</font>&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Term Loan Advance</font>&#8221; is defined in Section 1.2(a).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Term Loan Availability Amount</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Term Loan Maturity Date</font>&#8221; is set forth on Schedule I hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Termination Fee</font>&#8221; is defined in Section 1.5(c).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="font-weight:bold;">Trademarks</font>&#8221; means, with respect to any Person, any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Person connected with and symbolized by such trademarks.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Transfer</font>&#8221; is defined in Section 6.1. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Unused Revolving Line Facility Fee</font>&#8221; is defined in Section 1.5(d).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">USA Patriot Act</font>&#8221; means the &#8220;Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001&#8221; (Public Law 107-56, signed into law on October 26, 2001), as amended from time to time.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">[Signature page follows]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, the parties hereto have caused this Agreement to be executed as of the Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BORROWER:</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ George Elston</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George Elston</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Head of Corporate Development</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EYEPOINT PHARMACEUTICALS US, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ George Elston</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George Elston</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ICON BIOSCIENCE, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Philip Hoffstein</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philip Hoffstein</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BANK:</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SILICON VALLEY BANK</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Lauren Cole</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lauren Cole</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature Page to Loan and Security Agreement</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SCHEDULE I</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LSA PROVISIONS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:98.99%;">
<tr>
<td style="width:33.29%;"></td>
<td style="width:65.69%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LSA Section</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LSA Provision</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1(a) &#8211; Revolving Line &#8211; Availability</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts borrowed under the Revolving Line may be prepaid or repaid and, prior to the Revolving Line Maturity Date, reborrowed, subject to the applicable terms and conditions precedent herein.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2(a) &#8211; Term Loan &#8211; Availability</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After repayment, the Term Loan Advance (or any portion thereof) may not be reborrowed. </p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2(b) &#8211; Term Loan &#8211; Repayment</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencing on February 1, 2024 and continuing on each Payment Date thereafter, Borrower shall repay the Term Loan Advance in (i) 36 consecutive equal monthly installments of principal, plus (ii) monthly payments of accrued interest at the rate set forth in Section 1.4(b)(ii).</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4(a)(i) &#8211; Interest Payments &#8211; Advances</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on the principal amount of each Advance is payable in arrears monthly (A) on each Payment Date, (B) on the date of any prepayment of such Advance, and (C) on the Revolving Line Maturity Date.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4(a)(ii) &#8211; Interest Payments &#8211; Term Loan Advance</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on the principal amount of the Term Loan Advance is payable in arrears monthly (A) on each Payment Date commencing on the first Payment Date following the Funding Date of the Term Loan Advance, (B) on the date of any prepayment of the Term Loan Advance, and (C) on the Term Loan Maturity Date.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4(b)(i) &#8211; Interest Rate &#8211; Advances</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding principal amount of any Advance shall accrue interest at a floating rate per annum equal to the Prime Rate, which interest shall be payable in accordance with Section 1.4(a).</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4(b)(ii) &#8211; Interest Rate &#8211; Term Loan Advance</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding principal amount of the Term Loan Advance shall accrue interest at a floating rate per annum equal to the greater of (1) five and one half of one percent (5.50%), and (2) the Prime Rate plus the Prime Rate Margin, which interest shall be payable in accordance with Section 1.4(a).</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4(e) &#8211; Interest Computation</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest shall be computed on the basis of the actual number of days elapsed and a 360-day year for any Credit Extension outstanding.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8 &#8211; Borrower Liability</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Borrower hereunder shall be jointly and severally obligated to repay all Credit Extensions made hereunder and any other Obligations related thereto, regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Borrower&#8221; or &#8220;Borrowers&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Borrower</font>&#8221; or &#8220;<font style="font-weight:bold;">Borrowers</font>&#8221; means each of  (a) <font style="font-weight:bold;">EYEPOINT PHARMACEUTICALS, INC</font>.,<font style="font-weight:bold;"> </font>a Delaware corporation (&#8220;<font style="font-weight:bold;">Parent</font>&#8221;), (b) <font style="font-weight:bold;">EYEPOINT PHARMACEUTICALS US, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">EyePoint</font> <font style="font-weight:bold;">US</font>&#8221;), and (c) and <font style="font-weight:bold;">ICON BIOSCIENCE, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Icon</font>&#8221;).</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Effective Date&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Effective Date</font>&#8221; is March 9, 2022.<font style="font-style:italic;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Payment Date&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Payment Date</font>&#8221; is (a) with respect to Term Loan Advance, the first (1st) calendar day of each month and (b) with respect to Advances, the last calendar day of each month.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Prime Rate&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Prime Rate</font>&#8221; is the rate of interest per annum from time to time published in the money rates section of <font style="text-decoration:underline;">The Wall Street Journal</font> or any successor publication thereto as the &#8220;prime rate&#8221; then in effect; provided that if such rate of interest, as set forth from time to time in the money rates section of <font style="text-decoration:underline;">The Wall Street Journal</font>, becomes unavailable for any reason as determined by Bank, the &#8220;Prime Rate&#8221; shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero percent (0.0%) per annum, such rate shall be deemed to be zero percent (0.0%) per annum for purposes of this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:98.99%;">
<tr>
<td style="width:33.29%;"></td>
<td style="width:65.69%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Prime Rate Margin&#8221;</font></p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Prime Rate Margin</font>&#8221; is two and one quarter of one percent (2.25%).</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Revolving Line&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Revolving Line</font>&#8221; is an aggregate principal amount equal to $15,000,000.00.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Revolving Line Maturity Date&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Revolving Line Maturity Date</font>&#8221; is January 1, 2027.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Term Loan Availability Amount&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Term Loan Availability Amount</font>&#8221; is an original principal amount equal to $30,000,000.00.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 &#8211; &#8220;Term Loan Maturity Date&#8221;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Term Loan Maturity Date</font>&#8221; is January 1, 2027.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT A</font></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">COMPLIANCE STATEMENT</font></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#8220;[***]&#8221;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LOAN PAYMENT/ADVANCE REQUEST FORM</font></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="qsTmp"></a><a name="_iDocIDField_EOD"></a>&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>eypt-ex211_8.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex211_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1 </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">List of Subsidiaries of EyePoint Pharmaceuticals, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary Name<font style="font-weight:normal;">&#160;</font></p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation<font style="font-weight:normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals US, Inc.</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pSiMedica Limited</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals Securities Corporation</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Icon Bioscience, Inc.</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>eypt-ex231_9.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex231_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement Nos. 333-152146, 333-163208, 333-216166, 333-227525, 333-233137, 333-249902, and 333-258595 on Form S-8 and Registration Nos. 333-226341, 333-253053, 333-252170, and 333-258598 on Form S-3 of our report dated March 11, 2022, relating to the financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries appearing in this Annual Report on Form 10-K for the year ended December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte&#160;&amp; Touche LLP </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2022 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>eypt-ex311_11.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex311_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, <font style="font-weight:bold;">Nancy Lurker</font>, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of <font style="font-weight:bold;">EYEPOINT PHARMACEUTICALS, INC.</font>; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;11, 2022 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:216pt;;">
<tr>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nancy Lurker<font style="font-weight:normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nancy Lurker</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;&#160; President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>eypt-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, <font style="font-weight:bold;">George O. Elston</font>, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of <font style="font-weight:bold;">EYEPOINT PHARMACEUTICALS, INC.</font>; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;11, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:216pt;;">
<tr>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">/s/ George O. Elston<font style="font-weight:normal;">&#160;</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: George O. Elston</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: &#160;&#160;Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:31.5pt;;text-indent:-31.5pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>eypt-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of EyePoint Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the twelve months ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nancy Lurker, President and Chief Executive Officer of the Company, certify that to the best of my knowledge: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td colspan="3" valign="bottom"  style="width:44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nancy Lurker</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Lurker</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>eypt-ex322_10.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eypt-ex322_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of EyePoint Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the twelve months ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, George O. Elston, Chief Financial Officer of the Company, certify that to the best of my knowledge: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March&#160;11, 2022 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td colspan="3" valign="bottom"  style="width:44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">/s/ George O. Elston</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George O. Elston</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g0exp3o4wshp000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0exp3o4wshp000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *Y!44# 2(  A$! Q$!_\0
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M>PI]@]G$]A_X7H/^A<_\G?\ [71_PO0?]"Y_Y.__ &NO'J*/84^P>SB>P_\
M"]!_T+G_ ).__:Z/^%Z#_H7/_)W_ .UUX]11["GV#V<3V'_A>@_Z%S_R=_\
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MT'_0N?\ D[_]KKQZBCV%/L'LXGL/_"]!_P!"Y_Y._P#VNC_A>@_Z%S_R=_\
MM=>/44>PI]@]G$]A_P"%Z#_H7/\ R=_^UT?\+T'_ $+G_D[_ /:Z\>HH]A3[
M![.)[#_PO0?]"Y_Y._\ VNC_ (7H/^A<_P#)W_[77CU%'L*?8/9Q/8?^%Z#_
M *%S_P G?_M='_"]!_T+G_D[_P#:Z\>HH]A3[![.)[#_ ,+T'_0N?^3O_P!K
MH_X7H/\ H7/_ "=_^UUX]11["GV#V<3V'_A>@_Z%S_R=_P#M='_"]!_T+G_D
M[_\ :Z\>HH]A3[![.)[#_P +T'_0N?\ D[_]KH_X7H/^A<_\G?\ [77CU%'L
M*?8/9Q/8?^%Z#_H7/_)W_P"UT?\ "]!_T+G_ ).__:Z\>HH]A3[![.)[#_PO
M0?\ 0N?^3O\ ]KH_X7H/^A<_\G?_ +77CU%'L*?8/9Q/8?\ A>@_Z%S_ ,G?
M_M='_"]!_P!"Y_Y._P#VNO'J*/84^P>SB>P_\+T'_0N?^3O_ -KH_P"%Z#_H
M7/\ R=_^UUX]11["GV#V<3W76OBX-'_L[_B2>=]LLH[O_C[V[-^?E^X<XQUK
M+_X7H/\ H7/_ "=_^UUPWC7_ )EW_L"6W_LU<O2C0IM7:$H1L>P_\+T'_0N?
M^3O_ -KH_P"%Z#_H7/\ R=_^UUX]13]A3[#]G$]A_P"%Z#_H7/\ R=_^UT?\
M+T'_ $+G_D[_ /:Z\>HH]A3[![.)[#_PO0?]"Y_Y._\ VNC_ (7H/^A<_P#)
MW_[77CU%'L*?8/9Q/8?^%Z#_ *%S_P G?_M='_"]!_T+G_D[_P#:Z\>HH]A3
M[![.)[#_ ,+T'_0N?^3O_P!KH_X7H/\ H7/_ "=_^UUX]11["GV#V<3V'_A>
M@_Z%S_R=_P#M='_"]!_T+G_D[_\ :Z\>HH]A3[![.)[#_P +T'_0N?\ D[_]
MKH_X7H/^A<_\G?\ [77CU%'L*?8/9Q/8?^%Z#_H7/_)W_P"UT?\ "]!_T+G_
M ).__:Z\>HH]A3[![.)[#_PO0?\ 0N?^3O\ ]KH_X7H/^A<_\G?_ +77CU%'
ML*?8/9Q/8?\ A>@_Z%S_ ,G?_M='_"]!_P!"Y_Y._P#VNO'J*/84^P>SB>P_
M\+T'_0N?^3O_ -KH_P"%Z#_H7/\ R=_^UUX]11["GV#V<3V'_A>@_P"A<_\
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M;X/7&MR:5I1U*)'VS_V?#GA\#C;@\>U>>RVEQHGAJ]MM0A:WNKV:'R[>0;9
MJ;RS,O51D@#.,Y..E>K>'+76=.^#<B6MO=P:HHDDAC6,B3[^1A>IR.W>JJVW
M7<<CGKO3=*U#X3-K&KZ99Z;J:Y%O+! (#,0?E^50 <].GOQ7F^CZ?_:FK6]F
M7$:2-F20_P $8&YV_!03^%>M:U8Q_%#P=%JEC$$U[3\QS0'Y22/O)SZ]5S[C
MUKC]-T"^\/\ A>_U?5-'U!DNA]E"Q-Y3Q1'EW8E&V@[57D<@M[4X2LGW'%Z%
MWXK>&+32;O3]3TJ"./3[N$)B),*'4<'CCYE/Z$T[P+X:75O!FK7VG6UG=:XD
MPBA2[175$PIR%;*[CE@"1CCZUU6F6B^.?A+)I\-E=0-:_+9-=.'+E/ND.%4$
M=4X'%<=I>A:WI>A6NI:'++::['/-%<6@?$LJ+MQB-OO;<\C!^\*2D^7E;U0D
M]+&=KEREKI2VU_H5OIOB""\C=F%J%6:(*_.W&S&[&0!AN.N..V\0V:+\/O#M
M]I.BZ6-5U"6!'*:; V\O$S$8*$#D _A53QAJUSK/P_LX-?L$A\1R706UMT4B
M5EZ;MGWESR,=SC\.AUI?$>E_#;PX='M[S^T+1K<SP0HQ;:(V#*RCDC.,C_"I
M<MO43>QYAXJU.VWVEM%9:=#J6F7EQ#.]O9I&DZJR;'9,;3DA_E.1U]:[;Q<M
MMIW@#P]JNGZ-I*7UZ8#+MTV%@^Z(L0 5/4^G-<=XD\+:FJW&MW-E<02ZEJ92
MSM'7]ZROO;E1D@YV@#KG/M7IVMWNM>&? ?AF[L[6=I;!8/ML"@X\L0D.'QT
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MJQK(!(I8#8-F<?Q =,C/."_0O#6IV^EWUQ;.^G>(K&\1(HY)?*DD4H6,:@D
MDC#8[@>AKI]1U_4+WX:ZI#XTLTM[P;4L?-3RY9G_ +VSJ,'J0 "#^>C?O:;:
M%/<\?HHHKH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)\3I+%=&622RDE4AGCW$J5SU*]1ZK]#7CFNZ'?\ AW59-/U&$QRIRI_AD7)
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M7_"C[/X;_P"@99?^ B_X4?6EV#VOD?+E%?4?V?PW_P! RR_\!%_PH^S^&_\
MH&67_@(O^%'UI=@]KY'RY17U']G\-_\ 0,LO_ 1?\*/L_AO_ *!EE_X"+_A1
M]:78/:^1\N45]1_9_#?_ $#++_P$7_"C[/X;_P"@99?^ B_X4?6EV#VOD?+E
M%?4?V?PW_P! RR_\!%_PH^S^&_\ H&67_@(O^%'UI=@]KY'RY17U']G\-_\
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M!EE_X"+_ (4?6EV#VOD?+E%?4?V?PW_T#++_ ,!%_P */L_AO_H&67_@(O\
MA1]:78/:^1\N45]1_9_#?_0,LO\ P$7_  H^S^&_^@99?^ B_P"%'UI=@]KY
M'RY17U']G\-_] RR_P# 1?\ "C[/X;_Z!EE_X"+_ (4?6EV#VOD?+E%?4?V?
MPW_T#++_ ,!%_P */L_AO_H&67_@(O\ A1]:78/:^1\N45]1_9_#?_0,LO\
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MLO\ P$7_  H^S^&_^@99?^ B_P"%'UI=@]KY'RY17U']G\-_] RR_P# 1?\
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M^M5:M7O_ "[_ /7!?ZU5I %%%%, HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 6KW_ )=_^N"_UJK5J]_Y=_\ K@O]:JT@"BBBF 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2VW_'
MU#_OK_.BY_X^IO\ ?;^=%M_Q]0_[Z_SHN?\ CZF_WV_G2 Y?QQJ5EIWA._\
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MO-2%K)<BVB:5HT8 [0,DY/M6/XB9FUZTAN;^Y%DUL^RQL))$N9IMRX;,>#L
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MY=_^N"_UJK2 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!+;?\ 'U#_ +Z_SHN?^/J;_?;^=%M_Q]0_[Z_SHN?^/J;_
M 'V_G2 K7%Q#:V\EQ<2I%#&I9W<X"@=236);^*5O(1<V>C:K<6+#<MTD2!67
MU5&<2,/HIS7/_%R20>&]/M^1:7.I0Q71S@>7R<'VR!S[5WRJJ*%50JJ,  8
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MEVK;W#3 C<>261,'VP:T;&1_%>N:_#/>7EO;:=<"T@CM+AX2&"Y:0E2"Q)/
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M9?XN#U.3Z8XQTVL37%YX[L=%N;BYM=+EL))D:WG:%IYPX&S>I!X7YL \YYH
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M.@ZYI&H:O'<0ZK-)<%HK3RVBD<AB1\[97(''ZUV=% %/3+6YL[".&[NQ=3*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]&'.3["3_A')Q;ZK,+Z(ZMJ2+')=-;DHB 8"K'N!  +=6/)R<]*Z&B@#AI/
MVJOX0L_#HU^U6&U=668:<=Y",&0?ZW'!!R>_'3!S4\10RZSXC33#K.E+=6=F
MHFM]0LU>&5W.=T:,Q.<+@G)QD#N:]$JE?Z1IFJ!1J&G6EWM^[]H@63'TW T
M<I:?VO=:1JFCSZOI\$<=NJQ:CI4906[$GY-N<;L '"D'YNV173:!'>1:!8QW
M\KRW2PJ)))!AV]"P_O8QGWS5Z"WAM85AMX8X8D&%2-0JCZ 5)0 4444P"BBB
M@ HHHH **** "I;;_CZA_P!]?YU%4MM_Q]0_[Z_SH ZNBBBH$9FM_P#'K'_O
M_P!#6%6[K?\ QZQ_[_\ 0UA52&%%%%, HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH M7O_+O_ -<%_K56K5[_ ,N__7!?ZU5I %%%%, HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH EMO^/J'_ 'U_G1<_\?4W
M^^W\Z+;_ (^H?]]?YT7/_'U-_OM_.D!CZMI3:J]HK7=U!!%(7E6VN'A:3Y2
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M[Q-I_B6WF>S$T4UN_EW%M<1[)86]&7MW_(^E,#9HHHH **** "BBB@ HHHH
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M7VJ#[9]D\P?:/+\SR^^W.,_G4M !1163JFLM97UIIUK EQJ%VKO%'))Y:!4
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MC"/""Y<'=D[F#=#Q]*NZ-H&JV4L;:MXBFU1(,^0C6ZQ8/0%R,ER!TS]<9P0
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MA<W,*6%]=BT0/=/;(K"$$9&06!8XYPH)J:XUVWA2T$4%Q<W-W'YL-K"%\QE
M!).XA5 R.20,D"F!J45F:)KUGKUM-+:B6.2WE:">"9=LD4@ZJPY_0D4S6-)N
MM7:. :G=6-HJDN;-]DLC=ANQ\JCVY.>V.0#6JEJ&CZ9JWE_VEIUI>>5GR_M,
M"R;,XSC<#C.!^5<[X-;4[75]?T2]OYM0M=/EA%M=3G=(0Z%BC-W*_+^?X#:U
M[Q!9>';)+N^6;RFD6/=''N"DD %CT49/<T@-&""&U@C@MXHX88U"I'&H55 Z
M  < 5)7/VOB^PN-=CTB6VOK2>=2]J]U!L2Y Y.PYSD#G! -9GAWRK#QAXU+R
ML((9+:0M*Y;:##O;D]LDT =G17.6?C*RN[S3H6LKZWCU(%K*XFC41S@#=QAB
MRY'(W 9I9O&5C'JE]ID-EJ-S>V2JSPPV^2P;)&W)'''4X'(YYH Z*BN:F\<Z
M1#X07Q-BZ>P/!5(LNIW;=K#H#NXY.*G@\66,NOPZ.UO>P2W*.]M--#MCN-HR
MVPYR<#GD#B@#>HK U'Q;9Z<MU,;2]N+2S?9=75O&K1P'OG+!FQGG:&QWJU>^
M(+*TCLC$)+R6^&ZUAM@&>88W$C)  QCDD#D>M,#5HKA?!MREUXY\7.L%U;D"
MS#PW1^=&VR9'4C'?@D<Y%=U2 ***KWJ7,MG+':2K#.XVK*PSLSU8#N0,D \$
MXS3 L45P5YI^J>&/$FAS6>NZE?PZA=_9;FUOIO-!!4L708&W 4DX]JCURT=_
MBCH]B-1U2.SO+>:6>"+4)D1F4'& &&T>RXI >@T5P'Q#BEAU'PY);:AJ-L;W
M58;2<6][+&K1L>1M#8!]P,UW<$*V\$<*&0JBA09)&=B/=F))/N30!)17#^)]
M#U6/2;_7%\3:C;7]K&]Q'%%*%M5"@D(4Q\PP,9/.>?:GZKKVI2:7X7L%8VFH
MZX8Q.Z##0J$#R[<]&YP/3- ':T5R,-W+H'CFST3[3<3V&I6KO"+F9I7CFCY;
M#,2Q!4]">".*S?%.D:QI>B77B*+Q+J*ZE:KYY@\T?96YYC$>!D=@3R>] 'H%
M%8E_IM]KEM:I)J%UIL)B#S+9/Y<K2''&[!*J.>G)S[<Y?@UM3M=7U_1+V_FU
M"UT^6$6UU.=TA#H6*,W<K\OY_@ #KZ***8!1110 4444 %%%% !1110 4444
M %%%% $MM_Q]0_[Z_P Z+G_CZF_WV_G1;?\ 'U#_ +Z_SHN?^/J;_?;^=("*
MBN5^)$(E\ :N2TBM'#O4HY7D$>G4>U2:Q=:/$?#L&J6T\TLEU%]C,8;:DV/E
M)(('KP<_2@#IJ*R;_7HK2\:RM[.ZU"[CC$LL-H$)C0]"Q9E S@X&<G!P*AM_
M%>F7FC6>IVK33)>.8[>%8\2R.,Y4*<<C:V23@ 9SCFF!N5GWFA:1J%PMQ>Z5
M8W,R]))K='8?B1FJ5IXKLKD:DDEO=VUUIH#7-I+&#*JD9! 0L&!'<$U1C^(&
ME26^GW8M=06ROG6-+IH/W4;L<!6.?7TR!WQS2 ZI55%"JH55&  , "EK(O\
M7X[.^DLX;"]O9HHEFG%JBGRD8D*3N89)VM@+D\=*J+XQM&OM%MOL-\J:S$);
M2<JFP_)OPWS[@0,=J .BHK$L_$L%WJVIZ:UC?07&GJKR"2-2)%;.TIL9B<X]
MOYU4TCQQIVM_8WL[74/LUTLI^U/!B*+RR<AVSA20,CZCH>* .FHKG1XQL!<6
M*S6UY!:Z@XCM+V6-1%,Q&5 ^;<N>VY1FMN]N39V4URMO-<&)2WE0@%WQV )
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MHSSU&X?\!-=1IVE:[!XXU#5[B+3A8WD20XCN',J"/=M;!C ).>1D8]3CGJ:
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M$CRB,E<,,C.W)ZCCFM7XAZE866J>%$N+N"$QZI',ZNX&V,!AN([+GOTKO:*
M//GU[3S\5;O[+<P74PT+RXX8Y ?-E65G\L'INP1Q7,W>I6]]HGA343=.6@UJ
MU:XM+>$I;V*@ME-BC@@X^]DGG'!Q7L]% 'G?B.[TU-7U&[L=9?1M>AB3$<A^
M2^78&53$P^8\E>/F'Y57UB=;+5]$UW7[>^LM-N-*6WG^Q32Q"SFR'PWE$-MY
MQCGI7IE% '.>%+?1@MY?:)!<?9[ME9KJ>65S<L >1YA+8&<9[\^E/\2^+M*\
M-^5!>7T$%U<#]V),D*/[[ <X_F>/4CH** .9\*Z[H&H&:RT2\:]= 9[F?81N
M=CU8D#YCS@#H%QP *K?$N00^#VE8,0EW;,0HR3B5>@[FNOKFO&NDZMKFD16.
ME+9 ^>DTDEU*Z[=C*P "J<Y(YY&/?/ !FZO<6GBCQ)X<32+A+K[#=FZN9X6W
M+"@4C8Q'1F) V]>#Q6=IOB&Q/B3QY+8O;ZA,8XI(+97#?:?+@PP7^\,C!QFO
M1+<S-;QFY2..8J-ZQN74'N 2 2/? J2@#R"34K2>3P5J?V^6Y"W2B5(82L%L
M?+QY2(HP"#QCEN/2MS1]>TB/XH>*'DU.TC5K>W +S* 3&C;QDG^'G/I@^E>A
MT4 >(7VM:7/\$]7M(]0MFN6O6VPB0;SFYWCY>O*@G\#Z5U_B#Q'HC^-_!TZ:
MM9-$KW+LZS*54-$54DYX!;@9KT"B@#RBS?0M.N=4T'Q0VJQ7<MU.\<<=S="*
M]BD8L-B1MM).[!&.??FM&Z>+PGXQT+4;JV>ST,Z4;!-Q+K9OO##>W.,@*N>>
MAYXS7HU% '$>&M0M[OXB>*'@,CQSQ6ABD\IMK!4;)!QC'S#'KGBNIO["YO'1
MH-7O;$*,%;=(2&]SYD;'\L5>HH QTT:_616/B;57 ()5H[7#>QQ#FKVHZE9Z
M3837U_<)!;0C+R.>!_\ 7]JM44P.#L?'?A>^U2*\?4UGOI,06=I'&S-'N(&!
MQC>QQDYP,8S@$G+\5W_AZX^*NB0:I<:=+:P6TR7"7+(T<;D$J'W< _7VKU"B
MD!Y3X]A\+Z'K'A@6D&E6-U%J\$UP((XXW2$')9MHR%^M>I03PW4$<]O+'-#(
MH9)(V#*P/0@C@BI** .$U/QWX2OKQ[&[UJ!;."0>:@5F%PPYQD C8#U_O$8Z
M=7>(I(]1;POXNLHY9;.RN6=SY9W"WE&TR;>N!A6]<'-=S10!Q :#Q'\0]/U:
MRE2;3=(M)2;M#F-I9/EVJW1L+DG'3(J&[\?^$-0O0EWK4 L[67<(]C,)I%/#
M' ^Z#R/4@'H!GO:* .8UCQSHVE6-G)/>I;2WT8D@6=3E4/1V4<@>W!)XXYPO
MA77= U S66B7C7KH#/<S["-SL>K$@?,>< = N. !7344 %%%%, HHHH ****
M "BBB@ HHHH **** "BBB@"6V_X^H?\ ?7^=%S_Q]3?[[?SHMO\ CZA_WU_G
M1<_\?4W^^W\Z0'&_$R]MK/P!JJW$\<;3Q>5$K-@NQ/0#N?\ "L;Q9XBT9K3P
M=(NIVK1G4X+C<)00(U5U9CZ ,<$]B#Z&O1J* //EUNW\)^/-:;62\5CJ_DS6
M=X(RZ,53:4)4'GT'^(I?%UR9_P"P?$,]KJ*Z3;33"X6!Y(IDC=<+*0F'4 CD
M9SAN1V'H%% ' VL_A8:?JVNZ9).T36313:E=W,[*V>%C!F)R<^G0D#J<5SDN
MN:4GP:T2$ZC:^<LMNK1"4%P4E5G&WKP,$_4>HKV&B@#@=?O=$N=9:ZM?$(T?
M55M$>WO5E4PW49+%5*GY9,'/ YY&*I:IJ$T47@/7=7MA80PN_P!J"QD) 7CP
MH(ZJ#Z=NE>ET4 <)I>L6:^/]>OIF>"S:PMF6>:,HFU=^6)/W1R,;L9[5F^ P
MNL_!:72;"YC:^^RW,#(&&8V=I-H;TR"*]-HH \NT:?PQK5I8Z=<VVKS:S;F/
M?IMQ=W9\J5<?,0S;%4=<^G&,\5ZC110!YU!X?GGU+7_"$D;IHLS_ &Y)%Z!9
M0?W8],2J6'LI'>M;P.VH76G?;]90QW5K&=/!8]?*8B23_@3 9_W!77T4 >;Z
M!J-GJ\/CRWT^ZBN)IYYGB2-P2ZF(*&7U&X8R*QM7UG3C\%M,M?M48F06L91C
M@[D==ZCU*XYQTX]:]AHH X'6?$&CS?$7PBT6J6DB^7= LDH('F(FS)'3=@X]
M:[X@$8(R#110!P/AO3KRQU^[\,O$?[)TZY^WV[GH4DR8X_HK[V^J"I/M2>&_
MB5JUYJTHM]/U6WA^SW<IVQ(\8P8RQX4G);G&:[JB@#R76TCM?#OCS6)9EAM-
M6D2*R$AV^<57!90>NX[L>H7/3FMOQ$)-;^&NGW>BD7PM6M[DQP$,91&1N3ZC
MTZY&.M=_118#@M?NK/QG-X<BT2Z2XD@U.*\G:/K;QHK%M_\ <8D@!3@Y^E%M
MKFGGXKZM%#=P2SC3HX4B609>5&<M&/\ :&>1VY]#7>T4 >+W^IV^H^%]&OVN
M'22#5H#/86\)C@L )#E2JCKTY8DDGBNEMM=TK_A;U[(^H6T:G2$C_>2!,.'+
M%3GHP')!Y'->AT4 >7:/XAT<>#_&S'4K;YK^^=1Y@RRR9V$#N&[8ZT^:]MY/
M /@2^BD$MM8W=D;J2,%Q"$A96+8Z8/!KTZB@#C7\CQ'X]T34]+E6>STRWG,U
MU$<QR-(H58PPX8CYF..G&>M=E113 **** "I;;_CZA_WU_G452VW_'U#_OK_
M #H ZNBBBH$9FM_\>L?^_P#T-85;NM_\>L?^_P#T-854AA1113 ***JZAJ%M
MI5A+?7DACMX1EV",Y SCHH)/7L* +5%9.B>)=)\1>?\ V7</-Y&WS-T$D>-V
M<??49Z'I6'XSFOX]=\,PV>HW%JEU>&*58R,,NTG\3]<CIP:0'94R65(8GEE<
M)&BEF9C@ #J37#W;7>F:O8>&HIM:U.%K>:\F9+E%N'&\*J^:SIA1N/W6W<+V
MS61K%MK:^!/%<&KPW\=E"!+ISW5VK3%2#E',;MN /]XG.>^. #T.]O;E-.CN
MM,LOM[R%"L?FB+*,1ELMZ YQWJ_7!:]%/I'@/39=.O[Z B>U+_Z2[EP[(I7<
MQ+ <] 0*L:TU_-\1],TZ+5+NWM+BQF>2.)@!D$#CCK[G..<8ZT =K17#:+-J
M=M:>+M-CU9G?3Y2+.ZU"3?Y0:(,-['DA2>IS_2J&GZE+:>-/#-M9WFJ3VNHP
M7"7,EW+(T4[I&&#QASD<]U 4@C&: .NTOQ =2\0ZSI+64ENVF^3EW<'S?,#$
M$ =!A?4]>V*VJY+0O^2C>+O^N5C_ .@25/X[TR^U#PQ<R:7>7EM?VJ&:'[+<
M/'YF.2I"D9R 0/>@#IJ*Y&TFMO$O_".R6-W?1V\5N+N3R[R0%EQM6.7#?.2P
M)RV3^[8=SG$EO-;\1:?JEW86NM_;$N9HK"6UNHHH(_+8JH9&E4MDC+;U/4XX
M H [V]N+R">T6UL/M,<LNR=_.">0F#\^#][G P/6KE<3JMUK$=QX-ENIYK2X
MN+E(KVUB<;&;RV+9(ZC(Z9(J,1WVI?$36=+DUC4(K%;**41PR["I8GA2!\OU
M'/3GU .ZHKF/ 5U=W/AZ2.]NI+J2UO)[832G+NJ.0"Q[G'>H]5U"6^\<V?AH
M3S6]L;%[V=H9#&\OS;%0.O*CJ3@@].?4 ZNBO.9_$-]X2U;Q%IC337]O:Z;_
M &E9FY<N\?.WRV<\L-QR,\XSS6]9:%>2II.I0Z_?"X^26[WR-)%<J0"5$9.V
M,>A4<>] '45B^(/$!T*32U^Q23K?7T5GYBN%$9<X!/<]^WXUBV(F\7SZ^[ZC
M>6?V*]DL+5;6=X_** ?O&"D;R6.<-D8 XZTGBR"XMM(\+07=T;NXCUJQ62X*
M!/,8-RVT=,T =K17%6:RI\4=4T_[9>M9RZ6)S"]W(RH[28)3+?)QTVXQVQ5/
M2'UEO!_B*"PN;R[N[75YX(3+<%I3"DB@JKL3AMFX ^IH ]!JGIMQ>75IYE_8
M?8IM[+Y7G"3Y02 V1QR.<=LUS?A6YM+^]OUL=3U)0L*1RV%_+(T]K)DY;]YD
M\@CG)'%8EKXCU+3_ (;I.U[+-?W&IO8I=3?,4S,R[L>R@X'3I]* /2Z*X;7V
MN?"&J:'>V=]>W%M>WR6%U;7-P\P?S,X==Q.UA@\+@'TJ'3K6_P!<\2>+-.GU
MW4XK>VFB6'R)MC)NC)X(Z $]!C/?- '?T5SO@34;K5O!&E7U[*9;F2([W(Y;
M#$9/OQ714P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"U>_\N_\ UP7^M9]U,]O;/+';2W+J,B&(J&;Z
M;B!^9%:%[_R[_P#7!?ZU5I <?:_$*UN],N-331-8%A;2-'/.8XCY17[V5$A;
M [D U=OO%]M -#EM(3=VNKW"0Q7".%5=W?'7. >,>U<=X.AUZ\\)ZW8Z5%IZ
MI<:C=1FXN9G#1YP#A A#<=/F%6=8T!?#NE>!M%M[ACY&K(OG;1DLP=F8 Y[D
MX'/XT >ET5Q^G&ZTWX@W^DI?W-Q:2Z8EZJ7<K2^7)YC(<$\A2!G XKFWU2\T
M^3PU<Q:I?WMW<ZK%:7]RLSM93"0L"J*V%..Q1>,')S0!ZI17!^)KR2RUJ[;5
M[C5;+3I(D6QU"SE<0V[X(/FJG?=CEP1CTJ;4-3NY-:T[0TCO[V$::+N<Z=<+
M&\Q+! ?,9T.W@GY3DY&>.H!VU9>LZ[!HRQAK:\O+B7)CMK.$R2,!C)QT &1R
M2.HK-\')KL$>H6^L0W2VZ7&;%[N:.28Q'^%RC-D@]R<G-=$_DP[[B38FU/GD
M.!A1D\GT'- &5X>\3:?XEMYGLQ-%-;OY=Q;7$>R6%O1E[=_R/I6S7/>'=-9-
M5UG77C,3:K)'LB*X(CC7:K,.S-DG'8$9YS57X@3WMIX=CN+&^FM95NX$S&<!
M@TBJ0W?&#T!% '5UBZ1KYU76-8TYK*2V;39(T)=P2^]=P.!T&,=SUKG]234/
M#/BS0[B+5K^\M=3N#:75O<R;UW%<JZ#HF"#D#C%3Z091XQ\=&"2..8&UV/)]
MU6^SC!/MF@#LZ*\QMM2N;/6?"K6^HZE=F\D,%_<22NUK<L4R3&'XP&Y!10,5
MIP0WVJ^/O$>ES:SJ,=E#!;NB0S;"I922%('RCZ<G Y[$ [NBO*K_ %?5T^"M
MU??VK="_M)F@%RC;7D N/+^8]<[>X.:Z&ZCOM(\?>'PNK7MQ%J?VB.Y@F?,?
MR1[U*+T3!&..U ':45YM+>:WXBT_5+NPM=;^V)<S16$MK=1101^6Q50R-*I;
M)&6WJ>IQP!6F=1U+5?$&C^';]Y+"8Z9]OU%;>7:SMD((U=3D#=N)VG/ YH W
M=,UYM1\0:QI363P-IPA.]I WF"0,1P.F-OKWK9KB/"5D=/\ 'GBZW^TSW"JE
MD4:=R[@%)."QY;'J>?7-=+K.O:;X?MH[C4YWABD?8I6%Y,G&>B GM0!I5A:U
MXHM]&F, T_4]0F5/,DCL+8RF-3T+'( Z'C.?:K^DZO8ZW8B]T^5I;<L5#-&R
M'(Z\, ?TJ6YGM]/MYKJ1=HR&;8N6=N   .K'@#\!3 J:7XATS6-#&L6MTOV+
M:6=W^7R]OW@V>A%5;+Q79W<]FC6UY;17W_'G/<1A4N.-WRX)(R.0&"Y[9KCO
M%6EW6A?"'6A@)<WEP;JX2,\1>;,I*#V PI_&M;XC@0>%=,-KCS(M1M?LN/[P
M.!C'MFD!K:UXRL]%GFC.GZI>BW -S)9VID2#C/S-D#H02!G K1BUVPN-$CU>
MVE:XM)5#1&%"S.3QM"CG=GC';O4M_<QZ;8R.D&^1R1'"@&99&SQ]2>2?3)/0
MU3\+Z(?#OA>QTO*226Z$L1PN]B6;'H,L<>U $>C^*K35]3N-,-I>V-_!&)3;
MWD01FC)QO7!(*YXZUNUP>F7>I0?$EE\0Z=%%=7MHT6GSVLQ>(1(=[H<@'=D@
MDD#H!@5WE !1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6
MV_X^H?\ ?7^=%S_Q]3?[[?SHMO\ CZA_WU_G1<_\?4W^^W\Z0$5%<I\0)[VT
M\.QW%C?36LJW<"9C. P:15(;OC!Z BJ&I)J'AGQ9H=Q%JU_>6NIW!M+JWN9-
MZ[BN5=!T3!!R!QB@#NJ*\N\5ZA>V&FZ]?QZK?3ZI:76^!K&5Q;VL6Y0L<B\1
MEL$Y!W-DUL:Y-?W7CGP[91:G=VMK?6L[31POM'"#&/?GJ<X[8- ':274$5Q#
M;O(%FFW>6G=L#)_*I:\WGT&*#XCZ!937^I7)73IBT\E[*)&*D8R588]\8SWS
M5JQM[[6?&WB[2Y];U*.TMOLGE+#-L9-\;,=I ^49/;&<#)XH [ZBO-['Q)JO
M_"OO#[/+<7-_?WQLGEAVB5E5Y 2I<A0Q6/&2>^>M:FD6VOQ>)IHUMM6MM"N+
M4[OM]W'-)#.#U0^9(<$=CQF@#M**X'X<P7^K^'-&U^_UO49I@)PT!E_=2 R.
MHWC^(CJ#VX'05WU '-W?B\6OB%=#_L/59;QXVEB\OR DB X+ M*/R.#[5?LM
M9FNM1%E<:-J-B[0M*LEQY3(P4J",QR-@_,.#[US6O/>)\4M$:Q@@GG_L^?Y)
MYC$N-PS\P1C^E='I]WJYO+XZM:06T,44;0BWF,JM]_<=Q13G@<8XX]: ->BO
M.EFO-:^'E[XL;4K^WOC;W%U;+!<,D<*INVIL'RMPHR6!/)QCBG3374>M^ KA
M;^]!OHBMU']I<QRX@!!*9VYR<YQS0!Z'5/3KB\N8)&OK#['(LKHB><)-R _*
M^1TR.<=JYS1UFB\?>(K(7UZ]O]F@ECCEN&D$3/OW; Q..G3I^'%8?]H:FOPN
M\077]JW9O+6ZN52XW_/A7V@9[#'IB@#TNBN!F&H:9J?A.^&L7TS:A*MO=0RR
M9B96B+9"= 01UZ^I-7+&1_%>N:_#/>7EO;:=<"T@CM+AX2&"Y:0E2"Q)/ .1
M@=* .RHKSK34U3Q;X6U73YM7O+75=(OI[.*_MYVA$I3&"X4@'/0\>_4U8\#7
M!\1%-3GN[N*?3XUM'LA?2NI<#F5P6PV[/RDYR!G)/0 [VBBBF 4444 %%%%
M!1110 4444 %%%% !4MM_P ?4/\ OK_.HJEMO^/J'_?7^= '5T445 C,UO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %J]_Y=_P#K@O\ 6L^Z6X>V=;26**<CY'EC,BK]5#*3^8K0O?\
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M,OYA'^MQ][';U_#5O_#>MW^L:/J3ZW9)+IF\JJZ<VV0NNUL_O>!MZ8Z5U5%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+@9%%:_V:T_YX-_W\-'V:T_YX-_W\-%P,BBM?[-:?\\&_P"_AH^S6G_/!O\
MOX:+@9%%:_V:T_YX-_W\-'V:T_YX-_W\-%P,BBM?[-:?\\&_[^&C[-:?\\&_
M[^&BX&116O\ 9K3_ )X-_P!_#1]FM/\ G@W_ '\-%P,BBM?[-:?\\&_[^&C[
M-:?\\&_[^&BX&116O]FM/^>#?]_#1]FM/^>#?]_#1<#(HK7^S6G_ #P;_OX:
M/LUI_P \&_[^&BX&116O]FM/^>#?]_#1]FM/^>#?]_#1<#(HK7^S6G_/!O\
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M_ER]S9)OEBC3DD#>F,L5'WNF[K5#X<36]OI^J^(3X[U#Q%#;6K&2VNC(AM\
ML249VY(7 ./7!/- 'K%%>&MXHUM/AE'X].HW1U1]1P(?/;[/Y6\KY7E9VXXZ
MXW>]>U6-VE_I]M>1 B.XB65<]<, 1_.@"Q1110 4444 %%%% !1110 4444
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M>QW.H7MJ\$&GQG=<>8ZE=K1CYA@GGCM3OA%X2N_"?@\IJ*>7>WLQN)(CUC&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/GOKMREO A>1@C,0HZG"@D_@*LT4 >:7NG>&]?U_0]:\(-;-J:Z@D]U<Z?@
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M*** )9O^6?\ N"HJEF_Y9_[@J*@ HHHH **** "BBB@ HHHH **** "BBB@
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M>'S8YH2<['3<I.#R"&!KHJ* .7E\)SMINM"/4(AJNL*$N;U[;<H4+L"I&'&
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M/G8$="!CCWJ/5/!&K:GX+@\.-XBC54$2O.;#)98RI0*OF#'*@DG.?;I7;T4
M<]<:/KS7\5[:Z[:Q2FU6"XCDL"\4K L=X7S05/S'C<??-7?#NAP>'-#M]+MG
M9XXBS%V !9F8LQP.!RQX'2M2B@ HHHH **** "BBB@ HHHH EF_Y9_[@J*I9
MO^6?^X*BH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!T?^M3_>%$G^M?\ WC1'_K4_WA1)_K7_ -XT -HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *='_K4_WA3:='_K4_WA0!J4444@*UY_JE_P!ZJ57;S_5+
M_O52I@<MJ7CS3M.^WRFRO[FRTZ40WMY;QHT<#\9!!8,V-PSM4XS5'XBZS=V>
MAV<=C:W4L-Y=V\4DT#QJ&C:0 QY+A@6'&0,<\D5Q_B75$U;0/&UM,\ME=VT\
MP72[2+89% 7%Q*5&Y]P'4G;@#KP:U/&7B+28_ _ACS+Q(S)>64BJ_P K%$8%
MGVGG:,'G&.GK0 W7X(-(O]&CT[PE>V$.JWR+>VL<D"I<*HD(BV+-L!. QZ C
M@GJM=392:3X9WVND:!>+>7,8NYM,M"A,*],D&3RDYR,*WS$'&<&L/QQXGT)=
M;\'-_:UD4&HBY+K.I58MCJ')!X4DXSTZ^E5M>N]+T?QY<ZIKUQJ$6BZK9P?9
M=0LKN>.)73=\C&%AG(;<"<]3CJ: .RM_&6CW7A^/68I9#!)+]G2+RSYQFSM\
MK9UWY[?CTYIMIXLBN]0O-,_LO4(-5MH!<?8IA&'E0G *L'*=>.6%<3JUE::-
MI&DZ_P"'M)O6TNSUDWUS&QDDEG1X]CS@2$M],]?O=#FN[T/Q7IOB63=HS275
MH$+/=>4Z(K9&%&X#<>N<=,<]10!SV@>,5\0_#N\UG7-+NTL)(KAI&C"LLD.^
M1=JA&W_*@P2P7ID'O6BOBK0?#WAKPY)';W<.GZB+>"R01EO+$BC8'))Z#KR3
MP>M<?X2U:QTKX&W5A?7"P7-G;7D%Q')\ICD9Y-J'/\1R,#J:IZMKVD?\('\,
MQ_:5IF#4=.>8>:,QK$A60MZ!3P?2@#TG2?%MEJVN7.C?9+ZSOH81<".\A\LR
MQ$[=Z\GC/'.#[5FZM\1].TNQNM1&EZK>:;:S&"6]M8XS&'!VD?,ZL0#QNQC/
M>LS_ (2#1Y/C7:K'JEH_F:&T"%9E(,C3*RID'&XJ,@=?SKE8=3TAM"U3PA_;
MNDV>DSWTR[[R5ENH8_,RR^7MVDDAMK%QP02,\4 >SV5RUW9Q7#VTMLT@SY4I
M0LOU*,R_D37*:5XJOM6\<:]H4ND7:6MBD$9<21?NRZNQ=B'W88;,!=Q&.=I-
M=99O;O90M:21R6Q0>4\;!E*XX((X(Q7!:3?VNC?%7QJ=0F6W%W%93PF3@-&D
M+!WST"J>IZ"@#.\%^*+?PYX,O+BZM-0N;>'4KGSYX8_,$"^9C<Y8@G'?&XXY
M(KT&_P!=MK(6J1QRWEQ=@M;6]L 7E &21N(4  CEB!R!G)%>2:9X@T<?!GQ1
M =3M!-)-=JD9E 9C(6* #J=P!(^A]#6KJM]I\5QX7\374]Y+X=?2VLY;O3KB
M5/L\F4.YS"0VW*E2.<$<C(% 'H6@^(K/Q!'<_9TGAN+24PW-M<(%DA<=B 2/
MH02#ZU%K?BO3M O[&SO$NC)>LR1&* LN0I.,]R<8 &221Q5'P;;Z 9-0U/0(
M+IH;WRS)?7$TTANF4-C'FDDA0<;AP<X_AJAX\O8-.\2>#;JY?9!'?R[WQD*#
M"PR?89R3V&30!LZ+XOL=9U2\TLVUY8:A:H)'MKZ(1N8ST=<$@K[YJM-X]TRW
MMX[^2TOAH\D@C&J^6OV?).T$_-O"D\;MNWD<US^HV@\9>,+R]T*X5[>'0I[$
MW\39C>:7.U58<-MY8X)QD51AU6VO/A%)X6==GB".Q_L\Z6Z_O_- V*0G4KT;
M?T YSQ0!Z!J/B".RO([.WL;S4+EX?/,=H$)2/.-Q+LHY/0 DG!XKGO$/CJ:S
MTG0+W2],NI8]6U""V4N$1E!?E-K,,.RJP&< =R*S=6M=)TUM(TZ^U^30]<L-
M*BCM]5\T*DN,JR.&^5QE-VT\G/'>J.NWM]=^!O!NK:K;);-;>(+:XNW2,HBQ
MJ\@\TKU4-E6Y_O4 =_=>(5MC! --OI]0EA\_[!"(S+&@X)8EP@YX^]R<XS@U
MFS?$/0X/#!U]OM1M4G^SRH(?WD,H."K@G"D$CJ>]<SXBO--TWQR-:UN34X=#
MU&QCA@OK6XN(5BD1V^5_**G#!L@G/\ZS/&;>'=,^&UZ^EI):P:AJ44Z-=32-
M)>,'0O*!(2Y''7OC/0@D ZSQ)XIT&Z\+:P==T?5_[+MW2.97MGC\\$@JR$$?
M+G;R2OH:Z34M:MM)DM;00S7-Y<;A;VEN 9) HY/S$  <9+$#D<\UR?Q5UK3'
M^%>H2I?6[I?1HMJ4D!\X[U/R^O&3QZ5'JVH0V'Q#T7Q:TZR^'KK37LC>(=T4
M#E]ZNS#H&X7/08YH Z;3O%FGZC'J $5U;W>G'%W931?OX^,@[5)# CH5)!]:
MK:%XXL/$<MD-/L=2:"[C=TNFM\0J4."K,#PW_P"KKQ6"C6LOC;7O%J7<*:*F
MD)9_:BX$4TA;=E6Z, -HR.[8JW\(+ZUN_AMI4-O<1R2VR-',BMEHVWL<,.W'
M- '4ZMK$6DK;AH)[FXNI?)M[>W"EY6VEB!N(4856))('%4[?Q78R:9?WUS#=
M6*V$_P!GGBN8QY@DVHP"A2V[/F*!C.2>,\51\<-HIMM.BUNXFLD>YS;W\,OE
MM:RA&(;=T QD<\<C-<=>'6=5\'ZEB1]9ATO5K>XBO;)?*DU&%-C-M9,9=1QO
M4C.S@Y% '?6/BJVNM=_L6YLKW3[]HC-#%=JG[Y <$J49AQZ$@^U9VK?$/3]*
MM+Z]33-4OK"PF,%S=VD<;1I(, CYG5C@G!(! ]:S?#4O@_7M=L=2T0:EJ%[:
M!_W]U=7<@LPR$,#YK%=QR!M'U[9KE?[5TN.P\0^%$US2;/3KO4)U+WTK)<6Z
MEOW@";=K9(;:2PP""<]* /2+GQG96*:3]MLM0MY-4?9#&8ED*]2,F-F4D@9
M4D\CBF0>-K.;4+S33INJ1ZE;*KK9O OF3(W1TPQ7;QU8C'?%<WXPUS0+"_\
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M?^_G_P!:C^THO^?4_P#?S_ZU%@+%%5_[2B_Y]3_W\_\ K4?VE%_SZG_OY_\
M6HL!8KD?%.C^(-1\1:'?:7#IC6^F3-.1=74B/*64H5PL;!1@]<GZ>O3?VE%_
MSZG_ +^?_6H_M*+_ )]3_P!_/_K46 L457_M*+_GU/\ W\_^M1_:47_/J?\
MOY_]:BP%BBJ_]I1?\^I_[^?_ %J/[2B_Y]3_ -_/_K46 L457_M*+_GU/_?S
M_P"M1_:47_/J?^_G_P!:BP%BBJ_]I1?\^I_[^?\ UJ/[2B_Y]3_W\_\ K46
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M2P&?,Z<_2B;4(DGD4VQ)#$9\SKS]* ):*K_VE%_SZG_OY_\ 6H_M*+_GU/\
MW\_^M18"Q15?^THO^?4_]_/_ *U']I1?\^I_[^?_ %J+ 6**K_VE%_SZG_OY
M_P#6H_M*+_GU/_?S_P"M18"Q15?^THO^?4_]_/\ ZU']I1?\^I_[^?\ UJ+
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M_P#'K'_O_P!#6%5(84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"U>_\
MN_\ UP7^M5:M7O\ R[_]<%_K56D 4444P"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"6V_X^H?\ ?7^=%S_Q]3?[[?SHMO\
MCZA_WU_G1<_\?4W^^W\Z0$5%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J6V_X^H?]]?Y
MU%4MM_Q]0_[Z_P Z .KHHHJ!&9K?_'K'_O\ ]#6%6[K?_'K'_O\ ]#6%5(84
M444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M')+L=E17&_\ "U/#W_0.U3_OJ.C_ (6IX>_Z!VJ?]]1T>RGV#DEV.RHKC?\
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M^^HZ/^%J>'O^@=JG_?4='LI]@Y)=CLJ*XW_A:GA[_H':I_WU'1_PM3P]_P!
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M1JT?_K]A_P#0Q1XE_P"1JUC_ *_9O_0S4_:)ZF71115%!1110 4444 %%%%
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M_@,/_BJ/^%3:3_T'+K_P&'_Q5'MX=P]I$\GHKUC_ (5-I/\ T'+K_P !A_\
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M_P !A_\ %4?\*FTG_H.77_@,/_BJ/;P[A[2)Y/17K'_"IM)_Z#EU_P" P_\
MBJ/^%3:3_P!!RZ_\!A_\51[>'</:1/)Z*]8_X5-I/_0<NO\ P&'_ ,51_P *
MFTG_ *#EU_X##_XJCV\.X>TB<?XU_P"9=_[ EM_[-7+U[=KGPXT[4O[-\S5K
MB/[-816R[8 =RKG#'G@G/2LG_A4VD_\ 0<NO_ 8?_%4HUH);B4XV/)Z*]8_X
M5-I/_0<NO_ 8?_%4?\*FTG_H.77_ (##_P"*I^WAW'[2)Y/17K'_  J;2?\
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M  J;2?\ H.77_@,/_BJ/^%3:3_T'+K_P&'_Q5'MX=P]I$\GHKUC_ (5-I/\
MT'+K_P !A_\ %4?\*FTG_H.77_@,/_BJ/;P[A[2)Y/17K'_"IM)_Z#EU_P"
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MZ#EU_P" P_\ BJ/^%3:3_P!!RZ_\!A_\51[>'</:1/)Z*]8_X5-I/_0<NO\
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MFWTU+,>'9-%CB4$1;XF0D]=I1B3[E@,YK;H 9!#%;01P0QK'%$H1$48"J!@
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MKCCM0!QSK<0^)? +_9H+2V598K:-6W2B+R1]]@ N2,9 & >YKHK/_DJNJ?\
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MU#Q=:Q1K]@%L)?+QE5E,9)P.Q[_E55[2WB\%>'[F.%%N/M%LWF@8?.<=>O\
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M=XA_Y [>\T('U\U*U* &NQ1"RHSD?PKC)_,@5EZ-X@M-<:Z2W26*6U?9+',
M&'OP3QP?RK6K@(_^)'>:;KR\6T\TMI>GL 96VL?I_3WH ZS7-=M/#]B+N\$C
M*7"*D8!8GZ$BI&OKQK&*XM]+F,CNH:":1$9%/5C@D<>G6N4\9?Z?H6L7IP8;
M79;0>[>:AD;\P%_X"?6MGQ;+<6]G936]U-"?MD2,(VP'4MR#WI =#VK,TG5V
MU.6^C:U:!K2?R2&<,3P#GCIU]ZH2SR:KXJN-+-Q-#:V<"NZPR&-I';I\PP<
M>A[UC6E[)X>TKQ3<K(\\EO=X1Y3DDD*JD^N,CZXI@=1JVK-I<EB/LK2K=7,=
MN7#@!"QQGU-"ZNS>)&T=K5DQ;&X$Q888;@N !]?TZ5S^M:8]JF@SO?W4\IU&
MV$OF3%D<D]0O1?;&.M:9_P"2AI_V"F_]&B@#H**X5;C6-9T8ZA8PZG]NDD9[
M>2.>-(  Q 4H9!D8')*YS7;6[2O;1-.@CF9 70'.UL<C\Z )**** "I;;_CZ
MA_WU_G452VW_ !]0_P"^O\Z .KHHHJ!&9K?_ !ZQ_P"__0UA5NZW_P >L?\
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M!GQC<?7%/HH ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %J]_P"7?_K@O]:JU:O?
M^7?_ *X+_6JM( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:K9WXM;[RA%.1#OCF'^Z3Q^=1P^%D\G58;R]DN8M18M(I15VMQR,=Q@5T%%
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M 4444 6KW_EW_P"N"_UJK5J]_P"7?_K@O]:JT@"BBBF 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!:O?\ EW_ZX+_6JM6KW_EW_P"N"_UJ
MK2 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)X4T;4H98XYKFX2*4>6"&RQ!^G3T[UHVUUJ=IXK33KN]6[@N+5IE_=",QL&
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MFM_\>L?^_P#T-85;NM_\>L?^_P#T-854AA1113 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** +5[_ ,N__7!?ZU5JU>_\N_\ UP7^M5:0!1113 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** );;_CZA_WU_G1
M<_\ 'U-_OM_.BV_X^H?]]?YT7/\ Q]3?[[?SI 14444P"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +5[_ ,N__7!?
MZU5JU>_\N_\ UP7^M5:0!1113 **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** );;_CZA_WU_G1<_\ 'U-_OM_.BV_X^H?]]?YT
M7/\ Q]3?[[?SI 14444P"BBB@ HHHH **** "BBB@ IKND4;22,%1069B<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 6KW_EW_ .N"_P!:JU:O?^7?_K@O]:JT@"BB
MBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M2VW_ !]0_P"^O\Z+G_CZF_WV_G1;?\?4/^^O\Z+G_CZF_P!]OYT@(J***8!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !4MM_Q]0_[Z_SJ*I;;_CZA_P!]?YT =71114",S6_^
M/6/_ '_Z&L*MW6_^/6/_ '_Z&L*J0PHHHI@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% %J]_Y=_^N"_UJK5J]_Y=_P#K@O\ 6JM( HHHI@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $MM_Q]0_[Z_SHN?\
MCZF_WV_G1;?\?4/^^O\ .BY_X^IO]]OYT@(J***8!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4MM_P ?4/\ OK_.HJEMO^/J'_?7^= '5T445 BO=D"-<JK<]&&:I[E_YXP_
M]\"K=Y_JE_WJI4P';E_YXP_]\"C<O_/&'_O@4VB@!VY?^>,/_? HW+_SQA_[
MX%-HH =N7_GC#_WP*-R_\\8?^^!3:* ';E_YXP_]\"C<O_/&'_O@4VB@!VY?
M^>,/_? HW+_SQA_[X%-HH =N7_GC#_WP*-R_\\8?^^!3:* ';E_YXP_]\"C<
MO_/&'_O@4VB@!VY?^>,/_? HW+_SQA_[X%-IDLL<$3RRR+'&BEG=S@*!R23V
M% $NY?\ GC#_ -\"C<O_ #QA_P"^!7'6_P 2-$N[\VT"S.BD[I%>$LH'4F 2
M>>,'KF/CJ< $UUJ.LD:NC!D8 JRG((/<4 2;E_YXP_\ ? HW+_SQA_[X%-HH
M =N7_GC#_P!\"C<O_/&'_O@4VB@!VY?^>,/_ 'P*-R_\\8?^^!3:* ';E_YX
MP_\ ? HW+_SQA_[X%-HH =N7_GC#_P!\"C<O_/&'_O@4VB@!VY?^>,/_ 'P*
M-R_\\8?^^!3:* ';E_YXP_\ ? HW+_SQA_[X%-HH =N7_GC#_P!\"C<O_/&'
M_O@4VB@!VY?^>,/_ 'P*-R_\\8?^^!6>=:TH:D--.IV0OSTM3<+YI_X!G/Z5
M/<7MK:&$7-S# 9Y!%$)9 OF.>BKGJ3Z"@"SN7_GC#_WP*-R_\\8?^^!3:* '
M;E_YXP_]\"C<O_/&'_O@5ER^(=$M[R2TFUC3X[F-2TD+W*!T ZDJ3D"M!'62
M-71@R, 593D$'N* )-R_\\8?^^!1N7_GC#_WP*;10 [<O_/&'_O@4;E_YXP_
M]\"FT4 .W+_SQA_[X%&Y?^>,/_? IM% #MR_\\8?^^!1N7_GC#_WP*;4$]Y:
MVLD,=Q<PPO._EPK(X4R-C.U0>IP.@H L[E_YXP_]\"C<O_/&'_O@4VB@!VY?
M^>,/_? HW+_SQA_[X%-HH =N7_GC#_WP*-R_\\8?^^!6?=:UI5C>16=WJ=E;
MW4O^KAFN%1W^BDY-7J ';E_YXP_]\"C<O_/&'_O@57:[MDNDM6N(EN)%+)"7
M =@.I ZD"B.[MIKB:WBN(9)X,&6-7!:/.<;AU&<'&?0T 6-R_P#/&'_O@4;E
M_P">,/\ WP*;10 [<O\ SQA_[X%&Y?\ GC#_ -\"FU!<WMK9",W5S# )9!%&
M99 N]ST49ZD]A0!9W+_SQA_[X%&Y?^>,/_? IM% #MR_\\8?^^!1N7_GC#_W
MP*;10 [<O_/&'_O@4;E_YXP_]\"FT4 .W+_SQA_[X%&Y?^>,/_? IM% #MR_
M\\8?^^!1N7_GC#_WP*KK=VSW3VJW$37"*':$."ZJ>A(Z@5-0 [<O_/&'_O@4
M;E_YXP_]\"FT4 .W+_SQA_[X%&Y?^>,/_? IM% #MR_\\8?^^!1N7_GC#_WP
M*;10 [<O_/&'_O@4;E_YXP_]\"FT4 .W+_SQA_[X%&Y?^>,/_? IM% #MR_\
M\8?^^!1N7_GC#_WP*;10!-*5^3]U&?D'5!4>Y?\ GC#_ -\"GS?\L_\ <%14
M .W+_P \8?\ O@4;E_YXP_\ ? IM% #MR_\ /&'_ +X%&Y?^>,/_ 'P*;10
M[<O_ #QA_P"^!1N7_GC#_P!\"FT4 .W+_P \8?\ O@4;E_YXP_\ ? IM% #M
MR_\ /&'_ +X%&Y?^>,/_ 'P*;10 [<O_ #QA_P"^!1N7_GC#_P!\"FT4 .W+
M_P \8?\ O@4;E_YXP_\ ? IM% #MR_\ /&'_ +X%&Y?^>,/_ 'P*;10 [<O_
M #QA_P"^!1N7_GC#_P!\"FT4 .W+_P \8?\ O@4;E_YXP_\ ? IM% #MR_\
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MYXP_]\"C<O\ SQA_[X%-HH =N7_GC#_WP*-R_P#/&'_O@4VB@!VY?^>,/_?
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M3HV7S%_=1#D<A!4=.C_UJ?[PH U****0%:\_U2_[U4JNWG^J7_>JE3 ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@$XSC&<\G!K?HH **** )9O^6?\ N"HJEF_Y9_[@J*@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '1_P"M3_>%$G^M
M?_>-$?\ K4_WA1)_K7_WC0 VBBB@ HHHH **** "BBLG5-=CL+VWT^&![O4+
M@%H[="!A1U9F/W5]Z -:BL"Y\0W.DRPG6M/CMK69Q&+J"X,J(QZ!\JI7/K@B
MM_J,B@#"\0:'>ZS-8-;ZE%:I9W"W*JUMYA:1<XR=XXP>F/QK<3<$4.06Q\Q
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M** "BBB@ HHHH EF_P"6?^X*BJ6;_EG_ +@J*@ HHHH **** "BBB@ HHHH
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M],\_GZUTB>'K(:1<Z;*9KB.Y4B>6>0O))D8R6]1VQTJ@G@NQ"60FO=2N&LY
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M\K9"RAQ&.9&!8@#Y>.2.6%<TEP^@>/+>Y.FW&GZ?JR+:NDIBVB51A"-CMCC
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M]C?^\M'V-_[RU=HH I?8W_O+1]C?^\M7:* *7V-_[RT?8W_O+5VB@"E]C?\
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M% %+[&_]Y:/L;_WEJ[10!2^QO_>6C[&_]Y:NT4 4OL;_ -Y:/L;_ -Y:NT4
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6&_\ >6E6T=74[EX.:N44 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gzirfjcguvpf000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzirfjcguvpf000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" NX"(4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4#.>M "T44@S0 M%)WHYH 6BBB@ HH-)S0 M%%)STH 6BBB@ HHI* %HHHH
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MGUE%*DT22Q.KQNH964Y# ]"*?7G/P8\2?VWX)CLIGW76F'R#D\F/^ _E\O\
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M0CITKO\ XDZ-8S_#;5X1:0JMO 9X@B!=C*=V1Z=\_4UX3\'_ /DJ.C_]MO\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH 0# I:** "BBB@ H[T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 )1WZ4M% "=J6BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ H[T44 %%%% !1110 4E+10 4444 %)2T4 %%%% "4
M=Z6B@!.U%+10 4444 )1BEHH 3%%+10 F*.<TM% !24M% !1110 F**6B@!.
M@HQD4M% !1110 G%&/2EHH 2BEHH **** "BBB@!*6BB@!,"CI2T4 %)TI:*
M "FX'I3J* $Q1@>E+28I@':@<"@C-+2 **** &NZQ1M([!44%F8] !7S#J6H
MR_$[XKVT1+-9/<"&%/[L"G)/XC)_&O9_BYK;:)\/+XQ2%)[PK:QD?[7WO_'
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MG_Z2*OO'^NQ]:7%S!:0-/<S1PPH,M)(P51]2:P8?'WA.XN_LT7B"P,V< &4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,</%I-GE?Q[7/@>U;TOD_P#0'KC/@)I4%YXEO[^8;FLH5,2'H'<D;OJ &'_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M68C#9;5G&/[R=E;JH]?O[=C"<U*2CT/=Z*K6%]!J=A#>VI<P3+N0NC(<>X8
MC\:LU\G).+L]S=.ZN@KY;^+_ (=_L'QU<2Q)MMK\?:8\=,D_,/SR?QKZ8U34
M[71]-FO[QG6WA +F.-I&Y( PJ@D\D5\]_%KQ+_PFFH6$>E:5J'V>R60>=+;,
MID+%>@ZX&T=>>>E?3\*^VAB^>*]QIIOIW7SO;[S*M;D:9V_P*\2_VAX;GT*>
M0FXT]]T0/>%CG]&S^8KUFOD+PM?:]X3\06VK6>G73-$</&86 D0]5/'?U['%
M?27A7Q[IOBEUMXK2_L[SRR[07-NR@8QG#_=(R?4'VHXBRJ=/$2Q-%7A+5VZ/
MK_F10GIRL\'^,>BR:3\0+N?81#?J+B-L<$GAA^8_45Z#\"O%D-QH\GAFYE"W
M-L[26JL?OQGE@/<')^A]J[GQWX*M/&VA&SE817<)+VMQC/EMW!_V3CG\#VKY
MFU;PYXC\%ZLINK:XM)X'W17,6=IQT97'^?6O6P=6AG.7+!U)6J1M;Y;-=]-&
M*I%PGSH^PJ\J^/KH/ ]DA=0[:@A"D\D!'SQ^(_.N+T;XT^-)XX[&'3K;4KHX
M57$#ER>@R%('Z4WXB^'M=7PA;^)/%=XTNL7%VD,=LA'EVT15R5 '&XD#./3O
M7G9?DU7!8^G+$R2UT2=V_EV[MENJI1=C2_9[D']I:W'W,,;=?<_XUZKX_P!%
M?Q!X%U;3HEW3/#OB'JZ$.!^)7'XUX5\.?"OCZ/4EU+0HO[.C="C7-ZNV-U]-
MI!+<CL.O<5]#:%8ZCI^G>5JFJ-J5TSEVG,(C S_"%'0"L^('&EF/UJE4BVFG
M9:M-=^G3O<G#OW;-'R!HFJ3:%KUGJ40/FVDRR;>F<'D?B,BOL31]6L]=TBVU
M.PF66VN$#JP/3U!]"#P1V(KQCXG_  DNWOIM=\-P><DQWW-D@^=6/5D'<'N.
MH/3(/'G7AKQEXB\"W<B63M$CG,MI<(=C'UVGD'W&*]G'X:CGV'C7PLDIQZ/\
MG^C(5Z,M=CZZKY$^(CJ_Q#UUD8,INWY4Y%>F:7XM^(GQ&*V%A:P:18N<7&H1
MQL-J'KM+$Y/H%YYZ@<CS'7_#,\7C?4M$T6UNKS[/.8T55,CG'<XK+AW _4<1
M45::YN79.]E=;O9>A56?-#3N?5'AAQ+X3T:1>C6,!'/^P*\>_: T.1;K2]=C
M3,3*;69AV8?,N?J-W_?-='X"\-?$&STZPM]6UF*PTZV966T6-99F0'.QFZ*I
M'N3@XXKT36M'L_$&CW.EZA'YEM<)M8=QW!'N#@CZ5X%'$0RS,E5C-35W>W9_
MKUTOZFD%S4^5]CP;X._$.W\/R2:#K$XBL)Y-\$[GY87/!#'LIXYZ Y]37T.K
M*ZAE8,K#((.017RIXP^&.O>%+N1EMY+[3L_N[J!"1CT8#E3^GH:Q])\8>)M$
MB^RZ;K%[!']T0A\@>P4YQ^%?0X_(Z&:2^MX.HKRW[?YI]]#&$Y4_=DCZ[U#4
M+32[":^OKB."VA7<\DC8 %<=\.KZ\\0RZYXGG:9+34+D1V,+D[5AB!4,!ZDD
MY]Q7E/AWPEXS^)-_#-X@O;Y-(C;<\MRQ&[':-.A)]<8'/T/T18V5MIMA!96<
M2Q6\"".-%Z*!7S>.PU'+Z3H*:G4EO;:*6MO5NWR1M&3F]%H?-OQLT633?'DE
M\$(@U"-95;MN "L/T!_&NO\ @1XM@-G/X8NYE2=7,UH&.-ZG[RCW!YQZ$^E>
MC^-O!]GXTT!]/N3Y<Z_/;7 &3$_K[@]"*^8]<\*>(O!FIC[9:S0/"^Z*[AR4
M;'1E<?AZ&OHL!6P^;Y<L#5E:<5I\MFN_9F=6+C/VB/L"O+_CPZCP# I8!FOX
M\ GD_*_2N#T3XU>,C#'9)86VJ7 PJN87,C=N0A&?RIWQ T'Q#)X-3Q-XNNF.
MIRW20V]FA 2VC(8G@<;C@?3'//3S\#DM7!8ZG+$22UT2=V_1=N[9:JJ47RKH
M_P BS^S[(!XBU>+^)K16'/HX_P :^@:^8/AYX5\=_P!JQZIH$!L1M*&ZNUVQ
M%3VP02PR!T![5]%>'[#5-/T]DU?5CJ5W)(9&E$(C5 0/E51V&._J:QXGI4WB
MW5C43;MHM]-/3\2</=*QJT445\P= 5X[KWB9_B)XV3P-IEQY&CH[?;[A2-TX
M3EE7VR,<=>O05[!(N^)T#%=RD;AU%?(VL^&_$/@7Q0EN#-'>(3);7%J3F1?[
MRXYZ9R/KFOI.',+2KU*C<DJB7NW[ZZ_+3\S*LVHZ'NUW\$_!MPX:&WO+3 P1
M!<D@_P#?>ZM#1?A1X0T2X2YCTTW5PG*R7CF7!]=I^7/OCBO!_P#A9?CRV($F
ML78QVDB7^JU+'\7_ !M#G_B:AL_WX$./TKUIY+G,X<GUBZ_Q2_R,O:4^Q]44
M5\WZ5\=O$UI=*VHPVE];DC<FSRVQ[$=_J#7N6D^+])UCPJ/$5O)(+((6E7RR
MSQD=5*KDY'MFOF\?DN,P-G5C=/2ZUU[&T*L9.R.+^/7_ "(EM_U_I_Z ]<Q^
MSS_R$->_ZY0_S>HOBSXS7Q98VVDZ/INH2013>=)<26SH&(! "@C/<]0*Y[X8
M^(;SP1K\T]YI.H2V-U%Y4PB@.Y2#E6 /7'(QGO\ A7T^'P5;^PIT&K3>MNNZ
M?Z&%62]HFCZ?K(\4W\NE>$M7OX/]=;V<LD9]&"G!_.G:'XBT[Q%;R3Z<\S+$
MP5_-MWB()&?X@,_A5S4+*+4M-NK&<9AN87AD _NL"#_.OB8Q=&LE5CLU='7%
MIZH^6/A@\$GQ-TA[]MP:9F#.<YDVG:?KNQ7UA7Q_XE\*ZSX*UMH;J.1/*?=;
MW<8(5QGAE;L?;J*]!\/_ !3^(&O0Q:5I>F6UW=D;/MAA;(_VF.=@_&OM\_RR
M>8.&+P\UR6MJ[)+>_P#F<E.7LVU(Z#]H&1!X;TJ,NOF&[+!,\D!#DX].1^=9
MW[.[#'B)>^;8_P#HRJGQ#^'6IVO@XZ[?WLVKZZLZM>3 DI%$01MC7^Z&(YP/
M7 KDOAEKGB?2-5N;?PUIR7LEZJI(LB$HA!.&)!&,9/4XYHH8:%;(YX>A-.SW
M>BT:;WZ=KCJ2:J*31]45\D_$W_DI.N_]?'_LHKZ<\+Z1>:/I)CU*_>^U&>0S
MW4Y^Z7( PH[*  !].W2OF/XF_P#)2==_Z^/_ &45Q<)QC''5(Q=TH[]]476=
MZ=_/_,^G?"+J_@[1F1@RFSBP1_NBMFO$?!GC35? .D6FF>*=,N7TF2,2V6H6
MZ^8%1N=K>PS]1TP>,=1J'QJ\*0VQ.FM=ZI=,"([>"W=23CC)8# SW&3[&O(Q
M648MXB7LH.<6W9K5??LO.XZ<X\J3.3_:#U1"VC:4K9==]Q(,] <*O_LU=5\%
M?#SZ-X(%W/'LN-2D\_GJ(P,(/YG_ (%7(>'/A_KOCSQ0WBCQC"UM9NX=;5P0
MTH'W4"]50>_)_'(]U1%C1410J*,*H& !79F>*IX? T\MI2YFM9-;7WMYZ_D)
M+GJ<_1;'/>/O^2?:_P#]>$O_ *":^>/@_P#\E1T?_MM_Z)>O4?B3\0;2Y\.:
MAH>CV>H75W< P/(+1UCC&<-RP!)QD# Q[^OC_@VYU#POXMT_69-)O98[=SO1
M86R592IQ[X)KULDPE6&5UX35G-.R>C^&Q->2NO(^N:XOXM?\DOUO_<C_ /1J
M5KZ#XOTKQ$DIL3=!X4#R)/:R1E0?J,$_0FO./B?X^LM:\)SZ+HEI?W<EV4\R
M4VDB+&JL&_B ))(';'7FOFLLP6(^O4TX-<LHM^2O?7^M3?GBES'%? [_ )*,
MG_7I+_2OIFOD_P  ZC?>$/%UKJL^E7TMNH:.98X6W;&&,C/<<'\*^E],\4Z7
MJ^E7.I6CW!M[8$S;[:1&7"[CA2N6X],UZO%>'J2Q:K15XM)77>[T,,.[)I]S
MBOCN?^+?1^]]'_Z"]<;^SY_R']8_Z]4_]"J;XM^,H_%.F6ND:+8W\T*3">6=
M[5T!(!  !&>YSD>E<W\+M=N?!?B26>_TN_:RNH?)E:.!BR'((;&.0._U_"O1
MPN$K+(IT&K3=W;KNO\A5I)SC;I;\SZ>KX]\;:%)X;\8ZEIQ0K&DQ> D=8V.5
M/Y''U!KZTTG5[/7-/6^L'D>!F*@R1-&<@X/# &N2^)/P[A\;Z>DUNZ0:M;*1
M#*WW77^XWMZ'M7AY!F*R[%.%?2,M'Y-;7-JD>>%D5OA/XZM_$WA^+3KJ=1J]
MD@1XV;YI4'1QZ^A]#UZBO1*^,]1T;7/"VH[;VUNK"ZB;*R#*X/JKC@_4&MRS
M\:>/]6 L;'5=4NF8;0D(+,?Q S7KX[AB-:HZ^&J)0>NNR]&NAC"LX+EDCW3X
ME>*O[/TU?#^F2"37=686T,4;?/$K\%SCIQD#WY[&NPTK3X])TBST^'_5VT*Q
M+^ Q7G'PR^&=SH=V?$/B)_.UB0'RXV?>8<CEF;NY&1UX!]^/4Z^:S!T*2CA<
M/+F4=7+N_+R2V^9M!N3YF<MX%\4MXHT>YEG,0O+2[EMYEC&!PQVG&3U7'X@U
MT\D<<T312HKQN-K(PR&'H17S)X=U'Q9X3U^_\0:5I-U=:7+<R)./*8Q2J'/\
M0'!!S@]O?D5ZS9?&KPC/!F^FN].G'#07%L['/L4!&/KCZ5WYEDE:%9SPL>:+
M_EU:?9I:Z"C45VI'F_QE\!V'ANXMM8TF-8+2\<QR6Z_=CDQG*CL",\=L>^!W
M7P&EF?P+<)(Q,<=ZXCSV&U20/Q/ZUS7BN^U?XP:C9Z9X>TV>'1K:0N][=)L5
MF/&X^P&< <G/(';V#PQX=M/"OAZUTBS):.!?FD(YD<\LQ^I_+I77F>,G'*J>
M%Q+O5O>V[25[7\_Q(45*IS1V->JFJ7(L])O+IC@0P/(?P4FK=<A\3]3&E?#O
M5Y=P#S1>0F>Y<X_D37S.%I.M7A375I?B=*=M3Y>\/Z<VK^(]-TY02;FYCB..
MP+ $_@,FOL\    8 Z5\Z? KPZ]_XIEUN5/]'T]"J,>\KC _)=WYBOHROI>+
M<4JF*C1C]A?B_P#@6.7#QWD%%%%?)G2%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!['^T;?#!B(KZ10Q'J >:[6BBL:^)K5W>K)R?GJ-12V"BBBL!A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &;I.@:7HGG'3[..&2=R\TN,
MO(Q.268\GFM*BBJG.4Y<TW=A8****D HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **2B@!:*3M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13=PW8SR>U.H
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MX[B(21/N0]#3Y7:X$M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HH/M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% &5JT_E36J*K>8[':WE;UP!R#Z5/:W8>X>!F!8 ,I"XR/\
MZU27"NT@_=H0 2KEL8..E5M(-I+9J]JJ!$8I\AR,]^>]=&CI[;"ZFG1117.,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI"<4 +1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC2!D'M\_:NXK@U;;\;G!#'=I0 XX'S9KOP*O[7_ _P!"9=#O:***X"@HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4G>EHH :6 (![TZFL@8889IW2F
M4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS2T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/'N=A17'CXH>#RQ7^UUX.!^Z?GZ<4J?$[PC(S :J!M7<=T3#\.1UH_L_%_\
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MA+=M_MVT+$< $\_I5?4L3_S[E]S%S+N=/17*#XD>$2@;^VX "VT95NOY4O\
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MY%3/"8B$7*<&DNZ8^9/J:]%%%<XPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #O
M1110 4444 -D_P!6WT-?/G@-<_$NS<@EEFG4$GGG=UKZ$;[A^E?//@,,?B5:
MX1FVW4_'\('S<U]%DO\ NV)_P_I(QJ;H^AA2T@I:^=-@HHHH **** "BBB@
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MX=30[44=J*YQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWG_"/:,=V=*L_FZ_N5Y_2G-H6D,N#IEH1_UQ7TQZ5Q+ZK\4#AAH>G*$/S*)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *2EHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0_=/>OGKP6?\
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M +%J?S(GVB/:.:ANYVMK5Y5B:5EZ(O4UX\FNZJS1/%J-ZQ7<F=YQ^ _BKOO
ME[<WVAS274TDLJW+*2YY' X_6L,3ELL/#VDFFAJ=W8N76H6]KJPMTTMIKAX@
MS%$'*Y_QI(-4GBG%O_8<D6.=R[=JKG^=27]Y>QZDMKIUI#<3B/?(\C[=BDX'
M^?:HXH_$RM$));)E4_.PSEAGH!ZUFHQY%S);=6QEO6=WDPF*3R[@/F(E<CWR
M/I3M+BNHTD%]<+/<%B=RIM&TGY1BFZLR%8HGAF82$CS(ER8^.M2Z>AA$L'ER
MA$(VO(<E\C/%8W_<V_K[_P!!]2_1117,,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC5< <@Z2I/'3YL5W4<?7KTZM*HU91?1+JNR)<4FFCNJ***\,T"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4;OY&E$&$V&5\@#'3C'I79]7C;<FYT(N[<L%$\9).T#<.OI2&\ME5F,\852
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MYDD\ 7)CE0AIH>5^;/[P5?-N^6'G$$_=(1<H/0>U<WXVC6W\-.@WM#YB$QY
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MQUZ-TK*^"H_=:RQE+,7BPN>@VGM7TU/_ )$<_7]48O\ BGJ]%%%?,FP4444
M%%%% !1110 4444 %(:6D- '/:O!";_=#J;Z?<2J!*54'S%'3KTQDUL6(@6T
M1;8[HERH/KZFLV\FU";4)H;$6X$"!SYH/S$]L]NE:&F77VVPBN#&4+9RI[$'
M!KKJ\WLE?^OP^XE;ERJ>H" V3BY8+"1AB?TJY5'5+T:?I\ER5W%<!5QG+$X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M88:LOX*1JEIK! SF2+#>HVFOIZ3_ .$.?K^J,7_%/5:***^8-@HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=T6& QD8/:MKXQ$KX)C;^$7L18>H^;BLGX,/G^UDW,V!%@Y& ,'CZU]/2O\
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M7_%/_!+\B9]#N\48I:*X"A,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>U7:QE%Q=F,****D!.]%!K.U6^DM(TCM_*-Q,2$\QL!0!RQ'7 JX1<W9 :-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/K7?=ZX7P FS7/&?S;LZN_./:JGC9XJA6<TE9+_TI H\K1T7BL@>$M6)./\
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MRUPO XZ9]*BN8(GMD0QQL%D1EWCOFK0 SD\C'3-5[K/D(>3F5.0.GS"JBW=
M%O'%Y2[854ODD8!/YU-CL N7XSCK4,#IY*LN".GR].M3=,#/ Z'WI2O< PO9
M1E>.@XINQ" "D>%.0-HX-2$AF*8R<;CBD&<!B!C//-*X#,(JD;5QG)X[TJHG
MFYV*6<8SMY-*1U/KUI>G(P<#BBX#=JD@E$W#Y5.T<"N<\=I&/"%V%0?*5&T<
M @L/UKI,$GG'K7-^.1)_PB\F#E"ZAP.I!/\ GFNG!_[Q#U0I;,[_ $\8TVU
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M20*?G4@E:]F<E];C)?:B9KX35\*$MHV6#9,K'YASVK=%<[X1E#6,\."I28D
MGL<5T6*\C%JU:1I'86BD[U3O=1@L'@67<6GD$:!1GDG%81BY.R&7*X35B$^,
M>@$\EM/F49[<FN[KA-8)'QB\/ (6W6$V2!TY-=V7_'/_  2_])9,]CO****\
M\H**** "BBB@!#63/HD=SXAAU29@Z0PE$A9<C?G[WX"M>BKA4E#6(-7$I:**
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $YS[4M%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6UE;SU4QC>1L&6Z>].-KOE+G9A% CP3P?>BR[@3X(.<')XQFH;DXAPHW$.@
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M>LF3_A</AX(^%^PR[Q[9-=X:X/621\8O#Q_=@&PF!+=3R>GO7#E_QS_PR_\
M267/8[VBBBN H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,J.K,GW@#TI]%K %0W1E%I,8!F4(=@]\<5S?BSQ;+X=N+>"&U29Y4+L7<J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/XWU+_A%M5M=2\.:C]JNHI?-G,6Q%)&WYAV&,<UZ)X'&/ ^BCTM$_E5GQ/\
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MW"KC'6G:,&_LZ.1HQ&T@#E0?45 =!\Y%2[O[JX3^-&;"O]0*UD0(JJH 51@
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M:2X=\YZ\$XK?HQ1BLZM6=67-4=WY@DEL+11168PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,C.* %HHHH ***
M* "BBB@ KA-=V?\ "VO#7#EQ:S\KC&/>NZ-<%XAPWQ;\+#C*V\QZ\\UWY=_$
ME_AG_P"DLF>QWU%%%<!04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*CDF2)D#L 7
M;:ON?2G!LDCTIV8#J***0!1110 4444 %%%% !1110 4444 %%%% !1110 G
M:N-^(>E_:M)BOU&6M20_^XW!_I795'/!%=6\EO,@>*12K*>X/6NC#5G0JQJ+
MH)JZL8/@S4QJ7AZ%'<--;CR9!].GZ8KC_$MC)X3\1P:C8KLMY6+Q@= W\2_0
MBK&FA_!?BUX[PO%ILX9$F8$J0.5_$=*H>+O%RZ[&MG:1[;5'W[F&6?'0^PKW
M,/0FL6Y4E>G-7?:S_5&3:Y==S3\0^/C/$EKHN[=(HWRX^8$CHH]?>N:\/V=R
M_BVPMYD>.<3"1@1A@!R2:ZGX;6-F\%W?21*US')M61CDJN,\#M]:=X1@;5_%
MNI:ZPS K,D+=F)XR/H!^M7[2EAH5:5.-E%;]V]@LY6;/0.]+2#K2U\P;!111
M0 44G-% #7=(HV>1@J*,EB< "N<N?'6AP,%CFDN#G!\I,XK&^(VK7$2V^EP9
M595\R0C^(9P%_.G6_P -+1K*,SWMP+HJ"S)C:#Z 5ZM#"X>%*-7$R:YMDB')
MWLCKM,U>QU> S64ZR*IPR]U/N*O5X_X?DNM"\9QVI<)^_P#LTQ[.IZ9_0U[!
M6./PJP]1*+O%JZ'&5T<K\0;8S^&&E4C,$J2<GJ,X_K7-?#K4OLVKW&G.1Y=R
MN]/]\?\ UOY5M^,_#6K:W<QR6<Z- B8\AW(&[U':N(U+PSK6C0+>7-N$57 $
ML<O()Z=.GUKU<%&C4P?U>4U>7X&<KJ5S5NF/_"U!YNU,7:\^VT8KT&[\2:/9
MJQFU"#*D@JK;CD=L"O'+&PO-9U06L/SW$A+%I'/;N373P_#;5'E/G7EM$N.J
M DD^E7C,-AFX*M4MRI+^MPC)]$=IHGBO3==N)+>V,B3*"P21<%E]16#X$</X
MJ\;XZ#4@.G^R:T?"_@Z'0I4O))WENS$48?PKD\XK/\"$GQ1XVR-N-3''_ >M
M<#5!4ZZH.\;1_P#2D5K=7.E\3 MX5U8*NXFSEP .OR&JG@5MW@71",?\>B=!
M[5;\39_X175L'!^QR\YQ_":I> SGP+HN-V/LJCY^IKE7^Y/_ !+\F5]HZ.BB
MD)Q7"4+169-K^GP-M:;<<X(12<'WI(]>L9'V%W1^X9",#U^GO6OL*EK\K%=&
MI13%=70.C!E(R"#D&GUD,**** "BBFLX498@#U- #J*HR:I;QS-!DM,O)0=O
MQZ4^+4;>658E?$A_A/45?LYVO8+ENBDS14 +1110 4444 %%%% !1110 444
M4 %%)4$]W%;C+GC_ &1D_E32;T0%BBJ*:I Z&0[DC R6<;<?G5J*9)HUDC8,
MK#((IRA*.Z DHI,TM2 4444 %%(35.75+6+?F3)0@$*,\FJC%RV0%VBJ<>JV
M,LT<274;/)G8 ?O?2K=#C*.Z 6BBBI **** "BBB@ HHHH 1FVJ3@G Z#O63
MX>\26'B:PDN[!GQ%*T,L<B[71U/((K6/K6<DNEZ>;IH5AB+MYLYB4?,Q_B;'
M?WK:"BX-6;EI;]1,TJ*JIJ-G*^R.YB=A_=;-6<UDXM;C%HHHI %%%)0 9HSS
M3795C9I" BC+$] *SDU_37C#17"OD955ZL/4>HJXTY27NJX7-2BJ=MJ=I=MM
MAF!. >1C/TS5L4I1<79H [UR7Q-&?AQK0) _=+R?]]:ZVN1^)TBQ_#K6-Q49
MC4#<,Y^=:ZLO_P![I?XH_FB9_"SHM* &CV('06\?7_=%<C?.B?&O2PQPS:0Z
MKD=?G)XKK-'8-H>GL. ;:,]<_P (KD[UV'QJTQ<[5_LEQ]W.[YSW[5MA%^]J
M_P"&7Y"ELCNN]+2"EKS2PHHHH **2EH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3 S
MFEHH **** "BBB@ HHHH 2N$UX$_%OPQB,?\>LYW=_\ /^-=WZUPOB#</BQX
M58.0#;W ([=!7?EW\27^&?\ Z2R9['=T445P%!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(1FEH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "DI:* $IKABN%;:<]:?13N @I:**0!1110 4444 %%%% !1110 4444 %%%
M% !110>E #2=JDGH!DUY[??$PK-,EE9 H,A))6Y/N5KT.N(U_P !0W#27>D[
M8IV.6@;[CGV]#^E>AE[PO.UB%Z=OF1/FMH<W':^(O&M_^_W)"F"7D4JD8/\
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M !1110 4444 %%%% !1110 4444 %%%% !1129'K0 M%)WI: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*
MX+Q$S_\ "V?"R[&8>1,1@XQZD_I7>UP7B,[?BSX3"L S03@ANF..GN:]#+OX
MLO\ #/\ ])9$]COJ*2EKSRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%]_>LG5/BOH>H:-?VL-AJ+R2Q-%&C1 !\\$Y!. ,\UI>$8_*\,V<>",IR">
M?;VK?ZI5H85JM&UY+?T%S)RT.A^WW>642)G&1\O2F?;KQA&/-C.5PX:/J:B&
M>Q_$4F3AN.A]*Y>2/89-!>7J)'&\Z/@X)$8!-.DO[ORF"R ,3UV]!4!7+C@]
M,C-)R0 !U/:CEBW>P%E;FYCWJDB!=GRJ$^Z?7WI!?W>W'FKEDP,KT/K_ /6J
M#&1Q^=*?N$#\^]+ECV FDU.Z6 %7CWJ.6=< TU=0O7@R757(S]WI56Y"_9I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.\1$);?$)U9-Z:C;'.WD#N/_ -5>XUXGX@.W3_B$Z_*%U&W^\,Y/'->CD?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M,4M% "5P?B<JOQ1\(D[22DZ\GIP,5WE<'XES_P +3\)!=H/EW&2PZC X'O7H
M9=_%E_AG_P"DLB>QWG>EHHKSRPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+@;RQS@#I@8H,2$9\H#>,$=.*?=X_M5MV2YW $G''':@9&<$\#'->HF^5>A
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M**XNH@Q!CRIP1P#N'.:Z6LY='A\U':21@N/E)X)!R#^=:-8UIQE:PT@HHHK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 )7 ^+&*_$WP:1QDS@G&<C KOJX3Q
M4?\ BY/@\*H+9G).><8%>AEO\9_X9_\ I+)GL=Y124M>>4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4AI:0T >>_$'P\Y<:U:1EL +<JO7 Z/^'>G^%O'4?D)::Q/AE $=QC[P]&]
M_>N^90RE6 *D8(/>O,?$'@EK76$ELXI!ILS .8OF:$GV[BO;PE>CB:7U?$=-
MG^G];F<DT[HU/&^OZ3>Z"UK;745Q<-(I4(<[<<YJ]\.M_P#PC3,V<-.Y7/I[
M5YYHFFP:EXBBT^YGD$,CLFY>"<9Q^>*]HL;&#3K**TMDV0Q+M45681IX7#K#
M1NVW<4+R?,6*6BBO"-0HHHH SM:OI]-TFXN[:U:ZEC7*Q+W]_H*\;AU*_P!.
MU<7\2-;W!=I -A (8Y(P>HKTOQ'XTAT'4([-;8SN%#S8;&Q3Z>IJ]JVBV/BG
M3;=Y&=>!)!*OWER*]K!5?JD$ZT/=GU\O0SDN9Z,\JUJ[U+6+P75[:2+-L"DK
M;LN5ZC^=:FF>/[G2;"VL8K>U,4*;<MD,3ZFNJT7Q-Y6LIX<G\V5X2T374K#+
ML/;TKK#:6[N&:WB++T)09%;XC&P@E2K4?=W6O_ $HO=,\NE^)6K99EBMD1CA
M!L)_7/-5;G7/%&OY")>>4WR[+:,HOY__ %Z]>:"%\;HD;:<C*@XI]<T<QP\-
M:=!)^O\ P!\C>[,'PA%J4/AZ&/5-_G*Q"B3[P3L#6]5=[VUCNH[62XC6>0$I
M&6&X@>U>>>/]5O[;7X(([B:&&*(21F,X^8D@D^M<U*A/&5VOAO=_\,4VHH]+
MKRK7LZ5\1%N%^7=-%*/?. :[#P?XC_MS3_*N&'VZ 8EQ_&.S#ZUR'Q$B:+Q+
M#-GAH RYZ<&NO+:4J6*E1GU31,W>-T>J5P7@H_\ %=>-E/+?:XSEEP<;?Y5V
MUG)YME;R?WXU/Z5Q?A EOB!XS)5P1/$/F;/\/&/;%<V%5J-=?W5_Z5$<MT=7
MKF?^$?U+:-Q^S28![_*:Q?AL"/AYHN<9,&>/J:W-:!;0=0 ')MI,?]\FL3X;
M\?#W1LDG]QU/U-3'_<9?XE^4A_:.JJEJV#I\@*LWH%;!)["KM5[VUCO;9H),
MX/((."I[$5QTVE)-E,+2X6YMU=2,XPZC^$]Q4DDB1+N=L"L")+JWO)(9]/$D
MK@?Z3%(0)!C&6]#3Y/-=Q+%IDC2!-@9W.1G^@K=T%S;Z?+_,FY;TR222_P!2
M\PXQ*NU1V&W^=:M4M-L$T^W,:LS,S;F+-D_3/H*NUC5:<_=V&@HHHK,8AK,O
M7,>K6CE9'0 @A>B9SSBM,]:JWL+RQ!H@#*AW*"< ^V:TI-*6HF6%977<A!'J
M#4%[<QVULQ<,Q8%51?O,?05F6UG%'YRFPDA,Y\QBTI.XY[\\?2HGL6O&N'AL
M?*GE7RVEED.W\OIWK:-*'-J]/E_F%S9L5V6B)ECMROS')&#T-6!4<$*00I$@
MPJ# J05SR=VV,6BBBI ***3G!P.>U !^%+7S#J%]XFBN;ZUEO-360S8:,.YV
MY)X%?2>E^9_9-GYJNLGD)N#GY@<#.?>O6S'*W@HQDYJ7-V^7^9$)\Q;HHHKR
M2PHHHH K7@)LI@&*DH>?2JVDW,;6,,1'E2*N/+;@]>OXUH.BNA5AE3P0:Q&T
ML6^=UH)TB<O"=YR!U_/.<5O3Y91<6)FWD#N!CK69%(DNNR.GF<1;<Y^1N_'O
M[U3ND74(?+?39)X9!N4/+L;/OZ59T;3WMWFN);98&8[8T#[BJ>A[=:M0C"#;
M>OR_S%>YKTM%%<I04444 9VJD 6S$.VR4.$3^+'_ .OI5\$'IZ\U7O[=KJSE
MBC;;(5^1LXP>H_45AV_EK.EW<:;>6ET!Y;D2$J<'KQP<_2NF$%.'H*]F=%)(
ML43R/PJ@D_A6?H?-B3YSR@N67>>5!Y JF?+G>-%@NWN K,GF-P@QCG/_ .NM
M73K06=G'%R6P"YSG+=Z)14*;75ANRW116/XJGO+;PIJL]@S+=QVKM$RCD$#J
M*QIPYYJ"ZNPV[(V**^=_#WBWQ-/KVCP2ZM?/$T\0D#/D/D_-FOHBN[,<NG@9
M1C.2=^Q$)J0444@SWKSBQ:*** *]YDVD@QG(QC./UIFGS+<6,+J2?EP<C!!'
M%2W5O'=V\D$H)C<8(!Q7/);K:7"-<V]S');+@2PR$K(O08'<^HKHIQC.#5]1
M/<Z5F"@EB !U)K)T>Z:YOM3!7:JS*4&.Q7KGWQ5*6>.6$1M9WTLR,0(#)RX/
M!)[$"M;3;(VB2.[,9)FW,">%XP *IP5.#ON_\Q7NR_1117*4%)2TF* ,G6YS
M VFMP0;Q05SU^5NGJ>]:H(;D$'Z5GZU;7%SIQ%IS<1N'C&0,D=1D],C(S65:
MWF+;?)I-W:RQG9(C2DX],8^\#77&G[2FFMT3>S-V]D6.TFRN]BAPF?O<5%I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !0:** $HI:2@#R"*W_LOXA"%L?N[\?/
MZJ_(_0U[!7E?Q!MS9^)HKR/(,T2R<?WD/\^E>FVLZ7-K#<1G<DB!U/J"*]C,
MFZE*C6[JQG#1M$]%)WI:\<T"BBB@#S'XEZ='%?VM\@P\ZF.3WQT/Y5V?A*66
M?PMI[S,K-Y6 5'8<#\<5F?$*U\WP\MT%RUM,KY]%/!_I3_ %V+CPTL.07MY&
M0CT!Y'\Z]FK)U<N@_P"5V_K\#-:3..\71FQ\<33[MN6AG5@.@X!/Z&O6U.Y0
MPZ$9KS?XFP1K=V%R'42.C1E>Y .0?S-=OH-V;[0+"Y8DL\"EB>YQ@U.._>82
MC4^7]?<$=)-&E2=Z**\DT/$_$UQ/)XKOY&?]Y'.50@GY<=,58\1ZK'K,>F7A
M9OM(@:*X&.-P/]<FM'QOI\-KXH2=]OD76&<(<$$<$_7O7)RD)NB#[U5S@YZ^
M]?:890JTZ<TME^EFCF=TVC;-MJ/A&^L=0B821RH'CD PKY'*&KWCK4[368M+
MN[4GYXGW GE?8^]:MOJ?AV^\#VMAJ5V(W6,J 3ND1E)PW'^<5P,4#W-Y':1%
M6DEE$2.> <G ..U94%[6I[6HK2A=7MHUJ-Z*R/:O#4@D\-:<P;=^X49KEO!^
M1\1O&HRI'G0DD>NRNRTJS_L_2;6S."88PAQT)'6N0\(1@?$+QG)@#=/$!QUP
MO/ZUX=*2<,2ULU_[?$U?0ZW6O^0%J'./]&DY_P" FL'X9D'X>:/AMV(F'_CQ
MK>UI0^A:@C%@#;2 E1D_=/2L+X:.)/AWHS ?\L2.G7#'FLH_[C+_ !Q_*0_M
M'64AI:0UP%!12$@=3UHSSCO3 6EI*6D 4444 (:*.]%, HI"0!DD >]+0 M%
M%%( HHHH *2EHH C\F,L6\M-QZG:,T^EHIW !1112 ***0]* %I#11S3 *6F
M[ER1N&1UYI: %HI*6D 4444 (:*#UHI@% ZT44 +37 92K $$8(/>G44@*RV
M%FC(RVD"LGW2(P"/I5FBBFY-[@%%%%( HHHH 3O11WHI@)@4HHHH 6BBBD 4
M=Z** $HHHI@%%%% !VKFOB" ?A_KF1D?96.,UTM<S\0MA^'VN>8H9?LK<$XY
MXQ^M=."_WFG_ (E^9,OA9H>&,_\ "+:43U^R1_\ H(KF=9W#XQ^'2I)S83!A
MGH,UTWA<L?"ND[B2WV2/.?\ =%<QK:EOC#X<Q($VV<IQC[W7BNO#?[S5_P ,
M_P F)_"OD=[2TE+7E%A1163XBEU2'1I6T>,27>0 ."0O<@'J:NG#GDHWM?N#
M-1F5%+,P"CJ2<"N:UWQIIVE0.()%N;GHJ(> ?<UQM[8^)+M8QK.HK:1-D W4
MP'_CJUMZ%X1\,RL-U\NHW"89E$F%S]!U'UKU8X+#T%SUI<WE';[S/F;T1F>#
M]#O-9UE=<O01;I(9,L,&1^V/:O3Z146- B*%4# 51@"G5Q8O%2Q-3F:LEHEY
M%1C9"T4"BN0H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*X3Q<R_\ "Q/!
M:@,6\R<GYL#&%KNZX7Q:1_PL3P8"4.))SM9>G"\@^M=^6_QW_AG_ .DLF>QW
M5+24M<!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;;CGK5SVKHC44(62W%;4Q,K"J*EY<(I&Y0Z$E_;)_E5_3+Y=0LHYAP^,.O\
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M!THKR#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*X7Q;N/Q%\%@$A?,N"
M<#K\JUW5<%XO8GXC>"UZ*LLYSR,Y _/ITKT,M_CO_#/_ -)9,]CO:6BBO/*"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHI#0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !112 @YQV- "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJYU,P3*D4#R0DDNS-ROTSUJEQG'//K2ACGH.?6J5*"Z!<T&UE=FY+:9P5SC
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M9CD ;=B)NN?I7*:"P3Q/X"8@$MILZ!CR>IP/PKK[5O\ BD_#;-&A?Y,#./\
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MJ\S,G/ZU-3?_  W0N%N706BBBN H**** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW=\Q3>,KV%,BOK:5(V63[[E<;2.?Z4<LNP$^.-K=*4C)48SG]*@^V0>0TID
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\Q))S5G&"Q&,=LTG0Y.?3BIYGW B>T@D=I'12Q/7N/IZ4Y+6%)0_EC<%X/\
MGO4HQC/7US3>,*/4]:.:6UP(?LEOLC'E?=;=C/?WJ*:VB!B18LB23,@)] <5
M;S][ISTJ.;>TEN(^H+=NORFG&3ON!TD)+01G/514M0VP(M8?78,_E4U>7+<L
M*:>E.II^Z?I0@.2ABB-Q=NL8^=54]R1SUJ0VENC92%1M4[0#P,TRW*_:YP$
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MNZ:Q VWD(+0./7^Z?8UVX;-H^T2G!*/DMB73TT/(]-TN\U6\^QV$:R2X)P2
M,#OS7I?@OPO>:&]Q=7TJ&:9 @CC.0H'J?6N0^'P)\71[F,9$,AVXZGCC_/I7
MKU:9SBZD9>P6S2"G%;BBB@=**^=-0HHHH **** "BBB@!.]+110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 )7!^-F<>-_!02,OFZF#?-C PO-=Y7"^,U5_''@M3U-S,?R"UWY;_O'_
M &[+_P!)9,]CNN] H[TM<!04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112%@"!ZT +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOX)/&1=38ST^ZM=^6_Q_^W9?^DLF>QW-+24M<!04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !112$X!-  *6@=** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5.LZ%;W<A!F^Y+C^\.#7->%O._X6?XR+[A'F#8K#G[@Y'M4OPT;.DWR@847
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MBB@!#GM2T44 (:6BB@ HHI!G/6@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** $'2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+!!';6\<$*!(HU"(H[ =!4M%;5,16JI*I)M+NQ));!1116(PHHHH 3%%+10
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MR5/[K?X5J5\]BJM><[5WJC:*26@M%%%<HPHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHZS\.7MK+SM+N)+B1/OQ2X^8?[)'>O<I83"T)P56=IZ/R1DY2:T1I_#N0_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )@>E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0+=YSU,Q^8>A]J?_ ,(7H&71H;ME).,S'">];OS&(?*&.<$9QBI 1N.<[2H
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M\EJR[<;'$K$^^#FM& _V=96T5W,GGRMLZ[=TS<X'J?\ "K# @@'[P^\H/;U
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MQL"& =<=,$>E* "[E%^8].X^M)XS$?SL?*CFYO VG2.I6^OTW?*<2Y_.G?\
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MI$/X5\CO*CF#F"01_P"L*D+]<<5)17DK1FAX1J%S=&417CRF>%V!\P'<O/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444@SCF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!*X'QY)L\7^"<QLZ&]D)Q]%_QKOJX;QOSXM\%@LJC[=(<L/]D5WY9_O"])
M?^DLF>QW/>EHHK@*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBDQS0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %'>BB@ HI,TV*198UD0Y5AD$=Z+ /HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y#QIX>U+7Y[)+,QB!"1(7;&W/?'?BN@TC2[?1M.CLK
M8?(G)8]6/<U>Q1BNB>)J2I1HOX4*RO<0C<I!Y!&"*\F\#:E+:>)UL8^(;EG1
MU8<C;DCGUXKUKO7CMDS:1\1@I .V_9,>SD@'\F%>AED5.E6IOJORN1/1IG2?
M$YI5MM-PW[DR.&7L6P,'^=;'@%R_A&URS,0\@.X]/F/Z4WQ]9"[\+32!<R6S
MK*I].<']":J?#:X,F@7$);(AN#M]@0#_ #S3;4\L5OLR_K\PVF3?$.'S/#:R
M_P#/&X1NGKQ_6I? +;O"L('\,CCI[T[Q\"?"%U@='CS_ -]"JOPYS_PCDA)S
M_I#<9Z<"HWRWTE^@?;.P'6EI*6O)-!#UKA?#Q\OXJ^*H<,N8H) .H.5'.:[H
M]:XG0E(^*OBHX/,-MSG_ &!7?@_X=;_#_P"W1)ENCL+H V<X/3RVS^5<E\*\
M_P#"O-/SC.Z7/_?QJZV[4/93JV,-&P.?I7)?"K'_  KW3P !AY1Q[2-13_W*
MI_BC^4@?Q([.L3Q'XEM_#L,+2Q/-),Q"QH0#@=3S6YBN0\?Z'_:6C?;80?M-
MGE@!_$G\0_K^%98.-*=>,:NS'*]M#?T;58=:TN&_A1T23/ROU!!P:YWXB7MO
M#H:6LD:O-.XV9&2@')(]/2H?AQJPN--ETQEPUJ=Z''WD8Y_/.:R_B9YHU*Q.
M/W8B;:0>ISS7?A\*H9C[-Z).Z_-$.5X7.->QO([5+N2WDCM9#A)MORG\:9N:
MUF26"8[EP5ECRK(?K7N%E9VLN@VUJT2O;- HV.,Y&*Y75OAU!,=VDW'V7(.Z
M*0%D)[8[BO1HYQ2G)QJJWY?,ATWT-OPAKQUS2 TN?M,!$<Q_O''WOQKH*YGP
M=X;G\/6T_P!JG62:=@2J?=4"NFKY[&>R]O+V7PFT;VU.#\2D2?%'PQ 8S(/L
MUR2,8!!7&"?PKD?  D3PG;J6VGSY<*1P@!Z ]Q[UV&O9/Q9\,C (%K<$9.,'
M'./7M7(> I,^$K8D;MLTH&#G^+H:^AH?[DEY1_.H8OXOZ\CH3@@EL9SR*<=I
MF8A/E"\@GOBDVY W C:>>:"0,DA0&7##&?QK$8T,#L^; )R>.E.[L-R@$'D#
MFFID1*<C9NQMQR:EW#S9<@G (R.W'-# CW@QJ>KM^ QT_.ER#YA"DD#H.PI)
M&VK&A=?G^YS@M]*=AE,@  W#DYH RM4N);*ZM=2AM6NG1&@9(SSM8\'Z T:=
MI<B,NI:DPEU$#(R/E@&>@_"M12I9./G'IQ_DTT-M5@3@KRP'-:^U?)RI?/R[
M"L P"2,;2N,Y^:G1@Y4 X0-DG%)C)1@RA< Y"TY/7><%P3\M9,9YJC;-0B#-
M*LG_  DC9*CG'8X[YKTB39AE"DL6Z=*\^7#7\&V(';XH92Q.&([\^GM7H;AF
ME8*%8*<\GG&>E>CF#UA\R(#3E7+9*L!Q@\5D76G-#.+RT&Q51F=5;!B8_P :
M#OGN.]:[+Y<F&5=QZCTJA;:K]IU:^TZ*V>-K0+F=Q\L@/85QTG-7<>F_IL4R
M#27N+Z2XU&ZMQ&S!;>+<,$H.68=QDUIJ0S# !R,"G99=YW ]%(QD49&4; ('
M7':E.7,[I6&A"259023C!]R*YFZ9AK7C0D YT! %'4<@5TA'7>V5/ 'H:YJ7
MS3KGC8RJF!H0V[1GC(QFM\+O+T7_ *5$F0QQ&/#'A^/+N#&CER,],#''>NPE
M"^<P&0>N>V:Y'SC_ ,(SX=:1%5FC0%<_+MX[UT-QJMA TA^U)*<X1(6W.S>@
M IXB,I-)+K+\P1=&7"C<.OYUF,%U2_:( O;6DBF3/\<@Y !]%/6D,5YJ:+YZ
M"UM0VX1QD^:X]S_#]*T;>%8@8HD.S P.P%<^E-;Z_D5N8WB5(V.C&654QJ4;
M$L..C=^U1JL$GCZXN#<Q ?V<J[FD&T8<Y'IFI_$Z:5_9"2ZJDCVL,JE41L%W
M(( ]^M9?_"'Z(=)$G]G7TK,H=;<S8<\?<_'K771</9+F;6ZV75W[HEWN.T-T
M;QUXD=0'4[-NTYW=,X/2NCFNH(=VXJ[)RJ#DGVK$\(V.CPVTUSIB3QS8$<T,
ML@9HR.V/ZUK6 #0QN&PXD9FWH,M6>*<74>^B2^Y?/L$=B;[2FT,"ZJWKC(/7
M;]:$D26.4!]V(F+(Q^[P>OM33#,%?9-R7R6" X_Q%0GSOM<T8,0 M?DW#&\X
M/3VKG23V*.3T]5/AGP/$B-\NH7)PWW2,]CZ5V_.3B,X)]>.*X:QR?"W@5E*X
M&I7/RC/7/0?K7>#:)-P&0/?@5UX[XOG/_P!+D3$YRP9(M<\3,Y17:1<EB%.#
M'5 -$OPQDB>1(Y/LS>6K,"3AO3J:EU+2_#NJ>)I+&ZM[M]1=?,E:*0JN,<;O
M2L_5] \,:%/ EU;:D896 \^-\K$3P!D_RKII^SDXIWYGRNUOY5;37J2[G:VS
MDV5JQ&"T:;AC&/E'ZU.>2\@.%';%,"((Q$'W[0-I/<8X)_"L$,6^)CQ#S#&V
MF%PA)P3D9XKS80]HY-=$V7L="@&5#\ #).,<>U* <R8C.TY(R?O5DZ1?7-W?
M:M%<$D6UT$B79C8I7]>:UR#EP2"HXPW:HJ0<)<K_ *ZC0H*GRFW$*5. >PI$
MP%;/7.T?3_"D9F#+E5/IQ0=Y23RV4MM.W(Q\W;/M46 JW]\MGN5,/<D?*K=C
MVS_GFH+'3VC<W%TWFW3'=R.5]_K_ "K,TSR+2[\_6)GCU!WPXG3]VK'IM;OQ
MT/:NC4 PJX/R@XW YS^-=%1>R7+'KU[^GD):FWX: .HS-G(\L8R:ZOM7*^&O
M^/\ E(/RF(  ?7K74U\_C?XIK'86BDI:Y"@HHHH *P/&[*G@?6V?[OV.3/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,TXMEGXR1D9ST_\ K4 8FJK_ ,5#X<D./+\Z7)+8V_+Q4C7 'C&2W%S&;?\
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M@NI_-NDB D8#J?0_3I^%9FN:/9?;WU:YUN;39600(ZR  GT'>MBUNDO[)+R
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MFO7;&V-G86]L6+F*-4W'O@59HK#&8^IBK*222[#C%1"BBBN$H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*X'Q]_R-G@G
M&XW[C).,#:*[[O7 ^/U>3Q-X-1<8^WL3N'' 6O0RS_>5Z2_])9$]COJ6D[TM
M>>6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+?*<MNZGK5>2_M(92DM_:HR#&&D ^M2P/$ZQLDBE&;*NC9!_&H<6E=H9Y]L
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M]ZZ/X6[SH^L&7'FG5KC>-V3][O6^/DWEZCTT?_DTA1^,[O-+24M?+&X4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !112=Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM#TZVV^7LB1'#+C!^E75+!F4?<VX.#T_^O0#RI*-LSD'UK7$XV>(A&$DM/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"MJ"[]-ND&.8F
M'(]C7!?#//VB_P#F'W$X_$UZ*PRI'J*\O\#LUMXOGMW<*2LB%1T8AO\ ]=>I
M@_>PE:/HR)?$CM?%>D+K.@3PA<S1CS83W##_ !Z5Y8=7,GA<:1()3Y=P)H_1
M5QRI_')KVWKQ7@^JPNFL7=M&H,@N&10.YSP*[<EDIQE3E]EIHFIIJ>I^ [?R
M/"5JQ'S3%I3^)P/T KIN:J:7:+8:5:VB+M$42KCWQS^M6\XZFO%Q%3VE:4^[
M9HE9"U#=3I:VLMQ(<)$A=OH!FILU3U2Q35-+N;%V9%GC*%EZC/>LH)<RYMAG
MED7VGQKK,C7VH16EO$,J'8 !2> HZ9]ZIMH]A#XG;3&U#-N6"BY5A@9'?MUX
MJ"ST.2YUB72YKN&VGC8QJTJDJS ]/;-7-;\(ZGHD"W%Q+;21 A2T6<KGID$5
M]GS0A/V<:EDUHK?C?J<VK5[&=Y]QH>JO]EO%,L+\3V[_ "R ?H17N%K,;BTA
MF(QYB*V/3(KS_P +^![6[@MM3O+D7$+#>D"+@9ST;UYKT55"J%48 ' ':O#S
M?$4JLHQAJX[LUIIH=12=Z6O&-!#UKQ;Q:=2G\;^+M.T[39[_ .W6,,,@A&3%
M\BD,1W%>TGK7!Z)YG_"XO$X#J8Q:6_!Z@[1T]J]7*JOL74J6O:-__)HD35[(
MYO3-<\::39213^$)9I);>. 21J55%12H)'?CFNL^%*JGP]L%7;@/+G8<C[YK
MK[G_ (])CG'[MNOTKC_A28_^%?V?EA1^]FW;>[;S6U?%1Q&$G)047S1VOKI+
MNQ*-I+4[6L_4]<TW1U4WUVD3,"53JS?0"M"O%G@FUOQ9+!>3_9GFN"KM)U3_
M &?;CI7)@,)#$2DYNT8J[*E*VQU6H?$E8IW2QLUEC!^621]N?PK7T#QM9:S<
M+:S(;6Z;[BL<J_L#Z^U,@^'N@PQ[7BFF8_QO(<_I7)^)?!5QHVZ]L7>:Q5MQ
M49WP^_N/>NZ$,NK_ +J%XOHW_7^1'OK5GJ]>3:J!)\3B7'/VN(#W  Q75^#_
M !;'JL*V5[*@OE&$/02KZ_7U%<JK&[^*.\$?\?F.G91C^E+ 4)X>K5C-;182
M::5CUCO2T@ZTM>$:G"^* O\ PLWP>YZA;D#W^0<5QW@#R_\ A&5.T,!<R\XY
MSNXS79>)D/\ PLWPB^<@)<@+[[17&^ 5(\,1CA5%U+M53GOZU]3A_P#<5Z1_
M]*J&#^+^O(Z1CA &*@JW! KE[_Q#9Z=XKNV73;^YO1%';LT*9!7[P(]>M=-T
MC*%#\S#!J82.DA!^4A>PZFBE.,&^97NN]NP-7./F\<0QL4_LG43R=@V?>QU!
M]*Z6SN8[^RBNUBD2*>/?Y<GRLA]ZG$CE!D LG &._K04)+\ #G<,]:=6=.22
MA&S];@KF)X@@OUCTR^TU&N9;28R&,'Y64C!_*JSW=UXDO;.9-/N+.VL)&N9)
M9P5D<@<*GUKI,#RE9"0C?@:<S!!*/GP.1GD'Z54<1RQ2Y=5>S]?^'"Q@Z#%?
M7&HZGJ5]8_8OMQB\J(_[(.2?<ULGC=N+%T49VT\YRH<%MO3!YIVTL K??SD$
M]_0&LJE3GES6MM^&@TK##L)4!., \_SHY9UW!OOC">HI 22FU7# \@TY2?,R
MAVD-R#S^%0!YR)X7O\HI(;Q1N!(^8#Z_TKJ_%Q:/P]=C.S=+&C /U1G&0?0$
M5S%P8TO-X1?*/BH,S] /8UZ#*BR%Q*B-&YPRD9R*]3%34)TYVV_X!$=F<OJE
MKIMW?Z%X=L_L[VJRO/-%;.'"H!T;ZFIUDMV^( %CMWFP9;L0XV @X3IQG'Y5
MJ6&CZ;HQF:RL8K?S/OLG4^P]J-.TFQTB%[:SC*[VW2.W+,2<C+5@Z\.5I7>C
M6O6^K;_#\!V)[L,FG7I25E"PMCC/\)Z5Q_VP77ACPW90:CL%PZQ7#QRX?H<J
M>X)Z5VG)8G@'!!4\?7BLF3PUHLMY!=K8"&X#!MT1*KD'/3I4X:K"'Q][].S0
M--F3=Z?_ ,([J%C/IFH7'^D7*PS6MQ,9&9">H4\\5/<H$\3>,@_*?V 6SCIR
MN!FMM]-L9M3&KM;1O?J"BRECE1[#IGWK#F9E\3^+U8;O^*>./EZ<CK6].K[3
M?=+5_P#;T?R$U8U?#;F;PKI1&%_T91A:M:AJ%GI$#7%[,L<"ID*1EG/L.]5?
M"RL?"^E;AA?LRY11W]14^HZ-8:U%%%J4!G$9W1DL05/MCM7+/D^L2Y_AN]M]
MRE>QSR3ZQXNN \<ITW14ZL& DE4CGBNETO3[73[9;2QVI;1X'WMV3U+$^IJB
MWA+1$1!_9^2IP0LS#(]ZO6%A::9;O:6:[(5.X!F).3UJZ]:G./+3T7:WXMW=
MV"36YD>+"3::7>R%4MK>^22Y*C=L7D!N/?K]:Z S1M&EPES$T6X?.L@*C/;/
M:JEO%NM&A2&$Q9,=Q"?NOGJ:RE\&:()E46$ZQ2'<ZB8B,'/ *U-Z<H*$VU:^
MR3T^]?J&HFESVEUXPU*^LV4VKPK&\J'Y)9AU('TXS6KJDTEE8W%Q$0TT-M(\
M0(R PQ26D:QW$,$$"6T2+@PJN-JY/\ZM^6/-4%=RF-E&>X)&14U)Q=1/HDOP
M!;''R'4X8]+9?$/FR:HPCF&Y2%5AG*^GI6DMJ=!U>QM[2^FGAO6=)H+F;?M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 -9=RD'H1BD1-BA<DX[FGTE.X"T444@"BBB@ HHHH **** "BBB@
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M8_$X>-DT/0?F7ERG*'ICKTIWD^)MJ@^'?#@CB8\!3D_KUKIR VX#:0C9%'S
MY"]>I]^U+ZT_Y5^/^8^4Y067B?<T;:#X<ECQE<K@ _GZ56O]%\1W]G/ VBZ'
M ;@X<Q9##'<'/X5VAV_*<$@GYB/X33I"?G .>V>_/6JCC9Q::BOQ_P Q<J.,
MLM/\16%K'#_PC^AW4BD@22L=^T<<\]32-INLH69O!^AN"P+_ #'/U'/3_"NQ
MV[2&"[L<@]<'WI=J\[<@$Y;)YS1]=E>_*M?7_,.4Y$:;JX,L?_"*>'I'#%@'
M4A6SSCK47]E:^SL?^$;\.#?&#R/NX[=>M=DK!F7.=Q&&)'W?K4;RI;PF67Y4
M1OO'G=[#WIK&3_E7X_YARHY"T6]M/%7AB35=/TZP4W0\IK3"@*,Y#']<UW/P
MHVG3=<:.0/%_:TP0CD$9Z@^]8FG:-'XYU$0WZ[=.MV+K&%*L#TP&]?6O1M \
M.Z;X9T_[#ID)BA+EVRV2S'N37)FN+I^Q=%_&[:+9:M]]]2H1=[FM2T45\R;!
M110: "L;Q9_R)^M<9_T&;C_@!K8K'\5Y/A'6=I(/V*8\#/\  :VPW\:'JOS$
M]BKX#(/@31""2/LJ8R,5B>+-@^)7@TL5!+3#DG^[QC\:V_ 0 \!Z(%8L/LJ\
MFLGQ2SCXC>#P@!RT^X'L-HYKTJ7^_5?^XGY2(?PKY'<4445Y!H<OX\N[JT\/
M9MBX#R!963@A?KVK/^'VOO>6\FF74A::(;XBQR2G<?A73>(+0WV@7]LJ[F>%
MMH]6 R/U%>-:9?SZ7?V^H6_WHSD ]QW%>[@:,,3@YTK>\G_PW^1E)\LKG=_$
MRQ5K*SU$+\\4AB8^JM_]<?K6MX$U(W_AJ*-_OVI\GZ@?=/Y?RIWB18M=\%33
MVY#J8A.A^G/^-><^&/$$N@ZDDF2;>4A94SP5_O?44Z-&6)P#I+XH/^OU!OEE
M<] ^(-OYWA664(&:"1'!/51G!(_.CX?3"3PM&H;/ERNI_//]:J>,_$6G3>&9
M[>RO8)I9RJ%4;)"YR35_P':&U\*PLQ!\]VE'T/ _E7/*,HY=::M[VGW#^WH=
M,.E+117D&@4444 %%%% !1124 +VI***8%&YT?3;R?SKFQMY9?[[H"37)?$:
MPACTRRN8HU0Q2^7M10,@C_ZU=W7/^-;9;GPE?9&3&HD7V(-=N!K2CB(7>E[?
M?H3):,B\"7'G^%+9<C,+-&>?0UTM>=_#74XQ]LT^1U61V$L8)^]Q@X_*O1*,
MQI.GB9KN[_>$'>(M%%%<)04444 %%%% !1110 4444 %%%% !2&EI#0 5ERZ
M_I2WK6#7L0N<8*$\ ^F>F:B\4W\NF>'+RY@QYH7:I],\9_6O--*\*:AKFGW%
M[;2J#&V%1SS(0.>?7ZUZ>#P=.K3=6M+E6WS(E)IV1K_#UMOB>_3(YC?_ -#K
M5\9>$!=JVIZ9&JW* M-$HQYH]1_M5R?@VZ.G>+H%G!3>6@<$<AC_ /7%>R5U
MYC5J8;%JK#JE\R8)2C8X;P'XE-['_9=W(S31C]PS=64=03ZBNYKRGQ2MO:ZI
M;Z]HMRACGD.3&<;)5Z\>_>O2=*U!-4TNWO4P!*F2!V/<?G7+F-".F(@K*6Z[
M/J5!]&712T@I:\LL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2N ^(?\ R,/@W=_J_P"T3N&W/88KOZX3X@)OU[P@
M@<!O[0) SUP!7H98[8E>DO\ TED3^$[OO2TG>EKSRPHHHH **** $-,DE2)=
MTCJB^K'%/->0^-KV>\\47$.7V0[8T1B0/R]S7;@<(\54Y+VMJ3*7*CUM)$E0
M/&ZNIZ%3D&GUXW%+XB\'R"1EEMXVXP_SPO[>QKN?#WC:TU7R[:\VVUXW !/R
M2'_9/]*VQ&6U*<?:4WS1[H2FGHSJZ\?^(%Z]QXJFA(PMO&L8S[C<2/3K^E>P
M5Y/\0Q$?%2A  Y@0/VR23C]*UR6WUG5=&*I\)Z5HT4L&B6,4[EYD@0.Q.><5
M>%1PH(X(XQT50.OH*D%>5.7-)ON:(6BBBH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML/0IR=31_FNQG.+;T,+P?JEIH^H3:A?V\TBE=@F5=WE9/)/U]:[76]6L]?\
M!NIMIDXE*Q_,HX8 $$Y!]JY/6?#FH^%KLW=D7EL3_P M,;M@_NN.X]ZQKF:R
MDADGL0]K+MVRQ(Q*.I[J?3V->A/#TL54CB(/MKTTZ-="4W%69V_PT,9L=0VK
MA_.&6[D8XKNJ\R^'FKV.GR7%K=2^5+<R+Y18?*<#IGM7IG6O%S6$HXJ3:W_R
M-(/W3SC6T_X1?QW;ZF@Q:W)+N![\/_C7HR.LB*Z,&5AE2.A%<]XUTHZGX?E:
M) T]O^]08Y('4#\*9X&U5-0\/10;U,UL!&RCJ%_A)_"G7_?X6-;K'W7^@+25
MCIJ\>\4!?[?^(N&8,=(A)Z\?**]AKR#Q:0NL_$'E@QTF Y(XZ#I6V2_QI>B_
M]+B*IL=GX8+?V>RG;M&EVFUL'G]T:I_"1'3P!;;L?-/,PP>,;S^57?"LHETW
MS%#<Z;:]L<^6>U4OA.I7P-$Q9SONIVPW;YR,?I3Q'\"LO[T/RD"W1W-%%%>*
M:!24M)WH \F\0PK>?$,V\J;DDFC0KG&1@5ZNJJB!5&%48 ':O)_%#M;^/&E)
M+%9(V7V''%>L@[E#>HS7KYE?V5'MR_Y&<-V.HI!2UY!H)FES2=Z:[I&C.[!5
M49+,< 4[ .SQ7+ZMXQM[-W^Q[+KR&_?(N=S<\A /O$=?3 INHZW/J=__ &;I
M,/VF(?Z^17V@CZ_W?7UZ"MJPTN&S'F.D<ET5"O*$"\#HH'8>U=D:<**4JRNW
MT_S)NWL789H[B".>%P\4BAT8="#R#3S67HC>3%<:>TA=K24H,C&$/*_H<?A6
MI7-4CRR:0T4-:U6#0]%N]3N0YAMHR[!!DGV%<MI?CR/Q7>?V5I%O<VUT8O-E
MFG3 B3@9 [GD 5>^)"N_PZUP(2&%L3P<="*Y+3=0-AXT@:V'G3S>';>&V4<[
MY#MQQZ #)KUL%A:53#2J-7GK;731+=?,B4FI6.^+0:-''IVGQ>9>39=5)R6/
M>20_U[]!3?[!>]P^L7<ERV01#&3'$OX#D_C5[3]/6RC+/(9KJ3!FG;[SG^@]
M!5TUYTJSB_<>O?K_ , NQE?\(UH99F.DV9W#:1Y0QCZ=*AG\*Z0Z*;>%K&1&
MW++9N8F!/TX/X@UK3W$%K'YEQ-'$F<;G8 9KD-;N[/7;RR6)IOL<+.9[AG,4
M2C'49(+," 1@5KAW7J2^)I=Q.R-NVO;RPN!:ZL4,;-M@O%X5^P5_1S^1J?6]
M<L/#VG-?:C-Y< 8(,#)+'H /SJ+1IEUOPQ:O=PEQ-"%E65<;B."?Q(R/PKB/
MB$\MAI^EZ7>%[F!]2AD@E89.U3RC#N1GKWK7#X:-?$JE+1WU2\M[";LKG9^'
MO%FC^*!<'2KAI?LY4290KC/3K]*W*X#P/Y47C7QI;QQJ@6ZB*JJ[0!M/:N^[
MUACJ,*-9QIWM9/7S2?ZCBVUJ+1117&4%%%% !1110 4444 %%%% !4-US93X
M&?W;<'Z5-45UG[)-_N-_*JCN@/ ?#$.R_P##,SL\BR6]U^[V\Q8D8=>XKOE)
M(3&3C'MQ7GWA;>-4\/!@1$8KG!!'S'S"<>U>A#LK'.XYY.<#-?8YE_&^_P#]
M*D<\-A=I^ZQP.I+>G^-&')1,@,QX8CM31PSLNT'H1Z"C<&()!.T]Q7G%'.V$
MT^K^)-187<Z6FFNL<=JO )(();U]JNZ[ITEY:_:;:_FMKNU3=$Z284D<D,/P
MQ4-_IFI_VDVH:+>P6\LH7[5"ZY60#H?K4-YI?B+54^QWUY8PVTG,A@!W.G]W
MT_&N^\7.,XR222TZKOI;6^OK<GI8UK"_34M+M;Q X\Z,,1TP>]<]JL]WIWC.
M'4ETRYO+6.R,3- ,D%O4^U=3'&L$,<46%1%"(H/0 <5D:A=:K-JZZ5I;BV58
MQ/<717.U"< (.Y/Z5GAY)5)66C3W?0;V,*S\1SVE[JL\NAWQ^U2)*%V'*J%Q
M76Z7?MJEA%>_9I;9GW Q2CE2#BL:2;5=;U^\T^SU1[2UL(T7=& ?,E([_3%7
MO#FJOJVE,\UP)+F.1HIR$V@L#U_*M<3&,H<ZBD]+ZMV36GD*.YKX 9,9)7\2
M<T@#*'5#D_>.1S02%6/:W+# !I>0)B=W&, G&*\\HS[G1;6XE,D<D]K*R_?M
MWVX8_P 1'0U"5U2VC5@8]01/E8-^[?T!ST-:HY95('R#( /04QEQ$^TMACU)
MXK559;2U]?ZN%A="\1Z=I]_*^JS?V;LCZ70V \]0>GX5WUG?6NH6RW%G<17$
M+9 DB8,#CW%>6:Q;)=2Z+#-'YR2:E$K*PW*1SG.>U>IVMG;6%NMO:6\<$*YV
MQQJ%49]A7G9E3I)1FK\S^[3\2H-[%C-%)2UY)H%%%% "5D>*FV>$=88!CBRF
MX7K]PUKUD>*4$GA'64;H;*;OC^ UMA_XT+]U^8GL><:5\/\ P]J?@G1+R>.>
M.YN_*$DD<Y'+'!XZ5G>'=)T_3/$'@N[M(YEDN9[M)"QSOV,R X^@KM?#H"?#
M[PFH"!3);[@P]ST]\US.G/C5? (V;8S=ZASGH?,?BOJ(XFM/VL)2;5Y]>G+/
M_)&-EI_78]@HS117R1N5;_4K/2[<3WLZPQD[0S=S6%>^.M%M8V:*5KE@0 (U
MX.?<UH^(-"AU^Q6VEF>(H^]73L:Q+3X<:/#M-S)/=,.H9L*3]!7?AXX/DYJS
M=^R_K]27S7T.1\3>,7U^ 6@MDBA5@_/S-D53TG0->O88[[3;>18V)59A+M)[
M'OTKH/'\=GI=O8Z;8VD<"ONE8HH&<  <UW6A68L-!L;4'/EPKDCN<9/ZFO6G
MC8X?"1E0A92;T>NAFHWEJ><2^!_$4&95:$L 6+I*01Z_C6U\.GU4->QW,4_V
M1F#!YL@B3N!GD]J[ZBO-JYG4K4G3J16O7L6H).Z%[44#I17EEA1110 4444
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MAA_B/I775P&(HQYYQT)4D]C9S124M<904444 %%%% !1110 4444 %%'>B@
MHHHH **** "BBB@ HHHH 2N"^(?.L>$5 !)U+OQV%=[7"?$+<=8\)*L:.?[2
MSAFQT%>AEG^\KTE_Z2R9_"=WWHH[T=ZX"@K@IOB#)::]<V\]JC6<,S1';GS
M <%L5WM<YKW@W3-=<SL&M[HG)FBZM]1WKLP<\/&36(5T_P "97Z&OIVIV6JV
MXGLKA)4[X/*_4=JN9KR2^\.:[X8NOMML6EBCY^T0'D ?WUKH- ^(45R?)U95
MB8GY9T'RG_>':NBMEKY?:8=\\?Q_K^K"4^C.[I*1'61%=&#*PR&!R#3J\LLY
M+QKX6&LVWVVU4_VA F%"_P#+1?[I]_2N=^'<%\->N93#)'"(RDQ*D#?G@?7K
M7I])@#IQ7?3S"<<.\.U=/;R(<%>XM&*6BO/+$I:** "BBB@ HHHH ***1L\8
MQUYS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AKR_1"UC\1Y
MHI 5+3RH1G^]R*].EE2&-I)'5$499F. !7E/BS4[+_A*+74],NHY&&QG:,Y^
M93W_  KULKC*;G3MI)6^9$]+,],U33H=5TV>QG^Y*N,]P>Q_"L7PSX1BT!Y+
MF6?[3=N-F_;@*OL/6KT?BK0I2VW4[<;0"=S8J&[\9:%9NJM>K(67</*&X8^H
MKG@L7&#HQB[/I8;Y;W-[-1R3Q1;?-D1-QVKN;&3Z"O/]1^)F-R:=9_1Y3_05
MS]KIGB+Q;*+@^9+&"<3SMA%S_=_^M712RJ?+SUVH+S)=1=#V2@"JFEVLEEI5
MK:RR&22*)59R<Y('K5L5Y<DDVDS01D5U*L RD8((X-<#XV\,Z/8:/+J-O";>
M96  C/RL2>XKT"HIX(KF)HIXTEC;[R.,@_A6^%Q,J%123=NOF*2NCQ&R\/:K
MJ-N)[6S>2!G\L29P,^OT]Z]DT>"XMM'M(+LAKB.,*Y!SR*N(BQH%10JC@*!@
M"G5T8W,)XI)-))$QARB'D<\UYUI>WPEXZEL92?LMX L39Z9.1GZ'(KT:N/\
M'^CB\TD:C&#Y]IR=HY9">?RZTL!4CSNC/X9Z?/H.:TN=A7CWBH%_$7Q!1F"K
M_8T)ZYSP/RKT+P?J0U/PY;N<^9#^Z?)SDCO^(KS+QMJUMIWBOQG;W4OE_;M,
MCMXEV9+/L&/PKNRBC..*G3MJE^4XD5&N5,] \*G=IN5P VF6I'/(_=D<U5^$
MZA? 5O\ -N8W$^XYR,^8W2N;\,_$?PS;V;I>7,D#?8X+<!XB0Y1-IQCWKHOA
M+M/@. HVY3<3$'VWG%/&X>K2H5?:1:O*%KKRD$6FU8[FBBJU]?6NG6K75[<1
MP0)]Z21L 5X,4Y.R-2QFBL7P_P")K+Q$+K[*LD;6\FW;(,%U[./]D\X^E-\0
M^)K3PY]E-RDCK/)M<H,^4G=S[#BMOJU7VOLN7WNPKJUSS?Q<[3>,;ODKAE0$
M?05[! NVWB4DG" 9/TKR'Q0]K/XNEDB*&";RV#HV0V<<UZ_& (D Z!1BO3S/
M^!17E^B(ANQ_>EI.]+7BFAPWBCQ/XAL/%$>CZ)9V4X:Q-T[W#%2F&(/.<= *
MP?#WB?7_ ![+=:/<16,4<2AY;F#+H.> 03\Q]NE6O$_/Q.G#L>/#4Y1?4Y;.
M*V/A?I5K8^"-.NX[6.*[NH0T[J.7()QFOHI>PP^"53D7/:-GYN[OOV78QU<K
M'3Z7I=OI5H((!DGEW(Y<^I_PJ[BEH[5\_*3E+FEN;'F_COQC=^%O$UI%IT5H
M\MW;'S?/8@#!^4\=^M<_)\4_$J 9&@ L>\C8'L3GK70^)] ?Q'XR:UB^RJ\4
M(E+O'N) & A/;).:SQX+T.*0V^L)=6$S -YI13 3G P^,9]C7U&&> C0@JL+
MRMKU9@^:[L<]K?CC7_$&D7VBW$^C1+/$?-9&.Y1UQU-=9X:C=/B; LIA)7P[
M"%8#D\KDBN9\?>&M.\.Z7<2Z=LN'-N#,60 HK'"E"._!_"NC\+1J/B5:DG_F
M6X-@Q_N]ZWK^Q>$<J"M%J73K[O\ 7H)7YM3TVLW7Y[FWT>1[2989V>.-97 (
M3<X7.#UP#61K]Y =<6RU#59-.LUMA-&T;^7YDFX@Y;OC ./>LC4O$$UP+6WN
M;BQN=/6>*22]MU=QA'!RV!A2<=*^?H8.<I1EOUV_J_H:N1%<1W;W5^E]="]N
M;22"WBN)$ "!Y.2L?3=@XS6EJ?@2(S6MU92S2- P:2&64YFQZ,?NG\,5GV[G
M4=9U![6"XN;>^OK=TE2,[(A&<L6)Z?\ UZ]$KHQ.(JT''D=O+Y+ITUN)),P=
M&U61KG[%=W(E>13);LZ!'90<,C <;E/!K#^*8'_"/Z:V<,-4@VG'^]5S3'6?
M7UN+9RUK+>3R1$)PP\M59@?3=GGN:I?%5MOAS3LJ&4ZI;AE*YR.:,-!1Q].W
M7_@@W[K#P47/C?QL6S_Q]PCIQ]PUW?>O/_!+,?'_ (WSG;]JBY^BFO0*YLR5
MJ_\ V['_ -)0X;"T445YY84444 %%%% !1110 4444 %0W8)LYP#@F-L'\*F
MJ*Y_X]9?]P]?I3CN@/G_ ,/K;B[\)Y*>88KO?@\D^8<9]Z[Y2 H8''&#M'OV
MK@_#@0:CX;P@YBNL?+G!\PX-=W)*8K>2=E!6.-G88QTYK[+,=:J7K_Z5(YX;
M#CE0V"AXR1MZ<TX@'!8OAASFN&7XA[Y?*&E2@2.%C(?YN3W%=MYB,Q"<[,,?
MFX ]JYJV&JT;>T5KC33V.;O="TS7]7OG>[O[>YAV";RY-B,N,C ]?>JUIX7T
M36+;S;/5=5>WC9HU/G_=*]<''(HFU^/0_$>KB:UN)_M C:$Q+O7 7!'X&LKP
MYXE@T32WM9=/O))&N7D!1#@[NWM7I1IXKV5Z;?V;;=5K]Q%XWU.[LK2"RL8;
M1"Q6%=J%VW$CW/K6?J&C75QJ2ZGIE^;74(HS%B1-R21^A7V]:T(KAS#$XA?]
MX@?D E>.E5;_ ,06>EW=O!?1S0/= _.1P@'<D=!7G4W5YVX:MW\[]]"W:Q6M
M=&O-)T26+2KJ,ZC=3^9-<SI\I)ZD#V["K^DZ6FC:<MHLQE*DLTV,;G8Y)_.I
MC<1&%98=TT &Y9(F#*WTJP'#*X4$L5R0/IZ5-2K4DFI=7=_UY=@20%@=N5&>
MN>U*<;7S@KD$G/\ 2FKC;$,;B1@ C@"E);9)DKA3P<<U@,3"^;C=\K#.<?>%
M( 64DAL@XQ[4H9B^T X'0XXS3 C2.,.=['I[=>?:F!SGBJ*6^U#P]I]M,\$E
MS>;4G48V''4?2NP^&%[=W.CZE!>7LUY)::A+ )I3R0#V]JYO6%D/B;PO)&65
M!J(R!CCWK>^%JL(?$CEMRMK$^!Z8-;8UIY?;M9_/F8H_&>@4M)@YI:^6-PHH
MHH 2L?Q6N_PAK2YQ_H,W./\ 8-;'>L?Q8F_P?K2YQFQFS_WP:WP_\:'JOS$]
MCG_#Q6/X>^%V="P5X#\A[Y./_P!5<QICL;_P Q&9'N[_ #QS@R.:Z7PW(L7P
M\\)AUC7?);J WKDGCWXKF[3S)-8\"8+D+>W^7''_ "T?(-?04E[U7_%/_P!)
MJ&3Z?UV/7>]+117S)L%%%8,?C'0WU"2R-ZJ2(VW<XPA/LW2KA2G4OR)NPFTC
MC?B1()M?LX$/S)#@_4MQ7I=N-MM$/1 /TKRZ_9/$'Q'2.$J\0E5=P/!5>37J
MW3CTKTLP]RA1I/=*_P!Y$-6V%%0SW5O;+NGGCB&"<NX'2G0S17$2RPR+)&PR
MK*<@UY?*[7-"6BD'2EJ0"BBB@ HHHH *2EJ.:5((7EE8)&@+,Q[ 4TKL#R'Q
MQIG]G^)9F08AN5$RX&,'HV/QY_&O0_!^JOJWAZ&64YFB_=2'N2.Y^HKE/$NK
M:;XJT66>U)CNK%MP20@,Z'@D>HJ/X<:IY.HSZ8[C9.OF1C_:'7]/Y5]%B*<Z
MV 7.K3A_7Y:F*=I>ICZJS^'?'$\T8_U-P)E&,95N2/UKU^TNHKVUBNH'#Q2J
M&4@UY?\ $BW:/Q)%-@A9;<$'U*D@_P!*SM(\5ZEH5G/90[&C<':LF?W;'NO\
M\5=?"2QN&IU(?%8%+E;1I>#BZ>/YT0Y4F<,<=1G_ !Q7JM>+^#]333/$L$TD
M9=9082<98;B.1^->T=ZXLZ@XUXM]BJ>PM%%%>,:!1110 4444 %%%% !1110
M 4444 %(:6@T )7F?B#/ASQY!J>&,,K>:>/;:P^O>O3*Q?%6BG7=#EM8PGG@
MB2)F[,/\1D5VX"O&E5M/X9:/T9,E='(WWQ$O[F=H](L?W8'WG0NWUP.@J%?'
M\]SIUW::C:1R&6%T1X@5^8@CY@:P8H?$>@3;8+>_M9'ZF.,L&_($5GZA:ZG'
M.9K^VEADF!E_>)M+>IQ7TD,#A7:*2MT=]3'FD=U\+X)!%J%P5/EL416]2,Y_
MG7H=9GA_3X=-T.TMX%POEAF/]YB,DUIU\SCJRK8B4U_5M#:*LK!2$T&DKE*,
M#3O%^GZGK,FG0!PPR(Y&&%D(Z@?2M;4K;[7IEU;98>;$R?*<'D5Y;XKTF?P]
MXD2[LB$CF8SP$?P..67_ #ZUZEIMXFH:9;7:D$31JQQZD<UZ6+P\*4:=>@_=
M?YHB+;NF>8^"-)TW5;J\LM0M@\BQ@H22"I!P<?I4.N>'M1\*7L=Y;SR-:(^8
MKA1\T?LW^<&KFDXT3XC20R':CRO&.>S\C\,UZ;<6\-U;O!/&LD3C#(PR"*[\
M5C9T,0I[PDD[?Y$1BFCCO"WCB76M0ATZZM%69T9O.C;Y3@9Z=J[8=*QM'\,:
M5H4LDME;XE?C>[;F ] 3VK9'2O'QDZ$ZEZ"M$TC>VHM%%%<I04444 %%%% !
M1110 4444 (0#UI:** "BBB@ HHHH **** $K@OB$P&N^#]V-O\ :62>_08Q
M^==[7!?$-&;6/"+)]X:F%Q[$<_RKT,L_WE>DO_263/X3O>]+2=Z",]S7GE!B
MC%+10 A4$8(R#U%<OK?@?3-5)F@!L[K'#Q#Y3]5Z5U-)6M&O4HRYJ;LQ-)[G
MDOG>)/!<VV0G[-NZX+PM_P#$UV>A>-;#556.X*VMT<?(S?*WT-=))''-&T<J
M*Z,,,K#((KBM;^'MK.CS:01!,6SY+G]V?IZ5Z?UC#8O2NN67\R_4BTH[';YS
MS2UY3:^(/$/A)EM;^WE:W!PJS\C_ ("]=UHWBO2]9 2*817&.89#@_AZUS8C
M+ZM%<Z]Z/=%*:9N=J6DH[UP%"T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !24M)WH H:MI-MK-@]G=;_+;D%6P0>QKR[Q3X
M3'AV*UD2ZDG64E264#![5[!7)_$*W$WAH2X&89D;GT/!_G7J99BJE.M&FG[K
M>Q$XIJYBZ?\ #RUO].MKM-4G"S1AB-@ZGK6A:_#73(F#75U<7'.<9"@_E6CX
M%N6N/#$*L23"[1C/H#Q6CJ/B/2=*N1;WEXD4I .P@D@'H?I5UL7C?;2I0DW9
MO9?Y"48VN95]X#TBZAMX(%-K%$Y9_+&6DSV)-=+!#';01P1*%CC4*H'8"FV]
MS!=PK-;3)+&>C(<BIJ\^K7JS2C4;=NY:26PM%%%8#"BF--&IPTB*<9P6 I4D
M21=T;JR^JG-.S =1112 0]*P-;\6>'='E:QUC4H;=W3F-P3E3QV%;YZ5P-YI
MUKJ7Q=$5Y;6UQ"NE[O+FC#$-NX(_.NS!4J=2<G5O9)O3?0F3:6AR_AOQIHWA
MSQ%<P'4D;2Y,_.,D ?PM_0UL^'+[3_$OQ2UR\MF2]TYK.)49HPR%A@$C/3O4
MOCWP?I<&GV^HV.G6T)@;9(J1  J>A/T/\ZZ7P<NDR:2+K3+&WM9' 2X6) OS
MJ*]C$U\.\.\32B^:2Y7MIJG=^>AFD[V9HS:)I.TR?V99[D0[3Y"\<?2N;^%3
M[_ D"X4!+B=1M]/,/7WKM'!:-E'4@@5Y9I6C?$/PSI<EMIYTO[,DKR;)?F."
M2Q(/%<&&7M\/.E*:3O%KF?;F_P RWHT['I.IZI9Z/9/=WTZQ0H"23U/L!W-<
MQ:Z9=>+KVWU768WATV(EK73W'W\]'D'\A5+P=8S>+;6#Q+X@D2ZD8NEO;!0(
MD4'&2O<Y!KT #CCM6=2V#;IP=YK1OMY+_/[@7O:]#"OHA8:_IE[$!'#(ILYE
M5>,=8_8 '(_&GV$0U#4]1O9E#PDFTC1@""J'YOS;/Y5HZA:?;M/GMMY0R(0K
MCJI['\Z9I>GQZ7IEO91,SK"N"[=6/4D^Y.36'M5[+^]M\M_^!Z#MJ>+^.='C
M\.>)7;3$<VKP^8T&<[&SU7VKU_PWJ=OJV@6=U;W*3@PJ'93DAL<@^AK@OB8H
M&NVK!<$VWS'U^8TW4+2;PEX*M_$^B2K9W"6J"XM]F8YMQ^\1_>YKW:\%C,+0
MC)^^]$^[\_\ /[S->[)GJE'O7FZ2?%.YLHY89-%7?&)%W)RV>QYQ4CM\5RP
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M7R-2I.I+FF[LZ$K"T445F 4444 %%%% !1110 4444 %%%% !1110 4449H
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M#<7_ %]PHOWF='2UFQZ[I<NH+81WL+W+9Q&K9Z=OK6B*\F4)0^)6-+BT445
M!1110 4444 %%%% !1110 4444 %%%%  >12"EHH **** $K@OB'(L6L^$')
M((U/@XSV%=[7"^/V9=9\)%5)/]I>O&,5Z&6?[RO27_I+)G\)W5+24M>>4%%%
M% !1110 4F!2T4 13P17,313QI+&W!5QD&N&UCX=1DM<:-*(I,EO(E/RGZ'J
M*[TT5TX?%5<.[TW_ )"<4]SR6#7_ !%X7=+:]218P<!+@;E(]FKN=%\8:;K!
M6+<;>Y(_U4AZ_0]#6W<6L%W"8KF%)4(^ZZY%<+K7P[ #W&BRE3][[-(>#_NG
MM7H>VPF+TJKDEW6W]?U<BTH[:G>--$CK&\B*[_=4MR?I4E>%ZG)J-OJ$2W[W
M,5U;@*@D/*@="IKTCP=XK?7!)9W2J+N%-V]!\LB],^QS6>*RN=&DJL7S+J.,
M[NQUE+24M>46%%%% !1110 4444 %%%% !1110 4444 %%%% ""EI ,4M !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -) !8D
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M&?P]J](\#>$?^$0TA[5[MKB>9@\C D("!T4=OKWK3&_V7AXOV<$YI[7E_P
M4>=[B?#K3[G3/ NFVUY!)!< .[QR#YERQ/-=2*,4M?-UZSK5957O)M_>;)65
M@I#2TG>L1GEOQ$8S>)((#T$ ' ]371>.]'NM0^'EQI^GPO-.J1[(TZMM(KF/
M&TR3>-41V^6-8T/MSDUZJN-BXZ8XKW*]66'I8::Z:_D9I7;/-+3QQXIM[*&!
M/ FHN+>-4<L2"< #@8J=?B#XE9Y5_P"$"U/C'ED@C/?GCBO1JQO$_B&/PSI'
MV^6VEN<RK$(XR 23]>W%8PQ-&M-1CATV_.7^8[-+<Y)OB%XCA$;3^!]1 DX
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MS>R;[OJ/F[,[#XCJS_#O7%0X8V_!SCN*Y#18KN?XCV\=G?/;R#P_ 7D,8D#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAQDY,V***P/&%_J&FZ$USIX_>!P'<+N*(>IQ7G4J;JS4%U*;LKF_7G_Q+O\
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ME9V7_I3"/Q'?T4E+7RIN%%%% "&LKQ,6'A36"HRPLIL#'^P:U:R_$@)\+ZN
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M*H4!5  '0"N;&XK#5*:IT(6MU*C%IW;'4445Y984444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6-8YE6I?5FG93DEHEV;=^VPX)W\CHZ6BBOF#8**** $K*\3''A36#Z64Q_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGF%:IBZ%I64[-KINT_R)<$HL\A\$.4\66@<!F*R8.[U'(!KU8,-F-X)'!]<
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M!Y]S)]YS[>@]A6E6$L5*-53B[VT]1\NECDM(T^S@\1VEQ87=U-#+8O,3/(9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT\/ZKJ-BU[:V+30JQ&Y>IQUP*[,'A8X:CR5VOBO^5B92N[H]#^'%B8-#DO'
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M]$&S@HP7'3BN^KSGX8*1)J!QT1%_G7HPKCS5)8N=O+\BH?"+1117G%A1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME0=BY#;A\_M[5)C;N'\^U*O+Q[2H]\9KR[EG,V<R:=XKU2&_D,8U!$DMI),
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *0]*6B@ HHHH **** "BBB@ HHIH49SW- #J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HI:0T %0W4<$
MMM(MS&CQ;265QD8J:L7Q7?+I_AN\E/WG3RUY[MQ6M&#G4C&.[8GL<!X)M(;[
MQ?YI0!(-\J*.@.>/YUZS7 _#.SVVE[?'.'<1)D=@.?U-=]7?FU3GQ+CVT)IK
MW0KQ?5;6*_\ 'MS [8BFOA&S,?< C^8KVBO)_%ENND^-A>&,F)I([K;T#%2-
MP'Y5KDTK59I;M:"J;'JD,,=O D$2!8HU"JHZ #M49LK9H)(?(C$<BE7 4#(/
M6ID=9(U=#E6 8'U!IU>1S23-#R3PQ</HGC463[MOFM:, .O/RG^5>MUY%KJB
M'XAOY9*_Z9 V5/.3MKUTUZV;6DZ=7K*/]?F9T^J*]]>PZ=8S7EP2(HEW-@<U
MY"VO11>-CK<$#^49MYC<@,01M:O5;Z72[_S=)NKB!WD7#0>8 ^/IUKS+QEX6
MM_#S6\MJ\C6\VY3YAR5;KUK7*/8J3IU+\TE;R:%4ONC8N/B;(,B#3XA\_620
MGY?H.]<+?Z@=0U&>[81122G<5B4A<^W->K>'O#.BS:/9WDNDP>?+"I;S!NY]
M>:LZ]X2LM9TV&TB"6AA;=&T<8X]L5M1QV#PU7EA!KHW_ %<3C)HY[PL\LGPZ
MUA9'+JL4ZH&/0;#Q[5J_#1?^+>Z-N105B(&.?XCTJ>70;30O!VL6UJTA#VLS
M.[G))V'FHOAJ^_X=Z,?F.(, GOR>?I7+B:D:N'J3ALYK\F5%6:7D9GQ5G2UT
M7296!\I-3A=U5<@@'-(WQ?\ #0VG9?8)(8^1C:1Z\]Z[BY^S>4!=>3Y988$N
M,$]NO>JOFZ,[YWV#.S9ZH23_ (UC2KT'1C3JTW+EOJG;?Y,;3O=,X]OB_P"&
M5C!>"_V'[N;;@_2G_P#"W?#/E;PM]M)P/]'/-==NT<(J[K *#\HRF :4R:25
M!+V17H.4JG/!?\^9?^!?_:A:7<Y(_%WPL'"A[PDC/_'N>*4_%SPLN-\MTN6V
M\P'K75E-'?[RV#8&.0AQ4-U:Z/+;2O\ 9[!W,9P=B$G _I24L#>SI2_\"_\
MM0][N3Z-J]KKNEQ:A9,QADR!N&",'!R.U7Q7#_";/_"!P,55=UQ,<@YW?,>3
M_GM7<5RXRC&CB)TH[)M%1=TF+1245RC%JEJ>I6FCZ=/?WTHBMX5W.QJ[7'?$
M]-_P\U7! *HK#(S_ !#I[UT86E&K7A3ELVE][%)V5SCO%_C+PEKEH;NSNY3>
MQ#:!Y9"R+GD'W]*F\*_%K2;:#[!JUS)Y<8Q%/Y9^4 ?=;^E=[H^E:-_85@AL
M;%@UK&3NA3+#:#D\?C7)^-_"%A%$=7TRT@1D(:>**,$8/1P!TKW:-? U5]4G
M"5KZ-M:?@9-27O(U%^*_A!ES_:#C/0-"PS2_\+6\) ,?M[$CH!&<FI/#$^@:
M]IR>?8::;Z)<2H8$S@?Q#CH:=XL@TK1O#4][::9IHF^5(G-LA R>O3TS7)['
M!JM[%TY\U[?$O_D2KRM>Y3D^+OA- I^T7# \96$XSZ4[_A;7A3< MS.<_>/D
MG"<9YK*\":A%K-_=6]Y#9S6L:"1-UM& KYQQ@>F:[S^S]$4L_P!DT\;AAF\M
M.13Q-+!8>I[.5.5_\2_^1"+DU>YS)^+/A,, ;J<$@$?N&YXK#\0_$O\ M6?3
M=.\'7T?VN>XV2R30GY,CY1@]B>OTKT%=,T-2FRRTX%3\F(DX)].*XKQM9V=G
MXJ\'2645I;L;]EDV!4R, _X_G5X+ZC*LE&F[V;U::T3>JL*7-;<RO%<'Q%B\
M*ZM)JEYIDUBUNWG1P)A@N.=IZU%X/T'3;+Q]8PFVA>*ZT*.X6/ VK(=N3CUQ
MFN^\=F-_ ^M(70YMCD9^E?/^BB7[5&^HP:Q);KE%DM@P<';PI/\ =QS@5ZF7
M.>+P=2UH;KW5:]TK==T1/W9(^E(]'TJ$-&EA:KO&641CGZU$_A_0Y$,;Z99,
MCCE3$O->$[-#3J/%I=D(#<Y*DXZU [:/')%#Y?BM2A()+X(4'L/:N:.2U+Z5
M9?=_]L/VB['L6H_#KPS>'S([9;.4G >!@HS].AKDM6^&FI087398+@+R-N$=
M<^HZ$5QS#P\UPT>[Q7' 3L4,YP9,\?0U1N-3T>/#03^('N47:\DMQC9@G"\=
M<=*[\-@L73:4:K?K&_\ [<2Y1?0U].UO5?"6ND2P[)X#M=3TE7N"/Y5Z9H?Q
M+T_5M32SF@^S>:<1.9 1G'0^E?/JJ;^7<D.ISL" ) 2VT#W]!5EM)C5(WAM]
M5GD<Y8",@].QKNQ>48;$+][I*VZ_X?\ ,F-1K8^F+WQ5H]D0ANQ/*6"K%;CS
M&8GITJOYFJZZ1"]HVG:<V"[O(/.D']W ^[GUS7SK8SV5E((IQK4=L=I*QR^6
MZ]>@/6MB"_\ #N6CCG\4F5EQP^2V!U(S7DRX?C2^!MOO:_ZJWSN7[6^Y]'0P
MQ6T"00HL<:+A5'84X-GA2IYYYKYP4:;<VZ;CXN(3(9@<!#UP?YU()M(5E&/%
M[22*,*HX?/3'IFN5\/O^=W_P_P#!*]KY'T:SJH)+  #)R>E+YB;0=ZX/0YKY
MPBDT26YCA5O%4!,@61GRVSLQ(]!5B]AT2VO[JW'_  E$D49)4N2%)(Y_'T%3
M_8"3Y7-_^ _\$/:GT/O7'WATSU[4;@-N6'/3GK7S<#HB ,J>+69U(23/&"<=
M*DE72X]\2_\ "62*I?'S85"",G/MTI_ZO_WW_P" _P#!#VOD?1GFQYQYBY^M
M*"&&5((]17SF?['5E#1>)7RF$VMG))YW>_MZ5+!<:3:SJC:AXNM/,CW-#$I)
M?)X88/%)\/Z:3?\ X#_P0]J?1-%?/<FHZ64:6/Q/XPEE'/S1-A1VSSTH?4-/
M+R/_ ,)'XO#<[2(FP1QGOU_E4?V!+^=_^ L?M3Z#KA/BY")O S!@Q1;J)F"G
M!(S7F<NJ:<(V9O$/BR%@,HS1L!%D]#SZ4V:Y\/WA,/\ ;7B.]CW*Q$J%HW&<
M;E!/6NG"9-+#UH5N9OE=_A9,JEU87PS)8R>,M]@+B*S,FZWC+<$XP0<\UZ,D
M9V  , <\^G_UJ\W@_P"$3M)W^QW&O10MM(4VVYEVD_Q>_M4[ZCX?,2_\3+7
MD;X:-+<C&>F>>F*]+%X=UYJ45*UDM4V1%V1Z'L?+D(P.,G R1BF[&"?+OP"#
MD"O/CJ'A]#$8M1\0*H!PT=NQW'OGGI2O=:'%%.(=0U]6<D ^41@#'OP:Y?J$
MO/\ \!97,>A&*0%@0PX'(XYJ.2*5U4!#T&=PR#7 MJ&DQRQ>9J>L'";6!A(W
M$\],YS44FK: J&&'4=8$L<C [HR61<=<9QUIK+Y]+_\ @+#G1Z+Y955'S'+8
M&3S2[77<VS<%&%/K]*\\DU?PO*RA=2U>,HA+H8B9'.?X1G&,T/JGA?SHRNI:
MS$%91NCB.?P.>N:7]GSZW_\  6'.CT,(57'S#CHO4FH$BE2'SU$KMY6TKC!/
M.3^-<"=:\/"=FDU+6'*D+)OBQE3GD<]:B%UX?*H_]O>)7DE4,&53\@R?E(SW
M]:I9?-;W_P# 6',CT266X1H4^Q2.7#$G&0/_ *U0&.[>&XA:-AO8(QQC9[CU
MKA&N-%CBDBB\2>(TCVAFC$+$DGN#GD9IZWVF+(JMXOUU8Y1A2+9L @=N>,^]
M-8%I:7_\!D+F/1A$ZLJ;,!1C+>W]:3RBQ/#8]0,9KS2:^T<+&9_%?B1;=9=H
MS;]QTSSU]Z+N_P!(ENB\7B?Q%,RMDMY!^[TQUP:2RZ;ZO_P&0^<Z_76DB\0>
M%73*DZF%)QGL*Z+X<+LN/%2;=I769@1U[^O>N"\,P^')O$^EAM8UR;%RLD$=
MVNQ=XZ<YZ9]*[[X=,YN_%0D.7&L3;O3KVKES&/L\-*GKHENK?:'#65SNN]+2
M4M?*FX4444 %9GB$9\-:J-N[-G+\N<9^0UI5F^("!X:U4G&!9RYR<#[AK6C_
M !(^J$]C'^&__)/=%ZX\CC(YQDUF^-8MWC;P6X."+MQDGC&T?K7*Z)?^.]+\
M!Z;=:7'8S::(AY0 ,DV"V "._7M3+35_$FN>*/"5]K=K:Q6_VN58-H()895L
MCL<_RKZ)8&<<54Q"E%KW^NNTM+=S+F7*EZ'M/>BBEKY@V(+JVBO+66VF7='*
MA1A[&O,M"NI?"7BJ6QNVS Q$,C>H_@?_ !KU2N*\>>'S=V_]JVD1:XA&V95Z
MO'_B*]++JT>9T*GPS_/H1-=4=F#W]:P/&T:R>$;_ '<;5##Z@BJ7@KQ&NI6?
MV"XD4W,  1L_ZU/7ZCH:=\0+U+;PVT&X>9<.%"YYP.2:FCAZE+&1IO=-#;3C
M<B^'#$^'9,]!.V/R%=C7+?#^W>'PM&71D\V1G 8=1V-=366/:>)FUW"/PHXG
MXE6PDT6WN,\Q38QCU%1?#?4_-LKC39& >)O,C!/)4]?R/\ZW?&5O]I\*:@H&
M2D?F#C^Z0:\W\+:DFF>([:ZE \IP8F/H&QS^>*]3"P^L9?*GU3=OS(D[3N;/
MQ*L#%J=IJ" [9D\IC_M#I^A_2NN\&Y/A/3\N6^0_AR>*S/B/$TGAR)U&X).I
M./0U3^'.L&2"32I1RA,D1]L\BHFI5LMBU]E_A_3&M)F-=QBW^)N&Y#7:/U]1
M7J]>4JRZE\3 ?X1=_P#H(_\ K5ZK6.:;4D]^5#AU%J&XMX;JWD@GC62)QAE8
M<$5-4-Q<1VMM)<3-MCC4LQ] *\N-[Z;EG*R_#G1'1A&UU$QR01+G;^!%5D^&
M6FA@9;^]D [94?TJQ;_$32I;GRYHIX$)XD89&/4@=*ZV*6.>)98G5XW&593D
M$5Z57$X^AI4DU<A*#V.3'PXT+!#&[;/K-T_2KL?@OPX@,:V$;$8R"Y)'ZUK:
MI<-:Z5=SHVUXXF92>QQQ7F?@634)?%22>:[>:C/<,S;MP]_?-71EB:]&=5U6
ME'S$^5.UCU.WMX;2!(+>)8XD&%11@"I:!]*6O);;=V:!1112 **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=KI4.NZ-#9V$UY$";>7=)N)QC/;-==_PJ?PKM<&WG)9MP/G'*\Y.*B^)C*=
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M!M%OU:-&D**&_P"64GI]#3/!;/IGC"XTXDX/F1L.V5.1^E7/B%H3 ?VU:KT
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M)Q6LJU245"3ND*R%HHHK(84444 %%(>E+0 4444 %%%% "4#@8I:* "BBB@
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MQ8,#^[ED< 'W*X_K713JUJ\.2"=EYK\[":2=SG_%^OVM_J$?DR7#11I@!XR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>M>(R)<7GC!E10)F
MU X YP0W^%>W&O)]>B.A^/UN0FV-ITN%.."#PWZYKVLFG:4XK=K0SJ=#UD=*
M*0$$9I<UXIH%%%% !24M(: *&M9&A:B1C/V67DC/\)[5Y=X<4?V-X?9 H?\
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MBZ'H5]X@N98+5T#1IO9I,X]AFL[5?"6K6_BY+!S;B46$EPVQ\X4 _KQ7TE#
MX.GB)6E9\KTOY&+E)HW- \7V5AX.TFWB5KBX6V"/&HP4(S@DUTVB:];:Q"L:
M,R72 F2,]OI[5YUI'A?59O#5IJL,L;J\'F;4)W8YXZ<GBG^'"7U_3TA+QAI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUZGT'M6:]LT<7DK>-$\>2&&-Q';'M[U9M0C0%DN3,2V, X"$=LCDM3E%6NF
M0R(\3K&YPTY&>.>>WH*L*'79]Y4(.W:>WH!W/N:@A2..*5(E!43D':,8)/\
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M0".0>F*\_'854)^Z[Q>J9<970^BD%+7"4%%%% !1110 4444 %%%% !1110
M4444 )WI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 (: 01D'(]:6@  8 Q0 4444 %%%% !1110 444BMN4$=#0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/IWKNJX7XH;FTC28U#?/J< )5L$<]:[JBO\ [I2]9?H"^)BT4@I:X"@HHHH
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MORL1_=_[)/7'^-9\MMP&K'=O)*S!(Y"1L)/48_BI[S-;HLCJ[?WV0$X]\5,
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M-.G2Z7O\R8IIML*.] I:\TL**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNVLVF><PH$\QNIQ5P4"EKYJ4G)MO=FP44F>:6I **** "BBB@ HHHH ****
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M.3DUN5A^#E"^$[#DG*$\GW-;E<V*_CS]7^94=A:***YQA1110 4444 %%%%
M!1110 4444 %(:6D- !113%ECD!\N17P<':0:8#ZH7.BZ7>[OM%A;R%OO$H,
MG\:P/%WBZ?P_=V]M;VZ.TB>87DSC&<8&.]<[%\3+\./-M;8KGG&03]*]&AE^
M*G!5:?7S(<XWLST"QT;3=-W&TLXHBQ!) YR*T*YCP[XTL]=G:WD06MQG]VC/
MGS!['U]JZ>N7$4ZM.?+6O?S*336@49HKB_B-<7]MIEI):SR1V[2E)A&<$Y&1
MSZ<&EAZ+KU533M<&[*YV;9*D#&<<9KQ."V&H>)OL-VQMWEN3%,T?0-D]!V]*
M]&\"ZH^HZ (YYS-<6[F-RQR=O5<^O'\JX[QU92:;XI%[!\GV@+-&X[2+U_D*
M]C+8NC7J8=[VT?I_5S.>J3/2=*TBST6T%K91;(\Y8DY+'U)KS;QLHT[QJ+I.
M"RQ3\<<@X_I7IFF7JZCI=M=HVX2QAB<=^_ZUYW\3<'6;, #=]F.?S-8Y7*;Q
MC4]VFF.?PZ'IZG<H;U&:=5:Q<O86SMU:)2?R%6:\>2L[&@4444@"BBCO0 44
M44 %%%% !1110 4444 %%%% !1110 4444 )7"_$E3CPVP9@1J\*\>^?\*[J
MN'^)&=OAO !_XG$.<C/&#7?EO^]1^?Y,F?PG<=Z*.]!K@*(6O;5696N85*?>
M!D&5^M-74+)U5ENX"K8VD2#G->;?$7P3"]ZGB.VM[FX42+]NLX"<R)T+*!WQ
MUK4MOA7X2GM%FCMKU5F59%W3NK*",XQV^E>I]5P:HQJRJ/7M%:/JOB1'-*]K
M';B\MF<(+B$N3@*)!DU/7&6'PP\-:;J-K?6T5R)[:3S4+3L06]_6NSKBKQHQ
M:]C)M>:M^K*5^HAI"<4IKB/$?CO^R=5DL+>V\X1@"1]V,'J0/PHP^'J8B7)3
M5V#:6YV;HD@*,BMGG##(KR_Q3XAU'_A+OLEI=21PVTJ(B*-OS<9SZBO0M,O(
M]3L;6^@W;)D!YXQ[5YBTYUGXAQEF4*U\%7(_A0]/QVUZ>5TE&I-S5^5/?H_Z
MN1-Z*QZM>6R7=A<6TJY66,JP]>*\W^'E[]GUV6R/W9T8?BA_PKT\'+GG/K7D
MD&-(^(NW>$5+TJ<=-K__ *ZG+E[2C6I/JK_=_2">C3/70<BEI.^*4=*\@T#%
M Z<TM)GDCTI +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO7R!IME6RO(X_$>H:+#!9Q6UO!%-&(UQRW7..I]*UC@>:V[/S?-S@_\  O\
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M'I5SY>9 #U 'R\<=U_QIDT+7$.U?-7!^1T;.UA_Z$:N#L]1#!>+*'*07*L%
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M%_#W5)[S3Y[*3<T5L%\I_P#9/\/X5V?M7CXF@Z%5TWT-$[JXZBBBN<84444
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M** "BBB@ HHHH **** "DQSFEHH **** "BBB@ HHHH **** "BBB@ HHI*
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MO7PZX@T$J$V\QMR0,9/O1_PJ[Q&Y=Y$T'S6.=PA/0=L?X5W>QR[_ )_?BO\
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M9%)U>_O]Z*P.R)<;O;)KT10 H Z#@5Y&-AAH<JP\K]S2/-U%HHHKA*"BBB@
MHHHH **** "BBB@ HHHH **2EH **#4-R7^R3>6VU_+;:WH<=::5V!-17(?#
M?4+S4/!%M=W]W+=3EY=TD@^8@,>*9X"\5ZAXH756OH88OLMP(XA&I!*\\G)]
MJZZN!J0=7JJ;L_OL2I)V\SL:X7XE8:#P^K,%SJT1_#G-=U7$?$@J+?05*JQ.
MK0X#?C5Y;_O4/G^3"?PG;T445PE%6[TZROS&;NUAF,;!D,B E2.A%6J**;DV
MK,"G=:387UU;W5S:QR7%LP:&4CYD(]#5VN6\1^-K7PWK%CIDME=W-Q>J6A6!
M0<D'&/K6QHVKV^MZ9'?6PD6-BRE)%*LK*<$$>Q%;U*%>-*-2:?*]OZ^\2:O8
MT:XKXB:8;G3(-04%OLC8D4=T;J?P.*[2F2Q1S1-'(@='!#*1P14X:LZ%6-1=
M :NK'F;ZFVL?#J:*7YKBPE0' _@S\K?EQ^%;WPXG+Z#<0G_EE<-CZ'FN/\1:
M9<^&M3F@A9UM+E"(CGAD/5#]*Z'X8[_*U+G]WN3 ]\&O>Q=.'U*<X?"VI+YV
M,HM\VIWS(KH4<!E88(/0BHX+2WMO]1!'%D '8H&0.E3XHKYOF=K&P4444@"B
MBCO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%-4D@Y7'/K0 ZBBB@ HHHH **** "BBB@
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M.+"BBB@ HHHH **** "BBB@ HHHH 0T4M% !1110 F*6BB@ HHHH *3%+10
MG:B@D 9)  ZDUSFH^-]%L%(29KJ3.-D SCZGI6M*C4JNU-7$VEN='1FLW2-=
ML-<@:6QEW%" Z,,,I]Q6E4SA*$N62LQIW#-&:*X[7/'L.E:C-916AG:$X=R^
MT9]!ZUI0P]2O+EIJ[$VEN=C7"_$>RN7M[._BD816[%652003T:L*7Q[KFH2^
M79H$.20D$>]B*SM1B\37=@UWJ"7AM!@DS/@=>/ESG]*]G!Y=5P]:-2I)+R]3
M.4TU9'I'A'6Y=:TC=< _:8&\J5O[Q'?\:Z"O%-&E\16ME<W.D+/]G!_>F/#8
M..N.M>MZ(][+HMI)J  NFC!DQ_GK7'F6#5&;G%JS>W5%0E=&A6%KOA.P\07-
MO/=M*KPC;\C8W+Z&MVEKSZ=6=*7-!V932>Y0BT73884B2QM]B#"YC!JO<>&M
M&N;::!M.MP)<DE4 ()[@]JUC52_U.RTN!IKVY2) ,_,>3]!U-7"I6<O=;O\
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M<L3J.B!"./%=R K\C[W8_B:^GI?[Q6_Q2_)F#V1[%WHHHKY8W.!^)<;;-/E
M&W+H>.<D5U?AY_,\.:<X.?\ 1T&?PKS[QKXC>]NY]*>V5%M;C*.<[B /3WI=
M#\>-I.E064EHLL<((W^9ANN>E>_/!5ZF"IQ2U3_!F2DE)GI<]E:W+*\]M%*R
M_=+H#BI^@^45YS-\3F()@L$!SQO?/\JI'Q;XFUJ3RK"!QW/D1]/J37(LJQ37
MOV2\V5SQ/4)'2)&DE94C49)8X KCM6^(=I;/Y>GP_:6#8+L=JD#KCUKA;2UU
MOQ%?O9I++-(6)EWR$JG/5NU=MI_PUL(E#7US)</QPGRJ/6NCZGA,(_\ :9\S
M[(GFE+8['3[V+4=.M[R'_5SQAU]LBK-1V\$5M;QP0HL<4:A411P .U25XDK<
MSY=C42LW6M"LM=LS;W:G(Y21>&0^U:=(>>*<)RA)2B[-!N8OA[PU:>'8)4MW
M>624@O))C)QT'':ML4445*DZDG.;NV)*P4E+25 S@?'VOS0-)HYM8_)FAW>;
M)G).?X?I5'P9XKT_2M,:RO#(K&4N'"Y&#7H5]IMEJ4(BO;:*=!T#KG'T]*\?
MNM)L=/\ %<NGW[R162RD&1>JH1E3_*OH<"\/B,.\/*+36KMU_KL92NG<['Q-
MXFT75/#E[:P769BH* H>2#69X)\16&DZ==17LS1EI Z#:3V_^M6%J&F:1;W5
MS]GOI);7[+YEI)G/FR X*].U7/"?A&/7X9;F>XDBBB<)MC'+G&3S72\/A:>$
ME&3:C=/S_(F\G(U-:^(C26L<>E!K>0G]Y)(@) ]!5KP!=:K<7MVUS]J>T>,-
MOG)X?/;/J*W-,\':)II61;3SI0<A[CYB#]*Z(<#^5>77Q>&C2=&A#?J]RU&5
M[L=124M>2:!1110 4444 %%%% !1110 4444 %%%% %34;^#2["6\N2PBB&6
M*KDUD>&O%"^('N8C;&"2#!^]D,IZ5H:];FZT#4( NXO;N /4XXK@_AHD9U:[
MD8_O#;J5Y[9Y_I7I4*%*>$J5'\2L0V^9(]-KS'Q=NO\ Q[9V70 Q("/<YKTZ
MO,KDH_Q:C R0)U]^0E5E>E2<^T6PGL;OQ&M%E\.QW(3+VTZG<.H4Y!_I6AX+
MN6N?"EFS/O:,&,GZ'C],5IZMIZZII-S9.<"9"N?0]JSO".B3Z#HOV6YE5Y6E
M:1MA^49P,#\JS]M"6"]FW[REIZ#M[US>%+2"EKSR@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0U%<?\>TN!_ W\JE-%-.P' _"Z
M2WL_AO'.?+C\MYFE;&.0QZ_ABHOA5:2W%GJGB*Z^>?5+MF21DVDH#@'Z$_RJ
M+7OASHDNN+<?VT^GQ7<I>>S\T 2DXSM!/!/?K77SZ%Y/AC^Q=&N'TX)&$@EC
M.3'SG_'\Z]S%8BC*,W3D[U6F[KX5>]K]=;;=C**?7H<Y92)-\:]2\L9\K2E2
M0XZ-N4]?I3OB82+7P^J$!CJ\/UXS5OPGHVG>&]2N;![XWNN7*&YN)6'S%-V/
MPYJE\4%#6&A'>$(U:'#$9 Z\T4Y1ECJ2CLDDGWLM_0'\+.\HH_&BO#-0K/UC
M1-.UZQ>SU*U2>)@1R/F7W!Z@UYQ\1?#,UCJ0\20WMTMA)(BWL,4K!DR<;D]?
MI6G#\,[6Z@6Y@\3:O)%,H=#YQP5(R,5ZL,)1ITX5_;6OVB]&MUON9\S;M8[;
M2-*M]$TFWTVT#>1;KM3><G'N:OUPFG?#9+#5;*__ +?U.5K60/Y;2?(^.Q'I
M7=UQ8J--3O"?/?5NUM2XWML(::Z+(A1U#(PP5(R"*)76*)Y&^ZBEC]!7)6?Q
M%T>XW><L]N 1LW)NW#UXZ5-+#U:J<J<6[ VEN;4/AO18&1HM,ME*$E3LSUZU
MHI!#&N$BC4>@4"LJT\5:'>@>5J$0.<;9,H?UK1BOK.=V6&ZAD8=0K@D4ZJKW
M_>7^=P5NA8HIH8-T(./0TX5@,6BBBD 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>>6%%%% !1110 4444 %%%% !1110 4444 %%%)WH 6BBB@ HHHH *3M2TE
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MQ/)M#8!( ') -</9>.->LYUEFN&N(G&1'.@ ;W! %?09=#%+#N5%1UO:^_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "DI:2@"IJF3I%Z NXFW?"^ORGBO"M+T?QMK
MWA?2SIEJL=I:K*L$RSJC2H[#>K9/3BO==4_Y!%[QG_1Y.,_[)KF/A:NWX>:8
M-K(/G(5CG WFO:P&*EA<+.K&*;YH[^DO,SE'FE8XSQ;>>+Y-'L8]=TRVM+!;
MV >9'(&=7#<<9Y!KV6N/^).GQZCX75)-0@L?*N8Y5EFR!D'@#WK@F\2ZL6V?
M\+-TM75P3FU9?P/'3%;_ %=YAAX.%H\KE=)2MK;LF*_(]3VVBO$?^$KU(OE/
MB7IGRX'S6K?RQS2/XJUD%L_$;2P%Y#+;-@GZ8Z5G_85;^9?=/_Y$/:H]OHKQ
M!?%.N,^#X_TI3(,$>6?D/7@8I3XEUY4C;_A86E.S_<'E%?SXI?V%6_G7W2_^
M1#VJ/;J.]>)_\)5XB0LLGCO10T8W,@C.<GH"<=/I2?\ "4Z\Q"GQ[I1+= L)
M';UQ1_85;^=?=+_Y$?M4>VT5XC_PD7B H63XAZ46P25,/&!^'6IF\5:^7W_\
M)QHVT\*5C(!XZXQ1_8=;^=?=+_Y$/:H]HHKQ4>*/$)MG9/'>C,"V 7B(*?7C
MI5/4O'GB326BE_X2S3+U1*J^5##DMGKGCD4XY#7D^6,E?_M[_P"1%[5'NU%<
MROQ!\*-.(?[:M]Q&>^/7KBK'A#7I/$FA?VDZ!0]Q*D>!@%%8A3^5>7/"5Z<'
M4G%I:;JV]_\ (T4DW9&_129HR,XKF&%)6;X@U5-%T&\U!G16BB9HP_1FQP*\
MKT7Q'XUURQ$EMX@TMIWA:5K?:/,0+SZ?YQ7H87+ZF(INJFE%.VM_\F3*:3L>
MST"N<\":Q=:]X/L=0O75KB12'8+MS@XZ>M='7)6I2HU)4Y;IV^X:=U<6BBBL
MAA1110 AK!\5Z\= TGS8T+3RGRXB1\JGU-;5Q<0VL#37$JQ1KU9S@"H[FVM=
M2LVAN(TGMY5Y!Y!%;47&,U*HKQN)[:'C&L>)-2UF"&*_DC:.)LC8F,G&#6S\
M.;N-/$,B2LX>: I& /E.#GG\!Q75MX!\/1O-,\4@0J?E:7Y8_<>F*\YTZ%_^
M$BM[2UNF!^TB..=.N,XS^5?3PK8?%8>=*BN5)=C%IQ:;/<:.U(H*JH+9(&"?
M6L[7=8CT/2I+Z2-I-I"J@.-S$X S7RL(2G)0CJV;W,_QK=Q6?ABX>6W2?>1&
MH=<A2>_X5YKH7A6^\01W$MJR1QP\!I.C-_=%=3J&JR>,/".IXA-O/92K((T;
M=N '?]?RJK\.-7\J_FTV1ODN1YD?^^.OYC^5?0X95<+@ZG)\:>OX?H8NTI(X
MN:QN+6YD@G@"RQMM8$#UQUKJ?"_AO6X=>L;LVI@A5O,9RPP4Z=NN:Z[QMX?&
MJ:4]W;I_IEL-Z@?\M%[J:S/AWK4USY^F32;HXD#P;OO 9Y7Z#BM:F/G7P<JE
M-+31K_(2@E*S.]HHHQ7RYN>;?$Z-A?:=+N.&B=0O8$$'/ZUU=OI6FZYX5L()
MHTD@\A"C*,%3@<CTK%^)L1.CV4X /EW."<<X(-<SX7\7S:$1;W"M-8L22@^]
M&?\ 9]O:O?A1JU\#3E2?O1;,FTI.X6#7'@OQ=LN"QB4E9,=)(CT;ZCBH-#B3
M6/&T1\LF%YVF*J,8 .1_2M/QKJVCZ]96UY97/^EPMM:)T(9D/^!IOP[:WM;Z
M[U"[N8(45!"N]P"2QS_2NYSE]6E7E%J;5GZ_TR?M6Z'JF*6LY=>TEY5C34;9
MG8X4"0<FM&ODY0E'XE8WN%%%%2 4444 %4]3L4U/3;BRD.%F0J3Z>]7.U><>
M/?$&I6FK16-O-);0H@D#1\%V^OH/2NO!8>=>JHP=GO\ <3)I+4Q[G0/$7AVZ
M9+=)Y%E7R_.M"2''HP[&NB\"^&+O3;F;4=1@\E]FR)&(W*.YJYX.\7G6 +&]
MP+Q%RL@X$H'MZUTVHW*V>FW5RV,11,^"<9P*]#%XS$J^'G%)O1M=28Q6Z.&M
M/'=Y/XL%NL:26,DOD(BCYAS][/K[5Z'TKR#P'IYU#Q2MPP'EVJF9L^IX _,_
MI7K]8YM2I4JL84U:RU'3;:NQ:***\HL**** "BBB@ HHHH **** $[U3U< Z
M+?@HKC[/)\C=&^4\&KG>J.KEUT6^9!EA;R$*!G/RFM*7QKU$]CROPM9^.KOP
M9IQT:[TZ.P;/EQRKEU ;.<XQU%07&C^(=+\1Z!;ZS<6;13ZN;J,PGDRL06)]
M/:NW^%HV_#S31\I WXQ_O'K[U6\?(DGB'P<A)5SJ8(8=>!FOI%C9?7JE'EBE
M>>MM=$];F7+[J9W?>L[6]3_L?29K[R6F\L#Y%^O\JT>]-=%=&1U#*PP5(X(K
MYJ#BI)R5T;'EI^(^J>>QV6^TGA0A./Q[UF:GXDAU>\BNKZQ0R1\9C)7=SD U
MZS#HVFP;?*L+==IRI\L<&G/IEDRL!96YW,&;,8Y/K]:]B&886$KPI6^=C/DD
M]V>7ZIX[O-3T^>S,,<4,HVX522!]:S-#U#5K)IO[(CF9I,!V2+=]*[[Q\]O8
M^'#'%#&CW$@3*H <#DU+\/;5X/#7G, /M$K.N.Z]!_(UUK%4:>#=2--)-VL^
MI/*W*USB[+Q+X@3Q#:_:IKIF\U0]NPP""<=*]@J%K:!YQ,T,9E P'*C(_&I:
M\?&8F&(<7"'+8TC%H7BEIG?-!8!2Q. !DUQ6*'5A^*=3O]*TD3Z?;^=,T@3H
M3M!]AUJUIVNZ?JTTT5E.)'A^\,8X]1ZBM YXP!^-;13HU%[2.W1BW6APGAGQ
MK<W&H&RU@!6E?9&P3:4?^ZP[?6N]KRKQS"EEXJ$L)PT\:R$#C# ]?TKU&!BU
MO$QZE 3^5=F84J?+"M35E);$P;U3):***\PLJZE_R"KSK_J'Z?[IKB_@^Q;P
M'&Q'6YE[8SS7::DP32KQCC"P.>>GW37$_!V0/X$4 $!;J7 ]LYKTJ/\ R+ZO
M^*/Y2(?QH[\4M(*6O-+"BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ J"[M8KRTFM9EW12H48>QJ?-)33:=T!Y+<^%_$6G2W%K:6TTT$HV[XY5 D
M7/ 8$]:[CPIX?_L71&@N0#<7'S3 '@<8VY]A7)^.K[4+3Q1&R/(J1Q++;[6.
MT$$[B1WKT6PN1>Z=;70(_?1*_'N,U[6.K5Y8:#E:TM=/U,XI79YMXCL(/#'B
MJSN;(&*&1A*%7^'!PP'U!KU!'62-9$.58 @^QKA?B9!FRT^X_NRM&3]1G^E=
M-X9G%SX:T^123^Y .?4<5EBVZN$I5I:O5,<=)-&L*6BBO)+"BBB@ HHHH *3
M/-+10 44A&:6@ HHHH **** "BBB@ HHHH **** "BBB@ I& 92",@C!%*:2
M@#*;PUH;Y#:39G)SCR13V\/Z,S(QTJS)3&W]RO'Z5A:[\0;#1M0DLH;&]U&:
M  W M(]XBSTR?7VK*_X6[ILD_DV^D:E-(J[I5$>#&?0BO4A@\PJ14HIV]?\
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MJ:[6HY)X82HEE2/=]W<P&:D!Z8KAQ%>=>;J3ZE))*R%HHHKG&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 G-+110 4444
M%%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MARX. 0!V_#L*<JLTR%R=I&%&[ QZ8_K7&RAH),2;LF,].<$D>I_I3S\LC'H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ"=NIRWC#3HM!\+66FV[[DDG+2NP&YR!G/YUT?@6U^R^$[7*[6E+2-QUR?\
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M-KT*'[/=30(1L,K8 XX/-96I69T_49[7.3!*5 ^AKV>QU".]T*TOA^[,T2X
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M7RN+:=>;CM=_F;QV%HHHKG&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !11BB@ [T444 %%%% !1110 44G:
M@'/;% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 &::'RQ7!&.Y%+1WH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI
M:2@"KJ)9=+O"H)80N0 ,\[37D'A=E_X1SPKYD:[$T[4^3\P/W><#Z5Z]JA*Z
M1>L 21;R$ '_ &37DGA%MFA>%W3<P.G:D=NW'/R]*]W+/]WGZ_\ MDS*>_\
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MPQW?VI?\?*(1D^^[C^M>G5RYK!0Q4DAP?NBTF*6D/UKSBSC_ (AW8M] 6W"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXC.7/W5[9(ZFNG'I.DIM13=NC3LM-F]A1WL5?%-W=-%I5G93FWDU*[6!I_\
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M)/01-G\C7#?!\$>!LC[C74I7UZUZ5'_<*O\ BC^4B'\:._%+2"EKS2PHHHH
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MSXVK&I5O%WT5WW?5_/\ X(XJR%HHHKD*"BBB@ HHHH **** $I:** "BBB@
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MM_ 6A6\L+F!Y3&.?,;(<^IKJ<48KCEF&)EO-E<D>Q'##%;PI##&L<:#"JHP
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M*]:+=7+G%?9=_D9[3/0*YGQY9BY\+S2[07MV6523C'//Z5TU9VOQ&;P]J$8
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MMX2G?O/_ -M']ID7R["V[(!&T@<9^G?ZU)EA*H4/\O!7J/S[GTH5CL8,2R[
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M_O4/G^3)G\)WG>BB@5P%"T444 %%%% !1110 4444 -VC=GG-.HHH *0TM%
M$<<*1EV50"[;F([FI***;;8!1112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%Q;2E64 HV"AV_EGH/KUIVU?W;$1J0<C;DKG_P!F/I22$S13JQ0OM PZ8'_
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M444 %%%% !1110 4444 %%%% !534]W]DWNW[WD28YQSM/?M5NJFI'&E7A)
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M7J.G/O785S8R%6%:4:SO);N]^G<<6FM!:***Y2@HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_M&J7Q#<#7O!N2HQJJMAVP.U?4_7*;Q=3#JFD[SUN][,PY7RIW.^I"< DG
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M&,[P'U:$97MUKN*X;XE!1!X>D9#(%U>'Y,\'.>M=^6_[U#Y_DR9_"=S0*.]
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M:\J%EILDK#[:R%@"&%LY9N.3]/Y5$EI:?NXS=[<8 Q"_&>U=/U'$6_CO_P
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ME-<5\'E4> XR">;F7()R <]J]*E_R+ZG^*/Y2(?QH[^BBBO-+"BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"<=<;35T_C0,\H\"_$C0M!\)66F7ZWRR0*VZ40[HR2Q/!S[U/K/C;2?%.O\
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M$^BBW*#_ $@ !@?3;ZXY]*ZOPUI=OI.F-!!?&^D>5II[AF!,DC=2<=.,?A7
M#1M(\1W,EKX9\.VYLT^2;4KAW &?^>8SR1USTKT#PUX=L_"^CKIUF9'7<9'D
MD.6=SU)_(?E7IX^4(TE"]I:>[RI?-V;MZ?@1"]S8[TM)2UXIH%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,/_ $E$QV"BBBN0H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!QO?RM?\=/O)G\)ST1%I#'9P?$NVA2/ 2-(X@ O85V/A NVF3NWB :WF<XG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEWP-+NCTV H%S)]X@\]1ZUG5R%5'K-I;V25E\K_\."JVZ'TO_;VD$<:I9_\
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M^-6DYQN&F2D9'O7>"O,_%>K6WA_XI:5JVH&1;-+&2/<D>?F)(Q6A_P +=\+
M\R78_O$VYXKBQ&"Q%>G2E2@Y+E6R\V4I)-W.\S2UPC?%OPFC2!KJ8;1E3Y)^
M?U KL=.OX-4TZWOK8L8)T$B%A@X/M7GUL)7H)2JP<4^Z+4D]BU1117,,****
M "BBB@ HHHH **** "HYIH[>"2>5ML<:EW;T Y)J2J6K<:-?G_IWD_\ 0350
M5Y) >?\ @[QGI.H>.-6%O]I8:Q+&]J[QX!$<6TY].AQ7IM>+^%"SW/PYPFP>
M3>'"XYY8<U[17JYS2A3K+D72V]_A;C^449TVVM0HHHKR#0**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***.] !1110 4444 )535&*:3>
ML$#E8'.UNA^4\&KE4]3)72;T@X(@<@XSCY3V[U=/XT#.$\';3\(=+&"H+)G;
MSG]]6-.3]LT<F(.P\6W *CIU/(K-T3QQ%IOP\L](BTFZDN O^CS",^4\@;=U
M]NIJMINN3W-_H%G<VLZWXUMKJ64KL7,AY %?8+"5HU:LVM'*3^5GJ<_,K)'O
M5!H'6CO7QIT&%<>+=*MM;CTII':X9PC,JY1&/0$^M7]1U*QT](EOIEB6X?RE
MW=R:\J\8VG]D^+)F0'RY&6Y3'J3SS]0:ZOQCH[>(-'M]:LF)>*'?Y3'AD(R<
M>XKV)8&@G1ES-1DM7YF?,]30\/>#[;1-0DODNFG+J1&N,!03^M2Z]X,LM<NA
M=&:2WG( =HP#O Z9S7-?#O5I%OI=.EN)&@DC#P)(?NL.H'^>U>DUCC)XG#XE
MMSO*V_D.*3B4-(TBVT73TL[4'8O)9NK'U-7L4M%>=*<IR<I.[98F*,4M%2!S
MGB;PE;>(4202?9[N/A9@N=P]#[5)X7\/'P]92Q/<^?+,^]R%PH^@K=JA?ZUI
MVEO&E[=QPM(<*K'GZ_2NN->O.G]73NNQ-DG<T*3\: 00"#G-+7*4>2_#>]MO
M#&K^(-#U:6.UN5N#(LLS >8HSG'\_P :T?!;KXA^(7B#Q&&66TB1+>TD*=1Z
M@_@<_6MJ]L/"'CC5+BTN84NKW3F*2XW(R\D$$C&1D5LV&G:/96,^B:8L-NB(
M0\,3?,FX=3WKW<3C(2YY\LE4FDG=:):7:ZZV7WF48O3LCA=7U.3Q-\08[>P8
M/I^B6\LD\RKP9"I& >_8?G6I\("6\!1D@#_29C@=OFJS!:6'@^RM?#-A;L3>
M6UP_V@D;BZKDEO7.:J_"#'_"!1^OVF7=]<U6)G&6!DJ:M%.*7=KW]7ZNX+XM
M3O<U2_M?3_[7_LH749O_ "_,\@'Y@OK5SO7)>#[>";5?$5_)#&UXNJ30B<\O
MY8"X7V KQZ5*,H3G+HOQ?Z&C>H^/XB:!)X@&BB2<71N#;9,7R^8#C&:ZO->;
M^)M"MM&\%Z]>:CY(NI;YKJVG@3$BLSCRQGKGL?;-=]ISS2:9:R7(Q.T*&09S
M\V.:Z,70H1IQJ4+VNUKU:2=U]Y,6[V9;HHHKSRPKBO&HDTS6=$\2&*::UT]W
M6Y2,9V(XQO/TS7:UA>*=>CT33@!$;B\NF\FVMPN[S'/J/0=ZZL%*2KI15[W5
MO)JS]-.I,MB!_'GA:.V2X.M6QC?<%PV22!D\=:K>#)IM4FU;Q \,UM;ZC,GV
M:"4<^6B[1)[;L]/:N2?PUXE28:F/"GAXO#(7%JB_,_N#G&:]$\/:S%KNCQ7<
M<9BD4^7/"1@PR+]Y#]*[L51I4*+]A[U]&[IVUO;3O9:^6A,6V]35[TM)2UXY
MH%%%% !1110 4444 )BF2P13H%FC210<X=<C-244TVM@&[%V[<#;C&!TKGM&
M\&V&BZK-?P/([/GRT;&(P>H%='16D*U2$7&+LGN*R8F*,4M%9#"BBB@#)\1:
M.NN:1):&<V\JLLD,Z]8I%.5:N;6?XA6L0@*Z'=E1_P ?32,A;_@/8UU.LZ/;
M:YISV-V91"[ DQ.4;CW%>9ZOX?\ #QEDT7P_;7^I:O&K*2+Q]EL>F7)./PKV
M,OY)P]G/76^L;I>=^96_(SG=:G;>#] O='COKO5;Y+S4[^4/.\8PJ@#"J/ID
M_G73"N5\%^$I?#%O<-<ZC/>3W00N)&)5"H/ _.NJ%<6-FIUY-2YO.UNG;RV*
MCL+1117(4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )7#
M?$I2\&@#S2BG58LX&<]<5W)KA?B9(J0>'EWJLC:O#MS^.?YUWY9?ZU"WG^3)
MG\)W5+2=Z6N H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBUUXR2]CMO[5UP-<#"AK89;CG S33<^.(HR5U#6T(;:4-J6V_CWJ_P"Q9_\
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M2WP6&W';\:YZY^)=Q>64T">%-95IX&5&\LGDJ?2LG6[.7Q)KHNEU.6TGTM#
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M<YVN[VY%+\6S.46W<UO"-EXBLS>#7M8M]0+;/+$76,C.<_7BNH%<=X/TC3-
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MEXC!6/56QW].:ZKQGX/:]$FIZ<%$J)\\"KC>!W'OBOKXU\-AW""C936_^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@=*
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MV?:6KW,O@9[M2U4TW4+?5=-M[^U;=!.@="?0U;KYB47%\KW1N%%%%2 4444
M%%%% !7"_$58_MGA5G"G_B;QJ!_%D@]/RKN>U>>_%2_738_#MW*3Y4.IK*X"
M9R #W['K7H97%RQ<4M]?R9$_A.E\:%5\$ZX6Z?8I<_\ ?)I/ _\ R(VB8.?]
M#CY_"N/\1_$[P[J'AO5;*(W0EGMY(H]]N=K$KU^G-=CX)C>+P1HJ2(49;2,%
M2,$<5K6P]6A@;58N+<NOH":<M#>HHHKRBPHHHH QO$6DW.JV:+9W2P7$3;XS
M(FZ,G&,L/;J/>J>GWM_I$"6=[HS)!"N%FM&\Q2!W(Z@D\UTN*3%=$<1:G[.2
MNOZ_K6XK:W,F#Q+HEQ;B=-3M@A8K\[A2".HP>:T+>ZM[K<;>>*8(<,8V#8/X
M5P/Q,TJPO9?#EM<0(J7>II!+)&H#;2#QFG?"NU6P7Q'8Q!Q%;:F\4?F?>VC@
M9_ 5VSP5+ZI]8@W?L_6V_P#P">9\UCT.BDHS7E%BU1U@XT34#_T[2?\ H)J[
M5+6#C1-0)!(%M)Q_P$UI2^->HGL>(Z2N_3OAP"#M6*[8$>N\\5K>)=6UC3)[
M8:;9K-!Y;-+(06VX/.?;'-9FE;?[/^&_ELQQ'=<;N/OG/ZUT6IZ[8:');K>W
M B,N=JI@GCC./2OLZS?MU:/-\>G_ &_,YUL8EKKFKZB"+:YT9FR-T<F1N'/!
MSWK?TN&[M;&*&]%OYX3(^S#]V%SP *Y>ZO++7G,4<&F62D%EN;EPCJV?FX!Z
M^F:Z/0((K72+>"&_^W0QKM%RK;@[ \_@.E9XJ*C3T5M=K?JORW''<T001GE6
M.23WZTU\ ,0=O..GWJBO+U+22RBV,[W,X@0#C'4Y.>U/\^#[2UIYFZY11)Y?
M<+G&37#RNU[%%A9"9E.WY.!@C^M<):D#PC%.4&S_ (2Q2G/!!#=J[B+<9T89
MSC=M/;Z5P<;D^$%PN5?Q> <\8&#TKMP:T:\X_J3(^@:6DH%?&G0+1110 444
M4 &**** .<\??\B#KG!/^AOP/I7G%E'(/%?AT!]R-X9A*D=ASP3WKT7X@)YG
M@'6URP_T5C\O?':O/H2W_"4>&=P11_PC41"=#GGI7T>5/_99?]O?^DHQG\16
MU/Q-J6FZO)9OI,(M@?W5S*[;9/8$=_\ "K']HZYJ%G*$T'3+NR;*RB.\WB1?
M3ZUH7>N6-C)]B:7S[H;O]%0;W/'3';(S7./H]Y>2)=Z+9C0B7RQ:?!=0.!Y8
MX"G^=>E35.44Y04?-WL_/=/[KD.YU]KO6SMHWC6!@ 3$#D)_LCV%.SMWL54$
MY[YHA5X[>)&E,SJ K28 W'US5<ZA%_:W]F$.TQMS<(RI\H&=N,^O-<%G)NQ9
M8XDD4?-N!X8#!K$UKYM?\( A@YU>/=MXQ@C]*UH[B&X>6*"Z$IMF\N3:W*MZ
M'WK(UQMOB'PE(VX*-73<[\ <CK6V'352WD__ $EB>QEQ:Q=Z1#XFN+/2UO)4
MUJ1"%)'!SR<>G]:ELO%FJ:C\EKINE,2FYHGO-LB'W!JQH-W#97/BFYFO(H8%
MUB3]XQQUST/?Z5!?2Z5K<[1VGAQ=1F0C;<J!$I!'!+#!(S7<U3<VI4[[:_)=
MVE^).MMS7TD7OG7<U_H]I8RS[2[Q2;S*PXR?8"M5,$J^Q"3@$XYP.E8GAG3-
M0TNWDBU+41=.SY2-&W&'/8GUK1O+R'3K-[NZW%(_F;UQGJ/SK@K+FJN,-?2_
MZZE+8M!F"N5R"&...#45XO\ Q+KKYU!%M(2S'A?E/6EEE0*/,F \Y@(R2/F)
MY QZTEZ MA=R9(VP2#)&<?*<\=ZRBM4,VOA:V[X=:4V6.4;);_>/3VJGX_4_
M\))X-.U#_P 3+'S''8=ZXCP]X:UQ/ ^GZUI7B.ZM%D 06BYV L^W(YX]:CLK
M/5X]<T&[U75Y;]HM>DLS"[%A&RGEN>A/I6WU*FL94Q$:B>L]+.][/07,^5*Q
M[QWHH[T5\H;GE7Q*M/)UV&[&3Y\.",<94_\ UZ]/M]KVD6T$(8Q@'TQ7$_$J
MVWV^GW&&PLC(Q'0 BNC\*W1O/#%A*S[F$>PGW'']*];%-SP-&?:Z_K[C..DF
M<'X<#Z5X_:U4_*TLD3?3J*]5KRFYY^)H*_+B\4<'KQS7JW>EFNLJ<WNXH(=4
M%%9GB"]N-.T"\O+50TT2;E!&<<\G'L.:Y'PIXX,CFSUFYW%V_=7)4*/HV.GU
MKDI8.K5I.K#5+[RG))V%\9:!K^I:Q]HLU\ZV"+Y:B3:4(Z\5A?\ "->+C\AA
ME*L22#/P?KS7K@((!!R#R#ZTM=5+-:M."@HK3R_X(G!-W/);?X=Z\R;F>UAR
M.59R2/;BM*W^&-P6'VK55"$?,(8^?UKTC%&*)YQBI;-+Y![.)SOA_P &Z?X?
MG:XBDEGN"I7S)". ?0"NBHQ1WKSZM:=:7/4=V4DEL<-KOBC0/!M_)%IU@EUK
M5[)^\@MA\Y8]W/;DUEKXO\>MJ&X^%#Y"##PC.2>F0U)\+X?[1USQ'KUW&$O)
M;DQ^65YC&23C//H/PKT[->MB:E'"3]C*FIR25W)O>W2W1;$).2O>QQ.B>-[?
MQ38:K:/:2V%]#%+^YD.2R@$;@?KVJ+X1'=X#C^9F_P!)EY(QGFJGC*U5/&NE
M'31'%?7%G<BXVX&^+9U/ZU9^$!4^ HMN>+F4$'MS6F(ITE@)5*2LI.+MO;XE
M^F@DWS69WM><Z1X%T?7;[7=1UC2YA<R:I,$9W9<Q@C!&.QYKT:N%\3^#;,66
MK:P=2U@3+'+<[([LA 0I. O]WCI7#@*K@Y04W!RLKKU]45)%D_"_P@8V0:4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNNMV=K%AI]^GB"S<9>VN74RA>Y#<9Y[$"LZ.2R-E<:<L5Q<V4R!9=%NE_?P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%  :YWQT5'@76MS,!]D?.P9/TKHJYWQT0/ NM94L/LKC .#73@_]XI_XE^8I
M;,G\(9_X0_1R<?\ 'I'T_P!T5Q'QG,7V30S)D[;LL1C/R@<UVWA#)\':/GK]
MDC[8[5POQMW_ -FZ/L0;C<, W.1\O2O3RU?\*J]9?J1/^&=A9:-X;URW2]@T
MI8@&VD!#"Q(_O 8S^-3'PK$GRVNIZI:Q!LI%#<MM7U'.>IYK*\.>'K*\TKS1
M=WPWRY<)<N W X-:LGA6Q&YA>7\.<<K=L,>W6N>K4Y*C@JCT[J_ZC2NMA#IG
MB.%F>#7TFP/DBGM5VGZE>:42>*((W62VTZ\XR&1VCW>Q!S5*70M L3Y<^KW4
M1<<A[\C=[]:H,?#D6^2#4]7O)83@1V\TCMC/8="!ZTXQ4]E?_MRWY-!L6+V.
M.XN!)<^%+R.X5?GNK-E4C Z@J06QVK+NC;SP*+J_U&.VA \IM4LG4J3R,3 ;
MMW]*M&W!@D2QTG7YXP_S/)>F-MWH-QZ#UK)O+>\F5K.>_2V<_,JQWTEU)QT7
M8!]X^N:[:,5=*]K?A\FY-?(EF!XEO;K4M)G%S+'*L9!@GC.6$@_B!."2!W(K
M+@\97,>KZ9J\"R2:K;IY-\L2$B\1< ,V/XB/Y5?\3V-W:V27$DETUQ&!LAD(
MW!<\$IR5'KFL[2=2UCPIJ\^K6-NACO-L)1DW-)(W3'MFO>HPIRH623WLKV3Z
M-?/?U,FW<]N\,^*+#Q1927%D)4:%_+FBE7:R-Z&MNN1\ :/JFFV&H76LJD=[
MJ-V]T\2X_=Y[<5UU?$8R%.%>4:3O%>=_QZG3%MK4****YAB'.#BN"M95?Q'-
M?>+0;:2&0BPCG7]RBYP&5NA8^]=]4<L,<T1CE19$/57&0:Z:%=4KIK?2_5>G
MKU$U<2*:*XC$L,J21GHR,&!_$5(*PV\,VT$AETJ:73I,'"PG]V6/<IT-8.N>
M*O$7A7[*+_3+74%NIA##):2E6+$$@%2.IQVJZ>%]O+EHN[[/1_Y?B)RMN=WF
MBO,KGXD^(+2%Y9_!5[$BH6+._ QU)XZ5W^CZ@-6T:SU 1^7]IA679G.W(SBE
MB,#6P\5.HE9]FG^3!23V+U%%%<A049I#10 M(2 ,DX ZFN8C\37.LO(GAVT2
MYC1C&]W/)LC1N0?EZMBIHO#ES<X;6M7GO1C#0(HBB/X#D_G72\-R?Q7R^6[^
M[I\[$WOL<U\0]6LQ=Z!<13I<1V&I)-<QQ#>57!P>/\\U+\*[@7MOK]\L91;G
M4GE7*XR#S7;VNFV5E;+;6UK#%"HP$5!BK"1I$H1$5%'15&!75/'4_JOU>,?G
M?I>^W_!%ROFN.HI:*\PL2J.L,J:)?M(V%%O)DGM\IJ_5#6!G1-0&_9_H\GS>
MGRFM*7QKU$]CQ33CFP^'*;MY:*Z!7.#C<>?I76W%C8SS+-<V<%P^TJK21AL+
MG..>E<II8Q9?#K+ IY-V!@<_?-=#J5OJDUS$^F7\5G&D9W))"6);/4?A7U^*
MUJ))V^+7_M^78PCL3?V7IRJ NFV:JIS'F(?UJ>.&&%V2..-$5!B-$"\YY/%<
MS FOW.J7U@^N)$UH(V=Q!NWAP3P.V *W;&&\M[=8K^Z2YN,',J*5R,\<?2L*
MM-Q6L[_?UUZH:96UVWO8[BRU/3K075U9LP>(MC=$XP<>XXJII_V]KC4?$%YI
MKQS.HM[>R1<2% >I]23702%5A+_NT"*2[EL*!ZGVJB=:T[C_ (F5D0" O[X=
M>]%.I)PY5&_2^M[7O8&M2EX:TVXBO-1U:\A-O<ZC/\L9?<8HAT!':L* *OA6
M!0R'_BKU5G!X!VMVKO(@OFH5P4;!1U.0:\_CVGPG#G<AD\8 $ICYN#73AZCJ
MRE)]X_J2U8^@N] HH%?%'2+1110 4444 %%%% '-^/R!X!UPLF\"T?Y?6O.X
M1&OC'PZ&6/S3X9B+*!M"]>GK7H7Q"S_P@.M$/LQ;$DXSD>GXUP"NP\5>'MP&
M\^&HAN SZGBOH\J_W67_ &]_Z2C&?Q%N?P[HU[=?:[K3H))I&+/(2>3[X-0M
MX2\/R>:QTQ%SC#!VS^'/ J._E\4K)=26BZ8-/7,D1E!+X S@CWJ#3-2\3:OI
MD5_##I<$,N2IF9MQQQT[9KOBJZAS*II_B>GD3I?8WX(DA6..WC$<<:A8EQ@#
M%9.IB?2]8AUZ"RGO(UM6MYX(OOJ"P(91WY[5K6RWC01?;&B^T #S"A.,^U*9
MHS*\:R*)]NX(3\Y7ID"N:$W&;Z]_-#.>TL7&D:3J&L/IDTM_>7)G:TC'[Q4Z
M*#].OXU0TVSDL9_"!NQ_I=WK7VIQLQM+,#@GUKK+B^L[0_O[RVMV '#R 'FL
MG725\0>$7^8+_:T9WCD 9'!^OK773K2G)IJW-?\ "+LOD)HJZ7IMCJC>);74
M8A-$NL3.!R"K9/<?7%6U\(^'L+_Q*DST),C<CU)SS5+2?[0\WQ$--6*:X;69
M-QNLJ@7G)&/?%'V[Q;_:DECY.DB40"Y&XG&TDJ.?PJYJLYM0J66G6W1=!:6V
M-G3=(T[1_-^PVHB>0X<Y+9';K1K=G+>Z'<6L!)GD0E QSN(Y4$>F12:=_;+&
M;^UXK2-P!L-LY.6J]YJ1A':01JA&6;ISV-<<I353F;NUUW*TL<TLUYK>K:6L
MVGW-HFGGS;EY<A6EVXPH[\TANY=9UNXO39RV]GI=K.O[U2ID=D(SCN*Z=V"1
M/+*=J*/G+-A14-S.LVBWDD<RR1_9I =C _PGN.,UJJZOI'R7E??[[_(5BSX1
M /PET<*SJ%ECPV.?]:/TK"*[]1T220JH;Q9<_+V.>G'KQ5;0?'6A:;\-K/3/
M,E?4;0)+Y!4KO(?=PW2J^G:]8ZQJGAR*!F%T^OS7LT 7)C#GY<FJCAJT*E:<
MHM+FEKY6>OIYAS*R1[IWHHHKXXZ KB?%'C1[29M-T8>=>$[2Z+OVGT [FNSE
M+>3)L&7"G:/4XKS7X<6Z/KEY<2@F:.'Y<]LM\W\OUKT<#2I\DZ]17Y+:=[D2
M;V1EW<WB_2)(]3O9;J+S#PSMN4'T91P*[OP?XE?7K25+H(MW!C=LZ.#T(K?O
M+2"^M)+6Y0/#(NUE->4Z$6T#QTMIN/EK<FW.3C*MPI_E78IT\?0FG%*<5=6[
M$V<6>NC%+FDI"0 23@#K7A&HM-=%D1D=0R,,,&&016);>,-#NKQ[9+Y5D!P"
MX*JWT)ZUN @@$'(/0UI.E4IOWTT)-,\^U_P5-9S?VAH(?AMY@5L,A]4/]*FT
M#QT019ZUE9%.TS%=I4_[8[?6NVB$P:3S&!7=\F.N/>L77_"5AK@,I'D7F/EG
M0<GZ^HKT(8RG5C[+%:]I=5_7]7)<6M8FV;F 6_V@S1B';N\S<-N/7-$%S!=P
MB:VFCFC/ >-@P/XBO)[B'5/#*S:;J,8:QN_E)R2C8[@_PGVJMX?UR7P[J9>/
MS'M'/S0Y^\OJ.V16O]D<T'*G*_;L_P#@B]IKJ>I:WX@TSP]9M<ZC=+$H'RIG
M+O\ 1>IKS83^*/B=.\<,C:5HD9R" P\X9Z$_Q<#ITJI=^#-<\6:I+XALM1MI
MHC<L]NDS'<BAN%(Q@8':NA@L?B;;VQ2*?1H]A 2-5X(YSVP*ZZ-"AA87ISBZ
MO>7V?16W\R6W)ZK0ZF'1K7P[X+N--M"1!!;2_._4D@DD_G7/?!XLW@178DAK
MJ4KZ8R.E-T[POXA@2]U?7=;DFFEM9UEL!S""1@8YZ8'3'>I?A %'@&':#@W$
MIP?K7-626#J^_P [<HW?G[U_^'*7Q([RN!OHO%'A+4-1N]'L4UC3+R9KIH-V
M)89&QD*/XA7>UY^WA[XAO)*Q\5VBAW;"K#PB=NW6N3 .*<N>44NJE?7TMKH.
M8V9?$WCN#^S-1TG^Q]+$H-TTA)>91@A5'UZFO0(HUBB2*-=J(H50.P'2O-;S
M3/&NC*NIZEXNLX[2V*M([[@IR0,$;?\ )->EQNLL:2(<JX# CN#58])1BJ;7
M)K91O:^E]7N]@AYCZ***\PL*Q]>BUR>*&+1)[>W9B?-FF7=M'L/6MBL?7_$-
MIX=@AFNX;J597V*+:(R$<9Y'I6V'4W42A&[[;B>VIGV?@?3%ECN=5>75[Q!C
MSKUMX'T7H*V=-O[*\^TP66 +*<VTB!-H5P <#VP17.GXCZ, &^RZIL(&'%FV
M/I3_  '.MW!KMXD<T<=QJ\LB"5"IQL3G!^E=M:CB'3E4Q%]+6[;]B4U>R.MI
M:3O2UYA8E,EDC@A>65UCC12S.QP% ZDFGU%=6T5Y:36MPN^&9#&Z^JD8(IQM
M?78#CKGQU<Z@[0>%M&N=38N8TNV&VVW#KES4?A--;\2I:Z]JVJF.*.>3R["V
M7:@*L4PY_BP0:F;P&+"Y>X\-ZO<:7)P1;@[X/Q0^M4O"DOB70);70I],M[VQ
M^TR*U_;3@[-Q+DLO;EN]>XUAW0E]5M?S^*UG??3M\.NYEK?WCT*BBBO"-1,4
MM)F@T +1FN0N+C4]7^(4=C:7#VNG:.BS7>#S<M(#M3'H #6)%I-SXZO=:OWU
MRXB2TN7M=/CM6*+$4P0[?WCGK7?# JW-4G963>C=K[+YK7T\R>;L>E45A^$-
M7DUWPM8:A,I6:2/$F>[*<$_CC-;E<E6G*E-TY;IV&G=7"BBBLQB45G:U#JL^
MGE-'N8+>[W@[YU++M[C [USQT3QD(F9_%MNK@Y4_8QM]P>:Z:5",XW=11];_
M *)B;MT-C3]3N+CQ7K6GR?ZBTCMVB^7H7#%N?P%;0KCO!MN4UG7+B;7H-5O)
M#"EP(4VB(J&P/3&#_.NQ[T\9",*O+'HH^717WMU%'5"T445RE!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "5P?Q.A$L7ATY7=_:\2C<..
M<_X5WE</\2$+Q^'B,C&JQ?,.HX/:N_+';%0?K^3)G\)W%+24M<!04444 %%%
M(1D4 +1110 4444 %%%% !2$X&:6D-  "",@TM,5%3=M7&XY/N:?38!1112
M**** "BBB@ HHHH 2EHHH **** "BBB@!!2T44 %%%&: "BBB@ HHHH ****
M "BBB@ HHHH **** "FCGYORIU% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !29YQ2T4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\S5+6+NRU2\@T0SJT<@$]R5<;1&#PI/^T>WH#4OB34%@T;R;:> 2W<B6J,7
M"[SM)X]!DT^2<[)_%-_A_7Y(-#.T>.6W\*ZKJWF@SW[372OZ*1A.OL!5K4X!
M!X1LH4,:A&MA^]''WU_6I/$LMJOAU[565EE:.!$5ASE@,?3%'BBXMDT(@SQ!
M5FA_C' WK6L92J3C*V\ORM86R.@[TM0FY@!QYT>>GWQ3O/BZ>:G'7YA7F\K+
M)**:KJPRI!'J#2YI +129HS0 M<%\1G U7PBA88.JJQ4CK@>OXUWF:X/XC#?
MJ/A%0,'^UT.\G@  \8]_Z5WY9_O4?1_^DLF?PG<7%S#:6\EQ<2I%#&I9W<X"
MCU)K-;Q/H*$!M9L.1Q_I"_XU7\:_\B3K?('^AR=?]TURW@[P!X6O_".EWL^D
M1-// DCLS');UIT,/AW0=:LVM;:)=K]6)MWLB+Q'+I&O?$OPK$CV=_"8KE)5
M#AP>!@?SKL)/!WAJ3[VA:?P<_+ HY_"FZ9X+\/Z/?K?6.G1Q7*(463DD ]<5
MO8IXG&*T(8>4DHJW;JWT?F"CW&QJL:*BC"J, #L*?24M><RQ#7+?$:**7P'J
MAEA64I'OCRN=K9P"/?FNJJ&YM8;RUDMKB-9895*NC#@BML/5]E6C4[-,35U8
MY;PSXGT&'PII:2ZQ:(T=M&CK)*JLK;>A%;2^(]&>SFO%U2U-M"VR242#:K8S
MC/K6*OPQ\(*N!I"<]<NW^->8&UAC\(ZC9+$8K8>)HX5C')5.1C/<XKV*>$PF
M,G*5.4MU>Z75^IFY2CN>PCQEX:*[AKEB1_UV%2?\)7X?&<ZU8\'!'GKUK+/P
MT\(%57^QHMH.[&X\G&.>:#\-/"+2.[:/&6<8.6;TQQS7'RY=WG]T?\RO?-J+
MQ!H\R7,D6J6CQVH!G=9@5C!]3T%<\?BAX7^VQVZ7NY7;:9L81?<D]J\\UVUL
MM(T7XA:=86XCM(6LHXU7H,NN1GZYK+T/0++4=2TZ&>WBV/(BL#P,'K7KT,GP
MGLY5:DI6Z;?RJ7ZF;J2O9'MP\9>&FP1KEB01D'SA0?&7AH<_V[8= ?\ 7#O5
M(?#CPFL?EC1H0OU-.7X=^%%\W&C08E^\#G]/2O(MEW>?W1_S-/?-&U\3:'?&
MX^RZI:R_9T\R8K(,(OJ3Z4^U\1Z)>H7MM6LI5!P2LZ_XU4L/!?A[3!<"TTR%
M%N8O*F')#IG.#FLN7X6>$9)$9=,$2J,;(W(4\YR?>I4< VTY22Z:)^M]0]XZ
MHW]FI :[MP3TS(O- O;0XQ=0'(R/W@Z5QA^$7A;R]HCNP=VX-]H.1[?2G_\
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M!)Y!'8^HKW,%AJ>(P;C.35I-Z*_1>:[F4FU+0]R^VVFW?]JAVYQGS!C-.%S
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M[TI[_1EN88_,DM&\PJ.I3'S?XU%X!UD7FD?V?+(#/:\+D\O'V/X=*Z\J&!!
M((P0:\KUFPNO!WB 7MBC"V9LQ'^$ ]8V]J]7"-8F@\++=:Q_R,Y:/F/5*\Y^
M)MPK3V-MNPR*TI'UX%:T'Q#TMK-I)X9HKE%R8<9W'T!KD;&.[\9>,!<31!H
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M*.]%<!0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:*
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M?,3&=ZX'O5+/ZUK*G'[O^"'LEW/!E\'^.6GG>73,^:F5*NG''?GK4Q\&^.4
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MZG8FT'<QST_^O7T52-3$49MI5%OS*\7HG:]U9[^IBK)]CTBBBBOFS8*0T44
M<3KMIK.A>)KCQ-I4#7UM- D=W8@_.Y7(#)]!_,U0;QUK>NR3:5H?AZ^M+YL*
M;J\3"6^?XB/I5K6&U_7_ !E<Z-IFJ_V7;:?#'*\D8)>4N#@?3BL[3=7\9ZY!
M-H$*);W%G*]O>ZLS X(/R[%[G&,U]#2IQ=*,ZJBY)+=M671M;2]%KJD9-ZZ'
M<Z)I<>@Z+::9"&=84PS_ -YNI/XG-:2].1S5+1K*;3M(M;.YNWO)HDVO/)]Z
M0^IJ_7AUI<U23;OKOW\S1;!11160SGO%;S/;V%BC/'#>W:PW$H.-L>"2,]MV
M-N?>N;U#1+.Z\4Z'X2BW-H]A;R7,]N7)W9.$5CW&3T/:NC\:0:+<^'I(M>>5
M+,NN#%NW!_X<;><YKB].U_P9HD&J+#K>IFZU!-LE[+#(SQX7"D';QC/'N*]S
M QJ.A>DI75]DVKO2]^Z3?Z&4K7U-KPG;)HGCG7="T^.0Z6D$5P"TA<0R'C8,
M],CG\*[L5SG@_2](T[3'DTN]%^]P0UQ>&3>TS@=6/]*Z,5Y^.J*I6;[65WNV
ME:[]2XJR%HHHKC*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $KAOB/DR>&5"E@=6CR >>A_2NYK@OB5GS?"^&(;^UHR!V/![UWY9_O4?G
M^3)G\)WM H[TM<!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1WHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC4]0)< ,-_0?XUN7^HC39+-O*9OM5REN,<;2W<_2EGOK>#4;6P<GSK@.R'L
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MS4+N2UM;N.2>,D,@/(P<&KS21QD;V52QP,G&:N5.47:2LPN244@I:@ HHHH
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MEM;A \4J[64^E<]/-:C]W$)3CZ:E."Z'+^#_ !=)K<C65XB"Z1-XDC/RNO\
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M1110 AZUXAXDV-/\34$K;=EOD]!G*\?YZU[>>M>*>+?L\L_Q*_B"Q6I)')#
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MG'J,LL]Q9%(P<2'MGD<5Z7Z5P&@:%H^MOXDN-4L+:XNWU.>%I)CN;8N HSV
M'I7'@*GLU.;=DK;)/KIOV*DKB7W@#5]1T5],E\6W#V91%CB^SH%"J00#CDC@
M5W=M#Y%M##NW>6BIGUP,5S7P]NFE\":4;B53((V7);J Q Z^U=548VK5<W1J
M--1;V26NS>GH.*5KH6BBBN H*Y/Q@+V#4="U&TTR?4!:3R-)%"N6 9" ?S-=
M97)>-7U*YETC1M-O7L6U&X9)+J/[R(J%B!]<5UX'^.MNM[WM:SOMKL3+8Q;/
M5]9MO%6H:Q)X0U,Q7D$,2A5!="F<YYZ$G]*W/ L=\+/5[F^L9K)[O5)9T@F4
M!E0A0/Y&J7ANWU/0/&,N@W.JW&HV<NG_ &J%[ALNC*X4CZ'=^E=O77CJT4N2
M,59J.JOLMM'^(HKJ'>EI.]+7DEB57O[V#3=/N+ZZ<K!;QF21@,X4#)XJP:Q/
M&)QX+UL[2W^@R\+U^Z:UHP4ZD8OJT)Z(UK>>.ZM8KB(DQRH'4D8X(R*EK@]+
ML?'+Z18"#5]*C@%O&5W6[%R-HX/I6IIMGXSCU*W?4M4TR6S4GS8X86#,,<8)
M]ZZ:F$C%NU2.GK?\A*7D=31117"4%)2TAZT 85GJLE[XMU;298(?)L8H)(GZ
MLQ<$G/ITI-,OK;Q)/J"W6G1'^S+]X(C* ^2N/G'IUKF]6?Q1HOC?4]0T70$U
M"VO((5>1GVD,@(P/7K67HU_XYT:XU25?"*R+>W3W1'G8(+<8_2O;6"4Z?/3E
M%-QC;WDM;+FZ^IGS:ZG=>#]2NM7\+65]>.K7$H8N57:.&(Z?A6[7.^!K.ZL/
M!NFVU] \%TB'S(G.2I+$XKHJ\S%J*Q$U#:[M;U+CL@HHHKG&<CX\N(K"UTO4
M;PS'3[6^1[B.)=VX8.TD>@;!K=CUW2)(5F34[/RV7<I,RCC\^*O2!&1A(%*8
MYW#BO+?$-C\,M(U!YKJVCFNUP3:VVY@6[9 X!.>YKT\+"GB8JE)2NK_"K[]U
MI;UN1)N.IL>%I!??$3Q%?Z8RC2!%'"^T$+-<#DNO8X&03[BN\KGO"5]>W]A)
M)-HJZ58@K]BBR-[)CDLH^[70UACI-UK-6LDM[[*VK77O]PX["T445QE!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "5P_Q()$?ASD8_MB'
MC/4X.*[BN$^)1&?#0.0?[7BPV,@<']:[\L_WJ/S_ "9,_A.[[TM)WI:X"@HH
MHH **** "BBB@ HHHH **0G% .: %HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI ,>M+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %)FEI,4 +1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !128YS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 (:\2UG3-?U;QCXSTG1(;9X;DP_:A+P0-JD%37MIK
M@/"WF?\ "T_&0R2G[CJ>^P8_2O6RNLZ"JU8I-J*>O^*)G-7LC!TRP^(_A_3;
MN 6UE=1R+N>6=_GVA<8'/8#@5!X'PG@RQP26'F,V?=CQ^%>N7P)TZZ //DO@
MGZ&O)_!3.?!VGLZ_PNI)Y_B->A1Q;Q-"<I12?-';2^DB7'E:-X_+&6  &"3[
MU$TDSE98!&\3H>&/+>V>V*656^SA%8(6R@8CIGVI0FQ?+3 4QD,OY8./P-0K
M -3[0'@26( =6D#\?3'K69JVAPZO(+D74D%Q:GB,C,; '/SK6SL)(#9P1CD]
M:YC7K!M3\2V=A)>W$"/;R/(L38#J&P1GOFM\,VZET^6U_,3V*]_J;^'8&%U8
M:>\"RM(39RA6*GH0IZUO:9?VVLV1NK:29HBY1LY!)P#C\,UGZ=X=T!;NXB2R
M61X'",TK[\<9S[&K.A:G;ZMI\\UI;BW2&Y:#8N!NQCYN*VK.$H7@G=6N]M_*
M[$KW*GC(0)!ID]P=J+J,(?#<*/7'K6;=>(-(E\6:7=I>HUK;B:.1U)+(2.-P
M]#70:^8/(L8+BQCO$NKR. I)_#G/S#W'K5&6TT6'7[;3AI%O)YP;][Y6-NP9
MP?[V:O#SA[)*2;TEM;:VH.]S5LM6T[5GE6QNTF90&; Y /0U<.6>,##'..G>
MJEGI>GZ=)+]BLXK<LN"8UXZU+<+-):/%&V93$ZQX.T[L'!'IS7%-0<O<V\RM
M>HK7D1BFD$R-'%_K"&!"GT)[5'9ZG8WK^59WL,SQDAD5LD$>U<.MWHW]DZ=:
MS/\ 95CF_P")I '(>1@.,C^(9J\]QHMYXCT%?#L<)N!<>;<-;IM CQC#FNUX
M))-._76VFG?U_5$\QVF&*NS@ $CJ>OO3HT87*9QQC ;IFHU4?-@  /Z?>J2,
M'SE# <#//O7G/8LX[PC;JT=D0BAT\4$;CU(VD_I7N5>$^$+]1?VM@Z3&5O$1
MF23R\)MP1@MZU[M66?*2KJ_F%+8****\(U"BBB@ HHHH **** "BBB@ HI-R
M[MNX;O3/-+0 4444 %%%% "&N;\7^'6URQ26V"_;8/\ 5[CPRGJIKI#2$XY-
M:T:LZ,U.&Z$U=6/,_#_C.XT=AINJQN\,3;"Q_P!9#CL1W KT:UN[>]MUGM9D
MEB;HR'(K-U7PWI>MAGEB5;@C N(N''X]_P :XF;1_$?A.5I;"226!CEF@3<I
M'^TGK[BO3E'#XS6#Y)]GL_Z_I$:QW/3Z!7#Z;\1+:1=NH6[HV<&2(97'N.M=
M=8:E9ZE#YMG<I,G<J>GU]*X*^$K4/XD;%J2>Q;HHHKF&%%%% !1110!S7C\9
M\":QDG:(,MCKC(S7G^@W=OJ&L//9Y>V73U"#D.N7/!]*]!\?@'P'K0)P#;-F
MN"TF(1^)[B%5C#QZ; K(C9 ^O;-?19;;ZE/O=_\ MIE/XC>)PB' V^G3VI",
M[MV>!@DG.*4*5CR1C!.?QH)8;\$!?X2!S0!S7B6TM7N;:>37ETJ788P0<LRD
M]O2LA-$M[6XFDC\:*CR &7& )>P)&:Z_4ETJ&U^U:I#:M!&-I,L88_09Y/X5
M@IHJZP7C71;;3-. *F1XE^T2G/!![+BO3P]=JG9MI+RC;\5=_B9M:FOH=G;V
M&CP6]O>&[C5G83<8<DY)_.IM1%BNG2RZLT#6R'>[2CC/H!ZU+8V5OIMC%96D
M12WB&$0<@\Y)_.L+Q@JK;::\[1?8(KV,W*N,JRYZD^@YKFIKVN(W>KWZ_P##
ME/1&9$^G721W$7@:86S99)-V" /XL=>G:MW0/["EBN9]&@AAE!$<J!"DBCJ
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MJ5C/-J$AMX$A9P)>^!V4=*UJ47SQ<UR)6TO^0)Z:&-9>+]=E\'6?AK2=%,O
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7
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M",_K70"O/QDX3JW@[I)+MLDOT*BG;46BBBN4H**** "BBB@ HHHH *3M2T4
M%%%% !1110 4444 %%%% !1110 5P/Q+9TG\+$9 &KQY8#..#_\ 7KO>]<-\
M23)CPV$=%4ZO$#GUP<?UKORS_>H_/\F3/X3N>]+24"N H6BBB@ HHHH ****
M "BBB@ HHHH **** "DYSUXI:* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#
M7"^& J?$WQA&%P08&)(YY0'\J[H]:X3PNR_\+.\8*A.T>1PPYSL&?PKOP?\
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M53*V.AR1FO8R^E:'M4WO:R:BOO;U]$C.;UL=!X$N/$$T%ZNLQW'V<.K64MR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:6T5MJ+63V\AD!"D[CC@'!Z5T]<UXLL?[3DTRQ77+G2Y9IF"?9QS-A22N>W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(&A&67>9">2>A&*6[ =E=Q"AFPW4#'X?7WI!L9,@A5)/?FGAG8KA,%> '/\
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MWKW.O#O#WV87.B;5F$XUZ3#*,AUSWS_2O<:RSW^+'Y_FPI;!1117A&H4444
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M5D],CMZUKWV1IEVS$82VD![\[3^=82I^SJ*-T_34J]T;'PN4K\.M*!4+\C<
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M^Z-6C)'0=#WKN:X/XDH&G\+G:21JT>#GY1_]?T_&N_+/]ZC\_P F3/X3O.]
MHH%<!0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%)0 M%(#D9QBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)2T4 %%%% !2!0&)[FEHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?%9FHZ!IFK3QS7]JL[1KA=W0"C"5*5.KS5HW023:T/(-8\5:IJ]K';7EXCQ
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MPGS>]'57MM+^KCNW)'>"EI!2UXQH%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK9/_ .JD+X5E) VG!'I3OE&"&S@8QW!I"1MD7@Y.1QU]Z!BJI#$%0O'0]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!N<5Z;7F/AEW?XBW+' )EN-W?/->G5Z>:_Q8K^ZB(;"T445Y984444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:S[S6=-T^\CL[R[6*:<&1 P)X!ZD]A50C*3M%78C1/W@/F; QSTS_C3"P"]
M2H.3CI4=M=6US'$]O<1S!AN&QPV!_A4S;M@R.N>3_GK2M9V8&)XKN+N+2XX+
M+>D][,EJ)5ZQ;N_Y<5H6]C%;:2FG%Y)$CC$1<L0S>I'O4.M6,6HV'D2WOV)@
MPDBGW[=L@Z<_7M61%>^)H[5E>72&>/Y1<M< ;NP+#]:ZX1YZ*C%I6?IZ:BV9
M8\/6\FFZAJ6B/+)/;VZI-:O(^YU1QR#]#6OJ ,FF72(SDO;OM(^\6VGBL[1+
M!K1+F[N[^.]U*Z5?M$B/D!1TVX_A K4N919VC3%M\<,;2  9R%&:BM*]:ZU>
MGS=M?O8+8\_N/$%S=>&8=(30;Y7(CC+&,L 5.3V]JU--\3/8R16;:-?1V:R\
M2."1"AZ]N1FKBZWK%OX6N=8N+E'FO GV2*,X\LMT'/4]_P *6V.LZ+<Z6+_4
MS>P7[B":.5>59O3V]:[YN#BXN"W?VGJ[:VTZ;$ZG1J0T+%3E"V[(.<\T[@L'
MSP1P,<&LR72I869M.OGM=KY\D -'SUR#_2I/-UD3M$MI:SL!\K>9LW<= /4>
MM>7R)ZQDOR+N>A:-_P @BUSUV5?'2O.O#GQ FN?[-M'T22.WFN39_:Q*"@<=
MAWKT85XF,PU2A4:J*U[]GU\C2+36@4E+28KD*&>5&6R8TSZ[13^@I:*=P$%+
M112 2DIU% #2<#-4M,G%S'/<!=N^4X!ZC  Y_*KK E6 [BN;TV\OK>ZG@6PF
MD'F*)!N4>6< $]>0>M;TX<\)6W$WJ=+5.:98=1MQL!:564D=>",?A4OGML9O
M(E^7H,<M]*S3/>7.JP)):RQ0XWKE1@8/.XYZ^U*G!MNX,V:***R&%)UIU%("
MO>.8K.5E!W!3C YS4D:A8E'H!5?4T+6,G&=OS<=L=ZK6FI2-'&);>5PRY66-
M"0PZ9]JV4'*%T*^IIX'I52RG5Y;B#85>)^1VP>F*CGU011ADM+N1B^P*(CD>
M_P!/>H='-RTMTUU L<@?:SJ.&Y)&#WP#35-J#;"^IJXHP*7%%8C.0^(5LC^'
M$?RUS'<(<X['(J+X:0A- NI-N-]TV#Z@*O\ 7-:7CA"_A2[P =I1O_'A5#X;
M_P#(NW'S9_TM^/3Y5KUXS;RUK^\9_;.QI:2EKQS0**** .8^(;;? .M$;LFW
M(X'N*X72D@/BFZEA:1U;2K<[F;<%;NN1]XCUKOO'CF/P-K+A2V+8\#KVKS[3
MC-)XTO!=P"*X_LRW\P XR?4*.%X]*^BRS_=)_/\ ]L,I_$=!M0QX*\'(V9J"
M2"3=OC;!"88C@OZ#V%6&R54 DG/04F.) >I'W<=!33:$1;+CS OG2= 1P#]1
M]*2:,+&5$D@S*N&)YSFF3:C965U"EU>1123@^6KG&<=3[5-)_JU/#)O3![#G
MM5>\K-H"5EVN, 9Y(.,?I6!XFNY;6SL;&#SH_MUTL#SKU16.#@]B>U;C!2Y#
MKSG.>Y].:J:EIR:K9?9Y)FA=95FCE!Y1U.01[U5"48U(N>P/8(M*M[72/[+6
M2<QI&Z+)(^6YSR3ZUD:&D^CZO-X>:[-W:):I=P22K^\3<<%2?3O1)<>,EG%J
MNE65R%0A[QY@J%3_ !8]O2K&GZ1+917-Q>WOGWEZT?F,G(7'10>H&*Z;.,)*
MI)/F[.^M]_+KV)]!WB7>?#6J0H"SO!E1&">X_P XK%N-?M+N?0[N."^5;*1G
ME5K?&[Y,?IZ5TNI:@FDZ7<7;8;R\".'H7D)PJ_C6-J]]X@L=,L1,T$FJ7ET(
MHC$N5"D<AO7%5AM8I-=7;6VZL^G1 S2T_7;359Y+:."[1P-^98=B^]7=1 ;3
M+P%4YMI"Q<9'W>]8=A?7]AKD>A:IJ(NQ-;M.CA<,S[NF?8"MV]+)IMU*N3LM
MI.,<'@]*PJTU"HN79[?U9#3NC:^%Y9OAUI)88;8W?_:-5/'6!XJ\&,V,#42.
M?<<5;^%Z*OP[TG!!RC$D>NXU5\=%1XG\&[LY_M'@@9[5Y\?^1G4]9_E(O["^
M1W7>EI.]+7B&@E+110 4444 (:.]!HI@>7^&VS\1IR2#F6?YEZ'DUZA7E_A?
M;'\09E4@@R3@8^IKU"O4S;^-'_"B*>PM%%%>46%%%% !1110 4444 %%%% !
M1110 4AI:0T %%9?B._ETSP_>7</^M1/E.,X)XS6!X"U'5=1BO#?3O-!&0L;
MN!G=WY[UU0PLI4)5[Z+07-K8[.F2R)#"\LC!412S$]@*?6/XINEM/#-_(V3N
MB* #U/%8TH<\U#NP;LCS?4?%^H7.N->6]S+#'&V($!^0+VW#OFO3/#VJG6M$
MM[UU59'!#JO0,#@XKA/#/AA=8\+Z@TGRO*P$#XZ,G],\58^&^HM#=76ES-C<
M-\:D]&'# ?S_  KWL=2HU*,E26M.WW?U^1E%M/7J>CBEI!2U\Z;!1110 4F.
M:6B@ I!2T4 %%%% !1110 4444 %%%% !1110 44G>EH **** "BBB@ HHHH
M **** "BBB@ HHHH **3-,EFC@0O+(D:CJSL *:38#S63JOAO1M;1EU#3X)F
M(_UFW#CZ,.:P-<^*/AS2%=8KAK^=6V^7;#(SGGYNE<1?_$GQ/KUZ]GX?M"JN
M<IY,>^3 X(STQ[UZV$RK&R?M(KD7=Z?\$SE..VY>U[X4VU@IFL==CM8</MAO
M" ">H ?K^-87@SQ5KECXFT_37U.2:VN[I8Y4D/F =OE)['CFMJQ^%NN:WOG\
M2ZI)&6Y1!+YKC_>[=*[_ $#P1H?AT^9:6H>XXS/-\S9]O3\*]6MF-&G0E1K3
M]M+T5E\^O_ (4&W=*QT5<)\1L_;?"P7ACJB@,3\HX[CN?2N[K@OB03]K\*J,
M9.K(<]^E>'EG^]1^?Y,UG\)WO>@44"N H6BBBD 4444 %%'>B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3GFEHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPG4^$8%M_"FG(I^]$'/N6Y/\ZX+RIO#WQ%1$'[M[C*#&<H_6O3-*C$.D648
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(*6O(- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3=(SGA/K7 >(O'OAJXN(E@U/SMG#^5&S8)Z=J\/ 8>K4JWA%M+LC6321.>5
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M%V.W<-40 ,!CI7@97_O4?G^3-I_"=]0*.]%<!0M%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/;VOYH7-+L;WC?Q;H-SX-U.WAOHYI)8MJHH.>3]*\^/B:VT?Q'))M6^B-A!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI!P<D9_G2<G/4^F:=R/Y<BD_A'S=*@!,9.>F!Q0  1GH!WHVD'!/-!/L2&/
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M"YM3J@6.X8!8@#&.*7=@KN<GG' Z4*&^;GDGH#TH4<1KM(!8K@_Q>]<!0F&
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MC3C5E&D[Q3T9HKVU"BBBL1A1110 4444 %%%% !1110 4444 %%%% !1110
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MMV![ DXJ/X=MN\$:?D*JLK$?-]X;CR3V^E=)I3J+/6'#%E6WB /KB ?K7->
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MELXV:-$902 RL.9/1B>P/I4T2$&Y0,R_OVV[B 1TR,=A[U#22:L!:R3O0O\
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M);HT3OJ'->4_$33([/6X[J*/:MVA,A[%Q_\ 6KU>N1^(=B+CPV;@#+VT@?\
M \&NW*ZWLL3'L]/O_P""3-7B7O!^JMJWA^*21@TT1,4F/;I^E87Q'TS?!:ZF
MB9,9\J;'=3TS]#_.J7PRN-M]J-L6.6C211GC@D'^8KN]8M3>Z->6R@%I(F"Y
M&><<5M5_V/'WCM?\&)>] S?!NH_VAX=M]S%I8!Y+ECDG'0_EBNAKS#X;7C1:
MK-9LQ"RQ;@O^TIQ7I]<V8T?8XF45L]?O*@[H****X2A"<"EHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"DYI:* *][:1W]A<6<V?*N(VB?:<'##!Q^=<0OP@\,B/8QO& ^[F;I7?T5TT
M,97H)JE-QOV$XI[G R?"+PW(),F[RXP29<GICTIO_"H/#N1B6\&#D_O>M>@4
M5O\ VKC?^?K^\GDCV."/PC\-D8S=X!+(/.^X3UQ5C3_AAH6FZC:WL+7)EMI1
M)'F3CCH#[ UVM%2\SQDERNH[>H^2/82N!^)(;[=X493@C54SSVQ7?UP?Q%(%
M]X7+/M7^TE!R,@U66?[U'Y_DPG\)W?>O!?BM9S1>-I;F6UG%K+;KMF"G8Q Y
MY'IQ7O5->-)%VR(KCT89HRW'/!5O:VOI;L*<>96/EZTLAJCJ#J$,,A(1EEE*
MDKC.=QXQ72VWPM\1W<*R6=Y9-$S'+)=%@#Z\?K7J6K_#GPWJZDM8K;2DY\RW
M^4Y^G2N,D^%_B+06>?PWKF1S^[8F-FS^8S7TT<[IUU:G44'VDKK[U^IC[-K=
M7,=OA1XN$K 3VS(.#FX;#CV[_G2#X3^+ 2/,LU!!SMN6VD]N.QK8'Q!\7>&9
M!'XAT=IHCP'*E".>I89!XS76:+\3_#>K*J27/V*X/'E7''?CGI65;&9M3CSJ
M,91[Q5_R8U&FRY\/]!OO#GAD66HN&N6G>5@'W8SVS74U%#/%<1++!(DL;='1
ML@_C4M?*8BK.M5E4GNWJ;I65D%%%%8C"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDYS0 M
M%)VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;X>ZO*&WQ/;;@0?O#@BN(TUGD\4W+3P10S#3(%E51RWN>W(QTJ<MO]4EZO\
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MRUTBR2TLX]D2\]<ECW)]ZN445\U*3D^:3NS8.]4=7^R/ID\%Y/'#%.ACW.P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 449HH **** "BC-% !1110 4444
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M3Z;O\*!(7'W71CG/R<C_  %+V$0NS6.J6ZXW;UXR3C@5;B<21*X! 89 -<X
MNP#>?+V_(47.#[>OUKH;8?Z-%SGY1SFLJU.,%H-,I7NLP6-SY$BL7V[ABHCX
MBLE4$B3T("]*S/$1_P")I&JA<M&,[JPR 6R&^9C@$]J[*.$IS@I,ER=SL/\
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M/K-CKUC]MTZ;SK<NR;]I'(Z]:OURSA*$G&2LT4%%%%2 4444 %%%% !1110
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M)#W'CY,KN5<DGCM2!MPWDJQ(YSZ>U*6QN. 2>C#C-'S;D#+DA<\CG-:"$/\
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MO//%TB'6?$_FVC3$Z9$%<#88VR,$'N/KUKT<L_CNW]>]$B>Q[%IA+:79D]3
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MK[]NWC!4^_%>_@,-4Q.7U:=)7?-$RFTIIL]]NO\ CTFQ_P \V_E7BWP<W_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQQA!MP>@].*1OF#9 SG/'%.*EB1N#@XR>N1_C7%*<I?$RA!DJ0"N">6/7/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@""[M8KZSGM)U+0SQM&X!QE2,&N13X5^%4P#:3.H&-K3'!KM:*Z
M*.*KT4U2FU?LQ.*>YQ9^%GA0KM^Q2@9[3MZ8Q0/A;X46172RE3:"% F; S7:
M45K_ &EC/^?LOO8N2/8XK_A5?A'>['3W)?\ Z;-Q5FS^'7ARQO[>]@M91/;R
M"2-FE)P1TX]!7644GF&+DK.I+[V')'L)7!_$8A;WPJQ7/_$V09)Z<5WE<)\2
M#)]I\,*'Q&VJ('4#J>Q_G^=7EG^]1^?Y,)_"=WWHH[T'K7 4<[XWEUB+PQ-_
M8<7F7KNJ!?+#_*3\W!Z\5XZNB^,[>\FO;72KVTN73DVJ",$?@?TKV+QMK=WX
M>\./J5FJ-)%+&&5AD%2V"*Y70_C%IUXH&K6K6;%]H>-O,3KW[BOH\LGBJ>%<
MZ-)35]>_32W5&,^5RU9B)K?Q4D:.)+&56QL)-NN,8ZY/\7%+'K7Q4P";24X)
M8#[,N3CL:]2TOQ)HVLLZZ?J5O<.@RR*_S 9QG'7%:E8SS-0?++#03\T-0OU.
M>\%W6MWGA\3>((C'?F9P5*;?ESQQZ5T5)2UXU:HJE1S2M?HMD:)604445F,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** #FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@#GO$
MPXMVRO&[(/X5@\K(X!4Y&2 ,YK<\3@F2U7<%SNP>^:P@V&89&3V ZU[.%_@K
M^NIG+<<>"B@$9)..^:;N^5VP=H.#SR:4;D"[<$CU_E2')WKP><D+QS70("Q1
M QZ>G7#5?T,[M6CZ$<D''>J#<^4&VG/7-7M"&=6CQG W#/2LZO\ #EZ MSKI
MAF&0>JFL#&&;YL]AQ6_/_J)/]TUSZY(P3T.37FX?9EL.&; (Z8H'W0&Y/?%&
M.W/)H)QG'X'WKH$&<CT)-!P,X/X$4# /? _6E/.TXP10!MV'_'E'QC@_SK)U
MH_Z4O<!.G:M:Q(-G&1W!_G63K?\ Q^1<D +SZ&N:C_&?S&]C,+_(,$YS@<<F
MEWJ<9(VXX!'3Z>M SNVX [@9_F:-N#N^8X'3N?I7?H2*N3'A@HVG/7(_&C^-
ME4')/3_/:D.W8H!7DX!']*,_.2.>,'- %O3"#J$63V.WCM7129\M\$@[3T%<
M]I8_T^/@X&<<^U=$_P#JVXSP:X,3\:*CL<XCC>ZLTFY><'MQ_$?Z5&I=5W!
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MO2O&6QJ)R6 ';K[T<G'((X(&*<,;\YQZ>])DC)"'/H/2F(,*#DJ?F/(ZTFX
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MT4>I-=U95*J;J13WMKKZ)K=KS]"%9;'8-ME3:(Y#)GEF/4>N>P]*(V4R-^[
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MXKS[5?@UITZR'2[^:UW,"L3C>J^H!ZBN_P!8UBRT+3)=0U"7RK>+JP&22>@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!"XXP!ZYQ0%("L&)SQSQS0."21N&3D'I70(7!RJGYB1D-G'2K^A8_M:(X[,
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M;4K195SN0S+D8Z]Z:IS>R871H454AU.QN)5B@O;>61@2%20,3CZ5:S2<7'=
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MQU _D*6)5!501EN5,9_]!';ZTS"LK1A0K;N3N) SZ^I]JBOM5M=)&Z[.XO\
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M0>;M0;E!;@>];5::Q+A.M)V5--O=_$UW\^XD[;=SK?%5[:3>$M72*Z@=VM)
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MC]X$!SN;ZUU8P0,'//(KRL7"$*MH>5^MG;5?)FD;VU-RQ_X\X^>U9.MY-U&
M3TK6L1_H<?N#_.LK61_ID?'5.6KS:/\ &?S*>QF\X..<GG/]:7^, !@<94C_
M #Q01N"[L_*>E( 5)' 4]<G]#7<2*6/RXV[O2CD,3D'^5(65UP5.[J,C&?\
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MZ.7YE5P4[QUB]U_6S(G!21XIX4\,^"?%<0%IJ-_!>8(>TDF&X<8...173_\
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MC\5:(NIQV[VZF1X_+9LD%3BMVO,JTITING-6:W+3NKH****S&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!C^'_  ];>';>[AMI99%N;J2Y8R'HS]0/:E\0^';+Q+IOV*]#
MA5<.DD9 9&'<&M>BMOK%7VOMK^]W%96L4=(TJ'1=)MM.MV=HK==JLYRQYSS6
M5X@\&Z?XBU*ROKJ2=);8%"(FP)4)!*M[9'ZUT=%$,15A4]K&5I:Z^NX65K"
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M5?P[FH3Y;JP#H&7CG.6_WO\  5R__"RO#HNF(GN'5  Q$)&<^@[?6F'XA>'
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M8G$T14+R!*!N&>_8"M;1[R":2:".X#RH Q0$?*IZ8QVKQ][SP(&&Z_OE?RR
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MRA/W6W;WUM?_ !%Q<;:G=6]K!9P+!;0I#$OW41< 5Q/CW?\ \)'X/*L,'4@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ<>9/NOU(F>I>]+30-H '88IU>2:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4A%+10 4444 !Z4@I:* "BD%+0 4444 %%%% !
M1110 4444 %%%% !112=\4 0W5U!96TES<RI##&,O(YP *Q6EU+7CBSDET[3
M^\Y4>;./]C/W1[GFJ.OVM]%JB7T[+<6J2*84<XBB[$2+WSGANQQ726%]%J%N
M)8PR,.'C<89#Z$5V<BI4U4CJWUZ+Y=_7_@D[NQ4M/#NF6@DS;_:'E7;))<GS
M68>A+=O:M1$5  JA0!@ #H*6CO7-.I.;O)W*M86BBBH **** "BBB@ HHHH
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M;SPYH<HU!5CNKF0.T2G(0 8'3OZUV=>%CU1CB9*A\*V-8WMJ%%%%<904444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(0G.3RK<<U[5+DQ.7NCS)2@W*SZJWYF;NIW[BRB#1OCW%)))(?MJX&!_$Z8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_:1ZGK'>EK+T+7M/\1:>+W39O-BSM;@@JW<'Z5J5XTX2IR<9JS1HG<****@
MHHHH **** "DI:* (I&D5DV1A@6PQ)Q@>M2T44[@%%%(PW#!Z'K2 6BD4!5"
MCH.!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH ***3G/6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $KSO
MQ[XXN]+U#^PM.M[A)GC#S7<<>\QJ?[@[GZUZ)7%ZM?>.(M:NUTS0].N+%<""
M6:3:[<<]_K7H9<H>VYII.RV;LOQW]"9WL<KX<\5>'-'D5X]'U>[OVR9+^X@!
MD8GJ,YX'L*]/T758=<TBWU&"*:*.8$JDR[6&"1R/PKA)=3^)4-L6;1=*7:22
M_F 9^N3^%=YHEZ=0T6TNF,)E>)?-$)RBR8^<#Z-D5TYG&+BJB2NWNI\WZ:>1
M,.Q?HHHKQC0**** "BBB@#%TQ@WB+7"">&A!!&.=G^?RK8(!!!&<]0:R-.\W
M_A(M:#C]WNAV'/7Y.>*V*WK_ !KT7Y(2,GPR=WAG3B,_ZA<9&#6L*R_#80>&
M].$?""!=O.>*U:6(_BR]7^8+8****Q&%)2T4 -D_U;?0U@:780ZKX1LH;E"/
MDW(R\-&P)PP]"*WY.8G^AK+\-_\ (N6/_7+^M=$).-)M;W7Y,3W,37;VXC\.
MWVF:JH6?R,1WG2*XY'_?+>J_E785D>*;>*Z\+ZE%/LV"!GR_0%>0?S%:RG*J
M<YXZ^M55G&5*+2MJ_39 MQU%%%<HPHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *6L02W6BW]O -TTMM(D8W8RQ4@<]N:X#X;>$=>\.:S=3:JH6&
M2U"(%F\P!MP->F4E=E'&5*5"="*5I;DN*;N>+>(OA[XJO_$&K7=J%-M<3M+&
M#='E>W'8U1D^''C/9M"J2PP6%YV Z?3M7;>)/BE;^'M<N]+.G//);E06$H4'
M*AOZUF-\:K954G19MS= )EYKZ2C7S=THN%)-65O2VG4Q:IWW.8'PS\9;6Q&B
M+G*JMYDCZ?X5I:+\//%5IXFT[4+A(Q'%=)+(WVC=E1UR/7%:Y^,]HI/_ !*)
M< D']\O'I^-36'Q>@OM<LM.&D2QK=2)$':49!8@ _2G4KYPX2O25K/[OO!*G
MW/3,5P?Q.7,'AT; _P#Q-X?E/&>#W[5WE<'\2]H/AMB6!&K1@8Z5\]EG^]P^
M?Y,VG\)WE9FL>'M)U^ 1:G8Q7*@$*6'*Y]#U%:?>BN*$Y0DI0=F5:YYMJWP<
MTF[8R:;?7%B_&%/[Q!@8QS@_K7/'P-XX\,2F;1KQYXD0']W/DENGW&Z_TKV:
M:>&W3=-*D8P3EV X'6N5U/XE>&=,3/VW[2>,"W&[/T/3BO;PN99C47(E[1=F
MK_B92A!:['"6OQ0\4Z08QK6D>9'S&-ZF)F(/)W8P2/2NITCXO^&M2R)VFL6#
M$?OERN.QW#UK U;XNQRMM@T**6%&8%KL@\'H0.WO7'7J7_BVX,MAX9C2(3"-
M?L4!5!QG#=CZYKUEEM&O'FQ%'V7FI+\B.=K9W/HBRO;74K6.ZLYTG@?E70Y!
MJS7(?#;1K[0_"2VVH0""=YY)?*!SM5CP#[\=*Z^ODL33A2K2A!W2>C-T[J["
MBBBL!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
ME+24  (89!S2T#VHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4
M4F:,T +2&EI#0!SWB@MLM\' !)Z<]JYWG+;N<#!ST&*Z+Q/D"U8, 06/-<^C
M*7DW;MH0Y&,]J]K"?P5_74SEN(&<*C'''=N_T]J"<F3@ GH.N/QH/W$.<EB<
MCTX_G0-IW-M8+Z=:Z!#FR0HY//&#S5_1=W]KQG"G&5X/05G?, F%W,.N*T-"
M)_M=5Q@DDMQZ#^=9U?X<O0%N=?("8G Z[37-RR>7!)(5SL4OCUP,UTDHS$_T
M-<ZX#K(K*"C## ]QWKS,-U+9PGAYI[+0=0\:7]S-<7-U \D< ;<B)G*C%1:/
MX+C\0Z7#K/B&YO9[R[C+^7YF BD_*!Z<4Z+0_$VB&6T\-R66HZ/(&807#C";
MNJY^G2HM%M?'VD6!L;>UM7MTD_=F9]WEJ>P.>0*^HE)VG.C4BFVK:V?+V\K?
MB8^J-3PN+S1O$E]X:GO9;RU@M4N+>27[R#.-OOUKK^" 3W[5S7A;P[>:7+=:
MCJEPMUJEUA68'(1 >@-=,.3R/QKRL;.,JS<7?:[75VU9<=C:T_\ X\H_Q/ZU
MF:W@746>Z'FM2P_X\H_Q_G67K9'VJ,-TV\\<5Y='^,_F6]C-[#_8.>?\\T+D
M-P< \D_XT@! )QCG@]S]* 06!(XZ8QTKO)'-NP<DEP./I1PK;B,\<XZ"H_X0
M=I+*>26Z?6I,MGA1]2>32 M:: ;V+&,@G_/N:Z)L;&STQSFN=TW'VZ+..?NG
M'M70R?ZM^W![9KAQ/QHJ.QSS!,JRL S,54A<$CT'H/>HQA(FP'VK_<&Y0?\
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M^G- $O;\*=2#I2UF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\,V:.B[6C(*]01DUTTI*-*5U=77Y,3W%\2CS/"VI[,-FV<C!ZC%:B#;&HZ8
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MK=BUM$2<DH"3Z\5$XM4E?N_R0^I+1116 PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D[4M<YXD\:Z1X8")=R/+<29"00C<WX^@^M:T:-2M/DI
MJ[$VEN<GXN^&FH>(_$M]J<-Y;1QS)&J*ZG(PNT_RS6 ?@UK!^3[?:[0."222
M??CI7K'AS6E\0Z!:ZHD+0B<-^[8Y*X8K_2L[Q7XUTSPG !<EI;R1"T-NG5OJ
M>PS7M4,SS*$EA:>KCI:RZ:&;A#XF>?6OP;U(3CS[^U"L2'=%.5'J!ZUUOA/X
M9V7AK4QJ$EY)>7$8(B+*%"Y&"<=S7*+\8M44JTEEIS?-^\C65LH,],^N*[SP
MGXZTWQ4/*A5[>]52[6\G/RYQD$<'M71F$\WC2;K?"][6_P"'_04/9WT.IKA?
MB8X2#P[EE4?VO#DOTZ'O7=5P_P 2B!;^'PRY!U>'MGUX_&O'RS_>H?/\F:3^
M$[BEI.]&:X2A:,U'-,EO!)-*P6.-2S,>P'6N+\/?$>T\3^)%TRQLYTB\MY//
MEP P7 X'XUO2PM6K"4X1NH[OL)R2T9V^:*X_Q[XXC\(6<$<4?G7]T3Y2$?*J
MCJS>W:O/]-^+6O17L,FH1V]Q;#/GQHFQ@/4$]3[5VX;)\5B*7MH+3I?KZ$NI
M%.S/<*6J&CZQ8Z[IT>H:?,);>3@'&"".H([$5?KS)QE"3C)6:+"BBBI ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXR6YK!$G+G).$YQZXKT<+_!1$MQI.8P.F2<8%(P3<X^=01T]\49"HAW9V\Y
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M<50A2OSMG/3\Z5>I/WLC/%(.#US@TO7)9?S..*0$XI:;VIU9C"BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK[E!CPA#!QV]?<^U=!IYS80\,/E'WNM<_O<N@#$MM)4@YX] /ZUT&GC;80C
M!V\@'->+B?A1HCG?$R_\3"-L](N1ZBN*N4)\;:+(QPOV:=<,:[;Q*N[4$SG_
M %7  ZUPFLV^M'6K&^TF*!WAB:)O/^ZF[OBO7R[6"5[:/?S3,Y[D?BB7;JOA
MW"+Y8U Y;_@/3%2>//\ D4+I8]W#Q@D=1\U9.H6_C+4)[22XTVT;[!-YR!#@
M.V."><_E3M7A\8^(-,FL9K&UB@G(90A ; Y]?6O5ITXQE2;G'W=]?._Y$-[G
M9H@V1A0,F-<C/3@5L>'V']K*HSQ&QY[5DDG:=R#?M5<XXS@9_"M?P^/^)L "
M?EC.>.]>'B/X<O0T6YU;#*XQG/%0N"O))(SP *EDQLYQU'6F9()R!P<9S7BQ
M-1I'3OQP :",G;GDCG/]:,@ 84-D<]L"D(^5AG[QR#UJA#AD<<AC31EL$ \'
MZ4O&X#H,YR#U-*'8MZ<?Q=: )Z6DI:R&%%%)0 M%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "'..*!TYI:* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *0TN:S-;O);>T6"T4->73>5"#T!/5C[ 9-7"#G)10,JQK_ &[>B>0*=/M9
M3Y*YR)G'&X^P/3WK<%0VEK%96D5M H6.)0J@5-FJJS4G:.RV$A:**3-9#%HH
MHH **** "BBB@!.W-5[JZM+"(W-W/#;QY"F21@H]ADU8KAM1T:S\3?$&ZL=8
M5KFQM;"-XK8N0A9F(+$#OP*Z<-2C4D^=VBE=VW^0F[;':I-%+")8Y$:,C(=3
MD$?6F65[;7\!FM)EEB#LFY3QE3@_J*\VTKPI-JU_?:$]_<Q>&M)N6BCMXF*/
M(S -M9^ZC=7HVF:;::1IT-A8PB&WB&$0$G\R>IK3%8>C15HSO+TV72_GMIT[
MBBVRW1117$4%%%% !1110!CV!_XJ36!MQ\L'.>ORM6O638A1XDU<@C<5@R/^
M M6M6U?XEZ+\D)&3X:9F\.V;-P=I[_[1K6%9/AI0OARQ *8V'&SIU-:U&(_B
MR]7^8+86BBBL1A1110 AZ'-8_ADB3PY:_* #O&-N/XCVK8;.TXZXK!\(75O/
MH$4<4@:2%G29"?F1MQ/-;P3]C)^:_474S_$%G>:+H.IG3U^T:?);NK6K/M-N
M"#N9#CD8).VNJM^+6$ DX0<GJ>*H>(U#^&-54YP;27H<?P&KMH?]"@//^K7K
MUZ5=2;G13>]W\]$)*S)Z***Y2@HHHH **** "BBB@ HHHH **** $8A1DTM)
MM&<TM !1110 4444 %)2TE '!^.OB-#X7N/[-M(//U!DW,S'Y( <XSW)[XKB
MD^*7BQXXW6V@/F#@"W8CGN*FBTU/$7QGOK;4SOBBN6D"%<>8J* JGVZ5[.L,
M2!56)%"C  4#%?259X/ 4Z=.5)3DTFV_,Q7-)MW/$4^*OBA7=9882HY5_LS
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M_P L5P3>$/!T.J6VE/-,+MRS)&7P3CG'HN:[>=EM[&XF0A3 CM$[-D*P!/\
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MN<X3&XGJ>YK6\/?+JZJ,\QDGZUDD*^Y@X;<0<]..V*U_#^XZN,X^X<5XU?\
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MZ4N**M2G)6IQ:7F[_H@2?4****YQA1110 4444 %%%% !1110 4444 %%%%
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MYEG Z*>RCZ#^==;7/FM:%;&3J0=U?\E8<%:*3"BBBO.+"BBB@ HHHH ****
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M\"E]0,<C//I35.6R?OYVC(I0#DX.,=>] $_:G4G:EK(84444 %%%% !1110
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MMC01_P 3E>N1$1]:R4Y)4?,3SQT%:OAXG^V ,8RC9&?2O-Q'\.7H6MSK)/\
M5MZXXJ$=23P>XJ=P=IJN0<$JBEB>?>O%CL:"E0"H(4CKG/%&0#DGFDW;'X;Y
M#UXZ4+T4,<X'4TP',-V[M[TI)Z#@]QZTQ2.3GICC'-*2V,XVL.G?(H L=J=2
M4M9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*U:^0Q,JLJLG6^+KT.A6MH%%%%8#"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5)\59H8_ EU'*ZJ9I(XT#=SNS_(&N:^'_@?P]K&C#4;BUNG*S%<2R?))@#G
MZC->U@\)A5AOK6)NU>UE\C.4I<W+$HW'Q<UO4YXX-)TY(O-<HI53*_\ @#56
M/P7XX\6.T^J^7:!FW;Y\#=CIE5YYKV:QTJPTV!8;*TAA1>@1 /QS5RJ>;TZ&
MF#HJ/F]7_7WB]FW\3.>\'>%D\)Z4]DMP9S)(97<KMPQ'('M714@ZTM>-6JSK
M3=2;NV:)65D%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPZG/;FO0<</&,:S6_P!F_5/OO;\2==C1C6;RU\X@2D?O-HXW8YQ6OX?/_$W
M!Z(1BLO=DNP4N<8!SG/O6KH&#K*E2.(R#7E5_P"'+T+6YUD@RA'KQTS40X7<
M0H'&#UJ63.PX&:A'*XX^G:O%CL:BGYL%LY7L?ZT8^; &,CL>M)W ^;GHP[4N
M"Q;D GH33$&.!P,DX]J!\JY!P >>_-*!\^#GIUH7&/E_3BD!..@I:;VIU9C"
MBBB@ HHHH **** "BBB@ HHHH ***3O0 M%%% !1110 4444 %%%% !1110
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MN$J0I4N:OK%O16OKI=[JWZD23;T+/A;0Y;%KO5=19)-8U!]]RR.61 /NQK[
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M;V:"6 J59<#!X(YP:["N7,7+ZPU)-6TU;;?GKW^XJ&PM%%%<!04444 %%%%
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MN&T\P17*12R%A$[$@A<]L 5VU<F.O[:][W2:TMI;16Z6V*CL%%%%<A04444
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M4K[1[:SB*F:5P,8R,_X5]'-UYSO"K#I9:-_^DF.G5,]&B0QQ)&6+E5"[FZG
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MD5H94*E1B<E?J,=Q4\'PT\,6LUM-%9R":WE657,I))!R,^HKEG6R>S2IRO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?TKH-(_Y#,&6#?.>V,\5YN)4DIJ6^I<3LI/]6WT-<T^?*D"\O@LOUQQ72O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ(-=]2* H 4  #  [4M?,XO$2Q-:5:6[-HJRL%%%%<XPHHHH **** "BBB@
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M&<L1GTXK@?$^FWMU+8ZEI\<4MYIDGG+&[8#ICY@/?'2N]\5?-!;IC(+'/K7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNG7BN7U'X0Z!="XDL99[*67!C,9#(GT'_P!>OI<-C:%J3QD7&4+<KMNNE_\
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M5@,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3/.*6BB@
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MJ^#+"[MXSIC-I-[ FV"YL_D*\8 8#[P^M:7A]]6?1XO[;CB2_4LDGE-E6 )
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME @+,GE';DGCFO4RZIR*,N:WG:_<SFKG.+\/9G9XY/$!9@22I7<#^&[@T_\
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M4M-[4ZN H**** "BBB@ HHHH **** "BBB@ HHI,<YH 6BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 AKSGXRX;PK:HRN0UTH+*/N\5Z,:Q
M/%6M6>@:%-?WD4<WEX\J%\?O'[ >]=N7U)4\5"<8\S3V)FKQ9XYXH\?W/B/0
MH=+;3T@5)D<2*S%OE&!QCWZ5I:7\5KO3=,M[*+2("MO$J!1N&3G!/3CZ5);?
M%=UN$:;PU9>0SX8Q\%/?)&":]6TJ73M5TV#4;6VB$5R@<$Q@$CWKZ#&5*>&I
M1IUL-[M[KWNIE%.3NF5_">N/XC\-VNJ26Y@DF#;H^>""1Q[<5M4U$2- D:JJ
M@8"J, 4ZOEJLHRFY05DWHNQLMC \4<P0KW)/7I7G?BK3-6O;G3;C2DA,UI(S
MB1G *?+P1GM7H?BDD0V[>C'M7%>(-2?1=.DDAB\VXN&6&&/K\[<?I7N97*<>
M3D5WKOMKH9S\SE[_ $?QMJEC]GNV22(%6,;2)M=LYP<=.G%2M9_$23RY?M$*
M, 08BRC;Z''>IT\*:[?+&VJ>)+B)=N/*M^2/8GI39K;Q!X2@DOHK_P#M73U8
MFXMIP0ZI_>#>M>XJR?N0<&^BY7;Y-Z:_TS*W74ZBRCO$TJT2^D1[T)^^=?ND
M_A6MHY/]LPN 1\Q4@FLZVF2YL;:YB^>.9%E7!_A/-:>CA?[9BX/))X/3BO#K
MM\LK^9JCL7_U;<9XZ>M<ZV[#[ -Y! STS71/]QOI7.L0H<]E!;(KR</U-&<5
M_;/C'38 -8T"*_LU#F8VS MM[<=":DTK7_!D=^R16D6F73!<?:;7RB^>P/2G
MR_$.SFD$>AV%UJD@/S^6NT#V]<_A59D\5>)+.:WU'P_I5O%<@%9[AB6C';*]
M21_6OHO9-Q?MH>SOVER_^2N]_P #&_;4[.&ZMKM5>WN89E;)#(X8$?A4O.!C
M/)ZUR?AKP-#X?U)=0^U>9/Y+1-'&FV,9(Z9/M76$KCT_I7EUXTH3M2ES+O:Q
M:O;4V=/'^AKTZG^=9^M[O/A 8@8.3CC\:T=/.;-/QK.UL'S8B,8QSS_*N&E_
M&^\M[''>)M$N-6M;6YL9(TU*SE\V$LN=W^S["L:7QU=:5$L.KZ%>_;(I DIB
M7*%2<!E]<UT'B#7(O#]@)6@>XGF?RX8%/S2&I]&FU&YTBU?5K=(KJ3+-%G(
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MUY1<5&W1.Z6G<UB[HG[4M-["G5PE!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD];W_'4RU3-CQ,]M%X;U)KHHJ-"54O@Y?^''O2>$4G3PKI*W4;QS+;#<KG+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !WHHHH ***
M* "BBB@ I.]+10!3U0XTF]/I!)VS_":\A^%'B31="T[44U*]2U:61"IESEL
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M'-% !1110 4444 %%%% !1110 44G>EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HI" >M+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !28I:* "BBB@ HHHH *,4E+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M=Z6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **0X YI1R* "BBB@ HHHH **** "BBCK0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:* &Y&<9
MYI1TI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6B
MF(VXL-I&TXY[T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0^U+110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !12$X%+0 4444 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "=1T
MI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "DI:* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0Y X&
M:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *3'.:6B@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHIN?F- #J*** "BBB@ HHHH **** #O1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1128Y% "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&<=:*1@
M&!!Z'K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 9HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI-HR3C
MDT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !3/XJ?3>,FF@%I:**0!11
M10 4444 %%%% !1110 4F!G/>EHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI",CTI: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)(4"D(
MS9.#M[>]/HH0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (&R,XQ]:6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** &LVU20"<=A2YI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BD)QVI: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D+ #DX%+36174JP!4]0: %I:,44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(: %HIJ,6
M4$@J2.A[4Z@ HHHH *0D $GH*6B@! <C(I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD- "T4F32T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %-XR?6G4S/)^M- .^M+112 **** "BBB
M@ HHHH **** "BBB@ HHHH ***874.JE@&;H,\F@!]%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12"EH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0T Y&:6B@ HHHH **0$'H<TM !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1C/6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% " 8XI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *:/O&G4WO30#J***0!1110 4444 %%%!Y&*  '
M(R**0#'%+0 4444 %%%% !3/*0RB4HOF ;0^.0/2G;AG'>EIZH HHHI %%%%
M !1110 4444 %%%'- !1110 4444 %%%% !1110 4444 %%-WC?L[@9IU !1
M110 4444 (*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBF$MN4!<@]3GI0 ^B@44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A&:6BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 0#'2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BDQ\V<_A2T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !124
MM !1110 A&:6BB@ IKKN7&2/<4ZB@!*6BB@!K.J8W'&3@4ZD/6EH **** "B
MBB@ HHHH **** "D;.#C@TM% "#.T9Z]Z6BB@ HHHH ***0# Q0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !31]ZG4W^*F@'4444@"BBB@ HHI* %H
MHHH **** $)Q2]J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBD[T +1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!,Y_"EI,4M !1110 4"BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "BF[_WFS!Z9SVI
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !112&@!:*09QS2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 TYP<=>U #87)Y'7%+VHI@+1112 **** "BB
MB@ HHHH **** "BBD)(Z#- "T444 %%%% !1110 4444 (,XY%+110 4444
M%%%% !1110 4444 %%%% !2<TM% !1110 4444 %%%% !3>YIU-'4TP'44G.
M*6D 4444 %%%% !1110 4444 %%)0!@8H 6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $I:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!#G''7WHI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I#2TTJ#C.>#F@!12TE+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0].*6BB@ HHHH @N%G(5K
M>1596R0PR&'<>WUJ8$D D8]J6BG?2P!1112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "FCJ:=3<\FF ZBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%)FEH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **.E% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !12=Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "DI:B\A?M'G9;=MVXW<8^E-6 D%+28I:0!1110 44
M44 %%%% !1129H 6BBB@ HHHH **** "BBB@ HHHH **** "F?Q&GTSHU- /
MHH'2BD 4444 %%%% !1110 4444 %%(#FEH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $/2A<[1G&>^*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "DR,D4M)M&[=W- "T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !3.YI],SR:: <.E+24M( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 04M%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4SO3Z9_$:
M: =[4M-':G4, HHHI %%%% !1110 444$X&: "BD!#*".AZ4M !1110 44A&
M<>U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ IG<T^F8.[I30"CK2T@SWI1F@!:***0
M!1110 4444 %%%% !1110 4A.!FEIK*&0J1D$8(I@*IW#(Z&EIJ*$554851@
M"G4F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%%% !1110 4444 %%%%
M !1110 4444 %)CG-+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gzirfjcguvpf000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzirfjcguvpf000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,C F\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W2YOA#<16
MT49FN9.0@. J]V8]A^I[#K6?;>)[6?7SHLMM=6MYL+JLX3#CKP58YXR?P-0^
M&Y6O=2UZ\DY=;YK5>.B1@ #Z9)/XUF^);&666]U*S7-]ILD5Q%[J%^=?H1_(
M5WTZ%/VCI3WMOYNWX:GITL-2]JZ%3>RU[-VM\KNS^\[)F"*68@*!DDG@"LG0
M]?AU^%I[2TNDM@2HFE"!6([ !B?TIDE[%K5A8Q6^&BU!-\@/.(0,N#]20A_W
MO:L;1M471?!>HZ@R;_)NIR%SC<3)@#\R*F&'O3=U[UTE\[K\T13PEZ4DU[]T
MDO6Z_-'9T'ITS7-:M/JVAZ9_:SWQNA"5:YM3$BH5) .P@;@1GC)-6#?SZKKD
M^G6=T]K#:0QR32QHI<L^2JC<" ,#)XSSVK+ZM)QYDU;777I;ROU7WF2PDG'G
M33CKKKI:WE?JNG4DTS7)=3_M-$L&BFLI#$(GE&9&QGDC@<\=35J;4Q8Z(VI:
ME";;RXM\L08.5/\ =!'!.>*Y;2'OK:W\6RQSQ"[AN7<2F+*G:N?NY') _ ^M
M,\327-_\,([Z:[DWM;P/*BJ@65F9.3\N1@\_*176\)!UHP5E%N*ZWU2.YX&$
ML1&"LHN45UOJD_Q_K0W9-8UF._AMAH!E2;#":*Y!15SSN)488#!QSGL>*WJY
MK7)]2TB'3?(U)Y5FOXX93-"A=E8] 5  '!_ASSU%.OM8:76KG3X[B[MH[5$+
MO:6;3NSL,@?<8* ,=1DY[8YQE0=1)P22UVOT=OUZ'-+#.K&,J:25GMS/9I:W
MOW6QT=9.HZTVGZMIUB;-W6]D*";> JX&>G4G\NO6L>'Q'J4.@%KNV9=0:\6R
MMWF@:)9BQ^63:<'&,G'MCBH]9MKNW\2>&Q-?/=(UR_,B*K*VWMM &/KD^YJJ
M6$M.U2WVN^ME?3_@ET<%RU'&K:UI=];*]U_P3LJ*BN)3!;2S!"YC0MM'4X&<
M5QYUG6$TK1]46^B<ZG<I"T#P*T<6_.-H!#$C&#ECGVKGHX>5573M_7_ .6AA
M9UE>+2Z:^C?Z':T5RINM9E\83:.=2CCC.G&='BM@-C[@H.&+9_$XP?7FK%[-
MJ$%VD-UJGV.U6!52>-(S)<S<[@$(;V.T#OUJGA7=+F6JOU_R+>#DFES+57Z[
M?=^1T5%<)=>(]8/P]_M>*YBBNHI#'(WD<OA]@(!.%/<Y!_"MC5[W4=$O=/NG
MN_M%I<W"VT\#1JH0MT9"!G (Z$MUJW@IIVNKW:Z[KY>>A;R^HGRMJ]Y*VN\;
M7Z>>A<TK7&U+5=3L7LGMFL3&"7<,6W@GH,@< =SU[5?OI;F"REEM+7[5.HRD
M/F!-_MN/ KF-*AFG\8>*DAN7MR3;?.B*6!V''W@1^E02>(-5E^';ZO%<11WL
M+,LC^2#OP^W(&< ]#T(Z\5I/"IU%R6M[FFN\DG]S=^IM/!*56/L[6?(K.^\H
MI^MF[[,[522BEEVL1R,YQ2UB76H3SZU;:/;3&"1[8W4TRJ"RH"% 4$$9)/4@
M\#IZ02W&NZ=IVJM,GVHP$&TF55+R(>N57 W+]!FN=8>3MJDWT]7;^O(Y%A9.
MVJ3=M/5V_KK;4WYFD2%VBC$D@&0F[;N]LU'9W<5[!YL6X8)5T889&'52.Q%9
M>@Z@NH@RVVJC4+0(/G9%617SR&  QQT^4=^M06TK6WCZ]LU_U=U8I=L/]M6\
MO/XC'Y4_8-<T'NE?_@:C^K-<\)?%%7Z_-:G14445S'(%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!@Z1 =+UW5+1^([R7[9 3_$2 )!]00#]"*GL8-635KJ>[@LEMK@+@1W#,R;
M01T* '/U&/>M*>VAND59HPX5@ZGH58="#U!^E2UO*MS7=M6K/Y?\,=,\1S7;
M6K23^5M5]Q@:+H$GA^WO!:LMPSR$V\4LA1(X\Y"YP<<LQR!SQ533?#EZ= OM
M&U9;0PW+/();>5F*LS;A\K*.AYSGL.*ZJBJ^MU&VWNVG?K=;%O'56W)[MIWZ
MW6QS[:7JM_I2Z5J<EJ;?"I+<1.QDF4$?PD *3CDY/? ]'RZ3>VGB&35=,-NR
MW2+'=03L4!VC"LK 'G'&"*W:*7UF>JTL[Z=-?^&7W$_6ZBNE:SO==-;7_)>E
MM#E(M!UB"/70LUBYU(L40[UVLPVY+<\ 9XP<\<BF7V@ZS=^"8=!5; 2"-(Y)
M3.^ $*D$#9SG'/3'O7745:QM2ZE9733^[1&BS"JI*5E=-/;JE9'.:WIVM:M9
MZ>J1:?'-;W27$@:X<J=G0 [._P"GO1J&D:O'JS:KHMS:QW$\:I<V]R&,;[>A
M! SD9(KHZ*F.*E%))*VOXD1QDXI125E?2W?O?T.>O?#]UJ6D[;J[C74O/2Y2
M:-#Y<<B\* "<[<9ZGN3[5%?Z5KFIW&EW,CZ=;SV4A=MI>16)&,XPI_#/XFNF
MHHCBJD>W7IM=681QM6/;2]M-KJS^1!>7"6MC/<22K$D<;,9'&0N!U([UQ-CH
MGB*Q6&\^SZ(_E RXDEG&"1EF"Y\M&//*@ 9/:NZEBCGA>&:-9(W4JZ,,A@>H
M(JE::+8V6T0),$7[L;W$CQKZ81F*C\!54,0J4&N_E_P47AL4J%.4>K\NGWK]
M3+AT[5F\7C6VAM%MWM1;&,SMYBKN#;L;,9]L_C4W]E7T'BBZU2 VTT=S D0,
M[$/;[?[N <J3R1D<UO45#Q,GT6UOD9O%S?1;<OR//==TN\T?X<7UI=O Y$X<
M-%GG=*#WZ=>G/UKI9],U#5+FR&I?94MK.83@0.S&9USM)! V 9SC+?6KVJ:-
M8ZS"L-_')+$O.P3.BGIU"D9Z=^E6X84MX4A0N508&]RY_$DDG\:VGC.:FK?%
M=O;O;;7R['14Q_-25OCO)MV_F26FOEV]-CGM-TS6K+6]7U%X;!A?["J"Y?Y"
M@( )\OG.>:SD\,ZXO@NXT$_V?YDDF1-Y[XP6W'C9UZ ?7VY[:BH6-FG=)=/_
M "71$+,*B?,DOLO_ ,!T77HCF]3T34[F:PU2QN+>VU:VC\MU8EX9%/52< XS
M[?XU;CM==EL9&NKRTCOF*;! C^4@5LG()RQ(X/3CCCDULT5#Q,W%)I:>7SMZ
M&3Q<W%1:6FVGG>WH8=EI%POB*75[B.UMW:#R2ELQ;S3D'>Y('/  &#]:;IT'
MVSQ/?:P.85A6S@;LX!W.1[;N/P-;<T*7$+Q2@E'&&&2,C\*5$2*-8XU5$4!5
M51@ #H *'B&T^[5OD#Q4FG?=JWHAU%%%<YRA1110 4444 (1DCKQ[TM%% !1
M110 4444 %%%% !1110 4444 %%%% !V]:*** "BBB@ HHHH **** "BBB@
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M<,P^1V&<<G@U9;PEX=BM)5.FJD8/.Z4[NHXWD[AZ'!]?J<GE%%.WM'_X"O\
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MHHHHK$84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+J\D3?$?7D8X>.*/
M=N7@JR0[1UYY5^..ON:J:@S16T)CC0R+?6>%"YW$7$?&U03GH"OY#@5+K(;_
M (63XA\F0Q-)'%%-*DC*Z(8XMI7'\7$@!R,9S\V-M2&*-GC8BZ98Y$E16O[N
M58Y$92IVM(P8@[<9';IR,?80:C"FW_+'\D<[ZD3Q7+B&>W6%)(7,L8GC<9_U
ML9+$$;0T3Y*@!@V,\Y%5-.M9;.[NFN+A[I9)[S9^Y9I 6FAR651A05MPX '_
M "V&,]:U%&TE0I">6N6R,DY8;<;1CY1UR3D\#C-(B8F>X8*)W159U'S-D <D
M#J-O'0X7 [BA5&KK^OZU"Q51Y(M2:6.WNE@-B(4"VDH'F>;O(X7G(7/3US[6
MO/9G\I8KB,F3RX]]M,@;J<9*!5;"]"3U ZXR] S/Y8CPJA=C;@6;).5QCHH"
MD_WNN.-U0/:SMYQ,D,T<LVX13P;1$I*[4#@Y"JW.]D8Y'J,F;Q;U&6?!=Q%<
M_$R:5!\YTM\DPNA*9MRI&X#*\MC\^]>J5Y%X/F@LOB)<S-;S((],$&R!6N J
MCR-F,+YA[\LH_/->IV>I6.H!_L=W#.4.'6-P2A]&'4'V->3G$'[6+2=N5%TW
MH6J***\<T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N8
MU7PU<22^=ILL2,':5$<E"CLVYBL@!."3NVE3SSG&5/3T5K2K3I.\1-7.<U/2
M-4U#3;AY[A3>"W*6\5NVQ8G(PSAC]YB,CHN 2O&22W3?#<L=QHM]/>72RV%L
MT3022!][,#N9W4+O;GJ1SUQGD=+16GUNHH<BT7^:M8.5'#> [M]$\%:;INI6
M&IQ7ENC"5?L,SX)=CU52#USP:L:]=+XETZQ?1%N;I[?4V1A&[VQBDCCD!WDK
ME=K8ZC!. <@X/8UR7@#/V'7">^N7I_\ (IKJ5:,Y5,7;WKWWT]Z_S_$FUK1-
MGPY]J/AVP:]:9KIH@TIG4ARQY.0<$?0@'V'0:E%%>?.7/)R[EHPGNB^F6DSV
MP)-^$,<F"0?.*[N5ZC[W8C'7UD\3#=I=NOKJ%D?RN8C_ $JFF5T32\JA)OUP
M%.!@R-SR?3GOGIWJ]XA)%G:8/6_M@?\ OZM=:2C6C;^9_F3T.3UGXJ1Z/J6H
M6C:0\@LW==_V@#?M'/&TX_\ K5?\\3Z_=RO&<SQ+$/-LPH*EHN!)P)!EB!R?
M4 CKP>H,B^/]56SMKV.Z::8^;]KAV\#)(5K9R,X(P"QS@<Y%;E]XH.DW-S<1
MZ7!*JRBT5OM_[T;0 1M\DCD0@L.3C;GC;CVIX",8P5"&KCW6NW=Z?(SYNYZI
M15'1=1_M?0M/U/RO*^V6T=QY>[=LWJ&QG SC/7 J]7S,HN$G&6Z-@HHHJ0"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \BU90/B+XDE7=N/V=#@@XQ"A& >_P Q
M_P#'>.N7JC*N3''N)[;3GKV/7J/?Z"F:FHC^(7BF?!)>2U3 .  ENK$GU^__
M ..U*#&%8.<(!EF 'OD@<\CIP <D\<FOKK_NX?X8_P#I*,.I&K*UP49)&;8I
M+N-H;<6X&&Y((YSSAE/4BI"7\TE0P;K^\=1P?;&WD \]AD$8! ;YJ^<RJ&21
M(T9T'S%>6'3&",J_4Y 7')J56,;LJX20#A0PP#QCDCUYQP.?6D[@-0JS^6T,
M@V*,.T9*G() 7IDC:01T&X=:;(V5^8%P><= .,$#U]/P_$-6:*666%.3#M+J
M,97=RI(V]\$Y ZCC%.,BO)A05)SGDX/IT ('S?YS19W L^!HO^+B:E<;@<V*
MQ8'0;1"<Y[Y##\N]>BWFF6-^4:ZM8I70'9(R_.G^ZW53[@UYWX(C(^)&J2AL
MHVG0H!GH52'MZ88<]3SGW]/KQ\UDXXB+3^S'\C2&Q1M-.-G,3'?7CP8X@FD$
MB@^NY@7_ #8CVJ]117F2DY.[+ '(S1114@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &);>+=&O+:.YM[B:2"4;DE%K+M89QD';C
M&:H^!(I8]+U)Y(I(Q-JUY-'YD90LC2DJP! )!'.:;\-$*?#?0@PP?LP/YDFN
MKKNQ+A1E4P\$[7W;[-^2)5W9L*H:KK.FZ);B?4KR*VC8X7>>7/7"@<L<>@J_
M7 >)-3\+6/CECXH=&\O3H3:130M,F6DE$C!0IYX3D]AQT-9X2A[:IRM-V5[+
M5OT_K8).R-F"\TR;2](CCUBWE6>\_=.A?]_("SE>'R#D9.XD9&".@J_XB_X]
M+/\ ["%M_P"C5KR]_%'@O3O%^GZAI>H)'IRWJS2PQPNJH\EO-&\@7:,#_4#C
MUKN7\0V7B/3S/8-YEO;:Q;6XDP1O(:)B<$ CE\?AGO7H8C!5:52$^67*]7=6
MLV]O78E235A=0^&_AK4[VYN[FVN#+<LS2[;N10Q;KP&Q@^E/O?AUX;U"[GNK
MBUF::=BSD7#C)/X^_2NJHK@6/Q2M:I+3S97+'L5[&SAT[3[:QMPPAMHEAC#-
MD[5  R>_ JQ117*VV[LH****0!1110 4444 %%%% !1110 4444 %%%% !35
M14&$4*"2< =R<G]:=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >0:CN'Q$\4E\,C3V@C5FXR+=2WKC^#MS@9Z"I6/3>K#Y03@
MMNSV)YY[@'V]<+4&J%C\0/%JR'$7G683G !-N-Q/!S_!P?\ &II1D@#:V00!
MTW!N  IP,=!C)ZYXQ@_7_9A_AC_Z2OZ]3G[CRORY9SB,DL-PX[]#@=F]\KD<
M9R[[VY3M]2KX.!D ]!T.1U['%1J LGF"/$KC<"" [ 9X+#L,GUQG'5J7=OW8
MVJ4&[Y7!P>_/;@8R<=>A[188]S*43+,8MQVJQ(&<X/4GD\=B<>F1B'F0_P"N
M);@E^Q/)_E^6>>.JB-//>58T624H)F"_,Q' R_!;:#@ ].F0.*:DZ#,N0"KY
M9F(ZCG&<=>#]<XZ=:2[ 7_ XF'Q'UD.#Y8L( ,@<-LBSVSTV_P#UR":].KS'
MP#N_X6#X@3_EG%:VVP@8!W1H3^6U>G'/TKTZO%S?_>%_AC_Z2C2GL%%%%>66
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37YC8#
MT-.HH XKP3JUOI?@K1["]BOHKF&V1)(VL)\JWH?DKH9]?M(8;698[F:.XD:,
M&*%BRX!))3[Y'&. >H[<UJ55OM-L=3B6*_LX+E$;<JS1A@IP1D9Z'!(S[UU5
M*U*K5=246KMMZ]^VB)2:5B>&:.X@CGA=7BD4.CJ<A@1D$5&+.W%U+<^4OG2J
MJNY&20N=H_#<WYFI(88K>".&&-(HHU"(B* JJ.  !T %/KGO9OEV**=]I5AJ
M5E/9WEI%+;SJ4D0K]X$8/(Y!]QS6$^BII%I:6ZSO,T^J0RO+( &8J% )QP3B
M,9.!GD]<UU-9&N_ZW2/^P@G_ *"]=&'JSOR7T):1KT445RE!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4F!G.!D<9I:* "BBB@ HHHH \?U"9O^$[\79P(X[FT(91DD
MFVY!!X( 3ID=><]I57Y4<["2 0K97)'49/+'A">OTYJ&^GV^,?%Z$']W>VK<
M2<_- ?X<'CY?\X-2HZ[,E@QQD_/D*#@<' [XYYW$#G.:^OL^6.GV8_\ I,3G
M%0LLI*D;VQN.3D[<[2 00.7;[H&<CVP[!_>?(!G[F5'/]W'8'\>I/UIJ.X:1
MV\[;E) &V@1CH"/E!!.>!D_=&. 12MN\OH_R$[NN1GUQT(QGG'4>U2]QF)J>
M1?VNR2^C06LTKQVUW+$K!#"JX4/A1@MR  >N6ZTT>8DF'U75@ PP1J%SDY/N
M^1WZ@=#3[T/)K4;Y<QM8S,D4B #/F0 D$+N.X_WL@=L#BC?*N AF\O@A\<C)
MX< 'U !]SWY [HWY(K^MR.IN_##*^-/$,1>9RMM;,6EN6F/*#C<W.1C'X 8&
M*]7KR[X;?\CGX@4H5:.TM%8$ ')4^GIC'/I7J-?,YR[XOY1_])1O3^$***:9
M$$BQEAO89"]\>OTKRBQU(#GGGZ$4<$=?RJ.W.;:,Y!RHR0<_K3MH!+1112 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(
MUW_6Z3_V$$_]!>M>LG6B?M.CCUOQ_P"BY#_2MJ'Q_?\ D)[&M1116(PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHH_&@ HHHH **** "BBJ>J:I::-I[WU](R6Z,BDI&TAR
MS!5 502268#@=Z<8N348J[8'A6B6<M]X?2^MM4U2WN;F%'DD@GV%G1-I:3@/
M(-WJ^!D[>*U9=,G\@&WU#Q$S%2887U G?)_=P%4]<C'&XG@@C!R-$U?1K30;
M&SDO4AG6*(!9(Y&/F$ \$J5X8\<\9]!6O?:IH:W%SIVHZE'"&VQS1K%*60,
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M6^V/E23AMH[CCDY_4;=4(+%(C#F\G>&(?NXGVA1@<=%!.!ZD^O45<,D9!!;
MQR<X'YU,;I:F]=QE+W%_7W(Q[FYN].N+R5[B>2)+>22%)ECV.X&[ *@$8 QS
MURQYQFI+FYNM.9T-Q]H:2!GC,JJ-C@JHSMQ\I+CZ8///%A--A(,<T\UROEM&
MJROG:IX/3!)XQN.3UYY.7KIT9BDCGEFN!)&8B96&0AZ@%0,9[GJ<#G@5-I&O
MM*6EUZZ;_P!=?\A(3-!?"WEG:=)(S(C.JAE*D CY0 0=PQQZ\\C%VJ]O:^0[
M.\TLTC +ODQD =L  =SVS^0Q8JT<U1IO0****9 4444 %%%% !1110 4444
M%%%% !1110 4444 %9&L'_B9Z #_ !7[=O\ IVG/]*UZQ]9_Y"OA[_L(/_Z2
MSUM0^)^C_)B9L4445B,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJAK.HR:7IIN8;=;B8RQ11Q-)L#,\BH/FP<?>ST[4
MFTE=E0A*I)0CN]"_17+7GB;6--$;7V@VT22,54C4TR<*6/WE4= >_P#];?TV
M]74M*L[]$*+<P),%)Y4,H./UJ8SC)V1M5PM6E!3E:S[-/\FRU1115G.%%%%
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M&MZ8J73B=P+2)9IB8W&$;[I&1R#M/3T-1CQ/HTJI_I#E7VE<V\F"""V?N]
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M[U&<8[=#_>Z@9-8D5BMQ!-%)<SA6^3+NQSE1PWMRV.O:KY:YF/EI>)(<G=*
MF6&!SC'3 /?KQP>:ZWFE.UU3E:[_ )5UMMS7W_JY@\JFG9U(]']I[JZU4;;>
M?X:G8_"M]_B#Q/\ .Q*I: J?X#^^)'ZYYYYYYS7I]>$>'M3O[>_UZ[LM0ECC
M$5LH6*%70 S2*"6., ,Q( '1NGRUN?\ "0^(B=PUZX+$9'^CP=/IMP?Y]*^?
MS?%Q>+DW%K2/9_979V.K"Y-5K4N>,TM6M>;_ .1/6Z*\=?Q?KL=XEB-=NS<N
M"_%K 5P!GKLXS@XX]*LCQ%XC1Y#-X@F1$C=SNM(1C:">?D]CQ_\ JKS/K<.S
M_#_,Z7P_B%O./_DW_P B>LT5X_I_BK7KV$7 UJ\4.DC M;PC.U21@;",9'\Z
M@U'Q=XATVQ:0Z[.7)VQQM#$2Q_[XSC_]76E]<A:]F4N'<0Y\G/&_S_R/9Z*\
MBM_$?BMXD>XUF6)V&&0V\'R-SQ]WU'X=ZK#QGXB.HOIRZW<-,B;GD%G!M0^C
M#''4#.>N!3^MP[/\/\Q+A[$-M*<=/\7_ ,B>S45X]=>+?$%G;-//KTX0#C%M
M#\QP> =G!.*-/\4^*;O3X+B?6)87F#,J_9X,%1T(^7([]<],]Z/K<+VL_P"O
MF'^KN(Y>?GC;Y_\ R)[#17C>H^,M>T^TBD;7YI))) H1+:#)4CE@-F?3\Q5^
M'7_$LMU!&==E"NRJP^R0[ADC_9QWH6+@W:S_  _S)?#^(C'F<XV_[>Z?]NGJ
MM%>)OXV\3R:P+.UUJ1DC&;AS;0C9TR!\O;I]3CWK3?Q)XABL9KB;Q#(GDLFX
M_9H",%6)_A_V1CZTEBX/H_P_S*GP[B(6O..O^+K_ -NGK"]/Q-+7C&G>,?%>
MHQR7!U5X("P$/^C1$N!P3]WG\,<YZ8X34O&_B>QG@A@U4SW4[86'[+$ !T],
MY)]SW]J/KD+7L_Z^97^K>)Y^3GC?U?\ \B>T45XMJWC/Q)IL;/\ V\[Y&(@+
M6'YVR03G;T QQZYJS#XF\6+86T]UK,B32.ZO&+6'";0A&?EZD-T]J/KD+VL_
MP_S%_JYB.52YXV?^+_Y$]@K'UCQ/I>A2K'?RRHS1F0;('<!0<9)4''XUYQI_
MQ#\3R7-U8QK97/V:1@;JX@;D;L $1G&?\#S63XL\0WVHWB/<VD"7DT'V:%(7
M) RS98YP0?FP.W7G@BIGC(\MXFN&X=J^W4*]N7R>OXK]#T\?$#PT45Q?2E'Y
M5A9S$-U'!V>H(_ TX>/_  NPR-7C[=8W&,^O'%>3(\?A_18_-;<R@_(,_/(<
M\=>W0].GKC,>B6D]FD]Y=2O'<3'<^25V#KDGU)_+\\9?6ZETK+^OF=[X>P?+
M*2E*U[+5:_\ DI[0GBWPZ^-NNZ=SZW*#^M3Q>(=$G<)#K&GR,>BI<H2?R->$
MV-L=8OGU:XS]FCDV0*PSDCGD>@S^);OR*GUV2"WT_;'#&\\Y$:$1+D^I''T'
MX^U4L9*UVB)<-T/:*G&;O\M/^&ZGOL5Q#<!C#-'(%.#L8''Y5)7#?"R&6#P]
M?)/Y8E6]*LL:!0,11CH !G^?US7<UVTY\\%(^8QN'6'KRHIWMU"BBBK.4***
M* "L76_^0MX;_P"PB_\ Z2W%;58NM_\ (6\-_P#81?\ ]);BML/\;])?^DL3
M-JBBBL1A1110 4444 %%%% ",=JD^E1"X&WE3G!)Q[5-7,M\0?"Z3O"VID2)
MNW V\O\ #G=_#SC!_*IE.,?B=C>CAZM:_LX.5NR;_(?XY=E\%:CP,NJ)@]]S
MJN/UKS*.1_,,GF,2&SZ$D\\>O)';O76^*?&OAS6/#<]I8ZI').\L)"F-EX$J
M$GY@!@ $_A7)CR^&4JW4D@@YSCTX_7MFN#$24IWB[Z'UN44*E'#.-6#B^9[J
MW1=R9>-NWL>@'W>W'&.G]/2HT)(P,')!&1U'J/UQ3O,X^\#Z,<D'/IZ_X4HW
ML>7W9[<9SV!/%8GH;!P64@'<>O.,'_\ 7_GN0\)GDC&0>!C_  _&E5N 96WD
M==V>OTZ\9'IG/-0LPPRMN;^\21T]_P#/:@$KLF.PD"10,$9(P ,X_+C_ #ZH
MFU2%8MR1UY/L?;_'\,BGA "1SG*G)&>N/\_CS2@Y);<-K=< 8SS_ (_YZT"\
MA=V(USSSCDG /M[<8[YQ30R[F5CGYL;,>AZ8ZYQ]>1Q1E64<ML )''J<8Z>V
M>,?C2YRW)W..3P6Z=>_KC\Q3"P9.\M&VXCY=RGH,>N>YQ_GBA2?E8DX.&9AV
M'?\ SW]*3:P^8G/'4$9SP.OUQ_3%.W?*<. ,YP.><],9]1].@]: $7:%!)VD
M8!W<_7GUP.E("$B5.0,<[<#M]?8=/0TKX!^]P0>^>W^?SZ4A; ^1OFYW;2"<
MXXX_S^?%(!6"XVYR021G"XQU_KZ>F.A$^G*7U;3U"J +NWX ])5;Z_WO\YS%
MSU#ITXSU![?Y_P *N:!'O\1:8H)(,ZGYO92WI_L^O:JBKR1G5ERTY/LFSTK7
MA*="O?)\C(A8LL\9=&7'S @,IY&1UKPM=9U-[/S592P*9S%O+ J2>OT^OOZ^
MZZW(JZ->Q[AYDEO((TS\S':> .Y^E>,)I5G!8P&YL[Z(>7%YIDMI\"3: ?X<
M$Y)_I6V+3<E9GF\.RA&E/GC?56TN/GU6/3?!MOJ-TT[O<W3V\VR0L[@^:JA0
M3@%=Q(QCW[5WMO.+B,L!(FURDD<@&X$=B,]?0\Y!XX-<2ICMM!T6W>.79)K7
MDQH8LD(Q?J&QP5+9SV)]\=9<:+IMW<>?-IMC)<LP)DEME=CP >?O9P,#GC Z
MUZ:5+ZE14[IZZK7JNEUYZG'BW)XVJX[7_KN69733K4M++,T:L2S.V]F);@#
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M8,S,QR22 .]:%>I3BXP29\-C:L:V(G4CLV%%%%6<H4444 %8VM?\A;P[P/\
MD(/_ .DL];-9&K<ZOH(YXO'/7_IWE']:VH?$_1_DQ,UZ***Q&%%%% !1110
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M3\K!ORX ['GMV6X19KJW@EC0J%\XAFY?Y73"@ YVEE/;C'KR[[!;@Y\A.O\
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M7''/0GO65*1K^M+;IEK&U.68?\M#]<]SP#GID^U>?=Q7FSM48U)6O[D/ZO\
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M7&.*^SXJRY8?$K,,.[QD]?*5DU\FM3P,CQ?M:+PE56:6GFMOP9C^ )5?06+
M^9'*85;)SC[P ].7)Q^-=1LC299-GS;/+#9)PA.[IGI]0#TKDOA_(T3:KIXY
M2*8;?4DY!_1!^M=B7'E@C ./Z?R_P[5XO$$%',ZUMF[_ /@23_4[\HJ.6"IO
MRM]VGZ#&@C:17^?Y<A1G@@^H[GC^?;(&_P""H5_X2V(XY6TF;<>OWHA_[-ZU
MB!LR+RNX-@#''I^7^>];?@DO'XEB98F=#:R1L5.=F6CP?<9 'MGT!->53MSH
MWQKE]6GZ/\B_\3FF:'1K:"2X22:Z*CR'*L?EZ=?7%9,_A#1TT6YU*.\U.V@@
MN4CB#W>W8F44[OE.W&6(]L9':M76_&UI%J.D!X[&2'[06G9)%FEMP,8(4 E3
MSR,9QN P>11FU6YU+1M88:FMU!"8E*>7+$RN\D>TG>G?:QP,[=WH0%TJ>SE.
M3W_X8XL(L71H4H).*OJ^]Y6MM;RU?7S.3TBS:]M-)G&D:C.;1Y7$D$<RJ1)O
M5\.@.6^5!V'##VK5@N+2*0V=G9ZY%,69ILM<R>6I(+-L8G))88XQEN?0^A>!
MA;CPC:BSQ]F\V?RL$_=\Y\=>>GKS6/HWVMOBSXCD?8+*.%8XF.,E_*MV?W
MV=>.3COCV<%*M4H<O/90C=+6V_:]GK)O_@'CYCB:7UNH^1W<G?77?TTV_K<\
M=\/7>K>'[75I[FQCNGU=5=?,A#1N_P Q*N"R *P=P<9(QTQP=C0?$T,-]'+=
MJR"&_G?R5C4_N70E9<!SF3("YR?E=LY+&O2_"W_"5CP=HKVG]B/"UC R+()4
M8@HI^8C(SUY ZU:U6]\4);V\=UI6CGS+N!4,>IRCYA(&&08.GRU[6)Q,ZU2<
M&H^\[-IV>UEH^R['G4ZM*"3Y7IY_\ \_@FMTTS1YX;75I4-\XR(Y6AEC/G(
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M-4$IA)EC=)=[9S(<2%\ENYSD<'-:O]B:N(E"^+M3$H!)=@2P[]#+M/7'W?\
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MX;_1Y3S[?O*:^L>*!( )='"=]UM+G\O,]>*F3!_BR/IW]A_2HI6&>&PI&/E
M'TQ^73_"C7NQI0O\"^X:VL^*-_RS:)M ZF"7/3_?_P _@:4:SXG$GSOHJQ]?
M]5+NZ_[U.) QR<=0.V,']#_GO36W'H 3V#'Z?Y_PI:]QI4W]A?<<?<>.?$W]
MI?9SJ,,31W+VDJP6RNH<,VTC(SAL$#_=S3;K4-2U&^M9=4OS<10QSL,0JH09
MC4DA2NX'.""0 ,]>165-IE]+XLNG6TOY(6N99]D=H[B1/-)0@8P5)"G/ _6M
MF+2-7O=4BL8+&03"&1IQ=*Z1QERA7+;?F7,?0?>PPXYKD3G*Z=V?1RIX6CRR
M@HQTU=DK:/K;Y?<B;2-/T=]3:%;$7C3QK);6\UPRD)F8,1\Q&240 _[0Z9.)
MO$-CH,;6[V#2V^\S!DNDD92JQ%@R;S@*I"GC (/7 Q2CPYJ$.H-:7SP+'&EK
M%(+:5B#'+<2 ;<X*L"?R7K@D5JW.B"YO;^W-QIMC;VDX!O9(1Y]Q+)#E]Y#*
M.?-)&/Z5JH/EMRGGSQ$%7]I[5M6[MK9)=^Z>BOU](3I'AN*$78TY[MH@LL][
M<S.ORY7<T8+9)Y) 7@$8SG /)?9M/>YF>T#- )Y/)?SW/[L2-MYW>B\8]C70
MW&DP1Z/KE_%=0N]E-Y$<EC&(XY-Z)O+ ,<G$I7KVSG)-8D(<(V)2^Z1\G)8;
MBQ]23G)/4DGO45%JE9(Z,))\LI*HY:VU;[7_ %7;T*-[#'9V%Q-;M+%-&ORR
M+,^=V<X.>O3O_3)WQXC\3JS9\0.W)49M(>...B^_KU%8]_=/#I\L\$F-D9V.
M"#G..A[CI[<5-<7<$$(N#<)Y3EB'W95L8SP,DXS^A]\0GRO1V.J=-58KGBI:
MO=)]NZ9IZ5X\\2FW<M)IUVJR.HDF4J3CW3Y<<@]#WY]+=QXT\0SV5S%-:Z5M
M>)DVJT@/3GD^U<[9%F6=W\Q-]U(PWHRYR1C@^W3@8Q5B4 I@/M+)MRH'&<@]
M1COT]JI5)V^(PJ8/"^TNJ27R_P CH!XY\1 _-::2QZ !I03[]/0'M5.7QIKC
M:]:3/9:82D$P0+))C!,>23M]ACZ_2L]W5FV_,0V,=]P_SQ]:KNP_M2W()Q]G
MF/R\C&Z,\?3D_A^%=.'J3<W[W27Y,Y*N"PRC?V2W7?NO,Z5_'/B(' L]*!/;
M=*V/K@=>GY'\&/X\\21)N:PTQL'D!I!@=,^PSG.?2L7JV""&&<XS@?YZ?7ZT
M9QPS8;.>,#'W2?T_SZX>TJ?S&BP6%_Y]+\?\S<7Q]KWE!OL6E2%L$;)9!P1G
MTY_"GV7Q#U&;6+&QFMM-;S[A(7\F9RRACC(!'IS7)133Q^79M:L6$*@[)5&?
ME"\9.>WIWJWIC2RZEI,CKA3JB9#2DX;SCG"@8'.>_IUYP*M4ON54R["*+;IK
M[_+U/:****],^&"BBB@ HHHH **** "BBB@ HHHH **** "BBLOQ'JRZ%X:U
M+5"5S:V[R(&Z,P'RC\3@?C50A*<E".[T!NQ\W?%_Q NM_$*Z$  CTY19HZC!
M9D)+$_1BP'L!7O5KH>F^,?A[H]MK227T4UG!-YLK$2;S&/GW#G=R?S.<\U\Z
M6'AF34/AUKOB:0;GM;R%%D+$L<Y$GZR1'/L:[*_^)4<'P7TS1;6X5]6N(6LY
MU4\P0J2O/NR;0/8D]J^_S' RJTJ&'P;UIRY6UT?*FW_GYG)"5FW+J>D_#_P;
MX.T*6YOO#FH#4YF'E/<FZ28QC@[1L  S@'IFN[KQ']GA?W/B)O5K<?\ HS_&
MO;J^3SNG.ECITYS<VK:O?9,Z*;3BF@HHHKRBPHHHH *\5\*F71/#,>KN)GT^
M1W_M")5#^2!M"7"J.N%VAU')4!L$J<^U5Y%X.UO3;'PQ:0WE[!#=(2Q65B2H
M;D8)']QNG;..@P/9RSF]C445?6-UY>]_7K8SGNCKBP9?E,4B%=Q=3N5D(X8#
M^($$=^1S@XK-\0V%EJ>@7\=[:17"+;2S(&&[:ZQL05/8_-GC')ZXZX=CXCTO
M1-1_LE-7MWT><-)92&4$6C<DV[$XPO=&/NO/43>(?%FB?86MFU.VGBN%DCG:
MSN87F6,(W \QPH)W$ D,>" N6&WLAA:T*L>5/NGJO^&??\">96-+0[N=[?\
ML_4G3^TK6"-LJI5;F#'R3*I'N%<#[KCW JQ?V7V[0M0L+5%22YMKA%C4<;Y5
M?)_[[8D].<_2C4M,-]!!]E=([^U(EL;B1,["5VX;UC=?E<?S*BJQUBSU/PSJ
M5W/9DPPP7*7]F),M RQL98B5(Z_-M;N"""#P<_B:J0[JZ[/IIV?3MMVN_)D^
MH6 \0VDL:B>SO+:YS%(T8,EG<@*RD@%E(*LN0"0RMZUST.JRZCXX\,6<UL+:
M^M;BZCU2U'(C.(&1USSY;.J%3WSC)K1TOP=I6E)-:+IJH'F:1HX+J=DB^55
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M8 'S$<<]B>#G/.!G\*0!2"57KSRQ;C/89X]?YYI2P&T!3UY)!P>%QST__6*
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M!GCMZ4E2J=ASQ^$:;51?CV]#T2BBBO3/B HHHH **** "BBB@ HHHH ****
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MVZ%DD4JRDJ,@@\@^QYK1HKLQ&+]LK<MM;[DJ-@HHHKC*"BBB@ HHHH ****
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MOY95Q@#?MY!Y#!AV%=25:<)SE?X97O>WPO7_ #\_71:+0]CHHHKY(W"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3DL00
M-O&"#S3<R>9C:I3'WL\C\*!V'T4ASV )SWI%#!F);()R!C[HP./Z_C0(=111
M0 4444 %%%% !1110 4444 %%%% !7.:WJ4.D:[%?W"R/'!IMPQ2)=SN?,A
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MJRC*%MONU^?X:!%-!1117 4%%%% !1110 4444 %%%% !1110 4444 %%%%
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MS  X!/)Q2@Y./3VH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P !ZZL?56/4:***^;-AH=2[(""RXR,],TZBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ K%MO\ D=M4'_4.L_\ T9<UM5CVR_\
M%9:H_KI]HOY27!_K6U+X)^GZH3-BBBBL1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'FOQL\/G5_!7]H01EKK2Y/.!49;RSPX'M]UB?\
M8KF_A+X8N/$6D^*-5UV)F76P81,R;6<L6:1P,8^\RD$<94^E>W45Z]+-ZM+
MO"176Z?5*Z=E\U<S=-.7,>:_!HWEAHNK>'-05EN=(OFC[[=K#(VY[$AC]&%>
ME4P0Q+.\PC42NH5G Y(&< GVW'\S3ZXL9B/K->5:UN;7Y]?Q*BK*P4445RE!
M1110!C>+C&O@S7&F7=$+"<R*.I7RVR.HYQFN&T7P)_:]M'J:ZI=6DO*HJ33Y
MC4\[0WG9Q\QXSW/J:[CQ@ZQ^"];D9 ZK8S%E)X8;#D'V-<MX?FU./3-)^QZ1
M?SVUO=M+(UM- L<B&&1-J[I%) =@?F Z9'05[."J5:>$DZ4N5W\NVVIG))RU
M,FY&D>%_$KV'B36]4:U-MYD4B7M[EG+#((21L8'?C.?:GW&O> [N$6VF^)-7
MBO&9?*_TW4<G# E>2<;AD9P<9S@XJW>:GJ@\>W-Q!&=*=K!?,%^L;@(F]R<I
M(57.!R3Q@Y'>J?B?4=6UKPRUO<7,7V2XN[>">";3_*G7.V4$#S&VXP!\ZD'D
M_=Y/HPCSRINI)W:5[2T^[E:?WZ^1&U['7^$;C1K?P4E]90QV]IL>:Y(;S&+
M?,TAP&9R "<C=TR.U3>#D1=)D<6DD4LDN^6=X?*^U$J,2!<#:-N!MQ\NT@9
M#&W<:,%\.7^G6SEY[J"17GF(W2R,NW>Y QGIT&      *QM"U;Q/<6)MTT/2
MP;(BU=GU9OF957.-L!'?!YX(([5X\E[:%25-[OJUMTWM<TVM<["N14K_ ,+=
M<'?O_L/C^[CSAG\>GZ>]:7VKQ5_T!M&_\&TO_P C5C:?)=O\3BVHV%O;W;:0
MP#6]T\R[!*G&61,$EO3MU/03AZ4H*;=OA>S3_4&]CM:***\\L**** "BBB@
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M* .3^)"E_!4Z X+75H!R1_R\1^A!_(CZUL^'5">&-)4# %G"/_'!6#\3V5?
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MK_@?YHF70[NBBBN H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!,C<!W/M2T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6/H_.K^(.O%\@Y'_3M#6Q6-HI)U;Q&,]-10#C_ *=;>MJ7P3]/U0F;
M-%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#S_XPX'@@[MV/-;[H&?\ 4R^I''K[9QD\5WR*5C52<D
MGUK@_B^,^"B ,DR28&[;TMYB>Q[ G'?';J.^KT*_^Y4?67_MI"^)A5>)KPWE
MR)HX%M1M^SNDA+MQ\VY2H"X/3!.?:K%%<"=KEG&6'B[5-0UNXL+>QLB5DNDB
M$EP4W&&79R0&/(()^7C('?-=C)&DJ;)$5UR#M89'!R/UK,TSPWI6D:A>7]E:
MB.ZO6+3REB2Y+,QZ].6[=@H[#&K71B:E*4U[&-DOZ[LF*?4S)= TUYGGB@-K
M.[;WEM':!G;U8H1O^C9%<=IRZC;_ !1U>&WNOM;QVF__ $M0N[(AXWH %Z?W
M#TYZUZ)7$Z9\WQ;UHC=\MFBDY&.D9';(/7J?3'>NG!U9.-7FUM%[^J%);'6V
M<US-&PNK3[/(IP=L@=&]U/!Q]0#[59HHKSF[NZ5BPHI #DY.<GCVI:0!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6+HG_(6\2?\ 813_ -);>MJL71/^
M0MXD_P"PBG_I+;UO2^"?I_[<A,VJ***P&%%%% !1110 4444 %%%% !1110
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M+C\:M44XNSN 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %!.!D]J*K:C(8M,NY%SE(788Z\ TXJ[2 ;I0QH]B#VMX^_\
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M '@8[2 ^TA4Y88+"0KD5VE>3F'-]9ES.[T_)>2_(TAL%%%%<104444 %%%%
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M/0UPU(W]^.S_ #_K^MREV):***R&%%%% !1110 4444 %%%% !1110 4444
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M#U.1F+;KC4PR^2Z^7MDM(U&\\-E8U.!TS]*]+KSCX>W<-SK=]-&LBK>27M[
M74?O(WN=H88Z?< P<'TXKT>O2S72ORVV5OS_ .&(AL%5M0O[?2].N+^[<I;V
M\9DD8*6(4=>!R:LT5YT;7UV+(+*[AU"QM[VV8M!<1++&Q4J2K#(.#R.#WIM_
MJ%GI=F]W?W4-K;)C=+,X51DX&2?<U9J*YM;>]MWM[J"*>!_O1RH&5N_(/!JE
MR<^NWXV EZC(HHHJ "O-=6M[2Z^.>BJL%L\D5HT\K*JEPRK(!NXR,;D()]![
M8]*KS1=(MY?CNL_FS%X+26^()4@R%(H<< $ (0>IYKT\L:3JMNWN2_(B?3U/
M2Z***\PL1E#KAAD4M'>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *J6I#7=\>,B95S[>6IQ^I_.K=5;,?OKQ^<//D9'HBK_,&
MKCL_ZZ@6J***@ HHHH **** "BBB@ HHHH *\J\7^'KNWUB*"Z\7ZXMIKUX]
MND"QJ]O%OSB-M[  $$@ #)P<"O5:X+XI1:'-I6GIJ^FW>IW#W!2RLK20H\LA
M7G)'. !R>>HKTLJJRAB5%=?)-_CIH]=T147ND_A#P%>>$[B$#Q-?WEA"C*EE
M(N(P3WZ]N>/>LFXFUN*VM?[.347WVES%8BU4F(7;S,F^8C@*JL&&_P"7Y6[@
M52^&VG^';+Q5- /#NH:!K\=L9%M[J=I5E@8@%E8@9P>.GYX..B.LZGHOA>QN
MK.VTU[7SW%S/?WWV98E,I'=3US]?]DUZ%9U5B7S>_)VW48WNI=FT[][Z[$*U
MC0\*0S6][J\44FHR:9',B6[Z@\CNT@7$I4R?,4)Q[;MV.*Z>L#PUKDNN_:YF
MN='EBC*JB:;=FYV'!)WN57KQ@;>QY/;?KQL7S^V?.K/3\E^/?S-8[:!1117,
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHIDJAX9$9BJLI!8'I[T(#SKX5_99?MEQ EON,/+1*O&;N[...@VA./0#VKT
MBO/_ (5VKC18KR:16E.GV=N $"[456D7IU.)NOL*] KT<V:>-J6[D4_A052U
M?2+'7=+GTS4[<3V<X DC+%<X((Y!!'(!X-7:H:S::C>Z<\.EZF--NBRE;@VZ
MS8 /(VL0#D<5Q4FU--2Y==]=//373R*>Q<BB2"&.&)=L<:A5'H!P*I:OI*ZQ
M;PPM>WUIY4RS![.<Q,VW^$D=5.>16A5#4_[7W67]E?8MOVE/M?VK?GR/XO+V
M_P ?IGBBDY<Z:=GW![%^BBBLQA7EV@6NK?\ "ZM7DN9RWDQR%SORI@DV&)0"
MHP1M7./[AY/?U&O,O!FI2ZA\5_$TLD 0RVR!@&;,?EN8PI! P2!GM[9!S7J9
M?S*C7DE]G\VOTN1/='IM-8,=NU@.><C.13J*\LL0LJE06 +' !/4]?Z4M1L6
M\Q08]PW<,#]W@\G^7&>M/S[&G8!:***0!1110 4444 %%%% !1110 UE+,A$
MC*%.2!C#<$8.1^/&.E.HHH **** "BBB@ HHHH **** "JNG_P#'NYQC]_+W
MS_RT:K55=/ ^Q(XQB1FE&!C[S%OZU:^%_+]0+5%%%0 4444 %%%% !1110 4
M444 %<%\26MH;C0;I-=M=(UBWN)'L)+Q"8)/E ='8#" @CYC^'7([VN,^(R^
M()-)@BT+P_IVL*S,;B.]C601@ ;2JLP!.<^O3I7=EK2Q4+NV^[26SWO=6_/8
MF?PD?A71=<O-='B;Q%JFG7<JVQMK./3"3 J,06;)ZL2,=Q^F*^HD'P#I,HDN
M%O/MB2V8@@$\C2[V8!58JI^7=DD@8!]JYOX46NAP^+=1-O?:A'K A;SM/ELA
M:Q*FY1G8K,,@D8^;OTKI[R[M++X>:%/?P(ULLEL\D[NZBV .[S,I\P/&!CJS
M '@FO5Q,)4\6HK6SC;W;:6EHD]U^9FG>)J>"M:N]:L[F:\FF=@8VC$MM'#\C
MH'5@$D?((8<YZ@CJ#745Q?P[)6SOHFL8[:1'BWK&\K"+,:D0'S"2#&"%(4A1
MG@ Y%=I7D8^,8XB2BK+3MV\C2.P4445QE!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4-;6]DT'44TW_C^:UE%MR!^\VG;
MR>.N.M7Z*J$N62EV \P\-7/B;PO:-:R^'7FA(@15$\CM'LB2,\K!\WW<]<#L
M<<UO#QO?H[";PAK1"-@M#%D>Q!?9D9KL:*[JN,I59.<Z2N_-_P"9"BUHF<;)
M\0[>#?\ :- UB#8 6\W[.,9]O.S5:]^*.G0"+[+I]Y<G>IN  #Y,!X,OR;L@
M':,=<L.]=W7!?$"[:SU?1YPJ,88GF"R-A,K=69R?3C//;-:X/ZM7K1INEO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH AN#A$&1EI% ![\Y_D#4U%%.^@!1112 **** "BB
MB@ HHHH **** "O(IO'6MPW6IZZ=/TH^%=/U5K"=%0_:2-R@RC/!/*G'X8XW
M5Z[7CUY\+_%\MIJFFVVOZ='I5]?/>-;M!N.XL&&6VY_A7C..*]C*?JUY?6&E
MMO?:^MK=;;&=3FZ'4>#+[Q+KVL3ZU?Z9!I6AR0,EI:L@$\A+*1(_&>@;TZC@
M_>K+CLO$EQX>T&32S?-;_P!BV@B%K=I"J,%S,'#=6>/:J'G:W/R?>KH?"^F>
M-++499/$FO6>H6AA*QQ0VZH5?(P<A1QC(_&J:>"$OO#VAS2H(-8L].M[=UFR
M\;!5&8W4'L2V&4@@]R,@ZNO2A6D[QMI:R;6S[V;\W^@K-HV/"0N6LKF9UNX[
M*:4/917ES]HE6/8N27WOD%MQ W' /7! '05A^$= 3PUX9LM-"1+.D2?:&B)*
MO*% 9AGGG'H/I6Y7E8J495I.+NOZ]?S-([!1117.,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gzirfjcguvpf000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzirfjcguvpf000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" D."[@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]<+5M&><TT[,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_5GM\3_[XO\ "OS85X[\3D"^*58#EK=2?S->Q5X_\4/^1GC_ .O=?YFHR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-1TVSU6T:UO
MH%FA;LW;W!Z@U4T72KK2/,MFOVNK$ ?9UE7]Y%ZJ6_B'I6M16BJS4'3OI_7W
M&JKS5-TK^Z^G^7;Y!11169D%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!@ZCX?EUK4&.I7K-IB$&*RB&T/P.9&ZGG/ ]![UM0PQ6T*0P1K'
M$@PJ*, "I**TG5G.*BWHNG]?F:SKSG%0;T6RZ?\ #^>X4445F9!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2'/89I:* &[F_N?K2@GN,4M% PHHHH$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 457N+R*WR"VZ0+N$2<N
M1G'3Z]ZI2ZI<JKM'IUPX 3;T!;/7OQBJ46S6%&<MC5HJ@=194!:RN<DD85 >
MAZ]>]0R:Q]F17NK2XC0HK,RIN"DCD''IWH4)/1#5"H]D:M-9=P'/>F07$-S'
MYD$T<J9QN1@1G\*EJ6K:,R::>H4444""BBB@ HHHH **** "BBFNZQQL[G"J
M,D^E #J*K6-]!J-LMQ;.6C;H2,59IM-.S'*+B^66X4444A!1110 4444 %%%
M9Z:S8S7+6]O+YTJDAA&I(7 )Y/3M346TVEL7&$I7Y5>QH45ER:U'%+%&]K>;
MY -H$)/7U/059@U.SN+I[6.=3.@R8R"#C\:;A)*]BG1J)7:+=%%%29!1110
M4444 %%%% !137=8T9W8*JC)8G  K/BURQN9WAMI&G9%9B8U)'';/3/I5*,F
MKI%QISFFXK8TJ*SEU0M<&/['=;05&_9QDC)[]LTEOKFGSOY9G$,N,^7./+;K
MCO3]G)[(OV%2U[&E11FBH,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI:_:)KJUGEMKF5 K.IW*<8QE3QQC'&.IJ>RN?M,;95PR,4;<NW)'MZ59JG/
M8[V.]60(JJ4F#,=I3!(./4''/H3[55^969JI\ZY9?+_+_(N44@(90P.01D$4
MM28A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2'=GC%+10 WYO:EYI:*!B9;T_6D^;T!IU% "9;T_6CGTI:*!#-S_ -S]:=DX
MZ4M% [C26[ ?G1\V.U.IK'L.M "C/&<4M-4;13J 84444""BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"BBBI, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0G ZTB].:%^9<D4Z@?D%%%% @HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:J[>Y/UIU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 (<Y&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,\X
MHR,XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(S^5:M9VJ[2]AN;:/M2\[L<[6QS]?SK1JY6LOZZFU2SA#3I^H4445!B%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %-P2>3@4@8LV /QI] ]@HHHH$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2;AG&:6F[!NSZT#5AU&.:**!#>-V>])E,[J<5!
M_+%-$2A<4%:#Z***"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 0]*:BL"23G-/HH'<****!!1110 4444
M %%%% !36Y&*&/0#J:4#% Q:***!!1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *P/&/\ R+<W^^G_ *$*WZP/&/\ R+<W^^G_ *$*WPW\>'JOS.K!?[S3
M]5^9IZ7_ ,@RW_ZYK_*KE4]+_P"09;_]<U_E5RL7N8U?XC]0HHHI&84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBSM<MPDE=K0DHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***1B%&30 W=N;'YT^FJH'.!FG4#
M84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?4UQGB[3-1$\FH33)+:!@J*#@H#TXZ=3C(]:[F.1)HEEB=7C<;E93D$5F^)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M17%O%<PM%,@=&Z@BLC_A&UBXL]0O+9,8*(^1U]_K6Y15QG*.S-:=>I35HO0P
M!X;F P-9OL?+W';IVJ=-"+;EN]0N;N(C!CE(Q^E;%%4ZTWU-'BZSZ_@AD,,<
M$2QQ*%1>@ X%/HHK(YVVW=A1110(**** "BBB@ HHHH **** &)$L98J,;CN
M/UI]%% -W"BBB@ HHHH **** $(!&#T-9TVC0'S6M&:TFDP&EAP#@$?AVK1;
M/84M-2:>A<*DH:Q9B?V'>?\ 0<OOS7_"M*VM/)M?(EFDN,@AFE.2V:LT54JD
MI*S+G7G-6?Y(9%#' FR)%1?11BGT45!DVWJPHHHH$%%%% !1110 A (P:S[K
M1;6X:.2/=;S1*522$[2/\:T:*<9.+NBX5)0=XNQB?V'>?]!R^_-?\*N2:/:3
MM$]PGG21J%#.<DX[GWJ_15.I)]31XBH^MO33\AL<:Q($0!5 P .U.HHJ##<*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "L#QC_R+<W^^G_H0K?K \8_\BW-_OI_Z$*WP
MW\>'JOS.K!?[S3]5^9IZ7_R#+?\ ZYK_ "JY5/2_^09;_P#7-?Y5<K%[F-7^
M(_4****1F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2,/W9R:8A&(W#*Y]Z?N^;&.U1N 2 <T\??/TI#>PHSW%+113)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^%5M0AAMK"6:#3[5Y$ 8*85Y&>>WIFFJV$;LJ;^\<5@Y-)4]_-E;_A/(?\
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MR2IVNE &#]:?,A.E)%FBJPNE*$D\U+#)YB;O>BY+@UN24444R0HHHH ****
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M&<$'UI=WT_.H0.2<T?6BX^4GW#UI-Q],_2HFZ<]*:0WF9!PO>BXE%%C=1D5
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M_.X ]*+]AN+D_>T+E%,CD$BY''J*?3(:L%%%% @HHHH **** "BBB@ HHHH
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MHP<@8 [4B[I]!$D,C[F[5*0HQ@U"K*68JNT8]:>OWCQS3$T+NP,8&3WQ28Y
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MVI\S#VDOZ16CMI$1R;B7<6RN<87@\>XYIJVDIA"R7DK':%#+A3TP3^?-6-W
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MO,L0H#>6."#R>O>IECF$BL9\J <KMZ^G-3T47$ZC?_#(I&RE9XW-Y,, !PN
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M?+3^Z/RI]%49W8SRT_NC\JJS@+<Q@  8J[5.YYNHQ[4F73;N/:-5^;<?RIA
M R'^;ME:FD"[0&;C/I43! AY)(]J3*BP$.80X(W8STXI@.]0=@YZ\58.8[;M
MP*8%:.-510V1DDFBPU(B?;Y+C SZXIUH%:-MR@X-.< *'9< \,,T^)5 8IC:
MWO1U!OW23RH_[@_*FO'&$8[!TJ4<#%(R[E*^M49)NYG( $SOP#U&*MVQ!CQC
M[O<BE6WC5 II$;]\40#8HY/O4I6-)24D[$V!G.*K,EMDD]?8U/(S!?D&YO2J
M2QEI\%UW=<"ABIKK<E2 >67V<]0":@F8X P/P'2K2FYS@A0!WJO<9^[D$@\X
M%)[&D&^;420E!"P/\/>G+*&=02,'.[(Q0^T-%YF<!>U/1()3M 8'KS0#:MJ1
MIY2-B0 KV(JW&\> J$8["J?D8DPY*J>AJU# B<AMWO35R:G+:]R;:/053E -
MPY!(P,=,U=JIOV3R$HQ!QC ILBG?4A5 C]R".XQ3^#W-+)())$ 5AUZBD*D'
MG'M4FM[[B\_W1D].>E'?*X_&DZ..: 0 !0 O7/J: 3WH//4@<\4@XZGI[4 *
M"I(!Y]J3!(W<FE50".,'N<T@)' /U% >@N3U_P#K49&/0BD./XP?P-*  .>_
M;-  ,'.<YSTH.0#D<#I1UYQ@]N:&<,,9/OF@0F<<%N?:E..IXQZTFT;B>]*?
M<YH&!!R"!1M//'/6E#8[T,3GDT"U&\?4>M)R2"6QCM2D87V^E&!U&?>@8O?_
M .O1C)Z<&D(R>HSWR:4$CIVYH 4]<8/Y4W)Q@_K3MQ)W>]-SD]0?I0)#_FVD
MCI]*C)XSVS4@D(4CUINW<,=LYH!>8C?ZML?A59>H^M6&(\MO857'4?6DS2&Q
M87J?6E'(/%(H.6]_>G9QD\X:F0P [$#/J11Z^U!R>!C\:,8]>>M @W _,>E'
M.!VI."A7MGIBE.,^E Q,8.W'3UI2 >#C\:#GGC.>M(=I^\#@CM0 O\6!WXHQ
MM.#^- Z<?A1N)SN_.@!3D_PXS2'GG -+YC$8(' ZTA(#<&@6H?IBC&0<'!%*
M#R<C)/6D&1N ].* #HOT[T[DD9.:;CY3DC-#8/K[T &.F<=*4''3M2<\9[4=
M#\O/K0 $]?IUI%QM]SV-+CCZ]:#C(R?I0,3.0>>@Z9Z4N[JN,X/!HPN[(YSP
M>*0?SZT +SC@D9-'3DM@9H+;1D]C1P0./>@ ^O(-!! R<T9RN,X ZYH)) !!
M [9H$&/F]Q2@<]>,=Z3/S9SR3Z4C8XR>!Z4 +UP._:E/=B1D=,4W'3![<4#.
M,-T)YH&*%P0<=>:3JW;\Z=N/ )&!3>-V2>:!"X!]>.U' &?UIP/7'?N::<,
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M!ZF@!WJ?44A&5ZCT-#9QQU-*.F.E A1CH,8/>@-D=,A:;A@"!UIQ^X.,&@&
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ML;20=.U*ZTQ\B%B9K4GHRG[P'T./S-;KWZ5NL=?EU_KU.E2]I1<'O'7Y/?\
MKU-D=?J:5CUXV\4@]SWI&;8V<Y].:P.;J36Q_P!&Z4-G;@=>*2VS]GXQUI6)
M"# R:?0A_$S/T[:+O5"K*W^DCE<<'8N1QWK14Y4''2J%D7%WJ;/CB=<8]/+2
MKL;B16 ZC%74^+Y+\C2MK*_DOR0[.6Z'Z8ZTN,H!D\>U!'R_6FC._)_2H,A1
M\N3G(/- ['TJ.>7RYL#N,U)NSM(Z$9- [.UP&<\\=Z0Y.1GD]J<?O=>*=C&,
MDXH%<: <=Z.GTIL<JR<8&:=@'KC&<\T [IZA_DTT#@[>]+VY/>D=P@!)ZG%
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M^F*<;3Q&B2%+VUER/ES&!R>N..P]?7O6D;BZ(V'36V\Y)E3MTQSW..M'VF^
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MQ4\>F/K2J0,Y7/'%'U'#W^ /J&&_D-D>*=5P3Y\0QR 8AS^E"^*]5#JQDB8
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MOJ$?7T/^%1C2+Z>)@VLLRY^Z]I&<_I2'2+^1"AUER&&TC[-'THY,/_-^+_\
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M /";:@58BVBX')YXJII_BJ[TZT%O'#&PW,V23U)S_6L.BFL#A[<O+I\_\QK
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M5)?'%[N&ZVBVYYP3TJEXAT%=%>(QSF2.4G 8 $?Y]:Q:].A@L+4IJ25[^O\
MF>GA\%@ZE-3C&Z?J=0/'%YSFVCZ\8)J1?',_V@EK5?)YP WS>U<G16O]GX;^
M7\6;/+L*_L'81^.FS^\M#T[-WJJ_C>^+_+!$%#9P2>1Z5S).<< 8&..]/9I?
M+7<[%", ;O2DLOPZ^S^+$LNPJ=^0]$\+ZM<ZK9R-<^67C8+E>"?J*WJY3P,I
M_L^X;*X,@X"C/3U[UU=>%BX1A7E&.Q\SCX1AB91BK(****YSC"BBB@ HHHH
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M6!J.W5+NWN;8>9;6D$I:;^%F8  *?XB,<]A^E70E:7-T2?Y,TPDVJE]HI/\
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M[F_"G&-&Z,WOS2K]W':A>.AH"[$^7C'!QP*;)CRNO?I3BO(P.E+L#C;G@=Z
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M^T&P<( .,\"A0$0*/N@8%& !QS]*^7Q&)GB)\T_^&/E<3B9XB?-/Y"9!)&T
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MC=/L[9]/-?\ QK8&?F (I< MTS[T?6J_\[^]C^MXC^=_>S&_X172/^?9R?\
MKLW^-3V>@:?8W*W%O"RRJ" WF,<9&.YK3QR>Q]J/?/O2>(K-6<W;U8I8JM)6
M<W;U90?2B2Q_M"^1BNTD2CU!R..O&/H31_9K&82?VC?$AP^T2#:V,?+C'0XZ
M>]:!))SW-(/EZ$9J?:2(]M/N9O\ 9)";3J.H$^7LW&89'.=W3K4S:9%.BI/+
M-+L=G0N^"N>W&..>^:N;CTR,&C!/3M2=23Z@ZT^YFR:!ICHBR6BL5  8D[B
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M_?DQR?8>_P#+]*[B33#\LPO[E53:1'&P"G'8C'0]Q_*K$=O'8!+>"/\ =HN
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MJ\I6<GL^K[&9_P (GIYX^S.#ZB5N/UK/TC0;"[T\2RP.SAV4L9#S@D=L5W/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2;:6<VAWW!' !/W1DG!X.?\ )KK_ (9?#2>RC:_O7 \Y #@ X()X7^OTKL?
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M$.6.B1]'&,*4.5:)#(HY)Y%CBC>21NB(I)/X"NBTSPG<R2"2_0Q(K ^7D'<
M><X[5T>DZ1!I,&V,;I7P)')^]6A+Q%U.3Q7AXK-)2O&EHN_7_@'AXG-92?)1
MT7?J0'&[ QM'"@= ***<@).0 <5Y!Y9)$-L>3W.:<OWNO7M2N1QMZ=_:@X##
M8<TS*]R&,9D8^F:DCSYR]ZC3*N20<'VJ>++2*5&1W-)%2+E%%%:'(%,E!,3
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M5)*,%=ETJ<ZDE""U)-6U6#28M[N'E8?)$#RW_P!:O/KJYEO+I[B8@R/C.!Z
M ?H*2XN);N=YYW+R.<D_Y[5$3Q7TV"P4</&[UD_ZL?48/!QP\>\GU"M71M"N
M-6<OGR[=3@R$=?4"LT0S?9%N3&WDL^P/V+>E=[X99QH=ON/\1 X[=JG,,3*C
M2O3>M["Q^(E1I<U/>]B?3=%M=,E=X5.Y^-S')QZ5J(?X#W%0EY.FT_7%-W2;
M@QZCVKYF4Y3?-)W9\S.4ZCYIN[)> 3_*@\KZ=Z21I1*0I/J*9OESCO2(2;U)
MNHP <]Z&?=D8Z"H-\G3FC?)@C&!CGBE<?*<)XF4#66P.L:D_K68V^1N '(7+
M%%_$Y^F<?A6GXF!&LMDYS&I''3K66\C?,H?*OAF&,#/T]N:^LP=_80MV/K<-
M_!AZ'2>%T0ZI;;"'(M',FWG:=YZYZ<8Z?R-=)"UU8ROYXDGMG)*NB%FB] P'
M)!SU X[\5RWAG[1;:B& 5_,M&:-&;&1NZ#\03^9KK[;4(YIO(>.2&;LLBXW<
M=CT/_P!:O&QW\9]4>'F*E[9Z75B97BN4817*N-V"8W!P0>G%0VDEQ 4M+E7=
M@NU9E4X;'][T/Z5'<::CWCWL.Z*Z5=H(/RN/1A6/_;<UQ/<6]Y9RA5;"1Q[P
M[<XSD8X]\UR0IN:]W5=3EIT?:)\FJZ]U_G_6Q=L_,_M.=X();;3=K>8)8]@9
M\G)4'D#G.>E3P:?]FU2.YL=GV26(B90_5NJL/4GI]*@?Q D4<:W%I-"DLGEQ
MF5>&4]S_ (4EML^T7NASJ1"RE[; P"A ^4'N5S_G%:-3U=K*WK==_-HTE&I9
MMJRMZW6S?FT6;8P6VLSV2V^PW$8G#9)W8P#G/3FL::/;X5U>UCA53'(<)'D\
M!@?Y5>2XN/[/B*M*)+*Z43J_!>/D$GG'1MWX5"8_LY\01-(A9X7D5 .0"A'/
MY5<&XS3[-?@U^C-*=XRN^EOG9K]&7KW47>[T^&T*LERPD+!L-LQGIZ=*F2!?
M[;GOIF4QV\(B0!LE3C<Q(['!''IS6?9W9A-FSC;;P:>CR.8_]D<!OZ4*LS65
MK82&:2YO5,LSX"E!@9SC\!4<G+HO3S[M_<9NERKE6FEO/NW]R_$OV%YY]I)J
M4D) ?/E!$W/Y8Z8QR<]<>]):0+=W*:E-&ZLH(B65"K1@@@\>IS1#YLVK*BK+
M!;60*X/29F48_ <_F*FN[>>XO%C.Q[%XF66,CEB> ,^F#^E9NR>FE_R[?=_D
M^IC)I2:6EU]R[>MBO*&U9_*ADO+40.=S&,H)..Q/458GOK73VAMMK%Y#A(88
M\G&>3@= .YJE>7E]YXM[6)+6WC($ES* %"^PJ^L\6IZ<SV5P5#\+,B]/IFCE
MT3>W];_U<)1LH\WP_EZNWX;B:I&9+-@+,71!R(BVW/YU@7QU7[19P22PVJ7$
M<A,,:Y5 B]/Q!_.NFM;86EI';^8\FP8+NQ);U)_&L3Q J-JVE;@20EP5P#G<
M%7'3WQ6E!KFY;76OY/Y&F$J+GY$KK77Y/IL<!C'&0<=Q6WX> \R=\L&5H>,\
M']ZM8V'(9F#$@X8D=_?WZUKZ @+R,7"@2P8Y^\?,''^?2OH<9_!?R_-'TN*_
MA/Y?FCJ/#I/G:H"CC-[)AB.#R>E7M6AO)8 UBX69#G:QX;VJGX>9O-U-<_+]
MMD]?[QK:)<<@XY[U\YB':LWZ?D?+XB3CB')>7Y$%C<-<V<<TD+PN1\\;J05(
MZ]:L??W$?@*K74\\$UN8[=YXG;;)LZIZ'Z=?TJX>IYS6+74YIK[2ZD=U_J5Q
MGK5&RL(["2[>$X6>0.(Q]U..<5>O/]2,'O67+?2OJ_V*S 9(<"<G/RY'0>]"
MYK-+;J:45.4'&.W7Y$\227$TSS0A DFV,-ALX_C&.F<_I5?7\_V#>^GE&K[)
MOF9>>!TK.UU - O#GGRCWJJ3O5CZHTHN]:'JCG[@JEIJI8,0;.W VG').!^&
M:SO#?_(?M?F"Y)ZDCL:OW)"V>J$L5_T2W&?J<8K.\.H&UZU!(&,]?H:]NE_N
MM3T_]M1[\/\ =ZGI_P"VH]'VMG...^*:P)&!4(7]Z%;UYJ=P1(0HRN:^?/FF
MK,,'G;SF@9QT/'K3&4O(P!.!TI?+/RAF/7GF@!Y!)'!'X4F" !@_6F-&.BD]
M/6@0MTR??F@-!Y3("Y"\=^]*!M./7O1:J&=]W./6ASLW$?A0+K84_,VX ^XQ
M3 A'7O3$W2'+,<=,T,,$EGPH&6). !0.UM";\ <FL?5?$-II9:+'G7/_ #S4
M_=SZG^G6L#5/%$SR216#%4S@3'J?<"N9">YKV,)ECE[];1=O\_ZN>SA,JO[]
M;;M_F7+S4I]3N9)ILJ,X5 >%^E5ZKVL8A$@SG+$\FNL\->'7O;E;F]A(M5&0
MK?\ +0D<?AWKV*LZ6&AV2V/7KU*6%@V]$BAHVA7.L2Y4%+<'#RG^GK7HNGZ=
M;:9;""V3:N<DGDD^YJTJJBA5 "@8  X%+7SF)Q<Z[UT78^4QF/J8EV>D>P44
M45RG %%%% !1110 C?=.:\YTC_D=HO)V >=)TR1C:V>O/3->C-]TYKSK2Y-_
MC>)XE9LS/P[9.-K G/YUZ&"^"K_A9Z^6?PZW^%_DST:BBBO//("BBB@ HHHH
M **** "FO]QOI3J1_N-]*!K<SHCU&/QJ0$@8(Z]Z9#C.!4F%,>0>>PJ$=,MP
M Y))QBJNH:C!IUJ;B<X4<* >6/8"I+B[CL8&GE9515SR>OM7G>KZI)JU[Y[K
MM11M1,]!_C_]:NW!81XB>OPK<[<#@WB)W?PK^K#-3U*;5+LS2\*.$3/"BJ5%
M;&A:(^IS++(,6J,-W^WCJ*^CG.EAJ=WHD?22E3P].[T2)O#VARWDR7<L8^S*
M?EW?QG_"NZ*J$")A    !@4 ;0$50J 8  Q@>E*2._-?+XG$RQ$^:7W'R^*Q
M4\1/F>W1"]_RI&_3ID4O7[W2AL!OD^[BN<Y1@SGD]*?GT_2E*JIXR,TAW<C/
M% ;B%?,"\A>*7/' Z4G<]>V,4O4X'>@ !.<GGFFY+<$=.] !R0W44'G=CH.E
M #@0$*XR?6FD9&/;FGC)B)S\V:5",G=TQ0*Y0EC>SMH_L,*E$;<T(_B'/ ST
M.2*LPRK*H?:Z9_A==I'X4_H"3W-,,42S27"1CSF4*6 Y8#H#5-WWW-')26N_
M?_,>,[0.^:3&<'/'I3E^XI((8@$C.<>U X7DX]:DBXUES^!_.E/(';'&*4#J
M?RXI!]TCOB@!5/RD$CVYH'0#/--&0F /I]:D."H(/(H!C "K=<BE& !N_.C@
M8!''K2#^+]*  ]\&D0$8!YY_.EYQSWZ48 ''6@!$R"X.>>E/P-IR<8/6D)';
MK3Q@18YSWH$QA4D$ \XIH4@8R<9R33DQD9X&,9%)_>QGVH'Y"XQR#D4A7/(I
M5'&3QSS]*:"2^<#&: 'AAL89^]TK)UG6(=+M7'F*;EA\D8/S<]\=A[U+JNII
MI5J9I!DGB-?[QKSJ>>6YF:6>1I)&/)8Y_#Z5Z6 P3KOGE\*_$]/+\#[9\\_A
M7XC999)I6EE=G=CDLQY-,HY)P.OI72^'_#S3RBXOX3Y(! B<$$GU/MUKW:U>
MGAX7E]Q[]:M"A#FD9^EZ!=ZFP?'DP'_EHPZ_3_&NWABBMK9H--^S^9" I3=W
M_P!K'.?K2&[%UYMK92JLD>!O"95<'D>F<=JMK!'$[&*&-%=LOM4#)]3ZFOG<
M5BZE9^_HNB_S/G<7BZE9^_IV7^8U;= SS!0LLN-Y]<<"I5W8Z9/:@YQP:7''
M'7UKBO<X&V]QH! (;K_*G\ =,$>M-Z8^O-&#R#T[4"%(XW CZ49Y/0>QI6QP
M1G-,8L",<YZT!N._O#')H )&#V/6@GN..:"1U'7% " <[N,=\4H.!R.2?RI6
M*YP,BF<YP0,4!N#+GH<$]J</NG.#VIK?=&!3CG;Q]XT -"X/WOPH7.X&E&[;
M\WWN:%R7YZ4 *O&?<TC$;L^G:ER=IR?I1N((P,\#/% "$9.<_6E"GICBCUQZ
MT$%6YH 3_9Y'OBG=$VG&ZD!. ,THP8L'[] ANX8P#0<XX_#'>@YVX&=V:@O+
MJ&SMGGF<*B#DGU/04TFW9%1BY.R"_O8-.LVN+EMBKP!W8GH![UYSJ.H2ZE=M
M/)E5)^5,\**74M3GU2Y\V8X5>$0=%'^-4AGO7TN!P*H+GG\7Y'T^ P*P\>:7
MQ/\  *LV5C<:A<B"W0LW4GLH]32V6GW.HR^7;IGU8]!7HNF:;;:?;&"%-H)W
M,QY+'W-/&XZ-!<L=9?EZCQN.CAXV6LBIHVA1:7!E@KW)SNEQTSV%:N-O&<^]
M+P3STQ2MLW#;TKYN=2527--W9\S4JSJ2YIN[#DX'/3N*3.6! SQT%.; V^](
M#^Z/(#9Z5!F-P3C .1VI<GJ!VIK9'10:7&,8/)ZT#%7Y5 8<YI,9!!(Z]J<V
M,X!SZT?+G(X- A.0NTG%";5)W<YY%(<\X(H)89*YS0,.HQUS0!M_BZ]J/X>?
M2D7.W/K0 O [_-UI&R2 .PHS\_\ +WIW/WNQH 3'/(Q[&D*\D9QGI0VX#Y>N
M<TY0,_-TXH 0*>0"3[TF.3@]?TISA<X7N*"!NR.A'- 7"7/DX(J2S_U/6HG
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MY]O>NGF?LHJ+U_R;?ZGH\S]C%1W_ ,FW^I/%I&F@ G3K0Y&>8%_PIPTC36?
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M+!":_P"(WM)6LK3:S@$2.2?E.>@]_P#&N.)))))))Y)/)H9F9BS$EB<DGO0
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MDD^PJ1VVQ[1U/>HJXV<T5U U/$@("D=L\U"BEW QWJ<D' (H02?0"<!@>QI
M0PSC'M2]CGZ#VI!QQG\J9 %RJ%CSZ9J$,P.0Q7/H:"['*DTE(T2L68+E\[7.
M1ZU='(K,CB:5OE[5HHI5 "<XJHW,*JBGH.HHHJC$*0=*6DX H I/(?M#*0,8
MQTIP!%LWN12>8@F9Q'TX8DT\,A5B3PW%0=#V6A.5W1XSC(Y-1Y'D$ GY>/>F
MB4%-K8V].#S2>8B+M4=.Y-.Y"BQEP"\4;=^]*C;HUX& < 4X,$0[2&SZU"CJ
MF1)GYCD8I%K56'YY.,4BG<.G2E9D;E <8I,YZ<>E Q<';G(P.Q%*JECC/;-,
M. WI3QD'T^E ,:3CCKS1SD9^N0*,>G?O1P.] #RC 9R/I3?F//&#^=&./ND8
M[]S2 @?+CKW]*!",Q7@8SG'2G#DX-0W-S!;1%[B144=6-<IK7BEW9K;36"QX
MPTX^\3_L^GU_E6^'PU2O+E@CJP^%J5W:"^?0T/$>O'3LVEH +AA_K!T0?XUQ
M#N\CEY'9W;JS')/U-#,SL6=BS$Y))Y--KZ;"X6&'A9;]6?387"PP\.5;]6%;
MN@^'_P"U%:>YW+;C@8."QX_3GK4VC^%Y;AH[B^!2$X98^[_7T%=JJ+'&%50%
M' '0"N#'9CR_NZ+UZO\ R.#'9BH+V=%Z]^QR_BV!+?P]:>4"L,$N"B@8 P1G
M_/K5GPA,EQI4>R4OL;H6SMSSBD\5HKZ"VXKQ*N 1U^G^?6H_"4BV^C2M(1'$
M)."2,?YS7$WS8!7Z2_0YG[V7^?-_7YG3%OER,\'FD/7WIGGPMM"R(=PW#!SD
M>M.!!.,X)[5YQY-FB1CE!N )7@TW=\H.>.:<C -@C@CO364*Y':@E=@#=QD;
M>>:;E@2,YSTS3F!SCI2#!)Z_4&@9P'B198]99WVE60;#MSQ^/?\ ^M64<QI@
M,2)$!X.!U[COR#6[XM_X_;?_ '#_ #K ?@1C!!"<_B21W]"/3^I^IP+YL/!_
MUH?6X1\U"#_K0V+"2X:XM)UD_>6ULQ@"C_6;6.4/3L3^&/6NSM+BR\0:<X,:
MO$PP\3<$?U!]ZY/PN"NIV(VDB0S\L,K]U>!Z'CDCL16M<VEC8>(X)I6_=W;D
M[M^/+E7D=,?*<XP<\XKS<7%2J<NS2;5O)N_Y7/+QL8SJ\FTDKJWDW=?A<VSI
MSPF-[*XEC*(%$<DC/&0.V"<CZC\C5*'64>18+RWDM;ESL#'[N>F5/3Z9J:XL
M+A$=K34[F&39M02L)$S[[@3^.:KR7VJ0LJ7>D1W*YYDM7SD^RGD?B:X5'G6Z
M?SL_QT?XGGPBIK5J7SL_QT?XDEQ#*MLR:DD>HQ%E6/$6&Z<EATSGTJ@\#+-!
M:SMN4G.G7OWC$QSA2>_0=>#Q5E;C3X95N(KRXMFN"9##(WR.Q/<,#MY!Z8J:
M*2YFF=4M(XKC8"LI;S(6"L< 8((/S$]*I.47_2\MOSM?S-4Y05_^!Y;?G:]^
MI%(\EOIL\6HB-[AHOWRQCYI%)"!N.>.?_K4+8F2TFWH1J,UHT+$L2&P"H//K
M_6IM0T^XO(TG206]Y V8&QTSU5N2"#^GOSFK!KUW]LD2XMX!'$ZQ%$)\QG(R
M=O4$#T]!U-"NXWAONU_73^NFJCS3A>GON_\ +T_KHB""_M=2\/6UA"V^1TBB
ME0DC:.,DX^GZUHOJ%TMC;%+0+<R2&-89&Y"AB,Y_W1FN>TS4_L%M!NM<2WN2
MSH>B@XSP,]SSR>Y-:ZSW#7RV5A$LEM HBFFF)VJ!D87)Y/7)]JTK4VI-6TNW
MO]^OK\S:O049-6TNWJ_D_P ;>;--YO.O!;-))$T121=K!?-ZY&.I QS_ /KJ
MAJ%G-)YUQJ<TD]NK*([2WRJG) &[&"QR0?;%3RV%W#J(N+&WA:>155[B5OE1
M1V SG/ Z5J&*X/5T/_ :YU-PLX_\'_@?F<7M%2:<&OU\_3\RA#&^IV &I6@0
M,V[R=YY /&['7Z'BM#8.,=:BAE9V8.1@>@J7(Z;@#Z5DY7]#&I)MVV7;H+CY
M<FL'7!C5](/&&,T6".I95P/;Z]JW?85C:_N$NEE0I87J8W' ^ZU:T/C^3_)F
MN$=JJ]'^3//)%*3.A4+AB-H.0.?6M71&6-KH$N3&$E)4 J5C8,W/T!JC>(S:
MA<<ICS2"5P%&2?3BIM,0NE^=[J!:2?<ZG_ZWK[9KZ6O:='5]OS1]75]ZEKY'
M8Z%)Y5[JEJRD2+=-)]XD8;D<=!QBM\#+[<]NM86F%_\ A(M7&\!?,7*\?W1S
MC']:W"<8P,9KYJOK._=+\D?*8O\ B7[I/\$#)O1ER1GC()!J"TM7M(!"UQ+.
MPR=\AR<>F>M3]\TR53-#)&)'C+J0'0X9<]Q[UDGT,$W;EZ"W(_T<$9P.:JQF
M2",1[S(QY9VZDDY_+G@=ABJ$)-W,'O856Z@!$3JYPZY(W$= ?\\5J@D <=N]
M.:Y7RFTH>S7*]1!B)>F6/4U2UB/[1I%U&I +1L 2*O$\>]5[_P#X\9^/X#_*
MIBVFF@I.TT_,Y-7%S:W?SM$+C3EE##^$1G!!^O3Z5F:!<+;:U;.P)#MY?!(P
M6X'3K6E8[A;1;&VG^R9?FP>/F]JR=% .M688NH\P'*=?_P!7K[9KZ&DE[*K%
M[6_)-?DD?202]G5CT_X=?H>C,0)P1T)S3Y)&\Y@GRG/)]:9(/WP'2IB^#D ?
MB*^</F7T$50%Y/.>32@ D]*!R>W-*PPQ'%,BXFW!'3FD+8;GK]*!_+]*-V,
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MYRURPP[ALC\!7?C,7'#P_O/8[\9BXX>'F]B?2=*32;%(E(>1CNDDQC)_PK1
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M?K_D?0Y7ESBU6J_)?J5H_+^TRX4>9D9/?I5N.-Y9$CC4L[L%4#N3TJ&*'?<
MHF9&; P.37H7AKPR+#;>WJAKK^!.HC_^O7IXO%0H1N]^B/7QV,IX>'-+?HOZ
MZ#_#GAI=-(N[AM]PR\+V0'M]:V((O,+-O8?,>AJYVJM9_P"K/UKY:M5E5GS3
MW/D*N(J5FZDWJ21PB,ELEF/<TZ5/,C*YQFGTC'"FH,+N]S/$:I/M)/3K3I+C
M<A3:![BG1QK-*V_G XQ4OV.+_:_.HL^ANY1O[Q8I#TI:1NE6<Q7M<EI2?[U6
M:KVO23W:K%);%S^(SY"992H'2HV&R8*V3BI$D6.X9FSBER'O,CD$U!T)M>A)
M"1-,S,O & #3[OBWX]:G"@=!BFRX\MB0#CUJ[:&'-[R94L?OO]*O<54M#F1R
M  /:K04 \41V"K\0M%%%,S"BBB@ JEJ%M-,D;VIA6X1P0\B9X[CVS5VBFG9W
M*A)Q=T9Y;5?,(6.TVA5.XNW)QR.GK0AU8!MXLV."5VLP^@Z5H4'@4^9=B_:]
M.5&<K:N5!*68)'(WMQ^E9>M>(KC28$3;;273D@JCDA/0G_"C7_%4=@#;6066
MZ[EL[4'X=37 R2/+(TDKL\C'+,QR37IX/!>U]^HK1_,]G Y>ZO[RM%*/;O\
M\ EO+N>_NGN;F0O(Y_ #T'H*@HK<T;PQ=:LBS.WD6S=)",EOH/ZU[,YTZ,+R
MT2/=J5*="%Y.R12TK2+G5IF6  1QX\R0]%_Q/M776EG-I:I%IUM%(<L7:5\%
MCC@\>I_*MVWLH-/L?)MT5% [#&3ZU#;'-P,\YKYS%8Z5>25O=[?YGSN(S"5=
MNR]U=/\ ,C$^M&X -G;"'<H)\[G!^\>G:FK<:V8P6L;8/M.5\[OQCM]?RK7H
MKGYU_*OQ_P SS?;1_D7X_P"9C_:M;VG_ (ET&[Y<?O\ _OK_ .M3EN]8RF_3
MHL<[]LX_#']:UJ*.=?RK\?\ ,/;1_D7X_P"9R/B^6>70HS/!Y)%RN!O#9^5O
M2N)!"\C[W(Y (QC^=>H:U:V]]]AM;J-GBDN,85]O(C<]N>WM_2N8\1^&H+*W
MGN[65(XXH@1#@EB<XSDGWZUZ^ Q5.$52EHW]VNA[N6XRE&$:,M&_NWL-\$,/
M[1G7:N=@^;G/6N]K$L8K"QUA[*VM(XW6)6WJO./<YR?R_.MNO-Q555:KFE:]
MOR/)S"JJU;VB5KI!1117.<(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !112$XH 6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S),-._7KVK3K*QF
M5L'O4R-J/4THAB-1[5%>?ZD#U85,GW!]*@N_NI_O4WL1'XQ!9]]YH^RO_P ]
M/TJR.E+19![2166"5>D@_*D,<T:LWF#IZ5:I&&Y2/6BP<[ZE.&Y +&4GVP*F
M:ZBV$AN<<<4Y(548P#08%((P.?:EJ4W!L2VCV1*3U/)J.]/R 9JUVJI>1L^T
MJ"<=<4WL*#O.[)+=E6%02 ?K5>X(-PN&!I4MQ( 0W3J*&M'#@K@BIUL:+E4K
MW+HZ"EI!TI:LYP/2J'4MQC)J\>E40>&SZ]:EFM/J*!M&,;<U&7"J<?>-#L%'
M#9SZ5$*DW2%I0"W2DJ>./ RW?M0-NR +M4+WQ2@%3C-!Y4XX(IH^5,L>_-,C
M<?A5 +=!4+2LPQ_#1+*)#P.!3*3*C'N%.1"W)X7UI%1I/NBIU^4 'H!S0$G8
M0    8I<<=/QI!SR,^U&#W?/MZ4R!P8@8!X]Q36!;K^8I22>>@]*CD; V@Y/
M?% TM19&P"B]^OM45%&,G ZTC1*QEZWS#9X_Y_(?YUME1Y7ED@KW![UD:\$A
MM+1V=0HO(2Q)X !Y)K3:]M(G,<MQ K\?*T@!&>G!K=I^SC;S_0TJ)RI0LN_Z
M$(NI8KZ6&>!S$V##(BEE P 5; X.<G)XP?:K2NKC<&!'8@TU;BVE1OWL3+&2
MKD," 1U!]/QK*-OY69-,N8_)D *Q9RG<Y4CUJ'9KL0H*>CT?X&E<,JP2(ISE
M3DFO/M&539RQM-A'N8D*@<2#=T]1Z_A786\MV]O,+R".)@#@I)N!KSW0M;A6
MZGLI+>10DT3F<K\O!!./7CTKT<#2G*G44=6G':WF>O@*4E3J16KNCT355+:=
M(NPLK%0V,< L*U8QY:J$[#O6-J6KZ<;+[+%>0R2NRA1&=V?F'<<#\:V"N>IQ
MP.E>?*,HP5U;?]#R:BDJ:4E;5_H*<XSD<GM1U[YH7Y1@]:,YZ\&LS .V 329
MVG [\]*4D$8/'N*<&^7;MYSU- #2 1@G'-0R-O?/IQ2S'G9UQUIE)EQ74*E6
M+:-SGJ*9&NYB>P'6N=\0^(8A;M96;[I&&'D4\+]"#U[5M0H3K3Y(FU*C.M-0
M@)KOB=[>1K2QQO48>4C./8?XUQ]'08'%.1'E=8XT9W8X55&2:^IP^'IX>%H_
M-GT^'P]/#PY8_-BQ1/-*D42EY'.U5'4FNRT7PY_9S?:KPHUR/]6JG(3W^M.\
M/^'S8$W=YL,_\"]0@]?K6V[;FZY KQ\?F'/^[I/3KY_\ \G'8]S;I4GIU?<0
M4<DX%%31+\G:O(/);LAZ'9@#' QD]Z!C&!TSFD[ %22:.A Z>M,S @YP/UID
M:LK\D8'6I'P6)'<8I)B@BVC!- )]"!FW-D=.U)13D&3D]*1KLA\2C82W4]J?
M@9.WBCC@>GM2O\[9Z<4S)MW$+L1D*>.@IC3L4V #GK4F[:N<GBJHI,J*3%J2
M$'._TZ5'@G@ GZ5/@X4#J!SBA%2>@OWOO"D55R0O'O2J"!W_ !K"UCQ';V$<
MEO!B2[Q@8Z(??W]JUI4IU9<L%=CI49U9<D%<NZEJ]EIT9,T@,H&5B4\L?\]Z
MX+6=<DU"??.WEP@YCBSD+_B?>JTLLDTADE=G<]68\FJ5]=?9XOEA::0](TQD
M_G7TN"R^%'5ZR_K8^FP67TZ#OO+^MCS[QYXF;4'.@:.)9Y,_Z08EW9_V!W/O
M^7KBCX)^&&I^)+E9+J&2"V60!D=2I(YZG^$?J>W:O1_!/PXN/[4NM;O,1&[8
ML!C. 6)(7].3Z#%>N:?80V42P0(%0<GW^M>9C*T%4YI>]+MT7:_=^7W]CR\8
MZ?M/:5?>DMET2Z7[OJUWW[&;X;\)V/ANU7R8U\Q5&2JX ^E=!U967TI2<L><
M@CUHP5Q@<8YKS*E2523E)W;/,JU9U9<TW=@ZC/ )YI> O)XZTY6 _AR,5%(0
ML9!YW=*@S5WH,D96?Y<X'K3*.U*JEFVKUI&NQ-&H55;/-+G!SWI4PD.QL9-(
M5W#;@_E3,NH'G.<<\]:1B$3/!/:E/W.H'O43ON"C.2.M TKC/4GO112[>A)Q
MGM4FAH01"*/'<\FI:1>%'TI:U.)N[N%(S!%+'H*6F2_ZIOI0"W(OMD6/XORH
M%W#C&X_E5)59A\JDT%&'52,^HJ.9G3[*!('C/F!\_,<C%&Z' &6X]JC(^8 C
M&:"-IQZ]*5RN5$F8AR&)]L4$Q9SO)_"H]K=D;\J"K#JC?E0%EW)"8L<,<4UR
MK2!E!VXQS32K 9*G'THP05!^M [(M+;B1,JQ -.^R'C]X>/:I8?]6*DJ[(YG
M.294-H3_ ,M/TIWV9NTGZ59HHLA>TD4'1HY%3=G(S2XQ^![U)<*XF5U0D <X
MIAE#/\R[?K4FJ;: LV.3GVQ5#4M3MM,@:69\M_#&#\S'T_\ KU0U3Q):Z<IC
MMGCN9R<$*W"?4C\>]<1<7,UW+YL\A=_4]OI7I83+IUFI3TC^+/5P>6RJ^_4T
MC^9<U;6;C5I<R82%3E(QV^I[FLZBM;2M!N]2=69&AMB,F5AC(_V1W^O2O>;I
M8:GV2/>;I8>GVBC.M[::[G6"WC:21C@*/\\5V.D>%X[0I<7;"2;'W!@JO^)K
M6TS38--@V0J!G&YN[?6K:CYB!W->%B\RG6]R&D?Q9X6+S*=2\*>D?Q8[IUX]
M#0P++@<'WI0V.Q(H^ZI!KS#RCG_%*C^P&)(!$JG&.O-<[MQX15LC#W@!'3C#
M=:Z/Q01_8$GRECYBX.!\O/7^GXUSYQ_PA\!Z?Z:,_DU>S@OX$/\ '^A[V"?[
MB/\ C.V2VMVMU411A/+V#9R I'0'TJJ;:^M7:2TECG0L7\B8X().2%;MSZ\<
M]JTRXDVNN"IY!!R"/6D& W?\J\A3:9XL:LEO^)#!<+.64#;-'@21MU0D9Z]#
MP>W%66)^5L\'O]*JW7VCR?\ 1V_> Y /\7M26%W]MT\N8GB?<0\;]5(."*+:
M<RV%*%USK8M'YGSU]Z:,'@#ZT*>.!3MX) Z;1V%29G">+#F^A&#PA[>]89RV
M,LBJ<N .GTP.G3O6YXL5A?0DG(*' ].:Q9& W#*,&.?DR .3ZC_.:^GP'^[0
MMY_F?6X/^!"QKZ#,+:\T^8(\W[R93'""7!VJ,D'CH1T["NEU6WM=6CFM&M[B
M&9"3%.T)*9X)(8<8.,<XKGM(L+.0Z4THE\RY>4,R,> G0<?4<^QKIG\-V;M\
MLUR$W;L"9N*\[&3@JRE=IJ^O_;S\SS,94IQKJ=VFKZV\WYE"Q-A=Z<=1N;BZ
M9TC!F&]FV$=QCN.O'2KHW6]VI-W-L9P@#3(X((!#88Y&>1@9-4+:"#1O$9BE
MMV%O=KLCD<Y4MW!SZ_U]ZZ/[):!]WV> LN,'RQD8Z=JY:S2E=7L]5_7EL<F(
MG&,KJ[BU=?Y?(RKB6\DC8".UGC2$.KW)7._)RI"M@84CD?K6;%9RR>3,%-A=
MF;8'MYE>/:>F5+=\D<9/'X5TR6%K&FP6T(&6;[@P=QR:=]F@!9Q!$&)#;@@!
MR._UZU,:_*O=7]?>91Q:@FHK^OOL<Q>ZKJ=K=A)X8KJ&"3YC$X#/P6&5!.,;
M<].Q]:R;V\N=:N[=;.PDBG1MX*G+9SUS@8'O7H) ?;D<J<CV-+QOW8^8#J1V
MK6GBZ<&I>S5UYO\ +8UIX^%.S5-77G^FQQF@6\.EZCMU7S8KQ2$A'+#!'J,C
M'2NADTFZOK@M=W(CMXY2T4%OT89SE\]S[?UK7B<2H& ZT^LJN(=27/U?]:=C
MFKXV<ZG/:S^_[NWXB ;5 ]*#T-+2'[IK X2A;J&D<&I]HX)&?>H;7_6/[BIS
MR,?TJ%L=$_B%RPY&,YK#\2;PNFNBLSK=J<*,]F]C_*MS<!R1GZ5'-N-NX0X?
M'!(K2G/DES%49^SFI6/*[IA]LN/+5D5G(VL03US@D>XJSI<;;[\;MC+9S9Z9
MZ<C!JI*K&>56R\@8DE1QQDDX_6KVD*<:DR+OVV4H!.1@$=?3I7U%9VHV7E^A
M]?5TI.QUVEY_X2'5SAL&11D!<?='X_TK=.>..G-86F;O^$CU?DX+KQM./NCO
MTK;9<\;L5\U7^)>D?R1\KBOXB](_DA^>_7CFJ\5VD]U-"J2JT.-S.A"G//![
MT7<4TELZ02*CMP&(S@=Z6T@2VMA"C,P7HSG)K/2Q@E'EN]R2Y1?*+A1NQC-5
MH+N.Y1L*ZM&QC9'&""/Z'J/K5BY_X]\<\5FW-A(UY'?6Y_>#"2(6(#+_ (BD
MK/1ETE%QM)^AH8YSQTZ&J]]S87!_V#_*K&[:"2,Y/2JU\?\ 0)_]P_RI+<(?
M$CDK @6T9)&!I,N22<#YN^.?RK)T5=VM68/_ #T'\)/Z"M:PVBWCWD!?[)ES
MGIC=63HNXZS9!<[O-'3T[_I7T-+^'5]'^I]-#X:OS_4]'EXN,_SJ7C/3([5#
M*")R#4W<<]NM?.GS#V0GOZ4I.X9Y(/>D;E3@>W%( ?+7V/(H$.V@ L,\BD8;
M@!Z<9I'=%#.SJBJ"22< #WKD]9\6"1&M]-)"M]Z8@@_AG^M;T,/4KRY8+_(W
MP^&J5Y6@OGV+VL>(X-.N9(8E\ZY&,C^%?K_A7%W5U->7#3SN7D;N3T'I5?S"
M\\F<ENI8]R:D1'D=4C1G=C@*HR2?85]+AL'3PT=-^K/I\/A*>&6F_<;6]HOA
MJ74<37.^&W/W>Q?_  %7-#\,OYGVC4(L*!\L1]?]JNQ+%^?2O/QN96_=T7\_
M\CS\=F7+^[H[]_\ (BAAC@B6*% B+T51@"I1\V <?C33@-C.#[TA&_H>O/%>
M'<\%ZZL= ,W)'8"KM4H/^/HCVJ[51,JNX44A8*"2< 4H.1D4S,*KW!+.D6?E
M;K5BJTO%W$?8TF7#<EBB6(87O4E%%,EMO<****!"'I7G,P=_&ZL8G4_;$)!'
M(^8>E>CUEVS3-XAO\J!"D4:J0!RW).>_<5U86M[+G=KZ?JCOP-?V/.[7T_5%
MA2QN3G'0]ZKQY+I[&IHP1<L<'OVJ*%')#JN0#7$9*R-.BH8)Q*6XQBI68(NY
MC@"KN<S33L+134=7&5.13)IA$N<9S0"3;L2TUF./E&:A\]\\1-CZ5..G3K2&
MU;<KLQG51CHWS#TI;BY@L;=I9Y%CC7JS' J"ZN1817$\H(C W%@.@KS_ %O7
MIM7=4"LELAW*AZYQC)_SWKJPF%GB)66W5GH83 SQ,M-(K=AK7B1]9?RD3R8%
M.=F<D^Y_PK'IB ;B=N#6AIVF7.IS>7 AV@X>3'"U]*HTL-3TTBCZJ,*6'IV6
MD4+IFDW.JS,D 4*F"[L< ?SYKT"PTRWTVV\N!-H8#>>I)]33]-M(M.M(H(U7
MY5 9@/O'U/ZU9Y)_'-?.8S&2Q$K+X?ZW/F\;CIUY<JTB-4#''/:G8Y&6![BD
M'7CG-&W&,8/T-<)P";>QIPZ]^*.!ZYH'RCG!^IH "<]*.P!Q1T[9[FDP??KZ
M4 ' X'XTG<'KD=: NTYW4X'!_#M0 @RO0XI3DG/ZTC''/3/6EW<#IP/SH ,E
MAECGUHZ+M7'-- )7KU/Y4*ISG.: %XSD<5%<75O;!3</M#MM7CJ:D^;(/.,\
MBJ6I:5!JL<:3Y*H=PVG':JARW][8NFH.2YWH1&YTV&XDU WB$[/+P),@#[W
M'YTY=>TK./M\/+;<Y_'\N.O2JD?A/38Y%8QNVWD@MD&K:Z%I>WFRBS]#70_J
MW5R?W?YG5+ZKU<G]Q);:[I][*(8+I&D'08(S^=6!=1 <31_]]5R_B?3;>RL8
M9;6U2,^9S(IP5XXKE9%C1OE! '/# GUZCOC'XUUT<OA7CSTY-+S2_P SKHY=
M2KQYZ<FEYV9ZN"-OZT'![=>U-AV^6IR<%1BG<@CU)S7E'C[,0*-NW!YXIR]>
M./K2N=Q]_:D)W%1V'% %>TE-Q;>:R@-O=< _W6*C^53,!W[<53T=673T#-O(
MDD!/3)\QN:O8^;IFJFDI-+N742C4:71L3G:?856'4?6K!!VMU!)JO_C4,(D^
MT[CD=>E.QR6QTI@SD\]L?2EE>.-&EDD6-%^\68 #\::)ZV%8*3SG'M6!K?B6
M*RW6UK^]N,<N""L9Y'/J?;WK+U[Q(;AOL]@Y$:G)F!QOX'3TYS7-5[.#RQOW
MZR^7^9[>"RR]IUON_P R2>>2YF::5B\C'))J.BNKT3PO,L\=U?HH4#<L1Y.?
M]H?TKUJ]>GAX7E\D>K7KT\/"\ODBIHOAJ>[9;B[1HK<$$*PP7_\ K5VUO!';
MP+!"@2-!@*.PJ0L3ZBCOD]Z^8Q.)GB)<TON/E\3BZF(=Y;=AKNJ %V"@=STJ
M,7$')$Z';SUK-\41--H$X ^YAOJ 0:\] 4*W!R>..A'O^E=.$P"Q$'+FM9]O
M^"=6#R]8BFY\UM;'I'_"0Z3YC*;U 4;:P8'KTX]:#KND;6/VV$[.,[N3CT'?
M\*SM#TRQN](@DFL$\P#EF.=_/6M!M!TS<2+*+;]#64X8:$G%\VGH93AA83<7
MS:>A"^L:7'<-.-23$F-\8.X$XP#ZC@5JP7$5S LD#J\3#*L#5--!TH9W6,1X
M]#5NVMH;2(101JD0.X*.U8U/9->Y>_G8PJRHM>Y>_G8FR0N#C@YX-(3E=N[(
M/:CC=D=!ZTB@J<D@Y]*Q,!><9! 7N*:P^7!!/-.XVD'K37.5QZ=Z 0[.<8[<
M FC))RQS]*.@7OS0QW,2!VZ"@0$<<@BDXW@@GBD()/)('K3B0&)(()[4##HW
M8YYHX'  Z^M(V6X!P1VH&>.YZ4 *?O9(P>E!R<D]?Y48P,$D'O0W/.TCW]:
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M?P@&@!Q)%NPQU[TME]PTQA^X."1[4^R(\LCWIK<E_ RU1115& 4444 %%%%
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M]*RN96T)AM"@?Q=J8V2O/7/-*5X'[YN:#'Q_KFH$K&!XJ4'0222,3+@8//\
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M?];&GH/A\:8#<3+ONCPIQP@]O\:W<$=5^O%<_P#V/HA!Q;1\ D_OWX ZG[U
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M6'R1GD1C_&O4Q.*AAXWEOT1ZF*Q4<-#FEOT0[PQX92T5;V]CS<G[B,/]6/\
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MK*U*"]?T#@C'I^E, QG-.7D<T#M61R[$4@ @D.<@ \5Y4OW1]*]4O',=K,R
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M_P!I>)O^@)'_ -_1_P#%5D>"+FW@N+YII53]VA#,X"@9.<\^I'^37:_;[/\
MY^H._P#RT'89/Z<UYN)4:-5TXP32[W[>IY6+C##U72A232ZN_;U,![KQ3=#R
MDT^&U/7S&D!'TZFF?9_%O_/:T_/_ .M6W)K.G1"4M=Q[8D#N0<@*3@'CWI#K
M>FJ6!NX\J[1D<\,N<C]#6//+I37W/]3)5JJ7NT5_X"W^9B_9_%O_ #VM/S_^
MM2/<>)-*ADN[M+:>%%^95;! SUZ5LMK^EH,M>Q_<63C)^5ON_GD?G6=KVLZ?
M-H-TD=P&>0F%4P0Q? XP>>,BK@YRDDZ:U\C2G.K4FHRI*S?\IGWGC&TO=*NK
M9K>:.26%D7HPR01_A7.:)<PV>M6EQ.^R*-B6;!..#Z55%K<E]@MIBW/RB,YX
MZ_ED58TFS2^U>VM)2RI(^'QUX!./TKVHT*-*E-1V:=_N/=CAJ%"E.,=FG?[C
MK]5G\.ZV&66_C2:$$"3)'Y9X;\,UR%W81P%#;W]M=*P!^5]I&<]0>G3Z^U=C
M_P (1I^\'SIMH;)&1R.>/Y?E0?!&G^6 )9@VW!;(Z^N/Z5P4,31HZ1F[=FCS
M</C<-AURQG)KLT8FC0:)8O%>:AJ$,KG.V%5+!2,=1C^?![5UA\1Z-& /MT.,
M<!<G&!GM_G/'6LX^"-.R,2S?>!/(Y&.GY\YIK>![$J0MQ,&['@XZ?_7_ #K*
MK/#5I<TYR^XQKU<'B)\U2<ON_P" :C^)-'3;G4(3N7<-I)[9YQT/L>:#XDT<
M;<W\7S8QC)QGU]/QZ=ZS?^$(T_!_>S?=QU'7'6L+Q%H5MH]I;F%G>1V(9F/7
M\*FG0PE22A&3NR*.&P-6:A&4KL[>#5].N<>3?6[DKNVB09 ]QU%.&IZ>RJRW
MUL0QP")5YZ^_L?R-<'I_A2?4M/BNX[B(+)D@8)Q@D?TJU_P@UW_S\Q?]\FB>
M&PL9.+J;>0YX+!QDXNK:WD=M'?6DT@CBNH7<C<%60$X]:22_LXGV27<",,Y5
MI #P,_RYKB#X&O-ZKY\14@DG!XIW_""W0_Y>8O\ ODU/U?"_\_?P9'U/!W_C
M?@=M'>6LKA([F%W*APJN"=IZ'Z>]4SJ5H]VHBN8)2Z94+(I)&2,C\0?RKE?^
M$%NO^?F+_ODU#)X+N5EVF>,G&?NFD\/A?^?OX,N&$P=_XWX':VMW;;&/VF'!
M?'$@ZXS_ "Y^E/DU2PC@DF:\@\N,;F(<' Z#I[\5PZ>"[QXW82Q;@Q !'6IH
M?!%R;E1-,@B^;+*.>G'YTUA\*O\ E[^ I8/!W;=;\#K6UW24&3J5H>0.)E/7
MZ&A=<TEQD:E:#DCF91T^IKFU\"\INN^,_/A>V.WXT/X%^4;+OYLG.5[<X_I1
M[+!_\_']Q/U? ?\ /U_=_P  Z;^VM*_Z"=G_ -_U_P :/[:TK_H)V?\ W_7_
M !KF3X%X&+SGG.5]^/TH_P"$%_=2_P"EGS ?W?R\8]Z/983_ )^/[A?5\!_S
M]?W'2/K.E%& U.SY'_/=?\:XM]+@D>>4>(+6,.Q946X'?_@7TJV/ \H5BUTO
M$9(PO\?^%-C\&9MF=[H[AC@+QUYK2G]6I-N%5Z^7_ .O#_5:%_9U=_(A;1[;
MRW(\36^<':/M _#/S4HT>T_=X\30A<#<#<#/OW^E7)/ RA6*WC;<]U[<?KUJ
M.W\#NZ*9+H $'[J_E_6M?;4O^?K_ / 5_D;?6J-K^V_\E7^15?1XMWR>*+7;
MCO<?_94W2]8O;75+;3X[Q9[<W"IOQ]X$@'&:MKX&G^7==)]X[L+VXQC]:FT[
MP=<6VHVUQ+<H4BD#D*O)QR/UJG6PSBU.?-VT_P" .6)PSA)3J<VG;_@'77/^
MH;Z5!:(2 V>G:IKG_4-45F?W?7O7AO<^=C_#9;HHK.UG58=*L6ED=1(P/E(3
MRY'I5QBY/EBKLFG"522A%:LI>)==CTRS:&&1&O'^4)GE ?XB*\Y9F=F=V+,Q
MR2>I-27-S->7+W$[EY'.22?TJ(D 9-?3X3"QH0MU>Y]C@L''#4^5;O<BGC>:
M,Q1C+O\ *HSW->F>%-'_ +*TI?-VFXDY=@.@_N_2L70M :W2.^ND99B"4C8?
M='8GWKK4GAM;$S2N$C099CVKR\PQKJOV-/9?BSR\UQKJQ]A3U5_O9;HK)C\2
M:7+'NCN"[?\ /-4)<]3T_ U)!J8U!+F.UCF26-?E::(JI/.,9ZUY\J4X_$K'
MBO#U8_%%KU+\TR6\$DTK;8XU+,<= .360T3ZT]M=QNZ68;)BECQYH'1AW [B
MM&VAF$$)NG$EP@(9DR%)^E6:FZCMN$9JD_=W[_U^84445)B%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!R'CS_CUL_]]OY"N,^=9D4Q[71@NW9D
MY![CN?:NR\=L/(LUYSO8]/:N-A"FXB5_N%U#8&>,^E?1X#_=E\SZ[*_]TC\_
MS/7XL^4F?[H[8I]-3 1<=,<4ZOG#Y)[A115+5-3M]*LVGG;V1!U8^@IQBY/E
MCN.$)3DHQ5VR2^O[?3K5KBY<K&..!DD^E>:ZSK,^L71=_DA4GRXP>@XZ^IXJ
M*\O[C5))I[J7+#E$+?*OL!5*OH,%@HTO>GK+\CZO 9='#^]+67Y>@5>TK2KC
M6+OR(, *-SNP.%&?Y^WL:GT30I]8GXS';J?GD(^O3UZ5W92U\/:5BWA&XL%1
M%^]+(> .>YJL7C53_=T]9?D/&X]4G[*GK-_AZEBWM[/1[ )NCAA0#<[D*,],
MDGUJ-TFEF@-HMM]C959GQDL!T QQCWJE=7UO?:%-!<S6GVIXS^X\T'#]@<'/
M!QGTYK9B>#9''$T>W8"BH1C;VQ[5X$TTKRW=SYN:E#WI:R;?IZF7X5(/AVVP
MN/FD'7_;:M"VW?:;O<I \P;3LQD;%[_Q?7\.U5?#X4:#9[3GY,_=V\Y.?_U]
M^M6[<L;BZ!VX$@QALG[HZCM]/Q[TZKO4F_-_F%=WK5'YO\RQ11161RA7+>(L
M?\)%HXQR2V#Z<BNIKEO$0_XJ+1SD<%N/7D5OAOC^3_)G;@/XWR?Y,M>+_P#D
M6I?]]/\ T(5YT5VJ,JP8\\C@CM7HGC!E'AN0%@"SH ">O.:\ZQ\I.1P>G<U[
M&5?P7Z_HCW<F_P!W?J_T/3?#"LN@6I9]V5R..@R>*V*YG0M6TRQ\/V_G7D:,
M!AU+$D')[=:T)/$NDQLP-VAVAB=O.<=A[_SKR:U*HZLK1>[Z'A8C#U95YN,7
MN^AK4CJ'0JPRI&"*H1ZYIDC8%[$/F*Y8X&1UY/%375]%;V#7:YE0#*^4-^[T
MQBL'"2=FCF]E44DFFF<GJ-G<>%M3.J6,2O9N-KICA,]CZ#/?\*ZRPOX-1M([
MB!U8,.0#DJ>X-5--O)]6MY/M5BT,+K@+)U;/7(I=)T*VT=I3;O*1(>0YSBNB
MK44X6G\:Z]UY^:.W$5(SARUOXD>N]UY^:-2BBBN4\X*Y3QV$_L^U)*;Q*0 ?
MO8QSCVZ9_"NKKDO';@65I'_$TA(Y/8?EWKJP/^\1.[+?]ZA_70U_#7_(OV?_
M %S_ *FM:LGPU_R+]G_US_J:UJRK_P 67J_S,,3_ !Y^K_,****R, HHJAJN
MJVVDVIFG;YB#L0#ECZ548N3Y8J[*A"4Y*,5=LCUK6(='M/-<%I&XC0=S_A7F
M$LKSS/-*Q:1VW,Q/)-27=Y/?7+W%P[,[,2 3D+[#VJ"OI,'A%AXZ_$]SZ_ 8
M*.%AWD]PKL_".A%3_:-W"0W_ "Q5QT_VL>M0^$] $[&_O8FVHV(HW7&3_>/M
M7<5PYAC;WI4_F_T//S3,=Z%/YO\ 0****\<^>"BBB@#E/'3#^SK5<G<9L@9&
M#@'MU[T>!T9;&9R!M9^#N_IVH\=.PTZUC&S:TV3D_-D XP/3D_I4?@99!;W+
M%<1E_E.!SZUZ;_W#YGN)?\)?S_4Z^BBBO,/#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!&SVI:** "BBB@"*X_U#?2JVXB5QNQP/Y59N/\ 4M]*A@7S
M2[Y(Z#BI>YM#2-V,#'_GJ.GH:YSQ+K'V&+R()5:Y<C/?8OO[U/XEUX6"BVM)
MMUR?O'.0@Y_7('%<%*[RS,\C,[L<EF.2:]7 9>ZC52JO=[=_^ >WEN <VJM3
M;MW*DFGI(Y8LV3UYZT?V:CLH&XGI@9)8U=) &37<>%?#OD*E_>1E9CS$A_A'
MJ1ZU[>(QGU>GS-^B/:Q6/^K4^>3]$1>&/"<NG0B>ZVF9AE5/)C^OOTKH_L4G
MJ*O$ ]:6OE:]6=>;J5'JSX^OC*M>;J3>K*'V*3U%'V*3U%7Z*QY48^VD93(5
MD*#DBC8XZJWY5(=A=G9N<U>C),2D]<4DKFLJCBBK9 B1P01QW%7.<TM%4E8Y
MY2YG<@N_]0:@CG9G4?I5UE####(JA, +L@<?2DS2G9JQH45G[I/EQ(>?>@O)
MYNP.<9Q1S"]D^Y/._ES1DC(&:191)<* ",=:88]TZQR$D$9&:&B:&16C4GFC
M4I*-K=2[15033X'R'\JDAE)7]X0"/6G<S<&B>BF[T_O#\Z4$'H:9%A:*** *
MTBO',9$7<".0*16\RZ4[2,+SD5:J&X9U0;.I.*5C2,KZ$K,$4DD "J2J^))"
M#@CBGQQ22-^^R1Z5-/\ + ^/2EN->Z[(+;_CW3Z5SGB#Q5'9E[2R99+@95W!
MXC/]3_+%5/$'B5K=/L%A(-^W;)(O\'J![_RKC:]C X#G2J5=NB/:P&6*;]K6
M6G1?YBLS.[.[%F8Y))Y)I**[/PSX?BBQ>:@F)@08HV.-F.03[UZN(Q$,/#FE
M\D>SB<3##PYI?<,\->&9X[F#4;O8% #Q(#D\C@FNUHHKYJO7G6GSS/C\5B9X
MF?/,****Q.<**** "BBB@"I?'Y4'O199VM]:2^/*#ZTZRSL;/2I^T;_\NBU4
M1SYO?%2TTH"<U1BF(,J".IS3L_,![48&<T8!(/<4 <QXX_Y \7_7PO\ Z"U<
M)LQ$),YR<8P>/QKO/'/_ "!8?^OA?_06K@MV?O '"X&.,?XU]#EM_8*W<^KR
MC_=EZLZ[P-*H>ZBV+N.&W;AGZ8ZUVC$@<#-<AX$<>3=ISDNIZ<=#WKL:\K'_
M .\2_KH>)FC_ -JE\OR$'2EHHKC/."BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMSVSQBG=USWYI"2!DXI<=#6)SE?4#']@N=Q41B)B2PR,8YR.]<-I'_'DH/\
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M'-,D-OS8XILA(7@]1SBG!L]NG7FJ['<Q/0=A0RHJ["GPIODYZ#DTRIX@50'
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M^<[F'4XZ>G2N,B;;-&V_R\.#OQG;SU_"NR\=X\NS^_G<WKM_PS7&$EL9.<#
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M/M8'! .".0?KT->0;W_OMTQUH\V7.?,?G_:-<W]DO^?\/^"<3R1MW]IKZ?\
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MW;_A+^?ZG64445YIX@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5S?B3Q"-,!M+8*;EUYY^X#WX[T_P 0>)8]-B:"V*O=G@#LGN17GTTT
MEQ/)/*VZ21BS-ZDUZ>!P/M7[2?P_G_P#VLMRYU'[6JO=Z+O_ , 8222222>2
M3WHH[X%=7X:\,?:2+S4(V$2D&*(\;_\ >&.G2O:KUX48<TCW\1B(8>'/,L>&
M?#)21;[4(AD8:&-NWN1ZUV5(2%&3TJ'[7%ZFOEZ]>5:?/,^/Q%>KB9\\O^&)
MZ*K_ &R+U-'VR+WK&Z,>278L45 ;N+UH^UQ'N:+H7)+L4&'+$#C-:B?<7Z5G
M%OG*J3L)Z5HQG,:_2IB:UMD.HHHJS *SY\F[(!QFM"J$O_'[^(J9&M+=CUM9
M$.5?!^E-^SR>9NW9;K5ZC%/E0O:LI,TR2AC@D<=*#=R D%!5S /44;5]!19C
MYX]44_MC]TIGGH9&=XP<CO5_8O\ =%-\I/[H_*E9@IQ[% 2Q?-NB!R>*#)%\
MN$QZC-7_ "H_[@_*D\B+&-@HY65[2)1WQ;5X;/?FE4@%<,XSUP:N?9XO[@I#
M:Q'^&E9A[2)'$HD3)D?.?[U-D38\?[QFR>YS4OV6/MN'XT?98P0<MP<]:=A<
MZON3#..:Y3Q5XC^RQ26%J2+AAAY <;![>_\ *K/B/Q$FF1-:6S$WC+PV,B/W
M/OC.*\_E=YW9Y79W;EF8Y)KU\!@N=JK46G3S_P" >MEF7\[5:JM.B[_\ 8.E
M+0/0<UW'AOPN(%6]U",&8C,<3=$]S[_R_EZV)Q$*$.:7R1[>*Q5/#0YY_)=Q
M/#'AM88TU"\4&8C,49Z)[GW_ )5OO&^XX Y[XYJ\  , 8%&!Z5\Q7JSK3YYG
MR5;%SK5'.8#[HI:**S.4**** "BBB@ HHHH I7I_>(/;-36H_=]:AN_]>G?B
MI[<8CJ5N;2_AHFIA8*=N*?3"?GQD?E5&2 [3\I IPP!Q287/2C'R$8Q0!B>(
M(+6_GL+&Y2<K,[E7B? 4JI//8Y_SWKE];T 6!N+FV&;6!4)1R223].W^-=A=
M$)K&F(4C8/YH&\C<IVYRO?ID?C61XK+KI%\#)\NY %5FS^/48^F*]#"5JD)P
MC%Z/_,]G UJD)TX1>C_65B_IMC:66NWJV]OY?R(<J3M&<Y'_ -:MVLRU=?[<
MODS\VR,X]N:TZXIR<G>79?D>;B92E-.79?D@HHHJ#G"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***BGN(;6(RW$T<48."TC!1^9H6HTFW9$M%4O[8TS9O
M_M&TVDXSYZXS^=#:QIB %M1M!D9&9UY'YU?LY]B_8U/Y7]Q=HJG_ &MIHD,9
MU"U\Q205\Y<@CKQFE&IZ>0Q%];'8H=OWJ\*>A//3D?G2Y)=@]E4_E8Z]QY/X
M\5'9 ;V/<57OM5T[:$_M"UW!N1YRY'ZTVSU/3U#LU]:@ !CF9>!G&>O3)'YU
M/)*^QNJ53V6S->BJD>IV$K(L=];.SYV!95);'ISS0-4T]@I6^MCNQC$R\Y.!
MW]:KEEV.?V4^S+=07.U$+%221BFQZA92KNCNX'7)&5D!&0,GOV%1?VKIDJL%
MU"T;'7$RG'./7U(I<DGT*C3FG\+&H<IQV[4X,"<<^]$J>4VX<J>,CM2*I /0
MAO>LS71ZBAB%V_H:""3QVZ<T9(XI",XZCUH$ '3')!SBAVX9CUQC%+VXX/2H
MI.BCN.M TKL9113XT+'=V%(T;L/10$ /4]:<.P/:EW$/N[$4G<X_&F97#')(
M[U"S[L@#@FIVY)P,<8JJ*3*CJ+24M)2++ 'R@*>.M!Z9ZCO34!\OG//04Y1@
M<YJC-F/KY1%T]2HWM>Q;3D<8//O^5;7;%8GB(+))I;'<-EV@R!D<D?X>OYUM
M!MF5(Z]ZWJ6]E#Y_F;U/X,/G^8#D8ZT>HI=VPCCMBFX)).>]8'.5-39%TN[!
MP086R,<=/H?Y5Q&@QF:%5_Z?(VZXZ G^E=O?R&*VFE"&0I&2$7JW'05XUIWB
M^YM+R\MCI]S#$LP2*41%PQ(P"..,9//3WKU,!3E4HSA'>Z_4]O+8.5&<8[MH
M[KQ?XOLM'MWM3<;)F^4D=>?X0.I8^@YKRVQT"\UK5WUK7@5*.1:6IP?+7/WF
MY(+'ZG^6%T^RO-5\4W6JZIYZM;S-';Q2+E0,#+Y[DY_#I7H6DZ)<ZLS&/$<*
M\-(PXSZ#U->I1H4L+1O/2WXO^ME\]]O0IT:6'IWGHD^O7S?SV7SWV@TO2I]2
MN%@@"JH7<SL<  5W^G:5:Z9&R6P/S?>).2U36=JEE:1V\8"JF>!W/>K!'05X
MF,QLL0[;1[?YGB8S'3KNRTC_ %N!'0C\\TA Z9X]*=D$@#CUS31D,OZUQ'G@
M^W&6XS4+-O;., # I96#R$CH*;2-(H*E6,K\Q(Z=!38UW-GL*D'WL\CGO0A2
M?04\@YSSZ4A Z8IP;:FS'7UI"NX=^N>*9 #@#'X4IZ\Y'%-]0.IZ9H"GH2"<
M>M "/\B'U-0]JDFDWMM]*CI&D5H.1#(V <5, 0 0>G'-,C!\L]LGBN=UOQ+'
M:XMK%DEEP0\@.57Z>IK6C0G6ERP6I=*C.O/D@C0UC7H-+ 5P9KDC*QJ<#'J3
MV_S]:X&ZN9;NX>XF;+L<GT'TIDTKSS/+*VYW.6)[UFZTEU)I%S'9OLN7C*QM
MZ,1P?SKZ;!X*&'5]Y?UL?2X/!0P\=-9?UL>5>,;F[\3>*VL;"W\W[/E%$;9W
M'J23T&.GX5Z5\._A$+)AJ6K-NE(!C&W&,@'Y<_\ H7Y=ZZ/P%\/3H5E!+=X:
M8DO)O3#NQSDL#7I<0PV2!BO'Q.(C&JY1UF^O;R7IW^[N>/B*D:=5U5K-]?Y?
M)=VMK_=W&V5M'9VJ11+M1>B@=*FZMG!SZT,>/0#B@X/(.:\T\UMR?,Q,X!Y_
M2G=^N/;UI!S\HI& )R2 /K0(5Y/+7"GYC4%*YW/D=*2D7%60J#<X]!UJ;C))
M/4TV$$*Q/>G*"&)/(H1,GJ.QP1TQ3>!@Y(!''%'&,9.:0@LHYQBF(=@CD>G-
M1RD[0IZYR:D)ZMZ#%5\Y.:3'%=0J2-!MW'K4?7CUJQ@(0.XXQ0AR8A V\8/L
M:=D <_=QZT9]ORJ*8\!>_>F2E?0:[[R,#"CI3:*6,;I!QD4C31(EC3:,D\]Z
M>!N) &1G- R48XZT <Y)Q@"F9-D4Q'"#ZFHZ5CEV/O24C1+0?$NZ0$\ <U:L
M_P#5?C487:F."2*EL_\ 4"FMS*H[Q98HHHJSG"BBF3316\32SR)'&O5W8 #\
M30-)MV1G2J1*X(Y)Z5DZOKUII<GV= T]P!EE4X5#[GU]OY5D:YXG-W*T>GEE
MB(P9&&"?IZ5S3.<DG+,3DGJ37JX3*W+WJVW;_,^CPF6N24JWW?YD]]=W&HS>
M;<2$XX ' 'X51GM(KB%HI1NC;AE/0BIQTYKI]!\*27H2ZO0T=N<D1XPS>A]A
M7KU*U/#0UT71'K5:]/"T[R=DCG=(\'2WZQ0VENT5JH">8>$51_/Z"O0=*\)6
M&CPI':C[@P&(YQZ?2MV*)(8ECC0(BC"J!P!3Z\#%XZIB/=>D>W^9\SB\UKXC
MW4[1[%"2V$:Y+TVV)-POL*L7; ( >YJO;96X4,",CO7GO1G(FW!MFC1115G,
M%%%% !1110 4444 %%%%  >E%%% !1110 4444 %%%% !1110 445@>(/$::
M3Y<4 CFN&.60M]T>^*NG3E5ER06IK1HSK34(*[(/$2:);S_;+Z/SKC;M6%6&
M6'T]/>N"D<22NZHL89B0B]%]A4EU=37MPT]PY:1NOI^%0U]+A,,Z,+2=W^'R
M/L,'AG0II2E=_A\@J_8:3<:A;W-Q&42&W0LS.< D G /3MW(QFI=%T.XUF<B
M/Y((S\\K#C/H/4_R_*NXO;"#3?"U];VZ[8UMY#R>O!K+%8Q4Y*G#XG^!CC,?
M&E)4H/WFU\CS*KNGV3ZMJ$5JC1Q%EQNV\8'? ZFJ8VX.<].,>M;/AAF/B* J
M%'RG(QVQ_.NG$S<*4I1W29UXB3A2E*.Z3-;_ (0*7_H))_WX/_Q5'_"!2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME5K_ -+_ "T/I,3*'+3@TFW%6OMT]/Z0[7K:Y\NWU&QC!OH/E!./NMUS]/\
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M/K-Q;RF![;R_,B9#\R\XVL,]>?T]ZNI3;DWV_+;[S7$4).<I;)+\-E\^YL$
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MCF1^R"FZ;ITVJ7JVL! 8@DLW0"O3-)TN'2;%;>$9YW.QQEC58W&*A'EC\3_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N6\=_\@FV_P"O@?\ H+5U-<IX[+?V9:C
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M5;,S44ALG(_"G&,$D^9]<BK_ ):^E)Y*8(QUHY1^U,[;R06 QZU)'\O_ "T
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M'YD;GJU:"SQ!0-XX%><GW/.J0M9HDC01KM&<>].I%8.NY3D&EJC%WOJ%%%%
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M%9'*%%%% !1110 4444 %%%(2%!)( '4F@ 9@JEF. !DDUQ?B3Q22S6.G28
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M* &E%/84>6O]T4ZB@=V9]V )< 8J&M.2-7!W"LYXW1B-IQVJ&CIIS35AH&6
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MRC^ _E5BTC92SL"">*2U9;M&%D6Z***LY@HHHH **** "BBB@ HHHH ****
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MT*C#328,K^I'].OYUJT45\[.<IR<I.[9\G4J2JS<YN[84445) 4444 %%%%
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M>7/T+-^=-\J<-U;&?6E<?LUW+]%462XWG:S8SQS2;+G^\U.X>S7<OT50VS8
MWG?Z9[4;+G^\U*X>S\R_15)4N,G<S=/6F[+GU:G</9KN7Z*H;+GU:E*7&>&:
ME</9KN7J3(SUJCLN?5JP?$6K-ID7DQ.1=R+D,"/D]ZTI4YU9J$%JS6CA95IJ
M$7JRSXA\31:?OM+;$ER1AB#Q'D?SK@'=I)&D=BSN2S,>I)ZFH3YA))8DDY)/
M))H ?N3[5]3AL+##QLM^K/K<)@J>&ARQWZLGAADN)DAA3?(YVJN<9->@>&=
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MQBNIKS,7.-2LYQV9Y&8R4Z[G'9A2'I2TAZ5S'" Z4M(,8XI: "BBB@ HHHH
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M** "BBB@ HHHH *B>'?*K,<@=JEHH&FUL%%%% @HHHH **** "BBB@ HHHH
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MJM1S2MY%6_L(-2M'MKA<HW< 9'N,]ZY2:VU?PQ(D6G2&Z@N&VHKJ6\LCGIG
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M?^X/Y5)3(1B",'LH_E3Z\T\:6X4444"/./$T2S>*C$V=KF-3A\GG^7TKKO\
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M:@"!<=ZFJ*V_U"_2I:2V'/XF%%%%,D*B:WC>3>0<_6I:*!IM;!1110(****
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MJ<74/T_"D-['V!HL@<I]$0_8VQG=2"T8_P 7:IOMJ9^Z<4OVR/T-%HAS5.Q
M+5L?>[T?97SC=4_VR/T-'VR+T/Y460<U3L0FU<#[U-%NY(&:L?;(O0T?;(O0
M_E19!S5.Q +9S_%TH^SODC=4_P!LB]#^5'VR+T/Y460<U3L5S;N/XJ4VT@&=
MQ_.I_MD7H?RH^V1>A_*BR#FJ=BOY,GJ?SH\B3!^8\>]6/M<7H?RH^UQ<]?RH
ML@YI]B"U!\X\]*T*H6YW7)(Z5?IQV(K?$%%!.*X?7O%K3"2TT_8867#3@G)S
MZ?X\UT4*$ZT^6!IA<+4Q,^6"]?(WM6\2V6EMY9/FS?W$.2/KZ=*CT[Q59ZC?
M):HKH[CY2PP,\Y'Z?K7G').2<D]32J2K!E)5@<@CM7L+*J7+:[N?0+)J'L^6
M^O?_ (!ZAK3.HL"D[Q#[;$&VDC>"2-IQV-4O$Q3['>*6!8VO"!%+$;ASSSC^
M77K5;2+EM;TFU:]N!YEM=HQ(0%F(/RCV))&2.V?6K?B%7-M>,I5@+0_(RDCK
MR>.^*\R,>2K&#W3_ %/*IP]E6C3EO%_JAMC(\VI:?+(VZ1[!68XQDG&:Z&N;
MTS_C\TS_ +!R?R%=)6%56E9'-C%::2_K4*0]*6@]*S.013D4M(.G%+0 4444
M %%%% !1110 G>EI#G</2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HR&7)R3[5)2'I0-,;RQ([4-P0:?2''>@+C>^[':C=G;QWIP((R*7% 7&;?
MFS3E&!2T4!<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7(>/%)AL3M_C8;M^ .!QC^O;'O77UQWCS9MT_)
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M48TXJFMD>C0IQHP5..R.U\$,3I$BD/A93C(&/P]:Z>N9\$[/[&?:1O\ -.X
M\CTKIJ\#%?QY^K/E,P_WJ?J%%%%<YQA1110 4444 %%%% !1110 4444 %%%
M% '->./^1?\ ^VJ_R-:;WNI*%*Z27^1&.+A003]X<^GZUF>./^1?Y_YZK_(U
MKO/?QP BSCED"*2%FQENX&1T%=;_ ($-$]7O\O-'H_\ ,-3T3UEN[=O-$ U#
M5-YW:(_EY8+BY0MQTR,X&?8GO^+S?:@(DQH\IE(&X>='L7/7G.>/I4IN+\7
M3["AC)/[SS^@[9&*C%WJ)$>--4%E);=<#Y2#TZ=QS^?XY;_97W_\$QLG]B/W
M_P#VQB^*Y+F;PZ6FLS"5N0"/,W87G#<>O'7UK!T0J++GO?VX'RYYW?I]:W_%
MMQ<GP_MG@6(O.JX63=D8)]!W%86A.$L6!&=]];K]/F!_I7I4;_5-OM?Y'LX6
M_P!3>GVNGJO4[;6RPTQ]H!^=,Y.,#<*T%^Z*SM< .F-E&;]XG0]/F'-:*_=%
M>4_@7S_0\&7\*/J_T%HHHJ#$***1W5$9W8*JC)8G  H 6N2\5>(GMF;3[,KN
M= 7F5LE<Y^7'8].?>JGB7Q,D^+739G&UCOF0\,,=%/?Z^U<E7L8+ -VJ55\C
MZ#+LLVJUEZ+_ #"I(();JX2"",R2N<*H[U)965QJ%VEM;1[Y&_)1W)/85Z%H
M'A^/1XB[E9+EQ\[XZ>P]J[\7C(T(]Y=CTL;CH8:/>71$/A_PW'I]NDUU&C7I
M.[(YV>U=#117S=2I*I)SENSY*M7G6FYS>H4445!D%%%% !1110 4444 ,;&X
M9S3Z:>O3-.H&PHHHH$%%%% !1110 4444 %%%% !1110 445FZKKEGI$8,[[
MI&^[$OWC_@*J$)3ERQ5V73IRJ2Y8*[+\DL<*EI'5%'4L<"N*USQ@TX>VTT%8
MR"K3,.3S_#[>Y]>U8FL:U<:Q.3)\D ;*1 ]/KZFLVO;PF6J/OUM7V/I,%E,:
M=IUM7VZ+_,"222223U)HJUI^G7>IW'DVD1<C&YNBH/4G_)KO]'\-6NE?.V)Y
MNOF.O3Z>E=6)QE.AH]7V.S%X^EAE9ZOL<]H_@^:[59[\M!'G_4XP[#W]*[:T
MLX+&W6"VC$<8R0![U/17@5\34KRO-_+H?+XK&U<2_?>G;H%%%%<YR!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2 ,DXI
MLLT4$;232)&B\EG8 #\:X?Q!XJ-UFUT\LD:M\TP/+CV]!6]##U*\K01U87"5
M,3+E@M.YO:WXFM=+C:.$K-=D?+&.@]V/].O\ZX&_U&YU.Y,]RP+'H , ?A56
MBOH<-@Z=!76K[GU.$P-+#+W=7W"K-CI]WJ4_DVD)D8#)YP /<UI:-X:N]3,<
MTBF*T;D/D'=S@@<Y%>@V-A;Z=;+!;QJBJ,$@<GZGO6&*S"%*\(:R_!&&-S.%
M#W8:R_!&3H?AB#2@)IBLUUG(?'">P_QK?HHKP:E2=27--W9\Q6K3K3YZCNPH
MHHJ#(**** "BBB@ KS?Q5N7Q2[>6H_U97:?O\#D]>>WT KTBO.O%?EGQ3B(!
M6VQAR"#EO7\MO7TKT,M_C/T9ZV3?[P_1_H>@P$M;QDC!*CBF7K;+&=]RIMC8
M[F' X[T^ $0("<D*,FF7@W64Z[-^8V&TG&>.F>U>?$\U6Y_F>11X,85GVID9
M &3[D?\ ZQ5_1#G7K(X _> <#VK/7&S.>>,#'6M#1,?V]98)(\P<XQVKZS$?
MPI^C_(^WK_PY^C_(]5[44=J*^3/A HHHH *R/$Q8:#=;0IRG.6QQ^5:]8OBK
M/]@SX3=P,^WOUK2C_%CZK\SHPFM>'JBCX%8G1YP<86X('_?*FNHKE_ ISH]P
M, 8N#T[_ "K745KC/X\_4US'_>I^H4445S'$%(>E+2'H: /.[9TF\=QMYH93
M<'#2+C/!QQQSG@?AUKT6O/-/5X?'B*R983."%;/56YR?3K7H=>AF'Q0M_*OU
M/5S;XJ:7\J_4****\\\H**** "BBB@ HHHH **** "BBB@"IJ$UQ'"B6?DFY
MD;;&)MVP\$G)7IP#26]D!.MY<1Q?;3'L>2,'&/09[<4^S:25'EDW .V41DVE
M!Z$>M6:J[2LC5R<%R+YA112$A1DG J3(6BH_M$1/WQ3#=Q ]2?<"E=%<LNQ/
M14'VN(GO^5/\Z+NZ_G1= XR70DJG>$K(I![58\^+./,7GWJI>,K.NU@>.QI2
M>A=)/FU)[,?N2?4U8JM9LODA<C=GI5FFMB:GQ,**:\BQC+' J/[5#C[XIW)4
M6]B:L#Q-K_\ 95NL-LR&\DZ \[%_O$?R_P#K5;U;7;72K(SN0[$X1,XR:\QN
MKW[9=RW,LBF21MQYKT<OP?MI<\OA7XGKY9E[K2]I47NK\1))&EE:1SEG.2?>
MEBB>>9(8EW22,%5?4GI40=2<!@3Z UW'AG1([,I>WGRW(R40G[F?7WKV<5B(
MX:%WOT1[^*Q$<-3YGOT1K>'='&E:>OF(%NI!F7#9Y[#\O2MFF+-&_P!UP:?7
MS$ZCJ2<Y;L^-K5)U)N<]V%%1-. Y4*Q(ZX%)Y_\ TSD_[YK.Y'*Q;C_CW?Z5
M7M"V.V,U)-+NA8;'&1W6H(9_)7!4\]Z3>IK&+Y&C0HJO%<B0G/'U-3>8F,[U
M_.G<R<6G8=13?,3CYASTYJ&6Y$9P!FBX*+;L17'%PM.NU)TR95?:?*;YA@]J
MBFN!(, 5%+<B/3YD()^1N?P-$7[QT1A+W3D_!"[M<D.2-L#'@]>5ZUZ#D5YS
MX+G":Q<8!R+<CI_M+7:/(TCYSMSV)KT,T=L0_1'=FU-RQ+OV1HY'K2UE@MU\
MP<>]3B[//RGK7G<QYCI/H7:,U1-V2>%-,EF:5@1\N!W-',@5)]1=;W-H=Z$*
MY,3=1G([_CBKH**  0 .,5S^L^9_8]R=[*0H(*DDY!![?S[59EL[=YDD<,S*
M6X5R <C!S6EUR*_G^AT>R7LTF^K_ "1LT<#O53[;_L&J=Y#%?2!Y/.!",@V.
M5X/TJ$XWU,(TFW[VB)]9F,.ES.F=V .".,GKS5_*XY(KEM<@@_LR0[I$+21G
M.XG)7A1_GO5D:;&JL?.G.^)H?FD.0"<G\?>M'R<B=^KZ>AT^PA[)7?5]/0Z'
MCUHX]:RXV*HL88X50H)-<]XH\2):@V\#/Y\2D.RC(P1S^-.A2E7GR01%#!SK
M5%3@7?$/B>*T#6EDPDN#D.RL<1]NH[^U<(S,S%F))/4FLF7Q! D<<TD%X1,1
MM/D.Q)/J,9'XU-9ZJE]=BU@MKHREF4 P,,D8S@XYZC'KSCH:^GP^$AAX66_5
MGUF%P4,+#EC\V:"JSNJ(I9F. !U)KM-%\()&GGZGL<NORQ<X7ZY[UCK96MCI
MUZDVZ>]:)&$2QD-&,@YZ=/7Z8XS70W M]9$>+B<!@>$+*!SR&/0'V)S7FXW&
M2E%*%U'O;T9P8W$3DE&FVH]7;R3T&[!%J-W]@T\!HRD1?G! V^V"<?EBNF(5
MEPP!'<&N%GMWGUJ=G^U(LSK)&8]V0, 9*CD>^1Q6X;! 2PN[S<0 3YGI_P#K
MKS:W+9:]/T1YF)HQ:C>6MO7HO,Z  8XH) ZFJ(N0L(09.!C)J&;9<)LE0GMG
M)&!D'^@KGNCSU2=]0\07 AT*[D61EPH!:/&1D@=^OT[^U</HT.WQ3'%AOW<S
M#]Y@MP2.><9^F:W=?T^-=(N3&K%RP9=K$[F+ =/QZ5R^@7/VGQ,)5A*QF9F4
M.<D"O7P:_P!DJ27G?[E;]3W\!24<)4<7W_)'K%9]QII>YAGMKA[=X\@A0"K*
M3EACID^OL*479"XP32B[(.2IZ8KR5.SNCP8QG!WB7J3(]:I-=%N,8R,5"=ZG
M&\'Z-4\PE2?4GU"UGO8O)BO&MXV!#E%!8CV)Z5-9VL=C:1VT6=B# W')/O5-
M6;>,MT]ZG^V_[)JO:.UNA4E/EY%L7**J+>#NA]J7[:F?NFE=&7LY=BU7G/C#
M*^(2^TX$:'VZFN[>_BC0N_RHHR68X %4SK&D73!#/:3,W 7S$8G\,UU82M[&
M?/:Z.W U)X>I[3D;5CF?^$VU'<5CLX HX (8D >O-:>@>)KO5M3^S3I;QJ$+
M?*#EB.PR?Q_"M.[U#3;6-C*((W96*[BJELCG&?7BN1\&7*C7K@HF0(6#?[(R
MN/Z5V15&K0G.-.UD=ZIT:V'J3C2Y;+0]%HJK]M3^Z:/MJ?W37DW1X?LY=CS[
MQ2!+XDFCB)9FVIC&/F/;^7-= ECK]GJ,9M"A@F16F&5\M'Q@A1UQP.<?G7-^
M);F$>*3N?&]D/S@@#\?2O1$O4V+\IZ=J]7$U73HTM-''JO0][%U)TJ%)**:<
M>J]#'^S^+#@?;-/ W$[L$G''^SV_K5K2=#>PO)[VZNOM5U+QYFW;@>F,GTJ[
M]M']VE^V# ^7]:X)8EN/*K)/LCRY5JKBXI))[V21;HJG]M']V@-+-\Z#CZUC
M='-[-K<N4UW6-"[L%4#))[56V7'H/SKC?$OB S;K"TDRJG$LBG@^P_QK?#T)
MUY\L4=&%P<L14Y8_,C\4>(?[0=K*U8?9%(W.#GS".1^%<W3<&I[2SN+ZZ2WM
MHR\K]!V ]3Z"OIZ5*%"GRK1+^KGUU&C3P]/ECHE_5RQI>ESZM=B"$8'5W.<*
M/K@\UZE:VL5G;I#"@1% & *R]'MHM%LEM1EI,YD?U/\ A5_[:N/NFOGL;B_;
MST^%;'S688F>)G:/PK;S\RW7(>/';R+&,,=C.Q([$@#'\S72_;4S]TUR/CJY
M1XK$]/F<<_\  :67V>)BO7\F1EE.7UN%UW_)FMX/B\K1_P#61OER?D;./8UT
M5<CX0+_V4VUE_P!8>K5T6)B,@J?^!5EBG^_GZLC'0_VB=WU+E%4\3>J_]]4?
MOAR2O_?587.3D\RY2,H=2IZ&JHNU7AAS[&G"[5SA5);L*+H7LY(1K78=\38(
M[&IH7$B;^_0TSS)?^>1_.H1,;?<C+SG/6EHB[2DK=2[2'IQ53[:/[M'VT?W:
M?,B?92+9Y%%5/MH_NT?;1_=HYD'LY$9TM8[EI[24P,^-Z 91L=./\,4U=1DM
M89I=2MOLRQN%$B-YBR \9 '(_$5/]M7NIH^VKD_*:I37VM?Z_KN:WF])J_Y_
MUZW"+4[&8D1W438ZX85-#<PW"[H94D'JIS6'XC^R7FDN;B&1_*.]?+'S ]/R
MYR?I[5:L8+/3(3%:0;,GYCW;ZU3Y.3F3=_ZZ_P# +E0A[/F5[OI_P?\ @&O1
M5,7F!]PU%+.TI&WC'O67,C!4I7U-#(]:6LO+C^+_ ,>J2*Y\M2",\T<PW1?0
MT**I_;1_=H^V9XVXSWI\R)]E(N9%%9BNZL?FS^-/29HW+MR,8QFES%.BS0JO
M>W,-I9RSSR!(U4Y8U6N-5AM+=YYR$B099B:\H\0?$*TU*]ECF::WM8.5,D;+
M'Z9+D;23GUKLPF%EB)=HK=_UU.O!9?.O*[TBMV:^L:Y/J\BCF.V3_5Q_U/O6
M748?<H88((SUJYIFF7.J7.R( 1J<NYZ*/3ZU])RT\/3[11]6H4Z%.VR1=T+1
M)-:NV3?Y<$6#*XZ\] /?BO1K"P@TVU6W@&$'ZGUJAI\<6FVJVT"@(O4CN?4U
M:^UG(..E?-XO&/$3_N]$?,8[$U,3.R^'HB_29'K6?)<&10!QCWIGS_WA_P!]
M5Q\QP*B^IJ9HK.2<QK@G))]>E.-V=V<<8HYD+V3+](>G6J/VHE2N.2,9S49D
M?/WNGO1S#5)]2];_ .H3Z5+66A=2/FX'O5C[:/[M"D$J3OH7**I_;1_=J.2X
M,A&./QHYD)4I=30R**S=SCN/^^JE6\PH!6CF!TGT+M%4_MH_NTU[@RC:ORGW
M-/F0O92ZEZBJ"M+M[''?<*<DSQ??&1]:7,-TF03$&=B.1FK*3/Y:X\L<=R:I
MYR3ZFK* B->3T]#4HVFE9(D-PZ#)V$>Q-/2YC*Y+ &JTN?+.3W]*9'"\HRH%
M.[(Y(M79H+*CG"L":?5.VADCERRX&*N529C-).R*[,JW1+''RU3E,:K+,[[4
M7G-372;IR2RJH7)+' %<%KFN_;V-M;;EMU/S$_QG_"M\-A9XB?+';JST<%A9
M5Y6C\_(CUO7'U,&"'*6H/?J_3K^(KG[ZQ@U&V-O<+NC)R1GK5BI(89+F>.")
M=TDC!5'^>U?44Z=.A#ECHD?54Z<*,.6.B1B6W@/3M3OX(88"6"%%4NP0#DY.
M/J>?>O6](TF+2;!+6!2P4\MW8U/H^DQZ3;"),-*1F1\<L?\ "M&RZ./>OGL=
MC/;RY8:1_/S/G,=C_:WC37NK\?,K;&_YYM2;&[1FM6BN#E/,]L^QEF,XXC:D
M*A<9W ^E:M4+@YN@/3%)JQ4*CD[$&%SC:U!'L:U-BGG I-B^@HY1>V\C+[=#
MFE /7'2M3RU_NBD:-6 &!1RA[9=C-QQT'YT;>^WZ<UH&-54G:/7I5-Y Q&
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M5M3;S),L=H$9E;/IU[_GS6\;U>RFN>J_>U.'%TY.:TZ%NCVJG]M'=32B\#,
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M4 %%%% !1110 4444 %%%% !1110 5C>(M$.LVT2I,8Y(FRH/W3GKD>OI_\
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M'=-ETO2Q;S,"^XL<=!FM:BBN2<G.3D]V<%6I*I-SENPHHHJ3,**** "BBB@
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MP/+7 SR>WJ ?PK)UNXL](M-\5M;"[;/E?NE!!/!;CV_/I6D,1AZDE"-%7?\
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M()WN<]]BBU7Q'=6LTDK0) HV9X!/<9XS[^]7;SPEHSP_+:^61W1CS^>:EO\
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M?\)80JHI#Q@, .O'/UKO[>W1[=&8<^M<CXCT*YCO9=6+(8=ZM($R& &!G_\
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M'QK+M\O'[UADYSCVZ#GWQTJ--&U[[8S#6CO8Y/)QQZ#&!^%)X:G_ ,_%^/\
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MG%!V[N0,$<9'>DZC(--5BW!!/'4UP'GV%;8%R$ _"GXCR1L''M3,_+D\TN,
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MI\?-^%$,4D\HBB4O(S<*.IKZBA2AAX<L=D?9X>E"A!1CLAMI!-<-'$JL\[G
M4=2:]%T70;?3(E9CON67YW]/85'H.C1Z9;BY(W73##L1T!["MJ0$$*O\5>#F
M&/=9N$/A_/\ X!X.8X]UI>SIZ1_/_@$7S[B QP*L67W6^M-R%C* =NM.L?NL
M/>O+6YY,W>++=%%%6<P5GS_\??Y5H50GS]J&,9[5,C6EN7OX:I[6,32*6W[C
M4A:8/LRO3TJ2!65#N.23FGN)>ZKC+:1G!#_>%6*AD1P_F(0..>*KM-.H#%N#
M[47L/EYW=%ZJ5VAWJ47''.*F*2@9\[]*KRRN% W!OJ*3V'333T' ?\>X8>O6
MK@4#H /PJGR#"00.#S4P,A; D'3TH035R>D)P":K2R31)DLIR?2G;9I(QEP
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MNTMK6"SA6&WC6-%&  *F' Q17SE?$5*\KS9\GB<95Q$KS>G8****P.4****
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M9>X'3],5O"O4A"T7:WZ_\,=E+%5:=.T)6MY=_P#AOQ,(>#Y=J[M7EWJ,!A&
M<8P.^>.>_3'3%(O@Z9(0J:S<+(#@$+\H7KC&>N><Y_"NKHJOKE;O^"_R'_:.
M)_F_!?Y'+V_@R%)[>2YNVN5C)+QLF%<8X[^O7KFNAMK.VLX_+MH4B3.=J# J
M>BLZE:I4^-W,:V*K5OXDKA11161@%%%% !1110 4444 %%%% !1110 4444
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MDOI]C-^[((ED7HWL#_7WK>AAYUZG+$WPF&GB/<C\R3Q#XJ:Z#6FGR8@88DD
MY;V!STKE:*<B/+(L<:EG8@ #N:^GHT84(<L3ZNAAZ>'ARPV"&"6XG$<,;22-
MT51DFNXT#1$TR RR*K7;MAFZ[1V ]/>K7A_0DTD%I"LETZ?.XZ#V'M_.M#(
M;/0/7B8_'NK^[I_#^?\ P#Q<=F#K-TZ?P_G_ , D<[%Y .X8 I@&P@N=P[GT
MIV1+(IP0B],TFTL&4G :O+/)V'/G81G''(IUC]QOK4>_<OS<,!@YJ6R^XWUH
M6XI:09:HHHJSG"L^YS]I^7.ZM"J%RVVYR#R*F6QK1^(=&"LH\S/3O3V9XID)
M?<&[>E1[FEE&<' [43AGF^\J[1QFD7:[U)V5BV]).!U!Z5&;J-L@QD@=:;!*
M06C)W$C@BG00#:=ZD9I^@K)?$(DJ^2R.2!VJM(%&-K;A]*T#;QD8(JK.$B;
M3/'K2:'"2OH$F"L*EL?+G-"-'&Q?S"3C &*).D+;0<@C%.C5'?#(, 9R*"N@
MV.6,<L&9O>K!S*FY'VJ?:H0@DR(XL?[3&I$#1VA&,,*:(E;IN-BS,FQG(*G
M([T2HX6-=Q9MW!]JK\Q-N1PV>N*G>4D1.!C!P=WK2Z%--/0AE5UQNW8SW-7'
MFCMK8S3.$C1<LQ/ %4;Z\2.(O,Z(B\EL\5PVM>()]5/DKF.U!X3/WL=SP/RK
MKPF%EB)V6W5G5AL%4Q32V2W98\0^(Y=1N'@M9&2T7*_*W^M]SQTKGZ*DM[>:
M[G6&WC:21N@49KZ6E2A0ARQT2/IZ5*G0I\L=$B)E+C:O4]*Z[P3H4"0_;KEO
M/E<'8&'" _UK$NM.;3=9BLVEWN"A9MF ">>.I(_"NMT^S:XM#]GG>/J 8'9
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MYI.[/FJE2523E-W;"BBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUW^A^'#I\ >0J;AQ\S>GL*-"T*'3=C/MDN6'SMV'L*Z2O#QV.]L_9P^'\_\
M@'S^8YBYOV=+;\R!%V2;/1*J\$L-RC#YY-6\?Z0QX^[59(Q*SC'.[K7F,\R+
MZL'E*X *GG/RFFB<XY4FIDMML@.!@5-L.[G&*5F#E%%)G60C)VD"K%EQ&Q)[
MU(\0:(Y S5$*S8SG'2C9CTG&QI[E]1^=&0>A%0BVCP/EIBH$NU"# V\U5V8\
MJ>Q:K/G(%V<]*T*SW(^V_-TS2D52W8_S8U=6 8+CTIZH97)9?E/W327<B-&
MK \U+;?\>ZT=;%-VCS#&_<XPORJ02U*;M5Y*,!ZXI]S_ ,>[_2L\;\'Y2<CT
MH;L$(J:NR]]J&/\ 5OGZ5').'&!$V?<5:7[HSZ4M.S,U**>Q0$I\Q&\MB%7&
M,5(\Y*$"%QGCI5NBBP^==C.\R54&48#Z5,PDEPZY&.JFI+HXC&/45/2L4YZ)
MV( &1-PCRS=1Z54N+V*UMVFN 0D1+/@9P*N7=U!96[3W$@2-1R37FFM:VVK7
M.(]Z6Z=$)^\?4_E77A<)/$2TVZL[,#A)8F6J]U;LC\1ZZ^KSJ(HV^SH_[M=N
M"/4FL\45+;6TUY<);VZ%Y'. !_/Z5]-&,*-/E6B1]7"$*--1CHD%M;37EPEO
M;QEY7. !_,^U>D:#H4>CVI#%9)V.YI-O(XZ#VZ_G3M!T:+2;%!L'VAU!E?J<
M^@]A6M7@8W&NL^2'P_F?,9CF+KMTZ?P_F>=>)IIF\5;6*$Q;%3H!CKSGCO6U
MH^FWC0MY%U+;1,6)C= 67GCD_C6'XB9O^$NE)C8D,F%7DGY1BMO0KQ[2P=;>
MRDN?W@W/&0 Q.<GGT/\ .M,4G[&G:VR[?KI_7J=U?F6$I\EMEV_70UDTV^6(
MI_:CEL !B@R,5*UC>&4,+]@NYCMV#H>@_"JTM_<AO,73KGY'<'D<@#(/X]*F
M_M6X(W+IERR[4)(*]^HZ]J\[EDWT_ \EJMOI_P"2BFROW5 U\%(C13M3JP^\
M?QXIC:?J3  :EC]XQ)$8^Z1P/J,?K3X-3N9-IDTNYC!W9R5)&,8[]\G\J<-4
M;S75K*X"C9M.!D[@2>,\8QS]:;37;\"?WR>R_#T.8UBQ-UJRV#SS?;9(PJR,
MGR.@!8_J!^586IZ1+IQ^4>8BQAG9>W.,GT%=-+,]SXMLYV18=F]#&6&[/EM\
MQ'N,<U'K[I]@OD\L;_LX._O]\<5Z-'$5*52G3B]&E=>KL>UA\14IRIT^C2O\
MW8?HVF?V-KS6_F&4O "25P <]O6NI4$=LXK#+$^+W4/]VW'RGMS6WC/WNU>=
M6G*<N:;NVD>3BYRG*,Y;M(4'OCK2G!!P*0Y/ H^HZ5B<8@;<>@/XTF>?48]:
M4 =ASGFCK_/- Q0N2>>O-&.1],49  +#I0.IST[4 */]9_GBH&/S' (SZU,,
M"1<8QFH6(,G'K0QQW$/7BE/(XP,]Z0D\!>">M.0@-DXI%@IVY.,TK,"P)&.:
M:>?SXHR23F@0$\<>O>A00<YS[49&3Z=J4G&?<\4 -.6!P<$'M3L_+CWI"I8!
M1U H  &3]Z@ .TMD< 4FTDX /3%+DDY/KFFH<2<MQVH&.!(Z'CTH!"DY Y_2
ME&WC<.@Y-"D 9())H$-;DCM2A3@\]L49'RG!]Z4XW?*..] # /FY)]Z5OF(
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,DD2&-I)&"HHRS$\ 4
ME?8?6'KWB*'2H=D126Y)P$!^[UY/XBL#5O&=Q,YBTW]S%T,K+EF^GH/U^E<L
MS%V+,2S$Y)/>O6PN6N7O5M%V/>P642;4Z^W;_,M:AJ5WJ<_FW<I<_P *#A5^
M@[54HK?T?PK=ZEMEG)M[8\[L?,W/8=OJ?UKUYSI4(:Z(]N=2EAZ=Y.R1C6MK
M->W"P6Z%Y#V]*]!T7PQ9Z=&LLR+/=$ EG (4_P"R.WUK4LM-M-/A$5K J*.?
M4GZD\FK5>#BL?.M[L=(_UN?.8W-)U_<IZ1_%A1117 >2%%%% !1110 4444
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MN_\ 59]#2>Q4/B'P#Y6/^T:EJJELXP?./K5JA!.U]&%-D.(V/L:=3)?]4_\
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M<]<_G1L;;CUI.ISVH  02,C@T<9(]/6D+#W'-#/L&>IH'84_*<#!!]!2YSG
M(P..>M-4YP>YZ4['&<'!Z9- F+\N#G[PIGN5R.PH.-V">33L<<G'ZT!L-Y.
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M'2OG#YIN[NQ>>K-D=:3=@]3DT=,T%3NX[&@0F3V'/6G?U-+G#!A@\4W'8@T
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M;UB3Y2IY_P!D$+S[ FG#3;X1@#4Y=PB$>XJ.H.=WUQQ39-.O,R,FHN"Y8D%
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M6J" [I%![ YJ8*/*E..1T-55)R, \#M3@Q$39+9)XYH5ARCJ7#&!:[$4+QP
M,57EV_:MWRAAQNQS^=,\R01\L_MS3YX409!.?>F]28JSUZD-Q&C7&YD5B#E2
M1G%8_B#58=-7$/EM<N2 JD94'DD_I]>*?X@UF+0[%)G53NZ!CCMR<^E>.:)X
MHG\4^*=6N"S-:Q!4B8X(8Y;)!QZ8X] *]# 8-59*53X>GG;]/^&/6P&%4Y1E
M4V=[>=M?N.HR6)9CEB<D^M'045:N=-GMM.BNI04$S,JHPP>.]?2.48M)]3WW
M**:3ZG=>'="M[?2(VN[6)YY?G;S$!*@]!STXJU+96UO=%HK:&,XX*1@']*TK
M9D:UA9-VPH"NYLG&.Y[T]D5Q\R@_6ODJM6=23;>Y\7/$SE4E*3W*EOB,.68#
M(XYI(6S=CG(Q5IHHPIQ&OY5%;@;G  'X5C8CF3399HJ*=BD#$'G'!I\>?+7)
MR<<TS&VEQU%%%,056O#B'CUJS5>\_P!3]#2:T+I_$B=?NC/I2XI <J#2T6(#
M%,,,6[?Y:[@=V[;SG&,_EQ3Z#TIC39Y<$?\ X2Q%*-N^VJ<8Y^^#V]J]1KRR
M>[-IXCENU7>T<Y8+YAY_'K_G'2N@/CQ><63?>X^8?=_QKU\7AZM50<(WT/H<
MPPE?$>S=.-[([.J5Y_K4^E<RWCP?-MLFZ#;EOSS3)O&,4SJ1;LOR]ST.3D?E
MBN&6!Q%O@."&6XF+NX_D=;!*BQ\N,U+Y\?\ ?%<5%XJMR^)(650?O#G(VG^N
M/SH_X2N 1(QA8N1EE!Z>WUI?4L2M.0;RRLW\+.REE0Q,%<9Q4=E]UN>]8^C7
MZ:I8S7+0O'Y/W@/FR<9..]8<?C.YMG=/LT+_ #'!#GIGCM2A@Z\YN*CJMR88
M"K/FIP6JW._HKA/^$\NO^?.+_OX?\*5?'EQN&ZSCVYYPYS_*MO[.Q/\ +^*_
MS#^R,7_+^*.ZHKA/^$[NO^?*'_OX?\*4^.[@GY+*/&!U<_CVH_L[$_R_BO\
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MNE0^;N!NI!AGQT'H*UA).3C>>.:\+'8_VKY*?P_G_P  \#,<:Z]Z=)VC^?\
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MS2IXKM2N6M[I3D\>2?6N+V53^3\_\SSO85O^?2_'_,G6XUORCOLX-Y=<;9.
MI'S?ETI#?:KL:,V40E!;GS>#P<=OI4?_  E5G_SQNO\ OPU5)?$EHUQN\FYQ
M_P!<6I.G4_D_/_,J-"JWK2_/_,RO%'D32NIM,7T:(SN).Q'.!WQC\.M<PO\
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MU70@HW/?UH!=1N%5G$F"V:C*,(\]B:EC$1<*R9SWS1L0JQ /!X&:1=[ ,E\
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MZ]OK42-Z5KV1IK]T4M(OW1]*6K.<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O<VK7#Q,MS/"8
M\G]TP ;(QR"#G'6H1I[@2#[?=DR,K$[EXQC@<< XYQ^E7J*KF9:J22LB@=/E
M,B2'4[S<B%1@H <GJ1MP2.GX?6JJV+27$SF_NDR5R 5(X!' *G&>IK9/2J"1
M-++)M;;@TG-FU.K*S_R1GW=G)96K307]TTB+(RF1P1DCC(X! [ \5QDWBG6R
M%?[;R.WEJ!_*NUUB-ETN\C<@[H'VDM@ X/7->;;]@Z=1CITKU\KIQJ1DYQ3]
M4>[E=.%6+E42EZI%OP^5.L6A28KEL9&>?:O4$A$2M(57S7P&<#E@.F?S->6:
M%;QQZU:;3@;^!G@5ZE$[- =QS@X%99O;VZMV_5F6=_Q8V[?J,A1YBW[PC%3)
M&T+%VD+*!TJ"W1W+['VXZ\5:2)QN$DFY2.F*\E'BS=G:X17"2MM7-35%'%&A
MR@I[G:A/H*I&4K7T*L2>:&9I''S'@&I;5F*L"20#@$U%!$7CW^85W$\"GVIV
MF2/KM/6DC2>S)9VVP.<XXJFAC(^>5\^QJY,$:)@YPO<U$+:#;G.?QH>X0:4=
M1^!';':QQC()JJGE,@+R/N/7!J:+YK7]X?E]:!;P>6#GCUS1N--*]Q)"([4;
M&;D\$U$GELOSR/N)[&GJJ-#B0X4-\II7@A6%F4Y(Z'-(::6A;4;5 ':EJ*$N
M4&\=JD+!>I ^M68-:BU@Z[XFATG]S$HFN_[F<!>,Y-9FN^+PI^SZ4X8@G?/M
MX'LN>OU_*N-DD>60R2.7<]2QR37JX3+G/WZNB['MX#*G*U2NM.W^9->W]UJ,
MYFNIFD;L.R^P'857IR(\LBQQHSNQPJJ,DFNRT;P:H"SZD0^1D0KG R/XLCK7
MJUJ]+#0U^2/:KXBCA8>]IV1CZ+X8N=619W?R;5NC]2V#V']:[ZPTRTTV 0VL
M(1<Y)/))]S5B.-(8PD:A5'0 8 I]?/XG%U*[][;L?+XO'U<2[-VCV"BBBN4X
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBJ.I:K:Z7;F6XD /15[L?PII.3LMRH0E.7+%79<D=8XV=R JC))["N1UKQD
M@B\G2FS(3\TQ7(4>V>M8>K^);W5E,?\ J+<C!B0YS]3WK&KVL+EJC[U;[O\
M,^BP64*'OU]7VZ?,<[O*Y>1V=V.2S')--IT<;RRK'&I9V(  ]:[;1_!L21)/
MJ1+3GGRE;Y4],^I_3^==^(Q-/#QO+[CT\3BZ6&C>;^1B:#X:FU;;<2GRK,-@
MG^)_7'^-=_:6%K81^7;0)&O^R*FBB2&,1QJ%4= *?7SV)Q4Z\KRV['RN,QU3
M$RUTCT04445S'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%5[R^MK"W:>YE$<:]3C/Z4TFW9#C%R=HJ[)V944LQ 4=237#^(_%)N/-
ML+';Y!!624CEO9?0>_\ *J&M^)KC5@\$:B*TW<+_ !,.V3_0>O>L*O;P>7<K
MYZN_8^DP&5^S:J5M^B[!03@9-.C1Y9%CC1G=CA549)-=AH'A*6.9+O40@ &4
MAZGG^]_A7?B,3"A'FEOV/3Q.*IX>/--_+N1>'_":W$2W>HJVQN4AZ9'J?\*[
M:.-(D"1J%4= !BG=!17S5>O.O+FF?(8G%U,1/FF].W8****Q.8K2:=9S7*W$
MMM$\R]'9<D4BZ;9*VY;6$,,\A!W.3^M6J*=V7[2=K79'#!%;H4AC5%+%B%&!
MDG)-2444B6VW=A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ H/(P:** (OL\7]P5R_B/7XK 26MF/])(P7!_U?O[FM
M'7O$<.DP[(BLMVWW4ZA?=N<XKS65V<N[L6=B69CU)/4UZ> P*J/VE1:?F>YE
M>!=1^UJ[=//_ ( Q-Q&YSEFY)]:D13(ZHHRS' 'J:BC.8E.",CH>M=_X?T"*
MRM_/GVR7$@#*<?<'IS[]Z]?&8J.&C=[]$>YB\5'#1YI;]"30-%32H'>4AKE\
M;R.BCT%;'<_-G-&Q<'/3US1L /?_  KY6I4E4DYSW9\I5JRJS<YO5@Y^7J,>
ME*<!<8(QZ4TH,@#-/YZ ?G4&8= "<<TA()S2G)4 ]!2 #!&,<>M ";AC&0?0
M4[KR./:D"XZD#TI1Z<8]": $ R=N!G.:7&3CG)&*,9R1Q3(W+/\ =^[^E #@
M.W//04NT X'4^E&?XNY--+LG5#GUH#5B@@CJ>.WK2@%N@^M-#KC'EMQW% FV
M\JC"@+,<<_I2 \?7H:16$F>"/6G #I@@#IF@!)5(A[<\\4R/[H.>.XITG^J;
MDFFQ8*CG\*.HU\))M)(7'/6@YR1CG%)EL@]P,4N>Y//2@0W..O/:G88CH..E
M''^%)]&H BG.6X]*>C)M7<W:HY\!B>@]ZYGQ!XFBL"L-I)&S$$229R$/M[UK
M0H5*]3DIJ[.FAAYUVH011\87"2:K&BR;A%#A@/X3DY_3%<RMQ#++M5P20>*E
M+^=(69RS-SD]ZB@TR,W_ )L$1-Q(!& O.?08_&OKL/2C0I*#>Q]90I1H4E!O
M9%BWMC?3):H/FE.T>WO]*[O3-"M-.B0LBS7&,M(1T/H/:K&D>'[33+9'(=IR
M 7)QD'N/I6IY41Z;P:^>Q^/E7?)#2/YG@8[,?:ODIM\OYD7#$<]!VJ?!)4=S
MBF*B#KGTSBG<@@ALD=*\U'E-]A[1[3@L/7FF3P_)O#9IS9?Y^X'(%-Z#!)P>
MU!*ON!'/ QZ\TC8"C)(SR.*=Q@^_>DXXW#./:@:8#Y@,#-+_ !8Q@TG3&3CZ
M=J4D<MN!^E  =Q'./;UIO&<TN#GGG-'/0 8H &X'?KCK2YP#[=* .<8W>U)Q
MGGI0 H!ZGCFD)"L/FSSZ4XD$9!/^-(#D_P )H /X3QQFFD$G"@$YSSZ4[/RX
M]3TH7KD9SB@ [C)YH[FD/K_*CUSQ[>U !EC][\*Y7QH'\JU.%V9/.><XKJ\Y
MZY([5Y]83RZ_J5O#J,C2(%; 'R^_:N[ PM-UGM#5_B>CET'SNMTAO^)UGAX*
MGA^S!.<H3]W;U)_SGOU[UJ<=??BJ]K9PV-G';0 B.,G;N.>I)_F:L8' &,]:
MY*LE*I*2ZMG%6DIU)275L4\'.<TF!@]O0T8]>HZ4H;.!Q^509@.F <_45'-_
MJU/J:D7((/'(J*7'EKSR#TH8X[C8QE6^8C"YXJ>.*)XLL23VYJNA4;P3C(XH
M5F P#@4D5)-[$C.63[^2O08JKK-]'ID!FF+O@8"CJQ]*DDG@MK2::X=41!DL
M:\]U;5KC5[WSIOE4?<C!X0?U/O7=@<&\1*[^%;_Y';@L&Z]2[^%;E;4I&U:Y
M,]Y^\)& G\*CT JI:65M8PB*VA2*,?PH,"K&173>%] COB+^[*FW5L1QY^^1
MW/M_/^?T=6K##TKO1+9?H?0UJT,/2YI:)?U9!X6\/+?R?;;Q3Y$;?)&1_K#Z
MGV'Z_P [7CW>%M!N^3#?+@=?7UKKV:.WMW9=JJBD^U<=I>?%KLVJ%BL&=HC(
M5>?UXKQ:>)E.M]9G\,>GKV/!HXF=6N\7/X(=/7L=E;+LM85#A\(!N&<'CKR3
M_,U+4-NJP6\4'F;RB!=QZG QFIJ\QGBRW8C?=-5$:12_EJ#SWJTQ&T\]JAM_
MO/Z4F5'1,BC?SI LK$X/W<<5=JO-$%7S(QAEYJ=3N4'&,BA!-IZH6BBBF9A5
M:\_U0^M6:K7O^J'UI/8NG\2+(Z44@Z4M,@*0]*6L3Q+K,VC6L+P+"SR.5Q(3
MG&.H Z_GZ>M73IRJ24([LTHTI59J$-V<6/*D\6 3@RQO=;6!C W9.,8/&*[I
M?#6CI$D8L(B%.06R2?J3R?QK(T;0+*_L[74I&D^ULXF9P_&X-GIT[5UE=F+Q
M%VHP;7+H_D>GF&+;DH4I-<NCZ;&4?#>CD ?8(>&W=/?/Y>U)_P (SHY4+]AC
MX4KWSSCOZ\=:UJ*Y/;5/YG]YY_UFO_._O9D+X7T9#D6*'G/S$GU]3[_R]!3H
M_#6CQA<6$1VC WC=GZYZGWK5HH=:H_M/[P>*KO>;^]F?9Z+8V%O-!;1,D<PP
MX\QB3QCJ3Q3TT?3HX?)6R@$><[=@Z^M7:*3J3;NV2ZU1MMR>OF4AI&G!MPLH
M <DYV#N,'] *#H^G'.;* Y&#\@Z8(_D2/QJ[12YY=Q>VJ?S/[R@=%TPA@;"W
MPPP1L'/^<"EET;3)V+2V-N[$YR4%7JY#Q%XJ>"5K/3F7<O$DP(.#TP/>M:$*
MM6?+!ZG1AH8C$3Y:;?WE/Q'JUA&\MG86ENSN!YLX'W2.,#'< 5RM'?/<TJ@L
MP5068G  [U]+AZ$:$.5'UN'H1H0Y4.BBDGF2*)"\CG"J.I-7DL9M.UVTM[M5
M5Q*AP&R.O'0_Y]^E:2Z7=^';"+6'13="0*(V&1&I[GW/3_@7K3]'MHM:NIM0
MO"[7"S!P1PJXY '/-<M?%KDE)?!JK];_ .1SU,4G&4T[P6EUO?\ R.Q ^7=C
MI03@9([]*13\HZ@&G9^7GDFOFCY<0G!Y[=* 0>5Z>]+C/4=:, <#CG% #0RM
MTR/7-+\N?6EVX[#\*4#()P!^- 70PMM&>F>E+G..>/I0=N!W'TS1_(B@!<*.
M!^=(I4G"]CTH' XSQ2X"GH!GH10 WTX'UIW3ISFDSVQ^E';J!]: %^]NQVZT
M<=NQHZ X_P#UTG7G^= "[L@8)P#1]X],?C0=H4 $>XHP>3UYZT"#G(&0.,YI
M.JY'/.*1@3P/I2XP,#OZ4##E>HI=I&,C(/O28/0_CS2ELC'/% !NSQGFDQWQ
M^='\7]:"-W<C':@!>@^A[TTD9S_+M0[+&A=V 0#DDUQNO>)3<!K73Y,0D8>4
M#!?V&1D=_KFNC#X:>(GRP_X8Z,-AIXB?+'[QNO\ B,7T365LA2,-AY"?O8[#
MVKFZ*D@@EN9TAA7=(YPJYQFOJ*-&GAZ?+'9'U5&C3P\.6.B$BBDGE6*)"\C'
M 4=Z] T718=*MMY DN&Y:0J 1T^4>W%,T70HM*@#R8DNG'S..@]A[?SK9(&"
M.#Z5X6/QSK/DI_#^9X6/Q_M7[.G\/YB!MP'O3B"-HQR3VIH  !Q3N<C(./7-
M>8>4QF5R,$YIQZ=,@\XI,#&>AQZ4X#TS0##G&.XI,\<_2CD9&>@Y_I1UQDB@
M W8!!Z"EP22  >?QI-JC'()/7FCT^;![#'6@ W[3VYHR 3Z@9-*0",_SI,>V
M<\4 "D, ?6EP>2<C)I!C/9:4$XYY - #<@\YY%1S AA[5)QG/;'7%,G_ (>O
M/-)E1W+8=EC3 '(IWF-C) I@YC7UQ1VYXXJC&R'^8_\ ='YTN]B"0 :9WXSS
M3=Q'3OS3%9#S*X&0H/XT><V,X'O3#SP*7\/K2'9#A,3_  ]>E<WKGBU;026M
MFNZZ'!<CY8_\34WB#7%TJV\J$YNI ?+X!"<CD\^F<>XKSYG9W+NQ9F.22>2:
M]7+\%[7]Y4VZ>?\ P#V,NRZ-3][56G3S_P" )12&NT\.>&0J+>7Z R,,QQ'^
M$>I]_;M]>GLXG$0H0YI?)=SW,3B88>'/,7PUX<\D1ZA>H#(>8HFZ)_M'W_E]
M>G6;VQT'MBF*.-O3'%+CG![=.:^7K5YUI\\SY+$5YUYN<QZREFP,>]#,^WCK
M]*8N XX'N:>S@#&[DUD<[6N@FXN"02I!Y IJN3@$_P"-"L$.3GFFJX:0#RV
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M\GWH50HX_6D(R,9IPP-H!R!U- #MY*_=''3WII//3M@4W#9//?Y:-HR&;\*
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M"P8&[(HP<YYI ?DYQ21ON&,F@+,?T'3ZTQP-O))Y[4X#"YQ2[EWG=G''% "
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MB&I/2/?_ "-#7?%-Q>RO!92-#;#*EEZR X]LCOT]:YRBM/1]#NM8E_=#9 K
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MK]#JAC>>@XZFD)QD>U(W0=J.V1TZ5YYYPH.<^V,4F[C..:.AX[=*.K8P,9H
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M7S"1$9V((H$\J#:K<#@9%<29Y[A=:#)O]:_UJ6#_ %T>.X.:@))))ZFIK?\
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M/0G.:0 8 QP>O%&1SC'/%'8XZ>] Q&8[L$#ZXIP.#@_G2'[W(.<>M+M+]NE
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M:?FQ4*LX^4XP>O%2=#Q]/I1DX)..!S0-;6$#?,<<8/;O4I2-E+$MCJ1NJ$
M<'(I6'>@31*^-^. NW@&H^!SQTI\B[F49 &VF 9XQD?RIB6P YPP'-)N.3P1
MCH<T=?0"G'ZGZ4BAA"AO5LT[^'.>_>D!'M^5!('0\=J %Z<^U(,') Z'BEX"
M^QXI!@ <<'WH 7=\Y'(QWS5>;_6MQBI\XZ<#O4$O^L:DRH;FFGW%^E.IJ?<7
MZ4ZM#E>X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$U*[O+;L?+XK&U<2_>>G8****YSC"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **9))'#&TDKJD:C+,QP /<UR6M^,$"M;Z
M8P<D$--C@?[OK]:VHT*E:7+!'1A\+5Q$N6"_R-W4]=L=+A9I95:4#Y85/S,?
M\]ZX76/$5WJ[[>8+?&/)5LY]R>]8Y))+,26/4DY)HKWL-@*='WGK(^GPF6T<
M/[V\NX5)#!+<S+%!&TDC=%09)K0TG0;W5WS$AC@'WIG!"]<?+ZGK7?Z1HUOI
M$&R,!I#]Z0CYC1BL?"C[JUE_6X8S,:>'7*M9=O\ ,P]%\'"!EGU(H\@(*QJ<
MA?KZFNM1%1 B@!5& !VI:*\"K6G5ES39\QB,35Q$N:HPHHHK(YPHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0D*"20 .234-Y>V
MUA;F>ZF2*,=V/4^@]3QTK@M=\4S:FKV]LK16K#!S]YOK[>U=.'PM2N[1V[G9
MA,%5Q,O=V[FQKOBZ*%%ATN59)3R95P54>GN:XAW:1R[L68]23DTV@9)  ))Z
M #K7T6'PT*$;1^\^KPV$IX:/+#[^H5T7A_PQ+J+I=7:A+/GY22&?CC'H,]_:
MKN@>$F8BZU-"N""D)/7W;_"NU    & .@%>=C,QM[E%_/_+_ #/+S#-%&].@
M]>K_ ,AL44<$:QQ($11@*!P!3Z**\4^=;;U84444""BBB@ HHHH ***ANW:.
MSG=/O+&Q'REN<>@Y/X4#2N[$C2(B%F8!1U)-)YT><;USG&,UY0U_>7=J+>:\
M9HR>(V;@G/<G@#GUJ.W%S=7,<4,DAED;"Y<CD^]>K_9<DFY32L>ZLDLFY3V\
MCUG[1"&VF5,^FX4X2(>CJ?QKRM-*OYM4EL47==1DA@SXSW)&<$@YS^.:N#P]
MXA'2VG'.>)U_^*J)8"FMZJ_KYD2RJC'>LEZV_P STGS$SC>N>N,TGG188^8N
M%Z\]*\W_ .$?\0YS]FGSC&?/7_XJF_\ ".^(,,/LDV&^\/.7GZ_-2^HT_P#G
M]'\/\R?[,H?\_P!?A_F>E"6-LX=3CK@T"6,G =3^->86FCZU=VRW-I#,\4G(
M=9@-W)]3GKFIAX>\0 Y%K.#SR)U[\G^*F\!33LZJ_KYC>5T4VG67X?YGI6]?
M[P_.C>O]X?G7FW]@>(_^?>X_\"%_^*H_L#Q'_P ^]Q_X$+_\52^HT_\ G['^
MOF3_ &90_P"?\?P_S/2=Z_WA^= D0@$.I!Y!S7FW]@>(_P#GWN/_  (7_P"*
MIG]A>((RD8MKD9&%"RC Q]#@4?4:?_/V/]?,?]F4?^?R_#_,],WK_>'YT;U_
MO#\Z\U&A>(6+ 6]S\IP<S =L\?-SU[5(=$\2M&D9@N-J9VCSUXSU_BI?48?\
M_8_U\Q/+*/\ S^C^'^9Z/O7^\/SI:\NM5U"SUZT@G,RS+.F8WD.#R._/%>HU
MAB<-[!K6]SDQN#6&<;2O<****YCB"BBB@ HHHH **** "BBL[6M6BTBP:=MK
M2GB.,G[QJH1<Y*,=V73A*I)0BKMF=XB\2)IJM:V^'N74@_-CR_>O/G=Y9'DD
M8L[DLS'J2:=<3RW5S)<3-NDD;<QQ4?4X ))Z 5]/A<-'#PMUZGV.#P<,-"RW
MZL?%%)/,L4*%Y'.%4#DFO1_#VA+H\#,[%KB4#>2!Q["J/A/09+$-?7:%)W4J
ML9Q\B^OU-=37DYAC/:/V<'[J_$\7-,?[1NC3?N]?,*BN%S&>>/2I:CF_U3?2
MO+9X\=RK!EF+ X!& ":7;U-5U#XW '%*?,*XP>3FHN=+CKN3 ?3%&WD]>>IJ
M#$F. :<?,VXP:+AR^9,>1@TJKGT%09DVYVG'TIIWD#@\47%REC#$GGK2X(&&
M'457W/Z'B@EW7&#]:+CY2<'H 1^=&WJ,CZ9JOL?L,_2C8_H:+ARKN60!P,9]
MLTP*/-?VQ4.U_0\4;7R1@T7#E\RP<AAG%)_%V_$U!MDQG!H,;^GZT7#E\R8@
M"3@C\J<HP1TZ8ZU7(?I@GZ4;)&_A-%PY?,?M)=AD!<\U* ^, H15?8_3!HV/
MTQ^M VO,E=2T9)*9'7'6FQC(7)%,VOZ=:YCQ#KK0![.T.9<8D;IM]A_C6U"A
M.O44((VH8>=:7) G\0^(A!YEC:9\WH\G901GY3GKTKC>IR:BMF=X0SIL;)R*
ME +' !)/  %?58?"PPT>2/S9]1A\+##1Y(_-B@$D  DG@ 5VF@^&_LH2[O ?
M.(XC/11[^]1^&_#S6TB7EXA64'*1L/N^Y]ZZ64D@8S7CYAC^>]*GMU??_@'D
M9ACW)^RI/3JPFX 'M5:^^73Y'. HC.3^%2[7(/!XZT[]X1C:<$5Y"=G<\F/N
MM'*^"-XFOF7C C&,\?Q?X5UQ:7.2%_.LQ(HDUAQ'&J/]G&X*I QN..@QZ^Y_
M"KNQNE=&+K>VJNI:U[?D=&,FJM5U+6O;\B8F3 .5XI"9=A'RX[\U%L<'&#1L
M<]CS7-<YK(F4 1@''3H32[1M]!]:@\N3/W31L?T_6BXN7S)U Y"TD^"JC.>>
M:AVN.WZTFUAU_G1<:CK>Y8YZ<X/O3EX8\9XYJMM?N#1LD!Z?K1<7*NY/M)].
MM+S_ !=NHS5?#Y[TF'/K1<.7S+."5P3QVI<87I[U6VO^7O1MD(Z&BX<OF60#
MD\_C28XSQFJ^V3T-&U_0T7#E\RQC/84@7YCUYJ#;(.QHP_4YXHN'+YEC&.@X
M]J50=V. WO5?9)C.TBC$C<[3S1<.7S)SGKFC)QR03]:KX<\8//%!C=<9&/QH
MN'*B'61Y>C7KJR@F%AG=CK^!^G^'6L7P6[&SNDW#:)!QGVK2U<.NCWA#JG[I
MAN8\?3\>GXUB^#(2EC.<Y;S.?F'\NHKT*5OJ51^:/1I17U*=WU1USC*\4X<8
MZ8^M5]KYZ&DV..U>?<\[E\RR>3U'/IVHVCMG-5]C]<57OKI-/M'N9F 51P-W
M+'L![FJBG)V2U'&FY-1CN)J6LVFFQ['</<,#L0+DYQQGVKSB\N);B22>>0M*
MWWF;GH,4Y9+W4=?^U2%(R[9 W8 P/4].*PM8CU78?L3P@/*-Q<$D+CDC'>OJ
M,#@XX?1ZRLK_ (Z'U6"P4,-UO)I7_P D3Z7J*:C#(EM-YLT<K1-A#\K ]*].
M\):";.,7EXG^ED$ 9X4'V]:RO _A@VML+F9 LA7=&"N#D]6(]37=6\1B0@G/
M->?F6.]I)TJ>W5]_^ >7FV87O1IOU?\ 706>0QQ%AUJJ;MRI!4<U8N>8PO\
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M2*;J3ID9V#MC/0UTE>3C<?[2].GMW[_\ \7,<S<[TJ6W5]PHHHKRSPPHHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^9VX:E*.'KQ]/S/0:*I_;?\ 9JS$_F1A_6N--,\J4)15V/J.?_4/]*DJ.?\
MU#_2FR8[HBM?NU9JM:_=JS26Q53X@HHHID!36C5OO*#3J* N( %& ,"EJ&XN
MX+15:>58P[!5W'J3VIDHN9DE2*00,K860KNR,#G'XD?A3L6H-ZO1$2?\?QS6
M5XVE>/00BXVRS*K?09;^:BJNNQ7=KI3LNH3F>+EI PC+\CT_0#]:IZQ/->>"
M;*>4[G\Y2QS[,*Z\)2M.$[W7-8]7#8?]Y3JWNKV-3P5_R!V_ZZ&NEKFO!7_(
M';_KH:Z6LL5_'GZLX\P_WF?J%-**6W$#([TZN9\3^(?L"?9;1U-RWWC_ '%Y
M]._%12I2JRY(K4QP]"=::A#<?XGU]=/MVM+=_P#2W&#C^ $=?KTKSYF9F+,Q
M9CU+')-*[O(Y>1WD<\EG8DGZDTW!)P 23P *^EPN&CAX66_5GU^#PD,-3Y5O
MU8A( )/:O0/#.BKIN99E5KIUR6_N@]A5?PQX;6-$OKV/,IP\*[C\HQU(]>:Z
M5/\ C]D^@KRLQQO._94WIU\SR<RQZJ7HT]ENRS1117EG@!113))HHMOF2(FX
MX&Y@,F@:3>P^BL^(ZC->3EVCAM1E(UV[G)_O9Z8]O:L?6+&YT[PU,5U&^EG2
M7S?-$I!],=?NXYQ^-:PIJ32<M[?B=%/#J<U!R5W;\2?QH&/A]BH! E0L2N<#
M/;TYQ_DUA^#T7_2G,?.5&_/Z5)JD\ESX&M);B3S)6E7YGR23S^N/6H?" .ZY
M;:,9 W8Y^F:[^5QP,T_YOU1[-.FZ>!G!]'^J.PP=V:=C)&X'GL*:Q.1CIZ4Y
M1N(!(!]:\@\9B'[HQP<4+T'<YYH;(]\=/:@-T('U% =!>V<]^M)DAA_=[T@)
M(^[CFEW'D8_6@ .><]S2@C/.<4+@X!.,^E'3< 3QT]Z  DD\\4=.2.,4T<J2
M>M/90![8].M #,'<.O Z4I8 9YSFGC!!&2,4S./SH"XON,Y)H/7&<YH !()]
M:5N"2"/;% #5QN8GO2Y8],4NT8&#UZTQF55+-M"CJS<8_&@-R.ZN(K2!III%
MCC09):O.M8U)M4OVG.1&HVQH3]T?_7JQXAU5M2OV13FWA8K'@_>_VO\ "LBO
MH\OP7LH^TG\3_ ^ER_!*C'VD_B?X!6SX?T<:G=;I0?LZ'YA_>/I]*K:-IK:I
MJ"0\B%2&E8'HO^)KT:"&*V@5(HPB*,*JC  I9CC?9+V<'[S_  %F.-]BO9P^
M)_@.V[0%10J*,  8P/:A@#U_#-* "5Y^;%(3T^7IQ7SI\V/B_P!8,].:1L>:
M2#Q3HL^85)XQ36P),=>>M NHG  P.33MJ["<88=Z;N).#D8IP7"EL]* 8B[
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M "10YS)C'/K1U&1P30/H(,Y/YBB;D+&"=S'GZ4XGRXW?TZ5' =[-(_4\ ^E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>U=DJJ@PJ@ =@*6BOG:]>=:7-,^3Q.*J8B?--A1116)SA1110 4444 %%%%
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M 4ZBOG:^(J5Y<TSY3%8RIB97G]P4445@<H4444 %%%% !1110 4444 %%%%
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MY&<=*X>'P_K*3%AE6R<D3$$D]_SIC:#KHN=Q=_,V@%_..2/3-9_4Z-_XJ(6
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M0U9J)]Q?I2TU/N+]*=6ARO<****!!1110 4444 %%%% !1110 4444 %%%%
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M[JD]3Z5PE[J=QJDQFG=MN?DCW95/H*GUG56U>[#^6(X4&V.,,3^)]S_A6<
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MCCOT'%'7G] : 0J@,IZ=.])Q\N[T_*@(7^O>EP<XZ<X% " [C@'(]Z:A))]
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M\A0+[U+10"=B..+9DDY8]33&A=6+1,!GJ#TJ>BE8?,[W&1^9M_>;<^U/HH)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N9\;R(NC1QEOG>8%1ZX!S_ #KIJXSQW.,V
M<&#D;GS^E=>!CS8B*.[+8<V*@5])\7II^F0VLUO)*T60&#]1GCK73:+?6^K1
MRZA#&Z.Q$+JQZ;<D?^A5Y@#C/ .1CGM7?>!O^0+-_P!?#?\ H*UWYAA:<*;J
M16K9ZN:82E3I2JP5FW^9TU%%%>*?.!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%0W5W!9PM+<2K&@'4GK]*:3;LAI.3LB:N5\0>*DME:UT]P
MUP&PTF,JOKCU-8FO>)I]3+VUN3'9G@]F?Z^WM7/U[&$RW[=;[O\ /_(^AP.4
MVM4K_=_G_D*[-)(TCL6=CEF/4FDHK2TC1;C6)ML?R0@X:4C@>WUKUYSA3CS2
M=DCVYSC3CS2=DBE;VT]W*(K>)Y'/91G'N?05Z!X?\-PZ:GGSJLMTV""PX3Z?
MCWK3TW2K32H#%:Q[=V-[DY9R.Y/^15VOG\7CY5O=AI'\SYC'9I*NG"GI'\6%
M%%%>>>2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWZCBD5@R!U8,CC(/L:<<]?2L3#8:25/-*59F^4?+ZT]$#]P/PJ,9"<G.&Z4
M/(VJ%X)SFFKC/'7N*,\9XP<]*0$ER,8'TH"PF#GUS2$ S-CGBI.>1@X]<U&Q
M_?MD9Z4#0\\>]+@%1CK0><^@/%! '!'O0(3(;(STZ4$$.#V/6E.1ZX[4 9SS
MT/2@ ^[R,YHX/;ZT?C29Q@XR<\9H 5OO944<$?+1R2 12X!.#C'>@0=B#UIC
M;@..N>:?@[2W!I "YX.*!IV#C/X<T'D_*!BCL1GI2*3L![B@!>-@ 7F@@X/S
M?A3<DYZ>G2G9..,XH 7.#GDC&*0 ]^A-*N7QDXP.::>F<9H$/;[V/RIG.>GL
M#2@AAD#\*0'_ &<?6@:#CKCZTG.T!0,YY^E.)YQ0"02>M  ,9]0>M!QN^7IW
MI5^8,3P0.!2$G;ZYH%U& -NY_*HG_P!:?K4^\\87I4#\S'_>I,TCN:B_='TI
M:0?=%+6AQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5Q7COR=]G@'S\-SS]W_\
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M[1X"<<D70']*IZWJ^N65BDJ6,< *GS7SYGEG.!CM^8/TIW_"1ZK_ -"Y<_\
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M1C_3!Z\1)_A2G4-6UBTN(WO%9(E$AC"JI<#)XP.<8SCVK&JS9-=?;XWLD8W
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MZ#U'UJG_ &MJ6?\ D*W&.>?-;T_R*ANM-OK*39<6LJ$D@?+D''7![U!Y,O\
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MYZ$5*=%0;=EIO9'HTFC6LL9CDDNW1NJM=2$'_P >JO\ \(KI'_/&7_P(D_\
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M2!*Y'KN/-)YLG_/1_P#OHUK_ /"*:W_SY#_OZG^-13>'-8@ +V,C9_YYD/\
MRS70L10>BDOO1TK$X=NRFOO1F^9)_P ]'_[Z-7!J^J'(&HW(P.\QH_L75/\
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MNI36WVB.TD:/MTR?H.IJ74IQW:1+J0CNTC/KTS2"!H5BV<8@3^0K@?[&U/\
MZ!]S_P!^S7?Z,DJ:-:QW$!BD2,*48\C' /XC!QVSBO)S:<94X\K3U/(S><)4
MX\K3U+N<@#\0:KW<"W=G-;N#ME0H2.HJ<# P"!1M' #8^M>&FT[H\*+Y7=&%
MX5O#/9M9S*1);$H=IZBNA\M<9P^,>M<DH;1_%@/W8+WC<<=?_P!?'XUURY5"
M2W7H#71B8KGYUM+7_/\ &YTXZ*]I[2.TM?\ /\2+="@!R]*6A+$_,,TPJNT
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M*M+;5XMOVB]@E&0"/*QQW/7K4L=C=1[2+YV.TA]R Y/.#[?_ %JT**Y'-O\
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M_?(JRW@C3BK!7F5B.#NS@UTU%)XRN_ML3S+%/[9R'_""0_\ /[+_ -\BIH?
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M-(SDURWT)VXXP>*""0.V::1@<<'-+SD4C,4]!G.>G2FRKM0M@@GU-.))!I)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U5VJ%]*=10 4444
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MK1GGGTH$'IW'M1T;//6@_>)[8I,]STH&* >AQ0" >.#CO0.#D].U-7 (SUH
M4^XZ_I3@2#N].*;SMQWSUH]<GGM0 ]FRV>F!3 !YA.>O7CI0 P&2<]C0 P.3
MP* M84<# %(?Y=,48Y_"E)ZGC% #D.XGMA:8G'&>E.C^_P GC;^='&3@?A0(
M:,[C[G(J&;_6M4XZ@@U7E_UC4F7#<TX_]6N?2G4V/_5K]*=6ARO<****!!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)SQBD-;C!C[2GT%7ZH 9ND(]!5^G$BKT"BBBJ,@HHHH **** "BBB@ HHHH
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M?+<G';BBXU%HGXW8]>]-QMXSWZBH_//]U<T>:^W.0/;%%Q<K)=YR!MQ[TIW
MX'W3UJ'SY/4?E0)WYRPP?:BX<K)]JER#^=-SQUJ+SVS]U:5969L *">].XN5
MDIXZ<XH7!QD]>M0M(ZDC</P%(9G(QN'Y4KCY66.JYW=.V:0D \XQTYYJ#S7'
M<'/M1YS'K@_A1<7(R8\=^_6D0G!R<\'K4?FMMR"!STQ2&9SW'Y47'RLFY')Y
M].* 2S8R1[5%YSG@L,?2CSW]!FBX<K)<_P 1&>*#T_SQ47GMG[JTGG/ZC\J+
MARLG&,C':FECO*YR!TJ+SG]ORIV]E7.5.?:BX<K)@G&=WX4TX())QS47G-@#
MC I5<R<$JOOBG<7*UN3Q_,_I@&FG@MDG(]ZCC=O,;)!^7TIHE?.!CGVHN'*[
MDV#C(/.*KR_ZUOK3A,?[H_"HW;<Q8]32;*C%IFJG^K7Z4ZFQG,:D>E.K0Y'N
M%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9@<XI>>GYT<;5Z]...M.WD9R0,^M AN<=P:0# XQSQ3=R=V'/!I4:,.N7'%
M[#]@0AB2#Z 5&8@)-R'Y1ZT_S PQO7CF@. ."#SZT KH#D\YZT=0/:@ #FC!
M88[4 )P>_P"E#)\A& ,]*5@.0.!WYI4;E@%SQT- >:$S($SE<8]*C',(^M3*
MP"_=_6HMA7H,\YH!,=G!].*4GMS[TA&<9]>U*>1@\?6@ R&R!DX]:"><9--
M(SA3D^M*0O4GGK0 ')&#]:#@+GH12K_>'>D(^4Y[\F@ !R.>2>]''\-(% SC
M/(I<'L<^U :#L[?E]Z3=C&&(_"CC.X\^U .!MQG% @(SG/>D&W'&<>E*"<Y]
M!BCU'2@8'.0,8]*",G.,CU- ##EL#/0DT9QT!()H 0KD_AV&:4<#I]*%)7D
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M+(.>7<@%M&ASSD\4GV./.>:G;M]:6BR'SR[D'V2+^[1]DB_NU/119"YY=Q%
M50!T%+113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGS%NGU-,0N 00?7-)[=:5LXXXH(_ASU[B@!!D#Z#M2/_ *M_FXQTIV I('(
MZTV0#RG.!TI#6XN!]J'/85<JFK'[2..H%7*I&=3H%%%%,S"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** (YH4N(7BE4,CC!!%9/AEY%TZ2TFC:-[25H<-Z<$?H1
M6U6!<NUCXQMI-H6&]@\IB#@%U.1GU., 9]36U/WHN'S^[_@'50O.$J7S7R_X
M%S?HHHK$Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $S2T8S10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ,W;S@=.]0W-3JNTYIDZJ8RQZBD]BXM<Q @'VB0=*3.,GT-,C8NS.1R
MWI3N,'(J3:VHN2<GVS2R+M,9]Z:.F?PQ3GZQ@],T"ZB<[<8X[FC.T;N>:"2"
M1ZTAP1M[=J %'";B,\4G&0>?SI<?*!Z<4'IG XH&)SOV@<B@< 8STI>=W0@^
MM(3R,9Q]* #@\-]<4O?IP.* /3\.*.G'-  <%N@QGM3<DJWH1Q2] <<Y]:"P
MV8QT'2@!(5!BSCIWI=W4Y&/<40Y\GC 'OWI54'@>E /=@.JX/>@_>SUQUH!
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI ,"@!:*** "BBD)(Z#-
M S!5+'H*1)%D7*]*4@,N".M(J*@PHP*!Z6'4444""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I  ,^]+10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M/XELS=:0[H"9K=A-'CU';\LUL4R6,2Q-&PRK#!%5";A)270THU'3J*:Z%?3;
ML7UA#< J=Z@G;TS5NL+0D_LZ[N='SN$($J/TR&)X ]OK6[3J149-+;].A6(@
MH5&H[;KT>P4445!B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!GCI@5#YL@.<FD\Y_P"\:5Q\C+&#GKBD*Y!7GKFH/.DSG<>:/-?UHN'*R?:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS*I'.>: MJ.W'.",8Z4I;'R;1R>M/8.N"3QVJ+<H;!_#% EJ2,!Z*>/2DX[
M4F0IP2<=J7;D[?Q%  <!LD \>E!QQ\H(/Z4%=O! ]*"".3WH$( ,AMHSWXIM
MP,(IXY/I22Y$@&>#23J%<!>GUI,M+5$]HJ/&=R@X/<58\F/_ )YK^50V0_=$
M^]6:M;&%1OF8SR8_^>:_E1Y,?_/-?RI]%,B[&>3'_P \U_*CR8_^>:_E3Z*
MNQGDQ_\ /-?RH\F/_GFOY4^B@+L:(T7HH'T%.HHH%<**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBCG- !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "$ @@C(/6N;TA8]*U^YTQ#)Y<H\Z('[J^H
M%=+436\+7"SF)#,@*J^.0#VS5QG9.+V9O2J\D90>S7X]"6BBBH, HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TKRSQ!_P C!>_]=#7J
M9Z5Y9X@_Y&"]_P"NAKU,I_BOT/:R3^-+T_4V/!5UY$UXKJ! J>8\A/"X]:=X
ME\32O</96$H6).))4/+'N/I7-V][<6D4\<+[5G38X]15?H*]%8*+Q#K3^2/7
M^HPEB77FK]O\PKH/#GAQ]4D%S<@I9*?QE/H/;U/^0WP_X<DU8_:)\QVBG />
M0^@]O>O1(8EAA2)  J#  [5SX['<EZ=/?J^W_!.7,LQ]DG2I/WNOE_P?R$@@
MBMXA'"@1!T Z"I**K7]_;Z;:/<W+[47H.['T'O7AI.3LCYI*4Y66K8W4=1@T
MVSDN)G4;1\JD\L>PKRN\NI+Z]FNIO]9*VX^WH/P'%6-6U6;5[TSRC8@X2,'A
M1_C5:VMI[R=8+>)I)&Z "OHL%A5AH.<]WOY'UF P2PL'.?Q/?R&Q0R7$RPPH
M7D<X50.36QK^C?V3%8G+?O(R&#-DAAU]L<CI75^'O#J:0&FF827+C&['"CT%
M9OCW[EA]7_\ 9:RCC?;8J,(?#K\]#&.8>VQD:5/X=?GH<KIO_(6L?^OB/_T(
M5ZW7C6]HB)$8JZ'<I'8CI7LHZ5AFZ]Z#]3FSV.L'Z_H%%%%>0> (?NFO(+O_
M (_KG_KJ_P#,U[ >1BN<D\&:;)*\C-+N=BQ^?N:[\#B88>3<^IZN5XNEAG)U
M.MBGX$_X]KS_ *Z+_(UU]9VE:-;:0DB6^_$A!;<<UHUSXFJJM64X[,Y,;6C6
MKRJ0V84445@<ISGC;_D!+_UV7^1KSQONGZ5Z'XV_Y 2_]=E_D:\]ZBOHLK_@
M?,^LR;_=OFSV& C[/'S_  C^5.9U099@!ZFO*QKFI@ "]EP/>HI]4OKI DUW
M*Z@YQNKA64U>LD<']B5&]9(T_%FH0ZAJX^SL'2%-F\'ACG)J'PQ&\GB.T*#.
MPEVYZ#!']160/0#Z 5WGA7P_+8'[;=J%F=<*O=0?7WKOQ,H8;#>S\K(]'$RI
MX3".G?I9>9U->-M]]OJ:]DKQMOOM]37+E&\_E^IPY%_R\^7ZEI=0ECTEM/3Y
M8WF\UV!Y;@ +].,_E5:*-I9DC0%F=@H ZDFMKPSHT>L7DWGD^3 H+ '!).<?
MAP:ZYO"^G">WGAC\F2&19 4[X(.#^5=-;&TL/-PMK^IW5\PH8:;IVUW?J6[^
M]BT32/.?=((E"*"P#.>@Y_SWKS?4=6O=4E\RZER.R+PH_"M_QO>^9<P6B/D(
M-SK@]3T_2L'1[-;_ %6"W?'EDY?)QP*RP-*%*BZ\UKO\C'+:$*5#ZQ-:O7Y$
M<6F7TT GBLYWB(R'5"0:CMKJYL9O,MY7AD'7!Q^=>MH8HXU160*HP ".!7!^
M-+..#4X;J-@?M*G<!V9<<_CD?E3PV8?6*GLYQW#"9E]9JNE.-D]CI?#FN_VQ
M;,)5"W$6 X'0^XI_BG_D6KSZ+_Z$*XSPI<FV\16XWA4F#1ON/!X) ^N0/SKL
M_%/_ "+5Y]%_]"%<5:@J.+BH[-I_B>?B,-&ACH*.S:?XGF5:<NIZAJ5O;Z?"
M'\F*)8A%'D[\ <GUK,KT?PGIR6>C0SE5\ZX7S&8<\'[H_+'XUZV-K0HQ4VKO
MH>UC\1"A!5)*[OH>>W%I<6CA+F"2%F&0'4C(J[HVL3Z1>+(C,T!.)8NH8>WO
M78>-8$DT+SF'SPR*5/U.#_.O/:,/56+HOG7D&%K1QN'O->31IWVI:CKUULP[
M@G*01@D+_GUJA/;3VLGEW$+Q.1G:ZX.*]%\,:8ECI44OE[9IE#.2<Y]/TJKX
MUMXWTE;@C]Y&X"GZ]:Y:6.BJRHPC:-[')2S&"Q"P].-H['+:%K4^E7B ,6MW
M(5X^O?J/>O348.BL.A&:\;/W3]*]=T__ )!]O_US'\JPS:G&,HS76YS9W1A%
MQJ):LXOQU_R%+;_KC_[,:R_#?_(QV/\ OG_T$UJ>.?\ D*6W_7'_ -F-9?AO
M_D8['_?/_H)KLI?[C_VZ_P!3OP__ "+_ /MU_J>@ZQJ::5ITER0&<<(I_B8U
MYE>7]UJ$IENIFD;L">!]!^-=CXXAD>Q@E5,HC_,<],BN'4[75L X(.#WK/+*
M452]IU,LGHP5'VBU;+,.E7]Q&)(;*>1#T98R0:ADBFM9MDB/%(IZ,,$&NZL?
M&FG/'&EPDMNV,$[=RC'TY_2I-0@TGQ2D(AU",2QY8;&&_;WRIY]*?UZK"7[Z
M%D4LPK0J6KT[1[[F/X8\1RPW,=A=N7AD.V-V/*$]C[&N[KEHO ]BJ8DGF=L\
M,&VX_*NFDD6&%Y'.$12S''0"O+Q<Z-2IS4EON>+F$\/5J*5#KN<OXG\2RV-Q
M]AL2!, #))P=N>@'OW_$5Q($]W<  /-,YX'))-+<SO=74UQ(VYY'+$_6NR\%
M6,,=I)?R;/-D8HA)Y51P?ISG]*]>T,#0YK:_FSW>6GEV&YDKO\V<A<6%W:*&
MN;6:)3T+H16AH_B*[TJ9=[/-:]&B)Z#U7WKT.]AAO;*:VD92LJ%3S7DTB&*6
M2,D$HQ4D=\'%+#8B.,BX5(["PF)ACZ<H58['L,<B2Q+)&P9' 96!X(/0UP7B
M7Q%<3WTMG:2F.WB.QF0X,A[_ ( \?AFM[P==&?0Q&T@9H7* 9Y ZC/ZUY_/$
M\-S+%(NUT<JR^A!KEP&&BJ\U/7E_JYQ9;@X1Q-13U<=O\PAMY[J79!$\LA[(
MN34L^FWUK'YD]G/$F<;G0@5K^&_$,.C)+#/ S)(^_P Q,;AQC'N/\3750^)=
M&OXFB:Z2+>AW+.-N!TQD\?K797Q5>E.RIWB=V)QF)HU+*E>/<\_L-2NM-N$F
MMI2"I^Z?NM[$5Z=I6I1ZKI\=U&-N[AD)R58=17.P^";)V5Q>O)$>0%(Y';FM
M[2M'M](B>.W9RKMN(9LUY^.Q&'K*\/B/-S/$86O&\/B7D:-%%%>8>(%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %"X^^#Z&K5O\ ZA/I56Y^]5JW_P"/=/I4K<VG\"):***HQ"BBB@ HHHH
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MN"W_ ->INF".>.U0S  J,]*E)/\ 0F@;V0+@GUZT;NO/X4FW"L,_C2C@CU-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/05Y?KW_ ",=W_UVK+*?XDEY&.2M^UFO+]3U*BBBO+/$"BBB@ HHHH ****
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MNZYXJ.IT[Q0TJ"?FR >].ZY&*4;1][TIIR.GU% !@\9&#2@[.>GN:.2.1\U
M)W$-]T=* $P=P)R !1C\<4F[@CUZ&GJ,XR">.: 8@.#D<XXI=VXC.!CN*:%+
M9"_A2B.0#D4"=B _+,?QJ4CY\^U1ND@.2I'O4GS;P5^[2+8\/C/3TI 2N2._
M6FMG!ZD9P*=_2F38,G.>"2,=:3;\^X$'/:DSD'''I0"3QWH >"0IZ$8I-I[?
M7FFY!.!U[4[C9TR<\4 &?IDXXH[;>*!SCM0V"QQTH$)C&<8RU*!W]*3YUZG(
MQQ0<#('YT#'*0C;CGI2'E:3Y@00<4N21Q0*PBKL8=?QJ.3+R;<'CTIXR>WS>
M],&/M/S#/-!2WN'EY.</^5-.1*>,?6IEV!#N5L^M5WY?_&DRHN[+18YX&<<\
M4A);#$8;THR..1@CUH?9_"0!3,QLQ_<XQCFE(YSG!],4V9E,0P1GO3^.#E<?
M6@>R#&>X Z\TA&3W]>*3..C+^=+QC&X?G0 O(&.WO02$8-WST'>FJ?E/(SCU
MIL2$L6[XH';N*TC>5@H,'OFEW':N5X(X(IMP>5Y[5(C (FX9!6@'M<.H5@1B
ME/+9SFF# D<# [T[CL1^= A!T(HP3<$CK2*2<\CVH7_CX['GK0 A8\X1N#CB
ME&&RPSD]10N<2$9Y?M2LO[Y2!C(Q0,0)@8SGGGVI7^92!U(ZTLGW@%].<FG'
M&%R<8/- K]1,QA-ASZ9Q2%=ORDX]_6@(^[U'IFD</Y*!NH.*!+<"N>?7BEZ+
MCJ*0#"\]CUI7*Y^4C&*!CF<MCCI0&PFT#C'6D;;QM-(6 &W/)]Z8K#B^ ,F@
M'WX_QIC'Y>"/:C(QU''/-(+#P>.N<<TW#*X=1DT@;(.<#-)NQ\KMD>U [!O#
M$;AAA4JMC<<9[=:KR.K8(^]WJ=0"3GDXXQ0@DM"*$X+MCH:D+!B2. :@3/F,
M.Q[5(%*C#8%"'):CF.Y0,CCTI=V%/3FFG&UL?A00>>WH*";#7#-MVKG'6G%V
MR&$9X-!W#&WKWIZD9!]*!MD<C-(K80\XHC&!T/O4C=25S3"!@]<GO0">E@P,
MCU'I2GD 8Z4  MR#BDR@;]X?E/2@!_ 829&%7 &>IIKL9>2,<8Q30R,2 ><\
M4NTH<,?K0*UAX/[L*^ I[YH+[ $R,TS: Q.<YZ4H_P!5R/F'>@+(1AE"OO2K
MD #%)P>Y_"E[<T##!Q@]>M*26 !' [TFXX'&*",?_6H$)D=<]O2FN &4'D8S
M3G^;E>W2FS_ZL''>@I;DMF,-)QCI5NJEE]USZFK=5'8QJ?$%%%%,S"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHJM>ZA::=%YEW.D2GIN/)^@ZGK32<G9%1BY.
MT5=EFBL(^(VE"M::5>S*W<IL]QU[>],U#7;O3X6,UI&CLP$>9LXSW;C@>]:>
MPG=1MKZHZ%@ZS:C;5^:.@HK*EU&^B4D:7)( H)*2#GY03C\3C\*CM/$^EW3!
M&G\B3^Y.-G;.<],4E2FU=*_IJ1]6JM<R5UY:_D;-%(K*ZAE(*D9!!ZTM9F 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5A>)=!.L0QO"RK<Q9V[NC ]C^
M5;M%73J2IR4X[HUHUIT9JI#='D]Q::CHUR/-CEMW!RK@\-CT(X-7H_%NK11J
M@F1L#&60$FO2'19$9'4,K#!5AD$56_LS3_\ GQMO^_2_X5Z7]H4YK][339Z_
M]JTJB_?4DV><W7B35+L_-<E!@@B,;<BKFE>%+[4&\ZY5K>'.?WH^9^>>.H^I
MKO8K&T@??%:PQN.-R1@&K%1/,$H\M""B14S91CRX>"B,AB6&%(D "H,  =*Q
M?%MC-?:(1 I=X9!+L49+ 9!Q^>?PK=HK@IU'3FIKH>72K2I5%46Z=SR2QU&Z
MTV;SK:0H>X(X/U%=UIYG\1^&9$O (Y)"55PF,XZ''Z5NS00W";)HDD3.=KJ"
M/UJ2NS$8R-6THPM+O_2._%9C&NE*,+23W]/D>6PMJ/AO4EDDMVCD (PX^5Q]
M1P>HZ=*UO^$ZO/\ GTM_S-=T\:2H4D174\%6&0:KC3; $$65L".A\I?\*N6-
MI5/>JT[OU-)9C0K>]7I7EZG!,FM^*9@VPF%22"WRQK_B>W&:RX'DTO5HGE#H
MUO,-X YP#SC/J,_G7K=126T$TBR20QNZ'*LR E?H:<,RM>+@N7LBH9NHW@Z:
MY>R(KPF?2K@QJY+P-M7:0QRO QUS[5YEHO\ R&K,=_,%>KU!%96D,GF16L,;
M_P!Y8P#^=88?%*E3G"U^8YL'CEAZ<X<M^8F'W?PKS+5X6N/%<T"8WR7 5<],
MG%>G5$;: SB<P1F8=)-@W#MUZU.%Q/L).5KW1G@L7]6E*5KW1+1117*<0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% $5Q!'<V\D$JAHW4JP(KR[5]*F
MTB]:"0$H>8W[,/\ &O5JK7MA:ZA!Y-U"LJ=@>Q]0>QKLP>+>'EW3W/0P&.>%
MEKK%[GD=20P37+;8(GD.<?*,UZ;;^'=(ML>78Q$J=P9QO(/U.36BL4:?<15S
MZ#%=T\V7V(_>>G4SR"^"'WGG=IX1U.Y*F0)"K+G+'D>V*N?\(+=_\_D/Y&N[
MHKD>98AO>WR.&6<8ENZLOD<3!X$<EOM%ZH'\/EIG^=3?\('#_P _\G_?L?XU
MV%%0\PQ+^U^1D\TQ;=^;\$<?_P ('#_S_P G_?L?XU9B\#Z>L8$L]P[]V4A0
M?PQ73T4GCL0_M$RS+%-6<SF_^$(TO_GI<_\ ?8_PI5\%:4KJQ-PP!R5,@P?;
MI71T5'UNO_.R/K^)_G9C?\(IHG_/D/\ OX_^-:T,,5O$L4,:1QKT5%  _ 4^
MBLIU)S^)M^K,9UJM16G)OU84445!D%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"DX X_"G%0 &!!/7&*;SG--X!([^U 6'#H.F#[4#Y@<DTW>OIS2CYVQC]:
MD[2",T@SC)'('%.;*_A2 DKZYZF@.@I(ZKUH&2OO1E<$@_6D)'KUH "<#D9/
MM2YZ&@MM^?G%(/G4D?6@!V 3UJOR9N5SD]*F7H./SIJ965F- UI<BR<_<J>
M RN"@^A'2GC.S..E1AF64M_>H!NZ%*)U"#//%-"KU* 'TI^<,<D9S1][IB@5
MV-QGDH/RI-J<?*.E.4Y8CD<TN>_/- 7&E4VJ0@R?6C;&!DI^%.SE0>QXXHSV
MS0&HACCVY"#GI2@ 'VI=N%)QQBFJV[.#TH#4"0>&&3CO3OE+88X ':FY^<+C
MJ*4Y]/RH 1L$98;B.E&R/:#L&2>E+G STYHW#=CK0&H&%?0<^E'EQ[2P3G/2
M@<=CUZ9I X^[CKWS0&H%0JX7@9I64'@^N32;PISGJ.F*!S@#OTH#438AXV_C
M2F)/FX[>M+S[4@(W8YR#0%V-\E=W&<8]:40*Q^\0,TX@;<\_G1R,$G'X4!=D
M9B 8C<<;L4UHU\P*"<9ZT_\ B)_VQ0W,HQS\U(I-D:IDCG@FI(DB>/YCA@?6
M@<]@,'J*C*E0I897VH'N2^3&<8.,T-"B\=?>ABNQ2!A#T%*/Y4R;L0PH.G-'
ME1YQ@_6G AL%2:._7//'% KL184*DX.14<6SS&W]/K4H^\.HJ%$:1F5<=:!I
M[W$7&]L#OQ4XP>?K4<2?,0<'!Q3^AQVH02W 'YL<FCDE2S<D4!LG_9[4H4LG
MF=0*!; &XSS1Q@$\=S0<CI2;APQH %.[D<>E(N3P<CZFE4AMV,G'3-'S$\\=
MJ %"J5W9P1VICH7C7CI3N#2E@AS0%V0Q)\Q)'0=#WJ7J>F/:EYP,_I0>.221
M[T W<<P&%(')IIR%X)Z]* N%#'/Y]*0Y5@,<'WH$@&,?,.!2G@GTZT*,\8R.
MM'0@^U !N)R1Z<TI!"@D\4@R5W-^E!!QDCKTYH ,9W$GIVJ.=N%7L1FI"PSM
M[TR7[ZXZ8[T,J.Y+8GAQZ&K=5++[TGX5;JH[&-7XF%%%%,S"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBL?6;VX5DL;*58KF5<^8X)"+TSQT)Z"JC'F=C2E3=27*B+5
M=6NC<MI^DQK-=*N9&SQ%DX'X^WM4EGHKN!+J=U->2'K'(?W8X'5!\IP1P<?T
MJQI&E1:79^4#OED.Z:0D_.V.3S3-2U&'1[=(H(?,N)3M@@3JQ_H*VYKODI??
MU?\ DOZ9U<]W['#KY]7\^B_3<=K.L1:1;!W5FDDR(E SN;' _E5#3M%>](U#
M6U6>Y=?EA9<I$/3;ZTV*T> _VSKLZR2HH\N)5.V+/8#NU6M%U]=8>95MFB\L
MX^9AG\OSJK.$'[/IN_T7Z]_0TY94Z+]CT^*7Z+]?\BI)+-X<O2/E_LB0Y4$
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MM+^P-(_Z!MK_ -^A1_8&D?\ 0-M?^_0HOA>TOO7^0<^!_EE]Z,W_ (333/\
MIK_WQ1_PFFF?]-?^^*TO[ TC_H&VO_?H4?V!I'_0-M?^_0HOA>TOO7^0<^!_
MEE]Z,W_A--,_Z:_]\4?\)IIG_37_ +XK2_L#2/\ H&VO_?H4?V!I'_0-M?\
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M 5548  [4^N5VOH>?*UW;8****0@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ,T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD;.WY>M "TF1G'>D^;/:D8-D%<4#L/HIBJV\LQ'3 I] ,**
M**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4FT YQ2T4 - ^<GUIU%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9C?ZU_QJ4<0H>P'-0O_ *UZF! C0]\<"LSK>R'?* ,@]*08].O6FDD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %JU5+8PJ?$PHHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHY Y
M.5/:DVO@<\XH'8EHI@4XP:4* * %R/6C<,XS1@>E&!Z4!H&X4@8$]#^5.HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!H0!RPZFG444 %%%% " Y)]J6BB@ HHHH **** "BBB@#
M+;F1_I4PR43C/'6F./*9@1][BGKGRU]/K6:.I[ 5R,8H8C;C)]Z569%X&:!C
MC-,0@X7 _6EP.F,4XG+@D?A3  /QX)]* %Y SVH!.>*7DKGT]Z 0O.,Y[4"&
M]NF<TJ_ECFD-+@\@@T#(58>=NP>>E2YYQQQ5=/OU8X'0<&DBI+4"Q R, T#(
MP>A/O00" ,XQ2_CBF2!^8\GOUHQ\M&!G )/&<T=5QD4"#KUSFDP"3DD4\,=F
M.,>M1OEL=L?K0-#AP1R<TK8W=_PI.ISUXINW .#DT .'&2<_E1P&Z9.*<6+#
MG'KTIO?(Q0(,9Q^E+GC(ZCFHY)"DF!V%)$V[(QS059VN/SGG@D]Z7OC/7KD4
M=_3 HZX!P/QH$-."=W(]/>GCYCTQW--R0H!I>0QP#R!TH !G/ _&E.2>?YT9
MQT]*8,A<YH <#SP:3C.<=*5CU/IUI0=J[1@_4T"$P<YSCTHSQC//\J%^]D@\
MTHX8=P.: $^8GYJ&^A'K4=Q)NDXXXI4<R#!%!5G:X_H<C'X4;=V,CH*.I#=J
M7@]3Q02)G(HXP<<#MBCH#^5'5?EYH&'.1NQ[<TG( )P2.,T8P<]C2, 6'!H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*JELG/./3-+N]"1QZTKE\C+ X;)'R]Z"1NX&%Q448)&XL>!ZU(,%0?TIDM6
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MZK55K($(X/\ >JS5+8PJ?$PHHHID!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !32O)/<BG44
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MD*W(>((P?[H_E3Z*R<[P4.U_QM_D82JMTE3MLV_OM_D%%%%09!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI>X/'6D.2PY&/2@$.#=L=!2'D'([4F&#\<XI3R1QTH$ XQR*=O)&TXQCM0,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &9*I61CC-3H%\A23SCBDN
M0Z].3BD0?N02N<=ZCJ=-[Q3'H V<GI3,\9I0 P':@< <=Z!" \;1TIW)'S=!
M2' .,;2>V:3.<YS]*!BGDY/7-*H4DAC@+T]Z3YB1[^M-)  4XXH <PP5QSNS
MG%(%"G"^O!I5^;I^!HSCKG@]J &#'G9STYIXQQFJ_66IQT((&[/6A#D@R0<#
MD4['S 9I,D=,TG7.#TH$.8 /@=*&(4 KVIH!VG(Y^M+]%QWS0(."2#G/KFD8
MG''.>U!QO'7-.QNP.O&:!C<X3I^!I%).#TQ3L8.??I0QYP1@T *0!PN:0!6(
M!R#ZT[:< \8IF\<#GF@2U%8A5R3GVHR<#C/%(W'(^E+D>I]R*!B+G:..]#-C
M( [4N<MQ^M QC=QUYXH 5AZ#\:86.0/UIZCY<^_(SQ2*"3@ ''8T"0O\>">/
M6@XW'!^[SS28ZD=J",#)Q0 ;0!G(Y'.*,\XSUHP">/Y49RVT'!H&*F">?3%(
M>H[]Q2$\=,T=OI0 YN&XYI!_%DYXX%&#C[HZ=:7'N.G:@1"I_<?7VH<_Z.O%
M*H8VQ(Z"D<_N4'%(OJ3+@JO.,"@CY\;@0>IQ31G9@4X\'YNU,CJ,#')^7%#$
M(P Y]: 1N.1TI< 'ITH&-9OG7/I3V VCG/\ 2FG_ %H!Y^7C-./7#=Z &@D=
M"?7K0"<GC&#2]ACG)Q29&3ZYYH&28 3@CZ4T]=O44=3D#CKFD+ #<O<_G038
M<1T4'K3<D9X ]<4I[$<8[T'G/<T -'(_&G9)[]J3((//3L*4D%6X&:!D+9\M
M3N/(S@FG%<6H;<3Z#TH9=T4?0<4AD7R=O.ZD421@-$,GJ:3<<GC&*(L!!QS3
M\'@\_4FF2]QIR >FTCTJ$;1&"022?6IFX4YP/04U(E=!RV>IYH&G9#8VPAQW
MJ0$%<CH/UJ.-@"R8//>I ,#C(H02W#H>1U]:5C\^W.?>FC:20O..O-.[_=H$
M( ".>@..*7N IZYS1R!P/:C('7\/:@!,D<=>W-*>,C(Y%)N&":7J?NG\Z  ,
M>1DT*A;CT&>E W%2W84JJ6X SGWH$(HY /?BE.5YZ\]!3>?:EZ>E !@Y'<4G
M)[\XZ9I2A5<LN%^O6C!(!Q]30.XC,5 ( .?:EYZ9HP2P50.!00?3ZT (,<\=
MZ4GIP:  ?8#TI,X/S=Z ' ?*6XX]JCE.&7 R=O>GD_-C^(_E3)CC8Q! QC@T
M MR6R_Y:'WJW52SQF3'3CK5NJ6QC4^(****9 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 45P.J>*]3BU.ZAMWCCC
M1C&!@-@@_>!QU]CFL5=<U-6W#4;G/O(2/RKTJ>659QYFTCV*635IQYFTCUBB
MO*_^$BU;9L_M&;& .HSP<CGK]?7O3QXFU@-N_M!\\_PKCGVQ[?A5?V36[K\?
M\BO[#K?S+\?\CU&BO)O[9U/_ *"-U_W^;_&I4\0:LB!1J$V.?O')Y]SS_A3>
M4U>DD-Y'5Z27XGJE%>3?VSJ?_01NO^_S?XT_^WM5Z_VC<<@#[_IC_#\:/[)J
M?S(?]AU?YE^)ZM17E)UW52<_VC<=Q]_USG^?X=J5]>U:08;4)^@'RMCI]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><F@!-H4XZYH'W^&XI3RI!ZBD[8 [T +SR #S[TI)'*'%(1R2&YSTI,GL,T
M+C/'>C@<<CZTF#QSCFEZX!YY[=Z  EB,-R.U)N(X['FD /Y4I.#[9H"PHZCD
M_A0>AP:"Q[8- ..:!"+D#IUI3@@9  ]>M&1G/X]*!C=@8ZT#%.<9&#S4<_\
MJUI2F3N!'YTV<<H#Z4,<=T36/W'^M6ZJ6/\ RT^HJW51V,:OQ,****9F%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVTJLYX6KS.^WYG54445RGFA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!F/\ ZY_QJ0?=C.,C%1/_ *UZG"_N$8'MTK,ZWLA
M/RQWHP>W!IV V>E(!G@XIDW#&!SU)I#DM][Y?KTI<8#>W:D!R?NX]30 9.""
M.:4#.,D&F@DXP"/QZ4$X/'?J: '-D<]*3.X@CN:,X'3CO2C Q@T 0''G\>M3
M]@2.1UJ <S'UYQ4IY<8Z$9-)%2'Y8-P,^M)@G(.<YXII8[1M!!/I3L C ..*
M9.P %<;OQI,$ 9(-*5 ;&<CN:4C'*X- 7 8"GCG/%-^;/RD9I>G() ]*:Q8
M8YH!#CG@T@^\>,#M3E )&3BE;@L03P*!7Z$:AL$GOTI&7YQMI[.1S@].M&/G
M.3QG\Z!W#'S?A0V23M/TI">.!D>E+V!/KT]* $ ;:0?O8HP0>2#0&W-S0&8G
M!&.W2@-1P&8VX)-"$ 889[4A/3KR*!CN/UH$ P":4X.>,TWJ/0BE X//>@!#
MD$D#&3Q2\YQ_#GI1D \?>S1SD\]*!CHR <^N?QIK X],BD)(''K0Q 4=_3%
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M'%=7!_Q[Q_[@_E754_W>GZR_0]"O_N=+UE^A)1117*>>%%%% !1110 4444
M%<?XV/[_ $T?+_K,_>YZCMZ>]=A7'>-G;[3IL?\ !OW=>^173@_XZ^?Y,[\L
M_P!ZC\_R9UT7^J7Z4^F1?ZI?I3ZY5L<+W"BBBF(**** #I12,,C%+0 4444
M%%%% !1110 4444 %%%% !1110 U_N-]*Y?P<&\S4CN^7SR-N._K74/]QOI7
M,>#@V[4CGY?M!&,=_K713_A3^7YG=0_W:K\OS.IHHHKG.$**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,Z6,"0Y/)Z8IRM^[7
ML,47'^L'UI5!,2G Q4=3JO[JN+M;/'4\TUN#GN.].YSP>G HP,>OKF@0F2<$
MFD#9^@Z4[.2>F.U)C'4K^% "E@%VG(;]*!EAE0/SII&6(X_$TI],[: #.%))
MZ]:!@XQCK01TSR*4#DC@ ^E $&?WV:E+@-BH5YDJ?"EN<9I(J0A('/3OD4[C
MCIZG-! ( (SGO1QW]*9(9XX^HI3N#8/'I3>G&,>U+G=SSD= 10 < A2,_C0
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M]?Y+\@HHHKF. **** "BBB@ HHHH Y?QQYG]CJ5E58]XW(1RWIBNDA/[B/\
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MT W=:E>-@)"6.,]ZD3!+8.1ZT_W.*'VY.W&,?K0-NXISM4$#VI-QYXZ]J4X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3OCTHP",<9/M3L G); ([4 - )(&<<<TFT@$$Y(/Z4O7BD4Y7[H!SC% Q A
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MTS5FJME]Q_\ >JU5+8QJ?$PHHHID!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 F.32T44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %!Z444 9?\4GT[5.Q"JO.#MZ8J.0*)
M&"GKG-2*%:)2W)(XJ$=3Z,0D(,XSVYHS\IZ8QWI=N<@@'GBD.",'M0($QLZ<
M#G%*<8/)/:@ 8XZ'T-(H(/S#&>E "GAP/6C''M]:0 ;@2>>U'&WDX% "Y&.1
M_P#7HX[#"TA&54<G'44#A>AQZ9H 7WW<=Q2A05SG)[<4WCICK1_$#N(XZ4 (
MQZ#G)[TO0#U!I<9..ON*#TP1_P#7H !D@;<X-'3GTI!QTR/3- (QP: %'KCZ
M4F1MR1GM1CY@<].*4C+8QD'I@4  P?<8S1D-T&<4A&!UQQBA1@8X_"@ WC)Y
MY]*#G./Z\4@ .>F?I2GKU- "L0"0QQB@$D9SD$9H(W<X!)'<T<#@G QB@ SU
MY/3/-(&^;GCTQ2X4 @$X(ZT@(].G>@!!RHY( '6G Y.>/IBDX QTR/RH_0T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 4KOC!SWJOEE5?F/M6D\228W#.*8;6(_P_K4N+-XU$E9E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gzirfjcguvpf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzirfjcguvpf000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,C F\# 2(  A$! Q$!_\0
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M4 %%%([K&C.[!4499F. !ZT +12 @@$'(/0BEH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!EM_Z*6MRN/%?QY^K_,J.R"BBBL!A1110 4444 %%%% !1110 4444 %%%%
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M+5IN.C5TF^KCM?YD7>S/1Z***\(U"BBB@ HHHH **** "BBB@ HHHH ****
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M[M_,5:%J(X_)BDNX8-NT(ES(%QTQRV,8X]L=J:Q3_E_'_@&4LBI]*K_\!_\
MMCV>BO&8HKB"V6"+4M4B@4>6L:WD@ 7'0+G&/2IH)M1M@%36=9 4X :ZW#W!
M!7CD^O;MV?UKNB'D7\M3\/\ @L]@HKR*+6M<T^T=8==OFCA5GS<".8G'/+%"
MV/QXQBEM-=\3Q6[$Z\^%ED3$MHCD%7*]3@]O2G]:CV9+R"K:ZJ1M\_\ (]<H
MKR:U\3^)XWG1M867RY%4"6S3/S(K=F'][_Z_:K'_  F'B>U9LW-A.LDH5//M
MB-@)QU5AP,=336*CV9,LBKIV4XO[_P#(Z/0-5L'\8:K807<<TK1AVVN1AA++
MN4)C P",XZYR<DDG7LO-M]<N[>7[LZF= CY11D#[I VD]3@D$Y/%>=Z;K7B"
MR>\\J[M8XKB>2YV"$MM9F+$9(Z9(]>/3(-;OAC6_$&I:IJ#R6MG=-#'%&K"1
MH#M+R<D;6!.1VQC Z\U%.LG9=3HQN73CSU$U:R6_HK[)+T.SU#3X-3M);6Y3
M,<BXR ,CJ./SZ$8.2#D$BO/M7TK^RO$VDHUP+B:2*YEFF8,'?(11N9F8X
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MMN2T7=_Y'>^#^/!.@C_J'6__ *+6MJN T+4=>B\/:=%;2:<D"6T2Q"6WD+!
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M#[,$-C#'J#G!!R*J>! KZU=NK;BELN3D<[F/I_NUK>/F5="M6=T1%O[<LSL
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M>6SCJ<MV&>>F00]O^)GK9!;-KIY!8/R'F]/<+C\_]X55[Z_<9<JC>#V6LO\
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M\#(VDY8\ ]0 ?:/@IW<4[OSZ6[-=SV:<H3G=3<4E]_Y[]RI:_P!H&]DU"YM
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MMT<%=-U/@8R+5N.>W^37M-%'U5_S?@']NQ_Y]?\ DW_ /%3J&(LFPU(+[VC
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M7J==&+<G-<SN^6%]+?96GRV/G<1",*TXQ5E=V]+Z!29YQ[>E+17,8B,H888
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MZ<5J6K@11_PML!!Z9XX_SBJC5FI64CGJX#"RI*4J2_%?E:YTH^(&HD$G0;<
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M:>3R,8."1D''%7J**\633DVE8T"L;POSI,__ &$;[_TJEK9K$\,$C2)\#/\
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M?7[&W?;)(J_,R@O(B9*DJ<!F!P"",^U)M+<N%.<W:*N:E%8O_"4:?NQN4@G
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M QW_ ,BO2J[<-\!\SG?^\+T7YL****Z#QPHHHH **** "BBB@ HHHH ****
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M6U_Z_;?_ -&+6G4KXF;2_A1]7^@44451B%%%% !1110 4444 %%%% !1110
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MHQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD&.@]:
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M).E/&1G%O5[6_"]^GH1*_+8[2;_D8;/_ *])_P#T.&M"L^;_ )&&S_Z])_\
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M0QPW$2R3(JY!E39]T!22J@\>AKNJ**BG!05D88O%2Q-3GDK!1115G,9FN?\
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MT/\ Y!$.!C)<_P#CYK1K,\/MOT*U?^\I/7U)K9?PWZK]3'J:=%%%9C"BBB@
MHHHH *Q[G_D<-,_Z\+OO_MV];%8]R5_X3'3!@;O[/NR#_P!M+>MJ'Q/T?Y,3
M-BBBBL1A1110!F:Y_P >MK_U^V__ *,6M.LS7/\ CUM?^OVW_P#1BUIU*^)F
MTOX4?5_H%%%%48A1110 4444 %% ^N:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K \2B1KO0A$5$GVV7:6&0#]DN,9]JWZP]??R]1T!S(J*M](S%
MC@8%K/\ IW_"M\/\?R?Y,3.5GTWQ5;>#&GLVU5]0N;)HKVRN+P-+'/@CSH9
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M"K $-D $[E&0<'%3?\(PV<C7];'K_I*G/YK6(T5LWPU\,6TJ6_GR1V,5H\S
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M0J2F#Q@#'I]=V/<72IN+W6NKZ)6\EOLMKD0W84445Y984444 %%%% !1110
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M6MQ3FG%12LD%%%%,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_(5<YIA,E[KBM&"5UR]5<IU7S"?QY+?-GOCGI6F55<_.3\Q 5003DC^?'(Z
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M] ;Q5I(R,K;W+X]LQ#_V85M0^)^C_)B9L4445B,**** "BBB@ HHHH ****
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MN2RAN 3G^(5Q/@C0)];L--N$N5CCMX[29EEC#-\ES)* &[ @ #'08SR"*][
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M !1110 4444 %%%% !61<Y_X2_3!DX^PW9Q_P.W_ ,:UZR+G_D<--_Z\+O\
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M>X2\?<0.N,Q=:WZ\6=*4$F^OG<TN%%%85IJ6OWNG6]W%I.F 3Q+*JOJ4@P&
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M11A548 'H*4G!0Y8MO\ #]6&IXEI^JV.EC6UU&[^R"36[QT>1)&0H64#YE!
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MN;5%8O\ PA_AG_H7-(_\ 8__ (FE7PEX:1MR^'M)4^HLHQ_2O*Y:/\S^Y?\
MR1>ILT5DKX6\/+]W0=+'&.+./_"G?\(UH. /[$TW X'^BIQ^E*U+^9_<O\PU
M-2BLM/#.@QR)(FB::LB,&1A:1@J1T(..#6I4R4%\+O\ *WZL84445 !1110
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M%\MM?#=DB>,N&Q@$$,,/G('S#&>W7Z/J#ZEI$-W)'Y%ZI:&Z5>#'<)N24<9
M&X$Y]"OK7':MI!L/B-HL^DI%:+?W$33H(046=!,$<J&'4;L@8SACD$FNS"\M
MYTIJS2?I=*S^_?S:5K(F7<]HHK(.M/8$C6;;[(@Z7:-OMR.?O-@&/CKO 7G
M8UK*RNBNC!E89!!R"*^9G3E#<VN+1114#"BBB@ HHHH **** "BBB@ HHHH
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MFGS4VNJ_+_@.WWL?40*=,\7&$J[1ZY$94 '_ "\PJ-^/]^/:?<Q'UJGJ:?\
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M<CM2T@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D,,^,(C_=L'!_&1?\
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MTL:WKNLZ<UY>V0DT^SS/92^7*!YMP<!L'&<8/L:ZBL6VS_PFNJ<?\PZSP?\
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M)=DOR1O2^$****\DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:-G8#._M"*ZO#'%=VTD@F#\S E\<@*%SG&,DY'7OR%OQ;<;"JN,_+E0I).2
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MKD2.QF 18E(+,?Q]2" :]_,Z==SC2JJSMI\35KP6[6NUW9/5N^K:,H-;HR/
MWA_4%O+/53%9P6C2-=+<V]V\INUDMXXV&& .&>,3$O\ -D 8ZFO2J\S\+6ME
M;>+;>$C2X9K?S8%FL_#ZVJW<J+MD59BS$E?FR%"YP>H!%>F5Y&:R<JR;=]--
M&M+OOOZFD-@HHHKS"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM;>\'BB.[BFFA6WC<QPSM$S;8V. P(QGIZ<\\5[.)I0I34Z*Y4_7^:-])?\
M#/9F<6VM2?3_  M;Z=>Z4[7[2P6$;_987 W/.^XRS,W5F8,W P!ECSQCI:\U
M\#Q:7/J.G7$&I:#<S);%H[>&]FN)X05 .T22':0."=H.,CC.*]*KS,PC*-7E
ME)M^:MU?_#^I<-@HHHKA*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /"_B%=BZ^)LSH-JVMDMGO9P SJRRMP#G@2H
M.1USUP:SL*@7>@*XW#(^;&>F?7N3SG/J*L>,YXY?B=KK!D*(+:)BAQD^7R"1
MW[8Z_EQ 9D4_NR V[[I0$,><9/4]!G/3GG-?H%"/+AZ2M]E?DG^IRO=BYRK=
M$QNP@//  Z@8[_K_ !<&J=S&B6MPZH J0L["/Y<$ DX(]<#Z'C/!Q<4XC=6\
MM$'S8D<'!YP>N2?F[^_4<%L^UU8/R'0HV[ILP0?P.,$?_6K2+LQ&?9^2J,J&
M)D:5P!% 8D;"A<A2,J"$R1]3WQ5^4JT+QLL@7(>38V0@!&'Z'!S@\Y&=HQBL
M^SLK>"26.&6>+8\JA!/(@A'FDIM"N,@JH(/0D\$D8JU]D)1RUS(,H,!I9)"3
MP"<&49X9NA!S@Y]=)\O-NQ(DA C;8$$6'FBQ$VU?DE9?N=.BY(/&3TQTE8L,
MM$60M\P!)))QU)Y/8<<YZY'2H+2WECM1#*XD*A@[ G#DR;CR?4GI]?0BIW#(
M2%*J?X-W0\^IP0,CUQ]3@C*5N88-,-AV "-29% ;*Y(/)!!XZ#OUZ>L+0K>Z
MYI&GR&58+N=;>48'S(9K<$'((Z#MCMVR&M,VYHBK.^#PHPI/MSCGGT&,]N32
M:9#)=>+_  ]'"J'-XA602,@7:R2,2!][*1. .G.1[)/E3EV3?X/_ (<#Z HH
MHK\].L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJMWCSK-6S\T_\D8_TJU44L(EDA?=CRGW@8Z_*5_K51=F!+1114@%%%% !111
M0 4444 %%%% !1110 5G:ZE[)H=XFG/:I=F,^6UV,Q>^_@\8S6C6%XR_L[_A
M$=2&K6]S<6)BVRQ6P_>OD@ +R.<XK;#J]:*\UY]>W43V/*_#FO\ ASP_XMM+
M?4/"FEPZK<S"&.\TB\CN8U=F"Y$>XF$<_7&<"O4#]K^W^)/L 0WGD1^0)/NF
M3RVVY]LXKSGPAH7B_3]5M/\ A';"ZTGP^9 TZ:QY!ED3=E@ J>8IQG&?SKT*
MY6-IO%*RW;6D9M5#W*]81Y39<?3K^%>]F?LW6O!IZ*_O.7VENM;>B;^1E"]C
M \+Q:U'XJB6Z?6I(3$9"+R...-8VC3!/E@#S!*)%V<\8/8$^B5Y=X*AL7\3V
MTB%Q>(DF\KICVJ[5BA1(@7.=BIL;9R2SAN!FO4:\[-5:LEY+I;N7#8****\P
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M48SFO<Q>'C[9*-HW5^W6+ULW;UZ6?34RB]#/\)/"_BBUDN(6:=Q(D9BU%KE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:X:QM(;<W,IFF\I N]R "QQW.*MUYV+KJO5YU_7?J]W=E15D%%%%<Q04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>eypt-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-11T22:48:46.5630090+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ed9f53d5b78741d19b453bb1246c3522 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:eypt="http://eyepointpharma.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://eyepointpharma.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://eyepointpharma.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperations" id="Role_DisclosureOperations">
        <link:definition>100070 - Disclosure - Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances" id="Role_DisclosureProductRevenueReservesAndAllowances">
        <link:definition>100090 - Disclosure - Product Revenue Reserves and Allowances</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory" id="Role_DisclosureInventory">
        <link:definition>100100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100110 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100140 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreements" id="Role_DisclosureLoanAgreements">
        <link:definition>100150 - Disclosure - Loan Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards" id="Role_DisclosureShareBasedPaymentAwards">
        <link:definition>100170 - Disclosure - Share-Based Payment Awards</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreements" id="Role_DisclosureLicenseAndAssetPurchaseAgreements">
        <link:definition>100180 - Disclosure - License and Asset Purchase Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100190 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlans" id="Role_DisclosureRetirementPlans">
        <link:definition>100200 - Disclosure - Retirement Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureContingencies" id="Role_DisclosureContingencies">
        <link:definition>100220 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation" id="Role_DisclosureSegmentAndGeographicAreaInformation">
        <link:definition>100230 - Disclosure - Segment and Geographic Area Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables" id="Role_DisclosureProductRevenueReservesAndAllowancesTables">
        <link:definition>100270 - Disclosure - Product Revenue Reserves and Allowances (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryTables" id="Role_DisclosureInventoryTables">
        <link:definition>100280 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100290 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100300 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100310 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100320 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100330 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables" id="Role_DisclosureShareBasedPaymentAwardsTables">
        <link:definition>100340 - Disclosure - Share-Based Payment Awards (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100350 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationTables" id="Role_DisclosureSegmentAndGeographicAreaInformationTables">
        <link:definition>100370 - Disclosure - Segment and Geographic Area Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail" id="Role_DisclosureOperationsAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail" id="Role_DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail">
        <link:definition>100400 - Disclosure - Significant Accounting Policies - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail" id="Role_DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail">
        <link:definition>100410 - Disclosure - Product Revenue Reserves and Allowances - Disaggregation of Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail" id="Role_DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail">
        <link:definition>100420 - Disclosure - Product Revenue Reserves and Allowances - Disaggregation of Revenue (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail" id="Role_DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail">
        <link:definition>100430 - Disclosure - Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserves (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail" id="Role_DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Product Revenue Reserves and Allowances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail" id="Role_DisclosureInventoryScheduleOfInventoryDetail">
        <link:definition>100450 - Disclosure - Inventory - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail">
        <link:definition>100460 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail">
        <link:definition>100470 - Disclosure - Intangible Assets - Schedule of Net Book Value of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100490 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>100510 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100520 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail" id="Role_DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail">
        <link:definition>100530 - Disclosure - Leases - Supplemental Balance Sheet Related to Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail" id="Role_DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail">
        <link:definition>100540 - Disclosure - Leases - Supplemental Balance Sheet Related to Finance Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail">
        <link:definition>100550 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2">
        <link:definition>100560 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail" id="Role_DisclosureLoanAgreementsAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Loan Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail">
        <link:definition>100580 - Disclosure - Stockholders&apos; Equity - Equity Financings - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail" id="Role_DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail">
        <link:definition>100590 - Disclosure - Stockholders&apos; Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company&apos;s Common Stock (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Stockholders&apos; Equity - Warrants to Purchase Common Shares - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail">
        <link:definition>100610 - Disclosure - Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail" id="Role_DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail">
        <link:definition>100620 - Disclosure - Share-Based Payment Awards - Stock Option Activity Under Company&apos;s Equity Incentive Plan (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail">
        <link:definition>100630 - Disclosure - Share-Based Payment Awards - Stock Options - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail" id="Role_DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail">
        <link:definition>100640 - Disclosure - Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail" id="Role_DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail">
        <link:definition>100650 - Disclosure - Share-Based Payment Awards - Summary of Information about Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail">
        <link:definition>100660 - Disclosure - Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail" id="Role_DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail">
        <link:definition>100670 - Disclosure - Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail">
        <link:definition>100680 - Disclosure - Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail">
        <link:definition>100690 - Disclosure - Share-Based Payment Awards - Employee Stock Purchase Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail" id="Role_DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail">
        <link:definition>100700 - Disclosure - Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail">
        <link:definition>100710 - Disclosure - Share-Based Payment Awards - Stock-Based Compensation Expense - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail" id="Role_DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail">
        <link:definition>100720 - Disclosure - License and Asset Purchase Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail">
        <link:definition>100730 - Disclosure - Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100740 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail" id="Role_DisclosureRetirementPlansAdditionalInformationDetail">
        <link:definition>100750 - Disclosure - Retirement Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
        <link:definition>100760 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100770 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail" id="Role_DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail">
        <link:definition>100780 - Disclosure - Income Taxes - Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail">
        <link:definition>100790 - Disclosure - Income Taxes - Significant Components of Deferred Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail" id="Role_DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail">
        <link:definition>100800 - Disclosure - Segment and Geographic Area Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail" id="Role_DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail">
        <link:definition>100810 - Disclosure - Segment and Geographic Area Information - Summary of Company&apos;s Revenues and Long-Lived Assets, Net, by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100820 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" name="CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" name="AmortizationOfAcquisitionCostOfIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" name="StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" name="StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_AmortizationOfDebtDiscount" name="AmortizationOfDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" name="ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_ProceedsFromPaycheckProtectionProgramLoan" name="ProceedsFromPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_NonCashUnpaidStockIssuanceCosts" name="NonCashUnpaidStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_DebtInstrumentExitFee" name="DebtInstrumentExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" name="PaymentsForgivenUnderPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_ProductRevenueReservesAndAllowancesTextBlock" name="ProductRevenueReservesAndAllowancesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" name="LesseeOperatingAndFinanceLeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_DebtAndEquityInstrumentsPolicyTextBlock" name="DebtAndEquityInstrumentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ComprehensiveLossPolicyPolicyTextBlock" name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ProductRevenueAllowanceAndReserveTableTextBlock" name="ProductRevenueAllowanceAndReserveTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" name="ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NumberOfProducts" name="NumberOfProducts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_OperationsAbstract" name="OperationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_OperationsLineItems" name="OperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_OrganizationAndNatureOfBusinessTable" name="OrganizationAndNatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_YUTIQProductMember" name="YUTIQProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" name="CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_NumberOfProductsApproved" name="NumberOfProductsApproved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" name="NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NumberOfNewBlindnessCasesEveryYear" name="NumberOfNewBlindnessCasesEveryYear" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" name="ScheduleOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_InvestmentInstrumentsMember" name="InvestmentInstrumentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ASDSpecialtyHealthcareLLCMember" name="ASDSpecialtyHealthcareLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_McKessonSpecialtyCareDistributionLLCMember" name="McKessonSpecialtyCareDistributionLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_OcumensionTherapeuticsMember" name="OcumensionTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DEXYCUMember" name="DEXYCUMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_IconBioscienceIncMember" name="IconBioscienceIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_AccountsReceivableStandardPaymentTerms" name="AccountsReceivableStandardPaymentTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_AccruedRevenueBasedRoyaltyExpense" name="AccruedRevenueBasedRoyaltyExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PercentageOfAcceleratedMilestonePaymentReceived" name="PercentageOfAcceleratedMilestonePaymentReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_PercentageOfUpfrontPaymentReceived" name="PercentageOfUpfrontPaymentReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_PreFundedWarrantsToPurchaseCommonStock" name="PreFundedWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="eypt_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DEXYCUProductMember" name="DEXYCUProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" name="ContractWithCustomerAllowanceForCreditLossAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" name="ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" name="ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" name="DisclosureOfProductRevenueReservesAndAllowancesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" name="DisclosureOfProductRevenueReservesAndAllowancesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ChargeBacksAndDiscountsAndFeesMember" name="ChargeBacksAndDiscountsAndFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_GovernmentsAndOtherRebatesMember" name="GovernmentsAndOtherRebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ReturnsMember" name="ReturnsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_AmendedAlimeraScienceIncAgreementMember" name="AmendedAlimeraScienceIncAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_RoyaltyPurchaseAgreementMember" name="RoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SWKFundingLLCMember" name="SWKFundingLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_RoyaltySaleAgreementMember" name="RoyaltySaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_OncoSilMedicalUKLimitedMember" name="OncoSilMedicalUKLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_CollaborativeResearchAndDevelopmentMember" name="CollaborativeResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_RoyaltyPercentageEarnedFromProductSales" name="RoyaltyPercentageEarnedFromProductSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NonRoyaltyConsiderationPercentage" name="NonRoyaltyConsiderationPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LicenseAgreementStartYearMonth" name="LicenseAgreementStartYearMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_UpfrontLicenseFeeReceived" name="UpfrontLicenseFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" name="PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" name="PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" name="ProductSupplyMilestonesAndDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_DevelopmentMilestonePaymentReceived" name="DevelopmentMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" name="PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" name="PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" name="PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_UponAchievementOfMilestones" name="UponAchievementOfMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_SalesBasedRoyaltyExpense" name="SalesBasedRoyaltyExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_EstimatedRateOfAnnualAmortizationExpense" name="EstimatedRateOfAnnualAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PropertyAndEquipmentMember" name="PropertyAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_AccruedClinicalExpenseCurrent" name="AccruedClinicalExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" name="AccruedSalesChargebacksRebatesAndOtherRevenueReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_LeasePropertyAreaCovered" name="LeasePropertyAreaCovered" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LeaseExpirationMonthYear" name="LeaseExpirationMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LeaseInceptionDate" name="LeaseInceptionDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_AdditionalLeasePropertyAreaCovered" name="AdditionalLeasePropertyAreaCovered" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ConstructionAllowanceCredit" name="ConstructionAllowanceCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" name="TerminationOfPortionOfLeasePropertyAreaCovered" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LeaseTerminationDate" name="LeaseTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_DisclosureOfLeasesAbstract" name="DisclosureOfLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DisclosureOfLeasesLineItems" name="DisclosureOfLeasesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DisclosureOfLeasesTable" name="DisclosureOfLeasesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_MaMember" name="MaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_OriginalLeaseMember" name="OriginalLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SecondAmendmentLeaseMember" name="SecondAmendmentLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ThirdAmendmentLeaseMember" name="ThirdAmendmentLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_FourthAmendmentLeaseMember" name="FourthAmendmentLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_BaskingRidgeOfficeSpaceMember" name="BaskingRidgeOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_CaladriusMember" name="CaladriusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_FirstLabEquipmentMember" name="FirstLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SecondLabEquipmentMember" name="SecondLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ThirdLabEquipmentMember" name="ThirdLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_LeasePropertyOfficeAreaCovered" name="LeasePropertyOfficeAreaCovered" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LeaseInceptionMonthYear" name="LeaseInceptionMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NumberOfRenewalOptions" name="NumberOfRenewalOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" name="OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_AdditionalSubleasedPropertyOfficeArea" name="AdditionalSubleasedPropertyOfficeArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NumberOfFinanceLeases" name="NumberOfFinanceLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_FinanceLeasePropertyAndEquipmentGross" name="FinanceLeasePropertyAndEquipmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" name="FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_TermLoanAgreementLineItems" name="TermLoanAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_TermLoanAgreementTable" name="TermLoanAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" name="CoronavirusAidReliefAndEconomicSecurityActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_CrgServicingLlcMember" name="CrgServicingLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SecondAdvanceMember" name="SecondAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SeniorSecuredTermLoanMember" name="SeniorSecuredTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_InitialAdvanceMember" name="InitialAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_LoanPrepaymentPriorToDecember312019Member" name="LoanPrepaymentPriorToDecember312019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" name="LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" name="LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_LoanPrepaymentAfterDecember312021Member" name="LoanPrepaymentAfterDecember312021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PeriodAxis" name="PeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PeriodDomain" name="PeriodDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PeriodOneMember" name="PeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PeriodTwoMember" name="PeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PeriodThreeMember" name="PeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_PeriodFourMember" name="PeriodFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DebtInstrumentAccruedInterestForgiveness" name="DebtInstrumentAccruedInterestForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_TermLoansAgreementInitialAdvance" name="TermLoansAgreementInitialAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_TermLoanAgreementAdditionalAdvance" name="TermLoanAgreementAdditionalAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_LineOfCreditFacilityExitFeesPercentage" name="LineOfCreditFacilityExitFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_LineOfCreditFacilityFinancingFeePercentage" name="LineOfCreditFacilityFinancingFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ReimbursedExpense" name="ReimbursedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_PaidInKindInterestAddedToPrincipal" name="PaidInKindInterestAddedToPrincipal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" name="LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_MinimumLiquidityAmount" name="MinimumLiquidityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_AnnualMinimumProductRevenue" name="AnnualMinimumProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_AnnualMinimumProductRevenuePeriod" name="AnnualMinimumProductRevenuePeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_IncrementalChargesForIssuanceOfWaivers" name="IncrementalChargesForIssuanceOfWaivers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_OriginalAmountOfDebtDiscount" name="OriginalAmountOfDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_ExitFeeAccrued" name="ExitFeeAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_LineOfCreditFacilityLegalAndTransactionCosts" name="LineOfCreditFacilityLegalAndTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_DebInstrumentExitFee" name="DebInstrumentExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PaymentOfAccruedAndUnpaidInterest" name="PaymentOfAccruedAndUnpaidInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" name="StockIssuedDuringPeriodAdditionalSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" name="ClassOfWarrantOrRightIssuePriceOfWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="eypt_EquityFinancingsMember" name="EquityFinancingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" name="StockIssuanceCostsSalesAgentCommissionMaximumPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" name="WarrantsIssuedInConnectionWithTermLoanFacility" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ExercisePriceOfIssuedWarrants" name="ExercisePriceOfIssuedWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_WarrantsExercisePeriod" name="WarrantsExercisePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_WeightedAverageRemainingLifeOfLenderWarrants" name="WeightedAverageRemainingLifeOfLenderWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_TwoThousandSixteenIncentivePlanMember" name="TwoThousandSixteenIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" name="EquityIncentivePlansAndInducementAwardGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NewlyAppointedNonExecutiveDirectorMember" name="NewlyAppointedNonExecutiveDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_DirectorsAndExternalConsultantsMember" name="DirectorsAndExternalConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_EquityIncentivePlansMember" name="EquityIncentivePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="eypt_DeferredStockUnitsMember" name="DeferredStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_NonExecutiveDirectorsMember" name="NonExecutiveDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_SalesAndMarketingMember" name="SalesAndMarketingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_NonRefundableNonCreditableUpfrontCashPayment" name="NonRefundableNonCreditableUpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_CollaborativeAgreementsAndContractsLineItems" name="CollaborativeAgreementsAndContractsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_CollaborativeAgreementsAndContractsTable" name="CollaborativeAgreementsAndContractsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_AerpioPharmaceuticalsIncMember" name="AerpioPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_EquinoxScienceLLCMember" name="EquinoxScienceLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" name="MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eypt_DefinedContributionPlanContributionsByEmployer" name="DefinedContributionPlanContributionsByEmployer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" name="FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_FederalAndStateTaxMember" name="FederalAndStateTaxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" name="IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_DeferredTaxAssetsLeasingArrangements" name="DeferredTaxAssetsLeasingArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" name="ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" name="ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" name="OperatingLossCarryForwardsExpirationYearRangeStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" name="OperatingLossCarryForwardsExpirationYearRangeEnd" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_NetOperatingLossCarryforwards" name="NetOperatingLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" name="PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eypt_SeniorSecuredRevolvingCreditFacilityMember" name="SeniorSecuredRevolvingCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>eypt-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-11T22:48:46.5630090+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ed9f53d5b78741d19b453bb1246c3522 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="eypt-20211231.xsd#TemplateLink" roleURI="http://eyepointpharma.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10270.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" xlink:type="locator" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" xlink:type="locator" xlink:label="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfDebtDiscount" xlink:type="locator" xlink:label="eypt_AmortizationOfDebtDiscount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProceedsFromPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="eypt_ProceedsFromPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="eypt_ProceedsFromPaycheckProtectionProgramLoan" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eypt_AmortizationOfDebtDiscount" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10260.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureInventoryScheduleOfInventoryDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:href="eypt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" xlink:type="locator" xlink:label="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedClinicalExpenseCurrent" xlink:type="locator" xlink:label="eypt_AccruedClinicalExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="eypt_AccruedClinicalExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" xlink:type="locator" xlink:label="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FinanceLeasePropertyAndEquipmentGross" xlink:type="locator" xlink:label="eypt_FinanceLeasePropertyAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="eypt_FinanceLeasePropertyAndEquipmentGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="eypt_IncomeTaxReconciliationPermanentItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="eypt_IncomeTaxReconciliationPermanentItems" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredTaxAssetsLeasingArrangements" xlink:type="locator" xlink:label="eypt_DeferredTaxAssetsLeasingArrangements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:type="locator" xlink:label="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="eypt_DeferredTaxAssetsLeasingArrangements" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>eypt-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-11T22:48:46.5630090+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ed9f53d5b78741d19b453bb1246c3522 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="eypt-20211231.xsd#TemplateLink" roleURI="http://eyepointpharma.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" xlink:type="locator" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10160.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_LicenseAndCollaborationAgreementMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_LicenseAndCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureOperationsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfNewBlindnessCasesEveryYear" xlink:type="locator" xlink:label="eypt_NumberOfNewBlindnessCasesEveryYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" xlink:type="locator" xlink:label="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfProductsApproved" xlink:type="locator" xlink:label="eypt_NumberOfProductsApproved" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfProducts" xlink:type="locator" xlink:label="eypt_NumberOfProducts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OrganizationAndNatureOfBusinessTable" xlink:type="locator" xlink:label="eypt_OrganizationAndNatureOfBusinessTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperationsLineItems" xlink:type="locator" xlink:label="eypt_OperationsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_OrganizationAndNatureOfBusinessTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_YUTIQProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfProducts" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfProductsApproved" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfNewBlindnessCasesEveryYear" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_OperationsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_OperationsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PreFundedWarrantsToPurchaseCommonStock" xlink:type="locator" xlink:label="eypt_PreFundedWarrantsToPurchaseCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfUpfrontPaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfUpfrontPaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAcceleratedMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedRevenueBasedRoyaltyExpense" xlink:type="locator" xlink:label="eypt_AccruedRevenueBasedRoyaltyExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccountsReceivableStandardPaymentTerms" xlink:type="locator" xlink:label="eypt_AccountsReceivableStandardPaymentTerms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_McKessonSpecialtyCareDistributionLLCMember" xlink:type="locator" xlink:label="eypt_McKessonSpecialtyCareDistributionLLCMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ASDSpecialtyHealthcareLLCMember" xlink:type="locator" xlink:label="eypt_ASDSpecialtyHealthcareLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InvestmentInstrumentsMember" xlink:type="locator" xlink:label="eypt_InvestmentInstrumentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="eypt_InvestmentInstrumentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_ASDSpecialtyHealthcareLLCMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_McKessonSpecialtyCareDistributionLLCMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_OcumensionTherapeuticsMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eypt_DEXYCUMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_AccountsReceivableStandardPaymentTerms" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_AccruedRevenueBasedRoyaltyExpense" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_PercentageOfAcceleratedMilestonePaymentReceived" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_PercentageOfUpfrontPaymentReceived" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_PreFundedWarrantsToPurchaseCommonStock" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eypt_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eypt_EmployeeStockPurchasePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUProductMember" xlink:type="locator" xlink:label="eypt_DEXYCUProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_YUTIQProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_DEXYCUProductMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUProductMember" xlink:type="locator" xlink:label="eypt_DEXYCUProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_YUTIQProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_DEXYCUProductMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_OcumensionTherapeuticsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForCreditLossAdditions" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ReturnsMember" xlink:type="locator" xlink:label="eypt_ReturnsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_GovernmentsAndOtherRebatesMember" xlink:type="locator" xlink:label="eypt_GovernmentsAndOtherRebatesMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ChargeBacksAndDiscountsAndFeesMember" xlink:type="locator" xlink:label="eypt_ChargeBacksAndDiscountsAndFeesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:type="locator" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:type="locator" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="eypt_ChargeBacksAndDiscountsAndFeesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="eypt_GovernmentsAndOtherRebatesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="eypt_ReturnsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAcceleratedMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SalesBasedRoyaltyExpense" xlink:type="locator" xlink:label="eypt_SalesBasedRoyaltyExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UponAchievementOfMilestones" xlink:type="locator" xlink:label="eypt_UponAchievementOfMilestones" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DevelopmentMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_DevelopmentMilestonePaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductSupplyMilestonesAndDevelopmentMilestones" xlink:type="locator" xlink:label="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAgreementStartYearMonth" xlink:type="locator" xlink:label="eypt_LicenseAgreementStartYearMonth" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonRoyaltyConsiderationPercentage" xlink:type="locator" xlink:label="eypt_NonRoyaltyConsiderationPercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPercentageEarnedFromProductSales" xlink:type="locator" xlink:label="eypt_RoyaltyPercentageEarnedFromProductSales" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontLicenseFeeReceived" xlink:type="locator" xlink:label="eypt_UpfrontLicenseFeeReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="eypt_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyServiceMember" xlink:type="locator" xlink:label="us-gaap_TechnologyServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeResearchAndDevelopmentMember" xlink:type="locator" xlink:label="eypt_CollaborativeResearchAndDevelopmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OncoSilMedicalUKLimitedMember" xlink:type="locator" xlink:label="eypt_OncoSilMedicalUKLimitedMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltySaleAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltySaleAgreementMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltyPurchaseAgreementMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmendedAlimeraScienceIncAgreementMember" xlink:type="locator" xlink:label="eypt_AmendedAlimeraScienceIncAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_AmendedAlimeraScienceIncAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_RoyaltyPurchaseAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_RoyaltySaleAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_OncoSilMedicalUKLimitedMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_CollaborativeResearchAndDevelopmentMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_OcumensionTherapeuticsMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_LicenseAndCollaborationAgreementMember" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_TechnologyServiceMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eypt_UnderwrittenPublicOfferingMember" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_UpfrontCashPayment" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_UpfrontLicenseFeeReceived" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_RoyaltyPercentageEarnedFromProductSales" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_NonRoyaltyConsiderationPercentage" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_LicenseAgreementStartYearMonth" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" order="12810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_DevelopmentMilestonePaymentReceived" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" order="13140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_UponAchievementOfMilestones" order="13240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_SalesBasedRoyaltyExpense" order="13520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PercentageOfAcceleratedMilestonePaymentReceived" order="13560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eypt_DEXYCUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EstimatedRateOfAnnualAmortizationExpense" xlink:type="locator" xlink:label="eypt_EstimatedRateOfAnnualAmortizationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eypt_DEXYCUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="eypt_EstimatedRateOfAnnualAmortizationExpense" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:href="eypt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PropertyAndEquipmentMember" xlink:type="locator" xlink:label="eypt_PropertyAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_PropertyAndEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfFinanceLeases" xlink:type="locator" xlink:label="eypt_NumberOfFinanceLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AdditionalSubleasedPropertyOfficeArea" xlink:type="locator" xlink:label="eypt_AdditionalSubleasedPropertyOfficeArea" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" xlink:type="locator" xlink:label="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfRenewalOptions" xlink:type="locator" xlink:label="eypt_NumberOfRenewalOptions" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseInceptionMonthYear" xlink:type="locator" xlink:label="eypt_LeaseInceptionMonthYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeasePropertyOfficeAreaCovered" xlink:type="locator" xlink:label="eypt_LeasePropertyOfficeAreaCovered" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseTerminationDate" xlink:type="locator" xlink:label="eypt_LeaseTerminationDate" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TerminationOfPortionOfLeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ConstructionAllowanceCredit" xlink:type="locator" xlink:label="eypt_ConstructionAllowanceCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AdditionalLeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_AdditionalLeasePropertyAreaCovered" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseInceptionDate" xlink:type="locator" xlink:label="eypt_LeaseInceptionDate" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseExpirationMonthYear" xlink:type="locator" xlink:label="eypt_LeaseExpirationMonthYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_LeasePropertyAreaCovered" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ThirdLabEquipmentMember" xlink:type="locator" xlink:label="eypt_ThirdLabEquipmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondLabEquipmentMember" xlink:type="locator" xlink:label="eypt_SecondLabEquipmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FirstLabEquipmentMember" xlink:type="locator" xlink:label="eypt_FirstLabEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CaladriusMember" xlink:type="locator" xlink:label="eypt_CaladriusMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_BaskingRidgeOfficeSpaceMember" xlink:type="locator" xlink:label="eypt_BaskingRidgeOfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FourthAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_FourthAmendmentLeaseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ThirdAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_ThirdAmendmentLeaseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_SecondAmendmentLeaseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OriginalLeaseMember" xlink:type="locator" xlink:label="eypt_OriginalLeaseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MaMember" xlink:type="locator" xlink:label="eypt_MaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesTable" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesLineItems" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_DisclosureOfLeasesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="eypt_MaMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_OriginalLeaseMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SecondAmendmentLeaseMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_ThirdAmendmentLeaseMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_FourthAmendmentLeaseMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="srt_RangeAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_BaskingRidgeOfficeSpaceMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="srt_CounterpartyNameAxis" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eypt_CaladriusMember" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_FirstLabEquipmentMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_SecondLabEquipmentMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_ThirdLabEquipmentMember" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeasePropertyAreaCovered" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseExpirationMonthYear" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseInceptionDate" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_AdditionalLeasePropertyAreaCovered" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_ConstructionAllowanceCredit" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseTerminationDate" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeasePropertyOfficeAreaCovered" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseInceptionMonthYear" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_NumberOfRenewalOptions" order="12410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_AdditionalSubleasedPropertyOfficeArea" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="12570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_VariableLeaseCost" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_NumberOfFinanceLeases" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="12900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="12940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="12980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="13020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="13110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLoanAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentOfAccruedAndUnpaidInterest" xlink:type="locator" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebInstrumentExitFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityLegalAndTransactionCosts" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityLegalAndTransactionCosts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExitFeeAccrued" xlink:type="locator" xlink:label="eypt_ExitFeeAccrued" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OriginalAmountOfDebtDiscount" xlink:type="locator" xlink:label="eypt_OriginalAmountOfDebtDiscount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncrementalChargesForIssuanceOfWaivers" xlink:type="locator" xlink:label="eypt_IncrementalChargesForIssuanceOfWaivers" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AnnualMinimumProductRevenuePeriod" xlink:type="locator" xlink:label="eypt_AnnualMinimumProductRevenuePeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AnnualMinimumProductRevenue" xlink:type="locator" xlink:label="eypt_AnnualMinimumProductRevenue" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MinimumLiquidityAmount" xlink:type="locator" xlink:label="eypt_MinimumLiquidityAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ReimbursedExpense" xlink:type="locator" xlink:label="eypt_ReimbursedExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityFinancingFeePercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityFinancingFeePercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityExitFeesPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaidInKindInterestAddedToPrincipal" xlink:type="locator" xlink:label="eypt_PaidInKindInterestAddedToPrincipal" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:type="locator" xlink:label="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementAdditionalAdvance" xlink:type="locator" xlink:label="eypt_TermLoanAgreementAdditionalAdvance" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoansAgreementInitialAdvance" xlink:type="locator" xlink:label="eypt_TermLoansAgreementInitialAdvance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtInstrumentAccruedInterestForgiveness" xlink:type="locator" xlink:label="eypt_DebtInstrumentAccruedInterestForgiveness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodFourMember" xlink:type="locator" xlink:label="eypt_PeriodFourMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodThreeMember" xlink:type="locator" xlink:label="eypt_PeriodThreeMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodTwoMember" xlink:type="locator" xlink:label="eypt_PeriodTwoMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodOneMember" xlink:type="locator" xlink:label="eypt_PeriodOneMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodDomain" xlink:type="locator" xlink:label="eypt_PeriodDomain" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodDomain" xlink:type="locator" xlink:label="eypt_PeriodDomain_2" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodAxis" xlink:type="locator" xlink:label="eypt_PeriodAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltyPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312021Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312021Member" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentPriorToDecember312019Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentPriorToDecember312019Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InitialAdvanceMember" xlink:type="locator" xlink:label="eypt_InitialAdvanceMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondAdvanceMember" xlink:type="locator" xlink:label="eypt_SecondAdvanceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SiliconValleyBankMember" xlink:type="locator" xlink:label="eypt_SiliconValleyBankMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaycheckProtectionProgramLoanMember" xlink:type="locator" xlink:label="eypt_PaycheckProtectionProgramLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementTable" xlink:type="locator" xlink:label="eypt_TermLoanAgreementTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementLineItems" xlink:type="locator" xlink:label="eypt_TermLoanAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_TermLoanAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:to="eypt_PaycheckProtectionProgramLoanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_SiliconValleyBankMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_UnusualOrInfrequentItemAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualOrInfrequentItemDomain" xlink:to="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_CrgServicingLlcMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eypt_SecondAdvanceMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_CreditFacilityAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eypt_InitialAdvanceMember" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentPriorToDecember312019Member" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentAfterDecember312021Member" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="srt_ProductOrServiceAxis" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_RoyaltyPurchaseAgreementMember" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_TermLoanAgreementTable" xlink:to="eypt_PeriodAxis" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="eypt_PeriodAxis" xlink:to="eypt_PeriodDomain_2" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="eypt_PeriodAxis" xlink:to="eypt_PeriodDomain" order="12410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodOneMember" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodTwoMember" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodThreeMember" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodFourMember" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="13760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="13800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="13870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="13890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="13910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="13960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="14010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_DebtInstrumentAccruedInterestForgiveness" order="14050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="14090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1" order="14160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="14200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_TermLoansAgreementInitialAdvance" order="14240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_TermLoanAgreementAdditionalAdvance" order="14280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="14320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="14390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" order="14430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_PaidInKindInterestAddedToPrincipal" order="14450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="14470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityExitFeesPercentage" order="14490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityFinancingFeePercentage" order="14510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" order="14530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_ReimbursedExpense" order="14550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" order="14640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_UpfrontCashPayment" order="14720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_MinimumLiquidityAmount" order="14770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_AnnualMinimumProductRevenue" order="14820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_AnnualMinimumProductRevenuePeriod" order="14840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_IncrementalChargesForIssuanceOfWaivers" order="15090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_OriginalAmountOfDebtDiscount" order="15160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_ExitFeeAccrued" order="15180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityLegalAndTransactionCosts" order="15220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="15380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_DebInstrumentExitFee" order="15400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_PaymentOfAccruedAndUnpaidInterest" order="15420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="15490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" xlink:type="locator" xlink:label="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_GrossProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="eypt_GrossProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" xlink:type="locator" xlink:label="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="eypt_AtTheMarketOfferingMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SharePurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_SharePurchaseAgreementMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="eypt_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityFinancingsMember" xlink:type="locator" xlink:label="eypt_EquityFinancingsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_EquityFinancingsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eypt_UnderwrittenPublicOfferingMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SharePurchaseAgreementMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_AtTheMarketOfferingMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_GrossProceedsFromIssuanceOfCommonStock" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" order="11750.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WeightedAverageRemainingLifeOfLenderWarrants" xlink:type="locator" xlink:label="eypt_WeightedAverageRemainingLifeOfLenderWarrants" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WarrantsExercisePeriod" xlink:type="locator" xlink:label="eypt_WarrantsExercisePeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExercisePriceOfIssuedWarrants" xlink:type="locator" xlink:label="eypt_ExercisePriceOfIssuedWarrants" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WarrantsIssuedInConnectionWithTermLoanFacility" xlink:type="locator" xlink:label="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ExercisePriceOfIssuedWarrants" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_WarrantsExercisePeriod" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_WeightedAverageRemainingLifeOfLenderWarrants" order="10620.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityIncentivePlansAndInducementAwardGrantsMember" xlink:type="locator" xlink:label="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DirectorsAndExternalConsultantsMember" xlink:type="locator" xlink:label="eypt_DirectorsAndExternalConsultantsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NewlyAppointedNonExecutiveDirectorMember" xlink:type="locator" xlink:label="eypt_NewlyAppointedNonExecutiveDirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eypt_NewlyAppointedNonExecutiveDirectorMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eypt_DirectorsAndExternalConsultantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityIncentivePlansMember" xlink:type="locator" xlink:label="eypt_EquityIncentivePlansMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_EquityIncentivePlansMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:type="locator" xlink:label="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonExecutiveDirectorsMember" xlink:type="locator" xlink:label="eypt_NonExecutiveDirectorsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredStockUnitsMember" xlink:type="locator" xlink:label="eypt_DeferredStockUnitsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eypt_DeferredStockUnitsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eypt_NonExecutiveDirectorsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" order="10340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eypt_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_EmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SalesAndMarketingMember" xlink:type="locator" xlink:label="eypt_SalesAndMarketingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eypt_SalesAndMarketingMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:type="locator" xlink:label="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonRefundableNonCreditableUpfrontCashPayment" xlink:type="locator" xlink:label="eypt_NonRefundableNonCreditableUpfrontCashPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquinoxScienceLLCMember" xlink:type="locator" xlink:label="eypt_EquinoxScienceLLCMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AerpioPharmaceuticalsIncMember" xlink:type="locator" xlink:label="eypt_AerpioPharmaceuticalsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeAgreementsAndContractsTable" xlink:type="locator" xlink:label="eypt_CollaborativeAgreementsAndContractsTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeAgreementsAndContractsLineItems" xlink:type="locator" xlink:label="eypt_CollaborativeAgreementsAndContractsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="eypt_CollaborativeAgreementsAndContractsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_CollaborativeAgreementsAndContractsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_AerpioPharmaceuticalsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_EquinoxScienceLLCMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eypt_CollaborativeAgreementsAndContractsTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="eypt_NonRefundableNonCreditableUpfrontCashPayment" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" order="10450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10060.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="11450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExitFeeAccrued" xlink:type="locator" xlink:label="eypt_ExitFeeAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InvestmentInstrumentsMember" xlink:type="locator" xlink:label="eypt_InvestmentInstrumentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="eypt_InvestmentInstrumentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_CrgServicingLlcMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebt" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="eypt_ExitFeeAccrued" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="10820.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" xlink:type="locator" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" xlink:type="locator" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" xlink:type="locator" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLossCarryForwardsExpirationYearRangeStart" xlink:type="locator" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NetOperatingLossCarryforwards" xlink:type="locator" xlink:label="eypt_NetOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:type="locator" xlink:label="us-gaap_HerMajestysRevenueAndCustomsHMRCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FederalAndStateTaxMember" xlink:type="locator" xlink:label="eypt_FederalAndStateTaxMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" xlink:type="locator" xlink:label="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="eypt_FederalAndStateTaxMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_HerMajestysRevenueAndCustomsHMRCMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_NetOperatingLossCarryforwards" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentOfAccruedAndUnpaidInterest" xlink:type="locator" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityExitFeesPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebInstrumentExitFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" xlink:type="locator" xlink:label="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SiliconValleyBankMember" xlink:type="locator" xlink:label="eypt_SiliconValleyBankMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredRevolvingCreditFacilityMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredRevolvingCreditFacilityMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredRevolvingCreditFacilityMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_SiliconValleyBankMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VariableRateAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_CrgServicingLlcMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_UpfrontCashPayment" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_DebInstrumentExitFee" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_LineOfCreditFacilityExitFeesPercentage" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_PaymentOfAccruedAndUnpaidInterest" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11700.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>eypt-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-11T22:48:46.5640081+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ed9f53d5b78741d19b453bb1246c3522 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and other receivables, net (including due from a related party of $414 and $104 at December 31, 2021 and 2020, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts And Other Receivables Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue - noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities - noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies (Note 16)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2021 and 2020, respectively; 33,905,826 and 18,139,981 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of sales excluding amortization of acquired intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" xlink:type="locator" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of acquisition cost of intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" xlink:to="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LicenseAndCollaborationAgreementMember" xlink:to="eypt_LicenseAndCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Income [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales Excluding Amortization Of Acquired Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling And Marketing Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of acquired intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Acquisition Cost Of Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (loss) on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Related Parties</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" />
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares, issuance of stock and pre-funded warrants, net of issue costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:to="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" />
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value, issuance of stock and pre-funded warrants, net of issue costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:to="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issue costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issue costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock and pre-funded warrants, net of issue costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issuance Of Stock And Pre Funded Warrants Net Of Issue Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock and pre-funded warrants, net of issue costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Stock And Pre Funded Warrants Net Of Issue Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of stock units, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfDebtDiscount" xlink:type="locator" xlink:label="eypt_AmortizationOfDebtDiscount" />
    <link:label xml:lang="en-US" xlink:label="eypt_AmortizationOfDebtDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization Of Debt Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AmortizationOfDebtDiscount" xlink:to="eypt_AmortizationOfDebtDiscount_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" xlink:type="locator" xlink:label="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase or decrease in operating lease liability and right of use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" xlink:to="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of stock and pre-funded warrants, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProceedsFromPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="eypt_ProceedsFromPaycheckProtectionProgramLoan" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from paycheck protection program loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ProceedsFromPaycheckProtectionProgramLoan" xlink:to="eypt_ProceedsFromPaycheckProtectionProgramLoan_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonCashUnpaidStockIssuanceCosts" xlink:type="locator" xlink:label="eypt_NonCashUnpaidStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="eypt_NonCashUnpaidStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash unpaid stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NonCashUnpaidStockIssuanceCosts" xlink:to="eypt_NonCashUnpaidStockIssuanceCosts_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebtInstrumentExitFee" />
    <link:label xml:lang="en-US" xlink:label="eypt_DebtInstrumentExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument exit fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DebtInstrumentExitFee" xlink:to="eypt_DebtInstrumentExitFee_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" />
    <link:label xml:lang="en-US" xlink:label="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments forgiven under paycheck protection program loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" xlink:to="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AmortizationOfDebtDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AmortizationOfDebtDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on extinguishment of debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for excess and obsolescence inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Write Down</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable And Other Operating Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets and operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities And Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of stock and pre-funded warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds under paycheck protection program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProceedsFromPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Paycheck Protection Program Loan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of long-term debt principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of extinguishment of debt costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Extinguishment Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net settlement of stock units to satisfy statutory tax withholding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Principal Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonCashUnpaidStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonCashUnpaidStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Unpaid Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebtInstrumentExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued term loan exit fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebtInstrumentExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Exit Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments forgiven under paycheck protection program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Forgiven Under Paycheck Protection Program Loan</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductRevenueReservesAndAllowancesTextBlock" xlink:type="locator" xlink:label="eypt_ProductRevenueReservesAndAllowancesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProductRevenueReservesAndAllowancesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for product revenue reserves and allowances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ProductRevenueReservesAndAllowancesTextBlock" xlink:to="eypt_ProductRevenueReservesAndAllowancesTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProductRevenueReservesAndAllowancesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue Reserves and Allowances</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProductRevenueReservesAndAllowancesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Reserves And Allowances [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xlink:type="locator" xlink:label="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating and finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xlink:to="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating And Finance Leases Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payment Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Asset Purchase Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Area Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and Other Receivables, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Accounts Receivable Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtAndEquityInstrumentsPolicyTextBlock" xlink:type="locator" xlink:label="eypt_DebtAndEquityInstrumentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_DebtAndEquityInstrumentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt and equity instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DebtAndEquityInstrumentsPolicyTextBlock" xlink:to="eypt_DebtAndEquityInstrumentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DebtAndEquityInstrumentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt and Equity Instruments</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebtAndEquityInstrumentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt And Equity Instruments Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Software Development Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Computer Software Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ComprehensiveLossPolicyPolicyTextBlock" xlink:type="locator" xlink:label="eypt_ComprehensiveLossPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_ComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Comprehensive Loss, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="eypt_ComprehensiveLossPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ComprehensiveLossPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Loss Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted and Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductRevenueAllowanceAndReserveTableTextBlock" xlink:type="locator" xlink:label="eypt_ProductRevenueAllowanceAndReserveTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProductRevenueAllowanceAndReserveTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure of product revenue allowance and reserve.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ProductRevenueAllowanceAndReserveTableTextBlock" xlink:to="eypt_ProductRevenueAllowanceAndReserveTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProductRevenueAllowanceAndReserveTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue Allowance and Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProductRevenueAllowanceAndReserveTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Allowance And Reserve Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Book Value of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental balance sheet information related to operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Balance Sheet Information Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" xlink:type="locator" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental balance sheet information related to finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Balance Sheet Information Related to Finance Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Balance Sheet Information Related To Finance Lease Table [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" xlink:type="locator" xlink:label="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of future minimum operating and finance lease payments under non cancellable leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" xlink:to="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments Under Non-Cancellable Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Operating And Finance Lease Payments Under Non Cancellable Leases Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Warrants to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity Under Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Key Assumptions Used</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information about Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation Expense from Stock-Based Payment Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Carried at Fair Value Measured on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Loss Before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Components of Deferred Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company&apos;s Revenues and Long-Lived Assets, Net, by Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Revenues From External Customers And Long Lived Assets By Geographical Areas Table [Text Block]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfProducts" xlink:type="locator" xlink:label="eypt_NumberOfProducts" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NumberOfProducts" xlink:to="eypt_NumberOfProducts_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperationsAbstract" xlink:type="locator" xlink:label="eypt_OperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="eypt_OperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OperationsAbstract" xlink:to="eypt_OperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_OperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operations [Abstract]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperationsLineItems" xlink:type="locator" xlink:label="eypt_OperationsLineItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_OperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_OperationsLineItems_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OrganizationAndNatureOfBusinessTable" xlink:type="locator" xlink:label="eypt_OrganizationAndNatureOfBusinessTable" />
    <link:label xml:lang="en-US" xlink:label="eypt_OrganizationAndNatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization And Nature Of Business [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="eypt_OrganizationAndNatureOfBusinessTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_OrganizationAndNatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OrganizationAndNatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Table]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_YUTIQProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">YUTIQ product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_YUTIQProductMember" xlink:to="eypt_YUTIQProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_YUTIQProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">YUTIQ [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_YUTIQProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Y U T I Q Product [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of sales, excluding amortization of acquired intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Sales, Excluding Amortization of Acquired Intangible Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales Excluding Amortization Of Acquired Intangible Assets [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling And Marketing Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operations [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operations [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial products</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Products</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfProductsApproved" xlink:type="locator" xlink:label="eypt_NumberOfProductsApproved" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfProductsApproved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of products approved by by the United States (US) Food and Drug Administration (FDA).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NumberOfProductsApproved" xlink:to="eypt_NumberOfProductsApproved_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfProductsApproved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of products approved</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfProductsApproved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Products Approved</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" xlink:type="locator" xlink:label="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of people affected by posterior segment of eye in U.S. each year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" xlink:to="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfNewBlindnessCasesEveryYear" xlink:type="locator" xlink:label="eypt_NumberOfNewBlindnessCasesEveryYear" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfNewBlindnessCasesEveryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new blindness cases every year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NumberOfNewBlindnessCasesEveryYear" xlink:to="eypt_NumberOfNewBlindnessCasesEveryYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of people affected by posterior segment of eye in U.S. each year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of People Affected By Posterior Segment Of Eye In U S Each Year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfNewBlindnessCasesEveryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of new cases of blindness annually</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfNewBlindnessCasesEveryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of New Blindness Cases Every Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investments in marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_ScheduleOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InvestmentInstrumentsMember" xlink:type="locator" xlink:label="eypt_InvestmentInstrumentsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_InvestmentInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_InvestmentInstrumentsMember" xlink:to="eypt_InvestmentInstrumentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_InvestmentInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Instruments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_InvestmentInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Instruments [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ASDSpecialtyHealthcareLLCMember" xlink:type="locator" xlink:label="eypt_ASDSpecialtyHealthcareLLCMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_ASDSpecialtyHealthcareLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ASD specialty healthcare LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ASDSpecialtyHealthcareLLCMember" xlink:to="eypt_ASDSpecialtyHealthcareLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ASDSpecialtyHealthcareLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASD Specialty Healthcare LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ASDSpecialtyHealthcareLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A S D Specialty Healthcare L L C [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_McKessonSpecialtyCareDistributionLLCMember" xlink:type="locator" xlink:label="eypt_McKessonSpecialtyCareDistributionLLCMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_McKessonSpecialtyCareDistributionLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">McKesson specialty care distribution LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_McKessonSpecialtyCareDistributionLLCMember" xlink:to="eypt_McKessonSpecialtyCareDistributionLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_McKessonSpecialtyCareDistributionLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">McKesson Specialty Care Distribution LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_McKessonSpecialtyCareDistributionLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mc Kesson Specialty Care Distribution L L C [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Revenue, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_OcumensionTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ocumension Therapeutics.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OcumensionTherapeuticsMember" xlink:to="eypt_OcumensionTherapeuticsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_OcumensionTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ocumension Therapeutics [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OcumensionTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ocumension Therapeutics [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_DEXYCUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">DEXYCU.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DEXYCUMember" xlink:to="eypt_DEXYCUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DEXYCUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DEXYCU [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DEXYCUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">D E X Y C U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_IconBioscienceIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Icon Bioscience, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_IconBioscienceIncMember" xlink:to="eypt_IconBioscienceIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_IconBioscienceIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Icon Bioscience Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IconBioscienceIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icon Bioscience Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201912 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ScheduleOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income to foreign currency translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities matured</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing cash equivalent consisted of money market fund</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing cash equivalent consisted of investment-grade commercial paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperAtCarryingValue" xlink:to="us-gaap_CommercialPaperAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of concentration risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccountsReceivableStandardPaymentTerms" xlink:type="locator" xlink:label="eypt_AccountsReceivableStandardPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="eypt_AccountsReceivableStandardPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable standard payment terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AccountsReceivableStandardPaymentTerms" xlink:to="eypt_AccountsReceivableStandardPaymentTerms_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable Allowance For Credit Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccountsReceivableStandardPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable standard payment terms</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccountsReceivableStandardPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Standard Payment Terms</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedRevenueBasedRoyaltyExpense" xlink:type="locator" xlink:label="eypt_AccruedRevenueBasedRoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedRevenueBasedRoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued revenue based royalty expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AccruedRevenueBasedRoyaltyExpense" xlink:to="eypt_AccruedRevenueBasedRoyaltyExpense_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAcceleratedMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of accelerated milestone payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PercentageOfAcceleratedMilestonePaymentReceived" xlink:to="eypt_PercentageOfAcceleratedMilestonePaymentReceived_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfUpfrontPaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfUpfrontPaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upfront payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PercentageOfUpfrontPaymentReceived" xlink:to="eypt_PercentageOfUpfrontPaymentReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedRevenueBasedRoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued revenue-based royalty expense</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedRevenueBasedRoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Revenue Based Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of accelerated milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Accelerated Milestone Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upfront Payment Received</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PreFundedWarrantsToPurchaseCommonStock" xlink:type="locator" xlink:label="eypt_PreFundedWarrantsToPurchaseCommonStock" />
    <link:label xml:lang="en-US" xlink:label="eypt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrants to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PreFundedWarrantsToPurchaseCommonStock" xlink:to="eypt_PreFundedWarrantsToPurchaseCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PreFundedWarrantsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants To Purchase Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eypt_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_EmployeeStockPurchasePlanMember" xlink:to="eypt_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUProductMember" xlink:type="locator" xlink:label="eypt_DEXYCUProductMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_DEXYCUProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">DEXYCU product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DEXYCUProductMember" xlink:to="eypt_DEXYCUProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DEXYCUProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DEXYCU [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DEXYCUProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">D E X Y C U Product [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Disclosure of Product Revenue Reserves and Allowances [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment Arrangement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentMember" xlink:to="us-gaap_SupplyCommitmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForCreditLossAdditions" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" />
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer allowance for credit loss additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" xlink:to="eypt_ContractWithCustomerAllowanceForCreditLossAdditions_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer allowance for credit loss increase decrease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" xlink:to="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" />
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer allowance for deductions applied and payments made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" xlink:to="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:type="locator" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of product revenue reserves and allowances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:type="locator" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Product Revenue Reserves and Allowances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:to="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Product Revenue Reserves And Allowances [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Product Revenue Reserves And Allowances [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ChargeBacksAndDiscountsAndFeesMember" xlink:type="locator" xlink:label="eypt_ChargeBacksAndDiscountsAndFeesMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_ChargeBacksAndDiscountsAndFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Charge backs and discounts and fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ChargeBacksAndDiscountsAndFeesMember" xlink:to="eypt_ChargeBacksAndDiscountsAndFeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ChargeBacksAndDiscountsAndFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chargebacks, Discounts and Fees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ChargeBacksAndDiscountsAndFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Charge Backs And Discounts And Fees [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_GovernmentsAndOtherRebatesMember" xlink:type="locator" xlink:label="eypt_GovernmentsAndOtherRebatesMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_GovernmentsAndOtherRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Governments and other rebates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_GovernmentsAndOtherRebatesMember" xlink:to="eypt_GovernmentsAndOtherRebatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_GovernmentsAndOtherRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and Other Rebates [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_GovernmentsAndOtherRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Governments And Other Rebates [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ReturnsMember" xlink:type="locator" xlink:label="eypt_ReturnsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_ReturnsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Returns.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ReturnsMember" xlink:to="eypt_ReturnsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ReturnsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Returns [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ReturnsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Returns [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Product Revenue Reserves And Allowances [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Product Revenue Reserves And Allowances [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Accumulated Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision related to sales in the current year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Allowance For Credit Loss Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments related to prior period sales</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Allowance For Credit Loss Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deductions applied and payments made</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Allowance For Deductions Applied And Payments Made</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmendedAlimeraScienceIncAgreementMember" xlink:type="locator" xlink:label="eypt_AmendedAlimeraScienceIncAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_AmendedAlimeraScienceIncAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Alimera Science Inc Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AmendedAlimeraScienceIncAgreementMember" xlink:to="eypt_AmendedAlimeraScienceIncAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_AmendedAlimeraScienceIncAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Alimera Science Inc Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AmendedAlimeraScienceIncAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Alimera Science Inc Agreement [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltyPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_RoyaltyPurchaseAgreementMember" xlink:to="eypt_RoyaltyPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RPA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SWKFundingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">SWK Funding LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SWKFundingLLCMember" xlink:to="eypt_SWKFundingLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SWKFundingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SWK [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SWKFundingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">S W K Funding L L C [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltySaleAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltySaleAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltySaleAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty sale agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_RoyaltySaleAgreementMember" xlink:to="eypt_RoyaltySaleAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltySaleAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Sale Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltySaleAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Sale Agreement [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OncoSilMedicalUKLimitedMember" xlink:type="locator" xlink:label="eypt_OncoSilMedicalUKLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_OncoSilMedicalUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">OncoSil Medical UK Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OncoSilMedicalUKLimitedMember" xlink:to="eypt_OncoSilMedicalUKLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_OncoSilMedicalUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OncoSil Medical UK Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OncoSilMedicalUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Onco Sil Medical U K Limited [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeResearchAndDevelopmentMember" xlink:type="locator" xlink:label="eypt_CollaborativeResearchAndDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CollaborativeResearchAndDevelopmentMember" xlink:to="eypt_CollaborativeResearchAndDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Research And Development [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyServiceMember" xlink:type="locator" xlink:label="us-gaap_TechnologyServiceMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TechnologyServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technical Assistance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyServiceMember" xlink:to="us-gaap_TechnologyServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TechnologyServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Technology Service [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="eypt_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_UnderwrittenPublicOfferingMember" xlink:to="eypt_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Revenue</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:label xml:lang="en-US" xlink:label="eypt_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_UpfrontCashPayment" xlink:to="eypt_UpfrontCashPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Royalties</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPercentageEarnedFromProductSales" xlink:type="locator" xlink:label="eypt_RoyaltyPercentageEarnedFromProductSales" />
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltyPercentageEarnedFromProductSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty percentage earned from sales of product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_RoyaltyPercentageEarnedFromProductSales" xlink:to="eypt_RoyaltyPercentageEarnedFromProductSales_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonRoyaltyConsiderationPercentage" xlink:type="locator" xlink:label="eypt_NonRoyaltyConsiderationPercentage" />
    <link:label xml:lang="en-US" xlink:label="eypt_NonRoyaltyConsiderationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non royalty consideration percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NonRoyaltyConsiderationPercentage" xlink:to="eypt_NonRoyaltyConsiderationPercentage_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAgreementStartYearMonth" xlink:type="locator" xlink:label="eypt_LicenseAgreementStartYearMonth" />
    <link:label xml:lang="en-US" xlink:label="eypt_LicenseAgreementStartYearMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Start Year Month</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LicenseAgreementStartYearMonth" xlink:to="eypt_LicenseAgreementStartYearMonth_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontLicenseFeeReceived" xlink:type="locator" xlink:label="eypt_UpfrontLicenseFeeReceived" />
    <link:label xml:lang="en-US" xlink:label="eypt_UpfrontLicenseFeeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment received under license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_UpfrontLicenseFeeReceived" xlink:to="eypt_UpfrontLicenseFeeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_UpfrontLicenseFeeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of upfront license fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_UpfrontLicenseFeeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fee Received</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltyPercentageEarnedFromProductSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty percentage earned from sales of product</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_RoyaltyPercentageEarnedFromProductSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Percentage Earned From Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonRoyaltyConsiderationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of non-royalty consideration received from sublicense</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonRoyaltyConsiderationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Royalty Consideration Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LicenseAgreementStartYearMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LicenseAgreementStartYearMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Start Year Month</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future payments to be received upon the achievement of prescribed development and regulatory milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future payments to be received upon the achievement of prescribed commercial sales-based milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductSupplyMilestonesAndDevelopmentMilestones" xlink:type="locator" xlink:label="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" />
    <link:label xml:lang="en-US" xlink:label="eypt_ProductSupplyMilestonesAndDevelopmentMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product supply milestones and development milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" xlink:to="eypt_ProductSupplyMilestonesAndDevelopmentMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future payments based on achievement of development and regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Payments To Be Received Upon Achievement Of Prescribed Development And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future payments based on achievement of commercial-based milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Payments To Be Received Upon Achievement Of Prescribed Commercial Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProductSupplyMilestonesAndDevelopmentMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product supply milestones and development milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ProductSupplyMilestonesAndDevelopmentMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Supply Milestones And Development Milestones</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DevelopmentMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_DevelopmentMilestonePaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="eypt_DevelopmentMilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DevelopmentMilestonePaymentReceived" xlink:to="eypt_DevelopmentMilestonePaymentReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DevelopmentMilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DevelopmentMilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payment Received</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future payments to be received upon the achievement of prescribed combined remaining development and sales milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future payments to be received upon the achievement of prescribed remaining development and regulatory milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential future payments to be received upon the achievement of prescribed remaining commercial sales-based milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UponAchievementOfMilestones" xlink:type="locator" xlink:label="eypt_UponAchievementOfMilestones" />
    <link:label xml:lang="en-US" xlink:label="eypt_UponAchievementOfMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upon achievement of milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_UponAchievementOfMilestones" xlink:to="eypt_UponAchievementOfMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future payments based on achievement of combined remaining development and sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Payments To Be Received Upon Achievement Of Prescribed Combined Remaining Development And Sales Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future payments based on achievement of remaining development and regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Payments To Be Received Upon Achievement Of Prescribed Remaining Development And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future payments based on achievement of remaining commercial-based milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Future Payments To Be Received Upon Achievement Of Prescribed Remaining Commercial Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_UponAchievementOfMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upon achievement of milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_UponAchievementOfMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upon Achievement Of Milestones</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SalesBasedRoyaltyExpense" xlink:type="locator" xlink:label="eypt_SalesBasedRoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="eypt_SalesBasedRoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales based royalty expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SalesBasedRoyaltyExpense" xlink:to="eypt_SalesBasedRoyaltyExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SalesBasedRoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based royalty expense</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SalesBasedRoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Royalty Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials Net Of Reserves</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process Net Of Reserves</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods Net Of Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Gross carrying amount at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Gross carrying amount at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Accumulated amortization at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Accumulated amortization at end of period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net book value at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite lived intangible assets remaining amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Remaining Amortization Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EstimatedRateOfAnnualAmortizationExpense" xlink:type="locator" xlink:label="eypt_EstimatedRateOfAnnualAmortizationExpense" />
    <link:label xml:lang="en-US" xlink:label="eypt_EstimatedRateOfAnnualAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated rate of annual amortization expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_EstimatedRateOfAnnualAmortizationExpense" xlink:to="eypt_EstimatedRateOfAnnualAmortizationExpense_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred1</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EstimatedRateOfAnnualAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EstimatedRateOfAnnualAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Rate Of Annual Amortization Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PropertyAndEquipmentMember" xlink:type="locator" xlink:label="eypt_PropertyAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_PropertyAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PropertyAndEquipmentMember" xlink:to="eypt_PropertyAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PropertyAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PropertyAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:type="locator" xlink:label="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant And Equipment Useful Life And Values [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life And Values [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedClinicalExpenseCurrent" xlink:type="locator" xlink:label="eypt_AccruedClinicalExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedClinicalExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of estimated obligations incurred through that date and payable for obligations related to services of contract research organizations in conducting clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AccruedClinicalExpenseCurrent" xlink:to="eypt_AccruedClinicalExpenseCurrent_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" xlink:type="locator" xlink:label="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" />
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued sales chargebacks, rebates and other revenue reserves.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" xlink:to="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedClinicalExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trial costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedClinicalExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Expense Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales chargebacks, rebates and other revenue reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Sales Chargebacks Rebates And Other Revenue Reserves</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commissions due to commercialization partner for DEXYCU</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:to="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities For Commissions Expense And Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_LeasePropertyAreaCovered" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease property area covered.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LeasePropertyAreaCovered" xlink:to="eypt_LeasePropertyAreaCovered_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseExpirationMonthYear" xlink:type="locator" xlink:label="eypt_LeaseExpirationMonthYear" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseExpirationMonthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LeaseExpirationMonthYear" xlink:to="eypt_LeaseExpirationMonthYear_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseInceptionDate" xlink:type="locator" xlink:label="eypt_LeaseInceptionDate" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseInceptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease inception date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LeaseInceptionDate" xlink:to="eypt_LeaseInceptionDate_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AdditionalLeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_AdditionalLeasePropertyAreaCovered" />
    <link:label xml:lang="en-US" xlink:label="eypt_AdditionalLeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional lease property area covered.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AdditionalLeasePropertyAreaCovered" xlink:to="eypt_AdditionalLeasePropertyAreaCovered_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ConstructionAllowanceCredit" xlink:type="locator" xlink:label="eypt_ConstructionAllowanceCredit" />
    <link:label xml:lang="en-US" xlink:label="eypt_ConstructionAllowanceCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Its represent the construction allowance credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ConstructionAllowanceCredit" xlink:to="eypt_ConstructionAllowanceCredit_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TerminationOfPortionOfLeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" />
    <link:label xml:lang="en-US" xlink:label="eypt_TerminationOfPortionOfLeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination of portion of lease property area covered.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" xlink:to="eypt_TerminationOfPortionOfLeasePropertyAreaCovered_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseTerminationDate" xlink:type="locator" xlink:label="eypt_LeaseTerminationDate" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LeaseTerminationDate" xlink:to="eypt_LeaseTerminationDate_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesAbstract" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DisclosureOfLeasesAbstract" xlink:to="eypt_DisclosureOfLeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Leases [Abstract]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesLineItems" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesLineItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_DisclosureOfLeasesLineItems_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesTable" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesTable" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="eypt_DisclosureOfLeasesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Leases [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MaMember" xlink:type="locator" xlink:label="eypt_MaMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_MaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MA</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_MaMember" xlink:to="eypt_MaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_MaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_MaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ma [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OriginalLeaseMember" xlink:type="locator" xlink:label="eypt_OriginalLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_OriginalLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OriginalLeaseMember" xlink:to="eypt_OriginalLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_OriginalLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OriginalLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original Lease [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_SecondAmendmentLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SecondAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SecondAmendmentLeaseMember" xlink:to="eypt_SecondAmendmentLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SecondAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SecondAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment Lease [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ThirdAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_ThirdAmendmentLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_ThirdAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third amendment lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ThirdAmendmentLeaseMember" xlink:to="eypt_ThirdAmendmentLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ThirdAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Amendment Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ThirdAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Amendment Lease [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FourthAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_FourthAmendmentLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_FourthAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth amendment lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_FourthAmendmentLeaseMember" xlink:to="eypt_FourthAmendmentLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_FourthAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth Amendment Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FourthAmendmentLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fourth Amendment Lease [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:label xml:lang="en-US" xlink:label="stpr_NJ_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NEW JERSEY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_NJ_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">NEW JERSEY</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_BaskingRidgeOfficeSpaceMember" xlink:type="locator" xlink:label="eypt_BaskingRidgeOfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_BaskingRidgeOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basking ridge office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_BaskingRidgeOfficeSpaceMember" xlink:to="eypt_BaskingRidgeOfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_BaskingRidgeOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basking Ridge Office Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_BaskingRidgeOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basking Ridge Office Space [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CaladriusMember" xlink:type="locator" xlink:label="eypt_CaladriusMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_CaladriusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Caladrius.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CaladriusMember" xlink:to="eypt_CaladriusMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_CaladriusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Caladrius [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CaladriusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Caladrius [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FirstLabEquipmentMember" xlink:type="locator" xlink:label="eypt_FirstLabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_FirstLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_FirstLabEquipmentMember" xlink:to="eypt_FirstLabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_FirstLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FirstLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Lab Equipment [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondLabEquipmentMember" xlink:type="locator" xlink:label="eypt_SecondLabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SecondLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SecondLabEquipmentMember" xlink:to="eypt_SecondLabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SecondLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SecondLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Lab Equipment [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ThirdLabEquipmentMember" xlink:type="locator" xlink:label="eypt_ThirdLabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_ThirdLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ThirdLabEquipmentMember" xlink:to="eypt_ThirdLabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ThirdLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ThirdLabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DisclosureOfLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased office and laboratory space</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Property Area Covered</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseExpirationMonthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseExpirationMonthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month Year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseInceptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseInceptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Inception Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AdditionalLeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Space leased</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AdditionalLeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Lease Property Area Covered</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Irrevocable standby letter of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ConstructionAllowanceCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ConstructionAllowanceCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction Allowance Credit</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TerminationOfPortionOfLeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination portion of the lease</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TerminationOfPortionOfLeasePropertyAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Termination Of Portion Of Lease Property Area Covered</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Date</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeasePropertyOfficeAreaCovered" xlink:type="locator" xlink:label="eypt_LeasePropertyOfficeAreaCovered" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeasePropertyOfficeAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease property office area covered.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LeasePropertyOfficeAreaCovered" xlink:to="eypt_LeasePropertyOfficeAreaCovered_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseInceptionMonthYear" xlink:type="locator" xlink:label="eypt_LeaseInceptionMonthYear" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseInceptionMonthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease inception month year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LeaseInceptionMonthYear" xlink:to="eypt_LeaseInceptionMonthYear_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfRenewalOptions" xlink:type="locator" xlink:label="eypt_NumberOfRenewalOptions" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfRenewalOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of renewal options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NumberOfRenewalOptions" xlink:to="eypt_NumberOfRenewalOptions_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" xlink:type="locator" xlink:label="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" />
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease renewal term percentage of market rent at renewal date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" xlink:to="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AdditionalSubleasedPropertyOfficeArea" xlink:type="locator" xlink:label="eypt_AdditionalSubleasedPropertyOfficeArea" />
    <link:label xml:lang="en-US" xlink:label="eypt_AdditionalSubleasedPropertyOfficeArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional subleased property office area.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AdditionalSubleasedPropertyOfficeArea" xlink:to="eypt_AdditionalSubleasedPropertyOfficeArea_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LeasePropertyOfficeAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased office space</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeasePropertyOfficeAreaCovered_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Property Office Area Covered</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseInceptionMonthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease inception month year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LeaseInceptionMonthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Inception Month Year</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfRenewalOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of renewal options</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfRenewalOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Renewal Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional lease renewal option period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal rate at 95% of market rent at time of renewal</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Renewal Term Percentage Of Market Rent At Renewal Date</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AdditionalSubleasedPropertyOfficeArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional subleased property office area</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AdditionalSubleasedPropertyOfficeArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Subleased Property Office Area</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan facility term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities - operating lease current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfFinanceLeases" xlink:type="locator" xlink:label="eypt_NumberOfFinanceLeases" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfFinanceLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NumberOfFinanceLeases" xlink:to="eypt_NumberOfFinanceLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfFinanceLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance leases</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NumberOfFinanceLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Finance Leases</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FinanceLeasePropertyAndEquipmentGross" xlink:type="locator" xlink:label="eypt_FinanceLeasePropertyAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="eypt_FinanceLeasePropertyAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease property and equipment gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_FinanceLeasePropertyAndEquipmentGross" xlink:to="eypt_FinanceLeasePropertyAndEquipmentGross_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" xlink:type="locator" xlink:label="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease accumulated amortization property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" xlink:to="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_FinanceLeasePropertyAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FinanceLeasePropertyAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Property And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Accumulated Amortization Property And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities &#8211; finance lease current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, amortization expense of ROU asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense on finance lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, operating cash flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Payment On Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Finance lease, financing cash flows</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, weighted average Remaining term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, weighted average discount rate, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Operating [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementLineItems" xlink:type="locator" xlink:label="eypt_TermLoanAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_TermLoanAgreementLineItems_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementTable" xlink:type="locator" xlink:label="eypt_TermLoanAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan Agreement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_TermLoanAgreementTable" xlink:to="eypt_TermLoanAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Agreement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans Insured or Guaranteed by Government Authorities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loans Insured Or Guaranteed By Government Authorities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans Insured or Guaranteed by Government Authorities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loans Insured Or Guaranteed By Government Authorities [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaycheckProtectionProgramLoanMember" xlink:type="locator" xlink:label="eypt_PaycheckProtectionProgramLoanMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_PaycheckProtectionProgramLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck protection program loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PaycheckProtectionProgramLoanMember" xlink:to="eypt_PaycheckProtectionProgramLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PaycheckProtectionProgramLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaycheckProtectionProgramLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program Loan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lender Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit Facility, Lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Lender [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SiliconValleyBankMember" xlink:type="locator" xlink:label="eypt_SiliconValleyBankMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SiliconValleyBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon valley bank.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SiliconValleyBankMember" xlink:to="eypt_SiliconValleyBankMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SiliconValleyBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SiliconValleyBankMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual or Infrequent Item, or Both</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Or Infrequent Item [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual or Infrequent Item, or Both</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemDomain" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Or Infrequent Item [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus aid relief and economic security act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="eypt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Aid Relief And Economic Security Act [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_CrgServicingLlcMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CRG Servicing LLC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CrgServicingLlcMember" xlink:to="eypt_CrgServicingLlcMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_CrgServicingLlcMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRG Servicing LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CrgServicingLlcMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Crg Servicing Llc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondAdvanceMember" xlink:type="locator" xlink:label="eypt_SecondAdvanceMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SecondAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second advance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SecondAdvanceMember" xlink:to="eypt_SecondAdvanceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SecondAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Advance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SecondAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Advance [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SeniorSecuredTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Senior secured term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SeniorSecuredTermLoanMember" xlink:to="eypt_SeniorSecuredTermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SeniorSecuredTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Secured Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SeniorSecuredTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Secured Term Loan [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InitialAdvanceMember" xlink:type="locator" xlink:label="eypt_InitialAdvanceMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_InitialAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial advance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_InitialAdvanceMember" xlink:to="eypt_InitialAdvanceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_InitialAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Advance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_InitialAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Advance [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentPriorToDecember312019Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentPriorToDecember312019Member" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentPriorToDecember312019Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan prepayment prior to December 31, 2019 (not February 13, 2020).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LoanPrepaymentPriorToDecember312019Member" xlink:to="eypt_LoanPrepaymentPriorToDecember312019Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentPriorToDecember312019Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Prepayment Prior to December 31, 2019 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentPriorToDecember312019Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Prepayment Prior To December312019 [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Prepayment after December 31, 2019 and Prior to December 31, 2020.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" xlink:to="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Prepayment after December 31, 2019 and Prior to December 31, 2020 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Prepayment After December312019 And Prior To December312020 [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan prepayment after December 31, 2020 and Prior to December 31, 2021.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" xlink:to="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan prepayment after December 31, 2020 and prior to December 31, 2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Prepayment After December312020 And Prior To December312021 [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312021Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312021Member" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan Prepayment After December 31 2021.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LoanPrepaymentAfterDecember312021Member" xlink:to="eypt_LoanPrepaymentAfterDecember312021Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan prepayment after December 31 2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LoanPrepaymentAfterDecember312021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Prepayment After December312021 [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodAxis" xlink:type="locator" xlink:label="eypt_PeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PeriodAxis" xlink:to="eypt_PeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period [Axis]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodDomain" xlink:type="locator" xlink:label="eypt_PeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodOneMember" xlink:type="locator" xlink:label="eypt_PeriodOneMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PeriodOneMember" xlink:to="eypt_PeriodOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period One [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodTwoMember" xlink:type="locator" xlink:label="eypt_PeriodTwoMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PeriodTwoMember" xlink:to="eypt_PeriodTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Two [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodThreeMember" xlink:type="locator" xlink:label="eypt_PeriodThreeMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PeriodThreeMember" xlink:to="eypt_PeriodThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Three [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodFourMember" xlink:type="locator" xlink:label="eypt_PeriodFourMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PeriodFourMember" xlink:to="eypt_PeriodFourMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PeriodFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SWKFundingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SWK Funding LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Agreement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan proceeds date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="us-gaap_DebtInstrumentIssuanceDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentIssuanceDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Issuance Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual interest rate on term loan balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Description</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtInstrumentAccruedInterestForgiveness" xlink:type="locator" xlink:label="eypt_DebtInstrumentAccruedInterestForgiveness" />
    <link:label xml:lang="en-US" xlink:label="eypt_DebtInstrumentAccruedInterestForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument accrued interest forgiveness.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DebtInstrumentAccruedInterestForgiveness" xlink:to="eypt_DebtInstrumentAccruedInterestForgiveness_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, loan forgiveness amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Decrease Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebtInstrumentAccruedInterestForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, accrued interest forgiveness amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebtInstrumentAccruedInterestForgiveness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Accrued Interest Forgiveness</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoansAgreementInitialAdvance" xlink:type="locator" xlink:label="eypt_TermLoansAgreementInitialAdvance" />
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoansAgreementInitialAdvance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan agreement, initial advance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_TermLoansAgreementInitialAdvance" xlink:to="eypt_TermLoansAgreementInitialAdvance_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementAdditionalAdvance" xlink:type="locator" xlink:label="eypt_TermLoanAgreementAdditionalAdvance" />
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementAdditionalAdvance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of term loan agreement, additional loan advance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_TermLoanAgreementAdditionalAdvance" xlink:to="eypt_TermLoanAgreementAdditionalAdvance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInitiationDate1" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Initiation Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior secured term loan borrowing facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoansAgreementInitialAdvance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan agreement, initial advance</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoansAgreementInitialAdvance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Agreement Initial Advance</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementAdditionalAdvance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan agreement, additional loan advance</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TermLoanAgreementAdditionalAdvance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Agreement Additional Advance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityExitFeesPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage" />
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility exit fees percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LineOfCreditFacilityExitFeesPercentage" xlink:to="eypt_LineOfCreditFacilityExitFeesPercentage_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityFinancingFeePercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityFinancingFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityFinancingFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility financing fees percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LineOfCreditFacilityFinancingFeePercentage" xlink:to="eypt_LineOfCreditFacilityFinancingFeePercentage_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ReimbursedExpense" xlink:type="locator" xlink:label="eypt_ReimbursedExpense" />
    <link:label xml:lang="en-US" xlink:label="eypt_ReimbursedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense reimbursed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ReimbursedExpense" xlink:to="eypt_ReimbursedExpense_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaidInKindInterestAddedToPrincipal" xlink:type="locator" xlink:label="eypt_PaidInKindInterestAddedToPrincipal" />
    <link:label xml:lang="en-US" xlink:label="eypt_PaidInKindInterestAddedToPrincipal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Paid in kind interest added to principal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PaidInKindInterestAddedToPrincipal" xlink:to="eypt_PaidInKindInterestAddedToPrincipal_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Expiration Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:type="locator" xlink:label="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restriction of the right to capitalize a portion of quarterly interest in the event of a loan default</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:to="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Default Longterm Debt Description Of Violation Or Event Of Default</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaidInKindInterestAddedToPrincipal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paid in Kind Interest Added to Principal</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaidInKindInterestAddedToPrincipal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest Added To Principal</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront loan origination fee percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Commitment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exit fee percentage payable upon repayment of the total secured term loan</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Exit Fees Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityFinancingFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time upfront financing fee percentage applied to borrowing amounts under the line of credit facility</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityFinancingFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Financing Fee Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront loan original fee payment, initial advance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Commitment Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ReimbursedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of lender&apos;s legal fees and other transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ReimbursedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursed Expense</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" />
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility principal prepayment premium percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" xlink:to="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal prepayment premium percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Principal Prepayment Premium Percentage</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MinimumLiquidityAmount" xlink:type="locator" xlink:label="eypt_MinimumLiquidityAmount" />
    <link:label xml:lang="en-US" xlink:label="eypt_MinimumLiquidityAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum liquidity amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_MinimumLiquidityAmount" xlink:to="eypt_MinimumLiquidityAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_MinimumLiquidityAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum liquidity amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_MinimumLiquidityAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Liquidity Amount</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AnnualMinimumProductRevenue" xlink:type="locator" xlink:label="eypt_AnnualMinimumProductRevenue" />
    <link:label xml:lang="en-US" xlink:label="eypt_AnnualMinimumProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual minimum period revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AnnualMinimumProductRevenue" xlink:to="eypt_AnnualMinimumProductRevenue_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AnnualMinimumProductRevenuePeriod" xlink:type="locator" xlink:label="eypt_AnnualMinimumProductRevenuePeriod" />
    <link:label xml:lang="en-US" xlink:label="eypt_AnnualMinimumProductRevenuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual minimum product revenue period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AnnualMinimumProductRevenuePeriod" xlink:to="eypt_AnnualMinimumProductRevenuePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_AnnualMinimumProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual minimum product revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AnnualMinimumProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Minimum Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AnnualMinimumProductRevenuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual minimum product revenue period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AnnualMinimumProductRevenuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Minimum Product Revenue Period</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncrementalChargesForIssuanceOfWaivers" xlink:type="locator" xlink:label="eypt_IncrementalChargesForIssuanceOfWaivers" />
    <link:label xml:lang="en-US" xlink:label="eypt_IncrementalChargesForIssuanceOfWaivers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental charges for issuance of waivers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_IncrementalChargesForIssuanceOfWaivers" xlink:to="eypt_IncrementalChargesForIssuanceOfWaivers_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_IncrementalChargesForIssuanceOfWaivers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental charges for issuance of waivers</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncrementalChargesForIssuanceOfWaivers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Charges For Issuance Of Waivers</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OriginalAmountOfDebtDiscount" xlink:type="locator" xlink:label="eypt_OriginalAmountOfDebtDiscount" />
    <link:label xml:lang="en-US" xlink:label="eypt_OriginalAmountOfDebtDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original amount of debt discount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OriginalAmountOfDebtDiscount" xlink:to="eypt_OriginalAmountOfDebtDiscount_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExitFeeAccrued" xlink:type="locator" xlink:label="eypt_ExitFeeAccrued" />
    <link:label xml:lang="en-US" xlink:label="eypt_ExitFeeAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of exit fee accrued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ExitFeeAccrued" xlink:to="eypt_ExitFeeAccrued_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityLegalAndTransactionCosts" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityLegalAndTransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityLegalAndTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of legal and transaction costs related to line of credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_LineOfCreditFacilityLegalAndTransactionCosts" xlink:to="eypt_LineOfCreditFacilityLegalAndTransactionCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_OriginalAmountOfDebtDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt discount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OriginalAmountOfDebtDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original Amount Of Debt Discount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ExitFeeAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exit fee accrued</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ExitFeeAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exit Fee Accrued</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityLegalAndTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, legal and other transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_LineOfCreditFacilityLegalAndTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Legal And Transaction Costs</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebInstrumentExitFee" />
    <link:label xml:lang="en-US" xlink:label="eypt_DebInstrumentExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exit Fee Charged</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DebInstrumentExitFee" xlink:to="eypt_DebInstrumentExitFee_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentOfAccruedAndUnpaidInterest" xlink:type="locator" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest" />
    <link:label xml:lang="en-US" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment accrued and unpaid interest through the date of the secured term loan refinancing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PaymentOfAccruedAndUnpaidInterest" xlink:to="eypt_PaymentOfAccruedAndUnpaidInterest_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of senior secured term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Lines Of Credit</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebInstrumentExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of exit fee upon repayment of secured term loan</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DebInstrumentExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deb Instrument Exit Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of accrued and unpaid interest through the date of the secured term loan refinancing</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Accrued And Unpaid Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of debt discount (premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_GrossProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="eypt_GrossProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="eypt_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_GrossProceedsFromIssuanceOfCommonStock" xlink:to="eypt_GrossProceedsFromIssuanceOfCommonStock_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodAdditionalSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period additional shares issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:to="eypt_StockIssuedDuringPeriodAdditionalSharesIssued_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" xlink:type="locator" xlink:label="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right issue price of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" xlink:to="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityFinancingsMember" xlink:type="locator" xlink:label="eypt_EquityFinancingsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_EquityFinancingsMember" xlink:to="eypt_EquityFinancingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financings [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SharePurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_SharePurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SharePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SharePurchaseAgreementMember" xlink:to="eypt_SharePurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SharePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SharePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="eypt_AtTheMarketOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AtTheMarketOfferingMember" xlink:to="eypt_AtTheMarketOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodAdditionalSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, additional shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuedDuringPeriodAdditionalSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issued to purchase common stock shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issued, price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issue Price Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" xlink:type="locator" xlink:label="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" />
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance costs sales agent commission maximum percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" xlink:to="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuances, sales agent commission maximum percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs Sales Agent Commission Maximum Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Warrants, Outstanding and exercisable, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Warrants, Outstanding and exercisable, Ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding and exercisable, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding and exercisable, Ending balance</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WarrantsIssuedInConnectionWithTermLoanFacility" xlink:type="locator" xlink:label="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" />
    <link:label xml:lang="en-US" xlink:label="eypt_WarrantsIssuedInConnectionWithTermLoanFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in connection with term loan facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" xlink:to="eypt_WarrantsIssuedInConnectionWithTermLoanFacility_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExercisePriceOfIssuedWarrants" xlink:type="locator" xlink:label="eypt_ExercisePriceOfIssuedWarrants" />
    <link:label xml:lang="en-US" xlink:label="eypt_ExercisePriceOfIssuedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price of issued warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ExercisePriceOfIssuedWarrants" xlink:to="eypt_ExercisePriceOfIssuedWarrants_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WarrantsExercisePeriod" xlink:type="locator" xlink:label="eypt_WarrantsExercisePeriod" />
    <link:label xml:lang="en-US" xlink:label="eypt_WarrantsExercisePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercise period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_WarrantsExercisePeriod" xlink:to="eypt_WarrantsExercisePeriod_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WeightedAverageRemainingLifeOfLenderWarrants" xlink:type="locator" xlink:label="eypt_WeightedAverageRemainingLifeOfLenderWarrants" />
    <link:label xml:lang="en-US" xlink:label="eypt_WeightedAverageRemainingLifeOfLenderWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average remaining life of lender warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_WeightedAverageRemainingLifeOfLenderWarrants" xlink:to="eypt_WeightedAverageRemainingLifeOfLenderWarrants_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investor [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_WarrantsIssuedInConnectionWithTermLoanFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued in connection with term loan facility</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_WarrantsIssuedInConnectionWithTermLoanFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In Connection With Term Loan Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ExercisePriceOfIssuedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of issued warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ExercisePriceOfIssuedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Of Issued Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_WarrantsExercisePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_WarrantsExercisePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_WeightedAverageRemainingLifeOfLenderWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining life of lender warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_WeightedAverageRemainingLifeOfLenderWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Life Of Lender Warrants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_TwoThousandSixteenIncentivePlanMember" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Long Term Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock, authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant under the Long Term Incentive Plan, including forfeited and terminated awards transferred from the 2008 Incentive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityIncentivePlansAndInducementAwardGrantsMember" xlink:type="locator" xlink:label="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquityIncentivePlansAndInducementAwardGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plans and inducement award grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" xlink:to="eypt_EquityIncentivePlansAndInducementAwardGrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquityIncentivePlansAndInducementAwardGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans and Inducement Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EquityIncentivePlansAndInducementAwardGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plans And Inducement Award Grants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forefeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, Ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable at December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forefeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Outstanding, Ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding at January 1, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Exercisable at December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding at January 1, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" />
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award cliff vesting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" />
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period which an employee&apos;s right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NewlyAppointedNonExecutiveDirectorMember" xlink:type="locator" xlink:label="eypt_NewlyAppointedNonExecutiveDirectorMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_NewlyAppointedNonExecutiveDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Newly appointed non executive director.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NewlyAppointedNonExecutiveDirectorMember" xlink:to="eypt_NewlyAppointedNonExecutiveDirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_NewlyAppointedNonExecutiveDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Newly Appointed Non Executive Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NewlyAppointedNonExecutiveDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Newly Appointed Non Executive Director [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DirectorsAndExternalConsultantsMember" xlink:type="locator" xlink:label="eypt_DirectorsAndExternalConsultantsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_DirectorsAndExternalConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors and external consultant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DirectorsAndExternalConsultantsMember" xlink:to="eypt_DirectorsAndExternalConsultantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DirectorsAndExternalConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External consultant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DirectorsAndExternalConsultantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Directors And External Consultants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratable monthly vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratable annual vesting period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Prorata Vesting Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual life of option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock vested during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityIncentivePlansMember" xlink:type="locator" xlink:label="eypt_EquityIncentivePlansMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquityIncentivePlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_EquityIncentivePlansMember" xlink:to="eypt_EquityIncentivePlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquityIncentivePlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EquityIncentivePlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plans [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total cash received from exercise of stock options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSU [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ratable annual vesting period of equity awards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Stock Units Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock units, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Stock Units, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Stock Units, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Stock Units Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Nonvested, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Nonvested, Ending balance</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options vested weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining vesting term</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:type="locator" xlink:label="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" />
    <link:label xml:lang="en-US" xlink:label="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of equity-based payment instruments, excluding stock (or unit) options, that vested at balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:to="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredStockUnitsMember" xlink:type="locator" xlink:label="eypt_DeferredStockUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred stock units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DeferredStockUnitsMember" xlink:to="eypt_DeferredStockUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Stock Units [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonExecutiveDirectorsMember" xlink:type="locator" xlink:label="eypt_NonExecutiveDirectorsMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_NonExecutiveDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-executive directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NonExecutiveDirectorsMember" xlink:to="eypt_NonExecutiveDirectorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_NonExecutiveDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Executive Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonExecutiveDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Executive Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-vested deferred stock units outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested deferred stock units vested</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award consecutive six month offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price of common stock purchased twice a year under ESPP, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Employee stock purchase plan, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consecutive six month offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Consecutive Six Month Offering Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SalesAndMarketingMember" xlink:type="locator" xlink:label="eypt_SalesAndMarketingMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SalesAndMarketingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales and marketing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SalesAndMarketingMember" xlink:to="eypt_SalesAndMarketingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SalesAndMarketingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SalesAndMarketingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales And Marketing [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized compensation expense weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonRefundableNonCreditableUpfrontCashPayment" xlink:type="locator" xlink:label="eypt_NonRefundableNonCreditableUpfrontCashPayment" />
    <link:label xml:lang="en-US" xlink:label="eypt_NonRefundableNonCreditableUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable, non-creditable upfront cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NonRefundableNonCreditableUpfrontCashPayment" xlink:to="eypt_NonRefundableNonCreditableUpfrontCashPayment_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeAgreementsAndContractsLineItems" xlink:type="locator" xlink:label="eypt_CollaborativeAgreementsAndContractsLineItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeAgreementsAndContractsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreements and contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="eypt_CollaborativeAgreementsAndContractsLineItems_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeAgreementsAndContractsTable" xlink:type="locator" xlink:label="eypt_CollaborativeAgreementsAndContractsTable" />
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeAgreementsAndContractsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreements and contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_CollaborativeAgreementsAndContractsTable" xlink:to="eypt_CollaborativeAgreementsAndContractsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeAgreementsAndContractsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Agreements And Contracts [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeAgreementsAndContractsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreements And Contracts [Table]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AerpioPharmaceuticalsIncMember" xlink:type="locator" xlink:label="eypt_AerpioPharmaceuticalsIncMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_AerpioPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aerpio Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_AerpioPharmaceuticalsIncMember" xlink:to="eypt_AerpioPharmaceuticalsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_AerpioPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aerpio Pharmaceuticals, Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_AerpioPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aerpio Pharmaceuticals Inc [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquinoxScienceLLCMember" xlink:type="locator" xlink:label="eypt_EquinoxScienceLLCMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquinoxScienceLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equinox science, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_EquinoxScienceLLCMember" xlink:to="eypt_EquinoxScienceLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_EquinoxScienceLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equinox Science, LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_EquinoxScienceLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equinox Science L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeAgreementsAndContractsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Agreements And Contracts [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_CollaborativeAgreementsAndContractsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreements And Contracts [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonRefundableNonCreditableUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable and non-creditable upfront cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NonRefundableNonCreditableUpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Non Creditable Upfront Cash Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">R&amp;D expense</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:type="locator" xlink:label="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" />
    <link:label xml:lang="en-US" xlink:label="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments upon achievement of certain development and regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:to="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment upon achievement of development and regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Upon Achievement Of Certain Development And Regulatory Milestones</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of eligible compensation matched by employer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DefinedContributionPlanContributionsByEmployer" xlink:type="locator" xlink:label="eypt_DefinedContributionPlanContributionsByEmployer" />
    <link:label xml:lang="en-US" xlink:label="eypt_DefinedContributionPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan contributions by employer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DefinedContributionPlanContributionsByEmployer" xlink:to="eypt_DefinedContributionPlanContributionsByEmployer_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_DefinedContributionPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contributions to retirement plans</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DefinedContributionPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Contributions By Employer</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-U.S. operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" xlink:type="locator" xlink:label="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and State Research and Development Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" xlink:to="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State Research and Development Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State Research And Development Tax Credit Carry Forward [Member]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FederalAndStateTaxMember" xlink:type="locator" xlink:label="eypt_FederalAndStateTaxMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_FederalAndStateTaxMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal And State Tax [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_FederalAndStateTaxMember" xlink:to="eypt_FederalAndStateTaxMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_FederalAndStateTaxMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal And State Tax [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_FederalAndStateTaxMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State Tax [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service I R S [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:type="locator" xlink:label="us-gaap_HerMajestysRevenueAndCustomsHMRCMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HerMajestysRevenueAndCustomsHMRCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom Tax Authority [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:to="us-gaap_HerMajestysRevenueAndCustomsHMRCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HerMajestysRevenueAndCustomsHMRCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Her Majestys Revenue And Customs H M R C [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal corporate income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" />
    <link:label xml:lang="en-US" xlink:label="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation change in fair value of derivative liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:to="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="eypt_IncomeTaxReconciliationPermanentItems" />
    <link:label xml:lang="en-US" xlink:label="eypt_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_IncomeTaxReconciliationPermanentItems" xlink:to="eypt_IncomeTaxReconciliationPermanentItems_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-U.S. income tax rate differential</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Fair Value Of Derivative Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in federal tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Enacted Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredTaxAssetsLeasingArrangements" xlink:type="locator" xlink:label="eypt_DeferredTaxAssetsLeasingArrangements" />
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredTaxAssetsLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets leasing arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DeferredTaxAssetsLeasingArrangements" xlink:to="eypt_DeferredTaxAssetsLeasingArrangements_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:type="locator" xlink:label="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Liabilities Net Before Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredTaxAssetsLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredTaxAssetsLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Leasing Arrangements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Leasing Arrangements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net Before Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" xlink:type="locator" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" />
    <link:label xml:lang="en-US" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits expiration year range start.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" xlink:to="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" xlink:type="locator" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" />
    <link:label xml:lang="en-US" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits expiration year range end.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" xlink:to="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLossCarryForwardsExpirationYearRangeStart" xlink:type="locator" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" />
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" xlink:to="eypt_OperatingLossCarryForwardsExpirationYearRangeStart_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" xlink:type="locator" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" />
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year range end</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" xlink:to="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd_lbl" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NetOperatingLossCarryforwards" xlink:type="locator" xlink:label="eypt_NetOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="eypt_NetOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_NetOperatingLossCarryforwards" xlink:to="eypt_NetOperatingLossCarryforwards_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NetOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_NetOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards, expiration range start dates</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Year Range Start</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards, expiration range end dates</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Year Range End</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carry forwards expiration begin date</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credits Expiration Year Range Start</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carry forwards expiration end date</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credits Expiration Year Range End</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax years that remain subject to examination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued penalties or interest related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of business segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Country US [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:label xml:lang="en-US" xlink:label="country_CN_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_CN_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:label xml:lang="en-US" xlink:label="country_GB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UNITED KINGDOM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_GB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues From External Customers And Long Lived Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-lived assets, net</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" xlink:type="locator" xlink:label="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" />
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of accounts receivable eligible for maximum amount borrowing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" xlink:to="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredRevolvingCreditFacilityMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredRevolvingCreditFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="eypt_SeniorSecuredRevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Senior secured revolving credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eypt_SeniorSecuredRevolvingCreditFacilityMember" xlink:to="eypt_SeniorSecuredRevolvingCreditFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eypt_SeniorSecuredRevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Secured Revolving Credit Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_SeniorSecuredRevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Secured Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate Plus [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Senior secured facility</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of accounts receivable eligible for maximum amount borrowing</link:label>
    <link:label xml:lang="en-US" xlink:label="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Accounts Receivable Eligible For Maximum Amount Borrowing</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unused commitment fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Unused Capacity Commitment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceed from senior secured facility</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revolving line bears interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument effective rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Effective Percentage</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>eypt-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-11T22:48:46.5640081+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ed9f53d5b78741d19b453bb1246c3522 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/role/TemplateLink" xlink:href="eypt-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eypt-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" xlink:type="locator" xlink:label="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_LicenseAndCollaborationAgreementMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="eypt_AmortizationOfAcquisitionCostOfIntangibleAssets" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_li0l2" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_LicenseAndCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued_li0l2" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="eypt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebtInstrumentExitFee" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonCashUnpaidStockIssuanceCosts" xlink:type="locator" xlink:label="eypt_NonCashUnpaidStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProceedsFromPaycheckProtectionProgramLoan" xlink:type="locator" xlink:label="eypt_ProceedsFromPaycheckProtectionProgramLoan" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" xlink:type="locator" xlink:label="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmortizationOfDebtDiscount" xlink:type="locator" xlink:label="eypt_AmortizationOfDebtDiscount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eypt_AmortizationOfDebtDiscount" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eypt_ProceedsFromPaycheckProtectionProgramLoan" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="eypt_NonCashUnpaidStockIssuanceCosts" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="eypt_DebtInstrumentExitFee" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperations" xlink:href="eypt-20211231.xsd#Role_DisclosureOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowances" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductRevenueReservesAndAllowancesTextBlock" xlink:type="locator" xlink:label="eypt_ProductRevenueReservesAndAllowancesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="eypt_ProductRevenueReservesAndAllowancesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory" xlink:href="eypt-20211231.xsd#Role_DisclosureInventory" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="eypt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="eypt-20211231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases" xlink:href="eypt-20211231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" xlink:type="locator" xlink:label="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreements" xlink:href="eypt-20211231.xsd#Role_DisclosureLoanAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwards" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreements" xlink:href="eypt-20211231.xsd#Role_DisclosureLicenseAndAssetPurchaseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlans" xlink:href="eypt-20211231.xsd#Role_DisclosureRetirementPlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlans">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureContingencies" xlink:href="eypt-20211231.xsd#Role_DisclosureContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation" xlink:href="eypt-20211231.xsd#Role_DisclosureSegmentAndGeographicAreaInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="eypt-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ComprehensiveLossPolicyPolicyTextBlock" xlink:type="locator" xlink:label="eypt_ComprehensiveLossPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtAndEquityInstrumentsPolicyTextBlock" xlink:type="locator" xlink:label="eypt_DebtAndEquityInstrumentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eypt_DebtAndEquityInstrumentsPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eypt_ComprehensiveLossPolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductRevenueAllowanceAndReserveTableTextBlock" xlink:type="locator" xlink:label="eypt_ProductRevenueAllowanceAndReserveTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="eypt_ProductRevenueAllowanceAndReserveTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryTables" xlink:href="eypt-20211231.xsd#Role_DisclosureInventoryTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="eypt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="eypt-20211231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" xlink:type="locator" xlink:label="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" xlink:type="locator" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationTables" xlink:href="eypt-20211231.xsd#Role_DisclosureSegmentAndGeographicAreaInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureOperationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfNewBlindnessCasesEveryYear" xlink:type="locator" xlink:label="eypt_NumberOfNewBlindnessCasesEveryYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" xlink:type="locator" xlink:label="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfProductsApproved" xlink:type="locator" xlink:label="eypt_NumberOfProductsApproved" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfProducts" xlink:type="locator" xlink:label="eypt_NumberOfProducts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperationsLineItems" xlink:type="locator" xlink:label="eypt_OperationsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" xlink:type="locator" xlink:label="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OrganizationAndNatureOfBusinessTable" xlink:type="locator" xlink:label="eypt_OrganizationAndNatureOfBusinessTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperationsAbstract" xlink:type="locator" xlink:label="eypt_OperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsAbstract" xlink:to="eypt_OrganizationAndNatureOfBusinessTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_YUTIQProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OrganizationAndNatureOfBusinessTable" xlink:to="eypt_OperationsLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfProducts" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfProductsApproved" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsLineItems" xlink:to="eypt_NumberOfNewBlindnessCasesEveryYear" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_OperationsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PreFundedWarrantsToPurchaseCommonStock" xlink:type="locator" xlink:label="eypt_PreFundedWarrantsToPurchaseCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfUpfrontPaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfUpfrontPaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAcceleratedMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedRevenueBasedRoyaltyExpense" xlink:type="locator" xlink:label="eypt_AccruedRevenueBasedRoyaltyExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccountsReceivableStandardPaymentTerms" xlink:type="locator" xlink:label="eypt_AccountsReceivableStandardPaymentTerms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_McKessonSpecialtyCareDistributionLLCMember" xlink:type="locator" xlink:label="eypt_McKessonSpecialtyCareDistributionLLCMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ASDSpecialtyHealthcareLLCMember" xlink:type="locator" xlink:label="eypt_ASDSpecialtyHealthcareLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InvestmentInstrumentsMember" xlink:type="locator" xlink:label="eypt_InvestmentInstrumentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="eypt_InvestmentInstrumentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_ASDSpecialtyHealthcareLLCMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_McKessonSpecialtyCareDistributionLLCMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_OcumensionTherapeuticsMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eypt_DEXYCUMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_AccountsReceivableStandardPaymentTerms" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_AccruedRevenueBasedRoyaltyExpense" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_PercentageOfAcceleratedMilestonePaymentReceived" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_PercentageOfUpfrontPaymentReceived" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="eypt_PreFundedWarrantsToPurchaseCommonStock" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eypt_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eypt_EmployeeStockPurchasePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUProductMember" xlink:type="locator" xlink:label="eypt_DEXYCUProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_YUTIQProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_DEXYCUProductMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUProductMember" xlink:type="locator" xlink:label="eypt_DEXYCUProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_YUTIQProductMember" xlink:type="locator" xlink:label="eypt_YUTIQProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_YUTIQProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_DEXYCUProductMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="eypt_OcumensionTherapeuticsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_li0l2" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ContractWithCustomerAllowanceForCreditLossAdditions" xlink:type="locator" xlink:label="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:type="locator" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ReturnsMember" xlink:type="locator" xlink:label="eypt_ReturnsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_GovernmentsAndOtherRebatesMember" xlink:type="locator" xlink:label="eypt_GovernmentsAndOtherRebatesMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ChargeBacksAndDiscountsAndFeesMember" xlink:type="locator" xlink:label="eypt_ChargeBacksAndDiscountsAndFeesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:type="locator" xlink:label="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="eypt_ChargeBacksAndDiscountsAndFeesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="eypt_GovernmentsAndOtherRebatesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="eypt_ReturnsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesTable" xlink:to="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_ContractWithCustomerAllowanceForCreditLossAdditions" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_li0l2" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAcceleratedMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_PercentageOfAcceleratedMilestonePaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SalesBasedRoyaltyExpense" xlink:type="locator" xlink:label="eypt_SalesBasedRoyaltyExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UponAchievementOfMilestones" xlink:type="locator" xlink:label="eypt_UponAchievementOfMilestones" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DevelopmentMilestonePaymentReceived" xlink:type="locator" xlink:label="eypt_DevelopmentMilestonePaymentReceived" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ProductSupplyMilestonesAndDevelopmentMilestones" xlink:type="locator" xlink:label="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" xlink:type="locator" xlink:label="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAgreementStartYearMonth" xlink:type="locator" xlink:label="eypt_LicenseAgreementStartYearMonth" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonRoyaltyConsiderationPercentage" xlink:type="locator" xlink:label="eypt_NonRoyaltyConsiderationPercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPercentageEarnedFromProductSales" xlink:type="locator" xlink:label="eypt_RoyaltyPercentageEarnedFromProductSales" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontLicenseFeeReceived" xlink:type="locator" xlink:label="eypt_UpfrontLicenseFeeReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="eypt_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyServiceMember" xlink:type="locator" xlink:label="us-gaap_TechnologyServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="eypt_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OcumensionTherapeuticsMember" xlink:type="locator" xlink:label="eypt_OcumensionTherapeuticsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeResearchAndDevelopmentMember" xlink:type="locator" xlink:label="eypt_CollaborativeResearchAndDevelopmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OncoSilMedicalUKLimitedMember" xlink:type="locator" xlink:label="eypt_OncoSilMedicalUKLimitedMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltySaleAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltySaleAgreementMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltyPurchaseAgreementMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AmendedAlimeraScienceIncAgreementMember" xlink:type="locator" xlink:label="eypt_AmendedAlimeraScienceIncAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_AmendedAlimeraScienceIncAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_RoyaltyPurchaseAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_RoyaltySaleAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_OncoSilMedicalUKLimitedMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_CollaborativeResearchAndDevelopmentMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_OcumensionTherapeuticsMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_LicenseAndCollaborationAgreementMember" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_TechnologyServiceMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eypt_UnderwrittenPublicOfferingMember" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_UpfrontCashPayment" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_UpfrontLicenseFeeReceived" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_RoyaltyPercentageEarnedFromProductSales" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_NonRoyaltyConsiderationPercentage" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_LicenseAgreementStartYearMonth" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone" order="12800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_ProductSupplyMilestonesAndDevelopmentMilestones" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_DevelopmentMilestonePaymentReceived" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone" order="13130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_UponAchievementOfMilestones" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_SalesBasedRoyaltyExpense" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="eypt_PercentageOfAcceleratedMilestonePaymentReceived" order="13550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureInventoryScheduleOfInventoryDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_li0l2" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_li0l2" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eypt_DEXYCUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EstimatedRateOfAnnualAmortizationExpense" xlink:type="locator" xlink:label="eypt_EstimatedRateOfAnnualAmortizationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DEXYCUMember" xlink:type="locator" xlink:label="eypt_DEXYCUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eypt_DEXYCUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="eypt_EstimatedRateOfAnnualAmortizationExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:href="eypt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PropertyAndEquipmentMember" xlink:type="locator" xlink:label="eypt_PropertyAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_PropertyAndEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:type="locator" xlink:label="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" xlink:type="locator" xlink:label="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AccruedClinicalExpenseCurrent" xlink:type="locator" xlink:label="eypt_AccruedClinicalExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="eypt_AccruedClinicalExpenseCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfFinanceLeases" xlink:type="locator" xlink:label="eypt_NumberOfFinanceLeases" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AdditionalSubleasedPropertyOfficeArea" xlink:type="locator" xlink:label="eypt_AdditionalSubleasedPropertyOfficeArea" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" xlink:type="locator" xlink:label="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NumberOfRenewalOptions" xlink:type="locator" xlink:label="eypt_NumberOfRenewalOptions" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseInceptionMonthYear" xlink:type="locator" xlink:label="eypt_LeaseInceptionMonthYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeasePropertyOfficeAreaCovered" xlink:type="locator" xlink:label="eypt_LeasePropertyOfficeAreaCovered" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseTerminationDate" xlink:type="locator" xlink:label="eypt_LeaseTerminationDate" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TerminationOfPortionOfLeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ConstructionAllowanceCredit" xlink:type="locator" xlink:label="eypt_ConstructionAllowanceCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AdditionalLeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_AdditionalLeasePropertyAreaCovered" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseInceptionDate" xlink:type="locator" xlink:label="eypt_LeaseInceptionDate" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeaseExpirationMonthYear" xlink:type="locator" xlink:label="eypt_LeaseExpirationMonthYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LeasePropertyAreaCovered" xlink:type="locator" xlink:label="eypt_LeasePropertyAreaCovered" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesLineItems" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ThirdLabEquipmentMember" xlink:type="locator" xlink:label="eypt_ThirdLabEquipmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondLabEquipmentMember" xlink:type="locator" xlink:label="eypt_SecondLabEquipmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FirstLabEquipmentMember" xlink:type="locator" xlink:label="eypt_FirstLabEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CaladriusMember" xlink:type="locator" xlink:label="eypt_CaladriusMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_BaskingRidgeOfficeSpaceMember" xlink:type="locator" xlink:label="eypt_BaskingRidgeOfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ" xlink:type="locator" xlink:label="stpr_NJ" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FourthAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_FourthAmendmentLeaseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ThirdAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_ThirdAmendmentLeaseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondAmendmentLeaseMember" xlink:type="locator" xlink:label="eypt_SecondAmendmentLeaseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OriginalLeaseMember" xlink:type="locator" xlink:label="eypt_OriginalLeaseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MaMember" xlink:type="locator" xlink:label="eypt_MaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesTable" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesTable" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DisclosureOfLeasesAbstract" xlink:type="locator" xlink:label="eypt_DisclosureOfLeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesAbstract" xlink:to="eypt_DisclosureOfLeasesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="eypt_MaMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_OriginalLeaseMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SecondAmendmentLeaseMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_ThirdAmendmentLeaseMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_FourthAmendmentLeaseMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NJ" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_BaskingRidgeOfficeSpaceMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="srt_CounterpartyNameAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="eypt_CaladriusMember" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_FirstLabEquipmentMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_SecondLabEquipmentMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eypt_ThirdLabEquipmentMember" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesTable" xlink:to="eypt_DisclosureOfLeasesLineItems" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeasePropertyAreaCovered" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseExpirationMonthYear" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseInceptionDate" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_AdditionalLeasePropertyAreaCovered" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_ConstructionAllowanceCredit" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_TerminationOfPortionOfLeasePropertyAreaCovered" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseTerminationDate" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeasePropertyOfficeAreaCovered" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_LeaseInceptionMonthYear" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_NumberOfRenewalOptions" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_AdditionalSubleasedPropertyOfficeArea" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_VariableLeaseCost" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="eypt_NumberOfFinanceLeases" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="12890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="12930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_DisclosureOfLeasesLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" xlink:type="locator" xlink:label="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FinanceLeasePropertyAndEquipmentGross" xlink:type="locator" xlink:label="eypt_FinanceLeasePropertyAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eypt_FinanceLeasePropertyAndEquipmentGross" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLoanAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentOfAccruedAndUnpaidInterest" xlink:type="locator" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebInstrumentExitFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityLegalAndTransactionCosts" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityLegalAndTransactionCosts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExitFeeAccrued" xlink:type="locator" xlink:label="eypt_ExitFeeAccrued" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OriginalAmountOfDebtDiscount" xlink:type="locator" xlink:label="eypt_OriginalAmountOfDebtDiscount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncrementalChargesForIssuanceOfWaivers" xlink:type="locator" xlink:label="eypt_IncrementalChargesForIssuanceOfWaivers" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AnnualMinimumProductRevenuePeriod" xlink:type="locator" xlink:label="eypt_AnnualMinimumProductRevenuePeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AnnualMinimumProductRevenue" xlink:type="locator" xlink:label="eypt_AnnualMinimumProductRevenue" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MinimumLiquidityAmount" xlink:type="locator" xlink:label="eypt_MinimumLiquidityAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ReimbursedExpense" xlink:type="locator" xlink:label="eypt_ReimbursedExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityFinancingFeePercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityFinancingFeePercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityExitFeesPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaidInKindInterestAddedToPrincipal" xlink:type="locator" xlink:label="eypt_PaidInKindInterestAddedToPrincipal" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:type="locator" xlink:label="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementAdditionalAdvance" xlink:type="locator" xlink:label="eypt_TermLoanAgreementAdditionalAdvance" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoansAgreementInitialAdvance" xlink:type="locator" xlink:label="eypt_TermLoansAgreementInitialAdvance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebtInstrumentAccruedInterestForgiveness" xlink:type="locator" xlink:label="eypt_DebtInstrumentAccruedInterestForgiveness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementLineItems" xlink:type="locator" xlink:label="eypt_TermLoanAgreementLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember_li0l2" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodFourMember" xlink:type="locator" xlink:label="eypt_PeriodFourMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodThreeMember" xlink:type="locator" xlink:label="eypt_PeriodThreeMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodTwoMember" xlink:type="locator" xlink:label="eypt_PeriodTwoMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodOneMember" xlink:type="locator" xlink:label="eypt_PeriodOneMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodDomain" xlink:type="locator" xlink:label="eypt_PeriodDomain" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PeriodAxis" xlink:type="locator" xlink:label="eypt_PeriodAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_RoyaltyPurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_RoyaltyPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312021Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312021Member" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LoanPrepaymentPriorToDecember312019Member" xlink:type="locator" xlink:label="eypt_LoanPrepaymentPriorToDecember312019Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InitialAdvanceMember" xlink:type="locator" xlink:label="eypt_InitialAdvanceMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SecondAdvanceMember" xlink:type="locator" xlink:label="eypt_SecondAdvanceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SiliconValleyBankMember" xlink:type="locator" xlink:label="eypt_SiliconValleyBankMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaycheckProtectionProgramLoanMember" xlink:type="locator" xlink:label="eypt_PaycheckProtectionProgramLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:type="locator" xlink:label="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TermLoanAgreementTable" xlink:type="locator" xlink:label="eypt_TermLoanAgreementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="eypt_TermLoanAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis" xlink:to="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain" xlink:to="eypt_PaycheckProtectionProgramLoanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_SiliconValleyBankMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_UnusualOrInfrequentItemAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualOrInfrequentItemAxis" xlink:to="us-gaap_UnusualOrInfrequentItemDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualOrInfrequentItemDomain" xlink:to="eypt_CoronavirusAidReliefAndEconomicSecurityActMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_CrgServicingLlcMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eypt_SecondAdvanceMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eypt_InitialAdvanceMember" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentPriorToDecember312019Member" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eypt_LoanPrepaymentAfterDecember312021Member" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eypt_RoyaltyPurchaseAgreementMember" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="eypt_PeriodAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_PeriodAxis" xlink:to="eypt_PeriodDomain" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodOneMember" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodTwoMember" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodThreeMember" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_PeriodDomain" xlink:to="eypt_PeriodFourMember" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember_li0l2" order="13660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementTable" xlink:to="eypt_TermLoanAgreementLineItems" order="13740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="13750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" order="13790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="13860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="13880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="13900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="13950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="14000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_DebtInstrumentAccruedInterestForgiveness" order="14040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="14080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1" order="14150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="14190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_TermLoansAgreementInitialAdvance" order="14230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_TermLoanAgreementAdditionalAdvance" order="14270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="14310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="14380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" order="14420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_PaidInKindInterestAddedToPrincipal" order="14440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="14460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityExitFeesPercentage" order="14480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityFinancingFeePercentage" order="14500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" order="14520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_ReimbursedExpense" order="14540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage" order="14630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_UpfrontCashPayment" order="14710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_MinimumLiquidityAmount" order="14760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_AnnualMinimumProductRevenue" order="14810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_AnnualMinimumProductRevenuePeriod" order="14830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_IncrementalChargesForIssuanceOfWaivers" order="15080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_OriginalAmountOfDebtDiscount" order="15150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_ExitFeeAccrued" order="15170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_LineOfCreditFacilityLegalAndTransactionCosts" order="15210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="15370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_DebInstrumentExitFee" order="15390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="eypt_PaymentOfAccruedAndUnpaidInterest" order="15410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_TermLoanAgreementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="15480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" xlink:type="locator" xlink:label="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_GrossProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="eypt_GrossProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" xlink:type="locator" xlink:label="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_StockIssuedDuringPeriodAdditionalSharesIssued" xlink:type="locator" xlink:label="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="eypt_AtTheMarketOfferingMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SharePurchaseAgreementMember" xlink:type="locator" xlink:label="eypt_SharePurchaseAgreementMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="eypt_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityFinancingsMember" xlink:type="locator" xlink:label="eypt_EquityFinancingsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_EquityFinancingsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eypt_UnderwrittenPublicOfferingMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SharePurchaseAgreementMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_AtTheMarketOfferingMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_StockIssuedDuringPeriodAdditionalSharesIssued" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ClassOfWarrantOrRightIssuePriceOfWarrants" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_GrossProceedsFromIssuanceOfCommonStock" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_li0l2" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WeightedAverageRemainingLifeOfLenderWarrants" xlink:type="locator" xlink:label="eypt_WeightedAverageRemainingLifeOfLenderWarrants" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WarrantsExercisePeriod" xlink:type="locator" xlink:label="eypt_WarrantsExercisePeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExercisePriceOfIssuedWarrants" xlink:type="locator" xlink:label="eypt_ExercisePriceOfIssuedWarrants" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_WarrantsIssuedInConnectionWithTermLoanFacility" xlink:type="locator" xlink:label="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SWKFundingLLCMember" xlink:type="locator" xlink:label="eypt_SWKFundingLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_SWKFundingLLCMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_WarrantsIssuedInConnectionWithTermLoanFacility" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ExercisePriceOfIssuedWarrants" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_WarrantsExercisePeriod" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_WeightedAverageRemainingLifeOfLenderWarrants" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityIncentivePlansAndInducementAwardGrantsMember" xlink:type="locator" xlink:label="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_EquityIncentivePlansAndInducementAwardGrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DirectorsAndExternalConsultantsMember" xlink:type="locator" xlink:label="eypt_DirectorsAndExternalConsultantsMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NewlyAppointedNonExecutiveDirectorMember" xlink:type="locator" xlink:label="eypt_NewlyAppointedNonExecutiveDirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eypt_NewlyAppointedNonExecutiveDirectorMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eypt_DirectorsAndExternalConsultantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquityIncentivePlansMember" xlink:type="locator" xlink:label="eypt_EquityIncentivePlansMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_EquityIncentivePlansMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" xlink:type="locator" xlink:label="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_TwoThousandSixteenIncentivePlanMember" xlink:type="locator" xlink:label="eypt_TwoThousandSixteenIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonExecutiveDirectorsMember" xlink:type="locator" xlink:label="eypt_NonExecutiveDirectorsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredStockUnitsMember" xlink:type="locator" xlink:label="eypt_DeferredStockUnitsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eypt_DeferredStockUnitsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eypt_NonExecutiveDirectorsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_TwoThousandSixteenIncentivePlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" xlink:type="locator" xlink:label="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eypt_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eypt_EmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SalesAndMarketingMember" xlink:type="locator" xlink:label="eypt_SalesAndMarketingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eypt_SalesAndMarketingMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:type="locator" xlink:label="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NonRefundableNonCreditableUpfrontCashPayment" xlink:type="locator" xlink:label="eypt_NonRefundableNonCreditableUpfrontCashPayment" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeAgreementsAndContractsLineItems" xlink:type="locator" xlink:label="eypt_CollaborativeAgreementsAndContractsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_EquinoxScienceLLCMember" xlink:type="locator" xlink:label="eypt_EquinoxScienceLLCMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_AerpioPharmaceuticalsIncMember" xlink:type="locator" xlink:label="eypt_AerpioPharmaceuticalsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CollaborativeAgreementsAndContractsTable" xlink:type="locator" xlink:label="eypt_CollaborativeAgreementsAndContractsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="eypt_CollaborativeAgreementsAndContractsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_CollaborativeAgreementsAndContractsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_AerpioPharmaceuticalsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eypt_EquinoxScienceLLCMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_CollaborativeAgreementsAndContractsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_CollaborativeAgreementsAndContractsTable" xlink:to="eypt_CollaborativeAgreementsAndContractsLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="eypt_NonRefundableNonCreditableUpfrontCashPayment" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eypt_CollaborativeAgreementsAndContractsLineItems" xlink:to="eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10080.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10080.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ExitFeeAccrued" xlink:type="locator" xlink:label="eypt_ExitFeeAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CommercialPaperAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_InvestmentInstrumentsMember" xlink:type="locator" xlink:label="eypt_InvestmentInstrumentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="eypt_InvestmentInstrumentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_CrgServicingLlcMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommercialPaperAtCarryingValue" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebt" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="eypt_ExitFeeAccrued" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureRetirementPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail">
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DefinedContributionPlanContributionsByEmployer" xlink:type="locator" xlink:label="eypt_DefinedContributionPlanContributionsByEmployer" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="eypt_DefinedContributionPlanContributionsByEmployer" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" xlink:type="locator" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" xlink:type="locator" xlink:label="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" xlink:type="locator" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_OperatingLossCarryForwardsExpirationYearRangeStart" xlink:type="locator" xlink:label="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_NetOperatingLossCarryforwards" xlink:type="locator" xlink:label="eypt_NetOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HerMajestysRevenueAndCustomsHMRCMember" xlink:type="locator" xlink:label="us-gaap_HerMajestysRevenueAndCustomsHMRCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FederalAndStateTaxMember" xlink:type="locator" xlink:label="eypt_FederalAndStateTaxMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" xlink:type="locator" xlink:label="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IconBioscienceIncMember" xlink:type="locator" xlink:label="eypt_IconBioscienceIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eypt_IconBioscienceIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="eypt_FederalAndStateTaxMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_HerMajestysRevenueAndCustomsHMRCMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_NetOperatingLossCarryforwards" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_OperatingLossCarryForwardsExpirationYearRangeStart" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_OperatingLossCarryForwardsExpirationYearRangeEnd" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="eypt_IncomeTaxReconciliationPermanentItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" xlink:type="locator" xlink:label="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eypt_IncomeTaxReconciliationPermanentItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:type="locator" xlink:label="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DeferredTaxAssetsLeasingArrangements" xlink:type="locator" xlink:label="eypt_DeferredTaxAssetsLeasingArrangements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="eypt_DeferredTaxAssetsLeasingArrangements" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="eypt-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PaymentOfAccruedAndUnpaidInterest" xlink:type="locator" xlink:label="eypt_PaymentOfAccruedAndUnpaidInterest" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_LineOfCreditFacilityExitFeesPercentage" xlink:type="locator" xlink:label="eypt_LineOfCreditFacilityExitFeesPercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_DebInstrumentExitFee" xlink:type="locator" xlink:label="eypt_DebInstrumentExitFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_UpfrontCashPayment" xlink:type="locator" xlink:label="eypt_UpfrontCashPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" xlink:type="locator" xlink:label="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_CrgServicingLlcMember" xlink:type="locator" xlink:label="eypt_CrgServicingLlcMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SiliconValleyBankMember" xlink:type="locator" xlink:label="eypt_SiliconValleyBankMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredRevolvingCreditFacilityMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredRevolvingCreditFacilityMember" />
    <link:loc xlink:href="eypt-20211231.xsd#eypt_SeniorSecuredTermLoanMember" xlink:type="locator" xlink:label="eypt_SeniorSecuredTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredTermLoanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eypt_SeniorSecuredRevolvingCreditFacilityMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_SiliconValleyBankMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VariableRateAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="eypt_CrgServicingLlcMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_UpfrontCashPayment" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_DebInstrumentExitFee" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_LineOfCreditFacilityExitFeesPercentage" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eypt_PaymentOfAccruedAndUnpaidInterest" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014563672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EyePoint Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,044,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,416,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2774444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Pleasant Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2022 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015322584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 178,593,000<span></span>
</td>
<td class="nump">$ 44,909,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">32,965,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and other receivables, net (including due from a related party of $414 and $104 at December 31, 2021 and 2020, respectively)</a></td>
<td class="nump">18,354,000<span></span>
</td>
<td class="nump">9,453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,217,000<span></span>
</td>
<td class="nump">3,419,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,616,000<span></span>
</td>
<td class="nump">5,337,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">237,745,000<span></span>
</td>
<td class="nump">63,118,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">476,000<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,252,000<span></span>
</td>
<td class="nump">2,610,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">22,749,000<span></span>
</td>
<td class="nump">25,209,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">263,372,000<span></span>
</td>
<td class="nump">91,717,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,385,000<span></span>
</td>
<td class="nump">4,811,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">14,422,000<span></span>
</td>
<td class="nump">8,445,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,069,000<span></span>
</td>
<td class="nump">945,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">687,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,658,000<span></span>
</td>
<td class="nump">14,888,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">36,562,000<span></span>
</td>
<td class="nump">37,977,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - noncurrent</a></td>
<td class="nump">14,560,000<span></span>
</td>
<td class="nump">15,616,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="nump">1,860,000<span></span>
</td>
<td class="nump">2,330,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,352,000<span></span>
</td>
<td class="nump">2,365,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">78,992,000<span></span>
</td>
<td class="nump">73,176,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2021 and 2020, respectively; 33,905,826 and 18,139,981 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">752,602,000<span></span>
</td>
<td class="nump">528,362,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(569,097,000)<span></span>
</td>
<td class="num">(510,680,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">841,000<span></span>
</td>
<td class="nump">841,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">184,380,000<span></span>
</td>
<td class="nump">18,541,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 263,372,000<span></span>
</td>
<td class="nump">$ 91,717,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014536712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related party</a></td>
<td class="nump">$ 414,000<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">33,905,826<span></span>
</td>
<td class="nump">18,139,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">33,905,826<span></span>
</td>
<td class="nump">18,139,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014348968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 36,939<span></span>
</td>
<td class="nump">$ 34,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">8,177<span></span>
</td>
<td class="nump">5,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">28,500<span></span>
</td>
<td class="nump">17,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">27,503<span></span>
</td>
<td class="nump">25,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,575<span></span>
</td>
<td class="nump">20,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AmortizationOfAcquisitionCostOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">92,215<span></span>
</td>
<td class="nump">71,727<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(55,276)<span></span>
</td>
<td class="num">(37,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,498)<span></span>
</td>
<td class="num">(7,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="num">(905)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(3,141)<span></span>
</td>
<td class="num">(8,104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,417)<span></span>
</td>
<td class="num">$ (45,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (2.03)<span></span>
</td>
<td class="num">$ (3.54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">28,758<span></span>
</td>
<td class="nump">12,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,417)<span></span>
</td>
<td class="num">$ (45,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(58,417)<span></span>
</td>
<td class="num">(45,393)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35,312<span></span>
</td>
<td class="nump">20,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">$ 1,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AmortizationOfAcquisitionCostOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of acquisition cost of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AmortizationOfAcquisitionCostOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of sales excluding amortization of acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014560344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 543<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119016160392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 8,330<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 472,765<span></span>
</td>
<td class="num">$ (465,286)<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,941,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issue costs</a></td>
<td class="nump">49,853<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">49,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of stock units</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18,541<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">528,362<span></span>
</td>
<td class="num">(510,680)<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">18,139,981<span></span>
</td>
<td class="nump">18,139,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts', window );">Issuance of stock and pre-funded warrants, net of issue costs</a></td>
<td class="nump">216,586<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">216,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts', window );">Issuance of stock and pre-funded warrants, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,635,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of stock units</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 184,380<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 752,602<span></span>
</td>
<td class="num">$ (569,097)<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">33,905,826<span></span>
</td>
<td class="nump">33,905,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares, issuance of stock and pre-funded warrants, net of issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value, issuance of stock and pre-funded warrants, net of issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014342520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (58,417)<span></span>
</td>
<td class="num">$ (45,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguishment of debt</a></td>
<td class="num">(2,065)<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolescence inventory</a></td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,447<span></span>
</td>
<td class="nump">5,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets', window );">Accounts receivable and other current assets</a></td>
<td class="num">(10,603)<span></span>
</td>
<td class="nump">4,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="num">(3,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">8,476<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset', window );">Right-of-use assets and operating lease liabilities</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(931)<span></span>
</td>
<td class="nump">16,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50,097)<span></span>
</td>
<td class="num">(14,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(32,965)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(33,121)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of stock and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">216,825<span></span>
</td>
<td class="nump">49,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ProceedsFromPaycheckProtectionProgramLoan', window );">Proceeds under paycheck protection program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt principal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment of extinguishment of debt costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net settlement of stock units to satisfy statutory tax withholding</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligations</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">216,902<span></span>
</td>
<td class="nump">37,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">133,684<span></span>
</td>
<td class="nump">22,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">45,059<span></span>
</td>
<td class="nump">22,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">178,743<span></span>
</td>
<td class="nump">45,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash interest paid</a></td>
<td class="nump">4,846<span></span>
</td>
<td class="nump">5,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NonCashUnpaidStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DebtInstrumentExitFee', window );">Accrued term loan exit fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan', window );">Payments forgiven under paycheck protection program loan</a></td>
<td class="nump">$ 2,041<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase or decrease in operating lease liability and right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NonCashUnpaidStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash unpaid stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NonCashUnpaidStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments forgiven under paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ProceedsFromPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ProceedsFromPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables, and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018323560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Operations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Operations</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EyePoint Pharmaceuticals, Inc. (together with its subsidiaries, the &#8220;Company&#8221;), incorporated in Delaware, is<span style="Background-color:#FFFFFF;"> a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company&#8217;s pipeline leverages its proprietary Durasert</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup><span style="Background-color:#FFFFFF;">technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration (&#8220;wet AMD&#8221;), the leading cause of vision loss among people 50 years of age and older in the United States. The Company&#8217;s product candidate pipeline also includes YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application (&#8220;sNDA&#8221;) strategy. The Company also has two commercial products: YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a once every three-year treatment for chronic&#160;non-infectious&#160;uveitis affecting the posterior segment of the eye, and DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, a single dose treatment for postoperative inflammation following ocular surgery.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Local drug delivery for treating ocular diseases is a significant challenge due to the effectiveness of the blood-eye barrier. This barrier makes it difficult for systemically-administered drugs to reach the eye in sufficient quantities to have a beneficial effect without causing unacceptable adverse side effects to other organs. The Company&#8217;s validated Durasert technology, which has already been included in four products approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), is designed to provide consistent, sustained delivery of small molecule drugs over a period of months to years through a single intravitreal injection. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s lead product candidate, EYP-1901, combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor (&#8220;TKI&#8221;) that has demonstrated anti-VEGF activity. Current FDA approved anti-VEGF treatments for wet AMD require monthly or bi-monthly intravitreal injections in a physician&#8217;s office. The Company is currently evaluating EYP-1901 in a Phase 1 clinical trial as a potential six-month sustained delivery treatment for wet AMD and reported positive six-month interim safety and efficacy data in November 2021. In February 2022, the Company updated the results of the DAVIO clinical trial through 8-months reporting continued positive safety and efficacy results. The Company expects to initiate a Phase 2 clinical trial in wet AMD in the third quarter of 2022 and a Phase 2 clinical trial in diabetic retinopathy later in the second half of 2022.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;(fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is a non-erodible intravitreal implant containing fluocinolone acetonide (&#8220;FA&#8221;) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This disease affects between 60,000 to 100,000 people each year in the U.S. causes approximately 30,000 new cases of blindness every year and is the third leading cause of blindness. YUTIQ utilizes the Company&#8217;s proprietary Durasert<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;sustained-release drug delivery technology platform.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;(dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation, with the Company&#8217;s primary focus on its use&#160;immediately following cataract surgery as a single dose treatment. DEXYCU utilizes the Company&#8217;s proprietary Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;drug-delivery&#160;technology. In December 2021, the Company announced that its commercial alliance partner, ImprimisRx, assumed responsibility for all sales and marketing activity for DEXYCU effective January 1, 2022.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is also developing YUTIQ 50 as a potential six-month intravitreal treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. The Company dosed the first patient in a Phase 3 clinical trial in November 2021.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company is also seeking to potentially identify and advance additional product candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, potential research collaborations and/or&#160;in-licensing&#160;arrangements with partner molecules and potential acquisition of additional ophthalmic products, product candidates or technologies that complement the Company&#8217;s current product portfolio.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Effects of the COVID-19 Coronavirus Pandemic<span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span><span style="color:#000000;"> ongoing COVID-19 coronavirus pandemic</span><span style="Background-color:#FFFFFF;color:#000000;"> (the &#8220;Pandemic&#8221;)</span><span style="color:#000000;"> has had a material and adverse impact on the Company&#8217;s business, including as a result of measures that the Company, other businesses, and government have taken and will likely continue to take. This includes a significant impact on cash flows from expected revenues due to the closure of ambulatory surgery centers for DEXYCU and a significant reduction in physician office visits impacting YUTIQ in 2020. The ongoing Pandemic continued to have an adverse impact on the Company&#8217;s revenues, financial condition and cash flows through 2021. For the year ended December 31, 2021, the Company recorded impairment charges of $1.2 million to cost of sales, excluding amortization of acquired intangible assets and $0.1 million to sales and marketing expense, respectively, associated with the write-off of obsolete inventory of DEXYCU units and DEXYCU sample units, respectively, whose inventory levels were higher than the Company&#8217;s updated forecasts of future demand </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">for those units. </span><span style="color:#000000;">Additionally, the emergence of </span><span style="color:#000000;">the Omicron </span><span style="color:#000000;">variant has </span><span style="color:#000000;">continued to have an adverse impact on the Company&#8217;s revenues, financial condition and cash flows into the first quarter of 2022</span><span style="color:#000000;"> and may continue to cause intermittent or prolonged periods of reduced patient services at the Company&#8217;s customers&#8217; facilities, which may negatively affect customer demand. The progression of the Pandemic and its effects on the Company&#8217;s business and operations are uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, the Company&#8217;s revenues, financial condition and cash flows may be adversely affected in the future as well.</span><span style="color:#000000;"> </span><span style="color:#000000;">The Company is </span><span style="color:#000000;">continuously </span><span style="color:#000000;">monitoring the Pandemic and its potential effect on the Company&#8217;s financial position, results of operations and cash flows. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company&#8217;s periodic financial results, including reserves for variable consideration related to product sales, realizability of certain receivables, assessment for excess or obsolete inventory, and impairment of long-lived assets. </span><span style="Background-color:#FFFFFF;color:#000000;">Uncertainty around the extent and duration of the Pandemic, and any future related financial impact cannot be reasonably estimated at this time.</span><span style="Background-color:#FFFFFF;color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span><span style="color:#000000;"> Company had cash, cash equivalents, and investments in marketable securities of $211.6</span><span style="font-size:12pt;">&#160;</span><span style="color:#000000;">million at December 31, 2021.&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">The Company has a history of operating losses and has not had significant recurring cash inflows from revenue.</span><span style="color:#000000;"> The Company&#8217;s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates and the Company does not expect revenues from its product sales to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenues of its product sales, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents, and investments in marketable securities of $211.6</span><span style="font-size:12pt;">&#160;</span><span style="color:#000000;">million at December 31, 2021, coupled with expected cash inflows from its product sales will enable the Company to fund its current and planned operations for </span><span style="Background-color:#FFFFFF;color:#000000;">at least the next twelve months from the date these consolidated financial statements were issued. A</span><span style="color:#000000;">ctual cash requirements could differ from management&#8217;s projections due to many factors, including the continued effect of the Pandemic on the Company&#8217;s business and the medical community, </span><span style="Background-color:#FFFFFF;color:#000000;">the timing and results of the Company&#8217;s clinical trials for EYP-1901, </span><span style="color:#000000;">additional </span><span style="Background-color:#FFFFFF;color:#000000;">investments</span><span style="color:#000000;"> in research and development programs, the success of ongoing </span><span style="Background-color:#FFFFFF;color:#000000;">commercialization</span><span style="color:#000000;"> efforts for YUTIQ and DEXYCU, the actual costs of these ongoing commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018151880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements are presented in U.S. dollars in accordance with generally accepted accounting principles in the U.S. (&#8220;U.S. GAAP&#8221;) and include the accounts of EyePoint Pharmaceuticals, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to reserves for variable consideration related to product sales, revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recording of excess or obsolete inventory write-offs and reserves, and realization of deferred tax assets. Actual results could differ from these and other estimates and there may be changes to the Company&#8217;s estimates in future periods. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company and each of its subsidiaries is the currency of the primary economic environment in which each such entity operates&#8212;the U.S. dollar or the Pound&#160;Sterling. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities of the Company&#8217;s foreign subsidiary are translated at period-end exchange rates. Amounts included in the consolidated statements of comprehensive loss and cash flows are translated at the weighted average exchange rates for the period. Gains and losses from currency translation are included in accumulated other comprehensive income as a separate component of stockholders&#8217; equity in the consolidated balance sheets. The balance of accumulated other comprehensive income attributable to foreign currency translation was $841,000 and $841,000 at December&#160;31, 2021 and 2020, respectively. Foreign currency gains or </p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">losses arising from transactions denominated in foreign currencies, whether realized or unrealized, are recorded in interest and other income, net in the consolidated statements of comprehensive loss and were not </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for all periods presented.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents represent highly liquid investments with maturities of three months or less at the date of purchase, principally consisting of institutional money market funds and investment-grade commercial paper. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with an original or remaining maturity of greater than three months but less than six months at the date of purchase. The Company has historically classified its marketable securities as available-for-sale. Accordingly, the Company records these investments at fair value, with unrealized gains and losses excluded from earnings and reported, net of tax, in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. If the Company determines that a decline of any investment is other-than-temporary, the investment is written down to fair value. Marketable securities at December 31, 2021 consisted of investment-grade commercial paper. The Company had no marketable security investments at December 31, 2020. The Company&#8217;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. During fiscal 2021, $33.0 million of marketable securities were purchased and $0 matured.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of marketable securities is determined based on quoted market prices at the balance sheet date of the same or similar instruments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts through to the earlier of sale or maturity. Such amortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the specific identification method.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and investments in marketable securities. At December&#160;31, 2021, a total of $155.6&#160;million, or 90.4% of the Company&#8217;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $16.5 million, or 9.6% of the Company&#8217;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $33.0 million and $0 in marketable securities at December&#160;31, 2021 and 2020, respectively. The Company&#8217;s investment policy, approved by the Company&#8217;s Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, accounts receivable from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 54.7% and 38.3% of total accounts receivable, respectively. For the year ended December 31, 2021, revenues from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 46.6% and 43.1% of total revenues, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, accounts receivable from ASD Specialty Healthcare LLC and McKesson Specialty Care Distribution LLC accounted for 56.0% and 37.0% of total accounts receivable, respectively. For the year ended December 31, 2020, revenues from ASD Specialty Healthcare LLC, Ocumension Therapeutics, and McKesson Specialty Care Distribution LLC accounted for 39.0%, 33.0%, and 18.0% of total revenues, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;1 &#8211; Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;2 &#8211; Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets). </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;3 &#8211; Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#8217; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts and Other Receivables, Net</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables arise primarily from the Company&#8217;s products sold in the U.S. The balance in accounts and other receivables, net consists primarily of amounts due from customers, net of applicable revenue reserves. The majority of the Company&#8217;s accounts receivable have standard payment terms that require payment within 120-127 days. The Company <span style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.2pt;">performs ongoing credit evaluations of its customers&#8217; financial condition and continuously monitor collections and payments from its customers and</span> analyzes accounts that are past due for collectability. <span style="color:#000000;">The allowance for credit losses is estimated based on the Company&#8217;s analysis of trends in overall receivables aging, specific identification of certain receivables that are at risk of not being paid, past collection experience and current economic trends. </span>G<span style="Background-color:#FFFFFF;color:#000000;">iven the nature and limited history of collectability of the Company&#8217;s accounts receivable, </span>the Company recorded no allowance for credit losses as of December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inventory </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or net realizable value, net on a first-in, first-out (&#8220;FIFO&#8221;) basis. The inventory costs for YUTIQ include purchases of various components and the active pharmaceutical ingredient (&#8220;API&#8221;) and internal labor and overhead for the product manufactured in the Company&#8217;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalization of inventory costs begins after FDA approval of the product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assesses the recoverability of inventory and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Write-downs are based on the age of the inventory, lower of cost or market, along with significant management judgments concerning future demands for the inventory. Such impairment charges, should they occur, are recorded within cost of sales, excluding amortization of acquired intangible assets. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory might be recorded in future periods.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost <span style="Background-color:#FFFFFF;">of</span> sales, excluding amortization of acquired intangible assets, consist of costs associated with the manufacture of YUTIQ and DEXYCU, certain period costs for DEXYCU product revenue, product shipping and, as applicable, royalty expense. The inventory costs for YUTIQ include purchases of various components, the active pharmaceutical ingredient (&#8220;API&#8221;) and direct labor and overhead for the product manufactured in the Company&#8217;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly. Capitalization of inventory costs begins after FDA approval of a product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company accrued DEXYCU product revenue-based royalty expense of $2.5 million and $<span style="color:#000000;">2.3</span> million for the years ended December 31, 2021 and 2020, respectively, as a component of cost of sales, of which $0 and $<span style="color:#000000;">1.3</span> million of accrued revenue-based royalty expense were related to the partnering income equal to 20% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, in connection with the acquisition of Icon Bioscience, Inc. in March 2018 for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Debt and Equity Instruments </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Debt</span><span style="color:#000000;"> and equity instruments are classified as either liabilities or equity in accordance with the substance of the contractual arrangement. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Instruments </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Derivative</span><span style="color:#000000;"> financial liabilities are recorded at fair value, with gains and losses arising from changes in fair value recognized in change in fair value of derivative liability within the consolidated statements of comprehensive loss at each period end while such instruments are outstanding. The Company&#8217;s derivative liabilities from certain financing transactions were primarily valued using Monte Carlo simulation models. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated over their estimated useful lives (generally three to five years) using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining non-cancellable lease term or their estimated useful lives. Repair and maintenance costs are expensed as incurred. When assets are retired or sold, the assets and accumulated depreciation are derecognized from the respective accounts and any gain or loss is recognized. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Software Development Cost</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC 350 <span style="font-style:italic;">Intangibles &#8211; Goodwill and Other</span>, and classified as a prepaid asset in the balance sheets. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud completing arrangement, over the term of the arrangement, plus reasonably certain renewals.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases real estate and office equipment under operating leases. Its primary real estate lease contains rent holiday and rent escalation clauses. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether the arrangement is or contains a lease at inception. Operating leases are recognized on the consolidated balance sheets as ROU assets, current portion of lease liabilities and long-term lease liabilities. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. <span style="color:#000000;">For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. </span>The operating lease ROU assets also include any lease payments made and adjustments for prepayments and lease incentives. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilized its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Intangible Assets </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s finite life intangible assets include the DEXYCU product (utilizing the Verisome technology) following the March 2018 acquisition of Icon. The DEXYCU intangible asset is being amortized on a straight-line basis over its estimated useful life of thirteen years. The intangible asset lives were determined based upon the anticipated period that the Company would derive future cash flows from the intangible assets, considering the effects of legal, regulatory, contractual, competitive and other economic factors. The Company continually monitors whether events or circumstances have occurred that indicate that the remaining estimated useful life of its intangible assets may warrant revision. The Company assesses potential impairments to its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the future undiscounted net cash flows expected to result from the use of an asset are less than its carrying value. If the Company considers an asset to be impaired, the impairment charge to be recognized is measured as the amount by which the carrying value of the asset exceeds its estimated fair value. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Revenue</span><span style="color:#000000;"> is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product sales, net<span style="font-weight:normal;font-style:normal;"> &#8212; The Company sells YUTIQ and DEXYCU to a limited number of specialty distributors and specialty pharmacies (collectively the &#8220;Distributors&#8221;) in the U.S., with whom the Company has entered into formal agreements, for delivery to physician practices for YUTIQ and to hospital outpatient departments and ambulatory surgical centers for DEXYCU. The Company recognizes revenue on sales of its products when Distributors obtain control of the products, which occurs at a point in time, typically upon delivery. In addition to agreements with Distributors, the Company also enters into arrangements with healthcare providers, ambulatory surgical centers, and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products from Distributors. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reserves for variable consideration <span style="color:#000000;font-style:normal;">&#8212; </span><span style="font-style:normal;">Product sales are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, provider chargebacks and discounts, payor rebates, product returns, and other allowances that are offered within contracts between the Company and its Distributors, payors, and other contracted purchasers relating to the Company&#8217;s product sales. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified either as reductions of product revenue and accounts receivable or a current liability, depending on how the amount is to be settled. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#FF0000;font-style:normal;"> </span><span style="font-style:normal;">Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Distribution fees <span style="font-style:normal;">&#8212; </span><span style="font-style:normal;color:#000000;">The Company compensates its Distributors for services explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product sale is recognized. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Provider chargebacks and discounts <span style="font-style:normal;">&#8212; </span><span style="font-style:normal;color:#000000;">Chargebacks are discounts that represent the estimated obligations resulting from contractual commitments to sell products at prices lower than the list prices charged to the Company&#8217;s Distributors. These Distributors charge the Company for the difference between what they pay for the product and the Company&#8217;s contracted selling price. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of </span><span style="font-style:normal;">product revenue and the establishment of a current liability</span><span style="font-style:normal;color:#000000;">. Reserves for chargebacks consist of amounts that the Company expects to pay for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold under a contracted selling price, and chargebacks that Distributors have claimed, but for which the Company has not yet settled.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government rebates <span style="font-style:normal;">&#8212; The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payor rebates <span style="font-style:normal;">&#8212; The Company contracts with certain private payor organizations, primarily insurance companies, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Co-Payment assistance <span style="font-style:normal;">&#8212; The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Product returns </span><span style="font-style:normal;">&#8212; The Company generally offers a limited right of return based on its returned goods policy, which includes damaged product and remaining shelf life. The Company estimates the amount of its product sales that may be returned and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to trade receivables, net on the </span><span style="font-style:normal;">condensed</span><span style="font-style:normal;"> consolidated balance sheets. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and collaboration agreement revenue<span style="font-weight:normal;font-style:normal;"> &#8212; The Company analyzes each element of its license and collaboration arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#8217;s contracts contained a significant financing component as of December&#160;31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalties <span style="font-weight:normal;font-style:normal;">&#8212; The Company recognizes revenue from license arrangements with its commercial partners&#8217; net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner&#8217;s products occurs. The Company&#8217;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60&#160;days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company recognizes royalty income each quarter and subsequently determines a true-up when it receives royalty reports and payment from its commercial partners. Historically, these true-up adjustments have been immaterial. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sale of Future Royalties <span style="font-weight:normal;font-style:normal;">&#8212; The Company has sold its rights to receive certain royalties on product sales. In the circumstance where the Company has sold its rights to future royalties under a royalty purchase agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Collaborations<span style="font-weight:normal;font-style:normal;"> &#8212; The Company recognizes revenue over the term of the statements of work under any funded research collaborations (including feasibility study agreements). Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations (including feasibility study agreements). </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please refer to Note 3 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized within one year following the balance sheet date are classified as non-current deferred revenue. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are charged to operations as incurred. These costs include all direct costs, including cash and stock-based compensation and benefits for research, clinical development, quality assurance, quality control, operations and medical affairs personnel, amortization of intangible assets, third-party costs and services for clinical trials, clinical materials, pre-clinical programs, regulatory and medical affairs, external consultants, and other operational costs related to the Company&#8217;s research and development of its product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation cost related to share-based payment awards is based on the fair value of the instrument on the grant date and is recognized on a graded vesting basis over the requisite service period for each separately vesting tranche of the awards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may also grant share-based payment awards that are subject to objectively measurable performance and service criteria. Compensation expense for performance-based awards begins at such time as it becomes probable that the respective performance conditions will be achieved. The Company continues to recognize the grant date fair value of performance-based awards through the vesting date of the respective awards so long as it remains probable that the related performance conditions will be satisfied. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model and the fair value of performance stock units, restricted stock units and deferred stock units based on the observed grant date fair value of the underlying Common Stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the weighted-average number of common shares outstanding the average number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, 3,272,727 shares of Pre-Funded Warrants to purchase common stock, issued in connection with the November 2021 underwritten public offering (see Note 10), were included in the basic and diluted net loss per share calculation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,517,680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,965</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,881,903</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is comprised of net loss, foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Tax </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future benefit to be derived from tax credits and loss carry forwards. Such deferred income tax computations are measured based on enacted tax laws and rates applicable to the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is provided against net deferred tax assets if, based on the available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the uncertainty. The Company accounts for interest and penalties related to uncertain tax positions as part of its income tax benefit. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company&#8217;s financial position, results of operations and cash flows or do not apply to the Company&#8217;s operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740)</span><span style="color:#000000;"> (&#8220;ASU 2019-12&#8221;)</span><span style="font-style:italic;">: Simplifying the Accounting for Income Taxes.</span>&#160;The amendments simplify the accounting for income taxes by removing certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </span>(&#8220;ASU 2021-04&#8221;)<span style="font-style:italic;">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.</span> The amendments are designed to clarify an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options that remain equity-classified after modification or exchange. The ASU provides guidance on how an issuer would measure and recognize the effects of these transactions. The standard provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. ASU 2021-04 will be effective for the Company in the first quarter of its fiscal year ending December 31, 2022. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018140520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue Reserves and Allowances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ProductRevenueReservesAndAllowancesTextBlock', window );">Product Revenue Reserves and Allowances</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Product Revenue Reserves and Allowances</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product revenues have been primarily from sales of YUTIQ and DEXYCU in the U.S.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product revenues by product for the years ended December 31, 2021 and 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">YUTIQ (A)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,959</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU (B)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product sales, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,831</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(A)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(B)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance at January 1, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,712</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to sales in the current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,396</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior period sales</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(272</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deductions applied and payments made</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,645</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,029</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,153</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,821</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance at January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,241</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to sales in the current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">978</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,175</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior period sales</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(387</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deductions applied and payments made</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,798</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(777</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Returns are recorded as a reduction of accounts receivable on the condensed consolidated balance sheets. Chargebacks, discounts and fees and rebates are recorded as a component of accrued expenses on the condensed consolidated balance sheets (see Note 7). </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements and Royalty Income</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alimera </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a licensing and development agreement, as amended, Alimera Sciences, Inc. has a worldwide exclusive license to develop, make, market and sell ILUVIEN in return for royalties based on sales and patent fee reimbursements. Total revenue was $54,000 and $1.7 million for the years ended December 31, 2021 and 2020, respectively. In addition to patent fee reimbursements in those periods, the Company recorded royalty income totaled $0 and $1.7 million for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SWK Royalty Purchase Agreement</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2020, the Company entered into a royalty purchase agreement (the &#8220;RPA&#8221;) with SWK Funding LLC (&#8220;SWK&#8221;). Under the RPA, the Company sold its right to receive royalty payments on future sales of products subject to the Amended Alimera Agreement for an upfront cash payment of $16.5 million. Except for the rights to the royalties, the Company retains all rights and obligations under the Amended Alimera Agreement, pursuant to which, Alimera owns worldwide rights to the Company&#8217;s Durasert technology in ILUVIEN for DME and rights for ILUVIEN (currently marketed by the Company as YUTIQ in the U.S.) for non-infectious posterior uveitis in the EMEA. Alimera has the sole rights to utilize the intellectual property developed under the Amended Alimera Agreement. There has been no intellectual property developed jointly by Alimera and the Company as part of the Amended Alimera Agreement. The Company cannot utilize the intellectual property for the indication licensed to Alimera in order to manufacture and sell ILUVIEN.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ongoing efforts under the Amended Alimera Agreement will consist of continuing to maintain and enforce its patents as well as providing safety data and regulatory support as necessary. None of these obligations require significant efforts on the part of the Company with respect to the generation of sales in the market. The Company will only be required to expend more extensive efforts if litigation were to arise that requires the Company to protect its patents rights pursuant to the terms of the Amended Alimera Agreement. Historically, such a defense has not been required. Similarly, regulatory support and safety data is only provided </p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on an ad-hoc basis depending on the regulatory requests</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which has been </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">minimal </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">historically</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. It remains Alimera&#8217;s sole responsibility to manufacture, actively market and promote the products under the Amended Alimera Agreement to generate the sales, which ultimately generate the royalties to be paid to SWK.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified the proceeds received from SWK as deferred revenue, to be recognized as revenue under the units-of-revenue method over the life of the RPA because of the Company&#8217;s limited continuing involvement in the Amended Alimera Agreement. SWK has no recourse and the Company assumes no credit risk in event that Alimera fails to make a royalty payment. The Company must only forward all material correspondence from Alimera to SWK, including royalty reports, notices and any other correspondence with respect to royalties to SWK. SWK has the right to audit and inspect the books and records pertaining to net sales and royalties under the Amended Alimera Agreement. Neither the Company nor SWK has the unilateral ability to cancel the transaction. There is no cap or limitation on the royalties to be received by SWK in the future and its return will reflect all royalties paid by Alimera. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to SWK and there is no limitation on the rates of return to SWK, the Company recorded the total proceeds of $16.5 million as deferred revenue under royalty sale agreement. The deferred revenue is being recognized as revenue over the life of the RPA under the &#8220;units-of-revenue&#8221; method. Under this method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from SWK to the payments expected to be made by Alimera to SWK over the term of the Amended Alimera Agreement, and then applying that ratio to the period&#8217;s cash payment. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $872,000 of royalty revenue related to the RPA for the year ended December 31, 2021, in connection with the royalty payment of $2.8 million for the year ended December 31, 2021, from Alimera to SWK, pursuant to the Amended Alimera Agreement. No revenue was recognized related to the RPA for the year ended December 31, 2020. As of December 31, 2021, the Company has $1.1 million and $14.6 million as current and non-current deferred revenue recognized under royalty sale agreement, respectively. As of December 31, 2020, the Company classified $885,000 and $15.6 million as current and non-current deferred revenue recognized under royalty sale agreement, respectively. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OncoSil Medica<span style="font-weight:normal;">l</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with OncoSil Medical UK Limited (f/k/a Enigma Therapeutics Limited), a wholly-owned subsidiary of OncoSil Medical Ltd (&#8220;OncoSil&#8221;) for the development of BrachySil, the Company&#8217;s previous product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and milestone payments based on aggregate product sales. OncoSil is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year, the most recent of which was received in December 2021. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any patent maintenance costs, sales-based royalties and </span>sub-licensee<span style="Background-color:#FFFFFF;"> sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. </span><span style="color:#000000;">In March 2020, the U.S. Food and Drug Administration granted Breakthrough Device Designation for the OncoSil&#8482; device for treatment of unresectable locally advanced pancreatic cancer (LAPC) in combination with chemotherapy.&#160; In April 2020, the British Standards Institute (BSI) grants European CE marking for the OncoSil&#8482; System and designates OncoSil&#8482; a breakthrough device for the treatment of locally advanced pancreatic cancer (LAPC) in combination with chemotherapy.&#160;As of December 31, 2021, OncoSil has received regulatory approval in the EU, United Kingdom, Switzerland, Singapore, Malaysia, Hong Kong, New Zealand, Turkey, and Israel. </span><span style="Background-color:#FFFFFF;">The Company has no consequential performance obligations under the OncoSil license agreement. For the years ended December 31, 2021 and 2020, revenue of $100,000 and $100,000 was recorded for this agreement, respectively.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ocumension Therapeutics </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="Background-color:#FFFFFF;">November</span> 2018, the Company entered into an exclusive license agreement with Ocumension Therapeutics (&#8220;Ocumension&#8221;) for the development and commercialization of its three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (YUTIQ in the U.S.) in Mainland China, Hong Kong, Macau and Taiwan. The Company received a one-time upfront payment of $1.75&#160;million from Ocumension and is eligible to receive up to (i) $7.25&#160;million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and (ii) $3.0 million commercial sales-based milestones. In addition, the Company is entitled to receive mid-single digit sales-based royalties. Ocumension has also received a special approval by the Hainan Province People&#8217;s Government to market this product for chronic, non-infectious posterior segment uveitis in the Hainan Bo Ao Lecheng International Medical Tourism Pilot Zone (&#8220;Hainan Pilot Zone&#8221;). In March 2019, the Company entered into a Memorandum of Understanding (&#8220;2019 MOU&#8221;), pursuant to which, the Company will supply product for the clinical trials and Hainan Pilot Zone use. Paralleling to Ocumension&#8217;s normal registration process of the product with the Chinese Regulatory Authorities, the 2019 MOU modified the Company&#8217;s entitlement to the development and regulatory milestones of up to $7.25 million under the license agreement to product supply milestones or development milestones, whichever comes first, totaling up to $7.25 million. In August 2019, the Company began shipping this product to Ocumension.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was required to provide a fixed number of hours of technical assistance support to Ocumension at no cost, which support has been completed and no future performance obligation exists. Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested. Ocumension has a first right of negotiation for an additional exclusive license to the Company&#8217;s shorter-duration line extension candidate for this indication. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, the Company received a $1.0 million development milestone payment from Ocumension triggered by the approval of its Investigational New Drug (&#8220;IND&#8221;) in China for this program. The IND allows the importation of finished product into China for use in a clinical trial to support regulatory filing.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020,&#160;the Company entered into an exclusive license agreement with Ocumension for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU for the treatment of post-operative inflammation following ocular surgery. Pursuant to the terms of the license agreement, the Company received upfront payments of&#160;$2.0 million&#160;from Ocumension in February 2020 and will be eligible to receive up to (i) $6.0 million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and (ii) $6.0 million commercial sales-based milestones. In addition, the Company is entitled to receive mid-single digit sales-based royalties. In exchange, Ocumension will receive exclusive rights to develop and commercialize DEXYCU in Mainland China, Hong Kong, Macau and Taiwan, at its own cost and expense with the Company supplying product for clinical trials and commercial sale. In addition, Ocumension will receive a fixed number of hours of technical assistance support from the Company at no cost.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into a Memorandum of Understanding (&#8220;2020 MOU&#8221;), pursuant to which, <span style="Background-color:#FFFFFF;">the Company received a one-time non-refundable payment of $9.5 million (the &#8220;Accelerated Milestone Payment&#8221;) from Ocumension as a full and final payment of the combined remaining development, regulatory and sales milestone payments under the Company&#8217;s license agreements with Ocumension for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and for the treatment of post-operative inflammation following ocular surgery, respectively. Upon payment of the Accelerated Milestone Payment, the remaining $11.75 million in combined remaining development and sales milestone payments under the Company&#8217;s original </span>license agreement with Ocumension upon the achievement by Ocumension of (i) remaining development and regulatory milestones of $6.25 million and commercial sales-based milestones of $3.0 million for the development and commercialization of its three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and (ii) $6.0 million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and $6.0 million commercial sales-based milestones for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU for the treatment of post-operative inflammation following ocular surgery, totaling up to $21.25 million, <span style="Background-color:#FFFFFF;">were permanently extinguished and will no longer be due and owed to the Company. In exchange, Ocumension also received exclusive rights to develop and commercialize YUTIQ and DEXYCU products under its own brand names in South Korea and other jurisdictions across Southeast Asia in Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand and Vietnam, </span>at its own cost and expense with the Company supplying product for clinical trials and commercial sale. The Company continues to be entitled to royalties on future product sales by Ocumension. In April 2021, Ocumension announced its filing of a New Drug Application (&#8220;NDA&#8221;) for YUTIQ under Ocumension&#8217;s distinct name to Chinese regulatory authorities and it is under review. Ocumension has been granted approval to have its NDA submission reviewed based on the U.S. NDA data and the real world data Ocumension has collected from marketing the product in Hainan Pilot Zone. In September 2021, Ocumension announced its receipt of approval from Chinese regulatory authorities for DEXYCU under Ocumension&#8217;s distinct name to conduct a Phase 3 clinical trial in China.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than a fixed number of hours of technical assistance support to be provided at no cost by the Company, Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested. All technical assistance was provided during 2020. The Chief Executive Officer of Ocumension became a director of the Company starting December 31, 2020, pursuant to a Share Purchase Agreement pursuant to which the Company sold to Ocumension 3,010,722 shares of common stock, at which time, Ocumension became a related party of the Company.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, in addition to $308,000 and $213,000 of revenue from product sales, respectively, the Company recognized approximately $543,000 and $11.5 million of license and collaboration revenue, respectively, including $499,000 and $0 of revenue related to additional technical assistance, respectively. As of December 31, 2021 and 2020, no deferred revenue was recorded for this agreement, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> Company recognized </span> sales-based royalty expense of<span style="font-size:12pt;color:#000000;"> </span><span style="color:#000000;">$0</span> and $1.3 million during the year ended December 31, 2021 and 2020, related to the earn-out payment equal to 20% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, as the payment of the partnering income in connection with the Icon acquisition in March 2018. <span style="Background-color:#FFFFFF;"> </span> </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaborations</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third-party drug candidates. Consideration received is generally recognized as revenue over the term of the research collaborations. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations.  Revenues under research collaborations  totaled $60,000 and $</span><span style="color:#000000;">255,000 </span><span style="Background-color:#FFFFFF;"> </span>for the years ended December 31, 2021 and 2020, respectively. <span style="color:#000000;">At December 31, 2021 and 2020, $0 and $60,000 deferred revenue was recorded for the research collaborations, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ProductRevenueReservesAndAllowancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for product revenue reserves and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ProductRevenueReservesAndAllowancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018108664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Inventory </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,727</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,664</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">747</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,616</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018258120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Intangible Assets </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of intangible assets for the years ended December 31, 2021 and 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patented technologies</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross carrying amount at beginning of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross carrying amount at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization at beginning of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,460</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,460</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization at end of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net book value at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,209</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net book value of the Company&#8217;s intangible assets at December&#160;31, 2021 and 2020 is summarized as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful&#160;Life&#160;at</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patented technologies</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU / Verisome</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,209</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000517">9.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,209</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization expense totaled $2.5 million in each of the two years ended December 31, 2021 and 2020, respectively. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Icon Acquisition, the initial purchase price of $32.0&#160;million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected remaining useful life of 9.25 years at the rate of approximately $2.5&#160;million per year. Amortization expense was reported as a component of cost of sales for the years ended December 31, 2021 and 2020, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018265144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Property and Equipment, Net </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,732</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,658</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,256</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,028</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense totaled $311,000&#160;and $189,000 in the years ended December 31, 2021 and 2020, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018604936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Accrued Expenses </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">753</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales chargebacks, rebates and other revenue reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissions due to commercialization partner for DEXYCU</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,422</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018315880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Leases</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;17, 2018, <span style="Background-color:#FFFFFF;">the Company amended the lease for its headquarters in Watertown, Massachusetts. The original </span><span style="-sec-ix-hidden:F_000550">five-year</span><span style="Background-color:#FFFFFF;"> lease for approximately 13,650 square feet of combined office and laboratory space was set to expire in April 2019. Under the amendment, the Company leased an additional 6,590 square feet of rentable area of the building, with a commencement date of September&#160;10, 2018. The amendment extended the term of the lease for the combined space through May 31, 2025, and the landlord provided the Company a construction allowance of up to $670,750 to be applied toward renovations and improvements within the total space. On April 5, 2021, the Company further amended the lease to include an additional 1,409 square feet of rentable area of the building through May 31, 2025, with a commencement date of July 1, 2021. On March 8, 2022, the Company further amended the lease (i) to extend the term to May 31, 2028 for 13,650 square feet of laboratory and manufacturing operations space, with the landlord agreeing to provide the Company a construction allowance of up to $555,960 to be applied toward upgrades and improvements within the space; (ii) to rent an additional 11,999 square feet of office space within the building through May 31, 2028, with an anticipated commencement date in the third quarter of 2022; and (iii) to terminate a portion of the lease comprising 7,999 square feet of office space in the building on May 31, 2025. The Company previously provided a cash-collateralized $150,000 irrevocable standby letter of credit as security for the Company&#8217;s obligations under the lease, which will remain in effect through the period that is four months beyond the expiration date of the amended lease. The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises in excess of new base year amounts.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the Company leased approximately 3,000 square feet of office space in Basking Ridge, New Jersey under a lease term extending through June 2022, with two <span style="-sec-ix-hidden:F_000571">five-year</span> renewal options at 95% of the then-prevailing market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In June 2018, the Company subleased an additional 1,381 square feet of adjoining space from Caladrius Biosciences, Inc. (&#8220;Caladrius&#8221;) through May 2022. The Chief Executive Officer of Caladrius was a director of the Company through June 2020. Per the terms of the lease and sublease agreements, the Company does not have any residual value guarantees. The Company has given notice that the Company will not be renewing this lease and the Company will vacate the facility upon expiration.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified and assessed the following significant assumptions in recognizing its right-of-use (&#8220;ROU&#8221;) assets and corresponding lease liabilities:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized the borrowing rate under its existing 5-year term loan facility (see Note 9) as the discount rate.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">The expected lease terms include noncancelable lease periods. Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Variable lease payments, such as common area maintenance, real estate taxes and property insurance are not included in the determination of the lease&#8217;s ROU asset or lease liability.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the weighted average remaining term of the Company&#8217;s operating leases was 3.4&#160;years and the lease liabilities arising from obtaining ROU assets reflect a weighted average discount rate of 12.5%. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental<span style="color:#000000;"> balance sheet information related to operating leases as of December 31, 2021 and 2020, respectively are as follows (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities - operating lease current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities &#8211; noncurrent portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating<span style="color:#000000;"> lease expense recognized related to ROU assets was $885,000 and</span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="color:#000000;">$852,000, excluding $30,000 and $36,000 of variable lease costs, during each of the years ended December 31, 2021 and 2020, respectively, and were included in general and administrative expense in the Company&#8217;s statement of comprehensive loss. Cash paid for amounts included in the measurement of operating lease liabilities was $920,000 and $867,000 for the years ended December 31, 2021 and 2020, respectively. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="color:#000000;">Company</span> is a party to three finance leases for laboratory equipment. The equipment leases expire in December 2021, December 2022 and June 2023, respectively. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental<span style="color:#000000;"> balance sheet information related to the finance lease as of December 31, 2021 and 2020, respectively are as follows (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities <span style="font-family:Calibri;">&#8211;</span> finance lease current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of finance lease expense recognized during the years ended December 31, 2021 and 2020 related to ROU assets were&#160;$151,000 and $52,000, respectively. Interest on lease liabilities were $23,000 and $9,000&#160;during the years ended December 31, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of finance lease liabilities was operating cash flows of $23,000 and financing cash flows of $146,000 during the year ended December 31, 2021, respectively. Cash paid for amounts included in the measurement of finance lease liabilities was operating cash flows of $9,000 and financing cash flows of $49,000 during the year ended December 31, 2020, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the weighted average remaining term of the Company&#8217;s finance lease was 1.3 years and the lease liabilities arising from obtaining ROU assets reflect a weighted average discount rate of 12.5%.<span style="color:#000000;">&#160;&#160;</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T<span style="color:#000000;">he Company&#8217;s total future minimum lease payments under non-cancellable leases at December 31, 2021 were as follows (in thousands): </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">911</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,055</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,505</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018102760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Loan Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Loan Agreements </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Paycheck Protection Program Loan</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 8, 2020, the Company applied to Silicon Valley Bank (the &#8220;SVB&#8221;) for a Paycheck Protection Program Loan (the &#8220;PPP Loan&#8221;) of $2.0 million that is administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;), under the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;). On April 22, 2020, the PPP Loan was approved and the Company received the PPP Loan proceeds.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The PPP Loan bears interest at a fixed rate of 1.0% per annum and has a <span style="-sec-ix-hidden:F_000638">two-year</span> term that matures on April 21, 2022. Monthly principal and interest payments commenced on November 21, 2020, subject to possible partial or full forgiveness and principal and interest payments can be deferred as described below, if the PPP Loan proceeds are used for covered payroll costs, rent and utility costs and the maintenance of employee and compensation levels.</span> </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Paycheck Protection Program Flexibility Act of 2020 (the &#8220;PPP Flexibility Act&#8221;), enacted on June 5, 2020, amended the&#160;Paycheck Protection Program, among others, as follows: (i) extended the covered period from 8 weeks to the earlier of 24 weeks from the date the PPP Loan is originated and December 31, 2020, </span><span style="Background-color:#FFFFFF;color:#000000;">during which PPP funds needed to be expended in order to be forgiven</span><span style="Background-color:#FFFFFF;">.&#160;A borrower may submit a loan forgiveness application any time on or before the maturity date of the loan &#8211; including before the end of the covered period &#8211; if the borrower has used all of the loan proceeds for which the borrower is requesting forgiveness; (ii</span><span style="Background-color:#FFFFFF;color:#000000;">) at least 60% of PPP funds must be spent on payroll costs, with the remaining 40% available to spend on other eligible expenses;&#160;(iii)</span><span style="color:#000000;"> payments are deferred until the date on which the amount of forgiveness determined is remitted to the lender. If a borrower fails to seek forgiveness within 10 months after the last day of its covered period, then payments will begin on the date that is 10 months after the last day of the covered period.&#160;In addition, the PPP Flexibility Act modified the CARES Act by increasing the maturity date for loans made after the effective date from two years to a minimum maturity of five years from the date on which the borrower applies for loan forgiveness. Existing PPP loans made before the new legislation retain their original two-year term, but may be renegotiated between a lender and a borrower to match the 5-year term permitted under the PPP Flexibility Act</span>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company used all of the loan proceeds from the PPP Loan to pay expenses during the covered period that the Company believes were for eligible purposes. On September 25, 2020, the Company submitted an application to SVB for full loan forgiveness.<span style="Background-color:#FFFFFF;"> On June 19, 2021, the Company received notification from SVB that the PPP Loan of $2.0 million has been fully forgiven by the SBA, and that payment and all accrued interest of $24,000 thereon were remitted by the SBA to SVB on June 16, 2021. In connection with the full loan forgiveness, the Company recorded a gain on extinguishment of debt of approximately $2.1 million in the year ended December 30, 2021.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG Term Loan Agreement </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;13, 2019 (the &#8220;CRG Closing Date&#8221;), the Company entered into the CRG Loan Agreement among the Company, as borrower, <span style="Background-color:#FFFFFF;">CRG Servicing LLC, as administrative agent and collateral agent (the &#8220;Agent&#8221;),</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;">and the lenders party thereto from time to time (the &#8220;Lenders&#8221;), </span>providing for a senior secured term loan of up to $60&#160;million (the &#8220;CRG Loan&#8221;). <span style="color:#000000;">On the CRG Closing Date, $35 million of the CRG Loan was advanced (the &#8220;CRG Initial Advance&#8221;). The Company utilized the proceeds from the CRG Initial Advance for the repayment in full of all outstanding obligations under its prior credit agreement (the &#8220;SWK Credit Agreement&#8221;) with SWK. In April 2019, the Company exercised its option to borrow an additional $15 million of the CRG Loan (the &#8220;CRG Second Advance&#8221;). The Company did not draw any additional funds under the CRG Loan by the final draw deadline of March 31, 2020.</span> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CRG Loan is due and payable on December&#160;31, 2023 (the &#8220;Maturity Date&#8221;). The CRG Loan bears interest at a fixed rate of 12.5% per annum payable in arrears on the last business day of each calendar quarter. The Company is required to make quarterly, interest only payments until the Maturity Date. So long as no default has occurred and is continuing, the Company may elect on each applicable interest payment date to pay 2.5% of the 12.5% per annum interest as Paid In-Kind (&#8220;PIK&#8221;), whereby such PIK amount would be added to the aggregate principal amount and accrue interest at 12.5% per annum. Through December 31, 2021, PIK amounts of $<span style="color:#000000;">0</span> have been added to the principal balance of the CRG Loan. In addition, the Company is required to pay an upfront fee of 1.5% of amounts borrowed under the CRG Loan (excluding any paid-in-kind amounts), which is payable as amounts are advanced under the CRG Loan. The Company will also be required to pay an exit fee equal to 6% of (i) the aggregate principal amounts advanced and (ii) PIK amounts issued, under the CRG Loan Agreement. <span style="Background-color:#FFFFFF;">In connection with the CRG Initial Advance, a 1.5% financing fee of $525,000 and an expense reimbursement of $350,000 were deducted from the net borrowing proceeds. In connection with the CRG Second Advance, a 1.5% financing fee of $225,000 was deducted from the net borrowing proceeds.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of a bankruptcy-related event of default, all amounts outstanding with respect to the CRG Loan become due and payable immediately, and upon the occurrence of any other Event of Default (as defined in the CRG Loan Agreement), all or any amounts outstanding with respect to the CRG Loan may become due and payable upon request of the Agent or majority Lenders. Subject to certain exceptions, the Company is required to make mandatory prepayments of the CRG Loan with the proceeds of assets sales and in the event of a change of control of the Company. In addition, the Company may make a voluntary prepayment of the CRG Loan, in whole or in part, at any time. All mandatory and voluntary prepayments of the CRG Loan are subject to the payment of prepayment premiums as follows: (i)&#160;if prepayment occurs on or prior to December&#160;31, 2019, an amount equal to 10% of the aggregate outstanding principal amount of the CRG Loan being prepaid, (ii)&#160;if prepayment occurs after December&#160;31, 2019 and on or prior to December&#160;31, 2020, 5% of the aggregate outstanding principal amount of the CRG Loan being prepaid, which was waived on December 17, 2020 when the Company paid $15.0 million against the CRG Loan obligations in connection with the consummation of the RPA agreement (see Note 3), and (iii)&#160;if prepayment occurs after December&#160;31, 2020 and on or prior to December&#160;31, 2021, an amount equal to 3% of the aggregate outstanding principal amount of the Loan being prepaid. No prepayment premium is due on any principal prepaid after December&#160;31, 2021. Certain of the Company&#8217;s existing and future subsidiaries are guaranteeing the obligations of the Company under the CRG Loan Agreement. The obligations of the Company under the CRG Loan Agreement and the guarantee of such obligations are secured by a pledge of substantially all of the Company&#8217;s and the guarantors&#8217; assets.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CRG Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#8217; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the CRG Loan Agreement contains the following financial covenants requiring the Company and the Guarantors to maintain: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>liquidity in an amount which shall exceed the greater of (i) $5&#160;million and (ii)&#160;to the extent the Company has incurred certain permitted debt, the minimum cash balance, if any, required of the Company by the creditors of such permitted debt; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>annual minimum product revenue from YUTIQ and DEXYCU: (i) for the twelve-month period beginning <span style="color:#000000;">on January 1, 2019 and ending on December 31, 2019</span>, of at least $15&#160;million, (ii)&#160;for the twelve-month period beginning on <span style="color:#000000;">January 1, 2020 and ending on December 31, 2020</span>, of at least $45&#160;million, (iii)&#160;for the twelve-month period beginning on <span style="color:#000000;">January 1, 2021 and ending on December 31, 2021</span>, of at least $80&#160;million and (iv)&#160;for the twelve-month period beginning on <span style="color:#000000;">January 1, 2022 and ending on December 31, 2022</span>, of at least $90&#160;million.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, CRG waived the financial covenant associated with the Company&#8217;s revenue derived from sales of its products, DEXYCU and YUTIQ, for the twelve-month period ending December 31, 2019. In October 2020, CRG (i) waived the financial covenant associated with the Company&#8217;s revenue derived from sales of its products, DEXYCU and YUTIQ, for the twelve-month period ending December 31, 2020 and (ii) amended the financial covenant associated with the Company&#8217;s minimum product revenue to $<span style="Background-color:#FFFFFF;color:#000000;">45</span> million from $80 million, for the twelve-month period ending December 31, 2021. In May 2021, CRG further amended the financial covenant associated with the Company&#8217;s minimum product revenue to $25 million from $45 million, for the </p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">twelve-month period ending December 31, 2021. </span><span style="Background-color:#FFFFFF;color:#000000;">There were no other material changes to the Loan Agreement and the Company incurred </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="Background-color:#FFFFFF;color:#000000;"> incremental charges for the issuance of the waivers.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"> </span>The total debt discount related to the CRG Initial Advance was approximately $3.2 million and consisted of (i) the accrual of a $2.1 million exit fee; (ii) the $525,000 upfront fee; and (iii) $591,000 of legal and other transaction costs. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest rate method. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total debt discount related to the CRG Second Advance was approximately $1.1 million and consisted of (i) the accrual of a $900,000 exit fee; and (ii) the $225,000 upfront fee. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest rate method. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2020, the Company paid $15.0 million against the CRG Loan obligations in connection with the consummation of the RPA agreement (see Note 3). This payment included (i) a $13.8 million principal portion of the CRG Loan (ii) the $828,000 Exit Fee, and (iii) accrued and unpaid interest of $378,000 through that date. <span style="Background-color:#FFFFFF;color:#000000;">In connection with the partial prepayment of the CRG Loan, the Company recorded a loss on partial extinguishment of debt of $905,000 in the year ended December 31, 2020, associated with the write-off of the remaining balance of unamortized debt discount related to the partial prepayment of the CRG Loan.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization<span style="color:#000000;"> of debt discount under the CRG Loan totaled $628,000 and $745,000 for the years ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018262904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.<span style="margin-left:36pt;">Stockholders&#8217; Equity</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Financings</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Offerings</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Company sold 5,122,273 shares of its common stock in an underwritten public offering at a price of $13.75 per share, including the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of the Company&#8217;s common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price of $13.74 per pre-funded warrant. The gross proceeds of the offering to the Company were approximately $115.4 million. Underwriter discounts and commissions and other share issue costs totaled approximately $7.2 million. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pre-funded warrants were classified as a component of permanent equity because they met the permanent equity criteria classification. The pre-funded warrants are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable and permit the holders to receive a fixed number of shares of common stock upon exercise. The pre-funded warrants do not embody an obligation for the Company to repurchase its shares and do not provide any guarantee of value or return.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company sold 10,465,000 shares of its common stock in an underwritten public offering at a price of $11.00 per share, including the exercise in full by the underwriters of their option to purchase up to 1,365,000 additional shares of the Company&#8217;s common stock. The gross proceeds of the offering to the Company were approximately $115.1 million. Underwriter discounts and commissions and other share issue costs totaled approximately $7.2 million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 31, 2020, the Company entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Ocumension, pursuant to which the Company sold to Ocumension 3,010,722 shares of Common Stock, at a purchase price of approximately $5.22 per share, which was the five-day volume weighted average price of the Common Stock as of the close of trading on December 29, 2020. The aggregate gross proceeds from the Transaction were approximately $15.7 million. Share issue costs totaled approximately $0.1 million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company sold 1,500,000 shares of the Company&#8217;s common stock in an underwritten public offering at a price of $14.50 per share for gross proceeds of $21.75 million. Underwriter discounts and commissions and other share issue costs totaled approximately $1.8 million.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Annual Meeting of Stockholders held on June 23, 2020, the Company&#8217;s stockholders approved the adoption of an amendment to the Company&#8217;s Certificate of Incorporation, to increase the number of authorized shares of its common stock from 150,000,000 shares to 300,000,000 shares. The Company filed the Certificate of Amendment on June 23, 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATM Facility</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In August 2020, the Company entered into an at-the-market facility (the &#8220;ATM Facility&#8221;) with Cantor Fitzgerald&#160;&amp; Co (&#8220;Cantor&#8221;). Pursuant to the ATM Facility, the Company may, at its option, offer and sell shares of its Common Stock from time to time, through or to Cantor Fitzgerald, acting as sales agent. The Company will pay Cantor a commission of 3.0% of the gross proceeds from any future sales of such shares.</span> </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company sold 2,590,093 shares of its Common Stock at a weighted average price of $5.74 per share for gross proceeds of approximately $14.9 million. Share issue costs, including sales agent commissions, totaled $646,000 during the reporting period.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, the Company sold 48,538 shares of its Common Stock at a weighted average price of $11.37 per share for gross proceeds of approximately $552,000. Share issue costs, including sales agent commissions, totaled approximately $53,000 during the reporting period.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants<span style="color:#000000;"> to Purchase Common Shares</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of fixed price warrants to purchase shares of the Company&#8217;s Common Stock for the years ended December 31, 2021 and 2020:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance and exercisable at end of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a credit agreement, the Company issued a warrant to SWK Funding LLC to purchase (i) 40,910 Initial Advance Warrant Shares on March 28, 2018 at an exercise price of $11.00 per share with a <span style="-sec-ix-hidden:F_000736">seven-year</span> term and (ii) 7,773 Additional Advance Warrant Shares on June 26, 2018 at an exercise price of $19.30 per share with a <span style="-sec-ix-hidden:F_000737">seven-year</span> term. At December 31, 2021, the weighted average remaining life of the warrants was approximately 3.3 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018287240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Awards</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Share-Based Payment Awards </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Incentive Plans </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2016 Long-Term Incentive Plan (the &#8220;2016 Plan&#8221;), approved by the Company&#8217;s stockholders on December 12, 2016 (the &#8220;Adoption Date&#8221;), provides for the issuance of up to 300,000 shares of the Company&#8217;s Common Stock reserved for issuance under the 2016 Plan plus any additional shares of the Company&#8217;s Common Stock that were available for grant under the 2008 Incentive Plan (the &#8220;2008 Plan&#8221;) at the Adoption Date or would otherwise become available for grant under the 2008 Plan as a result of subsequent termination or forfeiture of awards under the 2008 Plan. At the Company&#8217;s Annual Meeting of Stockholders held on June 25, 2019, the Company&#8217;s stockholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by 1,100,000 shares. At the Company&#8217;s Annual Meeting of Stockholders held on June 22, 2021, the Company&#8217;s stockholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by 2,500,000 shares. At December 31, 2021, a total of 1,683,368&#160;shares were available for new awards. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain inducement awards, although not awarded under the 2016 Plan or the 2008 Plan, are subject to and governed by the terms and conditions of the 2016 Plan or 2008 Plan, as applicable.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of stock option activity under the Company&#8217;s equity incentive plans and for inducement awards for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.86</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,313,727</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.59</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,112</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,448</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,517,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000757">8.06</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916,461</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000758">6.25</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company expanded the terms of its annual stock option grants to include vesting ratable monthly over four years, or with 25% vesting after one year followed by ratable monthly vesting over three years. Previously, the Company&#8217;s option grants generally had ratable annual vesting over three years, or 1-year cliff vesting. Nonemployee awards are granted similar to the Company&#8217;s employee awards. All option grants have a 10-year term. Options to purchase a total of 297,361 shares of the Company&#8217;s Common Stock vested during the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the grant date fair value of option awards during the years ended December 31, 2021 and 2020, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option life (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000768">4.75 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000769">5.50 - 6.10</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000772">72% - 83%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000773">64% - 70%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000776">0.42% - 1.44%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000777">0.32% - 1.76%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividends</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about employee, consultant and director stock options under the Company&#8217;s equity incentive plans for the years ended December 31, 2021 and 2020 (in thousands except per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.07</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash received from exercise of stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intrinsic value of stock options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Time-Vested Restricted Stock Units </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time-vested restricted stock units (&#8220;RSUs&#8221;) issued to date under the 2016 Plan generally vest on a ratable annual basis over 3 years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period. The fair value of all time-vested RSUs is based on the closing share price of the Common Stock on the date of grant. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of RSU activity under the 2016 Plan for the year ended December&#160;31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at January 1, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,004</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.96</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,795</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining vesting term of the RSUs at December&#160;31, 2021 was 1.37 years. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Stock Units </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no non-vested deferred stock units (&#8220;DSUs&#8221;) issued and outstanding to the Company&#8217;s non-executive directors at each of December 31, 2021 and 2020, respectively. Each DSU vests one year from the date of grant. Subsequent to vesting, the DSUs will be settled in shares of the Company&#8217;s Common Stock upon the earliest to occur of (i) each director&#8217;s termination of service on the Company&#8217;s Board of Directors and (ii) the occurrence of a change of control as defined in the award agreement. At December 31, 2021, there was no vested DSUs that have not been settled in shares of the Company&#8217;s Common Stock.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 25, 2019, the Company&#8217;s stockholders approved the adoption of the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and authorized up to 110,000 shares of Common Stock reserved for issuance to participating employees. At the Company&#8217;s Annual Meeting of Stockholders held on June 22, 2021, the Company&#8217;s stockholders approved an amendment to the ESPP to increase the number of shares authorized for issuance by 250,000 shares. The ESPP allows qualified participants to purchase the Company&#8217;s Common Stock twice a year at 85% of the lesser of the average of the high and low sales price of the Company&#8217;s Common Stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. <span style="Background-color:#FFFFFF;">The number of shares of the Company&#8217;s Common Stock each employee may purchase under this plan, when combined with all other employee stock purchase plans, is limited to the lower of an aggregate fair market value of $25,000 during each calendar year, or 5,000 shares of the Company&#8217;s Common Stock in any one offering period. The Company has maintained consecutive six-month offering periods since August 1, 2019. </span>As of December 31, 2021, 43,365 shares of the Company&#8217;s Common Stock were issued pursuant to the ESPP.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company estimated the fair value of the option component of the ESPP shares at the date of grant using a Black-Scholes valuation model. During the year ended December 31, 2021, the compensation expense from ESPP shares was $113,000. During the year ended December 31, 2020, the compensation expense from ESPP shares was immaterial.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s statements of comprehensive loss included total compensation expense from stock-based payment awards as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense included in:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,294</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,411</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">907</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,966</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,229</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,447</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,547</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, there was approximately $9.3&#160;million of unrecognized compensation expense related to outstanding equity awards under the 2016 Plan, the 2008 Plan, The inducement awards and the ESPP that is expected to be recognized as expense over a weighted-average period of approximately 1.7 years. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018310728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Asset Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Asset Purchase Agreements</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.<span style="margin-left:22pt;"/>License and Asset Purchase Agreements</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aerpio Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the Company entered into an Asset Purchase Agreement with Aerpio Pharmaceuticals, Inc. (&#8220;Aerpio&#8221;), pursuant to which Aerpio sold to the Company all of its right, title and interest in and to certain of its patents and patent applications and other intellectual property, including but not limited to patents covering certain human protein tyrosine phosphate inhibitors and methods of use.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights purchased from Aerpio, the Company made a one time, non-refundable, non-creditable upfront cash payment of $450,000 to Aerpio in August 2021. The Company recorded $450,000 of R&amp;D expense for the year ended December 31, 2021, due to the early stage of its preclinical drug development activities.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equinox Science, LLC </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company entered into an Exclusive License Agreement with Equinox Science, LLC<span style="Background-color:#FFFFFF;"> (&#8220;Equinox&#8221;), pursuant to which Equinox granted us an exclusive, sublicensable, royalty-bearing right and license to certain patents and other Equinox intellectual property to research, develop, make, have made, use, sell, offer for sale and import the compound vorolanib and any pharmaceutical products comprising the compound for the prevention or treatment of age-related macular degeneration, diabetic retinopathy and retinal vein occlusion using our proprietary localized delivery technologies, in each case, throughout the world except China, Hong Kong, Taiwan and Macau (the &#8220;Territory&#8221;).</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In </span>consideration<span style="Background-color:#FFFFFF;"> for the rights granted by Equinox, the Company (i) made a one time, non-refundable, non-creditable upfront cash payment of $1.0 million to Equinox in February 2020, and (ii) agreed to pay milestone payments totaling up to $50 million upon the achievement of certain development and regulatory milestones, consisting of (a) completion of a Phase II clinical trial for the compound or a licensed product, (b) the filing of a new drug application or foreign equivalent for the compound or a licensed product in the United States, European Union or United Kingdom and (c) regulatory approval of the compound or a licensed product in the United States, European Union or United Kingdom.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company also agreed to pay Equinox tiered royalties based upon annual net sales of licensed products in the Territory. The royalties are payable with respect to a licensed product in a particular country in the Territory on a country-by-country and licensed product-by-licensed product basis until the later of (i) twelve years after the first commercial sale of such licensed product in such country and (ii) the first day of the month following the month in which a generic product corresponding to such licensed product is launched in such country (collectively, the &#8220;Royalty Term&#8221;). </span>The royalty rates range from the high-single digits to low-double digits depending on the level of annual net sales. The royalty rates are subject to reduction during certain periods when there is no valid patent claim that covers a licensed product in a particular country. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company recorded $0 and $1.0 million of R&amp;D expense during the years ended December 31, 2021 and 2020 for this license.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018593592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.<span style="margin-left:22pt;"/>Fair Value Measurements </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s assets carried at fair value measured on a recurring basis at December 31, 2021 and 2020, respectively, by valuation hierarchy (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 1:</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 2:</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,549</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,965</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,549</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,965</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,065</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,065</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,965</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 1:</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, a total of $155.6 million, or&#160;&#160;90.4% of the Company&#8217;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $16.5 million, or 9.6% of the Company&#8217;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $33.0 million in marketable securities at December 31, 2021.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#8217; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, substantially all of the Company&#8217;s interest-bearing cash equivalent balances were concentrated in one U.S. Government money market fund that has investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. The Company had no investments in marketable securities at December 31, 2020.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The </span><span style="color:#000000;">carrying</span><span style="Background-color:#FFFFFF;"> amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the Company&#8217;s CRG Loan is determined using a discounted cash flow analysis based on market rates for observable similar instruments as of the condensed consolidated balance sheet dates. Accordingly, the fair value of the CRG Loan is categorized as Level 2 within the fair value hierarchy. At December 31, 2021, the fair value of the CRG Loan was approximately $38.7 million, and the carrying value of the CRG Loan was approximately $</span><span style="color:#000000;">38.9</span><span style="Background-color:#FFFFFF;"> million, and consisted of $</span><span style="color:#000000;">36.6</span><span style="Background-color:#FFFFFF;"> million of its carrying amount as reported in long-term debt, and $2.3 million of debt exit fee as reported in other long-term liabilities of the consolidated balance sheet, respectively. At December 31, 2020, the fair value of the CRG Loan was approximately $38.0 million, and the carrying value of the CRG Loan was approximately $38.3</span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;">million, and consisted of $36.0</span><span style="font-size:12pt;color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;">million of its carrying amount as reported in long-term debt, and $2.3 million of debt exit fee as reported in other long-term liabilities of the condensed consolidated balance sheet, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018113608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plans</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retirement Plans </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a defined contribution plan intended to qualify under Section&#160;401(k) of the U.S. Internal Revenue Code. Participating U.S. employees may contribute a portion of their pre-tax compensation, as defined, subject to statutory maximums. The Company matches employee contributions up to 5% of eligible compensation, subject to a stated calendar year Internal Revenue Service maximum. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operated a defined contribution pension plan for U.K. employees pursuant to which the Company made contributions on behalf of employees plus a matching percentage of elective employee contributions. This pension plan was terminated in the quarter ending September&#160;30, 2016 following termination of employment of all U.K. employees. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company contributed a total of $1.0 million and $690,000 for the years ended December 31, 2021 and 2020, respectively, in connection with these retirement plans. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018266264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. operations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,517</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. operations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O<span style="color:#000000;">n December&#160;22, 2017, the </span><span style="font-style:italic;color:#000000;">Tax Cuts and Jobs Act </span><span style="color:#000000;">(the &#8220;Tax Act&#8221;) was signed into law, making significant changes to the federal tax law. Amongst other things, the Tax Act reduces the federal corporate tax rate from 34% to 21% effective for tax years beginning after December&#160;31, 2017 and has resulted in a remeasurement of the Company&#8217;s deferred tax assets included in the Company&#8217;s fiscal 2018 rate reconciliation.</span> The difference between the Company&#8217;s expected income tax benefit, as computed by applying the blended statutory U.S. federal tax rate of 21% for the year ended December 31, 2021 and 21% for the year ended December 31, 2020, to loss before income taxes, and actual income tax benefit is reconciled in the following table (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,268</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,533</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,890</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. income tax rate differential</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in federal tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(693</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(403</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,748</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,068</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(652</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<span style="font-size:10pt;">The significant components of deferred income taxes are as follows (in thousands): </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,026</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">722</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,503</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,005</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,291</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,696</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,963</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,087</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,578</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,896</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,896</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation allowance generally reflects limitations on the Company&#8217;s ability to use the tax attributes and reduces the value of such attributes to the more-likely-than-not realizable amount. Management assessed the available positive and negative evidence to estimate if sufficient taxable income will be generated to use the existing net deferred tax assets. Based on a weighting of the objectively verifiable negative evidence in the form of cumulative operating losses over the three-year period ended June&#160;30, 2018, management believes that it is not more likely than not that the deferred tax assets will be realized and, accordingly, a full valuation allowance has been established. The valuation allowance increased $15.7 million and $13.1 million for the years ended December 31, 2021 and 2020, respectively, with such increases attributed to the re-measurement of the net deferred tax assets at the year-end dates. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has tax net operating loss and tax credit carry forwards in its individual tax jurisdictions. Including approximately $49.3&#160;million related to the Icon acquisition, at December&#160;31, 2021, the Company had U.S. federal net operating loss carry forwards of approximately $301.2&#160;million. The net operating losses consist of $151.8 million, which expire at various dates between calendar years 2023 and 2038. The utilization of certain of these loss and tax credit carry forwards may be limited by Sections 382 and 383 of the Internal Revenue Code as a result of historical or future changes in the Company&#8217;s ownership. At December&#160;31, 2021, the Company had state net operating loss carry forwards of approximately $222.6&#160;million, which expire between 2033 and 2038, as well as U.S. federal and state research and development tax credit carry forwards of approximately $5.7&#160;million, which expire at various dates between calendar years 2021 and 2038. In addition, at December&#160;31, 2021 the Company had net operating loss carry forwards in the U.K. of &#163;20.9&#160;million (approximately $27.6 million), which are not subject to any expiration dates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s U.S. federal income tax returns for calendar years 2003 through 2020 remain subject to examination by the Internal Revenue Service. The Company&#8217;s U.K. tax returns for fiscal years 2006 through 2020 remain subject to examination. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through December&#160;31, 2021, the Company had no unrecognized tax benefits in its consolidated statements of comprehensive loss and no unrecognized tax benefits in its consolidated balance sheets as of December&#160;31, 2021 and 2020, respectively. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company had no accrued penalties or interest related to uncertain tax positions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018297848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to various other routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company&#8217;s financial position, results of operations or cash flows. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Securities and Exchange Commission Subpoena </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> Company previously disclosed that on May 14, 2020 it had received a subpoena from the Division of Enforcement of the SEC seeking production of certain documents and information on topics including product sales and demand, revenue recognition and accounting in relation to product sales, product sales and cash projections, and related financial reporting, disclosure and compliance matters. On May 4, 2021, the Company was advised by the SEC Division of Enforcement that it has concluded its investigation of the Company and that, based on the information it has to date, the Enforcement Division does not intend to recommend an enforcement action against the Company. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018153320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Area Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Area Information</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment and Geographic Area Information </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Segment </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, which is the business of developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating decision maker made such decisions and assessed performance at the company level, as one segment. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geographic Area Information </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s revenues and long-lived assets, net by geographic area (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve&#160;Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve&#160;Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At&#160;December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At&#160;December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,988</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.K.</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,939</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018102760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Events<span style="color:#000000;font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 9, 2022, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (the &#8220;SVB Loan Agreement&#8221;). The SVB Loan Agreement provides (i) a senior secured term loan facility of $30 million (the &#8220;Term Loan&#8221;) and (ii) a senior secured revolving credit facility of up to $15.0 million in available credit (the &#8220;Revolving Facility&#8221; and together with the Term Loan, &#8220;the SVB Loan&#8221;). The maximum amount available for borrowing at any time under the Revolving Facility is limited to a borrowing base valuation, or 80% of the Company&#8217;s eligible accounts receivable. An unused commitment fee of 0.25% per annum applies to unutilized borrowing capacity under the Revolving Facility. The SVB Loan Agreement replaced its existing CRG Loan (see Note 9). Pursuant to the SVB Loan Agreement, the Company (i) made an initial draw of $30 million with respect to the Term Loan and of approximately $11.5 million with respect to the Revolving Facility, to pay off the CRG Loan, including the accrued interests through this date. Certain prepayment premiums apply to any repayments made (i) with respect to the Term Loan prior to the maturity date on January 1, 2027, and (ii) with respect to the Revolving Facility prior to the maturity date on January 1, 2027.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SVB Loan Agreement bears interest at (i) the greater of (x) Wall Street Journal Prime Rate plus 2.25% and (y) 5.50%, with respect to the Term Loan; (ii) the Wall Street Journal Prime Rate, with respect to the Revolving Facility; per annum payable in arrears on the last business day of each calendar month. Commencing on February 1, 2024, the Company is required to repay the principal amount of the Term Loan in 36 consecutive equal monthly installments plus monthly payments of accrued interest. Amounts borrowed under the Revolving Facility may be prepaid or repaid and, prior to the Revolving Facility Maturity Date, reborrowed, subject to the applicable terms and conditions set forth in the SVB Loan Agreement. The SVB Loan is due at maturity on January 1, 2027 (the &#8220;Maturity Date&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the same date, the Company paid $41.4 million. This payment included (i) a $38.2 million principal portion of the CRG Loan (ii) an $2.3 million exit fee of 6% of the aggregate principal amount advanced under the CRG Loan (iii) accrued and unpaid interest of $0.9 million through that date. As a result of the early repayment of the CRG Loan, the Company expects to record a loss on extinguishment of debt of approximately $1.5 million for the quarter ending March 31, 2022 in association with the write-off of the remaining balance of unamortized debt discount.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014300440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements are presented in U.S. dollars in accordance with generally accepted accounting principles in the U.S. (&#8220;U.S. GAAP&#8221;) and include the accounts of EyePoint Pharmaceuticals, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to reserves for variable consideration related to product sales, revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recording of excess or obsolete inventory write-offs and reserves, and realization of deferred tax assets. Actual results could differ from these and other estimates and there may be changes to the Company&#8217;s estimates in future periods. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company and each of its subsidiaries is the currency of the primary economic environment in which each such entity operates&#8212;the U.S. dollar or the Pound&#160;Sterling. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities of the Company&#8217;s foreign subsidiary are translated at period-end exchange rates. Amounts included in the consolidated statements of comprehensive loss and cash flows are translated at the weighted average exchange rates for the period. Gains and losses from currency translation are included in accumulated other comprehensive income as a separate component of stockholders&#8217; equity in the consolidated balance sheets. The balance of accumulated other comprehensive income attributable to foreign currency translation was $841,000 and $841,000 at December&#160;31, 2021 and 2020, respectively. Foreign currency gains or </p>
<p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">losses arising from transactions denominated in foreign currencies, whether realized or unrealized, are recorded in interest and other income, net in the consolidated statements of comprehensive loss and were not </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents represent highly liquid investments with maturities of three months or less at the date of purchase, principally consisting of institutional money market funds and investment-grade commercial paper. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with an original or remaining maturity of greater than three months but less than six months at the date of purchase. The Company has historically classified its marketable securities as available-for-sale. Accordingly, the Company records these investments at fair value, with unrealized gains and losses excluded from earnings and reported, net of tax, in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. If the Company determines that a decline of any investment is other-than-temporary, the investment is written down to fair value. Marketable securities at December 31, 2021 consisted of investment-grade commercial paper. The Company had no marketable security investments at December 31, 2020. The Company&#8217;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. During fiscal 2021, $33.0 million of marketable securities were purchased and $0 matured.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of marketable securities is determined based on quoted market prices at the balance sheet date of the same or similar instruments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts through to the earlier of sale or maturity. Such amortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the specific identification method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and investments in marketable securities. At December&#160;31, 2021, a total of $155.6&#160;million, or 90.4% of the Company&#8217;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $16.5 million, or 9.6% of the Company&#8217;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $33.0 million and $0 in marketable securities at December&#160;31, 2021 and 2020, respectively. The Company&#8217;s investment policy, approved by the Company&#8217;s Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, accounts receivable from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 54.7% and 38.3% of total accounts receivable, respectively. For the year ended December 31, 2021, revenues from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 46.6% and 43.1% of total revenues, respectively.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, accounts receivable from ASD Specialty Healthcare LLC and McKesson Specialty Care Distribution LLC accounted for 56.0% and 37.0% of total accounts receivable, respectively. For the year ended December 31, 2020, revenues from ASD Specialty Healthcare LLC, Ocumension Therapeutics, and McKesson Specialty Care Distribution LLC accounted for 39.0%, 33.0%, and 18.0% of total revenues, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;1 &#8211; Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;2 &#8211; Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets). </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;3 &#8211; Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities. </span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#8217; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts and Other Receivables, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts and Other Receivables, Net</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables arise primarily from the Company&#8217;s products sold in the U.S. The balance in accounts and other receivables, net consists primarily of amounts due from customers, net of applicable revenue reserves. The majority of the Company&#8217;s accounts receivable have standard payment terms that require payment within 120-127 days. The Company <span style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.2pt;">performs ongoing credit evaluations of its customers&#8217; financial condition and continuously monitor collections and payments from its customers and</span> analyzes accounts that are past due for collectability. <span style="color:#000000;">The allowance for credit losses is estimated based on the Company&#8217;s analysis of trends in overall receivables aging, specific identification of certain receivables that are at risk of not being paid, past collection experience and current economic trends. </span>G<span style="Background-color:#FFFFFF;color:#000000;">iven the nature and limited history of collectability of the Company&#8217;s accounts receivable, </span>the Company recorded no allowance for credit losses as of December 31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inventory </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or net realizable value, net on a first-in, first-out (&#8220;FIFO&#8221;) basis. The inventory costs for YUTIQ include purchases of various components and the active pharmaceutical ingredient (&#8220;API&#8221;) and internal labor and overhead for the product manufactured in the Company&#8217;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalization of inventory costs begins after FDA approval of the product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assesses the recoverability of inventory and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Write-downs are based on the age of the inventory, lower of cost or market, along with significant management judgments concerning future demands for the inventory. Such impairment charges, should they occur, are recorded within cost of sales, excluding amortization of acquired intangible assets. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory might be recorded in future periods.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost <span style="Background-color:#FFFFFF;">of</span> sales, excluding amortization of acquired intangible assets, consist of costs associated with the manufacture of YUTIQ and DEXYCU, certain period costs for DEXYCU product revenue, product shipping and, as applicable, royalty expense. The inventory costs for YUTIQ include purchases of various components, the active pharmaceutical ingredient (&#8220;API&#8221;) and direct labor and overhead for the product manufactured in the Company&#8217;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly. Capitalization of inventory costs begins after FDA approval of a product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span> Company accrued DEXYCU product revenue-based royalty expense of $2.5 million and $<span style="color:#000000;">2.3</span> million for the years ended December 31, 2021 and 2020, respectively, as a component of cost of sales, of which $0 and $<span style="color:#000000;">1.3</span> million of accrued revenue-based royalty expense were related to the partnering income equal to 20% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, in connection with the acquisition of Icon Bioscience, Inc. in March 2018 for the years ended December 31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DebtAndEquityInstrumentsPolicyTextBlock', window );">Debt and Equity Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Debt and Equity Instruments </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Debt</span><span style="color:#000000;"> and equity instruments are classified as either liabilities or equity in accordance with the substance of the contractual arrangement. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative Instruments </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Derivative</span><span style="color:#000000;"> financial liabilities are recorded at fair value, with gains and losses arising from changes in fair value recognized in change in fair value of derivative liability within the consolidated statements of comprehensive loss at each period end while such instruments are outstanding. The Company&#8217;s derivative liabilities from certain financing transactions were primarily valued using Monte Carlo simulation models. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated over their estimated useful lives (generally three to five years) using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining non-cancellable lease term or their estimated useful lives. Repair and maintenance costs are expensed as incurred. When assets are retired or sold, the assets and accumulated depreciation are derecognized from the respective accounts and any gain or loss is recognized. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software Development Cost</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Software Development Cost</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC 350 <span style="font-style:italic;">Intangibles &#8211; Goodwill and Other</span>, and classified as a prepaid asset in the balance sheets. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud completing arrangement, over the term of the arrangement, plus reasonably certain renewals.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases real estate and office equipment under operating leases. Its primary real estate lease contains rent holiday and rent escalation clauses. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether the arrangement is or contains a lease at inception. Operating leases are recognized on the consolidated balance sheets as ROU assets, current portion of lease liabilities and long-term lease liabilities. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. <span style="color:#000000;">For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. </span>The operating lease ROU assets also include any lease payments made and adjustments for prepayments and lease incentives. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilized its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Intangible Assets</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Intangible Assets </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s finite life intangible assets include the DEXYCU product (utilizing the Verisome technology) following the March 2018 acquisition of Icon. The DEXYCU intangible asset is being amortized on a straight-line basis over its estimated useful life of thirteen years. The intangible asset lives were determined based upon the anticipated period that the Company would derive future cash flows from the intangible assets, considering the effects of legal, regulatory, contractual, competitive and other economic factors. The Company continually monitors whether events or circumstances have occurred that indicate that the remaining estimated useful life of its intangible assets may warrant revision. The Company assesses potential impairments to its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the future undiscounted net cash flows expected to result from the use of an asset are less than its carrying value. If the Company considers an asset to be impaired, the impairment charge to be recognized is measured as the amount by which the carrying value of the asset exceeds its estimated fair value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Revenue</span><span style="color:#000000;"> is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product sales, net<span style="font-weight:normal;font-style:normal;"> &#8212; The Company sells YUTIQ and DEXYCU to a limited number of specialty distributors and specialty pharmacies (collectively the &#8220;Distributors&#8221;) in the U.S., with whom the Company has entered into formal agreements, for delivery to physician practices for YUTIQ and to hospital outpatient departments and ambulatory surgical centers for DEXYCU. The Company recognizes revenue on sales of its products when Distributors obtain control of the products, which occurs at a point in time, typically upon delivery. In addition to agreements with Distributors, the Company also enters into arrangements with healthcare providers, ambulatory surgical centers, and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#8217;s products from Distributors. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reserves for variable consideration <span style="color:#000000;font-style:normal;">&#8212; </span><span style="font-style:normal;">Product sales are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, provider chargebacks and discounts, payor rebates, product returns, and other allowances that are offered within contracts between the Company and its Distributors, payors, and other contracted purchasers relating to the Company&#8217;s product sales. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified either as reductions of product revenue and accounts receivable or a current liability, depending on how the amount is to be settled. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.</span><span style="color:#FF0000;font-style:normal;"> </span><span style="font-style:normal;">Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Distribution fees <span style="font-style:normal;">&#8212; </span><span style="font-style:normal;color:#000000;">The Company compensates its Distributors for services explicitly stated in the Company&#8217;s contracts and are recorded as a reduction of revenue in the period the related product sale is recognized. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Provider chargebacks and discounts <span style="font-style:normal;">&#8212; </span><span style="font-style:normal;color:#000000;">Chargebacks are discounts that represent the estimated obligations resulting from contractual commitments to sell products at prices lower than the list prices charged to the Company&#8217;s Distributors. These Distributors charge the Company for the difference between what they pay for the product and the Company&#8217;s contracted selling price. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of </span><span style="font-style:normal;">product revenue and the establishment of a current liability</span><span style="font-style:normal;color:#000000;">. Reserves for chargebacks consist of amounts that the Company expects to pay for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold under a contracted selling price, and chargebacks that Distributors have claimed, but for which the Company has not yet settled.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Government rebates <span style="font-style:normal;">&#8212; The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payor rebates <span style="font-style:normal;">&#8212; The Company contracts with certain private payor organizations, primarily insurance companies, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Co-Payment assistance <span style="font-style:normal;">&#8212; The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Product returns </span><span style="font-style:normal;">&#8212; The Company generally offers a limited right of return based on its returned goods policy, which includes damaged product and remaining shelf life. The Company estimates the amount of its product sales that may be returned and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to trade receivables, net on the </span><span style="font-style:normal;">condensed</span><span style="font-style:normal;"> consolidated balance sheets. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and collaboration agreement revenue<span style="font-weight:normal;font-style:normal;"> &#8212; The Company analyzes each element of its license and collaboration arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#8217;s contracts contained a significant financing component as of December&#160;31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalties <span style="font-weight:normal;font-style:normal;">&#8212; The Company recognizes revenue from license arrangements with its commercial partners&#8217; net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner&#8217;s products occurs. The Company&#8217;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60&#160;days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company recognizes royalty income each quarter and subsequently determines a true-up when it receives royalty reports and payment from its commercial partners. Historically, these true-up adjustments have been immaterial. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sale of Future Royalties <span style="font-weight:normal;font-style:normal;">&#8212; The Company has sold its rights to receive certain royalties on product sales. In the circumstance where the Company has sold its rights to future royalties under a royalty purchase agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research Collaborations<span style="font-weight:normal;font-style:normal;"> &#8212; The Company recognizes revenue over the term of the statements of work under any funded research collaborations (including feasibility study agreements). Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations (including feasibility study agreements). </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please refer to Note 3 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Revenue </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized within one year following the balance sheet date are classified as non-current deferred revenue. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are charged to operations as incurred. These costs include all direct costs, including cash and stock-based compensation and benefits for research, clinical development, quality assurance, quality control, operations and medical affairs personnel, amortization of intangible assets, third-party costs and services for clinical trials, clinical materials, pre-clinical programs, regulatory and medical affairs, external consultants, and other operational costs related to the Company&#8217;s research and development of its product candidates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation cost related to share-based payment awards is based on the fair value of the instrument on the grant date and is recognized on a graded vesting basis over the requisite service period for each separately vesting tranche of the awards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may also grant share-based payment awards that are subject to objectively measurable performance and service criteria. Compensation expense for performance-based awards begins at such time as it becomes probable that the respective performance conditions will be achieved. The Company continues to recognize the grant date fair value of performance-based awards through the vesting date of the respective awards so long as it remains probable that the related performance conditions will be satisfied. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model and the fair value of performance stock units, restricted stock units and deferred stock units based on the observed grant date fair value of the underlying Common Stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the weighted-average number of common shares outstanding the average number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, 3,272,727 shares of Pre-Funded Warrants to purchase common stock, issued in connection with the November 2021 underwritten public offering (see Note 10), were included in the basic and diluted net loss per share calculation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,517,680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,965</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,881,903</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is comprised of net loss, foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable securities. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Tax </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future benefit to be derived from tax credits and loss carry forwards. Such deferred income tax computations are measured based on enacted tax laws and rates applicable to the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is provided against net deferred tax assets if, based on the available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the uncertainty. The Company accounts for interest and penalties related to uncertain tax positions as part of its income tax benefit. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company&#8217;s financial position, results of operations and cash flows or do not apply to the Company&#8217;s operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740)</span><span style="color:#000000;"> (&#8220;ASU 2019-12&#8221;)</span><span style="font-style:italic;">: Simplifying the Accounting for Income Taxes.</span>&#160;The amendments simplify the accounting for income taxes by removing certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) </span>(&#8220;ASU 2021-04&#8221;)<span style="font-style:italic;">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.</span> The amendments are designed to clarify an issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options that remain equity-classified after modification or exchange. The ASU provides guidance on how an issuer would measure and recognize the effects of these transactions. The standard provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. ASU 2021-04 will be effective for the Company in the first quarter of its fiscal year ending December 31, 2022. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Loss, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DebtAndEquityInstrumentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt and equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DebtAndEquityInstrumentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018624008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,517,680</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,965</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,881,903</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119019715304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue Reserves and Allowances (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net product revenues by product for the years ended December 31, 2021 and 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">YUTIQ (A)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,959</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU (B)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product sales, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,831</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(A)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(B)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ProductRevenueAllowanceAndReserveTableTextBlock', window );">Product Revenue Allowance and Reserves</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2021 and 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance at January 1, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,712</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to sales in the current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">785</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,396</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior period sales</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(272</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deductions applied and payments made</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,645</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,029</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,153</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,821</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chargebacks,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Discounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rebates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Returns</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance at January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">352</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,241</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision related to sales in the current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">978</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,175</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments related to prior period sales</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(387</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deductions applied and payments made</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,798</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(777</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">603</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ProductRevenueAllowanceAndReserveTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of product revenue allowance and reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ProductRevenueAllowanceAndReserveTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119101705528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,727</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,664</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in process</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">747</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">484</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,616</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018624600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Reconciliation of Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of intangible assets for the years ended December 31, 2021 and 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patented technologies</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross carrying amount at beginning of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross carrying amount at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,322</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization at beginning of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,460</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,460</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization at end of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net book value at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,209</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Net Book Value of Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net book value of the Company&#8217;s intangible assets at December&#160;31, 2021 and 2020 is summarized as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful&#160;Life&#160;at</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patented technologies</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEXYCU / Verisome</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,209</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000517">9.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,209</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018240376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,732</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,658</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,256</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,028</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018236232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">753</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales chargebacks, rebates and other revenue reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissions due to commercialization partner for DEXYCU</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,422</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,445</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018119864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Operating Leases</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental<span style="color:#000000;"> balance sheet information related to operating leases as of December 31, 2021 and 2020, respectively are as follows (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities - operating lease current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities &#8211; noncurrent portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Finance Lease</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental<span style="color:#000000;"> balance sheet information related to the finance lease as of December 31, 2021 and 2020, respectively are as follows (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities <span style="font-family:Calibri;">&#8211;</span> finance lease current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock', window );">Future Minimum Lease Payments Under Non-Cancellable Leases</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T<span style="color:#000000;">he Company&#8217;s total future minimum lease payments under non-cancellable leases at December 31, 2021 were as follows (in thousands): </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">911</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,055</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,505</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum operating and finance lease payments under non cancellable leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018318008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Reconciliation of Warrants to Purchase Common Stock</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of fixed price warrants to purchase shares of the Company&#8217;s Common Stock for the years ended December 31, 2021 and 2020:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance and exercisable at end of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119019330632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity Under Plan</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of stock option activity under the Company&#8217;s equity incentive plans and for inducement awards for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,880</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.86</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,313,727</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.59</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,112</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,448</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,517,680</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000757">8.06</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916,461</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000758">6.25</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions Used</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the grant date fair value of option awards during the years ended December 31, 2021 and 2020, the Company applied the Black-Scholes option pricing model based on the following key assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option life (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000768">4.75 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000769">5.50 - 6.10</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000772">72% - 83%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000773">64% - 70%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000776">0.42% - 1.44%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000777">0.32% - 1.76%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividends</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Summary of Information about Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about employee, consultant and director stock options under the Company&#8217;s equity incentive plans for the years ended December 31, 2021 and 2020 (in thousands except per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value per share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.07</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash received from exercise of stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intrinsic value of stock options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of RSU activity under the 2016 Plan for the year ended December&#160;31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at January 1, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,004</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.96</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,795</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Compensation Expense from Stock-Based Payment Awards</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s statements of comprehensive loss included total compensation expense from stock-based payment awards as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation expense included in:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,294</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,411</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">907</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,966</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,229</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,447</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,547</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018129240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Carried at Fair Value Measured on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s assets carried at fair value measured on a recurring basis at December 31, 2021 and 2020, respectively, by valuation hierarchy (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 1:</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 2:</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,549</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,965</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,514</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,549</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,965</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,065</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,065</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,965</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Level 1:</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015211080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Loss Before Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. operations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,517</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. operations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit</a></td>
<td class="text">The difference between the Company&#8217;s expected income tax benefit, as computed by applying the blended statutory U.S. federal tax rate of 21% for the year ended December 31, 2021 and 21% for the year ended December 31, 2020, to loss before income taxes, and actual income tax benefit is reconciled in the following table (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,268</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,533</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,890</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.S. income tax rate differential</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in federal tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(693</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(403</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,748</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,068</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(652</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<span style="font-size:10pt;">The significant components of deferred income taxes are as follows (in thousands): </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,026</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">722</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,503</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,005</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,514</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,291</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,696</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,963</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,087</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,578</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,896</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,896</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018097768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Area Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s revenues and long-lived assets, net by geographic area (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve&#160;Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve&#160;Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At&#160;December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At&#160;December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,988</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,713</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.K.</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,939</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018476008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operations - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Product </div>
<div>_People </div>
<div>Case</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperationsLineItems', window );"><strong>Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfProducts', window );">Number of commercial products | Product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfProductsApproved', window );">Number of products approved | Product</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments in marketable securities</a></td>
<td class="nump">$ 211.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember', window );">Cost of Sales, Excluding Amortization of Acquired Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperationsLineItems', window );"><strong>Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperationsLineItems', window );"><strong>Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember', window );">YUTIQ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperationsLineItems', window );"><strong>Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfNewBlindnessCasesEveryYear', window );">Number of new cases of blindness annually | Case</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember', window );">YUTIQ [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperationsLineItems', window );"><strong>Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear', window );">Number of people affected by posterior segment of eye in U.S. each year | _People</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember', window );">YUTIQ [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperationsLineItems', window );"><strong>Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear', window );">Number of people affected by posterior segment of eye in U.S. each year | _People</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NumberOfNewBlindnessCasesEveryYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new blindness cases every year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NumberOfNewBlindnessCasesEveryYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of people affected by posterior segment of eye in U.S. each year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NumberOfProductsApproved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of products approved by by the United States (US) Food and Drug Administration (FDA).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NumberOfProductsApproved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_OperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_OperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_YUTIQProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119010979336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2018</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive income to foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841,000<span></span>
</td>
<td class="nump">$ 841,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Marketable securities matured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Interest-bearing cash equivalent consisted of money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Interest-bearing cash equivalent consisted of investment-grade commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PreFundedWarrantsToPurchaseCommonStock', window );">Pre Funded Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,272,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">Accounting Standards Update 2019-12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember', window );">Icon Bioscience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PercentageOfAcceleratedMilestonePaymentReceived', window );">Percentage of accelerated milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember', window );">DEXYCU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AccruedRevenueBasedRoyaltyExpense', window );">Accrued revenue-based royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember', window );">DEXYCU [Member] | Icon Bioscience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AccruedRevenueBasedRoyaltyExpense', window );">Accrued revenue-based royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PercentageOfAcceleratedMilestonePaymentReceived', window );">Percentage of accelerated milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PercentageOfUpfrontPaymentReceived', window );">Percentage of upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AccountsReceivableStandardPaymentTerms', window );">Accounts receivable standard payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AccountsReceivableStandardPaymentTerms', window );">Accounts receivable standard payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">127 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember', window );">Investment Instruments [Member] | Credit Concentration Risk [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember', window );">Investment Instruments [Member] | Credit Concentration Risk [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | ASD Specialty Healthcare LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.30%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | McKesson Specialty Care Distribution LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.70%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ASD Specialty Healthcare LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.10%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | McKesson Specialty Care Distribution LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.60%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Ocumension Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AccountsReceivableStandardPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable standard payment terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AccountsReceivableStandardPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AccruedRevenueBasedRoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued revenue based royalty expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AccruedRevenueBasedRoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PercentageOfAcceleratedMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of accelerated milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PercentageOfAcceleratedMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PercentageOfUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PercentageOfUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PreFundedWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre Funded Warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PreFundedWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ScheduleOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ScheduleOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=eypt_ASDSpecialtyHealthcareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=eypt_ASDSpecialtyHealthcareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=eypt_McKessonSpecialtyCareDistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=eypt_McKessonSpecialtyCareDistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=eypt_OcumensionTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=eypt_OcumensionTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018478888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation</a></td>
<td class="nump">2,881,903<span></span>
</td>
<td class="nump">1,564,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation</a></td>
<td class="nump">2,517,680<span></span>
</td>
<td class="nump">1,338,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eypt_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation</a></td>
<td class="nump">23,965<span></span>
</td>
<td class="nump">27,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation</a></td>
<td class="nump">48,683<span></span>
</td>
<td class="nump">48,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation</a></td>
<td class="nump">291,575<span></span>
</td>
<td class="nump">149,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eypt_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eypt_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014409752">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Product Revenue Reserves and Allowances - Disaggregation of Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 36,939<span></span>
</td>
<td class="nump">$ 34,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember', window );">YUTIQ [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,959<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_DEXYCUProductMember', window );">DEXYCU [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">18,353<span></span>
</td>
<td class="nump">6,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35,312<span></span>
</td>
<td class="nump">$ 20,831<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_YUTIQProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_DEXYCUProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_DEXYCUProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014505928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Product Revenue Reserves and Allowances - Disaggregation of Revenue (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 36,939<span></span>
</td>
<td class="nump">$ 34,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember', window );">YUTIQ [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,959<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember', window );">YUTIQ [Member] | Ocumension Therapeutics [Member] | Supply Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_DEXYCUProductMember', window );">DEXYCU [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">18,353<span></span>
</td>
<td class="nump">6,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_DEXYCUProductMember', window );">DEXYCU [Member] | Ocumension Therapeutics [Member] | Supply Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </span></p></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_YUTIQProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_YUTIQProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=eypt_OcumensionTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=eypt_OcumensionTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_DEXYCUProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_DEXYCUProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014709816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserves (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems', window );"><strong>Disclosure Of Product Revenue Reserves And Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Beginning balance</a></td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 2,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossAdditions', window );">Provision related to sales in the current year</a></td>
<td class="nump">13,396<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease', window );">Adjustments related to prior period sales</a></td>
<td class="num">(272)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade', window );">Deductions applied and payments made</a></td>
<td class="num">(11,483)<span></span>
</td>
<td class="num">(4,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">3,353<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_ChargeBacksAndDiscountsAndFeesMember', window );">Chargebacks, Discounts and Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems', window );"><strong>Disclosure Of Product Revenue Reserves And Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Beginning balance</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossAdditions', window );">Provision related to sales in the current year</a></td>
<td class="nump">7,274<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease', window );">Adjustments related to prior period sales</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade', window );">Deductions applied and payments made</a></td>
<td class="num">(6,645)<span></span>
</td>
<td class="num">(2,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_GovernmentsAndOtherRebatesMember', window );">Government and Other Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems', window );"><strong>Disclosure Of Product Revenue Reserves And Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Beginning balance</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossAdditions', window );">Provision related to sales in the current year</a></td>
<td class="nump">5,337<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease', window );">Adjustments related to prior period sales</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade', window );">Deductions applied and payments made</a></td>
<td class="num">(4,029)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">1,821<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_ReturnsMember', window );">Returns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems', window );"><strong>Disclosure Of Product Revenue Reserves And Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Beginning balance</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossAdditions', window );">Provision related to sales in the current year</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease', window );">Adjustments related to prior period sales</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade', window );">Deductions applied and payments made</a></td>
<td class="num">(809)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ContractWithCustomerAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer allowance for credit loss additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ContractWithCustomerAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer allowance for credit loss increase decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer allowance for deductions applied and payments made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of product revenue reserves and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_ChargeBacksAndDiscountsAndFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_ChargeBacksAndDiscountsAndFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_GovernmentsAndOtherRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_GovernmentsAndOtherRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_ReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=eypt_ReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009395016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue Reserves and Allowances - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Mar. 31, 2013</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,939,000<span></span>
</td>
<td class="nump">$ 34,437,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember', window );">Icon Bioscience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_SalesBasedRoyaltyExpense', window );">Sales-based royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PercentageOfAcceleratedMilestonePaymentReceived', window );">Percentage of accelerated milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_AmendedAlimeraScienceIncAgreementMember', window );">Amended Alimera Science Inc Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_OncoSilMedicalUKLimitedMember', window );">OncoSil Medical UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UpfrontLicenseFeeReceived', window );">Receipt of upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_RoyaltyPercentageEarnedFromProductSales', window );">Royalty percentage earned from sales of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NonRoyaltyConsiderationPercentage', window );">Percentage of non-royalty consideration received from sublicense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LicenseAgreementStartYearMonth', window );">License agreement commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2012-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember', window );">Ocumension Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UpfrontLicenseFeeReceived', window );">Receipt of upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone', window );">Potential future payments based on achievement of development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone', window );">Potential future payments based on achievement of commercial-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DevelopmentMilestonePaymentReceived', window );">Development milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone', window );">Potential future payments based on achievement of combined remaining development and sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone', window );">Potential future payments based on achievement of remaining development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone', window );">Potential future payments based on achievement of remaining commercial-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember', window );">Ocumension Therapeutics [Member] | Share Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,010,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember', window );">Ocumension Therapeutics [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ProductSupplyMilestonesAndDevelopmentMilestones', window );">Product supply milestones and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UponAchievementOfMilestones', window );">Upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,000<span></span>
</td>
<td class="nump">$ 1,664,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Income [Member] | Amended Alimera Science Inc Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember', window );">RPA [Member] | SWK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_RoyaltySaleAgreementMember', window );">Royalty Sale Agreement [Member] | SWK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">885,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600,000<span></span>
</td>
<td class="nump">15,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_CollaborativeResearchAndDevelopmentMember', window );">Collaborative Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_CollaborativeResearchAndDevelopmentMember', window );">Collaborative Research and Development [Member] | OncoSil Medical UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,000<span></span>
</td>
<td class="nump">11,942,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement [Member] | Ocumension Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,312,000<span></span>
</td>
<td class="nump">20,831,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Ocumension Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,000<span></span>
</td>
<td class="nump">213,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember', window );">Technical Assistance [Member] | Ocumension Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disclosure of Product Revenue Reserves and Allowances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DevelopmentMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DevelopmentMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LicenseAgreementStartYearMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Start Year Month</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LicenseAgreementStartYearMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NonRoyaltyConsiderationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non royalty consideration percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NonRoyaltyConsiderationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PercentageOfAcceleratedMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of accelerated milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PercentageOfAcceleratedMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future payments to be received upon the achievement of prescribed combined remaining development and sales milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future payments to be received upon the achievement of prescribed commercial sales-based milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future payments to be received upon the achievement of prescribed development and regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future payments to be received upon the achievement of prescribed remaining commercial sales-based milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future payments to be received upon the achievement of prescribed remaining development and regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ProductSupplyMilestonesAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product supply milestones and development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ProductSupplyMilestonesAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_RoyaltyPercentageEarnedFromProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage earned from sales of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_RoyaltyPercentageEarnedFromProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_SalesBasedRoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales based royalty expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_SalesBasedRoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_UpfrontLicenseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_UpfrontLicenseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_UponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upon achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_UponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_AmendedAlimeraScienceIncAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_AmendedAlimeraScienceIncAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_OncoSilMedicalUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_OncoSilMedicalUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eypt_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eypt_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_RoyaltySaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_RoyaltySaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_CollaborativeResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_CollaborativeResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119020712024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,727<span></span>
</td>
<td class="nump">$ 2,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 3,616<span></span>
</td>
<td class="nump">$ 5,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119019605608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Reconciliation of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount at beginning of period</a></td>
<td class="nump">$ 68,322<span></span>
</td>
<td class="nump">$ 68,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount at end of period</a></td>
<td class="nump">68,322<span></span>
</td>
<td class="nump">68,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization at beginning of period</a></td>
<td class="num">(43,113)<span></span>
</td>
<td class="num">(40,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="num">(2,460)<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization at end of period</a></td>
<td class="num">(45,573)<span></span>
</td>
<td class="num">(43,113)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net book value at end of period</a></td>
<td class="nump">$ 22,749<span></span>
</td>
<td class="nump">$ 25,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015304104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Net Book Value of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 22,749<span></span>
</td>
<td class="nump">$ 25,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember', window );">DEXYCU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 22,749<span></span>
</td>
<td class="nump">$ 25,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite lived intangible assets remaining amortization period</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014803544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">$ 2,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember', window );">DEXYCU [Member] | Icon Bioscience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price of acquisition</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_EstimatedRateOfAnnualAmortizationExpense', window );">Annual amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_EstimatedRateOfAnnualAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated rate of annual amortization expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_EstimatedRateOfAnnualAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eypt_DEXYCUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014627512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 1,732<span></span>
</td>
<td class="nump">$ 1,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(1,256)<span></span>
</td>
<td class="num">(1,028)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_PropertyAndEquipmentMember', window );">Property and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119019678040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract', window );"><strong>Property Plant And Equipment Useful Life And Values [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property Plant And Equipment Useful Life And Values [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015360888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel costs</a></td>
<td class="nump">$ 7,321<span></span>
</td>
<td class="nump">$ 5,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AccruedClinicalExpenseCurrent', window );">Clinical trial costs</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves', window );">Sales chargebacks, rebates and other revenue reserves</a></td>
<td class="nump">2,974<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes', window );">Commissions due to commercialization partner for DEXYCU</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 14,422<span></span>
</td>
<td class="nump">$ 8,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AccruedClinicalExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of estimated obligations incurred through that date and payable for obligations related to services of contract research organizations in conducting clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AccruedClinicalExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued sales chargebacks, rebates and other revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119011787768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 08, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Tranche </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Loan facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 885,000<span></span>
</td>
<td class="nump">$ 852,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920,000<span></span>
</td>
<td class="nump">867,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease, amortization expense of ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense on finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance lease, operating cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease, financing cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease, weighted average Remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=eypt_CaladriusMember', window );">Caladrius [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AdditionalSubleasedPropertyOfficeArea', window );">Additional subleased property office area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_BaskingRidgeOfficeSpaceMember', window );">Basking Ridge Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfRenewalOptions', window );">Number of renewal options | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NumberOfFinanceLeases', window );">Number of finance leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_FirstLabEquipmentMember', window );">First Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseExpirationMonthYear', window );">Lease expiration month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_SecondLabEquipmentMember', window );">Second Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseExpirationMonthYear', window );">Lease expiration month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_ThirdLabEquipmentMember', window );">Third Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseExpirationMonthYear', window );">Lease expiration month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eypt_MaMember', window );">Massachusetts [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ConstructionAllowanceCredit', window );">Construction allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 670,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eypt_MaMember', window );">Massachusetts [Member] | Original Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeasePropertyAreaCovered', window );">Area of leased office and laboratory space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Original lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseExpirationMonthYear', window );">Lease expiration month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eypt_MaMember', window );">Massachusetts [Member] | Second Amendment Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseInceptionDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 10,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AdditionalLeasePropertyAreaCovered', window );">Additional Space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Irrevocable standby letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eypt_MaMember', window );">Massachusetts [Member] | Third Amendment Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeasePropertyAreaCovered', window );">Area of leased office and laboratory space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseInceptionDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eypt_MaMember', window );">Massachusetts [Member] | Fourth Amendment Lease [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeasePropertyAreaCovered', window );">Area of leased office and laboratory space | ft&#178;</a></td>
<td class="nump">13,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">May 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AdditionalLeasePropertyAreaCovered', window );">Additional Space leased | ft&#178;</a></td>
<td class="nump">11,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TerminationOfPortionOfLeasePropertyAreaCovered', window );">Termination portion of the lease | ft&#178;</a></td>
<td class="nump">7,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseTerminationDate', window );">Lease termination date</a></td>
<td class="text">May 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=eypt_MaMember', window );">Massachusetts [Member] | Fourth Amendment Lease [Member] | Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ConstructionAllowanceCredit', window );">Construction allowance</a></td>
<td class="nump">$ 555,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">NEW JERSEY | Basking Ridge Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DisclosureOfLeasesLineItems', window );"><strong>Disclosure Of Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseExpirationMonthYear', window );">Lease expiration month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeasePropertyOfficeAreaCovered', window );">Area of leased office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LeaseInceptionMonthYear', window );">Lease inception month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional lease renewal option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate', window );">Lease renewal rate at 95% of market rent at time of renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AdditionalLeasePropertyAreaCovered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional lease property area covered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AdditionalLeasePropertyAreaCovered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AdditionalSubleasedPropertyOfficeArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional subleased property office area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AdditionalSubleasedPropertyOfficeArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ConstructionAllowanceCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Its represent the construction allowance credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ConstructionAllowanceCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DisclosureOfLeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DisclosureOfLeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LeaseExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LeaseExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LeaseInceptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease inception date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LeaseInceptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LeaseInceptionMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease inception month year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LeaseInceptionMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LeasePropertyAreaCovered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease property area covered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LeasePropertyAreaCovered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LeasePropertyOfficeAreaCovered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease property office area covered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LeasePropertyOfficeAreaCovered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NumberOfFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NumberOfFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of renewal options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease renewal term percentage of market rent at renewal date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_TerminationOfPortionOfLeasePropertyAreaCovered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination of portion of lease property area covered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_TerminationOfPortionOfLeasePropertyAreaCovered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eypt_CaladriusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eypt_CaladriusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_BaskingRidgeOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_BaskingRidgeOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_FirstLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_FirstLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_SecondLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_SecondLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_ThirdLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eypt_ThirdLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=eypt_MaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=eypt_MaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_OriginalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_OriginalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_SecondAmendmentLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_SecondAmendmentLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_ThirdAmendmentLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_ThirdAmendmentLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_FourthAmendmentLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_FourthAmendmentLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015470424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Related to Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities - operating lease current portion</a></td>
<td class="nump">$ 645<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="nump">$ 1,860<span></span>
</td>
<td class="nump">$ 2,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,505<span></span>
</td>
<td class="nump">$ 2,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014661832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Related to Finance Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_FinanceLeasePropertyAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment', window );">Accumulated amortization</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Property and equipment, net</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Other current liabilities &#8211; finance lease current portion</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease accumulated amortization property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_FinanceLeasePropertyAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease property and equipment gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_FinanceLeasePropertyAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009313800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">2,505<span></span>
</td>
<td class="nump">$ 2,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119007172424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2021</div></th>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Feb. 13, 2019</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 08, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,065,000<span></span>
</td>
<td class="num">$ (905,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember', window );">RPA [Member] | SWK Funding LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount (premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628,000<span></span>
</td>
<td class="nump">745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault', window );">Restriction of the right to capitalize a portion of quarterly interest in the event of a loan default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">So long as no default has occurred and is continuing, the Company may elect on each applicable interest payment date to pay 2.5% of the 12.5% per annum interest as Paid In-Kind (&#8220;PIK&#8221;), whereby such PIK amount would be added to the aggregate principal amount and accrue interest at 12.5% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Upfront loan origination fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_MinimumLiquidityAmount', window );">Minimum liquidity amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OriginalAmountOfDebtDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenue', window );">Annual minimum product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenuePeriod', window );">Annual minimum product revenue period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">on January 1, 2019 and ending on December 31, 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenue', window );">Annual minimum product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenuePeriod', window );">Annual minimum product revenue period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 1, 2020 and ending on December 31, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenue', window );">Annual minimum product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenuePeriod', window );">Annual minimum product revenue period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 1, 2021 and ending on December 31, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_IncrementalChargesForIssuanceOfWaivers', window );">Incremental charges for issuance of waivers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Period Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenue', window );">Annual minimum product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_AnnualMinimumProductRevenuePeriod', window );">Annual minimum product revenue period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 1, 2022 and ending on December 31, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Loan Prepayment Prior to December 31, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage', window );">Principal prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Loan Prepayment after December 31, 2019 and Prior to December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage', window );">Principal prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Loan prepayment after December 31, 2020 and prior to December 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage', window );">Principal prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Loan prepayment after December 31 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage', window );">Principal prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate on term loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (905,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInitiationDate1', window );">Agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 13,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior secured term loan borrowing facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoansAgreementInitialAdvance', window );">Term loan agreement, initial advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PaidInKindInterestAddedToPrincipal', window );">Paid in Kind Interest Added to Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityExitFeesPercentage', window );">Exit fee percentage payable upon repayment of the total secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Upfront loan original fee payment, initial advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ReimbursedExpense', window );">Reimbursement of lender's legal fees and other transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ExitFeeAccrued', window );">Exit fee accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityLegalAndTransactionCosts', window );">Line of credit facility, legal and other transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of senior secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DebInstrumentExitFee', window );">Payment of exit fee upon repayment of secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PaymentOfAccruedAndUnpaidInterest', window );">Payment of accrued and unpaid interest through the date of the secured term loan refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Senior Secured Term Loan [Member] | RPA [Member] | SWK Funding LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Second Advance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementAdditionalAdvance', window );">Term loan agreement, additional loan advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OriginalAmountOfDebtDiscount', window );">Total debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Second Advance [Member] | Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityFinancingFeePercentage', window );">One-time upfront financing fee percentage applied to borrowing amounts under the line of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Upfront loan original fee payment, initial advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ExitFeeAccrued', window );">Exit fee accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Initial Advance [Member] | Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityFinancingFeePercentage', window );">One-time upfront financing fee percentage applied to borrowing amounts under the line of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Upfront loan original fee payment, initial advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis=eypt_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program Loan [Member] | Silicon Valley Bank [Member] | CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_TermLoanAgreementLineItems', window );"><strong>Term Loan Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Loan proceeds date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 22,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate on term loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Paycheck Protection Program Flexibility Act of 2020 (the &#8220;PPP Flexibility Act&#8221;), enacted on June 5, 2020, amended the&#160;Paycheck Protection Program, among others, as follows: (i) extended the covered period from 8 weeks to the earlier of 24 weeks from the date the PPP Loan is originated and December 31, 2020, during which PPP funds needed to be expended in order to be forgiven.&#160;A borrower may submit a loan forgiveness application any time on or before the maturity date of the loan &#8211; including before the end of the covered period &#8211; if the borrower has used all of the loan proceeds for which the borrower is requesting forgiveness; (ii) at least 60% of PPP funds must be spent on payroll costs, with the remaining 40% available to spend on other eligible expenses;&#160;(iii) payments are deferred until the date on which the amount of forgiveness determined is remitted to the lender. If a borrower fails to seek forgiveness within 10 months after the last day of its covered period, then payments will begin on the date that is 10 months after the last day of the covered period.&#160;In addition, the PPP Flexibility Act modified the CARES Act by increasing the maturity date for loans made after the effective date from two years to a minimum maturity of five years from the date on which the borrower applies for loan forgiveness. Existing PPP loans made before the new legislation retain their original two-year term, but may be renegotiated between a lender and a borrower to match the 5-year term permitted under the PPP Flexibility Act<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt instrument, loan forgiveness amount</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DebtInstrumentAccruedInterestForgiveness', window );">Debt instrument, accrued interest forgiveness amount</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AnnualMinimumProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual minimum period revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AnnualMinimumProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_AnnualMinimumProductRevenuePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual minimum product revenue period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_AnnualMinimumProductRevenuePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DebInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exit Fee Charged</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DebInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DebtInstrumentAccruedInterestForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument accrued interest forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DebtInstrumentAccruedInterestForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ExitFeeAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of exit fee accrued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ExitFeeAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_IncrementalChargesForIssuanceOfWaivers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental charges for issuance of waivers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_IncrementalChargesForIssuanceOfWaivers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LineOfCreditFacilityExitFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility exit fees percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LineOfCreditFacilityExitFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LineOfCreditFacilityFinancingFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility financing fees percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LineOfCreditFacilityFinancingFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LineOfCreditFacilityLegalAndTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of legal and transaction costs related to line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LineOfCreditFacilityLegalAndTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility principal prepayment premium percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_MinimumLiquidityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_MinimumLiquidityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_OriginalAmountOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original amount of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_OriginalAmountOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PaidInKindInterestAddedToPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid in kind interest added to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PaidInKindInterestAddedToPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PaymentOfAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment accrued and unpaid interest through the date of the secured term loan refinancing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PaymentOfAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ReimbursedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense reimbursed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ReimbursedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_TermLoanAgreementAdditionalAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of term loan agreement, additional loan advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_TermLoanAgreementAdditionalAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_TermLoanAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_TermLoanAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_TermLoansAgreementInitialAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term loan agreement, initial advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_TermLoansAgreementInitialAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=SL6230698-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInitiationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility first became available, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInitiationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PeriodAxis=eypt_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PeriodAxis=eypt_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PeriodAxis=eypt_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PeriodAxis=eypt_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PeriodAxis=eypt_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PeriodAxis=eypt_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PeriodAxis=eypt_PeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PeriodAxis=eypt_PeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentPriorToDecember312019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentPriorToDecember312019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentAfterDecember312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=eypt_LoanPrepaymentAfterDecember312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eypt_SecondAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eypt_SecondAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eypt_InitialAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eypt_InitialAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis=eypt_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis=eypt_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=eypt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=eypt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=eypt_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=eypt_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119011911416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Financings - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 23, 2020</div></th>
<th class="th"><div>Jun. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_EquityFinancingsMember', window );">Equity Financings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_EquityFinancingsMember', window );">Equity Financings [Member] | Share Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,122,273<span></span>
</td>
<td class="nump">10,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_StockIssuedDuringPeriodAdditionalSharesIssued', window );">Common stock, additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095,000<span></span>
</td>
<td class="nump">1,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Pre-funded warrants issued to purchase common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,272,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ClassOfWarrantOrRightIssuePriceOfWarrants', window );">Pre-funded warrants issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,400,000<span></span>
</td>
<td class="nump">$ 115,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="nump">3,010,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance costs</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_AtTheMarketOfferingMember', window );">At-the-Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,538<span></span>
</td>
<td class="nump">2,590,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 5.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.37<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552,000<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">$ 646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage', window );">Stock issuances, sales agent commission maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ClassOfWarrantOrRightIssuePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issue price of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ClassOfWarrantOrRightIssuePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs sales agent commission maximum percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_StockIssuedDuringPeriodAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_StockIssuedDuringPeriodAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_EquityFinancingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_EquityFinancingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eypt_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eypt_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119019330344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Outstanding and exercisable, Beginning balance</a></td>
<td class="nump">48,683<span></span>
</td>
<td class="nump">48,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Outstanding and exercisable, Ending balance</a></td>
<td class="nump">48,683<span></span>
</td>
<td class="nump">48,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Outstanding and exercisable, Beginning balance</a></td>
<td class="nump">$ 12.33<span></span>
</td>
<td class="nump">$ 12.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Outstanding and exercisable, Ending balance</a></td>
<td class="nump">$ 12.33<span></span>
</td>
<td class="nump">$ 12.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009298936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail) - SWK [Member] - Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 26, 2018</div></th>
<th class="th"><div>Mar. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember', window );">Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_WarrantsIssuedInConnectionWithTermLoanFacility', window );">Warrants issued in connection with term loan facility</a></td>
<td class="nump">7,773<span></span>
</td>
<td class="nump">40,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ExercisePriceOfIssuedWarrants', window );">Exercise price of issued warrants</a></td>
<td class="nump">$ 19.30<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_WarrantsExercisePeriod', window );">Warrants exercise period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_WeightedAverageRemainingLifeOfLenderWarrants', window );">Weighted average remaining life of lender warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ExercisePriceOfIssuedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of issued warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ExercisePriceOfIssuedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_WarrantsExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_WarrantsExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_WarrantsIssuedInConnectionWithTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in connection with term loan facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_WarrantsIssuedInConnectionWithTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_WeightedAverageRemainingLifeOfLenderWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining life of lender warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_WeightedAverageRemainingLifeOfLenderWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015304104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail) - 2016 Long Term Incentive Plan [Member] - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Jun. 25, 2019</div></th>
<th class="th"><div>Dec. 12, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock, authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the Long Term Incentive Plan, including forfeited and terminated awards transferred from the 2008 Incentive Plan</a></td>
<td class="nump">1,683,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014583640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail) - Equity Incentive Plans and Inducement Awards [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning balance | shares</a></td>
<td class="nump">1,338,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted | shares</a></td>
<td class="nump">1,313,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised | shares</a></td>
<td class="num">(8,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forefeited | shares</a></td>
<td class="num">(75,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired | shares</a></td>
<td class="num">(51,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending balance | shares</a></td>
<td class="nump">2,517,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable at December 31, 2021 | shares</a></td>
<td class="nump">916,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning balance | $ / shares</a></td>
<td class="nump">$ 20.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">12.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">12.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forefeited | $ / shares</a></td>
<td class="nump">16.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired | $ / shares</a></td>
<td class="nump">31.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">16.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2021 | $ / shares</a></td>
<td class="nump">$ 22.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding at January 1, 2021</a></td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable at December 31, 2021</a></td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at January 1, 2021 | $</a></td>
<td class="nump">$ 775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2021 | $</a></td>
<td class="nump">$ 103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_EquityIncentivePlansAndInducementAwardGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_EquityIncentivePlansAndInducementAwardGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009318600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Stock Options - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember', window );">2016 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Ratable monthly vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of option grants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Ratable monthly vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Common stock vested during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=eypt_NewlyAppointedNonExecutiveDirectorMember', window );">Newly Appointed Non Executive Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod', window );">Ratable annual vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=eypt_DirectorsAndExternalConsultantsMember', window );">External consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award cliff vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eypt_NewlyAppointedNonExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eypt_NewlyAppointedNonExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eypt_DirectorsAndExternalConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eypt_DirectorsAndExternalConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009318472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail) - 2016 Long Term Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Stock volatility, minimum</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Stock volatility, maximum</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">1.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option life (in years)</a></td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option life (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119112399112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Summary of Information about Stock Options (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Total cash received from exercise of stock options</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eypt_EquityIncentivePlansMember', window );">Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Total cash received from exercise of stock options</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_EquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_EquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015323480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail) - 2016 Long Term Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Ratable annual vesting period of equity awards</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Ratable annual vesting period of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 13 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014608760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail) - 2016 Long Term Incentive Plan [Member] - RSU [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Stock Units Outstanding, Beginning Balance | shares</a></td>
<td class="nump">149,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of stock units, granted | shares</a></td>
<td class="nump">242,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Stock Units, Vested | shares</a></td>
<td class="num">(89,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Stock Units, Forfeited | shares</a></td>
<td class="num">(10,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Stock Units Outstanding, Ending Balance | shares</a></td>
<td class="nump">291,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Nonvested, Beginning balance | $ / shares</a></td>
<td class="nump">$ 13.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">12.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair value, Vested | $ / shares</a></td>
<td class="nump">13.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair value, Forfeited | $ / shares</a></td>
<td class="nump">12.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Nonvested, Ending balance | $ / shares</a></td>
<td class="nump">$ 13.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119015352104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember', window );">2016 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Ratable annual vesting period of equity awards</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=eypt_NonExecutiveDirectorsMember', window );">Non Executive Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested deferred stock units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eypt_DeferredStockUnitsMember', window );">Deferred Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Ratable annual vesting period of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eypt_DeferredStockUnitsMember', window );">Deferred Stock Units [Member] | 2016 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested', window );">Vested deferred stock units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested at balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_TwoThousandSixteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eypt_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eypt_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eypt_DeferredStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eypt_DeferredStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119016114792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Employee Stock Purchase Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 25, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="nump">$ 294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,905,826<span></span>
</td>
<td class="nump">18,139,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,447,000<span></span>
</td>
<td class="nump">$ 5,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eypt_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock, authorized for issuance</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of common stock purchased twice a year under ESPP, percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod', window );">Consecutive six month offering period</a></td>
<td class="text">Aug.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award consecutive six month offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eypt_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eypt_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009349240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,447<span></span>
</td>
<td class="nump">$ 5,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,294<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=eypt_SalesAndMarketingMember', window );">Sales and Marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,966<span></span>
</td>
<td class="nump">$ 3,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eypt_SalesAndMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eypt_SalesAndMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018225928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Awards - Stock-Based Compensation Expense - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted average period</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119016322136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Asset Purchase Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_CollaborativeAgreementsAndContractsLineItems', window );"><strong>Collaborative Agreements And Contracts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="nump">$ 17,424,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_AerpioPharmaceuticalsIncMember', window );">Aerpio Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_CollaborativeAgreementsAndContractsLineItems', window );"><strong>Collaborative Agreements And Contracts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NonRefundableNonCreditableUpfrontCashPayment', window );">Non-refundable and non-creditable upfront cash payment</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_EquinoxScienceLLCMember', window );">Equinox Science, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_CollaborativeAgreementsAndContractsLineItems', window );"><strong>Collaborative Agreements And Contracts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NonRefundableNonCreditableUpfrontCashPayment', window );">Non-refundable and non-creditable upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eypt_EquinoxScienceLLCMember', window );">Equinox Science, LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_CollaborativeAgreementsAndContractsLineItems', window );"><strong>Collaborative Agreements And Contracts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones', window );">Payment upon achievement of development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_CollaborativeAgreementsAndContractsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreements and contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_CollaborativeAgreementsAndContractsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments upon achievement of certain development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NonRefundableNonCreditableUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable, non-creditable upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NonRefundableNonCreditableUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_AerpioPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_AerpioPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eypt_EquinoxScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eypt_EquinoxScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009236312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">$ 32,965,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Value</a></td>
<td class="nump">205,065,000<span></span>
</td>
<td class="nump">23,538,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">205,065,000<span></span>
</td>
<td class="nump">23,538,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="nump">172,100,000<span></span>
</td>
<td class="nump">23,538,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">32,965,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Value</a></td>
<td class="nump">155,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">155,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="nump">155,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Value</a></td>
<td class="nump">155,551,000<span></span>
</td>
<td class="nump">23,538,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">155,551,000<span></span>
</td>
<td class="nump">23,538,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="nump">155,551,000<span></span>
</td>
<td class="nump">23,538,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Value</a></td>
<td class="nump">49,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="nump">16,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">32,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Value</a></td>
<td class="nump">49,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">49,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="nump">16,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">$ 32,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009211640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Interest-bearing cash equivalent consisted of money market fund</a></td>
<td class="nump">$ 155,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Interest-bearing cash equivalent consisted of investment-grade commercial paper</a></td>
<td class="nump">16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">32,965,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of loan</a></td>
<td class="nump">38,900,000<span></span>
</td>
<td class="nump">38,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">long-term debt</a></td>
<td class="nump">36,600,000<span></span>
</td>
<td class="nump">36,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ExitFeeAccrued', window );">Exit fee accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of loan</a></td>
<td class="nump">38,700,000<span></span>
</td>
<td class="nump">38,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember', window );">CRG Servicing LLC [Member] | Other Long-term Liabilities [Member] | Senior Secured Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ExitFeeAccrued', window );">Exit fee accrued</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember', window );">Investment Instruments [Member] | Credit Concentration Risk [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">90.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember', window );">Investment Instruments [Member] | Credit Concentration Risk [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ExitFeeAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of exit fee accrued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ExitFeeAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=eypt_InvestmentInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014495240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plans - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum percentage of eligible compensation matched by employer</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DefinedContributionPlanContributionsByEmployer', window );">Employer contributions to retirement plans</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 690,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DefinedContributionPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan contributions by employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DefinedContributionPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014458776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. operations</a></td>
<td class="num">$ (58,517)<span></span>
</td>
<td class="num">$ (45,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S. operations</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (58,417)<span></span>
</td>
<td class="num">$ (45,394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119009267224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal corporate income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 15,748,000<span></span>
</td>
<td class="nump">$ 13,068,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued penalties or interest related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">U.S. Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">301,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_NetOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 151,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperatingLossCarryForwardsExpirationYearRangeStart', window );">Operating loss carry forwards, expiration range start dates</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperatingLossCarryForwardsExpirationYearRangeEnd', window );">Operating loss carry forwards, expiration range end dates</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years that remain subject to examination</a></td>
<td class="text">2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 222,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperatingLossCarryForwardsExpirationYearRangeStart', window );">Operating loss carry forwards, expiration range start dates</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_OperatingLossCarryForwardsExpirationYearRangeEnd', window );">Operating loss carry forwards, expiration range end dates</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_HerMajestysRevenueAndCustomsHMRCMember', window );">United Kingdom Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years that remain subject to examination</a></td>
<td class="text">2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember', window );">Federal and State Research and Development Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=eypt_FederalAndStateTaxMember', window );">Federal And State Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart', window );">Research and development tax credit carry forwards expiration begin date</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd', window );">Research and development tax credit carry forwards expiration end date</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember', window );">Icon Bioscience Inc [Member] | U.S. Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 49,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_NetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_NetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_OperatingLossCarryForwardsExpirationYearRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year range end</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_OperatingLossCarryForwardsExpirationYearRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_OperatingLossCarryForwardsExpirationYearRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_OperatingLossCarryForwardsExpirationYearRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credits expiration year range end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credits expiration year range start.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_HerMajestysRevenueAndCustomsHMRCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_HerMajestysRevenueAndCustomsHMRCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=eypt_FederalAndStateTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=eypt_FederalAndStateTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119019512632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory rate</a></td>
<td class="num">$ (12,268)<span></span>
</td>
<td class="num">$ (9,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(2,890)<span></span>
</td>
<td class="num">(2,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Non-U.S. income tax rate differential</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in federal tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(693)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">15,748<span></span>
</td>
<td class="nump">13,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(626)<span></span>
</td>
<td class="num">(652)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119011908696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 84,026<span></span>
</td>
<td class="nump">$ 74,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,822<span></span>
</td>
<td class="nump">6,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credits</a></td>
<td class="nump">5,446<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">105,291<span></span>
</td>
<td class="nump">89,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">5,963<span></span>
</td>
<td class="nump">6,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">6,578<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance', window );">Deferred tax assets, net</a></td>
<td class="nump">98,713<span></span>
</td>
<td class="nump">82,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">98,713<span></span>
</td>
<td class="nump">82,896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Liabilities Net Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119018107384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Area Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119014585304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Area Information - Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 36,939<span></span>
</td>
<td class="nump">$ 34,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets, net</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Country US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">35,988<span></span>
</td>
<td class="nump">22,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets, net</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">11,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">UNITED KINGDOM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140119016559528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Dec. 17, 2020</div></th>
<th class="th"><div>Feb. 13, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,065,000<span></span>
</td>
<td class="num">$ (905,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan [Member] | CRG Servicing LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior secured facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceed from senior secured facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of senior secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DebInstrumentExitFee', window );">Payment of exit fee upon repayment of secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityExitFeesPercentage', window );">Exit fee percentage payable upon repayment of the total secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PaymentOfAccruedAndUnpaidInterest', window );">Payment of accrued and unpaid interest through the date of the secured term loan refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (905,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan [Member] | CRG Servicing LLC [Member] | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan [Member] | Subsequent Event [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior secured facility</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceed from senior secured facility</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">Jan.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument effective rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan [Member] | Subsequent Event [Member] | Silicon Valley Bank [Member] | Prime Rate Plus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Revolving line bears interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan [Member] | Subsequent Event [Member] | CRG Servicing LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="nump">$ 41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of senior secured term loan</a></td>
<td class="nump">38,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_DebInstrumentExitFee', window );">Payment of exit fee upon repayment of secured term loan</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_LineOfCreditFacilityExitFeesPercentage', window );">Exit fee percentage payable upon repayment of the total secured term loan</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PaymentOfAccruedAndUnpaidInterest', window );">Payment of accrued and unpaid interest through the date of the secured term loan refinancing</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredRevolvingCreditFacilityMember', window );">Senior Secured Revolving Credit Facility [Member] | Subsequent Event [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior secured facility</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing', window );">Percentage of accounts receivable eligible for maximum amount borrowing</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused commitment fee</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceed from senior secured facility</a></td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_DebInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exit Fee Charged</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_DebInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_LineOfCreditFacilityExitFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility exit fees percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_LineOfCreditFacilityExitFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PaymentOfAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment accrued and unpaid interest through the date of the secured term loan refinancing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PaymentOfAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of accounts receivable eligible for maximum amount borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eypt_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eypt_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eypt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eypt_SeniorSecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=eypt_CrgServicingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=eypt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=eypt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eypt_SeniorSecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eypt_SeniorSecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>eypt-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:eypt="http://eyepointpharma.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eypt-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001314102_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_20220304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="C_0001314102_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001314102_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptCostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">eypt:InvestmentInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">eypt:InvestmentInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:McKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-27</startDate>
            <endDate>2018-03-28</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:YUTIQProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:DEXYCUProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ChargeBacksAndDiscountsAndFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:GovernmentsAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">eypt:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AmendedAlimeraScienceIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltySaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-17</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltySaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltySaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20130331_20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-31</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OncoSilMedicalUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20181101_20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20190801_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:TechnologyServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:TechnologyServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OcumensionTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:CollaborativeResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eypt:DEXYCUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OriginalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:OriginalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SecondAmendmentLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SecondAmendmentLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:ThirdAmendmentLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:FourthAmendmentLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-08</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">eypt:MaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:FourthAmendmentLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-08</instant>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:BaskingRidgeOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:BaskingRidgeOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:BaskingRidgeOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtCounterpartyNameAxis_eyptCaladriusMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eypt:CaladriusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptFirstLabEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:FirstLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptSecondLabEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:SecondLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptThirdLabEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eypt:ThirdLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-08</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210616_20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis">eypt:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">eypt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-13</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptInitialAdvanceMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:InitialAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentPriorToDecember312019Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentPriorToDecember312019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eypt:LoanPrepaymentAfterDecember312021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eypt:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-13</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="eypt:PeriodAxis">eypt:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-13</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-13</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eypt:SecondAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-13</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2020-12-17</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eypt:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquityFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-22</instant>
        </period>
    </context>
    <context id="C_0001314102_20200623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <instant>2020-06-23</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-27</startDate>
            <endDate>2018-03-28</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-24</startDate>
            <endDate>2018-06-26</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20161212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-12</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20190625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansAndInducementAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansAndInducementAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansAndInducementAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-30</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181230_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-30</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtTitleOfIndividualAxis_eyptNewlyAppointedNonExecutiveDirectorMember_20181230_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:NewlyAppointedNonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-30</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtTitleOfIndividualAxis_eyptDirectorsAndExternalConsultantsMember_20181230_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:DirectorsAndExternalConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-30</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eypt:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eypt:DeferredStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eypt:DeferredStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:TwoThousandSixteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-25</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-24</startDate>
            <endDate>2019-06-25</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eypt:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eypt:SalesAndMarketingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eypt:SalesAndMarketingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210801_20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AerpioPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:AerpioPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eypt:EquinoxScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eypt:IconBioscienceIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eypt:FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:HerMajestysRevenueAndCustomsHMRCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateTaxMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eypt:FederalAndStateTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:HerMajestysRevenueAndCustomsHMRCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryCN_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryGB_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryCN_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryGB_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_srtStatementGeographicalAxis_countryUS_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20220309_20220309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_0001314102_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eypt:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eypt:CrgServicingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_eyptProduct">
        <measure>eypt:Product</measure>
    </unit>
    <unit id="U_eypt_People">
        <measure>eypt:_People</measure>
    </unit>
    <unit id="U_eyptCase">
        <measure>eypt:Case</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_eyptTranche">
        <measure>eypt:Tranche</measure>
    </unit>
    <unit id="U_eyptLease">
        <measure>eypt:Lease</measure>
    </unit>
    <unit id="U_iso4217GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001314102_20210101_20211231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001314102_20210101_20211231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001314102_20210101_20211231" id="F_000006">0001314102</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001314102_20210101_20211231" id="F_000007">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000388">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000390">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:OpenTaxYear
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231"
      id="F_000956">2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20210101_20211231"
      id="F_000957">2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020</us-gaap:OpenTaxYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20211231"
      id="F_000550">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20211231"
      id="F_000571">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422"
      id="F_000638">P2Y</us-gaap:DebtInstrumentTerm>
    <eypt:WarrantsExercisePeriod
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328"
      id="F_000736">P7Y</eypt:WarrantsExercisePeriod>
    <eypt:WarrantsExercisePeriod
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626"
      id="F_000737">P7Y</eypt:WarrantsExercisePeriod>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231"
      id="F_000517">P9Y3M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20211231" id="F_000579">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20201231" id="F_000580">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20211231" id="F_000601">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20201231" id="F_000602">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20211231" id="F_000605">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20201231" id="F_000606">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20211231" id="F_000609">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001314102_20201231" id="F_000610">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      id="F_000757">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      id="F_000758">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      id="F_000768">P4Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      id="F_000769">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000772"
      unitRef="U_xbrlipure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000773"
      unitRef="U_xbrlipure">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000776"
      unitRef="U_xbrlipure">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000777"
      unitRef="U_xbrlipure">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      id="F_000770">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      id="F_000771">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000774"
      unitRef="U_xbrlipure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000775"
      unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000778"
      unitRef="U_xbrlipure">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000779"
      unitRef="U_xbrlipure">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001314102_20211231"
      id="F_000077"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001314102_20201231"
      id="F_000078"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001314102_20211231"
      id="F_000079"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001314102_20201231"
      id="F_000080"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001314102_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001314102_20210101_20211231" id="F_000023">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001314102_20210101_20211231" id="F_000002">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001314102_20210101_20211231" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001314102_20210101_20211231" id="F_000024">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001314102_20210101_20211231" id="F_000015">000-51122</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001314102_20210101_20211231" id="F_000005">EyePoint Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001314102_20210101_20211231" id="F_000025">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001314102_20210101_20211231" id="F_000016">26-2774444</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001314102_20210101_20211231" id="F_000017">480 Pleasant Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001314102_20210101_20211231" id="F_000018">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001314102_20210101_20211231" id="F_000019">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001314102_20210101_20211231" id="F_000020">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001314102_20210101_20211231" id="F_000021">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001314102_20210101_20211231" id="F_000022">926-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001314102_20210101_20211231" id="F_000026">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001314102_20210101_20211231" id="F_000009">EYPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001314102_20210101_20211231" id="F_000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001314102_20210101_20211231" id="F_000030">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001314102_20210101_20211231" id="F_000031">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001314102_20210101_20211231" id="F_000029">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001314102_20210101_20211231" id="F_000028">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001314102_20210101_20211231" id="F_000008">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001314102_20210101_20211231" id="F_000013">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001314102_20210101_20211231" id="F_000012">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001314102_20210101_20211231" id="F_000032">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001314102_20210101_20211231" id="F_000014">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001314102_20210630"
      decimals="0"
      id="F_000011"
      unitRef="U_iso4217USD">192416944</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001314102_20220304"
      decimals="INF"
      id="F_000010"
      unitRef="U_xbrlishares">34044255</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000272">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2022 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001314102_20210101_20211231" id="F_000033">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001314102_20210101_20211231" id="F_000034">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001314102_20210101_20211231" id="F_000035">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">178593000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">44909000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">32965000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000093"
      unitRef="U_iso4217USD">414000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217USD">104000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">18354000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">9453000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">4217000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">3419000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">3616000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">5337000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">237745000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">63118000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">476000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">2252000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2610000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">22749000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">25209000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">150000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">150000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">263372000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">91717000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">7385000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">4811000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">14422000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">8445000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">1069000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">945000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">782000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">687000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">23658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">14888000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">36562000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">37977000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">14560000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">15616000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">1860000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">2330000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">2352000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">2365000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">78992000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">73176000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000095"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000102"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000103"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000104"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000105"
      unitRef="U_xbrlishares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000106"
      unitRef="U_xbrlishares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000107"
      unitRef="U_xbrlishares">33905826</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000109"
      unitRef="U_xbrlishares">33905826</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000108"
      unitRef="U_xbrlishares">18139981</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000110"
      unitRef="U_xbrlishares">18139981</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">18000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">752602000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">528362000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">-569097000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">-510680000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">841000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">841000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">184380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">18541000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">263372000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">91717000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">35312000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">20831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">543000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">11500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">756000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">11942000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20210101_20211231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">1664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">36939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">34437000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">8177000</eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets>
    <eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">5824000</eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">28500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">17424000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">27503000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">25293000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">25575000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">20726000</us-gaap:GeneralAndAdministrativeExpense>
    <eypt:AmortizationOfAcquisitionCostOfIntangibleAssets
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">2460000</eypt:AmortizationOfAcquisitionCostOfIntangibleAssets>
    <eypt:AmortizationOfAcquisitionCostOfIntangibleAssets
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">2460000</eypt:AmortizationOfAcquisitionCostOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">92215000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">71727000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-55276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-37290000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">292000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">58000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">5498000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">7257000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">2065000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">-905000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">-3141000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">-8104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-58417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">-45394000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001314102_20210101_20211231"
      decimals="2"
      id="F_000143"
      unitRef="U_iso4217USD_xbrlishares">-2.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001314102_20200101_20201231"
      decimals="2"
      id="F_000144"
      unitRef="U_iso4217USD_xbrlishares">-3.54</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000145"
      unitRef="U_xbrlishares">28758000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_xbrlishares">12836000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-58417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-45394000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">-58417000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-45393000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000155"
      unitRef="U_xbrlishares">10941659</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">472765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-465286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_20191231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">8330000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">-45394000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-45394000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">7100815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">49846000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">49853000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000169"
      unitRef="U_xbrlishares">33697</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">294000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">294000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000172"
      unitRef="U_xbrlishares">63810</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-90000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-90000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">5547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">5547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000177"
      unitRef="U_xbrlishares">18139981</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">528362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-510680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">18541000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-58417000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">-58417000</us-gaap:NetIncomeLoss>
    <eypt:StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000185"
      unitRef="U_xbrlishares">15635811</eypt:StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts>
    <eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">16000</eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts>
    <eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">216570000</eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts>
    <eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">216586000</eypt:StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000189"
      unitRef="U_xbrlishares">43365</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">273000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">273000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000192"
      unitRef="U_xbrlishares">8112</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000195"
      unitRef="U_xbrlishares">78557</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-150000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-150000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">7447000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">7447000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000200"
      unitRef="U_xbrlishares">33905826</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">752602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">-569097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">184380000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">-58417000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">-45394000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">2460000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">2460000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">311000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">189000</us-gaap:Depreciation>
    <eypt:AmortizationOfDebtDiscount
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">628000</eypt:AmortizationOfDebtDiscount>
    <eypt:AmortizationOfDebtDiscount
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">745000</eypt:AmortizationOfDebtDiscount>
    <us-gaap:PaidInKindInterest
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">977000</us-gaap:PaidInKindInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">2065000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">-905000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InventoryWriteDown
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">1278000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">7447000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">5547000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">10603000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">-4846000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">-1347000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">3200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">8476000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">1872000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <eypt:IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">-28000</eypt:IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset>
    <eypt:IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">72000</eypt:IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">-931000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">16546000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">-50097000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">-14435000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">32965000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">156000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">362000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">-33121000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-362000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <eypt:ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">216825000</eypt:ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <eypt:ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">49918000</eypt:ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <eypt:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">0</eypt:ProceedsFromPaycheckProtectionProgramLoan>
    <eypt:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">2041000</eypt:ProceedsFromPaycheckProtectionProgramLoan>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">13794000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">828000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">150000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">90000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">373000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">294000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">146000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">49000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">216902000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">37492000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">133684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">22695000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">45059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001314102_20191231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">22364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">178743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">45059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">4846000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">5510000</us-gaap:InterestPaidNet>
    <eypt:NonCashUnpaidStockIssuanceCosts
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">294000</eypt:NonCashUnpaidStockIssuanceCosts>
    <eypt:NonCashUnpaidStockIssuanceCosts
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">0</eypt:NonCashUnpaidStockIssuanceCosts>
    <eypt:DebtInstrumentExitFee
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">0</eypt:DebtInstrumentExitFee>
    <eypt:DebtInstrumentExitFee
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">122000</eypt:DebtInstrumentExitFee>
    <eypt:PaymentsForgivenUnderPaycheckProtectionProgramLoan
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">2041000</eypt:PaymentsForgivenUnderPaycheckProtectionProgramLoan>
    <eypt:PaymentsForgivenUnderPaycheckProtectionProgramLoan
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">0</eypt:PaymentsForgivenUnderPaycheckProtectionProgramLoan>
    <us-gaap:NatureOfOperations contextRef="C_0001314102_20210101_20211231" id="F_000273">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Operations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;EyePoint Pharmaceuticals, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;), incorporated in Delaware, is&lt;span style="Background-color:#FFFFFF;"&gt; a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company&#x2019;s pipeline leverages its proprietary Durasert&lt;/span&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae; &lt;/sup&gt;&lt;span style="Background-color:#FFFFFF;"&gt;technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration (&#x201c;wet AMD&#x201d;), the leading cause of vision loss among people 50 years of age and older in the United States. The Company&#x2019;s product candidate pipeline also includes YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application (&#x201c;sNDA&#x201d;) strategy. The Company also has two commercial products: YUTIQ&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;, a once every three-year treatment for chronic&#160;non-infectious&#160;uveitis affecting the posterior segment of the eye, and DEXYCU&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;, a single dose treatment for postoperative inflammation following ocular surgery.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Local drug delivery for treating ocular diseases is a significant challenge due to the effectiveness of the blood-eye barrier. This barrier makes it difficult for systemically-administered drugs to reach the eye in sufficient quantities to have a beneficial effect without causing unacceptable adverse side effects to other organs. The Company&#x2019;s validated Durasert technology, which has already been included in four products approved for marketing by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), is designed to provide consistent, sustained delivery of small molecule drugs over a period of months to years through a single intravitreal injection. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s lead product candidate, EYP-1901, combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor (&#x201c;TKI&#x201d;) that has demonstrated anti-VEGF activity. Current FDA approved anti-VEGF treatments for wet AMD require monthly or bi-monthly intravitreal injections in a physician&#x2019;s office. The Company is currently evaluating EYP-1901 in a Phase 1 clinical trial as a potential six-month sustained delivery treatment for wet AMD and reported positive six-month interim safety and efficacy data in November 2021. In February 2022, the Company updated the results of the DAVIO clinical trial through 8-months reporting continued positive safety and efficacy results. The Company expects to initiate a Phase 2 clinical trial in wet AMD in the third quarter of 2022 and a Phase 2 clinical trial in diabetic retinopathy later in the second half of 2022.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;YUTIQ&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;(fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is a non-erodible intravitreal implant containing fluocinolone acetonide (&#x201c;FA&#x201d;) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This disease affects between 60,000 to 100,000 people each year in the U.S. causes approximately 30,000 new cases of blindness every year and is the third leading cause of blindness. YUTIQ utilizes the Company&#x2019;s proprietary Durasert&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;sustained-release drug delivery technology platform.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;DEXYCU&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;(dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation, with the Company&#x2019;s primary focus on its use&#160;immediately following cataract surgery as a single dose treatment. DEXYCU utilizes the Company&#x2019;s proprietary Verisome&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;drug-delivery&#160;technology. In December 2021, the Company announced that its commercial alliance partner, ImprimisRx, assumed responsibility for all sales and marketing activity for DEXYCU effective January 1, 2022.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company is also developing YUTIQ 50 as a potential six-month intravitreal treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. The Company dosed the first patient in a Phase 3 clinical trial in November 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The&lt;/span&gt; Company is also seeking to potentially identify and advance additional product candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, potential research collaborations and/or&#160;in-licensing&#160;arrangements with partner molecules and potential acquisition of additional ophthalmic products, product candidates or technologies that complement the Company&#x2019;s current product portfolio.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effects of the COVID-19 Coronavirus Pandemic&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;"&gt; ongoing COVID-19 coronavirus pandemic&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; (the &#x201c;Pandemic&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;"&gt; has had a material and adverse impact on the Company&#x2019;s business, including as a result of measures that the Company, other businesses, and government have taken and will likely continue to take. This includes a significant impact on cash flows from expected revenues due to the closure of ambulatory surgery centers for DEXYCU and a significant reduction in physician office visits impacting YUTIQ in 2020. The ongoing Pandemic continued to have an adverse impact on the Company&#x2019;s revenues, financial condition and cash flows through 2021. For the year ended December 31, 2021, the Company recorded impairment charges of $1.2 million to cost of sales, excluding amortization of acquired intangible assets and $0.1 million to sales and marketing expense, respectively, associated with the write-off of obsolete inventory of DEXYCU units and DEXYCU sample units, respectively, whose inventory levels were higher than the Company&#x2019;s updated forecasts of future demand &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;for those units. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Additionally, the emergence of &lt;/span&gt;&lt;span style="color:#000000;"&gt;the Omicron &lt;/span&gt;&lt;span style="color:#000000;"&gt;variant has &lt;/span&gt;&lt;span style="color:#000000;"&gt;continued to have an adverse impact on the Company&#x2019;s revenues, financial condition and cash flows into the first quarter of 2022&lt;/span&gt;&lt;span style="color:#000000;"&gt; and may continue to cause intermittent or prolonged periods of reduced patient services at the Company&#x2019;s customers&#x2019; facilities, which may negatively affect customer demand. The progression of the Pandemic and its effects on the Company&#x2019;s business and operations are uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, the Company&#x2019;s revenues, financial condition and cash flows may be adversely affected in the future as well.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;The Company is &lt;/span&gt;&lt;span style="color:#000000;"&gt;continuously &lt;/span&gt;&lt;span style="color:#000000;"&gt;monitoring the Pandemic and its potential effect on the Company&#x2019;s financial position, results of operations and cash flows. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company&#x2019;s periodic financial results, including reserves for variable consideration related to product sales, realizability of certain receivables, assessment for excess or obsolete inventory, and impairment of long-lived assets. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Uncertainty around the extent and duration of the Pandemic, and any future related financial impact cannot be reasonably estimated at this time.&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidity&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;"&gt; Company had cash, cash equivalents, and investments in marketable securities of $211.6&lt;/span&gt;&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;"&gt;million at December 31, 2021.&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The Company has a history of operating losses and has not had significant recurring cash inflows from revenue.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The Company&#x2019;s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates and the Company does not expect revenues from its product sales to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenues of its product sales, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents, and investments in marketable securities of $211.6&lt;/span&gt;&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;"&gt;million at December 31, 2021, coupled with expected cash inflows from its product sales will enable the Company to fund its current and planned operations for &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;at least the next twelve months from the date these consolidated financial statements were issued. A&lt;/span&gt;&lt;span style="color:#000000;"&gt;ctual cash requirements could differ from management&#x2019;s projections due to many factors, including the continued effect of the Pandemic on the Company&#x2019;s business and the medical community, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;the timing and results of the Company&#x2019;s clinical trials for EYP-1901, &lt;/span&gt;&lt;span style="color:#000000;"&gt;additional &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;investments&lt;/span&gt;&lt;span style="color:#000000;"&gt; in research and development programs, the success of ongoing &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;commercialization&lt;/span&gt;&lt;span style="color:#000000;"&gt; efforts for YUTIQ and DEXYCU, the actual costs of these ongoing commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <eypt:NumberOfProducts
      contextRef="C_0001314102_20210101_20211231"
      decimals="INF"
      id="F_000335"
      unitRef="U_eyptProduct">2</eypt:NumberOfProducts>
    <eypt:NumberOfProductsApproved
      contextRef="C_0001314102_20210101_20211231"
      decimals="INF"
      id="F_000336"
      unitRef="U_eyptProduct">4</eypt:NumberOfProductsApproved>
    <eypt:NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMinimumMember_20210101_20211231"
      decimals="INF"
      id="F_000337"
      unitRef="U_eypt_People">60000</eypt:NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear>
    <eypt:NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_srtRangeAxis_srtMaximumMember_20210101_20211231"
      decimals="INF"
      id="F_000338"
      unitRef="U_eypt_People">100000</eypt:NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear>
    <eypt:NumberOfNewBlindnessCasesEveryYear
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20210101_20211231"
      decimals="INF"
      id="F_000339"
      unitRef="U_eyptCase">30000</eypt:NumberOfNewBlindnessCasesEveryYear>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptCostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember_20210101_20211231"
      decimals="-5"
      id="F_000340"
      unitRef="U_iso4217USD">1200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20210101_20211231"
      decimals="-5"
      id="F_000341"
      unitRef="U_iso4217USD">100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000342"
      unitRef="U_iso4217USD">211600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000343"
      unitRef="U_iso4217USD">211600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000274">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Significant Accounting Policies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements are presented in U.S. dollars in accordance with generally accepted accounting principles in the U.S. (&#x201c;U.S. GAAP&#x201d;) and include the accounts of EyePoint Pharmaceuticals, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to reserves for variable consideration related to product sales, revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recording of excess or obsolete inventory write-offs and reserves, and realization of deferred tax assets. Actual results could differ from these and other estimates and there may be changes to the Company&#x2019;s estimates in future periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company and each of its subsidiaries is the currency of the primary economic environment in which each such entity operates&#x2014;the U.S. dollar or the Pound&#160;Sterling. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities of the Company&#x2019;s foreign subsidiary are translated at period-end exchange rates. Amounts included in the consolidated statements of comprehensive loss and cash flows are translated at the weighted average exchange rates for the period. Gains and losses from currency translation are included in accumulated other comprehensive income as a separate component of stockholders&#x2019; equity in the consolidated balance sheets. The balance of accumulated other comprehensive income attributable to foreign currency translation was $841,000 and $841,000 at December&#160;31, 2021 and 2020, respectively. Foreign currency gains or &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;losses arising from transactions denominated in foreign currencies, whether realized or unrealized, are recorded in interest and other income, net in the consolidated statements of comprehensive loss and were not &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;material &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for all periods presented.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents represent highly liquid investments with maturities of three months or less at the date of purchase, principally consisting of institutional money market funds and investment-grade commercial paper. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of investments with an original or remaining maturity of greater than three months but less than six months at the date of purchase. The Company has historically classified its marketable securities as available-for-sale. Accordingly, the Company records these investments at fair value, with unrealized gains and losses excluded from earnings and reported, net of tax, in accumulated other comprehensive income, which is a component of stockholders&#x2019; equity. If the Company determines that a decline of any investment is other-than-temporary, the investment is written down to fair value. Marketable securities at December 31, 2021 consisted of investment-grade commercial paper. The Company had no marketable security investments at December 31, 2020. The Company&#x2019;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. During fiscal 2021, $33.0 million of marketable securities were purchased and $0 matured.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of marketable securities is determined based on quoted market prices at the balance sheet date of the same or similar instruments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts through to the earlier of sale or maturity. Such amortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the specific identification method.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and investments in marketable securities. At December&#160;31, 2021, a total of $155.6&#160;million, or 90.4% of the Company&#x2019;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $16.5 million, or 9.6% of the Company&#x2019;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $33.0 million and $0 in marketable securities at December&#160;31, 2021 and 2020, respectively. The Company&#x2019;s investment policy, approved by the Company&#x2019;s Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, accounts receivable from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 54.7% and 38.3% of total accounts receivable, respectively. For the year ended December 31, 2021, revenues from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 46.6% and 43.1% of total revenues, respectively.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, accounts receivable from ASD Specialty Healthcare LLC and McKesson Specialty Care Distribution LLC accounted for 56.0% and 37.0% of total accounts receivable, respectively. For the year ended December 31, 2020, revenues from ASD Specialty Healthcare LLC, Ocumension Therapeutics, and McKesson Specialty Care Distribution LLC accounted for 39.0%, 33.0%, and 18.0% of total revenues, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;1 &#x2013; Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;2 &#x2013; Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets). &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;3 &#x2013; Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#x2019; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts and Other Receivables, Net&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivables arise primarily from the Company&#x2019;s products sold in the U.S. The balance in accounts and other receivables, net consists primarily of amounts due from customers, net of applicable revenue reserves. The majority of the Company&#x2019;s accounts receivable have standard payment terms that require payment within 120-127 days. The Company &lt;span style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.2pt;"&gt;performs ongoing credit evaluations of its customers&#x2019; financial condition and continuously monitor collections and payments from its customers and&lt;/span&gt; analyzes accounts that are past due for collectability. &lt;span style="color:#000000;"&gt;The allowance for credit losses is estimated based on the Company&#x2019;s analysis of trends in overall receivables aging, specific identification of certain receivables that are at risk of not being paid, past collection experience and current economic trends. &lt;/span&gt;G&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;iven the nature and limited history of collectability of the Company&#x2019;s accounts receivable, &lt;/span&gt;the Company recorded no allowance for credit losses as of December 31, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is stated at the lower of cost or net realizable value, net on a first-in, first-out (&#x201c;FIFO&#x201d;) basis. The inventory costs for YUTIQ include purchases of various components and the active pharmaceutical ingredient (&#x201c;API&#x201d;) and internal labor and overhead for the product manufactured in the Company&#x2019;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalization of inventory costs begins after FDA approval of the product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company assesses the recoverability of inventory and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Write-downs are based on the age of the inventory, lower of cost or market, along with significant management judgments concerning future demands for the inventory. Such impairment charges, should they occur, are recorded within cost of sales, excluding amortization of acquired intangible assets. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory might be recorded in future periods.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost &lt;span style="Background-color:#FFFFFF;"&gt;of&lt;/span&gt; sales, excluding amortization of acquired intangible assets, consist of costs associated with the manufacture of YUTIQ and DEXYCU, certain period costs for DEXYCU product revenue, product shipping and, as applicable, royalty expense. The inventory costs for YUTIQ include purchases of various components, the active pharmaceutical ingredient (&#x201c;API&#x201d;) and direct labor and overhead for the product manufactured in the Company&#x2019;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly. Capitalization of inventory costs begins after FDA approval of a product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The&lt;/span&gt; Company accrued DEXYCU product revenue-based royalty expense of $2.5 million and $&lt;span style="color:#000000;"&gt;2.3&lt;/span&gt; million for the years ended December 31, 2021 and 2020, respectively, as a component of cost of sales, of which $0 and $&lt;span style="color:#000000;"&gt;1.3&lt;/span&gt; million of accrued revenue-based royalty expense were related to the partnering income equal to 20% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, in connection with the acquisition of Icon Bioscience, Inc. in March 2018 for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt and Equity Instruments &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;"&gt; and equity instruments are classified as either liabilities or equity in accordance with the substance of the contractual arrangement. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative Instruments &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Derivative&lt;/span&gt;&lt;span style="color:#000000;"&gt; financial liabilities are recorded at fair value, with gains and losses arising from changes in fair value recognized in change in fair value of derivative liability within the consolidated statements of comprehensive loss at each period end while such instruments are outstanding. The Company&#x2019;s derivative liabilities from certain financing transactions were primarily valued using Monte Carlo simulation models. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives (generally three to five years) using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining non-cancellable lease term or their estimated useful lives. Repair and maintenance costs are expensed as incurred. When assets are retired or sold, the assets and accumulated depreciation are derecognized from the respective accounts and any gain or loss is recognized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized Software Development Cost&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC 350 &lt;span style="font-style:italic;"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;, and classified as a prepaid asset in the balance sheets. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud completing arrangement, over the term of the arrangement, plus reasonably certain renewals.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases real estate and office equipment under operating leases. Its primary real estate lease contains rent holiday and rent escalation clauses. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether the arrangement is or contains a lease at inception. Operating leases are recognized on the consolidated balance sheets as ROU assets, current portion of lease liabilities and long-term lease liabilities. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. &lt;span style="color:#000000;"&gt;For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. &lt;/span&gt;The operating lease ROU assets also include any lease payments made and adjustments for prepayments and lease incentives. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilized its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Intangible Assets &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s finite life intangible assets include the DEXYCU product (utilizing the Verisome technology) following the March 2018 acquisition of Icon. The DEXYCU intangible asset is being amortized on a straight-line basis over its estimated useful life of thirteen years. The intangible asset lives were determined based upon the anticipated period that the Company would derive future cash flows from the intangible assets, considering the effects of legal, regulatory, contractual, competitive and other economic factors. The Company continually monitors whether events or circumstances have occurred that indicate that the remaining estimated useful life of its intangible assets may warrant revision. The Company assesses potential impairments to its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the future undiscounted net cash flows expected to result from the use of an asset are less than its carrying value. If the Company considers an asset to be impaired, the impairment charge to be recognized is measured as the amount by which the carrying value of the asset exceeds its estimated fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;"&gt; is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Product sales, net&lt;span style="font-weight:normal;font-style:normal;"&gt; &#x2014; The Company sells YUTIQ and DEXYCU to a limited number of specialty distributors and specialty pharmacies (collectively the &#x201c;Distributors&#x201d;) in the U.S., with whom the Company has entered into formal agreements, for delivery to physician practices for YUTIQ and to hospital outpatient departments and ambulatory surgical centers for DEXYCU. The Company recognizes revenue on sales of its products when Distributors obtain control of the products, which occurs at a point in time, typically upon delivery. In addition to agreements with Distributors, the Company also enters into arrangements with healthcare providers, ambulatory surgical centers, and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#x2019;s products from Distributors. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Reserves for variable consideration &lt;span style="color:#000000;font-style:normal;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:normal;"&gt;Product sales are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, provider chargebacks and discounts, payor rebates, product returns, and other allowances that are offered within contracts between the Company and its Distributors, payors, and other contracted purchasers relating to the Company&#x2019;s product sales. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified either as reductions of product revenue and accounts receivable or a current liability, depending on how the amount is to be settled. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.&lt;/span&gt;&lt;span style="color:#FF0000;font-style:normal;"&gt; &lt;/span&gt;&lt;span style="font-style:normal;"&gt;Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Distribution fees &lt;span style="font-style:normal;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;The Company compensates its Distributors for services explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product sale is recognized. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Provider chargebacks and discounts &lt;span style="font-style:normal;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;Chargebacks are discounts that represent the estimated obligations resulting from contractual commitments to sell products at prices lower than the list prices charged to the Company&#x2019;s Distributors. These Distributors charge the Company for the difference between what they pay for the product and the Company&#x2019;s contracted selling price. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of &lt;/span&gt;&lt;span style="font-style:normal;"&gt;product revenue and the establishment of a current liability&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;. Reserves for chargebacks consist of amounts that the Company expects to pay for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold under a contracted selling price, and chargebacks that Distributors have claimed, but for which the Company has not yet settled.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Government rebates &lt;span style="font-style:normal;"&gt;&#x2014; The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Payor rebates &lt;span style="font-style:normal;"&gt;&#x2014; The Company contracts with certain private payor organizations, primarily insurance companies, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Co-Payment assistance &lt;span style="font-style:normal;"&gt;&#x2014; The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Product returns &lt;/span&gt;&lt;span style="font-style:normal;"&gt;&#x2014; The Company generally offers a limited right of return based on its returned goods policy, which includes damaged product and remaining shelf life. The Company estimates the amount of its product sales that may be returned and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to trade receivables, net on the &lt;/span&gt;&lt;span style="font-style:normal;"&gt;condensed&lt;/span&gt;&lt;span style="font-style:normal;"&gt; consolidated balance sheets. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;License and collaboration agreement revenue&lt;span style="font-weight:normal;font-style:normal;"&gt; &#x2014; The Company analyzes each element of its license and collaboration arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#x2019;s contracts contained a significant financing component as of December&#160;31, 2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Royalties &lt;span style="font-weight:normal;font-style:normal;"&gt;&#x2014; The Company recognizes revenue from license arrangements with its commercial partners&#x2019; net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner&#x2019;s products occurs. The Company&#x2019;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60&#160;days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company recognizes royalty income each quarter and subsequently determines a true-up when it receives royalty reports and payment from its commercial partners. Historically, these true-up adjustments have been immaterial. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Sale of Future Royalties &lt;span style="font-weight:normal;font-style:normal;"&gt;&#x2014; The Company has sold its rights to receive certain royalties on product sales. In the circumstance where the Company has sold its rights to future royalties under a royalty purchase agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research Collaborations&lt;span style="font-weight:normal;font-style:normal;"&gt; &#x2014; The Company recognizes revenue over the term of the statements of work under any funded research collaborations (including feasibility study agreements). Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations (including feasibility study agreements). &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Please refer to Note 3 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Revenue &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized within one year following the balance sheet date are classified as non-current deferred revenue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are charged to operations as incurred. These costs include all direct costs, including cash and stock-based compensation and benefits for research, clinical development, quality assurance, quality control, operations and medical affairs personnel, amortization of intangible assets, third-party costs and services for clinical trials, clinical materials, pre-clinical programs, regulatory and medical affairs, external consultants, and other operational costs related to the Company&#x2019;s research and development of its product candidates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation cost related to share-based payment awards is based on the fair value of the instrument on the grant date and is recognized on a graded vesting basis over the requisite service period for each separately vesting tranche of the awards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may also grant share-based payment awards that are subject to objectively measurable performance and service criteria. Compensation expense for performance-based awards begins at such time as it becomes probable that the respective performance conditions will be achieved. The Company continues to recognize the grant date fair value of performance-based awards through the vesting date of the respective awards so long as it remains probable that the related performance conditions will be satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model and the fair value of performance stock units, restricted stock units and deferred stock units based on the observed grant date fair value of the underlying Common Stock.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the weighted-average number of common shares outstanding the average number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, 3,272,727 shares of Pre-Funded Warrants to purchase common stock, issued in connection with the November 2021 underwritten public offering (see Note 10), were included in the basic and diluted net loss per share calculation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,517,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,338,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,881,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,564,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is comprised of net loss, foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Tax &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future benefit to be derived from tax credits and loss carry forwards. Such deferred income tax computations are measured based on enacted tax laws and rates applicable to the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is provided against net deferred tax assets if, based on the available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the uncertainty. The Company accounts for interest and penalties related to uncertain tax positions as part of its income tax benefit. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted and Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company&#x2019;s financial position, results of operations and cash flows or do not apply to the Company&#x2019;s operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;"&gt; (&#x201c;ASU 2019-12&#x201d;)&lt;/span&gt;&lt;span style="font-style:italic;"&gt;: Simplifying the Accounting for Income Taxes.&lt;/span&gt;&#160;The amendments simplify the accounting for income taxes by removing certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt &#x2013; Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) &lt;/span&gt;(&#x201c;ASU 2021-04&#x201d;)&lt;span style="font-style:italic;"&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&lt;/span&gt; The amendments are designed to clarify an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options that remain equity-classified after modification or exchange. The ASU provides guidance on how an issuer would measure and recognize the effects of these transactions. The standard provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. ASU 2021-04 will be effective for the Company in the first quarter of its fiscal year ending December 31, 2022. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000291">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements are presented in U.S. dollars in accordance with generally accepted accounting principles in the U.S. (&#x201c;U.S. GAAP&#x201d;) and include the accounts of EyePoint Pharmaceuticals, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001314102_20210101_20211231" id="F_000292">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to reserves for variable consideration related to product sales, revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, recording of excess or obsolete inventory write-offs and reserves, and realization of deferred tax assets. Actual results could differ from these and other estimates and there may be changes to the Company&#x2019;s estimates in future periods. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000293">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company and each of its subsidiaries is the currency of the primary economic environment in which each such entity operates&#x2014;the U.S. dollar or the Pound&#160;Sterling. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities of the Company&#x2019;s foreign subsidiary are translated at period-end exchange rates. Amounts included in the consolidated statements of comprehensive loss and cash flows are translated at the weighted average exchange rates for the period. Gains and losses from currency translation are included in accumulated other comprehensive income as a separate component of stockholders&#x2019; equity in the consolidated balance sheets. The balance of accumulated other comprehensive income attributable to foreign currency translation was $841,000 and $841,000 at December&#160;31, 2021 and 2020, respectively. Foreign currency gains or &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;losses arising from transactions denominated in foreign currencies, whether realized or unrealized, are recorded in interest and other income, net in the consolidated statements of comprehensive loss and were not &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;material &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for all periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="C_0001314102_20211231"
      decimals="0"
      id="F_000344"
      unitRef="U_iso4217USD">841000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="C_0001314102_20201231"
      decimals="0"
      id="F_000345"
      unitRef="U_iso4217USD">841000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000294">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents represent highly liquid investments with maturities of three months or less at the date of purchase, principally consisting of institutional money market funds and investment-grade commercial paper. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001314102_20210101_20211231" id="F_000295">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of investments with an original or remaining maturity of greater than three months but less than six months at the date of purchase. The Company has historically classified its marketable securities as available-for-sale. Accordingly, the Company records these investments at fair value, with unrealized gains and losses excluded from earnings and reported, net of tax, in accumulated other comprehensive income, which is a component of stockholders&#x2019; equity. If the Company determines that a decline of any investment is other-than-temporary, the investment is written down to fair value. Marketable securities at December 31, 2021 consisted of investment-grade commercial paper. The Company had no marketable security investments at December 31, 2020. The Company&#x2019;s investment policy, approved by the Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. During fiscal 2021, $33.0 million of marketable securities were purchased and $0 matured.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of marketable securities is determined based on quoted market prices at the balance sheet date of the same or similar instruments. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts through to the earlier of sale or maturity. Such amortization and accretion amounts are included in interest and other income, net in the consolidated statements of comprehensive loss. The cost of marketable securities sold is determined by the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000346"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001314102_20210101_20211231"
      decimals="-5"
      id="F_000347"
      unitRef="U_iso4217USD">33000000.0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000348"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001314102_20210101_20211231" id="F_000296">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and investments in marketable securities. At December&#160;31, 2021, a total of $155.6&#160;million, or 90.4% of the Company&#x2019;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $16.5 million, or 9.6% of the Company&#x2019;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $33.0 million and $0 in marketable securities at December&#160;31, 2021 and 2020, respectively. The Company&#x2019;s investment policy, approved by the Company&#x2019;s Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, accounts receivable from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 54.7% and 38.3% of total accounts receivable, respectively. For the year ended December 31, 2021, revenues from McKesson Specialty Care Distribution LLC and ASD Specialty Healthcare LLC accounted for 46.6% and 43.1% of total revenues, respectively.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, accounts receivable from ASD Specialty Healthcare LLC and McKesson Specialty Care Distribution LLC accounted for 56.0% and 37.0% of total accounts receivable, respectively. For the year ended December 31, 2020, revenues from ASD Specialty Healthcare LLC, Ocumension Therapeutics, and McKesson Specialty Care Distribution LLC accounted for 39.0%, 33.0%, and 18.0% of total revenues, respectively.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000349"
      unitRef="U_iso4217USD">155600000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000351"
      unitRef="U_xbrlipure">0.904</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000350"
      unitRef="U_iso4217USD">16500000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000352"
      unitRef="U_xbrlipure">0.096</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000353"
      unitRef="U_iso4217USD">33000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="0"
      id="F_000354"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000356"
      unitRef="U_xbrlipure">0.547</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000355"
      unitRef="U_xbrlipure">0.383</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000358"
      unitRef="U_xbrlipure">0.466</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000357"
      unitRef="U_xbrlipure">0.431</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000359"
      unitRef="U_xbrlipure">0.560</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000360"
      unitRef="U_xbrlipure">0.370</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptASDSpecialtyHealthcareLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000361"
      unitRef="U_xbrlipure">0.390</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000362"
      unitRef="U_xbrlipure">0.330</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptMcKessonSpecialtyCareDistributionLLCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000363"
      unitRef="U_xbrlipure">0.180</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000297">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;1 &#x2013; Inputs are quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;2 &#x2013; Inputs are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities with insufficient volume or infrequent transaction (less active markets). &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;3 &#x2013; Inputs are unobservable estimates that are supported by little or no market activity and require the Company to develop its own assumptions about how market participants would price the assets or liabilities. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#x2019; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="C_0001314102_20210101_20211231" id="F_000298">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts and Other Receivables, Net&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivables arise primarily from the Company&#x2019;s products sold in the U.S. The balance in accounts and other receivables, net consists primarily of amounts due from customers, net of applicable revenue reserves. The majority of the Company&#x2019;s accounts receivable have standard payment terms that require payment within 120-127 days. The Company &lt;span style="Background-color:#FFFFFF;color:#000000;letter-spacing:-0.2pt;"&gt;performs ongoing credit evaluations of its customers&#x2019; financial condition and continuously monitor collections and payments from its customers and&lt;/span&gt; analyzes accounts that are past due for collectability. &lt;span style="color:#000000;"&gt;The allowance for credit losses is estimated based on the Company&#x2019;s analysis of trends in overall receivables aging, specific identification of certain receivables that are at risk of not being paid, past collection experience and current economic trends. &lt;/span&gt;G&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;iven the nature and limited history of collectability of the Company&#x2019;s accounts receivable, &lt;/span&gt;the Company recorded no allowance for credit losses as of December 31, 2021 and 2020.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <eypt:AccountsReceivableStandardPaymentTerms
      contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000366">P120D</eypt:AccountsReceivableStandardPaymentTerms>
    <eypt:AccountsReceivableStandardPaymentTerms
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000367">P127D</eypt:AccountsReceivableStandardPaymentTerms>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000364"
      unitRef="U_iso4217USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000365"
      unitRef="U_iso4217USD">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000299">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is stated at the lower of cost or net realizable value, net on a first-in, first-out (&#x201c;FIFO&#x201d;) basis. The inventory costs for YUTIQ include purchases of various components and the active pharmaceutical ingredient (&#x201c;API&#x201d;) and internal labor and overhead for the product manufactured in the Company&#x2019;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalization of inventory costs begins after FDA approval of the product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company assesses the recoverability of inventory and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Write-downs are based on the age of the inventory, lower of cost or market, along with significant management judgments concerning future demands for the inventory. Such impairment charges, should they occur, are recorded within cost of sales, excluding amortization of acquired intangible assets. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory might be recorded in future periods.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost &lt;span style="Background-color:#FFFFFF;"&gt;of&lt;/span&gt; sales, excluding amortization of acquired intangible assets, consist of costs associated with the manufacture of YUTIQ and DEXYCU, certain period costs for DEXYCU product revenue, product shipping and, as applicable, royalty expense. The inventory costs for YUTIQ include purchases of various components, the active pharmaceutical ingredient (&#x201c;API&#x201d;) and direct labor and overhead for the product manufactured in the Company&#x2019;s Watertown, MA facility. The inventory costs for DEXYCU include purchased components, the API and third-party manufacturing and assembly. Capitalization of inventory costs begins after FDA approval of a product. Prior thereto, inventory costs of products and product candidates are recorded as research and development expense, even if this inventory may later be sold as commercial product.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The&lt;/span&gt; Company accrued DEXYCU product revenue-based royalty expense of $2.5 million and $&lt;span style="color:#000000;"&gt;2.3&lt;/span&gt; million for the years ended December 31, 2021 and 2020, respectively, as a component of cost of sales, of which $0 and $&lt;span style="color:#000000;"&gt;1.3&lt;/span&gt; million of accrued revenue-based royalty expense were related to the partnering income equal to 20% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, in connection with the acquisition of Icon Bioscience, Inc. in March 2018 for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <eypt:AccruedRevenueBasedRoyaltyExpense
      contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231"
      decimals="-5"
      id="F_000368"
      unitRef="U_iso4217USD">2500000</eypt:AccruedRevenueBasedRoyaltyExpense>
    <eypt:AccruedRevenueBasedRoyaltyExpense
      contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231"
      decimals="-5"
      id="F_000369"
      unitRef="U_iso4217USD">2300000</eypt:AccruedRevenueBasedRoyaltyExpense>
    <eypt:AccruedRevenueBasedRoyaltyExpense
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231"
      decimals="-6"
      id="F_000370"
      unitRef="U_iso4217USD">0</eypt:AccruedRevenueBasedRoyaltyExpense>
    <eypt:AccruedRevenueBasedRoyaltyExpense
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200101_20201231"
      decimals="-5"
      id="F_000371"
      unitRef="U_iso4217USD">1300000</eypt:AccruedRevenueBasedRoyaltyExpense>
    <eypt:PercentageOfAcceleratedMilestonePaymentReceived
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200801_20200831"
      decimals="2"
      id="F_000372"
      unitRef="U_xbrlipure">0.20</eypt:PercentageOfAcceleratedMilestonePaymentReceived>
    <eypt:PercentageOfUpfrontPaymentReceived
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20200201_20200229"
      decimals="2"
      id="F_000373"
      unitRef="U_xbrlipure">0.20</eypt:PercentageOfUpfrontPaymentReceived>
    <eypt:DebtAndEquityInstrumentsPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000300">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt and Equity Instruments &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;"&gt; and equity instruments are classified as either liabilities or equity in accordance with the substance of the contractual arrangement. &lt;/span&gt;&lt;/p&gt;</eypt:DebtAndEquityInstrumentsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000301">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative Instruments &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Derivative&lt;/span&gt;&lt;span style="color:#000000;"&gt; financial liabilities are recorded at fair value, with gains and losses arising from changes in fair value recognized in change in fair value of derivative liability within the consolidated statements of comprehensive loss at each period end while such instruments are outstanding. The Company&#x2019;s derivative liabilities from certain financing transactions were primarily valued using Monte Carlo simulation models. &lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000302">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives (generally three to five years) using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the remaining non-cancellable lease term or their estimated useful lives. Repair and maintenance costs are expensed as incurred. When assets are retired or sold, the assets and accumulated depreciation are derecognized from the respective accounts and any gain or loss is recognized. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001314102_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000374">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000375">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000303">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized Software Development Cost&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC 350 &lt;span style="font-style:italic;"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;, and classified as a prepaid asset in the balance sheets. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud completing arrangement, over the term of the arrangement, plus reasonably certain renewals.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000304">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases real estate and office equipment under operating leases. Its primary real estate lease contains rent holiday and rent escalation clauses. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether the arrangement is or contains a lease at inception. Operating leases are recognized on the consolidated balance sheets as ROU assets, current portion of lease liabilities and long-term lease liabilities. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. &lt;span style="color:#000000;"&gt;For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. &lt;/span&gt;The operating lease ROU assets also include any lease payments made and adjustments for prepayments and lease incentives. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilized its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. &lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000305">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Intangible Assets &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s finite life intangible assets include the DEXYCU product (utilizing the Verisome technology) following the March 2018 acquisition of Icon. The DEXYCU intangible asset is being amortized on a straight-line basis over its estimated useful life of thirteen years. The intangible asset lives were determined based upon the anticipated period that the Company would derive future cash flows from the intangible assets, considering the effects of legal, regulatory, contractual, competitive and other economic factors. The Company continually monitors whether events or circumstances have occurred that indicate that the remaining estimated useful life of its intangible assets may warrant revision. The Company assesses potential impairments to its intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the future undiscounted net cash flows expected to result from the use of an asset are less than its carrying value. If the Company considers an asset to be impaired, the impairment charge to be recognized is measured as the amount by which the carrying value of the asset exceeds its estimated fair value. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328"
      id="F_000376">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000306">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;"&gt; is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Product sales, net&lt;span style="font-weight:normal;font-style:normal;"&gt; &#x2014; The Company sells YUTIQ and DEXYCU to a limited number of specialty distributors and specialty pharmacies (collectively the &#x201c;Distributors&#x201d;) in the U.S., with whom the Company has entered into formal agreements, for delivery to physician practices for YUTIQ and to hospital outpatient departments and ambulatory surgical centers for DEXYCU. The Company recognizes revenue on sales of its products when Distributors obtain control of the products, which occurs at a point in time, typically upon delivery. In addition to agreements with Distributors, the Company also enters into arrangements with healthcare providers, ambulatory surgical centers, and payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company&#x2019;s products from Distributors. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Reserves for variable consideration &lt;span style="color:#000000;font-style:normal;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:normal;"&gt;Product sales are recorded at the wholesale acquisition costs, net of applicable reserves for variable consideration. Components of variable consideration include trade discounts and allowances, provider chargebacks and discounts, payor rebates, product returns, and other allowances that are offered within contracts between the Company and its Distributors, payors, and other contracted purchasers relating to the Company&#x2019;s product sales. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified either as reductions of product revenue and accounts receivable or a current liability, depending on how the amount is to be settled. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.&lt;/span&gt;&lt;span style="color:#FF0000;font-style:normal;"&gt; &lt;/span&gt;&lt;span style="font-style:normal;"&gt;Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual results in the future vary from the estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Distribution fees &lt;span style="font-style:normal;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;The Company compensates its Distributors for services explicitly stated in the Company&#x2019;s contracts and are recorded as a reduction of revenue in the period the related product sale is recognized. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Provider chargebacks and discounts &lt;span style="font-style:normal;"&gt;&#x2014; &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;Chargebacks are discounts that represent the estimated obligations resulting from contractual commitments to sell products at prices lower than the list prices charged to the Company&#x2019;s Distributors. These Distributors charge the Company for the difference between what they pay for the product and the Company&#x2019;s contracted selling price. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of &lt;/span&gt;&lt;span style="font-style:normal;"&gt;product revenue and the establishment of a current liability&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;. Reserves for chargebacks consist of amounts that the Company expects to pay for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold under a contracted selling price, and chargebacks that Distributors have claimed, but for which the Company has not yet settled.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Government rebates &lt;span style="font-style:normal;"&gt;&#x2014; The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Payor rebates &lt;span style="font-style:normal;"&gt;&#x2014; The Company contracts with certain private payor organizations, primarily insurance companies, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Co-Payment assistance &lt;span style="font-style:normal;"&gt;&#x2014; The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Product returns &lt;/span&gt;&lt;span style="font-style:normal;"&gt;&#x2014; The Company generally offers a limited right of return based on its returned goods policy, which includes damaged product and remaining shelf life. The Company estimates the amount of its product sales that may be returned and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to trade receivables, net on the &lt;/span&gt;&lt;span style="font-style:normal;"&gt;condensed&lt;/span&gt;&lt;span style="font-style:normal;"&gt; consolidated balance sheets. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;License and collaboration agreement revenue&lt;span style="font-weight:normal;font-style:normal;"&gt; &#x2014; The Company analyzes each element of its license and collaboration arrangements to determine the appropriate revenue recognition. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606-10-55-65. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company&#x2019;s contracts contained a significant financing component as of December&#160;31, 2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Royalties &lt;span style="font-weight:normal;font-style:normal;"&gt;&#x2014; The Company recognizes revenue from license arrangements with its commercial partners&#x2019; net sales of products. Such revenues are included as royalty income. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the commercial partner&#x2019;s products occurs. The Company&#x2019;s commercial partners are obligated to report their net product sales and the resulting royalty due to the Company typically within 60&#160;days from the end of each quarter. Based on historical product sales, royalty receipts and other relevant information, the Company recognizes royalty income each quarter and subsequently determines a true-up when it receives royalty reports and payment from its commercial partners. Historically, these true-up adjustments have been immaterial. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Sale of Future Royalties &lt;span style="font-weight:normal;font-style:normal;"&gt;&#x2014; The Company has sold its rights to receive certain royalties on product sales. In the circumstance where the Company has sold its rights to future royalties under a royalty purchase agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.13%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research Collaborations&lt;span style="font-weight:normal;font-style:normal;"&gt; &#x2014; The Company recognizes revenue over the term of the statements of work under any funded research collaborations (including feasibility study agreements). Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations (including feasibility study agreements). &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Please refer to Note 3 for further details on the license and collaboration agreements into which the Company has entered and corresponding amounts of revenue recognized during the current and prior year periods.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Revenue &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized within one year following the balance sheet date are classified as non-current deferred revenue. &lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001314102_20210101_20211231" id="F_000307">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are charged to operations as incurred. These costs include all direct costs, including cash and stock-based compensation and benefits for research, clinical development, quality assurance, quality control, operations and medical affairs personnel, amortization of intangible assets, third-party costs and services for clinical trials, clinical materials, pre-clinical programs, regulatory and medical affairs, external consultants, and other operational costs related to the Company&#x2019;s research and development of its product candidates.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001314102_20210101_20211231" id="F_000308">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation cost related to share-based payment awards is based on the fair value of the instrument on the grant date and is recognized on a graded vesting basis over the requisite service period for each separately vesting tranche of the awards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may also grant share-based payment awards that are subject to objectively measurable performance and service criteria. Compensation expense for performance-based awards begins at such time as it becomes probable that the respective performance conditions will be achieved. The Company continues to recognize the grant date fair value of performance-based awards through the vesting date of the respective awards so long as it remains probable that the related performance conditions will be satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model and the fair value of performance stock units, restricted stock units and deferred stock units based on the observed grant date fair value of the underlying Common Stock.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000309">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by adding to the weighted-average number of common shares outstanding the average number of dilutive common equivalent shares using the treasury stock method, unless the effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, 3,272,727 shares of Pre-Funded Warrants to purchase common stock, issued in connection with the November 2021 underwritten public offering (see Note 10), were included in the basic and diluted net loss per share calculation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,517,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,338,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,881,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,564,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <eypt:PreFundedWarrantsToPurchaseCommonStock
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000377"
      unitRef="U_xbrlishares">3272727</eypt:PreFundedWarrantsToPurchaseCommonStock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000313">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding potential Common Stock equivalents excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,517,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,338,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,881,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,564,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="INF"
      id="F_000378"
      unitRef="U_xbrlishares">2517680</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000379"
      unitRef="U_xbrlishares">1338880</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000380"
      unitRef="U_xbrlishares">23965</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eyptEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000381"
      unitRef="U_xbrlishares">27713</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="INF"
      id="F_000382"
      unitRef="U_xbrlishares">48683</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231"
      decimals="INF"
      id="F_000383"
      unitRef="U_xbrlishares">48683</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000384"
      unitRef="U_xbrlishares">291575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000385"
      unitRef="U_xbrlishares">149004</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_20210101_20211231"
      decimals="INF"
      id="F_000386"
      unitRef="U_xbrlishares">2881903</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001314102_20200101_20201231"
      decimals="INF"
      id="F_000387"
      unitRef="U_xbrlishares">1564280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <eypt:ComprehensiveLossPolicyPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000310">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is comprised of net loss, foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable securities. &lt;/p&gt;</eypt:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000311">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Tax &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method. Deferred income tax assets and liabilities are computed for the expected future impact of differences between the financial reporting and income tax bases of assets and liabilities and for the expected future benefit to be derived from tax credits and loss carry forwards. Such deferred income tax computations are measured based on enacted tax laws and rates applicable to the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is provided against net deferred tax assets if, based on the available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the uncertainty. The Company accounts for interest and penalties related to uncertain tax positions as part of its income tax benefit. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000312">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted and Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company&#x2019;s financial position, results of operations and cash flows or do not apply to the Company&#x2019;s operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;"&gt; (&#x201c;ASU 2019-12&#x201d;)&lt;/span&gt;&lt;span style="font-style:italic;"&gt;: Simplifying the Accounting for Income Taxes.&lt;/span&gt;&#160;The amendments simplify the accounting for income taxes by removing certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt &#x2013; Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) &lt;/span&gt;(&#x201c;ASU 2021-04&#x201d;)&lt;span style="font-style:italic;"&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&lt;/span&gt; The amendments are designed to clarify an issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options that remain equity-classified after modification or exchange. The ASU provides guidance on how an issuer would measure and recognize the effects of these transactions. The standard provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. ASU 2021-04 will be effective for the Company in the first quarter of its fiscal year ending December 31, 2022. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001314102_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000389">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <eypt:ProductRevenueReservesAndAllowancesTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000275">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Product Revenue Reserves and Allowances&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s product revenues have been primarily from sales of YUTIQ and DEXYCU in the U.S.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net product revenues by product for the years ended December 31, 2021 and 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;YUTIQ (A)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,959&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DEXYCU (B)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product sales, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(A)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(B)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2021 and 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Chargebacks,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;603&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision related to sales in the current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments related to prior period sales&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions applied and payments made&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,029&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,821&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Chargebacks,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision related to sales in the current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,175&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments related to prior period sales&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions applied and payments made&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;603&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Returns are recorded as a reduction of accounts receivable on the condensed consolidated balance sheets. Chargebacks, discounts and fees and rebates are recorded as a component of accrued expenses on the condensed consolidated balance sheets (see Note 7). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Agreements and Royalty Income&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Alimera &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to a licensing and development agreement, as amended, Alimera Sciences, Inc. has a worldwide exclusive license to develop, make, market and sell ILUVIEN in return for royalties based on sales and patent fee reimbursements. Total revenue was $54,000 and $1.7 million for the years ended December 31, 2021 and 2020, respectively. In addition to patent fee reimbursements in those periods, the Company recorded royalty income totaled $0 and $1.7 million for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;SWK Royalty Purchase Agreement&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 17, 2020, the Company entered into a royalty purchase agreement (the &#x201c;RPA&#x201d;) with SWK Funding LLC (&#x201c;SWK&#x201d;). Under the RPA, the Company sold its right to receive royalty payments on future sales of products subject to the Amended Alimera Agreement for an upfront cash payment of $16.5 million. Except for the rights to the royalties, the Company retains all rights and obligations under the Amended Alimera Agreement, pursuant to which, Alimera owns worldwide rights to the Company&#x2019;s Durasert technology in ILUVIEN for DME and rights for ILUVIEN (currently marketed by the Company as YUTIQ in the U.S.) for non-infectious posterior uveitis in the EMEA. Alimera has the sole rights to utilize the intellectual property developed under the Amended Alimera Agreement. There has been no intellectual property developed jointly by Alimera and the Company as part of the Amended Alimera Agreement. The Company cannot utilize the intellectual property for the indication licensed to Alimera in order to manufacture and sell ILUVIEN.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s ongoing efforts under the Amended Alimera Agreement will consist of continuing to maintain and enforce its patents as well as providing safety data and regulatory support as necessary. None of these obligations require significant efforts on the part of the Company with respect to the generation of sales in the market. The Company will only be required to expend more extensive efforts if litigation were to arise that requires the Company to protect its patents rights pursuant to the terms of the Amended Alimera Agreement. Historically, such a defense has not been required. Similarly, regulatory support and safety data is only provided &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on an ad-hoc basis depending on the regulatory requests&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, which has been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;minimal &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;historically&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. It remains Alimera&#x2019;s sole responsibility to manufacture, actively market and promote the products under the Amended Alimera Agreement to generate the sales, which ultimately generate the royalties to be paid to SWK.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classified the proceeds received from SWK as deferred revenue, to be recognized as revenue under the units-of-revenue method over the life of the RPA because of the Company&#x2019;s limited continuing involvement in the Amended Alimera Agreement. SWK has no recourse and the Company assumes no credit risk in event that Alimera fails to make a royalty payment. The Company must only forward all material correspondence from Alimera to SWK, including royalty reports, notices and any other correspondence with respect to royalties to SWK. SWK has the right to audit and inspect the books and records pertaining to net sales and royalties under the Amended Alimera Agreement. Neither the Company nor SWK has the unilateral ability to cancel the transaction. There is no cap or limitation on the royalties to be received by SWK in the future and its return will reflect all royalties paid by Alimera. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to SWK and there is no limitation on the rates of return to SWK, the Company recorded the total proceeds of $16.5 million as deferred revenue under royalty sale agreement. The deferred revenue is being recognized as revenue over the life of the RPA under the &#x201c;units-of-revenue&#x201d; method. Under this method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from SWK to the payments expected to be made by Alimera to SWK over the term of the Amended Alimera Agreement, and then applying that ratio to the period&#x2019;s cash payment. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized $872,000 of royalty revenue related to the RPA for the year ended December 31, 2021, in connection with the royalty payment of $2.8 million for the year ended December 31, 2021, from Alimera to SWK, pursuant to the Amended Alimera Agreement. No revenue was recognized related to the RPA for the year ended December 31, 2020. As of December 31, 2021, the Company has $1.1 million and $14.6 million as current and non-current deferred revenue recognized under royalty sale agreement, respectively. As of December 31, 2020, the Company classified $885,000 and $15.6 million as current and non-current deferred revenue recognized under royalty sale agreement, respectively. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;OncoSil Medica&lt;span style="font-weight:normal;"&gt;l&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company entered into an exclusive, worldwide royalty-bearing license agreement in December 2012, amended and restated in March 2013, with OncoSil Medical UK Limited (f/k/a Enigma Therapeutics Limited), a wholly-owned subsidiary of OncoSil Medical Ltd (&#x201c;OncoSil&#x201d;) for the development of BrachySil, the Company&#x2019;s previous product candidate for the treatment of pancreatic and other types of cancer. The Company received an upfront fee of $100,000 and is entitled to 8% sales-based royalties, 20% of sublicense consideration and milestone payments based on aggregate product sales. OncoSil is obligated to pay an annual license maintenance fee of $100,000 by the end of each calendar year, the most recent of which was received in December 2021. For each calendar year commencing with 2014, the Company is entitled to receive reimbursement of any patent maintenance costs, sales-based royalties and &lt;/span&gt;sub-licensee&lt;span style="Background-color:#FFFFFF;"&gt; sales-based royalties earned, but only to the extent such amounts, in the aggregate, exceed the $100,000 annual license maintenance fee. &lt;/span&gt;&lt;span style="color:#000000;"&gt;In March 2020, the U.S. Food and Drug Administration granted Breakthrough Device Designation for the OncoSil&#x2122; device for treatment of unresectable locally advanced pancreatic cancer (LAPC) in combination with chemotherapy.&#160; In April 2020, the British Standards Institute (BSI) grants European CE marking for the OncoSil&#x2122; System and designates OncoSil&#x2122; a breakthrough device for the treatment of locally advanced pancreatic cancer (LAPC) in combination with chemotherapy.&#160;As of December 31, 2021, OncoSil has received regulatory approval in the EU, United Kingdom, Switzerland, Singapore, Malaysia, Hong Kong, New Zealand, Turkey, and Israel. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company has no consequential performance obligations under the OncoSil license agreement. For the years ended December 31, 2021 and 2020, revenue of $100,000 and $100,000 was recorded for this agreement, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ocumension Therapeutics &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In &lt;span style="Background-color:#FFFFFF;"&gt;November&lt;/span&gt; 2018, the Company entered into an exclusive license agreement with Ocumension Therapeutics (&#x201c;Ocumension&#x201d;) for the development and commercialization of its three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (YUTIQ in the U.S.) in Mainland China, Hong Kong, Macau and Taiwan. The Company received a one-time upfront payment of $1.75&#160;million from Ocumension and is eligible to receive up to (i) $7.25&#160;million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and (ii) $3.0 million commercial sales-based milestones. In addition, the Company is entitled to receive mid-single digit sales-based royalties. Ocumension has also received a special approval by the Hainan Province People&#x2019;s Government to market this product for chronic, non-infectious posterior segment uveitis in the Hainan Bo Ao Lecheng International Medical Tourism Pilot Zone (&#x201c;Hainan Pilot Zone&#x201d;). In March 2019, the Company entered into a Memorandum of Understanding (&#x201c;2019 MOU&#x201d;), pursuant to which, the Company will supply product for the clinical trials and Hainan Pilot Zone use. Paralleling to Ocumension&#x2019;s normal registration process of the product with the Chinese Regulatory Authorities, the 2019 MOU modified the Company&#x2019;s entitlement to the development and regulatory milestones of up to $7.25 million under the license agreement to product supply milestones or development milestones, whichever comes first, totaling up to $7.25 million. In August 2019, the Company began shipping this product to Ocumension.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company was required to provide a fixed number of hours of technical assistance support to Ocumension at no cost, which support has been completed and no future performance obligation exists. Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested. Ocumension has a first right of negotiation for an additional exclusive license to the Company&#x2019;s shorter-duration line extension candidate for this indication. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2019, the Company received a $1.0 million development milestone payment from Ocumension triggered by the approval of its Investigational New Drug (&#x201c;IND&#x201d;) in China for this program. The IND allows the importation of finished product into China for use in a clinical trial to support regulatory filing.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2020,&#160;the Company entered into an exclusive license agreement with Ocumension for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU for the treatment of post-operative inflammation following ocular surgery. Pursuant to the terms of the license agreement, the Company received upfront payments of&#160;$2.0 million&#160;from Ocumension in February 2020 and will be eligible to receive up to (i) $6.0 million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and (ii) $6.0 million commercial sales-based milestones. In addition, the Company is entitled to receive mid-single digit sales-based royalties. In exchange, Ocumension will receive exclusive rights to develop and commercialize DEXYCU in Mainland China, Hong Kong, Macau and Taiwan, at its own cost and expense with the Company supplying product for clinical trials and commercial sale. In addition, Ocumension will receive a fixed number of hours of technical assistance support from the Company at no cost.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company entered into a Memorandum of Understanding (&#x201c;2020 MOU&#x201d;), pursuant to which, &lt;span style="Background-color:#FFFFFF;"&gt;the Company received a one-time non-refundable payment of $9.5 million (the &#x201c;Accelerated Milestone Payment&#x201d;) from Ocumension as a full and final payment of the combined remaining development, regulatory and sales milestone payments under the Company&#x2019;s license agreements with Ocumension for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and for the treatment of post-operative inflammation following ocular surgery, respectively. Upon payment of the Accelerated Milestone Payment, the remaining $11.75 million in combined remaining development and sales milestone payments under the Company&#x2019;s original &lt;/span&gt;license agreement with Ocumension upon the achievement by Ocumension of (i) remaining development and regulatory milestones of $6.25 million and commercial sales-based milestones of $3.0 million for the development and commercialization of its three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and (ii) $6.0 million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and $6.0 million commercial sales-based milestones for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU for the treatment of post-operative inflammation following ocular surgery, totaling up to $21.25 million, &lt;span style="Background-color:#FFFFFF;"&gt;were permanently extinguished and will no longer be due and owed to the Company. In exchange, Ocumension also received exclusive rights to develop and commercialize YUTIQ and DEXYCU products under its own brand names in South Korea and other jurisdictions across Southeast Asia in Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand and Vietnam, &lt;/span&gt;at its own cost and expense with the Company supplying product for clinical trials and commercial sale. The Company continues to be entitled to royalties on future product sales by Ocumension. In April 2021, Ocumension announced its filing of a New Drug Application (&#x201c;NDA&#x201d;) for YUTIQ under Ocumension&#x2019;s distinct name to Chinese regulatory authorities and it is under review. Ocumension has been granted approval to have its NDA submission reviewed based on the U.S. NDA data and the real world data Ocumension has collected from marketing the product in Hainan Pilot Zone. In September 2021, Ocumension announced its receipt of approval from Chinese regulatory authorities for DEXYCU under Ocumension&#x2019;s distinct name to conduct a Phase 3 clinical trial in China.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other than a fixed number of hours of technical assistance support to be provided at no cost by the Company, Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested. All technical assistance was provided during 2020. The Chief Executive Officer of Ocumension became a director of the Company starting December 31, 2020, pursuant to a Share Purchase Agreement pursuant to which the Company sold to Ocumension 3,010,722 shares of common stock, at which time, Ocumension became a related party of the Company.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2021 and 2020, in addition to $308,000 and $213,000 of revenue from product sales, respectively, the Company recognized approximately $543,000 and $11.5 million of license and collaboration revenue, respectively, including $499,000 and $0 of revenue related to additional technical assistance, respectively. As of December 31, 2021 and 2020, no deferred revenue was recorded for this agreement, respectively.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="color:#000000;"&gt; Company recognized &lt;/span&gt; sales-based royalty expense of&lt;span style="font-size:12pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;$0&lt;/span&gt; and $1.3 million during the year ended December 31, 2021 and 2020, related to the earn-out payment equal to 20% of DEXYCU share of the Accelerated Milestone Payment received in August 2020 and upfront payment received in February 2020 from Ocumension, as the payment of the partnering income in connection with the Icon acquisition in March 2018. &lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt; &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaborations&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company from time to time enters into funded agreements to evaluate the potential use of its technology systems for sustained release of third-party drug candidates. Consideration received is generally recognized as revenue over the term of the research collaborations. Revenue recognition for consideration, if any, related to a license option right is assessed based on the terms of any such future license agreement or is otherwise recognized at the completion of the research collaborations.  Revenues under research collaborations  totaled $60,000 and $&lt;/span&gt;&lt;span style="color:#000000;"&gt;255,000 &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;for the years ended December 31, 2021 and 2020, respectively. &lt;span style="color:#000000;"&gt;At December 31, 2021 and 2020, $0 and $60,000 deferred revenue was recorded for the research collaborations, respectively.&lt;/span&gt;&lt;/p&gt;</eypt:ProductRevenueReservesAndAllowancesTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000314">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net product revenues by product for the years ended December 31, 2021 and 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;YUTIQ (A)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,959&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DEXYCU (B)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product sales, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(A)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(B)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20210101_20211231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">16959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptYUTIQProductMember_20200101_20201231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">13878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20210101_20211231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">18353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptDEXYCUProductMember_20200101_20201231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">6953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">35312000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">20831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">25000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptDEXYCUProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20200101_20201231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">8000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <eypt:ProductRevenueAllowanceAndReserveTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000315">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2021 and 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Chargebacks,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;603&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision related to sales in the current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments related to prior period sales&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions applied and payments made&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,029&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,821&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Chargebacks,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Returns&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,241&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision related to sales in the current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,175&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.4%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments related to prior period sales&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(387&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions applied and payments made&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.4%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;603&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eypt:ProductRevenueAllowanceAndReserveTableTextBlock>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20201231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">574000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">535000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20201231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">603000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">1712000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">7274000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">5337000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">785000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">13396000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">-50000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">-22000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">-200000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">-272000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20210101_20211231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">-6645000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20210101_20211231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">-4029000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20210101_20211231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">-809000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">-11483000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20211231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">1153000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20211231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">1821000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20211231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">379000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">3353000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20191231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">1618000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20191231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">271000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20191231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">352000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_20191231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">2241000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">2141000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20200101_20201231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">1056000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">978000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossAdditions
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">4175000</eypt:ContractWithCustomerAllowanceForCreditLossAdditions>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">-387000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">50000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">-337000</eypt:ContractWithCustomerAllowanceForCreditLossIncreaseDecrease>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20200101_20201231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">-2798000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20200101_20201231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">-792000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20200101_20201231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">-777000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">-4367000</eypt:ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptChargeBacksAndDiscountsAndFeesMember_20201231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">574000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptGovernmentsAndOtherRebatesMember_20201231"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">535000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_us-gaapValuationAllowancesAndReservesTypeAxis_eyptReturnsMember_20201231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">603000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">1712000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231"
      decimals="0"
      id="F_000440"
      unitRef="U_iso4217USD">54000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000441"
      unitRef="U_iso4217USD">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20210101_20211231"
      decimals="0"
      id="F_000442"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_eyptAmendedAlimeraScienceIncAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000443"
      unitRef="U_iso4217USD">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <eypt:UpfrontCashPayment
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217"
      decimals="-5"
      id="F_000444"
      unitRef="U_iso4217USD">16500000</eypt:UpfrontCashPayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217"
      decimals="-5"
      id="F_000445"
      unitRef="U_iso4217USD">16500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231"
      decimals="0"
      id="F_000451"
      unitRef="U_iso4217USD">872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231"
      decimals="-5"
      id="F_000450"
      unitRef="U_iso4217USD">2800000</us-gaap:PaymentsForRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20200101_20201231"
      decimals="INF"
      id="F_000452"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20211231"
      decimals="-5"
      id="F_000446"
      unitRef="U_iso4217USD">1100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20211231"
      decimals="-5"
      id="F_000448"
      unitRef="U_iso4217USD">14600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201231"
      decimals="0"
      id="F_000447"
      unitRef="U_iso4217USD">885000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltySaleAgreementMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201231"
      decimals="-5"
      id="F_000449"
      unitRef="U_iso4217USD">15600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <eypt:LicenseAgreementStartYearMonth
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231"
      id="F_000459">2012-12</eypt:LicenseAgreementStartYearMonth>
    <eypt:UpfrontLicenseFeeReceived
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20130331_20130331"
      decimals="0"
      id="F_000453"
      unitRef="U_iso4217USD">100000</eypt:UpfrontLicenseFeeReceived>
    <eypt:RoyaltyPercentageEarnedFromProductSales
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231"
      decimals="INF"
      id="F_000454"
      unitRef="U_xbrlipure">0.08</eypt:RoyaltyPercentageEarnedFromProductSales>
    <eypt:NonRoyaltyConsiderationPercentage
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231"
      decimals="INF"
      id="F_000455"
      unitRef="U_xbrlipure">0.20</eypt:NonRoyaltyConsiderationPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231"
      decimals="0"
      id="F_000460"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20210101_20211231"
      decimals="0"
      id="F_000456"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20211231"
      decimals="0"
      id="F_000457"
      unitRef="U_iso4217USD">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOncoSilMedicalUKLimitedMember_20201231"
      decimals="0"
      id="F_000458"
      unitRef="U_iso4217USD">100000</us-gaap:ContractWithCustomerLiability>
    <eypt:UpfrontLicenseFeeReceived
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20181101_20181130"
      decimals="-4"
      id="F_000461"
      unitRef="U_iso4217USD">1750000</eypt:UpfrontLicenseFeeReceived>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="-4"
      id="F_000462"
      unitRef="U_iso4217USD">7250000</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">3000000.0</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="-4"
      id="F_000464"
      unitRef="U_iso4217USD">7250000</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone>
    <eypt:ProductSupplyMilestonesAndDevelopmentMilestones
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="-4"
      id="F_000465"
      unitRef="U_iso4217USD">7250000</eypt:ProductSupplyMilestonesAndDevelopmentMilestones>
    <eypt:DevelopmentMilestonePaymentReceived
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20190801_20190831"
      decimals="-5"
      id="F_000466"
      unitRef="U_iso4217USD">1000000.0</eypt:DevelopmentMilestonePaymentReceived>
    <eypt:UpfrontLicenseFeeReceived
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200201_20200229"
      decimals="-5"
      id="F_000467"
      unitRef="U_iso4217USD">2000000.0</eypt:UpfrontLicenseFeeReceived>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20200131"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">6000000.0</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20200131"
      decimals="-5"
      id="F_000469"
      unitRef="U_iso4217USD">6000000.0</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone>
    <eypt:UpfrontLicenseFeeReceived
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-5"
      id="F_000470"
      unitRef="U_iso4217USD">9500000</eypt:UpfrontLicenseFeeReceived>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-4"
      id="F_000471"
      unitRef="U_iso4217USD">11750000</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-4"
      id="F_000472"
      unitRef="U_iso4217USD">6250000</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-5"
      id="F_000473"
      unitRef="U_iso4217USD">3000000.0</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-5"
      id="F_000474"
      unitRef="U_iso4217USD">6000000.0</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone>
    <eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-5"
      id="F_000475"
      unitRef="U_iso4217USD">6000000.0</eypt:PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone>
    <eypt:UponAchievementOfMilestones
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200801_20200831"
      decimals="-4"
      id="F_000476"
      unitRef="U_iso4217USD">21250000</eypt:UponAchievementOfMilestones>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231"
      decimals="INF"
      id="F_000477"
      unitRef="U_xbrlishares">3010722</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="0"
      id="F_000480"
      unitRef="U_iso4217USD">308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapProductMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231"
      decimals="0"
      id="F_000481"
      unitRef="U_iso4217USD">213000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="0"
      id="F_000478"
      unitRef="U_iso4217USD">543000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">11500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20210101_20211231"
      decimals="0"
      id="F_000482"
      unitRef="U_iso4217USD">499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_us-gaapTechnologyServiceMember_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20200101_20201231"
      decimals="0"
      id="F_000483"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20211231"
      decimals="INF"
      id="F_000484"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptOcumensionTherapeuticsMember_20201231"
      decimals="INF"
      id="F_000485"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <eypt:SalesBasedRoyaltyExpense
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20210101_20211231"
      decimals="0"
      id="F_000486"
      unitRef="U_iso4217USD">0</eypt:SalesBasedRoyaltyExpense>
    <eypt:SalesBasedRoyaltyExpense
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20200101_20201231"
      decimals="-5"
      id="F_000487"
      unitRef="U_iso4217USD">1300000</eypt:SalesBasedRoyaltyExpense>
    <eypt:PercentageOfAcceleratedMilestonePaymentReceived
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20200101_20201231"
      decimals="2"
      id="F_000488"
      unitRef="U_xbrlipure">0.20</eypt:PercentageOfAcceleratedMilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20210101_20211231"
      decimals="0"
      id="F_000489"
      unitRef="U_iso4217USD">60000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20200101_20201231"
      decimals="0"
      id="F_000490"
      unitRef="U_iso4217USD">255000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20211231"
      decimals="0"
      id="F_000491"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptCollaborativeResearchAndDevelopmentMember_20201231"
      decimals="0"
      id="F_000492"
      unitRef="U_iso4217USD">60000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:InventoryDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000276">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Inventory &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,727&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,664&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;747&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;484&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,616&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000316">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,727&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,664&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;747&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;484&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,616&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">2727000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">2664000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">405000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">747000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">484000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">1926000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">3616000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">5337000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000277">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Intangible Assets &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of intangible assets for the years ended December 31, 2021 and 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patented technologies&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross carrying amount at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross carrying amount at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net book value at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The net book value of the Company&#x2019;s intangible assets at December&#160;31, 2021 and 2020 is summarized as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful&#160;Life&#160;at&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patented technologies&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DEXYCU / Verisome&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000517"&gt;9.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company amortizes its intangible assets with finite lives on a straight-line basis over their respective estimated useful lives. Amortization expense totaled $2.5 million in each of the two years ended December 31, 2021 and 2020, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Icon Acquisition, the initial purchase price of $32.0&#160;million was attributed to the DEXYCU product intangible asset. This finite-lived intangible asset is being amortized on a straight-line basis over its expected remaining useful life of 9.25 years at the rate of approximately $2.5&#160;million per year. Amortization expense was reported as a component of cost of sales for the years ended December 31, 2021 and 2020, respectively. &lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000317">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of intangible assets for the years ended December 31, 2021 and 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patented technologies&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross carrying amount at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross carrying amount at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net book value at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">68322000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001314102_20191231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">68322000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">68322000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">68322000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">43113000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001314102_20191231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">40653000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">2460000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">2460000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">45573000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">43113000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">22749000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">25209000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000318">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The net book value of the Company&#x2019;s intangible assets at December&#160;31, 2021 and 2020 is summarized as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful&#160;Life&#160;at&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patented technologies&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DEXYCU / Verisome&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000517"&gt;9.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,209&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">22749000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">25209000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">22749000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000516"
      unitRef="U_iso4217USD">25209000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001314102_20210101_20211231"
      decimals="-5"
      id="F_000518"
      unitRef="U_iso4217USD">2500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001314102_20200101_20201231"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">2500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">32000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20210101_20211231"
      id="F_000522">P9Y3M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <eypt:EstimatedRateOfAnnualAmortizationExpense
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231"
      decimals="-5"
      id="F_000521"
      unitRef="U_iso4217USD">2500000</eypt:EstimatedRateOfAnnualAmortizationExpense>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000278">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Property and Equipment, Net &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,732&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense totaled $311,000&#160;and $189,000 in the years ended December 31, 2021 and 2020, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000319">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,732&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20211231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">1477000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptPropertyAndEquipmentMember_20201231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">1403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">255000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">255000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">1732000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">1658000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">1256000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">1028000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">476000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">311000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">189000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000279">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Accrued Expenses &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales chargebacks, rebates and other revenue reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commissions due to commercialization partner for DEXYCU&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,422&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000320">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales chargebacks, rebates and other revenue reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commissions due to commercialization partner for DEXYCU&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,422&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">7321000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">5686000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <eypt:AccruedClinicalExpenseCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">753000</eypt:AccruedClinicalExpenseCurrent>
    <eypt:AccruedClinicalExpenseCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">0</eypt:AccruedClinicalExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">712000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">647000</us-gaap:AccruedProfessionalFeesCurrent>
    <eypt:AccruedSalesChargebacksRebatesAndOtherRevenueReserves
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">2974000</eypt:AccruedSalesChargebacksRebatesAndOtherRevenueReserves>
    <eypt:AccruedSalesChargebacksRebatesAndOtherRevenueReserves
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">1109000</eypt:AccruedSalesChargebacksRebatesAndOtherRevenueReserves>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">1518000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">254000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">1144000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">749000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">14422000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">8445000</us-gaap:AccruedLiabilitiesCurrent>
    <eypt:LesseeOperatingAndFinanceLeasesDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000280">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May&#160;17, 2018, &lt;span style="Background-color:#FFFFFF;"&gt;the Company amended the lease for its headquarters in Watertown, Massachusetts. The original &lt;/span&gt;&lt;span style="-sec-ix-hidden:F_000550"&gt;five-year&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; lease for approximately 13,650 square feet of combined office and laboratory space was set to expire in April 2019. Under the amendment, the Company leased an additional 6,590 square feet of rentable area of the building, with a commencement date of September&#160;10, 2018. The amendment extended the term of the lease for the combined space through May 31, 2025, and the landlord provided the Company a construction allowance of up to $670,750 to be applied toward renovations and improvements within the total space. On April 5, 2021, the Company further amended the lease to include an additional 1,409 square feet of rentable area of the building through May 31, 2025, with a commencement date of July 1, 2021. On March 8, 2022, the Company further amended the lease (i) to extend the term to May 31, 2028 for 13,650 square feet of laboratory and manufacturing operations space, with the landlord agreeing to provide the Company a construction allowance of up to $555,960 to be applied toward upgrades and improvements within the space; (ii) to rent an additional 11,999 square feet of office space within the building through May 31, 2028, with an anticipated commencement date in the third quarter of 2022; and (iii) to terminate a portion of the lease comprising 7,999 square feet of office space in the building on May 31, 2025. The Company previously provided a cash-collateralized $150,000 irrevocable standby letter of credit as security for the Company&#x2019;s obligations under the lease, which will remain in effect through the period that is four months beyond the expiration date of the amended lease. The Company will also be required to pay its proportionate share of certain operating costs and property taxes applicable to the leased premises in excess of new base year amounts.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2017, the Company leased approximately 3,000 square feet of office space in Basking Ridge, New Jersey under a lease term extending through June 2022, with two &lt;span style="-sec-ix-hidden:F_000571"&gt;five-year&lt;/span&gt; renewal options at 95% of the then-prevailing market rates. In addition to base rent, the Company is obligated to pay its proportionate share of building operating expenses and real estate taxes in excess of base year amounts. In June 2018, the Company subleased an additional 1,381 square feet of adjoining space from Caladrius Biosciences, Inc. (&#x201c;Caladrius&#x201d;) through May 2022. The Chief Executive Officer of Caladrius was a director of the Company through June 2020. Per the terms of the lease and sublease agreements, the Company does not have any residual value guarantees. The Company has given notice that the Company will not be renewing this lease and the Company will vacate the facility upon expiration.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified and assessed the following significant assumptions in recognizing its right-of-use (&#x201c;ROU&#x201d;) assets and corresponding lease liabilities:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized the borrowing rate under its existing 5-year term loan facility (see Note 9) as the discount rate.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;The expected lease terms include noncancelable lease periods. Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Variable lease payments, such as common area maintenance, real estate taxes and property insurance are not included in the determination of the lease&#x2019;s ROU asset or lease liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the weighted average remaining term of the Company&#x2019;s operating leases was 3.4&#160;years and the lease liabilities arising from obtaining ROU assets reflect a weighted average discount rate of 12.5%. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental&lt;span style="color:#000000;"&gt; balance sheet information related to operating leases as of December 31, 2021 and 2020, respectively are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities - operating lease current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities &#x2013; noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;span style="color:#000000;"&gt; lease expense recognized related to ROU assets was $885,000 and&lt;/span&gt;&lt;span style="font-size:12pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;"&gt;$852,000, excluding $30,000 and $36,000 of variable lease costs, during each of the years ended December 31, 2021 and 2020, respectively, and were included in general and administrative expense in the Company&#x2019;s statement of comprehensive loss. Cash paid for amounts included in the measurement of operating lease liabilities was $920,000 and $867,000 for the years ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The &lt;span style="color:#000000;"&gt;Company&lt;/span&gt; is a party to three finance leases for laboratory equipment. The equipment leases expire in December 2021, December 2022 and June 2023, respectively. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental&lt;span style="color:#000000;"&gt; balance sheet information related to the finance lease as of December 31, 2021 and 2020, respectively are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities &lt;span style="font-family:Calibri;"&gt;&#x2013;&lt;/span&gt; finance lease current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of finance lease expense recognized during the years ended December 31, 2021 and 2020 related to ROU assets were&#160;$151,000 and $52,000, respectively. Interest on lease liabilities were $23,000 and $9,000&#160;during the years ended December 31, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of finance lease liabilities was operating cash flows of $23,000 and financing cash flows of $146,000 during the year ended December 31, 2021, respectively. Cash paid for amounts included in the measurement of finance lease liabilities was operating cash flows of $9,000 and financing cash flows of $49,000 during the year ended December 31, 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the weighted average remaining term of the Company&#x2019;s finance lease was 1.3 years and the lease liabilities arising from obtaining ROU assets reflect a weighted average discount rate of 12.5%.&lt;span style="color:#000000;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T&lt;span style="color:#000000;"&gt;he Company&#x2019;s total future minimum lease payments under non-cancellable leases at December 31, 2021 were as follows (in thousands): &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;877&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;373&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,055&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</eypt:LesseeOperatingAndFinanceLeasesDisclosureTextBlock>
    <eypt:LeasePropertyAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20210101_20211231"
      decimals="0"
      id="F_000549"
      unitRef="U_utrsqft">13650</eypt:LeasePropertyAreaCovered>
    <eypt:LeaseExpirationMonthYear
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptOriginalLeaseMember_20210101_20211231"
      id="F_000551">2019-04</eypt:LeaseExpirationMonthYear>
    <eypt:AdditionalLeasePropertyAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231"
      decimals="0"
      id="F_000554"
      unitRef="U_utrsqft">6590</eypt:AdditionalLeasePropertyAreaCovered>
    <eypt:LeaseInceptionDate
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231"
      id="F_000552">2018-09-10</eypt:LeaseInceptionDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20210101_20211231"
      id="F_000553">2025-05-31</us-gaap:LeaseExpirationDate1>
    <eypt:ConstructionAllowanceCredit
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_20211231"
      decimals="INF"
      id="F_000556"
      unitRef="U_iso4217USD">670750</eypt:ConstructionAllowanceCredit>
    <eypt:LeasePropertyAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231"
      decimals="0"
      id="F_000557"
      unitRef="U_utrsqft">1409</eypt:LeasePropertyAreaCovered>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231"
      id="F_000559">2025-05-31</us-gaap:LeaseExpirationDate1>
    <eypt:LeaseInceptionDate
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptThirdAmendmentLeaseMember_20210101_20211231"
      id="F_000558">2021-07-01</eypt:LeaseInceptionDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308"
      id="F_000561">2028-05-31</us-gaap:LeaseExpirationDate1>
    <eypt:LeasePropertyAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308"
      decimals="0"
      id="F_000563"
      unitRef="U_utrsqft">13650</eypt:LeasePropertyAreaCovered>
    <eypt:ConstructionAllowanceCredit
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308"
      decimals="INF"
      id="F_000564"
      unitRef="U_iso4217USD">555960</eypt:ConstructionAllowanceCredit>
    <eypt:AdditionalLeasePropertyAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308"
      decimals="0"
      id="F_000560"
      unitRef="U_utrsqft">11999</eypt:AdditionalLeasePropertyAreaCovered>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308"
      id="F_000562">2028-05-31</us-gaap:LeaseExpirationDate1>
    <eypt:TerminationOfPortionOfLeasePropertyAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308"
      decimals="0"
      id="F_000565"
      unitRef="U_utrsqft">7999</eypt:TerminationOfPortionOfLeasePropertyAreaCovered>
    <eypt:LeaseTerminationDate
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_eyptFourthAmendmentLeaseMember_20220308_20220308"
      id="F_000566">2025-05-31</eypt:LeaseTerminationDate>
    <us-gaap:SecurityDeposit
      contextRef="C_0001314102_srtStatementGeographicalAxis_eyptMaMember_us-gaapTypeOfArrangementAxis_eyptSecondAmendmentLeaseMember_20211231"
      decimals="0"
      id="F_000555"
      unitRef="U_iso4217USD">150000</us-gaap:SecurityDeposit>
    <eypt:LeaseInceptionMonthYear
      contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231"
      id="F_000568">2017-07</eypt:LeaseInceptionMonthYear>
    <eypt:LeasePropertyOfficeAreaCovered
      contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231"
      decimals="0"
      id="F_000567"
      unitRef="U_utrsqft">3000</eypt:LeasePropertyOfficeAreaCovered>
    <eypt:LeaseExpirationMonthYear
      contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231"
      id="F_000569">2022-06</eypt:LeaseExpirationMonthYear>
    <eypt:NumberOfRenewalOptions
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231"
      decimals="INF"
      id="F_000570"
      unitRef="U_eyptTranche">2</eypt:NumberOfRenewalOptions>
    <eypt:OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate
      contextRef="C_0001314102_srtStatementGeographicalAxis_stprNJ_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptBaskingRidgeOfficeSpaceMember_20210101_20211231"
      decimals="2"
      id="F_000572"
      unitRef="U_xbrlipure">0.95</eypt:OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate>
    <eypt:AdditionalSubleasedPropertyOfficeArea
      contextRef="C_0001314102_srtCounterpartyNameAxis_eyptCaladriusMember_20210101_20211231"
      decimals="0"
      id="F_000573"
      unitRef="U_utrsqft">1381</eypt:AdditionalSubleasedPropertyOfficeArea>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="C_0001314102_20210101_20211231" id="F_000574">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001314102_20211231" id="F_000575">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001314102_20211231"
      decimals="3"
      id="F_000576"
      unitRef="U_xbrlipure">0.125</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000321">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental&lt;span style="color:#000000;"&gt; balance sheet information related to operating leases as of December 31, 2021 and 2020, respectively are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities - operating lease current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;645&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities &#x2013; noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">645000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">568000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">1860000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">2330000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">2505000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">2898000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000585"
      unitRef="U_iso4217USD">885000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000586"
      unitRef="U_iso4217USD">852000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000587"
      unitRef="U_iso4217USD">30000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000588"
      unitRef="U_iso4217USD">36000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000589"
      unitRef="U_iso4217USD">920000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000590"
      unitRef="U_iso4217USD">867000</us-gaap:OperatingLeasePayments>
    <eypt:NumberOfFinanceLeases
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231"
      decimals="INF"
      id="F_000591"
      unitRef="U_eyptLease">3</eypt:NumberOfFinanceLeases>
    <eypt:LeaseExpirationMonthYear
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptFirstLabEquipmentMember_20210101_20211231"
      id="F_000592">2021-12</eypt:LeaseExpirationMonthYear>
    <eypt:LeaseExpirationMonthYear
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptSecondLabEquipmentMember_20210101_20211231"
      id="F_000593">2022-12</eypt:LeaseExpirationMonthYear>
    <eypt:LeaseExpirationMonthYear
      contextRef="C_0001314102_us-gaapPropertyPlantAndEquipmentByTypeAxis_eyptThirdLabEquipmentMember_20210101_20211231"
      id="F_000594">2023-06</eypt:LeaseExpirationMonthYear>
    <eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000322">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental&lt;span style="color:#000000;"&gt; balance sheet information related to the finance lease as of December 31, 2021 and 2020, respectively are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities &lt;span style="font-family:Calibri;"&gt;&#x2013;&lt;/span&gt; finance lease current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock>
    <eypt:FinanceLeasePropertyAndEquipmentGross
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000595"
      unitRef="U_iso4217USD">371000</eypt:FinanceLeasePropertyAndEquipmentGross>
    <eypt:FinanceLeasePropertyAndEquipmentGross
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000596"
      unitRef="U_iso4217USD">239000</eypt:FinanceLeasePropertyAndEquipmentGross>
    <eypt:FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000597"
      unitRef="U_iso4217USD">205000</eypt:FinanceLeaseAccumulatedAmortizationPropertyAndEquipment>
    <eypt:FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000598"
      unitRef="U_iso4217USD">52000</eypt:FinanceLeaseAccumulatedAmortizationPropertyAndEquipment>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">166000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">187000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">137000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">119000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000607"
      unitRef="U_iso4217USD">36000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000608"
      unitRef="U_iso4217USD">71000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">173000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">190000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000613"
      unitRef="U_iso4217USD">151000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000614"
      unitRef="U_iso4217USD">52000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000615"
      unitRef="U_iso4217USD">23000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000616"
      unitRef="U_iso4217USD">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0001314102_20210101_20211231"
      decimals="0"
      id="F_000617"
      unitRef="U_iso4217USD">23000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">146000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000618"
      unitRef="U_iso4217USD">9000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">49000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001314102_20211231" id="F_000621">P1Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001314102_20211231"
      decimals="3"
      id="F_000622"
      unitRef="U_xbrlipure">0.125</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <eypt:ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000323">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T&lt;span style="color:#000000;"&gt;he Company&#x2019;s total future minimum lease payments under non-cancellable leases at December 31, 2021 were as follows (in thousands): &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;877&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;373&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,055&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eypt:ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000623"
      unitRef="U_iso4217USD">911000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000630"
      unitRef="U_iso4217USD">149000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000624"
      unitRef="U_iso4217USD">877000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000631"
      unitRef="U_iso4217USD">37000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000625"
      unitRef="U_iso4217USD">894000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000626"
      unitRef="U_iso4217USD">373000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000627"
      unitRef="U_iso4217USD">3055000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000632"
      unitRef="U_iso4217USD">186000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000628"
      unitRef="U_iso4217USD">550000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000633"
      unitRef="U_iso4217USD">13000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000629"
      unitRef="U_iso4217USD">2505000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000634"
      unitRef="U_iso4217USD">173000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LongTermDebtTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000281">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Loan Agreements &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On April 8, 2020, the Company applied to Silicon Valley Bank (the &#x201c;SVB&#x201d;) for a Paycheck Protection Program Loan (the &#x201c;PPP Loan&#x201d;) of $2.0 million that is administered by the U.S. Small Business Administration (the &#x201c;SBA&#x201d;), under the Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;). On April 22, 2020, the PPP Loan was approved and the Company received the PPP Loan proceeds.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The PPP Loan bears interest at a fixed rate of 1.0% per annum and has a &lt;span style="-sec-ix-hidden:F_000638"&gt;two-year&lt;/span&gt; term that matures on April 21, 2022. Monthly principal and interest payments commenced on November 21, 2020, subject to possible partial or full forgiveness and principal and interest payments can be deferred as described below, if the PPP Loan proceeds are used for covered payroll costs, rent and utility costs and the maintenance of employee and compensation levels.&lt;/span&gt; &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Paycheck Protection Program Flexibility Act of 2020 (the &#x201c;PPP Flexibility Act&#x201d;), enacted on June 5, 2020, amended the&#160;Paycheck Protection Program, among others, as follows: (i) extended the covered period from 8 weeks to the earlier of 24 weeks from the date the PPP Loan is originated and December 31, 2020, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;during which PPP funds needed to be expended in order to be forgiven&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;.&#160;A borrower may submit a loan forgiveness application any time on or before the maturity date of the loan &#x2013; including before the end of the covered period &#x2013; if the borrower has used all of the loan proceeds for which the borrower is requesting forgiveness; (ii&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;) at least 60% of PPP funds must be spent on payroll costs, with the remaining 40% available to spend on other eligible expenses;&#160;(iii)&lt;/span&gt;&lt;span style="color:#000000;"&gt; payments are deferred until the date on which the amount of forgiveness determined is remitted to the lender. If a borrower fails to seek forgiveness within 10 months after the last day of its covered period, then payments will begin on the date that is 10 months after the last day of the covered period.&#160;In addition, the PPP Flexibility Act modified the CARES Act by increasing the maturity date for loans made after the effective date from two years to a minimum maturity of five years from the date on which the borrower applies for loan forgiveness. Existing PPP loans made before the new legislation retain their original two-year term, but may be renegotiated between a lender and a borrower to match the 5-year term permitted under the PPP Flexibility Act&lt;/span&gt;.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company used all of the loan proceeds from the PPP Loan to pay expenses during the covered period that the Company believes were for eligible purposes. On September 25, 2020, the Company submitted an application to SVB for full loan forgiveness.&lt;span style="Background-color:#FFFFFF;"&gt; On June 19, 2021, the Company received notification from SVB that the PPP Loan of $2.0 million has been fully forgiven by the SBA, and that payment and all accrued interest of $24,000 thereon were remitted by the SBA to SVB on June 16, 2021. In connection with the full loan forgiveness, the Company recorded a gain on extinguishment of debt of approximately $2.1 million in the year ended December 30, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;CRG Term Loan Agreement &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&#160;13, 2019 (the &#x201c;CRG Closing Date&#x201d;), the Company entered into the CRG Loan Agreement among the Company, as borrower, &lt;span style="Background-color:#FFFFFF;"&gt;CRG Servicing LLC, as administrative agent and collateral agent (the &#x201c;Agent&#x201d;),&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;and the lenders party thereto from time to time (the &#x201c;Lenders&#x201d;), &lt;/span&gt;providing for a senior secured term loan of up to $60&#160;million (the &#x201c;CRG Loan&#x201d;). &lt;span style="color:#000000;"&gt;On the CRG Closing Date, $35 million of the CRG Loan was advanced (the &#x201c;CRG Initial Advance&#x201d;). The Company utilized the proceeds from the CRG Initial Advance for the repayment in full of all outstanding obligations under its prior credit agreement (the &#x201c;SWK Credit Agreement&#x201d;) with SWK. In April 2019, the Company exercised its option to borrow an additional $15 million of the CRG Loan (the &#x201c;CRG Second Advance&#x201d;). The Company did not draw any additional funds under the CRG Loan by the final draw deadline of March 31, 2020.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The CRG Loan is due and payable on December&#160;31, 2023 (the &#x201c;Maturity Date&#x201d;). The CRG Loan bears interest at a fixed rate of 12.5% per annum payable in arrears on the last business day of each calendar quarter. The Company is required to make quarterly, interest only payments until the Maturity Date. So long as no default has occurred and is continuing, the Company may elect on each applicable interest payment date to pay 2.5% of the 12.5% per annum interest as Paid In-Kind (&#x201c;PIK&#x201d;), whereby such PIK amount would be added to the aggregate principal amount and accrue interest at 12.5% per annum. Through December 31, 2021, PIK amounts of $&lt;span style="color:#000000;"&gt;0&lt;/span&gt; have been added to the principal balance of the CRG Loan. In addition, the Company is required to pay an upfront fee of 1.5% of amounts borrowed under the CRG Loan (excluding any paid-in-kind amounts), which is payable as amounts are advanced under the CRG Loan. The Company will also be required to pay an exit fee equal to 6% of (i) the aggregate principal amounts advanced and (ii) PIK amounts issued, under the CRG Loan Agreement. &lt;span style="Background-color:#FFFFFF;"&gt;In connection with the CRG Initial Advance, a 1.5% financing fee of $525,000 and an expense reimbursement of $350,000 were deducted from the net borrowing proceeds. In connection with the CRG Second Advance, a 1.5% financing fee of $225,000 was deducted from the net borrowing proceeds.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the occurrence of a bankruptcy-related event of default, all amounts outstanding with respect to the CRG Loan become due and payable immediately, and upon the occurrence of any other Event of Default (as defined in the CRG Loan Agreement), all or any amounts outstanding with respect to the CRG Loan may become due and payable upon request of the Agent or majority Lenders. Subject to certain exceptions, the Company is required to make mandatory prepayments of the CRG Loan with the proceeds of assets sales and in the event of a change of control of the Company. In addition, the Company may make a voluntary prepayment of the CRG Loan, in whole or in part, at any time. All mandatory and voluntary prepayments of the CRG Loan are subject to the payment of prepayment premiums as follows: (i)&#160;if prepayment occurs on or prior to December&#160;31, 2019, an amount equal to 10% of the aggregate outstanding principal amount of the CRG Loan being prepaid, (ii)&#160;if prepayment occurs after December&#160;31, 2019 and on or prior to December&#160;31, 2020, 5% of the aggregate outstanding principal amount of the CRG Loan being prepaid, which was waived on December 17, 2020 when the Company paid $15.0 million against the CRG Loan obligations in connection with the consummation of the RPA agreement (see Note 3), and (iii)&#160;if prepayment occurs after December&#160;31, 2020 and on or prior to December&#160;31, 2021, an amount equal to 3% of the aggregate outstanding principal amount of the Loan being prepaid. No prepayment premium is due on any principal prepaid after December&#160;31, 2021. Certain of the Company&#x2019;s existing and future subsidiaries are guaranteeing the obligations of the Company under the CRG Loan Agreement. The obligations of the Company under the CRG Loan Agreement and the guarantee of such obligations are secured by a pledge of substantially all of the Company&#x2019;s and the guarantors&#x2019; assets.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The CRG Loan Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on our and our subsidiaries&#x2019; abilities, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the CRG Loan Agreement contains the following financial covenants requiring the Company and the Guarantors to maintain: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;liquidity in an amount which shall exceed the greater of (i) $5&#160;million and (ii)&#160;to the extent the Company has incurred certain permitted debt, the minimum cash balance, if any, required of the Company by the creditors of such permitted debt; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;annual minimum product revenue from YUTIQ and DEXYCU: (i) for the twelve-month period beginning &lt;span style="color:#000000;"&gt;on January 1, 2019 and ending on December 31, 2019&lt;/span&gt;, of at least $15&#160;million, (ii)&#160;for the twelve-month period beginning on &lt;span style="color:#000000;"&gt;January 1, 2020 and ending on December 31, 2020&lt;/span&gt;, of at least $45&#160;million, (iii)&#160;for the twelve-month period beginning on &lt;span style="color:#000000;"&gt;January 1, 2021 and ending on December 31, 2021&lt;/span&gt;, of at least $80&#160;million and (iv)&#160;for the twelve-month period beginning on &lt;span style="color:#000000;"&gt;January 1, 2022 and ending on December 31, 2022&lt;/span&gt;, of at least $90&#160;million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2019, CRG waived the financial covenant associated with the Company&#x2019;s revenue derived from sales of its products, DEXYCU and YUTIQ, for the twelve-month period ending December 31, 2019. In October 2020, CRG (i) waived the financial covenant associated with the Company&#x2019;s revenue derived from sales of its products, DEXYCU and YUTIQ, for the twelve-month period ending December 31, 2020 and (ii) amended the financial covenant associated with the Company&#x2019;s minimum product revenue to $&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;45&lt;/span&gt; million from $80 million, for the twelve-month period ending December 31, 2021. In May 2021, CRG further amended the financial covenant associated with the Company&#x2019;s minimum product revenue to $25 million from $45 million, for the &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;twelve-month period ending December 31, 2021. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;There were no other material changes to the Loan Agreement and the Company incurred &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; incremental charges for the issuance of the waivers.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;The total debt discount related to the CRG Initial Advance was approximately $3.2 million and consisted of (i) the accrual of a $2.1 million exit fee; (ii) the $525,000 upfront fee; and (iii) $591,000 of legal and other transaction costs. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest rate method. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total debt discount related to the CRG Second Advance was approximately $1.1 million and consisted of (i) the accrual of a $900,000 exit fee; and (ii) the $225,000 upfront fee. This amount is being amortized as additional interest expense over the term of the Loan using the effective interest rate method. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 17, 2020, the Company paid $15.0 million against the CRG Loan obligations in connection with the consummation of the RPA agreement (see Note 3). This payment included (i) a $13.8 million principal portion of the CRG Loan (ii) the $828,000 Exit Fee, and (iii) accrued and unpaid interest of $378,000 through that date. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;In connection with the partial prepayment of the CRG Loan, the Company recorded a loss on partial extinguishment of debt of $905,000 in the year ended December 31, 2020, associated with the write-off of the remaining balance of unamortized debt discount related to the partial prepayment of the CRG Loan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;span style="color:#000000;"&gt; of debt discount under the CRG Loan totaled $628,000 and $745,000 for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200408"
      decimals="-5"
      id="F_000635"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIssuanceDate1
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422"
      id="F_000636">2020-04-22</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422"
      decimals="INF"
      id="F_000637"
      unitRef="U_xbrlipure">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20200422_20200422"
      id="F_000639">2022-04-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210101_20211231"
      id="F_000640">The Paycheck Protection Program Flexibility Act of 2020 (the &#x201c;PPP Flexibility Act&#x201d;), enacted on June 5, 2020, amended the&#160;Paycheck Protection Program, among others, as follows: (i) extended the covered period from 8 weeks to the earlier of 24 weeks from the date the PPP Loan is originated and December 31, 2020, during which PPP funds needed to be expended in order to be forgiven.&#160;A borrower may submit a loan forgiveness application any time on or before the maturity date of the loan &#x2013; including before the end of the covered period &#x2013; if the borrower has used all of the loan proceeds for which the borrower is requesting forgiveness; (ii) at least 60% of PPP funds must be spent on payroll costs, with the remaining 40% available to spend on other eligible expenses;&#160;(iii) payments are deferred until the date on which the amount of forgiveness determined is remitted to the lender. If a borrower fails to seek forgiveness within 10 months after the last day of its covered period, then payments will begin on the date that is 10 months after the last day of the covered period.&#160;In addition, the PPP Flexibility Act modified the CARES Act by increasing the maturity date for loans made after the effective date from two years to a minimum maturity of five years from the date on which the borrower applies for loan forgiveness. Existing PPP loans made before the new legislation retain their original two-year term, but may be renegotiated between a lender and a borrower to match the 5-year term permitted under the PPP Flexibility Act</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210616_20210616"
      decimals="-5"
      id="F_000641"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DebtInstrumentDecreaseForgiveness>
    <eypt:DebtInstrumentAccruedInterestForgiveness
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210616_20210616"
      decimals="0"
      id="F_000642"
      unitRef="U_iso4217USD">24000</eypt:DebtInstrumentAccruedInterestForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapLoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis_eyptPaycheckProtectionProgramLoanMember_us-gaapUnusualOrInfrequentItemAxis_eyptCoronavirusAidReliefAndEconomicSecurityActMember_20210101_20211231"
      decimals="-5"
      id="F_000643"
      unitRef="U_iso4217USD">2100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityInitiationDate1
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      id="F_000644">2019-02-13</us-gaap:LineOfCreditFacilityInitiationDate1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213"
      decimals="INF"
      id="F_000645"
      unitRef="U_iso4217USD">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <eypt:TermLoansAgreementInitialAdvance
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213"
      decimals="-6"
      id="F_000646"
      unitRef="U_iso4217USD">35000000</eypt:TermLoansAgreementInitialAdvance>
    <eypt:TermLoanAgreementAdditionalAdvance
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190430"
      decimals="-6"
      id="F_000647"
      unitRef="U_iso4217USD">15000000</eypt:TermLoanAgreementAdditionalAdvance>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20200331"
      decimals="INF"
      id="F_000648"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      id="F_000649">2023-12-31</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213"
      decimals="INF"
      id="F_000650"
      unitRef="U_xbrlipure">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231"
      id="F_000651">So long as no default has occurred and is continuing, the Company may elect on each applicable interest payment date to pay 2.5% of the 12.5% per annum interest as Paid In-Kind (&#x201c;PIK&#x201d;), whereby such PIK amount would be added to the aggregate principal amount and accrue interest at 12.5% per annum.</us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault>
    <eypt:PaidInKindInterestAddedToPrincipal
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231"
      decimals="-6"
      id="F_000652"
      unitRef="U_iso4217USD">0</eypt:PaidInKindInterestAddedToPrincipal>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000653"
      unitRef="U_xbrlipure">0.015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <eypt:LineOfCreditFacilityExitFeesPercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000654"
      unitRef="U_xbrlipure">0.06</eypt:LineOfCreditFacilityExitFeesPercentage>
    <eypt:LineOfCreditFacilityFinancingFeePercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptInitialAdvanceMember_20190212_20190213"
      decimals="INF"
      id="F_000655"
      unitRef="U_xbrlipure">0.015</eypt:LineOfCreditFacilityFinancingFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptInitialAdvanceMember_20190212_20190213"
      decimals="0"
      id="F_000656"
      unitRef="U_iso4217USD">525000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <eypt:ReimbursedExpense
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="0"
      id="F_000657"
      unitRef="U_iso4217USD">350000</eypt:ReimbursedExpense>
    <eypt:LineOfCreditFacilityFinancingFeePercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213"
      decimals="INF"
      id="F_000658"
      unitRef="U_xbrlipure">0.015</eypt:LineOfCreditFacilityFinancingFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213"
      decimals="0"
      id="F_000659"
      unitRef="U_iso4217USD">225000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage
      contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentPriorToDecember312019Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000660"
      unitRef="U_xbrlipure">0.10</eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage>
    <eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage
      contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312019AndPriorToDecember312020Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000661"
      unitRef="U_xbrlipure">0.05</eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage>
    <eypt:UpfrontCashPayment
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217"
      decimals="-5"
      id="F_000664"
      unitRef="U_iso4217USD">15000000.0</eypt:UpfrontCashPayment>
    <eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage
      contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312020AndPriorToDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000662"
      unitRef="U_xbrlipure">0.03</eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage>
    <eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage
      contextRef="C_0001314102_us-gaapDebtInstrumentRedemptionPeriodAxis_eyptLoanPrepaymentAfterDecember312021Member_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000663"
      unitRef="U_xbrlipure">0</eypt:LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage>
    <eypt:MinimumLiquidityAmount
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000665"
      unitRef="U_iso4217USD">5000000</eypt:MinimumLiquidityAmount>
    <eypt:AnnualMinimumProductRevenuePeriod
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231"
      id="F_000667">on January 1, 2019 and ending on December 31, 2019</eypt:AnnualMinimumProductRevenuePeriod>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodOneMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000666"
      unitRef="U_iso4217USD">15000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenuePeriod
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231"
      id="F_000669">January 1, 2020 and ending on December 31, 2020</eypt:AnnualMinimumProductRevenuePeriod>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodTwoMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000668"
      unitRef="U_iso4217USD">45000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenuePeriod
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231"
      id="F_000671">January 1, 2021 and ending on December 31, 2021</eypt:AnnualMinimumProductRevenuePeriod>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000670"
      unitRef="U_iso4217USD">80000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenuePeriod
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210101_20211231"
      id="F_000673">January 1, 2022 and ending on December 31, 2022</eypt:AnnualMinimumProductRevenuePeriod>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodFourMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000672"
      unitRef="U_iso4217USD">90000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031"
      decimals="INF"
      id="F_000674"
      unitRef="U_iso4217USD">45000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="INF"
      id="F_000676"
      unitRef="U_iso4217USD">80000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20210501_20210531"
      decimals="INF"
      id="F_000677"
      unitRef="U_iso4217USD">25000000</eypt:AnnualMinimumProductRevenue>
    <eypt:AnnualMinimumProductRevenue
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031"
      decimals="INF"
      id="F_000675"
      unitRef="U_iso4217USD">45000000</eypt:AnnualMinimumProductRevenue>
    <eypt:IncrementalChargesForIssuanceOfWaivers
      contextRef="C_0001314102_eyptPeriodAxis_eyptPeriodThreeMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201001_20201031"
      decimals="INF"
      id="F_000678"
      unitRef="U_iso4217USD">0</eypt:IncrementalChargesForIssuanceOfWaivers>
    <eypt:OriginalAmountOfDebtDiscount
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213"
      decimals="-5"
      id="F_000679"
      unitRef="U_iso4217USD">3200000</eypt:OriginalAmountOfDebtDiscount>
    <eypt:ExitFeeAccrued
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190213"
      decimals="-5"
      id="F_000680"
      unitRef="U_iso4217USD">2100000</eypt:ExitFeeAccrued>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="0"
      id="F_000681"
      unitRef="U_iso4217USD">525000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <eypt:LineOfCreditFacilityLegalAndTransactionCosts
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20190212_20190213"
      decimals="0"
      id="F_000682"
      unitRef="U_iso4217USD">591000</eypt:LineOfCreditFacilityLegalAndTransactionCosts>
    <eypt:OriginalAmountOfDebtDiscount
      contextRef="C_0001314102_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213"
      decimals="-5"
      id="F_000683"
      unitRef="U_iso4217USD">1100000</eypt:OriginalAmountOfDebtDiscount>
    <eypt:ExitFeeAccrued
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190213"
      decimals="0"
      id="F_000684"
      unitRef="U_iso4217USD">900000</eypt:ExitFeeAccrued>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapStatementClassOfStockAxis_eyptSecondAdvanceMember_20190212_20190213"
      decimals="0"
      id="F_000685"
      unitRef="U_iso4217USD">225000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <eypt:UpfrontCashPayment
      contextRef="C_0001314102_srtProductOrServiceAxis_eyptRoyaltyPurchaseAgreementMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20201217_20201217"
      decimals="-5"
      id="F_000686"
      unitRef="U_iso4217USD">15000000.0</eypt:UpfrontCashPayment>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217"
      decimals="-5"
      id="F_000687"
      unitRef="U_iso4217USD">13800000</us-gaap:RepaymentsOfLinesOfCredit>
    <eypt:DebInstrumentExitFee
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217"
      decimals="0"
      id="F_000688"
      unitRef="U_iso4217USD">828000</eypt:DebInstrumentExitFee>
    <eypt:PaymentOfAccruedAndUnpaidInterest
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201217_20201217"
      decimals="0"
      id="F_000689"
      unitRef="U_iso4217USD">378000</eypt:PaymentOfAccruedAndUnpaidInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20200101_20201231"
      decimals="0"
      id="F_000690"
      unitRef="U_iso4217USD">-905000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20210101_20211231"
      decimals="0"
      id="F_000691"
      unitRef="U_iso4217USD">628000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20200101_20201231"
      decimals="0"
      id="F_000692"
      unitRef="U_iso4217USD">745000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000282">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;span style="margin-left:36pt;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity Financings&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common Stock Offerings&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, the Company sold 5,122,273 shares of its common stock in an underwritten public offering at a price of $13.75 per share, including the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of the Company&#x2019;s common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price of $13.74 per pre-funded warrant. The gross proceeds of the offering to the Company were approximately $115.4 million. Underwriter discounts and commissions and other share issue costs totaled approximately $7.2 million. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The pre-funded warrants were classified as a component of permanent equity because they met the permanent equity criteria classification. The pre-funded warrants are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable and permit the holders to receive a fixed number of shares of common stock upon exercise. The pre-funded warrants do not embody an obligation for the Company to repurchase its shares and do not provide any guarantee of value or return.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, the Company sold 10,465,000 shares of its common stock in an underwritten public offering at a price of $11.00 per share, including the exercise in full by the underwriters of their option to purchase up to 1,365,000 additional shares of the Company&#x2019;s common stock. The gross proceeds of the offering to the Company were approximately $115.1 million. Underwriter discounts and commissions and other share issue costs totaled approximately $7.2 million.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 31, 2020, the Company entered into a Share Purchase Agreement (the &#x201c;Share Purchase Agreement&#x201d;) with Ocumension, pursuant to which the Company sold to Ocumension 3,010,722 shares of Common Stock, at a purchase price of approximately $5.22 per share, which was the five-day volume weighted average price of the Common Stock as of the close of trading on December 29, 2020. The aggregate gross proceeds from the Transaction were approximately $15.7 million. Share issue costs totaled approximately $0.1 million.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company sold 1,500,000 shares of the Company&#x2019;s common stock in an underwritten public offering at a price of $14.50 per share for gross proceeds of $21.75 million. Underwriter discounts and commissions and other share issue costs totaled approximately $1.8 million.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the Annual Meeting of Stockholders held on June 23, 2020, the Company&#x2019;s stockholders approved the adoption of an amendment to the Company&#x2019;s Certificate of Incorporation, to increase the number of authorized shares of its common stock from 150,000,000 shares to 300,000,000 shares. The Company filed the Certificate of Amendment on June 23, 2020.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATM Facility&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In August 2020, the Company entered into an at-the-market facility (the &#x201c;ATM Facility&#x201d;) with Cantor Fitzgerald&#160;&amp;amp; Co (&#x201c;Cantor&#x201d;). Pursuant to the ATM Facility, the Company may, at its option, offer and sell shares of its Common Stock from time to time, through or to Cantor Fitzgerald, acting as sales agent. The Company will pay Cantor a commission of 3.0% of the gross proceeds from any future sales of such shares.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company sold 2,590,093 shares of its Common Stock at a weighted average price of $5.74 per share for gross proceeds of approximately $14.9 million. Share issue costs, including sales agent commissions, totaled $646,000 during the reporting period.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the year ended December 31, 2021, the Company sold 48,538 shares of its Common Stock at a weighted average price of $11.37 per share for gross proceeds of approximately $552,000. Share issue costs, including sales agent commissions, totaled approximately $53,000 during the reporting period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;span style="color:#000000;"&gt; to Purchase Common Shares&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of fixed price warrants to purchase shares of the Company&#x2019;s Common Stock for the years ended December 31, 2021 and 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance and exercisable at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to a credit agreement, the Company issued a warrant to SWK Funding LLC to purchase (i) 40,910 Initial Advance Warrant Shares on March 28, 2018 at an exercise price of $11.00 per share with a &lt;span style="-sec-ix-hidden:F_000736"&gt;seven-year&lt;/span&gt; term and (ii) 7,773 Additional Advance Warrant Shares on June 26, 2018 at an exercise price of $19.30 per share with a &lt;span style="-sec-ix-hidden:F_000737"&gt;seven-year&lt;/span&gt; term. At December 31, 2021, the weighted average remaining life of the warrants was approximately 3.3 years.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130"
      decimals="INF"
      id="F_000693"
      unitRef="U_xbrlishares">5122273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130"
      decimals="INF"
      id="F_000696"
      unitRef="U_iso4217USD_xbrlishares">13.75</us-gaap:SharesIssuedPricePerShare>
    <eypt:StockIssuedDuringPeriodAdditionalSharesIssued
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130"
      decimals="INF"
      id="F_000694"
      unitRef="U_xbrlishares">1095000</eypt:StockIssuedDuringPeriodAdditionalSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130"
      decimals="INF"
      id="F_000695"
      unitRef="U_xbrlishares">3272727</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <eypt:ClassOfWarrantOrRightIssuePriceOfWarrants
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211130"
      decimals="INF"
      id="F_000697"
      unitRef="U_iso4217USD_xbrlishares">13.74</eypt:ClassOfWarrantOrRightIssuePriceOfWarrants>
    <eypt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130"
      decimals="-5"
      id="F_000698"
      unitRef="U_iso4217USD">115400000</eypt:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20211101_20211130"
      decimals="-5"
      id="F_000699"
      unitRef="U_iso4217USD">7200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228"
      decimals="INF"
      id="F_000700"
      unitRef="U_xbrlishares">10465000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210228"
      decimals="INF"
      id="F_000702"
      unitRef="U_iso4217USD_xbrlishares">11.00</us-gaap:SharesIssuedPricePerShare>
    <eypt:StockIssuedDuringPeriodAdditionalSharesIssued
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228"
      decimals="INF"
      id="F_000701"
      unitRef="U_xbrlishares">1365000</eypt:StockIssuedDuringPeriodAdditionalSharesIssued>
    <eypt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228"
      decimals="-5"
      id="F_000703"
      unitRef="U_iso4217USD">115100000</eypt:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20210201_20210228"
      decimals="-5"
      id="F_000704"
      unitRef="U_iso4217USD">7200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231"
      decimals="INF"
      id="F_000705"
      unitRef="U_xbrlishares">3010722</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201231"
      decimals="INF"
      id="F_000706"
      unitRef="U_iso4217USD_xbrlishares">5.22</us-gaap:SharesIssuedPricePerShare>
    <eypt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231"
      decimals="-5"
      id="F_000707"
      unitRef="U_iso4217USD">15700000</eypt:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptSharePurchaseAgreementMember_20201230_20201231"
      decimals="-5"
      id="F_000708"
      unitRef="U_iso4217USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229"
      decimals="INF"
      id="F_000709"
      unitRef="U_xbrlishares">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200229"
      decimals="INF"
      id="F_000710"
      unitRef="U_iso4217USD_xbrlishares">14.50</us-gaap:SharesIssuedPricePerShare>
    <eypt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229"
      decimals="-4"
      id="F_000711"
      unitRef="U_iso4217USD">21750000</eypt:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001314102_us-gaapSubsidiarySaleOfStockAxis_eyptUnderwrittenPublicOfferingMember_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200201_20200229"
      decimals="-5"
      id="F_000712"
      unitRef="U_iso4217USD">1800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquityFinancingsMember_20200622"
      decimals="INF"
      id="F_000713"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001314102_20200623"
      decimals="INF"
      id="F_000714"
      unitRef="U_xbrlishares">300000000</us-gaap:CommonStockSharesAuthorized>
    <eypt:StockIssuanceCostsSalesAgentCommissionMaximumPercentage
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200801_20200831"
      decimals="INF"
      id="F_000715"
      unitRef="U_xbrlipure">0.030</eypt:StockIssuanceCostsSalesAgentCommissionMaximumPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000716"
      unitRef="U_xbrlishares">2590093</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20201231"
      decimals="INF"
      id="F_000717"
      unitRef="U_iso4217USD_xbrlishares">5.74</us-gaap:SharesIssuedPricePerShare>
    <eypt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231"
      decimals="-5"
      id="F_000718"
      unitRef="U_iso4217USD">14900000</eypt:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20200101_20201231"
      decimals="0"
      id="F_000719"
      unitRef="U_iso4217USD">646000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231"
      decimals="INF"
      id="F_000720"
      unitRef="U_xbrlishares">48538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20211231"
      decimals="INF"
      id="F_000721"
      unitRef="U_iso4217USD_xbrlishares">11.37</us-gaap:SharesIssuedPricePerShare>
    <eypt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231"
      decimals="0"
      id="F_000722"
      unitRef="U_iso4217USD">552000</eypt:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAtTheMarketOfferingMember_20210101_20211231"
      decimals="0"
      id="F_000723"
      unitRef="U_iso4217USD">53000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000324">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of fixed price warrants to purchase shares of the Company&#x2019;s Common Stock for the years ended December 31, 2021 and 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance and exercisable at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000724"
      unitRef="U_xbrlishares">48683</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000728"
      unitRef="U_iso4217USD_xbrlishares">12.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001314102_20191231"
      decimals="INF"
      id="F_000725"
      unitRef="U_xbrlishares">48683</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001314102_20191231"
      decimals="INF"
      id="F_000729"
      unitRef="U_iso4217USD_xbrlishares">12.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000726"
      unitRef="U_xbrlishares">48683</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001314102_20211231"
      decimals="INF"
      id="F_000730"
      unitRef="U_iso4217USD_xbrlishares">12.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000727"
      unitRef="U_xbrlishares">48683</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000731"
      unitRef="U_iso4217USD_xbrlishares">12.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eypt:WarrantsIssuedInConnectionWithTermLoanFacility
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328"
      decimals="INF"
      id="F_000732"
      unitRef="U_xbrlishares">40910</eypt:WarrantsIssuedInConnectionWithTermLoanFacility>
    <eypt:ExercisePriceOfIssuedWarrants
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180327_20180328"
      decimals="INF"
      id="F_000734"
      unitRef="U_iso4217USD_xbrlishares">11.00</eypt:ExercisePriceOfIssuedWarrants>
    <eypt:WarrantsIssuedInConnectionWithTermLoanFacility
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626"
      decimals="INF"
      id="F_000733"
      unitRef="U_xbrlishares">7773</eypt:WarrantsIssuedInConnectionWithTermLoanFacility>
    <eypt:ExercisePriceOfIssuedWarrants
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626"
      decimals="INF"
      id="F_000735"
      unitRef="U_iso4217USD_xbrlishares">19.30</eypt:ExercisePriceOfIssuedWarrants>
    <eypt:WeightedAverageRemainingLifeOfLenderWarrants
      contextRef="C_0001314102_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20210101_20211231"
      id="F_000738">P3Y3M18D</eypt:WeightedAverageRemainingLifeOfLenderWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000283">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Share-Based Payment Awards &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2016 Long-Term Incentive Plan (the &#x201c;2016 Plan&#x201d;), approved by the Company&#x2019;s stockholders on December 12, 2016 (the &#x201c;Adoption Date&#x201d;), provides for the issuance of up to 300,000 shares of the Company&#x2019;s Common Stock reserved for issuance under the 2016 Plan plus any additional shares of the Company&#x2019;s Common Stock that were available for grant under the 2008 Incentive Plan (the &#x201c;2008 Plan&#x201d;) at the Adoption Date or would otherwise become available for grant under the 2008 Plan as a result of subsequent termination or forfeiture of awards under the 2008 Plan. At the Company&#x2019;s Annual Meeting of Stockholders held on June 25, 2019, the Company&#x2019;s stockholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by 1,100,000 shares. At the Company&#x2019;s Annual Meeting of Stockholders held on June 22, 2021, the Company&#x2019;s stockholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by 2,500,000 shares. At December 31, 2021, a total of 1,683,368&#160;shares were available for new awards. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain inducement awards, although not awarded under the 2016 Plan or the 2008 Plan, are subject to and governed by the terms and conditions of the 2016 Plan or 2008 Plan, as applicable.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of stock option activity under the Company&#x2019;s equity incentive plans and for inducement awards for the year ended December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,338,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,313,727&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,517,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000757"&gt;8.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;775&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;916,461&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000758"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, the Company expanded the terms of its annual stock option grants to include vesting ratable monthly over four years, or with 25% vesting after one year followed by ratable monthly vesting over three years. Previously, the Company&#x2019;s option grants generally had ratable annual vesting over three years, or 1-year cliff vesting. Nonemployee awards are granted similar to the Company&#x2019;s employee awards. All option grants have a 10-year term. Options to purchase a total of 297,361 shares of the Company&#x2019;s Common Stock vested during the year ended December 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the grant date fair value of option awards during the years ended December 31, 2021 and 2020, the Company applied the Black-Scholes option pricing model based on the following key assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000768"&gt;4.75 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000769"&gt;5.50 - 6.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000772"&gt;72% - 83%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000773"&gt;64% - 70%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000776"&gt;0.42% - 1.44%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000777"&gt;0.32% - 1.76%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about employee, consultant and director stock options under the Company&#x2019;s equity incentive plans for the years ended December 31, 2021 and 2020 (in thousands except per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.07&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash received from exercise of stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total intrinsic value of stock options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Time-Vested Restricted Stock Units &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Time-vested restricted stock units (&#x201c;RSUs&#x201d;) issued to date under the 2016 Plan generally vest on a ratable annual basis over 3 years. The related stock-based compensation expense is recorded over the requisite service period, which is the vesting period. The fair value of all time-vested RSUs is based on the closing share price of the Common Stock on the date of grant. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of RSU activity under the 2016 Plan for the year ended December&#160;31, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89,795&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average remaining vesting term of the RSUs at December&#160;31, 2021 was 1.37 years. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Stock Units &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no non-vested deferred stock units (&#x201c;DSUs&#x201d;) issued and outstanding to the Company&#x2019;s non-executive directors at each of December 31, 2021 and 2020, respectively. Each DSU vests one year from the date of grant. Subsequent to vesting, the DSUs will be settled in shares of the Company&#x2019;s Common Stock upon the earliest to occur of (i) each director&#x2019;s termination of service on the Company&#x2019;s Board of Directors and (ii) the occurrence of a change of control as defined in the award agreement. At December 31, 2021, there was no vested DSUs that have not been settled in shares of the Company&#x2019;s Common Stock.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 25, 2019, the Company&#x2019;s stockholders approved the adoption of the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) and authorized up to 110,000 shares of Common Stock reserved for issuance to participating employees. At the Company&#x2019;s Annual Meeting of Stockholders held on June 22, 2021, the Company&#x2019;s stockholders approved an amendment to the ESPP to increase the number of shares authorized for issuance by 250,000 shares. The ESPP allows qualified participants to purchase the Company&#x2019;s Common Stock twice a year at 85% of the lesser of the average of the high and low sales price of the Company&#x2019;s Common Stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. &lt;span style="Background-color:#FFFFFF;"&gt;The number of shares of the Company&#x2019;s Common Stock each employee may purchase under this plan, when combined with all other employee stock purchase plans, is limited to the lower of an aggregate fair market value of $25,000 during each calendar year, or 5,000 shares of the Company&#x2019;s Common Stock in any one offering period. The Company has maintained consecutive six-month offering periods since August 1, 2019. &lt;/span&gt;As of December 31, 2021, 43,365 shares of the Company&#x2019;s Common Stock were issued pursuant to the ESPP.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company estimated the fair value of the option component of the ESPP shares at the date of grant using a Black-Scholes valuation model. During the year ended December 31, 2021, the compensation expense from ESPP shares was $113,000. During the year ended December 31, 2020, the compensation expense from ESPP shares was immaterial.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s statements of comprehensive loss included total compensation expense from stock-based payment awards as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation expense included in:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,411&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,547&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2021, there was approximately $9.3&#160;million of unrecognized compensation expense related to outstanding equity awards under the 2016 Plan, the 2008 Plan, The inducement awards and the ESPP that is expected to be recognized as expense over a weighted-average period of approximately 1.7 years. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20161212"
      decimals="INF"
      id="F_000739"
      unitRef="U_xbrlishares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20190625"
      decimals="INF"
      id="F_000740"
      unitRef="U_xbrlishares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210622"
      decimals="INF"
      id="F_000741"
      unitRef="U_xbrlishares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000742"
      unitRef="U_xbrlishares">1683368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000325">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of stock option activity under the Company&#x2019;s equity incentive plans and for inducement awards for the year ended December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,338,880&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,313,727&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,517,680&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000757"&gt;8.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;775&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.96%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;916,461&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000758"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231"
      decimals="INF"
      id="F_000743"
      unitRef="U_xbrlishares">1338880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231"
      decimals="2"
      id="F_000750"
      unitRef="U_iso4217USD_xbrlishares">20.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="INF"
      id="F_000744"
      unitRef="U_xbrlishares">1313727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="2"
      id="F_000751"
      unitRef="U_iso4217USD_xbrlishares">12.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="INF"
      id="F_000745"
      unitRef="U_xbrlishares">8112</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="2"
      id="F_000752"
      unitRef="U_iso4217USD_xbrlishares">12.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="INF"
      id="F_000746"
      unitRef="U_xbrlishares">75448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="2"
      id="F_000753"
      unitRef="U_iso4217USD_xbrlishares">16.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="INF"
      id="F_000747"
      unitRef="U_xbrlishares">51367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20210101_20211231"
      decimals="2"
      id="F_000754"
      unitRef="U_iso4217USD_xbrlishares">31.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231"
      decimals="INF"
      id="F_000748"
      unitRef="U_xbrlishares">2517680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231"
      decimals="2"
      id="F_000755"
      unitRef="U_iso4217USD_xbrlishares">16.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">775000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231"
      decimals="INF"
      id="F_000749"
      unitRef="U_xbrlishares">916461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231"
      decimals="2"
      id="F_000756"
      unitRef="U_iso4217USD_xbrlishares">22.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20211231"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">103000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131"
      id="F_000761">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181230_20190131"
      id="F_000763">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181230_20190131"
      id="F_000762">P3Y</eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod>
    <eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod
      contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptNewlyAppointedNonExecutiveDirectorMember_20181230_20190131"
      id="F_000764">P3Y</eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod>
    <eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod
      contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptDirectorsAndExternalConsultantsMember_20181230_20190131"
      id="F_000765">P1Y</eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131"
      id="F_000766">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000767"
      unitRef="U_xbrlishares">297361</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000326">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the grant date fair value of option awards during the years ended December 31, 2021 and 2020, the Company applied the Black-Scholes option pricing model based on the following key assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000768"&gt;4.75 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000769"&gt;5.50 - 6.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000772"&gt;72% - 83%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000773"&gt;64% - 70%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000776"&gt;0.42% - 1.44%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000777"&gt;0.32% - 1.76%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="3"
      id="F_000780"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20200101_20201231"
      decimals="3"
      id="F_000781"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000327">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about employee, consultant and director stock options under the Company&#x2019;s equity incentive plans for the years ended December 31, 2021 and 2020 (in thousands except per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.07&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash received from exercise of stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total intrinsic value of stock options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.4%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231"
      decimals="2"
      id="F_000782"
      unitRef="U_iso4217USD_xbrlishares">8.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20200101_20201231"
      decimals="2"
      id="F_000783"
      unitRef="U_iso4217USD_xbrlishares">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231"
      decimals="-3"
      id="F_000784"
      unitRef="U_iso4217USD">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231"
      decimals="-3"
      id="F_000785"
      unitRef="U_iso4217USD">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      id="F_000786">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000328">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of RSU activity under the 2016 Plan for the year ended December&#160;31, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at January 1, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89,795&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000787"
      unitRef="U_xbrlishares">149004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231"
      decimals="2"
      id="F_000792"
      unitRef="U_iso4217USD_xbrlishares">13.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000788"
      unitRef="U_xbrlishares">242399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000793"
      unitRef="U_iso4217USD_xbrlishares">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000789"
      unitRef="U_xbrlishares">89795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000794"
      unitRef="U_iso4217USD_xbrlishares">13.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000790"
      unitRef="U_xbrlishares">10033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000795"
      unitRef="U_iso4217USD_xbrlishares">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000791"
      unitRef="U_xbrlishares">291575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231"
      decimals="2"
      id="F_000796"
      unitRef="U_iso4217USD_xbrlishares">13.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231"
      id="F_000797">P1Y4M13D</eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20211231"
      decimals="INF"
      id="F_000798"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20201231"
      decimals="INF"
      id="F_000799"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_20210101_20211231"
      id="F_000800">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <eypt:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested
      contextRef="C_0001314102_us-gaapAwardTypeAxis_eyptDeferredStockUnitsMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000801"
      unitRef="U_xbrlishares">0</eypt:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190625"
      decimals="INF"
      id="F_000802"
      unitRef="U_xbrlishares">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210622"
      decimals="INF"
      id="F_000803"
      unitRef="U_xbrlishares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625"
      decimals="2"
      id="F_000804"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625"
      decimals="0"
      id="F_000805"
      unitRef="U_iso4217USD">25000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625"
      decimals="INF"
      id="F_000806"
      unitRef="U_xbrlishares">5000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190624_20190625"
      id="F_000807">2019-08-01</eypt:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000808"
      unitRef="U_xbrlishares">43365</us-gaap:CommonStockSharesIssued>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="0"
      id="F_000809"
      unitRef="U_iso4217USD">113000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000329">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s statements of comprehensive loss included total compensation expense from stock-based payment awards as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation expense included in:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,411&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,547&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000810"
      unitRef="U_iso4217USD">2294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000811"
      unitRef="U_iso4217USD">1411000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20210101_20211231"
      decimals="-3"
      id="F_000812"
      unitRef="U_iso4217USD">1187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_eyptSalesAndMarketingMember_20200101_20201231"
      decimals="-3"
      id="F_000813"
      unitRef="U_iso4217USD">907000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000814"
      unitRef="U_iso4217USD">3966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000815"
      unitRef="U_iso4217USD">3229000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000816"
      unitRef="U_iso4217USD">7447000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000817"
      unitRef="U_iso4217USD">5547000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000818"
      unitRef="U_iso4217USD">9300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001314102_20210101_20211231" id="F_000819">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000284">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&lt;span style="margin-left:22pt;"/&gt;License and Asset Purchase Agreements&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aerpio Pharmaceuticals, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2021, the Company entered into an Asset Purchase Agreement with Aerpio Pharmaceuticals, Inc. (&#x201c;Aerpio&#x201d;), pursuant to which Aerpio sold to the Company all of its right, title and interest in and to certain of its patents and patent applications and other intellectual property, including but not limited to patents covering certain human protein tyrosine phosphate inhibitors and methods of use.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration for the rights purchased from Aerpio, the Company made a one time, non-refundable, non-creditable upfront cash payment of $450,000 to Aerpio in August 2021. The Company recorded $450,000 of R&amp;amp;D expense for the year ended December 31, 2021, due to the early stage of its preclinical drug development activities.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equinox Science, LLC &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company entered into an Exclusive License Agreement with Equinox Science, LLC&lt;span style="Background-color:#FFFFFF;"&gt; (&#x201c;Equinox&#x201d;), pursuant to which Equinox granted us an exclusive, sublicensable, royalty-bearing right and license to certain patents and other Equinox intellectual property to research, develop, make, have made, use, sell, offer for sale and import the compound vorolanib and any pharmaceutical products comprising the compound for the prevention or treatment of age-related macular degeneration, diabetic retinopathy and retinal vein occlusion using our proprietary localized delivery technologies, in each case, throughout the world except China, Hong Kong, Taiwan and Macau (the &#x201c;Territory&#x201d;).&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In &lt;/span&gt;consideration&lt;span style="Background-color:#FFFFFF;"&gt; for the rights granted by Equinox, the Company (i) made a one time, non-refundable, non-creditable upfront cash payment of $1.0 million to Equinox in February 2020, and (ii) agreed to pay milestone payments totaling up to $50 million upon the achievement of certain development and regulatory milestones, consisting of (a) completion of a Phase II clinical trial for the compound or a licensed product, (b) the filing of a new drug application or foreign equivalent for the compound or a licensed product in the United States, European Union or United Kingdom and (c) regulatory approval of the compound or a licensed product in the United States, European Union or United Kingdom.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company also agreed to pay Equinox tiered royalties based upon annual net sales of licensed products in the Territory. The royalties are payable with respect to a licensed product in a particular country in the Territory on a country-by-country and licensed product-by-licensed product basis until the later of (i) twelve years after the first commercial sale of such licensed product in such country and (ii) the first day of the month following the month in which a generic product corresponding to such licensed product is launched in such country (collectively, the &#x201c;Royalty Term&#x201d;). &lt;/span&gt;The royalty rates range from the high-single digits to low-double digits depending on the level of annual net sales. The royalty rates are subject to reduction during certain periods when there is no valid patent claim that covers a licensed product in a particular country. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The&lt;/span&gt; Company recorded $0 and $1.0 million of R&amp;amp;D expense during the years ended December 31, 2021 and 2020 for this license.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <eypt:NonRefundableNonCreditableUpfrontCashPayment
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210801_20210831"
      decimals="0"
      id="F_000820"
      unitRef="U_iso4217USD">450000</eypt:NonRefundableNonCreditableUpfrontCashPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210101_20211231"
      decimals="0"
      id="F_000821"
      unitRef="U_iso4217USD">450000</us-gaap:ResearchAndDevelopmentExpense>
    <eypt:NonRefundableNonCreditableUpfrontCashPayment
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229"
      decimals="-5"
      id="F_000822"
      unitRef="U_iso4217USD">1000000.0</eypt:NonRefundableNonCreditableUpfrontCashPayment>
    <eypt:MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
      contextRef="C_0001314102_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200201_20200229"
      decimals="-6"
      id="F_000823"
      unitRef="U_iso4217USD">50000000</eypt:MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20210101_20211231"
      decimals="0"
      id="F_000824"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001314102_us-gaapTypeOfArrangementAxis_eyptEquinoxScienceLLCMember_20200101_20201231"
      decimals="-5"
      id="F_000825"
      unitRef="U_iso4217USD">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000285">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.&lt;span style="margin-left:22pt;"/&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&#x2019;s assets carried at fair value measured on a recurring basis at December 31, 2021 and 2020, respectively, by valuation hierarchy (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Level 2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,549&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,549&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2021, a total of $155.6 million, or&#160;&#160;90.4% of the Company&#x2019;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. $16.5 million, or 9.6% of the Company&#x2019;s interest-bearing cash equivalent balances consisted of investment-grade commercial paper. Generally, these investments may be sold upon demand and, therefore, the Company believes they have minimal risk. The Company had investments of $33.0 million in marketable securities at December 31, 2021.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents and marketable securities are classified within Level 1 or Level 2 on the basis of valuations using quoted market prices or alternative pricing sources and models utilizing market observable inputs, respectively. The marketable securities have been valued on the basis of valuations provided by third-party pricing services, as derived from such services&#x2019; pricing models. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The pricing services may use a matrix approach, which considers information regarding securities with similar characteristics to determine the valuation for a security, and have been classified as Level 2.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2020, substantially all of the Company&#x2019;s interest-bearing cash equivalent balances were concentrated in one U.S. Government money market fund that has investments consisting primarily of U.S. Government Agency debt, U.S. Treasury debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. The Company had no investments in marketable securities at December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;"&gt;carrying&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; amounts of accounts receivable, accounts payable and accrued expenses approximate fair value because of their short-term maturity.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The fair value of the Company&#x2019;s CRG Loan is determined using a discounted cash flow analysis based on market rates for observable similar instruments as of the condensed consolidated balance sheet dates. Accordingly, the fair value of the CRG Loan is categorized as Level 2 within the fair value hierarchy. At December 31, 2021, the fair value of the CRG Loan was approximately $38.7 million, and the carrying value of the CRG Loan was approximately $&lt;/span&gt;&lt;span style="color:#000000;"&gt;38.9&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; million, and consisted of $&lt;/span&gt;&lt;span style="color:#000000;"&gt;36.6&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; million of its carrying amount as reported in long-term debt, and $2.3 million of debt exit fee as reported in other long-term liabilities of the consolidated balance sheet, respectively. At December 31, 2020, the fair value of the CRG Loan was approximately $38.0 million, and the carrying value of the CRG Loan was approximately $38.3&lt;/span&gt;&lt;span style="font-size:12pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;million, and consisted of $36.0&lt;/span&gt;&lt;span style="font-size:12pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;million of its carrying amount as reported in long-term debt, and $2.3 million of debt exit fee as reported in other long-term liabilities of the condensed consolidated balance sheet, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000330">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&#x2019;s assets carried at fair value measured on a recurring basis at December 31, 2021 and 2020, respectively, by valuation hierarchy (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;155,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Level 2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,549&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,549&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,965&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="22" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000826"
      unitRef="U_iso4217USD">155551000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000831"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000836"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000841"
      unitRef="U_iso4217USD">155551000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000846"
      unitRef="U_iso4217USD">155551000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000851"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000827"
      unitRef="U_iso4217USD">155551000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000832"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000837"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000842"
      unitRef="U_iso4217USD">155551000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000847"
      unitRef="U_iso4217USD">155551000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000852"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000828"
      unitRef="U_iso4217USD">49514000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000833"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000838"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000843"
      unitRef="U_iso4217USD">49514000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000848"
      unitRef="U_iso4217USD">16549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000853"
      unitRef="U_iso4217USD">32965000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000829"
      unitRef="U_iso4217USD">49514000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000834"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000839"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000844"
      unitRef="U_iso4217USD">49514000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000849"
      unitRef="U_iso4217USD">16549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000854"
      unitRef="U_iso4217USD">32965000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000830"
      unitRef="U_iso4217USD">205065000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000835"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000840"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000845"
      unitRef="U_iso4217USD">205065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000850"
      unitRef="U_iso4217USD">172100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000855"
      unitRef="U_iso4217USD">32965000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000856"
      unitRef="U_iso4217USD">23538000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000858"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000860"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000862"
      unitRef="U_iso4217USD">23538000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000864"
      unitRef="U_iso4217USD">23538000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000866"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000857"
      unitRef="U_iso4217USD">23538000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000859"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000861"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000863"
      unitRef="U_iso4217USD">23538000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000865"
      unitRef="U_iso4217USD">23538000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000867"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000868"
      unitRef="U_iso4217USD">155600000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000869"
      unitRef="U_xbrlipure">0.904</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000870"
      unitRef="U_iso4217USD">16500000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001314102_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapConcentrationRiskByBenchmarkAxis_eyptInvestmentInstrumentsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20210101_20211231"
      decimals="3"
      id="F_000871"
      unitRef="U_xbrlipure">0.096</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_20211231"
      decimals="-5"
      id="F_000872"
      unitRef="U_iso4217USD">33000000.0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001314102_20201231"
      decimals="INF"
      id="F_000873"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231"
      decimals="-5"
      id="F_000880"
      unitRef="U_iso4217USD">38700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebt
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231"
      decimals="-5"
      id="F_000874"
      unitRef="U_iso4217USD">38900000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231"
      decimals="-5"
      id="F_000876"
      unitRef="U_iso4217USD">36600000</us-gaap:DebtInstrumentCarryingAmount>
    <eypt:ExitFeeAccrued
      contextRef="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231"
      decimals="-5"
      id="F_000878"
      unitRef="U_iso4217USD">2300000</eypt:ExitFeeAccrued>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231"
      decimals="-5"
      id="F_000881"
      unitRef="U_iso4217USD">38000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebt
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231"
      decimals="-5"
      id="F_000875"
      unitRef="U_iso4217USD">38300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231"
      decimals="-5"
      id="F_000877"
      unitRef="U_iso4217USD">36000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <eypt:ExitFeeAccrued
      contextRef="C_0001314102_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20201231"
      decimals="-5"
      id="F_000879"
      unitRef="U_iso4217USD">2300000</eypt:ExitFeeAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000286">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Retirement Plans &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates a defined contribution plan intended to qualify under Section&#160;401(k) of the U.S. Internal Revenue Code. Participating U.S. employees may contribute a portion of their pre-tax compensation, as defined, subject to statutory maximums. The Company matches employee contributions up to 5% of eligible compensation, subject to a stated calendar year Internal Revenue Service maximum. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operated a defined contribution pension plan for U.K. employees pursuant to which the Company made contributions on behalf of employees plus a matching percentage of elective employee contributions. This pension plan was terminated in the quarter ending September&#160;30, 2016 following termination of employment of all U.K. employees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company contributed a total of $1.0 million and $690,000 for the years ended December 31, 2021 and 2020, respectively, in connection with these retirement plans. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001314102_20210101_20211231"
      decimals="2"
      id="F_000882"
      unitRef="U_xbrlipure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <eypt:DefinedContributionPlanContributionsByEmployer
      contextRef="C_0001314102_20210101_20211231"
      decimals="1"
      id="F_000883"
      unitRef="U_iso4217USD">1.0</eypt:DefinedContributionPlanContributionsByEmployer>
    <eypt:DefinedContributionPlanContributionsByEmployer
      contextRef="C_0001314102_20200101_20201231"
      decimals="0"
      id="F_000884"
      unitRef="U_iso4217USD">690000</eypt:DefinedContributionPlanContributionsByEmployer>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000287">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of loss before income taxes are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-U.S. operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;O&lt;span style="color:#000000;"&gt;n December&#160;22, 2017, the &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Tax Cuts and Jobs Act &lt;/span&gt;&lt;span style="color:#000000;"&gt;(the &#x201c;Tax Act&#x201d;) was signed into law, making significant changes to the federal tax law. Amongst other things, the Tax Act reduces the federal corporate tax rate from 34% to 21% effective for tax years beginning after December&#160;31, 2017 and has resulted in a remeasurement of the Company&#x2019;s deferred tax assets included in the Company&#x2019;s fiscal 2018 rate reconciliation.&lt;/span&gt; The difference between the Company&#x2019;s expected income tax benefit, as computed by applying the blended statutory U.S. federal tax rate of 21% for the year ended December 31, 2021 and 21% for the year ended December 31, 2020, to loss before income taxes, and actual income tax benefit is reconciled in the following table (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,268&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,533&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-U.S. income tax rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of derivative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in federal tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;729&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;span style="font-size:10pt;"&gt;The significant components of deferred income taxes are as follows (in thousands): &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;806&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,005&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,963&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,087&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The valuation allowance generally reflects limitations on the Company&#x2019;s ability to use the tax attributes and reduces the value of such attributes to the more-likely-than-not realizable amount. Management assessed the available positive and negative evidence to estimate if sufficient taxable income will be generated to use the existing net deferred tax assets. Based on a weighting of the objectively verifiable negative evidence in the form of cumulative operating losses over the three-year period ended June&#160;30, 2018, management believes that it is not more likely than not that the deferred tax assets will be realized and, accordingly, a full valuation allowance has been established. The valuation allowance increased $15.7 million and $13.1 million for the years ended December 31, 2021 and 2020, respectively, with such increases attributed to the re-measurement of the net deferred tax assets at the year-end dates. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has tax net operating loss and tax credit carry forwards in its individual tax jurisdictions. Including approximately $49.3&#160;million related to the Icon acquisition, at December&#160;31, 2021, the Company had U.S. federal net operating loss carry forwards of approximately $301.2&#160;million. The net operating losses consist of $151.8 million, which expire at various dates between calendar years 2023 and 2038. The utilization of certain of these loss and tax credit carry forwards may be limited by Sections 382 and 383 of the Internal Revenue Code as a result of historical or future changes in the Company&#x2019;s ownership. At December&#160;31, 2021, the Company had state net operating loss carry forwards of approximately $222.6&#160;million, which expire between 2033 and 2038, as well as U.S. federal and state research and development tax credit carry forwards of approximately $5.7&#160;million, which expire at various dates between calendar years 2021 and 2038. In addition, at December&#160;31, 2021 the Company had net operating loss carry forwards in the U.K. of &#xa3;20.9&#160;million (approximately $27.6 million), which are not subject to any expiration dates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s U.S. federal income tax returns for calendar years 2003 through 2020 remain subject to examination by the Internal Revenue Service. The Company&#x2019;s U.K. tax returns for fiscal years 2006 through 2020 remain subject to examination. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through December&#160;31, 2021, the Company had no unrecognized tax benefits in its consolidated statements of comprehensive loss and no unrecognized tax benefits in its consolidated balance sheets as of December&#160;31, 2021 and 2020, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021 and 2020, the Company had no accrued penalties or interest related to uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000331">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of loss before income taxes are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-U.S. operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000885"
      unitRef="U_iso4217USD">-58517000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000886"
      unitRef="U_iso4217USD">-45492000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000887"
      unitRef="U_iso4217USD">100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000888"
      unitRef="U_iso4217USD">98000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000889"
      unitRef="U_iso4217USD">-58417000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000890"
      unitRef="U_iso4217USD">-45394000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001314102_20170101_20171231"
      decimals="2"
      id="F_000891"
      unitRef="U_xbrlipure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001314102_20190101_20191231"
      decimals="2"
      id="F_000892"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000332">The difference between the Company&#x2019;s expected income tax benefit, as computed by applying the blended statutory U.S. federal tax rate of 21% for the year ended December 31, 2021 and 21% for the year ended December 31, 2020, to loss before income taxes, and actual income tax benefit is reconciled in the following table (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,268&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,533&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-U.S. income tax rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of derivative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in federal tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;729&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001314102_20210101_20211231"
      decimals="2"
      id="F_000893"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001314102_20200101_20201231"
      decimals="2"
      id="F_000894"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000895"
      unitRef="U_iso4217USD">-12268000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000896"
      unitRef="U_iso4217USD">-9533000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000897"
      unitRef="U_iso4217USD">-2890000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000898"
      unitRef="U_iso4217USD">-2760000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000899"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000900"
      unitRef="U_iso4217USD">-8000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <eypt:IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000901"
      unitRef="U_iso4217USD">0</eypt:IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability>
    <eypt:IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000902"
      unitRef="U_iso4217USD">0</eypt:IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000903"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000904"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000905"
      unitRef="U_iso4217USD">693000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000906"
      unitRef="U_iso4217USD">403000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <eypt:IncomeTaxReconciliationPermanentItems
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000907"
      unitRef="U_iso4217USD">729000</eypt:IncomeTaxReconciliationPermanentItems>
    <eypt:IncomeTaxReconciliationPermanentItems
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000908"
      unitRef="U_iso4217USD">288000</eypt:IncomeTaxReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000909"
      unitRef="U_iso4217USD">15748000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000910"
      unitRef="U_iso4217USD">13068000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000911"
      unitRef="U_iso4217USD">-626000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000912"
      unitRef="U_iso4217USD">-652000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000913"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000914"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000333">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;span style="font-size:10pt;"&gt;The significant components of deferred income taxes are as follows (in thousands): &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;806&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,005&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,963&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,087&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000915"
      unitRef="U_iso4217USD">84026000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000916"
      unitRef="U_iso4217USD">74876000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000917"
      unitRef="U_iso4217USD">4270000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000918"
      unitRef="U_iso4217USD">150000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <eypt:DeferredTaxAssetsLeasingArrangements
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000919"
      unitRef="U_iso4217USD">722000</eypt:DeferredTaxAssetsLeasingArrangements>
    <eypt:DeferredTaxAssetsLeasingArrangements
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000920"
      unitRef="U_iso4217USD">806000</eypt:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000921"
      unitRef="U_iso4217USD">7822000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000922"
      unitRef="U_iso4217USD">6847000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000923"
      unitRef="U_iso4217USD">5446000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000924"
      unitRef="U_iso4217USD">4503000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000925"
      unitRef="U_iso4217USD">3005000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000926"
      unitRef="U_iso4217USD">2514000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000927"
      unitRef="U_iso4217USD">105291000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000928"
      unitRef="U_iso4217USD">89696000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000929"
      unitRef="U_iso4217USD">5963000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000930"
      unitRef="U_iso4217USD">6087000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000931"
      unitRef="U_iso4217USD">615000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000932"
      unitRef="U_iso4217USD">713000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000933"
      unitRef="U_iso4217USD">6578000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000934"
      unitRef="U_iso4217USD">6800000</us-gaap:DeferredIncomeTaxLiabilities>
    <eypt:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000935"
      unitRef="U_iso4217USD">98713000</eypt:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <eypt:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000936"
      unitRef="U_iso4217USD">82896000</eypt:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000937"
      unitRef="U_iso4217USD">98713000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000938"
      unitRef="U_iso4217USD">82896000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000939"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000940"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001314102_20210101_20211231"
      decimals="-5"
      id="F_000941"
      unitRef="U_iso4217USD">15700000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001314102_20200101_20201231"
      decimals="-5"
      id="F_000942"
      unitRef="U_iso4217USD">13100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231"
      decimals="-5"
      id="F_000943"
      unitRef="U_iso4217USD">49300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231"
      decimals="-5"
      id="F_000944"
      unitRef="U_iso4217USD">301200000</us-gaap:OperatingLossCarryforwards>
    <eypt:NetOperatingLossCarryforwards
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20211231"
      decimals="-5"
      id="F_000945"
      unitRef="U_iso4217USD">151800000</eypt:NetOperatingLossCarryforwards>
    <eypt:OperatingLossCarryForwardsExpirationYearRangeStart
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231"
      id="F_000954">2023</eypt:OperatingLossCarryForwardsExpirationYearRangeStart>
    <eypt:OperatingLossCarryForwardsExpirationYearRangeEnd
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20210101_20211231"
      id="F_000955">2038</eypt:OperatingLossCarryForwardsExpirationYearRangeEnd>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000946"
      unitRef="U_iso4217USD">222600000</us-gaap:OperatingLossCarryforwards>
    <eypt:OperatingLossCarryForwardsExpirationYearRangeStart
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000947">2033</eypt:OperatingLossCarryForwardsExpirationYearRangeStart>
    <eypt:OperatingLossCarryForwardsExpirationYearRangeEnd
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000948">2038</eypt:OperatingLossCarryForwardsExpirationYearRangeEnd>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember_20211231"
      decimals="-5"
      id="F_000949"
      unitRef="U_iso4217USD">5700000</us-gaap:TaxCreditCarryforwardAmount>
    <eypt:ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart
      contextRef="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateTaxMember_20210101_20211231"
      id="F_000952">2021</eypt:ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart>
    <eypt:ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd
      contextRef="C_0001314102_us-gaapTaxCreditCarryforwardAxis_eyptFederalAndStateTaxMember_20210101_20211231"
      id="F_000953">2038</eypt:ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20211231"
      decimals="-5"
      id="F_000950"
      unitRef="U_iso4217GBP">20900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001314102_us-gaapIncomeTaxAuthorityNameAxis_us-gaapHerMajestysRevenueAndCustomsHMRCMember_20211231"
      decimals="-5"
      id="F_000951"
      unitRef="U_iso4217USD">27600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001314102_20211231"
      decimals="0"
      id="F_000958"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001314102_20201231"
      decimals="0"
      id="F_000959"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001314102_20211231"
      decimals="0"
      id="F_000960"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001314102_20201231"
      decimals="0"
      id="F_000961"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000288">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Contingencies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal Proceedings &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to various other routine legal proceedings and claims incidental to its business, which management believes will not have a material effect on the Company&#x2019;s financial position, results of operations or cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;U.S. Securities and Exchange Commission Subpoena &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="color:#000000;"&gt; Company previously disclosed that on May 14, 2020 it had received a subpoena from the Division of Enforcement of the SEC seeking production of certain documents and information on topics including product sales and demand, revenue recognition and accounting in relation to product sales, product sales and cash projections, and related financial reporting, disclosure and compliance matters. On May 4, 2021, the Company was advised by the SEC Division of Enforcement that it has concluded its investigation of the Company and that, based on the information it has to date, the Enforcement Division does not intend to recommend an enforcement action against the Company. &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000289">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Segment and Geographic Area Information &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Business Segment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one business segment, which is the business of developing and commercializing innovative ophthalmic products for the treatment of eye diseases. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief operating decision maker made such decisions and assessed performance at the company level, as one segment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic Area Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s revenues and long-lived assets, net by geographic area (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Twelve&#160;Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Twelve&#160;Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;At&#160;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;At&#160;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,988&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.K.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,939&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001314102_20210101_20211231"
      decimals="INF"
      id="F_000962"
      unitRef="U_xbrlipure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000334">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s revenues and long-lived assets, net by geographic area (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Twelve&#160;Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Twelve&#160;Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;At&#160;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;At&#160;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,988&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.K.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,939&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20210101_20211231"
      decimals="-3"
      id="F_000963"
      unitRef="U_iso4217USD">35988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20200101_20201231"
      decimals="-3"
      id="F_000967"
      unitRef="U_iso4217USD">22624000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20211231"
      decimals="-3"
      id="F_000971"
      unitRef="U_iso4217USD">476000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-3"
      id="F_000973"
      unitRef="U_iso4217USD">630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryCN_20210101_20211231"
      decimals="-3"
      id="F_000964"
      unitRef="U_iso4217USD">851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryCN_20200101_20201231"
      decimals="-3"
      id="F_000968"
      unitRef="U_iso4217USD">11713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryGB_20210101_20211231"
      decimals="-3"
      id="F_000965"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_srtStatementGeographicalAxis_countryGB_20200101_20201231"
      decimals="-3"
      id="F_000969"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_20210101_20211231"
      decimals="-3"
      id="F_000966"
      unitRef="U_iso4217USD">36939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001314102_20200101_20201231"
      decimals="-3"
      id="F_000970"
      unitRef="U_iso4217USD">34437000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_20211231"
      decimals="-3"
      id="F_000972"
      unitRef="U_iso4217USD">476000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001314102_20201231"
      decimals="-3"
      id="F_000974"
      unitRef="U_iso4217USD">630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001314102_20210101_20211231" id="F_000290">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Subsequent Events&lt;span style="color:#000000;font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 9, 2022, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (the &#x201c;SVB Loan Agreement&#x201d;). The SVB Loan Agreement provides (i) a senior secured term loan facility of $30 million (the &#x201c;Term Loan&#x201d;) and (ii) a senior secured revolving credit facility of up to $15.0 million in available credit (the &#x201c;Revolving Facility&#x201d; and together with the Term Loan, &#x201c;the SVB Loan&#x201d;). The maximum amount available for borrowing at any time under the Revolving Facility is limited to a borrowing base valuation, or 80% of the Company&#x2019;s eligible accounts receivable. An unused commitment fee of 0.25% per annum applies to unutilized borrowing capacity under the Revolving Facility. The SVB Loan Agreement replaced its existing CRG Loan (see Note 9). Pursuant to the SVB Loan Agreement, the Company (i) made an initial draw of $30 million with respect to the Term Loan and of approximately $11.5 million with respect to the Revolving Facility, to pay off the CRG Loan, including the accrued interests through this date. Certain prepayment premiums apply to any repayments made (i) with respect to the Term Loan prior to the maturity date on January 1, 2027, and (ii) with respect to the Revolving Facility prior to the maturity date on January 1, 2027.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SVB Loan Agreement bears interest at (i) the greater of (x) Wall Street Journal Prime Rate plus 2.25% and (y) 5.50%, with respect to the Term Loan; (ii) the Wall Street Journal Prime Rate, with respect to the Revolving Facility; per annum payable in arrears on the last business day of each calendar month. Commencing on February 1, 2024, the Company is required to repay the principal amount of the Term Loan in 36 consecutive equal monthly installments plus monthly payments of accrued interest. Amounts borrowed under the Revolving Facility may be prepaid or repaid and, prior to the Revolving Facility Maturity Date, reborrowed, subject to the applicable terms and conditions set forth in the SVB Loan Agreement. The SVB Loan is due at maturity on January 1, 2027 (the &#x201c;Maturity Date&#x201d;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On the same date, the Company paid $41.4 million. This payment included (i) a $38.2 million principal portion of the CRG Loan (ii) an $2.3 million exit fee of 6% of the aggregate principal amount advanced under the CRG Loan (iii) accrued and unpaid interest of $0.9 million through that date. As a result of the early repayment of the CRG Loan, the Company expects to record a loss on extinguishment of debt of approximately $1.5 million for the quarter ending March 31, 2022 in association with the write-off of the remaining balance of unamortized debt discount.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309"
      decimals="-6"
      id="F_000975"
      unitRef="U_iso4217USD">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309"
      decimals="-5"
      id="F_000976"
      unitRef="U_iso4217USD">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <eypt:PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="2"
      id="F_000977"
      unitRef="U_xbrlipure">0.80</eypt:PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="4"
      id="F_000978"
      unitRef="U_xbrlipure">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="-6"
      id="F_000979"
      unitRef="U_iso4217USD">30000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredRevolvingCreditFacilityMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="-5"
      id="F_000980"
      unitRef="U_iso4217USD">11500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      id="F_000981">2027-01-01</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20220309_20220309"
      decimals="4"
      id="F_000982"
      unitRef="U_xbrlipure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309"
      decimals="4"
      id="F_000983"
      unitRef="U_xbrlipure">0.0550</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptSiliconValleyBankMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      id="F_000984">2027-01-01</us-gaap:LineOfCreditFacilityExpirationDate1>
    <eypt:UpfrontCashPayment
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="-5"
      id="F_000985"
      unitRef="U_iso4217USD">41400000</eypt:UpfrontCashPayment>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="-5"
      id="F_000986"
      unitRef="U_iso4217USD">38200000</us-gaap:RepaymentsOfLinesOfCredit>
    <eypt:DebInstrumentExitFee
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="-5"
      id="F_000987"
      unitRef="U_iso4217USD">2300000</eypt:DebInstrumentExitFee>
    <eypt:LineOfCreditFacilityExitFeesPercentage
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="2"
      id="F_000988"
      unitRef="U_xbrlipure">0.06</eypt:LineOfCreditFacilityExitFeesPercentage>
    <eypt:PaymentOfAccruedAndUnpaidInterest
      contextRef="C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220309_20220309"
      decimals="-5"
      id="F_000989"
      unitRef="U_iso4217USD">900000</eypt:PaymentOfAccruedAndUnpaidInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_0001314102_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20220101_20220331"
      decimals="-5"
      id="F_000990"
      unitRef="U_iso4217USD">-1500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000392"
          xlink:label="F_000392"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000391"
          xlink:label="F_000391"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><xhtml:span style="Background-color:#auto;text-decoration:none;"/><xhtml:span style="color:#000000;">Included approximately $25 and $205 of revenue recognized from YUTIQ product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000392"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000391"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000393"
          xlink:label="F_000393"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000394"
          xlink:label="F_000394"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><xhtml:span style="Background-color:#auto;text-decoration:none;"/><xhtml:span style="color:#000000;">Included approximately $283 and $8 of revenue recognized from DEXYCU product sales to Ocumension under a supply agreement for the years ended December 31, 2021 and 2020, respectively. </xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000393"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000394"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "/G6M4:"LK=]4&  "U&P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*6976_;-A2&K[=?0;A%T0)U+%&RG;1) ,>.-Z])ZL5IBVS8!2W1EA!)]$@J
MB?_]#B79=#+YR,-N$NOCO'K$C_<<D:=/0CZHB'--GM,D4V>M2.O5ITY'!1%/
MF3H2*Y[!E860*=-P*)<=M9*<A450FG2HX_0Z*8NSUOEI<6XJST]%KI,XXU-)
M5)ZF3*XO>"*>SEIN:W/B-EY&VISHG)^NV)+/N/ZVFDHXZFQ5PCCEF8I%1B1?
MG+4&[J>1[YB XH[O,7]2.[^)>96Y$ _F8!*>M1Q#Q!,>:"/!X-\C'_(D,4K
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M^O-(!24\6@-5+HI[=HI4-XHBI0EDT%D?A9[CM%!VI6#@]L$,:YBA%>9<A[O
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M1J'(S)?*7-F_Z+&6C9,)2BNEY;X9# CVHJA_V5-CB),!>#XP@#0#2'] .#"
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M/XH&=WEA-Z+# YP'=LDKIVWOA=HK46EO7:6<7XJ?\,3$H=6C)UYTNE,40M'
M*@>"\1P0;-$A& $,)*YZAX)V 3%9/7KX1 15UL8V=KL7H#O$S@?0&H<#"+!E
MWT@G*M=OX2D9B"40M::OR+N7/]^<KKXY!W@1+!M@,P')Z[O3EHH$$0GZ]/W+
M[ZY% 'L& A>>UG17LQ>P!ZFC=79@8EA[ZA!_BBN"'O=56V42>L27*8MT\\7K
MJS&+'#N0,ZU4RMXKBN&M9@YMK$<F8<U6=,IVC1)?G8N]DHX#C3TY:[9!3 D
MM-0[& @;N!SNB[.S55\&[&8J*BXU1A[(M"E"B/[/[WYZ]0]L>5^ QK!0\(TU
MI]ILF+R1\/Y6(50P?\.7X *9UUD?"!'(E=KRHW"$?@ ^%L(:-7R?A83=+6!A
M910BTAMR6"+='6)"J\"L']!/KBC3%[@(Q,^B[G^XNAA"+H@<@MKN9]&)KM<2
MX-[922$,T?+?IG DY*4_WUNJK3G"*!@<&K)_P*#V2I(C7)I>;XW>P$CX7]:
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MFE=]8>AQ&8N6\WIOKIL2&'6]R4#)<M-WP+C*ILG;&K:=7H4G[S9 [7[2W-5
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M#H5Y1)3Q/>+G"F5(^*C;2RVT2J4'V6G2U-(NX+^,>H[9[IP4ZF[,C8R3Z$R
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M8CTF&SS$#.%DBEQ,,K;M[CAL7!2G5#GI/6G:TM!Q^4]U<P?6(>J/7QE-:@_
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MI_'9Z(Q>#./)>-)Q_!]<'';ZDW@X&G;H@6'G2U&*K&:9!8^C7)98.1S%P_X
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M6D2?*FTJ ;Y@>A%E3(W,04M2)+ZL6%F?]M1B%FC)V2VNR=PF2A)NB(E^%\"
MA ;0SE+@5 E)43D,TK';0=)VCGP,-[F3]+^^DS9X@,:SZ/K]UU^NKSZ01VLV
M,N=7S6)0MB60G9+JK.-;QRNY6DA2OUI.(9O5 &H EVF?RA_ W_X(V:+7LY6K
MWQT#-F<9*>[_5FRNT4*DJ6(34#CM8LE&:@%5V%B#ZLH&<S7NHYW=E+5;27+@
MX_V_G/';7]_53@*O2&!#V3A1]#%O:/7'L2,1LHRG@,!2<,J^Y!E?>5I-.3^@
M991.!KT7GS^=\ZO^BT/T- #5Q,?;RB:%]^\OHP/W(#[W#W:CKXP4B S6M]E
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M]3@OG*?R7#U?^WEK*&$"7J'[K29Q?>.V;\!;3B/N:>60M\NKW%F7KFE=\BE
M[#%1;9^8PEDZN!+XRE-FX-FQ#U*?T_B@_&U1V'!^HZMY=)Y2"TKW#=AGYD"
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M$_O3W)S2_ /=A@H%+3T6H[%+<-;]/0E]-=SQ7'./]S288D6#D3VM.M_R^X3
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MN7<XKQ7\(N<<Q9YRV5$[@3KD@G-'.PKIZOKW+Y?W$,-GPL:9$E]!YVTO'>T
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MRPQT/C?&KQ=L8/.ZG/P%4$L#!!0    ( (^=:U06WU&%Q (   H&   9
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MTD_F]Q2R6"L7.22!>6B Q"PJG6>Z7/61,WXM)*F-35)%.XD,!M+,CVKC5;&
M)G$4G!Z<U.@$[?W![_!KL=_@X#2Z:YP2S/=K:ZK5FL-9PS;ILZ=X*2YR8S,!
M9]_JO? FT!!6 I9534TYN%%"<=JXVI!'SR?3J#]%9'"]4!2T7),0S(-0N,/<
M2EKK>$==T#9LMV-G(!)LC/'P*.L[(.B%Z"0AQ[JQ6%86M_8$!J&!+M.\RM11
MI.+^.)K_4*0><-ICX7M3$4J#QH.0/C9=BQF/#+_7AB?Z:< I1?H09PRU-)EQ
MJ$]G1 O]Y/!"EM42I%)9L@HETM;18%_7%G5P(%=6*7:!V6/B1R&1)$E_/GD
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M&5^7@4Q0 J:GZU"G,HXXAM_ STOI_B#5/^ALA5C\BIW?H$2K71TGN>=08IO
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MD\%+F_Y]8X#ZL.,\+FAI<0](4#GUOQ/R;P/(#CF<J+&<U[F@8^IP1-%+%7R
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M [0 W\\L<B*]H0.:W_>]^ ]02P,$%     @ CYUK5,3.&66E!P  F!8  !D
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M484%M6$@%K0WNDQ]L5GI9$63:%B+ZNZE6W@7H*"\J'H.(@_0[!WPH&Z?Q+B
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M5IX6X/O4X5+8#\C!ZBU^^B]02P,$%     @ CYUK5"S$C?P/!P  W!0  !D
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M1<+MG#9K$[ 4&;ZEF"B&@M<L\;T"KE)O.._Q%W-(A:TGL,^XX..]5+N-$FY
M;-W:RFWYP$4R%C8+SF*TRH+?M2XIFKL+'H.];J&T$(EMH3TF7D^<%+M6QH9^
M<Q=.VX)TL+_[S#D:;M.OGK>6>^:"G[^8G8]>[9H3&8*DYR+?C", =+$/M->@
M8,'9KKL,+4O[E=AS1=9 E_\AOC;EJO&8)L(8]44\FO5A> ;.J!#B1(< AEN7
M'HQ6,D&]#0&RL^T)BQX6WN,9[KM4/OE?J!PXL^<T#H5/_I@*_VHP':C^V+7(
MN'?CA$YW%>[5.)M#K.;RJ1OMKNYNFQNKW?+FW@\?<2L$OM"TQ-;)Z-5BB XV
MW*4U+]Y4X?XJ,=Z;(CSFA.[$\@+,+PUZP/:%#^@N-&_^ U!+ P04    " "/
MG6M46Z8NOI4#   ,"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RE
M5MMNXS80?>]7#(0MT )>76PGNPUL [FTZ*)8P(B[[4/1!TH:6VPH4DM24?SW
MG:%DV4[7>>F+)5*<,V?.7.A%9^R3JQ ]O-1*NV54>=_<)(DK*JR%BTV#FKYL
MC:V%IZ7=):ZQ*,I@5*MDFJ;722VDCE:+L+>VJX5IO9(:UQ9<6]?"[N]0F6X9
M9=%AXU'N*L\;R6K1B!UNT']IUI96R8A2RAJUDT:#Q>TRNLUN[N9\/ASX0V+G
M3MZ!(\F->>+%IW(9I4P(%1:>$00]GO$>E6(@HO%UP(Q&EVQX^GY _R7$3K'D
MPN&]47_*TE?+Z&,$)6Y%J_RCZ7[%(9XKQBN,<N$7NO[L51I!T3IOZL&8&-12
M]T_Q,NAP8O#QDL%T,)@&WKVCP/)!>+%:6-.!Y=.$QB\AU&!-Y*3FI&R\I:^2
M[/SJ$;VT2"I[6"NAW2+QA,K?DF) N.L1IA<0LBE\-MI7#G[6)9;G  G1&3E-
M#YSNIF\B/F 1PRR;P#2=9F_@S<889P%O=@'OWM14PTZ$,KC5)9P$_2!=H8QK
M+<)?M[GSELKD[S=\SD>?\^!S_C]T?1.!N_'&-:+ 943MYM ^8[3*8 [Q=Z_!
MX?<*@:,4>@_4KU9X=""X.@FTA(+R8V7>!@$:L@"I/7*VP!OXV@HEMWMH:</"
M9FB7>9K]\/0CF"UX O\2;V+X1$96"T7Z/:-NV66),:R%];*0#>FK=_U)K!ME
M]D@D:K$_ND?BU!@;\'M@:8&">^_%"YTZ9FD"PAW83VA@Y/\0*^;JO/"M-W;/
M/2#KMG;Q6?#4IC2VW$C@+'0';<,@5]^S=U1R)W.%KQR?.!/!'>LG%*DE+.R1
M?OXCPX9R(PL\4(J_E8[R8CJ& 1?20D.6!/SM5,"FM:X5.A#J*EE4(1_'>,O7
M,1)6CI50VQ#D$4>U7!)!(,X3T2JH@&CP]F)@&(\7A..0I#OGVE&*2 B:22$\
MJ0,Q*B9+NT!ZL9<--A[KG#9F*?=S=DTQ*KH)^./!>BB'WG6H:EH)I5Y)<:[K
ML:A86F\\)83,WF5Q2G-2J3#RJ=??7?^43M(T#=HR0\ZA@[[Z:=(,[(9I$TSH
MA<A2SS6]*&H_X?#(HQZ:HY,^Y,$A'1M[D64AEM^:'LG)A*[1[L(]Y BRU;X?
MUN/N>-7=]A/^>+R_)S\+NY.49X5;,DWC#U<1V/[NZ1?>-&'>Y\;3[1%>*[JN
MT?(!^KXUQA\6[&#\ [#Z%U!+ P04    " "/G6M4&+H&U9@(  #N%0  &0
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MRM\GX*=[^&F G_[_F3T-G,$,DN@_PL--Y\C>.=@9O*\1;DW3"OT,=+>M\.A
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M>R9HN\W:)%NO0>K2R<+2ZH;89>>/("_LJJQMU]!FX'$C7Y1%MBS*HL6+F/$
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M4VO/QY%%#:=>M6P1TQZN@=6*-OE0V$]#ZNT/#)>\<1Z&@(E8YNV!-6&'I$W
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M'6G827%B^$A(NH-$8FA,Y708)+2$<)@M(,D,-!")9MA^"=2V8C"70+F26#E
MW@Y2$Q3]W$I(1VS!:M_!XYUE=;VC19-%X ? ,ZV7N$-B?T&6+,!C^0_2T&S
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M\]-@^":ZY6'2U)C<]IGG\_%<\0\2K_O@*Z8'9?7H*,.R>F#H1#\;X(#,!<5
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MPV0,%FNGZVEK8<(,+TI\\T&%88G8#IO?<?/0\'.N/@W$P)&Q$E8J^H(;QX/
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M%MKA! IBB2,?C%? [TNMW7;A"=J?B.E/4$L#!!0    ( (^=:U0]+ZKNC0(
M ) %   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(5466_;, Q^]Z\0
MC#ZT0%"?.5 D 9*V.X!U"-H=#\,>%)N.A>KP)+EI]^M'R8F; FGV8(FDR(^7
MR>E6Z4=3 UCR++@TL["VMKF*(E/4(*BY5 U(?*F4%M0BJS>1:330TAL)'J5Q
M/(H$93*<3[ULI>=3U5K.)*PT,:T05+\L@:OM+$S"O>">;6KK!-%\VM -/(#]
MWJPT<E&/4C(!TC EB89J%BZ2JV7N]+W"#P9;<T 3E\E:J4?'?"YG8>P" @Z%
M=0@4KR>X!LX=$(;Q9X<9]BZ=X2&]1__@<\=<UM3 M>(_66GK63@)20D5;;F]
M5]M/L,MGZ/ *Q8T_R;;3S>.0%*VQ2NR,,0+!9'?3YUT=#@PF[QFD.X/4Q]TY
M\E'>4$OG4ZVV1#MM1'.$3]5;8W!,NJ8\6(VO#.WL?*6QO]J^$"I+<ONG90U6
MW [(5_P?SK_1-0=S,8TL>G+Z4;%#77:HZ3NH24KNE+2U(;>RA/(M0(0A]G&F
M^SB7Z4G$&R@N298,2!JGR0F\K,\[\WC9__)><2HM61QF3WXMUL9J_&%^G_"4
M]YYR[RE_Q],#SE'9<B"J(L>K?:R^IS'?X,!KUR1VK5 X,<9"Z1S:&DBE.(X>
MDQMRSB1*5&O0S%Q<!5A4$&O0KK!O&5=E=\3!<5?!69 ,\O&XN^,L^ (X&K7B
M)6&BT>H)G)8)TN'0?Q^U,H8TQ[&2P3A+\1P-)\&B*%K1<NKB+P'W3,%H-[YH
M0H72EOWU@N \&:3#47#AB#B=('$6Y.,1GJ,L/M:WZ&!*!.B-WP4&Z]5*VPU,
M+^W7S:*;LE?U;E?=4;UATA .%9K&E^-A2'0W_QUC5>-G;JTL3K G:UR9H)T"
MOE=*V3WC'/1+>/X/4$L#!!0    ( (^=:U2\RP7 TP(  +8%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;'U4R6[;,!"]ZRL(-2@:0(BLQ4M2VX#M
MI&@/08VXZ8*B!TH:640HTB6I..G7=TC9JE/$OHB<[<V;H6;&6ZD>= 5@R%/-
MA9[XE3&;JS#4>04UU1=R P(MI50U-2BJ=:@W"FCA@FH>QKW>(*PI$_YT['1+
M-1W+QG F8*F(;NJ:JN<Y<+F=^)&_5]RQ=66L(IR.-W0-*S#WFZ5"*>Q0"E:#
MT$P*HJ"<^+/H:IY:?^?PE<%6']R)K223\L$*GXJ)W[.$@$-N+ +%XQ$6P+D%
M0AJ_=YA^E](&'M[WZ!]<[5A+1C4L)/_&"E--_)%/"BAIP\V=W'Z$73U]BY=+
MKMV7;%O?)/%)WF@CZUTP,JB9:$_ZM.O#0<"H=R0@W@7$CG>;R+&\IH9.QTIN
MB;+>B&8OKE07C>28L(^R,@JM#./,=);GJH&"W#SA,VO0Y-T7FG'0Y^/0(+QU
M"O,=U+R%BH] 13&YE<)4FMR( HJ7 "'RZLC%>W+S^"3B->07)(D"$O?BZ 1>
MTA6;.+SD"-Z2/KOBR$P4Q%5.N28_9YDV"G^/7R=2I%V*U*5(CZ18X=04#0<B
M2_)_;U]KZ6FT/0+L7R>7. [:H KQ306DE!SGBHDU><<$:F2CJ2CT^96'S8,Z
M V4;^%*PW;2?GK<$I:40P!%8&^V=><,@0>.9UP\&HX&W0$(LIYP8Q>C>:=A/
MO+=O1G$4O_>62I:@[82BN01 :Q1[@W3HK:AM=%Y1M8:,Y@\ZP!G.J$$E$B02
MR2O4/()H $\-ZA&CX^!RF'I1$/4NO86L:^:P-2G0R4@D4->@<N3"_E WU1NJ
MC$ D7$_D^N;[C\4]1O>CD1?W4^^S36+1TM0;II=85I0&:1SC912D:?^U]PX/
M9@ESK=W&L(UOA&G'JM-V2VG6SN(_]W:CW6+M#,ES*#&T=S'L^T2U6Z(5C-RX
MR<RDP3EWUPH7*RCK@/922K,7;()N54__ E!+ P04    " "/G6M4$,38..,#
M   Z"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R]5DUOXS80O>M7
M$&Y1)( 3?5FRG=@&XFR#+K#9&'&V/10]T#)M$TN16I*JU_WU.T/)6ME(M.BA
MO5#\F'GSAO-(<;)7^K/9,6;)UUQ(,^WMK"UN?-]D.Y93<ZT*)F%EHW1.+0SU
MUC>%9G3MG'+A1T&0^CGELC>;N+F%GDU4:067;*&)*?.<ZL.<";6?]L+><>*9
M;W<6)_S9I*!;MF3V4['0,/(;E#7/F31<2:+99MJ["V_F*=H[@]\YVYM6GV F
M*Z4^X^#]>MH+D! 3++.(0.'S-[MG0B 0T/A28_::D.C8[A_1'USND,N*&G:O
MQ!]\;7?3WJA'UFQ#2V&?U?XW5N>3(%ZFA'$MV5>VPW&/9*6Q*J^=@4'.9?6E
M7^M]:#F,@C<<HMHA<KRK0([E.VKI;*+5GFBT!C3LN%2=-Y#C$HNRM!I6.?C9
MV0<&*1ER\4)7@IG+B6\!%)?\K :85P#1&P!A1!Z5M#M#?I5KMCX%\(%-0RDZ
M4II'G8CO6'9-XK!/HB *._#B)L78X<7=*?YYMS)6@PK^ZL <-)@#ASEX W,)
MAV-="D;4ABS+HA ,A&JI(',JJ,P86;H3]5Y6QP;U]\P$M6Q-K")/!=,P*;>D
MXO;:KO\@?COFJHY9G6+>BJF_QU1-3%'M!S5('C:;Y2NFFPTG5*ZQ$_3!VQ3,
MG1IQ(%0S=-DH ><8!,,EL3M5&C WES=>&^=T@*#8!-Z3W<%<5FH-O(G@=,4%
MMQRX7)W3:ZP*I3$3[V<O'230)NG(>SJS;2/]\M,H"L-;(I4\APC[HS3PHGX<
M!]Z+PHT[#]H"@E!1/PD2]QV-1QV:21K-)/^A9AZX=$9.,:\)Y@?!_[5@H%AD
M4P>MMN?_5\Q"8XGLP85@7TI>8 9]0BW)E+%0G'@88HGBL7>7965>5O1ICC7_
MQ^7D7410QDOO(HF@?0M1,D0+TQ3;T;!#J[7"T"X>8AN.:VNAY/;*,IV?""E.
M/>!8">YT/T_E%@YC;,=!A]321FII9[4?2EO"[C]RR?,RKS1#%O2 N1KR"2YJ
M33XJ>76/;(3 N[_C*NJ.]4) */<J+Z@\N+T9WAK0CTNWHI'7-*JLBR.-TM&
M@WJ5M6@<;R?[BM#VK%M2Y_>J=W)H#&HJ\L9AZ(6#,0YB;S0<@H2P/_!&XX'G
M$HAN<2*!A;B9J.IWF@'*KQ\DB9-,ZGU@QA">%R4JD$L0 @.)7B1)@.H+8V@=
M2NMJ@9J_5FV_]3_/F=ZZ5XL!R9?25K_V9K9Y&-U5[X'OYM6KZI'J+9<&F&_
M-;@>PC6AJY=*-;"J<*^#E;+PUG#='3SNF$8#6-\H98\##- \%V?? %!+ P04
M    " "/G6M459X!R\("   ^!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6R=5=]OVC 0?N>O.&73?D@5"0EM40=(I>VT/71";;=JFO9@D@NQZMBI
M[13X[W=V($NK@J:]$-_YON^^.]O'>*7T@RD0+:Q+(<TD**RMSL+0I 66S/15
MA9)V<J5+9LG4R]!4&EGF0:4(XR@Z"4O&93 =>]]<3\>JMH)+G&LP=5DRO9FA
M4*M), AVCAN^+*QSA--QQ99XB_9[-==DA2U+QDN4ABL)&O-)<#XXFPU=O _X
MP7%E.FMPE2R4>G#&UVP21$X0"DRM8V#T><(+%,(1D8S'+6?0IG3 [GK'_MG7
M3K4LF,$+)>YY9HM), H@PYS5PMZHU1?<UG/L^%(EC/^%51-[D@20UL:J<@LF
M!267S9>MMWWH $;1'D"\!<1>=Y/(J[QDEDW'6JU NVAB<PM?JD>3."[=H=Q:
M3;N<<'9Z:U7Z4"B1H3;OX>JQYG8#'^[80J#Y. XMI7"!8;JEFS5T\1ZZ00S7
M2MK"P)7,,'M.$)*V5F"\$SB+#S)>8MJ'9' $<10/#O E;<&)YTOV\&U+_'6^
M,%;3G?A]@'/8<@X]YW!?$YL;#2J'&TR53+G@S%\Z\MPSK9FT!JR">:W3@NX0
M7*BRI&W?_=>Z?#C?78&0*T$/BLLE6'=84&GUQ#,TP.BMO-20\S5F%,)3A%5'
M3[738PJF"4NAMO#J*B8W[]Z,XL'I)_-,+276/FB#3!M =\Q AX3E G5[4,!D
MYA;16>\GQ36WH;OL(IX;#NY^HMZWVCL[/>S=^U=&&<^?4-/0@*LUZI13!7-7
MW/] 9DPP27UA%A:XY%*ZGA)!A9JKK#<<'9V,DM[;WB#N)\E+LP53N=CP^M,@
M,NK,O]*\=@7#SILN42_]Y#*0JEK:YGFWWG8XGC<SX6]X,UFOF::Z# C,"1KU
M3X\#T,VT:@RK*C\A%LK2O/'+@@8\:A= ^[E2=F>X!.U?QO0/4$L#!!0    (
M (^=:U3[KB\P. 8  +@/   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;*57;6_;-A#^SE]!>,N0 (JL=\EI$L!)7Y9M;8.D:3$,^T!+M$U$$E622N+]
M^MU1MN(TBK>B7VSQ[?CP[KGGR.-[J6[UDG-#'ZJRUB>CI3'-T7BL\R6OF'9E
MPVL8F4M5,0--M1CK1G%6V$55.0X\+QE73-2CTV/;=ZE.CV5K2E'S2T5U6U5,
MK<YX*>]/1OYHTW$E%DN#'>/3XX8M^#4W-\VE@M:XMU*(BM=:R)HJ/C\93?VC
MLPSGVPF?!;_76]\43S*3\A8;%\7)R$- O.2Y00L,_N[X.2]+- 0POJYMCOHM
M<>'V]\;Z6WMV.,N,:7XNRR^B,,N343:B!9^SMC17\OY7OCY/C/9R66K[2^^[
MN6DPHGFKC:S6BP%!)>KNGSVL_;"U(/->6!"L%P06=[>11?F:&79ZK.0]53@;
MK.&'/:I=#>!$C4&Y-@I&!:PSI]=+IOCA&9RKH)=L!>XV='K/5*'I_B<V*[D^
M.!X;V BGC_.UT;/.:/""43^@[V5MEIJ^J0M>/#4P!H0]S& #\RS8:?$USUT:
M^@X-O,#?82_LCQU:>^%+]H3.2ZE;Q>G'.3V7%9!<,\N3*UXR ]XXE]IH:OTS
MVW:/IG]-9]HHX-/?.Y!$/9+((HE>"H"1^2W]V-B]I\A185;T!ORFZ&7)ZB'O
M[[;X:<GI7):0;J)>4(-!I(V2=Z+@FC+(I%S6N2A%=UPYI]I"D,UCFB"$UD(P
M8 S=P^K5+S]E@9^^TI1_;7&"J'-P!^04;0 GF*X+V%=!?]'FW#*)=4S"7C2T
MXDQ1CI2@$%!>S6"#35"/R(?6=@"@#HHF7VQ.P>SI'5<@$?3- U>YT)Q>*I'S
MY^-7''4(CWT._,,0M:RD?X@Y)]/%0O$%1)9>P(@ 5<GI9U:VG.R+VB+3!_;3
M+&6KX2S0_-@:;> 3#3)#?V-U"\)%UXB)[X1AYF291WXF@>=F"7FG6 UX<,0/
MG31(B1^X\81L<!=D/W-\/R '.! D!)1ES@4NV4]C)XHR'$G<*($EC5#8'X.Q
M)(7^T'>]Z%M,S_Q( B?V4R>QJ-#4A&2NET C3>,-$,N)P=43/W&BQ,<3!6[D
MD\0-8C3DA3NX'O=<CW=S'4I*T<+6$./?^8I.-=2"+M;T1G\K%!W7=UN\J$&"
M#5=5%W4DV0)C0 N,])P)1>\PR(^LVG"R:-5FA0W^2[RTM(8/S]G.!<J:IA0P
M'_O.2I;?'L+A),CE9IL&&(H;5++@)>T41-9V_F-RWH(3V*,3CLB?F"%OGB%Y
ML;^+.* C:P4I@>MTB]&1F\;TD":NEY'8C3W[[7NDDYT["5H'4F!6) WV8"P+
M]T@2X5?J[9$KH6\/YXISR&EP,M>&*O K\=S(SO;=*-J#5KANI<D>\A8*+N L
M!"H.Y!%,\/;LSPX*)3V%DMT4ZBX/&,^+NKN3V*#.X,)!M[54#Y%IM^TAX>PN
M*^(?"*QXMA^OFE*N.'<H2*J&>P R#_E20.KF!E1O6UKU]TOJMG#^-T/I$_FB
M_"'GC:$-3-58Q2BK9 OUZ^!':+:1W$.VEMSA=.LW!>W(W "U*'6]E'R2!@0Y
M9WJ)=8C#2:%F*%D!V+6R?U./-$B/1ZR?@E?KY:(7\#ZWG_J9]W+K]VMW<"_M
MN9?^7^Y=02Y @B//.]+=U,+TY7N(>KM-?W?-OKJ^&2K5@><G]MKPW35W\$0#
M)=B6./H:X_T6X]W5T ^RO@,#,&^H3D83QX/2!64D=+.XKY)!%#CA9(*E<)*0
MSW8]%,B)DTYBK(,A",IVA?0]QPO#KG;Z\=,]!^K@Q'?B-.YV]2<[XI_U\<]V
M!NG)-1%UK@:^6O9:CPW>HH>HL'N73P/R !7?\.[R":'*853Q);Z,0"G@&HO:
ME)<MQMAT";:-E&\CM8ERV)6C9HUT71&97E-0/Q62']*+\R$D/5I1'Q$@'EC)
MEYUP\CMX)S8("Z\@3C"QM'$BWR?7#,LKSH(LO.4&,@5&_"PE$U"6=[P&@I9V
MG!5X'\ [.FHI"9U)DL!O$$Q0A^":E<)_[,11.L2*\=9KJN)J8=^,&GP*XMD]
MK/K>_EDZ[5YCC].[-^U[IA:@5+3D<UCJ02T>4=6]$[N&D8U]F\VD@9>>_5S"
MTYHKG #C<RG-IH$;](_UTW\!4$L#!!0    ( (^=:U0N6HYB00,  %4(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,U66V_;.@Q^]Z\@O&'8 *.^
M).XE2P(T[;8SH 6*7G8>ACW(-A,+E2U/DI?E_/I1<N*D2],#[+R<EY@2R8\?
M24G,>"G5HRX1#?RL1*TG?FE,,PI#G9=8,7TD&ZQ),Y>J8H:6:A'J1B$KG%,E
MPB2*CL.*\=J?CMW>C9J.96L$K_%&@6ZKBJG5#(5<3OS8WVS<\D5I[$8X'3=L
M@7=H'IH;1:NP1REXA;7FL@:%\XE_'H]F0VOO#+YP7.H=&6PFF92/=O&YF/B1
M)80"<V,1&'U^X 4*88&(QO<UIM^'M(Z[\@;]H\N=<LF8Q@LI_N:%*2?^J0\%
MSEDKS*U<_H7K?%*+ETNAW2\L.]N3@0]YJXVLUL[$H.)U]V4_UW78<3B-#C@D
M:X?$\>X".9:7S+#I6,DE*&M-:%9PJ3IO(L=KVY0[HTC+R<],/S*NX L3+<(U
M,MTJI(H;#6_O6290OQN'AJ)8VS!?(\XZQ.0 8IS M:Q-J>%#76#Q%" D>CW'
M9,-QEKR(>(GY$0SB )(HB5_ &_0Y#QS>X-]SON0Z%]*FK>'K>::-HF/R[848
MPS[&T,48'HAQKC52&5E=P!5G&1?<<(IQP93B6  SL%_Y NB8WF+>DDV]@!G3
M7#]7_Y<CWY<(<RGHMED0X]JXOG/\'P1#Z@M9-:Q>O7EUFL0G[XEE1S;?DIM;
M<C\<N6J''*-[N*&767K6EMJ#58:J;Y'+FH0H('/=H+MX8A5 MG*8S-W'DJ-B
M*B]7\);71$NVFOSTNY&W!^C9LJUL4%<O[Y.26L-#3:^0H)P*^$2OC][?OJ(U
M:F];:0+2)7SXWG+B8<^Y=\W4([HBP9U-S;7)NT(B#/'(HY.,*[IOU@CF+?'S
M7GMQF@9I&I/D*IB\?R)MM?MV=VUFI&'B/X%TY)*11VVL4.6<"6A8@XILAF=!
M&@\/@/;*^#A(AV<D#)+@[#C=I?5G /=K[R1*@XC6S[MOM?%)$L11M 7XO>71
M_ZSER2!(!Z>'\MHH]ZSZNOR1^W//4+CSU%/S%VZ@T=65;6VZ5[_?[6?F>3<J
MMN;=P*4Z+*B&('!.KM'12>J#ZH98MS"R<8,CDX;&D!-+FONHK 'IYU*:S<(&
MZ/])3'\!4$L#!!0    ( (^=:U1BIQCF! 4  ((,   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;*U7;6_;-A#^SE]!>-V0 $HLR7ISFAC(2X<%2+L@
M23L,PS[0TLDF*I$N2<7QO]^1LA6YL;T.V!>+HNZ>>WGNCO3Y4JJO>@Y@Z$M=
M"7TQF!NS.!L.=3Z'FNE3N0"!7TJI:F;P5<V&>J& %4ZIKH:A[R?#FG$QF)R[
MO7LU.9>-J;B >T5U4]=,K:Z@DLN+03#8;#SPV=S8C>'D?,%F\ CF\^)>X=NP
M0REX#4)S*:B"\F)P&9Q=)5;>"7SAL-2]-;613*7\:E]NBXN!;QV""G)C$1@^
MGN$:JLH"H1O?UIB#SJ15[*\WZ+^ZV#&6*=-P+:L_>&'F%X-L0 LH65.9![G\
M#=;QQ!8OEY5VOW39RJ;I@.:--K)>*Z,'-1?MD[VL\]!3R/P]"N%:(71^MX:<
MES?,L,FYDDNJK#2BV84+U6FC<UQ84AZ-PJ\<]<SD5N2R!OK$7D#3HR<VK4 ?
MGP\-0EN!8;Z&N6IAPCTP04@_2F'FFGX0!13; $/TJ7,LW#AV%1Y$O('\E(X"
MCX9^&!S &W6!CAS>Z%\#I3=<YY74C0+ZU^54&X6E\?<!$U%G(G(FHCTFKF6]
MD *$T526]$YJ3:\ ^P9H/\N[DGL0U_;EF5ZP'"X&V'@:U#,,)D]SH/F6P<H:
MG+8&>6O0.%H9;C!-2UEA"R++7% SEXUFHM#'9^1/8*JEC6+2H9Z"LHG?NV\)
ML3\^^7SZ>$IQ/BAF.TR3=^0HSKPX2,FQ74>Q%XU#7'^2XN1[V<#WR3@C=WN<
M7F-%/:S1."+'] !/<<=3?)"G&UZ6H$#D@/R8)8"@'UX6."8PTEZ97(& DAN*
M::*7N6E8M>/K+C8/6[?$%:\>3-<>&-RV!<3$ZI>?LC!(WVL*&Z]>,X/RSJYG
M&;7\-_;[=$798E&MN)@Y(.QBQYLVS#1&JA5UZ2^AP/Q7#@=Y %LU8? S5H9R
M:BO+.+QAW+6@2\,/"OL>-7)O/7H.BK49?1L9Y1JG?2Y%SBL7NK/6%J^+S\ZH
M_[&(;]]ZP$PO<S91M@*#T N3K*W&L1>/1KA\-#:+V\$)/$DQKYM<KS')4>AE
M8Q]U<)$F?K\K>CEPK&RJPW!6$5<,X7MR9$U?SYF868.T9%S19U8UCD0TQ9^9
M/=\Z^<VSI_(=^V]$'W"V,)7/'3\%/..)O<#SUSB-7$'!C29'R=A&?A3Y]G$/
M>#+:"42Y@5J3-!R3,,O65K4U:YUD[0EL*618]"2(O33*2##R?$SI[TBP<HE#
M]#"QZ$ELY\9;:C#Y&V^[U8&)D'03(3G8DX]\)GC)<X:!;$_Q&T JU-9@V#W"
M#QNP3:][1K8G=[$Q\E_&]E8Y[ZGMSGN;0J8U&'U&/MD";0<QMI/KTIPIM<)&
M73)5V-&;19Z/1+PC:>1E:?**H[ J1 ,D\L+41QI]<@=X)Z(59U-><;/""@A)
MYB?8&C+_>F(O3(6+%N]QK@I(ZF4HDGA9E)*G7F'A81$E"!QC8;F*(%@=?DQ"
M/% B\B0-EF[Q-AX\2&(O' <D&WO).-D.>>,6!XS[5A@L2FZGQUHU]L;)"%WQ
MLY2XZ^B)+$\:W7U/@IBDP6B7\1XR L1I9B/R=V:\K>QQYEFHS(Z!A'S9T13;
M$@=LKGZT"X:]>V$-:N9NO_;8:(1IKXC=;G?!OFSOE:_B[>W\(U,S+C2MH$15
M_S3%0TZU-][VQ<B%NV5.I<$[JUO.\4\"*"N WTLIS>;%&NC^=DS^ 5!+ P04
M    " "/G6M4B77M0]4"   U!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6R%5=M.&S$0?=^OL+95"U*:O>4&))&2T LJ5(A ^U#UP<E.=BV\]M9V
M"/3K._9NEH @/,0[MF?.G+EX,MQ(=:MS $/N"R[TR,^-*8^#0"]S**ANRQ($
MWJRD*JC!K<H"72J@J3,J>!"'82\H*!/^>.C.+M5X*->&,P&7BNAU45#U, 4N
M-R,_\K<'5RS+C3T(QL.29C '<U->*MP%#4K*"A":24$4K$;^)#J>=JR^4_C)
M8*-W9&(C64AY:S=GZ<@/+2'@L#06@>+G#F; N05"&G]K3+]Q:0UWY2WZ%Q<[
MQK*@&F:2_V*IR4?^P"<IK.B:FRNY^09U/%V+MY1<NY5L*MU^WR?+M3:RJ(V1
M0<%$]:7W=1YV# ;A*P9Q;1 [WI4CQ_*4&CH>*KDARFHCFA5<J,X:R3%ABS(W
M"F\9VIGQ'#),L2%4I.0KR$S1,F=+,L$"DS-1%=UF[^":+CCHPV%@T*NU#9:U
MAVGE(7[%0Q23"RE,KLEGD4+Z%"! N@WG>,MY&N]%/(5EFR11B\1A'.W!2YH<
M) XO>2,'5U!*99C(R._)0AN%'?-G#WRG@>\X^,YK\%6_$[DB,UF45#Q\U.CK
M#L0:M$O\N139IW/LSI1,M :C6^0'F!99/#ROR4OIW^_].@>RDAP?GPW,V"K6
M+Y#]0_<&KVM6']X-XJA_HO&M[7#CEAMWW&C-3>"L0&K9(S5JV^6 "823:XUF
M^O#8VX;HG;\(X5UO@-_!D^8@6%HH%J!L>=]6F)C]>]L?=@EWI)OVO.V]]Y)N
MZV@P0"&.6[VX@T*GW\.UEX3>+&>">H-NY$51JQ\EGLM,?-)\;]K?VUX4AN[W
M_'(FA9:<I=1 :AWU6D?)D14ZK4[2WW7T4F\%.T^Y )6Y@:7)4JZ%J5YU<]K,
MQ$DU"A[5JX%Z057&A"8<5F@:MOM=GZAJ2%4;(TLW&!;2X)AQ8HYS'915P/N5
ME&:[L0Z:?XKQ?U!+ P04    " "/G6M4;_>R7,4#  "D#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6S%5UV/XC84_2L6VH==:4KBP##,"I"8CZI(
MI:5+IU6UJBJ37, :Q\[:#A_5_OB]=C()*R#E :D\@)W8YYY[?'-R&6R5?C5K
M $MVJ9!FV%I;FWT, A.O(66FK3*0>&>I=,HL3O4J,)D&EOA-J0BB,.P%*>.R
M-1KX:S,]&JC<"BYAIHG)TY3I_0,(M1VV:.OMPB>^6EMW(1@-,K:".=B7;*9Q
M%E0H"4]!&JXDT; <ML;TXT/D-_@5?W#8FH,Q<:DLE'IUDTDR;(6.$0B(K8-@
M^+.!1Q#"(2&/+R5HJXKI-AZ.W]!_],EC,@MFX%&)/WEBU\-6OT426+)<V$]J
M^Q.4"=TZO%@)X[_)MEP;MDB<&ZO2<C,R2+DL?MFN%.)@0^?^S(:HW!!YWD4@
MS_*)638::+4EVJU&-#?PJ?K=2(Y+=RISJ_$NQWUV]&L&FCE]#/F!C).$NS$3
M9"*+$W?*O7\"R[CX0-X1+LF4"^'6#P*+\1U*$)>Q'HI8T9E8-")3)>W:D&>9
M0/(]0(#$*_;1&_N'J!'Q">(VZ= ;$H41?9D_D??O/LRT2O+8_C,#E0EXQ!-K
M"-2I9.KX0)W_ENGSSWB/3"RDYN\&Y&Z%W/7(W3/(O^3I C112Q*K- 4=<U0_
M*W(PY"LITSFE=@%\ZX'=T[<918-@<X++;<7E]D(N%0&6X7 #23.3VR,FW=-,
M>A637B,3/+;U#8GQF\"7G&^8 .G8R 1+< /&IGZ.Y8A>\HKEN1! #,2YQ@*&
MD[59!+P_5(O2=N\TS[N*YUTS3V6LTVN.!,T->=[%(D^X7)%QJK3E_Q8/$"X8
MQYB&1ATGTC*YXH[OV!C )#Y/P<G>5$S]BD[_RF5Z7R'?-R8Z23/&M5.=Q&NF
M5Z<U+C!H>" R;9\I2AK6%A4VQO;B^K.?^L-V^C[O\+UDX!+QZ($7TBO+1Z,:
M.[J"@"7(896&;7I&P-J\:*<Q]E\OOT]^NTBJVK5H]]I2U2Y$+[4AB6]U- $\
M?9PL<%TBP;A2D#D38H^F=.SOI9#'EM0)\7-&RMJ7:+,Q?2\E$IARR=,\O4C=
MVE7HW;75K2V"]B\U>?^&)&RYQ!8)K6FQ)QGZ&6BNL&^#E2]67 =[<$[[TIZW
M";!X3?; -*9>OF)/RM\_DK_7('_M0K39AH[E9[M+Y8]JPXG"*\L?U1X3T?]?
M_I+#H?PT/*%_<- X8N^Q\NVQP4XDE[;H(:NK50L^+AK/>GG1OZ,UKS@*)F")
M6\/V'0;714M<3*S*?!NZ4!:;6C]<X]\(T&X!WE\J9=\F+D#UQV3T#5!+ P04
M    " "/G6M4@33\ZT '  !Y)@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6S%6FUOVS80_MS]"L+8@!5(;$F4_%(D 1([1K,U:Y LZX:B'QCI;!/1
MBTM2>0'VXW>4%=%)9$I) Z\!:LGB'8^\A\]SI+5WFXEKN0!0Y"Z)4[G?62BU
M_-#KR7 !"9/=; DI/IEE(F$*;\6\)Y<"6%08)7'/<YQ^+V$\[1SL%=^=B8.]
M+%<Q3^%,$)DG"1/W1Q!GM_L=M_/PQ3F?+Y3^HG>PMV1SN !UN3P3>->KO$0\
M@53R+"4"9ON=0_?#-.AK@Z+%7QQNY=HUT4.YRK)K?7,2[7<<'1'$$"KM@N''
M#8PACK4GC.-[Z;13]:D-UZ\?O$^+P>-@KIB$<19_X9%:['>&'1+!C.6Q.L]N
M/T(YH$#["[-8%O^3V[*MTR%A+E66E,880<+3U2>[*R=BS<#U-QAXI8'7UH"6
M!K2M@5\:^$\-!AL,@M(@:-M#OS0HDME;358QTQ.FV,&>R&Z)T*W1F[XHTE58
MXP3S5"/K0@E\RM%.'5SP><IG/&2I(H=AF.6IXNF<G&4Q#SE(LDL.HXAK$+"8
MG*0K*&M(_#H!Q7C\'EM<7DS(KS^_W^LI#$B[[85EYT>KSKT-G9\RT27><(=X
MCCNL,1_;S0_S>9=05YM[3HWYQ&X^A2OL?;31_-AN/H&PZMVM,9^V-W_2>P]S
M6"72JQ+I%?[HID0BYT1Y#.3SC#0E]>LG-"8G"A+YS=(UK;JF1=?^ICR$89[D
M,5,0D4PM0) P2Y#G%IJ ;H#P%.^!J(P@?'"IIPAL(2 -[XD2+)5Q@:BZ#*SZ
M[1?]:HZ\.1CZKN/@?-VLSW1CLT?#\JMA^=9A(3JO$>-7.*<2,&)<!2#KHERY
M"=:ZI]0I_CV)\WG##2$&58B!-<2S7(0+Y%5)LAFR0LMX@^9X'T73KZ+IOWS"
M,"R5"XCJ NFWG8]!%<' &L%)JD" 5+M7P(2&?,CD@L#WG-^P&' UA!E"4A9
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M&^#S69:IAQO]JD_UMMG!?U!+ P04    " "/G6M4=K4&QFD#  "A#0  &0
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MN!-$5GG.Q.L4,KX96]3:3MRGRY72$_9D5+(E/(!Z+.\$CNPV2I+F4,B4%T3
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M=V]R:W-H965T<R]S:&5E=#0U+GAM;,6:46_;.!* _PIAW &[0!J+I$3)BR1
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M4$_U@]"6.W@I2 5,$LZ0@/74N?&O9XG!6\!/ JW<6R.3R8KS%V/<%U/',X*
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M4H]W$ :@S]><JYUA)LCPAY']!5!+ P04    " "/G6M4!@Z\-/0"  #="
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M#C/]_P'"&.CG"\[59F("-'\THW]02P,$%     @ CYUK5%8+Y02$ @  ? 8
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M32 ^0Z%_@@(O\%OHX\/IWDNZJ]VI+0IJBP(;+WS+HBG%NN#+%^7_OM%H=*V
MR3][<H5UKM#FZNS(]55P*5'>M!HVN=J,+*-U;33SQ:Y&?B\,!NZJ:5<+J!OU
M:] +H9U::&>OT,LX+EA!L8)$?S5Z!XD)+K]++1DS+A3Y:Q?:5)>AHX:@4S^(
MNENRVU!>L$-W5.N.]NJ>MEI[@C)H]3=ZI:'3V];Y&M,-O7:5W5IE]W"5C6:[
M!38'L:_1>G6&WH<W=;_.U7_7INZ_,M3O]'I;KK>!O+#=]O-:Z/E>H3>@#X24
MTP1=,RUW!4:A/,1VW_N_WWH?;KS?V-W]=[6^"M?<*X(HVK+^#5 IU6V<2>:'
MX!:+)<DDHK#0+.^LIU^=*,_8<J)X;H^I.5?ZT+/#5/^7@#  _7S!N=I,S,E7
M_^F,_@%02P,$%     @ CYUK5 *=T>93 @  0 4  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3$N>&ULC53;3MPP$/V54=0'D"BY+92BW4A[H2I2J590Z$/5
M!V\RV5@X=K =%OZ^8R>;;BE+^Y+X,N?XG/&,QQNE[TV%:.&I%M),@LK:YCP,
M35YAS<RQ:E#23JETS2Q-]3HTC496>% MPB2*3L.:<1ED8[^VU-E8M59PB4L-
MIJUKII]G*-1F$L3!=N&:KROK%L)LW+ UWJ"];9::9N' 4O :I>%*@L9R$DSC
M\_G(Q?N .XX;LS,&YV2EU+V;7!:3('*"4&!N'0.CWR/.40A'1#(>>LY@.-(!
M=\=;]D_>.WE9,8-S);[SPE:3X"R  DO6"GNM-I^Q]W/B^'(EC/_"IH^- LA;
M8U7=@TE!S67W9T]]'G8 \>D>0-(#DI> T1Y V@-2;[13YFTMF&796*L-:!=-
M;&[@<^/1Y(9+=XLW5M,N)YS-EIH*0MMG8+* BX>6-W1%]@B^4@&]AVE1<)=M
M)N!2=B7C<G^P0,NX.*2(VYL%'+P[A'? )7RK5&N(R(Q#2]K<"6'>ZYAU.I(]
M.N($KI2TE8$+66#Q)T%(I@9GR=;9+'F3<8'Y,:3Q$211$K\B:/[_\.@-.>F0
MZ-3SI?]*]%(P:6&ZFVZX-5BV K[P$OW.'1,M&O@Q71FKJ=)_OB%@- @8>0&C
MO8:HS7/N;_"U^^G0IQ[M>O\Q2V/*V^-NROZ.B<\^#C&=K'"G&&O4:]^C!G+5
M2MO=WK Z/ -37_TOUF?T/'3=_)NF>UNNF%YS:4!@2931\8>3 '37K]W$JL:7
M_$I9:B _K.B)0^T":+]4RFXG[H#AT<Q^ 5!+ P04    " "/G6M4T)_9@?D"
M  !J"   &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6R-EEMOVC 4Q[^*
M%?6AE;KF0D*@ B0*G;:'::BLNVC:@TD.C54G9K8#[3[]CIT041)07Q)?SCG^
M_8\=GXQV0CZK#$"3EYP7:NQD6F]N75<E&>14W8@-%#BS%C*G&KORR54;"32U
M3CEW \_KNSEEA3,9V;&%G(Q$J3DK8"&)*O.<RM<[X&(W=GQG/_# GC)M!MS)
M:$.?8 GZ<;.0V'.;*"G+H5!,%$3">NQ,_=O9T-A;@^\,=NJ@38R2E1#/IO,Y
M'3N> 0(.B381*+ZV, /.32#$^%O'=)HEC>-A>Q_]H]6.6E94P4SP'RS5V=@9
M."2%-2VY?A"[3U#KB4R\1'!EGV17VWH.24JE15X[(T'.BNI-7^H\'#CXX0F'
MH'8(WNO0JQUZ5FA%9F7-J::3D10[(HTU1C,-FQOKC6I8879QJ27.,O33DVF2
MR!)2<O^"YT*!(A_($D]*6G(@8DU:TY=ST)3Q*[1[7,[)Y<45N2"L(-\R42I:
MI&KD:L0RP=VD1KBK$((3"'-(;DC/OR:!%_@=[K/WNWMOW5U,1I.1H,E(8./U
M3L1;T%>ZXBAU6J25?LH5^3U=*2WQT/TYLT2O6:)GEPA/+0%2B:( 3A*A=&?*
MJ@!]&\!\B=M)W#/9V1XFIFT4]0?]QN@-6]BPA6?99CC $LJ)EHR> :RB1(>
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M[CD^]]S+)5U+]:P+ $->2R[TP"N,J:Y\7V<%E%1?R@H$OEE(55*#6[7T=:6
MY@Y4<C\,@L0O*1/>,'7/IFJ8RI7A3,!4$;TJ2ZK>1L#E>N!UO?<']VQ9&/O
M'Z857<(,S&,U5;CS6Y:<E2 TDX(H6 R\Z^[5.+'Q+N G@[7>6!.;R5S*9[OY
MG@^\P H"#IFQ#!1O+S &SBT1ROC3<'KMD1:XN7YGOW&Y8RYSJF$L^2^6FV+@
M]3V2PX*NN+F7ZV_0Y!-;ODQR[:YDW<0&'LE6VLBR :."DHGZ3E\;'S8 87($
M$#: \*. J %$+M%:F4MK0@T=IDJNB;+1R&87SAN'QFR8L%6<&85O&>+,\!;0
M TT^D=FJJCA@?0SE9$0Y%1F0F6ND>^#40$Z,)'<5*&J86)(&>#X!0QF_0(;'
MV82<GUV0,\($>2CD2E.1Z]0W*-,>YF>-I%$M*3PB:0+9)8FZ'1(&8?< ?/QQ
M>+ -]]&<UJ&P=2AT?-%IAYZNY]HH[+K?)SBCEC-RG+TCG'>F (7E50K])IS1
M.>/,,%<(V5K,[<EM5"65;?Q#?M:')>XP^]F^#)->G/HOFZ;MQ\1)OXW9RJ+7
M9M$[G<5V,W3(;9/(6X>,:]4=,C/8.[:MB%R0&R:PKQAVV%1JYK[CIZ^OQ@Z%
M.0?$ZUU[ZP3_H>.8FX>:Y[]0;=D5MW;%'[2K+NQVV844S;&'#(CWJM?M)\%.
MB?>#PB@*#M<X:44G)T4_2#L/=GORM,>C9%]('.PVY(&@_I?=CO0W)IO]J_R@
M:LF$1AD+A 67GS%G54_J>F-DY8;=7!H<G6Y9X,\-E W ]PLIS?O&SL_V=SG\
M"U!+ P04    " "/G6M4\-Z+[E8#  "."P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6RM5FMOVC 4_2M65DV=!,VKO#I  MIJD[H-E7;[4/6#"1>P
MZMBI[91VOWZVDV8$ GVH7TB<W'-R[KF^YG977-S))8!"CS%ELN<LE4I.7%=&
M2XBQ/.(),/UFSD6,E5Z*A2L3 7AF03%U \]KNC$FS.EW[;.QZ'=YJBAA,!9(
MIG&,Q=,0*%_U'-]Y?G!)%DME'KC];H(7, %UG8R%7KD%RXS$P"3A# F8]YR!
M?S+R+<!&_":PDFOWR*0RY?S.++[/>HYG% &%2!D*K"\/, )*#9/6<9^3.L4W
M#7#]_IG]W":ODYEB"2-._Y"96O:<MH-F,,<I59=\]0WRA!J&+^)4VE^TRF,]
M!T6I5#S.P5I!3%AVQ8^Y$6N H+T#$.2 X+6 , >$-M%,F4WK%"O<[PJ^0L)$
M:S9S8[VQ:)T-8::,$R7T6Z)QJG\!V@.)ZFB2)@D%72"%*1IBBED$:&)WTB50
MK&"&%$?GA-D7.>SP%!0F](O&7T].T>'!%W2 "$-72YY*S&:RZRHMTGS*C7)!
MPTQ0L$/0*41'*/1K*/ "OP(^>CW<*\-=;4WA3U#X$UB^<+\_-X.I5$+ON=L]
MG&'!&5K.XQV<8Z&[4*@GI!U"<)^2Q-A>0UBAB$M5Y5E&V+2$IC,?^F%+N_.P
M;LQV3!!VBIB2TN-"Z?%>I8,H2N,TJSZ.N5#D+S;=5R4Q8VJL?;X>>(T-C15!
MC:!:8Z/0V'B7FPPJG6QLN>0WFQLJ*V+:K6J5S4)E<Z_*4N/4D#TNZWQ>OY:
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MN"BT)>7'7VO4:YE:V'U_LWYC@E?!+)' ,U;\(;G<3KS4 SE>H[J0=VSW#=N
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M8:X7J.]KQN3;0)_W[?UN^@]02P,$%     @ CYUK5/,N<N=+#0  FD   !D
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULQ5Q;<]NV$G[N^148][3'F7%L
MWD4WB6<<.VF=.!./G;0/G3Y )"1APHL"D%;4.3_^+$"(H$029*QJSDLLB=C%
M8B_?+A9@7JYR]H4O""G0MS3)^*NC15$L?SD[X]&"I)B?YDN2P9-9SE)<P%<V
M/^-+1G LB=+DS+&LX"S%-#NZ>"E_NV,7+_.R2&A&[ACB99IBMGY-DGSUZL@^
MVOQP3^>+0OQP=O%RB>?D@12?EW<,OIW57&*:DHS3/$.,S%X=7=J_W(;G@D".
M^)V2%6]\1F(ITSS_(K[<Q*^.+"$124A4"!88_CR2*Y(D@A/(\54Q/:KG%(3-
MSQON;^7B83%3S,E5GOQ!XV+QZB@\0C&9X3(I[O/5;T0MR!?\HCSA\E^T4F.M
M(Q25O,A310P2I#2K_N)O2A$- MOK(7 4@;-+X/<0N(K W24(>@@\1>"-)? 5
M@;]+X/80!(H@&+OHB2*8C"4(%4&X0]!KAW-%<#YV!MO:6,X:35(;>[2U[8VY
M;6GOL\JQI%=>XP)?O&3Y"C$Q'OB)#]*U)3TX(\U$%#X4#)Y2H"LN;G.<H<LY
M(P1"J^#H.;J,8RH"!"?H)JO"7(3+\34I,$V>P8C/#]?H^-_/7IX5((!@<Q:I
MR5Y7DSD]D[TKLU-D!R?(L1R[@_S*3'Y-(B"?2'*K@_S:3'ZY9*?(<7K)WYC)
MWY(IS.X*<ON\@_RMF?P#7B/7[EWZKV;JCU%QNB'ODOVWH<F9D?QFA.(-PK\;
M3]XU^_L1=K/"7O+;$>2NU66W,PB6.F*<.F(<R<_MX?>)L!1MAPWZ\Q8&H9N"
MI/POPQ1N/84KI_!ZIO@5LB<Z3G+.GR$(/?*MH-F\I'PA)\MGD&:F19<9*[:!
M9"OR[^.%8P6^98':'IOV:H][?FYMC=N2VZOE]HQRW]]=HC\_D'1*V%_HO^CA
MC_?H;9G%(#RZO;VJ'QDTY-<S^8<R0E!/$1@7\WDY8SFPC3!?H"5>BSFZ,"MH
MZ=*6*N]3YJ2>?V*<_X%D-&?H@40E(S'2*QZAQK">(SR4&L_K*<Z-R[A,<U;0
MOZLDHEP7Q91'>0F3'4/IF-(R[4HF-^<MS09.V';F:IC?&#;Q^GW9MG1FM(R2
M7]W_"MIGCS3Z#@>V&XG7/I3N;8U5MF..2,(+1J.-\HL%04S4I:C(P;&7M, )
M_9L@C);"2M6@KR5F!6')&M$,_@('^"!)R:/"'XP2(;BJ=CL3BEFNAQPX@%8Q
M1UF^X8,6\#6/P-^%P^,L1I2C"&*09B68X$3*<)6G2YRMH0A:(UG+2X3$T0+A
MY3*A$9XF1 NNXA;%N"!BS? =.:?^3QMEV/++DC"8+BM330B2W&$:0PGT_#T%
M28Y__C%T'.O%W<U[^<E^\>P$K18P>+J&+0Q,#T\03J57K_(RB=$4]!K'L!*8
M5\R%YV#GN1!DR6@6T2546(I K!5'$2L;HN-B5[I3DTOHW&*;D\L&UZ0%<_ &
MFE7!.2-$S!6!OF#_U5D@F3G;I[[UDTE&G4=L<R+Y0#.:@CD2^K6D4(ZNE:(Z
MA?):,%'!;Q\ Z!QC^T8I/N40'MN U2F WP(@US$)H#.0;4Y!_0@$V?6.,)K'
MZ", QAA<TFG'GAP,EW3>L4-S5@!_!MVFRLY+EL<EA#(3"%-V^U[8TK)MMK/.
M4/9 BC(*(V("%-T)<F:^$%/O,+!F:V17Y:<,=%)51/ 4"F-I.%4<F\M3G;><
MI^8M[36?5OD8KW%T-G,.ELV<1N5MSAK?[S6*8=-K/*/7.!I''3/:/=EK!OAN
MN8QCF5UF=T.TO1:-MXX9;T>YS +L.LII-, Z!ZOB'0VBCAE$G^ T0<MI0FO'
M::HMO],N_IU=]ZJV]QTC!QQ1 [9CWB@\W1'-?+<=T1YP1-MD+)T7''->N,DB
M)OT %A0M,)L3CF:P"Z*<ESB+B*C;5I@^$L:[FBB*>U/+?>K5V<$QH_B8V'B;
MEVQ,:+@:Q%WK8%T&#=JN_0^'AF+85/#Y;FAL"Z/!W=T'W UN/,!WVXV= 3=V
M3(IM]&_,&&[T&6G5.T8V>Y,[)O;YL$EHE0.C7$J#O.L=S*4TI+OFFOFNWMHL
M]0K5)G]@=S' V;9.+>/VPM4IP=VCKMXU#Y[!AJS#-L*/^DP':7N,Z33$NP>K
MR5V-O:X9>_<QG9FS/V0Y#<;N'F L%;0<L)RJJ)9]EK/'6,[3..X=#,<]C>.>
M&<?WL-P 9W? <IZ&=\\,P_M9;KQE-$9[[L$LTVB(FPOK?2QCYCR$AIZ&;,\,
MK$;+[-.%]C0@>\'!;*%!U!M5)]<--B9:<5 "%&)RV0V;XD04F9W6,/,6G3JS
M.30,>V:P?.KASSNO7?R:3W4TZGH##9+:***/VJD>,X/-V>F_?OAAH,WA:V3U
MS6T.Y9E<>6;#BCD#9L*79SBB"2W671(K[ENG"\9*UM=P[)M!\U,M"MXH[@3<
MCA94='SCQSX?\]O%M6O<(_H:?7TS^MZQ/"(DALT4R].MW91HPS^7RNOQJ]\4
MZQ&;*E^#KV\ND#_@HF2BK]OG4 /TFR-EZ5".:W(HC=7^ %:+?C_$GNSWWVQ0
MXG+3PJ^AO&L/XK>;T'TZ:AQQFG'YS3=:[#3EQ?F%/. HE_(2U":CJ-.,0C:L
M6Q'1J5_SW,% =O$UM/OCCE&;QPU)M:Q*^'&AT6Z?^$X_M/DZ*?AFX+XG-)V6
MC).-'A/8&Q+V'PX?YI6@7!:,.2@8"D:&,XZK\[0HYT57%^*-FM)OQ7&/L#HU
M^.;44'M$=5;4M1M^X[?[Y(YMPA"=!7PSB,M\#!J*P+F$' I<3Y2FOE=)[6-;
M_]SN%3/0>2$PYX7[9E3PGB31>9!OM4\8W-"@ND!GA&"@0-<2D8T-VR$\3DJ[
MW9S</A7?EE&GB& @16A!E'M)DY;9LL)%A8?%@N7E?"'Q1IZJ*NQIYV%&9A#K
MF:@J.Q?2;LV[$\-"=&X)]FB^#-:S,&;_:RR!3CK!P9HR@<XD@1G-1U]E\=MW
M68P%2-"X3+-'RP6LD8.K75;X/TK!&N"#@[5. @W,@1F8.RL^K"]25H]ZT]MM
MT"[=!Q2O43LPH_;(0^R@?=G&-J6-B<;CR1['D3V6WW/C.=' /#G8L>5$(^O$
MC*P?,_*\H*F _"H.:US<+>_D%9:JW-2[F.KJ P<DCD5R!:Q-NC-QEUT'1!NZ
MLC'1J#OY_FLEWU_G33IN,!KJO(G&V8FYN!]3.DW:1?RY*00T_D[VZ+#<**W\
MTS&@H7ERL.;+I'&9T5QG_U]C8*!W,Q0#.@U,S&G@'XJ!=C(P[74F.A5,S*D
M*KQH0:(OL)7-"_46#'R<,]RN@1Y FP#-Z'><)&2-7N/L2_/QU>7]FP=T&16C
M;J/J7!$>K%L>:LP/S<6XY-][G^Q]V.[".*94'.H\$)K!5G6Y52>FI_-Q/<!D
M\Q9#U?DP7?\(-7:'HZZR/*DS>CW VQ[H)(0:PD,SA%^+&H9FO&"E= PA7:=
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M8&KQ2%J+$_ZBL@I( J*HU ^Z!S7%9$;D[79(/C1I-%&RQBK5I7 0NVFZF C
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M6#(0U:,$V4=)SZJZT#0M"38!C8=[^XPX%Z=B2TX_8/9 Q'<]&:&ZA2/W%0H
MU;T8V7MQOP*XTBS- O FOCMYEH0&,^1/'6?J=L2Z;J'(WD)[U(EF:%= 8UII
M3XZM(!RZP7-/7B!KNU%W363OFC]83E>:OIG+OH^.W\D,=M";VK*^;LG(_I+0
ML^RN-$U+JFM0>FPV]L;=.NO6CNRM?56EM-+)Y;L53M2KU48-*15GN:2^%Z7X
M*4[S5.56*)?DNNF3RPLW<X>.\ZNI($>-3V'J Z]L%ILXXR A:TGDR,?% 6#E
M-]/R1-!=\77LG@I!T^)P2W!$F#*0ZVM*Q>%$?7"KOES/_P-02P,$%     @
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M,Z#S7"G[N'"SIOT66?T'4$L#!!0    ( (^=:U0GW+GVPP(  -<&   9
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MPHXUN]PPBGVBGH"_KSA7SS?:0/FOP_0W4$L#!!0    ( (^=:U3@[Z[Y6P,
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MD^*G.[",BY]QAW%P9AQ;I.8.B/..QKRED9Z@0<FCDK8RY%X64!RQ7YRQ3P,
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MN1JA-KKM_]J)58UOH5;*8D/FAQ7VS*#=!OQ>*F5W$W= WX5/?P!02P,$%
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M9MI]85&=#3Q("FUD7H%)@YR+\L]>*D>L 8AG,R"J -%;0'L+H%4!6F\!\19
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M[\?#S?]?]M.:K6V8[WGCX()CSUT=#[?U[VF3->7X[-QZW?39K<N1OOM^)/Q
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MK%^J5"I!S!O]/V<.^_MX_N=5<7^OX^#C50S>7(A!I]D\5O&$E3Z?1S*ZE<Z
M@EC8ADEJ*FNF\M>R7"V;LH%M18[6AZ99LQW''B;O]/097:1,H@SF&M*[:>F-
M)?+F*9\HOK+]QXPKW<W88:(;3A#&0'^?<ZYV$Q.@;&'[_P!02P,$%     @
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MP1;.#3/LXT'9#?A\):5YGEB"YI_!Y#]02P,$%     @ CYUK5&>CR?OZ!
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M=T?WN@(\RBHK@/,+*<UN8!TTOS!,_@=02P,$%     @ CYUK5.YJ5VE_ @
M\04  !D   !X;"]W;W)K<VAE971S+W-H965T-S4N>&ULC53;;MLP#/T5P=B
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MS\+!:-84$UDH/-\\7+]; (?(0B'W&@_"7&J*"7>&<:_QP&C2.CU$%@K/MC7
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M7=N\F!F9[O]Y:?^/5Q_^!5!+ P04    " "/G6M49LT1.G0"  !M,   &@
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M<' N>&UL4$L! A0#%     @ CYUK5&3]61SO    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ CYUK5)E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "/G6M4:"LK=]4&  "U&P  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ CYUK5&;AS%A0
M!@  'QH  !@              ("!&0\  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( (^=:U3!CR:C\@(  .T)   8              "
M@9\5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "/G6M4
M[)6\_\8%  "E%@  &               @(''&   >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ CYUK5%_6N MH @  0 4  !@
M     ("!PQX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M (^=:U3YG#W(/@4  *(6   8              " @6$A  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " "/G6M4>0SV:[0'  #N'@  &
M            @('5)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ CYUK5&2ARI3:#   22$  !@              ("!ORX  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (^=:U0F8Y(M_"@  'B#
M   8              " @<\[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " "/G6M4V0749, 3  "B.@  &0              @($!90
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (^=:U3]U(-8
M5P(  /X$   9              " @?AX  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ CYUK5&L>?:U*!   :0H  !D
M ("!AGL  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "/
MG6M4%M]1A<0"   *!@  &0              @($'@   >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (^=:U1O"IREQ0(  *4%   9
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M970Q."YX;6Q02P$"% ,4    " "/G6M4B5$Z-(8&  "7#P  &0
M    @(&YL0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M (^=:U0LQ(W\#P<  -P4   9              " @7:X  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ CYUK5%NF+KZ5 P  # @  !D
M             ("!O+\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " "/G6M4&+H&U9@(  #N%0  &0              @(&(PP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (^=:U1$MF4LU ,
M % (   9              " @5?,  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ CYUK5,?,">/" P  A @  !D              ("!
M8M   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "/G6M4
M0U>/X0@&  #<#@  &0              @(%;U   >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( (^=:U07O9]GH"H  "Z0   9
M      " @9K:  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ CYUK5$!T; WO @  $08  !D              ("!<04! 'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "/G6M4" ??YXL$  !L"P
M&0              @(&7" $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( (^=:U1B %?R90(   \%   9              " @5D- 0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ CYUK5!H]"\M?
M P  4 @  !D              ("!]0\! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " "/G6M4/2^J[HT"  "0!0  &0
M@(&+$P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (^=
M:U2\RP7 TP(  +8%   9              " @4\6 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ CYUK5!#$V#CC P  .@H  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( (^=:U2)=>U#U0(  #4&   9
M  " @8XO 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MCYUK5&_WLES% P  I P  !D              ("!FC(! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " "/G6M4@33\ZT '  !Y)@  &0
M            @(&6-@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( (^=:U1VM0;&:0,  *$-   9              " @0T^ 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ CYUK5-XJG'2U P
M-0T  !D              ("!K4$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " "/G6M41:>Q._P#  "^#@  &0              @(&9
M10$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( (^=:U3S
M*?B7N00   ,5   9              " @<Q) 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ CYUK5-Q+3YX9"   RB\  !D
M     ("!O$X! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (^=:U0>V'PPR@(  /4(   9              "
M@8YB 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ CYUK
M5 *=T>93 @  0 4  !D              ("!CV4! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " "/G6M4T)_9@?D"  !J"   &0
M        @($9: $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( (^=:U2==5<#KP<  %DH   9              " @4EK 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ CYUK5"GW9!"K @  .@<
M !D              ("!+W,! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " "/G6M4\-Z+[E8#  "."P  &0              @($1=@$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( (^=:U1.$-R>
M^@(  .L)   9              " @9YY 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ CYUK5/,N<N=+#0  FD   !D
M ("!SWP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "/
MG6M4I3IZ9_L$  #%%@  &0              @(%1B@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( (^=:U1-M2.,E0(  &T'   9
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M970V,RYX;6Q02P$"% ,4    " "/G6M4EA<:Q7 #  " #   &0
M    @(' H $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M (^=:U14]"!LX@(  &@'   9              " @6>D 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ CYUK5.*)0]#  @  E@<  !D
M             ("!@*<! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " "/G6M4X4@(@7X#  #@"@  &0              @(%WJ@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( (^=:U1'Q#J%(0,
M (P*   9              " @2RN 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ CYUK5#I@D)&= P  X L  !D              ("!
MA+$! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "/G6M4
M#6<]5Q8#  #."@  &0              @(%8M0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( (^=:U0+D&%L>@(  *,%   9
M      " @:6X 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ CYUK5%CJ5R*- P  )0P  !D              ("!5KL! 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " "/G6M49Z/)^_H$  #8&P
M&0              @($:OP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( (^=:U0;['MF0P0  &T0   9              " @4O$ 0!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ CYUK5.YJ5VE_
M @  \04  !D              ("!Q<@! 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " "/G6M4ILYS)(D"  !R!@  &0
M@(%[RP$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( (^=
M:U1 7+O?%04  #05   9              " @3O. 0!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ CYUK5) G54&< P  60L  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( (^=:U0#5=BM/ ,   P4   -
M  "  :+F 0!X;"]S='EL97,N>&UL4$L! A0#%     @ CYUK5)>*NQS
M$P(   L              ( !">H! %]R96QS+RYR96QS4$L! A0#%     @
MCYUK5,L+;>0-!@  _#4   \              ( !\NH! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( (^=:U1FS1$Z= (  &TP   :              "
M 2SQ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (^=
M:U02 6)0(0(  " O   3              "  =CS 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !: %H K1@  "KV 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>283</ContextCount>
  <ElementCount>541</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>110</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperations</Role>
      <ShortName>Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Product Revenue Reserves and Allowances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances</Role>
      <ShortName>Product Revenue Reserves and Allowances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Loan Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreements</Role>
      <ShortName>Loan Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Share-Based Payment Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards</Role>
      <ShortName>Share-Based Payment Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - License and Asset Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreements</Role>
      <ShortName>License and Asset Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Retirement Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlans</Role>
      <ShortName>Retirement Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureContingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Segment and Geographic Area Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation</Role>
      <ShortName>Segment and Geographic Area Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Product Revenue Reserves and Allowances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables</Role>
      <ShortName>Product Revenue Reserves and Allowances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Share-Based Payment Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables</Role>
      <ShortName>Share-Based Payment Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Segment and Geographic Area Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationTables</Role>
      <ShortName>Segment and Geographic Area Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail</Role>
      <ShortName>Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Significant Accounting Policies - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail</Role>
      <ShortName>Significant Accounting Policies - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Product Revenue Reserves and Allowances - Disaggregation of Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail</Role>
      <ShortName>Product Revenue Reserves and Allowances - Disaggregation of Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Product Revenue Reserves and Allowances - Disaggregation of Revenue (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail</Role>
      <ShortName>Product Revenue Reserves and Allowances - Disaggregation of Revenue (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserves (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail</Role>
      <ShortName>Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserves (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Product Revenue Reserves and Allowances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail</Role>
      <ShortName>Product Revenue Reserves and Allowances - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Inventory - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail</Role>
      <ShortName>Inventory - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Reconciliation of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Intangible Assets - Schedule of Net Book Value of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Schedule of Net Book Value of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Leases - Supplemental Balance Sheet Related to Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail</Role>
      <ShortName>Leases - Supplemental Balance Sheet Related to Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Leases - Supplemental Balance Sheet Related to Finance Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail</Role>
      <ShortName>Leases - Supplemental Balance Sheet Related to Finance Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail</Role>
      <ShortName>Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Loan Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail</Role>
      <ShortName>Loan Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stockholders' Equity - Equity Financings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Equity Financings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail</Role>
      <ShortName>Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Share-Based Payment Awards - Stock Options - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment Awards - Stock Options - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail</Role>
      <ShortName>Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Share-Based Payment Awards - Summary of Information about Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail</Role>
      <ShortName>Share-Based Payment Awards - Summary of Information about Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail</Role>
      <ShortName>Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Share-Based Payment Awards - Employee Stock Purchase Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment Awards - Employee Stock Purchase Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail</Role>
      <ShortName>Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Share-Based Payment Awards - Stock-Based Compensation Expense - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payment Awards - Stock-Based Compensation Expense - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - License and Asset Purchase Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License and Asset Purchase Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Retirement Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail</Role>
      <ShortName>Retirement Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Income Taxes - Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail</Role>
      <ShortName>Income Taxes - Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Income Taxes - Significant Components of Deferred Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Segment and Geographic Area Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail</Role>
      <ShortName>Segment and Geographic Area Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Segment and Geographic Area Information - Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail</Role>
      <ShortName>Segment and Geographic Area Information - Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="eypt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="eypt-10k_20211231.htm">eypt-10k_20211231.htm</File>
    <File>eypt-20211231.xsd</File>
    <File>eypt-20211231_cal.xml</File>
    <File>eypt-20211231_def.xml</File>
    <File>eypt-20211231_lab.xml</File>
    <File>eypt-20211231_pre.xml</File>
    <File>eypt-ex1019_924.htm</File>
    <File>eypt-ex1028_1698.htm</File>
    <File>eypt-ex1045_1565.htm</File>
    <File>eypt-ex1046_2496.htm</File>
    <File>eypt-ex211_8.htm</File>
    <File>eypt-ex231_9.htm</File>
    <File>eypt-ex311_11.htm</File>
    <File>eypt-ex312_6.htm</File>
    <File>eypt-ex321_7.htm</File>
    <File>eypt-ex322_10.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g0exp3o4wshp000001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="747">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eypt-10k_20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 39,
   "contextCount": 283,
   "dts": {
    "calculationLink": {
     "local": [
      "eypt-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eypt-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "eypt-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eypt-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eypt-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eypt-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 721,
   "entityCount": 1,
   "hidden": {
    "http://eyepointpharma.com/20211231": 2,
    "http://fasb.org/us-gaap/2021-01-31": 34,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 40
   },
   "keyCustom": 106,
   "keyStandard": 435,
   "memberCustom": 63,
   "memberStandard": 41,
   "nsprefix": "eypt",
   "nsuri": "http://eyepointpharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eypt:ProductRevenueReservesAndAllowancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Product Revenue Reserves and Allowances",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances",
     "shortName": "Product Revenue Reserves and Allowances",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eypt:ProductRevenueReservesAndAllowancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Inventory",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Intangible Assets",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eypt:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Leases",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eypt:LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Loan Agreements",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreements",
     "shortName": "Loan Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders' Equity",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Share-Based Payment Awards",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards",
     "shortName": "Share-Based Payment Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - License and Asset Purchase Agreements",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreements",
     "shortName": "License and Asset Purchase Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Fair Value Measurements",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Retirement Plans",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlans",
     "shortName": "Retirement Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Contingencies",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureContingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Segment and Geographic Area Information",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation",
     "shortName": "Segment and Geographic Area Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Subsequent Events",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "eypt:ProductRevenueReservesAndAllowancesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Product Revenue Reserves and Allowances (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables",
     "shortName": "Product Revenue Reserves and Allowances (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "eypt:ProductRevenueReservesAndAllowancesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Inventory (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Intangible Assets (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Leases (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Share-Based Payment Awards (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables",
     "shortName": "Share-Based Payment Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Segment and Geographic Area Information (Tables)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationTables",
     "shortName": "Segment and Geographic Area Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eypt:NumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_eyptProduct",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Operations - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
     "shortName": "Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eypt:NumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_eyptProduct",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "eypt:CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Significant Accounting Policies - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail",
     "shortName": "Significant Accounting Policies - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Product Revenue Reserves and Allowances - Disaggregation of Revenue (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
     "shortName": "Product Revenue Reserves and Allowances - Disaggregation of Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Product Revenue Reserves and Allowances - Disaggregation of Revenue (Parenthetical) (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
     "shortName": "Product Revenue Reserves and Allowances - Disaggregation of Revenue (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_srtMajorCustomersAxis_eyptOcumensionTherapeuticsMember_srtProductOrServiceAxis_eyptYUTIQProductMember_us-gaapSupplyCommitmentAxis_us-gaapSupplyCommitmentMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ProductRevenueAllowanceAndReserveTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserves (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail",
     "shortName": "Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserves (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ProductRevenueAllowanceAndReserveTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Product Revenue Reserves and Allowances - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
     "shortName": "Product Revenue Reserves and Allowances - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_20210101_20211231",
      "decimals": "0",
      "lang": null,
      "name": "eypt:SalesBasedRoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Inventory - Schedule of Inventory (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail",
     "shortName": "Inventory - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Intangible Assets - Reconciliation of Intangible Assets (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Reconciliation of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Intangible Assets - Schedule of Net Book Value of Intangible Assets (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Schedule of Net Book Value of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Intangible Assets - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapBusinessAcquisitionAxis_eyptIconBioscienceIncMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eyptDEXYCUMember_20180327_20180328",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_srtProductOrServiceAxis_eyptLicenseAndCollaborationAgreementMember_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Leases - Supplemental Balance Sheet Related to Operating Leases (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail",
     "shortName": "Leases - Supplemental Balance Sheet Related to Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eypt:FinanceLeasePropertyAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Leases - Supplemental Balance Sheet Related to Finance Leases (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail",
     "shortName": "Leases - Supplemental Balance Sheet Related to Finance Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eypt:FinanceLeasePropertyAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail",
     "shortName": "Leases - Future Minimum Lease Payments Under Non-Cancellable Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eypt:ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Loan Agreements - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
     "shortName": "Loan Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_20210101_20211231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stockholders' Equity - Equity Financings - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Equity Financings - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20200623",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail",
     "shortName": "Stockholders' Equity - Summary of Reconciliation of Warrants to Purchase Share of the Company's Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20191231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eypt:WarrantsIssuedInConnectionWithTermLoanFacility",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Warrants to Purchase Common Shares - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_eyptSWKFundingLLCMember_20180624_20180626",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eypt:WarrantsIssuedInConnectionWithTermLoanFacility",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210622",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail",
     "shortName": "Share-Based Payment Awards - Equity Incentive Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210622",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail",
     "shortName": "Share-Based Payment Awards - Stock Option Activity Under Company's Equity Incentive Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansAndInducementAwardGrantsMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Share-Based Payment Awards - Stock Options - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
     "shortName": "Share-Based Payment Awards - Stock Options - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
     "shortName": "Share-Based Payment Awards - Summary of Company Applied the Black-Scholes Option Pricing (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Share-Based Payment Awards - Summary of Information about Stock Options (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail",
     "shortName": "Share-Based Payment Awards - Summary of Information about Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptEquityIncentivePlansMember_20210101_20211231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail",
     "shortName": "Share-Based Payment Awards - Time-Vested Restricted Stock Units - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20210101_20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
     "shortName": "Share-Based Payment Awards - Summary of Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptTwoThousandSixteenIncentivePlanMember_20181230_20190131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
     "shortName": "Share-Based Payment Awards - Deferred Stock Units - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_srtTitleOfIndividualAxis_eyptNonExecutiveDirectorsMember_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Share-Based Payment Awards - Employee Stock Purchase Plan - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
     "shortName": "Share-Based Payment Awards - Employee Stock Purchase Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapPlanNameAxis_eyptEmployeeStockPurchasePlanMember_20190625",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail",
     "shortName": "Share-Based Payment Awards - Compensation Expense from Stock-Based Payment Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Share-Based Payment Awards - Stock-Based Compensation Expense - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail",
     "shortName": "Share-Based Payment Awards - Stock-Based Compensation Expense - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - License and Asset Purchase Agreements - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
     "shortName": "License and Asset Purchase Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapTypeOfArrangementAxis_eyptAerpioPharmaceuticalsIncMember_20210801_20210831",
      "decimals": "0",
      "lang": null,
      "name": "eypt:NonRefundableNonCreditableUpfrontCashPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Retirement Plans - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail",
     "shortName": "Retirement Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Income Taxes - Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail",
     "shortName": "Income Taxes - Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Income Taxes - Significant Components of Deferred Income Taxes (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail",
     "shortName": "Income Taxes - Significant Components of Deferred Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Operations",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperations",
     "shortName": "Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Segment and Geographic Area Information - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail",
     "shortName": "Segment and Geographic Area Information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Segment and Geographic Area Information - Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail",
     "shortName": "Segment and Geographic Area Information - Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_srtStatementGeographicalAxis_countryUS_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapCreditFacilityAxis_eyptSeniorSecuredTermLoanMember_us-gaapLineOfCreditFacilityAxis_eyptCrgServicingLlcMember_20220101_20220331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Significant Accounting Policies",
     "role": "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eypt-10k_20211231.htm",
      "contextRef": "C_0001314102_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 110,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [Member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "UNITED KINGDOM [Member]"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Country US [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "verboseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "verboseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "eypt_ASDSpecialtyHealthcareLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASD specialty healthcare LLC.",
        "label": "A S D Specialty Healthcare L L C [Member]",
        "terseLabel": "ASD Specialty Healthcare LLC [Member]"
       }
      }
     },
     "localname": "ASDSpecialtyHealthcareLLCMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_AccountsReceivableStandardPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable standard payment terms.",
        "label": "Accounts Receivable Standard Payment Terms",
        "terseLabel": "Accounts receivable standard payment terms"
       }
      }
     },
     "localname": "AccountsReceivableStandardPaymentTerms",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eypt_AccruedClinicalExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of estimated obligations incurred through that date and payable for obligations related to services of contract research organizations in conducting clinical trials.",
        "label": "Accrued Clinical Expense Current",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "AccruedClinicalExpenseCurrent",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_AccruedRevenueBasedRoyaltyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued revenue based royalty expense.",
        "label": "Accrued Revenue Based Royalty Expense",
        "terseLabel": "Accrued revenue-based royalty expense"
       }
      }
     },
     "localname": "AccruedRevenueBasedRoyaltyExpense",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_AccruedSalesChargebacksRebatesAndOtherRevenueReserves": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued sales chargebacks, rebates and other revenue reserves.",
        "label": "Accrued Sales Chargebacks Rebates And Other Revenue Reserves",
        "terseLabel": "Sales chargebacks, rebates and other revenue reserves"
       }
      }
     },
     "localname": "AccruedSalesChargebacksRebatesAndOtherRevenueReserves",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_AdditionalLeasePropertyAreaCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional lease property area covered.",
        "label": "Additional Lease Property Area Covered",
        "terseLabel": "Additional Space leased"
       }
      }
     },
     "localname": "AdditionalLeasePropertyAreaCovered",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "eypt_AdditionalSubleasedPropertyOfficeArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional subleased property office area.",
        "label": "Additional Subleased Property Office Area",
        "terseLabel": "Additional subleased property office area"
       }
      }
     },
     "localname": "AdditionalSubleasedPropertyOfficeArea",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "eypt_AerpioPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aerpio Pharmaceuticals, Inc.",
        "label": "Aerpio Pharmaceuticals Inc [Member]",
        "terseLabel": "Aerpio Pharmaceuticals, Inc [Member]"
       }
      }
     },
     "localname": "AerpioPharmaceuticalsIncMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_AmendedAlimeraScienceIncAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Alimera Science Inc Agreement.",
        "label": "Amended Alimera Science Inc Agreement [Member]",
        "terseLabel": "Amended Alimera Science Inc Agreement [Member]"
       }
      }
     },
     "localname": "AmendedAlimeraScienceIncAgreementMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_AmortizationOfAcquisitionCostOfIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10150.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of acquisition cost of intangible assets.",
        "label": "Amortization Of Acquisition Cost Of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfAcquisitionCostOfIntangibleAssets",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_AmortizationOfDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Debt Discount",
        "label": "Amortization Of Debt Discount",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscount",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_AnnualMinimumProductRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual minimum period revenue.",
        "label": "Annual Minimum Product Revenue",
        "terseLabel": "Annual minimum product revenue"
       }
      }
     },
     "localname": "AnnualMinimumProductRevenue",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_AnnualMinimumProductRevenuePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual minimum product revenue period.",
        "label": "Annual Minimum Product Revenue Period",
        "terseLabel": "Annual minimum product revenue period"
       }
      }
     },
     "localname": "AnnualMinimumProductRevenuePeriod",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-Market Offering [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_BaskingRidgeOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basking ridge office space.",
        "label": "Basking Ridge Office Space [Member]",
        "terseLabel": "Basking Ridge Office Space [Member]"
       }
      }
     },
     "localname": "BaskingRidgeOfficeSpaceMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_CaladriusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caladrius.",
        "label": "Caladrius [Member]",
        "terseLabel": "Caladrius [Member]"
       }
      }
     },
     "localname": "CaladriusMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_ChargeBacksAndDiscountsAndFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge backs and discounts and fees.",
        "label": "Charge Backs And Discounts And Fees [Member]",
        "terseLabel": "Chargebacks, Discounts and Fees [Member]"
       }
      }
     },
     "localname": "ChargeBacksAndDiscountsAndFeesMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_ClassOfWarrantOrRightIssuePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right issue price of warrants.",
        "label": "Class Of Warrant Or Right Issue Price Of Warrants",
        "terseLabel": "Pre-funded warrants issued, price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuePriceOfWarrants",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "eypt_CollaborativeAgreementsAndContractsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreements and contracts.",
        "label": "Collaborative Agreements And Contracts [Line Items]",
        "terseLabel": "Collaborative Agreements And Contracts [Line Items]"
       }
      }
     },
     "localname": "CollaborativeAgreementsAndContractsLineItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_CollaborativeAgreementsAndContractsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreements and contracts.",
        "label": "Collaborative Agreements And Contracts [Table]",
        "terseLabel": "Collaborative Agreements And Contracts [Table]"
       }
      }
     },
     "localname": "CollaborativeAgreementsAndContractsTable",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_CollaborativeResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative research and development.",
        "label": "Collaborative Research And Development [Member]",
        "terseLabel": "Collaborative Research and Development [Member]"
       }
      }
     },
     "localname": "CollaborativeResearchAndDevelopmentMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_ComprehensiveLossPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Loss, Policy [Policy Text Block]",
        "label": "Comprehensive Loss Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_ConstructionAllowanceCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Its represent the construction allowance credit.",
        "label": "Construction Allowance Credit",
        "terseLabel": "Construction allowance"
       }
      }
     },
     "localname": "ConstructionAllowanceCredit",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ContractWithCustomerAllowanceForCreditLossAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer allowance for credit loss additions.",
        "label": "Contract With Customer Allowance For Credit Loss Additions",
        "terseLabel": "Provision related to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerAllowanceForCreditLossAdditions",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ContractWithCustomerAllowanceForCreditLossIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer allowance for credit loss increase decrease.",
        "label": "Contract With Customer Allowance For Credit Loss Increase Decrease",
        "terseLabel": "Adjustments related to prior period sales"
       }
      }
     },
     "localname": "ContractWithCustomerAllowanceForCreditLossIncreaseDecrease",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer allowance for deductions applied and payments made.",
        "label": "Contract With Customer Allowance For Deductions Applied And Payments Made",
        "terseLabel": "Deductions applied and payments made"
       }
      }
     },
     "localname": "ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_CoronavirusAidReliefAndEconomicSecurityActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus aid relief and economic security act.",
        "label": "Coronavirus Aid Relief And Economic Security Act [Member]",
        "terseLabel": "CARES Act [Member]"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales excluding amortization of acquired intangible assets.",
        "label": "Cost Of Sales Excluding Amortization Of Acquired Intangible Assets",
        "terseLabel": "Cost of sales, excluding amortization of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales, excluding amortization of acquired intangible assets.",
        "label": "Cost Of Sales Excluding Amortization Of Acquired Intangible Assets [Member]",
        "terseLabel": "Cost of Sales, Excluding Amortization of Acquired Intangible Assets [Member]"
       }
      }
     },
     "localname": "CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssetsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_CrgServicingLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRG Servicing LLC",
        "label": "Crg Servicing Llc [Member]",
        "terseLabel": "CRG Servicing LLC [Member]"
       }
      }
     },
     "localname": "CrgServicingLlcMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_DEXYCUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DEXYCU.",
        "label": "D E X Y C U [Member]",
        "terseLabel": "DEXYCU [Member]"
       }
      }
     },
     "localname": "DEXYCUMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_DEXYCUProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DEXYCU product.",
        "label": "D E X Y C U Product [Member]",
        "terseLabel": "DEXYCU [Member]"
       }
      }
     },
     "localname": "DEXYCUProductMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_DebInstrumentExitFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee Charged",
        "label": "Deb Instrument Exit Fee",
        "terseLabel": "Payment of exit fee upon repayment of secured term loan"
       }
      }
     },
     "localname": "DebInstrumentExitFee",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DebtAndEquityInstrumentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt and equity instruments.",
        "label": "Debt And Equity Instruments Policy [Text Block]",
        "terseLabel": "Debt and Equity Instruments"
       }
      }
     },
     "localname": "DebtAndEquityInstrumentsPolicyTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_DebtInstrumentAccruedInterestForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument accrued interest forgiveness.",
        "label": "Debt Instrument Accrued Interest Forgiveness",
        "terseLabel": "Debt instrument, accrued interest forgiveness amount"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterestForgiveness",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DebtInstrumentExitFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument exit fee.",
        "label": "Debt Instrument Exit Fee",
        "terseLabel": "Accrued term loan exit fee"
       }
      }
     },
     "localname": "DebtInstrumentExitFee",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DeferredStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred stock units.",
        "label": "Deferred Stock Units [Member]",
        "terseLabel": "Deferred Stock Units [Member]"
       }
      }
     },
     "localname": "DeferredStockUnitsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets leasing arrangements.",
        "label": "Deferred Tax Assets Leasing Arrangements",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Liabilities Net Before Valuation Allowance",
        "label": "Deferred Tax Assets Liabilities Net Before Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DefinedContributionPlanContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan contributions by employer.",
        "label": "Defined Contribution Plan Contributions By Employer",
        "terseLabel": "Employer contributions to retirement plans"
       }
      }
     },
     "localname": "DefinedContributionPlanContributionsByEmployer",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DevelopmentMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payment received.",
        "label": "Development Milestone Payment Received",
        "terseLabel": "Development milestone payment received"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentReceived",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_DirectorsAndExternalConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors and external consultant.",
        "label": "Directors And External Consultants [Member]",
        "terseLabel": "External consultant [Member]"
       }
      }
     },
     "localname": "DirectorsAndExternalConsultantsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_DisclosureOfLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases",
        "label": "Disclosure Of Leases [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfLeasesAbstract",
     "nsuri": "http://eyepointpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "eypt_DisclosureOfLeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases",
        "label": "Disclosure Of Leases [Line Items]",
        "terseLabel": "Disclosure Of Leases [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfLeasesLineItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_DisclosureOfLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases",
        "label": "Disclosure Of Leases [Table]",
        "terseLabel": "Disclosure Of Leases [Table]"
       }
      }
     },
     "localname": "DisclosureOfLeasesTable",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_DisclosureOfProductRevenueReservesAndAllowancesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of product revenue reserves and allowances.",
        "label": "Disclosure Of Product Revenue Reserves And Allowances [Line Items]",
        "terseLabel": "Disclosure Of Product Revenue Reserves And Allowances [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfProductRevenueReservesAndAllowancesLineItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_DisclosureOfProductRevenueReservesAndAllowancesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Product Revenue Reserves and Allowances",
        "label": "Disclosure Of Product Revenue Reserves And Allowances [Table]",
        "terseLabel": "Disclosure Of Product Revenue Reserves And Allowances [Table]"
       }
      }
     },
     "localname": "DisclosureOfProductRevenueReservesAndAllowancesTable",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_EquinoxScienceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equinox science, LLC.",
        "label": "Equinox Science L L C [Member]",
        "terseLabel": "Equinox Science, LLC [Member]"
       }
      }
     },
     "localname": "EquinoxScienceLLCMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_EquityFinancingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity financings.",
        "label": "Equity Financings [Member]",
        "terseLabel": "Equity Financings [Member]"
       }
      }
     },
     "localname": "EquityFinancingsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_EquityIncentivePlansAndInducementAwardGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plans and inducement award grants.",
        "label": "Equity Incentive Plans And Inducement Award Grants [Member]",
        "terseLabel": "Equity Incentive Plans and Inducement Awards [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlansAndInducementAwardGrantsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_EquityIncentivePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plans.",
        "label": "Equity Incentive Plans [Member]",
        "terseLabel": "Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlansMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_EstimatedRateOfAnnualAmortizationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated rate of annual amortization expense.",
        "label": "Estimated Rate Of Annual Amortization Expense",
        "terseLabel": "Annual amortization expense"
       }
      }
     },
     "localname": "EstimatedRateOfAnnualAmortizationExpense",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ExercisePriceOfIssuedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of issued warrants.",
        "label": "Exercise Price Of Issued Warrants",
        "terseLabel": "Exercise price of issued warrants"
       }
      }
     },
     "localname": "ExercisePriceOfIssuedWarrants",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "eypt_ExitFeeAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of exit fee accrued.",
        "label": "Exit Fee Accrued",
        "terseLabel": "Exit fee accrued"
       }
      }
     },
     "localname": "ExitFeeAccrued",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and State Research and Development Tax Credit Carryforward [Member]",
        "label": "Federal And State Research And Development Tax Credit Carry Forward [Member]",
        "terseLabel": "Federal and State Research and Development Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "FederalAndStateResearchAndDevelopmentTaxCreditCarryForwardMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_FederalAndStateTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal And State Tax [Member]",
        "label": "Federal And State Tax [Member]",
        "terseLabel": "Federal And State Tax [Member]"
       }
      }
     },
     "localname": "FederalAndStateTaxMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_FinanceLeaseAccumulatedAmortizationPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease accumulated amortization property and equipment.",
        "label": "Finance Lease Accumulated Amortization Property And Equipment",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseAccumulatedAmortizationPropertyAndEquipment",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_FinanceLeasePropertyAndEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease property and equipment gross.",
        "label": "Finance Lease Property And Equipment Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "FinanceLeasePropertyAndEquipmentGross",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_FirstLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First lab equipment.",
        "label": "First Lab Equipment [Member]",
        "terseLabel": "First Lab Equipment [Member]"
       }
      }
     },
     "localname": "FirstLabEquipmentMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_FourthAmendmentLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth amendment lease.",
        "label": "Fourth Amendment Lease [Member]",
        "terseLabel": "Fourth Amendment Lease [Member]"
       }
      }
     },
     "localname": "FourthAmendmentLeaseMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_GovernmentsAndOtherRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Governments and other rebates.",
        "label": "Governments And Other Rebates [Member]",
        "terseLabel": "Government and Other Rebates [Member]"
       }
      }
     },
     "localname": "GovernmentsAndOtherRebatesMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "verboseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_IconBioscienceIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Icon Bioscience, Inc.",
        "label": "Icon Bioscience Inc [Member]",
        "terseLabel": "Icon Bioscience Inc [Member]"
       }
      }
     },
     "localname": "IconBioscienceIncMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation change in fair value of derivative liability.",
        "label": "Income Tax Reconciliation Change In Fair Value Of Derivative Liability",
        "terseLabel": "Change in fair value of derivative"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase or decrease in operating lease liability and right of use asset.",
        "label": "Increase Decrease In Operating Lease Liabilities And Right Of Use Asset",
        "terseLabel": "Right-of-use assets and operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_IncrementalChargesForIssuanceOfWaivers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental charges for issuance of waivers.",
        "label": "Incremental Charges For Issuance Of Waivers",
        "terseLabel": "Incremental charges for issuance of waivers"
       }
      }
     },
     "localname": "IncrementalChargesForIssuanceOfWaivers",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_InitialAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial advance.",
        "label": "Initial Advance [Member]",
        "terseLabel": "Initial Advance [Member]"
       }
      }
     },
     "localname": "InitialAdvanceMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_InvestmentInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment instruments.",
        "label": "Investment Instruments [Member]",
        "terseLabel": "Investment Instruments [Member]"
       }
      }
     },
     "localname": "InvestmentInstrumentsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_LeaseExpirationMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month year.",
        "label": "Lease Expiration Month Year",
        "terseLabel": "Lease expiration month year"
       }
      }
     },
     "localname": "LeaseExpirationMonthYear",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "eypt_LeaseInceptionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease inception date.",
        "label": "Lease Inception Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseInceptionDate",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "eypt_LeaseInceptionMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease inception month year.",
        "label": "Lease Inception Month Year",
        "terseLabel": "Lease inception month year"
       }
      }
     },
     "localname": "LeaseInceptionMonthYear",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "eypt_LeasePropertyAreaCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease property area covered.",
        "label": "Lease Property Area Covered",
        "terseLabel": "Area of leased office and laboratory space"
       }
      }
     },
     "localname": "LeasePropertyAreaCovered",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "eypt_LeasePropertyOfficeAreaCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease property office area covered.",
        "label": "Lease Property Office Area Covered",
        "terseLabel": "Area of leased office space"
       }
      }
     },
     "localname": "LeasePropertyOfficeAreaCovered",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "eypt_LeaseTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination date.",
        "label": "Lease Termination Date",
        "terseLabel": "Lease termination date"
       }
      }
     },
     "localname": "LeaseTerminationDate",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "eypt_LesseeOperatingAndFinanceLeasesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating and finance leases.",
        "label": "Lessee Operating And Finance Leases Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesDisclosureTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_LicenseAgreementStartYearMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Start Year Month",
        "label": "License Agreement Start Year Month",
        "terseLabel": "License agreement commencement date"
       }
      }
     },
     "localname": "LicenseAgreementStartYearMonth",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "eypt_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_LineOfCreditFacilityExitFeesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility exit fees percentage.",
        "label": "Line Of Credit Facility Exit Fees Percentage",
        "terseLabel": "Exit fee percentage payable upon repayment of the total secured term loan"
       }
      }
     },
     "localname": "LineOfCreditFacilityExitFeesPercentage",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_LineOfCreditFacilityFinancingFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility financing fees percentage.",
        "label": "Line Of Credit Facility Financing Fee Percentage",
        "terseLabel": "One-time upfront financing fee percentage applied to borrowing amounts under the line of credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityFinancingFeePercentage",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_LineOfCreditFacilityLegalAndTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of legal and transaction costs related to line of credit facility.",
        "label": "Line Of Credit Facility Legal And Transaction Costs",
        "terseLabel": "Line of credit facility, legal and other transaction costs"
       }
      }
     },
     "localname": "LineOfCreditFacilityLegalAndTransactionCosts",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility principal prepayment premium percentage.",
        "label": "Line Of Credit Facility Principal Prepayment Premium Percentage",
        "terseLabel": "Principal prepayment premium percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityPrincipalPrepaymentPremiumPercentage",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Prepayment after December 31, 2019 and Prior to December 31, 2020.",
        "label": "Loan Prepayment After December312019 And Prior To December312020 [Member]",
        "terseLabel": "Loan Prepayment after December 31, 2019 and Prior to December 31, 2020 [Member]"
       }
      }
     },
     "localname": "LoanPrepaymentAfterDecember312019AndPriorToDecember312020Member",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan prepayment after December 31, 2020 and Prior to December 31, 2021.",
        "label": "Loan Prepayment After December312020 And Prior To December312021 [Member]",
        "terseLabel": "Loan prepayment after December 31, 2020 and prior to December 31, 2021 [Member]"
       }
      }
     },
     "localname": "LoanPrepaymentAfterDecember312020AndPriorToDecember312021Member",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_LoanPrepaymentAfterDecember312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Prepayment After December 31 2021.",
        "label": "Loan Prepayment After December312021 [Member]",
        "terseLabel": "Loan prepayment after December 31 2021 [Member]"
       }
      }
     },
     "localname": "LoanPrepaymentAfterDecember312021Member",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_LoanPrepaymentPriorToDecember312019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan prepayment prior to December 31, 2019 (not February 13, 2020).",
        "label": "Loan Prepayment Prior To December312019 [Member]",
        "terseLabel": "Loan Prepayment Prior to December 31, 2019 [Member]"
       }
      }
     },
     "localname": "LoanPrepaymentPriorToDecember312019Member",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_MaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MA",
        "label": "Ma [Member]",
        "terseLabel": "Massachusetts [Member]"
       }
      }
     },
     "localname": "MaMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_McKessonSpecialtyCareDistributionLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson specialty care distribution LLC.",
        "label": "Mc Kesson Specialty Care Distribution L L C [Member]",
        "terseLabel": "McKesson Specialty Care Distribution LLC [Member]"
       }
      }
     },
     "localname": "McKessonSpecialtyCareDistributionLLCMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments upon achievement of certain development and regulatory milestones.",
        "label": "Milestone Payments Upon Achievement Of Certain Development And Regulatory Milestones",
        "terseLabel": "Payment upon achievement of development and regulatory milestones"
       }
      }
     },
     "localname": "MilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_MinimumLiquidityAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum liquidity amount.",
        "label": "Minimum Liquidity Amount",
        "terseLabel": "Minimum liquidity amount"
       }
      }
     },
     "localname": "MinimumLiquidityAmount",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_NetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards.",
        "label": "Net Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwards",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_NewlyAppointedNonExecutiveDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newly appointed non executive director.",
        "label": "Newly Appointed Non Executive Director [Member]",
        "terseLabel": "Newly Appointed Non Executive Director [Member]"
       }
      }
     },
     "localname": "NewlyAppointedNonExecutiveDirectorMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_NonCashUnpaidStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash unpaid stock issuance costs.",
        "label": "Non Cash Unpaid Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "NonCashUnpaidStockIssuanceCosts",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_NonExecutiveDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive directors.",
        "label": "Non Executive Directors [Member]",
        "terseLabel": "Non Executive Directors [Member]"
       }
      }
     },
     "localname": "NonExecutiveDirectorsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_NonRefundableNonCreditableUpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable, non-creditable upfront cash payment.",
        "label": "Non Refundable Non Creditable Upfront Cash Payment",
        "terseLabel": "Non-refundable and non-creditable upfront cash payment"
       }
      }
     },
     "localname": "NonRefundableNonCreditableUpfrontCashPayment",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_NonRoyaltyConsiderationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non royalty consideration percentage.",
        "label": "Non Royalty Consideration Percentage",
        "terseLabel": "Percentage of non-royalty consideration received from sublicense"
       }
      }
     },
     "localname": "NonRoyaltyConsiderationPercentage",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_NumberOfFinanceLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance leases.",
        "label": "Number Of Finance Leases",
        "terseLabel": "Number of finance leases"
       }
      }
     },
     "localname": "NumberOfFinanceLeases",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eypt_NumberOfNewBlindnessCasesEveryYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new blindness cases every year.",
        "label": "Number Of New Blindness Cases Every Year",
        "terseLabel": "Number of new cases of blindness annually"
       }
      }
     },
     "localname": "NumberOfNewBlindnessCasesEveryYear",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eypt_NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of people affected by posterior segment of eye in U.S. each year.",
        "label": "Number Of People Affected By Posterior Segment Of Eye In U S Each Year",
        "terseLabel": "Number of people affected by posterior segment of eye in U.S. each year"
       }
      }
     },
     "localname": "NumberOfPeopleAffectedByPosteriorSegmentOfEyeInUSEachYear",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eypt_NumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of products.",
        "label": "Number Of Products",
        "terseLabel": "Number of commercial products"
       }
      }
     },
     "localname": "NumberOfProducts",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eypt_NumberOfProductsApproved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of products approved by by the United States (US) Food and Drug Administration (FDA).",
        "label": "Number Of Products Approved",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "NumberOfProductsApproved",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eypt_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal options.",
        "label": "Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eypt_OcumensionTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ocumension Therapeutics.",
        "label": "Ocumension Therapeutics [Member]",
        "terseLabel": "Ocumension Therapeutics [Member]"
       }
      }
     },
     "localname": "OcumensionTherapeuticsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_OncoSilMedicalUKLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OncoSil Medical UK Limited.",
        "label": "Onco Sil Medical U K Limited [Member]",
        "terseLabel": "OncoSil Medical UK Limited [Member]"
       }
      }
     },
     "localname": "OncoSilMedicalUKLimitedMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease renewal term percentage of market rent at renewal date.",
        "label": "Operating Lease Renewal Term Percentage Of Market Rent At Renewal Date",
        "terseLabel": "Lease renewal rate at 95% of market rent at time of renewal"
       }
      }
     },
     "localname": "OperatingLeaseRenewalTermPercentageOfMarketRentAtRenewalDate",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_OperatingLossCarryForwardsExpirationYearRangeEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year range end",
        "label": "Operating Loss Carry Forwards Expiration Year Range End",
        "terseLabel": "Operating loss carry forwards, expiration range end dates"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYearRangeEnd",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "eypt_OperatingLossCarryForwardsExpirationYearRangeStart": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Loss Carry Forwards Expiration Year Range Start",
        "terseLabel": "Operating loss carry forwards, expiration range start dates"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYearRangeStart",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "eypt_OperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations [Abstract]",
        "label": "Operations [Abstract]"
       }
      }
     },
     "localname": "OperationsAbstract",
     "nsuri": "http://eyepointpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "eypt_OperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations.",
        "label": "Operations [Line Items]",
        "terseLabel": "Operations [Line Items]"
       }
      }
     },
     "localname": "OperationsLineItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_OrganizationAndNatureOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Nature Of Business [Table]",
        "label": "Organization And Nature Of Business [Table]",
        "terseLabel": "Organization And Nature Of Business [Table]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessTable",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_OriginalAmountOfDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original amount of debt discount.",
        "label": "Original Amount Of Debt Discount",
        "terseLabel": "Total debt discount"
       }
      }
     },
     "localname": "OriginalAmountOfDebtDiscount",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_OriginalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original lease.",
        "label": "Original Lease [Member]",
        "terseLabel": "Original Lease [Member]"
       }
      }
     },
     "localname": "OriginalLeaseMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PaidInKindInterestAddedToPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid in kind interest added to principal.",
        "label": "Paid In Kind Interest Added To Principal",
        "terseLabel": "Paid in Kind Interest Added to Principal"
       }
      }
     },
     "localname": "PaidInKindInterestAddedToPrincipal",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program loan.",
        "label": "Paycheck Protection Program Loan [Member]",
        "terseLabel": "Paycheck Protection Program Loan [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PaymentOfAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment accrued and unpaid interest through the date of the secured term loan refinancing",
        "label": "Payment Of Accrued And Unpaid Interest",
        "terseLabel": "Payment of accrued and unpaid interest through the date of the secured term loan refinancing"
       }
      }
     },
     "localname": "PaymentOfAccruedAndUnpaidInterest",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PaymentsForgivenUnderPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments forgiven under paycheck protection program loan.",
        "label": "Payments Forgiven Under Paycheck Protection Program Loan",
        "terseLabel": "Payments forgiven under paycheck protection program loan"
       }
      }
     },
     "localname": "PaymentsForgivenUnderPaycheckProtectionProgramLoan",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PercentageOfAcceleratedMilestonePaymentReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of accelerated milestone payment received.",
        "label": "Percentage Of Accelerated Milestone Payment Received",
        "terseLabel": "Percentage of accelerated milestone payment received"
       }
      }
     },
     "localname": "PercentageOfAcceleratedMilestonePaymentReceived",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of accounts receivable eligible for maximum amount borrowing.",
        "label": "Percentage Of Accounts Receivable Eligible For Maximum Amount Borrowing",
        "terseLabel": "Percentage of accounts receivable eligible for maximum amount borrowing"
       }
      }
     },
     "localname": "PercentageOfAccountsReceivableEligibleForMaximumAmountBorrowing",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_PercentageOfUpfrontPaymentReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment received.",
        "label": "Percentage Of Upfront Payment Received",
        "terseLabel": "Percentage of upfront payment received"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentReceived",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period [Axis]",
        "terseLabel": "Period"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_PeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period [Domain]",
        "terseLabel": "Period"
       }
      }
     },
     "localname": "PeriodDomain",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period four.",
        "label": "Period Four [Member]",
        "terseLabel": "Period Four [Member]"
       }
      }
     },
     "localname": "PeriodFourMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one.",
        "label": "Period One [Member]",
        "terseLabel": "Period One [Member]"
       }
      }
     },
     "localname": "PeriodOneMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three.",
        "label": "Period Three [Member]",
        "terseLabel": "Period Three [Member]"
       }
      }
     },
     "localname": "PeriodThreeMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two.",
        "label": "Period Two [Member]",
        "terseLabel": "Period Two [Member]"
       }
      }
     },
     "localname": "PeriodTwoMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future payments to be received upon the achievement of prescribed combined remaining development and sales milestone.",
        "label": "Potential Future Payments To Be Received Upon Achievement Of Prescribed Combined Remaining Development And Sales Milestone",
        "terseLabel": "Potential future payments based on achievement of combined remaining development and sales milestone"
       }
      }
     },
     "localname": "PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future payments to be received upon the achievement of prescribed commercial sales-based milestone.",
        "label": "Potential Future Payments To Be Received Upon Achievement Of Prescribed Commercial Sales Based Milestone",
        "terseLabel": "Potential future payments based on achievement of commercial-based milestones"
       }
      }
     },
     "localname": "PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future payments to be received upon the achievement of prescribed development and regulatory milestone.",
        "label": "Potential Future Payments To Be Received Upon Achievement Of Prescribed Development And Regulatory Milestone",
        "terseLabel": "Potential future payments based on achievement of development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future payments to be received upon the achievement of prescribed remaining commercial sales-based milestone.",
        "label": "Potential Future Payments To Be Received Upon Achievement Of Prescribed Remaining Commercial Sales Based Milestone",
        "terseLabel": "Potential future payments based on achievement of remaining commercial-based milestones"
       }
      }
     },
     "localname": "PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future payments to be received upon the achievement of prescribed remaining development and regulatory milestone.",
        "label": "Potential Future Payments To Be Received Upon Achievement Of Prescribed Remaining Development And Regulatory Milestone",
        "terseLabel": "Potential future payments based on achievement of remaining development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PreFundedWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrants to purchase common stock.",
        "label": "Pre Funded Warrants To Purchase Common Stock",
        "terseLabel": "Pre Funded Warrants to purchase common stock"
       }
      }
     },
     "localname": "PreFundedWarrantsToPurchaseCommonStock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eypt_ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of stock and pre-funded warrants, net of issuance costs.",
        "label": "Proceeds From Issuance Of Stock And Pre Funded Warrants Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of stock and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ProceedsFromPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from paycheck protection program loan.",
        "label": "Proceeds From Paycheck Protection Program Loan",
        "terseLabel": "Proceeds under paycheck protection program loan"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgramLoan",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ProductRevenueAllowanceAndReserveTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of product revenue allowance and reserve.",
        "label": "Product Revenue Allowance And Reserve Table [Text Block]",
        "terseLabel": "Product Revenue Allowance and Reserves"
       }
      }
     },
     "localname": "ProductRevenueAllowanceAndReserveTableTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_ProductRevenueReservesAndAllowancesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for product revenue reserves and allowances.",
        "label": "Product Revenue Reserves And Allowances [Text Block]",
        "terseLabel": "Product Revenue Reserves and Allowances"
       }
      }
     },
     "localname": "ProductRevenueReservesAndAllowancesTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowances"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_ProductSupplyMilestonesAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product supply milestones and development milestones.",
        "label": "Product Supply Milestones And Development Milestones",
        "terseLabel": "Product supply milestones and development milestones"
       }
      }
     },
     "localname": "ProductSupplyMilestonesAndDevelopmentMilestones",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_PropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment.",
        "label": "Property And Equipment [Member]",
        "terseLabel": "Property and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyAndEquipmentMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant And Equipment Useful Life And Values [Abstract]",
        "label": "Property Plant And Equipment Useful Life And Values [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract",
     "nsuri": "http://eyepointpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "eypt_ReimbursedExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense reimbursed.",
        "label": "Reimbursed Expense",
        "terseLabel": "Reimbursement of lender's legal fees and other transaction costs"
       }
      }
     },
     "localname": "ReimbursedExpense",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credits expiration year range end.",
        "label": "Research And Development Tax Credits Expiration Year Range End",
        "terseLabel": "Research and development tax credit carry forwards expiration end date"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditsExpirationYearRangeEnd",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "eypt_ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credits expiration year range start.",
        "label": "Research And Development Tax Credits Expiration Year Range Start",
        "terseLabel": "Research and development tax credit carry forwards expiration begin date"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditsExpirationYearRangeStart",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "eypt_ReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Returns.",
        "label": "Returns [Member]",
        "terseLabel": "Returns [Member]"
       }
      }
     },
     "localname": "ReturnsMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_RoyaltyPercentageEarnedFromProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage earned from sales of product.",
        "label": "Royalty Percentage Earned From Product Sales",
        "terseLabel": "Royalty percentage earned from sales of product"
       }
      }
     },
     "localname": "RoyaltyPercentageEarnedFromProductSales",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_RoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Member]",
        "terseLabel": "RPA [Member]"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_RoyaltySaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty sale agreement.",
        "label": "Royalty Sale Agreement [Member]",
        "terseLabel": "Royalty Sale Agreement [Member]"
       }
      }
     },
     "localname": "RoyaltySaleAgreementMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SWKFundingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SWK Funding LLC.",
        "label": "S W K Funding L L C [Member]",
        "terseLabel": "SWK [Member]",
        "verboseLabel": "SWK Funding LLC [Member]"
       }
      }
     },
     "localname": "SWKFundingLLCMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SalesAndMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing.",
        "label": "Sales And Marketing [Member]",
        "terseLabel": "Sales and Marketing [Member]"
       }
      }
     },
     "localname": "SalesAndMarketingMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SalesBasedRoyaltyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales based royalty expense.",
        "label": "Sales Based Royalty Expense",
        "terseLabel": "Sales-based royalty expense"
       }
      }
     },
     "localname": "SalesBasedRoyaltyExpense",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum operating and finance lease payments under non cancellable leases.",
        "label": "Schedule Of Future Minimum Operating And Finance Lease Payments Under Non Cancellable Leases Table [Text Block]",
        "terseLabel": "Future Minimum Lease Payments Under Non-Cancellable Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumOperatingAndFinanceLeasePaymentsUnderNonCancellableLeasesTableTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_ScheduleOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Significant Accounting Policies [Line Items]",
        "label": "Schedule Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Schedule Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to finance lease.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Finance Lease Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Finance Lease"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToFinanceLeaseTableTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to operating leases.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eypt_SecondAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second advance.",
        "label": "Second Advance [Member]",
        "terseLabel": "Second Advance [Member]"
       }
      }
     },
     "localname": "SecondAdvanceMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SecondAmendmentLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment lease.",
        "label": "Second Amendment Lease [Member]",
        "terseLabel": "Second Amendment Lease [Member]"
       }
      }
     },
     "localname": "SecondAmendmentLeaseMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SecondLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second lab equipment.",
        "label": "Second Lab Equipment [Member]",
        "terseLabel": "Second Lab Equipment [Member]"
       }
      }
     },
     "localname": "SecondLabEquipmentMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SeniorSecuredRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured revolving credit facility.",
        "label": "Senior Secured Revolving Credit Facility [Member]",
        "terseLabel": "Senior Secured Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "SeniorSecuredRevolvingCreditFacilityMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SeniorSecuredTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured term loan.",
        "label": "Senior Secured Term Loan [Member]",
        "terseLabel": "Senior Secured Term Loan [Member]"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award cliff vesting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period",
        "terseLabel": "Cliff vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award consecutive six month offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Consecutive Six Month Offering Period",
        "terseLabel": "Consecutive six month offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveSixMonthOfferingPeriod",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eypt_ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Prorata Vesting Period",
        "terseLabel": "Ratable annual vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardProrataVestingPeriod",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eypt_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested at balance sheet date.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested",
        "terseLabel": "Vested deferred stock units vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVested",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eypt_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon valley bank.",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_StockIssuanceCostsSalesAgentCommissionMaximumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance costs sales agent commission maximum percentage.",
        "label": "Stock Issuance Costs Sales Agent Commission Maximum Percentage",
        "terseLabel": "Stock issuances, sales agent commission maximum percentage"
       }
      }
     },
     "localname": "StockIssuanceCostsSalesAgentCommissionMaximumPercentage",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eypt_StockIssuedDuringPeriodAdditionalSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period additional shares issued.",
        "label": "Stock Issued During Period Additional Shares Issued",
        "terseLabel": "Common stock, additional shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalSharesIssued",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eypt_StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares, issuance of stock and pre-funded warrants, net of issue costs.",
        "label": "Stock Issued During Period Shares Issuance Of Stock And Pre Funded Warrants Net Of Issue Costs",
        "terseLabel": "Issuance of stock and pre-funded warrants, net of issue costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "eypt_StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value, issuance of stock and pre-funded warrants, net of issue costs.",
        "label": "Stock Issued During Period Value Issuance Of Stock And Pre Funded Warrants Net Of Issue Costs",
        "terseLabel": "Issuance of stock and pre-funded warrants, net of issue costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfStockAndPreFundedWarrantsNetOfIssueCosts",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_TermLoanAgreementAdditionalAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of term loan agreement, additional loan advance.",
        "label": "Term Loan Agreement Additional Advance",
        "terseLabel": "Term loan agreement, additional loan advance"
       }
      }
     },
     "localname": "TermLoanAgreementAdditionalAdvance",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_TermLoanAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan agreement.",
        "label": "Term Loan Agreement [Line Items]",
        "terseLabel": "Term Loan Agreement [Line Items]"
       }
      }
     },
     "localname": "TermLoanAgreementLineItems",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_TermLoanAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Agreement [Table]",
        "label": "Term Loan Agreement [Table]",
        "terseLabel": "Term Loan Agreement [Table]"
       }
      }
     },
     "localname": "TermLoanAgreementTable",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eypt_TermLoansAgreementInitialAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan agreement, initial advance.",
        "label": "Term Loans Agreement Initial Advance",
        "terseLabel": "Term loan agreement, initial advance"
       }
      }
     },
     "localname": "TermLoansAgreementInitialAdvance",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_TerminationOfPortionOfLeasePropertyAreaCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of portion of lease property area covered.",
        "label": "Termination Of Portion Of Lease Property Area Covered",
        "terseLabel": "Termination portion of the lease"
       }
      }
     },
     "localname": "TerminationOfPortionOfLeasePropertyAreaCovered",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "eypt_ThirdAmendmentLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third amendment lease.",
        "label": "Third Amendment Lease [Member]",
        "terseLabel": "Third Amendment Lease [Member]"
       }
      }
     },
     "localname": "ThirdAmendmentLeaseMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_ThirdLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third lab equipment.",
        "label": "Third Lab Equipment [Member]",
        "terseLabel": "Third Lab Equipment [Member]"
       }
      }
     },
     "localname": "ThirdLabEquipmentMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_TwoThousandSixteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen incentive plan.",
        "label": "Two Thousand Sixteen Incentive Plan [Member]",
        "terseLabel": "2016 Long Term Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenIncentivePlanMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Share Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eypt_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment.",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_UpfrontLicenseFeeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment received under license agreement.",
        "label": "Upfront License Fee Received",
        "terseLabel": "Receipt of upfront license fee"
       }
      }
     },
     "localname": "UpfrontLicenseFeeReceived",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_UponAchievementOfMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upon achievement of milestones.",
        "label": "Upon Achievement Of Milestones",
        "terseLabel": "Upon achievement of milestones"
       }
      }
     },
     "localname": "UponAchievementOfMilestones",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eypt_WarrantsExercisePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise period.",
        "label": "Warrants Exercise Period",
        "terseLabel": "Warrants exercise period"
       }
      }
     },
     "localname": "WarrantsExercisePeriod",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eypt_WarrantsIssuedInConnectionWithTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued in connection with term loan facility.",
        "label": "Warrants Issued In Connection With Term Loan Facility",
        "terseLabel": "Warrants issued in connection with term loan facility"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithTermLoanFacility",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eypt_WeightedAverageRemainingLifeOfLenderWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average remaining life of lender warrants.",
        "label": "Weighted Average Remaining Life Of Lender Warrants",
        "terseLabel": "Weighted average remaining life of lender warrants"
       }
      }
     },
     "localname": "WeightedAverageRemainingLifeOfLenderWarrants",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eypt_YUTIQProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "YUTIQ product.",
        "label": "Y U T I Q Product [Member]",
        "terseLabel": "YUTIQ [Member]"
       }
      }
     },
     "localname": "YUTIQProductMember",
     "nsuri": "http://eyepointpharma.com/20211231",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r71",
      "r73",
      "r139",
      "r140",
      "r318",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r219",
      "r364",
      "r368",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r317",
      "r336",
      "r394",
      "r397",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r627",
      "r687",
      "r691",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r317",
      "r336",
      "r394",
      "r397",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r627",
      "r687",
      "r691",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r219",
      "r364",
      "r368",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r215",
      "r364",
      "r366",
      "r631",
      "r686",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r215",
      "r364",
      "r366",
      "r631",
      "r686",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r317",
      "r336",
      "r373",
      "r394",
      "r397",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r627",
      "r687",
      "r691",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r317",
      "r336",
      "r373",
      "r394",
      "r397",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r627",
      "r687",
      "r691",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r72",
      "r73",
      "r139",
      "r140",
      "r318",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r160",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r160",
      "r165",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r364",
      "r367",
      "r689",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r364",
      "r367",
      "r689",
      "r706",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r160",
      "r165",
      "r297",
      "r395",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r221",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update201912 [Member]",
        "terseLabel": "Accounting Standards Update 2019-12 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts And Other Receivables Net Current",
        "terseLabel": "Accounts and other receivables, net (including due from a related party of $414 and $104 at December 31, 2021 and 2020, respectively)"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r52",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.",
        "label": "Accrued Liabilities For Commissions Expense And Taxes",
        "terseLabel": "Commissions due to commercialization partner for DEXYCU"
       }
      }
     },
     "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r57"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r50",
      "r288"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r78",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income to foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r76",
      "r77",
      "r78",
      "r675",
      "r699",
      "r703"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r75",
      "r78",
      "r86",
      "r87",
      "r88",
      "r149",
      "r150",
      "r151",
      "r500",
      "r694",
      "r695",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r439",
      "r440",
      "r441",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r153",
      "r154",
      "r155",
      "r156",
      "r165",
      "r230",
      "r231",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r301",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r472",
      "r473",
      "r474",
      "r475",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r585",
      "r633",
      "r634",
      "r635",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r399",
      "r401",
      "r445",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash flows used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r401",
      "r431",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r100",
      "r120",
      "r321",
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "verboseLabel": "Amortization of debt discount (premium)"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r120",
      "r275",
      "r280"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "negatedLabel": "Amortization expense",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive common stock equivalents outstanding excluded from diluted earnings per share calculation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r120",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r201",
      "r205",
      "r211",
      "r245",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r496",
      "r501",
      "r538",
      "r590",
      "r592",
      "r650",
      "r672"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r70",
      "r133",
      "r245",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r496",
      "r501",
      "r538",
      "r590",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r236",
      "r264"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Carrying Value"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r233",
      "r237",
      "r264",
      "r656"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r235",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r403",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r393",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r393",
      "r396",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r488",
      "r489",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Purchase price of acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r47",
      "r122"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, cash equivalents and investments in marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r115",
      "r122",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r115",
      "r548"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents At Carrying Value",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r149",
      "r150",
      "r152",
      "r230",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r301",
      "r435",
      "r436",
      "r437",
      "r472",
      "r512",
      "r514",
      "r515",
      "r539",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r564",
      "r585",
      "r633",
      "r634",
      "r692",
      "r693",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r149",
      "r150",
      "r159",
      "r230",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r301",
      "r435",
      "r436",
      "r437",
      "r472",
      "r512",
      "r514",
      "r515",
      "r516",
      "r519",
      "r539",
      "r541",
      "r542",
      "r543",
      "r546",
      "r547",
      "r564",
      "r585",
      "r633",
      "r634",
      "r692",
      "r693",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r153",
      "r164",
      "r232",
      "r253",
      "r442",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r130",
      "r133",
      "r166",
      "r167",
      "r168",
      "r170",
      "r172",
      "r177",
      "r178",
      "r179",
      "r245",
      "r302",
      "r307",
      "r308",
      "r309",
      "r313",
      "r314",
      "r334",
      "r335",
      "r339",
      "r343",
      "r538",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding and exercisable, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding and exercisable, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Pre-funded warrants issued to purchase common stock shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "periodEndLabel": "Number of Warrants, Outstanding and exercisable, Ending balance",
        "periodStartLabel": "Number of Warrants, Outstanding and exercisable, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReconciliationOfWarrantsToPurchaseShareOfCompanySCommonStockDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r491",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Asset Purchase Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Commercial Paper At Carrying Value",
        "terseLabel": "Interest-bearing cash equivalent consisted of investment-grade commercial paper"
       }
      }
     },
     "localname": "CommercialPaperAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r64",
      "r296",
      "r658",
      "r679"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Contingencies (Note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r298",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2021 and 2020, respectively; 33,905,826 and 18,139,981 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r94",
      "r662",
      "r683"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r219",
      "r535",
      "r536",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r219",
      "r535",
      "r536",
      "r704",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r219",
      "r535",
      "r536",
      "r704",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r183",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r187",
      "r188",
      "r219",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Percentage of concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r219",
      "r535",
      "r536",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": {
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Accumulated Allowance For Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r360",
      "r361",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r360",
      "r361",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r360",
      "r361",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk [Member]"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r186",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "verboseLabel": "Revolving line bears interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r24",
      "r323",
      "r653",
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "terseLabel": "long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument Decrease Forgiveness",
        "terseLabel": "Debt instrument, loan forgiveness amount"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r23",
      "r24",
      "r351",
      "r651",
      "r653",
      "r667",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument Description",
        "terseLabel": "Debt Instrument Description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r315",
      "r326",
      "r327",
      "r560",
      "r562",
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r59",
      "r325",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Debt instrument effective rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r59",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Annual interest rate on term loan balance"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "auth_ref": [
      "r61",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format.",
        "label": "Debt Instrument Issuance Date1",
        "terseLabel": "Loan proceeds date"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r60",
      "r317",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument Redemption Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Term",
        "terseLabel": "Debt instrument term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault": {
     "auth_ref": [
      "r142",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.",
        "label": "Default Longterm Debt Description Of Violation Or Event Of Default",
        "terseLabel": "Restriction of the right to capitalize a portion of quarterly interest in the event of a loan default"
       }
      }
     },
     "localname": "DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r461",
      "r652",
      "r670"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10040.0,
       "parentTag": "eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue - noncurrent"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10030.0,
       "parentTag": "eypt_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r467",
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities Leasing Arrangements",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Maximum percentage of eligible compensation matched by employer"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r120",
      "r286"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r141",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives Policy [Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "verboseLabel": "Disclosure of Product Revenue Reserves and Allowances [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Share-Based Payment Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r8",
      "r19",
      "r31",
      "r138",
      "r305",
      "r307",
      "r308",
      "r312",
      "r313",
      "r314",
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due From Related Parties Current",
        "terseLabel": "Due from related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r136",
      "r454",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory federal corporate income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Personnel costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "verboseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "verboseLabel": "Unrecognized compensation expense weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockBasedCompensationExpenseAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r86",
      "r87",
      "r88",
      "r149",
      "r150",
      "r151",
      "r154",
      "r161",
      "r163",
      "r176",
      "r252",
      "r350",
      "r357",
      "r439",
      "r440",
      "r441",
      "r474",
      "r475",
      "r522",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r694",
      "r695",
      "r696",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r525",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r320",
      "r326",
      "r327",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r389",
      "r526",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r525",
      "r526",
      "r528",
      "r529",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r320",
      "r374",
      "r376",
      "r381",
      "r389",
      "r526",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r320",
      "r326",
      "r327",
      "r374",
      "r376",
      "r381",
      "r389",
      "r526",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r320",
      "r326",
      "r327",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r389",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r531",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r568",
      "r574",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease Interest Expense",
        "terseLabel": "Interest expense on finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r571",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease Interest Payment On Liability",
        "terseLabel": "Finance lease, operating cash flows"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r566",
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease Liability",
        "terseLabel": "Total",
        "totalLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease Liability Current",
        "terseLabel": "Other current liabilities \u2013 finance lease current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease Liability Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r570",
      "r576"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease Principal Payments",
        "negatedLabel": "Principal payments on finance lease obligations",
        "positiveTerseLabel": "Finance lease, financing cash flows"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r568",
      "r574",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset Amortization",
        "terseLabel": "Finance lease, amortization expense of ROU asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Finance lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r577",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Finance lease, weighted average Remaining term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r322",
      "r348",
      "r513",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r224",
      "r256",
      "r258",
      "r259",
      "r657",
      "r740",
      "r741",
      "r742"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable Allowance For Credit Losses",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedPeriodEndLabel": "Accumulated amortization at end of period",
        "negatedPeriodStartLabel": "Accumulated amortization at beginning of period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r276",
      "r277",
      "r279",
      "r281",
      "r632",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r279",
      "r636"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "periodEndLabel": "Gross carrying amount at end of period",
        "periodStartLabel": "Gross carrying amount at beginning of period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r279",
      "r632"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net book value at end of period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsReconciliationOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Assets Remaining Amortization Period1",
        "terseLabel": "Finite lived intangible assets remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r120",
      "r328",
      "r329"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gains Losses On Extinguishment Of Debt",
        "negatedLabel": "(Gain) loss on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10140.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HerMajestysRevenueAndCustomsHMRCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of United Kingdom.",
        "label": "Her Majestys Revenue And Customs H M R C [Member]",
        "terseLabel": "United Kingdom Tax Authority [Member]"
       }
      }
     },
     "localname": "HerMajestysRevenueAndCustomsHMRCMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]",
        "terseLabel": "Impairment of Intangible Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r135",
      "r479"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "U.S. operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r201",
      "r204",
      "r207",
      "r210",
      "r213",
      "r649",
      "r659",
      "r664",
      "r684"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r135",
      "r479"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Non-U.S. operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r455",
      "r459",
      "r466",
      "r477",
      "r481",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r137",
      "r162",
      "r163",
      "r200",
      "r453",
      "r478",
      "r482",
      "r685"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r451",
      "r452",
      "r459",
      "r460",
      "r465",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r450",
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Income Tax Reconciliation Change In Enacted Tax Rate",
        "terseLabel": "Change in federal tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Income Tax Reconciliation Foreign Income Tax Rate Differential",
        "terseLabel": "Non-U.S. income tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate",
        "terseLabel": "Income tax benefit at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Income Tax Reconciliation Other Adjustments",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Income Tax Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesDifferenceBetweenExpectedIncomeTaxBenefitAndActualIncomeTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other.",
        "label": "Increase Decrease In Accounts Receivable And Other Operating Assets",
        "negatedLabel": "Accounts receivable and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r119",
      "r628"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r90",
      "r199",
      "r558",
      "r561",
      "r663"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r113",
      "r116",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service I R S [Member]",
        "terseLabel": "U.S. Federal [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r39",
      "r272"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory Finished Goods Net Of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r67",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r68",
      "r127",
      "r175",
      "r269",
      "r271",
      "r273",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r41",
      "r272"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory Raw Materials Net Of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r40",
      "r272"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory Work In Process Net Of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write Down",
        "terseLabel": "Provision for excess and obsolescence inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease term expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Operating [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Additional lease renewal option period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Original lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r55",
      "r133",
      "r206",
      "r245",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r497",
      "r501",
      "r502",
      "r538",
      "r590",
      "r591"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r133",
      "r245",
      "r538",
      "r592",
      "r655",
      "r677"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r133",
      "r245",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r497",
      "r501",
      "r502",
      "r538",
      "r590",
      "r591",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r54",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Line Of Credit Facility [Axis]",
        "terseLabel": "Lender Name"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line Of Credit Facility Commitment Fee Amount",
        "terseLabel": "Upfront loan original fee payment, initial advance"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line Of Credit Facility Commitment Fee Percentage",
        "terseLabel": "Upfront loan origination fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Line Of Credit Facility Expiration Date1",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line Of Credit Facility Expiration Period",
        "terseLabel": "Loan facility term"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInitiationDate1": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility first became available, in YYYY-MM-DD format.",
        "label": "Line Of Credit Facility Initiation Date1",
        "terseLabel": "Agreement date"
       }
      }
     },
     "localname": "LineOfCreditFacilityInitiationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r54",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line Of Credit Facility Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line Of Credit Facility Maximum Borrowing Capacity",
        "terseLabel": "Senior secured term loan borrowing facility",
        "verboseLabel": "Senior secured facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line Of Credit Facility Unused Capacity Commitment Fee Percentage",
        "terseLabel": "Unused commitment fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by US and non-US government sponsored enterprise, authority, agency and program guarantees for government insured loans.",
        "label": "Loans Insured Or Guaranteed By Government Authorities [Axis]",
        "terseLabel": "Loans Insured or Guaranteed by Government Authorities"
       }
      }
     },
     "localname": "LoansInsuredOrGuaranteedByGovernmentAuthoritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guarantee by US and non-US government sponsored enterprises, authorities, agencies and programs for government insured loans.",
        "label": "Loans Insured Or Guaranteed By Government Authorities [Domain]",
        "terseLabel": "Loans Insured or Guaranteed by Government Authorities"
       }
      }
     },
     "localname": "LoansInsuredOrGuaranteedByGovernmentAuthoritiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r319",
      "r324",
      "r326",
      "r327",
      "r653",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "terseLabel": "Carrying value of loan"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long Term Debt Fair Value",
        "terseLabel": "Fair value of loan"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long Term Debt [Text Block]",
        "terseLabel": "Loan Agreements"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r9",
      "r56"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds At Carrying Value",
        "terseLabel": "Interest-bearing cash equivalent consisted of money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesCarriedAtFairValueMeasuredOnRecurringBasisDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r180",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r115",
      "r118",
      "r121"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r79",
      "r82",
      "r88",
      "r92",
      "r121",
      "r133",
      "r153",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r169",
      "r201",
      "r204",
      "r207",
      "r210",
      "r213",
      "r245",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r524",
      "r538",
      "r660",
      "r681"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted and Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Tax years that remain subject to examination"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r201",
      "r204",
      "r207",
      "r210",
      "r213"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r569"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail2": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Other current liabilities - operating lease current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetRelatedToOperatingLeasesDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r572",
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating lease weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r577",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r57"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r80",
      "r83",
      "r86",
      "r87",
      "r89",
      "r93",
      "r350",
      "r549",
      "r554",
      "r555",
      "r661",
      "r682"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r57",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10130.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Long-term Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid In Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments For Royalties",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payments Of Debt Extinguishment Costs",
        "negatedLabel": "Payment of extinguishment of debt costs"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "verboseLabel": "Share issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Net settlement of stock units to satisfy statutory tax withholding"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r103",
      "r105",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments To Acquire Available For Sale Securities Debt",
        "terseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r373",
      "r375",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureRetirementPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r403",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r29",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r45",
      "r46"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate Plus [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt",
        "verboseLabel": "Proceed from senior secured facility"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r103",
      "r104",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities",
        "terseLabel": "Marketable securities matured"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r107",
      "r434"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Total cash received from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r79",
      "r82",
      "r88",
      "r114",
      "r133",
      "r153",
      "r162",
      "r163",
      "r201",
      "r204",
      "r207",
      "r210",
      "r213",
      "r245",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r495",
      "r498",
      "r499",
      "r503",
      "r504",
      "r524",
      "r538",
      "r664"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r291",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r49",
      "r287"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Gross property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r289",
      "r592",
      "r666",
      "r678"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Long-lived assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r289",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r383",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r383",
      "r586",
      "r589",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r110",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments Of Lines Of Credit",
        "terseLabel": "Repayment of senior secured term loan"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Payment of long-term debt principal"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r448",
      "r630",
      "r724"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "R&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r282",
      "r283",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research Development And Computer Software Policy [Text Block]",
        "terseLabel": "Capitalized Software Development Cost"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r12",
      "r22",
      "r122",
      "r125",
      "r707"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted stock units [Member]",
        "verboseLabel": "RSU [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r357",
      "r442",
      "r592",
      "r676",
      "r698",
      "r703"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r149",
      "r150",
      "r151",
      "r154",
      "r161",
      "r163",
      "r252",
      "r439",
      "r440",
      "r441",
      "r474",
      "r475",
      "r522",
      "r694",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r197",
      "r198",
      "r203",
      "r208",
      "r209",
      "r215",
      "r216",
      "r219",
      "r363",
      "r364",
      "r631"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "positiveTerseLabel": "Revenue",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r96",
      "r305",
      "r307",
      "r308",
      "r312",
      "r313",
      "r314",
      "r705"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue From Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues From External Customers And Long Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty Income [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r187",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Sales Revenue, Net [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Significant Components of Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Difference Between Expected Income Tax Benefit and Actual Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r401",
      "r430",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsCompensationExpenseFromStockBasedPaymentAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r401",
      "r430",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Compensation Expense from Stock-Based Payment Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Assets and Liabilities Carried at Fair Value Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r276",
      "r278",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]",
        "terseLabel": "Schedule of Net Book Value of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]",
        "terseLabel": "Reconciliation of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r17",
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureInventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r97",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule Of Revenues From External Customers And Long Lived Assets By Geographical Areas Table [Text Block]",
        "terseLabel": "Summary of Company's Revenues and Long-Lived Assets, Net, by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.",
        "label": "Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Table [Text Block]",
        "terseLabel": "Summary of Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r403",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r410",
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Stock Option Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Key Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r65",
      "r130",
      "r177",
      "r178",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r343",
      "r348",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r358",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Reconciliation of Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Irrevocable standby letter of credit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r195",
      "r196",
      "r201",
      "r202",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Geographic Area Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling And Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling And Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing Expense [Member]"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Ratable monthly vesting period",
        "verboseLabel": "Ratable annual vesting period of equity awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of Stock Units, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of stock units, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Stock Units Outstanding, Ending Balance",
        "periodStartLabel": "Number of Stock Units Outstanding, Beginning Balance",
        "verboseLabel": "Non-vested deferred stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Nonvested, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Nonvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of Stock Units, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Stock volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Stock volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of common stock, authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available for grant under the Long Term Incentive Plan, including forfeited and terminated awards transferred from the 2008 Incentive Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of Options, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Options, Forefeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "verboseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding at January 1, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r412",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options Outstanding, Ending balance",
        "periodStartLabel": "Number of Options Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r400",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsDeferredStockUnitsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfRestrictedStockUnitActivityDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsTimeVestedRestrictedStockUnitsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forefeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r403",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Contractual life of option grants"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r427",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Option life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfCompanyAppliedBlackScholesOptionPricingDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding at January 1, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Common stock vested during the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Price of common stock purchased twice a year under ESPP, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r126",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r130",
      "r133",
      "r166",
      "r167",
      "r168",
      "r170",
      "r172",
      "r177",
      "r178",
      "r179",
      "r245",
      "r302",
      "r307",
      "r308",
      "r309",
      "r313",
      "r314",
      "r334",
      "r335",
      "r339",
      "r343",
      "r350",
      "r538",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r66",
      "r86",
      "r87",
      "r88",
      "r149",
      "r150",
      "r151",
      "r154",
      "r161",
      "r163",
      "r176",
      "r252",
      "r350",
      "r357",
      "r439",
      "r440",
      "r441",
      "r474",
      "r475",
      "r522",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r694",
      "r695",
      "r696",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r176",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfNetBookValueOfIntangibleAssetsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSegmentAndGeographicAreaInformationSummaryOfCompanySRevenuesAndLongLivedAssetsNetByGeographicAreaDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsSummaryOfInformationAboutStockOptionsDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Stock Compensation Plan [Member]",
        "terseLabel": "Stock Compensation Plan [Member]"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r29",
      "r30",
      "r350",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "positiveTerseLabel": "Employee stock purchase plan, shares",
        "terseLabel": "Employee stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r350",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of stock, net of issue costs, shares",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r350",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "terseLabel": "Vesting of stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r350",
      "r357",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsStockOptionActivityUnderCompanySEquityIncentivePlanDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r29",
      "r30",
      "r350",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "positiveTerseLabel": "Employee stock purchase plan",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureShareBasedPaymentAwardsEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r350",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of stock, net of issue costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r357",
      "r402",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "terseLabel": "Vesting of stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r350",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r35",
      "r36",
      "r133",
      "r228",
      "r245",
      "r538",
      "r592"
     ],
     "calculation": {
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r335",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r556",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r556",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r556",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r556",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r593",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r25",
      "r654",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Member]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r25",
      "r654",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentMember": {
     "auth_ref": [
      "r25",
      "r654",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments.",
        "label": "Supply Commitment [Member]",
        "terseLabel": "Supply Agreement [Member]"
       }
      }
     },
     "localname": "SupplyCommitmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesDisaggregationOfRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Research and development tax credit carry forwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyServiceMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology assistance, including but not limited to, training, installation, engineering, and software design.",
        "label": "Technology Service [Member]",
        "terseLabel": "Technical Assistance [Member]"
       }
      }
     },
     "localname": "TechnologyServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade And Other Accounts Receivable Policy",
        "terseLabel": "Accounts and Other Receivables, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r322",
      "r348",
      "r513",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r153",
      "r154",
      "r155",
      "r156",
      "r165",
      "r230",
      "r231",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r301",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r472",
      "r473",
      "r474",
      "r475",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r585",
      "r633",
      "r634",
      "r635",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLicenseAndAssetPurchaseAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityEquityFinancingsAdditionalInformationDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r449",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued penalties or interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual Or Infrequent Item [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual Or Infrequent Item [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLoanAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r181",
      "r182",
      "r184",
      "r185",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReservesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r575",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesDetail",
      "http://eyepointpharma.com/20211231/taxonomy/role/DisclosureStockholdersEquityWarrantsToPurchaseCommonSharesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://eyepointpharma.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r725": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r726": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r727": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r728": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r729": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r730": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r731": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r732": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r733": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r734": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r735": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r736": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r737": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r738": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r739": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r740": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r741": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)"
  },
  "r742": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405"
  },
  "r743": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r744": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001564590-22-009929-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-009929-xbrl.zip
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MH4M&.(D4>_U__<J>/F%SE.,W]94Y#O7D5_D=[KU2,V,QY[>=B_LR_@>4\<@
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M$JWSEBM1(\FU\6>H"B%43^C P/$KXYU)OSCZ31-QC+ H'9*J&DX$(H&8(.*
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MHZ "K.><,9?'./0M4:/+'3*?>,W]#?4Q5\6"U^A;5GO-BX[F_+B[;?[7^('
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MXPX;,'2+N*QA#-U<+VB\I5M7P*4,P^VY6,1XEF6O/=MO,_<;=9A-W+L_+MF
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MX)ICTD,OJ+98$U/D3E?DE"DROPYCE,P;\E,QE@(VI>/ -("F@M&-"^\ W&\
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M.>G';&XN=D")D5$CHV\KH\41D-D86/<' \JQ*-\-@9>N&P*K1KRV5+RJ&X#
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MRV)IY-/(YSM[IA,2NH1G.O'$V^[)YM#&W0(A-L:ND=J"2*V^^)UP1CHN;6$
M<^JA&PY<@C\:(3="OI[W3[):\N()9C-Z9:-I4HPMD&4U\<9GZXTEL,;MA[9-
M/5!Z?DW7G8F^7_B<VD1,0/%[9Y^H1CN>(*CYV@?99D$=VP-*,Y@JHS.;Q38C
MGRON_$KY?/W.+WOZQ*DKTW*(/AM:+O-^MGQWG%?QP3V?]SY6R^7]CQPN?\3[
M=BS";;[X9GW'QRZQ@U+7]P//#^B.%?@MVA6_[5Q<W:(Z@/]VK"[W!_I7_&W_
MM&+I#]6=+[]^G.AIQOI?F='__:C_!_/ZKW\5?LAM*O G^4N?$D?RVZ\?'?8
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M'.V?M?;OS:NOM]=7N]9YW:J6#P].I\8W+D!MWV6.5=X[GB,_+Z"&_HH"_ND
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MVX\\F+$?.6".@]M;&] M:5T[8_IF]NQ=Q/HE'7L?67M)S]Z%XV=U;%[D[I;
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MHC 3E4X,&Z"$0[OPBEY4BCD!!!ED@EN2/?3%@2"]_E@@2P0B 6Z_C:6!>:"
M.)@!R\.D-KM6 /0O8<:R<""W!SV56(W9N-$GDWB@!:CRX@V&KESS59EO_#
M_U[U;>*%^JRMK=805"8F!_!O% ].[FG2*/>Y/AJ%NYC,(]&O:#*.-XR_1@23
MFY]AM $Z1=EH76)&/I1963"PAW&>DX*L5QBT-6AKT-:@;;[1MCZ. %$Z(PRQ
MQ!@9&5L9#F5.*!(Y4BO A-'UN>55H^N-KC>ZODBZ7A^^E>[)>#8&'B=>DQF
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M-/MULB<A=' MGES$$YQ_R3RDOA5Z21YO+&JN*F?+(_H8EXN5KQEW2FC]HS?
M!IT0\$'&\0XYL0-FJQRO:A/>QO4U3I'08.UCS!>F 1_;@]>^P) (48I.<(J
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M6+E/O)[R1U(Q"]*UP 4UYMF<$D&EZQ(OHXVTBR "N<ZGW8ZQ:&>]XH?WJ67
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M(D).@P^YY6^##P8?##X4#Q_ LX!^P-# 21 AU468$![JWZZE-R ] 4:YB!'
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M-SVD7A14U6>@(RS-+:3=*?:LE/+:@CG![88A&U*7>9@Q'#A2)J'06?6&G-&
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M3C8\+C7MS'*74YFO:JZSDW-!<A@<$-@M?0"&-[_,_=NCIW0'QM.7&D5!";J
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MCMG;<87JGWOB[R1N\J7)$0^]MZX\B=O-CLA7]2X;KVUYWE=$U\ZT7-;C JD
M)KK(%R1P)MUN@EHD[^'^+PV< OSOLV1V\8@-K/X>A#>2!+PA6TLT"ST'5O9U
M'@2*4*IF\1<9<%@?' >M][_?M>^$5FTOE]R=N1+!*^'>CO.0UT&,V@!$X'HN
M9G@S/(ZLAT6RF[[I8Y2T(K"XC^_#;HO7Z2OI3TGQ:Q8KY."0< 2&DWDN'H5
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M))I"Z0@8$LD1XO4YV4ZY77,^<.I:!Y"X*\J\YT<N-A'PL#(^>-E$<8[E2+/
MOQ=^^24#;)S8?W@XBE_R&],,789.3+T'\*#DE!MX8_:_C]@QW3%4"$" ? AH
M.CPJ<U9/\E*!E/QOHR03* #)#95<?6 -L+;1Z;\LYI #TYS/(32YY]WGZ^%;
MS_D?**J/QH)2T)G<5<&7:P6FV:;X"DK),NZN&48R?*B*MB+M+91>UYG=7>!
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M\NE));.ZLD$S> +''8EZF(\8"_^*]N'RFC2?(=\0KB*_I46.8\8TXUDI=U6
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M<Y=5(@6?64=>4UCW['S 3-90! 3 /1M=S6VET(CW@?!_#EOIH<QQ$T$ B?O
MA$]UD#6?,,8](-]DOF*'P1&_ANTK*W!MK<\T^"O"!X NJ72-'=4'<3&C:4V&
MK$08%WJO\8+@Y]7$O\#X[Z21LG2)Q==QKVGV8ZDMW=__P7L.CHQP9DR+TOH:
M[)/Z&B6.5"9#NTG9Y I2R;#ERE$K#YX47!G/%0L63=CF0.>AZ5=:XBT_X^>>
M(W):AW23*!1AKS/(6.#@*^MH:&+PF6OATB @23+X5XG;>$IBQ^>2 _5D\-9L
M7H1(N;$ I"X:<^VG<(0#E@'_TH#H_N6+X<!5;7@V8[UYZPCEW>1ME'M+.U7I
MDD2K R2=B^9$[I:;4LBJ2U_QOA1R)=5"]0EY97)%^;\NM=$R_5/R![1%"N^-
M'J?7V<'>6F21%T7+2A_JVI>T<-H%;&AY_L&R81J9Q03%]-.VQ)+2H _]M"WK
MA-N,K?=[OJ#CFVLD+F(DU4C VOJ>U-Y5M1TSXBF?1HH^ 4,&7M,@)(P,:<CI
ME4HN-N2YY7!Q=I5W."CX>T$@ MG;ZSS1DZ)</0*RV$T.@P%(. 5EZP%G*FTO
M^@JF_"F_+<3A",6/_*4' <A^_:26!L62Y)FP\$1K'2ZL:GM6TZV._3E57NB5
M!CK<U\5O5QJ['""Z;+Q*2>RV+7*/33+-KP&JA*^1Z_L4<FJ0V> "0W8O2-SW
M,/EU[YRK(&,_I"L=Q!)TJ$178%UI!#&J04NCX:6.$$K6/^UV.>?C5B!' ;I4
M3<BF"6="4>JM4-)&<PN3NE5XI]#(\ 00,T,#[]1G_B4['X")I]+T\ X;4WTA
MFGF8+4YXZ0EN)-.+LK&@<V5P[Z,==>R-=:.8D5$>G1QI8:>@D=2U TM=OZ^
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M0_B!'3>^>_Z&IX/]QT_W'JM<42G!W#LD*DE29UJ!:DA8_9/G;WG[\Z%G4M[
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MXVGF<D0+,AE4^$Q2\/(:IC>/T SXV6U7PE=CEG!9)OKH&]E3XB><OGH1\9U
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M_=W&R!FIK!7>$OA+M883PSH4#0K5?ATA*KG>;^:-%<'*8=^ 8-&$.MA'<YG
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M1"/"MU(38/JEC7X3<9P7YREWT6ENG=MPS2JEX:)@M'NWP?>OPEI3=!3[I!I
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M+>[TRS(1^\-]WGL$&8E,R<J=8''Z,) *_6CLF\GE+R.3-ACEP52HD@*?E,H
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M^:7.%)_JVVQSE5!K.)S@2I(8Y&[>(J5E@$Q"\):)+,SAC >@N.-^Z;^L/W4
M(%$IT[5-+#-^53Q^_RZ>B"V_1)(&[>WEB6GM2X3@.X@PYD^UXZT]1IX^9-XO
M!ITY.$D5H<8-R=%Q<LF+A,-B(])_#(,-RMX8Q' 9B+>16SMO.,R,JP_*$^T
M,4^HA!*=2*T(PCI-SQE\?C04OK)0F+.<X[-LM?^!"X\7&!]:<#T=DG7;\K?W
M6FG2G![K88696-LBH&KEOAVB#"O/R**4OKEYLR47;5>AK4#I\.01S6NY(-%S
MY+.CMENRC"<JC ]-7AIT O2UMB2 2V&)L<@TE,#ZTCY%O3==CY-G4A)\&YI
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MW>AJZC" : #18:88:+ VQ\G%RRMYLFP+<\>2!(&Q%'KI1UZ<EU2]%W')H@T
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MDTA>L$!&?Q9N6#B9J;F\]FKW#GKD*?A."UI]25\E; %%D1#R&%QNBO119KQ
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M:/.4&NA)&0]531(]DOXJ='CBV:!IL]ZT]UF9(&+N7B.V?_SB/"P S..3!P6
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MKG]\C*,']UXON/_D8/%X7CZ;"D/R@8NPDFUUS8SL9%2.U<O$(Z#$9BF%]9B
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M+-?L(,."^S?@;HK%C&VUYW DN K*PS-[B*JX0V3('1$C+.Y=3DG<NV+IAV*
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MNW[3<Q>9/R8Y^W\C..C//C;>(#@4KER+G^:'3X=#IV3SN%R\[!LL.VY_1H8
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MR5=1D!N'[A\];9O&O&T%44S@B0*G<"$_MWJR(-L!-L1*#$U\U:<'$ NC>Z2
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MV4%XTWJF7(.Q7J5C1E93HX0[9>O$+RI:0<Q3OQ1/_LQU40M*7%RW-FD(J?<
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M;LHA0QF4%,JY=>R"#.U/^9K%V&7]DET"Z+]& *7Z-.I)7"EPAQU]O+!JBYO
M=W:Q8N =W[WVA4*T 7I[2#"7NB3J"ZL^%0-!TS!<US@1ZN:XV4&+-KB;>E\Z
M8=SQHO>$4PC?W4@%+I(]<;30V%6BM'Z@+),-9G!D7Q\08?IEGM:/CA;0XO*5
MQ_*X$6C,([R8WM'FKWB<0O]9W%_@Y MBYHE+T%]FZ5F6T IS@AA2<C$-."I
M_)W6D"'*%#M!AOPHIGFEC@XS$S \@(3,(SZ:S02O':Z(/+JNKNM!0[*"89KC
MSK#L+1<2@JK/T[ZT7;_67DG^0W@EW?,;,LDY_3=H!\A;Y?'8<!% S-FCJV@9
M6T_,P<$*>H&*&E2^"!\#%^?O=A'_HIQ?U2]!@+\EXR7'H@%C@[%2%]_1A\AU
MA#2W-N*W[[Z[LC[BS S=MUSG],VO?^-E&@V )" M9KU#^5VVT B('^^%,D^4
M^"-2QO2O\D)*X 5<2.+H] VF\G+F>8I.=  5,O.OS3>*;G'7ZL0+09] +P[O
MO"P3*E-<HWBUVZ)<;^MZ[:L@#/#0+Q&V5?D_RN*C*X>A-5[6ZYH[^EI?[90H
MG!B(UOP-"XMHX=?..=$ TUDN[(7.=3RXL-?,@@!8 S0 D(L:4?X*M[&76NKH
M"I115-:SY" '-TTH#FA,3>1C5V/=RYJ-^4"Y[B&O(NQUNO5O5EW-0%9/GCUA
M^!*.$9-T*U(@8OKHWTBG[>RSIVY[TJ+P3,FN*-ITJH@0 6]A39[:-1MZS )3
MX:HP&*U#6+FN/"2*24\Z05V]X@OE[PP3@*@S)^5+: !Y@5)!N$O?^;UX)UMT
M!NL:7-=\=%UMB<S.9#438(E#T: :QCB% :NYL("M)#@]BY@\NT5[Y$6_%T$7
MA0'X@6(+BJI;UZUJG%S+NZ*=M#B%E+60;_[2+1O_&S9,HNLD$F!B/ZV*5!VW
MOLIOZD) 8@+T>-R! .<D@V>'D6D7+.KD,ENKM[C[NV)U!D>$HQ.0=)$0,P4?
MZ491\FG>J,R7KF1GP;-[9+00-9S\+$$,STPKQ6H^$T^B*UIY1E/O:G,64']V
M\=&Y?4B_1X%N?5CPJ0;&1!)Q1#74EHQPJ9!"X9EU+?X-PK0==)C4%0AXXU8*
M[^_<>*.6<;?5OTR( O$$J*G.BH(WGB-+)1.]]+XQ<0N-[0G"XY!3"-KW>\6)
MR3TM??"C%-^:KW%,L^?;UU.0I6'O9N;G8-LJ-F&$"!_T\E78.*MWD+VC=YJ?
MJ$W0<1U3Y"OX88^++6U+@RUI^'QE"&X%@QC^M&(EAX_%;^'8A0&;UWW7*H&6
M-.EP\]+"FJSW0#?W:X2QNRX&]+%"7&]DR]=BBX3!I92OZ^Q0.7YS5J41CTH6
M/Y9BB3N:BPVP/*EUDJI_^A"BZ=;M&UO$5JZXX1+G+A?SF!0R&NR<!>K9@N 8
M/A.FLE3ADB,R6(I*W"A<K\@Z#/+_B%/L2R**4,N\^O/KMR,AE*^W(9"(XN:B
MLWS-VB62FS2FE0$\DOUB16%M=K&T9:)8M7EHN3RP8BK3XZ7@*+L31,-AD3 '
M! 2C6>D#$@)#25!H WIHU8TCM\PM*10,$UL2-A-F VFJ05FI-S:3LKFCYR*B
M:O&]JD@T\1OB])66>E1D?.XD;Q.&)^B$;"-F4J/7]'N+K<JCV)7TC79%ZT]+
M=',0$BW+"X :MMO(6&*=+N;2D)5U7*H4F1M<^!SNF[KWZ6^B("L? =HJ25XZ
M927@?K[#J*;P$"VJI=V2A@8IY!YV-!BQA2Y]1#N1-H;'&68ZU-%)B/*_(<[>
MC= "I](SMA>2P,&=1]\!;!%??BS=,_F.EUIJ'/LN/R>FBT&A#>[4*,"EYW04
MA4RE?"Q# D=&;<#G*E'^ QTUM/G25D$^<X &IQWXC_?OLH@'51#B2B&%UO+_
MR^>H!FA6/1FXSU&\RF"?C"K7AK8*^MJ?7=5;*K5<?'"K;<5(.#2=O_[U^>+F
M$E,4"Y!>NV <"%HNK7\[+OG^H3. 2EKGC19L&/>IRL$85""R+Z.DRU"7)&T0
MGB?*OT2#6KQ*^93B.F22'+UAK 8:1=VW##^)DB;>"1J P7/+5OJFDI!Y'C@M
MM+3D]D:9N=:!"+5C))@-.]$5V"RE[SIZ06YRY1 X@6).D>CH(*XY.2%C'H7%
MG(2B&<62 Z&J7WS?ELBTHC$-5-RXP>X%<9<26QE[+M<6LC3 /-9-?AMHWFW\
M'JY77$>L'G>8FZQ)Z;"\G&$=LTKU@/Z\/-S+#';J<N9HE\K8_1HEA$(.)#JR
MQP_-'VVQUL6-+9?X3J7;P/"G/PE[TY)Q,O[?7SWY%8FLLB2!CN()__,>HE%_
MUN?(-RX0(\SWK?NC_>-/-)EUMZ6%)2]$WM#P_S/5,+V;?+AZ[Q\C'Y9=N=T6
MG;O N[&PMTV^_]4QWX_'?Z=/%#;VOLVCD=?-'_\O6KGZX1LIL>X+7:@_/N@4
MR8%[-G"Y_I]?=^M[%^B;RV^^>10+=,?-^5^#2?^OG[6:4P[=@Z[A&L$OUB?R
MPF_)7)2*PHMX(E]J4I_G_(Q>CY/S^V?/_O5/D=5UY 2=[=U)%N_(]DX>A>GE
MUZ\]X?\];(N&7[&$V&TNT5W+A+6M:SK/1:_5.&22"5YQU#-1YK="X#'<5OJ_
M!O\'*4W_)4'^/U2>/^XC^>7%^2S-9VE^BC?G\0GSUKF/@A'^8U]Y-T7]KW&,
M) FD^/ *=VK/(OV$#^8LTF>1/HOT,Q'I')<"#3IX"P]Q5&NJV'26VR=\^F:Y
M/<OM66Z?E=P6C&TMJO,UE%R7.MO8IWSB9ED]R^I95I^'K$;;92L]J5(:RS7S
MDL5'5:Y@8>DOHNI;J1KPM<>:P#1$\[AJ5VC?*GN:_/#0)X52?D8'F]7&"1_^
M66W,:F-6&^>A-EHWJ'(4R:RX K. /LEC-@OH64#/ OH\!'1DUZ/+75O2I9V^
MJ!B#CF',#/8EJ2>-ZGS]WR\?*-5/$#_D#9?&:S4S$Y%P96<@_<@"BX1"D0,Y
M,H*L&+9H1$6A*#^^^%BL/B[I6&2+39/WTCZ?+[%!T[@X23>2%B ES472++QO
MBANPKD1P9^0FT0IO$TBL:#L-;)*;"-N VW;KL1523.@A<F%<^2IL&CP!I0;\
MQ,EV.6J6:3? +6DX2ICJ(YCTT)E XP4T=0K%HU#5Q^%T)M!W3K_H^$W$>\63
M%"R9:.K#=J64I2(B&!LU/PQ.%%X.6#D^S.-NTPCN;?K ?@AG07@*IAO)U6#$
M,5D+FT(67/^,91+W'@/N@ YC0BGI6^9P?HH4?FEP!B)2#AOKZ'8G?5Q\H;,!
MJMW&,=X2&C-\-T0@>U+.T*63QFU:<V0J ^%3XZE'XUZ@N+'"-R8I3X6_B;XN
MGTF@8P*<86.1![6K[STJ0PD5, '#K"]XG=QZ$6CYHIV>!#J*\3[N;0. O$F[
MT.X70!\,S5G4$RTW0$(P&Z"C,-$,-]IE2@ZBF"YS$?VC-9:^O)LQ%]'/?L9I
MWIW'YVA\,!/8K(8K&+S_K@;OXGW X=X62R"9D4IJN:.R"6"Y:$F;MA@"HCFT
M#<"V-CU:K%O0-1=B-C Z*_]+F+:TR9BTNB!U0&WM^DI581;H!QG_T'[*&/E2
M?[W2?S.T\2IOM_+9Q<>"6=/0A$VZR@D_R6W>D"(L=-Q.V*D;:;SCBE320<6Z
M%V22S#J7S53(&,^)6R/73OXL]HMQD? [U,(P$)K!E[DCKQ%@E8QG? WH,J9]
M8WI>0=]5$C"%)E ,$C3[*X)S72HF)-LF!JIL&SN!^7LWY"^8PF2W_6:#S]*U
MK+JM>5^ -E<=U@>[7;KUM>_@-QAWS$2!9;@E77"II2'#@=R\B$BC!2N;\0P$
M(LDW;BB&FST5>,P,0^B9:&1('N$[,22-"U?9"5W?"8VAP9XP)FB%IU8#HFGS
M'K-@-<+<M$ULU'XE$8&V8<;KSJ\9>D)<3+X2 Z]P %7+T&W<N&* ?$(8&)QZ
MX/"WT9%HU9WB8X:6T'S<X!(\@<B)]<O'MGB!?[;<,5O*0607MR\Y>N!)"VFN
ML/K;X9./P35?E8HJR0R%@M>TJ'J&?P.FAC=0W2>WVP=',#(\@9<$WW$)9QVX
M7^BH12F*00/1":&I)KC2P:$8NA 1IA>O%E .W:KW1(9'?%O9J,$@DY$QGU23
MWU:+BEY*Y_^0*;I01.R4#$?XM*N;NF18L2#:)F"%/.]\P>ON^61C:DB&Y-,!
M\@$)P^-#E^#N92'H\0(\?QY;4?G ,?2_]+2HQ@S>"B8[,S#G<6]WO@0V9"5@
M3'0X<NZMS2'F%.A8P;*C\<2A#CU)T_J&*1'XT#6XU&ZS47YP,,CPWP%$Q!R;
M#-*1X&?7BQ*(2-J,71:M )-[XBG[NP>Z5P"U@ E^ .321;VYV-<K\N6$K";!
M7(?>;'H@?8I4!J>#)R)O2T/F M[W BK/@(<]BGVFV-]8T-:U=ZS%Y$(B&OB)
M/:KT!A@M"?U]"&4.+E]: M5TL18U%_;MMZ_I Y\9*#QQ<*C?/GYPJ-D'?FQV
M_#_-!_X?[0#=XYJ(J&\5\C06?@+;3%8?1#3BD)Y=$A$HP4<2;".FBQ82C9O<
MH%C9&O%$)AIWC85_WBFE4_0*C6C?.28US00A; ]:E.5AK)P@9>./PY*#I:X:
M(X5A:E*F#X8OZ6H2_HQ/0Y^'S>WY"?#E;P%]NKB*[!DF/P (.IAW(?H%&XH\
MGX9.I+@LG&7J5*DQW7,MB2;16S+[6RRJ"SQG_-F?X'3"SA%J]PH4N3537!J6
MEV?<V-01M!0'?2<UFOA[GMJYJ%I>Z<N?,C#A^C3#S7AOA#N!R7%:0<IDD!9E
ME<8:TB61'8T.A)FL,"(U;R-<W8',( [H,OVH!LD!,+0#^,Z*D>;R\M#RMM/.
M"<U/3#>6&@T_8=+O?\)WU#0)?#1ST<AIIKZ_?#1W#N;.P=Q3O#F/,Y9[=V!F
M\97QO%5,IB/9O[5W )4AXA]]09[K+C-*:8D]MEWIEN(YYY;X7QZDB@'AI**C
MD0F6\-)M\W(S#!:%>-?744 9X4X-,SXDCJPLC09N!I!T915:.ONCI\V<"&<I
MZ4? =XVB<$)A1'\.K]OE'_E5\I;1"QEJ%72RK2#)R6L%"ER0,I45-S 1205]
M %\VEB^@&!S&_$GI<!3&N4%F&#\"$Y['1X<,W+HV2%"2Y:7$S^][5Q+^C\FH
M7O/6I.'2D/^.XLDAAAJH80*MDY.5"+8.\L$]MGYY2,^5F#\*MY^O0.87H^^&
M"@$RZCMK3_"DP1/U,G=P6PE-.(2"$H\P/98+RQLW-?C@85QF)04"$G]U 9\/
M0:J^)7'&Y08V."'*TDW8JH,1?4Y,0K;2TZA4ZZE0DE+=\')F(]$XL,,(&1P<
ME%88%4G"&U?&=0OBZ$A?1ZB1BI(B]*D=_]&"W1Y6G,Z#AZ4TR]Q7#@L[2U<8
M/V6K4/3BUIB4$$=MWR]]_XAY019)RYF!1;X%YTWI1HO=LF]:N4L-^V"RN=%N
M3V0X[HZZ2YQ6!C8XB'P(]_3&'AQOP\,CKH"1J!W-*&PB>2&20460"(^(Z"(%
MS@WHCLH=()%,[PPQ77?EP?#!A70)!I_/N*B,63LH*I&/V_F+!LPW-C[Z7LL8
M'DOTCE B)T\((E 3#^J<,XT,[S(8;4;;:.<TVLK9Q3A)0VEV,6878W8QSL/%
M^,NKMU=7"LO5!O$O42MX'#XB),42GU,3XCYQ0E8-^YR6#CE-,;7E;PC"+EJR
M"W=.HF&F:PZQ AHHCFQL08=W0D45FP._-#*:+0R)?X,0*ECO&R6-%;^ 7VU_
MT\=%&B^;HJ#EW*@KBQMPU:'>(W)'H-C',X'J'67_F53YKEEK7E+*+ELI*Y^V
M?3!PX87VMJ$I7;'NC#%FRF&8S%EFW'7\N$I'9NOA)&7@;#W,UL-L/9R1]2"Q
M""B98J<8$T5*Z9-YW$\M]8J8RF(O= =V"JX5LS8W:!)DR!!,&/36(#5WW>=-
MJ,&4[BOT::QZ!N_G+!TV1JFZA7+6JC]!!Z*DDJP(U$V-:/MBDC72<YY&+V%:
MT[8SIK@0DIPEQ[H"S8,TA;&NUX%]YCAF77>B-W;6=;.NFW7=>>BZO_4[UZ G
M<YK\<]B#J05+ZW6#\F53 D( UN5>%<3J3Q[&?U85DB@=B=G&#:!#706L#[#>
M=>1:V1OE6QR]'8U;>,]=7-HB<_G*75Y?9HOW\CN18K_U+'[ZG \-<F7/X9R)
M=KU"61$-X>6'Y_CWUYFZIYIN*$NKGNE;8>9=E35J>XR\U89 [Y'Y^?['J$F3
MG5 N"_)39X)(5JKB(J\+-*!(6;AH8B')JV(2N05*0.7!&W)"?0?COG$(4PC"
ME=HWW;970C+>"\[1>,HX*65N+[$2":%@U(]=M#PHT)!UF=3I"X^=0]$X!RN,
MC'[AR>BMY=HB_'R@M%Q\W/<=G424.6WRE<&L>VCUR]F*.$E9.%L1LQ4Q6Q'G
M845\X$SPC[6Y@0K\(9'3=;T7;9>7]35,C2G#8FPQI-U@(5&KN6FQ %A[<%>:
M-=,E@ V^2#9^/#K[AUW]*,C)F]4V"R@(K((9/4*YU'V9Q;!I2T<DO5+X1!3O
MGNJ'TQH!UL50\0.0"+1GQN4;DO@/!<-OE,EWO,2\L%B2Z8R&PBH<+P080Z\,
M/XO:"UJ?4%]!4^XK9C6)C(?KOD#JH'*>Q1K8&.XFK[KAQ_@?H+CO2ZG!4:[A
M(]4^@2GRMH@8+RTST88#855/"+<G!1?&I1R,+U^C[%MJ6SI%*Q<5C=QG$=O2
M<A7(J)1^4S!O(\I,C)A3\D4H,Y'\3'S $B-0C+] ,DLGFE,ZU\6FBV>1=.A)
MZ(I/W@8BL?<S7X\79(! 8NW2@YH49KR.#QTO1N $'1P4N3@T9REURWT3W)(9
M+.F2<2=!C<:WE:ND+HT7&L5%BH*B02J^J%RPMZHO]M*"6DC=N:S^T0.- D+N
MVX[PC.8*C5/5>[/%.%N,L\5X/A;C6ROK7+PU]?V^!WI6Y23JXC,O4GL(N^ -
M^?WAX[Z*X/Y<C6EH2]:D2IK4)%1WFP5N\F7!3.@K-?^4NIP!#7W< AK4[#E6
M"5+L:0U@F0>I\'@<S[=%N6Y<Y0TH;6A_!?..-=I;;?,FC24F [V_DH2*%C8\
M?_T^B9%9/ GFFW'*VPJQ#:3)G#V 2Z08E[0S*-,7![)Z(R-"SJ(NB-@-:?DM
MFW.(/K&96[=[0"8B$M<N;AE'C+YY2V8((-"TVA;UU5S*P? 7] /9#ZYD0V_X
M8"X?+798:YA;<KIIZ0$+0&K[6[(;JDHL)+2E/\MB",1T0[EPE-L)V>#@O5]'
M:YJNW[4FW/RR^1Q;NABQ$>4'[\T15,!4L.S5[\##&8+#TY+(7[E0)$?#/_X&
M%MA-0<^4/^9D-=-"=/BK>!?I!RYVQ?H6QM0#XUZG"DL( 4&G:&.!26N<C&.4
MU4W1U"GDI!7M+'NZ9VI7T\'#G6AJ\@L5]N_3'DE9')OVT+*A//!])-KJ4H>%
MD2%P?$2Z1"!U$"BH;B?I,\*>XXX'IZVZ=%2T\$P!5");'!564Y;L06.?"2V\
M%(;Q6 $'P_R2C94EM2X9WN7B.PGG"CHK1Z?Y]2FZ8>S7!O1"CR#(M^D(*?T]
MT(T\ <,2B7LE!+%B(0W#LCJECBTX?8CN1_!^.@ZI&)N81^B,G0@K1V,>@J2:
M9WGO9)"/4->5AK[AMP\P$#=0K^KN##F=-:H?!=(9'>6@;T_F/7(TDUA'WV:"
MY#C"8XDR APNS](BR &,C(^ED_K+=_DU_L$DI:R"Z337ZGPSE@=G13@-,>A)
MHILWT=N0W0W?E,4@D7A>"Q$R E4]<?B.?WW\\!V?H2B^X$H^U OXI<<A,F%:
M%VQP*9< 4QOTSI-MO8=Y[=@6NI9JGFNDYK1>E,PC%I'<Y&729L.=)ZNC>3C?
MMP]H'])TI?7C<72LAT6D_3FIH&+9%811;(UY41CB93&0'@_@=DL2X-9:QKC0
MN0Y"N&A5!D( >SDXG$0DC2V>ZPX3\HPK;?.=&^$]0W(>A7L.050OM]K/$%RD
M-6_0(;@Q;&Q,Q4,;A-)@+?)=)UL2O2&T&*I!(!.BCQ9MV\.5..RA[4L/?.M;
M\0 RW8M6CT4ZC@D'*'GGD1OG0U7QF;FQOC7.PVLC;8IP/8%CK0C P",</!YC
M095[9?H+3Q#L.%E +*B>*ARS!%<WLE%/W!:M5P*<M7*FP[4VKE'U>:"S(8V(
M,"C <25&#_</\[)8RX$8<1X^VXUQLQ/0]WB+&[RT#UV(M[JQS*CEJ__S-?2H
M,PR4.H6QSH[N_R3R^<\%./^2F/NOXB9%FA/D=5\IOAZ$7(1S;?4:W!U+UVQ-
M%EZ79HZ^^\^W%T__\.1I)BV).XAIN/6DD5CBEP5MC\@P]OZ/H\FKB-.-0K\'
M;Y45A<3F+#[:]O!&3AYJ_@<8QJN^M87AE%NR[FM:P++>[Y1W@.:#" ":D8%H
M)/H5&^<.3HR7=='"NU(. 7K,CV[E]:;G* B0CGM7PT<#OCK?&A'$]I0DD,%*
MAWP5U\5?#+K7OI0\+,HFL=:3;A>6D7X*ZK4]Y.R9Z5R/)S>8EU%'B&ZF,5^]
M?N%AY.\:AQUJ*+J"_3#?L;L1R  Y[LL<*4O:"B@SB!H/R.]_H9#UD'VF\LGD
M 8 ?3Y"QJ#JZ2H(V.2!KY2^OMG!!1?_I4Q%#6J&4>*5X]^X&T:M5Y.N&0_!A
M>E&&\M25K;MER$^\E%0L)*39*8;*R("5>[Z5F0=96KHH_0@420_.=7QW.?B'
MR?OQR)ZP@:CQ >GZ\N54W.<NY=-<8XT6[D6^6D$@(%^MR$ZQ$AC*DGNX+%(]
M_1)WZE..Z*FG M&[:$J]=+GA":3'-(ODHH$ A-7 *.4T)A!A'GDU$IQV:G$$
M#3<U55"Y'P7ZU?D$W!3LCY9UJY 9<D^!S/7;)S+34A"/:0[AI)K-ZV_K2$<(
M:JF_'2JQ_8F^/&FMJ&9_(H-8A-$QY7/8<F.A9&CU(#B!E.WXBM.IWRG5AM=4
M 3#,-8J^"I/3K4]><5W)=6,CSH1CD-T:T;!H<^2WH.&CJ(#-$"(;6N#P4HA*
M%<Q@3&BQK->%0<&"MB*O('[REH-WA[J7<-"#MDO=#!X?/Z0AX16!']\ZA;E;
MHD@%@>8ZV)+I,^#E\94/0V)T/9:>#!@LG^,P%5YCHE>H0H:"QJI,]"[C5,J,
MY#;24+B@@IM(;^&'!E*B>J^!L<R.6S![;[R09:M=U5XA[;CR7P$W+CIIB-5
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M:EG0CS.7X3MP-TM_RP/2194OHE-+IH>/_;!.1/N[R@5J)YNO:@%+ 6%3DV2
M51N[G%O=Z_!VSHTK\6P:3 GN8HLW3FPBEJ=JO,(I&YN%1I\,[>'QNYU71Z%O
M-OC-6FN"$E%\8,Q>[)'8DE1:Y?8T ,R_@2_!R5([)]B;8LIZ5XNW7(O>X^!L
MRDFQM=A-R/>E)J6&UIO)\GV@--[67.%606L3=,9 #:@^QIS27TXE:A?9XZI7
M@],"PI%4<ECDU+H=I!&],EC/ */? <:9BPI=T_5!IMS-E:RWRFTK+L6K6K77
MM5:Z+F'X(%PJ.$(@0*4MGJ'X0#O#8U>D,TB+I>(4B>XIUU'J/'A*-XKMY*WZ
M7 GNB!SK'%<[RXXXD_I?S%5-8*@8[&U@<Z_QWU-KMDHPEF3G?:P8E*4S;)5P
M!07]5>I,Z.),G.D!E9BM6CE4/25P L$6254BINM+(6"*9-2Q^EP/3_]^H&%_
M6%QWS9:X)Z06[ ,:TWA,<*]ORVJ^^W7/KZ3BTT>F).#,CJ.M8I:V[)Z,1=_"
M!$<6OD!HCER6:\+<FIG;NNB^_,=;8&M]$Z)PR/^F4$[-VCLKQ!RSME?7"&$S
MCC-+:)E2[<24W[G>5"5A)CTRVQL^R%WANAPQ"TTISCR?2ET6J:S^EBR-,E$/
M*X6#:+21+6E#.11:)?@,3&OY@C O5X,@E&"DX$Q9!)S,X\KD :"HTWF6>2JV
M$.TU?J"*7HHQ4IFE?99?S8Z9+7*)Z[+E(]KQU;\=$5;G6_O[4SB;69K\/4-E
MCJ,]FH%&2-E60XG9PF,KS1M0V!47EIM3I%76FQ6WB/JC.6+43/.Y;V3QD\JK
M<;M  W#,RH[;G47HUFO 2OO)$:PD+)]#,!%O-]'X%)<,%W9"57RA.(KQ^C@!
M,9'&$VEK"4/SKP^N(-7>1FU;BO>RT;E*>M!>Y(ZH<6(\])P"[ENN*<<**"X@
M^# X>L(DBW*+%$67C//C T!Y_JAJ7(:*EK]%5Z I-11A1;3W5R(I*B78W3H,
M7\VIS#SDMU1-6^0J-^+D:5MW;&FI^XW+<#ELH<D-BA=I+UI/TU_I^\XXF TB
MT-1QL"8A55Y64@AWRZA;WGCVUQD%GZLJ'&\(G^@XUE[-Z+S\(8MM):FFC$*X
M)9HHB@1BUOF*.Y]LAYHZ$F0'VP#SEA42'2_@-*MNVY-:+9UNB6HKX.9Z'VH(
MM5*CGNWM#_(7FR&D$$.0M-2@YWG#=#MG*NKIQV'">\I*2CRD2N$.0%A*J@0[
MSH-FV<Y9;9Q,8K)6#]WB^S!#8J+WK5%\3S,3FD+RM1:2E_/Y,C_Y=0--+9-)
MMJ N4+\O7IE*PX7VKJ5V4R*\S(7+L*13"BYVO*3EC#9,C7MM=NT$&8P(8*0S
M!JE$R* \(.CCP\NV]C 0V1Q\RA*L'WR$C2U,G?-^>HCM1C8CZG\))%YC *G
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M^LS!5T^[E]-'1Z@M&-XABPSCSV'J7$/E,%]X5B3';LSO_XQ>?] W9Z[C-=+
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M@IO3B7J'-%1 V/EU^:C=C3U@;09;31M382$MN=F/)5MA+:D3<C>H[FNRIVU
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M+6FG4[S#J ;4-R%W!%M#LR9#-Z:1O!FU3G$I.1UV*7-W<KU@^0SH19"-X(7
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MG1R!MP??*_+,VTMPM4"#86BV","9H'&?AK<RK@ZA:%>%RM->2[)R=!)9EG;
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M=VZ7%A^&$?BSK'S/&^4&IV.5O7)29=,F^ +K+FU7SQ"1N5<H)\?G7QM//,*
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M.6L^^HZGT5\\JC3Z@PJ'/)3$^B''M7W0"XND"FU/#UH^(R@D8E1ON0K\?DZ
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M.M>,O< .J 5%9A+2=;*6$%[&.[Y02_18=,](9V$@.M\$,:R=2S5Q\H?%"7Q
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M4:M,>5ZR0I=1F/+U=.PHHF #, 92=AL!..W YPE"[))CNQXRW[7M^31('NS
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MHI[<O#%OR'0=D@S-##;:ZLCU GF840^EOU,[(ER)]DG&^SP$!@D%U^3;@V(
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M8:%_'BM!Q:4*Z:DRZ$@:_'@S;C"R&V9^*DP%M"A\'D0$C%Z@)$U'*?Q3L5"
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MR)#$!!<\L3"%>"R1C42-$R])A9+#8[RY\!G0P'(5RY(LR2'W.!9]K$+T2'>
MUW!DL6 ?YL^2Q-D;@62D,PLN<S'@*8TYTQ1C[.@U# 1<,H<WH]K&X\0ET;8<
M B+J*^VJS/N$$6BP$8Y^H"4+\GTB(3MDW$JQ[4>PN)#D&-DGJ'[Q_D""2V=G
M9\9G$#.Y]D,&-J[$^K"E]4&Y(04-^@(><?U2#(YP6G+DE<(:I>S+G>U61XH<
M+]]>7 17++2E5<O0ELW7^N&G2\@-P'(';CA#7D3FRCX\CN,4PQOR"(2S* Q"
M#$/EH1 ['MWXD<(QQBEH853F:1;Q&\D5L)5ER3[T^+(H@1FSPK*81F;IMDSC
MQ07&RXT]!]Y=6,H0Y+7'@&.EY@>!@ E 9 UP-Q"-GHL$/N#+G=DF_#3D&#XW
MK"Z\XNC'Q!MA5'+N019N-2Z<"7-3#,I^\526]],SZV</=*V+VA:G>6C/4.?E
M?G6U#*:O[(XX4F%$O'AG3.QK!O_@P1VX<W3RCPJ*!Z$#IV%I.YE@ /II%#,$
M&#!,0^%,X&XPT@D"1M/5"\9@K8LH>1$+Q $*</:6P8\;.0!R#'!KI'20@@D+
M#-[@\1.];F^8 V*-0M3L*>A3)6Z>YC1B8&QQRXJYBMU&@\H23% 3"RLLQDEX
M/,X"=ZDM)DKV.@T>S<(1/%%:\C*$=<SP'A@98G)!=@X)GT7%6+<<HL-;2"B
M@2#\WF*TJD#*XTT)B=[*N@@J:TCA6X3#TVK@=;\W+AJ&;X/@F<B%X+<F-V$!
MLA?I*.92,D[#^!5\,C!Q34Y"6/0@3/)9Q2GF&'B%2.XL<:*8M(-)*6DQ^0'?
M X]U0WHH.CW.1L_AD!Z(3^7U^&R*@4,T+*8DB+#(,@+>",!\WT,/\#ES$)[#
M[-Z4C3Y*5P2T3>)=TW:H1C;"@HQ8]/ANP 1>*RY>=CJ-(9<XBE5-LH[R%_ 7
ME"+7P(2H:Q4QQ^\2L@Z<R(63/ZLY:+26GBS2H1S&W#@'Q4[":RXY:<"DQF]
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MY2>L(<"J3UA#@'6! #OE4(D: BPUSSP&!-AJ=ONM]K[;:[=[@Q9!@/<-Y+N
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M\%YIC65=>*]B]IE&_"IO-6G$K^IVC$;\-.+W-+;;0"-^.VC%5 7Q:ST0\?O
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M1+EJ[5:KU3?-O%N59-?]*?XX/@#+_0=VP4/A45*I=S.UKAZ?M47FW9$0"*)
MY3N,*%#U#B,*A,!T]-V#P*285T)HH7R'$5JHWF&$%@H+3'4(3$<9R% 0F.JW
M>K55WU!@NO#$<U%B%C<GOAT^I?.^OAJ^.6*M2$;22VM>XO#2[]FWP?21GNFY
M[(OM!:8M+]A>3!*S'5O^\D_#<?@3^V*XWZ%!(5!$H'C<@>*!TXN04'7('BL=
M*]+3,13J'F0HQ:@'T87R'88,I7J'(4,I*D/IVJFFI@B%^PCR5J%T3;MM;JA
M#2;#P+9L\=FBJ=[=&\K2H@ZT^(8##@*;M8G"C%%[17NP\XN%BAT+>JZP4-$C
MI*F-XL<<O3C4J6/N'M0IQ1:V4*>4[S#4*=4[#'5*576J G7J2..8PZM3%>VV
MM?$!/#>0A^J\.]83/Q[SJ&OLFM_;@7 AW&)7DZ%CFZQMFM[$#<78LG/;?RBQ
M,^YX=ACR&-!__5)I?F8WWL0<<79Q<04=Z[ Q)G2L D29T+'4CS.A8T''4B,
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MUUIEXLTW=(!ZDWZ=:/!F0;;4B2,07UBU0Q$ VPZ*Z=UK7*]0<)]% Z<UK\)
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MJ5$SG0)LCA[1.CK9&J6G+B'&@*A77!@08V0Z79.ZT6OJY_9U@U>M5&WM+N;
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ME->.E;S+R<.0^_V[2&'OSW6\'>U;KU\QOUEJ$+J-%UH\73\"^J6#!>A7 :A
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MI[9I3AXFCI'<B5R07D<I^/#>Y'"!]R:, [PW.9QNO! R!D%<UC_04]@-/*I
M@7#(X' 0PGDYY729@]9-.2WV7E]\23'S[@JTN(@N9#[T44'L;![0B6?R#?#R
M\/)'BNN5X;,_#6?""^3EVP_"'D-X^>)Y^2*-+VGG#-\;^5[;.NFY!?*\'6-L
M0_:BB Q<-%PT7#3V6*->G_$[V[0/'R'#39-UTY!#X,Z/#[:E:@<%<NAQ88>#
M^W/X:?AI CC 3U.'+3I@.!*OYWZ0'(,OD+?N_GMBAT_PU@1S?EXOXKN;4LNK
M$WX.7X=N+0AV>%;_B^$8KLF9$;(S;O(H&Z&BE9A>UEJ'OKP ^-"MAZ] F4!
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M,0$7SA\Q>ZO[)/)+K$?D<I S*45R1511B .30L<=6RYK,4/4GB$@!YA^05$
M.8 <J,! <X: '&#Z!44!Y !RH (#S1D"<H#I%Q0%D /(@0H,-&<(R &F7U 4
M0 X92E!5GJ<ZO%3?468^7/*P?W=C_#Q 5<FW\BKFESB1*6H%?T';7X J8?H%
M10%4F8$JJSNF2I#:$9L/BC(>& !YW[?AFIQY=Z)WGOF]Q%P>RN]L>1.XF'9!
MB(J-AYX4- :]Z*Z)!@H(.EX+.GX.?<<.1H;/@Z6HH[:R1K3T?MPZF_ABJ*^X
M;WO6(/I3T?3H5[LZ:[[J&N57HI;>Y?EK1QM^:Y2T<KG4U'9W*2.<AMI. WP)
MTR\H"N#+#(OT^IIT^:?A3/B!V7)YC=\ )Q*S/JJ. 9P(TR\H"N#$#)S8."0G
MM@64LIV&<V785L_M&&,[-)QU^7&]<_*M4K.ZNQN!X434=B+@3YA^05$ ?Z+<
M&!48:,X0D -,OZ H@!Q #E1@H#E#0 XP_8*B '+(H+PU=ZV\[4XOJU6@EQ&S
MKUWEE**X9$8 N@]CQWOB/$XH9>.);XZ,@+.Q8[CT$JX1C"#+O: H(!C)DDK:
MVBB5=.H,HX>N$E=X)3PAT=S22J54;^TNB08N1&T7 O:$Z1<4!; GJNA0@8'F
M# $YP/0+B@+(87.=MU'>1.=]<6%%(^-R+A/K.[Q["&Y#;;<!QH3I%Q0%,":6
M4U1@H#E#0 XP_8*B '( .5"!@>8, 3G ] N* L@A@]:FY:VU02$[:HM"9<X#
M _ G#T+1\5EASFA.HQ3GH6<!C4$ONB^B@0("CPSYDPU]H_S)Z-]?1+AAR6TZ
M[@:&? _-W,EZI=34RC@00LQ&J;H/,"=,OZ H@#EQ1IX*##1G",@!IE]0%$ .
MO[W?7-!-74'XFJ";ZZIJV\S)R/Y.%@7B%A95U"ST ST 0)FP^H*B ,K$>HH*
M##1G",@!IE]0%$ .( <J,-"<(2 'F'Y!40 Y9!';4I>8[U1L@T2FA%U]V#Y[
M<MMLUJ5423;T?(O[T[$-/,>V6/P@BWHT%G;JANH"$DW2DZ&<B6+RS:?BH7*-
M%Z*/PF-#]7#!Z]!,QZU(;HTJ4G$DLQ.T5(YV#GR.<*UIM>CQ,+5 1T5# G1T
M_$B!CD!'1X\-Z A(@(Y40 ITE--!^MIS*;AM_>\D"&629'#CO9 +&4G"P^>2
M\#7_]\0.Q.@/N/]HFSS6D*^YZ=V[T:=$<C*-+,VU;DBJE6I5.G<)@.O)^BUP
M/14DP/7'CQ2X'DO/H\<&= 0D0$<J( 4Z AT=/3:@(R !.E(!*=!13DIHG9 2
M"OVR\ Q]F'JEKV7<6MYDZ'"FGQ:&K;\8CN&:G!DA.^-FM+7 *EJ)R5EYJ/3T
MEZ.IXN%#]53*'!HYIBO)^37L$&[1@7(YW,H7SH+&8R]56FT\#\@6ZIW&U57C
M$TNY5E/=M(BJUBQIE5:IU=3('&AZ*?!ZD2_@=T#F14,"9+Y#*/]!#T7P^*%T
ME>;*P\8CSQ'C',2$O%<&7[Z\16N"IX_![L#30 (\#9X&3^?%TZV]\?3;N=O9
MMSST9JE2U\'IQV"CX'0@ 4X'IX/3\ZKTU2SOC=2O>6C8+K>ZAN\*,PC>6H%/
M:X"M1^M:N51OTJD1!EJG6%L?C Y&5Q!*,+JRC+XYH:^^^#R75;II3AXFCGC2
MZH<C[LNG?#[B;F _\IYK>@]\;96]6<5V^%$8));D0 ($#@('@>=%X*OO#U^7
MP+<2Q[5FJ08B/@[#VM6!@-P.(B5G!)0%X)*'S/&"@-X),%SW<= #DG),"Q_2
M4(4I'=<@9B%V4O^U.88I='@40"^@%\ $>@&]'#D,-*<0Z 7T IA +Z"7(X>!
MYA0"O8!> !/H98\YMI7G.WJ7/(SS8RZ\(,@]O5:;%@K3=I!GVRQ5-3HEPT"V
M6V;4@F>5<N#@V:. "3R+9=S1P$!S"H%>0"^ "?2RQV5<->LR#FNP(GB##]OG
M8N:6SJUZ+J:L\QD58O;N1.\\\SLS7(N-?7YR)X:76^R'X8L/"H,2<WDHG[)E
M95 Q98,P<P)G?LGW"&X.<FZE2-Z**@IQ[%+HT&3S2LC-V26]_&D<Q@=&XM+'
M9Q-?C'-\O<2\)+)TE?V[Z+&V:UWY_#SRDG\E3E+$-?V[Z.\[TC_F67SQY;CH
MS3K*M5*]4BLU-3KG5>!;:/L6T"I,OZ H@%8SG,2LK\.JT4U-QT*JSTH;UT&=
MQ(R4JO\ =<+T"XH"J#,#=3;H4V?;>J/(\.LTNI94KVOU4JU!IRPA? UM7P.:
MA>D7% 70[+8I3Y@A:L\0D -,OZ H@!Q #E1@H#E#0 XP_8*B '+((- U#R/0
M[5!6:V+WBIH9HB;I@0'H/HP=[XGS) EV//'-D1%P-G8,EUY^.&(6).47% 7$
M+%G27%??0/I2INO4&48/726N\$IX0J(9K=5*J5*OX5P/,3NEZD+ GC#]@J(
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M JFPJ"@@+LD0EZ1JTU_S<5)DIW]W(?S>C7![9\+KT5]S8WZK/;_!;;#]HJ(
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MPE?W71F6R?_OSGWS-0]"WS9#;LE?M%UK^0<+3]*O2(@]*V6=#JB<#!2@\@)
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M!*&  J@!EE],RP<UD(6FZ!,$>Z?[QF 0>N9W9@?!1*SG.#.](/L=>\<F,:M
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MCU1K]B#:[N$MK=B>B61-'Q=X"]M96T G-A[O(X 299>%8J@#WI[U5DRC%(D
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MWH )^0]0[EO,HCA2YM8G^'IT#3+WXH<7TXF(O.1?/Y#4PH]_L<$PIL_ #Q\
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M/Y\QF<FP(:O7][$^9"-P#@5,]]EO5:"@U5%N:?+-B=F2E";0,F\S8FELN93
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MZ?]9E1RW*F(TLL2,K+5T!70AIT[!_[>X"@T30/F(C]&1*=9<^8LSI9=8[P:
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MNA0=-:@>0D$-@^B8>#-M+Q)FS 88AJFLHS+VUOGH9\$IJ48J_WM>S60(X5*
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M\ACR]5,QIYK!A(,=M"_#ID@Z#Z^H&@RX842<4>.E>@=5_6CEV&RADB:RBJ1
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MOGW;?7OYLW*.1X![;1:X7QD%@?&A1']OX+^GV&]MH'\W67-O8.]E.AB!6JF
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M =6.CQ.@ ENY1\*O/'$M8A8,D4*OO!V=1YZE  .MJ!8VO-L&<QV8'>^L+)[
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MS$,Q]]YS\+($N,O0]VT0(.0561?S2 B>O8%__!*N;3]96^\"@*+8<&%]O3(
MZG+A"Q^>%MEW1!ES7&U4[.<TBE/X%2Z?L"V?<(IE4(@X5UP+/UPA)BU;X;1%
M# '_ MYH60HF5XXGT ]N(98[UH*8YB:,?!<4C !.<?PT]JZ%?(/ U\G'MZRE
M_5W@_T;?14(OCH7O6^_>?_O;NS<?+2\ 7D0A@>K5BHB8/(#)U$9. W*C-1ER
MY$N"9P5^AJ]XRRG<C>FP8WT-$]N'WUZ+(!76#9SO/_>V+H;=HG7QA9_W-@J7
M58;&&[PV:ERT..#_W*_VC]O#"QA ^#2[B !_<SJ^CB9<,-@ET"7, >":X;(X
M0T^5E?:*ADIWFYWRVVC8@A.5S!,"[P$0ZYT.Q+84XHZT_78&]ENG7&)K :_Z
M"!$D450%:V%'L47O+I41]@B8^*(6$&2\$O ,X(1U!WC'0@N-8(O+8#:1,_)$
ML@B!C7A3#+ =OO02E)0=K#/5%4G)ZY'DA4<"#XB#\-B_7SS&4?(Y"E'??XJN
M1'0-0H)0*-\F-8C$U<]BD]^.QP:#1PJ^A^>9TS4GKO[^5VT:@19V0&>*S'2Z
MV[T>W*S_%&0H[(U;$G.FD()C"C#Q03:1Y:%$U4I!0AL<UG/\&L[)[W=??OE\
M0?_JO7QAW0##6 C%MRF7;K]_?VD]EQ^$WZL/=JQO !6F,?A^_AA@IL,9T+'
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M%R 9Z&U3(0(X[*V/_3WT"!(  /4\!%L!&"L[(B:[_?7Z6XX=!&&RPQ45)8(
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M9$WBCSQY.J0Z MU*ZS(S[+RQ!N44+0N#FO9GZ-$]9ZL?(-Q^:!G 9-ROK@-
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M3)%0NDCGV#%2EDI3,4=_8N&M5FP+&Z(VQ_J=)]!M.SG];MN=FF6W==OV1L!
MY_VS=F\\[L(#SJ?MR6@VQ9[=\:P_&9_#A_?MMJVQ2YWKPK?U# !7RC!L- =E
M/?-^P*^"E*)RH$06V.]%B@Z=4-*J6(F&"AQ'0\H&]AS_X I2[!8*4:)QDD=]
M3O>N8E>"3[,_N*9(]0951QC!8X<WYDTQ+\ZZ(WT.C&/SD"%P<ZWV>5]<I7>R
MSC!J8I/6(UH.5;>5C<'8SU^T"5F R]XO@%8@YB'HS*Q3(S"?7CE6L$K]QV S
M "^VW312LSD"/1X!K>)"3039?VJ0QW$:)&I#O]MDNV&.'Z SSW(ZLTHS2J/G
M9T05SKL3CBK /[87^V[QEBK-#AUQ*48;P$R>S\EBEZZ+=F5DK.I=< V/D,P(
MOT8D4]9/F>_O/K[6D3!P0"A,E)$D/&P>V4L.#<%'D5&Q58[FSBQ1,.C(V R3
MB OA:LU,/D3V/&S^P[DI!1L?^4?)&(/I9QX:4Z69-!N#B:?.'_]M@[J$>U,"
MA97IL>*@N\<W]XL74J+QS?_^X_+;AK(N$-1MG%5$=1'P\)EO+Y=*L"(=T1 '
M;'@#4R:-@([7'>OSMM$NI<MND"6%0"5^GV%Z@(@9/WBXLM_%_(O\1_]\6Y?.
M9L'"]R_*#\#X6S&--.D1>LE!GXKCQS GC\4[S?IP\)F;$7*V3=+7.7IY_ABB
MET?!T@-&+]^1G%_@O5LF5<BV>WY8I@FR\7B20$I27BAYO9^@;Z%;@,9$>!.0
M^<W#SW@4O1$Z4_,M4]44G N'5D3V"K M0'+3C0_U=$CVY29?:&?GZ=@9V@Z_
M93CJ;I%?4!BW17YWS05O\ ET[A&CZ)&8P5>I@NQ.*<AQMPXZ?:*$TU9GX7S;
M9 1S3NV%XPB?QONXEA:OEI356;*[F*XD#SC%@86XEL)#'\& +<7DJ>R,JL66
M<MC)-E>=)Z!4U UGP=CRG)N"61=O-&+O*7M.ES^6$5OLD4+=6 3J5FRUY%PS
M!>X#*+QW7 5.!/!%'2AO>Y%6_TD*?2//Y-/VE7E[S36ZE'(331]*QR&H8.(@
M6=!RNV^VFPV(YO;F@V[,(AU -L>L,MA +C_=5-^-9LZV)I(JK)6R)7@@S(]9
M*:!A_H!&]VYZ;6O)P*,HR?JO_QB=O[R+%S9^--G<78GBP?WE Y T>ARN\A$0
M=+N /*50Y!%2^N.S@I]10'P=TO>[ZL=^;YN"W-W/HP'@@ GP;P4-T(=+ XQ3
MSAWH\"/.W -4@Z$U%328CSJ#;[*I--+VVAPER1=[[1<FX5I:ZI!BJBJ,8U7!
MD&E$.5![R9/3K\(4S+N_AD!Z1B?S[UBCY7H.-US8H)WBF#\J;'#%+V*/AO2_
MBM) >"WK50JPL9Y_6-O!TH[ J;ZTE]/0Q>Z:KQXXY>WWF,C$K6<N4@[^_KT=
MQF87#L+G\\+SJ5X"19O1J_-U87L^S\QTK;]Y(H'3MY3!^K/B/&9"6Z7YU03*
M7,1,=]AEFU!RO:9Y^=_)M8'U\N00!$"/V&*%-^3T$C419BFQ"[B/VJ2@8AP?
M7U_D"L69,I@**DK.7"^&R\#ID"8LF?_">C+32<[JR>1 30P4RJ$;XMH3-Z4D
M]?]G[]V;U$:2]>&O4M%G9X\= 0P2]_:L(]IM]X1W;;=?=WOGMW]-"*EH="PD
M1I=NLY_^S:R2A(2$ "&@0!5[SKB;%I(J;T]F5E8FVWB/#N;%6WQP>];^$A<$
M[XD'>6>FQ[[$[\,F08:'=>/#?WAE/(B QYEP+]:Y@7^^\FQ08(NW$&2Y U[N
M&/L_\5Y?MDR/<>.!SOWEH= "CC!-G?-SG=$"V0,W4)#-+.%*NCU7<&PFOK8&
M:H*3?SJKFY+13F@E0S&$R?_=\\X*4RQI*%\N,J;+Z0;+%.K*))B&. 4?-]::
M:U[B&1WH) :L3PEO9/;(*T'IA'SX2?6 .0WWDXFI<U(EEH8=G&>8DS9,D&!X
M_=7!&Q[V*L$[Y[2)FJ<F83Y,<0AL=BY7-JN:?@".DTI7\6QJ:.#AD[R4IY(Y
M=/?@._J/CYX70.C 2/.5]?-D+^F!B+(_;='LX2%N/H(N[?V$W3?V3EAB^054
M&;SFKZP/ 9"9XN.J\V^V;9FW>H:MTX"O-@9J=G(VX03DTV%F,P?]'E@5VR<)
M&02:W,B5DZBY'@YI6:P(RV59&RXV.QT<-=/3*'?WN(<G:@,1/BW\V^%+:XM/
M7W;:PRK/H0Y/U*3V,$1=;Q"*B:HJG?7]:<,#S\QA23FHZ;V ;'OPJ \UNCP_
MHSD-)2+-S%'AX[4_B;ISV49J)O?.'? .I0V][AK&E4SX9)H*7AZIMQZRJA3M
M3F)_B\3$=CTUL3T>K9'6CZ675\).G79D\&.<6 [_>&K![XY&E<+ :4<*'XR\
M18"0-Y Y8>\3G9(W!"3;M8Y-^D*[\Z=[O'81FR1VY_;4NZ^VLE$8^PO0SJO-
MZ=>2E;-,B]9=>V=<4"P!A"_L=)7G4T5=);+5=8LXJ>E,UDT4PY-@F:=LTW2K
MA&%-;Q,LMW["MH(?^,MN%N%WN-T)EO9&_RLP/6:.8B'^"%]^9SI>/%N]]$3Z
MB*XE461PVL5N/S^^4W!((QW:;M42*=53'QO&-9U@V4J#_A7PC.ZNS2B'*T75
M<==)L&7+&J/RQV$J)[.Z55/*,*7+$BU;U4RE.A$FJAP9#U8;ER2O3=>_K]3'
M-4@X>FNE? NS-S;+4Z''"DBS;K((DHAH2]JE^OT.6UMOF\76K 8G7$?G?\)U
M]P.JFRJ.\Q>EB-11?6T/]:.^1=2 =>W$T%.\U/K1JJ=XFU3RP)-][;GKR,\'
MF'R'D/W+K*?'2^*Q\AP3=<L299Q\_JQ90310=1Z5_I!PI"<K3%M6FWFL=RC?
ML?0 GK2P -6B6C0"U'2-)M\8,'!#.CXC[+5(JK=T L"\<*8A=A'=,-@N.=S-
M#;4DG96!YWQ+SX.(CT&G6D,W<*H[V^5+1L!QML>9\Y=D1ZHQ1 GC__1N='RR
MCQ<3P+N$._S9LEEX/O:2QNW+%]-+#V+UHR)U/)4>IIT*5Q@M<;GGGGLAX?4_
MI<:V#$^8(]R^&_4>J:5^8:/++:*DG4DZ.HL&W_OL+_36S+[9L4]N='UR9-=V
M35M3<UV*F'?C%]YI=WT997:8#C'7=#?-V"X96"X('F4RU2=?[X[2NLX ;).T
M6FN;UW=_S48\ZV;'J(-,FV?L@6!C9<E[T],MQP.,>01BOK,<_4<!:7/,(X7(
M=8XAEAM0YKX;YG.D)#SBLN@$@P7X$^]T/L:%NXR:.,X8%H2=[^/?YY@V#G\/
M[\._T624F7OT.OKA#025AC\%7PI\?/X$E_W7(,_LV?!:SCR^#;^8NV4O4].G
M37PV^E(OKC;/;8Y3$&+4/*;H"N6^IQ7#-W*DH!KVEGJ_G8+JS6.WPK7&.DSB
M5<-_7/P/ZAG\"ZJXUBATE(Q1>-"GU BP(BF^=3@][Q%O6)6!V($)0DTX7M*;
M.?Y821<YULN"^5>L8Z43>(""WNOK=4V+=LO'Y.=<N*W=QZ[R1U]K@>^\V61C
MAVM-+%_+TEBO\\/"%V@B'K"E1A]\8RQJMP:]Q(>/2 _^$7^!_J#5Z?_R)EQF
M1$'/L4R#\ L)X^,<!X^%@+,Y ;B>$>&O\=NF.8,?))FC'ED8$ZFWK+D[$D>4
M5K<T0RH@OR =[',Y :^"-IJE]H_&E>BC=TNBAHSJM(;=8DXM(YF#JXT@?(O"
M-<X_B-E63?4E+Q[A^<3&(\\'KY>1D.9:%$Y(<RT\W^INKMO27)_22/P:ACU%
M^:4L[6_O[MIWMP<P$6$P5#G]A=FM_*:]$"S]9R=FRXK^P<C/H?1RJ;^?NW(X
MLB]!$8F:BXC'L%+"\.EOXK%(3?DNY=F4@'.V:5X%F@O#M]UWQS('#>)L)%C*
MSY&A_$+]^PEN:[G/A0=1<T=3=(IVMZ("Q0XX(XV!.L@I@15-$H_CL0@C4Z+:
M; F5$BH%X).$RO/DV^Y0F3GSM2]49H]%; ^5_7Y70J5H,E55>'^P#.#%A_=_
M..X/8L:S!T^5VY)>BV!DK[TA$H,-W#.1CL=NCD?F^'7L>*"Y^VA_Y<9NWR!]
MZ5YTV]E6$^()D]1I(=@@$4U*?WW9(!&M#**M/S=0%M%R8^DEH@VZU666I4X+
M%B[OF[^HH [XDMAR%TT7?7(<XV1[Y$+4E@G#$_%W XJJR6INU<1@E;IU\9_T
M9G;S9C(-G6-O)C*EOZ,EK3 ^'XJ3_-_*$"2-M#0&$D-KR N)H1? *HFAA\+0
M3%/MO3&T_.ZZTABI?0FP9R%IHFRY%^40#"? <]1JJSY8^XC]G(@9Z;" !]1J
MR!11<^A;U*H5,:^6'E+ILL-#;X4<AY72>TIY3YD>>+'W! [3H>KU.XV^4IV;
M5-EQPFWM?*W,A;#GQ"4,"V._)0Q+&)8P7!Z&>^U,W]3M8;A\MJ+7Z'3$*6XX
M+Q@^N>4/DQ6ISGH':NL6B4C8L2_[^]HNGSG[6[YF/^& 66SXZWNRV6>)9I^Q
M.:MOK\_>Y?;Z+.!NJ=?;O.IRK3XC129<DTNV_,R.-$ZT_$S;BAN;9?)?3,N2
MW3_#L0C8M-G63<O4HJ[ZYI(Q&F?,;CW&9;_02SA6ER!ZO?J 'ONT0<92B](>
M2M0><O7I#_<?'#KW <VM>,I0\]YI8C!!6B1ID:1%DA:IJ/;D\EQ38;*T$A:$
MD'P)"Z?F26XC8[%THN;H( 83I&&2ADD:)FF81'!;Y<EK@2!#B--BPNJ(J#@B
MIWG(^4."Z8FT6*)P0EHLX?DF1_"<6D]J,H)'$/I_U7Q488/X5)_:\ I/)JW-
M(!Y!>"#J\7I!9@M(+A5RZ0#C!2X.U47E7<VA7@PF2&R1V"*Y)+'EPGA7<VR1
MHUZ.NUGRN^MX'M$UUUT  8@V [+Z1//)F,(2;/S,F9 Y=4U'P$(YV37_@C=Z
MA6&#L,?3Y<GRW4Z6*ZL'[+ KGD\_F<_46#UAQPSCH4Z;]X>-CJH*<]Q<:KK@
M!E?BG)1^B7,2Y[;$.;52G%-&$N<N3--%V;Z5E8O;!>/4-O8/PV4??'%\EI-F
MZ&6C_#/A9;DF=+*3?@4N5*?:5$'Y_K 5NU"RC_[E&A()T.+P0@)T'7@I ?ID
M -V]T%R^!.AS2'S(@H.R'+C1]6 66!H6KVLSQ_7-__)^C;+F0 C^B+L7(T3E
MH>33\6L/+\_=>;6[O]/;P=])V-B;A(D]E ?4[304I2-W>423LM?B<4""IP1/
MR2<)GD<&S_Z!P7./$HENN]'O2? 43LI>G[XZHL9)@F1B@/Z<4]NCXF5_I3-S
MP2>D)!MD:>8A7)',D)^DK<L.^MEMGD\)_T-M=/MM878OI-;O&[M+N+LP.ULS
MP1>5#1+N2L'=L$JX:T=P5SY7+>%.2,FJ(-J6792/MD]?R7&$BVA;*@R[1,UH
MRVK'R^&EK'8\G1\U.O3V?_D,0K?7Z W$V<&0!9!"U@1(N#X'$R_A^G)X*>'Z
M9'"MM&6UGH1K,?(BA^S18#@!B#%16_5![B_4!R(X/Y#Z 3V'Y@PU9)*HFPB[
MPW&*>;5TKTIWI1+MV&<Y5EZT9[6[8[5+"T<PU8?*>:AJ8] =";./M,Z)6FOZ
M:V5!A.W*()%9&),ND5DBLT3F?9!YEZ:3&Y%YCP*/7D-M2V0N)V4G!X,PQ?&K
MKP%UX%/#?'X;\?)+,(,06]^-&*FU_[*J4:E72#UE*=D=)5/#]*!/J1%8]'Y2
M(../N(1'>/P[R]%_[%;'2T&>YVABW(#NR/WD@KNM7C>SYF,R^'%*B9U.F#@3
MXL.GM\YLKMF+O__/$$S)&X^8,?6(QLB'F97,S'N")"*:;> /;6)ZQ MF0 !8
MG '? PMA6<Z+1UZ9-CS%"3RXU'M]39"_!Q(;N"T**9H59'BHYO^X:@/'J86#
M8W4P"?'OH8E@OZ=>YEH+?.=-:"1 02UM[M'KZ(<WA!N283LLP3W^E/FUH-L;
MM$:KA<$);*QN<E"2#>K)3940M%=:JIR"=J%'(243"ID %_0E(P1@A&2" $R0
M." EOYY,V!('#N*12M9(_1"="?5#!G@5D#B@NGHE @,49J#J8XT^>+XYPVHV
M\72AY@9I70%9#7)'PO)$"#;4$"0$('K-K9$83)!I)$$8(9D@ !,D#DC)KR<3
M9!I)6-9(_1" "?5#!IE&.BE/OM&99N(P&/%TH>8&2::1Q..)$&RH(4@(0/2:
M6R,QF"#32((P0C)! "9(')"27T\FR#22L*R1^B$ $^J'##*-=%*>?/?H)+ X
M9SZ9$\I_TGSQ5*/F]DEFE<3CB1!LD)AQ:@;4#3,RYX[%TXF:@X483)"&21HF
M:9BD81*."=(P2<,D#9,T3"*$U\E8NMS@ATM6G-,B2!(N3C:40V1." DKVTQL
MJ(\&84LP$=%&E#DI@K!)'$-7*PI+ R8\W["5X<FGKTA+)"V1M$32$DE72GPV
M"13<R[US(4!%9H*%(OH6$PAJ;:[$X%([Y0&4YY0T:U+#))<D^ A"=*D:Y\ E
M"3[GRSN9+1. "?7#%J$3:&LM6'W,U:O_4,WU7HNG*M(C*)<]\P\Z5WVGU-GE
MD/^KYJ/B&\2G^M2&5W@RJ2?>(,GZP8L 1#^.8[4?S869*78X-NQ^AOWRYI^*
MRANI(D*P0<*#E/VZRKZ$!W%Y(U5$"#8<!AXDV:7TGP,;)$"(RYO:JTBY9-_I
M#\%=$E?>?_A__[G]3GXE_Z:NZ3DS*D(QMF2+J%M]XA0 "\.JOXG'I?;6!?7U
M]@Q^,W_BW^]<3?=-QR:!;?K?Z.0?5]__!%O8597!]X?W5\0T_G%U]R>\:T_I
M7!%;FP%= J_YI&GSZSL3OD,_F<_4^&C[FOUDCBUZXWG4][Y0_XKH\&1X(7;7
M6[R'TE&Z2EO],[Q!P???+3YK_^>XMY;F>3<_3>]/NIC[W%Y_9B?\_\1# HK:
M4:Z(0743UN3]XZH)KX@+U_Q_7)D_@4[!S'#\\.\@C;J&;.U<O575QJ [^NW7
M- W>BB?-TN8(!@\2JL7AA50;"=42JO.@NBL:5+?+0W6OH;;%@>JM#$S2^-?*
MR$ALEKR0>G(FO-D,OSOQY[(A&$N>HY4V/:HWS9_-J6G JUZ'F#NX>CMJJ;W?
M?L5+)3X)R491BFX+\O"&$X!K1=261*KC;%(5> V2%P)M&&X\/%#$/!GRB\'&
M+<\;5L+*RW9(=LX)]"K+"8B4>I<61R2IE$@N>2'U2B*Y1/)#(GF_2B07)C-?
MD?7?WO37RH)(9):\D'IR)KS)S<R7Y\]%PZ<0##L393HY:\)L^Z^^!M2!3PWS
M^6WD0'P)9M0U]=V(D5K[+ZMRF'R%TK?MMGK=S)V/2<;'*26WSFRNV0NBS1S7
MA[?PB.G#_\?.'M&8MT=>3']*)LP=)!;X@QX!CU*#=;L:OD_3,FU*QIIGPA^>
MJ4O\*35=XE)O3L%[>Z:$>C[X>=@8(V 3B_E=6N2&/UAC+BK].:>V1XGO^. ,
M&N1ON_NPPU4?-OF ^\FJ&[LA&]6&_^6GI7JQQ]HOXVJ/JGS-=O2:69\[]9I@
M-7*\ZI4/",B>A8LP@1^:/B7.!+E)_!>'++ #$*$@OP:)1F*1CM(@2"*BV0;^
MT&XD^&XM6F0G+5&$4Y./-A+?IIRU3!&0'A_A0W*C_Q68GHE_:;!/44-,S2+S
MP-6G&HCR'$P/11KN+LMJ>U5(W@4>Z)GG@=:.39O)RJUC>R8 !/OED2V(NBXU
ME,VU5]'=$HN(ZZQP=>],Q]--:NOTHZV')5?5E&TIPW9''40_#-=+;$=MM3,2
MRFUO)*8OFD<TWW?-<<#:[CB,#^$1G+GK&('N9PQ:BSQ.P51Q@]9$4V1DKB%P
MP9@"+L?&T=A@]-!TH@G3\45<.M/@]O#UV.!-F"#\EH*E)+_5[>-O/O8=![Z+
MS.>, 4W$_UCL<&T$+MJ4J,(A#=BAN=%\QE&0<$8^;0Y,_<FPQ%J4T2HEHC*^
M\/6'")>^P7_N)S>V'6A6TAA_X)@D-IEWM_MI)9J#]"*UU^ QZIA+Y_ 7$&S4
M-R#&; XVT_:1);KCL7\]>*"'/&8,*P\619[;V@Y[##S4>5X04NS,'1-+[II\
M%@ZL:.I&2YIK3[0Y=JGVHZE-8$77FO6B+0#S?]W?9RWLGY+KSZXS3^H@XUI]
M=1T0''_QU8)5WMC&!Q#\^0P>_][T=,OQ I<^PCN]LQS]QVZ.%@7AG2.WW8"R
M, 8<^H@.G/D8IO (A_G\89CTCRO 3)U:V$E2!]L;_QZ&6.SW*&CC@14$-98V
M]^AU],,;$D7+[;#)06$1#[^8>RG9(&R'&&PIC,D6.;L*:R6%:"=[BWY4Y2;$
MV[2*:^Y0"JIA;ZGWVTF_UQ)T*0!\K9%.,P,=*W0#[NV3F XLWEZ)MM>8C4XV
MU%EK-JHR%N<:::1H3Y>TMX'V.OKY'N)O&(]-P%PY+^A?OH)(S9\Z@0=?\UY?
M[Q9O[9SL0&;O877YHZ^UP'?>;++ P[4&^'2'B_J#5N<XHZ^3?%!/GF$3@OA*
MJUNWOG2"=<7NM(;=.LV]DH/?Q>*'-$RB$%T:)FF8I&$J<0+H2$>U0D>UW'G5
M2]8<(<Y(,KPXV5EBD3DA)*[(.<JBS%&6V"(MEF"<D!9+>+[A3J.T6")ZPR<:
M0I6;QKVD\M7\O03QCOL<)G$B#!O.^+!<K<KS!3P(IZ9PO#R;+KI*?_?RKTRW
MV;7;T;^[CE=4>1O>8.WWWRT>%W,:%VU%UR4OJ:+GK-+H#@;"G)8[=3I0&,D4
MU?)+P)6 *P"?).">)]]V!]Q,SU@Q +?\^70 W'9' JYHDBG6+)R]MM\NB2V?
MJ.;1J6,9Q)S-7>>9HAJ6GHA]$<EL87@C:C6-;+-_-JQ2M]YMD'[3;GY3IJ_>
M,?RF\-+8:'],V.P-R8ID Y^\<\:R;[%X4BEWEB4O)!A?#*LD&!\*C#.M\<0!
MX]Q$A@3C\Y-*631Q:@XPW<6F(;)TXO3,D#LYDD]R.T<X3VA0F2>T9]7#H*/*
M31C1Y$E48R"Q4F*EY)/$RN-BY?8=L[; RGT*%OJ]H<1*T>1)%BP(R98;70]F
M@<5Z%1MT[H(^\6Z(F [0$NT1Y;:)".P2-1<OMTW.AE5RVV0[_KW:W0/*]CE?
M6M?W">,*/UN4M<RUC60+VK4.T^'R"FJO+S=,SD(>7TL$%H$-HIIUB<!GPRJ)
MP(="X$YFB,1Q$'B?;$5;K2Y;(1'X: A\FFJ%HNR%G %XY-Q>@6,D>2%0GE5.
M2J[/>54Y*;GRC9V.LO7&SL8YR1O.4G0'U64CZC64LE[67B*O.+R0R"N15R+O
M89 W,R.Q//)N.#C1[V1'3TKDE>.@+W4<=#(96,$DYDZFT5KR :7G+A=F$=]V
M%*4!MUHS[1(+.$HL)-/ 9ON%%$QF+EZ(,ASE+H2P65]5#M=</^\Q;^\6C)KO
M?=46J%B8*-9U-Z#&)U,;FY;IF]23HQ_EZ,=2;S&0HQ^W?K_-RRXS^C%49A).
M//;*S7O,3BU_T*?4""R<KIPQ%X]XRZHLQ;G.?8P(3R/"RV&/8NQ+]X:M]E .
M>SS53+7A<6B?L<RB],P7;[8$Z,-QAI\*PA,Y94TL?IR1J;IPHDO#) V3-$PE
MSG(=J6(M=%WE^$>Q("2)%Y(WYXLT<KR:' @IF)Z<D0V[<$Y(BR4\W^1 R%/K
MB6"]#7-3O9=4:O.5NIYCV]0"\^2M'<!P(NH?*($B#/'/N!Y1UAJ>ED6#%'K+
MUDP5U1%FIBM\F,TM9T'I-\J.1B;VJ&\#USU@QX%!HX/1DR"5AJ?.YPDC4J*:
M;(F4$BD%X)-$RO/DV^Y(F1E]L"=2EN\,T&OTA^*<AI-(67%L?]PRKDOBP*UE
MVB:H"?'A+_L$^.=6(2$,!T0M3*F]*1*##=PUD9[';IY'/&H ISE?AU72D:T+
MJ]3+!^>)"+Q7W3AGJ<H7KLH2R*3TUY<-$LC* -FP*B#;&#O_E[J.H7E3E*"A
MJJAO)+"))CYR*_S4'/CJ.A/J>: -$"Q/*)6;X6>$;3)M=^%LD"Y&&1<CKUD#
M>AE)6W=']]G,3L3+BIR\)YS(B*K.$LRD]->7#1+,2H!9-Z]G?6DPV]3FK3N0
M8"::R,@MY5-SX 'TPR/Z%-Z8(ET]["4VUGSX$+N+.?Z4NO#),[4#BEW&J/M<
M,HZ6J?H+RQ'7WE:)P0;I>I1Q/92\5#TSAK=+6_B-6\(;V[A'._B-F\%OH14\
M5*&XVA@-NC*?+YJ,B:K_$OVD]->7#1+]RJ"?>FCTVV<LG-(>2?033<;D;O:I
M.7#KS&8F2XIYQ BP93MHX&Q&7=T$RO,ACF2NN;X-$3O<C;S_\/_^<_M=[GF?
M#TS*O.*%LT%Z*V6\E<R$B6Q_\3O'3=C'L-0./)='[>?A G6ET5.JFV KE?_"
ME5]"GY3^^K)!0E\9Z,O,)*H4^C9LF:N]ZM+04K\%"\0%:#]\26QA*;*3[(L+
MT:93&#Z(FJ?>KC%GS2V9&*P:;-U'57HSNWDSF69LS&IF79H#=V)3&DI7G WV
MK0R$,#-?ZV4D)+:*PPN)K1? *HFMA\+63/NV?;!U0V)@T!5GAU["Y[EG"]8.
MMZ\36T1(%TA&"(.36_0W+6)>+7V>TJUJC^7N'):5TA]*^4.#S3LGATXS=!M=
MM;H3](=RE-9:_5H9#V'S#!*4A;'F$I0E*$M0W@>4AQ6!<OGC!<-&M]N3F%Q*
MODX. V'NXE=? ^K IX;Y_#;BY9=@1EU3WXT8J;7_LJI+Z5=(/^:WU*]+&5>'
M[=39FD_4\RB]GU-7\X'Y-[9Q9]J:K=-/5/.H]][T=,OQ I<^PJN\LQS]QP9W
MM W_2_BE%$1[CH8&U(A_T[1!H6[\Y?O\:>BV_Z<Z'O7&>D]I*GV]W>P.-+6I
MM?5QD_9'XZ[2[[<'?8V)$A UHA\W7"@J7,H8W4-1_<<5+%2G%H[ U&%E\>^A
MF+/?(\7AP@V"96ESCUY'/[PAH0*TVV%E9&%:BE_<;?6Z>34_.^I!4EI/.##Q
M-YP@&KVT(.\T;/WV*[[6.K.(/#D L4N][68B)-0Y1>ST*UR]Y0JYNG)F<](6
M)V?EN$XEL>X$)9(FAHNN,/A];Y//VH+;.&70( "KPP9)$>G=.LB[>NM/*;EU
M9G#Q@H"]@Q4:!#^SD([L )+I>V1*->.O0'-]ZGK$M,D?&OSD.R]V Y[M>9H^
M#3SJ^UZ+/,)W'7"23.S6&;$A^2Y-C^I-\V=S:AI S6ON4O3:5V\GYC-M+JCF
MYGVK8 6)5]7F<]?Y"<Z"3ZT%*7!L M_U_IKX*:]FM&+QX:9?70=,OK^X<:EV
MZSQ3EQH%=MUS_0<?'@U4]'^GSA-8LRFV#+[Y:7I_XDT_:Y_I;$S=/T._Z7$Q
MI_>3&Q?8_,2^%5]Y'U*0O47XI1S86'I.[2+'Z:W2:?1[[8R_1#SD*<6FJCYQ
M)G@0;6S:( #.9&+JE+6.L30P^YKON O"S#1YT3P"O,:#:_3GW(2O@SRLP]%>
M3\E2]0-^C1UT^PRDG/X'6"X459.$-/#)^)8HF-2^>GLS=TT+=6RTZDNTR'?0
M'I=I#],D?':#)!6,2:H!="6(KCYO:;N;F/:ZZ4._\7U.*[ /%)YBW$3+KDAN
M^XW>:+/8HDO-7!KX4,,/D.3CP+30@6F <^)/B<9/68+'AJ]'D*UXY7JY5;-R
M^Q&^/<<W> _?%I&LN8)K:(M(=A_@]=F70[!H<[#("O)C4H1!S?TE+H#=GT4T
M7AI>_"VV'MQ.^%,PUT_3 A)G#H2M6 <DLW*.= 8X)AT%B:OV5HG;8%:540]^
M "0S"&#6LQG1-\9B7+<'\0 W"IIE.2\8<"#M@SE:W[_M'+CW^BFAODT\X":Z
M_RV8#+,H;@>J?T/Z,=K!+Y\U -Q@%E)K>Y[D68./7^Z*[<&@W1CD 1F08TP1
M_BT3Z0A+ ;H"+YQG)DF\"YHY0TJS5_.850#@8B+M^&"&F=2V"'A3W,3W&/^4
MM &?!"YKI9;UE. -3%NW H/N9]X' GDACU/3K=RF*XUN3F>(G6SZ%K8ETV#Y
M=+9E)RKN9UK*0=U0"*BKE$S_#,#_YV12LO#&(B97GY(ANT+=5L=?F:^YVXMX
MN$1#^&@M<?O*L07Q(1A[]*\ +O_P#/]!@K-K\_^\+7?N'*3*.O:H[4Y[&/^P
MDQ1GO _F3^QF-/N=HQM-$:A<<?27B/00+6>:'4S@TL!%B^OPU"="*0/*T-:D
M_!CMR:64F6<G\FD.[M+TNP*Y-*>6C5U<J5ZOUQCUMW6E@CDLVZ#%?A03C+__
M3V_T!BPE-Y4(XWOY0_WV"</=LU)RI3$:;?:KPLQ.F,I9\FY[UZJO2D3;#=$B
MOPS4P/9-W9SC'.X<)RT*1] 1(F&V%7F&;\'5"K4/5(OK%OH>IHU?U,C<<9DR
MI0)S> )$,AYR=4>EZZ64[C%\$'SQ?O*5/^E^(A4PK8"#W?5O5?><@D1JOY_U
M<1*,J=I/%X'R^\1"/(<5>1YSESZ;3N!9BV6R!;P1S9ORW4Q0)6R^!I^62*ID
MCD,^4!V<)G_QGLX=;Y/C<:0,UHXQ>J_=@-?,2K/I B4=G47FG@_F:(Q);3\T
M5#ISM C;(. DB).#(2?8F,/!&X\X8\M\"AW*($Z;,[L%YA*(, 6C:5G@0,PT
M4!/X/SJ94-V/\0DO!]-C.AB(:3XQ/7A6X!(F)!ZX, LGC-%HC$QQ+!RGZ('C
M[)EI<6%/!C(Q3\@%.3==Y@J1.4@<;H>!$(46%V_H35'#<?U@"O%MG:A.@,]V
M9V9['EI*XF-##^Y?<3JB*8_6CM?1F>E1MLM&?^K4\_#.-GTA8[3I*/OPZDX
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MK%]T]\B+?IR:;A5KCL80=K(<7C6912WPU I:X"4MB>Q_=^C^=VP07=+XB=<
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ML<F_D#F83,VV@QG3C2DJ"TF)2-.C>M/\V9R:!HCS=<B]X=5;_\5IHD:&2D*
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M_^JM1Y^IW5Q0S?WM5_S"6^+#REF5SBNSG IVZJV"?;4;_=#?104'C<$@ZS^
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MSD.\I4L@>2%=@OKP4OH%QZM;&%Z][;?4WIYU"U*O16*[Q$O)"ZE7,H264'G
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M9=X7C-\&TP76!? ;PT5S8:[^F-X,JPK)T$T<<C578!ADXK&0SE,5'A@.9Y\
M+,!!C%[LA-B1W_MVVAI8<GW&MGR-F[+N^;!=R"TK*/0QJ$$!JXB:B\NWZ^@^
M GO9T'Q]UC^!7FDTCF^OY5R73V4;Q2\X1S,(J)5=3X(]T95- YG:K4KKHHB)
MFRBT<B/'#CBPV4@3<U3SF6M;PQ:!F\!I,I71P04"B)>!"I]28%*^(KTL!%P<
MPYL5B$^)>D+'PZ(GC442YSYG-RXTI'IG ?V'2_'9VHTU\FWAUI@VN.I^Q1#!
MO*,#8ZYG2;4BL01,/.'?0GORLLU![],6F%IP@E\#";9P:.:;HO?Z_?OB]HM.
M>BP'T4:C-1<%UAWH^J8#[8Q0>T 3W5ILL?;E+MI_[5HECZH2-,M*FL6B5BZC
M1?C5:A9W4:RAL"/<P4@EKAVW"[!-ZQO\]77P75C^O8=K1XU9M[X,Y0_HR@U<
M\W.)SLW1'0%KC#'&! 61V"#6H6'BUN <UP)B*WIYM?]Z- X$$'F)7,3UI41/
M@AO9BIB'W%VBV8K95]6B$9:[BD]HK[=$=_C UTOBE\H?KCVZ\M75(B_B+B(H
MX+%Q?(8*UX@C7)0%L(3K8@P+S.CT<QP=HS[G&G/%H]!_$\?' !:X?"S%5?+'
M&Z9C:'KU.#-;X0C2\<Y@SLVHFPEMVUW-\JP<FD</TS%B\/>4K*]@W4VI4Q[B
M0@9GE:<<,P8(H*4"1@^@_8;(Y#_(2]XC+YFUJN?<ZT*,F'F6X# 9V R1!YEC
M4P:=S#&98S+'9([73)5PH)P6S\J(><XSY[C :43^*Y,E822:KI->J3PSZ#E9
M1G:6L*?4V$(6RR!)D,4R7FZX9406RT0V3$7P]N.MOYVW@91N,CG>E7F)!ZCJ
MCJEI.TJ5DL-4.:V9EZ/<.3=,%5[IB\.8(0:"&((8DA-!S#D*K_00<YSZ8WM<
M8F+E.[.%\%U(P0-+'^NRQ8-P_3%&))JW&4G(?\9[P,:(8>MTCONN#U)NR-[X
ME$6CD&EF5Z<L/GJ6/Q)W23CXISB4?B89F3*JUY[];FI2XS>L<_:BVEIV^"(Y
MR]MZ\;99:?;:QM3B("MBN#$G#"7M)PPE#%T30PLE$LS#T'J"H85,?&MC:*/2
M;C0(0TU3UQ+L0)OO'KA325[0-Z"3B<! F.<W(U9#[LKRBH&HS3;4II#5[Q#4
M!G,R*(L*I.9S8D]WZ@]H5!K=2V.*)I#M,-QV$'*2]I=7#(2<VR!G(8NI <BY
MW LPA<=>G<#1.!4T)0Y@!Z<NSVSU_YOP1,!=G4K;'CF>(^%&3'A8ZJ-,QLC'
MW/V.=0XOE=S(F2&JYMIGS8@G;<:3"NG$#[AY$AMN($O7.;.]CQ"$5J5W<6',
M]LE:%LB8.HWELD($WN;(@L#[#$1%X+TO\"[4/3 1O'<0^]"J-)N[*[),X'T*
M?I+=E,*>[R=96 Z[3&(Y0EWR>9R*9&&01W?ED;QEPBLEZ=HZBO3HIRMW(DHB
M9#E"5JBE]&Q"MAOOQV6EW39G3VD1@5H(!:6R*(34) M":D)J0NI](O7E/I!Z
M!ZZ.3J5#2+VEUAT='&)/QVM5H B^C>L5[:,:TFR%Q+5?8UX=J^N0%;+,3ZO<
M!4(55E-ELI]4;3YWLD4]NT:AVN-:1<B^^-Z#D& 55"U-^0.+9F5_QT)D7_SP
M/R*<EBA;P>8+IJ&3SO^+%V][M59A]NM1 5FX<4GZR O2M\TOX14(E\?E=_TH
ME"'W<&HS\5?DA).DCE=2\U=@S<T+5:B^$G^L=^./6&0,%"6R1*X"F&=GZI,/
M>8@E?_'=5OS2/C8A;2*7:</\!W@E9UI]A%U-:C?'%92Q0G!.T@OKHS8*]>7V
M)E!=<^Z#'\1?X76-S=9L&=M?E<*ZLJ, RPZ^>-NH7<Y.95604-98.LWQ18ZG
M"T6NETI73?3F>![(+S<QAYSW'ZK-;EQ*8Q@D71J#,E3[@> _JWP /;KB[B.?
MR!?L]?,MZ=(,M/.M[ +M:W8+<1.W6$ .4%)M@F3J\KYSI.7Z,@K$#[&?>H6I
M55]/V,<H)0E,-U>--0ORS:8:]+A<YB>8N6@GT,)<2RE"EE0$9=?W@="U#7=?
M4_,XZ8NO13!V?/8-+-4(&%,4.H #LL(^>M:B4KP;@;HQ_/RCQ^("S]/JM6G)
M731<*E<PX :HR"*IZQKTRX:,O<0ZF,WZ&WV1^M!X\ZJ2JW4,#-5*'P/+K;1$
M?=(>5>5^P)Q0,K50@M8ZH:LUTE%MA6ZHTN#J5DL$6/<[N64,L(75-_%7_3<"
MFNOH#53]O8^T1CW+=0$Q(^XR@#Q P'!2B7,G(UCWHQ!&,&2N,W)B6$V>;B&,
MXC7)VX<1B V?$@JLR#D)?.EX@*I#7XZ'6(C8\89.WPG](#XG*\(A%B%',B'%
MV2D;EF!W@-QH4@1W* DK<4K4!J5:MBYTJE4AKY,C;H/ 5>7W$%I;@8=[U4 ,
M@#$AM=>?+=!:1]<BC<;P*!"UQ>4PK98*8[LY3VW6<V7?@:Y\3U\+'V[3=_ZN
M7WD+;XS+O:_>UO\Q&8NO@PPXI:<6]"#,S"J84]D8O&X,2_7N)B68VYWZW!+,
MJ,[Q+'1RUJ'&L@6YD44&F$I\BZ$L)(98FJUAW\.W707KA<,'VO7]?_^GU7WS
M;EJW-];SY97#[4@D)@^N XH-JX-[D=HO&'#7\; #S ZB^VRV/8;O?@#Z*^0S
M*\6; \'O847D^4_LSG*$9\',_O3I=K,JQB=@#C^(?A#Q8)(I:;X(?=\_ ?RH
M<M$)$YL!X'D#EN-V-XL";EZ\30$Z?L@RA$[><P^=1/2+$+A U>/F59B,^JYJ
MHK;(@3_A;CBI]D&I$1F5L5=8Y\8=R8!U%J4U&B>OFXO*>&L0VXY*,B,J@!(_
MX<5#6,(JP*@@E$*[X/X*3*<!/!5GI.0)>1B-_2!,"\KC"+$'/_!AG>WT]>D5
M$,@X9T2P";#X5I _&@>.=.*B]>D3DDD/$_<!^J0\!/ -K*#"!(5P294X!.#1
MD0OFP1;W*H +;X N.;POX(702UAI^C \PXEJD?H,S7A 6N%;:O#1]JIV^%&@
MABAP1(C:A0Y45RWX;>&"C."K4%A##[3@'FP&<ALP.2!;@$F!:@A:<C_T(STF
MCWX 9 P$+,8ANQW":ROL'SZ\YE_PGPK[P9U'KEG79V[QB+W$FV)]^B&" ,G-
M)-&H6KR<.*N9O.XT@QD?=S_'@]:>I3-\*9F!_4DR2_(FY*7SZIB$J7D4PA2/
M1&P%P09F QZ;\2Y O=GL+7;U-6IS8#WQ\H'%F9JD60..D^"E \/.T3;'*X,)
MW@MK$Y1!/*(2?@EA2L(DBL9XU1;#V\H-[^?D%?$0RM_'OG=M#1TP/OCYZ^!6
MF]@,OP*V]5W<@]7!"9H^0"X9?1F$WW'$U6C#A\_\R1E%HWB(]R2;BZQL.DM$
M$XU1/C !^+3?J+L)N.08D[*A2>>G$@)CJ.:F#)4A';"7_)6RZ:X(8R<OQT4N
MP-;'CRQE9"&8!#>=GRD&^.A2C6'.3B"CPE[V7ZGK!HX;OX4S#ZR3XG6952G>
M#\\$0^4I#_$#C *T?;W7H'KB5;][:I&J8H:A=^\CQ$ZP-_"]?D-\P;^@*38L
MNY0.6Z^RHZ,\O_!R;.G>7EQJ9/B1\W-(?\: )!8'&#YR0DVI +E97RV7E>)S
MST-JY(E0,1OE0I@5C4QDD^*R7M1-'\@#9:04%BA:"?0*=P^P)?-%S>'Z "B*
M8B\6]"X$C9E]#<,&)K]6^Y-J<F&&!Z9/Q=\+;X*>.K@S$CJN>C2RID!-4#"W
MX:-P'_3Z"KJ [NEX?@6P=@5M'8G P@FJ*!_<(R,@._,ZHW[(MDU9\^FS;!!&
M/ E&(/$AS$77]1\3\J>_@^=HJLR9XG) WY)7P)H9!]37NSXPI@M:(J%_D6<-
MU0(@WZJ7H#O(@X''N1,-^#'9^JZ9-H[Z*.5;">.8BAG6[C@CF;+/VM6"#QF"
MTE>1/L(0V<Z]HT *J.-C-=Y4CK^T!2QJ5?-C:^NB655&;$8#L[J5O!3U"Q8(
M?\8J!=H<:<"SHYS?3&\[21A(X<6[C3 HGJ^VV%,/GN5R9Z3WN93G36Z@H[7S
M6DUN8&EBC=B)*Z>PW;(W5\X2\K#,A_-V#F' B;U%7PNG>H[1UR6A+.N3V#D^
MJGC^)6XJN<A/I08/7Q_3$#15>L;5YH4_+-ZH*XSF!^X$_^9N)*8[<W(76W,L
MWJ85]G4X??L?MN6%?S0Z]187O7JU=]'O5=MMP:M@-WG5ZESTF_W+EC40S9/=
MVVNMN[>'(\_4T+//@N/ ZT7*LIW65JN0(O\.\2IR0:=34:H](\RZ\\GA?6"[
MR#'B5]A?84%H10&JW0V"^P\D'7L2.+16"_RR.ZASWFU4>?O"KK;KHE/E@T8;
M_NK6A=7@%ZT>?X[ CQZT@Y";(24XIA(0=P3-AO9D_0-($1J7;P SE9!@R0^R
MP* 06&&@0CPHA1C%TM(,+D@D%O,Q'BZQ$)6$/,94I3]1S]1+&UBA!6@[T4V!
M".]'$NZ3KZXV0N7-8K/@L7'DEW9VZ-@YY>FWA(M%G"WH6OHYCKM3GW.-N>)1
MZ+^)(^^0CO&Q%%?)'V^8CL[KUN/D>(4#=@<Z"=ELUMK-;<_*+PQA>4Z$8%8X
MS:-'!1XC>4&#BJBO*J)N1!7URTZ-BJC/R*U@Z8]^T)LJJI\HNIRS7 A6#)+$
M%%9,0)4&7'"Q^<&BDN/.+2Q,)KCF4$M* ITR&[>MI@Q9/[)^)RO8WP)?2O:[
M%X@XAN<W[GB2K"!9P973XLQ%0-;M] 5;L&Z?X+,XOGDS*86<(:(B,VBF",@,
MGKY@ISNP9/G,D\X)63Y:!I.%/$L+B<<#5!RL#H(^/D,D^T?V[T1$1?;O] 7[
M696M4V%+=QB$I4+IR B:N &_W_SI"^=5O"%_OHDB<]&LZCX;(]=5/.&5RIGE
M.G#WB[>?U(F$QE7F1)%9^245EIVOH$XX.VNI,J\:*J?>>OR@W)E5#94=59\U
M0PR$,(0P)"="F/.3'2&,&6(@A"&$(3D1PIR?[ AAS! #(0PA#,F)$.;\9$<(
M8X88"&$(84A.A##G)SM"&#/$0 A#"$-R(H0Y/]D1PFP7_W<>V7>,$<MG^ WK
M0F%T+,/Z L<.BCUN+AYCY'+<,P/K,(-E<>6ELFQ;%V#?FY3RO.!9@CIK:K!Y
M#NN+0GGU!^ZX>*S@@Q_<<5>\$_UP>L#@>N0'(9[+Q_*[*DOOZK36:?+?FXE*
M_WOK<BE5:NOX F6R]7F&#VBP\^5#,K>G?_XC21:K(KNSSTHO^>B-HU"JWQL+
M'YC);OPA$']%PK,F<Y^638.<9BG.)!S?NHQ\H].I=#J-G162/\MCO\;,+_,.
MOA&A, RJB% 0H3@?R6U,*%J%6JXK"(5E1:-(E3Q4J7^FF7\PK=F-P')7/_@3
ML8QU6,9_1>#;7 [1.':;C>8;HA4G,<N(5I LB%80K2!:L9!6;.JG6$@K,)\@
MT0JB%26PCT0K2!9$*XA6$*U81"O:*[T54TJ1)QC$'&C;HS06D8@$R8*(!!$)
M(A(+B43!/X'Y:3/I::_#I&J5 E:B#T0?2F,'B3Z0+(@^$'T@^K"(/G0*?HC/
M:7KGJ<_A%@ 4.DO<@38MSM?JF9)6>]FQ&MN/,.]ZLU8>WG 7]4,_Y.ZQCITM
M87$EE(:Y1P WK>*0$Q[1/"/$N.8IW)U(DGA@[CC.Y4&/XYPNNSN89VA'N+4^
M:)7*]AT7QXA3F",+XA3$*8A3["5TMGG\$SFG2S3VYT8B9G&^:$;,PAQ9$+,@
M9D',8B_,8E-OQ1X.Y1"S(&91)C0C9F&.+(A9$+,@9K&7<-J5/HN=G,LY7?)
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M3N^@9W+.D.OM>(MI1[!%550,A#&B%.;(@B@%40JB%'N)H&T?_US.Z?*,_<7
M$K,X7S0C9F&.+(A9$+,@9K$79K&ILV(/9W.(61"S*!.:$;,P1Q;$+(A9$+/8
M2V#M2I_%3L[GG"YYH.V/<Y@71"5(%D0EB$H0E=@CE2@X*79X1N<,"<2.3]D0
M@3A?T"("88XLB$ 0@2 "L9=S.@5?Q*[.Z9PA>]CQ21MB#Z=PTF:?-6Q*2"1^
M/.>8S1Y/3I=0%.:?G%Y8)8TXW8D=K=ZO)(G3Y2)7Z@<]9G-\7M:L=RKU$S@"
M3<3L^+!#%, <61 %( I %& O%*!S_&,Q9Q!K2D3@?,&'B( YLB B0$2 B,!>
M D0V]07LX10+$0$B @:##Q$!<V1!1("( !&!O1"!E1Z!G1PZH<T @O[3@1N"
M?G-D0=!/T$_0OY<8SX(/8(>'1(X/^(W+9J51KQ/@GX3V$N"3+ CP"? )\/<(
M^(6U_JX.=1P?[4^DVHF98']T?(F/8+Q6J@C?VL[#9IW/]?67V5F9?Z56D2_1
M2 2.5?B\P'Q8\&019%_;:([GV9/E+3GD,'^H-GO88^C1,$BZ-.;WHMH/!/]9
MY0/HT15W'_E$OF"OGS_@R_JU0!@P]FAF'"_BRH:EQJK9[?QA6U[X1Z-3;W'1
MJU=[%_U>M=T6O-IM-GG5ZESTF_W+EC40S1=+'M1JU?6#+KN#.N?=1I6W+^QJ
MNRXZ, *--OS5K0NKP2]:/;[AE-O-(, K8WU7ZA];C+^_@.69)5P7;0)8E_1S
M;&W4YUQ#KW@4^F]B>P-SW>5C*:Z2/]XP;9.ZT- 7<\\['>A@6K-9NR@>>5JS
M0N'"&?D<NY@53O/HMM"0P^R'*QF9'=*^[]K/9%@[E00T!?H-HF@V7QAP(/JR
M4ULQ=9)1.\"T,41N[X2E^"-K-2H,.&3]Z.=N#\'E#!G\]4_3G@*ZG+-<"%8,
MDL045DQ E09<T,R[9-;)LU%RW$GV1IAR;!#HE-FX;35ER/J1]3M9P:HH<#8-
M V=X($R2%20KN'):G+D(R+J=OF +U@U/N8CCF[=UZ02903*#9 ;)##Y3L+AM
M;\CREBS?*5L^6@:3A3Q+"XD1TRP3,GUT.TGVC^S?B8B*[-_I"W8:0,JF$:1D
M!$W<@-]O.NN%\RK>D#_?"/M?T8CEYKHM+#]088A7,,(B<!VX^\5;E<>>-:Y^
M?8UW'"TT>;$%5%AVOH(ZC6,M<P&E5$=6#)53;SU^4.XS*8;*[D"<@,1 "&/B
ML!/"G(2<"&%.5W:$,&:(@1"&$(;D1 AS?K(CA#%##(0PA# D)T*8\Y,=(8P9
M8B"$(80A.1'"G)_L"&',$ ,A#"$,R8D0YOQD1PBS7?S?>63?,48LG^&W"1NI
MZ%@V@'$^=E#L<7/Q&".7XYX96(<9+(LK+Y5EVSIS]=ZDE.<%SQ+465.#S1-3
M7VQ8C7+D!R&>R[_U97C#I;-9,:IK*45XZW(ILSFJE<G6YQD^H,&.LU(7;T__
M_(<C AY8PXF*[)Z;[_JC-XY"J7YO+'S@KK)GU[<OCM6J=%K=G67//LM3O\9,
M+_/.O1&?, RIB$\0GS@?R6W.)[J[JFZ-6<VVJVY=6I*QOVK;1"O.%\J(5I@C
M"Z(51"N(5A1IQ46A8.:VM +3"1*M(%I1 OM(M()D0;2": 71BH6THKF*5DPI
M19Y@$'.@78^R&$3B$20+XA'$(XA'+.01[5D>@=EI,\EIK\.D9I7"56(/Q![*
M8@:)/9 LB#T0>R#VL) ]%&(P/Z>YG:<>AUO 3^@L40?:LCA?JV=*3NUE9VIL
M/\*DZ\U:>7C##S_D[K$.G"VA<"44A;F'_S:MWY 3'G$\(\2XYOG;G4B22& N
M</;RH =QSLZ)LR.461]B2F6ICHLZQ #,D04Q &( Q #VP@!ZQS\Z<P8.&B("
MYPL^1 3,D041 2("1 3VLA_4./YA%R("1 0,!A\B N;(@H@ $0$B GLA JV#
M'$^AO0!"_I-!&T)^<V1!R$_(3\B_%^3O[/% ">$]X?W)8 SAO3FR(+PGO">\
MWPO>%Z+_=G4$A!SY)P;O1T>4^,3%:Z5\\*WM/+Q5LD2M<[R(*V'.&0[L?"/3
M^\SP9+O?KG7:OQQS=EZ'[)VPE&:S5J/"0+OAOYR%>,J!^0/VM\WG;R'M[>PA
MJ_4).S:G,-DZ*7V^>/&VT>G4+@K3B\'@N?!'A?F!EFHLV\6=>>H'KC.&69_K
M2R$.Z=;W+)!<H"3_W9$_OXD O^#WHK':&.'*Y=JS9Q<P:Q](*[S]9G(#5FP(
M6O93/45,QN%'[T'($(W71T^&0:3,V,KG_)B,1;8AMX&PG;!PX=0*-NKP?W,E
MU$H%5&V^>-NKU]H% ?V"NA4.!;OU1V/N392=O'PCF0,#&$#SJWW!T>HR"\:*
MB72P6)^['-HD*^P1+L01CQLH;+B9P?"QWVMW-?:;_R "#_L.7\O0"2-\,2CU
M:+8H#K2#AVS(\?YDY"0^6#IP'S1A'$#' IB.V.C9AU_?(XQ [_MA1?_X(U#P
M,?^[[P)TS!IR*>#.0&B,81Q:L>#!<V^H;3$O+PMY(V'L1Z"]#G>_\;$(=CHM
M+VJ=I;.2;3H5+PN1 /N>BC/#<P8S<8ZE?/Y$3&8*S#]XU'0*5>\#;N,$34:1
MC7$80<>%)P+NNI,*OACT.COM1GS"^H(!V;99- :]L,4(9P?\O[H\4"$<E6R3
MX7K7$? (_'("$_E!@*9Y. 0L@(&"V9>Y>':>;X5QEX5D:=MQU-43J=6JU1=.
M)#1XH_3%3*9O9GP.KM>0V9PP5_DQ1TMGE%);T@5#@FB!Y[^=@0.Z^NB$0Q@^
M=4J;-= BZ3^; "%*N_IXD C5 QZMB9YDD<29\%?DH[;'$ +H@+, 'L!=F#(>
M7 H*B-_BM=('ZRWB=OFV<.$AH>,Z_\4?XR?X?2F"!]5>1QT=KS"8>6-AX9/<
MB=;?^9U2RMX7PE.MQ"FXN/'CP']P;+BF/X%KG,"N L</)].F0B,<A:Q<@CX&
M\'*;#0)_Q&1D#=.?X[%/;].]JC%]ZAV8HVI W%><SHYGN9$-<[8?A4H*GA\R
MUQDY.(BACYT=^X'Z@!8#WB^>H(>ZKWU'S7UHTL]XI.$Y@?]3!*]M 3(/E#1T
M#RL964P<X=IJ!#*CA3)G$M[L\H !IN)\@GX"REOXV,1^,[CA03_&\?2Z#B<;
M&*^0@UV!/L>==*2,1*#&ZU&X+OX+DR4"4S]1C18P\?V18S'0+(7:*,C9X59C
M%($9Y/!7&#A/C(]!5-P: L49.C#RRL""0&2N.8&XYX&MG[16#['5MH"/8!R%
M:G^J'+AZA??'#P+#C*V?ZE9FVD 7XWERZN8DL_31BX/83M8KH.]]&<+5#J(4
M3&OW^2"Y-EE=2$_E*='36<3='&$+\1Y;(VS!7?/QRX><OZ8*>H\;-(]^8$OA
MO7CK^47(S0[^)K!;W\D\,<>=)T&F24]N%J4$T6#]ZVN\.']+OB,OWEKQDF/>
MM4L>S_@(OM?TC5N6_CN H7<4CE:F7X[Y1$E)@8AE!0B2XFDL/(GR0DO[!&H1
M"C;@3J!1%(R>Q=$BZUD/7\LA %0532?::&4C:TF+RRK=S'@ML(ZWWW]CGWQX
MH".GP&/')(HSVY%*1O"5,IL#UW\$,7%W@MP%&(RF,[$I1*,I%4YEZ%*"=,YT
M>84(%;<'C(*-<K:5M43WO3*\L4T&H0IX+GX'!NL:]$6A:;PLF=>]3'<LN.O>
M#S"P/ .)":F<N7^8I R"U\SUMZUXWR//:2H8^LU7+-W"ZO^3[]W_ )E@M%SJ
M^5YCW:Q6HQ^X!20VG*1+W3OA.7Z@++.P\;'8\OQ2]Q-(_^M@P?VWP?V=(D0@
M@D^NE5G<KE@?=6N72QP-7.$GJ$)L9C88X36,U^:H5DB.F97"*0Y^;\[6QF:6
M/">KG"]A3S(HI!C#L9\Z:!(GV+5"F-.3R<4<+\^6,E$.'22;R>S1J(L6+UVS
M@;ES08<U.&I*B8+<PJ>2[AM@]Z_>/\&@"'&M(7NU&&ZT5;]#H_[)M]2R)NM%
M^XK.HR] P#5E_.3P/@XXL+89AYQ9XFS66HO=/R >'''@,PZL%828%8R/?<Z(
MQYUV.H.1"Y!QU@DQ![KJAX&N@N?W1*"KN$\\:ST7N_:>!5T;3[U"B)W9L+1Z
M8(N39IX)S##M)C#M66A)]H,WLIW+X&QCN11"(4X+JE;)Z6+.!#BPG X+<;U2
M0MP*-3@ Q*U<!LZ 769M7PSWB,7^!:9@X%A3\3:[!6;Y#=Z+0O)L)9MO/LQ<
M$3HZM.A&>&( NO<.UL&NCP%'/T#Z-ZYO_5RQ932SWR=@+,<81P9JI()S;.<A
MF0$ZK R#;W3<3NQ55\$_?W\!BT)+N"Z&]X#0TL]QX)#ZG(0BZ7 AF$4N'TMQ
ME?SQAL4A1?7Z+_$;EJ4GU1=KKT<QM&B#R**I:R1V?_1]U][8=;(3/\G16M%8
M:"N/T9JV4:W)3^%"H!WJY&Z4;:OVK>YV.D(OWGY/+0;[!B9+LK1/*CXM'YVV
M69^,VI#)[AGX8Z$=?AS,_T"Y#=$B!DX_TGMQ+OKAP$1ZMMI$9']%(-G!!# 8
MS!2[$PI&-#%HUQLO?[Y*T$#M8WSTU$ZMR[[CSER$[[5%C7WC00CP->9J7T5=
M*49CUY^(>)LN;0/NUB$(Q1"EO<3C0%1#_H0A#^A?5F@1;Z:J+JB-I3^A:=A@
M&?(P"OT ]WJ ND>CF5T3(//6$%Z;-"#7?\FB,3YDTR":;B%NX9UNVFWFX:AD
M[_5;@\_8"AB,W.\ZS&8SC)J"?S,7DU*,$E(1*0*FJ8-(E1_+S/AQ-8+*=^R"
M%O" 303\IR!934E$,LHUML!A?\*SQ%XX2S3]T+,%7>>_U_Z556E0#QG!XW$\
M]59SF-- >U;KX%E],>3N0,EH^APWDGK[6BD+[I3'@5A:EII7+5!E5'M'YMN*
MBUJ]7Y!LE6+#8(X#[0L8B!O?<B?&87;[MHX^B<8%=-1U_4>U31\_(IZE^OW*
MD.*VD>O.C,=9Z<;45-G/B^?MMG*+E@4&(_M9WDP2^[&MD6@ NUD6^+3=^JO;
MWEM7ZDE7"HN=^K*#@&\O>O4*/*G84YRNJ/1HU233.%?8.E+CH!UQV?5+!6<,
MM-;3,*BC0G2LW73YH69:K//)Z^,US:+3*3BI19"; \V56YSUHTZ)#]56/9[5
MPR#ITA@L4[4?"/ZSR@?0HRON/O*)?,%>;W:T85XWUV5UF<,&"]>3!??/1P_P
M$!-8[7;-R.+UK;"OP^G+_[ M+_Q#='O-2\NVJ_5>KU%M=UJ-:I>W^M5.N]WC
M]4Z]+7B'%IVTZ#Q.:SI&M>:,%IW:TC P-4(N6V\N,EZM5F'7Y@[6,W;DBJ\#
M_7"=C6]JTN ?C%.\]NP/\#V,V ]\SZY\8J?,Z7 1!)?$\4Y@]R70<!P\C*U%
M,84H)A5;RV7,?R5[J6BS'TD@"?+5U6;D=C6*9R%,F__GF'K]ZBL.2^(WJ\Q^
M=Z'5/UY%N(O+6NOBE\4'>_/4Z3FG);-R:![]A*01@]^HM0MCOX.1+AC?Y\7I
M[730H2D(-<J=8H  6K5N^R#:;XA,_H.^IO>X*)NUJN?<ZT*\O'F68![#+Y=E
M,$ (9([)'),Y)G-<>G.\J&+K@4KKQHN2[8J]G_/,.2YP9E%R.]F<N22,1--U
MJKV79P:AI\U$N%E'2J6&I&,9NE*-,!DPX^6&N^9'GA=$CE=NW1XPX^=<#_XY
M9>)4\8PZ9 PC6XQ+N;HGG#!F_$\X83$E(SZNB)HY -]>3&>=:?CEYO& A7./
M.AH!:P5^"/P11@(Z7@0R^9J:S9FH!2&3N(5M0QTQ>;!4"E9=LV1 IUOI-(I9
M#\Q36[(L>0U]99Z("'-I9A@@)\+<TY3;%IA;."2[-\Q=')._.>:V.Y5VKWD2
MF%LJP_'J^1X% _;:SDDB7WRONB-7PUELM!DC&%.CA<S9M"%1;<2)GB6NLZ9%
MF[.B!4>]-F)%\;&)9SDB4L+3F',HT3R%)-MAF.T@R#5'%C1MSD!4!+G[@MQ"
MG;)]0>X*/T0*N;W=E0'>683"NC:\Y+;B.+$,RSP/):P(_&G!P=ACUVN>PX5*
M*)T3WHJA>LUGLUU#!9OWL*53J)*Z!9-Z_P3-4R4X>##Y&(J1Q$RV<&?@NR[<
M^C$NM730,(OVN819D 4S)12#2 &1@O.4)9$"(@534M K%)PZ&BG8<1Q(JU>L
M9WYD-%D?2DIED>8%AVR7+1L_KI\.:UDZS8U>8UAYP*]+*W%Y,_54FTV5D/=2
M%PE:7-=#-<8)8<I8A=(>8 78;127(/VGWY?LV@K7*BSY$E^*I0B;]3?X%+A/
M?6J\>:72"^.T5ZF%0Y^Y_+'"1ORG@\5TX7MGX%B8%MD:<N]>I#6-!\+&PN7H
M5,);:NQZY'OW,HR+4&#IOWNI>QN_D07"CBQ=F3R]W?*#L8]YF]6#U!^JRO*F
MR;Q[A0Q[[P<#G0(V-:'?X>G?L0PQUNK0!4/"#[H==TD"\MS%2RUIXS*VI(W+
MY5F]6T4+^<LV^<I[A7SE>^]B+^EB;WD7\?ASH8LB:9U.WPOBU>E[^P)FN*H<
MK?+-SBT\W+B,JRYC@1,9N7'B:\XP72]6YQ5)YNIYM39M,1!!@+GPX:5<2J'*
MU*K"VVG^[-E[!@[V!U_=U6H8Y(8QR6;)%N=X+(AGFN-Q'4'M+,'CG 2VT+@_
M,']M0Z=0M!UH#R"@A=5=PT>L:CUO2+ RK*5'/O$?8UUPK-.B,OEC)D:54KL_
MP:I;KBH9I JNNSI%\S2MOXJ!RYH,-<0@OHTG0:$4\KXGP=K9^^=.@FSFZJ6)
MJS<>B$+US+T/Q&+JN)N!P IZ_L*,GI6X:G$8@0H5-1(+T293=CK+,^GO52[.
MF32@L]R$)2FHLS6.<G,\F4:4.Y1RAYYA@ 5EIS B.T5Y,D]0LCI*5G=\>9 Y
M-F70R1R3.29S3.:8<H>>J*1*=[["9$D8B::4>L^4W*&$+62Q#),$62SCY4;)
M0H\]3RA9Z&&]]1^+NTT\S.QNXF:F>?%^E,W,U&C94L6=G6XD+$6Y;ACENB"#
M* 87Y*(0TJ_?/V&E>W&CC>J>HC0VCVMM-"O-B]V=/Z;\9J=^3H5 UK!A)Y E
MD#T'N6T!L@M2AAX$9'=Y>*17Z;1:A+&F::0!.43+ZVC .3D;]>H)%>>>!$_'
M#@CS=JB)"9UQ8 ")82VV0V1F0S*S(--G@<PHPWCMV9]\X ^9,[&'\PDT*]W>
M:20!+94]V-HE0$!X9A:X9(IOJA@("+<"P@7Y-W<$A+M<MS<KEQ<$A,;IW [6
M[10@L.W@IV4^,N=2U0GGY*1UZ'#7/-<6,17R*)97#,14MD@4WEN0WK) 5.)D
MX+G-A7<9:_B<E7N6I_Q7!+[-Y1#UK-ML--_0EH)I2F:J 2#X(^TOKQ@(_K98
MJ/?J"S(Y[AC_UERP3U?E%*UFG'+13OH1!_]692O$-% #[@0XW)'*-V:+P'G@
MF"7+/(\5\1%R%)97#,1'-E^.]^IIVE,Q&8>+N(@VAA^]#V *_XV6\.O@76H'
M/SF\#Q>&$_-7Y&0#SMP&E!$!C3SQ3#9WB<UM'LKF+E\%DLT]*3VC8]S'ED!F
M33B3B=H\7TD9D=" 82^]33)##+06W(:7%%+CKZ F[SV.Z?UW<+R:-F1/2K5,
MG?9E!+VMEG_[$P$M_U::V4+AC1V:61-6?&1F#5OQT2[@MA+X+J3@@354I6-L
M\2!<?ZP*1^'"SPJ$[832/,=(&6'0@&$OO74R0PRT]MLJ+FG=W%OPQ:TV?(EQ
M?-89VC0 Z:*WNV0>-,?I=.R)CKBI5K5DBF^J& C<M@*W=7->;0IN*\)LIX7.
MZP1NQND1G7@]XN!_$_"'ATMIT+C1UHMH\B6?F0N_9#;(5#$0S]C&LW^Y3F!7
M:OD^HN';S>+YLMDC][UI^F/JW"9D(^TOKQ@(V;9!MNZND6W=E7.S2R=3C=,?
MVI@^M@1T;(C$6&0\FJJF'^.NZS]RSZ*CJ<>?$&8,>^GMDAEB(,ZQ#>=8-U-4
M$B?W3@Q$$*A N6LI12C_G5C&Z\0P[BI&>7'EIT[ELKT[QD*6X<PM ^$B:7]Y
MQ4"XN 4N-M;-(+4S7%P_J'PQ+K8J]1U61"3+8-A*_KFNE=RR_6B%[8T1R]=P
M* )5NNE8OJXL/R%YF.K,7BZ;4E:R-%54^7*6SQ+76?.AS:/[&HTU"9&RJM?V
MGY$,\1#/;HH_92+8FQ?&;%6L91^RMKM4-N)H=: )54_!5!.JGHRH"%7WAJK-
MO:#JQHFI+SI-0M63T#$#\E4O<R/8?M1W!6O6R@.P'Z?5I(Y<]GD)\2FA7$SU
MQT]E@X,Z%T:7":^4S.AOYHDQ3XKV*\JS9DV;DZ;%*=3>/XV%)\6-ML/F)TO;
MD<5?W]R7RFH<%P$(C<V1!:$QH3&A\7[0>'&FO4W0V(2<>N5"XZ,#0.R]>!UR
M&!WXUG8>-NM\KJ^_S,Z:_"M!15#]'$\'Y21Z_B4:B<"QIOK<:A78Y9TU%';D
MJMH ,T$^6.,]KA+@"/D#._(#&G7C^M;/S=BGD!8?HW$)(K&A#F2'H5WKM',C
MT3R*F..1QYRI23<*TODQ%,H5Z0P<"YX!HS4:^WBP2>H28'JH,\6ZH=TP;1B7
M8 XPIDJREX['PJ$?2>[9\M45^_4UOE'-_STI$CPV5E.EM?%$__N+.DA;N)@D
MU@*CD'Z.C83ZG&O,%8]"_TUL)F"*NGPLQ57RQQNF34FW'L>M%CQ\QX/:N:=^
M,I!HP2"*8!>8>'PU-H_G[">4.3MZ?=^UGTE'=CKHIU5Y9W?:;XA,W@E+C/HB
MT+)I-2KFS8G#1),:(@\R3*8,.ADF,DQDF+8(<C_0.OQ9<>[G/'.,=8L?+CK/
M9$D8B2OK!'^59P:AV^;H3L928PM9+(,D01;+>+GAQ@I9+!/9,.4^WH\'-]FK
M48&97.W67)D76D^I*8Y\^&1AJ$"I(CI,E=.:81WE#MDP57BES_)@AA@(8@AB
M2$X$,><HO-)#S-FE!&ZT:I=F"^&+")D_%@$/80B8ZTO)+!X$$[CQD0<VE:H]
M_JPP8]A+9IR,/150;NC>/*"_4*2V$/;\-3%_G\#ZW6:-WXJ@YZU3&W;;E?H.
M,__0I#]SVTN01]I/D$>0MR;D%4K7[@SRML_F>]FN="\)\HS3KA)L[9J_"$]W
M=P/Q(+QHZV(\Y'8GCR")@6B(&33D<B4-2;[09^SWM=IN5YJ7=6,2 M)D-WRR
M$]21]I=7# 1UVT!==Z=0MZ*^;:-#:&:<SM!FM@%"^"2X%,R-<]A,S',N$;<@
MGUYYQ4#<8AMND=:T%9-Q6"06:/-@N*^# $OWK5.D9CF[N&SN+GD^S>@SG]&$
M9Z3]Y14#X=D6>-:L[QC/5JR6NW7:=39.:VC7V0 AW(6^];/:AR6SK=*5"D^J
M;++F^9*(9I +K[QB()JQ#<TH5'@M, WX(_DNSNU^F[&"UYX=IWJ7=T,>B!NT
MD]D+;GVYJB;+]M%RE>X.E^%D(<[<0A ^DO:75PR$C]O@8Z%6Z^'Q<?MH\HM*
MMWU)^&B:%M(FN %"@&G++)BS,#'-\W,14R'W8GG%0$QE&Z92*&$UCZG<*HN7
M.\KV74C! VNXKT5ZI])NT]Z"<0IFZN0GZ"/M+Z\8"/JV@;Y"-=*=0M_VZ^]V
MI5-O$?29IF"F;*OOH&3-F2W*OX9#$1S+/V5$R0=C1&&J&WN](@\EMV=FB*JY
M=DT.(CR;$9XULK6A)=W7DKY5J=<[QNPKK&48C*G 7B[C0)AJCBP(4\] 5(2I
M^\+4-=+!K<;4[7T%S4JGT29,/0GE,F4#_] .!,/%\L,/N0MSKU #K-1%)(T1
MCZD^]S4*@1 ].A%9KEG8A?C3[OG3ZCQVOP6^W%NR^$:]4VGV&L;LMA"#,M=^
M$"Z;(PO"Y3+(DG#Y:+B\.NG>&KB\O5^CVZM<],R)_R-8/H7(B#V>3#!< KD*
MYDF*/D=0&7,#YH(9PTXU9D]#3E1C]H2%5_J(2#/$0!!#$$-R(H@Y1^&5'F+H
MT/O!A?#1"[EW[_1=<>2=<8)\PX:]]-;(##'0^;]M7-R])2[N3U,?VF^^;S\Z
MKGOMV5-#J%W@LY_W=QB^=T$G HU3.5/- 8$A:7]YQ4!@N 48MNH'!L/GI*>K
M=W>7GH[,@6$K=3H>OVO)J!&K^H-J))^[@*>#?>8@*!WL(U'1P;Z]$:)E*>XS
MA&C7%>(N&G1$_C14BH[(DRP(2<]&5(2D^T+29<GPGX.D*VK3739VYS(G)#T%
MUP$=C-_WP?A,:#F=PC-!1J8ZX>D4WOG(DD[A'8TZ+<S._]&S_)'($ZA]11]<
M5#J776,V7(A*F6M#")O-D05A<QED2=A\-&Q>6#Y@<VQ^5JV^>IVP^214S)0(
MB3V>93!< N^*2?XJS!.A>=YH"N&D(XPD)SK">%A*DQ8($)-Q6,SXD^$S7T1X
M(Z %XM_<C73)8M?U'[EGB7VY(7K=BDE;.A3X:;B-( @E""4Y$80>%D(O]@^A
MS\BJUZQT=YA5CR#4,,\ !4#L5"SIQ&0\F9FTLV*"8$SUQE.XY\F(BL(]]\6
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MN]H=]+O5>J=I]3N=KNCVZL3HB=$?IS671K7FC!A];'"42?U-^/<P48#)L>M
M</8Q8T_/C^LGH9$L&8+3YT\I0&IVK*-XEGC8GOJ!ZXP!7'(.MD+\-0!77P1?
M!^EF6CQBJWSA"X/(/W[YL-R3!MTL>LZ2Q0;P,?7Z9-'AZ(,;Z<] %N+0"!6/
MJUD,0"]2'>>_FD=Y_D-R/&$(3,(=@<['_$FFD=PA3((P(8-B(I <J<ALX$#I
M5F_<&*EVY]3RR!DXR#6E(D_0DWBG0G$)8%#C )[">!]67'$'I!AS%)<B7X&
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MI18U8/ET +^\"\M=(^+LN0[$WU7*\J72&\\+L#4.8/'@@1<A#M;!=Z@VUA*
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M"]'HS/D,T\3]UZ5.._U(SO?O],)GSL)@'#^X_NANP3&$)]93:JH(M5FFJ+.
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MY'CG@?9/)Z"S9Z[P&OWU_P%02P,$%     @ CYUK5!4H\(D?$P  ""4! !4
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MIYA%D@9)PE];L !0BKP>-8>(Z_$5*.P-W?Z"BQ[4[X1/A>&8KUL(*;I\8EI
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M/T1-!J7Z('410YHFI6(6P.B<F:P\A*RY5-ZLNK7KT*VZGOOP\RUQR70^#<?
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M\I7M:3OE\5'5]:D>34(2)RE"S<-I]:]?@)0(2N(1 9( 2&O>;G6FTPA$!(%
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MP$2 ,N;TJW5%*Y[<'.?*//1]Z&?1%4]*8BZ")?V7IV5!,7/Z?-3W2JL(!U)
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MN/]\5:2*S.Y 05:5PE*&5);?G?SC PGFV+I%%&3EY-X&KF^["\M;=R>0I:X
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M?Z1K  V(&&57M00+[&6M!"/WTK"GBIW;WRS/(\M3R_^!?6W*UFL+ME_S*H\
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M_DZ4N[4%O;JU@K:N 2(P(8C7;1NT13PTB"0H'X#T@\7X!,E#DG=5 5K1578
M%#<+NF>L^ Q6_O5FE:R%U -=:[&K3YU^Y0YS3!KO;&K&B3QA,J[^WPE_=X@S
M>B8!.X)WA%\!WL3,G?!:RF3P!#KHC@,J%:)8+[]X8=?'#;/$:2B&)<OEPB5K
M(.G#G2HP:*;50&G$I138E7]&?3\=A?:[&\W627'KU%4T]Z!@E7C@5TCAPSI;
M"]4$;;A%S,Q<T5V378_Q9.4*Y)=[G6(:<E=K6/Q/^+AGN_ON607<5]FXWP(4
ML.' 4A!RZ1%50Q.@V1%5,-1$]ZKF0T"">X7K-:"./0RM358O;(\*_?Y%:_?)
M!/MD@BWDK_QG$C+4\!]C>Z42=.^(EW36LP(9D5*TNI=H*WL;\UOG+]CI,O\O
MV ./@;I/J=FGU.Q3:EK/)L!<01/S;*JF.$D(K1+.% RAT][W$)1BT38+^I5C
M5/'<TG(%9O 91'5I= ;-MM>;1M>#.>^=CMXP?^2[Y VH'*:J/2U W7C18_,/
M>'OC1;5G!79UFDN]CAGE)^8<Z2J%K<X#FW_#6O8P"U;I[G('NOV:.)7GD_FB
MHY/H1XZS6\$OP1K=ID%;N1C86&7&@0^Z#<2V.% 36!99QKH%;-N??#NX+R@=
M0#:91*)%1O\G<!*ETNPBGN!R:H7<V$TGH_ZT F>5%7/E\R0I]YG<>KS#>WN)
M1:UN:DA.43LT*6N'D:!Z1N>\BZN5WK',_#M=%E.3)4NG65'/#&&N6E[2X!L_
M[2A/=V<XJ.LHT@+Z4IUW.MA<*KS\\),^S&@<6DQ+<ME](O[&.4<&G('0U'06
M8AORXBI\J&U[9:_051857&^+C?MMKMM']O:1O7UDKW6OT.8EZUOLKE"T%%#7
MV\@<CL!^Q=U*'C**4Q&,B<.U7J?7KM(GHC4#J 'JWK"0<(H;8,DG'!LG>(UL
M=E,8ODD[ ,X=RU_>%QBH;=KTC;<WVKJ7ITZ9D?I4?Q6>MNE**5J[\O@MN/*C
MP&5OD_V;Y<5\S!G26NT("[-M_14!XS@*(RL)E6\2H,3FKT="'1/;.05E_M<S
MIID'EAW%EL<C#+H.*1R]7C ^=W" E!VK9+P4>KT0&^5':B.VI%*(@%$R@\%A
M+3GKV9WAE9_&JY1QNG7<^L%RIDU/B!O%O.6(:2Q'X]8/EJ^1-H_A2,SZP>YO
M:>*#:;S&H&4&H^$*K2G/(QBE7C X]]BGKA%-FL9Z\YXP;>?95LNV@NU[P;B"
MQU<EXPJWUS\+(N=?REY+'%\DH/?BO&R^9TEK,Y7GI7#[7C N]TBI%^L%FS>8
ME;"55>4[5[X3VR3;-/U(4G,4<*![E>2Q3_&H2/&05K.;)(0TW=1LN;,;K>M2
MT%QK3DQID4W%62Q-#\OKRWEIZ4[W*D-FGS]2E#\B\[;W*9FD(^'3OM)G3GUA
M7YE::("(,JI7RU8)>[=/M5AF'L9"[XDH?-JSM45O7L;6SWNVMN9;SICZ=<_4
MCF,?6;?U0_/KP#6QNLU8GICDLF>WFC"UF"6QY[BJ3(R,YSUH+F$HS]$)1QG/
M/^QYWG$ZG1C6\JI9K3I-5 R&,;]UA9ELETJ+SMC^]56SO9MD_S5SCU^W.[.=
M,[U3CY)Q]QC,7;-*Q+IO\H+<K"_E7V8T=6EPK'\C(9/.FT60*@LYBO<WNT1&
MZ,R2&6OM;"HW&T16N-X&E&UO\>^5^=?!V34M[ZJ6\C//G4P4TUVTI]GY'LE_
M-C#&5^*UMN^^K]$^ATQ=&F_^Q.)."@B,&?>^U)&4YLPP(D>^(W_0NME_SSK)
M_96U!!,H("_[UD(IB7_N!L1F6_!LH LFHP.FQI\QI33V(HD48B T*4R_DY_>
M<K1(+!C"N_8S<]2.^6.RWA6)+!R@S#$(@RAW!-C?MC\_^]&?#V[$$_6N?,=]
M=IW8\GB3X&0$!S<,9N[B@5ZP]Q(S^4H*[, )E+W*<B1"KW'%XGU_OWU_OWU_
MO];Z^U7<-!-3F(N:_-5+FC(ZZT5C3]H =L6"?B1Z-WE-*5KCZ4/N=QL< 2JL
MHE^@YE$G774^W3(E!+W@UOU:6Y\6FU"M)(E4&XCFS#T#5<!HX9-!P]':"+TV
M<65LY^N7^;L$PS0_2(H[+1^;(VZZJ"/3/4U-?1_B8W,5*KS!U6I\1A2"Z3[S
M;4T':C72)]BCVR[3SI[B +!@T-!:6+>3&B J @=PO[I--9&806="[E8\GUO!
M<CQ9M9QF=JWG$N?4L^P?3!MA,,*4:IY*S"Y.JZE<C?8V.[-+CC0CHHQE$O32
M<H,D47$4AO$\R_IGEC]QSKGC@''VSHK4M,R#(V-&Z!9#QYT;_K@,"$\/)4RT
M1)R.&^O%G<=S;;RMQ&D@+&9"PS@6KW'J'XO7M_$WROV(?$ZK">>X!JO!L%GS
M6:[!RNRTW"J"U$T& &#1631^=1_@J2 %B[I#+CU%2.0V%W6&W!W_K#C4-I9T
MBQ@FJ2*W8)\%N\^"W7=2!&QJMOJPZQ39=U+<=U)4&--JZ4[O.RF:'P\:V"1.
MO:=]2QT3<6W=W:9J,\UVM4Y:H/2:D_]1G2=5I-S30ONB#[D:=11MFG/&)%/T
MK_ ?8,F+4+_N*]V[GA42[B?!;?.COOWE]MJGVJ<<C1YPNS),('B][WW3==1K
MWRU90?2VYUD5N5XNHR<:1_F.+YVD4L W[$?^!( >HWUN93U 'VC$._WH&N<-
MPT>->SJ@-B%.>,D$5N-Y90!@9OMH(2UZDW\\9^(Q$Z,JCPX:M=8F=+4PB6L?
M)QI&G"AB1XP?3'RP9VNE6G3E(C %J_5$5,K)H.4<?BUACN(CN8]5F.\NE)CZ
M9%R  F(#PJZO:O5 .)9[X+( L1"@A/;*WZODW, L$L&W/KD#'IB(38M&[MA_
M Y>[.9*#\<@PZKYE;N/MC785R%.GM/GG^A5A*,9)]'<<S4CP,+/\C:HB8)MS
ML!%D#+YFF]W[IJ/[=,O79T87"<R[^T=\V]$:0&;<_1YVSQQ4[\Q]P[U]P[U]
MPSWH$0:TE>J'YTAWMZ0>.*!4=4NJ>::-<68I[I=D=AIM8P^LP4FU'66+&YQT
MBW\O.^J7I/O,:V\(U+:#0[ 6?/H,<$UFB38%;\/(9C>,=_WL(E$)O)_1SD<$
M.4;8P-*7(3=2UXQLE)8Q-L-%T5!6F94OU#[2/?]()B9UM8]TSS_2=^H_%SW\
MIGX?#+X]_S0KB2Y$AAE?H "MGC-Z4S";P>5MG'K.XDVQ:@:+MW'J.8LSR9AV
MZC2#QSM([0-]^T#?P )]^PP%,%_W&0K@8.^^(=2^(=2^(=2PHM_[AE#[(HM]
M0RCYTUXZ<$QW7Y->9(8<:QY#U\/,D&/S<PD,:W6!]PADS/YH?HR^;\S>=G$)
M7N][$W7ML16\UJV,#8_7!3$(P>X>U%7VC-V8H%OV'3[MWT[MP6GQ,<Q/$>S;
MQT"G<XB/8;[YVK>/@<M^$E\";%8;D+MX3B8D")264DMM:70&(XXBZ9+II_I#
M_B0I<< AH^X1,=O=WZ,B9]VL>A7)!?LX[3Y.6W(&V$FZ>"%VS#_3N1L0F^V&
M[;]7":.S.5</;L2=[5>^P_O(QI;WNQO-[HB77+)PYBX>Z 4[?=$2?@BDP*HC
M$#/4JV2QU!G9U1R0!Z0<@!F/PSZ/:-\P8-\PH)EIO6\8L&\8T+.P< ^2*;H.
M"]<\S[W.PJBZ0!4JDLBMT!TIK!VZ5:TAEI%9I]#VH;J^B0% (6:+,5.P5+?(
MZ$5"D73^7 \R@5K.G^M!(D_W+3(:Y.8<FQ]4W[<8:;/%2*=Q \&S/K4UOI@O
M/+HD)&'?;1S8,_8K7-IT'H9KLK/1T3@IPI1X?+S$M<"L@4)AP8=W^2'*GP*%
MJ,:U0N=SZB=<3] )K\(PQHT>*@4AY5R5ELEG3*RLM%>F"-Q0/YJ-)\R0RT0T
M+ES:$0J*QJZP;Y%^A?-8[)Y^G=*;AIS-(KF%3@8D21^ER+5 ?MT&ZMS[,J]V
MAFO@VLQLRMUK1IV=>@IQ3OZ.L# C2E(F!5*5>57V$H[B:,8TFG_A9&H'F\M-
M(RL[R]B19'5P]F'P?;GRT,N57WT8:U\GK+]R<E\G;*A+IFX86]T+:DQLR@@/
M7;D>9$X\JVT^=:1M]VE.'9QA<@9<G\;7->5%O2TO,93.7&YT[OH1W-(=4VSQ
M[)0Z_X1G?T!B%NJZ%<2#1:8!88T"4K))GD7U,^V%-9KL;'180XJP?5BC,7G?
MB$\"RQOYSLB9LT,01H'%9?,*"WS_1R! N9"'Y3$5U7=NK. 'X2%EI'.M=+VJ
M%IN$R=H90^"</!./+OB!EF8T")P2PJY\=O.)& +,T>:Q1[3SL :03F*PKL5*
M,(H]C9EF2H)G9KR4J&ZI5&)_XJ,J;#KUN168JF1G-(R:I,.WBH 2YK6#L93O
MLO6MM7@]NV)@H;^TU?/UZGRG78@'"I2$/7.K0AZ'>M+[Z'2%O?$4J9[TR14+
MYD"UJBF<A.9G%*,_.E#Y[]/@004/&=I9 O<OJW267#/V,#SYQP]#$JU=H*-I
M0-(07'M)GVUL988[I!$E,C;TC<L$4T1]LG*HA(\+=G[MF<N$-/_[>')& @;=
MSTEMAMT=F<8>UUJ7&0"05MO^GOIM]=:L=/G6"^S.QK[#52[VE[. L#/"__*X
M8,++C\ZL<+9B-?@;X8!VUKO@AMV\>3R'NT,*%G6'G/4B@=SFHLZ0N^.1%QQJ
M&TNZ10S3@B*W0"X7[Y^QZ].7>]LEODVNK\^P.7AEZZ6P&9%@X=+;Y$VP21RY
MMN6%3+-"(E4'1DU7AUQ"#9-H3$Q8XB</[$^A92=E*WAW)AJT$H)Y'?1XDL,-
MZP<L 2!UDLZHQZ#35*7.:0B^LQXU#'?2(0%VA2_*0R8!5*GO2YYHBOX@ _=2
MR9UW6GOO>N9OJA8_M('T[)/O2?;5H<"GLT]>J*:\*-5M^M.W0%HV;.F6YJ2H
MU?;KV%6A:8$&WX?2_3)+A18:2X(BLSN*5%&T:9L*BLR5N\WU&)PS02()K%\\
M 3J#!!_,S7ML?C9:=09F+/L %A J7>)9 _4;8O&_IVSBCE[.K&O7>G(]A@,)
MS]@K[A)G%&VO<,;L)MEQP/-C3ZW0E<LF[!P/,YSIW9&IPM>0A@JYD+SG**2(
M,E20]<258-24[S'ASO7,9\M+/D#$V;UD'%W-$H#34@=)C=/KF9T SL]+&O"P
MKF#K.7F*Q-]0WBXP3"TD;B(QLNUXSH4O<;X%- P?_8!8'H]P7K._G9()#<B#
M]=*$?LD-C6;.-_:&*67.UH8F,&=.@XBCQH/@B3QMD0\%L)5U@F$6JFMYMQ8S
M5?&N[A( 2I"_87K3,GTB+IE^+N&H+X.@!/WLO4Y?];)7^]&G3R$)GOGAN?(7
M<<23,GR;O?Y)^/QTF2Q/JEGP6<K=X;!G84,<_CQ6S<0\#MC84 40M40DO VO
MN;UUC!<(E6"T$7+4#B%'>@C)&S#9#__FDH"[#Q"#*20!OR)B=8B,75R2L]9
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M8C><\1,VGF '0P. 215BW%K+%,;*<<?NP:._L-S,H0=!$@I)"L/K@@Z[J]Y
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MU<R.2;959#=):41I9IYE77SU5-U9KZI:%)>V)D,A([,P'8E( LCJ3GWZC0M
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MROE9^I7=8- IPN*0JEVDAT/$1M:@M$X((Q"&V,&*)@N4"223$,!(8!<';D/
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M=%0X/(U51AJ_.J>+'$$_68%CY@$^=N;]!9*?I)?JYR^Y;Z1TOK#2]^XSL1W
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M&9G;CX,O5BM6&"U"]U&RNDTOHUU21$C?V0<$F9/0*]A#D;P*#E"\\]L4",3
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M-_=)?30/5=.HAZZ9A[+U0[TG%%7H@3R79T$]MC?Z_&@6'1*]F,58+A4 %P=
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MRY3-"Y;*I8TUA-GO.G0*]QP\[;= 58;QL?>/AKELV38:,&NXO'5L$I47[YN
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M9?MM^:[Q[VA6&>T>STXZ2?ZJ<>W$]/=A=)P3N3.>UAE^7:Z+I#0JV^X6\#:
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M-(_8.ZQT1XI]B_CC7A;CB06(1::7*:B'_#RN"BAU"2.*[*G'SJP]6YI1.\-
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MT!%I;<_>!1"&#S"'A.>7*_@*$>8/9-);4=O=GOC>(UX7GZ(,6L2D(8 YS4:
M/HZP=TD1H>0?< 5*4"#IQ H_AA&\=CZ G9A^EGR+&"\U:-#+[_=Q)6H'""#B
MZ3,V../OU5C$=:\8F^>@.L5.\S#16$&H0@O6L%/ %*#2^A2G?#DI@,BXW>ZB
M)*/1N\RNDGR'\P@MU_1MDCLR:U[QE\UOTQCM5TFZ.7YCW?I T N\Q::>>W4\
M;,962M*#^Y-GZ,,(;9]^A4<@[ OT(73B/LL,E!K2Y'#V(A%34K@2J-0\=;.
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MLC")0!8<^-JV*.]WW4<[F!DLPMH%V"R+6P1Z>4"PO-C&< *+@GY>L)*Y@N0
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M/=3I- 9%N:NA>"3:QP,PY#N8%^?/,,KH-M/1*Z* 1&*>Y&SS@$P'6/U%/BD
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M:+_#.EH=Y^[W<'O-%)C5A6=;O!+;=9Z>9'E!>#1]UKGS\Z;'M^WR_!RC4RQ
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M;PK:\F%SDY\(<^_P)42YK,-](_"8SM[- AXT4' 61T?&YOY]V6OL,7KV^^A
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M>)JC$5\6Y9CW6K2O<1_A='/.RH4%ER"HRMM0"!\;,7".!H*NA@LLCD8<XLU
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MUVKA'$2!-WZIK;IQNGC.BRR*M>*V4X3E ]NG(KT7>PIDWCY$RO'SYEV6"I0
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M GF97$I*@"A9@8RI :)T!:!0!.1"$Q#%022B&%./K2P_*YKE[O)R\7#]" B
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M9L,5>Z@SF&1<%8ZPJMU"Y:,Y[6)D"#10WU!S.0'[_]O[^M[(<://K\*_@EW
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M01KJ7PBUR-3\E-::$/9]3GIA@PO'\"*)AW+YT"UD,4(D]BE91L2$].NNIWW
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M?QHUIM08C@^AB@ #(?0W#J$8/P&CMJ@"'/MN+OD>5IIQ8B&L-)ACWIBP&U9
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M*Q Y767>%Z$-F$+%AS+,^B3(,4K_ML\D_5$Z3A3CCL@+Q<Z_P!OZ\!)AMH%
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M?UX<:-TT"%4MTXQ'1C=LM]X1AS*Q9:_E6/>#S*R!D*Z6US9""Y_5^FB=ARM
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MSCW_MW9K"QVK)TB88/'HO%K/MT"HO_7%8?0.LI'SPFZ' \S3#J@MEU9TF)Z
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MJHGL]/&Z[N=TK5:P9HU5%*12*F[#S3,B\^4M^G%&?WOA(=\_9V'$ER^([/Y
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MCO$"]=0(D=/LH:D&6]X_TT2SW[63\<@($.M="1>?<*GGI6G1QE*,"WPT,/"
M<R#-+@X-$9XB&.:E_UA\!)";%0NH ]Q.9G9_#B!N0NK=6%P$G0C 4ENWV1<)
MX"4E@N!^K1C#6PO(H:?.=L"-CNH\"L.LPJ%XGQ;32]ZK+^K><RF("NNCNO0(
M^0$&;J#M.UDB+Q$@C[_B=ZVL/ >GA?LYZ$^C2A@^Y'W:@GAO<J<](+AJ;?BS
M0+G8*7,#ZQ4\]&XC(5HDSL5<'96]?Y 2.G+$AR)P@-QK\IRPD=/FQ0[RLP;0
M(%=(%1$M-K1YL$9$R4R:*.GR9NV-?X4)ZR7E^#[=IWZR3:C@>;1>8;T&P*2E
MKI%DE*B9SCD]'ROT;-G?_7OZGR!J:QC!G'26@;1,:$-=Y]+1:V.)(D0M]PJU
M.5.5E-HLS#G]3<>VW&2U =R)4-$"]"65Y7C'FF!'KZAVIUZ F!Y?@+5C%@NV
MAR.,+1>D90F1Z?\=)S!)#%J;#@NH#LO6((:<R!GMHB3J$4,F*G1'8]6"[S3H
M==Q%9=,CAE):0>NRFND1X]BDR'=A-S4 -A'$S+.51OXTA95CA.D-Q3#1S+"F
MQ'/+LV-F?D?.:LV*8K\@8JT08Q6'7L!"V9.&HQ"-&$I95YY]%5-9-:?H'Q\1
MV4"K^((H:Y_N'7$\V]E:;MI96W9V)82T3^;:HQ(?^4'"PMQ+I>=.=E9U%'N;
M'J#ND1 9[1.Y9P=AOGSRX]2-%FV+Q$A*66AN0Q;%$>7P9:.(F\8JOM9CA-U&
M*5J)9)$YV%44M+#_FT4<IBE%8Y]C'W2_E'S< ^82)[2"0 _,J[WPX;3[GW++
M2Q].6T]&@^.A^?*</@6<X,JRHUN,[C.'Y"I4@E(;A.C)6<<S_?<AI(>9 K5(
M_;_SY=*QT8P@2]Q*+D9-BM/B6M\C#_VP7+:JR7:F*SY??K/(=Q3<L\CJ(/F5
M"[KCA2?0;A!-Z3+TVD65C,)29AI(M;K.$TKSZ($,O\_W/Y?B)5'#;!11^8:]
M8/T'LL3S=RJ_E^?F\$"<8RJPD)!$$"(CSQM;]20#'71LRC^6XB-'9;Z\8[HE
M^T-ARC*80<E*\<ZR]@,2VI&MRW7Q#Z:0QF);F-%:&GH2D) =,AO7!=IB7XSS
MRD];WDFMEUV$E+XD1WYGLP,"TG3*OU<@$^'G?.]3>1[X="0%<RF!WBYA)F*H
MED8Y@3JO1:BUOW!:7S7M!22WOB:R%U;%MYF&W)6S=@@SVLLF^59^+\7- VO3
MWH:=:@)2_%PYQ ]:L%/YO9Z8&3C7E9_*Z026:RV($P(RVLN_DX'+)T$.*OJW
M?9CHC_Z\1]N0V&MZDF8K@J+$JG-F*D!D:]%3#ROS"R38V:3V!Q3-!Z_^5FKU
MSRS_.Y7H]\Z"/1R9IOZPM6P$W L-5*9" @87$O"1_<L*O[SU@RV))\7^%$TF
MWNST;W_>_A^AO9W^JIYG1/CLH[]".O/+%RGY6T&@#^;E]G@-D;XF =W-E20Z
M$]S?',_9A!OQ[5+R47?,6:\2S!4_ZNX>M[P5X&8Y^*1;QB 7<.X#.945AR18
MSZC4743)DNR5 -5::TC(/S):L51#H<5#HQ5+=23DC/S$63FIM0;(3.FW>C(@
M"&$[-G+=TBO_%GL6_TE4O=.*['D25:W I+5,F-T#\V6.-^B]4D% :L]\LX ;
MA7_0F<A[0*NH, #"*V)MURP<'?:&JB'0'=-I0[[\J!"Y74- D;E(N/)5_?>*
MN &G ]>1Z#?I5V!RN E5T]M_".U)W'@43&_I(29*<*.<,[U%A]@]@0\N+=,+
M;(D>LP9=8BS--NIU,=Q"E<P0_&#F 6RKON.ZAP<'S\Q3J@J\NB=DAN%'L\N1
MM<6PQC*00?C)3)U,%81U]AZ.H9E'&:+7YDQSQ0OV@W&PE)LN<8GE-$/BLYER
MJLJZC$L-W!P-,]6&)C2*OH@,C2]FEG6%:NN5'J6B./ED'%"B7KEZK X>QU_,
M%#GBCMAJO Z/H+D"2<B0D 4 I(B<&%KG%RJ4@,7AF8#Z;!QH,@$QLL7A3PSO
MNB93'+XARHM#-[U"RB/T"@?TQ#R$&N,:,3C^,MM4'\PT#\C%M^*J&%P.EYGW
MIJ3XJHR8SO#Z:.;CIXVXKXR+YZ"9>2;;@%:=V\!1FXYFJ7VX'C0SU3%1G:(Y
ML8@C-2KMZZ:RTW)U9AB'RLPJAQ"H(!E^&6Z?S(P+D=MBI3F>'"HS*QG*0;67
MF)N!]*N9]6[ESF%9&C5'RLP2M^#M))(VST&;Q'QE_8,,I,^33&\N;\'1FL2Z
M5-62%,!30PLCR]V+!X5I.$S3/A.J*)0!]M[,QW5+?:M$,SU]/ZH7=3525>6\
M,J ^F&D:5/5*+-1CXZ"9:1H$[ZYV]?HXG)-8@]1OY+A-0@Y6HS-#[N/T)I<O
MXLI1G/:??/5?CN)DTFZH#9U!-9EFZ^I_<YBF=U53@?<,J\DZ6UO'G^,T22EP
M.X8,O,^3C5:H04<&V)=)T$.[M'#L)NDOV+<GA>R]^J;HD0/">6$J\_%#!WD4
MO!]76KPLAK5/@O<G&HQR??2[>PBW6S<* ;7<,\MEX#RL$3,.19UV'W%17?-;
MM,)K-U2\A8;2)4]R+OK;RTBU(:LDT4-_G&ST6^S9\*[> L3ZG%326#.K#I-J
M^PZ]%*/["GN7; ?[#GM8.K"&5.K&' !$ZB:NL\&!5.OVP13":IA*Y:/^$''3
M2SRI0@IR*,?2\5X:T[R0YYW&IPU8<;ESB-3OIT'T=FY4V@J6MBXUW9J!CDS/
M+9N)[IZNK5OM]ME9MT1:=:,-*AQT"" IG'J?$^KT :!JQ-[A437I_AM.=[_0
M+0;L&QQ%4Y;NZ\0ISFP[W(31'9=W(&4QQKDT0Q&FV]%O/9LRLE\)]L5[C E2
MFQ[6JK1U".K\(6AFMHX$6J#SQ?%3YQ3^$N/GH17C8?@("HG5+A_1!R_$8X5)
MRH33P9/[.$ZNF-:6X61H&H\:G*1VGJ$9/RT1+34=OC<S,$T95%+[[_U8=98&
M0Q0'2'VDVB"LL5=A0/^<%(<MQ((^>73J=%N=,UQ<-XNI;6.2;3W:L.RR\M.9
MC+,RS%-4D_ @M+A\M9'OTV=%J, P54VXO\FF6^DB%.HL)4YK$%-B::FLN+W*
MJ7&:@YGB(QU1Z?+EB YGDC^P\BDRDH.8X"V].QY_(/<%1>G4H':"<-J]3=E!
M?HXQ&;,>A&J?D4S'$X)7EG>M]"Z4'*#_R4O>C>(T!S5%F;L23GMP4P;?G1+$
MAS=IV%T*)CVH";>Y6^7'T.@>R]B3]Y.5D)C\>ZJM/Y50=^&4&JZ!K'J[-E2#
M$3MXXXK^5 IF)K\YAF.PV*K',+[VQ^7Q4XYBK#!R$"?9"'Y@<,^?>G?6\)SX
M[<&K?HUR)-5)Q"''C0AAV9Q>,'F< ?8JCIK9HD[",MCD0Q73"-^;K1%VB^NA
M<FBX.U\#G'MZXGNSI67W@.ZIC!V$4XP'SQR.'\S6'CO 44"1_&"Z(MD!K'GX
M-,A*S:%2V/*R)GT^KT9[[2TQ)1)5<)<*BH+2'4SXDS#C.DS5^=R"^?("/0=I
M%:$[@C9.N(%8KP6(264"I:7)EC/;)B%:S+S%D[>UG$5:NTPX"TB DA2'=*[7
M41<,1OWRU0FNQ-QO-1]K\53<HVTBN.9+NO7I"WF9=NX07_8:(E)@WI347;ZA
MMX!+5^N16)YO1;U&6(%2\?PO&%$IOI.E2[:6,&?[GTF-/2?.BMXM;GPA%P^?
M,"?U1*3XNO9LDF3?GU,AN4+^%2;7OA^R:W"^_-UR7N@%)<RA*#DI7F>>%UIN
M$I)Z1_ BM(-[](*\$*7%O@79%*"DFD,5O$ERE0;Q.G^%#CU=._%@FMK/I7AY
MVE)US0O.+7^=R'IA/LH^52:_>*5(DDK+Y$[D;0U:R3*Q :3F<X^<S7-(U<A%
M5E15D-&2+_4XX$L .L>;C1,P7)BPA<=[B9)4MF62#!1O18DKVB15))7QG-QE
MOB)^R\@-8P/!)BA%5E)59KKL/QTOTVCI"X.5N<GD T!7;B:E93$NT-(*W> &
M>RO*QR;22I!O$V<;/S1^<[ ;OSG(Y0N*%9?H"\C2M!BDMQUYT/6RW4X\(*=E
M8E0%L1%:^%<$;[@FQ];A,5D'R+Q$J$D=+/9YX>G.7^ZSQ0L;1OA@B9!JQ:.?
M4;[V*&%Y#JL)];;GOUFO3%L\PX3@'_0F.[>V]%]@H>DPNKU--<9<V?$^(*=E
M8E\MQ_-OL,^\[RR'ED(;.OYZ@](')F1: L1DS3<!-\$D+_'TUJ,OS!5]5GH(
M4&U&G*"F&S3/S@6BCVC+1\") 8CU,JGLLFXSF1R1'B;QS0KB9L-1+SO9612I
M]#"-N+.A+/OQUSVPG9Y/5C\_J@2PD-/R(53[F&:B%H$OE5HR/4R$7FP2#_EJ
M&FKTPIN#[@U@?3!'0HJGA]__>15Z"Q;"=G/^#;$F3,+,E'S[I^N\<T]E'Z21
MO9.%,  9.?RPQ?A13(H4 X4OVW#P \N-S[]K,?K<DYM][KL6HU]@UMP%.'3Z
M48MQ9Z^.^"G,?S*$4Z=)I,X(L;Q5XHSV%K?T%<I_DG.,^>(SDB:M9<*/E//Y
M,L>;Z"YI("!G6L<[RPUV=R&QUZSH7WH# +=/$QD98'T2Y$"E?]L'E/[HS\1_
MQ);W 9$7QT:^^&%O(- UTW.2C"BZ :J_E;.?TRN?.VMF2ZHFTL=4M&+O3]BO
M S>!,+U.N'U'5_".12T]XDYGT3A.%[,[^5(QZCNULVL>1\'L2NB??&DUCUJ*
M/3P,[M$";:)7/%3_@-$;P-2@EY<(-<E C[R!&+B=RC^6T\*01S?C [)#@A;I
MRPJJC=71T++H1<LM?/^6?]\#Z]#]6?:UY#ZPL;>0VXZEW^H!S[5\?[Y\"+#]
M76+52[[6PG96-S// 73I:XA([8!SLHJ5-/:J<FW@'JCX6HX33.C;Y\4AH3]S
M%O?(=="2%?"V68"P8T>"ANUV&ZKWPPEKV0Y/7NB'ECLGU]Z2H+]"9BVD2PO?
MT V$^IP,='?7DI&3<%1$TH7^S7)=M#NSO.]0*5?U?6\.SQL6:4_@VZ295F]3
M@FZ3:AJRD?/V&MG?Z;,U0';20&!%+!FM2(B6'J!9: +58IEZ-B=?0XM87H#0
MXFSW%;\@XD5OJS!8LQ0:!V*1:#G $"</WH RY-5X3AY9J5]YKTGRN;9'&4_I
MD:GT5$6A]P2WAJGA!OAYU:=3(]-41;8N;GF<1M-KMH4HD\<XE=8<Y4\3RI6W
M)8;<_AS2ST9""CW\E<I<\82?&@>4L$K<@%91B^=5L\R\6\!O(]STE..(?3 2
M,>"!K'V$%\_D!^.P@A@TFC$[/)-FBGR830M+&^9XF:QW1N,(EFT5AM@,K\]F
MX@64;#7&\Z)<^V0<4N)."%SO*LF ^F*V>E'C9,)U'C".SZ1,5+@JBV?MLW$0
M"3AY*Q$Z/&9F:PRU/GPL$FJ0(D6WD]E(-0ND\@B1#*!/9@($E$@BP3T%"75B
M'F0285/"".Y+L),O9FX[J:@Z# \-Y#B:K7 IP%$B5)2C:Z:ZUB6ZS6'&'%VS
MO0>=H%N"HIFZH. %7IU94+RNS7,4-.9CX,8\D12B4T,]SF)Y-NG1:TH%XFB9
M>2L 5>:*9*[BL3/7%U"?#)?#"9S+Q_>9F9*];?YD9@ HR_S,P#LQ\X$A>$@/
M\G*+Q](\4W95[G(1BX.+[X/!NZ16SSQ(4N>0F*D+B$*2JQK (3'SH2(,2;Z0
M0P;*QW$?G7QY#8Z)F9IAAS=V6B$EA?#])^5G[0619]P_B)";NZZN38;4KV9N
M-M':0)6VYWQA(@Z6F;VI6H.U5XN*XV5FJZ3V>-76),O@^VRPQM &OKA"'8?)
MS!=N:YB*=0@SN QUFK6&JU!\DJ,UB7SQNJ,I:A\,#9@ H 8L0\N1F_2Q9+\)
M%!OFJ$U70$U\[T'EZ0RWDTFZU>!679.< SAZ#5>P8'V&V*F9.96RB-4U(>"8
MF=G"5^*8BO27R&![K[[#[)'"5B;=#MJ-<-RFVS33>:6[TF1HFNP* 0@\D79&
M'+-)"ZXYN94MJSA^H[<<Q7%P@CW-.&ZCEWR5N%7UKLNP,]F5I_C,[CL6/GR<
M[HA=>;]*#M'HKX3*HRG6>S1#\M/T F._6M9O-L/HU]$_':)?K>H-S'&:% WV
MJ[5-G3.P/D^;J@&LM#LWAVR257'ZI5C?]12WCY-!//K5.7%6#C.I17(K=ANP
MXGI%*?9Q,H-'OYH\C1(_51Z?T=L?*W6O&[2BV\M;Y +7SK$?Y,_BZ>C%?OHP
MND_54W^^9+_HIVCFT'H_[;7$=<P]Q\G!S*,T^9V2JHBQ/SB16?0@/GG;R-(8
MVQASD'V8CF$:@;O!)'#^'1NN"W=B\FS,HZ9<D2B+I/V/MP>PT1E\C_\M^B?V
MZ3U:OF'_?;J_S@9!.[3%CA=LJ5JTL7ZQ\>9M6NKX;6"]LGI?NWA<7E0W*G2Q
MQBZ=HG])7S;!+O[?S,3E<V?<M;?$E'#D)D&!Y;@IH%6UE>_I6'\J'BO>.+ZS
MV?(*RX<;C2%6^ "]!JRR5[9A"GM-/W!21?;9B*FB&UVL#Y:+_-F*3CHRJ?D^
M'2!QU,/:Q;:CKZ<=">4 >Q&/#W29*%]QG=A_\S45ZDM21T;+1.ZR:_\0<,A,
MZNE(E4'_2K#OE[N5<[@);RA1<G*-3.)"/;]'"1/!G-P[JW44?(WNB!,_!*-_
M$>^Z":"HIY--M#\C!A81!_3,13^#[)(:(CJ["!5!O0U9I@K=N''M20?YYZQ<
M[.)LET*<_"*L7U/;H>1:GZ2'#RTNZ C>*LF9S(1_?@7@LEB,JJ;.2J4\Q9S<
MHA_1/P';+(E1U-[OZE!E!+:\RA&0VE6SX'&-OEGD.Z(*/54H*3; %BDU%.3V
M.5N4MLUAZXE(\?7$ZK7^H$>;ZG=WX;/KV)* -1/2<\JHSI5LHEMK0_^8LZ;
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ME#S&J++X#7O!>KZDTB:['F A(!VQH,^,'J_"1<A'CU>G\J3!"B;)#M$G %%
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MMI)BW% R;NGZ;&G<56"M[YW07ZU+Z%VO^"4DS_FB6BHBY\=S?$]B_E&Z]VA
M# ]3>R\0X=.]XWJW^"4*9- %[/]\9-PR0AVK2) 5<QY)FWA!6]VUU"]GHM^@
MO_W15_*W!ZS/;_%^W96<$1 N:]D0YKIWW0@#6D9M'F.:)Z3@L'^+W:'RJ,TV
M+3&]?TA"$ /IOF<+5;@"5&%\<U %4RE'^T0Q1;K5$$<3=:B%T^)W;$6N#S.R
M&".@HJF8H5TTT<1#2CL0G16H' >]@V.L#=)A%ZL+.[(KT "D'I!GB[?Y0B)>
MDY%] 1&_Q@HO#* "@M'AR!!,;@@CJ\D9G0;D^4WDWT1K2QU]?%>58Z52 :II
M>#(,Q9353?/.$$U -1Y =W$0[%LJVIR*U(U3D46R#XA.-VGIBYC6!KA"0UM^
M"MPF3&L00BGVI9D:5B\IDBE[=C">Z:(LA8$[1NB6C*] QI.;)V-)8O>)6&-N
M\=\VK1[K)915H9:UA .BB<+,4:Z;0"5XQF5;H=)78XR M@ST@H7Y!)]'>L/4
M^:KQ*H54Y435-25=UI30085L^ 4PT+G*3<(]Z)(MY8PT'$NDH>$"%*:2PRCC
M*)Z>B,K58@9[&G$>#3X.WP"1PE J!U.V6MI,3\79L$OX%V8NYC$I-%A1JAPG
MN3B=%29U-<EG+&PCB5BEGQQ3LU<;([-RPW165Z7AG'#'%.Z.J#6+9,E% $.)
M6'%T]O[-AU,TB/&F\ZMQK; G28X^G=@4%N0M3;-ZU%:U%!9$9(,I6,#S:98+
M^$-7G\H(7D85H%))W2PT$@*-7S@A!N%@9DJJ)DJ25!:5 HX@\6#]$$>>Z"&,
M%9T#GZ$L,_P!AX#+RO\E5I RQXZ)GYJ_<:82\!RP[A=\Y/AUXHA7S^.C*5I(
MF<H#:7K>R8(7RF4>5,2P>UFB=6Z4>?&J711O@TIR(0Y"1Q)Z$#T<9DENA$TG
M=)&X2"2[6.D:6K%VZU%]"[<*%E&_5V^&G7? \T<E'HPI4HFUR.@3(U1DCO@I
M&6PP$,8[SI.<:%'\@;L4;72#!"9;B/V=!5IX_8WQ%)S0-AF4^P*9"TM+55"Z
MTUPD"U%7K?Q" B9.*54&PC>)0I:-DUII"*T7LB7"4U*BDTU:'6!UETW'RG5!
M-,;:K'I"J*..5)XE4N14Y]S!-SH+W?>-)F,0"RFEP\G6^(M!(G=W& D]-9D1
M>EB<.-5 Y0PWP6*!;$^3\ZP9V$3@YC!J'E&I.HYY&5D@:)-I6:;1),&)_=6F
M4[UXSLJ0GQL4.V)%VCE5K2ND6!777:%0HAXZ>)L==Z%-)S5B:@YO@M->)!FO
M'.2P%,GP*4U.CI_'>>HYUZRK%,J6@]QJX%^DNDQO7'7! UHHVDJX+T1J02,.
MJ^I,LFH><WH,*ZOLG;!?T06!BT6:"67?$"7I GU8.=0)>N#ON+10)MH+@:!0
M@M9< 477VD#<S\3B5G751Z,TI1Z*ZH5+^IU0#\[>9YKXH=3]A?_ M+DZE<R)
M'1=DC[IHU&ZJK%ZAE O2I3"=-X5Y*!O%/'!F'M8<UX3O>Z59=:7C71K"1*]$
M"QPPGZ?L&R0;!\48EW$ESMI]@RDDX[&1MWYJK42F)?&6X]@4PUB7M#SNXV73
MQ4[DPTEMIC<G G%UE5TJ&=*.&X8;(-XTR7*:E%,!$I% Q03&(J:EO1?L57"R
M+.3D+R$:*7Q+17ITL;0-16B_[*$V'DV]!5!FQ<HT(H.T?[PV744TL-WPNXFJ
M!&F2C$I;I 5K:2UM62Y?U&CF[9;9MB*$B__&;O56+CN9S),IU?[TBO_"WKG*
M4S>-2K2B8@J_I4],Z22NG'0OXT/'=R,?X]L2G9OE8^S,;DYT?NPP.LMC!QP
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M%48$#;T9,!C6O;4]O<-8([I\S7+5_0WU4NY4P$,=N"[G2MQ@7&S&Q<?$I('
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MR;OT M/ #4VKY$+'!;M5=&=TAKZ-'QX%\314+;*S!Y9Q7,#<P!PZZD,HL8Y
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M@X1G"L\PU2)!C%9P<@C]0[17@9_ KB53Y%-S-1_QG0+ZR)(*08M34?=TC<D
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M(WH>V?8R!Y5BR8.:0:+\$4^,L9:50@2KHF*=YZK>OQQ1N:US,"2&GMZ&&/J
ML1E103:6/F^Z$4_TXZZ "%O.0N4H=3DV03=G.=-4-R?7>)@ED>@"A%%=XKQ%
M=,$=H"%@"3'3)>I3'DB:52SC/IY+[=F5DW5XDVYM15J;!HDFY%ZL7.&DS[(_
M&/(/>:EQEKN1XO6W0XK+"?A-BO%=^BNWTI-3PXDCI%QR"KDN,"%&%$D/8<MR
M>-,\]K\>./2$Q'QGP3ZA=*N@$5)SWG-=>2X?C&_"0\2,/3"!MLW)(^]%,J1,
MH7:F#P=P&1&Y,]X=6F()W%..8C4HWB&B^!Y1$>=#@E1HT9-1BE"D'0_N,C#8
M;,(H7Z&L;4&<JPN*9[<A*,XL)OY^QE(>;=,F N2Z]0_>&>B?-A%LH5Z4@1E&
M.TE31RE1"UOGB@]T"RECO6_DB176SI5NMZJ]C36J :74$L616!6@LKGB8<PP
M%UYUP,L;V?_]QE>PU[IH8!U*H 7;>&F,T3XZ3OLVN=HSVFID1V\XK6U$Z(XA
M<GKZCRG-0XHA'#3F,]J$*]5<8-IVP"W1K=V,C^B>E5)1W.D+6[<8T%0I(F8Q
MODGX2/,>W4X78::2&T"8'2R;H#./" <WIQJY\;7,:[BC2+^04\+U>4V$3$!Y
MTADCD8I5&Z%NF6-T<+O6/O QPPG[7.BH3.X5]S+#XD@9.15FY 61.+6%XW5J
M[O'/.5MMJS1>66E\?AM*XV]EZOLJ_TRPU?O&CH:WI4//<31WAT4:TGCE52X'
MX\SD?MB"7J!K@5=6FN;U+V@7;WM!2S!>NLGE-F#7O$6/I'8JZCN2=,<E)]O*
M80LS#EOS]'-O2$<07O@;O[U FUZ@HX/;R?8A**$74]C<3>>FY)*2R$!%SG-$
MM.*DD\1IKP1I6R/%-<NJ<YT\S]Z'^9Q*.H^--P.8_J)411)3-#-'O"SE!F?C
M1@#T?@EVIG*-[7'"'V6@&X@(0P[M2#%QI^GT!L$<C94=3H-V6I)VE-S@AED1
M6)F&#GY",G5I-_%\7D/6T#*X&%$O1WLHC]<"/[;.]JO?YL/;N\WUQA?XE(D+
M?QMKU ;%;& O4S<H@U'(MI ;,%"3P$@CYY9;-6Z@56#:YCI3(YN0UST%0C>(
M\QGIAI330<AL:6'GR-,E)XHA(B+AIBX$D:Y"$^\586*[#?5>="7/X6[R:VW_
M!4JIF&8UV[OX!/,IL&,;A*N#Q;Q(T+,IP6_LEI?:\!^VXNN$O-U;FE$^#K\W
M)K^PG0,,W#:D$"-3*2C! ^NM9!(JOMD=H;)&V,9!JDU,DG$-RC4ZY_%VF6I,
MF)("4S8=; Q^'FT6[4?0?=ITCT)O"%/F5:-A7FQ-Y3OE(GHSZ9:G$)A7DJ;H
M+V(Y3(A@N008 4X05Q2AES-4%KJL7 "3'@@HH8<%$=/4*:WZ1>Z4[[F>P4V6
M[9QT#@C^#!_1Y7?6G9"<AWQ$5KS^[.YX^,^6ZAVAZ=[-$OAHK%K@N$E>8S[5
M>/_'414]?'G\["!ZEZND1F3,AP8N0L-?_(EHJ::\ "7WM]/HX.CXZ1%_<8K.
M'CJ_Z-4L4Y/H5XJ<_<[N17[F9\V57T0[3PZ?[D;/CY[L/3YX?,!?GR%K?A%5
MLQ+$Q_]52[7 :2YHEOL@!ZZ;P][N,; +R-JX#E<QVC )FDE;H9-HJ,6493'W
M*0IU?#<R>KXI$V"SA!YC AS=A@GP"GY59:/V2O4X/@X#+AB0,%!=07JP]AH$
M:&0@EYP*N)';PN9Y]KOC!#$Y7CX2U8("@[AUT99+O\RNB["CG3%*A,"RP[6U
M;#&!"9<0F$JK.FPF5V,%@2+)N66<^CPF/&#RF<KRFBQ#KO\OY?7Q+PHCF;ZA
MTKD*A[=%?0<J>G&.I^^_Z"2<<)97.(4K*PR60V-!$FKK(;;8),FT-6$ZPM'.
M2O4(!]+H]V(+ITV:.%ZE)MAOCBJ^,C)*DOA-'0*#?>^DHG7*/W=2-4U6VTZ]
MJ_>1[CJG@N&G8$P2;E9WPNQ,\T3_C(JV>G.;),Y;]'QV*,+1U)<D5DND%"EE
MM[N&P-'2I%8OY+MUJ291D<QAI?^OS<:??DNJ3\@:DVMQSCRZ#<Y\:IGFKX(B
M V9=2P#MGV#1URGW$%Z+;P_MSPKTOHZ(:VAM+FX<X%C2Y4%')HRO9DI.![J>
M'(RSL"P'_Y@&<J5C20*X,)!G+ 5#5J"NV6(1:Q7,J.)"JPTUI9WD&0/M:8 *
M.V9X/M0S;C <ZI<;+IY[*6J>^T^$C-05;$E#%T!\G)=C:@;,@5NLYD_E20@1
M3@6O<4!V?CC5=1BGJ%DGW(N:G-&M^$["E:@'XD]2[9'J"TI6_BO=>>75# ^F
M6@Z>1;2#'R.,^^C@Q'Q(OZ</#T]VF0 <@"?KUS4/!8), >ESG]2JT3/XHZ T
M)'H?48(T/-$M=\S#;NH6R$],\2+6/+9WI&Y'\\S$L&V1F;^<NZ,7Z"^AUVSO
M.H] =[<"K:BD@(2/*I5$3'3("1K2IA XX07"EW#8G*9##I6A>^,2W/M?_Y[,
M%R<_ R'S"%A\:3\&&_ @>DLE&OX;%\3&9AP=_5BW1HI8;O[L\0\GR+;V9BP,
M#H] YS]'_R>8L")H0(P\>%FD/SZ$$5Y&/^<EAMS_S/(YC-]@> 9Y_ZND!@4'
MM[U N+0YA\/GSPX.2>M =,-44#5A6DQJ9]=L)V+Z$2F&8[S]&F7 [,S9M) "
MQ76G@B<N562=<S*U'FK@L+KJ,R5WXPW06'!:S$2'K2B0Y8S!7:3H^NL2L^&S
MI#YB%#Z5*,Y?RI2[8!9*"BW\!O2$UI14&EZ0O,J_ 7QY=_2K8@OIXM9N)76K
MUPHK)CS'CN)IV-;P6S7[";[=>G>=QU"#G:-&RD69,F2:L,1,3KF=?[>JSS6H
M.+?2U/(-;B\R#+[^JL*KL'DXJJ.V2"C6!51@4A]&;+'8_-AYE>#=38(>"T=B
M&>A#U@*@VXJ:TGFS*:4$@H&HS1WI,EU.V0[L82IP%EJG(DX1KE7_.PID?%;7
MRM?3C:2=FQ>TT>R((C>=_!**$]'U*>#6U;9S&V<;4R4T,+B1+[( PH"5P6)M
M^\5>S]6ZE;*LOV7U6.5Y4JBRW?Q&_6$ZW<-MJL<MO@+IIH#%AP*SG%2BHK8V
M@1NPBQ5U)[8_O$#UE_K/EXL*.Q_T8 XS[J@RU'H""!TT#'$0&>X_EAK90]@_
M3L[1EY N4K!>9E-*[A'[+=AP$='*B,?[F6CP^%I<O -+##*'2SC![>R#=SEN
M<1YOWD9_OOGX]NS#A^C/?YR]/_O]Y]A' 5*6.[JINO5 A;^+E$B,(4UH K@<
ME-+._1>3$1CJ&AH\0-;]$UTCAK-JDW@_F;'J@L[XQC0[A_]ET,*(?('_]>#@
M083\2[BQ^7N!93SE;R(MX&-TY1[H6?, R*#S9%&K%_H?)Q%3KGC=X7T5_D^J
M?\??/MM_\O@'8KY-&OCZ\)ABB(/?'QWL'QVO^OWCU;]_OO_D:,77CP[WGZ[Z
MOO/VA[Q$62=L!.PF;-CQ S))<._00HN^]!:[D@S_]ND"/[C-(.N_SM[]_N;M
MQZ@O1^T [0)L"JQP"#\(!V/M!;%;;S;TZ'O:T#=O7Y_]]O;-Q[,S?S=N8P<V
M9S;!F_%-3?T;G.]M7Y3O::^W\[T=MJ&G+0J,GC?5@HD.]I\^7C0<J ,U#F;S
MY;KSG182/RU?K#CF=?;*VJ5WG";N$W_;$O'W2\3?%.%N&?&:-/PVF:L7:W*K
M[L[A H/D?*6M'722#?L7[O3.OB^+Z!\(D/T&^>E68'RMRW;]%VPK4[8RY7;)
MG%,)KBA4OFN9$4K(^/:8ZU9ZW AQG'+>R5: ?!<6U[?M@5[+XW'?N#?!)@VR
M]X,:5ZI)JN4WK/)\Z_-=FQ_>>79P?U?&C.XA1??A,X[UKX\Q<*?'$)&[@YQQ
MT4O1IN")]19V%3C%G9K#-XZ->G)#V*@;0M)\B>R].[O^83Q3:9L3D/ WS'/'
M7LROL\E$58CVJZ\#I\0K.UQK!\/0UCN]A50SJLSS\@*Q]B8'D9.PN)D==5OF
MA$0"5VI\F==-PN3F6I"9278P.;4^ACJA-GIN@XO,P+P1Q9_G6#F+#U52L4R3
M5[]]PXI)3*C<#:(R.6.CCLX^S[)1UD2'!_N'SS'9!_.]$C,RYKYI/!S7&2FK
MI4%CIY)E02LQ7YM,DL%YQ,Z:\XSJB8\4;/I^A ? #9N&?\W[KONDNSEF;QSL
MZ1%]T*AY].3@$"?Y7DU;3L6+/NS]=[?>P,W<AFL=]:OB_9X\VW_T](=AQ-^C
MX_TGJR!WC_:?/AG$U-V<=:Z?(=F\\@FN;G*Y<GASYICPK5&9I]V#OUR270=:
M=Q@6CSU-=?9E$,2W/<$[?X)G!,I'>? :V'3_%+_=*WF]_I"U3NM:PUW%>!E]
MV(]^;:M/&WFRM\=PG=HR*#K4[C(Z?!Q'1P=HLVSOQBT?RFOXI(S>)=-I!O\J
MRCCZ;?_U_O:*W/85.7JRO2)WY%#>8[9[&OVY'YTE=0-OV-Z.VSF(WY(*3-BC
M9W0SGFUOQJT?R#\34JM>MY^P?-E6<-P)P?%T*SCNR*'\\O>_'1T_.8%GH],B
MW:I6M\NKVD)%A\=;V7%7SJ.<%=&OV *JWEZ)VSF"W\=-B2+CT<'V5MR1(WF=
MG,/ZWN]'O[1+.)FMP+A-Y;9HL67R$3NKGF]OQZT?R8<QS#OZ)SRQE1FWJD8=
M;*_$'3F//U61+J/7V:ML/"ZWE^*V+D6^U$&-[:6X_?/X19755$5G>=V46V_M
M;45=RW.)]AUO+\8=.9-_J>C7K-W>B%LR[M28;\2C0[P11P?;&W'K9_);-IXE
M*H]>[4?OLD)MK\;M&MML61P=75]>QO4@UG]\."K3)8+K'\Z:>0[_^/]02P,$
M%     @ CYUK5"(_(2NS-0  H98! !0   !E>7!T+65X,3 R.%\Q-CDX+FAT
M;>U]:5,;2;;H]QOQ_D-=9GH&(H1 8L<]CBN#W.9>&Q- C^_$BQ>.5%5*JG:I
MJKH69.;7O[-D5F4MVD &@=7=;H-4R\F3)\^^_/J?YY_/;O]UU;4^W'[Z:%W]
M_N[CQ9FUL;VS\V7O;&?G_/:<O]AO[K:LVTCXL9NX@2^\G9WNY8:U,4R2\'1G
M9SP>-\=[S2 :[-Q>[PR3D;>_XP5!+)M.XFR\_3__\2M^1G]+X>#?B9MX$GZ0
M]V&R+;^W=MO'7UN')\=-N!"^WM'?_[JC[_C/[6WK\C?K+/#O9)3(R+H[:.XV
MV\VCEK6]C1?T N<>_OZ/7T,K3NX]^8^-D8@&KK_="Y(D&)WNALD;]4D2A/1K
M(K\GVZ[O2#\YW?WE33_PD^V^&+G>_>FM.Y*Q=2G'UG4P$CY_%[O_EJ<MO'/C
M[=_\7AR^^74G?&N\D1XH/'?@GT;N8)B]<#((]-RQQ(M/>X'GF"]JZ>^GPH1O
M/O6#:"0\7E""^]2'#^!37_)5=R)R!:S2,B]4*S]J'K9_@15UOP_=GIM8+4#K
M\:,75GU#9:GEM<Y&J@U/DU'IY:WV?#M;0JH)20EO:1C*R!:Q7!#]M:C>>/LK
M?EY8C2/M(!)XE$Y3 #+R7-BHC;?O/_]^??O!$B/I._ GL9+ ^B@!CE]W\!%O
M)R/FCS1.W/[]4K;E:2APX^WMAXL;2RVY\ZE[>0Y_;JW;S];';N>F:Q6P9@*9
M/6 S&;JQ];>_'+?;NV\4BCH:=[-OIQM;;[8L>,A(.-(2OF,1@4G'<GW O8BM
MH&\E0VE]_?KU.!E^_>J(>_P(?OWZ243V\*OQ3\-J[[;;UB9>7P2JV^]+.W'O
MI'4N$CD_9 VK=T]0]60REM*WU/-^N^Y:UQ?_[%Y_^7S]/S<-Z^/'L]D/;5C"
M.I>>&(M(6IX[<A-8IN>*GNNYR;UE!Z-0^/?69A'TC_!Z+XB<18!&B/7*_]6]
M^GP!VWKUH7/]J7/6_?WVXJSS$6"^N#QK+@@TG)E0'9LRF+?2%XOL>?/'G*@J
MJWD@3UOX/3-/:1$3CSJXU]VSBUO8Q!5 7OV+9DF$*N.;B!8[ .H__8M(DV 1
ME,^-34\FL/O;<2ALUQ^<LF[QJ[!\$ +_V/CZP?MV?+Q_TCK>:\/'.\+XR@Z_
MXEN^MKY.^6I??64>C'?"_C:( A \V^;JRH*)8-YXV\F.2N5P,2H,7'NRGYSN
M'<('ZL&[] ^NJ.89Y6LTJ\$SVCIZ$ULA,&)IRS@.HABV#OY#WAPGR& F F5*
MLO(;K'G 8%92% 3)4"26#7JG<'V6R)8CD']>!G=RU -MM(7<O[57Q_T7@_$S
MZ%<N:-A%P3\-8(/QQJP[ & @. I OW<C0%RGHEFH=;R7O2@5T;UU2.O8?_PZ
M2B]<;"$%T&^ )D&B3(3]$\CDUC[!??QXN,MO>P3@8*OT73CE)+! :[A)0>9:
MG>UV:]<JJ@1E:FJ?+&LY)@R++(6$>&$UMT,WFK(+G3!R/>N E*#6X^$NO6T!
MT-^ GN!YC%SOWAJ[R9!4N.+!:M!G)2+E#ROTQJB0A?WD2Q^SPKG/]Q1ID!->
MF$9Q*GA;QD/7'EJ*C]EI%,$B !,>OC#.]A.XZ\C%#[[YP=A'WC%%MBC21<H%
M6L:EQXRE/MCY$6#<QV>"!+-$&$;!=Q>PA-@_:IR<G%@(@.AY<-.?*2IR?2F3
ML@:WX"G-X%D,@Q7)J#!(>PQX '9O>ZD#6,$/X!>E<L('M&AZ+8ITL-GN<\PQ
M..\61D^KL;];CQX^@.JY>[O9<Q,Z%[,>N]<X/-C]86A'>!843)Z':(J'B*_
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M.(6B<VZFNH!BLDE/:2*DEHVIMBE+_QF*R%%M<_M)$5G(DDA;Z61Y(<3W>Y2
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MJ(\4420WDF+BQ)+NF-NR9/Y*JGN;IMN7-%E2&W,?$KG X!QA1:2N_!M+#T[
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M@)ZJYKO@ ( BH6JUP<0GVB#6( A8<N,KX%!Y[C<<V.'[-*8>)TPY\VP%3LF
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MQ@6S219_Y:\[O<"Y1RZQ,TQ&'OSP_P%02P,$%     @ CYUK5.6]?6U'&@
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M$PH5213.,M'P^F!6K,\CLPTP,ARYP$Y[2&&M,!4NB81#F"T^9#0"IJ&(8IH
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M[4G9^= 5EA?Y#&5!8&Z%!(U\CD<)UP6G8R,4^2Q_4:J:\XB820XRET%"RY$
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MD?\42"^EE)ADLP34+J,_8--U^)94>(F4S!_@CN.,S0FZ@CF4^>)8E8,BZ0L
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M+9Q]$UHL)E_MEDWAS]HWLFR9T-^9[8^H/P%_3[W@$!>>$:"')J/%TG,JJ3=
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M@$!+E8VD8ZI<168XJB?N5-/JQ.UO]WI^5/^$6@=F=WPXI90PC:&G")&PY)O
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MTZ;[FG18'[??";$X2G.#6N9X;C3':!^V0?&NTEOSEZAB7#KV@_![]+Z;%KI
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M%%E61=IXI(QB/I]FA7/\Q)P4?E@31-(@C?Z5J$GFW7LC+=>0EM,;3!V<Y@L
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M-NT:TG1VY.E:X_Y<W>U:S#SGP,ED&W<U6)(P\%,NS4T,$,SSEFC6Q"-EU)M
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MD/@LI?&9(?6V&A^6#1"$-*63FA8Z:T4QD"W"A=NOY<0UC*=FA*Y;G'UC2\D
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M6+V-2SC*_>F["7\$(V.&XX,_?\A+)@2P;?3!)O9&>%'"UI<2@3<L!JXLR6N
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M2!YHODC"EK<SIH+NT6:WEI(.<P102C1+:,/(Q+=N'F"G<.[D3[A^P9--]?J
M6A 2:]E1G'PI6,$7K0>MW]&@_H)V&C:92C]S6Y/#K&QPPKJ95YI[4T0+P#.Y
M:]N($+P(F_7=YK1783\A[=/S'$R&-*CDA]!D6DKJ[]/@FXL?,_1'6,$,'1+G
M8DH(A4OJ_4B]/H0[[DSD]F:&MJ#N=;O#DO&J]C49>6:20AN'Z>K2NE@*5&>L
MP8./ZS$_5&1/['WB)YG\S^OLQ-:824"JR+]DYI@1$B8M[SBOD+R::5Z"RZ*%
M!I;9'A!7XU\HX-4!GIB+HCDU/$[N3UP]@N]B>#F3_84@"LZ@*8'K_1.&M;WG
M'L?HN.K2KHYBD@[X%C_!#69TO/U=@#3(+(&ILZ)LMP?D3P<=1;@V_QZNRKJ+
M<O3K6A4G3W9VM^YCC^KUI\EPY%ZA1[DGK:,]R-]FD[K#0;C[E/N0O_).9MM@
MB(M7)AX&X,2T_8L55%IR V,AGS:)9JX1/?I5Z'R\>ESD%4Y,KGGJ0H7\X8-=
MWC>"!5G9T%@J6,2,8/^0-+[FYA=)TW#OGIG2DM2T6.UI;- FCO(- )DS12KH
M Q_ZA(/J;Z24:ZSB[3)2RKL()'BZ 1)L@ 2W"4APJU3);2E1OAJKR!O#<76$
M0Z/+;EF]M6]M%ZZENM0-B:.3EV=5/E6N9;&RN0&LU^E XC4&!2W>%YR@9<8$
MU]5)R=3L"6[,LW!OD[+K.C^]X,&%B</+[M4K5.K[UJ/9Q4UR\1HVB@U?7[IZ
M7BS-1NNS!NS0$C#P8;R\$M8C]<MB91<B!-7WE1]N1LO4G(_9YK% FKGH?9J%
MG8A,EQ7I)X/ZN*46O9LB]E[S'(Z,/K$<JPU:RB,!(E\WL</N<J8*JZ17*J6U
M-%_L#&FI@8>#[)Y49/8GVL]CF$EC.]_P\\V +N_[W6LC%)9X[+Y\]&3WA0E>
MOLF*Y!QAMG>X =/RF< ^DN8<:9E*AJG07[C0_Y1_@;@F5M$^R=Z3Z_/M<U\\
MHG4</)>.OQP)7U.W;L;QT7$7#D;@\1I>^&@-^21E4E0GW-5;:8J2+UD91'Y=
M9*C'5C76PFI:T58TI%6K9F49T"]ZK(HL8@]WFW)^T,1Y8[--USW1@JL][NBN
ML6S'4,;F?O\[=-&KLF *LUE7*#F[7A.B[(V5XH3"Y!;[;#ZV8IBC.28!R62E
MK>.#MJ/@H3&O!RJ0A1+?2[5J=WHZ5U-:0.SALZQN33+FTG'?/YE:VVB2I+.C
MR1_K\.(3M *2,+:S-2GIP4IP<JC,:J6._$9;FTRN<I]DT(M'3AJ/758OY.C<
M3'A>].DK6A,')6K*;<P,VY8'^C0K'RW(O$ZD**96<A&;)4?P!"V+ (\!RB'V
M>B@)  3$W/9^_5<0\ $O9^9XK;4A$1B;; 'BIA&1BFL(TQX:B9N6\./3UF_7
M/1J&M=!S82SQ&XN*I9=PQ>]JY,8P]6/XVUG+ST&P.,I24*-[4F/H*N48T0X"
MREIO3*%G.T^U0I!+"R995L:&L[I:^%A[9N&8Y6SAC+0T\EOQS%RGCSV'ON',
M*=E#:2<D!S(K#/PQR?(WV82IZY743K)AYY"_I=^1::3K> !NX=]A FHEBS3\
M,I[FO8"1=$5?<Y.:!>I \GB @XLAS9PG*83>)W28UCGSX7O;B E$3*VL=;>B
MD@3<_EJXSK=Y%B3!& J28*78ILO10ZONS1]NT)]1>AIWVX'(!$,3XL"!0 ?S
M^5GZ%@H:P13V"5*C\3IDQ</;:-&(AUK:T/3<$IH>CY=GNX?5ZHE3W@PUS-X,
ME:U*X(NBSSJ.X.55RXQWD#2A$+_GQ(#O6*H=OA;9CZGU[&0TKS?U,K>*1,1*
MB64&[ D'*F2PO1=)+D!4T@>[Y%RGR;*QW!40K]^F?P<[@]!Y[1V_B8[1>CLI
MR$W]&]-!,1N4$T2O$P8D</>IN2>WXN!XK]"7AGZ0^<JP0ND=N,YG(URWJQC+
M"A=;$ ;[DA0X71N!L1E1DD//7_>;$:ZP"M'$NWI#V\C1->0H_09RY-M'Y> 8
MFT7/'X_TI!J[VB\==9J.+$2H.AC)H_JNKYIN0D0WLG<-V<N^M^S!QM+^R0;%
MS^($/T.)@\!R E8V'[)O?,,!GSA;4M(%:9(7'$U)TK3&)=RGSOH;IK^!"R4;
M ;5<3CK4;<,=-/;,V/0NM]U[M;: W %Q?@QK7J_H&MO,>0RKN^M>+M9W$2WS
M;(.6V:!E;BM:YFYI_%'5ON(8((T_^P8:'YH7!.*B\M,?&5JY3-:Y!Q2Q'P]$
MQ[0\M2;).K<(SX2MIIIGPC\%9HXLM2TG+#;&T+!N;TR(:Y@0)]] H/+2K_L)
M+85$^T0ZQG*E0Z&5';*?:'4:6+*")/)FZ:^Q]*??3I=X:D1L-12/V;RL(^?7
M3-QF.:^QG/GW=@9&F%Q]SDE3:BZ=H;GB5%,N)5JXEZ5+;O:]C*314 5"KP63
MH0IS=I%+(8:SQ1]%@Q/#DH  (VFQ>9:FT?S+2"?JG!N2)B8_8!P9NR8:*[&G
M3<QUMHQW& ^N''JE]=X[(W'U^G(VOHV #P3\CV\5L1-4@ $<H%IQ.JVY;>Z,
M,23UETP84=&T(1&25O)U@3LZ0]QV(JXE%\)[59#(-()#26M_4D!/\D;(\U-3
M8:VMR=Q#1.Z<I[J6VWFI<.I=-XKV&G+XY7LK6H>G[$503BR5N(+@##XO!82R
MU7SUB>!B6,H-/7;"N#K39T9%+:0+8Q9?:&Q1E?P4UZU"H#*E\ MXC+^XE .+
M-,=E=4[Z^,1""1GLDJ5"D.61!,\B:< EG+"S:/?5L\=2/@=*V"S=2.TUI+;X
M9OF.P>FIUE\?QM4C'#A-O.('$OIN0>*/3)?(VLH<1N]QYFF]RS<R<PV9F7\#
MF9DQ_<H<Q9FU)=9')YE*6W]FKG6.',PB-]R&AP.QW(@)JBFVS$%(1QB[#]@Z
M1V:2VDB;_S5S^;==78Y_6^I9FQ3V>XLV%J;%?-93THX9456E0D]IL%+S0>NU
M$<FKBV3Y_0]?.B-5^AP+>^/2:*B\XA.OYG+P+%WEU0P<E3EM Y/W:&0;9(_,
MWYOPUG7$I?H&XM)TDS_T2#-U>"!,]4B28 *UYY )U[6!^RF-"Y>J#(,R(ZW1
M*$15R*JZ3&&*"K\$V*C(C.Z<=<6,9$;L,]=)8RR6ZI4-FI=Q;<NX;]()Y]Z,
M#,81+2\04&7F?=9[IKWI1F*O([&+[ZW@/.HPKK_ 8:N'ER?I,.; !8X;31+E
MDQQJ.<=D36_9S!)'<]U'WJD09T%UZ]9J-]8;)H\E*]+7P]@/6MWG)5@A-GKT
MKTCEO[ZM'B6OM&F]%D>(]DU(&XF!:+HE@N!O4DD7,%L2QL1D8/;KF$N-[[19
M\FLL>?W]%5'BQ0]LO@\.@YA?#M]OX4NH!%RL-+DZ!_CN,]6-0D#/LAY;7^GQ
M^*$AX:)-3,H3\8]S;1\]<C,O_*$#![PDEQ>4_K#*%80/T-M1JQI%T\D+][LZ
MFG9UV 5(I(':C!T6_R*^WY2KX+2=E324HF?3ZSL'Q0)GY+*16@A= @4M6E-F
M:%>H\P25*Z]$!T4_\+[1P]?9E,TW\LA7@N8-+CK8DYNEO,92MM\*W6ZKINA5
MRD?"@.AU)PY8O9F(45(*6M#KDK/7*.BZG_"WYQOXVP;^MH&_?0?X6_=-C[\@
M-2'-FEK7X7$LT+O.@[2C(7NRZ+R^) \FVGVRSJ4*Q_>Z=86IEX1C0UP]Q!H=
M-.2H"&#UO<X#KC2,0>G*Z.+T+UYK'%Y]P3H_7ZL&8:W!A74*:UTRK&58Y[*-
MR70-D^GL&VQ_%*];IW1Z2O?.)C3*!FV$T80&0?K&I7^,]Y1F:#8O7%[,?<-=
MOWNZ8K/HUUCT\V^]Z(NZPEIJ1M"FKPV=QU@@76T9Y2)8>K0Y^@V91AL'^&M(
MPY_?$J\\XO^F>;-@+GFO(0_@6E\R[?< Y(H7M^X6)A:E5W(*AW]EFXUL2V9[
M-O:\/(B+)NC_U%3%&0-G/THW1PCNEN%).JL*NEJ;/>!PUC_E&=+H&F\H-Y&<
M^@D0V: X\TJT-A#%ZTCG\N:D<YPM8YA!O +(ID^0>E&Z1?MNA!=L;Z3D.E+R
M[^\<68^UQ+*MVB1L5^77[FB_H"?/N;9X%O0F_RH5P C](#-'*HX+F&/796ON
MA:]LWZ*D]:Z*_6"^@<+ZK"W<DVLCG=?@9OD6Y"R>D[V:_,BQL37<($&IF(3:
M)ZVZ23OKBLNY.AVT0>.@$M]4RZS.9O3IJ06&>48;*<KEM'#?F/S'@Z=0/BC/
M\KHJ!3B,^JMQHC FP G)/OU&X_2M!%6XF1!@])KK/8$1C=:(IL4D6A/2Q)?\
M+YN!:]1X,9AG&@J*Q.I<_+!M^JL0UE?TO"/YZ0Q$1CJ[&5P^E-LI*ZHX:I)9
MUDH6F<\_]Z+F([IIIE7B4KC"?%-%(QG"_D7>^[:L<WE,DJ \3?Z=U"E(4^U-
MZ.URTKSSW$P%-@/[H*R;SY.FE587Z'\TC9HE_3UO)*LGKR#]P/DM<%NT,7RX
MO6) 5UE6?T;O1'BNTC#FX$]:MP:%&H.+XZ!SS'\G)3>.>;J+QC%/'L?B^:<6
M\N6WD.$OS*B.IWG&?&OOWNUSC9/"V^749C(W2!3][\->P<6*[GIDC^A=+$3X
MIIC798<IU5LS<LSP:.8)::LRJTE_S/(_VZZ&NN)L>AR=973:(=OF:81Y!8O=
M?L,PA#K)"^Q9Y17T.X=JJ9PF]U$'?5+1;1ZN;!P='N^-$\ ?*&4;.2JMXA]-
MX^1C4U1LBTM>//.+2W2IV5XXZ0HQC._?'*]]U/?Z)*W5(NC%_9NO=:?+</Z2
M=(V+IM>JTO^QB.+30!0?\BQ"T1KW+;KL]ROH:L>%\_G.JXO[5SV,N;V@@WQP
MRJ#&%8>5='D/F\?W@TW"I%H;V'FJKIK!YTJG9<36+;V(S9_HU4(</O:LJS2J
MC_O=Z46IC_6GCRW_[91[GS,J3Q^,G8C70WLT90NFUY&N$B>)--9QE8P%N4$1
M>I8*=-!TFW T6$(HRG%9I!R<8X2^@=+MEG^@X#X:F)"7_T'ZHDG%JY&Q6<)O
M>H5H2VL\R<,AM3*E!S7=Q+;6T)+.[2%/Z0>.%^]79:D;0^<#C.N?=XYWHIF6
M9OI0[\'*F%"-H7:@=:SJL7;I I <,+F'%%Z>I3-HO&(<L*/LK"IX>M_1U@Y[
M3& 1>$&9^MA TCDA;ON08(4E:#1E*6UD*OV'L\'8[_NRXOEF7OF6)D.$!0Y7
MU4;,?'$;H4R(@Q=2G?4?_VOWI\>O=W=>QG:^^S-IQ '6J=:0\)PJD;-N+PM6
MD I=B.*<6T"W6;&,[A=*ZZ<-2FN#TKI-**WO* RWI>?=!"TW,G.23KE)M[;+
MU6ZYE=55@6K2"TDABXI-1U4LV76J Y.VK?-)%\#SK?*;D8_=U9DMG5L&5/^B
M;&]9LT#2_;=L1"O(1[_CB+2X(=UF<VBUU2(FV]N]3_M[]S:2OZXSL,P^5F3Y
M1)^/-TU2UIPS%IQ1OTD52!/M/GNQ2]9<774GI_CCF7&G#F%&@=3 9-P1EHPU
MDNQ,U7Z3$6OCFPBQE.I,F0DK(N]'37V!?)+YCTX>8!DJM%=:S7K0=-TRZ0;Z
M5@BCRZQ&&B+4AQR"7&K[K%:J?!'3].-BC(.#\J6[B06]0,6E1E;%]9#;N*Q-
M6%*UVMJE.2179&MW^\+)LV'26=[ ]V'OD\>'ZK\B.\F;0A.!=:?5#@N4)W,A
M4Y)6"VYWUVM4QZ\29)82%_UOR7H4V _W#RLE_LOMXG_U+]GKVM-*0ST<4T2!
M*[ZS[IL5F(O>\.%NM!Q3\5$"!"/Q?QL[V.+VN!+0-U5TW%U.M@)ZON.;F<W@
MG7!W&5JQ]I2$W9;;H[6N1UK-W0RG=2>BRL[A-@.LU:W,DKK(X3'";$&!'6Z
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MGPWK7.)+*E?$JS&=6M), T%5Z><@N2[&;H4@*ZF-2>D'C.!X4TT[JR(8\1$
M_0%.<6Y.FC73.I_(ND^+I*//Z)UBK=#@\3]@$;"8B'7WR\L'/%EYRQFSCC3M
M<+H"$#2='HML=3L&Q_0BV90"M 4U8E^<%N[__)>J D6>V59=T7HM'YB'O[J(
MZ>/^K=CZILP(G==X-&;AZ+Y$.R4G"6P /]KERM'"SH"8>Z1&Z#$".=5(CBC,
MB?M6N@*:(17)N<>OXO7U:RQ&@RP3VH6M.^&KFK-17*>FUH=G"+B4M5#*MXU_
MF;3^TK=$VCK[@N?6F1_QC/W6.K&ALU*Z?!/5K;,BSV;W3Z[6%JN1Y./8Z1F/
M'H4B39+'-.1?\IG=\9PZBZ5U@<F(^D0%M@>#+2']>4/#=!4:IIMC8<*FVZ\6
M2Y,I_@1*>+KS%W$&/B8P4C8,@-=:MLG-+1NGOY 1 KB*6?R;#.>G90ZQGU@,
MP&746'1'EP+OR@6O/!M4BFNG>Z!OR:/3ZES<7>E?#/(2\-X4FP["UQ&2Z;<1
MDJ;JZBF ?FFV6:9K+%/Z;99)T-UF(P8-UY*S)"\,LLP[A3?+>8WE'"]8_.K+
M*0 OZ6O+,"6&(IXG#"5?) U*_+4?"R[1HJJ\G-6YVK0VUM!C>E);C:M'Q/H"
M7RN""0SIM)&)6*1%.#?Q#*TQ$ DR@^(X99*G42? L/X(3$'2P(RT$#&(C 1G
MDDEUEFT8-Z\IF+,;%$QTX$*^7<.T-;E?YV K',9G/8E;81R2D*AM>&\S$%=P
MKP:%>BM(!3-A4QFO7F36IY<_N1YT4J3(V$2OS!+]L+OB1)@CD9-B/S\6)A&/
M.1 \.09*\0#*?M9>+5BSH^5:'KSXLKOD*^YRN[#'0D28 >];I@R?K)-SGV 4
MV!W.: &UGO$'TR_"QYI*^T2Q[NT%YU7-83L.S#0BFS/@W$XY;\:]$GQ78VQ0
MRK"C$XBW0ZE5-E^0*JQS0(J[=C0,.27!K%(.2RVJIA'PO4(T648TU132RDKG
M!AJ>-HE7&%VJ47G!XW//1<L);"XUH'\<: ]ZPS3MBK+;<JDQ/R[.<)TJ^SR5
M&I'TH-VTE-,O(H%Z48QV*A/S;QN\&[FI@VO^JP-<T\$E/:K,H@)*/-'R611H
M:T:4 >G@ [$5PF9\]PQ7]G*#*]O@RC:XLA7B<5L /+<-_70UG-O?LV6(8+A5
MKR&G%!O&8P;%+1OR]#3/9J[@0)FLR+*7+V:V"++W14I.1%$MU%</OD)A+DH9
MAA>!3FOJ/I;0 '_CPKKZW4-W\-ZQC\_5K)R='*,?07UG.E$B&#OGA;U2D5"V
M[$B+J1?H8$]6#%LU'H1DDC YU:(J/5I,">=8''[,P+9YF6N/ @,%LTBL^V>R
MKNN>O<NS$81((N$X5!C4[0G7#*;H)@,SO^X0BRNR,Y03M2UI#-Y.TF^!S%1N
MUAY'I\L%+$^S%K8R<\0T+<F_F$AUH5='B%KAL#D7/!XRB[DE.V?BM?T<A$EV
MHJ RP&8:5$3X&7^#5'S 2^Y#K?K8L*3.8DNN B:LN$^J9:NK%.[+0(73?"(-
M25RQ(?TE982-\S2T)-<ZE%Y;CSZW#MQ).BYG"K;9]ZL8F1 <7E'TD:7-OPZ/
M84J'JG ?-_(Y:Y)CA:?V+VJZB?3HEGA ^"6 I;%61@J<5)6+%)[A'%)E9?22
M(D5LM15M&9H%,OC3Z#QAX(7&F+G$$Z!5M##(5GP93J )A#MR,3O<8 S:@C$8
MAP11/+80#XEBH$93QVZLH?-  NC"8"8%\.#W G E2L$^M$&V7 ""=<J;WH;G
M$<.Q!&@/=X/^IE$D,%IEZ!6_SW6-XY#MQ :=@-5,\EIKW*5;C]M C!'*N?;3
M++6U[G (N"B<P:R9>!%]>)84768A+>XGKQFEZ0TAT1%K):9>;FK-8Z>G!;5$
M@J;\8UN>S>;7O?MG_6MA]!I]80U D78W!<@A59A0?=>.R2LHP7MM2+]8KEW_
MK-@W+P*>*3_#:(-IVO\B 3D OONC2T^,-DM:$6PY7HO\2U;DIU6E'=KLEA6&
M'E"M]GE6*V'-%NI!37'9.9M69UF9:!=.2]D?I5TM/92RJ"0Y%?9#P<*Y:VF>
M,#$@ZN">S/=NWZV_[1SCW,JLQ J&.J-K>S3G/1:[Q">PW[F .?Q^S_3[S/25
M&<?6)=PA>-J)<<",1C@*JR*7%E*T*7/)Q#JV-E-C*VW%,=&MQZ'5(X^)=4NT
MVM6 F4*+JN&HJ*.(:RS_H>+D9^$#34M&/%':5W/O QBE1<B P[^Y?R?:FNOM
M:=JAN3D,-O1::Y(6ARM0,HDD+VDV83X70SH96Z<BCF89%HK5^,&?"^U]9XB1
M+"VFFI?NA'B;J5GYN>P:Z=3J;^.WR52:%MO???*8(?E#5]5D>@TX4_!<H<0T
M<>R9\.GI_!N#/AX:P'+#T& /;:K+P6I%V*O4[^X7VL,!&)4I/#F[P]MA%&_=
MD.UXHJA571/3WIE39%58X>7O'H%$B^4O#4P4^@J+A:1K*!1IQ[:V0VJ'L_)P
M]];;O?UQ/L8/VCC%T<;M-4W&(%9QC]2*""'O;S(DF@*&U9I[R"R=YV<YE-O[
M2FJ]KJG^P48 +W2HS>ED .)CR'!G7*9NJ^,DM+QPY-II*RRP1==LQ_.J\?&%
M#!_9Z>RB,]O+]BH,>M 9ATE67)6 G+9\:!IB[+)2SEXM$7OZF+Y?-N).&+CZ
M 2?M$8M52P<!'"XI#<:@P:6J7E2&=2AGTCEN P374WFS,1M2[#EV U9P-".N
MFSSS=9=+N=W*KST_>6LL#JA)4;@98X_U4K"LQO4Q06:6FQ=YOTM\MWGDBC6&
M9*+R :I-G )&SNF4.<"2 [1,?5+QF]VHZ\'%OMM&'6W;M%YIAQQ083>$7I.K
M)(C)T."8ZM,^S)*$,K.G8I8N;5#EJC+=K1H;]62@$M]0VV:9,!1BM06"2/CG
M)!.^/&T7 N8N/6*U&<B@2-F6!J6. :[_A= R8<=C*D:"NP9H52)XG-H>G/)&
M6-A$7MNCY&9[(8.//<W284VH!.XK:8=FS8>D'  HQAI@!7>ZT29VWV<77&D3
M7-#!KBA&8HM-F\P7E@W,'$Y)S1QBADJ1A8/CIR<^D9Q19[)YM(E:;CAO!^7#
M*C:"P>/"7\[PX9A0F5Y:^4VX"; *C%&P/J'=/6O,]6J#4=E@5&X31N4[ZKNA
MHOL^XP"]HE56?#HN6N]P5/OZ@@,R2(_T[(YX[!#4=HCJAIV&BG55=TIKM8PU
MDK3%R0\=O/"!CA<%0:['F7 ?*4;6M:>UHF&U&2'?Q_H/'YBAZ4RD0!!F;8UA
M>R$4FB08O./J%AN24R5PSLO.W-E4:N!?#"$)ZNACDU9UE]#,/_*)&4'">/^6
M=>U5K4?1RYN>9BNFBVW7'TWGH;=T_5@LCI3S5%ALV3<T:5'^MT!H2+-H)\<$
M#<X93A']\M G=D5KE(<FC6OKY%&XS'AP>/RW+G(0X$@NA83<OSE??\KIB&HS
M4\!Y.>$[NF<+P\OXV1F$1\XAT@&BQS3?5EIAV[10VID4-JAO2CBX>$0)8I2A
M#V"(H+O'5K*NA'T"QJ]W/FR;IAY"7,2 J"!@J3PF#NS1;"A-;@FE20]V,LED
MJ\_)5@N164.D2=@<QT).=G8?FY67IGPN_.UWE=?@.H22'1-?Z+6Y#7@=);[)
MHS \CZ-X&1DX7219%/\5M@S.S>^+[(2R/<^*,_K5[I-MZ6RHN?KMB]Z]N?++
M2Q;U))= K10XMI5LE)4SL:$KN%U,,JM%5J2P*AF@#.0 @ JF18($VQ7#*1G8
MHIH*/#(?Z8CGJIHE9@_E3?^ 8IUDG)*?:D/+O#$W8.IX!,9[)X*)OX)G%*)I
MN[XD#I^P$;/;Q4535M'!F>;?WV2S!"FF4W3#FBKTG8$:C7%C-=)^7G4%N GR
M9J6V88AM3]%J JEQN9V ?W"%UA7!ZQ\4S+#$$%[ULDV-]DAG9A%Q))A;NGCL
M[%GO);8WTGN[*'KZ0I8W0<\XA@.;9G@I:3'(6=,','#A<55$>*7%MFFC8;3@
M4 HV0G#+B'T*+AYO2'EH+H[6;((#+4_[%0J<A3ZF4RLGZZS&^HZXFXAW#P_<
M21:$4F!5LKLCG:PCG^_<4S*B18&M:;JYUBCXVG.0_O=*.@9C[>$ V/6BB<E(
MC4EEBQMTP+-L'<=@E+$9.A#Y?V7,3,8@MH8/N[N9-^#!;K;@[:(PLFNNKI0B
M4+=R\FQJK%MIFE_KH@>60<ML^&VTJUBO20;@D0A'(4"5X64*GLKI$=-JD6?-
MZ*V#0C+MZFT*.GJ588"3F=Z@*T12^%=<PU+GK'GE&K'W<5(FQ;+)&P_)8.IC
M*FW$Z)!X/EA66&;\)^N4BBZR91]+6Z9ZO5G<;*1K;*23;["1I'JYJ\_$)"VR
M$Q(G]?'$6&7K-?-KC%:)[6:1K['(IS=KM:Y4,>)K-73(=:Q <$*7CTXK6J!B
M0Q%ZG97,;Y934L+47IRD'!Q#K+0%ZID[2+/;M61FS1-_)P?G7!">S'(^-_ZH
M<NGQ$APK*.+CUA2*UN"!L3&LN,QI]6AB-(REJ)-0SO]K[UJ8VS:2]%]!Y39W
M8A5,2W)D)W%VJVA92;3K6#K)WESJZFH+!(8D8A!@ % *]]=?/^:%!T5(?A"D
MIFHW%DE@,)CI[NGGUU/5=W'C(*:ZUPQQ0 AKLI+1 "FT=Q(8(/CEE,M1-A+T
M#F;/?7/HLN=<]ESOLN?Z+]CKXI4,S8J(XQ(SE=K ZCBYH$/1WLO$@K9C?W:Q
MQ$JE6% :N#=%228SY4%OSXO2%*Y3H?H!C/^[M'-K1NB@UD3!F,"6Y'0NPX<<
MV;]_.9<A;J ZPG/!/<O)%HP9IU/Z.0J'G/S O?SPQ2+*L^#&3BHQU9[:-/9>
MJ9#4ZT91&<>*4YE?H'->:[HYNQ:US@:/.5"UV51HR\,P>"IY'SHH0X&-9,,Y
MO%= =>C21&"'"PD%9OG6_#4BT/(+M$E#!9FS8IP&3.,U21SH2  %ECTBE9 S
MA5,H)Y7A,VB=QUABI+(P(N[7Q@Y$ZTN#!&*Y5BK:+H<YEXB%6UA=Y@.3N;*W
MF<+WR+1J\=XV,JU<GDO/\EQT"6PE-* 4D[8Z?!V+;RO%=XI$OQ(T*KM*@1%R
ML:8M%<KR3,%LTEEVFZJ+UJ1%'H@_-<@"YA.%29 3F"!W>[">2LUR@:!.KWYR
M>F;/$BNN-<(;[-%KV#.W0?W*'5BF5"A5.U9)3Z$V7;KEH8&!E*X]WM=\156J
M1275R35DZUER0&5O]4;6PM BC6"?47RG8IJ5,>&I6:V[3;Y2!PIP!-"KT+1A
M<XW06S2P,SUUC?%MPY96S]K)QEMB1@6>@CHW)2MPSEVIER7!$!-]99R*^R>B
M&GE_.3H\]&&:P\-#A2"&36 <"?4K*%NA [7MXY7,FUEH\XQ5>M4=/!PHR]HR
MG>$;:?75G(G*CM,A%4<$_0K:KE$7;-V@GD?6[)0CH8B4<N&%F)M(UX[F(@?U
M/T4@N9P'OJ\P>=$J3+P#),'[= ^HO[FA5(EV<@JS[K)DJF;'D7*_HM;M! R4
MQ(E+I/HL&2(=:'$>+^?%'8I/@\J=)O01V_X9(Q^9Q']LE6,H2PPXA#G33(A_
MC4"J":'C$RV$;%%E:S?.1.I7%(5@0A1F784H#!F0P60[HE7SL9K2,VU3>B3&
M.D70W.8_8/.3S[?Y-EQ%+F3F:CHM_"JFGV\#_G'G2P+=UZWZD'9B^$P?VB,6
MA-!8SN"UIS,/")H;^.G\IDCCEANP725D) 4Q0"2"KX48Z>*P4P/+G^*X>)GN
M ("PZ01*PX#FXV4.-%-@-A/?2(CK:_/65X2,R77.. 2U?=[;J-0#@E)*%K2@
MD;J@5$^"4IB*;^V4E1?3CN1L5VT,NH4WD.T^7WS#RO>G&?RQC-/L3S">0\3=
MKL?03-"^J*7:,LC!9MUT%_,.CUS>H<L[[%/>X>Y*[E81O4:<?]XX,R@=LXKH
MKH'E7.LNN]YIEB^&+VL*%4I^]"O5J[RC3+ V)<NX6?4BEY'4YR@WQSR9)3 7
M EKWM5=.K[V?)/C=)9F4A\>Y23B=3F@);27B!BKCNTY'9. \53T+HM>U%BKS
ME9K(Q#M%SCC3A=R%16!LRIH;C25K<8_V6,7&G%UD21RRQB\;C$G,3>0+C W#
MOW6317=.KXS!L .:#[3]I.#1!X2$0&ETNF8=B!CK)66?0<P3<A39KZR!]=0H
M._" :CU>E@S/(G,>R<8NFZ@6ABCAPGF ^-9  $PM:C +L]R69TV4"\I&9T5<
MPVPT4MH-CGH3)/:@.EN9#AK=8P:.5ON6^V!H%0A*+,KV.-4[>F_L UD1DVJS
MGP^/W,[V*ZEAO10B#J9T%J':ZJS):4'3.Q+8"*+D[HC<AI5SMA644\60WAP#
M<G32M\P%V^,SH.;%J:B8#PJ>T906:"6J0Y8,#F!Y2JTV/J"_;[Q;H>5IBJ)R
M9X']GHB^9*\9T_E<R"YKNG+ >K2,3[5&I:P\&TG$)HXE.WFLP^9S)-VO/(SU
MH@\)'-[V1E!G6#0#.52!OK]L);#"A:#P4,0E&>&?:E 0?8WY08^Q.>?/XAF^
M'TE/CDB='*F AZ#$)0:5K[LR^:#YI<%4=6&>B_D8_[;!0"@DHDMD)H1=!9I;
M80S_3; [M@ZG7U4.HT=>)#CUMK90352M5XBJY2*YO4OL:'/P4[M$N_72H)+/
MV@1;%MX8+(A\N2C#%?>YJ39MFX!D+F ?D4ZI^ WA]A4!HP4#2Y9H]0,+\M(_
MEO2ITJ#1;F,9Q<5BB1T!<0K^VO%E-RJ7A;MKN2?KI3;WN&>")!T5"8.J!@4!
MN.79*DA(R!EJD=ES=NP:42LTT7!1I**:VUFF0\*C";:+8N#3+MG\]=AT3/WV
M0# &BYD'"R8K3TG=62S8Y+??U1;,4M$P*HLCTGXEPB"H2NFAGWR)J.<H>K"[
MEYC&(3JCXTWJP-I,N!8;#4%]* Y:8!0UH2BF^EF$LQ2F-I4AT4B 2I,M=)=4
M_;/*?F BM>^.0T1C!P[(L(M:E8B1!BFF$*^)*429=.\W,KJ<[KS;R3XF:</J
M#.!JEAZT3?//"%%1<<2B["CC<DG2 RQ<.Z"FO;C2D</ZDP?7JK;8H--','ID
M'Y_4#(G;,13<"O$A,NW>^: 13)5P!SCMJNE =A ;#Z3%]',G#=LJS;I,X8K'
M^+EUA."F=_' 3.("CZV5"/*]S:Z[/^8#50>YQ+K>)M9Q$=B729"C%HWT/(1_
M"6ZX3!&SX\C#*JWC5F0)Y6E]$+#$+N;"';M<.)<+YW+A]BL7CH4?A8VPU2R(
M1W*P(_)>44B/BX*0FF8W(J=>LUXX0X W^BT1-Z072QQ5C!F@IA(M!;>""E;L
MA,IE"$S(9F(EZ#_L+YUF603"EQL%1#09F7:A#&B5R@$Z=R3^6*)(QS[G^0U.
M(6VJU*^R[$-1-]/3S(),UUE$A$FH\X8F<<(U$-P.79<@<R(U[&H*^M25N!$I
MO-YI%HG6 M#Z(CMSL%])<#I ,X=G*04 "1=H";/?V#.D\8<)ES>I]U2419Y(
MK;K(A]5PXPE0OBDS*-N75&K,I3/4C.$O)W<H\\TZ95]SDZTEF8?<SC %3D[?
M]V+9TPPIG<&PN1FR"H2IUH(4;+ :]9I&5GF&9D?1>!WGZ.A9,AV3,L:3@CR/
M*1AZ"TKR+%M2]HIOG/BF>;EV7.@VY(N,Q'_&.0!I@-[;>X2*O"+SD@Q]*X61
ML85LE:OS^- "QIR%E6^8(HF#L72TK.6#]>X02J;6=@$=0E:D#&4ZGB/Z1%)%
M.@L!0IT;M9F[-Q]3( THAKO(,?JA> 0K_>0P]C<$\$@N*,[GAM5:Y'B,E$IJ
M !%.X C%E48W>9#HSAZ:/S5P+J>[.E]POY(#F<JQU0BEY2"=J0C#;99_ ":3
M^@FEU<.ULC",TP?H4@T3 -R91$_ M$+JE &Y(J,.*-I#67,_VJ'@>^!K>0=6
M4R!I"L^Y12)0.%@:UR.7AMJS9$7EL:ANL@[>8MUQ*FZ#A(6>T4ZD0+D;?2<2
M19C'8QZW4F <#GP/,[%1=U[WL$42A.P?(75C#G2!"+94"-FB<@AX!TS/,7DP
M6J.A^XT&4JM?EJ\2VZ^"=<1V,;,CVW[E3N*>S+FL),=5*YYDDR>W 2@ _\Y2
MW'+,FL]CF1MKQ)O*GF)BR64>&OL#Z2X@"TU1=/;Z#>W!USJ!U6&5_.1$3[ZE
M/,AHK?2ARPIU[G"58%P(M@4.8:YA@4?<!,ERXUF-S&$-0B4"$_C%) A9(CJ-
MEJ&F<"VGY6=,BHA#4F!8;W-4WJ]T2@1&E[D.R['Z,*E1*75)N/-\7A\F/,AR
MLNE LHL\EQF-U9[P=Z7BD$;.ES7&EC7A/&O?O(#?FEUAWE)_G&#X"@'3K7>U
M%0STH5!6/+9BNI17#'J\'-)V;ED1_=(2,%Y_EO(#WG\6C^.27P[G)9MB- N%
M2$C$CI-[EOS9# QQ0ES!J@X[ 6%RLTPF#2L3F0K%0-R7W&,@"6[;S0(U7+0L
MUS1.)1UGCDE'.E,4S5"7C=FS;$PF%>W'6(/Y5$5VBKO"6=JCV:B63F+T+=^1
M@Q_M)^6D_?#39Q^91G$>Z3[97:LD-C^"''NAAAF0,,U4:<1M,$M9KT@$&9?&
M]R3'CLQI3F,Q8I-G7C-.=5L?N\EPB2<R]4O1#>,;MP:,$*ZO)/\@?\D]700<
MH2*C!&'*P@S0N"-W./;PDQ-]GY)]>8T06L5+=HY;:9X^-NJ#=YAG['.!D<'2
M &-6-2R2:=!9D@1C(AB<60[+,I6^\%OD.%E*;'^O>@FJRBM;-<+Y)UE!/KUU
M>]/!0X/SD_FNY-W'@V$*1G<.XP#9?A"H;&!)(=I%UCSE5%3A<2%S2.-0G4&@
MZ3#F5XH_@7@";04]CXP_AJ_&EL@-XDK(NYE$$'2P&ET3Z-NM/-; 8;#/<SVQ
MJ?:\[2ND2:?Y".5>"&#0I5Y[I)YLP3XLU 7U]ZJ6+I!O6>E$E)JN/R]5]9&$
M1AHE\,)YT(1&<O*W7^FX,M @U3 RT3GJH"/9OR^CJ?1!8'Q7QD%@EKF0&EB<
MA\LYTP&3;SU=M('[PL>Z3-4KO!?#;XA^7@Q?N/S+_N4"L]*-HE8'R]#/,Y8-
MQ>H:.((R+CE,%6;S.58Z@CHO13*Y@E!8L3^+[$E19I.)1'0$82XCLCB4/"$5
MF(\J%9?(%&1+FP)$_:W=HZPJ<O<RR^R9RS)S669]RC+;$0';9HH\#+:FAIC3
M*<'IXZ%NNCS&[S0773ENOT4#'6@L=%;9FGEV>5A'(+3F^^YM/G[W=/PB2VM9
M^*B:(^IQ&L5PS,&YZG-O3\ZR$%CF/XL7IM*?/JC0HLH=67D2>=OW*N6'OOD>
MC(4"3$*P=U+=0 +3O$Q)-F5 8KR=/ZBK8O8E2W606LF3XQ>H*143;#]A7P@\
M-U>3 )TC_&!FP%C/\&]:QIQZ8B57PEF7AJNZN-Q]TNA<JH&%RNPD_5&(&HUP
M>3#:?&"X1Q%YS4 !FP@$D9.9/;HY:UWM0A'U#BNE*%]_Q'@4?A7H!/-+P4C-
M9#T(D*)'J_[7KU#O1"VCI(>,R7[XZU>'7WDA6*U2-.O/"YR<_*S>E6]Y0EZ&
M12&^5W^\]&IZ3)GC?R*,+=*383N_4H/PI;R9MS,@?3H5<#]N\V#QU7Z13)-4
MMC,/J]X%J.*'IV74W*#/M?*?[#7NI4!-"&%H85A1.MH:[,/UCBV-B5GE.#@J
M2D2/3+&'-($0J2322D$/%F;#T8AG-%HMWL&SX>'7VD%N-[Y8EPK2G%@\GXL(
MD_.255MC:M4J6;\B9K/*S87_Y/@?Y'3X%X2 $P5.%+ H&#M1<*<H8/SB!T@
M1OELR!&P4#)4Z8]_*):+"@'0)+\]^?IE DK\DQDOSM$Q<,X-%O^%02(7GO8$
M/7$PPM^Z2:/;S,BB8R>+G"SJI2P*G2SJ*(NV(D762#2.\QX\^\BIY/>9"J)4
M:H%VM V!1J$0)].<3-L@TR(GTSK*M&W($11I%7XWL_P%"\70G:4ESI-9D$QP
MI(KT.1R>?''Q,[Q;]'2GI@UQBJVS\=NL1*^77E)96R:F&16.Z@ABFC4#V1@J
MR$+5T1VK0;G74YPNZ69"V*@XYXP[[C:()9HIN][B"8<?, &&J[3Q;E6-(F2
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ML$'T9.KB:-L@@;,_>D! QAK<P/Q.X^CO)G:1 NT:Q\?*@RFH*.CFA <<' U
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M(/UJB(LF- F$% YXYQD18"I[&FC32.,1A>Q,]0JFB?J.GZ6FSE E:J-XFMT
MOBC*H_S(6C@WZ1?]^N+]HWK6N;Q"4WQ'Z[W,N\Z:F<3N'!B0Y&*Q23BSSDQ
MA/#E33L"!F^RG99G)Z7)NN=1OX, A9@-$-@1E/<^4V#94+AC\V%\*C4N[8Q$
MA3?-E]WJ*,28H4ED!]\9UWT/G_!KN.3F(;=@ZG3!J4+/,0.?>D/T\D>?S8_E
MXH-^D64_2$Q.?(2+#6& _8H"1:?=4!ED(W\/U4@P)2_[@#G*LN1(WV]@U2=
MSTOLQ2/9G=,WDE.1W+S3!05R3=F2@1 'S &TJ+S7'.":AR<E\\"4W*AF ILV
MM ;ZQUZI/*^FSSUQQ6/.V*$1Z-OEFW59'7;E?J2417 E+S'CF/BMV$W5'H\@
M!X]#&(@'0DF/7^525)&?=TO-BH>2F^4<Z,PKJT2)Z>KS7Z,E&3742H2^=/I*
M:RTJ(R9T^*B=L+YFEGW/=WI59I1C\L;-_@5;_>27E]<?U>K>>,?L!6^UO+P1
M_25V]K7$S(AN?F6X8:HGI_)HAB5B?<1:@$4K+>*BY%T+KO%SAN1AAFCA6=I\
MB4!Z!!9S>^!2H$"BNPXR)9T[R?Q(KJ7F'-%+P**YVZ!:G;@RS D#],/BR-Z_
M>2NY]8Z'>V_T&V3TIN/N3JC7*<C,($\,/?8P2KB&Q<7 QH?(<:V5=*/FK94?
M%)(;M6'\M3E.U]\XE8)E!$^BG4C(7X@8LF&%8L9VLR!7KR&J01?TJ<BY]_E;
M\L,')+[P)L7QS[-FF";$O'C^*>M"P:Y^<4=QWY6OWMN8F>&BXEKVK7UFED.U
MB><9E95YFYIEY9")>J>#Y^S8(\2Z;%#94E/]^6-L%B)1*-!VM<B*@4EF6IJ@
M"PZ$E.$LSR\S0#K$+>D9M?4QB')7C2@1O=M&;>DJ)MS?E7 %<(3(DLU_+Y<R
M5-VI>T<R]! E)B;0KB.3FZLB>WN/<,&O_F1K,?^1K8$4.W7..8QAP.4=YJ,_
M[1G34^K4^_!M^"EU2N3G@ &4RA$P0.<I8=K5B\"& 7W3Q9ZSARNW1 5W'R]9
M=_^_AE?C_H8YHIO8W@*QZ6S4AI15S 9>,D>MC9^96W CL:=D%#R_I'U3*Z6A
MX6+(LB1"%SB5DD]FVSN&J:XP'W3HVI*A:T313<> @8EI8FMB-Q]$\RZO]\?H
MZ*\3U*B!_,V-,XX=;<K3I<1[D:0/XYNHEA.%FRD=I/E,(RZH_?<L6E;==\V>
MLK,O$F=.Y&LGJ6I5!S^P%8M^JG^QNN'(,EM^56KT89SQ8A1-Q]G_3K(E%?7'
MXRA!9#N1_A?W?@G:!160I4V?W66IJY.\0GVR8WW.F5@G/J^YNDQ95C>QR>QS
M>J$&.;@OK,4V4Y773ZZGV)VBIFK:BNG0@8RWXY@P$_MEZ@27 77Y-SU6L0J.
ML5W\O0T=/R?UC\HJULAP&ER-,4/+*G&OA(.1P6^%2>'48 "8W4-*9N;2L+FB
MKE8I\*.ZZD#86I67K&*$K&D"TU)=\UC2M3HFLCK4#'H2R/Z@\WY20[+6Y+U6
M3K(U8?G-LV9X&( AXQKJ4";D84GVEJZ$3[IJ<D>D*6ZCN;XZW(5<$)YV.1ON
M/.8I93M:F;:_6[F12%([E0V:4"T-K90PH"K\P.\6I%"_KY)_J9-11CG%3U>\
MM_SBL2NZ1XWI1]H;2H5ETU^_F I/9=R^[!!RV!\NU&VTY&7?RYD)H2P;'^4:
M0WG%:&.'2?;&RF,L%^$E-QT$D(M7X/=OT3:4DC0GV"'E!.(OF4R(.!_-Q*UU
M+"5#X6+&7.%Z\GKN2 HR)ZQ>U<8=I6,'Y2A1ZR_*H??6R)+.XF09)^:,>CD,
M_J!GI/*7L)@GDDM90TOJNP11<N\I(J10>Q[(*=OP2BMV,*R>D)J<+T#5EXU=
MXZ:LOS_Y&A_++RCN;:N_(L7R>-J'*-"H?77.++9:<G)-%-]1H0O%F[^"(\25
MK]U:U:_=F(I1%\+@MT)?RG0VTWSS>HB$R*"=2 $EXQH!/N_THA@&^,PXB743
M<&4NZU26%'490AVMZ ,L78U(UP,<B-Y8>B^/;"2>L:>X/MXIC%\$L1-"XLM5
M5Z2^ZW()JJDI4J7+'R1/W/\SU> *M!\EN G^I3!&(=L2CU4$Z<X9VO\H\6R9
MI>EI28F00=P[>^H4SZJ#JD]PS;9>_9CK4E^F"_A$%Q<9WORL;0=7HLSP+JC5
M/J0#OR;QJG$=74AEK'IFH@0JEV!B1(I$+PAO)=S:&9.:16;6?XE\M#Y5FE4=
MV6\>P]NQ<Q.)4_U(B7?4X'%R3S5<?$/3M4>O(JI&51FM]#)5H*M \Y)NRK5L
M;#;<K($,!@0XJ+$_B.*0%@RDK479"AL(M/?^YK!/:SK^3)YK@2NOD8B(*R_\
M-S)U-GL4+:%X;-6% 6/=!C-Y_JV;IN,PX."*X@%-(7Y(5G\?2IO9%!/Y2RBL
M]?SMG.?L[A.0O.EM"V1*H7M5WM,*=_SXM[)JIY?-+%+5M]&UUELD-<_55T_9
MN/U$63^)Z@1;9<7Y%MXEQ?P]%PP0'F2Z1] YS3I\)($!Z08)C_!,-\IIZEK!
M5RUB@[$J4YY&IRL/(/K64RS/CHBJ&ZM'[WB=&^36-;&9A"]_0OZ$_ GY$_(G
MY%\+\7&>?318N8/7\#R<'IR=YGJ^*[WE<H5?%M@6X5"94C"'P4T^C?E'[YU#
M*BDY@Z@PJ+\U0+<O],<)_XC*N\R9$RB+^N>^7_Y/T)^@/T%_ _T*^&/\);^N
M\YL8$G'[D 0#/G!<Q#([N\L2A<A4J8'00VL*D7E6=W"EP0%#YT3V!YR1%<O#
MIMDQJ3(V4@=OK\O=I!T%U3);LNZ$_)]20"(#&. 5\HCKD=;I>8%6"0/:1&
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M1^6FKAO6U:>T(:F1%+2M8GAAM*'DK1_!GW1!6289+@D/]:*F<QQK?JG5E!N
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M/=!*P863_02IKRH/)VFL<&#U(GY'&$H*<&LFVU]R!.4[VRDWGEF4UB-56:!
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MV?&UPKM'-?(N.:0P/.]U3 +5&\/M 0'1Y3W=QMB/"6^?]WS?B/]="8QJ*C\
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MJ1**Y'@%#DC+Y'8@_5#U:912EF]$]P9RW-U*>LK5,%D!-0L^9*8(4L?(U W
M9[F'6]&GVQYF?D5:&M?G"'E0!1=Z:'7Q7[O-!K%^,X'KC;)YTFH:$J1O)_9*
MTHGMVRWWJ"QX5-MC1PNHQ.PQ#0WS1I)$#NY04-[2I&.C.<^2" *6<VMX#XUM
MA$/SK.L$',A)WW.PY?#+=:/=8E0Q;K)X(A]CWQ(6_1]+-_S#M((>PV8-HG^B
M5+"#Z\/XCSON.-D5$!(?X<8\1O,2^BR?0MNKO1^+<P;Z] +<-MP_5 (^JX5
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M09A1T/8)-H$</0("-F'G#!\OE*5,W\BY.5-L/J/+"D*7?=:&I]#?JZ3Y$MP
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M.%7FPDX/M#F,VD\Z-N/:GHB#4*1@A\YR_KJD7B(6>>EH.B*+@ZD!9"IJB/;
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M]06A:;HV("D%NFE^_5%-(5/4\C$]3W>)Q8O6&9R)$OQ6)W56D[NQ4[/O/2A
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MTWHIC9#!FB_XD0KV5FI-R4H*7=QSN.F>YHGF7R;X_X^4?XL85?X0#5[]T?Z
MV:RP=PC?2A\!O24^AX\ 4765QM\_2!K\>S?3_@]+OV-O5BW5?00,M-[;Z>VJ
M6/PISM/_]+CB3W*E_A?5]U^\!/A_;F+X%T-9_LY^,4^Q%/[;;F-]9OUO*+S"
M_XFA2/L7ZF&+A[6G.4C*_U7U_0LVQ/Z9#"D3HRR,IN#5'SXULYX'LLJCC01;
M9Z^G76/]7)$?G@JC6/#?VFM3WS'(8?J,\BH_ EJR2XUD%=4D<W$N>&GI(A\!
M087+AS<HEAF7,">?#MC1Y3TB1.YVAZ?<1*!S+<FH,JMN\4HSG?@1D.GRRQ5X
M24C\OJKL&;D?#M(5,PK:MG_(?L#)#VG=(BKR6508V\N?YJ:<WBLHX_Q][B,
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M(1)!C,)-?,X9<K9/TB/'&(\=J*E:8F3!8!)L0?#N8\07D]BO4=Q]_*WOAVR
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MR0S52UVT(?KU8'I.RBBZBOY&W=SQ)R>/,+)[6D\9'P'3KV<? :9EN@W1!(^
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MR=>&EKR& $NT@OGPC5T':EOFX^CFU+.5$)F%Y8'2H9'GTS49KLYE.SA**=9
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MNH9HUN67E$='OIXQ.IH>U4E&.(X&UJ1Q8\"[XO4$%<--^75?-A5EH"<8366
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MU=;2 B)%Y>X04B>A+(R.6X-9VXTO.*RHZ=^F0UV*$/E1JCP?<1K-2QDZ,.P
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M-?W,?,R.Q4\ %(FA_X*D%R:(F3T_D* Z#V?-#!;'6;!Z'>1.FHW&-_08E5-
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M>X#>LZLIG2K/>P#;/0#9YE.LGH7R7UARZI'N/RQWS?B'0DY;*"1_AQ^.#]&
M*R1MSD#;0!["VV@N647@;U*.@[\5[ ='*->-%>_[U.ROI%BJ?+9<_$7MVT-C
M (W9^>!6%>O%F!_WW!P#E;%)M6)L-TERPC:KOB[T7:0>J6<?!6<-V*$( >W)
M)48IA^8CK);)2M9,['<BHV3&N4WRGZ0E>RY_F>:YY&G+9QCG3=]Z/B*R0K:3
M?!1>]4TL%WTF<)$T1UA^OF.0/QXUE;Y:JB :0XD[9N*$)#:=-_2.( Z^?-&Y
M $?+ZNUP C42F_S""99P#BG5$GGF0/>^>^RM(NWO62'_9*\LU%_CEA3M.SJF
MK@9J494XL98)LO0K:*'\U-W@5_#E0[T="N\+/\^L"ARV1;(3H@TXN2<?T&G7
M\G"]/'>K^4E9XOX67;C =\&UX.A./ R0R>4#XRY,#OG0.,/K.: H! 5;F,[K
MS:"@-D:[J@]+H$[ZZS\1&J#H#24GP]"@?LS;XZ:5\ZW8&JZX$YB3N#BK6YF,
M%7E%:ZAR1]PZJ^4,UE<8^X0X*WQF3ICP4N7ESZQP-930:SSHCJKB,C4;%IR<
M+9"9\?O(6IVTSWY\]ZAW4&&8*^%L<:WPNJU"*8-L_BG)AL[0K*8![A1#530E
MT,3)!8YG&G73%F>L)%L"(.O1D7"-UYE/,G,^TPV!A7LGG3V5[UFZ4Q0:T)I
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ME$.?RW!&+&14$"]%<HGA<3;J:R,P$T"B6/&C^:.&\A^M)F]4'.N_!HWC+>C
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MCQ![C)E%@3(>5"\41X#J.#M%5')%<' ^C_=FHN?*>'1L>2G*S"SE>0Z[F"<
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M<>9_ 5!+ 0(4 Q0    ( (^=:U1LRYEA?U,$  J1.P 5              "
M 0    !E>7!T+3$P:U\R,#(Q,3(S,2YH=&U02P$"% ,4    " "/G6M4\5SW
M'.8>  #A<0$ $0              @ &R4P0 97EP="TR,#(Q,3(S,2YX<V10
M2P$"% ,4    " "/G6M4%2CPB1\3   ()0$ %0              @ ''<@0
M97EP="TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ CYUK5!3IB)S:20
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M<'0M97@Q,#$Y7SDR-"YH=&U02P$"% ,4    " "/G6M4(C\A*[,U  "AE@$
M%               @ '?- 8 97EP="UE>#$P,CA?,38Y."YH=&U02P$"% ,4
M    " "/G6M4Y;U];4<:  "BI $ %               @ '$:@8 97EP="UE
M>#$P-#5?,34V-2YH=&U02P$"% ,4    " "/G6M4D2X+:G02 0#X P@ %
M            @ $]A08 97EP="UE>#$P-#9?,C0Y-BYH=&U02P$"% ,4
M" "/G6M40&/ZR!8#  #F$P  $               @ 'CEP< 97EP="UE>#(Q
M,5\X+FAT;5!+ 0(4 Q0    ( (^=:U3/_QFPWP(  *8(   0
M  "  2>;!P!E>7!T+65X,C,Q7SDN:'1M4$L! A0#%     @ CYUK5&YWCT8F
M"   CRP  !$              ( !-)X' &5Y<'0M97@S,3%?,3$N:'1M4$L!
M A0#%     @ CYUK5+.?L&8S"   LRP  !               ( !B:8' &5Y
M<'0M97@S,3)?-BYH=&U02P$"% ,4    " "/G6M4K1JYNI4$   '&0  $
M            @ 'JK@< 97EP="UE>#,R,5\W+FAT;5!+ 0(4 Q0    ( (^=
M:U1&"?+0G 0  !\9   1              "  :VS!P!E>7!T+65X,S(R7S$P
M+FAT;5!+ 0(4 Q0    ( (^=:U1@&RO7-S(! *6< 0 6              "
M 7BX!P!G,&5X<#-O-'=S:' P,# P,#$N:G!G4$L%!@     1 !$ 3P0  ./J
$"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
